<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Nucl Med</journal-id><journal-id journal-id-type="iso-abbrev">J Nucl Med</journal-id><journal-id journal-id-type="pmc-domain-id">3060</journal-id><journal-id journal-id-type="pmc-domain">jnucmed</journal-id><journal-id journal-id-type="publisher-id">jnm</journal-id><journal-title-group><journal-title>Journal of Nuclear Medicine</journal-title></journal-title-group><issn pub-type="ppub">0161-5505</issn><issn pub-type="epub">1535-5667</issn><publisher><publisher-name>Society of Nuclear Medicine and Molecular Imaging</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12487868</article-id><article-id pub-id-type="pmcid-ver">PMC12487868.1</article-id><article-id pub-id-type="pmcaid">12487868</article-id><article-id pub-id-type="pmcaiid">12487868</article-id><article-id pub-id-type="pmid">40841153</article-id><article-id pub-id-type="doi">10.2967/jnumed.125.270325</article-id><article-id pub-id-type="publisher-id">270325</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Continuing Education</subject></subj-group></article-categories><title-group><article-title>When Age Is More Than a Number: Acceleration of Brain Aging in Neurodegenerative Diseases</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Doering</surname><given-names initials="E">Elena</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hoenig</surname><given-names initials="MC">Merle C.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cole</surname><given-names initials="JH">James H.</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Drzezga</surname><given-names initials="A">Alexander</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><aff id="aff1"><label>1</label>Forschungszentrum J&#252;lich, Institute of Neuroscience and Medicine&#8211;Molecular Organization of the Brain (INM-2), J&#252;lich, Germany;</aff><aff id="aff2"><label>2</label>Department of Nuclear Medicine, Faculty of Medicine and University Hospital, University of Cologne, Cologne, Germany;</aff><aff id="aff3"><label>3</label>Hawkes Institute, Department of Computer Science, University College London, London, United Kingdom;</aff><aff id="aff4"><label>4</label>Dementia Research Centre, Queen Square Institute of Neurology, University College London, London, United Kingdom; and</aff><aff id="aff5"><label>5</label>German Center for Neurodegenerative Diseases, Bonn-Cologne, Germany</aff></contrib-group><author-notes><corresp>For correspondence or reprints, contact Elena Doering (<email>elena.doering@uk-koeln.de</email>).</corresp><fn><p><bold>Learning Objectives:</bold> On successful completion of this activity, participants should be able to (1) describe how brain age and brain age gaps are computed from different neuroimaging modalities; (2) explain how modality-specific brain age gaps relate to phenotypes and progression of neurodegenerative diseases; and (3) discuss the potential applications and limitations of brain age gaps for disease monitoring and treatment evaluation.</p></fn><fn><p><bold>Financial Disclosure:</bold> Elena Doering is a stockholder of NVIDIA and Microsoft. James H. Cole is a shareholder and scientific advisor for BrainKey and Claritas HealthTech PTE. Alexander Drzezga receives research support from Siemens Healthineers, Life Molecular Imaging, GE HealthCare, AVID Radiopharmaceuticals, SOFIE, Eisai, Novartis/AAA, and Ariceum Therapeutics; receives speaker/advisory board honoraria from Siemens Healthineers, Sanofi, GE HealthCare, Biogen, Novo Nordisk, Invicro, Novartis/AAA, Bayer Vital, Lilly, Peer View Institute for Medical Education, and International Atomic Energy Agency; and has stocks from Siemens Healthineers, Lantheus Holding, and Lilly. He holds the patent for <sup>18</sup>F-JK-PSMA-7 (patent no. EP3765097A1). The authors of this article have indicated no other relevant relationships that could be perceived as a real or apparent conflict of interest.</p></fn><fn><p><bold>CE Credit:</bold> SNMMI is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Registry for Radiologic Technologists (ARRT) and Nuclear Medicine Technology Certification Board (NMTCB) to sponsor continuing education for physicians, pharmacists, and nuclear medicine technologists. You may make 3 attempts to pass the test and must answer 80% of the questions correctly to receive credit&#8212;number of credits awarded will be determined by the length of the article. Participants can access this activity through the SNMMI website (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.snmmilearningcenter.org" ext-link-type="uri">http://www.snmmilearningcenter.org</ext-link>) through October 2028. Additional details such as the number of credits issued per article, expiration dates, financial disclosure information, and the process to earn CE credit can also be found in the SNMMI Learning Center.</p></fn><fn><p>Published online Aug. 21, 2025.</p></fn></author-notes><pub-date pub-type="ppub"><month>10</month><year>2025</year></pub-date><volume>66</volume><issue>10</issue><issue-id pub-id-type="pmc-issue-id">498107</issue-id><fpage>1516</fpage><lpage>1521</lpage><history><date date-type="received"><day>05</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>29</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>02</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-02 11:25:38.340"><day>02</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the Society of Nuclear Medicine and Molecular Imaging.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>. Details: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://jnm.snmjournals.org/page/permissions">https://jnm.snmjournals.org/page/permissions</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jnumed.125.270325.pdf"/><abstract><p>Aging of the brain is characterized by deleterious processes at various levels including cellular/molecular and structural/functional changes. Many of these processes can be assessed in&#160;vivo by means of modern neuroimaging procedures, allowing the quantification of brain age in different modalities. Brain age can be measured by suitable machine learning strategies. The deviation (in both directions) between a person&#8217;s measured brain age and chronologic age is referred to as the brain age gap (BAG). Although brain age, as defined by these methods, generally is related to the chronologic age of a person, this relationship is not always parallel and can also vary significantly between individuals. Importantly, whereas neurodegenerative disorders are not equivalent to accelerated brain aging, they may induce brain changes that resemble those of older adults, which can be captured by brain age models. Inversely, healthy brain aging may involve a resistance or delay of the onset of neurodegenerative pathologies in the brain. This continuing education article elaborates how the BAG can be computed and explores how BAGs, derived from diverse neuroimaging modalities, offer unique insights into the phenotypes of age-related neurodegenerative diseases. Structural BAGs from T1-weighted MRI have shown promise as phenotypic biomarkers for monitoring neurodegenerative disease progression especially in Alzheimer disease. Additionally, metabolic and molecular BAGs from molecular imaging, functional BAGs from functional MRI, and microstructural BAGs from diffusion MRI, although researched considerably less, each may provide distinct perspectives on particular brain aging processes and their deviations from healthy aging. We suggest that BAG estimation, when based on the appropriate modality, could potentially be useful for disease monitoring and offer interesting insights concerning the impact of therapeutic interventions.</p></abstract><kwd-group><kwd>brain age</kwd><kwd>machine learning</kwd><kwd>neuroimaging</kwd><kwd>neurodegeneration</kwd><kwd>dementia</kwd></kwd-group><counts><page-count count="6"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>The common saying that &#8220;age is just a number&#8221; is often used to comfort those who feel overwhelmed by the seemingly relentless and uncontrollable progress of aging. However, from a biologic standpoint, age is more than a single number, and the biologic aging process may not, indeed, be entirely uncontrollable. As the brain ages, it undergoes profound alterations at various levels, including molecular composition, structural integrity, and functional connectivity. The biologic processes associated with brain development and aging are sequential, nonlinear, and complex. During the first years of life, brain development is associated with cortical maturation and the formation of neuronal connections (<xref rid="bib1" ref-type="bibr">1</xref>,<xref rid="bib2" ref-type="bibr">2</xref>). Brain development is strongly accelerated during infancy and early childhood and typically peaks before the age of 30 (<xref rid="bib1" ref-type="bibr">1</xref>). As opposed to brain development, brain aging is generally seen as the accumulation of deleterious biologic changes during adulthood, resulting in progressive impairment of brain function (<xref rid="bib3" ref-type="bibr">3</xref>). Regions throughout the brain display differential vulnerability toward the aging process, with brain regions that are believed to develop later also showing signs of earlier degeneration (<xref rid="bib4" ref-type="bibr">4</xref>). A multitude of factors, including genetic, developmental, environmental, and disease-specific attributes can influence how fast the brain ages, leading to a heterogeneous expression of brain aging. Most people experience some degree of normal age-related changes, including loss or alterations of brain structure and function. Some individuals are able to maintain exceptional cognitive function until highly advanced age, potentially indicative of a slowed brain aging process (so-called super agers (<xref rid="bib5" ref-type="bibr">5</xref>,<xref rid="bib6" ref-type="bibr">6</xref>)). On the other hand, patients with specific neurodegenerative diseases, for example, Alzheimer disease (AD), demonstrate profound neurodegeneration and decline in cognitive abilities, which in turn has been associated with accelerated brain aging (<xref rid="bib7" ref-type="bibr">7</xref>&#8211;<xref rid="bib11" ref-type="bibr">11</xref>). Importantly, brain aging and neurodegeneration are not necessarily synonymous. Although some age-related changes may contribute to neurodegenerative processes, others might occur independently or even provide resilience against neurodegeneration. To further study this, recent advances in data science have allowed the estimation of an individual&#8217;s brain age from neuroimaging data using machine learning. Given the tremendous interindividual differences in brain aging, understanding brain age as a potential biomarker, as well as its clinical implications, may advance risk assessment, diagnosis, staging, and monitoring of various age-related neurodegenerative diseases and their therapies.</p><p>Brain age models are trained to estimate chronologic age from neuroimaging data on the basis of large datasets of healthy agers, where they learn to identify specific patterns that associate neuroimaging features&#8212;such as regional gray matter volume, connectivity, or metabolic activity&#8212;with chronologic age. These models summarize age-related changes derived from neuroimaging features, yielding a personalized estimate of brain age. The difference between measured brain age and chronologic age of an individual is called the brain age gap (BAG; sometimes also called brain-predicted age difference or brain-age gap estimation). The BAG is a number representing the deviation from normal aging in years (i.e., the deviation from chronologic age) at a particular point in time and for a particular examined modality (e.g., structural MRI): a positive BAG (&gt;0 y) indicates that an individual&#8217;s brain appears older on this modality than a person&#8217;s chronologic age, whereas a negative BAG (&lt;0 y) suggests the opposite (<xref rid="fig1" ref-type="fig">Fig. 1</xref>). In neurodegenerative disorders, the BAG can be understood as a marker that quantifies pathophysiologic brain changes resembling accelerated aging. That is, if a neurodegenerative process and aging typically affect similar regions of the brain, the BAG can quantify the extent to which the disorder causes an acceleration of the aging process. Moreover, a positive BAG may then also indicate increased susceptibility to additional age-associated neurologic conditions. Although it may be challenging to reduce brain age itself (i.e., to rejuvenate the brain), slowing down an accelerated aging process seems conceivable&#8212;meaning it may be possible to reduce the BAG by means of successful therapies against neurodegeneration or neurodegenerative pathology (<xref rid="bib12" ref-type="bibr">12</xref>,<xref rid="bib13" ref-type="bibr">13</xref>). As a consequence, the BAG and its potential reduction through intervention not only could be useful for disease monitoring but also could be a valuable readout for clinical trials assessing treatment efficacy.</p><fig position="float" id="fig1" orientation="portrait"><label>FIGURE 1.</label><caption><p>Chronologic and structural MRI brain ages of 6 patients with MCI. Age effects are distinctly apparent on structural MRI, for example, in enlargement of ventricles, as well as general cortical and subcortical atrophy. BAG captures acceleration of brain aging, for example, due to neurodegenerative disease, and can provide useful information for disease and therapy monitoring. Brain age was estimated using our models previously implemented in Doering et&#160;al. (<xref rid="bib19" ref-type="bibr">19</xref>) for our previous publication. Same slice is depicted for all scans.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jnumed.125.270325f1.jpg"/></fig><p>This article will therefore outline how to compute brain age, how BAGs estimated from different neuroimaging modalities are associated with specific phenotypes of neurodegenerative disease and provide current evidence on the association of BAGs and treatment efficacy.</p><sec><title>COMPUTATION OF BRAIN AGE</title><p>The computation of brain age is accomplished using supervised machine-learning regression models (<xref rid="fig2" ref-type="fig">Fig. 2</xref>), whereas the specific pipeline depends on sample size, computational resources, as well as processing time (<xref rid="bib14" ref-type="bibr">14</xref>). Overall, support vector, relevance vector, and gaussian process regression are popular model types. Usage of convolutional neural networks for this task is on the rise (<xref rid="bib15" ref-type="bibr">15</xref>&#8211;<xref rid="bib17" ref-type="bibr">17</xref>), due to fewer preprocessing requirements; however, they require larger sample sizes for training and are more computationally expensive.</p><fig position="float" id="fig2" orientation="portrait"><label>FIGURE 2.</label><caption><p>Computation of brain age. Prespecified portion of data (1) is allocated for training of machine-learning regression algorithm (2). Resulting brain age (BA) estimates are known to have inherent bias, which can be eliminated using bias correction (3). Trained machine-learning model can then be applied to test data to yield BA estimate (4). Bias correction parameters inferred during training stage can be applied to model output to obtain bias-free BA estimates (5). Finally, BAG is computed by subtracting chronologic age (CA) from BA (6). Figure created with BioRender.com.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jnumed.125.270325f2.jpg"/></fig><p>For each machine-learning task, there are 2 phases, namely the training and the test phase, for which different and independent parts of the data are reserved. Partitioning of the data into training and test sets can be achieved either by allocating a specific percentage of the data to training and testing (e.g., using a 70%&#8211;30% split) or by using cross-validation, wherein multiple splits are performed on the data. In the initial training phase, training data of healthy agers, for example, cognitively normal subjects, are provided to the model as input for learning to associate neuroimaging-derived features to an individual&#8217;s chronologic age. Healthy agers are used since they allow the model to learn the estimation of a person&#8217;s age from their brain scan in the absence of known neurologic abnormalities. For reliable assessment of patients&#8217; brain ages in subsequent analyses, healthy agers used to train and validate the models should cover approximately the patients&#8217; age range. Data can be provided to the model in the form of either voxels, pattern expression scores obtained through principal component analysis, or as specific metrics in a set of brain regions (e.g., average voxel value, cortical thickness, or fractional anisotropy per region) (<xref rid="bib14" ref-type="bibr">14</xref>). Notably, brain age estimates obtained from such a pipeline yield a bias, wherein the brain age of older individuals is underestimated, and the brain age of younger individuals is overestimated, caused by a regression-to-the-mean effect. Several straightforward bias correction methods have been suggested and were thoroughly discussed by de Lange and Cole (<xref rid="bib18" ref-type="bibr">18</xref>). Briefly, bias correction can be achieved using residual approaches with or without consideration of chronologic age. Although there is no universally preferred option, it is worth noting that accounting for chronologic age in bias correction increases the similarity between brain and chronologic age, whereas not accounting for chronologic age decreases the similarity, that is, accuracy. Alternatively, explicit bias correction can be avoided, and chronologic age can be used as a covariate in subsequent analyses in which the BAG is the dependent variable. This covariate approach is sometimes preferred as it circumvents the need to choose among competing bias correction methods. Accuracy assessment of the trained model is accomplished by computing the mean absolute error (lower is better, and the optimal value is 0) and other quantitative metrics, for example, the coefficient of determination (<italic toggle="yes">R</italic><sup>2</sup>; higher is better, and the optimal value is 1), between brain and chronologic age in the test set of healthy agers. A mean absolute error below 5 y is generally considered acceptable when predicting values across the adult life span (<xref rid="bib14" ref-type="bibr">14</xref>). To compare the performance of different brain age models across studies, <italic toggle="yes">R</italic><sup>2</sup> is the preferred choice, as it is unaffected by potentially different age distributions in the test sets. Finally, a reliable brain age estimation pipeline can be applied to compute the BAG of individuals both in another previously untouched test set of healthy agers and in patients with assumed neurologic abnormalities to quantify their magnitude of deviation from healthy aging. Given that aging is a multifactorial phenomenon, BAGs may be estimated from different modalities, with potentially different implications for the divergence from healthy aging.</p></sec><sec><title>DIFFERENT BAGS AND THEIR ASSOCIATION WITH NEURODEGENERATIVE DISEASE</title><p>Brain age, or BAGs, have previously been estimated from various modalities, yielding structural, molecular, functional, or microstructural perspectives on brain aging. The most common modality to estimate BAGs in neurodegenerative diseases is structural MRI, which depicts atrophy. Additionally, features from molecular imaging, such as PET, functional imaging, such as resting-state functional MRI (fMRI), and electroencephalography, or microstructural imaging such as diffusion MRI have previously been used to estimate BAGs.</p><sec><title>Structural BAGs from T1-Weighted MRI</title><p>BAGs estimated from T1-weighted MRI relate to the deviation from normal structural brain aging, and they have been the most extensively researched thus far. Such structural BAGs can be understood as phenotypic biomarkers; that is, they reflect observable patterns of brain changes associated with aging, rather than directly reflecting underlying cerebral mechanisms. Higher structural BAGs (i.e., older-looking brains) have consistently been associated with more severe cognitive dysfunction (<xref rid="bib15" ref-type="bibr">15</xref>,<xref rid="bib19" ref-type="bibr">19</xref>&#8211;<xref rid="bib21" ref-type="bibr">21</xref>) and future progression from mild cognitive impairment (MCI) to dementia (<xref rid="bib11" ref-type="bibr">11</xref>,<xref rid="bib15" ref-type="bibr">15</xref>,<xref rid="bib19" ref-type="bibr">19</xref>). Consistently, structural BAGs have been shown to increase over time in patients clinically diagnosed with AD dementia (<xref rid="bib20" ref-type="bibr">20</xref>,<xref rid="bib22" ref-type="bibr">22</xref>). Evidence suggests that elevated structural BAGs may be more specific to AD compared with other neurodegenerative diseases, as they correlate with AD biomarkers and are significantly higher in MCI patients on the verge of progressing to AD dementia compared with those progressing to other types of dementia (such as frontotemporal or Lewy body dementia) (<xref rid="bib15" ref-type="bibr">15</xref>). The authors speculated that AD may thus mimic an accelerated version of normal structural aging, whereas other types of dementia present with distinct, disease-specific structural damage that makes the brain appear older but does not follow the typical order of age-related structural changes. Unlike existing structural MRI biomarkers for AD, for example, those obtained from individual regions such as the hippocampus, structural BAGs integrate atrophy patterns across the entire brain, potentially capturing AD-related changes in more complex regional (co)variance patterns across the brain. Furthermore, structural BAGs offer an individual marker of deviation from expected aging patterns, allowing for individualized risk stratification beyond established absolute measures of brain structure. In summary, the extant literature provides convincing evidence that structural BAGs may complement prognostic and monitoring assessments for (especially AD) dementia patients. It appears promising to test the added potential of considering structural BAGs alongside, for example, &#946;-amyloid PET for patient stratification in clinical trials (<xref rid="bib9" ref-type="bibr">9</xref>), as BAGs may capture broad neurodegenerative changes that could aid in risk stratification of early AD cases.</p><p>Beyond AD, structural BAGs are also elevated in Parkinson disease (<xref rid="bib23" ref-type="bibr">23</xref>&#8211;<xref rid="bib25" ref-type="bibr">25</xref>), multiple sclerosis (<xref rid="bib12" ref-type="bibr">12</xref>,<xref rid="bib26" ref-type="bibr">26</xref>,<xref rid="bib27" ref-type="bibr">27</xref>), and some patients with amyotrophic lateral sclerosis (<xref rid="bib28" ref-type="bibr">28</xref>) compared with healthy agers. In multiple sclerosis patients, structural BAGs increase with disease duration and predict the progression of disability (<xref rid="bib26" ref-type="bibr">26</xref>,<xref rid="bib27" ref-type="bibr">27</xref>), suggesting structural BAGs could be useful as a marker of the biologic progression of multiple sclerosis. For Parkinson disease and amyotrophic lateral sclerosis, on the other hand, the association of the BAG and clinical disease parameters was most convincingly shown for cognitive dysfunction, rather than overall symptom severity. Hence, the involvement of structural BAGs in Parkinson disease or amyotrophic lateral sclerosis is possibly restricted to the frequent cooccurrence of dementia in these disorders (<xref rid="bib29" ref-type="bibr">29</xref>,<xref rid="bib30" ref-type="bibr">30</xref>), rather than representing an isolated disease mechanism (<xref rid="bib31" ref-type="bibr">31</xref>).</p></sec><sec><title>Molecular Imaging&#8211;Derived BAGs</title><p>Molecular imaging techniques, such as PET or SPECT, can be used to visualize the brain&#8217;s metabolism, the accumulation of protein pathologies using compound-specific tracers (e.g., for amyloid or tau deposits), or the integrity of neurotransmitter systems (e.g., for dopamine). Unlike structural BAGs, molecular imaging&#8211;derived BAGs could capture mechanistic deviations from healthy aging trajectories that may reflect emerging pathophysiologic processes. Several molecular imaging techniques capture age-associated changes and thus might be suitable candidates for brain age estimation. For example, [<sup>18</sup>F]FDG PET studies have shown that brain metabolism declines by &#8764;12%&#8211;13% over the adult life span, most notably in the neocortex (<xref rid="bib32" ref-type="bibr">32</xref>). Likewise, amyloid accumulation is not exclusive to AD but is also&#8212;to some extent&#8212;a part of normal aging (<xref rid="bib33" ref-type="bibr">33</xref>). Even dopamine transporter imaging, typically indicated for the assessment of movement disorders, shows a gradual decrease in striatal binding ratios with healthy aging (<xref rid="bib34" ref-type="bibr">34</xref>,<xref rid="bib35" ref-type="bibr">35</xref>). Given that such molecular changes often precede atrophy (<xref rid="bib36" ref-type="bibr">36</xref>), BAGs estimated from PET or SPECT could theoretically be more sensitive to early-stage neurodegenerative changes than structural BAGs. In practice, however, only a few studies investigated molecular imaging&#8211;derived BAGs and their association with neurodegenerative disease, which are summarized here.</p><p>Metabolic BAGs were previously derived from [<sup>18</sup>F]FDG PET and found to be positively correlated with structural BAGs; however, they were neither strongly associated with markers of AD pathology nor significantly elevated in individuals progressing from MCI to AD dementia during follow-up (<xref rid="bib15" ref-type="bibr">15</xref>,<xref rid="bib19" ref-type="bibr">19</xref>). These findings do not support a primary role for metabolic BAGs in the early detection of AD, possibly because age-related hypometabolism involves primarily the frontal lobes, whereas AD affects the frontal lobe only later on in the disease course (<xref rid="bib32" ref-type="bibr">32</xref>). Instead, data from Lee et&#160;al. (<xref rid="bib15" ref-type="bibr">15</xref>) indicated that metabolic BAGs might represent a useful biomarker for the timely identification of frontotemporal dementia, as metabolic, but not structural BAGs were significantly increased in MCI&#8211;to&#8211;frontotemporal dementia progressors, and both BAGs were higher in patients with frontotemporal dementia than in stable controls. Finally, 1 recent study estimated BAGs using [<sup>18</sup>F]flortaucipir, which depicts cerebral tau pathology accumulation (<xref rid="bib37" ref-type="bibr">37</xref>). The tau-derived brain age was close to chronologic age in cognitively healthy subjects and increased with disease progression and symptom severity of AD, indicating that the model may have identified subtle age-related patterns of tau accumulation that are exacerbated in AD. To the best of our knowledge, to date, no studies exist that estimate brain age from amyloid PET or dopamine PET/SPECT. Taken together, molecular imaging&#8211;derived BAGs remain underexplored but hold considerable promise for advancing our understanding of neurodegenerative diseases as potential manifestations of accelerated aging of individual physiologic processes. We encourage future research to systematically assess molecular imaging&#8211;derived BAGs across various tracers and clinical populations, given their expected potential for early detection and disease characterization. In addition, evaluating whether structural information can improve molecular imaging&#8211;based brain age estimation may be a valuable next step. For example, incorporating partial volume correction as a preprocessing step in brain age models may improve regional signal accuracy, especially in cortical and subcortical gray matter.</p></sec><sec><title>Functional BAGs from fMRI or Electroencephalography</title><p>Recent studies have also explored BAGs derived from resting-state fMRI and electroencephalography, which reflect deviations from typical age-related changes in brain function. Functional BAGs, from both fMRI and electroencephalography, have been found to be elevated in AD (<xref rid="bib38" ref-type="bibr">38</xref>,<xref rid="bib39" ref-type="bibr">39</xref>) and to a lesser extent in MCI and the behavioral-variant of frontotemporal dementia (<xref rid="bib38" ref-type="bibr">38</xref>). Higher sleep electroencephalography&#8211;derived BAGs were not only found to be associated with greater cognitive dysfunction but also to cooccur with modifiable dementia risk factors&#8212;such as a higher apnea&#8211;hypopnea index and greater smoking exposure (<xref rid="bib40" ref-type="bibr">40</xref>). Although studied mostly in cognitively impaired individuals, sleep electroencephalography&#8211;derived BAGs may aid early detection, as sleep disturbance tends to be an early indicator of various forms of neurodegeneration (<xref rid="bib41" ref-type="bibr">41</xref>&#8211;<xref rid="bib43" ref-type="bibr">43</xref>), and the association of sleep electroencephalography&#8211;derived BAGs with modifiable risk factors further underscores sensitivity to preneurodegenerative changes. However, further research is warranted for both functional BAGs. For instance, fMRI-based BAGs were not found to be linked to the amount of amyloid or tau pathology in amyloid-positive, cognitively impaired individuals (<xref rid="bib44" ref-type="bibr">44</xref>), nor in preclinical familial AD (<xref rid="bib45" ref-type="bibr">45</xref>), suggesting non-AD pathologies may drive fMRI-based functional brain age acceleration, or the latter may be masked by compensatory mechanisms. Moreover, abnormally high fMRI-derived BAGs have been associated with cognitive decline beyond neurodegenerative diseases, such as in patients with epilepsy (<xref rid="bib46" ref-type="bibr">46</xref>). Thus, the specific mechanisms contributing to accelerated aging of brain function and their potential involvement in neurodegenerative diseases remain to be further elucidated.</p></sec><sec><title>Microstructural BAGs from Diffusion MRI</title><p>Finally, some studies estimated BAGs from white matter microstructure data using diffusion-weighted MRI in the context of neurodegenerative diseases. Microstructural BAGs were found to be elevated in initially cognitively normal individuals who later progressed to MCI (<xref rid="bib47" ref-type="bibr">47</xref>) or increased in clinical dementia ratings (<xref rid="bib48" ref-type="bibr">48</xref>). Although pending further investigation, these observations are in line with previous studies outlining the early diagnostic value of white matter alterations on diffusion-weighted MRI (<xref rid="bib49" ref-type="bibr">49</xref>,<xref rid="bib50" ref-type="bibr">50</xref>), for which microstructural BAGs may be a useful summary marker.</p></sec></sec><sec><title>BAGS AND TREATMENT</title><sec><title>Effect of BAGs on Treatment Outcomes</title><p>A recent study by Tseng et&#160;al. (<xref rid="bib51" ref-type="bibr">51</xref>) found that lower baseline structural BAGs were associated with better treatment response to cholinesterase inhibitors in patients with MCI (mean BAG of responders = 3.9 y; mean BAG of nonresponders = 8.4 y) despite comparable cognitive performance at baseline. Similarly, the effectiveness of repetitive transcranial magnetic stimulation in treating depression among patients with AD or vascular dementia was more closely linked to lower baseline structural BAGs than to gray matter volume or to baseline depression or cognitive impairment severity (mean MRI BAG of remitters = &#8722;3.0 y; mean MRI BAG of nonremitters = 4.6 y) (<xref rid="bib52" ref-type="bibr">52</xref>). Notably, the diverging significance of differences in baseline BAGs and clinical scores in the dementia studies demonstrate that the BAG does not always correlate directly with cognitive function, as factors such as cognitive reserve may modulate the impact of age-related brain changes on clinical symptoms. Cognitive reserve refers to the ability of the brain to compensate for ongoing neurodegenerative processes (<xref rid="bib53" ref-type="bibr">53</xref>,<xref rid="bib54" ref-type="bibr">54</xref>). As such, individuals with similar BAGs may show markedly different cognitive trajectories, warranting further research on the interplay of cognitive reserve and BAG. Together, current evidence suggests that structural BAGs, as a biologic marker of disease progression, might provide a useful predictive indicator of treatment efficacy in patients with dementia, and they could potentially facilitate patient stratification for clinical trials.</p></sec><sec><title>Effect of Treatment and Intervention on BAGs</title><p>To the best of our knowledge, only 1 study has investigated whether treatment can reverse BAGs in neurodegenerative diseases: McMurran et&#160;al. (<xref rid="bib12" ref-type="bibr">12</xref>) reported an 11-mo reduction in structural BAGs after 6 mo of bexarotene therapy in patients with multiple sclerosis. Beyond neurodegenerative diseases, 3 studies further support the notion of BAGs as a potential marker to reflect the effect of treatment or interventions: Chu et&#160;al. (<xref rid="bib55" ref-type="bibr">55</xref>) demonstrated that a single night of sleep deprivation increased an individual&#8217;s structural BAG by 1&#8211;2 y, which, in turn, was reset to baseline levels after 1 night of recovery sleep. In individuals aged 26&#8211;58 y, Wan et&#160;al. (<xref rid="bib13" ref-type="bibr">13</xref>) recently outlined that regular aerobic exercise over the course of 12 mo reduces structural BAGs by approximately 7 mo. Finally, structural BAGs were shown to be reduced by 1.1 y in healthy individuals aged 23&#8211;47 y after administration of the antiinflammatory drug ibuprofen (<xref rid="bib56" ref-type="bibr">56</xref>). Taken together, the current body of literature not only provides compelling evidence for considering (structural) BAGs as an additional indicator of treatment efficiency in clinical trials but also points to the potential sensitivity of BAGs toward lifestyle differences and common medication intake. Such factors should influence the evaluation of the BAG in potential diagnostic or monitoring contexts.</p></sec><sec><title>Availability and Limitations of the BAG</title><p>Most neurodegenerative disease trials already include neuroimaging as part of their protocols&#8212;commonly used for eligibility screening, stratifying participants by biomarker status, or monitoring disease progression. In such cases, BAG metrics might be considered an attractive candidate for secondary or exploratory endpoints, as they require no additional data acquisition, cost, or participant burden. In these contexts, the BAG does not necessarily need to outperform established biomarkers such as hippocampal volume or regional PET signal to be valuable. By capturing complementary information&#8212;such as diffuse or distributed brain changes not adequately represented by conventional regional biomarkers&#8212;it may enhance trial readouts or facilitate the identification of responder subgroups (<xref rid="bib57" ref-type="bibr">57</xref>).</p><p>However, BAG metrics also have certain drawbacks, as they may be influenced by modality-specific factors (e.g., image resolution or preprocessing choices) or by the training data and modeling approach (<xref rid="bib58" ref-type="bibr">58</xref>). Moreover, interpretation of BAGs can be confounded by the model&#8217;s accuracy, as well as by factors such as head motion (<xref rid="bib59" ref-type="bibr">59</xref>), scanner variability (<xref rid="bib58" ref-type="bibr">58</xref>), and comorbidities (<xref rid="bib60" ref-type="bibr">60</xref>,<xref rid="bib61" ref-type="bibr">61</xref>). Furthermore, as outlined above, not every BAG may show strong and consistent associations with clinical outcomes in every disease. This is likely due to the fact that brain age models derived from neuroimaging data of healthy agers predominantly capture deviations in typical age-related patterns. Thus, they may have limited sensitivity to pathologic changes in regions other than those typically affected by aging. Finally, current imaging-based brain age models may not capture upstream mechanisms such as inflammation, proteostasis failure, or epigenetic changes, as they are not currently measurable by imaging. As such, whereas easily implemented, BAGs should be interpreted with awareness of their context-specific strengths and limitations.</p></sec></sec><sec sec-type="conclusion"><title>CONCLUSION</title><p>In this article, we outlined that brain age is more than a number; there are multiple brain ages derived from different modalities, and they represent measurable and potentially modifiable markers of the progression of neurodegenerative diseases. Although structural BAGs (derived from structural MRI) have been the most extensively studied to date, emerging evidence suggests that BAGs from different imaging modalities capture distinct aspects of deviation from a typical aging trajectory, including molecular, functional, pathologic, and microstructural brain aging patterns. In the context of neurodegenerative diseases, the (limited) existing data indicate that the choice of imaging modality for BAG estimation may be relevant for assessing disease progression in different neurodegenerative diseases. Structural BAGs, in particular, have shown associations with cognitive decline and AD biomarkers, suggesting their potential as a monitoring tool. Pending further investigation in clinical and real-world settings, BAGs may offer a sensitive, imaging-based tool for identifying individuals at risk, monitoring disease trajectories, and assessing therapeutic impact in neurodegeneration.</p></sec></body><back><ref-list><title>REFERENCES</title><ref id="bib1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bethlehem</surname><given-names>RAI</given-names></name><name name-style="western"><surname>Seidlitz</surname><given-names>J</given-names></name><name name-style="western"><surname>White</surname><given-names>SR</given-names></name><etal/></person-group>.; <collab>VETSA</collab>. 
<article-title>Brain charts for the human lifespan</article-title>. <source>Nature.</source><year>2022</year>;<volume>604</volume>:<fpage>525</fpage>&#8211;<lpage>533</lpage>.<pub-id pub-id-type="pmid">35388223</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-022-04554-y</pub-id><pub-id pub-id-type="pmcid">PMC9021021</pub-id></mixed-citation></ref><ref id="bib2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>MH</given-names></name></person-group>. 
<article-title>Functional brain development in humans</article-title>. <source>Nat Rev Neurosci.</source><year>2001</year>;<volume>2</volume>:<fpage>475</fpage>&#8211;<lpage>483</lpage>.<pub-id pub-id-type="pmid">11433372</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/35081509</pub-id></mixed-citation></ref><ref id="bib3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harman</surname><given-names>D</given-names></name></person-group>. 
<article-title>Aging: overview</article-title>. <source>Ann NY Acad Sci.</source><year>2001</year>;<volume>928</volume>:<fpage>1</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="pmid">11795501</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1749-6632.2001.tb05631.x</pub-id></mixed-citation></ref><ref id="bib4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Douaud</surname><given-names>G</given-names></name><name name-style="western"><surname>Groves</surname><given-names>AR</given-names></name><name name-style="western"><surname>Tamnes</surname><given-names>CK</given-names></name><etal/></person-group>. 
<article-title>A common brain network links development, aging, and vulnerability to disease</article-title>. <source>Proc Natl Acad Sci U S A.</source><year>2014</year>;<volume>111</volume>:<fpage>17648</fpage>&#8211;<lpage>17653</lpage>.<pub-id pub-id-type="pmid">25422429</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1410378111</pub-id><pub-id pub-id-type="pmcid">PMC4267352</pub-id></mixed-citation></ref><ref id="bib5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoenig</surname><given-names>MC</given-names></name><name name-style="western"><surname>Willscheid</surname><given-names>N</given-names></name><name name-style="western"><surname>Bischof</surname><given-names>GN</given-names></name><name name-style="western"><surname>Van Eimeren</surname><given-names>T</given-names></name><name name-style="western"><surname>Drzezga</surname><given-names>A</given-names></name></person-group>, <collab>Alzheimer&#8217;s Disease Neuroimaging Initiative</collab>. 
<article-title>Assessment of tau tangles and amyloid-&#946; plaques among super agers using PET imaging</article-title>. <source>JAMA Netw Open.</source><year>2020</year>;<volume>3</volume>:<fpage>e2028337</fpage>.<pub-id pub-id-type="pmid">33306113</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2020.28337</pub-id><pub-id pub-id-type="pmcid">PMC7733158</pub-id></mixed-citation></ref><ref id="bib6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rogalski</surname><given-names>E</given-names></name><name name-style="western"><surname>Gefen</surname><given-names>T</given-names></name><name name-style="western"><surname>Mao</surname><given-names>Q</given-names></name><etal/></person-group>. 
<article-title>Cognitive trajectories and spectrum of neuropathology in superagers: the first 10 cases</article-title>. <source>Hippocampus.</source><year>2019</year>;<volume>29</volume>:<fpage>458</fpage>&#8211;<lpage>467</lpage>.<pub-id pub-id-type="pmid">29341318</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hipo.22828</pub-id><pub-id pub-id-type="pmcid">PMC6050141</pub-id></mixed-citation></ref><ref id="bib7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wyss-Coray</surname><given-names>T</given-names></name></person-group>. 
<article-title>Ageing, neurodegeneration and brain rejuvenation</article-title>. <source>Nature.</source><year>2016</year>;<volume>539</volume>:<fpage>180</fpage>&#8211;<lpage>186</lpage>.<pub-id pub-id-type="pmid">27830812</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature20411</pub-id><pub-id pub-id-type="pmcid">PMC5172605</pub-id></mixed-citation></ref><ref id="bib8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Statsenko</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kuznetsov</surname><given-names>NV</given-names></name><name name-style="western"><surname>Morozova</surname><given-names>D</given-names></name><etal/></person-group>. 
<article-title>Reappraisal of the concept of accelerated aging in neurodegeneration and beyond</article-title>. <source>Cells.</source><year>2023</year>;<volume>12</volume>:<fpage>2451</fpage>.<pub-id pub-id-type="pmid">37887295</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells12202451</pub-id><pub-id pub-id-type="pmcid">PMC10605227</pub-id></mixed-citation></ref><ref id="bib9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Popescu</surname><given-names>SG</given-names></name><name name-style="western"><surname>Whittington</surname><given-names>A</given-names></name><name name-style="western"><surname>Gunn</surname><given-names>RN</given-names></name><etal/></person-group>.; <collab>Alzheimer&#8217;s Disease Neuroimaging Initiative</collab>. 
<article-title>Nonlinear biomarker interactions in conversion from mild cognitive impairment to Alzheimer&#8217;s disease</article-title>. <source>Hum Brain Mapp.</source><year>2020</year>;<volume>41</volume>:<fpage>4406</fpage>&#8211;<lpage>4418</lpage>.<pub-id pub-id-type="pmid">32643852</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hbm.25133</pub-id><pub-id pub-id-type="pmcid">PMC7502835</pub-id></mixed-citation></ref><ref id="bib10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chai</surname><given-names>L</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhuo</surname><given-names>Z</given-names></name><etal/></person-group>. 
<article-title>Estimated brain age in healthy aging and across multiple neurological disorders</article-title>. <source>J Magn Reson Imaging.</source> November 26, <year>2024</year> [Epub ahead of print].<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jmri.29667</pub-id><pub-id pub-id-type="pmid">39588683</pub-id></mixed-citation></ref><ref id="bib11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biondo</surname><given-names>F</given-names></name><name name-style="western"><surname>Jewell</surname><given-names>A</given-names></name><name name-style="western"><surname>Pritchard</surname><given-names>M</given-names></name><etal/></person-group>. 
<article-title>Brain-age is associated with progression to dementia in memory clinic patients</article-title>. <source>Neuroimage Clin.</source><year>2022</year>;<volume>36</volume>:<fpage>103175</fpage>.<pub-id pub-id-type="pmid">36087560</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nicl.2022.103175</pub-id><pub-id pub-id-type="pmcid">PMC9467894</pub-id></mixed-citation></ref><ref id="bib12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McMurran</surname><given-names>CE</given-names></name><name name-style="western"><surname>de Meo</surname><given-names>E</given-names></name><name name-style="western"><surname>Cunniffe</surname><given-names>NG</given-names></name><etal/></person-group>. 
<article-title>Exploratory analysis of biological age measures in a remyelination clinical trial</article-title>. <source>Brain Commun.</source><year>2025</year>;<volume>7</volume>:<fpage>1</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/braincomms/fcaf032</pub-id><pub-id pub-id-type="pmcid">PMC11852336</pub-id><pub-id pub-id-type="pmid">40008332</pub-id></mixed-citation></ref><ref id="bib13"><label>13.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Wan</surname><given-names>L</given-names></name><name name-style="western"><surname>Molina-Hidalgo</surname><given-names>C</given-names></name><name name-style="western"><surname>Crisafio</surname><given-names>ME</given-names></name><etal/></person-group>. 
<article-title>Fitness and exercise effects on brain age: a randomized clinical</article-title>. medRxix website. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.medrxiv.org/content/10.1101/2025.02.25.25322645v1" ext-link-type="uri">https://www.medrxiv.org/content/10.1101/2025.02.25.25322645v1</ext-link>. Published February 26, <year>2025</year>. Accessed August 4, 2025.</mixed-citation></ref><ref id="bib14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baecker</surname><given-names>L</given-names></name><name name-style="western"><surname>Dafflon</surname><given-names>J</given-names></name><name name-style="western"><surname>da Costa</surname><given-names>PF</given-names></name><etal/></person-group>. 
<article-title>Brain age prediction: a comparison between machine learning models using region- and voxel-based morphometric data</article-title>. <source>Hum Brain Mapp.</source><year>2021</year>;<volume>42</volume>:<fpage>2332</fpage>&#8211;<lpage>2346</lpage>.<pub-id pub-id-type="pmid">33738883</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hbm.25368</pub-id><pub-id pub-id-type="pmcid">PMC8090783</pub-id></mixed-citation></ref><ref id="bib15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name><name name-style="western"><surname>Burkett</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Min</surname><given-names>H-K</given-names></name><etal/></person-group>. 
<article-title>Deep learning-based brain age prediction in normal aging and dementia</article-title>. <source>Nat Aging.</source><year>2022</year>;<volume>2</volume>:<fpage>412</fpage>&#8211;<lpage>424</lpage>.<pub-id pub-id-type="pmid">37118071</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43587-022-00219-7</pub-id><pub-id pub-id-type="pmcid">PMC10154042</pub-id></mixed-citation></ref><ref id="bib16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cole</surname><given-names>JH</given-names></name><name name-style="western"><surname>Poudel</surname><given-names>RPK</given-names></name><name name-style="western"><surname>Tsagkrasoulis</surname><given-names>D</given-names></name><etal/></person-group>. 
<article-title>Predicting brain age with deep learning from raw imaging data results in a reliable and heritable biomarker</article-title>. <source>Neuroimage.</source><year>2017</year>;<volume>163</volume>:<fpage>115</fpage>&#8211;<lpage>124</lpage>.<pub-id pub-id-type="pmid">28765056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2017.07.059</pub-id></mixed-citation></ref><ref id="bib17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wood</surname><given-names>DA</given-names></name><name name-style="western"><surname>Kafiabadi</surname><given-names>S</given-names></name><name name-style="western"><surname>Busaidi</surname><given-names>AA</given-names></name><etal/></person-group>. 
<article-title>Accurate brain&#8208;age models for routine clinical MRI examinations</article-title>. <source>Neuroimage.</source><year>2022</year>;<volume>249</volume>:<fpage>118871</fpage>.<pub-id pub-id-type="pmid">34995797</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2022.118871</pub-id></mixed-citation></ref><ref id="bib18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Lange</surname><given-names>AMG</given-names></name><name name-style="western"><surname>Cole</surname><given-names>JH</given-names></name></person-group>. 
<article-title>Commentary: correction procedures in brain-age prediction</article-title>. <source>Neuroimage Clin.</source><year>2020</year>;<volume>26</volume>:<fpage>102229</fpage>.<pub-id pub-id-type="pmid">32120292</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nicl.2020.102229</pub-id><pub-id pub-id-type="pmcid">PMC7049655</pub-id></mixed-citation></ref><ref id="bib19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doering</surname><given-names>E</given-names></name><name name-style="western"><surname>Antonopoulos</surname><given-names>G</given-names></name><name name-style="western"><surname>Hoenig</surname><given-names>M</given-names></name><etal/></person-group>.; <collab>Alzheimer&#8217;s Disease Neuroimaging Initiative and the DELCODE Study Group</collab>. 
<article-title>MRI or <sup>18</sup>F-FDG PET for brain age gap estimation: links to cognition, pathology, and alzheimer disease progression</article-title>. <source>J Nucl Med.</source><year>2024</year>;<volume>65</volume>:<fpage>147</fpage>&#8211;<lpage>155</lpage>.<pub-id pub-id-type="pmid">38050112</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.123.265931</pub-id><pub-id pub-id-type="pmcid">PMC10755522</pub-id></mixed-citation></ref><ref id="bib20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>L&#246;we</surname><given-names>LC</given-names></name><name name-style="western"><surname>Gaser</surname><given-names>C</given-names></name><name name-style="western"><surname>Franke</surname><given-names>K</given-names></name></person-group>, <collab>Alzheimer&#8217;s Disease Neuroimaging Initiative</collab>. 
<article-title>The effect of the APOE genotype on individual BrainAGE in normal aging, mild cognitive impairment, and Alzheimer&#8217;s disease</article-title>. <source>PLoS One.</source><year>2016</year>;<volume>11</volume>:<fpage>e0157514</fpage>.<pub-id pub-id-type="pmid">27410431</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0157514</pub-id><pub-id pub-id-type="pmcid">PMC4943637</pub-id></mixed-citation></ref><ref id="bib21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>X</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W</given-names></name><etal/></person-group>. 
<article-title>Predicting brain age gap with radiomics and automl: a promising approach for age-related brain degeneration biomarkers</article-title>. <source>J Neuroradiol.</source><year>2024</year>;<volume>51</volume>:<fpage>265</fpage>&#8211;<lpage>273</lpage>.<pub-id pub-id-type="pmid">37722591</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurad.2023.09.002</pub-id></mixed-citation></ref><ref id="bib22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franke</surname><given-names>K</given-names></name><name name-style="western"><surname>Gaser</surname><given-names>C</given-names></name></person-group>. 
<article-title>Longitudinal changes in individual BrainAGE in healthy aging, mild cognitive impairment, and Alzheimer&#8217;s disease</article-title>. <source>GeroPsych: J Gerontopsychology Geriatr Psychiatry.</source><year>2012</year>;<volume>25</volume>:<fpage>235</fpage>&#8211;<lpage>245</lpage>.</mixed-citation></ref><ref id="bib23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eickhoff</surname><given-names>CR</given-names></name><name name-style="western"><surname>Hoffstaedter</surname><given-names>F</given-names></name><name name-style="western"><surname>Caspers</surname><given-names>J</given-names></name><etal/></person-group>. 
<article-title>Advanced brain ageing in Parkinson&#8217;s disease is related to disease duration and individual impairment</article-title>. <source>Brain Commun.</source><year>2021</year>;<volume>3</volume>:<fpage>fcab191</fpage>.<pub-id pub-id-type="pmid">34541531</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/braincomms/fcab191</pub-id><pub-id pub-id-type="pmcid">PMC8445399</pub-id></mixed-citation></ref><ref id="bib24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beheshti</surname><given-names>I</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>S</given-names></name><name name-style="western"><surname>Sone</surname><given-names>D</given-names></name><name name-style="western"><surname>Khanna</surname><given-names>P</given-names></name><name name-style="western"><surname>Matsuda</surname><given-names>H</given-names></name></person-group>. 
<article-title>T1-weighted MRI-driven brain age estimation in Alzheimer&#8217;s disease and Parkinson&#8217;s disease</article-title>. <source>Aging Dis.</source><year>2020</year>;<volume>11</volume>:<fpage>618</fpage>&#8211;<lpage>628</lpage>.<pub-id pub-id-type="pmid">32489706</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14336/AD.2019.0617</pub-id><pub-id pub-id-type="pmcid">PMC7220281</pub-id></mixed-citation></ref><ref id="bib25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chariss&#233;</surname><given-names>D</given-names></name><name name-style="western"><surname>Erus</surname><given-names>G</given-names></name><name name-style="western"><surname>Pomponio</surname><given-names>R</given-names></name><etal/></person-group>. 
<article-title>Brain age and Alzheimer&#8217;s-like atrophy are domain- specific predictors of cognitive impairment in Parkinson&#8217;s disease</article-title>. <source>Neurobiol Aging.</source><year>2022</year>;<volume>109</volume>:<fpage>31</fpage>&#8211;<lpage>42</lpage>.<pub-id pub-id-type="pmid">34649002</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2021.08.020</pub-id></mixed-citation></ref><ref id="bib26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cole</surname><given-names>JH</given-names></name><name name-style="western"><surname>Raffel</surname><given-names>J</given-names></name><name name-style="western"><surname>Friede</surname><given-names>T</given-names></name><etal/></person-group>.; <collab>MAGNIMS study group</collab>. 
<article-title>Longitudinal assessment of multiple sclerosis with the brain-age paradigm</article-title>. <source>Ann Neurol.</source><year>2020</year>;<volume>88</volume>:<fpage>93</fpage>&#8211;<lpage>105</lpage>.<pub-id pub-id-type="pmid">32285956</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.25746</pub-id></mixed-citation></ref><ref id="bib27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brier</surname><given-names>MR</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ly</surname><given-names>M</given-names></name><etal/></person-group>. 
<article-title>&#8220;Brain age&#8221; predicts disability accumulation in multiple sclerosis</article-title>. <source>Ann Clin Transl Neurol.</source><year>2023</year>;<volume>10</volume>:<fpage>990</fpage>&#8211;<lpage>1001</lpage>.<pub-id pub-id-type="pmid">37119507</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/acn3.51782</pub-id><pub-id pub-id-type="pmcid">PMC10270248</pub-id></mixed-citation></ref><ref id="bib28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hermann</surname><given-names>A</given-names></name><name name-style="western"><surname>Tarakdjian</surname><given-names>GN</given-names></name><name name-style="western"><surname>Temp</surname><given-names>AGM</given-names></name><etal/></person-group>. 
<article-title>Cognitive and behavioural but not motor impairment increases brain age in amyotrophic lateral sclerosis</article-title>. <source>Brain Commun.</source><year>2022</year>;<volume>4</volume>:<fpage>fcac239</fpage>.<pub-id pub-id-type="pmid">36246047</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/braincomms/fcac239</pub-id><pub-id pub-id-type="pmcid">PMC9556938</pub-id></mixed-citation></ref><ref id="bib29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aarsland</surname><given-names>D</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>K</given-names></name><name name-style="western"><surname>Larsen</surname><given-names>JP</given-names></name><name name-style="western"><surname>Lolk</surname><given-names>A</given-names></name><name name-style="western"><surname>Kragh-S&#248;rensen</surname><given-names>P</given-names></name></person-group>. 
<article-title>Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study</article-title>. <source>Arch Neurol.</source><year>2003</year>;<volume>60</volume>:<fpage>387</fpage>&#8211;<lpage>392</lpage>.<pub-id pub-id-type="pmid">12633150</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archneur.60.3.387</pub-id></mixed-citation></ref><ref id="bib30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Majoor-Krakauer</surname><given-names>D</given-names></name><name name-style="western"><surname>Ottman</surname><given-names>R</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>WG</given-names></name><name name-style="western"><surname>Rowland</surname><given-names>LP</given-names></name></person-group>. 
<article-title>Familial aggregation of amyotrophic lateral sclerosis, dementia, and Parkinson&#8217;s disease: evidence of shared genetic susceptibility</article-title>. <source>Neurology.</source><year>1994</year>;<volume>44</volume>:<fpage>1872</fpage>&#8211;<lpage>1877</lpage>.<pub-id pub-id-type="pmid">7936240</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.44.10.1872</pub-id></mixed-citation></ref><ref id="bib31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teipel</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>H</given-names></name><name name-style="western"><surname>Storch</surname><given-names>A</given-names></name><name name-style="western"><surname>Hermann</surname><given-names>A</given-names></name><name name-style="western"><surname>Dyrba</surname><given-names>M</given-names></name><name name-style="western"><surname>Schumacher</surname><given-names>J</given-names></name></person-group>. 
<article-title>Brain age in genetic and idiopathic Parkinson&#8217;s disease</article-title>. <source>Brain Commun.</source><year>2024</year>;<volume>6</volume>:<fpage>fcae382</fpage>.<pub-id pub-id-type="pmid">39713239</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/braincomms/fcae382</pub-id><pub-id pub-id-type="pmcid">PMC11660940</pub-id></mixed-citation></ref><ref id="bib32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berti</surname><given-names>V</given-names></name><name name-style="western"><surname>Mosconi</surname><given-names>L</given-names></name><name name-style="western"><surname>Pupi</surname><given-names>A</given-names></name></person-group>. 
<article-title>Brain: normal variations and benign findings in fluorodeoxyglucose-PET/computed tomography imaging</article-title>. <source>PET Clin.</source><year>2014</year>;<volume>9</volume>:<fpage>129</fpage>&#8211;<lpage>140</lpage>.<pub-id pub-id-type="pmid">24772054</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cpet.2013.10.006</pub-id><pub-id pub-id-type="pmcid">PMC3998066</pub-id></mixed-citation></ref><ref id="bib33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>J</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y</given-names></name></person-group>. 
<article-title>Exploring the pattern associated with longitudinal changes of &#946;-amyloid deposition during cognitively normal healthy aging</article-title>. <source>Front Med.</source><year>2021</year>;<volume>7</volume><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmed.2020.617173</pub-id><pub-id pub-id-type="pmcid">PMC7874155</pub-id><pub-id pub-id-type="pmid">33585514</pub-id></mixed-citation></ref><ref id="bib34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nobili</surname><given-names>F</given-names></name><name name-style="western"><surname>Naseri</surname><given-names>M</given-names></name><name name-style="western"><surname>De Carli</surname><given-names>F</given-names></name><etal/></person-group>. 
<article-title>Automatic semi-quantification of [<sup>123</sup>I]FP-CIT SPECT scans in healthy volunteers using BasGan version 2: results from the ENC-DAT database</article-title>. <source>Eur J Nucl Med Mol Imaging.</source><year>2013</year>;<volume>40</volume>:<fpage>565</fpage>&#8211;<lpage>573</lpage>.<pub-id pub-id-type="pmid">23232506</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-012-2304-8</pub-id></mixed-citation></ref><ref id="bib35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsuda</surname><given-names>H</given-names></name><name name-style="western"><surname>Murata</surname><given-names>M</given-names></name><name name-style="western"><surname>Mukai</surname><given-names>Y</given-names></name><etal/></person-group>. 
<article-title>Japanese multicenter database of healthy controls for [<sup>123</sup>I]FP-CIT SPECT</article-title>. <source>Eur J Nucl Med Mol Imaging.</source><year>2018</year>;<volume>45</volume>:<fpage>1405</fpage>&#8211;<lpage>1416</lpage>.<pub-id pub-id-type="pmid">29478082</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-018-3976-5</pub-id><pub-id pub-id-type="pmcid">PMC5993845</pub-id></mixed-citation></ref><ref id="bib36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Minoshima</surname><given-names>S</given-names></name><name name-style="western"><surname>Cross</surname><given-names>D</given-names></name><name name-style="western"><surname>Thientunyakit</surname><given-names>T</given-names></name><name name-style="western"><surname>Foster</surname><given-names>NL</given-names></name><name name-style="western"><surname>Drzezga</surname><given-names>A</given-names></name></person-group>. 
<article-title>
<sup>18</sup>F-FDG PET imaging in neurodegenerative dementing disorders: insights into subtype classification, emerging disease categories, and mixed dementia with copathologies</article-title>. <source>J Nucl Med.</source><year>2022</year>;<volume>63</volume>(<issue>suppl 1</issue>):<fpage>2S</fpage>&#8211;<lpage>12S</lpage>.<pub-id pub-id-type="pmid">35649653</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.121.263194</pub-id></mixed-citation></ref><ref id="bib37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Wei</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><etal/></person-group>.; <collab>Alzheimer&#8217;s Disease Neuroimaging Initiative</collab>. 
<article-title>Tau protein accumulation trajectory-based brain age prediction in the Alzheimer&#8217;s disease continuum</article-title>. <source>Brain Sci.</source><year>2024</year>;<volume>14</volume>:<fpage>575</fpage>.<pub-id pub-id-type="pmid">38928575</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/brainsci14060575</pub-id><pub-id pub-id-type="pmcid">PMC11201453</pub-id></mixed-citation></ref><ref id="bib38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moguilner</surname><given-names>S</given-names></name><name name-style="western"><surname>Baez</surname><given-names>S</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>H</given-names></name><etal/></person-group>. 
<article-title>Brain clocks capture diversity and disparities in aging and dementia across geographically diverse populations</article-title>. <source>Nat Med.</source><year>2024</year>;<volume>30</volume>:<fpage>3646</fpage>&#8211;<lpage>3657</lpage>.<pub-id pub-id-type="pmid">39187698</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-024-03209-x</pub-id><pub-id pub-id-type="pmcid">PMC11645278</pub-id></mixed-citation></ref><ref id="bib39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Peng</surname><given-names>D</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name></person-group>. 
<article-title>Brain age prediction using the graph neural network based on resting-state functional MRI in Alzheimer&#8217;s disease</article-title>. <source>Front Neurosci.</source><year>2023</year>;<volume>17</volume>:<fpage>1222751</fpage>.<pub-id pub-id-type="pmid">37457008</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2023.1222751</pub-id><pub-id pub-id-type="pmcid">PMC10347411</pub-id></mixed-citation></ref><ref id="bib40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>E</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H</given-names></name><name name-style="western"><surname>Leone</surname><given-names>MJ</given-names></name><etal/></person-group>. 
<article-title>Association of sleep electroencephalography-based brain age index with dementia</article-title>. <source>JAMA Netw Open.</source><year>2020</year>;<volume>3</volume>:<fpage>e2017357</fpage>.<pub-id pub-id-type="pmid">32986106</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2020.17357</pub-id><pub-id pub-id-type="pmcid">PMC7522697</pub-id></mixed-citation></ref><ref id="bib41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anghel</surname><given-names>L</given-names></name><name name-style="western"><surname>Ciubar&#259;</surname><given-names>A</given-names></name><name name-style="western"><surname>Nechita</surname><given-names>A</given-names></name><etal/></person-group>. 
<article-title>Sleep disorders associated with neurodegenerative diseases</article-title>. <source>Diagnostics.</source><year>2023</year>;<volume>13</volume>:<fpage>2898</fpage>.<pub-id pub-id-type="pmid">37761265</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/diagnostics13182898</pub-id><pub-id pub-id-type="pmcid">PMC10527657</pub-id></mixed-citation></ref><ref id="bib42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Westwood</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Beiser</surname><given-names>A</given-names></name><name name-style="western"><surname>Jain</surname><given-names>N</given-names></name><etal/></person-group>. 
<article-title>Prolonged sleep duration as a marker of early neurodegeneration predicting incident dementia</article-title>. <source>Neurology.</source><year>2017</year>;<volume>88</volume>:<fpage>1172</fpage>&#8211;<lpage>1179</lpage>.<pub-id pub-id-type="pmid">28228567</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000003732</pub-id><pub-id pub-id-type="pmcid">PMC5373785</pub-id></mixed-citation></ref><ref id="bib43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Postuma</surname><given-names>RB</given-names></name></person-group>. 
<article-title>Prodromal Parkinson&#8217;s disease: using REM sleep behavior disorder as a window</article-title>. <source>Park Relat Disord.</source><year>2014</year>;<volume>20</volume>(<issue>suppl 1</issue>):<fpage>S1</fpage>&#8211;<lpage>S4</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1353-8020(13)00400-8</pub-id><pub-id pub-id-type="pmid">24262156</pub-id></mixed-citation></ref><ref id="bib44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Millar</surname><given-names>PR</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>BA</given-names></name><name name-style="western"><surname>Luckett</surname><given-names>PH</given-names></name><etal/></person-group>.; <collab>Dominantly Inherited Alzheimer Network</collab>. 
<article-title>Multimodal brain age estimates relate to Alzheimer disease biomarkers and cognition in early stages: a cross-sectional observational study</article-title>. <source>Elife.</source><year>2023</year>;<volume>12</volume>:<fpage>e81869</fpage>.<pub-id pub-id-type="pmid">36607335</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7554/eLife.81869</pub-id><pub-id pub-id-type="pmcid">PMC9988262</pub-id></mixed-citation></ref><ref id="bib45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonneaud</surname><given-names>J</given-names></name><name name-style="western"><surname>Baria</surname><given-names>AT</given-names></name><name name-style="western"><surname>Pichet Binette</surname><given-names>A</given-names></name><etal/></person-group>.; <collab>Pre-symptomatic Evaluation of Experimental or Novel Treatments for Alzheimer&#8217;s Disease (PREVENT-AD) Research Group</collab>. 
<article-title>Accelerated functional brain aging in pre-clinical familial Alzheimer&#8217;s disease</article-title>. <source>Nat Commun.</source><year>2021</year>;<volume>12</volume>:<fpage>5346</fpage>.<pub-id pub-id-type="pmid">34504080</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-25492-9</pub-id><pub-id pub-id-type="pmcid">PMC8429427</pub-id></mixed-citation></ref><ref id="bib46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hwang</surname><given-names>G</given-names></name><name name-style="western"><surname>Hermann</surname><given-names>B</given-names></name><name name-style="western"><surname>Nair</surname><given-names>VA</given-names></name><etal/></person-group>. 
<article-title>Brain aging in temporal lobe epilepsy: chronological, structural, and functional</article-title>. <source>Neuroimage Clin.</source><year>2020</year>;<volume>25</volume>:<fpage>102183</fpage>.<pub-id pub-id-type="pmid">32058319</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nicl.2020.102183</pub-id><pub-id pub-id-type="pmcid">PMC7016276</pub-id></mixed-citation></ref><ref id="bib47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>C</given-names></name><name name-style="western"><surname>Kim</surname><given-names>ME</given-names></name><name name-style="western"><surname>Ramadass</surname><given-names>K</given-names></name><etal/></person-group>. 
<article-title>Brain age identification from diffusion MRI synergistically predicts neurodegenerative disease</article-title>. <source>Imaging Neurosci.</source><year>2025</year>;<volume>3</volume><pub-id pub-id-type="doi" assigning-authority="pmc">10.1162/imag_a_00552</pub-id><pub-id pub-id-type="pmcid">PMC12320004</pub-id><pub-id pub-id-type="pmid">40800739</pub-id></mixed-citation></ref><ref id="bib48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tseng</surname><given-names>WYI</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>YC</given-names></name><name name-style="western"><surname>Kao</surname><given-names>TW</given-names></name></person-group>. 
<article-title>Brain age difference at baseline predicts clinical dementia rating change in approximately two years</article-title>. <source>J Alzheimers Dis.</source><year>2022</year>;<volume>86</volume>:<fpage>613</fpage>&#8211;<lpage>627</lpage>.<pub-id pub-id-type="pmid">35094993</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-215380</pub-id></mixed-citation></ref><ref id="bib49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gyebn&#225;r</surname><given-names>G</given-names></name><name name-style="western"><surname>Szab&#243;</surname><given-names>&#193;</given-names></name><name name-style="western"><surname>Sir&#225;ly</surname><given-names>E</given-names></name><etal/></person-group>. 
<article-title>What can DTI tell about early cognitive impairment? Differentiation between MCI subtypes and healthy controls by diffusion tensor imaging</article-title>. <source>Psychiatry Res Neuroimaging.</source><year>2018</year>;<volume>272</volume>:<fpage>46</fpage>&#8211;<lpage>57</lpage>.<pub-id pub-id-type="pmid">29126669</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pscychresns.2017.10.007</pub-id></mixed-citation></ref><ref id="bib50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moody</surname><given-names>JF</given-names></name><name name-style="western"><surname>Dean</surname><given-names>DC</given-names></name><name name-style="western"><surname>Kecskemeti</surname><given-names>SR</given-names></name><etal/></person-group>. 
<article-title>Associations between diffusion MRI microstructure and cerebrospinal fluid markers of Alzheimer&#8217;s disease pathology and neurodegeneration along the Alzheimer&#8217;s disease continuum</article-title>. <source>Alzheimer Dement (Amst).</source><year>2022</year>;<volume>14</volume>:<fpage>e12381</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dad2.12381</pub-id><pub-id pub-id-type="pmcid">PMC9720004</pub-id><pub-id pub-id-type="pmid">36479018</pub-id></mixed-citation></ref><ref id="bib51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tseng</surname><given-names>WYI</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>YC</given-names></name><name name-style="western"><surname>Huang</surname><given-names>LK</given-names></name><etal/></person-group>. 
<article-title>Brain age is associated with cognitive outcomes of cholinesterase inhibitor treatment in patients with mild cognitive impairment</article-title>. <source>J Alzheimers Dis.</source><year>2024</year>;<volume>98</volume>:<fpage>1095</fpage>&#8211;<lpage>1106</lpage>.<pub-id pub-id-type="pmid">38517785</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-231109</pub-id></mixed-citation></ref><ref id="bib52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Chan</surname><given-names>SSM</given-names></name><etal/></person-group>. 
<article-title>Predictive values of pre-treatment brain age models to rTMS effects in neurocognitive disorder with depression: secondary analysis of randomised sham-controlled clinical trial</article-title>. <source>Dialogues Clin Neurosci</source>. <year>2024</year>;<volume>26</volume>:<fpage>38</fpage>&#8211;<lpage>52</lpage>.<pub-id pub-id-type="pmid">38963341</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/19585969.2024.2373075</pub-id><pub-id pub-id-type="pmcid">PMC11225634</pub-id></mixed-citation></ref><ref id="bib53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoenig</surname><given-names>MC</given-names></name><name name-style="western"><surname>Bischof</surname><given-names>GN</given-names></name><name name-style="western"><surname>Hammes</surname><given-names>J</given-names></name><etal/></person-group>. 
<article-title>Tau pathology and cognitive reserve in Alzheimer&#8217;s disease</article-title>. <source>Neurobiol Aging.</source><year>2017</year>;<volume>57</volume>:<fpage>1</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">28577411</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2017.05.004</pub-id></mixed-citation></ref><ref id="bib54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>H&#246;nig</surname><given-names>M</given-names></name><name name-style="western"><surname>Altomare</surname><given-names>D</given-names></name><name name-style="western"><surname>Caprioglio</surname><given-names>C</given-names></name><etal/></person-group>.; <collab>AMYPAD Consortium</collab>. 
<article-title>Association between years of education and amyloid burden in patients with subjective cognitive decline, MCI, and Alzheimer disease</article-title>. <source>Neurology.</source><year>2024</year>;<volume>102</volume>:<fpage>e208053</fpage>.<pub-id pub-id-type="pmid">38377442</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000208053</pub-id><pub-id pub-id-type="pmcid">PMC11033981</pub-id></mixed-citation></ref><ref id="bib55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chu</surname><given-names>C</given-names></name><name name-style="western"><surname>Holst</surname><given-names>SC</given-names></name><name name-style="western"><surname>Elmenhorst</surname><given-names>EM</given-names></name><etal/></person-group>. 
<article-title>Total sleep deprivation increases brain age prediction reversibly in multisite samples of young healthy adults</article-title>. <source>J Neurosci.</source><year>2023</year>;<volume>43</volume>:<fpage>2168</fpage>&#8211;<lpage>2177</lpage>.<pub-id pub-id-type="pmid">36804738</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.0790-22.2023</pub-id><pub-id pub-id-type="pmcid">PMC10039745</pub-id></mixed-citation></ref><ref id="bib56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le</surname><given-names>TT</given-names></name><name name-style="western"><surname>Kuplicki</surname><given-names>R</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>HW</given-names></name><etal/></person-group>. 
<article-title>Effect of ibuprofen on BrainAGE: a randomized, placebo- controlled, dose-response exploratory study</article-title>. <source>Biol Psychiatry Cogn Neurosci Neuroimaging.</source><year>2018</year>;<volume>3</volume>:<fpage>836</fpage>&#8211;<lpage>843</lpage>.<pub-id pub-id-type="pmid">29941380</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bpsc.2018.05.002</pub-id><pub-id pub-id-type="pmcid">PMC6510235</pub-id></mixed-citation></ref><ref id="bib57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Persson</surname><given-names>K</given-names></name><name name-style="western"><surname>Leonardsen</surname><given-names>EH</given-names></name><name name-style="western"><surname>Edwin</surname><given-names>TH</given-names></name><etal/></person-group>. 
<article-title>Diagnostic accuracy of brain age prediction in a memory clinic population and comparison with clinically available volumetric measures</article-title>. <source>Sci Rep.</source><year>2023</year>;<volume>13</volume>:<fpage>14957</fpage>.<pub-id pub-id-type="pmid">37696909</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-023-42354-0</pub-id><pub-id pub-id-type="pmcid">PMC10495330</pub-id></mixed-citation></ref><ref id="bib58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jirsaraie</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Kaufmann</surname><given-names>T</given-names></name><name name-style="western"><surname>Bashyam</surname><given-names>V</given-names></name><etal/></person-group>. 
<article-title>Benchmarking the generalizability of brain age models: challenges posed by scanner variance and prediction bias</article-title>. <source>Hum Brain Mapp.</source><year>2023</year>;<volume>44</volume>:<fpage>1118</fpage>&#8211;<lpage>1128</lpage>.<pub-id pub-id-type="pmid">36346213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hbm.26144</pub-id><pub-id pub-id-type="pmcid">PMC9875922</pub-id></mixed-citation></ref><ref id="bib59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moqadam</surname><given-names>R</given-names></name><name name-style="western"><surname>Dadar</surname><given-names>M</given-names></name><name name-style="western"><surname>Zeighami</surname><given-names>Y</given-names></name></person-group>. 
<article-title>Investigating the impact of motion in the scanner on brain age predictions</article-title>. <source>Imaging Neurosci.</source><year>2024</year>;<volume>2</volume>:<fpage>1</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1162/imag_a_00079</pub-id><pub-id pub-id-type="pmcid">PMC12235560</pub-id><pub-id pub-id-type="pmid">40800263</pub-id></mixed-citation></ref><ref id="bib60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cole</surname><given-names>JH</given-names></name><name name-style="western"><surname>Leech</surname><given-names>R</given-names></name><name name-style="western"><surname>Sharp</surname><given-names>DJ</given-names></name></person-group>, <collab>Alzheimer&#8217;s Disease Neuroimaging Initiative</collab>. 
<article-title>Prediction of brain age suggests accelerated atrophy after traumatic brain injury</article-title>. <source>Ann Neurol.</source><year>2015</year>;<volume>77</volume>:<fpage>571</fpage>&#8211;<lpage>581</lpage>.<pub-id pub-id-type="pmid">25623048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.24367</pub-id><pub-id pub-id-type="pmcid">PMC4403966</pub-id></mixed-citation></ref><ref id="bib61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franke</surname><given-names>K</given-names></name><name name-style="western"><surname>Gaser</surname><given-names>C</given-names></name><name name-style="western"><surname>Manor</surname><given-names>B</given-names></name><name name-style="western"><surname>Novak</surname><given-names>V</given-names></name></person-group>. 
<article-title>Advanced BrainAGE in older adults with type 2 diabetes mellitus</article-title>. <source>Front Aging Neurosci.</source><year>2013</year>;<volume>5</volume>:<fpage>90</fpage>.<pub-id pub-id-type="pmid">24381557</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2013.00090</pub-id><pub-id pub-id-type="pmcid">PMC3865444</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Theranostics</journal-id><journal-id journal-id-type="iso-abbrev">Theranostics</journal-id><journal-id journal-id-type="pmc-domain-id">1512</journal-id><journal-id journal-id-type="pmc-domain">theranostics</journal-id><journal-id journal-id-type="publisher-id">thno</journal-id><journal-title-group><journal-title>Theranostics</journal-title></journal-title-group><issn pub-type="epub">1838-7640</issn><publisher><publisher-name>Ivyspring International Publisher</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12486142</article-id><article-id pub-id-type="pmcid-ver">PMC12486142.1</article-id><article-id pub-id-type="pmcaid">12486142</article-id><article-id pub-id-type="pmcaiid">12486142</article-id><article-id pub-id-type="pmid">41041062</article-id><article-id pub-id-type="doi">10.7150/thno.110292</article-id><article-id pub-id-type="publisher-id">thnov15p10064</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>Deep brain stimulation-induced normalization of hippocampal synchrony in a transgenic rat model of Alzheimer's disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Trevisiol</surname><given-names initials="A">Andrea</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="FNA_envelop" ref-type="corresp">&#9993;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Beckett</surname><given-names initials="T">Tina</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vila</surname><given-names initials="MB">Monica Bell</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hill</surname><given-names initials="M">Mary</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>McLaurin</surname><given-names initials="J">Joanne</given-names></name><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Stefanovic</surname><given-names initials="B">Bojana</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A4" ref-type="aff">4</xref><xref rid="FNA_envelop" ref-type="corresp">&#9993;</xref></contrib></contrib-group><aff id="A1"><label>1</label>Physical Sciences, Sunnybrook Research Institute, Toronto, ON, Canada.</aff><aff id="A2"><label>2</label>Biological Sciences, Sunnybrook Research Institute, Toronto, ON, Canada.</aff><aff id="A3"><label>3</label>Department of Laboratory Medicine and Pathobiology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.</aff><aff id="A4"><label>4</label>Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.</aff><author-notes><corresp id="FNA_envelop">&#9993; Corresponding authors: Dr. Andrea Trevisiol, <email>andrea.trevisiol@utoronto.ca</email>; and Dr. Bojana Stefanovic, <email>bojana.stefanovic@utoronto.ca</email>.</corresp><fn fn-type="COI-statement"><p>Competing Interests: The authors have declared that no competing interest exists.</p></fn></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>22</day><month>9</month><year>2025</year></pub-date><volume>15</volume><issue>18</issue><issue-id pub-id-type="pmc-issue-id">498071</issue-id><fpage>10064</fpage><lpage>10075</lpage><history><date date-type="received"><day>11</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>5</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>22</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>02</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-03 09:25:16.947"><day>03</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The author(s)</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>). See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://ivyspring.com/terms">https://ivyspring.com/terms</ext-link> for full terms and conditions.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="thnov15p10064.pdf"/><abstract><p><bold>Background and Aim:</bold> Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by disrupted neural network dynamics and neuronal loss. Deep brain stimulation (DBS) may restore network function and abate cognitive deficits. In a transgenic rat model of AD, we investigated the dependence of hippocampal neuronal activity on a range of DBS parameters, aiming to identify stimulation conditions that transiently restore impaired network function.</p><p><bold>Material and Methods:</bold> We used 16-month-old TgF344-AD and NTg rats under light anesthesia and performed simultaneous DBS and high-resolution intracerebral recordings in the hippocampus using a linear multielectrode array. DBS was delivered in bipolar mode, at varying frequencies, amplitudes and duration, while monitoring local field potentials (LFP) and spiking activity. Phase-amplitude coupling (PAC), neuronal power, and firing rates were analyzed prior to and following DBS. Linear mixed effects models were used to evaluate the influence of genotype, sex, and stimulation parameters on the electrophysiological markers.</p><p><bold>Results:</bold> With increasing DBS frequency and amplitude, hippocampal power and PAC rose in all rats, particularly within the delta-theta range. When compared to NTgs, TgAD rats showed attenuated power but increased PAC responses to DBS. Low frequency DBS induced higher entrainment in the post- relative to during-DBS period in all animals. Compared to their non-transgenic littermates, TgAD rats showed reduced entrainment responses.</p><p><bold>Conclusions:</bold> These findings demonstrate that hippocampal responses to DBS have a parameter-dependent profile that is differentially modulated by AD pathology. Our study provides a foundation for tailoring DBS parameters to compensate for distinct neuronal deficits in established AD, supporting the use of electrophysiological biomarkers to guide individualized neuromodulation strategies</p></abstract><kwd-group><kwd>Alzheimer's disease</kwd><kwd>TgF344-AD rats</kwd><kwd>neuromodulation</kwd><kwd>deep brain stimulation</kwd><kwd>electrophysiological recordings</kwd><kwd>local field potentials</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by the accumulation of amyloid-beta (A&#946;) plaques and hyperphosphorylated tau tangles <xref rid="B1" ref-type="bibr">1</xref>. AD patients show progressive memory and cognitive impairments linked to alterations in neural network dynamics, synchronization, and connectivity (for an in-depth review see <xref rid="B2" ref-type="bibr">2</xref>). Notably, network changes have received considerably less research attention than pathological and genomic AD biomarkers <xref rid="B3" ref-type="bibr">3</xref>. One prominent AD network alteration is reduced cross-frequency coupling between prefrontal gamma amplitude and hippocampal theta phase <xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B5" ref-type="bibr">5</xref>. In addition to theta-gamma coupling deficits, hippocampal network dysfunction in AD includes impaired sharp-wave ripples and disrupted hippocampal-entorhinal coordination, preceding cognitive decline <xref rid="B6" ref-type="bibr">6</xref>. Altered inhibitory circuitry, particularly GABAergic synapse loss, disrupts the excitation-inhibition balance, leading to hyperexcitability and network asynchrony <xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B8" ref-type="bibr">8</xref>. These disturbances extend across frequency bands, reducing power, coherence, and prefrontal-hippocampal connectivity <xref rid="B9" ref-type="bibr">9</xref>. Moreover, tau pathology, independent of amyloid, impairs CA1 complex-spike bursting and associated rhythms essential for memory, underscoring the need for interventions that restore circuit synchrony <xref rid="B10" ref-type="bibr">10</xref>. Many of these network abnormalities likely stem from impaired neurotransmission and post-synaptic dysfunction due to reduced presenilin function, which disrupts synaptic calcium homeostasis <xref rid="B11" ref-type="bibr">11</xref>, and leads to A&#946; accumulation <xref rid="B12" ref-type="bibr">12</xref>. The marked electrophysiological alterations in the pre-symptomatic phase of AD have prompted efforts to systematically characterize their temporal dynamics, both as potential early biomarkers and as quantitative indicators of disease progression <xref rid="B2" ref-type="bibr">2</xref>. Current therapeutic treatments - both symptomatic and disease-modifying - have been largely ineffective in improving AD patients' cognition and overall quality of life <xref rid="B13" ref-type="bibr">13</xref>. In an effort to improve cognitive symptoms, few pioneering studies have tested the effectiveness of electrical stimulation through deep brain stimulation (DBS) for managing AD <xref rid="B14" ref-type="bibr">14</xref>. Since its introduction as a neurotherapeutic in Parkinson's disease (PD) patients who did not adequately respond to levodopa <xref rid="B15" ref-type="bibr">15</xref>, DBS has shown promising results for attenuation of clinical symptoms of severe depression, epilepsy, and AD <xref rid="B16" ref-type="bibr">16</xref>,<xref rid="B17" ref-type="bibr">17</xref>. While the role of DBS in inhibiting the hyperactive subthalamic nucleus in PD is well-established, the targets and criteria for DBS in AD and other neurodegenerative diseases remain ill-defined.</p><p>Hitherto studies investigating DBS for memory enhancement <xref rid="B18" ref-type="bibr">18</xref> and stabilization of AD cognitive decline have reported diverse outcomes <xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B20" ref-type="bibr">20</xref>, and the cellular changes underpinning these outcomes remain poorly understood <xref rid="B19" ref-type="bibr">19</xref>. The efficacy of DBS in modulating and potentially restoring brain function seems to be contingent on brain disease stage and anatomical targeting of relevant brain areas, as well as the DBS amplitude, frequency, stimulation duration, and duty cycle <xref rid="B21" ref-type="bibr">21</xref>. The preponderant DBS targets have been areas directly connected to the hippocampus (HIP): the fornix, an efferent white matter tract emerging from the HIP <xref rid="B22" ref-type="bibr">22</xref> and the nucleus basalis of Meynert that projects to the neocortex, amygdala, and thalamus and is involved in memory formation <xref rid="B23" ref-type="bibr">23</xref>. Inhibition of these targets using high-frequency stimulation has led to mixed outcomes, as indicated by a recent meta-analysis <xref rid="B20" ref-type="bibr">20</xref> and remains confounded by our limited understanding of their functional connections with the HIP. Neuromodulating regions central to AD pathology &#8212;such as the HIP, entorhinal cortex <xref rid="B24" ref-type="bibr">24</xref>, or prefrontal cortex&#8212; are thus anticipated to elicit greater clinical benefits, but challenging to achieve via non-invasive neuromodulation (gamma-frequency sensory stimulation and temporal interference <xref rid="B25" ref-type="bibr">25</xref>,<xref rid="B26" ref-type="bibr">26</xref>) due to the limited spatial and temporal precision of non-invasive approaches. To advance neuromodulatory strategies, more reliable biomarkers are needed to guide intervention efficacy at every stage of the disease. In addition to molecular biomarkers <xref rid="B14" ref-type="bibr">14</xref>, a promising yet understudied biomarker is neuronal network activity, which can be monitored in real time, using the same electrode through which DBS can be delivered, so as to enable high-precision, closed-loop stimulation. We presently examined the effects of hippocampal DBS by high-sensitivity monitoring of neuronal network activity via intracerebral electrophysiological recordings. We acutely and directly targeted the hippocampal circuit in 16-month-old TgF344-AD rats, which display advanced amyloid and tau pathologies in combination with frank neuronal loss and pronounced impairments in memory, executive function, and long-term extinction memory <xref rid="B27" ref-type="bibr">27</xref>,<xref rid="B28" ref-type="bibr">28</xref> recapitulating the advanced stage of AD, when invasive interventions are most likely to be applied clinically. Through the same linear multi-array electrode, we monitored the effects on network activity and neuronal spiking. By modeling hippocampal network responses to DBS across a range of stimulation parameters, we established a predictive framework to inform DBS parameter selection and support its therapeutic application to counteract AD-induced hippocampal dysfunction.</p></sec><sec sec-type="methods"><title>Materials and Methods</title><p>We used TgF344-AD rats as an Alzheimer's disease model <xref rid="B29" ref-type="bibr">29</xref>, following approved ethical guidelines set by the Animal Care Committee of the Sunnybrook Research Institute. Sex-balanced, age-matched TgAD and NTg rats were kept under a 12-hour light-dark cycle, with physiological monitoring during anesthesia.</p><p>Isoflurane anesthesia (2-2.5%) enabled the placement of a 3 mm craniotomy at AP -3.5 mm, ML -2.5 mm. After electrode positioning, rats were transitioned to intravenous propofol anesthesia (40-50 mg/kg/hr) via tail vein catheter for stable electrophysiological recordings. A double-shank 2x6 linear multielectrode array (LMA) was inserted into the left hippocampus (HIP), at a depth of -6.0 mm from the surface, ensuring full dorsoventral HIP coverage. Signals were recorded under low isoflurane (1.2-1.5%) and propofol at 24.4 kHz and divided into low-frequency (LFP: 0.3-300 Hz) and high-frequency (AP band: 0.75-3 kHz) components for analysis. Modulation index (MI), representing phase-amplitude coupling (PAC) and power, was derived from the LFP. Firing rate (FR) and phase-locking consistency (PPC) were computed from AP band activity (spiking events), and the number of responding units (NRU) was determined based on FR and PPC changes relative to a shuffled null distribution. DBS was delivered in bipolar mode via the most dorsal and ventral contacts of the LMA using 0.05 ms square pulses at amplitudes of 2, 5, 10, and 20 &#181;A (corresponding to 20, 50, 100, and 200 &#956;C/cm&#178; per pulse) and frequencies of 1 Hz,10, 20, 40, 100, and 130 Hz. Each DBS block lasted 10 seconds, followed by a 20-second recovery. Linear mixed-effects (LME) models were employed to examine the effects of genotype, sex, DBS amplitude/frequency, and regional variability on electrophysiological parameters, with model selection guided by Akaike Information Criterion. Pairwise comparisons were conducted following ANOVA with Tukey-Kramer correction.</p><p>Further details on the experimental procedures and analyses are provided in the <xref rid="SM0" ref-type="sec">supplementary materials</xref>.</p><sec sec-type="data-availability"><title>Data availability</title><p>Raw and processed data acquired in these experiments, along with the analysis scripts and models, are available upon request.</p></sec></sec><sec sec-type="results"><title>Results</title><p>To evaluate the acute effects of DBS on hippocampal (HIP) networks in advanced AD, we used a double-shank linear electrode array targeting the HIP of 16-month-old TgF344-AD rats (Figure <xref rid="F1" ref-type="fig">1</xref>A). The HIP of these animals showed a significant burden of A&#946; and phosphorylated tau (Figure <xref rid="F1" ref-type="fig">1</xref>B-D). A fast-switching headstage enabled alternating between DBS stimulation and recordings of low-frequency (LFP) and high-frequency (AP band) extracellular activity (Figures <xref rid="F1" ref-type="fig">1</xref>B, 1C).</p><sec><title>Effects of DBS on LFP power</title><p>At baseline, TgAD rats displayed significant HIP network dysfunction, manifested as reduced power across all frequency bands (Figure <xref rid="F2" ref-type="fig">2</xref>C-D): these effects included genotype-sex interaction (<xref rid="SM0" ref-type="sec">Figure S1</xref>). For instance, dorsal HIP theta power was reduced in TgAD animals (-5.0 dB; 95% CI: -5.6 to -4.6) relative to NTgs. To test whether DBS could ameliorate these impairments, we systematically varied stimulation parameters &#8212; frequency (1-130 Hz), amplitude (1-20 &#181;A), and duration (10 vs. 900 s) &#8212; and quantified the relative change in LFP power from baseline (DBS-baseline, &#916;Power; Figures <xref rid="F3" ref-type="fig">3</xref>-<xref rid="F4" ref-type="fig">4</xref>). To describe the power responses to DBS in TgAD and NTg hippocampi, we modeled the change in power (&#916;Power) as a function of stimulation frequency (1-130 Hz), amplitude (1-20 &#956;A) and as a function of time following DBS offset (post-DBS window, 0-10 sec) using linear models. Both DBS amplitude and frequency increased LFP power independently (p=0.013 and p=0.007 respectively), with a significant interaction effect between the two (p &lt;0.001). Notably, power enhancement with increasing DBS intensity was higher in the lower-frequency oscillations (delta-theta, Figure <xref rid="F3" ref-type="fig">3</xref>D-E). Stimulation duration also modulated the persistence of power changes (p = 0.01; Figure <xref rid="F3" ref-type="fig">3</xref>F). DBS amplitude, but not frequency, had significant genotype-specific effects on hippocampal LFP power (p &lt; 0.001), indicating that genotype (i.e. AD pathology) is more sensitive, in terms of power changes to DBS, to amplitude selection. While DBS produced increases in neuronal power, the magnitude of this increase was higher in NTg than in Tg animals, across all oscillation bands (Figure <xref rid="F3" ref-type="fig">3</xref>D-F and <xref rid="SM0" ref-type="sec">Figure S2</xref>B-D), irrespective of other DBS parameters. For example, 40Hz/9&#956;A DBS induced +3.2 dB (95% CI: 2.7-3.8 dB) increase in NTg vs +2.0 dB (95% CI: 1.7 to 2.4 dB) in TgAD in the theta band of the dorsal HIP, i.e. DBS responses in power in the HIP of TgAD rats were attenuated when compared to those in the HIP of NTgs.</p><p>Given these differences, we used our fitted model to identify DBS parameter combinations that could compensate for HIP neuronal deficits in TgAD animals. For instance, based on the observed -5.0 dB resting power deficit in theta band of the dorsal HIP, the model predicted that a 10-second DBS pulse at 19.0 &#181;A and 34.9 Hz would transiently restore LFP power to levels comparable to NTgs. Similarly, post-stimulation analysis (Figure <xref rid="F3" ref-type="fig">3</xref>F) showed that in the AD cohort, dorsal HIP theta power reached 50% of its DBS-induced maximum approximately 4s and 3s after the end of stimulation for 900&#8239;s and 10&#8239;s DBS durations, respectively, exemplifying the potential of our parameter-response model to guide the optimization of DBS protocols based on disease-specific network impairments.</p></sec><sec><title>DBS effects on phase amplitude coupling</title><p>Consistent with the advanced stage of the AD pathology and the widespread reduction in hippocampal LFP power, TgAD rats also exhibited impaired network coordination at baseline, as reflected by a reduction in phase-amplitude coupling (PAC; Figure <xref rid="F2" ref-type="fig">2</xref>E-H). Specifically, the modulation index (MI) was significantly decreased in several PAC frequency pairings, including delta-Low gamma (D-LG), theta-Low gamma (T-LG), and beta-Low gamma (B-LG). For example, in the D-LG combination, baseline MI in NTg rats was 0.0084 (95% CI: 0.0080 to 0.0086), while TgAD rats showed a significantly lower MI of 0.0072 (95% CI: 0.0070-0.0079; p &lt; 0.001; Figure <xref rid="F2" ref-type="fig">2</xref>E-G).</p><p>To assess whether DBS could mitigate synchronization changes in the HIP of TgAD, we quantified DBS effects on network coordination by reporting changes in MI (&#916;MI) from baseline to DBS across PAC pairings (Figure <xref rid="F4" ref-type="fig">4</xref>A-E). These changes were modeled using a linear mixed-effects model that included fixed effects for genotype, sex, DBS parameters (amplitude and frequency), and their interactions (Figure <xref rid="F4" ref-type="fig">4</xref>C-E, <xref rid="SM0" ref-type="sec">Figure S3</xref>A-H). The model revealed a significant genotype:sex interaction on &#916;MI (p = 0.037), and both DBS amplitude and frequency significantly influenced MI changes individually (p &lt; 0.001), and through their interaction (p &lt; 0.001). Similarly to LFP power changes, increases in DBS amplitude and frequency were correlated with increases in MI. For instance, in the D-LG PAC of the dorsal HIP of NTg rats, DBS at 40Hz/9&#956;A increased MI by +0.0267 (95% CI: 0.0200 to 0.0355) while the increase was +0.0251 (95%CI: 0.0188 to 0.0334) in TgAD. These correspond to relative increases of +318% and +349%, respectively, indicating that DBS induced a marked enhancement of network coordination that exceeded even NTg baseline levels. Importantly, all tested DBS parameter combinations produced changes in MI that exceeded the minimum required to normalize PAC in TgAD rats. For example, in the dorsal HIP and for D-LG coupling, a &#916;MI of 0.0012 would be required to restore PAC to NTg baseline levels, yet even the smallest DBS-induced change observed in TgAD rats was 0.0015. This indicates that DBS can elicit at least transient hypersynchronization.</p></sec><sec><title>Comparison of DBS effects on power vs. modulation index</title><p>Interestingly, network power was influenced by DBS amplitude alone, in a genotype-dependent manner (p &lt; 0.001). LFP power consistently increased less in TgAD than in NTg rats across all DBS parameters (Figure <xref rid="F3" ref-type="fig">3</xref>D-F). Of note, power levels recorded in both cohorts were affected by anesthesia. To minimize anesthetic-specific confounding effects, we compared DBS responses obtained under propofol with DBS responses under isoflurane, which shows a less specific effect on GABA-A than does propofol <xref rid="B30" ref-type="bibr">30</xref>,<xref rid="B31" ref-type="bibr">31</xref>. Notably, TgAD animals showed larger theta power increases under isoflurane than they did under propofol whereas NTg animals displayed relatively consistent power responses to increasing DBS frequency and amplitude under both anesthetics (<xref rid="SM0" ref-type="sec">Figure S2</xref>E-H).</p><p>In contrast to power, MI responses were influenced by both DBS frequency and amplitude in a genotype-dependent manner (both p &lt; 0.001), indicating a significant interaction between stimulation parameters and genotype, and suggesting that HIP network synchronization is more sensitive to DBS frequency. The TgAD MI increased with increasing stimulation amplitude and frequency, and this TgAD MI response exceeded that of the NTg cohort (Figure <xref rid="F4" ref-type="fig">4</xref>C-D). Indeed, at higher stimulation levels (DBS &gt;50Hz and &gt;5 &#956;A) TgAD MI responses to DBS surpassed those of NTg rats (Figure <xref rid="F4" ref-type="fig">4</xref>C-D). This increase in PAC observed in the HIP network of TgAD was very large at higher frequencies (e.g. at 130Hz for theta-low-gamma, MI reached a 28-fold increase compared to baseline values, Figure <xref rid="F2" ref-type="fig">2</xref>G-H and Figure <xref rid="F4" ref-type="fig">4</xref>C-D): the emergent DBS-induced hypersynchrony may have resulted from an AD-induced alteration in inhibitory control mechanisms. Taken together, these findings suggest that hippocampal circuits in TgAD rats exhibit not only blunted power responses to DBS but also very large increases in PAC in response to DBS, potentially <italic toggle="yes">indicative of pathological hypersynchrony under high-frequency or high-amplitude DBS conditions</italic>. PAC responses were largely consistent across genotypes among the anesthetics tested (<xref rid="SM0" ref-type="sec">Figure S3</xref>E-H).</p></sec><sec><title>Spiking activity responses to DBS</title><p>We analyzed spiking activity in two temporal windows: during DBS and post-DBS (Figure <xref rid="F5" ref-type="fig">5</xref>A), excluding frequencies &gt;10&#8239;Hz due to limited temporal resolution. We quantified firing rate (FR) and pairwise phase consistency (PPC) in isolated units across DBS frequency and amplitude (Figure <xref rid="F5" ref-type="fig">5</xref>A-I). We assessed changes from baseline and defined the number of responding units (NRU) as those showing significant changes in FR or PPC during and after DBS (Figure <xref rid="F5" ref-type="fig">5</xref>G,I). GLME analysis showed that DBS frequency (but not amplitude) significantly affected NRU (p &lt; 0.001 for both PPC and FR; Figure <xref rid="F5" ref-type="fig">5</xref>G,I) and PPC entrainment (p &lt; 0.001; Figure <xref rid="F5" ref-type="fig">5</xref>D), while the effect on FR was marginal (p=0.064; Figure <xref rid="F5" ref-type="fig">5</xref>E). FR and PPC distributions were narrower at 10 Hz than at 1 Hz, with significantly reduced standard deviations: PPC from 0.046 to 0.030, FR from 5.22 to 3.30 (both p &lt; 0.001, Levene's test). These results suggest that <italic toggle="yes">increasing DBS frequency from 1 to 10&#8239;Hz leads to a more consistent neural response</italic>, as reflected by reduced variability in PPC and FR across neurons.</p><p>DBS frequency exerted genotype-specific effects on both PPC and FR responses (p=0.0449 and p=0.0022, respectively; Figure <xref rid="F5" ref-type="fig">5</xref>F,H), indicating selective sensitivity of AD-affected neurons. A significant interaction between DBS frequency and time window (during vs. post-DBS) was observed for NRU in both FR and PPC (p = 0.005 and p = 0.002, respectively; Figure <xref rid="F5" ref-type="fig">5</xref>D,E), irrespective of genotype. Fewer neurons were entrained at 10 Hz than at 1 Hz in both genotypes; PPC responders dropped from 39.8% (CI: 36.9 to 42.6%) at 1 Hz to 30.3% at 10 Hz (Figure <xref rid="F5" ref-type="fig">5</xref>E; p &lt; 0.001). Surprisingly, the NRU increased further during the post-stimulation period: for example, the NRU increased from 39.8% during 1 Hz DBS to 81.0% post 1 Hz DBS (CI: 78.9% to 83.1%, p &lt; 0.001; Figure <xref rid="F4" ref-type="fig">4</xref>E), indicating a <italic toggle="yes">strong post-DBS entrainment</italic>. Overall, HIP TgAD neurons showed reduced level of entrainment response compared to NTg: at 1 Hz, PPC increased by +9.9% (CI: 9.2% to 10.5%) in NTg vs. +7.1% (CI:6.7% to 7.6%) in TgAD; Figure <xref rid="F4" ref-type="fig">4</xref>D, p &lt; 0.001). FR increases were large and variable in both genotypes, for instance +73.5% (CI: -20% to 167%) for NTg and +93.7% (CI: 26.9% to 160.6%) for TgAD at 1 Hz; Figure <xref rid="F4" ref-type="fig">4</xref>F, p=0.987.</p><p>To examine the effects of DBS frequencies &gt;10&#8239;Hz on neuronal firing and the potential confounding influence of anesthesia, we quantified post-DBS firing rates (FR) across all frequencies (1-130&#8239;Hz) and compared anesthetic conditions (<xref rid="SM0" ref-type="sec">Figure S4</xref>A-E). Although all FR responses were variable across the different DBS conditions, post-DBS FR tended to be higher under propofol than under isoflurane, with no significant modulation by DBS frequency or amplitude. Paralleling the effects observed in power and PAC, genotype-dependent differences in post-DBS firing rate responses were also significantly modulated by anesthetic (interaction effect, p = 0.009).</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><sec><title>Advanced AD pathology leads to power and modulation index attenuation</title><p>Electrophysiological recordings revealed marked differences between TgAD rats and age-matched non-transgenic animals, particularly in local field potentials (LFP) power and cross-frequency coupling (modulation index, MI). These differences reflect neurodegeneration and disrupted hippocampal network synchronization characteristic of advanced AD <xref rid="B29" ref-type="bibr">29</xref>,<xref rid="B32" ref-type="bibr">32</xref>. Changes in LFP power were widespread and pronounced across all frequency bands, while deficits in modulation (MI) were concentrated in theta and delta-low gamma pairs. This selective disruption is consistent with the functional role of theta-gamma PAC in coordinating hippocampal information processing, especially during memory encoding and retrieval <xref rid="B33" ref-type="bibr">33</xref>,<xref rid="B34" ref-type="bibr">34</xref>. These effects were not attributable to anesthesia depth, as physiological parameters were similar in both genotypes, confirming that the differences were specific to synaptic dysfunction and connectivity loss. The decline in power and phase-amplitude coupling (PAC) in the 16-month-old TgAD rats reflects disease progression compared to our prior observations of PAC attenuation in 9-month-old rats <xref rid="B32" ref-type="bibr">32</xref>.</p></sec><sec><title>Neuromodulation with DBS</title><p>We investigated the effects of DBS on the AD pathology affected brain by targeting the hippocampal (HIP) network, severely affected in AD. Standard DBS protocols often yield inconsistent outcomes, likely due to the diversity of neuronal circuitry and variability in disease progression, emphasizing the need for more sensitive assessments and personalized treatments <xref rid="B35" ref-type="bibr">35</xref>. To date, only a few studies have systematically investigated the effects of DBS on brain networks, and they have largely neglected low frequencies (&lt;40&#8239;Hz), despite their potential to match the endogenous firing patterns of hippocampal neurons, which typically fire at an average of about 2 Hz <xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B36" ref-type="bibr">36</xref>. In contrast, high-frequency DBS, commonly used to restore excitatory/inhibitory balance in neurodegenerative conditions <xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B37" ref-type="bibr">37</xref>, preferentially recruits inhibitory interneurons <xref rid="B38" ref-type="bibr">38</xref>. While potentially beneficial, this approach may also produce functional lesions <xref rid="B39" ref-type="bibr">39</xref>,<xref rid="B40" ref-type="bibr">40</xref> and suppress low-firing neuronal activity by limiting repolarization time <xref rid="B41" ref-type="bibr">41</xref>. As a result, high-frequency DBS can impair theta coupling that is essential for memory and spatial navigation, and is already compromised in AD <xref rid="B42" ref-type="bibr">42</xref>. To better understand the effects of DBS on the local HIP network affected by AD pathology, we systematically explored a range of DBS parameters, using charge densities (amplitudes) consistent with previous reports <xref rid="B43" ref-type="bibr">43</xref>,<xref rid="B44" ref-type="bibr">44</xref> and selecting frequencies spanning the entire oscillatory range of HIP neurons. We assessed how DBS modulates neuronal power, modulation index (MI), pairwise phase consistency (PPC), and firing rate (FR) in the context of AD pathology and modeled the data to provide a predictive framework for estimating stimulation outcomes.</p></sec><sec><title>DBS parameters influence the local HIP network</title><p>DBS is believed to produce an &#8220;information lesion&#8221; by overriding intrinsic neuronal activity and suppressing low-frequency oscillations within the targeted network, a mechanism referred to as synaptic filtering <xref rid="B45" ref-type="bibr">45</xref>. This disruption of endogenous rhythms is expected to affect PAC, and manifests as changes in the modulation index (MI). In our data, DBS consistently induced PAC hyper-coupling (markedly elevated MI values), regardless of stimulation parameters. By imposing a stable oscillatory drive, DBS entrains local circuits and promotes excessive cross-frequency coupling (PAC hyper-coupling). PAC and power showed distinct sensitivities to DBS frequency: while PAC increased nonlinearly with frequency, power rose roughly linearly. This divergence suggests that power may be a more reliable marker of immediate network recruitment <xref rid="B46" ref-type="bibr">46</xref> in response to DBS, whereas PAC, though less suited to capturing graded, real-time responses, may offer a valuable readout of long-term circuit reorganization or dysfunction in unstimulated conditions <xref rid="B47" ref-type="bibr">47</xref>.</p><p>At the single-neuron level, entrainment (measured by pairwise phase consistency, PPC) and firing rate (FR) were more responsive to changes in DBS frequency than DBS amplitude (especially so for PPC), confirming a strong entrainment even at the individual neuron level. We note that the weak dependency on amplitude may simply result from the spike-detection (AP) band's high-frequency nature, which limits its detection radius and causes depolarization of nearby neurons even at the lowest charge densities. Conversely, the effective detection radius for local field potentials (LFPs) may be larger than the stimulation radius, making LFP-based parameters like power and MI dependent on amplitude, as our findings suggest. Notably, changes in entrainment (PPC) were more pronounced during the post-DBS period in the 1-10Hz range, which may account for the significant increases in PAC observed during this window. This suggests that the duration of stimulation-free intervals (duty cycle) could be critical for optimizing DBS efficacy. Despite the complexity of the relationship between DBS parameters and network responses, key features emerged: while frequency band selectivity was limited to power responses, both MI and power responses increased with increases in DBS amplitude and frequency, highlighting their role in guiding parameter selection and maximizing DBS efficacy.</p></sec><sec><title>DBS and AD pathology</title><p>Overall, we observed attenuated responses to DBS in both LFP power and MI in the HIP of TgAD rats, when compared to NTg littermates. The attenuated hippocampal power responses of TgAD to DBS align well with the notion of reduced HIP excitability <xref rid="B48" ref-type="bibr">48</xref>, loss of synaptic activity <xref rid="B49" ref-type="bibr">49</xref>, and frank neuronal loss observed in AD and in the TgAD rat model used here. PAC responses in TgAD were attenuated primarily at lower stimulation frequencies and amplitudes, suggesting altered thresholds for neuronal and network recruitment in the diseased brain, and underscoring the importance of tailoring DBS parameters to disease stage. Spiking unit analysis revealed that genotype differences depended more on DBS frequency than on amplitude. Despite exhibiting similar changes in FR, TgAD neurons were less entrained than NTg neurons in the low-frequency range (1-10Hz DBS). Altogether, our findings highlight the therapeutic potential of DBS in AD, and emphasize that DBS parameter optimization can, at least transiently, reverse the AD pathology-induced attenuation of neuronal activity. Future longitudinal studies using electrophysiological biomarkers and adaptable closed-loop protocols will be essential to assess the long-term efficacy of DBS in advanced AD.</p></sec><sec><title>Therapeutic potential: retain and re-train</title><p>While prevention and early detection would be ideal, in the absence of a cure and given the slow progression of the disease, addressing neuronal dysfunction in symptomatic and advanced-stage AD will remain highly impactful for years to come. In advanced stage AD, DBS has been shown to slow disease progression <xref rid="B50" ref-type="bibr">50</xref>,<xref rid="B51" ref-type="bibr">51</xref>. We propose that DBS may not simply stimulate surviving neurons in AD-affected regions to promote their retention under the &#8220;use it or lose it&#8221; paradigm, but that DBS may also serve to re-train the partially disconnected network. Some of the network's neurons, while partially deprived of inputs and not fully active, remain potentially responsive to external stimulation. We hypothesized that applying DBS within the functional frequency range (i.e. physiological oscillation bands within which neurons operate <xref rid="B52" ref-type="bibr">52</xref>) allows for retaining and strengthening of their existing connections, ultimately promoting functional network reorganization and efficient information processing. Although baseline PAC and power were reduced and DBS responses attenuated, pointing to a shift in thresholds for neuronal recruitment by AD pathology, we showed that frequency-selective DBS could transiently normalize these deficits in the advanced stage of AD progression, underscoring the need for disease stage-specific optimization of neuromodulatory protocols (DBS parameters). While the mechanisms through which DBS produces neuromodulation are still incompletely understood <xref rid="B53" ref-type="bibr">53</xref>, our study shows that precise DBS parametrization can enhance local network responsiveness and help re-establish more physiological activity patterns in hippocampal circuits disrupted by AD pathology. These findings may thus inform future translational efforts aimed at optimizing neuromodulation strategies for improving hippocampal network function in clinical AD.</p></sec></sec><sec id="SM0" sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="SM1" position="float" content-type="local-data" orientation="portrait"><caption><p>Supplementary methods and figures.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="thnov15p10064s1.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack><p>We thank Margaret Koletar and Adrienne Dorr for their expert guidance and constructive feedback on animal surgery and anesthesia, contributing to the quality and rigor of the experimental procedures.</p></ack><glossary><title>Abbreviations</title><def-list><def-item><term id="GL1">AD</term><def><p>Alzheimer's Disease</p></def></def-item><def-item><term id="GL2">ANOVA</term><def><p>ANalysis Of VAriance</p></def></def-item><def-item><term id="GL3">AP</term><def><p>Antero-Posterior</p></def></def-item><def-item><term id="GL4">AP<sub>band</sub></term><def><p>Action-Potential (band)</p></def></def-item><def-item><term id="GL5">bpm</term><def><p>Beats per Minute</p></def></def-item><def-item><term id="GL6">BR</term><def><p>Breathing Rate</p></def></def-item><def-item><term id="GL7">brpm</term><def><p>Breaths per Minute</p></def></def-item><def-item><term id="GL8">CSD</term><def><p>Current Source Density</p></def></def-item><def-item><term id="GL9">DBS</term><def><p>Deep Brain Stimulation</p></def></def-item><def-item><term id="GL10">DV</term><def><p>Dorso-Ventral</p></def></def-item><def-item><term id="GL11">FR</term><def><p>Firing Rate</p></def></def-item><def-item><term id="GL12">GLME</term><def><p>Generalized Linear Mixed Effects</p></def></def-item><def-item><term id="GL13">HIP</term><def><p>Hippocampus</p></def></def-item><def-item><term id="GL14">HR</term><def><p>Heart Rate</p></def></def-item><def-item><term id="GL15">Hz</term><def><p>Hertz</p></def></def-item><def-item><term id="GL16">LFP</term><def><p>Local Field Potential</p></def></def-item><def-item><term id="GL17">LMA</term><def><p>Linear Multi-Array</p></def></def-item><def-item><term id="GL18">MI</term><def><p>Modulation Index</p></def></def-item><def-item><term id="GL19">ML</term><def><p>Medio-Lateral</p></def></def-item><def-item><term id="GL20">MUA</term><def><p>Multi-Unit Activity</p></def></def-item><def-item><term id="GL21">NRU</term><def><p>Number of Responding Units</p></def></def-item><def-item><term id="GL22">NTg</term><def><p>Non-Transgenic</p></def></def-item><def-item><term id="GL23">PAC</term><def><p>Phase-Amplitude Coupling</p></def></def-item><def-item><term id="GL24">pO2</term><def><p>Partial (pressure) of Oxygen</p></def></def-item><def-item><term id="GL25">PPC</term><def><p>Pairwise Phase Consistency</p></def></def-item><def-item><term id="GL26">SD</term><def><p>Standard Deviation</p></def></def-item><def-item><term id="GL27">TgAD</term><def><p>Transgenic Alzheimer's disease rat model (F344-AD)</p></def></def-item></def-list></glossary><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><name name-style="western"><surname>Frisoni</surname><given-names>GB</given-names></name><etal/><article-title>The probabilistic model of Alzheimer disease: the amyloid hypothesis revised</article-title><source>Nat Rev Neurosci</source><year>2022</year><volume>23</volume><fpage>53</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">34815562</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41583-021-00533-w</pub-id><pub-id pub-id-type="pmcid">PMC8840505</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><name name-style="western"><surname>Babiloni</surname><given-names>C</given-names></name><etal/><article-title>What electrophysiology tells us about Alzheimer's disease: a window into the synchronization and connectivity of brain neurons</article-title><source>Neurobiol Aging</source><year>2020</year><volume>85</volume><fpage>58</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">31739167</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2019.09.008</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><etal/><article-title>A review and analysis of key biomarkers in Alzheimer's disease</article-title><source>Front Neurosci</source><year>2024</year><volume>18</volume><fpage>1358998</fpage><pub-id pub-id-type="pmid">38445255</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2024.1358998</pub-id><pub-id pub-id-type="pmcid">PMC10912539</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><name name-style="western"><surname>Goodman</surname><given-names>MS</given-names></name><etal/><article-title>Theta-Gamma Coupling and Working Memory in Alzheimer's Dementia and Mild Cognitive Impairment</article-title><source>Front Aging Neurosci</source><year>2018</year><volume>10</volume><fpage>101</fpage><pub-id pub-id-type="pmid">29713274</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2018.00101</pub-id><pub-id pub-id-type="pmcid">PMC5911490</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><name name-style="western"><surname>Stam</surname><given-names>C J</given-names></name><name name-style="western"><surname>Jones</surname><given-names>B F</given-names></name><name name-style="western"><surname>Nolte</surname><given-names>G</given-names></name><name name-style="western"><surname>Breakspear</surname><given-names>M</given-names></name><name name-style="western"><surname>Scheltens</surname><given-names>P</given-names></name><article-title>Small-world networks and functional connectivity in Alzheimer's disease</article-title><source>Cereb Cortex</source><year>2007</year><volume>17</volume><fpage>92</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">16452642</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cercor/bhj127</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><name name-style="western"><surname>Sanchez-Aguilera</surname><given-names>A</given-names></name><name name-style="western"><surname>Quintanilla</surname><given-names>JP</given-names></name><article-title>Sharp wave ripples in Alzheimer's disease: In search of mechanisms</article-title><source>J Neurosci</source><year>2021</year><volume>41</volume><fpage>1366</fpage><lpage>1370</lpage><pub-id pub-id-type="pmid">33597170</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.2020-20.2020</pub-id><pub-id pub-id-type="pmcid">PMC7896023</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><name name-style="western"><surname>Hollnagel</surname><given-names>J-O</given-names></name><etal/><article-title>Early alterations in hippocampal perisomatic GABAergic synapses and network oscillations in a mouse model of Alzheimer's disease amyloidosis</article-title><source>PLoS One</source><year>2019</year><volume>14</volume><fpage>e0209228</fpage><pub-id pub-id-type="pmid">30645585</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0209228</pub-id><pub-id pub-id-type="pmcid">PMC6333398</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><name name-style="western"><surname>Palop</surname><given-names>J J</given-names></name><name name-style="western"><surname>Mucke</surname><given-names>L</given-names></name><article-title>Network abnormalities and interneuron dysfunction in Alzheimer disease</article-title><source>Nat Rev Neurosci</source><year>2016</year><volume>17</volume><fpage>777</fpage><lpage>792</lpage><pub-id pub-id-type="pmid">27829687</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrn.2016.141</pub-id><pub-id pub-id-type="pmcid">PMC8162106</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><name name-style="western"><surname>Ahnaou</surname><given-names>A</given-names></name><etal/><article-title>Emergence of early alterations in network oscillations and functional connectivity in a tau seeding mouse model of Alzheimer's disease pathology</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><fpage>14189</fpage><pub-id pub-id-type="pmid">29079799</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-017-13839-6</pub-id><pub-id pub-id-type="pmcid">PMC5660172</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><name name-style="western"><surname>Harris</surname><given-names>S S</given-names></name><etal/><article-title>Alzheimer's disease patient-derived high-molecular-weight tau impairs bursting in hippocampal neurons</article-title><source>Cell</source><year>2025</year><volume>188</volume><fpage>3775</fpage><lpage>3788.e21</lpage><pub-id pub-id-type="pmid">40300603</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2025.04.006</pub-id><pub-id pub-id-type="pmcid">PMC12255526</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Cai</surname><given-names>F</given-names></name><name name-style="western"><surname>Song</surname><given-names>W</given-names></name><article-title>Biological function of Presenilin and its role in AD pathogenesis</article-title><source>Transl Neurodegener</source><year>2013</year><volume>2</volume><fpage>15</fpage><pub-id pub-id-type="pmid">23866842</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/2047-9158-2-15</pub-id><pub-id pub-id-type="pmcid">PMC3718700</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="other"><name name-style="western"><surname>Sheng</surname><given-names>M</given-names></name><name name-style="western"><surname>Sabatini</surname><given-names>B L</given-names></name><name name-style="western"><surname>S&#252;dhof</surname><given-names>T C</given-names></name><article-title>Synapses and Alzheimer's disease</article-title><source>Cold Spring Harb Perspect Biol</source><year>2012</year><comment>4</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/cshperspect.a005777</pub-id><pub-id pub-id-type="pmcid">PMC3331702</pub-id><pub-id pub-id-type="pmid">22491782</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><name name-style="western"><surname>Landhuis</surname><given-names>E</given-names></name><article-title>Researchers call for a major rethink of how Alzheimer's treatments are evaluated</article-title><source>Nature</source><year>2024</year><volume>627</volume><fpage>S18</fpage><lpage>S20</lpage><pub-id pub-id-type="pmid">38480971</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/d41586-024-00756-8</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><name name-style="western"><surname>Luo</surname><given-names>Y</given-names></name><etal/><article-title>Deep Brain Stimulation for Alzheimer's Disease: Stimulation Parameters and Potential Mechanisms of Action</article-title><source>Front Aging Neurosci</source><year>2021</year><volume>13</volume><fpage>619543</fpage><pub-id pub-id-type="pmid">33776742</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2021.619543</pub-id><pub-id pub-id-type="pmcid">PMC7990787</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><name name-style="western"><surname>Limousin</surname><given-names>P</given-names></name><etal/><article-title>Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation</article-title><source>Lancet</source><year>1995</year><volume>345</volume><fpage>91</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">7815888</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0140-6736(95)90062-4</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><name name-style="western"><surname>Mayberg</surname><given-names>H S</given-names></name><etal/><article-title>Deep brain stimulation for treatment-resistant depression</article-title><source>Neuron</source><year>2005</year><volume>45</volume><fpage>651</fpage><lpage>660</lpage><pub-id pub-id-type="pmid">15748841</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2005.02.014</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><name name-style="western"><surname>Miocinovic</surname><given-names>S</given-names></name><name name-style="western"><surname>Somayajula</surname><given-names>S</given-names></name><name name-style="western"><surname>Chitnis</surname><given-names>S</given-names></name><name name-style="western"><surname>Vitek</surname><given-names>J L</given-names></name><article-title>History, applications, and mechanisms of deep brain stimulation</article-title><source>JAMA Neurol</source><year>2013</year><volume>70</volume><fpage>163</fpage><lpage>171</lpage><pub-id pub-id-type="pmid">23407652</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/2013.jamaneurol.45</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><name name-style="western"><surname>Suthana</surname><given-names>N</given-names></name><etal/><article-title>Memory enhancement and deep-brain stimulation of the entorhinal area</article-title><source>N Engl J Med</source><year>2012</year><volume>366</volume><fpage>502</fpage><lpage>510</lpage><pub-id pub-id-type="pmid">22316444</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1107212</pub-id><pub-id pub-id-type="pmcid">PMC3447081</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><name name-style="western"><surname>Neumann</surname><given-names>W-J</given-names></name><name name-style="western"><surname>Steiner</surname><given-names>L A</given-names></name><name name-style="western"><surname>Milosevic</surname><given-names>L</given-names></name><article-title>Neurophysiological mechanisms of deep brain stimulation across spatiotemporal resolutions</article-title><source>Brain</source><year>2023</year><volume>146</volume><fpage>4456</fpage><lpage>4468</lpage><pub-id pub-id-type="pmid">37450573</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awad239</pub-id><pub-id pub-id-type="pmcid">PMC10629774</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><name name-style="western"><surname>Majdi</surname><given-names>A</given-names></name><etal/><article-title>Deep brain stimulation for the treatment of Alzheimer's disease: A systematic review and meta-analysis</article-title><source>Front Neurosci</source><year>2023</year><volume>17</volume><fpage>1154180</fpage><pub-id pub-id-type="pmid">37123370</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2023.1154180</pub-id><pub-id pub-id-type="pmcid">PMC10133458</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><name name-style="western"><surname>Ramasubbu</surname><given-names>R</given-names></name><name name-style="western"><surname>Lang</surname><given-names>S</given-names></name><name name-style="western"><surname>Kiss Z</surname><given-names>H T</given-names></name><article-title>Dosing of Electrical Parameters in Deep Brain Stimulation (DBS) for Intractable Depression: A Review of Clinical Studies</article-title><source>Front Psychiatry</source><year>2018</year><volume>9</volume><fpage>302</fpage><pub-id pub-id-type="pmid">30050474</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpsyt.2018.00302</pub-id><pub-id pub-id-type="pmcid">PMC6050377</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></name><etal/><article-title>Deep brain stimulation of the nucleus basalis of Meynert modulates hippocampal-frontoparietal networks in patients with advanced Alzheimer's disease</article-title><source>Transl Neurodegener</source><year>2022</year><volume>11</volume><fpage>51</fpage><pub-id pub-id-type="pmid">36471370</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40035-022-00327-9</pub-id><pub-id pub-id-type="pmcid">PMC9721033</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><name name-style="western"><surname>Lee</surname><given-names>J E</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>D U</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name><name name-style="western"><surname>Chang</surname><given-names>W S</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J W</given-names></name><article-title>The effect of nucleus basalis magnocellularis deep brain stimulation on memory function in a rat model of dementia</article-title><source>BMC Neurol</source><year>2016</year><volume>16</volume><fpage>6</fpage><pub-id pub-id-type="pmid">26757896</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12883-016-0529-z</pub-id><pub-id pub-id-type="pmcid">PMC4711102</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Hu</surname><given-names>W-H</given-names></name><name name-style="western"><surname>Wu</surname><given-names>D-L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J-G</given-names></name><article-title>Behavioral effects of deep brain stimulation of the anterior nucleus of thalamus, entorhinal cortex and fornix in a rat model of Alzheimer's disease</article-title><source>Chin Med J (Engl)</source><year>2015</year><volume>128</volume><fpage>1190</fpage><lpage>1195</lpage><pub-id pub-id-type="pmid">25947402</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/0366-6999.156114</pub-id><pub-id pub-id-type="pmcid">PMC4831546</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><name name-style="western"><surname>Martorell</surname><given-names>A J</given-names></name><etal/><article-title>Multi-sensory gamma stimulation ameliorates Alzheimer's-associated pathology and improves cognition</article-title><source>Cell</source><year>2019</year><volume>177</volume><fpage>256</fpage><lpage>271.e22</lpage><pub-id pub-id-type="pmid">30879788</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2019.02.014</pub-id><pub-id pub-id-type="pmcid">PMC6774262</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><name name-style="western"><surname>Wu</surname><given-names>W</given-names></name><etal/><article-title>Modulation of glymphatic system by visual circuit activation alleviates memory impairment and apathy in a mouse model of Alzheimer's disease</article-title><source>Nat Commun</source><year>2025</year><volume>16</volume><fpage>63</fpage><pub-id pub-id-type="pmid">39747869</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-55678-w</pub-id><pub-id pub-id-type="pmcid">PMC11696061</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><name name-style="western"><surname>Hernandez</surname><given-names>C M</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>N L</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>A R</given-names></name><name name-style="western"><surname>McMahon</surname><given-names>L L</given-names></name><article-title>Impairments in fear extinction memory and basolateral amygdala plasticity in the TgF344-AD rat model of Alzheimer's disease are distinct from nonpathological aging</article-title><source>eNeuro</source><year>2022</year><volume>9</volume><fpage>ENEURO.0181</fpage><lpage>22.2022</lpage><pub-id pub-id-type="pmid">35998297</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/ENEURO.0181-22.2022</pub-id><pub-id pub-id-type="pmcid">PMC9239848</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><name name-style="western"><surname>Morrone</surname><given-names>C D</given-names></name><etal/><article-title>Regional differences in Alzheimer's disease pathology confound behavioural rescue after amyloid-&#946; attenuation</article-title><source>Brain</source><year>2020</year><volume>143</volume><fpage>359</fpage><lpage>373</lpage><pub-id pub-id-type="pmid">31782760</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awz371</pub-id><pub-id pub-id-type="pmcid">PMC6935751</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><name name-style="western"><surname>Cohen</surname><given-names>R M</given-names></name><etal/><article-title>A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric a&#946;, and frank neuronal loss</article-title><source>J Neurosci</source><year>2013</year><volume>33</volume><fpage>6245</fpage><lpage>6256</lpage><pub-id pub-id-type="pmid">23575824</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.3672-12.2013</pub-id><pub-id pub-id-type="pmcid">PMC3720142</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><name name-style="western"><surname>Herring</surname><given-names>B E</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Z</given-names></name><name name-style="western"><surname>Marks</surname><given-names>J</given-names></name><name name-style="western"><surname>Fox</surname><given-names>A P</given-names></name><article-title>Isoflurane inhibits the neurotransmitter release machinery</article-title><source>J Neurophysiol</source><year>2009</year><volume>102</volume><fpage>1265</fpage><lpage>1273</lpage><pub-id pub-id-type="pmid">19515956</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/jn.00252.2009</pub-id><pub-id pub-id-type="pmcid">PMC2724342</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><name name-style="western"><surname>Trapani</surname><given-names>G</given-names></name><name name-style="western"><surname>Altomare</surname><given-names>C</given-names></name><name name-style="western"><surname>Liso</surname><given-names>G</given-names></name><name name-style="western"><surname>Sanna</surname><given-names>E</given-names></name><name name-style="western"><surname>Biggio</surname><given-names>G</given-names></name><article-title>Propofol in anesthesia. Mechanism of action, structure-activity relationships, and drug delivery</article-title><source>Curr Med Chem</source><year>2000</year><volume>7</volume><fpage>249</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">10637364</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/0929867003375335</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><name name-style="western"><surname>Bazzigaluppi</surname><given-names>P</given-names></name><etal/><article-title>Early-stage attenuation of phase-amplitude coupling in the hippocampus and medial prefrontal cortex in a transgenic rat model of Alzheimer's disease</article-title><source>J Neurochem</source><year>2018</year><volume>144</volume><fpage>669</fpage><lpage>679</lpage><pub-id pub-id-type="pmid">28777881</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jnc.14136</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><name name-style="western"><surname>van den Berg</surname><given-names>M</given-names></name><name name-style="western"><surname>Toen</surname><given-names>D</given-names></name><name name-style="western"><surname>Verhoye</surname><given-names>M</given-names></name><name name-style="western"><surname>Keliris</surname><given-names>G A</given-names></name><article-title>Alterations in theta-gamma coupling and sharp wave-ripple, signs of prodromal hippocampal network impairment in the TgF344-AD rat model</article-title><source>Front Aging Neurosci</source><year>2023</year><volume>15</volume><fpage>1081058</fpage><pub-id pub-id-type="pmid">37032829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2023.1081058</pub-id><pub-id pub-id-type="pmcid">PMC10075364</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><name name-style="western"><surname>Lega</surname><given-names>B</given-names></name><name name-style="western"><surname>Burke</surname><given-names>J</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>J</given-names></name><name name-style="western"><surname>Kahana</surname><given-names>M J</given-names></name><article-title>Slow-theta-to-gamma phase-amplitude coupling in human hippocampus supports the formation of new episodic memories</article-title><source>Cereb Cortex</source><year>2016</year><volume>26</volume><fpage>268</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">25316340</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cercor/bhu232</pub-id><pub-id pub-id-type="pmcid">PMC4677977</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><name name-style="western"><surname>Vatsyayan</surname><given-names>R</given-names></name><etal/><article-title>Electrochemical and electrophysiological considerations for clinical high channel count neural interfaces</article-title><source>MRS Bull</source><year>2023</year><volume>48</volume><fpage>531</fpage><lpage>546</lpage><pub-id pub-id-type="pmid">37476355</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1557/s43577-023-00537-0</pub-id><pub-id pub-id-type="pmcid">PMC10357958</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><name name-style="western"><surname>Maidana Capit&#225;n</surname><given-names>M B</given-names></name><name name-style="western"><surname>Kropff</surname><given-names>E</given-names></name><name name-style="western"><surname>Samengo</surname><given-names>I</given-names></name><article-title>Information-theoretical analysis of the neural code in the rodent temporal lobe</article-title><source>Entropy (Basel)</source><year>2018</year><volume>20</volume><fpage>571</fpage><pub-id pub-id-type="pmid">33265660</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/e20080571</pub-id><pub-id pub-id-type="pmcid">PMC7513095</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><name name-style="western"><surname>Scaduto</surname><given-names>P</given-names></name><etal/><article-title>Functional excitatory to inhibitory synaptic imbalance and loss of cognitive performance in people with Alzheimer's disease neuropathologic change</article-title><source>Acta Neuropathol</source><year>2023</year><volume>145</volume><fpage>303</fpage><lpage>324</lpage><pub-id pub-id-type="pmid">36538112</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-022-02526-0</pub-id><pub-id pub-id-type="pmcid">PMC9925531</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><name name-style="western"><surname>Qiu</surname><given-names>C</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>L</given-names></name><name name-style="western"><surname>Ma</surname><given-names>W</given-names></name><article-title>Selective modulation of neuronal firing by pulse stimulations with different frequencies in rat hippocampus</article-title><source>Biomed Eng Online</source><year>2019</year><volume>18</volume><fpage>79</fpage><pub-id pub-id-type="pmid">31337402</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12938-019-0700-z</pub-id><pub-id pub-id-type="pmcid">PMC6651985</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><name name-style="western"><surname>Jakobs</surname><given-names>M</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D J</given-names></name><name name-style="western"><surname>Lozano</surname><given-names>A M</given-names></name><article-title>Modifying the progression of Alzheimer's and Parkinson's disease with deep brain stimulation</article-title><source>Neuropharmacology</source><year>2020</year><volume>171</volume><fpage>107860</fpage><pub-id pub-id-type="pmid">31765650</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuropharm.2019.107860</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><name name-style="western"><surname>Benabid</surname><given-names>A L</given-names></name><name name-style="western"><surname>Pollak</surname><given-names>P</given-names></name><name name-style="western"><surname>Louveau</surname><given-names>A</given-names></name><name name-style="western"><surname>Henry</surname><given-names>S</given-names></name><name name-style="western"><surname>de Rougemont</surname><given-names>J</given-names></name><article-title>Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease</article-title><source>Appl Neurophysiol</source><year>1987</year><volume>50</volume><fpage>344</fpage><lpage>346</lpage><pub-id pub-id-type="pmid">3329873</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000100803</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><name name-style="western"><surname>Lowet</surname><given-names>E</given-names></name><etal/><article-title>Deep brain stimulation creates informational lesion through membrane depolarization in mouse hippocampus</article-title><source>Nat Commun</source><year>2022</year><volume>13</volume><fpage>7709</fpage><pub-id pub-id-type="pmid">36513664</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-022-35314-1</pub-id><pub-id pub-id-type="pmcid">PMC9748039</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><name name-style="western"><surname>Bott</surname><given-names>J-B</given-names></name><etal/><article-title>Spatial Reference Memory is Associated with Modulation of Theta-Gamma Coupling in the Dentate Gyrus</article-title><source>Cereb Cortex</source><year>2016</year><volume>26</volume><fpage>3744</fpage><lpage>3753</lpage><pub-id pub-id-type="pmid">26250776</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cercor/bhv177</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><name name-style="western"><surname>McCreery</surname><given-names>D B</given-names></name><name name-style="western"><surname>Agnew</surname><given-names>W F</given-names></name><name name-style="western"><surname>Yuen</surname><given-names>T G</given-names></name><name name-style="western"><surname>Bullara</surname><given-names>L</given-names></name><article-title>Charge density and charge per phase as cofactors in neural injury induced by electrical stimulation</article-title><source>IEEE Trans Biomed Eng</source><year>1990</year><volume>37</volume><fpage>996</fpage><lpage>1001</lpage><pub-id pub-id-type="pmid">2249872</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/10.102812</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><name name-style="western"><surname>Han</surname><given-names>M</given-names></name><name name-style="western"><surname>Manoonkitiwongsa</surname><given-names>P S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C X</given-names></name><name name-style="western"><surname>McCreery</surname><given-names>D B</given-names></name><article-title>In vivo validation of custom-designed silicon-based microelectrode arrays for long-term neural recording and stimulation</article-title><source>IEEE Trans Biomed Eng</source><year>2012</year><volume>59</volume><fpage>346</fpage><lpage>354</lpage><pub-id pub-id-type="pmid">22020666</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/TBME.2011.2172440</pub-id><pub-id pub-id-type="pmcid">PMC3265636</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><name name-style="western"><surname>Lozano</surname><given-names>A M</given-names></name><etal/><article-title>Deep brain stimulation: current challenges and future directions</article-title><source>Nat Rev Neurol</source><year>2019</year><volume>15</volume><fpage>148</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">30683913</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41582-018-0128-2</pub-id><pub-id pub-id-type="pmcid">PMC6397644</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><name name-style="western"><surname>Buzs&#225;ki</surname><given-names>G</given-names></name><name name-style="western"><surname>Anastassiou</surname><given-names>C A</given-names></name><name name-style="western"><surname>Koch</surname><given-names>C</given-names></name><article-title>The origin of extracellular fields and currents-EEG, ECoG, LFP and spikes</article-title><source>Nat Rev Neurosci</source><year>2012</year><volume>13</volume><fpage>407</fpage><lpage>420</lpage><pub-id pub-id-type="pmid">22595786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrn3241</pub-id><pub-id pub-id-type="pmcid">PMC4907333</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><name name-style="western"><surname>Tort A</surname><given-names>B L</given-names></name><name name-style="western"><surname>Komorowski</surname><given-names>R</given-names></name><name name-style="western"><surname>Eichenbaum</surname><given-names>H</given-names></name><name name-style="western"><surname>Kopell</surname><given-names>N</given-names></name><article-title>Measuring phase-amplitude coupling between neuronal oscillations of different frequencies</article-title><source>J Neurophysiol</source><year>2010</year><volume>104</volume><fpage>1195</fpage><lpage>1210</lpage><pub-id pub-id-type="pmid">20463205</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/jn.00106.2010</pub-id><pub-id pub-id-type="pmcid">PMC2941206</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><name name-style="western"><surname>Hatch</surname><given-names>R J</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xia</surname><given-names>D</given-names></name><name name-style="western"><surname>G&#246;tz</surname><given-names>J</given-names></name><article-title>Hyperphosphorylated tau causes reduced hippocampal CA1 excitability by relocating the axon initial segment</article-title><source>Acta Neuropathol</source><year>2017</year><volume>133</volume><fpage>717</fpage><lpage>730</lpage><pub-id pub-id-type="pmid">28091722</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-017-1674-1</pub-id><pub-id pub-id-type="pmcid">PMC5389999</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><name name-style="western"><surname>Walsh</surname><given-names>C</given-names></name><name name-style="western"><surname>Drinkenburg W H</surname><given-names>I M</given-names></name><name name-style="western"><surname>Ahnaou</surname><given-names>A</given-names></name><article-title>Neurophysiological assessment of neural network plasticity and connectivity: Progress towards early functional biomarkers for disease interception therapies in Alzheimer's disease</article-title><source>Neurosci Biobehav Rev</source><year>2017</year><volume>73</volume><fpage>340</fpage><lpage>358</lpage><pub-id pub-id-type="pmid">28027953</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neubiorev.2016.12.020</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><name name-style="western"><surname>Laxton</surname><given-names>A W</given-names></name><etal/><article-title>A phase I trial of deep brain stimulation of memory circuits in Alzheimer's disease</article-title><source>Ann Neurol</source><year>2010</year><volume>68</volume><fpage>521</fpage><lpage>534</lpage><pub-id pub-id-type="pmid">20687206</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.22089</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><name name-style="western"><surname>Sankar</surname><given-names>T</given-names></name><etal/><article-title>Deep Brain Stimulation influences brain structure in Alzheimer's Disease</article-title><source>Brain Stimul</source><year>2015</year><volume>8</volume><fpage>645</fpage><lpage>654</lpage><pub-id pub-id-type="pmid">25814404</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.brs.2014.11.020</pub-id><pub-id pub-id-type="pmcid">PMC5659851</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><name name-style="western"><surname>Harmony</surname><given-names>T</given-names></name><article-title>The functional significance of delta oscillations in cognitive processing</article-title><source>Front Integr Neurosci</source><year>2013</year><volume>7</volume><fpage>83</fpage><pub-id pub-id-type="pmid">24367301</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnint.2013.00083</pub-id><pub-id pub-id-type="pmcid">PMC3851789</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><name name-style="western"><surname>Xu</surname><given-names>W</given-names></name><etal/><article-title>Neuronal and synaptic adaptations underlying the benefits of deep brain stimulation for Parkinson's disease</article-title><source>Transl Neurodegener</source><year>2023</year><volume>12</volume><fpage>55</fpage><pub-id pub-id-type="pmid">38037124</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40035-023-00390-w</pub-id><pub-id pub-id-type="pmcid">PMC10688037</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="F1" orientation="portrait"><label>Figure 1</label><caption><p>DBS e<italic toggle="yes">xperimental setup.</italic> (A) The dual-shank linear multi-channel array electrodes used for DBS and LFP recording were lowered along the dorsoventral axis into the hippocampus of 16-month-old TgAD rats or their NTg littermates; a switching head stage allowed for fast switching between recording and stimulation. (B-C) Widespread amyloid plaque deposition in the hippocampus of 16 m.o. TgAD rats (C) vs. NTg (B) as shown by 6F3D A&#946;42-antibody. (D) Hippocampal distribution of hyperphosphorylated tau in 16 m.o. TgAD rats detected by PHF1-antibody. (E-G) Physiological parameters (E: heart rate, F: breathing rate, G: arterial O<sub>2</sub> saturation) of TgAD and NTg rats undergoing the transition from isoflurane to continuous infusion of low-dose propofol anesthesia. (H) Representative extracellular recordings in the 0.3-300Hz band (local field potentials, LFP). (I) Representative current source density (CSD) analysis of hippocampal network activity in TgAD rats localizes current sinks (red, positive voltage deflections) and sources (blue, negative voltage deflection). (J) Representative extracellular recordings in the high frequency band (action potentials, AP<sub>band</sub>): 0.75-3kHz. (K) Representative spiking unit distribution in the hippocampus along the x-z axis, identified by the clustering analysis. (L) Representative raster plot of the spiking units in a sample animal. Scale bar in B-D: 1 mm.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="thnov15p10064g001.jpg"/></fig><fig position="float" id="F2" orientation="portrait"><label>Figure 2</label><caption><p><italic toggle="yes">Attenuation of TgAD hippocampal resting power and synchronization under propofol anesthesia at baseline (no stimulation).</italic> (A-B) LFP power spectrum analysis in the dorsal (A) and ventral (B) hippocampus indicates a decrease in power in the TgAD cohort (right image) across the frequency spectrum (0.1-120 Hz) compared to that of the NTg (left) cohort. (C-D) LFP power quantification in dorsal (C) and ventral (D) hippocampus in different bands (delta D: 0.1-4Hz; theta T: 4-8Hz; alpha A: 8-12Hz; beta B: 12-30 Hz; low-gamma LG: 30-60Hz and high-gamma HG: 60-120Hz) showing attenuation in TgAD (red) rats across all bands. (E-F) Phase-amplitude coupling analysis of the LFP signal rendered as comodulograms in dorsal (E) and ventral (F) hippocampus. (G-H) Modulation index (MI) across all combinations of the low-frequency band (D, T, A, B) phases and high-frequency band (LG/HG) amplitudes in TgAD (red) and NTg (black) rats. Images in A, B, E, and F display averages across all subjects. <italic toggle="yes">Statistical significance between genotypes is indicated with asterisks:</italic> * p &lt; 0.05, ** p &lt; 0.01, *** p &lt; 0.001, based on Tukey-adjusted post-hoc comparisons. Tg n=17, NTg n=19.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="thnov15p10064g002.jpg"/></fig><fig position="float" id="F3" orientation="portrait"><label>Figure 3</label><caption><p><italic toggle="yes">Attenuation of TgAD DBS-induced hippocampal power changes depends on frequency and amplitude.</italic> (A) combination of DBS parameters (frequencies and amplitudes) used (left) and schematic of the stimulation protocol (right). Deep brain stimulation (DBS) was delivered to the hippocampus in 10-second trains at all combinations of frequencies (1-130 Hz) and amplitudes (2-20 &#956;A), followed by a post-stimulation period used for LFP analysis. (B-C) Time-frequency representations of hippocampal power in NTg (B) and TgAD (C) rats following DBS at 20 &#956;A for 1 Hz (left) and 10 Hz (right). Compared to NTg animals, TgAD rats show a reduced power increase in the low-frequency range following DBS. (D) Frequency-dependent effects of DBS on power across canonical oscillation bands (delta, theta, alpha, beta, Low gamma, High gamma), plotted separately for NTg (black) and TgAD (red) rats. Linear mixed-effects model predictions show a strong positive relationship between DBS frequency and post-stimulation power, particularly in low-frequency bands, with attenuated responses in TgAD rats. (E) Same analysis as in panel (D), but for stimulation amplitude (2-20 &#956;A). Increased amplitude leads to enhanced power responses, again less prominent in TgAD animals. (F) Analysis of post-stimulation persistence of theta power changes following either short (10s) or long (900s) DBS trains. DBS-induced increases in theta power decay similarly over time in both genotypes, with NTg rats consistently showing larger power changes.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="thnov15p10064g003.jpg"/></fig><fig position="float" id="F4" orientation="portrait"><label>Figure 4</label><caption><p><italic toggle="yes">DBS-induced increases in PAC (modulation index) in the hippocampus of TgAD rats, in frequency- and amplitude-dependent manner.</italic> (A) The averaged modulation index (MI) map of LFP following DBS at 20 &#181;A/ 1 Hz (left) and 20 &#181;A/ 10 Hz (right) in NTg rats. (B) The corresponding MI co-modulation map in TgAD rats. (C) Frequency-dependent effects of DBS on PAC across low-high frequency combinations of oscillation band (delta (D), theta (T), alpha (A), beta (B) vs. Low (loG) and High (hiG) gamma), plotted separately for NTg (black) and TgAD (red) rats. Linear mixed-effects model predictions showed a positive relationship between DBS frequency and post-DBS modulation, particularly in low-frequency bands, with attenuated responses in TgAD rats at low DBS frequencies and increased at high DBS frequencies. (D) Same analysis as in panel (C), but for stimulation amplitude (2-20 &#956;A). Increased amplitude leads to enhanced modulation index responses, more prominently in TgAD animals at higher amplitudes. (E) Analysis of post-stimulation PAC response persistence of MI changes in theta-low gamma modulation following either short (10 s) or long (900 s) DBS trains. DBS-induced increases in theta-low gamma modulation decay at similar rates over time in both genotypes, with NTg rats showing larger changes in modulation overall.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="thnov15p10064g004.jpg"/></fig><fig position="float" id="F5" orientation="portrait"><label>Figure 5</label><caption><p><italic toggle="yes">DBS-elicited post-stimulation entrainment in TgAD rats with greater neuronal recruitment by 1 Hz than by 10 Hz DBS.</italic> (A) Representative spiking unit showing changes in its firing rate (FR) following DBS stimulation (start and end indicated by red lines) at different amplitudes (y-axis) and different frequencies (top panel: 1 Hz, bottom panel: 10 Hz). (B) Spiking unit characteristics: average waveform (black) with individual waveforms (gray) of a putative hippocampal neuron during recording. (C) Normalized polar-plot histogram of spike phases for two representative units following DBS (colored bins) compared to baseline (no stimulation, red-dotted line) indicating an increase in entrainment, i.e. with spike phases aligning to the stimulation. (D) Change in Pairwise Phase Consistency (PPC, calculated from all spike phases) during stimulation (light blue) and following stimulation (orange) at different DBS frequencies. (E) Change in Firing Rate (FR) during DBS (light blue) and after DBS (orange) at different frequencies. (F) Change in PPC relative to pre-stimulus baseline of spiking units in NTg (black) and TgAD (red) rats at 1 Hz (left) and 10 Hz (right): mean change at 1 Hz: NTg = +9.9%&#177;14.8% vs. TgAD = +7.1%&#177;11.2%, p &lt; 0.001; mean change at 10 Hz: NTg = +7.8%&#177;14.2% vs. TgAD = +6.2%&#177;10.5%, p &lt; 0.001. (G) Number of responding units (NRU), expressed as a percentage of the total number of recorded units, showing significant PPC changes during (top) and after (bottom) DBS, in response to different DBS frequencies (1 Hz, green vs. 10 Hz, purple). The number of neurons entrained during 10 Hz DBS was 30.3&#177;16.4%; while the number of neurons entrained post-10 Hz DBS was significantly higher, namely, 81.6&#177;15.7% p &lt; 0.001. (H) Change in spiking units' FR relative to pre-stimulus baseline in NTg (black) and TgAD (red) in response to 1 Hz DBS (left) and 10 Hz DBS (right). (I) Number of spiking units showing significant FR changes during (top) and post (bottom) DBS, in response to different DBS frequencies (1 Hz, lime vs. 10 Hz, lavender). Pairwise test for significance performed using Tukey-Kramer post-hoc test.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="thnov15p10064g005.jpg"/></fig></floats-group></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Arch Endocrinol Metab</journal-id><journal-id journal-id-type="iso-abbrev">Arch Endocrinol Metab</journal-id><journal-id journal-id-type="pmc-domain-id">4353</journal-id><journal-id journal-id-type="pmc-domain">archem</journal-id><journal-id journal-id-type="publisher-id">aem</journal-id><journal-title-group><journal-title>Archives of Endocrinology and Metabolism</journal-title></journal-title-group><issn pub-type="ppub">2359-3997</issn><issn pub-type="epub">2359-4292</issn><publisher><publisher-name>Sociedade Brasileira de Endocrinologia e Metabologia</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12483173</article-id><article-id pub-id-type="pmcid-ver">PMC12483173.1</article-id><article-id pub-id-type="pmcaid">12483173</article-id><article-id pub-id-type="pmcaiid">12483173</article-id><article-id pub-id-type="pmid">40893026</article-id><article-id pub-id-type="doi">10.20945/2359-4292-2025-0074</article-id><article-id pub-id-type="other">01108</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original</subject></subj-group></article-categories><title-group><article-title>Study of the early metabolic characteristics in patients undergoing
sleeve gastrectomy for the treatment of obesity and type 2 diabetes mellitus
(T2DM) using high-performance liquid chromatography combined with
high-resolution mass spectrometry via metabolomics technology</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0003-4586-4291</contrib-id><name name-style="western"><surname>Lu</surname><given-names initials="J">Junxuan</given-names></name><role>read</role><role>approved the final manuscript</role><role>responsible for the study design</role><role>literature research</role><role>clinical studies</role><role>experimental studies</role><role>data acquisition</role><role>analysis</role><role>statistical analysis</role><role>manuscript editing</role><xref rid="aff1" ref-type="aff">1</xref><xref rid="fn2" ref-type="fn">#</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0003-9544-9176</contrib-id><name name-style="western"><surname>Yang</surname><given-names initials="Y">Yinghui</given-names></name><role>read</role><role>approved the final manuscript</role><role>responsible for the clinical studies</role><role>manuscript preparation</role><xref rid="aff2" ref-type="aff">2</xref><xref rid="fn2" ref-type="fn">#</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0003-2049-5952</contrib-id><name name-style="western"><surname>Lyu</surname><given-names initials="D">Deyu</given-names></name><role>read</role><role>approved the final manuscript</role><role>responsible for the experimental studies</role><role>statistical analysis</role><role>manuscript editing</role><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1251-6760</contrib-id><name name-style="western"><surname>Ouyang</surname><given-names initials="Y">Yiming</given-names></name><role>read</role><role>approved the final manuscript</role><role>responsible for the definition of intellectual content</role><role>manuscript review</role><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0002-4050-7415</contrib-id><name name-style="western"><surname>Liao</surname><given-names initials="Y">Yingzhong</given-names></name><role>read</role><role>approved the final manuscript</role><role>responsible for the literature research</role><role>data acquisition</role><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-9978-0064</contrib-id><name name-style="western"><surname>Li</surname><given-names initials="Y">Yuejin</given-names></name><role>read</role><role>approved the final manuscript</role><role>responsible for the study design</role><role>data analysis</role><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0009-3683-836X</contrib-id><name name-style="western"><surname>Hou</surname><given-names initials="D">Dezhi</given-names></name><role>read</role><role>approved the final manuscript</role><role>responsible for the data acquisition</role><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-2499-6319</contrib-id><name name-style="western"><surname>Sheng</surname><given-names initials="P">Ping</given-names></name><role>read</role><role>approved the final manuscript</role><role>responsible for the guarantor of integrity of the entire study</role><role>experimental studies</role><role>manuscript review</role><xref rid="aff1" ref-type="aff">1</xref><xref rid="fn1" ref-type="fn">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0009-6837-0351</contrib-id><name name-style="western"><surname>Li</surname><given-names initials="L">Linhai</given-names></name><role>read</role><role>approved the final manuscript</role><role>responsible for the guarantor of integrity of the entire study</role><role>study concepts</role><xref rid="c1" ref-type="corresp"/><xref rid="aff1" ref-type="aff">1</xref><xref rid="fn1" ref-type="fn">*</xref></contrib></contrib-group><aff id="aff1">
<label>1</label> Department of General Surgery, The First People&#8217;s Hospital of
Yunnan Province, The Affiliated Hospital of Kunming University of Science and
Technology, Kunming, Yunnan Province, China </aff><aff id="aff2">
<label>2</label> Department of General Surgery, The Affiliated Hospital of Kunming
University of Science and Technology, The First People&#8217;s Hospital of Yunnan
Province, Kunming, Yunnan Province, China </aff><aff id="aff3">
<label>3</label> Department of General Surgery, Yong Ren People&#8217;s Hospital,
Chuxiong, Yunnan Province, China </aff><author-notes><corresp id="c1"><bold>Correspondence to:</bold> Linhai Li, Department of General
Surgery, The First People&#8217;s Hospital of Yunnan Province, The Affiliated Hospital
of Kunming University of Science and Technology, No. 157 Jinbi Road, Kunming
650032, Yunnan Province, China, <email>linhai2525@163.com</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>18</day><month>8</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2025</year></pub-date><volume>69</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">495514</issue-id><elocation-id>e250074</elocation-id><history><date date-type="received"><day>02</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>23</day><month>5</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>18</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-01 11:25:52.917"><day>01</day><month>10</month><year>2025</year></date></event></pub-history><permissions><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="2359-4292-aem-69-04-e250074.pdf"/><abstract><sec><title>Objective</title><p>To investigate the impact of laparoscopic sleeve gastrectomy (SG) on plasma
metabolites in obese patients with type 2 diabetes mellitus (T2DM) and
identify key metabolites associated with weight loss. Subjects and</p></sec><sec><title>methods</title><p>Nineteen obese T2DM patients who underwent SG surgery were selected as the
study participants. Preoperative and postoperative plasma samples and
clinical data were collected. High-performance liquid chromatography-mass
spectrometry (LC-MS/MS) was used to detect plasma metabolites, and changes
in the levels of metabolites before and after surgery were analysed and
compared.</p></sec><sec><title>Results</title><p>After the surgery, metabolic indicators such as body weight, BMI, fasting
blood glucose, and glycated haemoglobin significantly decreased. Metabolomic
analysis revealed 85 metabolites with differential abundance, among which
the levels of 50 metabolites (such as homocysteine and oleic acid)
significantly increased after the surgery, and the levels of 35 metabolites
(such as corticosterone and glutamic acid) significantly decreased. The
changes in the abundance of these metabolites were closely related to
surgical weight loss and improvements in glycolipid metabolism.</p></sec><sec><title>Conclusion</title><p>Laparoscopic sleeve gastrectomy effectively improves glycolipid metabolism in
obese patients with T2DM by affecting the levels of specific metabolites.
Metabolites such as homocysteine and chenodeoxycholic acid can serve as
potential markers for assessing surgical efficacy. This study provides an
important basis for developing a deeper understanding of the metabolic
mechanisms of SG surgery and can aid clinicians in evaluating surgical
outcomes and the prognosis of this surgery in patients.</p></sec></abstract><kwd-group><kwd>Obesity</kwd><kwd>type 2 diabetes mellitus</kwd><kwd>laparoscopic sleeve gastrectomy</kwd><kwd>metabolomics</kwd><kwd>weight loss</kwd></kwd-group><funding-group><award-group><funding-source>Yunnan Digestive Endoscopy Clinical Medical Center Foundation
for Health Commission of Yunnan Province</funding-source><award-id>2021LCZXXF-XH10</award-id><award-id>2022LCZXKF-XH09</award-id><award-id>ZX2019-01-02</award-id></award-group><award-group><funding-source>Yunnan Fundamental Research Projects</funding-source><award-id>202201AU070031</award-id></award-group><funding-statement><bold>Funding:</bold> this study was founded by the Yunnan
Digestive Endoscopy Clinical Medical Center Foundation for Health Commission of
Yunnan Province (2021LCZXXF-XH10) and (2022LCZXKF-XH09) of (ZX2019-01-02),
Yunnan Fundamental Research Projects (grant NO.
202201AU070031).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Obesity is a complex metabolic disease affecting individuals worldwide. Approximately
39% of adults worldwide are overweight, and 13% are obese (<sup><xref rid="r1" ref-type="bibr">1</xref></sup>). Obesity significantly increases
the risk of metabolic diseases such as diabetes, particularly type 2 diabetes
mellitus (T2DM), which has become one of the most common complications in obese
patients and poses a serious threat to human health, as well as cardiovascular
diseases. Currently, there are over 400 million diabetic patients globally, with
T2DM accounting for more than 90%, and insulin resistance is its core feature
(<sup><xref rid="r2" ref-type="bibr">2</xref></sup>). Elevated insulin
levels not only affect lipid metabolism, leading to increased fat synthesis and
hyperlipidaemia but also may exacerbate insulin resistance through &#946;-cell
apoptosis, thereby promoting the development of T2DM (<sup><xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r4" ref-type="bibr">4</xref></sup>).</p><p>In recent years, bariatric surgery has emerged as a new strategy for the treatment of
T2DM, achieving remarkable results. Studies have shown that bariatric surgery is
highly effective in achieving stable blood glucose control in T2DM patients with
concurrent obesity, outperforming comprehensive medical treatment (<sup><xref rid="r5" ref-type="bibr">5</xref></sup>). Among the various procedures,
sleeve gastrectomy (SG) has become the preferred option for treating obese T2DM
patients because of its advantages of simple operation, few complications,
significant weight loss, and stable glycaemic control, especially when combined with
laparoscopic techniques, which further reduce the risk of trauma and infection.</p><p>In exploring the mechanisms of bariatric surgery, metabolomics, as an emerging
technology, provides a powerful tool for revealing metabolic changes during the
disease process through comprehensive analysis of body metabolites using
high-performance liquid chromatography-mass spectrometry (LC-MS/MS). Metabolomics
can reflect changes in metabolites under pathophysiological conditions, aiding in
the understanding of disease-related metabolic pathways and potential pathogenesis
(<sup><xref rid="r6" ref-type="bibr">6</xref></sup>). Recent studies have
further emphasized the role of metabolomics in elucidating the metabolic effects of
bariatric surgery. For example, a 2023 study utilizing metabolomics demonstrated
that metabolic changes postsurgery, particularly in amino acid and lipid metabolism,
correlate with improvements in cardiovascular function and insulin sensitivity
(<sup><xref rid="r7" ref-type="bibr">7</xref></sup>). Another 2024 study
highlighted the utility of LC-MS/MS in profiling metabolic alterations, revealing
that postbariatric surgery patients develop significant shifts in the levels of
branched-chain amino acids and acylcarnitines, which are linked to enhanced
metabolic health (<sup><xref rid="r8" ref-type="bibr">8</xref></sup>). Although
bariatric surgery has achieved significant clinical success, its specific mechanisms
are not fully understood.</p><p>Previous studies using metabolomics technology to analyse metabolic changes in
patients before and after bariatric surgery have identified key metabolites related
to surgical outcomes (<sup><xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref></sup>). However, the focus of these
studies has been mostly on postoperative metabolic changes, with less comprehensive
comparisons of preoperative and postoperative metabolic characteristics. Therefore,
the aim of this study is to systematically analyse changes in the levels of plasma
metabolites in obese T2DM patients before and after laparoscopic sleeve gastrectomy
using LC-MS/MS technology, identify metabolites that mediate the effects of
bariatric surgery, and explore their correlation with weight loss, providing a
scientific basis for predicting surgical efficacy and developing novel therapeutic
strategies.</p></sec><sec sec-type="materials|methods"><title>MATERIALS AND METHODS</title><sec><title>Study design</title><p>This study is a prospective observational prepost study designed to identify
changes in the levels of plasma metabolites before and after weight loss surgery
using liquid chromatography-tandem mass spectrometry (LC-MS/MS) and to analyse
the correlation of these changes with weight loss.</p></sec><sec><title>Study subjects and sample collection</title><sec><title>Study subjects</title><p>In this study, 19 obese patients with type 2 diabetes mellitus (T2DM) who
underwent laparoscopic sleeve gastrectomy (SG) in our hospital between May
2022 and October 2022 were selected as study participants. All participants
signed informed consent forms before recruitment, and this study was
approved by the Ethics Committee of our hospital (Ethical code:
KHLL2022-KY021; Ethical approval date: 2022.02.21).</p><p>The inclusion criteria were as follows:</p><list list-type="simple"><list-item><p>(<sup><xref rid="r1" ref-type="bibr">1</xref></sup>) aged between 16
and 65 years;</p></list-item><list-item><p>(<sup><xref rid="r2" ref-type="bibr">2</xref></sup>) no severe organ
dysfunction;</p></list-item><list-item><p>(<sup><xref rid="r3" ref-type="bibr">3</xref></sup>) body mass index
(BMI) &gt; 27.5 kg/m<sup>2</sup> with two metabolic syndrome
components or 32.5 kg/m<sup>2</sup> &lt; BMI &lt; 50
kg/m<sup>2</sup>; and</p></list-item><list-item><p>(<sup><xref rid="r4" ref-type="bibr">4</xref></sup>) diagnosed with
type 2 diabetes.</p></list-item></list><p>The exclusion criteria were as follows:</p><list list-type="simple"><list-item><p>(<sup><xref rid="r1" ref-type="bibr">1</xref></sup>) aged less than
16 years or greater than 65 years;</p></list-item><list-item><p>(<sup><xref rid="r2" ref-type="bibr">2</xref></sup>) had severe organ
dysfunction;</p></list-item><list-item><p>(<sup><xref rid="r3" ref-type="bibr">3</xref></sup>) were not
eligible for weight loss surgery according to guidelines;</p></list-item><list-item><p>(<sup><xref rid="r4" ref-type="bibr">4</xref></sup>) had a definitive
diagnosis of type 1 diabetes;</p></list-item><list-item><p>(<sup><xref rid="r5" ref-type="bibr">5</xref></sup>) were unwilling
to undergo weight loss surgery or participate in postoperative
follow-up; and</p></list-item><list-item><p>(<sup><xref rid="r6" ref-type="bibr">6</xref></sup>) were suffering
from uncontrollable mental illness or intellectual disability.</p></list-item></list></sec><sec><title>Sample collection</title><p>Fasting peripheral blood samples were collected from all patients one month
before and after surgery. During collection, EDTA anticoagulant vacuum tubes
were used, and the blood samples were gently mixed six to ten times to
prevent coagulation. The samples were subsequently centrifuged at 3000 rpm
for 20 minutes at 4 &#176;C, and the plasma was transferred to new centrifuge
tubes and quickly frozen in liquid nitrogen. All separated plasma samples
were stored in a -80 &#176;C freezer for subsequent analysis.</p></sec></sec><sec><title>Surgical procedure</title><p>After general anaesthesia, patients were placed in the supine position, and
laparoscopic sleeve gastrectomy was performed. The surgical procedure included
establishing pneumoperitoneum, inserting trocars, performing laparoscopic
exploration to ensure no abnormalities were present in the abdominal cavity,
flattening the greater omentum and gastrocolic ligament downwards, dissociating
the greater curvature of the stomach and the cardia, transecting the gastric
wall, suturing the incision margin, and other steps. After the surgery, a
drainage tube was placed, and the incision was closed.</p></sec><sec><title>Clinical data collection</title><p>Clinical data, including basic information, medical history, surgical details,
postoperative recovery, and other relevant information, were collected for
subsequent analysis and statistical analysis.</p></sec><sec><title>Metabolite extraction and analysis (<sup><xref rid="r11" ref-type="bibr">11</xref>,<xref rid="r12" ref-type="bibr">12</xref></sup>)</title><sec><title>Blood sample collection and processing</title><p>Stored plasma samples were thawed at 4 &#176;C and vortexed for 1 min to ensure
uniform mixing. The samples were then transferred to 2 mL centrifuge tubes,
and an internal standard mixture working solution and methanol were added.
After shaking, the samples were centrifuged to obtain the supernatant.
Following vacuum concentration and drying, the samples were reconstituted in
80% methanol solution, centrifuged and filtered again to obtain the final
samples for LC-MS detection.</p></sec><sec><title>Metabolomics detection and data analysis</title><p>Metabolomic analysis was performed using a Thermo Vanquish
ultrahigh-performance liquid chromatography system and a Thermo Orbitrap
Exploris 120 mass spectrometer. For data processing and statistical
analysis, MetaboAnalyst 5.0 and KEGG databases were used for pathway
enrichment and functional annotation.</p><p>Chromatographic and mass spectrometric conditions were specifically set, and
gradient elution and secondary fragmentation were conducted in positive and
negative ion modes to acquire metabolite mass spectrometric data. The
obtained metabolomics data were standardized, including centring and
adaptive scaling. Multivariate statistical analysis methods such as
Principal Component Analysis (PCA), Partial Least Squares Discriminant
Analysis (PLS-DA), and Orthogonal Partial Least Squares Discriminant
Analysis (OPLS-DA) were subsequently used for differential analysis of
metabolites. Metabolites with significant differences in abundance were
identified by setting screening criteria of VIP &gt; 1 and P &lt; 0.05.</p><p>To address the issue of multiple comparisons, the Benjamini-Hochberg (false
discovery rate, FDR) method was applied to correct P values, ensuring the
reliability of the differentially abundant metabolites that were
identified.</p><p>Functional annotation and pathway analysis were performed on the selected
metabolites whose levels significantly differed, and visualizations were
created using charts to facilitate a more intuitive understanding of
metabolite trends and their correlation with weight loss.</p></sec></sec><sec><title>Data analysis and statistics</title><p>Clinical data were analysed using SPSS 25 software for descriptive statistics, t
tests/ANOVAs, chi-square tests, and correlation analyses to assess changes in
clinical indicators before and after surgery. After preprocessing and
multivariate statistical analysis of the metabolomics data, the screening
results of significantly different changes in metabolite levels were further
verified through t tests or nonparametric tests. Finally, a comprehensive
analysis and discussion were conducted in conjunction with the clinical
data.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>This study aimed to explore the impact of laparoscopic sleeve gastrectomy (SG) on the
preoperative and postoperative metabolic characteristics of patients with obesity
and type 2 diabetes mellitus (T2DM). By analysing plasma samples from 19 patients
who underwent SG surgery using liquid chromatography-tandem mass spectrometry
(LC-MS/MS) and integrating clinical data, we systematically assessed metabolic
changes before and after surgery.</p><sec><title>Changes in clinical indicators</title><p>One month after surgical intervention, patients&#8217; weight, BMI, and multiple
biochemical indicators significantly changed (<bold><xref rid="t1" ref-type="table">Table 1</xref></bold>). Specifically, the average weight of the
patients significantly decreased from 103.58&#177;11.02 kg before surgery to
86.53&#177;12.34 kg after surgery (P&lt;0.01), and the BMI also decreased from
37.74&#177;2.86 kg/m<sup>2</sup> to 31.78&#177;3.35 kg/m<sup>2</sup>
(P&lt;0.01), indicating the surgery&#8217;s marked effectiveness in weight reduction.
In terms of biochemical indicators, fasting blood glucose, glycated haemoglobin,
total cholesterol, triglycerides, and low-density lipoprotein significantly
decreased (P&lt;0.01), demonstrating that surgery improved patients&#8217; glucose and
lipid metabolism. However, uric acid levels significantly increased (P&lt;0.05),
possibly related to the metabolic adaptation process after surgery. Notably,
serum C-peptide, high-density lipoprotein, bilirubin, and transaminase levels
did not significantly change between before and after surgery.</p><table-wrap position="float" id="t1" orientation="portrait"><label>Table 1</label><caption><p>General clinical data of patients before and after surgery</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Name</th><th align="center" rowspan="1" colspan="1">7 Days Pre-Operation</th><th align="center" rowspan="1" colspan="1">1 Month Post-Operation</th><th align="center" rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Weight (kg)</td><td align="center" valign="top" rowspan="1" colspan="1">103.58&#177;11.02</td><td align="center" valign="top" rowspan="1" colspan="1">86.53&#177;12.34</td><td align="center" valign="top" rowspan="1" colspan="1">P&lt;0.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" valign="top" rowspan="1" colspan="1">37.74&#177;2.86</td><td align="center" valign="top" rowspan="1" colspan="1">31.78&#177;3.35</td><td align="center" valign="top" rowspan="1" colspan="1">P&lt;0.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fasting Blood Glucose (mmol/L)</td><td align="center" valign="top" rowspan="1" colspan="1">8.77&#177;1.89</td><td align="center" valign="top" rowspan="1" colspan="1">5.32&#177;1.06</td><td align="center" valign="top" rowspan="1" colspan="1">P&lt;0.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Glycated Hemoglobin (%)</td><td align="center" valign="top" rowspan="1" colspan="1">8.85&#177;1.11</td><td align="center" valign="top" rowspan="1" colspan="1">5.66&#177;0.65</td><td align="center" valign="top" rowspan="1" colspan="1">P&lt;0.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total Cholesterol (mmol/L)</td><td align="center" valign="top" rowspan="1" colspan="1">5.65&#177;1.07</td><td align="center" valign="top" rowspan="1" colspan="1">4.13&#177;0.57</td><td align="center" valign="top" rowspan="1" colspan="1">P&lt;0.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Triglycerides (mmol/L)</td><td align="center" valign="top" rowspan="1" colspan="1">2.36&#177;0.71</td><td align="center" valign="top" rowspan="1" colspan="1">1.36&#177;0.49</td><td align="center" valign="top" rowspan="1" colspan="1">P&lt;0.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Low-Density Lipoprotein (mmol/L)</td><td align="center" valign="top" rowspan="1" colspan="1">3.69&#177;0.79</td><td align="center" valign="top" rowspan="1" colspan="1">2.54&#177;0.69</td><td align="center" valign="top" rowspan="1" colspan="1">P&lt;0.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Uric Acid (mmol/L)</td><td align="center" valign="top" rowspan="1" colspan="1">441.00&#177;95.38</td><td align="center" valign="top" rowspan="1" colspan="1">532.74&#177;184.03</td><td align="center" valign="top" rowspan="1" colspan="1">P&lt;0.05</td></tr></tbody></table></table-wrap></sec><sec><title>Metabolomics analysis and pathway enrichment</title><sec><title>Pathway analysis</title><p>To elucidate the biological pathways affected by SG surgery, we performed
pathway enrichment analysis using the KEGG database. The analysis revealed
significant alterations in several metabolic routes, including the
following:</p><p><bold>Urea cycle: I</bold>ncreased levels of metabolites such as homocysteine
and &#947;-aminobutyric acid suggest enhanced urea cycle activity
postsurgery, potentially contributing to improved nitrogen metabolism.</p><p><bold>Glycolysis:</bold> Upregulation of intermediates such as
dihydroxyacetone phosphate and fructose 1,6-bisphosphate indicates enhanced
glycolytic flux, which aligns with the observed improvements in glucose
metabolism.</p><p><bold>Fatty acid metabolism:</bold> Elevated oleic acid and decreased sebacic
acid levels suggest a shift towards healthier fatty acid profiles,
potentially reducing cardiovascular risk.</p></sec><sec><title>Principal Component Analysis (PCA)</title><p>PCA was performed on the metabolite data before and after surgery, and the
results revealed that the PCA score plots in both positive and negative ion
modes clearly exhibited intergroup separation trends (<bold><xref rid="f1" ref-type="fig">Figure 1</xref></bold>). This finding
indicates that the surgery had a significant effect on patients&#8217; metabolic
profiles. In positive ion mode, although some overlap was present, samples
from the preoperative and postoperative groups could generally be
distinguished. In negative ion mode, the intergroup separation was even
clearer, further confirming the significant impact of the surgery on the
patients&#8217; metabolic profiles.</p><p>
<fig position="float" id="f1" orientation="portrait"><label>Figure 1</label><caption><p>PCA Score Plots in Positive/Negative Ion Modes.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="2359-4292-aem-69-04-e250074-g01.jpg"/><attrib>(Note: A represents the PCA score plot in positive ion mode, and
B represents the PCA score plot in negative ion mode. Circles of
different colors represent samples from different groups
(preoperative and postoperative groups).</attrib></fig>
</p><p>Partial Least Squares Discriminant Analysis (PLS-DA) and Orthogonal Partial
Least Squares Discriminant Analysis (OPLS-DA)</p><p>To further enhance the significance of intergroup differences, we employed
two supervised data analysis methods: PLS-DA and OPLS-DA. As shown in
<bold><xref rid="f2" ref-type="fig">Figure 2</xref></bold>, both
methods effectively distinguished between the preoperative and postoperative
groups. In both positive and negative ion modes, the PLS-DA score plots
showed more pronounced intergroup separation trends than the PCA score plots
did, highlighting the advantage of PLS-DA in discerning intergroup
differences. Through orthogonal transformation correction, OPLS-DA further
reduced the interference of intergroup data, making the intergroup
differences even more significant, indicating that surgery had a profound
impact on the patients&#8217; metabolic profiles.</p><p>
<fig position="float" id="f2" orientation="portrait"><label>Figure 2</label><caption><p>PLS-DA and OPLS-DA Score Plots in Positive/Negative Ion
Modes.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="2359-4292-aem-69-04-e250074-g02.jpg"/><attrib>(Note: A represents the PLS-DA score plot in positive ion mode,
B represents the PLS-DA score plot in negative ion mode, C
represents the OPLS-DA score plot in positive ion mode, and D
represents the OPLS-DA score plot in negative ion mode.)</attrib></fig>
</p></sec></sec><sec><title>Screening of differentially abundant metabolites</title><p>On the basis of the results of the OPLS-DA model, we further screened for
metabolites with significant differences in abundance. By setting a screening
criterion of VIP &gt; 1 and P&lt;0.05, we identified a total of 85 metabolites
with differential abundance (<bold><xref rid="f3" ref-type="fig">Figure
3</xref></bold>). To focus on the most relevant findings, we present the top
10 upregulated and downregulated metabolites in the main manuscript (<bold><xref rid="t2" ref-type="table">Tables 2</xref> and <xref rid="t3" ref-type="table">3</xref></bold>), while the full list is available in the
Supplementary Material (all indicators are listed in <xref rid="t4" ref-type="table">Appendix Tables S1</xref> and <xref rid="t5" ref-type="table">S2</xref>).</p><table-wrap position="float" id="t2" orientation="portrait"><label>Table 2</label><caption><p>Top 10 upregulated metabolites post-surgery</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Name</th><th align="center" rowspan="1" colspan="1">FC</th><th align="center" rowspan="1" colspan="1">P.value</th><th align="center" rowspan="1" colspan="1">VIP</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Homocysteine</td><td align="center" rowspan="1" colspan="1">1.05</td><td align="center" rowspan="1" colspan="1">0.04061</td><td align="center" rowspan="1" colspan="1">1.378637</td></tr><tr><td align="left" rowspan="1" colspan="1">Dihydroxyacetone phosphate</td><td align="center" rowspan="1" colspan="1">1.01</td><td align="center" rowspan="1" colspan="1">0.00001</td><td align="center" rowspan="1" colspan="1">2.952681</td></tr><tr><td align="left" rowspan="1" colspan="1">Homocitrulline</td><td align="center" rowspan="1" colspan="1">1.06</td><td align="center" rowspan="1" colspan="1">0.00012</td><td align="center" rowspan="1" colspan="1">2.479983</td></tr><tr><td align="left" rowspan="1" colspan="1">Diaminopimelic acid</td><td align="center" rowspan="1" colspan="1">1.01</td><td align="center" rowspan="1" colspan="1">0.00810</td><td align="center" rowspan="1" colspan="1">1.8863</td></tr><tr><td align="left" rowspan="1" colspan="1">Capsidiol</td><td align="center" rowspan="1" colspan="1">1.13</td><td align="center" rowspan="1" colspan="1">0.01109</td><td align="center" rowspan="1" colspan="1">1.87746</td></tr><tr><td align="left" rowspan="1" colspan="1">Lidocaine</td><td align="center" rowspan="1" colspan="1">1.01</td><td align="center" rowspan="1" colspan="1">0.01817</td><td align="center" rowspan="1" colspan="1">2.071903</td></tr><tr><td align="left" rowspan="1" colspan="1">Oleic acid</td><td align="center" rowspan="1" colspan="1">1.01</td><td align="center" rowspan="1" colspan="1">0.00024</td><td align="center" rowspan="1" colspan="1">2.732886</td></tr><tr><td align="left" rowspan="1" colspan="1">Avermectin A1b aglycone</td><td align="center" rowspan="1" colspan="1">1.03</td><td align="center" rowspan="1" colspan="1">0.00068</td><td align="center" rowspan="1" colspan="1">1.537676</td></tr><tr><td align="left" rowspan="1" colspan="1">gamma-Aminobutyric acid</td><td align="center" rowspan="1" colspan="1">3.35</td><td align="center" rowspan="1" colspan="1">0.00003</td><td align="center" rowspan="1" colspan="1">1.697852</td></tr><tr><td align="left" rowspan="1" colspan="1">(R)-3-Hydroxybutyric acid</td><td align="center" rowspan="1" colspan="1">4.18</td><td align="center" rowspan="1" colspan="1">0.00015</td><td align="center" rowspan="1" colspan="1">1.762207</td></tr></tbody></table></table-wrap><table-wrap position="float" id="t3" orientation="portrait"><label>Table 3</label><caption><p>Top 10 downregulated metabolites post-surgery</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Name</th><th align="center" rowspan="1" colspan="1">FC</th><th align="center" rowspan="1" colspan="1">P.value</th><th align="center" rowspan="1" colspan="1">VIP</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Methyl jasmonate</td><td align="center" valign="top" rowspan="1" colspan="1">0.99</td><td align="center" valign="top" rowspan="1" colspan="1">0.00000</td><td align="center" valign="top" rowspan="1" colspan="1">3.26913</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">5-Nitro-2-(3-phenylpropylamino)benzoic
acid</td><td align="center" valign="top" rowspan="1" colspan="1">0.99</td><td align="center" valign="top" rowspan="1" colspan="1">0.02193</td><td align="center" valign="top" rowspan="1" colspan="1">1.054522</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Corticosterone</td><td align="center" valign="top" rowspan="1" colspan="1">0.99</td><td align="center" valign="top" rowspan="1" colspan="1">0.04412</td><td align="center" valign="top" rowspan="1" colspan="1">1.705961</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Glutaric acid</td><td align="center" valign="top" rowspan="1" colspan="1">0.75</td><td align="center" valign="top" rowspan="1" colspan="1">0.00001</td><td align="center" valign="top" rowspan="1" colspan="1">1.874209</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">alpha-Ketoisovaleric acid</td><td align="center" valign="top" rowspan="1" colspan="1">0.69</td><td align="center" valign="top" rowspan="1" colspan="1">0.00119</td><td align="center" valign="top" rowspan="1" colspan="1">1.676745</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Indole</td><td align="center" valign="top" rowspan="1" colspan="1">0.68</td><td align="center" valign="top" rowspan="1" colspan="1">0.00015</td><td align="center" valign="top" rowspan="1" colspan="1">1.860401</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Guanidoacetic acid</td><td align="center" valign="top" rowspan="1" colspan="1">0.72</td><td align="center" valign="top" rowspan="1" colspan="1">0.00119</td><td align="center" valign="top" rowspan="1" colspan="1">1.780082</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3-Methylthiopropionic acid</td><td align="center" valign="top" rowspan="1" colspan="1">0.65</td><td align="center" valign="top" rowspan="1" colspan="1">0.00017</td><td align="center" valign="top" rowspan="1" colspan="1">1.952029</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mesaconate</td><td align="center" valign="top" rowspan="1" colspan="1">0.67</td><td align="center" valign="top" rowspan="1" colspan="1">0.00810</td><td align="center" valign="top" rowspan="1" colspan="1">1.532931</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">L-Ribulose</td><td align="center" valign="top" rowspan="1" colspan="1">0.83</td><td align="center" valign="top" rowspan="1" colspan="1">0.04412</td><td align="center" valign="top" rowspan="1" colspan="1">1.155728</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tartaric acid</td><td align="center" valign="top" rowspan="1" colspan="1">0.79</td><td align="center" valign="top" rowspan="1" colspan="1">0.02404</td><td align="center" valign="top" rowspan="1" colspan="1">1.337211</td></tr></tbody></table></table-wrap><p>
<fig position="float" id="f3" orientation="portrait"><label>Figure 3</label><caption><p>Pie Chart of Differential Metabolites. Metabolite pie chart.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="2359-4292-aem-69-04-e250074-g03.jpg"/></fig>
</p></sec><sec><title>Heatmap analysis of differentially abundant metabolites</title><p>Through heatmap analysis (<bold><xref rid="f4" ref-type="fig">Figure
4</xref></bold> and <bold><xref rid="f5" ref-type="fig">Figure
5</xref></bold>), we can more intuitively demonstrate the differences in
metabolic profiles before and after surgery. The heatmaps revealed that
metabolites such as homocysteine and oleic acid were significantly upregulated
in the postoperative group, whereas metabolites such as corticosterone and
glutamic acid were markedly downregulated. <bold><xref rid="f5" ref-type="fig">Figure 5</xref></bold> further illustrates the clustering of
differentially abundant metabolites based on their biological categorization,
highlighting the coordinated changes in amino acids, carbohydrates, and fatty
acids.</p><p>
<fig position="float" id="f4" orientation="portrait"><label>Figure 4</label><caption><p>Heatmap of Differential Molecules.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="2359-4292-aem-69-04-e250074-g04.jpg"/><attrib>Differential molecular heat map.</attrib><attrib>(Note: The relative content changes of differential metabolites
before and after surgery are displayed. Redder colors indicate higher
expression levels, while bluer colors indicate lower expression
levels.)</attrib></fig>
</p><p>
<fig position="float" id="f5" orientation="portrait"><label>Figure 5</label><caption><p>Differential Molecular Class Heat Map.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="2359-4292-aem-69-04-e250074-g05.jpg"/><attrib>Note: Cluster analysis was performed based on the categories of
differential metabolites, showcasing the trends in metabolite changes
before and after surgery across different categories.</attrib></fig>
</p></sec><sec><title>Volcano plot analysis of differences</title><p>The volcano plot (<bold><xref rid="f6" ref-type="fig">Figure 6</xref></bold>)
visually represents the distribution of differentially abundant metabolites.
Through this plot, we can clearly identify metabolites with significant
differences in abundance before and after surgery, providing a foundation for
subsequent functional analysis. The red dots represent upregulated metabolites,
the blue dots represent downregulated metabolites, and the grey dots represent
metabolites whose levels did not significantly change. Notably, metabolites with
the greatest fold changes, such as homocysteine and corticosterone, are clearly
visible at the extremes of the plot.</p><p>
<fig position="float" id="f6" orientation="portrait"><label>Figure 6</label><caption><p>Differential Volcano Map.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="2359-4292-aem-69-04-e250074-g06.jpg"/><attrib>(Note: The x-axis represents the log2FC value, indicating the
logarithmic change in metabolite expression levels between postoperative
and preoperative states; the y-axis represents the -log10P value,
indicating the statistical significance of metabolite
differences.)</attrib></fig>
</p></sec><sec><title>Scatter diagram analysis of charge ratio and P-value for differentially
abundant metabolites</title><p>The scatter diagram of the charge ratio and P value (<bold><xref rid="f7" ref-type="fig">Figure 7</xref></bold>) displays the relationship between the
mass-charge ratio (m/z) of the metabolites and their P values in the statistical
tests. This plot allows us to observe the distribution of metabolites whose
levels were significantly different in terms of their mass-charge ratios and P
values. Metabolites with lower P values (higher statistical significance) are
clustered towards the top of the plot, whereas those with higher m/z values are
distributed towards the right.</p><p>
<fig position="float" id="f7" orientation="portrait"><label>Figure 7</label><caption><p>Scatter diagram of charge ratio and P value of different metabolic
substances.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="2359-4292-aem-69-04-e250074-g07.jpg"/><attrib>(Note: The x-axis represents the mass-to-charge ratio (m/z) of
metabolites, and the y-axis represents the P-value of metabolite
differences. Each point represents a single metabolite.)</attrib></fig>
</p></sec><sec><title>Z score plot analysis of differentially abundant metabolites</title><p>We created a Z score plot (<bold><xref rid="f8" ref-type="fig">Figure
8</xref></bold>) on the basis of metabolic data to visually represent
changes in the relative content of metabolites. The Z score, calculated using
the mean and standard deviation of the preoperative group, provides a
standardized measure of metabolite levels. Positive Z scores indicate increased
metabolite levels postsurgery, whereas negative Z scores indicate decreased
levels. This plot facilitates a direct comparison of metabolite changes across
the cohort.</p><p>
<fig position="float" id="f8" orientation="portrait"><label>Figure 8</label><caption><p>Difference Metabolite Z-score Score Chart.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="2359-4292-aem-69-04-e250074-g08.jpg"/><attrib>(Note: The figure shows the Z-score values of different metabolites
before and after surgery, reflecting changes in their relative
content.)</attrib></fig>
</p><p>In summary, through clinical indicator analysis and metabolomics analysis, we
systematically assessed the impact of laparoscopic sleeve gastrectomy on the
preoperative and postoperative metabolic characteristics of obese patients with
type 2 diabetes. These results indicate that while surgery significantly reduces
patients&#8217; weight, it also exerts a profound and stable influence on their
metabolic profiles. The observed metabolic changes, particularly in the urea
cycle, glycolysis, and fatty acid metabolism pathways, provide new insights into
the mechanisms by which surgery improves glucose and lipid metabolism. These
findings offer important data support for future research with the aim of
optimizing surgical outcomes and developing novel therapeutic strategies.</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>The aim of this study is to systematically analyse the changes in plasma metabolites
before and after laparoscopic sleeve gastrectomy (SG) in patients with obesity and
type 2 diabetes mellitus (T2DM) using liquid chromatography-tandem mass spectrometry
(LC-MS/MS). The objective of this study is to identify metabolites that mediate the
effects of bariatric surgery and explore their correlation with weight loss
outcomes. The main results revealed that, after surgery, patients presented
significant reductions in weight, BMI, and the levels of fasting blood glucose,
glycated haemoglobin, total cholesterol, triglycerides, and low-density lipoprotein,
whereas uric acid levels increased notably. Metabolomic analysis revealed 85
metabolites with differential abundance, with 50 showing a significant increase and
35 showing a significant decrease in relative abundance. Notably, the levels of
metabolites such as homocysteine, chenodeoxycholic acid, corticosterone, and
glutamic acid exhibited particularly significant changes before and after surgery,
revealing the potential of these metabolites as biomarkers for assessing the
efficacy of bariatric surgery.</p><p>Compared with previous studies (<sup><xref rid="r13" ref-type="bibr">13</xref>,<xref rid="r14" ref-type="bibr">14</xref></sup>), in this study, postoperative
metabolic changes were evaluated, and preoperative and postoperative metabolic
profiles were systematically compared. The emphasis of earlier research has been
primarily postoperative metabolic alterations (<sup><xref rid="r15" ref-type="bibr">15</xref>,<xref rid="r16" ref-type="bibr">16</xref></sup>), whereas this
study, through comprehensive preoperative and postoperative comparisons, reveals
deeper insights into the impact of bariatric surgery on metabolites. Furthermore, a
more diverse range of differentially abundant metabolites, encompassing amino acids,
peptides, carbohydrates, fatty acids, and other categories, were identified in this
study, offering a more holistic perspective on the metabolic mechanisms of bariatric
surgery. For example, compared with studies by Yadav and cols. and Tan and cols.
(<sup><xref rid="r17" ref-type="bibr">17</xref>,<xref rid="r18" ref-type="bibr">18</xref></sup>), this study not only identified similar
metabolite changes, such as decreases in corticosterone and glutamic acid levels,
but also revealed additional potential metabolic markers, including increases in
homocysteine and chenodeoxycholic acid levels.</p><p>Changes in the levels of metabolites before and after surgery reveal the impact of SG
on the metabolic mechanisms of patients with obesity and T2DM. The significant
increase in homocysteine levels postsurgery is noteworthy (<sup><xref rid="r19" ref-type="bibr">19</xref></sup>). While homocysteine is often
associated with cardiovascular risk, its elevation in this context may reflect
complex metabolic adaptations following surgery (<sup><xref rid="r20" ref-type="bibr">20</xref></sup>). Importantly, hyperhomocysteinaemia is more
commonly linked to cardiovascular risk than to improved metabolic status, suggesting
that the observed increase in homocysteine should be interpreted with caution.</p><p>The marked decrease in glutamic acid levels may reflect adjustments in energy
metabolism status after surgery, echoing the findings of Lecoutre and cols. on
glutaminase activity and metabolic health (<sup><xref rid="r20" ref-type="bibr">20</xref></sup>).</p><p>Furthermore, the increase in homocysteine levels may indirectly reflect improvements
in insulin resistance and inflammatory responses due to surgery. However, it is
crucial to consider nutritional deficiencies, particularly in vitamin B12 and
folate, as potential explanations for elevated homocysteine levels (<sup><xref rid="r21" ref-type="bibr">21</xref></sup>). Bariatric surgery can sometimes
lead to malabsorption of these essential nutrients, which are critical for
homocysteine metabolism. Clinicians should be vigilant about monitoring and
addressing potential deficiencies to mitigate any associated risks.</p><p>To further explore the metabolic effects of SG, we performed a pathway enrichment
analysis. This analysis revealed significant alterations in key metabolic pathways,
including amino acid metabolism, fatty acid metabolism, and the
hypothalamic-pituitary-adrenal (HPA) axis (<sup><xref rid="r22" ref-type="bibr">22</xref></sup>). These pathways are closely linked to glucose metabolism,
insulin resistance, and inflammation, providing a broader context for understanding
the metabolic improvements observed after surgery.</p><p>The changes in amino acid abundance, particularly glutamic acid, suggest improvements
in insulin sensitivity and pancreatic beta-cell function. An increase in oleic acid
levels indicates increased insulin sensitivity and reduced lipotoxicity,
contributing to the overall metabolic benefits of SG (<sup><xref rid="r23" ref-type="bibr">23</xref>,<xref rid="r24" ref-type="bibr">24</xref></sup>). The
decrease in corticosterone levels may reflect normalization of the HPA axis,
potentially leading to reduced inflammation and improved glucose metabolism.</p><p>These metabolic changes may also have implications for other systems. For example,
alterations in the gut microbiota, mediated by the gut-brain axis, could influence
host metabolism and energy balance, partly contributing to the observed metabolic
improvements (<sup><xref rid="r25" ref-type="bibr">25</xref></sup>). Similarly,
changes in adipose tissue function and its communication with other organs might be
reflected in the plasma metabolic profile (<sup><xref rid="r26" ref-type="bibr">26</xref></sup>).</p><p>The identification of key metabolites and pathways affected by SG offers the
potential for therapeutic interventions. Targeting these pathways could enhance the
metabolic benefits of SG or provide alternative treatment options to patients
ineligible for surgery. Modulating the HPA axis or gut-brain axis represents an
additional strategy for improving metabolic health.</p><p>The marked decrease in glutamic acid levels may promote energy expenditure and
metabolic health, as suggested by its inverse relationship with metabolic syndrome
components in prior studies (<sup><xref rid="r27" ref-type="bibr">27</xref></sup>).</p><p>The results indicate that various metabolites undergo significant changes after
sleeve gastrectomy, which are closely related to surgical improvements in glucose
and lipid metabolism (<sup><xref rid="r28" ref-type="bibr">28</xref>-<xref rid="r30" ref-type="bibr">30</xref></sup>). Specifically, the increase in
homocysteine levels may be associated with postoperative malnutrition and
deficiencies in vitamin B12 and folate, suggesting the need for clinical attention
to hyperhomocysteinaemia in patients and guidance on timely vitamin supplementation
(<sup><xref rid="r31" ref-type="bibr">31</xref>,<xref rid="r32" ref-type="bibr">32</xref></sup>). The significant downregulation of corticosterone
may indicate reduced aldosterone secretion in patients, thereby improving insulin
resistance and glucose metabolic disorders (<sup><xref rid="r33" ref-type="bibr">33</xref>,<xref rid="r34" ref-type="bibr">34</xref></sup>). The decrease in
glutamic acid levels may be related to improvements in metabolic abnormalities in
patients after surgery, indicating that glutamic acid levels can serve as a
potential target for assessing the efficacy of bariatric surgery (<sup><xref rid="r35" ref-type="bibr">35</xref></sup>). Additionally, the decrease in
phenylacetylglutamine (PAG) levels reflects a reduction in the risk of metabolic
syndrome-related diseases in patients after surgery (<sup><xref rid="r36" ref-type="bibr">36</xref></sup>).</p><p>Although this study has several meaningful findings, it also has limitations. First,
as a small-sample cross-sectional study, the results may be limited by sample size
and require validation through large-scale prospective cohort studies. Second,
although 85 differentially abundant metabolites were identified when the
preoperative status was compared with one month after surgery, weight loss continues
after receiving sleeve gastrectomy, and metabolic processes in the body also evolve.
Thus, short-term metabolic changes may differ from long-term metabolic processes in
patients, necessitating longer follow-up studies. Furthermore, this study employed
only a single high-performance liquid chromatography-high-resolution mass
spectrometry technique, which may not comprehensively screen all metabolites. Future
research should utilize a combination of techniques to validate the results.</p><p>The findings of this study are important for understanding the mechanisms by which
sleeve gastrectomy improves metabolic characteristics in patients with obesity and
T2DM. By identifying potential metabolic biomarkers, such as homocysteine,
corticosterone, glutamic acid, and phenylacetylglutamine, this study provides a
scientific basis for predicting surgical outcomes and developing novel therapeutic
strategies. Moreover, these metabolic biomarkers have great potential for clinical
application, assisting in postoperative follow-up monitoring and the formulation of
individualized treatment plans. For example, monitoring homocysteine levels can
guide timely vitamin B12 and folate supplementation (<sup><xref rid="r37" ref-type="bibr">37</xref></sup>); observing changes in corticosterone and glutamic
acid levels can be used to assess improvements in insulin resistance and glucose
metabolic disorders; and monitoring phenylacetylglutamine levels can be used to
understand the risk of metabolic syndrome-related diseases. Future research can
further explore the application value of these metabolic biomarkers in the
management of bariatric surgery patients.</p><p>In conclusion, in this study, changes in plasma metabolite levels before and after
laparoscopic sleeve gastrectomy (SG) in patients with obesity and type 2 diabetes
mellitus (T2DM) detected using liquid chromatography-tandem mass spectrometry
(LC-MS/MS) were systematically analysed. Various potential metabolic biomarkers
closely related to the effects of bariatric surgery, including homocysteine,
chenodeoxycholic acid, corticosterone, and glutamic acid, have been successfully
identified. The significant changes in the levels of these metabolites not only
reveal evidence of the relevant early impact of surgery on the metabolic system but
also provide new insights into the mechanisms by which surgery improves glucose and
lipid metabolism.</p><p>Despite limitations such as small sample size, short follow-up duration, and a single
technical approach, the results of this study still provide a scientific basis for
predicting surgical outcomes and developing novel therapeutic strategies. The
identified potential metabolic biomarkers have important applications in clinical
practice and can be used for postoperative follow-up monitoring and the formulation
of individualized treatment plans.</p><p>Future research needs to expand the sample size, conduct long-term follow-up, and
employ a combination of techniques to validate and extend the findings of this
study, aiming for a more comprehensive understanding of the impact of sleeve
gastrectomy on the metabolic characteristics of patients with obesity and T2DM. This
study offers new ideas and directions for research in this field.</p></sec></body><back><ack><title>Acknowledgements:</title><p>not applicable.</p></ack><fn-group><fn fn-type="other" id="fn2"><label>#</label><p>Junxuan Lu and Yinghui Yang are the co-first authors.</p></fn><fn fn-type="other" id="fn1"><label>*</label><p>Ping Sheng and Linhai Li are the co-corresponding authors.</p></fn><fn fn-type="other"><p><bold>Ethics approval and consent to participate:</bold> all participants signed
informed consent forms before recruitment, and this study was approved by the
Ethics Committee of The First People&#8217;s Hospital of Yunnan Province, The
Affiliated Hospital of Kunming University of Science and Technology (Ethical
code: KHLL2022-KY021; Ethical approval date: 21st., Feb., 2022).</p></fn><fn fn-type="other"><p><bold>Consent for publication:</bold> not applicable.</p></fn><fn fn-type="COI-statement"><p><bold>Disclosure:</bold> no potential conflict of interest relevant to this
article was reported.</p></fn></fn-group><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> this study was founded by the Yunnan Digestive Endoscopy
Clinical Medical Center Foundation for Health Commission of Yunnan Province
(2021LCZXXF-XH10) and (2022LCZXKF-XH09) of (ZX2019-01-02), Yunnan Fundamental
Research Projects (grant NO. 202201AU070031).</p></fn><fn fn-type="COI-statement"><p><bold>Disclosure:</bold> no potential conflict of interest relevant to this
article was reported.</p></fn></fn-group><sec sec-type="data-availability"><title>Availability of data and material:</title><p>all data generated or analysed during this study are included in this. Further
enquiries can be directed to the corresponding author.</p></sec><app-group><table-wrap position="anchor" id="t4" orientation="portrait"><label>Appendix Tables S1</label><caption><p>Upregulation of metabolites</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Name</th><th align="center" rowspan="1" colspan="1">FC</th><th align="center" rowspan="1" colspan="1">P.value</th><th align="center" rowspan="1" colspan="1">VIP</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Homocysteine</td><td align="center" valign="top" rowspan="1" colspan="1">1.05</td><td align="center" valign="top" rowspan="1" colspan="1">0.04061</td><td align="center" valign="top" rowspan="1" colspan="1">1.378637</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Dihydroxyacetone phosphate</td><td align="center" valign="top" rowspan="1" colspan="1">1.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.00001</td><td align="center" valign="top" rowspan="1" colspan="1">2.952681</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Homocitrulline</td><td align="center" valign="top" rowspan="1" colspan="1">1.06</td><td align="center" valign="top" rowspan="1" colspan="1">0.00012</td><td align="center" valign="top" rowspan="1" colspan="1">2.479983</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diaminopimelic acid</td><td align="center" valign="top" rowspan="1" colspan="1">1.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.00810</td><td align="center" valign="top" rowspan="1" colspan="1">1.8863</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Capsidiol</td><td align="center" valign="top" rowspan="1" colspan="1">1.13</td><td align="center" valign="top" rowspan="1" colspan="1">0.01109</td><td align="center" valign="top" rowspan="1" colspan="1">1.87746</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lidocaine</td><td align="center" valign="top" rowspan="1" colspan="1">1.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.01817</td><td align="center" valign="top" rowspan="1" colspan="1">2.071903</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Oleic acid</td><td align="center" valign="top" rowspan="1" colspan="1">1.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.00024</td><td align="center" valign="top" rowspan="1" colspan="1">2.732886</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Avermectin A1b aglycone</td><td align="center" valign="top" rowspan="1" colspan="1">1.03</td><td align="center" valign="top" rowspan="1" colspan="1">0.00068</td><td align="center" valign="top" rowspan="1" colspan="1">1.537676</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">gamma-Aminobutyric acid</td><td align="center" valign="top" rowspan="1" colspan="1">3.35</td><td align="center" valign="top" rowspan="1" colspan="1">0.00003</td><td align="center" valign="top" rowspan="1" colspan="1">1.697852</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">(R)-3-Hydroxybutyric acid</td><td align="center" valign="top" rowspan="1" colspan="1">4.18</td><td align="center" valign="top" rowspan="1" colspan="1">0.00015</td><td align="center" valign="top" rowspan="1" colspan="1">1.762207</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">o-Cresol</td><td align="center" valign="top" rowspan="1" colspan="1">2.71</td><td align="center" valign="top" rowspan="1" colspan="1">0.00068</td><td align="center" valign="top" rowspan="1" colspan="1">1.630099</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2-Furoate</td><td align="center" valign="top" rowspan="1" colspan="1">2.88</td><td align="center" valign="top" rowspan="1" colspan="1">0.00000</td><td align="center" valign="top" rowspan="1" colspan="1">2.333531</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">L-Malic acid</td><td align="center" valign="top" rowspan="1" colspan="1">1.69</td><td align="center" valign="top" rowspan="1" colspan="1">0.00033</td><td align="center" valign="top" rowspan="1" colspan="1">1.917608</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Urocanic acid</td><td align="center" valign="top" rowspan="1" colspan="1">1.5</td><td align="center" valign="top" rowspan="1" colspan="1">0.02632</td><td align="center" valign="top" rowspan="1" colspan="1">1.240233</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Oxoglutaric acid</td><td align="center" valign="top" rowspan="1" colspan="1">3.88</td><td align="center" valign="top" rowspan="1" colspan="1">0.00000</td><td align="center" valign="top" rowspan="1" colspan="1">2.330583</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">D-Xylose</td><td align="center" valign="top" rowspan="1" colspan="1">1.29</td><td align="center" valign="top" rowspan="1" colspan="1">0.03142</td><td align="center" valign="top" rowspan="1" colspan="1">1.093397</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gentisic acid</td><td align="center" valign="top" rowspan="1" colspan="1">2.32</td><td align="center" valign="top" rowspan="1" colspan="1">0.02878</td><td align="center" valign="top" rowspan="1" colspan="1">1.376312</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">beta-D-Glucosamine</td><td align="center" valign="top" rowspan="1" colspan="1">3.54</td><td align="center" valign="top" rowspan="1" colspan="1">0.00000</td><td align="center" valign="top" rowspan="1" colspan="1">2.516825</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">L-Fucose</td><td align="center" valign="top" rowspan="1" colspan="1">10.71</td><td align="center" valign="top" rowspan="1" colspan="1">0.00000</td><td align="center" valign="top" rowspan="1" colspan="1">2.561717</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Capric acid</td><td align="center" valign="top" rowspan="1" colspan="1">13.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.00000</td><td align="center" valign="top" rowspan="1" colspan="1">2.64952</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">N-Acetylornithine</td><td align="center" valign="top" rowspan="1" colspan="1">2.06</td><td align="center" valign="top" rowspan="1" colspan="1">0.00000</td><td align="center" valign="top" rowspan="1" colspan="1">2.299557</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Shikimic acid</td><td align="center" valign="top" rowspan="1" colspan="1">4.83</td><td align="center" valign="top" rowspan="1" colspan="1">0.00001</td><td align="center" valign="top" rowspan="1" colspan="1">2.192109</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">D-Mannose</td><td align="center" valign="top" rowspan="1" colspan="1">1.89</td><td align="center" valign="top" rowspan="1" colspan="1">0.00003</td><td align="center" valign="top" rowspan="1" colspan="1">1.976012</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hydroxyphenyllactic acid</td><td align="center" valign="top" rowspan="1" colspan="1">4.67</td><td align="center" valign="top" rowspan="1" colspan="1">0.00015</td><td align="center" valign="top" rowspan="1" colspan="1">2.026631</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Homo-L-arginine</td><td align="center" valign="top" rowspan="1" colspan="1">1.78</td><td align="center" valign="top" rowspan="1" colspan="1">0.00002</td><td align="center" valign="top" rowspan="1" colspan="1">2.103923</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">N-Acetylglutamic acid</td><td align="center" valign="top" rowspan="1" colspan="1">2.7</td><td align="center" valign="top" rowspan="1" colspan="1">0.00079</td><td align="center" valign="top" rowspan="1" colspan="1">1.617506</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">4-Hydroxy-2-oxo-heptanedioate</td><td align="center" valign="top" rowspan="1" colspan="1">2.69</td><td align="center" valign="top" rowspan="1" colspan="1">0.00091</td><td align="center" valign="top" rowspan="1" colspan="1">1.620938</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Quinate</td><td align="center" valign="top" rowspan="1" colspan="1">1.63</td><td align="center" valign="top" rowspan="1" colspan="1">0.04412</td><td align="center" valign="top" rowspan="1" colspan="1">1.043983</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">N-Acetyl-D-glucosamine</td><td align="center" valign="top" rowspan="1" colspan="1">4.33</td><td align="center" valign="top" rowspan="1" colspan="1">0.00000</td><td align="center" valign="top" rowspan="1" colspan="1">2.145168</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Azacitidine</td><td align="center" valign="top" rowspan="1" colspan="1">6.52</td><td align="center" valign="top" rowspan="1" colspan="1">0.00000</td><td align="center" valign="top" rowspan="1" colspan="1">2.532691</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pseudouridine</td><td align="center" valign="top" rowspan="1" colspan="1">2.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.00227</td><td align="center" valign="top" rowspan="1" colspan="1">1.674488</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Uridine</td><td align="center" valign="top" rowspan="1" colspan="1">7.24</td><td align="center" valign="top" rowspan="1" colspan="1">0.00012</td><td align="center" valign="top" rowspan="1" colspan="1">1.665664</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">1,2-Bis(4-hydroxy-3-methoxyphenyl)ethylene</td><td align="center" valign="top" rowspan="1" colspan="1">1.85</td><td align="center" valign="top" rowspan="1" colspan="1">0.01817</td><td align="center" valign="top" rowspan="1" colspan="1">1.263925</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">7,8-Dihydroneopterin</td><td align="center" valign="top" rowspan="1" colspan="1">5.79</td><td align="center" valign="top" rowspan="1" colspan="1">0.00002</td><td align="center" valign="top" rowspan="1" colspan="1">2.209484</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Glucose 6-phosphate</td><td align="center" valign="top" rowspan="1" colspan="1">1.52</td><td align="center" valign="top" rowspan="1" colspan="1">0.01227</td><td align="center" valign="top" rowspan="1" colspan="1">1.249277</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Epiandrosterone</td><td align="center" valign="top" rowspan="1" colspan="1">2.76</td><td align="center" valign="top" rowspan="1" colspan="1">0.00584</td><td align="center" valign="top" rowspan="1" colspan="1">1.394962</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">9-OxoODE</td><td align="center" valign="top" rowspan="1" colspan="1">3.14</td><td align="center" valign="top" rowspan="1" colspan="1">0.00005</td><td align="center" valign="top" rowspan="1" colspan="1">1.990856</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">19(S)-HETE</td><td align="center" valign="top" rowspan="1" colspan="1">1.77</td><td align="center" valign="top" rowspan="1" colspan="1">0.00227</td><td align="center" valign="top" rowspan="1" colspan="1">1.449327</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Docosapentaenoic acid (22n-3)</td><td align="center" valign="top" rowspan="1" colspan="1">6.97</td><td align="center" valign="top" rowspan="1" colspan="1">0.00000</td><td align="center" valign="top" rowspan="1" colspan="1">2.729892</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">14,15-DiHETrE</td><td align="center" valign="top" rowspan="1" colspan="1">1.33</td><td align="center" valign="top" rowspan="1" colspan="1">0.01817</td><td align="center" valign="top" rowspan="1" colspan="1">1.040876</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fructose 1,6-bisphosphate</td><td align="center" valign="top" rowspan="1" colspan="1">2.27</td><td align="center" valign="top" rowspan="1" colspan="1">0.00000</td><td align="center" valign="top" rowspan="1" colspan="1">2.420665</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ginkgoic acid</td><td align="center" valign="top" rowspan="1" colspan="1">2.94</td><td align="center" valign="top" rowspan="1" colspan="1">0.00001</td><td align="center" valign="top" rowspan="1" colspan="1">2.407066</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">dGMP</td><td align="center" valign="top" rowspan="1" colspan="1">1.65</td><td align="center" valign="top" rowspan="1" colspan="1">0.04788</td><td align="center" valign="top" rowspan="1" colspan="1">1.194425</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Dehydroepiandrosterone sulfate</td><td align="center" valign="top" rowspan="1" colspan="1">5.38</td><td align="center" valign="top" rowspan="1" colspan="1">0.00000</td><td align="center" valign="top" rowspan="1" colspan="1">2.619969</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Chenodeoxycholic acid</td><td align="center" valign="top" rowspan="1" colspan="1">7.38</td><td align="center" valign="top" rowspan="1" colspan="1">0.00000</td><td align="center" valign="top" rowspan="1" colspan="1">2.656323</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cortisone acetate</td><td align="center" valign="top" rowspan="1" colspan="1">2.67</td><td align="center" valign="top" rowspan="1" colspan="1">0.00000</td><td align="center" valign="top" rowspan="1" colspan="1">2.193134</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Astragalin</td><td align="center" valign="top" rowspan="1" colspan="1">2.28</td><td align="center" valign="top" rowspan="1" colspan="1">0.00200</td><td align="center" valign="top" rowspan="1" colspan="1">1.366379</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mesobilirubinogen</td><td align="center" valign="top" rowspan="1" colspan="1">2.14</td><td align="center" valign="top" rowspan="1" colspan="1">0.02404</td><td align="center" valign="top" rowspan="1" colspan="1">1.222938</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sphinganine</td><td align="center" valign="top" rowspan="1" colspan="1">1.29</td><td align="center" valign="top" rowspan="1" colspan="1">0.00004</td><td align="center" valign="top" rowspan="1" colspan="1">3.05958</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lithocholic acid</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0.00038</td><td align="center" valign="top" rowspan="1" colspan="1">2.513967</td></tr></tbody></table><table-wrap-foot><attrib>Note: Metabolites with significantly increased postoperative relative
levels and their corresponding FC values, P-values, and VIP values are
listed. (Metabolites with significantly decreased postoperative relative
levels and their FC values, P-values, and VIP values are listed, with
specific data omitted.)</attrib></table-wrap-foot></table-wrap><table-wrap position="anchor" id="t5" orientation="portrait"><label>Appendix Tables S2</label><caption><p>Downregulated metabolites</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Name</th><th align="center" rowspan="1" colspan="1">FC</th><th align="center" rowspan="1" colspan="1">P.value</th><th align="center" rowspan="1" colspan="1">VIP</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Methyl jasmonate</td><td align="center" valign="top" rowspan="1" colspan="1">0.99</td><td align="center" valign="top" rowspan="1" colspan="1">0.00000</td><td align="center" valign="top" rowspan="1" colspan="1">3.26913</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">5-Nitro-2-(3-phenylpropylamino)benzoic
acid</td><td align="center" valign="top" rowspan="1" colspan="1">0.99</td><td align="center" valign="top" rowspan="1" colspan="1">0.02193</td><td align="center" valign="top" rowspan="1" colspan="1">1.054522</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Corticosterone</td><td align="center" valign="top" rowspan="1" colspan="1">0.99</td><td align="center" valign="top" rowspan="1" colspan="1">0.04412</td><td align="center" valign="top" rowspan="1" colspan="1">1.705961</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Glutaric acid</td><td align="center" valign="top" rowspan="1" colspan="1">0.75</td><td align="center" valign="top" rowspan="1" colspan="1">0.00001</td><td align="center" valign="top" rowspan="1" colspan="1">1.874209</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">alpha-Ketoisovaleric acid</td><td align="center" valign="top" rowspan="1" colspan="1">0.69</td><td align="center" valign="top" rowspan="1" colspan="1">0.00119</td><td align="center" valign="top" rowspan="1" colspan="1">1.676745</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Indole</td><td align="center" valign="top" rowspan="1" colspan="1">0.68</td><td align="center" valign="top" rowspan="1" colspan="1">0.00015</td><td align="center" valign="top" rowspan="1" colspan="1">1.860401</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Guanidoacetic acid</td><td align="center" valign="top" rowspan="1" colspan="1">0.72</td><td align="center" valign="top" rowspan="1" colspan="1">0.00119</td><td align="center" valign="top" rowspan="1" colspan="1">1.780082</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3-Methylthiopropionic acid</td><td align="center" valign="top" rowspan="1" colspan="1">0.65</td><td align="center" valign="top" rowspan="1" colspan="1">0.00017</td><td align="center" valign="top" rowspan="1" colspan="1">1.952029</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mesaconate</td><td align="center" valign="top" rowspan="1" colspan="1">0.67</td><td align="center" valign="top" rowspan="1" colspan="1">0.00810</td><td align="center" valign="top" rowspan="1" colspan="1">1.532931</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">L-Ribulose</td><td align="center" valign="top" rowspan="1" colspan="1">0.83</td><td align="center" valign="top" rowspan="1" colspan="1">0.04412</td><td align="center" valign="top" rowspan="1" colspan="1">1.155728</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tartaric acid</td><td align="center" valign="top" rowspan="1" colspan="1">0.79</td><td align="center" valign="top" rowspan="1" colspan="1">0.02404</td><td align="center" valign="top" rowspan="1" colspan="1">1.337211</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">(<sup><xref rid="r3" ref-type="bibr">3</xref></sup>)-Isopiperitenone</td><td align="center" valign="top" rowspan="1" colspan="1">0.68</td><td align="center" valign="top" rowspan="1" colspan="1">0.01000</td><td align="center" valign="top" rowspan="1" colspan="1">1.115139</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">4-Acetamidobutanoic acid</td><td align="center" valign="top" rowspan="1" colspan="1">0.46</td><td align="center" valign="top" rowspan="1" colspan="1">0.00079</td><td align="center" valign="top" rowspan="1" colspan="1">1.738108</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">L-Glutamic acid</td><td align="center" valign="top" rowspan="1" colspan="1">0.44</td><td align="center" valign="top" rowspan="1" colspan="1">0.04412</td><td align="center" valign="top" rowspan="1" colspan="1">1.282315</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Citramalic acid</td><td align="center" valign="top" rowspan="1" colspan="1">0.84</td><td align="center" valign="top" rowspan="1" colspan="1">0.04412</td><td align="center" valign="top" rowspan="1" colspan="1">1.426335</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">L-Histidine</td><td align="center" valign="top" rowspan="1" colspan="1">0.70</td><td align="center" valign="top" rowspan="1" colspan="1">0.00522</td><td align="center" valign="top" rowspan="1" colspan="1">1.425186</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">beta-D-Fructose</td><td align="center" valign="top" rowspan="1" colspan="1">0.77</td><td align="center" valign="top" rowspan="1" colspan="1">0.02632</td><td align="center" valign="top" rowspan="1" colspan="1">1.121338</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Alpha-D-Glucose</td><td align="center" valign="top" rowspan="1" colspan="1">0.40</td><td align="center" valign="top" rowspan="1" colspan="1">0.00227</td><td align="center" valign="top" rowspan="1" colspan="1">1.156317</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Caffeate</td><td align="center" valign="top" rowspan="1" colspan="1">0.59</td><td align="center" valign="top" rowspan="1" colspan="1">0.01227</td><td align="center" valign="top" rowspan="1" colspan="1">1.153765</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">D-Iditol</td><td align="center" valign="top" rowspan="1" colspan="1">0.64</td><td align="center" valign="top" rowspan="1" colspan="1">0.00079</td><td align="center" valign="top" rowspan="1" colspan="1">1.428746</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sebacic acid</td><td align="center" valign="top" rowspan="1" colspan="1">0.49</td><td align="center" valign="top" rowspan="1" colspan="1">0.00079</td><td align="center" valign="top" rowspan="1" colspan="1">1.820414</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Azelaic acid</td><td align="center" valign="top" rowspan="1" colspan="1">0.64</td><td align="center" valign="top" rowspan="1" colspan="1">0.00291</td><td align="center" valign="top" rowspan="1" colspan="1">1.694793</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Salicyluric acid</td><td align="center" valign="top" rowspan="1" colspan="1">0.35</td><td align="center" valign="top" rowspan="1" colspan="1">0.00017</td><td align="center" valign="top" rowspan="1" colspan="1">2.039439</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ribose 1-phosphate</td><td align="center" valign="top" rowspan="1" colspan="1">0.64</td><td align="center" valign="top" rowspan="1" colspan="1">0.00584</td><td align="center" valign="top" rowspan="1" colspan="1">1.587454</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cytidine</td><td align="center" valign="top" rowspan="1" colspan="1">0.52</td><td align="center" valign="top" rowspan="1" colspan="1">0.00522</td><td align="center" valign="top" rowspan="1" colspan="1">1.43258</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Phenylacetylglutamine</td><td align="center" valign="top" rowspan="1" colspan="1">0.28</td><td align="center" valign="top" rowspan="1" colspan="1">0.00020</td><td align="center" valign="top" rowspan="1" colspan="1">2.031314</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pentachlorophenol</td><td align="center" valign="top" rowspan="1" colspan="1">0.47</td><td align="center" valign="top" rowspan="1" colspan="1">0.01498</td><td align="center" valign="top" rowspan="1" colspan="1">1.322638</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Formononetin</td><td align="center" valign="top" rowspan="1" colspan="1">0.46</td><td align="center" valign="top" rowspan="1" colspan="1">0.00466</td><td align="center" valign="top" rowspan="1" colspan="1">1.594809</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hexadecanedioate</td><td align="center" valign="top" rowspan="1" colspan="1">0.34</td><td align="center" valign="top" rowspan="1" colspan="1">0.00000</td><td align="center" valign="top" rowspan="1" colspan="1">2.329282</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">N2-gamma-Glutamylglutamine</td><td align="center" valign="top" rowspan="1" colspan="1">0.25</td><td align="center" valign="top" rowspan="1" colspan="1">0.00001</td><td align="center" valign="top" rowspan="1" colspan="1">2.018138</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">6beta-Hydroxytestosterone</td><td align="center" valign="top" rowspan="1" colspan="1">0.70</td><td align="center" valign="top" rowspan="1" colspan="1">0.01000</td><td align="center" valign="top" rowspan="1" colspan="1">1.166668</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">5,6-DHET</td><td align="center" valign="top" rowspan="1" colspan="1">0.54</td><td align="center" valign="top" rowspan="1" colspan="1">0.02632</td><td align="center" valign="top" rowspan="1" colspan="1">1.169176</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cellobiose</td><td align="center" valign="top" rowspan="1" colspan="1">0.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.00017</td><td align="center" valign="top" rowspan="1" colspan="1">2.228107</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">1D-Myo-inositol1,4,5,6-tetrakisphosphate</td><td align="center" valign="top" rowspan="1" colspan="1">0.28</td><td align="center" valign="top" rowspan="1" colspan="1">0.00000</td><td align="center" valign="top" rowspan="1" colspan="1">2.246215</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Uracil</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0.04788</td><td align="center" valign="top" rowspan="1" colspan="1">1.383472</td></tr></tbody></table></table-wrap></app-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohajan</surname><given-names>D</given-names></name><name name-style="western"><surname>Mohajan</surname><given-names>HK.</given-names></name></person-group><article-title>Obesity and its related diseases: a new escalating alarming in
global health</article-title><source>J Innov Med Res</source><year>2023</year><volume>2</volume><issue>3</issue><fpage>12</fpage><lpage>23</lpage></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruze</surname><given-names>R</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T</given-names></name><name name-style="western"><surname>Zou</surname><given-names>X</given-names></name><name name-style="western"><surname>Song</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>R</given-names></name><etal/></person-group><article-title>Obesity and type 2 diabetes mellitus: connections in
epidemiology, pathogenesis, and treatments</article-title><source>Front Endocrinol (Lausanne)</source><year>2023</year><season>Apr</season><day>21</day><volume>14</volume><fpage>1161521</fpage><pub-id pub-id-type="doi">10.3389/fendo.2023.1161521.</pub-id><pub-id pub-id-type="pmid">37152942</pub-id><pub-id pub-id-type="pmcid">PMC10161731</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Devkota</surname><given-names>R</given-names></name><name name-style="western"><surname>Small</surname><given-names>JC</given-names></name><name name-style="western"><surname>Carbone</surname><given-names>K</given-names></name><name name-style="western"><surname>Glass</surname><given-names>MA</given-names></name><name name-style="western"><surname>Vetere</surname><given-names>A</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>BK.</given-names></name></person-group><article-title>KD025 Is a Casein Kinase 2 Inhibitor That Protects Against
Glucolipotoxicity in &#946;-Cells</article-title><source>Diabetes</source><year>2024</year><season>Apr</season><day>1</day><volume>73</volume><issue>4</issue><fpage>585</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.2337/db23-0506.</pub-id><pub-id pub-id-type="pmid">38211571</pub-id><pub-id pub-id-type="pmcid">PMC10958584</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barone</surname><given-names>E</given-names></name><name name-style="western"><surname>Di Domenico</surname><given-names>F</given-names></name><name name-style="western"><surname>Perluigi</surname><given-names>M</given-names></name><name name-style="western"><surname>Butterfield</surname><given-names>DA.</given-names></name></person-group><article-title>The interplay among oxidative stress, brain insulin resistance
and AMPK dysfunction contribute to neurodegeneration in type 2 diabetes and
Alzheimer disease</article-title><source>Free Radic Biol Med</source><year>2021</year><season>Nov</season><day>20</day><volume>176</volume><fpage>16</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2021.09.006.</pub-id><pub-id pub-id-type="pmid">34530075</pub-id><pub-id pub-id-type="pmcid">PMC8595768</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vrakopoulou</surname><given-names>GZ</given-names></name><name name-style="western"><surname>Theodoropoulos</surname><given-names>C</given-names></name><name name-style="western"><surname>Kalles</surname><given-names>V</given-names></name><name name-style="western"><surname>Zografos</surname><given-names>G</given-names></name><name name-style="western"><surname>Almpanopoulos</surname><given-names>K.</given-names></name></person-group><article-title>Type 2 diabetes mellitus status in obese patients following
sleeve gastrectomy or one anastomosis gastric bypass</article-title><source>Sci Rep</source><year>2021</year><season>Feb</season><day>24</day><volume>11</volume><issue>1</issue><fpage>4421</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-83807-8.</pub-id><pub-id pub-id-type="pmid">33627710</pub-id><pub-id pub-id-type="pmcid">PMC7904834</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonzalez-Covarrubias</surname><given-names>V</given-names></name><name name-style="western"><surname>Mart&#237;nez-Mart&#237;nez</surname><given-names>E</given-names></name><name name-style="western"><surname>del Bosque-Plata</surname><given-names>L.</given-names></name></person-group><article-title>The potential of metabolomics in biomedical
applications</article-title><source>Metabolites</source><year>2022</year><season>Feb</season><day>19</day><volume>12</volume><issue>2</issue><fpage>194</fpage><pub-id pub-id-type="doi">10.3390/metabo12020194.</pub-id><pub-id pub-id-type="pmid">35208267</pub-id><pub-id pub-id-type="pmcid">PMC8880031</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colosimo</surname><given-names>S</given-names></name><name name-style="western"><surname>Mitra</surname><given-names>SK</given-names></name><name name-style="western"><surname>Chaudhury</surname><given-names>T</given-names></name><name name-style="western"><surname>Marchesini</surname><given-names>G.</given-names></name></person-group><article-title>Insulin resistance and metabolic flexibility as drivers of liver
and cardiac disease in T2DM</article-title><source>Diabetes Res Clin Pract</source><year>2023</year><season>Dec</season><volume>206</volume><fpage>111016</fpage><pub-id pub-id-type="doi">10.1016/j.diabres.2023.111016.</pub-id><pub-id pub-id-type="pmid">37979728</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>D</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>G</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W</given-names></name><etal/></person-group><article-title>Serum metabolomic and lipidomic profiling reveals the signature
for postoperative obesity among adult-onset
craniopharyngioma</article-title><source>Metabolites</source><year>2024</year><season>Jun</season><day>17</day><volume>14</volume><issue>6</issue><fpage>338</fpage><pub-id pub-id-type="doi">10.3390/metabo14060338.</pub-id><pub-id pub-id-type="pmid">38921473</pub-id><pub-id pub-id-type="pmcid">PMC11205291</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Angelidi</surname><given-names>AM</given-names></name><name name-style="western"><surname>Kokkinos</surname><given-names>A</given-names></name><name name-style="western"><surname>Sanoudou</surname><given-names>D</given-names></name><name name-style="western"><surname>Connelly</surname><given-names>MA</given-names></name><name name-style="western"><surname>Alexandrou</surname><given-names>A</given-names></name><name name-style="western"><surname>Mingrone</surname><given-names>G</given-names></name><etal/></person-group><article-title>Early metabolomic, lipid and lipoprotein changes in response to
medical and surgical therapeutic approaches to obesity</article-title><source>Metabolism</source><year>2023</year><season>Jan</season><volume>138</volume><fpage>155346</fpage><pub-id pub-id-type="doi">10.1016/j.metabol.2022.155346.</pub-id><pub-id pub-id-type="pmid">36375643</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>WM</given-names></name><name name-style="western"><surname>Ziegler</surname><given-names>KM</given-names></name><name name-style="western"><surname>Yilmaz</surname><given-names>A</given-names></name><name name-style="western"><surname>Saiyed</surname><given-names>N</given-names></name><name name-style="western"><surname>Ustun</surname><given-names>I</given-names></name><name name-style="western"><surname>Akyol</surname><given-names>S</given-names></name><etal/></person-group><article-title>Association of metabolomic biomarkers with sleeve gastrectomy
weight loss outcomes</article-title><source>Metabolites</source><year>2023</year><season>Mar</season><day>31</day><volume>13</volume><issue>4</issue><fpage>506</fpage><pub-id pub-id-type="doi">10.3390/metabo13040506.</pub-id><pub-id pub-id-type="pmid">37110164</pub-id><pub-id pub-id-type="pmcid">PMC10145663</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grijseels</surname><given-names>S</given-names></name><name name-style="western"><surname>Vasskog</surname><given-names>T</given-names></name><name name-style="western"><surname>Heinsvig</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Myhre</surname><given-names>TN</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>T</given-names></name><name name-style="western"><surname>Mardal</surname><given-names>M.</given-names></name></person-group><article-title>Validation of two LCHRMS methods for large-scale untargeted
metabolomics of serum samples: Strategy to establish method
fitness-for-purpose</article-title><source>J Chromatogr A</source><year>2024</year><season>Sep</season><day>13</day><volume>1732</volume><fpage>465230</fpage><pub-id pub-id-type="doi">10.1016/j.chroma.2024.465230.</pub-id><pub-id pub-id-type="pmid">39142167</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Younis</surname><given-names>IY</given-names></name><name name-style="western"><surname>Khattab</surname><given-names>AR</given-names></name><name name-style="western"><surname>Selim</surname><given-names>NM</given-names></name><name name-style="western"><surname>Sobeh</surname><given-names>M</given-names></name><name name-style="western"><surname>Elhawary</surname><given-names>SS</given-names></name><name name-style="western"><surname>Bishbishy</surname><given-names>MHE.</given-names></name></person-group><article-title>Metabolomics-based profiling of 4 avocado varieties using
HPLC-MS/MS and GC/MS and evaluation of their antidiabetic
activity</article-title><source>Sci Rep</source><year>2022</year><season>Mar</season><day>23</day><volume>12</volume><issue>1</issue><fpage>4966</fpage><pub-id pub-id-type="doi">10.1038/s41598-022-08479-4.</pub-id><pub-id pub-id-type="pmid">35322072</pub-id><pub-id pub-id-type="pmcid">PMC8943142</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dan</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><etal/></person-group><article-title>The early effects of sleeve gastrectomy on postprandial
chylomicron triglycerides during the progression of type 2
diabetes</article-title><source>Clin Chim Acta</source><year>2023</year><season>Sep</season><day>1</day><volume>549</volume><fpage>117558</fpage><pub-id pub-id-type="doi">10.1016/j.cca.2023.117558.</pub-id><pub-id pub-id-type="pmid">37709114</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Shi</surname><given-names>C</given-names></name><name name-style="western"><surname>Yan</surname><given-names>H</given-names></name><name name-style="western"><surname>Xia</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X</given-names></name><etal/></person-group><article-title>Acute effects of sleeve gastrectomy on glucose variability,
glucose metabolism, and ghrelin response</article-title><source>Obes Surg</source><year>2021</year><season>Sep</season><volume>31</volume><issue>9</issue><fpage>4005</fpage><lpage>4014</lpage><pub-id pub-id-type="doi">10.1007/s11695-021-05534-3.</pub-id><pub-id pub-id-type="pmid">34240316</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vrakopoulou</surname><given-names>GZ</given-names></name><name name-style="western"><surname>Theodoropoulos</surname><given-names>C</given-names></name><name name-style="western"><surname>Kalles</surname><given-names>V</given-names></name><name name-style="western"><surname>Zografos</surname><given-names>G</given-names></name><name name-style="western"><surname>Almpanopoulos</surname><given-names>K.</given-names></name></person-group><article-title>Type 2 diabetes mellitus status in obese patients following
sleeve gastrectomy or one anastomosis gastric bypass</article-title><source>Sci Rep</source><year>2021</year><season>Feb</season><day>24</day><volume>11</volume><issue>1</issue><fpage>4421</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-83807-8.</pub-id><pub-id pub-id-type="pmid">33627710</pub-id><pub-id pub-id-type="pmcid">PMC7904834</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al</surname><given-names>M</given-names></name><name name-style="western"><surname>Taskin</surname><given-names>HE.</given-names></name></person-group><article-title>Weight loss, type 2 diabetes, and nutrition in 355 patients with
obesity undergoing sleeve gastrectomy with transit bipartition: two-year
outcomes</article-title><source>Obes Facts</source><year>2022</year><volume>15</volume><issue>5</issue><fpage>717</fpage><lpage>729</lpage><pub-id pub-id-type="doi">10.1159/000526718.</pub-id><pub-id pub-id-type="pmid">36070685</pub-id><pub-id pub-id-type="pmcid">PMC9669945</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yadav</surname><given-names>M</given-names></name><name name-style="western"><surname>Maiwal</surname><given-names>R</given-names></name><name name-style="western"><surname>Kumar Br</surname><given-names>V</given-names></name><name name-style="western"><surname>Tripathi</surname><given-names>G</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>N</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>N</given-names></name><etal/></person-group><article-title>Comparative metabolome analysis reveals higher potential of
haemoperfusion adsorption in providing favourable outcome in ACLF
patients</article-title><source>Liver Int</source><year>2024</year><season>May</season><volume>44</volume><issue>5</issue><fpage>1189</fpage><lpage>1201</lpage><pub-id pub-id-type="doi">10.1111/liv.15858.</pub-id><pub-id pub-id-type="pmid">38358068</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>EY</given-names></name><name name-style="western"><surname>Muthiah</surname><given-names>MD</given-names></name><name name-style="western"><surname>Sanyal</surname><given-names>AJ.</given-names></name></person-group><article-title>Metabolomics at the cutting edge of risk prediction of
MASLD</article-title><source>Cell Rep Med</source><year>2024</year><season>Dec</season><day>17</day><volume>5</volume><issue>12</issue><fpage>101853</fpage><pub-id pub-id-type="doi">10.1016/j.xcrm.2024.101853.</pub-id><pub-id pub-id-type="pmid">39657668</pub-id><pub-id pub-id-type="pmcid">PMC11722125</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>W</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y</given-names></name><name name-style="western"><surname>He</surname><given-names>H</given-names></name><name name-style="western"><surname>Ma</surname><given-names>H</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Association of homocysteine and insulin resistance with increased
risk of mortality in a nondiabetic population: third national health and
nutrition examination survey</article-title><source>Metab Syndr Relat Disord</source><year>2022</year><season>Jun</season><volume>20</volume><issue>5</issue><fpage>255</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1089/met.2021.0119.</pub-id><pub-id pub-id-type="pmid">35467972</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lecoutre</surname><given-names>S</given-names></name><name name-style="western"><surname>Maqdasy</surname><given-names>S</given-names></name><name name-style="western"><surname>Rizo-Roca</surname><given-names>D</given-names></name><name name-style="western"><surname>Renzi</surname><given-names>G</given-names></name><name name-style="western"><surname>Vlassakev</surname><given-names>I</given-names></name><name name-style="western"><surname>Alaeddine</surname><given-names>LM</given-names></name><etal/></person-group><article-title>Reduced adipocyte glutaminase activity promotes energy
expenditure and metabolic health</article-title><source>Nat Metab</source><year>2024</year><season>Jul</season><volume>6</volume><issue>7</issue><fpage>1329</fpage><lpage>1346</lpage><pub-id pub-id-type="doi">10.1038/s42255-024-01083-y.</pub-id><pub-id pub-id-type="pmid">39009762</pub-id><pub-id pub-id-type="pmcid">PMC11272588</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sobczy&#324;ska-Malefora</surname><given-names>A</given-names></name><name name-style="western"><surname>Delvin</surname><given-names>E</given-names></name><name name-style="western"><surname>McCaddon</surname><given-names>A</given-names></name><name name-style="western"><surname>Ahmadi</surname><given-names>KR</given-names></name><name name-style="western"><surname>Harrington</surname><given-names>DJ.</given-names></name></person-group><article-title>Vitamin B12 status in health and disease: a critical review.
Diagnosis of deficiency and insufficiency - clinical and laboratory
pitfalls</article-title><source>Crit Rev Clin Lab Sci</source><year>2021</year><season>Sep</season><volume>58</volume><issue>6</issue><fpage>399</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1080/10408363.2021.1885339.</pub-id><pub-id pub-id-type="pmid">33881359</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beaupere</surname><given-names>C</given-names></name><name name-style="western"><surname>Liboz</surname><given-names>A</given-names></name><name name-style="western"><surname>F&#232;ve</surname><given-names>B</given-names></name><name name-style="western"><surname>Blondeau</surname><given-names>B</given-names></name><name name-style="western"><surname>Guillemain</surname><given-names>G.</given-names></name></person-group><article-title>Molecular mechanisms of glucocorticoid-induced insulin
resistance</article-title><source>Int J Mol Sci</source><year>2021</year><season>Jan</season><day>9</day><volume>22</volume><issue>2</issue><fpage>623</fpage><pub-id pub-id-type="doi">10.3390/ijms22020623.</pub-id><pub-id pub-id-type="pmid">33435513</pub-id><pub-id pub-id-type="pmcid">PMC7827500</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oberhauser</surname><given-names>L</given-names></name><name name-style="western"><surname>Maechler</surname><given-names>P.</given-names></name></person-group><article-title>Lipid-induced adaptations of the pancreatic beta-cell to
glucotoxic conditions sustain insulin secretion</article-title><source>Int J Mol Sci</source><year>2021</year><season>Dec</season><day>28</day><volume>23</volume><issue>1</issue><fpage>324</fpage><pub-id pub-id-type="doi">10.3390/ijms23010324.</pub-id><pub-id pub-id-type="pmid">35008750</pub-id><pub-id pub-id-type="pmcid">PMC8745448</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lemos</surname><given-names>GO</given-names></name><name name-style="western"><surname>Torrinhas</surname><given-names>RS</given-names></name><name name-style="western"><surname>Waitzberg</surname><given-names>DL.</given-names></name></person-group><article-title>Nutrients, physical activity, and mitochondrial dysfunction in
the setting of metabolic syndrome</article-title><source>Nutrients</source><year>2023</year><season>Feb</season><day>28</day><volume>15</volume><issue>5</issue><fpage>1217</fpage><pub-id pub-id-type="doi">10.3390/nu15051217.</pub-id><pub-id pub-id-type="pmid">36904216</pub-id><pub-id pub-id-type="pmcid">PMC10004804</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Weng</surname><given-names>P</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><etal/></person-group><article-title>The gut microbiota-brain axis: Role of the gut microbial
metabolites of dietary food in obesity</article-title><source>Food Res Int</source><year>2022</year><season>Mar</season><volume>153</volume><fpage>110971</fpage><pub-id pub-id-type="doi">10.1016/j.foodres.2022.110971.</pub-id><pub-id pub-id-type="pmid">35227482</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dilworth</surname><given-names>L</given-names></name><name name-style="western"><surname>Facey</surname><given-names>A</given-names></name><name name-style="western"><surname>Omoruyi</surname><given-names>F.</given-names></name></person-group><article-title>Diabetes mellitus and its metabolic complications: the role of
adipose tissues</article-title><source>Int J Mol Sci</source><year>2021</year><season>Jul</season><day>16</day><volume>22</volume><issue>14</issue><fpage>7644</fpage><pub-id pub-id-type="doi">10.3390/ijms22147644.</pub-id><pub-id pub-id-type="pmid">34299261</pub-id><pub-id pub-id-type="pmcid">PMC8305176</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imenshahidi</surname><given-names>M</given-names></name><name name-style="western"><surname>Hossenzadeh</surname><given-names>H.</given-names></name></person-group><article-title>Effects of glycine on metabolic syndrome components: a
review</article-title><source>J Endocrinol Invest</source><year>2022</year><season>May</season><volume>45</volume><issue>5</issue><fpage>927</fpage><lpage>939</lpage><pub-id pub-id-type="doi">10.1007/s40618-021-01720-3.</pub-id><pub-id pub-id-type="pmid">35013990</pub-id></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ji</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H</given-names></name><name name-style="western"><surname>Kaura</surname><given-names>S</given-names></name><name name-style="western"><surname>Yip</surname><given-names>J</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H</given-names></name><name name-style="western"><surname>Guan</surname><given-names>L</given-names></name><etal/></person-group><article-title>Effect of bariatric surgery on metabolic diseases and underlying
mechanisms</article-title><source>Biomolecules</source><year>2021</year><season>Oct</season><day>26</day><volume>11</volume><issue>11</issue><fpage>1582</fpage><pub-id pub-id-type="doi">10.3390/biom11111582.</pub-id><pub-id pub-id-type="pmid">34827579</pub-id><pub-id pub-id-type="pmcid">PMC8615605</pub-id></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dan</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><etal/></person-group><article-title>The early effects of sleeve gastrectomy on postprandial
chylomicron triglycerides during the progression of type 2
diabetes</article-title><source>Clin Chim Acta</source><year>2023</year><season>Sep</season><day>1</day><volume>549</volume><fpage>117558</fpage><pub-id pub-id-type="doi">10.1016/j.cca.2023.117558.</pub-id><pub-id pub-id-type="pmid">37709114</pub-id></element-citation></ref><ref id="r30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bagheri</surname><given-names>M</given-names></name><name name-style="western"><surname>Tanriverdi</surname><given-names>K</given-names></name><name name-style="western"><surname>Iafrati</surname><given-names>MD</given-names></name><name name-style="western"><surname>Mosley</surname><given-names>JD</given-names></name><name name-style="western"><surname>Freedman</surname><given-names>JE</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>JF.</given-names></name></person-group><article-title>Characterization of the plasma metabolome and lipidome in
response to sleeve gastrectomy and gastric bypass surgeries reveals
molecular patterns of surgical weight loss</article-title><source>Metabolism</source><year>2024</year><season>Sep</season><volume>158</volume><fpage>155955</fpage><pub-id pub-id-type="doi">10.1016/j.metabol.2024.155955.</pub-id><pub-id pub-id-type="pmid">38906372</pub-id><pub-id pub-id-type="pmcid">PMC11755375</pub-id></element-citation></ref><ref id="r31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Argyrakopoulou</surname><given-names>G</given-names></name><name name-style="western"><surname>Konstantinidou</surname><given-names>SK</given-names></name><name name-style="western"><surname>Dalamaga</surname><given-names>M</given-names></name><name name-style="western"><surname>Kokkinos</surname><given-names>A.</given-names></name></person-group><article-title>Nutritional deficiencies before and after bariatric surgery:
prevention and treatment</article-title><source>Curr Nutr Rep</source><year>2022</year><season>Jun</season><volume>11</volume><issue>2</issue><fpage>95</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1007/s13668-022-00400-9.</pub-id><pub-id pub-id-type="pmid">35174473</pub-id></element-citation></ref><ref id="r32"><label>32</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Elhag</surname><given-names>W</given-names></name><name name-style="western"><surname>El Ansari</surname><given-names>W.</given-names></name></person-group><part-title>Nutritional deficiencies post bariatric surgery: a forgotten area
impacting long-term success and quality of life</part-title><person-group person-group-type="editor"><name name-style="western"><surname>Saiz-Sapena</surname><given-names>N</given-names></name><name name-style="western"><surname>Oviedo</surname><given-names>JM.</given-names></name></person-group><source>Bariatric surgery-from the non-surgical approach to the post-surgery
individual care</source><publisher-loc>London</publisher-loc><publisher-name>IntechOpen;</publisher-name><year>2021</year></element-citation></ref><ref id="r33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beaupere</surname><given-names>C</given-names></name><name name-style="western"><surname>Liboz</surname><given-names>A</given-names></name><name name-style="western"><surname>F&#232;ve</surname><given-names>B</given-names></name><name name-style="western"><surname>Blondeau</surname><given-names>B</given-names></name><name name-style="western"><surname>Guillemain</surname><given-names>G.</given-names></name></person-group><article-title>Molecular mechanisms of glucocorticoid-induced insulin
resistance</article-title><source>Int J Mol Sci</source><year>2021</year><season>Jan</season><day>9</day><volume>22</volume><issue>2</issue><fpage>623</fpage><pub-id pub-id-type="doi">10.3390/ijms22020623.</pub-id><pub-id pub-id-type="pmid">33435513</pub-id><pub-id pub-id-type="pmcid">PMC7827500</pub-id></element-citation></ref><ref id="r34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Janssen</surname><given-names>JA.</given-names></name></person-group><article-title>New insights into the role of insulin and
hypothalamic-pituitary-adrenal (HPA) Axis in the metabolic
syndrome</article-title><source>Int J Mol Sci</source><year>2022</year><season>Jul</season><day>25</day><volume>23</volume><issue>15</issue><fpage>8178</fpage><pub-id pub-id-type="doi">10.3390/ijms23158178.</pub-id><pub-id pub-id-type="pmid">35897752</pub-id><pub-id pub-id-type="pmcid">PMC9331414</pub-id></element-citation></ref><ref id="r35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Engin</surname><given-names>A.</given-names></name></person-group><article-title>Bariatric Surgery in Obesity: Metabolic Quality Analysis and
Comparison of Surgical Options</article-title><source>Adv Exp Med Biol</source><year>2024</year><volume>1460</volume><fpage>697</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.1007/978-3-031-63657-8_24.</pub-id><pub-id pub-id-type="pmid">39287870</pub-id></element-citation></ref><ref id="r36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Podg&#243;rska</surname><given-names>B</given-names></name><name name-style="western"><surname>Wielog&#243;rska-Partyka</surname><given-names>M</given-names></name><name name-style="western"><surname>Godzie&#324;</surname><given-names>J</given-names></name><name name-style="western"><surname>Siemi&#324;ska</surname><given-names>J</given-names></name><name name-style="western"><surname>Ciborowski</surname><given-names>M</given-names></name><name name-style="western"><surname>Szelachowska</surname><given-names>M</given-names></name><etal/></person-group><article-title>Applications of metabolomics in calcium metabolism disorders in
humans</article-title><source>Int J Mol Sci</source><year>2022</year><season>Sep</season><day>8</day><volume>23</volume><issue>18</issue><fpage>10407</fpage><pub-id pub-id-type="doi">10.3390/ijms231810407.</pub-id><pub-id pub-id-type="pmid">36142318</pub-id><pub-id pub-id-type="pmcid">PMC9499180</pub-id></element-citation></ref><ref id="r37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Plattel</surname><given-names>CHM.</given-names></name></person-group><article-title>Lack of Clinical Evidence Regarding the Guidelines for Vitamin
B12 Deficiency: An Analysis from Literature and Recommendations FROM
Clinical Practice</article-title><source>Food Nutr Bull</source><year>2024</year><season>Jun</season><volume>45</volume><issue>1 Suppl</issue><fpage>S80</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1177/03795721241241552.</pub-id><pub-id pub-id-type="pmid">38987878</pub-id></element-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="editorial" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Invest</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Invest</journal-id><journal-id journal-id-type="pmc-domain-id">120</journal-id><journal-id journal-id-type="pmc-domain">jcinvest</journal-id><journal-id journal-id-type="publisher-id">J Clin Invest</journal-id><journal-title-group><journal-title>The Journal of Clinical Investigation</journal-title></journal-title-group><issn pub-type="ppub">0021-9738</issn><issn pub-type="epub">1558-8238</issn><publisher><publisher-name>American Society for Clinical Investigation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12483549</article-id><article-id pub-id-type="pmcid-ver">PMC12483549.1</article-id><article-id pub-id-type="pmcaid">12483549</article-id><article-id pub-id-type="pmcaiid">12483549</article-id><article-id pub-id-type="pmid">41031881</article-id><article-id pub-id-type="doi">10.1172/JCI198725</article-id><article-id pub-id-type="publisher-id">198725</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Viewpoint</subject></subj-group></article-categories><title-group><article-title>Ruling in, ruling out: the clinical utility of plasma biomarkers in diagnosis of Alzheimer&#8217;s disease</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Wisch</surname><given-names initials="JK">Julie K.</given-names></name><email>julie.wisch@wustl.edu</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ances</surname><given-names initials="BM">Beau M.</given-names></name><email>bances@wustl.edu</email></contrib></contrib-group><aff>Department of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA.</aff><author-notes><corresp>Address correspondence to: Julie Wisch or Beau Ances, Department of Neurology, Washington University in Saint Louis School of Medicine, Campus Box 8111, 660 South Euclid Avenue, St. Louis, Missouri 63110, USA. Email: <email>julie.wisch@wustl.edu</email> (JW); <email>bances@wustl.edu</email> (BA).</corresp></author-notes><pub-date date-type="pub" publication-format="electronic" iso-8601-date="2025-10-01T12:00:00-0400"><day>1</day><month>10</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic" iso-8601-date="2025-10-01T12:00:00-0400"><day>1</day><month>10</month><year>2025</year></pub-date><volume>135</volume><issue>19</issue><issue-id pub-id-type="pmc-issue-id">498024</issue-id><elocation-id>e198725</elocation-id><pub-history><event event-type="pmc-release"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-02 13:25:38.967"><day>02</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 Wisch et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Wisch et al.</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://creativecommons.org/licenses/by/4.0/" ext-link-type="uri">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jci-135-198725.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.jci.org/articles/view/198725">This article is available online at https://www.jci.org/articles/view/198725</self-uri><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>On May 16, 2025, the US FDA approved the first blood-based test for amyloid plaques &#8212; the Lumipulse G pTau217/&#946;-Amyloid 1&#8211;42 Plasma Ratio &#8212; for adults aged 55 years and older who are exhibiting signs and symptoms of Alzheimer disease (AD) (<xref rid="B1" ref-type="bibr">1</xref>).</p><p>The presence of amyloid plaques has long been recognized as the earliest pathological indicator of looming cognitive decline and functional impairment associated with AD. First documented by Alois Alzheimer in 1906 (<xref rid="B2" ref-type="bibr">2</xref>), the field of AD research was hampered by limitations in their detectability: amyloid plaques could only be identified at autopsy. Nearly 100 years later, a radiotracer known as the Pittsburgh Compound B (PiB) was the first approved in vivo approach for visualizing and quantifying amyloid plaques via PET imaging (<xref rid="B3" ref-type="bibr">3</xref>). The challenges, costs, and lack of availability of PET led to development of cerebrospinal fluid (CSF) assays, with the first approval occurring in 2022 (<xref rid="B4" ref-type="bibr">4</xref>). The development of a blood-based test for AD pathology has long been an aim of the field; the possibility was first suggested in 1984 by Glenner and Wong, who isolated the amyloid protein (<xref rid="B5" ref-type="bibr">5</xref>). The successful development of a blood-based assay has the potential to transform screening for AD pathology, expanding accessibility and allowing for application in nonspecialized clinical practice.</p><p>Diagnosing AD can be difficult owing to variable clinical presentation and the presence of copathologies. In specialized memory centers, clinical diagnosis rates based on patient history and cognitive testing alone range from 70% to 87% sensitivity and 44% to 71% specificity (<xref rid="B6" ref-type="bibr">6</xref>), suggesting diagnostic accuracies of 50%&#8211;75% compared with assessment at autopsy. Adding amyloid PET imaging to clinical evaluations increases diagnostic sensitivity to 79%&#8211;98% and specificity to 76%&#8211;100% (<xref rid="B7" ref-type="bibr">7</xref>), increasing the estimated diagnostic accuracy to between 78% and 98%. Methods that increase access to amyloid status substantially enhance diagnostic precision and ensure that available antiamyloid therapies are given to appropriate individuals. A blood-based alternative to PET or CSF could further expand access to biomarker data, reduce misdiagnosis, and improve patient care.</p></sec><sec><title>Biological context</title><p>&#946;-Amyloid 1&#8211;42 is a core component of amyloid plaques (<xref rid="B5" ref-type="bibr">5</xref>), and its accumulation in the brain is an early hallmark of AD pathology. As amyloid accumulates, it triggers downstream processes, including the hyperphosphorylation of tau proteins at more than 40 known amino acid sites (<xref rid="B8" ref-type="bibr">8</xref>) &#8212; events that have been quantified in both CSF (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>) and, more recently, in plasma (<xref rid="B11" ref-type="bibr">11</xref>). Longitudinal work has demonstrated that the association between PET change rates for amyloid and tau is largely mediated by soluble tau, indicating that tau phosphorylation represents a critical step in the transition from amyloid accumulation to the development of tau tangles (<xref rid="B8" ref-type="bibr">8</xref>). Among the many phosphorylated tau species, plasma pTau217 &#8212; measuring phosphorylation at amino acid site 217 &#8212; has emerged as a leading biomarker owing to its strong and early association with amyloid pathology (<xref rid="B12" ref-type="bibr">12</xref>). Despite its name, pTau217 does not reflect tau tangle burden. Rather, it rises in response to amyloid plaque formation and appears to be more responsive to the presence of amyloid plaques than neurofibrillary tangles, making it a reliable marker of amyloid-related disease activity (<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B14" ref-type="bibr">14</xref>).</p></sec><sec><title>Underlying studies</title><p>In the clinical study submitted with the application (<xref rid="B1" ref-type="bibr">1</xref>), 499 individuals with either cross-sectional paired plasma and amyloid PET measurement or cross-sectional plasma and CSF quantification were assessed using a two-threshold model that classified individuals as low, high, or indeterminate for amyloid positivity. This approach, widely applied in the field, is designed to maximize both sensitivity and sensitivity while identifying individuals who would benefit from additional screening (i.e., PET or CSF) (<xref rid="B15" ref-type="bibr">15</xref>). In this cohort, the positive predictive value was 91.7% and the negative predictive value was 97.3%, while roughly 20% of individuals landed within the indeterminate zone, suggesting that they would need to be referred for further clinical testing. However, the full FDA review is not publicly available, limiting independent evaluation beyond the press release.</p><p>Outside of the FDA submission, this assay has been evaluated in multiple research settings. The largest published study (<italic toggle="yes">n =</italic> 1767) compared plasma pTau217 and the pTau217/&#946;-amyloid 1&#8211;42 (pTau217/A&#946;42) ratio to CSF A&#946;42/pTau181 in 5 European cohorts, yielding positive predictive values of 89%&#8211;95% and negative predictive values of 77%&#8211;90%. When using plasma pTau217 alone 12%&#8211;17% of individuals were classified as indeterminate, compared with 7%&#8211;10% when the plasma pTau217/A&#946;42 ratio was employed (<xref rid="B16" ref-type="bibr">16</xref>). Similar performance in other studies using CSF as the standard (AUC = 0.90&#8211;0.97, refs. <xref rid="B17" ref-type="bibr">17</xref>&#8211;<xref rid="B19" ref-type="bibr">19</xref>) as well as in comparisons to amyloid PET imaging (AUC = 0.94&#8211;0.96, ref. <xref rid="B20" ref-type="bibr">20</xref>) have been observed. Studies using the two-threshold approach report indeterminate rates of 12%&#8211;18% (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B22" ref-type="bibr">22</xref>). Although evaluation of the performance of plasma pTau217 alone rather than the ratio of pTau217/A&#946;42 is the predominant means by which the Lumipulse assay has been evaluated in the literature, the findings broadly suggest that the performance of pTau217/A&#946;42 is similar to pTau217 alone while greatly decreasing the number of individuals who receive an indeterminate designation.</p><p>While multiple assays have been developed, the Lumipulse G pTau217/&#946;-Amyloid 1&#8211;42 Plasma Ratio is the first to receive approval. In one head-to-head comparison of some of the most common pTau217 assays, the Lumipulse pTau217 plasma assay (AUC = 0.896, 95% CI: 0.864, 0.928) outperformed assays developed by ALZpath (AUC = 0.885, 95% CI: 0.851, 0.920) and Janssen (AUC = 0.882, 95% CI: 0.848, 0.916), but not C2N (AUC = 0.927, 95% CI: 0.900, 0.955) (<xref rid="B12" ref-type="bibr">12</xref>). The Alzheimer&#8217;s Association Global Biomarker Standardization Consortium conducted the broadest evaluation of the developed plasma assays, evaluating the fold change in CSF-confirmed AD cases versus individuals acting as controls, considering 33 different assays. The Lumipulse pTau217 plasma assay generated one of the highest median fold changes (5.69), indicating that the presence of AD pathology triggers a substantive change in circulating levels of plasma pTau217 (<xref rid="B23" ref-type="bibr">23</xref>). However, the pTau217/A&#946;42 ratio was not specifically included in these analyses.</p><p>Importantly, while current evidence supports the diagnostic utility of plasma pTau217, the ratio of plasma pTau217/A&#946;42 has received considerably less attention in the literature. Further, longitudinal data remains limited. Such evidence is essential for clinical interpretation, especially in the context of monitoring disease progression and treatment response over time.</p><p>In one of the few published longitudinal studies, evidence suggests that plasma pTau217 is a dynamic biomarker that is responsive to the development of AD pathology over time, although again, it did not investigate the ratio of plasma pTau217/A&#946;42. In this evaluation of 209 individuals with a mean follow-up time between samples of 2.1 years, amyloid-positive individuals displayed a higher annualized rate of change of plasma pTau217 than amyloid-negative individuals. Within the amyloid-negative cohort, apolipoprotein e4 carriers had higher mean plasma pTau217 (<xref rid="B21" ref-type="bibr">21</xref>).</p><p>A separate study using the Quanterix pTau217 assay examined short-term biological variation by measuring weekly plasma samples over 10 weeks in 20 healthy adults (age 40&#8211;60 years). Within-subject biological variation was 10.3% (95% CI: 9.2%&#8211;11.7%) and between-subject biological variation was 21.1% (95% CI: 15.1%&#8211;29.3%). Short term fluctuations of plasma pTau217 were apparent in some, but not all, individuals. Their analysis concludes that 3 samples would allow for estimation of the individual&#8217;s true homeostatic point within 5% of the true value (as compared with the roughly 20% error yielded with a single sample) (<xref rid="B24" ref-type="bibr">24</xref>). This finding has practical implications for clinical implementation, highlighting the potential value of repeat sampling to improve measurement precision in individual patients. This within-subject biological variation is likely to be assay dependent, and the results may not generalize to the recently approved Lumipulse G pTau217/&#946;-Amyloid 1&#8211;42 Plasma Ratio; however, the methodological rigor and practical relevance of this study suggests that high-frequency sampling of relatively few individuals may provide key performance insights, and studies similar to this one may be highly informative for this newly approved assay.</p></sec><sec><title>Implications for clinical practice</title><p>The FDA approval of the Lumipulse G pTau217/&#946;-Amyloid 1&#8211;42 Plasma Ratio as a blood-based test for AD is likely to be just the first of many approvals, as the field of blood-based biomarkers in AD is rapidly expanding. More than 30 assays have been published in the literature (<xref rid="B23" ref-type="bibr">23</xref>), and it will be incumbent on physicians to keep track of the myriad advantages and disadvantages associated with each. For the use case outlined in the FDA approval, that this specific test is relevant for adults over the age of 55 exhibiting signs and symptoms of AD, the weight of evidence suggests that the test has a high degree of utility most particularly in ruling out AD as the source of observed clinical symptoms (97% negative predictive value) but also in suggesting that AD pathology is present (90% positive predictive value). This test will be informative for 4 in 5 patients, with the remaining 20% falling in an indeterminate zone. The bulk of the literature evaluating plasma pTau217 suggests referring these individuals to follow-up assessments like lumbar puncture or PET scanning; although work by Brum et al. is suggestive that multiple plasma evaluations could also suffice (<xref rid="B24" ref-type="bibr">24</xref>). A similar evaluation of the biological variation of the Lumipulse G pTau217/&#946;-Amyloid 1&#8211;42 Plasma Ratio has not been released, but the field would benefit from this analysis, and a conclusion regarding the number of samples required to reliably estimate an individual&#8217;s true homeostatic level of circulating plasma pTau217 and &#946;-amyloid 1&#8211;42.</p><p>Importantly, the Lumipulse G pTau217/&#946;-Amyloid 1&#8211;42 Plasma Ratio is also only approved for initial assessment of the presence of amyloid plaques in the brain. With the recent approval of drugs such as donanemab (<xref rid="B25" ref-type="bibr">25</xref>) and lecanemab (<xref rid="B26" ref-type="bibr">26</xref>), antiamyloid therapies are being deployed in memory clinics across the country. Plasma biomarkers have not yet been approved for monitoring response to drug when there is a pharmacological intervention applied. Importantly, plasma pTau217 (but not the ratio of plasma pTau217/AB 42) has been collected in several clinical trials as researchers attempt to understand their utility in this context. In the TRAILBLAZER-ALZ trial, plasma pTau217 (Quanterix) showed a measurable response to donanemab as early as 12 weeks after initial dosing. Over the 76-week study, mean plasma pTau217 levels decreased by 23% from baseline in the treatment group and increased by 6% in the placebo group. Percentage change in amyloid PET signal was significantly correlated with percentage change in plasma pTau217 levels (R = 0.484, 95% CI: 0.359&#8211;0.592), suggesting that reductions in plasma pTau217 may reflect reductions in amyloid plaque burden (<xref rid="B26" ref-type="bibr">26</xref>). This suggests plasma pTau217 may be useful in monitoring response to drug; however, assay-specific validation is required.</p></sec><sec><title>Conclusion</title><p>The recent FDA approval of the first blood-based test for amyloid pathology marks a major milestone in AD diagnostics. Incorporating blood-based biomarkers into clinical practice has the potential to enhance diagnostic accuracy while reducing patient burden. However, substantial work remains. Given the growing number of assays reported in the literature, additional regulatory approvals are likely, each with unique performance characteristics. Further research is needed to characterize intraindividual variability and assay-specific responses to antiamyloid therapies. Notably, limited attention has been given to individuals who fall within the indeterminate classification range (exceptions are found in refs. <xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B28" ref-type="bibr">28</xref>) &#8212; an issue that will gain importance as therapeutic strategies shift toward earlier intervention. Ultimately, blood-based screening could play a critical role in ruling out AD or prompting clinical action, helping patients and their caregivers navigate the challenges of an AD diagnosis.</p></sec></body><back><ack><p>We acknowledge support provided by the Barnes-Jewish Hospital Foundation, the Charles F and Joanne Knight Alzheimer&#8217;s Research Initiative, the Hope Center for Neurological Disorders, the Mallinckrodt Institute of Radiology, the Paula and Rodger Riney fund, and the Daniel J Brennan MD fund. The authors are supported by the National Institute on Aging U19 AG068054-04. The views expressed in this Article are those of the authors alone. This work is the result of NIH funding, in whole or in part, and is subject to the NIH Public Access Policy. Through acceptance of this federal funding, the NIH has been given a right to make the work publicly available in PubMed Central.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>Conflict of interest:</bold> The authors have declared that no conflict of interest exists.</p></fn><fn><p><bold>Copyright:</bold> &#169; 2025, Wisch et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.</p></fn><fn><p><bold>Reference information:</bold><italic toggle="yes"> J Clin Invest</italic>. 2025;135(19):e198725. https://doi.org/10.1172/JCI198725.</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="webpage" publication-format="online"><comment>Food and Drug Administration. FDA clears first blood test used in diagnosing Alzheimer&#8217;s Disease. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease" ext-link-type="uri">https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease</ext-link> Updated May 16, 2025. Accessed July 29, 2025</comment></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stelzmann</surname><given-names>RA</given-names></name><etal>et al</etal></person-group><article-title>An English translation of Alzheimer&#8217;s 1907 paper, &#8220;Uber eine eigenartige Erkankung der Hirnrinde&#8221;</article-title><source>Clin Anat</source><year>1995</year><volume>8</volume><issue>6</issue><fpage>429</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1002/ca.980080612</pub-id><pub-id pub-id-type="pmid">8713166</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klunk</surname><given-names>WE</given-names></name><etal>et al</etal></person-group><article-title>Imaging brain amyloid in Alzheimer&#8217;s disease with Pittsburgh Compound-B</article-title><source>Ann Neurol</source><year>2004</year><volume>55</volume><issue>3</issue><fpage>306</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1002/ana.20009</pub-id><pub-id pub-id-type="pmid">14991808</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gobom</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid</article-title><source>Clin Chem Lab Med</source><year>2022</year><volume>60</volume><issue>2</issue><fpage>207</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1515/cclm-2021-0651</pub-id><pub-id pub-id-type="pmid">34773730</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glenner</surname><given-names>GG</given-names></name><name name-style="western"><surname>Wong</surname><given-names>CW</given-names></name></person-group><article-title>Alzheimer&#8217;s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein</article-title><source>Biochem Biophys Res Commun</source><year>1984</year><volume>120</volume><issue>3</issue><fpage>885</fpage><lpage>890</lpage><pub-id pub-id-type="doi">10.1016/S0006-291X(84)80190-4</pub-id><pub-id pub-id-type="pmid">6375662</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beach</surname><given-names>TG</given-names></name><etal>et al</etal></person-group><article-title>Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010</article-title><source>J Neuropathol Exp Neurol</source><year>2012</year><volume>71</volume><issue>4</issue><fpage>266</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1097/NEN.0b013e31824b211b</pub-id><pub-id pub-id-type="pmid">22437338</pub-id><pub-id pub-id-type="pmcid">PMC3331862</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fink</surname><given-names>HA</given-names></name><etal>et al</etal></person-group><article-title>Accuracy of Biomarker Testing for Neuropathologically Defined Alzheimer disease in older adults with dementia</article-title><source>Ann Intern Med</source><year>2020</year><volume>172</volume><issue>10</issue><fpage>669</fpage><lpage>677</lpage><pub-id pub-id-type="doi">10.7326/M19-3888</pub-id><pub-id pub-id-type="pmid">32340038</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pichet Binette</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer&#8217;s disease</article-title><source>Nat Commun</source><year>2022</year><volume>13</volume><issue>1</issue><elocation-id>6635</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-34129-4</pub-id><pub-id pub-id-type="pmid">36333294</pub-id><pub-id pub-id-type="pmcid">PMC9636262</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barth&#233;lemy</surname><given-names>NR</given-names></name><etal>et al</etal></person-group><article-title>Site-specific cerebrospinal fluid tau hyperphosphorylation in response to Alzheimer&#8217;s disease brain pathology: not all tau phospho-sites are hyperphosphorylated</article-title><source>J Alzheimers Dis</source><year>2022</year><volume>85</volume><issue>1</issue><fpage>415</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.3233/JAD-210677</pub-id><pub-id pub-id-type="pmid">34806603</pub-id><pub-id pub-id-type="pmcid">PMC8842784</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barthelemy</surname><given-names>N</given-names></name><etal>et al</etal></person-group><article-title>CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer&#8217;s disease</article-title><source>Nat Aging</source><year>2023</year><volume>3</volume><issue>4</issue><fpage>391</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1038/s43587-023-00380-7</pub-id><pub-id pub-id-type="pmid">37117788</pub-id><pub-id pub-id-type="pmcid">PMC10154225</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barth&#233;lemy</surname><given-names>NR</given-names></name><etal>et al</etal></person-group><article-title>Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer&#8217;s disease</article-title><source>J Exp Med</source><year>2020</year><volume>217</volume><issue>11</issue><elocation-id>e20200861</elocation-id><pub-id pub-id-type="doi">10.1084/jem.20200861</pub-id><pub-id pub-id-type="pmid">32725127</pub-id><pub-id pub-id-type="pmcid">PMC7596823</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schindler</surname><given-names>SE</given-names></name><etal>et al</etal></person-group><article-title>Head-to-head comparison of leading blood tests for Alzheimer&#8217;s disease pathology</article-title><source>Alzheimer&#8217;s &amp; Dementia</source><year>2024</year><volume>20</volume><issue>11</issue><fpage>8074</fpage><lpage>8096</lpage><pub-id pub-id-type="doi">10.1002/alz.14315</pub-id><pub-id pub-id-type="pmid">39394841</pub-id><pub-id pub-id-type="pmcid">PMC11567821</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horie</surname><given-names>K</given-names></name><etal>et al</etal></person-group><article-title>Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer&#8217;s disease</article-title><source>Nat Med</source><year>2025</year><volume>31</volume><issue>6</issue><fpage>2044</fpage><lpage>2053</lpage><pub-id pub-id-type="doi">10.1038/s41591-025-03617-7</pub-id><pub-id pub-id-type="pmid">40164726</pub-id><pub-id pub-id-type="pmcid">PMC12176612</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horie</surname><given-names>K</given-names></name><etal>et al</etal></person-group><article-title>CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer&#8217;s disease</article-title><source>Nat Med</source><year>2023</year><volume>29</volume><issue>8</issue><fpage>1954</fpage><lpage>1963</lpage><pub-id pub-id-type="doi">10.1038/s41591-023-02443-z</pub-id><pub-id pub-id-type="pmid">37443334</pub-id><pub-id pub-id-type="pmcid">PMC10427417</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brum</surname><given-names>WS</given-names></name><etal>et al</etal></person-group><article-title>A two-step workflow based on plasma p-tau217 to screen for amyloid &#946; positivity with further confirmatory testing only in uncertain cases</article-title><source>Nat Aging</source><year>2023</year><volume>3</volume><issue>9</issue><fpage>1079</fpage><lpage>1090</lpage><pub-id pub-id-type="doi">10.1038/s43587-023-00471-5</pub-id><pub-id pub-id-type="pmid">37653254</pub-id><pub-id pub-id-type="pmcid">PMC10501903</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palmqvist</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Plasma phospho-tau217 for Alzheimer&#8217;s disease diagnosis in primary and secondary care using a fully automated platform</article-title><source>Nat Med</source><year>2025</year><volume>31</volume><issue>6</issue><fpage>2036</fpage><lpage>2043</lpage><pub-id pub-id-type="doi">10.1038/s41591-025-03622-w</pub-id><pub-id pub-id-type="pmid">40205199</pub-id><pub-id pub-id-type="pmcid">PMC12176611</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arranz</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Diagnostic performance of plasma pTau<sub>217</sub>, pTau<sub>181</sub>, A&#946;<sub>1-42</sub> and A&#946;<sub>1-40</sub> in the LUMIPULSE automated platform for the detection of Alzheimer disease</article-title><source>Alzheimers Res Ther</source><year>2024</year><volume>16</volume><issue>1</issue><elocation-id>139</elocation-id><pub-id pub-id-type="doi">10.1186/s13195-024-01513-9</pub-id><pub-id pub-id-type="pmid">38926773</pub-id><pub-id pub-id-type="pmcid">PMC11200993</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cecchetti</surname><given-names>G</given-names></name><etal>et al</etal></person-group><article-title>Diagnostic accuracy of automated Lumipulse plasma pTau-217 in Alzheimer&#8217;s disease: a real-world study</article-title><source>J Neurol</source><year>2024</year><volume>271</volume><issue>10</issue><fpage>6739</fpage><lpage>6749</lpage><pub-id pub-id-type="doi">10.1007/s00415-024-12631-7</pub-id><pub-id pub-id-type="pmid">39174818</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pilotto</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Plasma p-tau217 in Alzheimer&#8217;s disease: Lumipulse and ALZpath SIMOA head-to-head comparison</article-title><source>Brain</source><year>2025</year><volume>148</volume><issue>2</issue><fpage>408</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1093/brain/awae368</pub-id><pub-id pub-id-type="pmid">39679606</pub-id><pub-id pub-id-type="pmcid">PMC11788209</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhong</surname><given-names>X</given-names></name><etal>et al</etal></person-group><article-title>Plasma p-tau217 and p-tau217/A&#946;1-42 are effective biomarkers for identifying CSF- and PET imaging-diagnosed Alzheimer&#8217;s disease: Insights for research and clinical practice</article-title><source>Alzheimers Dement</source><year>2025</year><volume>21</volume><issue>2</issue><elocation-id>e14536</elocation-id><pub-id pub-id-type="doi">10.1002/alz.14536</pub-id><pub-id pub-id-type="pmid">39887504</pub-id><pub-id pub-id-type="pmcid">PMC11848202</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mart&#237;nez-Dubarbie</surname><given-names>F</given-names></name><etal>et al</etal></person-group><article-title>Diagnostic performance of plasma p-tau217 in a memory clinic cohort using the Lumipulse automated platform</article-title><source>Alzheimers Res Ther</source><year>2025</year><volume>17</volume><issue>1</issue><elocation-id>68</elocation-id><pub-id pub-id-type="doi">10.1186/s13195-025-01719-5</pub-id><pub-id pub-id-type="pmid">40140924</pub-id><pub-id pub-id-type="pmcid">PMC11948696</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feizpour</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Accurate detection and staging of Alzheimer&#8217;s disease by plasma Ptau217 on a high throughput immunoassay platform</article-title><source>EBioMedicine</source><year>2024</year><volume>109</volume><elocation-id>105405</elocation-id><pub-id pub-id-type="doi">10.1016/j.ebiom.2024.105405</pub-id><pub-id pub-id-type="pmid">39437657</pub-id><pub-id pub-id-type="pmcid">PMC11536028</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashton</surname><given-names>NJ</given-names></name><etal>et al</etal></person-group><article-title>The Alzheimer&#8217;s Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau round robin study</article-title><source>Alzheimers Dement</source><year>2025</year><volume>21</volume><issue>2</issue><elocation-id>e14508</elocation-id><pub-id pub-id-type="doi">10.1002/alz.14508</pub-id><pub-id pub-id-type="pmid">39907496</pub-id><pub-id pub-id-type="pmcid">PMC11851162</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brum</surname><given-names>WS</given-names></name><etal>et al</etal></person-group><article-title>Biological variation estimates of Alzheimer&#8217;s disease plasma biomarkers in healthy individuals</article-title><source>Alzheimers Dement</source><year>2024</year><volume>20</volume><issue>2</issue><fpage>1284</fpage><lpage>1297</lpage><pub-id pub-id-type="doi">10.1002/alz.13518</pub-id><pub-id pub-id-type="pmid">37985230</pub-id><pub-id pub-id-type="pmcid">PMC10916965</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sims</surname><given-names>JR</given-names></name><etal>et al</etal></person-group><article-title>Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial</article-title><source>JAMA</source><year>2023</year><volume>330</volume><issue>6</issue><fpage>512</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1001/jama.2023.13239</pub-id><pub-id pub-id-type="pmid">37459141</pub-id><pub-id pub-id-type="pmcid">PMC10352931</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Dyck</surname><given-names>CH</given-names></name><etal>et al</etal></person-group><article-title>Lecanemab in early Alzheimer&#8217;s Disease</article-title><source>N Engl J Med</source><year>2023</year><volume>388</volume><issue>1</issue><fpage>9</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2212948</pub-id><pub-id pub-id-type="pmid">36449413</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wisch</surname><given-names>JK</given-names></name><etal>et al</etal></person-group><article-title>Predicting continuous amyloid PET values with CSF tau phosphorylation occupancies</article-title><source>Alzheimers Dement</source><year>2024</year><volume>20</volume><issue>9</issue><fpage>6365</fpage><lpage>6373</lpage><pub-id pub-id-type="doi">10.1002/alz.14132</pub-id><pub-id pub-id-type="pmid">39041391</pub-id><pub-id pub-id-type="pmcid">PMC11497729</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Devanarayan</surname><given-names>V</given-names></name><etal>et al</etal></person-group><article-title>Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer&#8217;s disease</article-title><source>Alzheimers Dement</source><year>2024</year><volume>20</volume><issue>8</issue><fpage>5617</fpage><lpage>5628</lpage><pub-id pub-id-type="doi">10.1002/alz.14073</pub-id><pub-id pub-id-type="pmid">38940656</pub-id><pub-id pub-id-type="pmcid">PMC11350129</pub-id></element-citation></ref></ref-list><notes notes-type="version-changes"><sec sec-type="version-changes"><label>Version 1</label><title>10/01/2025</title><p>Electronic publication</p></sec></notes></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="mds30293" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Mov Disord</journal-id><journal-id journal-id-type="iso-abbrev">Mov Disord</journal-id><journal-id journal-id-type="pmc-domain-id">379</journal-id><journal-id journal-id-type="pmc-domain">blackwellopen</journal-id><journal-id journal-id-type="publisher-id">MDS</journal-id><journal-title-group><journal-title>Movement Disorders</journal-title></journal-title-group><issn pub-type="ppub">0885-3185</issn><issn pub-type="epub">1531-8257</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Wiley Open Access Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12485586</article-id><article-id pub-id-type="pmcid-ver">PMC12485586.1</article-id><article-id pub-id-type="pmcaid">12485586</article-id><article-id pub-id-type="pmcaiid">12485586</article-id><article-id pub-id-type="pmid">40678921</article-id><article-id pub-id-type="doi">10.1002/mds.30293</article-id><article-id pub-id-type="publisher-id">MDS30293</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Review</subject></subj-group><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Attention/Working Memory and Executive Function in Parkinson's Disease: Review, Critique, and Recommendations</article-title><alt-title alt-title-type="right-running-head">Fronto&#8208;Striatal Neuropsychological Tests in PD</alt-title><alt-title alt-title-type="left-running-head">Biundo et al</alt-title></title-group><contrib-group><contrib id="mds30293-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Biundo</surname><given-names initials="R">Roberta</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5846-755X</contrib-id><xref rid="mds30293-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="mds30293-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>roberta.biundo@unipd.it</email></address></contrib><contrib id="mds30293-cr-0002" contrib-type="author"><name name-style="western"><surname>Bezdicek</surname><given-names initials="O">Ondrej</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5108-0181</contrib-id><xref rid="mds30293-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="mds30293-cr-0003" contrib-type="author"><name name-style="western"><surname>Cammisuli</surname><given-names initials="DM">Davide Maria</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8340-1867</contrib-id><xref rid="mds30293-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="mds30293-cr-0004" contrib-type="author"><name name-style="western"><surname>Cholerton</surname><given-names initials="B">Brenna</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2139-987X</contrib-id><xref rid="mds30293-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="mds30293-cr-0005" contrib-type="author"><name name-style="western"><surname>Dalrymple&#8208;Alford</surname><given-names initials="JC">John C.</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6672-033X</contrib-id><xref rid="mds30293-aff-0006" ref-type="aff">
<sup>6</sup>
</xref><xref rid="mds30293-aff-0007" ref-type="aff">
<sup>7</sup>
</xref><xref rid="mds30293-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="mds30293-cr-0006" contrib-type="author"><name name-style="western"><surname>Edelstyn</surname><given-names initials="N">Nicola</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6795-0145</contrib-id><xref rid="mds30293-aff-0009" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib id="mds30293-cr-0007" contrib-type="author"><name name-style="western"><surname>Fiorenzato</surname><given-names initials="E">Eleonora</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7947-5903</contrib-id><xref rid="mds30293-aff-0010" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib id="mds30293-cr-0008" contrib-type="author"><name name-style="western"><surname>Holker</surname><given-names initials="E">Erin</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0004-5319-8767</contrib-id><xref rid="mds30293-aff-0011" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib id="mds30293-cr-0009" contrib-type="author"><name name-style="western"><surname>Martinez&#8208;Horta</surname><given-names initials="S">Saul</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0125-7249</contrib-id><xref rid="mds30293-aff-0012" ref-type="aff">
<sup>12</sup>
</xref><xref rid="mds30293-aff-0013" ref-type="aff">
<sup>13</sup>
</xref></contrib><contrib id="mds30293-cr-0010" contrib-type="author"><name name-style="western"><surname>Martini</surname><given-names initials="A">Alice</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6349-0831</contrib-id><xref rid="mds30293-aff-0014" ref-type="aff">
<sup>14</sup>
</xref></contrib><contrib id="mds30293-cr-0011" contrib-type="author"><name name-style="western"><surname>Santangelo</surname><given-names initials="G">Gabriella</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7728-852X</contrib-id><xref rid="mds30293-aff-0015" ref-type="aff">
<sup>15</sup>
</xref></contrib><contrib id="mds30293-cr-0012" contrib-type="author"><name name-style="western"><surname>Segura</surname><given-names initials="B">Barbara</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9673-5479</contrib-id><xref rid="mds30293-aff-0016" ref-type="aff">
<sup>16</sup>
</xref><xref rid="mds30293-aff-0017" ref-type="aff">
<sup>17</sup>
</xref><xref rid="mds30293-aff-0018" ref-type="aff">
<sup>18</sup>
</xref></contrib><contrib id="mds30293-cr-0013" contrib-type="author"><name name-style="western"><surname>Siri</surname><given-names initials="C">Chiara</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9199-4084</contrib-id><xref rid="mds30293-aff-0019" ref-type="aff">
<sup>19</sup>
</xref></contrib><contrib id="mds30293-cr-0014" contrib-type="author"><name name-style="western"><surname>Tr&#246;ster</surname><given-names initials="A">Alexander</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8898-3878</contrib-id><xref rid="mds30293-aff-0020" ref-type="aff">
<sup>20</sup>
</xref></contrib><contrib id="mds30293-cr-0015" contrib-type="author"><name name-style="western"><surname>Mestre</surname><given-names initials="TA">Tiago A.</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6973-7479</contrib-id><xref rid="mds30293-aff-0021" ref-type="aff">
<sup>21</sup>
</xref></contrib><contrib id="mds30293-cr-0016" contrib-type="author"><name name-style="western"><surname>Ferro</surname><given-names initials="&#xC1;S">&#193;lvaro S&#225;nchez</given-names></name><degrees>MD, PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2461-2485</contrib-id><xref rid="mds30293-aff-0013" ref-type="aff">
<sup>13</sup>
</xref><xref rid="mds30293-aff-0022" ref-type="aff">
<sup>22</sup>
</xref></contrib><contrib id="mds30293-cr-0017" contrib-type="author"><name name-style="western"><surname>Hyczy de Siqueira Tosin</surname><given-names initials="M">Michelle</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7309-1407</contrib-id><xref rid="mds30293-aff-0023" ref-type="aff">
<sup>23</sup>
</xref></contrib><contrib id="mds30293-cr-0018" contrib-type="author"><name name-style="western"><surname>Skorvanek</surname><given-names initials="M">Matej</given-names></name><degrees>MD, PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5497-8715</contrib-id><xref rid="mds30293-aff-0024" ref-type="aff">
<sup>24</sup>
</xref><xref rid="mds30293-aff-0025" ref-type="aff">
<sup>25</sup>
</xref></contrib><contrib id="mds30293-cr-0019" contrib-type="author"><name name-style="western"><surname>Weintraub</surname><given-names initials="D">Daniel</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0633-7168</contrib-id><xref rid="mds30293-aff-0026" ref-type="aff">
<sup>26</sup>
</xref></contrib><contrib id="mds30293-cr-0020" contrib-type="author"><name name-style="western"><surname>Geurtsen</surname><given-names initials="GJ">Gert J.</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2508-340X</contrib-id><xref rid="mds30293-aff-0027" ref-type="aff">
<sup>27</sup>
</xref></contrib><contrib id="mds30293-cr-0021" contrib-type="author"><collab collab-type="authors">the members of the MDS Clinical Outcome Assessment Scientific Evaluation Committee</collab></contrib></contrib-group><aff id="mds30293-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of General Psychology</named-content>
<institution>University of Padua</institution>
<city>Padua</city>
<country country="IT">Italy</country>
</aff><aff id="mds30293-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>IRCCS, San Camillo Hospital</institution>
<city>Venice</city>
<country country="IT">Italy</country>
</aff><aff id="mds30293-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology and Centre of Clinical Neuroscience</named-content>
<institution>First Faculty of Medicine and General University Hospital in Prague, Charles University</institution>
<city>Prague</city>
<country country="CZ">Czech Republic</country>
</aff><aff id="mds30293-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Psychology</named-content>
<institution>Catholic University of the Sacred Heart</institution>
<city>Milan</city>
<country country="IT">Italy</country>
</aff><aff id="mds30293-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<institution>Stanford University School of Medicine</institution>
<city>Stanford</city>
<named-content content-type="country-part">California</named-content>
<country country="US">USA</country>
</aff><aff id="mds30293-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Te Kura Mahi &#257;&#8208;Hirikapo School of Psychology, Speech and Hearing</named-content>
<institution>University of Canterbury</institution>
<city>Christchurch</city>
<country country="NZ">New Zealand</country>
</aff><aff id="mds30293-aff-0007">
<label>
<sup>7</sup>
</label>
<institution>New Zealand Brain Research Institute</institution>
<city>Christchurch</city>
<country country="NZ">New Zealand</country>
</aff><aff id="mds30293-aff-0008">
<label>
<sup>8</sup>
</label>
<named-content content-type="organisation-division">Department of Medicine</named-content>
<institution>University of Otago</institution>
<city>Dunedin</city>
<country country="NZ">New Zealand</country>
</aff><aff id="mds30293-aff-0009">
<label>
<sup>9</sup>
</label>
<named-content content-type="organisation-division">Department of Psychology</named-content>
<institution>Bath Spa University</institution>
<city>Bath</city>
<country country="GB">UK</country>
</aff><aff id="mds30293-aff-0010">
<label>
<sup>10</sup>
</label>
<named-content content-type="organisation-division">Neurodegenerative Disease Unit, Department of Neuroscience</named-content>
<institution>University of Padua</institution>
<city>Padua</city>
<country country="IT">Italy</country>
</aff><aff id="mds30293-aff-0011">
<label>
<sup>11</sup>
</label>
<named-content content-type="organisation-division">Department of Rehabilitation Medicine</named-content>
<institution>University of Minnesota</institution>
<city>Minneapolis</city>
<named-content content-type="country-part">Minnesota</named-content>
<country country="US">USA</country>
</aff><aff id="mds30293-aff-0012">
<label>
<sup>12</sup>
</label>
<named-content content-type="organisation-division">Movement Disorders Unit, Department of Neurology</named-content>
<institution>Hospital de la Santa Creu i Sant Pau, Research Institute Sant Pau</institution>
<city>Barcelona</city>
<country country="ES">Spain</country>
</aff><aff id="mds30293-aff-0013">
<label>
<sup>13</sup>
</label>
<institution>Centro de Investigagi&#243;n Biom&#233;dica en Red&#8208;Enfermedades Neurodegenerativas (CIBERNED)</institution>
<city>Madrid</city>
<country country="ES">Spain</country>
</aff><aff id="mds30293-aff-0014">
<label>
<sup>14</sup>
</label>
<named-content content-type="organisation-division">Addiction and Mental Health Department</named-content>
<institution>Azienda Sanitaria Friuli Occidentale</institution>
<city>Pordenone</city>
<country country="IT">Italy</country>
</aff><aff id="mds30293-aff-0015">
<label>
<sup>15</sup>
</label>
<named-content content-type="organisation-division">Department of Psychology</named-content>
<institution>University of Campania, &#8220;Luigi Vanvitelli&#8221;</institution>
<city>Caserta</city>
<country country="IT">Italy</country>
</aff><aff id="mds30293-aff-0016">
<label>
<sup>16</sup>
</label>
<named-content content-type="organisation-division">Medical Psychology Unit, Department of Medicine</named-content>
<institution>Institute of Neurosciences, University of Barcelona</institution>
<city>Barcelona</city>
<country country="ES">Spain</country>
</aff><aff id="mds30293-aff-0017">
<label>
<sup>17</sup>
</label>
<institution>Institut d'Investigacions Biom&#232;diques August Pi i Sunyer (IDIBAPS)</institution>
<city>Barcelona</city>
<country country="ES">Spain</country>
</aff><aff id="mds30293-aff-0018">
<label>
<sup>18</sup>
</label>
<institution>Centro de Investigaci&#243;n Biom&#233;dica en Red sobre Enfermedades Neurodegenerativas</institution>
<city>Barcelona</city>
<country country="ES">Spain</country>
</aff><aff id="mds30293-aff-0019">
<label>
<sup>19</sup>
</label>
<named-content content-type="organisation-division">Parkinson's Disease and Movement Disorders Neurorehabilitation Unit</named-content>
<institution>Moriggia Pelascini Hospital</institution>
<named-content content-type="country-part">Como</named-content>
<country country="IT">Italy</country>
</aff><aff id="mds30293-aff-0020">
<label>
<sup>20</sup>
</label>
<named-content content-type="organisation-division">Department of Clinical Neuropsychology and Center for Neuromodulation</named-content>
<institution>Barrow Neurological Institute</institution>
<city>Phoenix</city>
<named-content content-type="country-part">Arizona</named-content>
<country country="US">USA</country>
</aff><aff id="mds30293-aff-0021">
<label>
<sup>21</sup>
</label>
<named-content content-type="organisation-division">Parkinson's Disease and Movement Disorders Center, Division of Neurology, Department of Medicine</named-content>
<institution>The Ottawa Hospital Research Institute, University of Ottawa Brain and Mind Institute</institution>
<city>Ottawa</city>
<named-content content-type="country-part">Ontario</named-content>
<country country="CA">Canada</country>
</aff><aff id="mds30293-aff-0022">
<label>
<sup>22</sup>
</label>
<named-content content-type="organisation-division">Movement Disorders Unit, Neurology Department</named-content>
<institution>Hospital Universitario 12 de Octubre</institution>
<city>Madrid</city>
<country country="ES">Spain</country>
</aff><aff id="mds30293-aff-0023">
<label>
<sup>23</sup>
</label>
<named-content content-type="organisation-division">Department of Neurological Sciences</named-content>
<institution>Rush University Medical Center</institution>
<city>Chicago</city>
<named-content content-type="country-part">Illinois</named-content>
<country country="US">USA</country>
</aff><aff id="mds30293-aff-0024">
<label>
<sup>24</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>Safarik University</institution>
<city>Kosice</city>
<country country="SK">Slovakia</country>
</aff><aff id="mds30293-aff-0025">
<label>
<sup>25</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>University Hospital of Louis Pasteur</institution>
<city>Kosice</city>
<country country="SK">Slovakia</country>
</aff><aff id="mds30293-aff-0026">
<label>
<sup>26</sup>
</label>
<named-content content-type="organisation-division">Department of Psychiatry</named-content>
<institution>University of Pennsylvania School of Medicine; Parkinson's Disease Research, Education and Clinical Center (PADRECC), Philadelphia Veterans Affairs Medical Center</institution>
<city>Philadelphia</city>
<named-content content-type="country-part">Pennsylvania</named-content>
<country country="US">USA</country>
</aff><aff id="mds30293-aff-0027">
<label>
<sup>27</sup>
</label>
<named-content content-type="organisation-division">Department of Medical Psychology</named-content>
<institution>Amsterdam UMC Location, University of Amsterdam, Amsterdam Neuroscience</institution>
<city>Amsterdam</city>
<country country="NL">The Netherlands</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence to:</bold> Dr. Roberta Biundo, Department of General Psychology, University of Padua, Padua, Italy; E&#8208;mail: <email>roberta.biundo@unipd.it</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>9</month><year>2025</year></pub-date><volume>40</volume><issue seq="60">9</issue><issue-id pub-id-type="pmc-issue-id">498039</issue-id><issue-id pub-id-type="doi">10.1002/mds.v40.9</issue-id><fpage>1791</fpage><lpage>1804</lpage><history><date date-type="rev-recd"><day>10</day><month>6</month><year>2025</year></date><date date-type="received"><day>27</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>24</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>02</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-03 00:25:14.440"><day>03</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Movement Disorders</italic> published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="MDS-40-1791.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:MDS-40-1791.pdf"/><abstract><title>Abstract</title><sec id="mds30293-sec-0001"><title>Background</title><p>Cognitive impairment in Parkinson's disease (PD) is a well&#8208;established non&#8208;motor complication that significantly affects the quality of life and well&#8208;being of both patients and care partners. To optimally detect mild cognitive impairment or dementia, extensive neuropsychological assessment is essential. A wide range of cognitive tests and clinical outcome assessments have been used in clinical settings, often without regard to their clinimetric quality.</p></sec><sec id="mds30293-sec-0002"><title>Methods</title><p>We performed a literature review of tests assessing attention/working memory and executive domains in PD (tests on other domains are included in an accompanying review). The selected tests were evaluated for their clinimetric properties and categorized by a panel of experts as &#8220;recommended,&#8221; &#8220;recommended with caveats,&#8221; &#8220;suggested,&#8221; or &#8220;listed&#8221; according to the International Parkinson and Movement Disorder Society Clinical Outcome Assessment Scientific Evaluation Committee guidelines.</p></sec><sec id="mds30293-sec-0003"><title>Results</title><p>A total of 30 tests were reviewed. Eight tests were &#8220;recommended,&#8221; including four tests assessing attention/working memory abilities (WAIS&#8208;IV Digit Span, Coding and Symbol Search subtests, and Trail Making Test) and four tests assessing executive abilities (WAIS&#8208;IV Similarities, Wisconsin Card Sorting Test, Fluency Tests, and Stroop Color&#8208;Word Test). These tests demonstrated good to excellent levels of reliability and validity, have normative datasets, and are sensitive to change. Eight other tests were &#8220;recommended with caveats&#8221;, eleven were &#8220;suggested,&#8221; and three were &#8220;listed.&#8221;</p></sec><sec id="mds30293-sec-0004"><title>Conclusions</title><p>The recommended tests for attention/working memory and executive functioning in PD can guide PD cognitive assessment. Other tests were identified as potentially useful; however, caution is advised due to their clinimetric limitations. Further validation studies are required for these tests. &#169; 2025 The Author(s). <italic toggle="yes">Movement Disorders</italic> published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="mds30293-kwd-0001">attention&#8208;executive functions</kwd><kwd id="mds30293-kwd-0002">cognition</kwd><kwd id="mds30293-kwd-0003">Parkinson's disease</kwd><kwd id="mds30293-kwd-0004">psychometric properties</kwd><kwd id="mds30293-kwd-0005">rating test</kwd></kwd-group><counts><fig-count count="0"/><table-count count="2"/><page-count count="14"/><word-count count="10600"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>September 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:01.10.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="mds30293-ntgp-0001"><fn id="mds30293-note-0001"><p>
<bold>Relevant conflicts of interest/financial disclosures:</bold> Nothing to report.</p></fn><fn id="mds30293-note-0002"><p>
<bold>Funding agency:</bold> None.</p></fn></fn-group></notes></front><body id="mds30293-body-0001"><p>The diagnosis of Parkinson's disease (PD) relies on the presence of specific motor symptoms, but cognitive decline is one of the most frequent non&#8208;motor symptoms (up to six times more common than in healthy controls), often occurring in the early or even prodromal stage of the disease and significantly impacting the quality of life and increasing caregiver burden.<xref rid="mds30293-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="mds30293-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="mds30293-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>
</p><p>The fronto&#8208;striatal network&#8208;based dysexecutive alterations represent the most predominant cognitive symptoms. The dorsolateral and medial prefrontal cortex provides top&#8208;down regulation of attention, inhibition, and cognitive control through connections with the posterior cortex and subcortical structures which include the striatum (caudate, putamen, or ventral striatum), as well as the globus pallidus, substantia nigra, and thalamic nuclei.<xref rid="mds30293-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="mds30293-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>
</p><p>Given the trajectory of the pathophysiological process that characterize PD and their early effects on fronto&#8208;striatal circuits, it is predictable that patients with PD will develop attention/executive impairments that are dependent on these systems.</p><p>Studies show that PD patients experience a range of cognitive issues. These include non&#8208;executive cognitive deficits, and the cognitive profile of PD varies in quality and severity. This spectrum of impairment can range from subjective cognitive decline (SCD) and mild cognitive impairment (PD&#8208;MCI) to dementia (PDD). The progression of cognitive deficits and time to onset of dementia are also variable.<xref rid="mds30293-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>
</p><p>To support clinicians, the International Parkinson and Movement Disorder Society (MDS) provides guidelines for assessing cognitive statuses, including recommendations for clinical outcome assessments (COAs).<xref rid="mds30293-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="mds30293-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>
</p><p>Since these guidelines were published, several studies have focused on early identification of the PD&#8208;MCI phenotype, with the primary objective of identifying specific cognitive profiles that are most indicative of progression to PDD.<xref rid="mds30293-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="mds30293-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> However, the heterogeneous criteria used to define PD&#8208;MCI, the unclear methodological parameters, and the lack of robust discussion of the clinimetric properties of the heterogenous tests/scales proposed (and the even wider range of tests used in studies), may have contributed to a poorly characterized PD&#8208;MCI profile.<xref rid="mds30293-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="mds30293-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>
</p><p>From a clinimetric perspective, a selected COA should possess good reliability, validity, and, for the neuropsychological tests, robust normative data. Furthermore, it should be sensitive to early, subtle alterations, capable of tracking change over time, and able to evaluate the effects of cognition&#8208;enhancing treatments. It is important to recognize that the most suitable instrument(s) may vary depending on the purpose of the assessment. For instance, the tests best suited for detecting subtle deficits may not be the same as those most effective in measuring deficit progression, or the outcome of treatments.<xref rid="mds30293-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>
</p><p>In this MDS&#8208;commissioned review, the psychometric properties of the attention/working memory and executive tests (see an accompanying review on language, memory, and visuospatial functions) were investigated, following similar procedures employed in the &#8220;global scales&#8221; review for PD cognitive screening.<xref rid="mds30293-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> These assessments have the potential to aid in the identification of PD&#8208;MCI or PDD in clinical settings.</p><sec sec-type="methods" id="mds30293-sec-0006"><label>1</label><title>Methods</title><sec id="mds30293-sec-0007"><label>1.1</label><title>Organization and Review Process</title><p>An international group of experts on neuropsychological assessment in PD was selected by the MDS COA Program Scientific Evaluation Committee (SEC). The group focused on reviewing attention/working memory and executive COAs and was chaired by R.B.</p><p>A panel of 14 experts (O.B., D.M.C., B.C., J.C.D.&#8208;A., N.E., E.F., E.H., S.M.&#8208;H, A.M., G.S., B.S., C.S., A.T., G.J.G.) conducted a thorough review and evaluation of the measures assessing attention/working memory and executive functions in PD. Each assessment was carried out using a systematic procedure, with all evaluations documented in a template provided by the MDS COA program SEC, specifically tailored for the review of neuropsychological assessments.</p><p>Each review included a detailed description of the COAs, along with their properties, contemporary applications, psychometric properties, and an overall evaluation of the suitability and applicability within a clinical setting for PD patients. Initially, each scale or test was evaluated independently by two neuropsychologists, followed by an additional review by the chair of the group (R.B.). If there was disagreement, group discussion was convened to facilitate a consensus. The final decision was based on agreement of all expert panel members. The recommendation criteria were adopted from a previous review<xref rid="mds30293-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> to include the categories &#8220;recommended,&#8221; &#8220;recommended with caveats,&#8221; &#8220;suggested,&#8221; and &#8220;listed.&#8221; Oversight of the entire project was provided by two liaisons (M.S., D.W.) who also reviewed the project. Finally, the manuscript was reviewed and approved by the MDS COA program SEC chairs (M.S., M.H.S.T.), COA program directors (T.A.M., A.S.F.), and the members of the MDS COA program SEC.</p></sec><sec id="mds30293-sec-0008"><label>1.2</label><title>Literature Search</title><p>A literature search was conducted using PubMed, Web of Science, Medline, and Scopus for all publications from 1975 to December 2022. Keywords used in the search contained &#8220;Parkinson*&#8221; and the terms &#8220;cognit*&#8221; OR &#8220;test&#8221; OR &#8220;neuropsych*&#8221; OR &#8220;cognition&#8221; OR &#8220;cognitive deficits&#8221; OR &#8220;neuropsychological assessment&#8221; OR &#8220;cognitive testing&#8221; OR &#8220;neurocognitive&#8221; OR &#8220;neurocognitive assessment&#8221; OR &#8220;screening&#8221; OR &#8220;evaluation.&#8221; Tests accepted for the review were those included in published or in&#8208;press peer&#8208;reviewed articles with full text in English available to the expert members.</p></sec><sec id="mds30293-sec-0009"><label>1.3</label><title>Selection of <styled-content style="fixed-case" toggle="no">COAs</styled-content>
</title><p>The review examined COAs that are part of the diagnostic criteria for PD&#8208;MCI<xref rid="mds30293-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> or that have been used at least once in PD research. It specifically addressed assessments of attention/working memory and executive functions. Individual measures were considered for inclusion if they are part of a multi&#8208;test battery but have been independently used in PD for the cognitive functions pertinent to this review. Assessments undergoing re&#8208;standardization, unstandardized tests, or those that are not commercially available were excluded from this review. Furthermore, computerized neuropsychological tests and assessments without an English version or with copyright issues were also excluded, as these may not be widely accessible in clinical settings.</p></sec><sec id="mds30293-sec-0010"><label>1.4</label><title>Recommendation Levels</title><p>Each COA was categorized as follows: a test was &#8220;recommended&#8221; if (1) it has been applied to PD populations, (2) there are data on its use in studies beyond the group that developed the test, and (3) it has been studied clinimetrically in PD and found to be valid, reliable, and sensitive to change. &#8220;Recommended with caveats&#8221; indicates that the test's properties were generally found to be adequate, but some of the measurement properties were not evaluated specifically at different stages of cognitive impairment in PD. A COA was &#8220;suggested&#8221; if it had been applied to PD, but only one of the other criteria was met. A test is &#8220;listed&#8221; if it has been used in PD but does not meet the other two criteria defined for recommended tests.</p></sec></sec><sec sec-type="results" id="mds30293-sec-0011"><label>2</label><title>Results</title><sec id="mds30293-sec-0012"><label>2.1</label><title>Identified <styled-content style="fixed-case" toggle="no">COAs</styled-content> and their Use in Clinical Research</title><p>A total of 30 assessments of attention/working memory and executive function were identified, 16 of which are recommended for use in the MDS Task Force guidelines for PD&#8208;MCI diagnostic criteria. After reaching a consensus, the expert panel recommended eight COAs: four assessing attention/working memory abilities and four evaluating executive functions. These COAs have shown good to excellent levels of reliability and validity, supported by normative datasets that span a wide age range and demonstrate sensitivity to change.</p><p>Moreover, eight COAs were designated as &#8220;recommended with caveats,&#8221; primarily due to inadequate psychometric quality or lack of sensitivity to change. Eleven additional COAs were classified as &#8220;suggested&#8221; level, and three were classified as &#8220;listed&#8221; (see Table&#160;<xref rid="mds30293-tbl-0001" ref-type="table">1</xref>).</p><table-wrap position="float" id="mds30293-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Overview of the clinical outcome assessments for each domain investigated</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Attention/working memory domain</th><th align="center" valign="bottom" rowspan="1" colspan="1">Executive domain</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Recommended</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="mds30293-list-0001"><list-item id="mds30293-li-0001"><p>WAIS&#8208;IV Digit Span</p></list-item><list-item id="mds30293-li-0002"><p>WAIS&#8208;IV Coding</p></list-item><list-item id="mds30293-li-0003"><p>WAIS&#8208;IV Symbol Search</p></list-item><list-item id="mds30293-li-0004"><p>Trail Making Test</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="mds30293-list-0002"><list-item id="mds30293-li-0005"><p>WAIS&#8208;IV Similarities</p></list-item><list-item id="mds30293-li-0006"><p>Wisconsin Card Sorting Test</p></list-item><list-item id="mds30293-li-0007"><p>Verbal Fluency Tests</p></list-item><list-item id="mds30293-li-0008"><p>Stroop Color&#8208;Word Test</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Recommended with caveat</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="mds30293-list-0003"><list-item id="mds30293-li-0009"><p>WAIS&#8208;IV LNS</p></list-item><list-item id="mds30293-li-0010"><p>SDMT</p></list-item><list-item id="mds30293-li-0011"><p>Modified Levin's PASAT</p></list-item><list-item id="mds30293-li-0012"><p>Corsi Block Tapping</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="mds30293-list-0004"><list-item id="mds30293-li-0013"><p>Tower of London</p></list-item><list-item id="mds30293-li-0014"><p>10&#8208;Point Clock Drawing Test</p></list-item><list-item id="mds30293-li-0015"><p>Frontal Assessment Battery</p></list-item><list-item id="mds30293-li-0016"><p>WAIS&#8208;IV&#8208;Matrix Reasoning</p></list-item><list-item id="mds30293-li-0017"><p>Iowa Gambling Task</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Suggested</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="mds30293-list-0005"><list-item id="mds30293-li-0018"><p>Digit Ordering Test</p></list-item><list-item id="mds30293-li-0019"><p>Visual Search Test</p></list-item><list-item id="mds30293-li-0020"><p>Brief Test of Attention</p></list-item><list-item id="mds30293-li-0021"><p>TEA: Map Search/Visual Elevator</p></list-item><list-item id="mds30293-li-0022"><p>Serial Reaction Time Task</p></list-item><list-item id="mds30293-li-0023"><p>WMS&#8208;III&#8208;Digit Span</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="mds30293-list-0006"><list-item id="mds30293-li-0024"><p>Behavioral Assessment of the Dysexecutive Syndrome</p></list-item><list-item id="mds30293-li-0025"><p>Hayling Sentence Completion Test</p></list-item><list-item id="mds30293-li-0026"><p>Brixton Spatial Anticipation Test</p></list-item><list-item id="mds30293-li-0027"><p>Design Fluency Test</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Listed</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="mds30293-list-0007"><list-item id="mds30293-li-0028"><p>Odd&#8208;Man Out Test</p></list-item><list-item id="mds30293-li-0029"><p>WSM&#8208;III Mental Control</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot id="mds30293-ntgp-0002"><fn id="mds30293-note-0003"><p>Abbreviations: LNS, Letter Number Sequencing; PASAT, Paced Auditory Serial Addition Test; SDMT, Symbol Digit Modality Test; TEA, Test of Everyday Attention; WAIS&#8208;IV, Wechsler Adult Intelligence Scale 4th edition; WMS&#8208;III, Wechsler Memory Scale 3rd edition.</p></fn></table-wrap-foot></table-wrap><p>Comprehensive and detailed clinimetric properties regarding each COA are provided in Table&#160;<xref rid="mds30293-tbl-0002" ref-type="table">2</xref> (only the recommended COAs) and in the <xref rid="mds30293-supitem-0001" ref-type="supplementary-material">Supplementary Materials</xref> (comprising a table detailing all the other COAs reviewed followed by all COA grids provided by reviewers). Namely, reliability (internal consistency, intra&#8208;rater, inter&#8208;rater and/or test&#8211;retest reliability); validity (including construct and empirical validity indices); sensitivity to change (from longitudinal studies or clinical trials); strengths and weaknesses; and level of recommendation and justification are provided.<xref rid="mds30293-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>
</p><table-wrap position="float" id="mds30293-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Recommended neuropsychological tests including their psychometric properties</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Scale/test</th><th align="center" valign="bottom" rowspan="1" colspan="1">Reliability</th><th align="center" valign="bottom" rowspan="1" colspan="1">Validity</th><th align="center" valign="bottom" rowspan="1" colspan="1">Sensitive to change</th><th align="center" valign="bottom" rowspan="1" colspan="1">Strengths</th><th align="center" valign="bottom" rowspan="1" colspan="1">Clinimetric limitations</th><th align="center" valign="bottom" rowspan="1" colspan="1">Recommendation level</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Attention/working memory</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">1. WAIS&#8208;IV Coding</td><td align="left" valign="top" rowspan="1" colspan="1">Good to excellent</td><td align="left" valign="top" rowspan="1" colspan="1">Good</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="mds30293-list-0008"><list-item id="mds30293-li-0030"><p>Strong normative data, based on a large sample</p></list-item><list-item id="mds30293-li-0031"><p>Sensitive to subtle cognitive deficits in the early PD stages</p></list-item><list-item id="mds30293-li-0032"><p>It is feasible and easy to administer: 5&#8211;10&#8201;min</p></list-item><list-item id="mds30293-li-0033"><p>Translated into several languages</p></list-item><list-item id="mds30293-li-0034"><p>Applicable to PD normal cognition, MCI, and early dementia</p></list-item><list-item id="mds30293-li-0035"><p>Suitable for screening</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="mds30293-list-0009"><list-item id="mds30293-li-0036"><p>Copyrighted</p></list-item><list-item id="mds30293-li-0037"><p>Severe motor deficits (such as tremor, bradykinesia, or dyskinesia) can hamper its administrations as well as score interpretations</p></list-item><list-item id="mds30293-li-0038"><p>No parallel forms available</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">Recommended</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2. WAIS&#8208;IV Digit Span</td><td align="left" valign="top" rowspan="1" colspan="1">Good to excellent</td><td align="left" valign="top" rowspan="1" colspan="1">Good</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="mds30293-list-0010"><list-item id="mds30293-li-0039"><p>Strong normative data, based on a large sample</p></list-item><list-item id="mds30293-li-0040"><p>Parallel form available</p></list-item><list-item id="mds30293-li-0041"><p>It is feasible and easy to administer: 5&#8211;10&#8201;min</p></list-item><list-item id="mds30293-li-0042"><p>Verbal administration suitable in the context of marked motor deficits</p></list-item><list-item id="mds30293-li-0043"><p>Sensitive to subtle cognitive deficits in the early PD stages</p></list-item><list-item id="mds30293-li-0044"><p>Applicable to PD normal cognition, MCI, and early to moderate dementia</p></list-item><list-item id="mds30293-li-0045"><p>Translated into several languages</p></list-item><list-item id="mds30293-li-0046"><p>Suitable for screening</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="mds30293-list-0011"><list-item id="mds30293-li-0047"><p>Copyrighted</p></list-item><list-item id="mds30293-li-0048"><p>Hearing deficits must be taken into account</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">Recommended</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3. WAIS&#8208;IV Symbol Search</td><td align="left" valign="top" rowspan="1" colspan="1">Good</td><td align="left" valign="top" rowspan="1" colspan="1">Good</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="mds30293-list-0012"><list-item id="mds30293-li-0049"><p>Strong normative data, based on a large sample</p></list-item><list-item id="mds30293-li-0050"><p>It is feasible and easy to administer: 3&#8211;4&#8201;min</p></list-item><list-item id="mds30293-li-0051"><p>Applicable to PD normal cognition, MCI, and early dementia</p></list-item><list-item id="mds30293-li-0052"><p>Translated into several languages</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="mds30293-list-0013"><list-item id="mds30293-li-0053"><p>No parallel forms available</p></list-item><list-item id="mds30293-li-0054"><p>Hearing&#8208;visual and motor deficits must be taken into account</p></list-item><list-item id="mds30293-li-0055"><p>Copyrighted</p></list-item><list-item id="mds30293-li-0056"><p>Small literature in PD</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">Recommended</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">4. Trail Making Test (TMT)</td><td align="left" valign="top" rowspan="1" colspan="1">Adequate to good</td><td align="left" valign="top" rowspan="1" colspan="1">Good</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="mds30293-list-0014"><list-item id="mds30293-li-0057"><p>It is feasible and easy to administer: 5&#8211;10&#8201;min</p></list-item><list-item id="mds30293-li-0058"><p>Comparable forms are available</p></list-item><list-item id="mds30293-li-0059"><p>Used a lot in many studies including lesion and MRI studies</p></list-item><list-item id="mds30293-li-0060"><p>Many international groups use the TMT and have developed norm groups for determination of severity of impairment</p></list-item><list-item id="mds30293-li-0061"><p>It is extensively used in PD</p></list-item><list-item id="mds30293-li-0062"><p>Suitable for screening</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="mds30293-list-0015"><list-item id="mds30293-li-0063"><p>Copyrighted</p></list-item><list-item id="mds30293-li-0064"><p>Mostly not applicable for H&amp;Y score: 4 (several disabilities or confined to bed)</p></list-item><list-item id="mds30293-li-0065"><p>Floor effects in severe cognitive impaired patients</p></list-item><list-item id="mds30293-li-0066"><p>Standard deviation is broad</p></list-item><list-item id="mds30293-li-0067"><p>Determining change in individual cases is difficult due to broad RCIs</p></list-item><list-item id="mds30293-li-0068"><p>Partially loading in different domains</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">Recommended</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Executive domain</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">1. WAIS&#8208;IV&#8208;Similarities</td><td align="left" valign="top" rowspan="1" colspan="1">Good to excellent</td><td align="left" valign="top" rowspan="1" colspan="1">Good</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="mds30293-list-0016"><list-item id="mds30293-li-0069"><p>Strong normative data, based on a large sample</p></list-item><list-item id="mds30293-li-0070"><p>Verbal administration suitable in the context of marked motor deficits</p></list-item><list-item id="mds30293-li-0071"><p>It is feasible and easy to administer: 10&#8211;15&#8201;min</p></list-item><list-item id="mds30293-li-0072"><p>Sensitive to subtle cognitive deficits in the early PD stages</p></list-item><list-item id="mds30293-li-0073"><p>Applicable to PD normal cognition, MCI, and early dementia</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="mds30293-list-0017"><list-item id="mds30293-li-0074"><p>Copyrighted</p></list-item><list-item id="mds30293-li-0075"><p>Does not provide impairment&#8208;only scaled scores</p></list-item><list-item id="mds30293-li-0076"><p>Lack of validity studies specific for PD population</p></list-item><list-item id="mds30293-li-0077"><p>Risk of possible floor/ceiling effects should be better investigated</p></list-item><list-item id="mds30293-li-0078"><p>Hearing and language deficits must be taken into account</p></list-item><list-item id="mds30293-li-0079"><p>No alternate forms available</p></list-item><list-item id="mds30293-li-0080"><p>Scoring can be ambiguous</p></list-item><list-item id="mds30293-li-0081"><p>Not suitable for screening</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">Recommended</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2. SCWT&#8208;VST version</td><td align="left" valign="top" rowspan="1" colspan="1">Good test&#8211;retest reliability</td><td align="left" valign="top" rowspan="1" colspan="1">Good criterion and convergent validity</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="mds30293-list-0018"><list-item id="mds30293-li-0082"><p>Several comparable versions exist</p></list-item><list-item id="mds30293-li-0083"><p>Public domains</p></list-item><list-item id="mds30293-li-0084"><p>Translated and validated in several languages</p></list-item><list-item id="mds30293-li-0085"><p>It is feasible and easy to administer: 5&#8201;min</p></list-item><list-item id="mds30293-li-0086"><p>Good measure of executive functions</p></list-item><list-item id="mds30293-li-0087"><p>Useful in PD population since a poor performance is a good predictor of conversion from PD&#8208;normal cognition to PD&#8208;MCI and to PDD</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="mds30293-list-0019"><list-item id="mds30293-li-0088"><p>Not suitable for color blind people or patients with dyslexia, aphasia, hemianopsia, neglect</p></list-item><list-item id="mds30293-li-0089"><p>Floor effect for severe cognitive deficits</p></list-item><list-item id="mds30293-li-0090"><p>It may be difficult for patients with important dyskinesia, and it should not be administered in OFF condition</p></list-item><list-item id="mds30293-li-0091"><p>Dopamine intake and motor severity affect performance</p></list-item><list-item id="mds30293-li-0092"><p>Too many versions and too many scoring methods could make it difficult to choose which one to use</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">Recommended</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3. WCST</td><td align="left" valign="top" rowspan="1" colspan="1">Good to excellent</td><td align="left" valign="top" rowspan="1" colspan="1">Good to excellent. More sensitive than specific. Good divergent validity also in PD</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="mds30293-list-0020"><list-item id="mds30293-li-0093"><p>Several forms available, also PC based</p></list-item><list-item id="mds30293-li-0094"><p>Can be used in PD with MMSE&gt;19</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="mds30293-list-0021"><list-item id="mds30293-li-0095"><p>Copyrighted</p></list-item><list-item id="mds30293-li-0096"><p>It takes 20&#8211;30&#8201;min to administer for long version or 10&#8211;15&#8201;min for short version</p></list-item><list-item id="mds30293-li-0097"><p>Dopamine intake and motor severity affect performance</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">Recommended</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">4. VFTs/COWAT</td><td align="left" valign="top" rowspan="1" colspan="1">Good</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Good content and criterion validity.</p>
<p>Mixed construct validity: good within subtest, poor between subtest validity</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="mds30293-list-0022"><list-item id="mds30293-li-0098"><p>Parallel/alternates forms available</p></list-item><list-item id="mds30293-li-0099"><p>Translated in different languages</p></list-item><list-item id="mds30293-li-0100"><p>Some versions are free on website</p></list-item><list-item id="mds30293-li-0101"><p>It is easy and quick to administer (4&#8211;5&#8201;min)</p></list-item><list-item id="mds30293-li-0102"><p>Good psychometric properties</p></list-item><list-item id="mds30293-li-0103"><p>Applicable to PD normal cognition, MCI, and early dementia</p></list-item><list-item id="mds30293-li-0104"><p>It is extensively used in PD</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="mds30293-list-0023"><list-item id="mds30293-li-0105"><p>Standard deviation is broad</p></list-item><list-item id="mds30293-li-0106"><p>Determining change in individual cases is difficult due to broad RCIs</p></list-item><list-item id="mds30293-li-0107"><p>Loading partially on different domains</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">Recommended</td></tr></tbody></table><table-wrap-foot id="mds30293-ntgp-0003"><fn id="mds30293-note-0004"><p>Abbreviations: COWAT, Controlled Oral Word Association Test; H&amp;Y, Hoehn and Yahr Scale; MCI, mild cognitive impairment; MMSE, Mini&#8208;Mental State Examination; MRI, magnetic resonance imaging; PD, Parkinson's disease; PDD, Parkinson with dementia; RCI, Reliable Change Index; SCWT, Stroop Color&#8208;Word Test; TMT, Trail Making Test; VFT, Verbal Fluency Test; VST, Victoria Stroop Test; WAIS&#8208;IV, Wechsler Adult Intelligence Scale 4th edition; WCST, Wisconsin Card Sorting Test.</p></fn></table-wrap-foot></table-wrap><p>The following section provides a summary (test description, strengths, and weaknesses) of the recommended COAs.</p></sec><sec id="mds30293-sec-0013"><label>2.2</label><title>Attention/Working Memory Domain</title><p>The Wechsler Adult Intelligence Scale, 4th edition (WAIS&#8208;IV),<xref rid="mds30293-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> was developed to evaluate intelligence and cognition in adolescents and adults aged 16&#8211;90&#8201;years, encompassing both normal and clinical populations, and has been translated into multiple languages. The subtests of the WAIS&#8208;IV recommended in this review (Digit Span, Coding, and Symbol Search), have been used in the evaluation of PD, showing good to excellent reliability and validity. These subtests are supported by strong normative data based on large samples. Each subtest provides a scaled score, by converting the raw score into an age&#8208;corrected scaled score, with a mean of 10 and a standard deviation of 3. These scaled scores can subsequently be converted into z&#8208;scores and percentile ranks, assuming near normal score distributions. This allows for meaningful comparisons between the performance of the patient and the normative population, as well as among other subtests. Moreover, these subtests have demonstrated sensitivity to changes associated with PD and have been employed in research protocols within both PD and non&#8208;PD populations. However, it is important to note that the WAIS&#8208;IV is copyrighted (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pearsonassessments.com/" ext-link-type="uri">https://pearsonassessments.com/</ext-link>), and access to the full battery must be purchased to administer the subtests. In 2024, after the systematic review, the WAIS&#8208;IV was superseded by the WAIS&#8208;5,<xref rid="mds30293-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> and was not yet independently used in PD. The WAIS&#8208;5 incorporates several different working memory tests and has a modified factor structure compared with its predecessor.</p><sec id="mds30293-sec-0014"><label>2.2.1</label><title>Digit Span Subtest</title><sec id="mds30293-sec-0015"><label>2.2.1.1</label><title>Test description</title><p>The Digit Span Subtest is a core component of the WAIS&#8208;IV Working Memory Index and is divided into three parts: Digit Span Forward (DSF), Digit Span Backward (DSB), and Digit Span Sequencing (DSS). It assesses auditory processing, attention, and encoding (mainly DSF), and auditory working memory and mental manipulation (DSB and DSS). DSB and DSS demand additional working memory load. In the DSF, the patient is asked to repeat digits in the order provided, whereas in the DSB subtest the digits must be recited in the reverse order. Finally, with DSS, patients are tasked with repeating the digits in ascending order. Each subtest starts with a relatively short string of digits, which is progressively extended with each successful trial until errors in recall are encountered. Each item is scored as either correct or incorrect, with higher scores indicating better cognitive performance. Estimates of working memory capacity may be derived from the total score across all subtests, reported as Working Memory Index, or the maximum span achieved within each subtest. Administration time is about 5&#8211;10&#8201;min.</p></sec><sec id="mds30293-sec-0016"><label>2.2.1.2</label><title>Strengths and Weaknesses</title><p>This subtest, particularly the DSB, has been used in PD research.<xref rid="mds30293-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="mds30293-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="mds30293-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> It is demonstrated to be sensitive to change with ageing and PD&#8208;MCI.<xref rid="mds30293-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="mds30293-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> Outside of the PD field, it has been included in research related to MCI and dementia due to Alzheimer's disease (AD), and several other neurological disease.<xref rid="mds30293-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="mds30293-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="mds30293-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="mds30293-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="mds30293-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="mds30293-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="mds30293-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> Research&#8208;based alternate forms exist,<xref rid="mds30293-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> and it is quick and easy to administer. Moreover, as it requires a verbal response, there is minimal motor component and it can be used across PD cognitive stages,<xref rid="mds30293-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="mds30293-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> with this version reducing floor effects so it can be administered into the advanced stages of the disease. It is suitable for screening as it is sensitive to subtle cognitive deficits in the early PD stages. However, as subjects receive different numbers of trials the variance of the total correct score is high relative to the mean and it is highly skewed. Such high variance may reduce sensitivity to clinical abnormalities.<xref rid="mds30293-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> Hearing deficits (for test instructions) and language skills must be taken into account during administration.</p></sec></sec><sec id="mds30293-sec-0017"><label>2.2.2</label><title>Coding Subtest</title><sec id="mds30293-sec-0018"><label>2.2.2.1</label><title>Test Description</title><p>The Coding Subtest is a core subtest of the WAIS&#8208;IV Processing Speed Index.<xref rid="mds30293-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="mds30293-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> In this subtest, individuals are asked to record associations between different symbols and numbers within time limits. It evaluates attention and executive domains, processing speed, visual&#8208;motor coordination, and visual working memory. The administration time is 5&#8211;10&#8201;min, and the test is scored on a continuum based on the number of correct responses (maximum number of items&#8201;=&#8201;135). Higher scores reflect better cognitive performance.</p></sec><sec id="mds30293-sec-0019"><label>2.2.2.2</label><title>Strengths and Weaknesses</title><p>It is easy and quick to administer and can be used across PD cognitive stages of disease.<xref rid="mds30293-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>, <xref rid="mds30293-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>, <xref rid="mds30293-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> It is suitable for screening and is also demonstrated to be sensitive to change (either over time or due to treatment)<xref rid="mds30293-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>, <xref rid="mds30293-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref>, <xref rid="mds30293-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref>, <xref rid="mds30293-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> and is predictive of cognitive decline in PD and non&#8208;PD.<xref rid="mds30293-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref>, <xref rid="mds30293-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref> Research&#8208;based alternate forms exist.<xref rid="mds30293-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref> However, adequate vision, motor abilities, and language skills (sufficient to understand test instructions) must be present. As this subtest is timed and requires fine hand movements, severe motor disabilities associated with PD (such as tremor, bradykinesia, or dyskinesia) can hamper its administration and interpretation.</p></sec></sec><sec id="mds30293-sec-0020"><label>2.2.3</label><title>Symbol Search Subtest</title><sec id="mds30293-sec-0021"><label>2.2.3.1</label><title>Test Description</title><p>Symbol Search is also a core subtest of the WAIS&#8208;IV Processing Speed Index.<xref rid="mds30293-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> This subtest evaluates visual information processing speed as well as short&#8208;term visual memory, visual&#8208;motor coordination, cognitive flexibility, visual discrimination, attention, and concentration. During the subtest, the examinee is allowed 2 min to scan a group of items (ambiguous, geometric shapes) presented sequentially as a row, and indicate whether one of the symbols in the target group matches with those items. The overall administration time is about 3&#8211;4&#8201;min. The subtest is scored on a continuum based on the number of correct responses (maximum number of items 60) with higher scores indicating better cognitive performance.</p></sec><sec id="mds30293-sec-0022"><label>2.2.3.2</label><title>Strengths and Weaknesses</title><p>Symbol Search is easy to administer and can be used across PD cognitive stages. It has been shown to be sensitive to changes due to treatment,<xref rid="mds30293-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> although there are no parallel forms available. There have been relatively few studies specific to the PD population. It is not suitable for screening. The potential floor/ceiling effects should be further investigated. Additionally, individuals must have adequate hearing (for test instructions), vision, motor abilities, and language skills (to understand test instructions). Severe motor disabilities, such as tremors, bradykinesia, or dyskinesia, can hinder the administration and interpretation of this subtest, as it is time&#8208;based and requires precise hand movements.</p></sec></sec><sec id="mds30293-sec-0023"><label>2.2.4</label><title>Trail Making Test (<styled-content style="fixed-case" toggle="no">TMT</styled-content>)</title><sec id="mds30293-sec-0024"><label>2.2.4.1</label><title>Test Description</title><p>The TMT was developed in 1938 by Partington and Leiter as a &#8220;distributed attention&#8221; test and published in 1949 as part of the Army Individual Test Battery.<xref rid="mds30293-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref> The test provides estimates of visual search, visual attention, speed of processing, and mental flexibility.<xref rid="mds30293-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> TMT consists of two parts, A and B. In both parts, the examinee is required to connect spatially distributed target circles. In Part A, the target circles each contain a number, and the task is to link them in ascending order, from 1 to 25, as quickly as possible. In Part B the participant is asked to alternate between numbers and letters in ascending order and alphabetical sequence as quickly as possible. Part B is often regarded as an executive function measure due to rapid set shifting between numbers and letters, monitoring for speed of visual search, and elements of working memory. Performance indicators include the difference in time to completion and error scores between Parts A and B. Scores (ie, time in seconds, with lower scores representing better performance) can be compared with normative groups for determination of severity of impairment.<xref rid="mds30293-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> Some authors include a time limit of 5 min on Part B. Administration time is about 5&#8211;10&#8201;min.</p></sec><sec id="mds30293-sec-0025"><label>2.2.4.2</label><title>Strengths and Weaknesses</title><p>The TMT is a widely recognized standard test in neuropsychological test batteries. It is relatively quick to administer. Poor performance is a good predictor of conversion to PD&#8208;MCI and to PDD<xref rid="mds30293-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref> and it is suitable for screening. Normative data are available across several countries/languages and age and education groups.<xref rid="mds30293-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref>, <xref rid="mds30293-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref> However, it has no parallel versions but only comparable forms.<xref rid="mds30293-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref>, <xref rid="mds30293-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref> It is in the public domain, although copyrighted versions (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.neuropsych.com/" ext-link-type="uri">https://www.neuropsych.com/</ext-link>) can be found. The risk of possible floor effects in more advanced dementia patients should be investigated. Moreover, as this test is timed and requires fine hand movements, severe motor disabilities (such as tremor, bradykinesia, or dyskinesia) can hamper its administration and interpretation in PD.</p></sec></sec></sec><sec id="mds30293-sec-0026"><label>2.3</label><title>Executive Domain</title><sec id="mds30293-sec-0027"><label>2.3.1</label><title>
<styled-content style="fixed-case" toggle="no">WAIS</styled-content>&#8208;<styled-content style="fixed-case" toggle="no">IV</styled-content> Similarities Subtest</title><sec id="mds30293-sec-0028"><label>2.3.1.1</label><title>Test Description</title><p>The Similarities Subtest is included as a core test of the WAIS&#8208;IV Verbal Comprehension Index. It evaluates both language abilities and executive functions, particularly verbal abstract reasoning and conceptualization. There is ongoing discussion about whether language or executive functions are more prominent in this assessment. For our classification, we have opted to categorize this test under executive functions. Similarities consists of 18 pairs of words. The examinee is asked to identify the qualitative relationship between the two words. Higher scores reflect better cognitive performance; each item is scored on an ordinal scale (0, 1, 2 points) based on the correctness of the response, and the instrument has a maximum score of 36. The test takes 10&#8211;15&#8201;min (including the instructions, the example, and items) and requires less time if the discontinuation criterion is met (ie, three consecutive failures).</p></sec><sec id="mds30293-sec-0029"><label>2.3.1.2</label><title>Strengths and Weaknesses</title><p>It can be administered across cognitive stages of the disease. It is commonly included in research related to AD, MCI, multiple sclerosis (MS), Huntington's disease, and others.<xref rid="mds30293-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref>, <xref rid="mds30293-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref>, <xref rid="mds30293-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref> It is suitable for screening as it is sensitive to subtle cognitive deficits in the early PD stages and to MCI status.<xref rid="mds30293-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="mds30293-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> Additionally, it is sensitive to changes due to dopaminergic treatment.<xref rid="mds30293-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>, <xref rid="mds30293-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref>, <xref rid="mds30293-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref> As it is verbally administered, and there are no motor or timed components, it is suitable for more advanced PD stages. It is relatively quick to administer. However, it has no parallel forms and there is a lack of validity studies in PD. It is not suitable for screening. Scoring can be ambiguous and thus potentially time&#8208;consuming. The risk of possible floor effects in advanced dementia patients should be investigated. For more detailed clinimetric properties see the earlier WAIS&#8208;IV Subtests section.</p></sec></sec><sec id="mds30293-sec-0030"><label>2.3.2</label><title>Stroop Color&#8208;Word Test</title><sec id="mds30293-sec-0031"><label>2.3.2.1</label><title>Test Description</title><p>The Stroop Color&#8208;Word Test was developed by John Ridley Stroop in 1935 and is used to measure interference effects in sequential verbal reactions.<xref rid="mds30293-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref> It evaluates mainly executive functions, in particular working memory, cognitive inhibition, and flexibility, and speed of visual search. The Stroop Test exists in several comparable versions.<xref rid="mds30293-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref>, <xref rid="mds30293-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref> The Victoria version, called the Victoria Stroop Test (VST), is a shorter version of the original test (30 items for each condition compared with 100 items) and a psychometrically&#8208;sound version of Stroop's original task.<xref rid="mds30293-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref>, <xref rid="mds30293-bib-0053" ref-type="bibr">
<sup>53</sup>
</xref> VST is the most used in PD patients and thus is assessed in this review. It takes approximately 3&#8211;5&#8201;min to administer. The VST includes three cards presented in a fixed order: color dot naming (D), word reading (W), both as control tasks, and incongruent color&#8208;naming of color words (C) (such as the word red printed in green ink), as interference task. The test assesses response inhibition using two measures: Interference Effect (IE) and Error Score (ES). IE is a reaction time score whilst ES is the number of errors. These measures in each card are recorded, and the time difference and error between cards C and D is calculated. In some versions each score is obtained by subtracting the mean score of the two &#8220;control&#8221; tasks (reading neutral words and colored dots naming) from the interference task score, which is predicted by both conflict monitoring and working memory; one can also calculate the ratio score (color&#8208;word divided by color&#8208;naming) (predicted by conflict monitoring alone).<xref rid="mds30293-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref>, <xref rid="mds30293-bib-0054" ref-type="bibr">
<sup>54</sup>
</xref>
</p></sec><sec id="mds30293-sec-0032"><label>2.3.2.2</label><title>Strengths and Weaknesses</title><p>The Stroop Test is widely utilized in diagnosing and researching executive functions due to its ease of administration and diagnostic importance.<xref rid="mds30293-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref> The Stroop Test has been translated and validated in numerous languages with normative data available for a wide age range group (&lt;20 to &gt;94&#8201;years)<xref rid="mds30293-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref>, <xref rid="mds30293-bib-0053" ref-type="bibr">
<sup>53</sup>
</xref>, <xref rid="mds30293-bib-0055" ref-type="bibr">
<sup>55</sup>
</xref>, <xref rid="mds30293-bib-0056" ref-type="bibr">
<sup>56</sup>
</xref>, <xref rid="mds30293-bib-0057" ref-type="bibr">
<sup>57</sup>
</xref>, <xref rid="mds30293-bib-0058" ref-type="bibr">
<sup>58</sup>
</xref> and is highly sensitive in differentiating several neurological diseases from the normal population.<xref rid="mds30293-bib-0059" ref-type="bibr">
<sup>59</sup>
</xref>, <xref rid="mds30293-bib-0060" ref-type="bibr">
<sup>60</sup>
</xref>, <xref rid="mds30293-bib-0061" ref-type="bibr">
<sup>61</sup>
</xref>, <xref rid="mds30293-bib-0062" ref-type="bibr">
<sup>62</sup>
</xref> Poor performance is a good predictor of conversion to PD&#8208;MCI and PDD.<xref rid="mds30293-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="mds30293-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>, <xref rid="mds30293-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref>, <xref rid="mds30293-bib-0058" ref-type="bibr">
<sup>58</sup>
</xref>, <xref rid="mds30293-bib-0063" ref-type="bibr">
<sup>63</sup>
</xref>, <xref rid="mds30293-bib-0064" ref-type="bibr">
<sup>64</sup>
</xref> It is also suitable for screening and is sensitive to change due to treatment in PD.<xref rid="mds30293-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref>, <xref rid="mds30293-bib-0065" ref-type="bibr">
<sup>65</sup>
</xref>, <xref rid="mds30293-bib-0066" ref-type="bibr">
<sup>66</sup>
</xref> The VST is in the public domain, and users may make their stimuli (eg, Prague Stroop test)<xref rid="mds30293-bib-0058" ref-type="bibr">
<sup>58</sup>
</xref> or purchase them from the University of Victoria, although at least one version has been copyrighted (https://<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.parinc.com" ext-link-type="uri">www.parinc.com</ext-link>). In addition, adequate psychometric data, including reliability and validity, have been obtained for the VST.<xref rid="mds30293-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> There are no parallel versions and many not completely comparable versions and scoring methods. Gaze palsy can hamper its administration. It may be difficult for patients with troublesome dyskinesia. Moreover, it is not suitable for people with certain types of color blindness or patients with dyslexia, aphasia, hemianopsia, severe hypokinetic dysarthria, and neglect. Finally, floor effects in advanced dementia patients are observed.</p></sec></sec><sec id="mds30293-sec-0033"><label>2.3.3</label><title>Wisconsin Card Sorting Test (<styled-content style="fixed-case" toggle="no">WCST</styled-content>)</title><sec id="mds30293-sec-0034"><label>2.3.3.1</label><title>Test Description</title><p>The WCST was developed in 1948 to assess perseveration, abstract reasoning, and set&#8208;shifting in normal adult populations.<xref rid="mds30293-bib-0067" ref-type="bibr">
<sup>67</sup>
</xref> It is now generally used to assess clinical populations.<xref rid="mds30293-bib-0068" ref-type="bibr">
<sup>68</sup>
</xref> This test is often viewed as the &#8220;gold standard&#8221; for examining executive function in terms of cognitive flexibility and attention/task switching, especially through the number of perseverative errors&#8212;that is, category repetitions in response to negative feedback.<xref rid="mds30293-bib-0069" ref-type="bibr">
<sup>69</sup>
</xref> The test also gauges strategic planning, working memory, response inhibition, and impulsive responses.<xref rid="mds30293-bib-0070" ref-type="bibr">
<sup>70</sup>
</xref> There is evidence that the test reflects both automatic stimulus&#8211;response learning as well as higher&#8208;order concept/category formation/learning.<xref rid="mds30293-bib-0071" ref-type="bibr">
<sup>71</sup>
</xref> During the test, participants are presented with four multidimensional stimulus cards featuring different colors, shapes, and numbers, and are required to sort the cards based on an undisclosed rule. There are two versions of the tests: a longer (20&#8211;30&#8201;min) version (WCST&#8208;128) and a short version (WCST&#8208;64).<xref rid="mds30293-bib-0072" ref-type="bibr">
<sup>72</sup>
</xref> Scores on the two versions are generally similar but may not be identical.<xref rid="mds30293-bib-0073" ref-type="bibr">
<sup>73</sup>
</xref> A modified version<xref rid="mds30293-bib-0074" ref-type="bibr">
<sup>74</sup>
</xref> with 48 deck cards also exists aiming to minimize participant frustration; at least 10 scores can be generated by the standard WCST, but a measure of perseveration (errors) and total categories achieved are generally the primary measures used.<xref rid="mds30293-bib-0075" ref-type="bibr">
<sup>75</sup>
</xref> Normative data are utilized to assess impairment and severity.</p></sec><sec id="mds30293-sec-0035"><label>2.3.3.2</label><title>Strengths and Weaknesses</title><p>The WCST is widely used to assess executive function.<xref rid="mds30293-bib-0076" ref-type="bibr">
<sup>76</sup>
</xref> It has been translated into numerous languages with normative data available for a wide age range group (6&#8211;89&#8201;years).<xref rid="mds30293-bib-0077" ref-type="bibr">
<sup>77</sup>
</xref>, <xref rid="mds30293-bib-0078" ref-type="bibr">
<sup>78</sup>
</xref>, <xref rid="mds30293-bib-0079" ref-type="bibr">
<sup>79</sup>
</xref>, <xref rid="mds30293-bib-0080" ref-type="bibr">
<sup>80</sup>
</xref>, <xref rid="mds30293-bib-0081" ref-type="bibr">
<sup>81</sup>
</xref>, <xref rid="mds30293-bib-0082" ref-type="bibr">
<sup>82</sup>
</xref> The WCST has been utilized in various neurological patient groups and neurodevelopmental disorders.<xref rid="mds30293-bib-0075" ref-type="bibr">
<sup>75</sup>
</xref>, <xref rid="mds30293-bib-0083" ref-type="bibr">
<sup>83</sup>
</xref> The WCST has been applied in a range of clinical and research applications for PD,<xref rid="mds30293-bib-0075" ref-type="bibr">
<sup>75</sup>
</xref> including those with PD&#8208;MCI, mild Lewy body dementia patients (based on the MMSE &gt;19).<xref rid="mds30293-bib-0084" ref-type="bibr">
<sup>84</sup>
</xref> While evidence in PD is limited, the WCST has shown sensitivity to treatment&#8208;induced changes.<xref rid="mds30293-bib-0085" ref-type="bibr">
<sup>85</sup>
</xref>, <xref rid="mds30293-bib-0086" ref-type="bibr">
<sup>86</sup>
</xref> It is suitable for screening. Multiple forms of the test are available, including a computer&#8208;based version. However, it is copyrighted. Additionally, the WCST&#8208;128 requires long administration and can be impacted by PD medication use and motor severity.</p></sec></sec><sec id="mds30293-sec-0036"><label>2.3.4</label><title>Verbal Fluency Test (<styled-content style="fixed-case" toggle="no">VFT</styled-content>)</title><sec id="mds30293-sec-0037"><label>2.3.4.1</label><title>Test Description</title><p>The VFT, also known as the Controlled Oral Word Association Test (COWAT), the Controlled Oral Word Association (COWA), the Word Fluency, the Letter Fluency, the FAS&#8208;Test, the Category Fluency, the Phonemic Fluency, the Semantic Fluency, Thurstone Word Fluency Test, and so on, is a widely&#8208;used neuropsychological tool developed by Thurstone (1938).<xref rid="mds30293-bib-0087" ref-type="bibr">
<sup>87</sup>
</xref> It is considered a classical tool for neuropsychological assessment,<xref rid="mds30293-bib-0088" ref-type="bibr">
<sup>88</sup>
</xref> and explores various domains such as word production, verbal fluency, word search, semantic memory, mental lexicon, mental flexibility, and retrieval from semantic memory. The test evaluates an individual's ability to generate as many words as possible within a specified time frame, either from a given letter of the alphabet (eg, English FAS; Dutch DAT, KOM, or PGR; Spanish PMR) or from a semantic category (eg, animal, fruit, color, vegetables, supermarket items) within a 1&#8208;min period. Less frequently used fluency tests involve action verb generation, writing, or design tasks. Number of correct words is calculated. A more detailed scoring of the individual's performance such as perseverations, stuck in a set, intrusions, paraphasias, spelling errors, clustering, and switching have been proposed as valuable sources of information.<xref rid="mds30293-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref>, <xref rid="mds30293-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref> Normative data are used to measure impairment and severity.</p></sec><sec id="mds30293-sec-0038"><label>2.3.4.2</label><title>Strengths and Weaknesses</title><p>It is easy to administer. It is useful in PD populations since it shows high sensitivity across all PD cognitive statuses.<xref rid="mds30293-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="mds30293-bib-0088" ref-type="bibr">
<sup>88</sup>
</xref> There are several versions of the tests. It has been translated into numerous languages, and normative data are provided for a wide age range (6&#8211;89&#8201;years).<xref rid="mds30293-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> The VFT is useful for screening, and it is very sensitive to change over time due to the progression of the disease and due to interventions, such as deep brain stimulation (DBS).<xref rid="mds30293-bib-0089" ref-type="bibr">
<sup>89</sup>
</xref>, <xref rid="mds30293-bib-0090" ref-type="bibr">
<sup>90</sup>
</xref>, <xref rid="mds30293-bib-0091" ref-type="bibr">
<sup>91</sup>
</xref> However, depending on which version is used, it can be free of charge, or be part of copyrighted batteries,<xref rid="mds30293-bib-0092" ref-type="bibr">
<sup>92</sup>
</xref>, <xref rid="mds30293-bib-0093" ref-type="bibr">
<sup>93</sup>
</xref> or require purchase from PAR (https://<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.parinc.com" ext-link-type="uri">www.parinc.com</ext-link>/). Moreover, increasing evidence has made clear that cultural, linguistic, and sociodemographic factors influence performance on verbal fluency.<xref rid="mds30293-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref>, <xref rid="mds30293-bib-0094" ref-type="bibr">
<sup>94</sup>
</xref>, <xref rid="mds30293-bib-0095" ref-type="bibr">
<sup>95</sup>
</xref>, <xref rid="mds30293-bib-0096" ref-type="bibr">
<sup>96</sup>
</xref>, <xref rid="mds30293-bib-0097" ref-type="bibr">
<sup>97</sup>
</xref> Finally, hypokinetic dysarthria severity should be considered when interpreting VFT performance in PD.<xref rid="mds30293-bib-0098" ref-type="bibr">
<sup>98</sup>
</xref>
</p></sec></sec></sec></sec><sec id="mds30293-sec-0039"><label>3</label><title>Discussion and Recommendations</title><p>This review provides critique and recommendations of COAs that assess attention/working memory and executive measures in PD. The MDS COA Program SEC commissioned a subcommittee comprising a panel of 14 expert neuropsychologists to investigate the attention/working memory and executive measures used in PD, namely the COAs whose psychometric properties could better contribute to cognitive diagnostic accuracy. Namely, from a plethora of 30 COAs, 8 tests were recommended according to the guidelines adopted in the review,<xref rid="mds30293-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> including 4 tests assessing mainly attention/working memory abilities and 4 tests assessing mainly executive functions (see Table&#160;<xref rid="mds30293-tbl-0001" ref-type="table">1</xref>).</p><sec id="mds30293-sec-0040"><label>3.1</label><title>Attention/Working Memory Domain</title><p>Overall, three of four recommended attention/working memory tests (Digit Span, Coding, and Symbol Search), are part of the WAIS&#8208;IV Processing Speed and Attention/Working Memory indices, a scale with excellent clinimetric properties including normative data with an upper age limit to the 90s and several language translations. In PD, the WAIS&#8208;IV verbal span tasks, including Digit Span and Letter Number Sequences WAIS&#8208;IV Subtest (which reached the &#8220;recommended with caveats&#8221; level), offer a potentially straightforward and quick assessment of baseline attention/working memory abilities. Evidence<xref rid="mds30293-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> shows that Digit Span Backward successfully distinguishes PD cognitive statuses (regardless of whether ON or OFF medications). Moreover, the Digit Spans involve minimal training, and do not necessitate good motor abilities, whilst the other three recommended tests (Coding, Symbol Search, and TMT) require additional cognitive functions (eg, visual&#8211;motor coordination, cognitive flexibility, visual discrimination, attention, and concentration), are time&#8208;based, and require fine hand movements possibly hampering administration and making interpretation difficult if motor dysfunction is present. In general, these issues are quite common in several tests assessing attention/working memory domain in PD (eg, the Symbol Digit Modality Test [SDMT], which reached the &#8220;recommended with caveats&#8221; level) despite otherwise adequate clinimetric properties. Future research should be directed at developing more attention/working memory tests that minimize the role of the aforementioned limitations.</p></sec><sec id="mds30293-sec-0041"><label>3.2</label><title>Executive Domain</title><p>Executive dysfunction (EF) is perhaps one of the most frequently present cognitive impairment in PD.<xref rid="mds30293-bib-0099" ref-type="bibr">
<sup>99</sup>
</xref> Significant impairment in the VFT (semantic, phonemic, and alternating), various measures of the WCST and the Stroop Test (all recommended tests in this review), are confirmed, by meta&#8208;analysis and reviews, being very sensitive in detecting impairment in PD, relative to age&#8208;matched HC.<xref rid="mds30293-bib-0100" ref-type="bibr">
<sup>100</sup>
</xref>, <xref rid="mds30293-bib-0101" ref-type="bibr">
<sup>101</sup>
</xref> However, in movement disorders research, a major limitation in the accurate assessment of those abilities is the severity of motor impairment. For example, although altered WCST performance can be considered a well&#8208;established neuropsychological symptom in patients with PD, as it is present in non&#8208;demented, non&#8208;medicated, and non&#8208;depressed PD, it may also be linked to the severity of patients' motor symptoms.<xref rid="mds30293-bib-0075" ref-type="bibr">
<sup>75</sup>
</xref> Similarly, Stroop task performances change as a function of two markers of disease severity (ie, disease duration and levodopa medications), supporting the concept that declining test performance may be associated with more severe motor symptoms. Of note, the version used (pen and paper vs. computerized), the influence of multiple domains involved, and the wider brain areas implicated, which may be only partially sensitive to PD medications,<xref rid="mds30293-bib-0102" ref-type="bibr">
<sup>102</sup>
</xref> may contribute to contradictory findings.<xref rid="mds30293-bib-0103" ref-type="bibr">
<sup>103</sup>
</xref>, <xref rid="mds30293-bib-0104" ref-type="bibr">
<sup>104</sup>
</xref>
</p><p>Interestingly, it has been proposed that motor severity constitutes a confounding variable during neuropsychological testing, likely affecting performance, rather than resulting entirely from underlying neuropathological changes to dopaminergic systems.<xref rid="mds30293-bib-0105" ref-type="bibr">
<sup>105</sup>
</xref>, <xref rid="mds30293-bib-0106" ref-type="bibr">
<sup>106</sup>
</xref> Further, understanding the complex impact of motor symptom therapies in PD is highly relevant, as it may differentially affect performance on cognition.<xref rid="mds30293-bib-0102" ref-type="bibr">
<sup>102</sup>
</xref> Future research should be considered in this regard.</p><p>Conversely, the verbally administered fluency tests and the Similarities subtest of the WAIS&#8208;IV should be considered when exploring executive abilities in advanced PD stages or when motor complications are present. Specifically, the fluency tests, despite their simple and quick administration, provide the clinician with valuable information on PD cognitive status,<xref rid="mds30293-bib-0107" ref-type="bibr">
<sup>107</sup>
</xref>, <xref rid="mds30293-bib-0108" ref-type="bibr">
<sup>108</sup>
</xref> as they are among the earliest cognitive changes in the disease and have low floor effects in advanced cognitive stages.<xref rid="mds30293-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> Moreover, reduced verbal fluency is a potential risk factor for the development of PDD.<xref rid="mds30293-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="mds30293-bib-0109" ref-type="bibr">
<sup>109</sup>
</xref>, <xref rid="mds30293-bib-0110" ref-type="bibr">
<sup>110</sup>
</xref> Of note, unlike verbal fluency, Similarities subtest scoring may be highly variable due to the examiner judgement required for scoring. Furthermore, floor effects can be observed in advanced dementia patients.</p><p>Finally, because of the influential role of sociodemographic factors (eg, previous occupation, socioeconomic level, education, and premorbid intelligence quotient [IQ]) on attentional&#8208;executive functions test scores,<xref rid="mds30293-bib-0111" ref-type="bibr">
<sup>111</sup>
</xref>, <xref rid="mds30293-bib-0112" ref-type="bibr">
<sup>112</sup>
</xref> cognitive measures with normative data correcting for demographic factors may be preferred as part of a valid cognitive battery.</p><p>This review has some limitations. First, we did not include the domain of social cognition. Although evidence recognizes the role of social cognition as a possible early marker of cognitive decline,<xref rid="mds30293-bib-0113" ref-type="bibr">
<sup>113</sup>
</xref> the lack of standardized instruments and the relatively recent focus on this area have prevented their inclusion in our current review. A future review is needed once the conceptual framework and measurement methods are more developed. Second, although digital versions have been developed for some of the included scales/tests, which may appear similar to the original paper&#8208;and&#8208;pencil formats, we decided to exclude them <italic toggle="yes">a priori</italic>, as they need thorough validation before they can be used appropriately (ie, reaching the appropriate level for critique and recommendations). Third, journal readers should consider that many of the recommended tests (eg, TMT, Stroop Color&#8208;Word Test&#8208;) require involvement of multiple cognitive domains with lack of expert consensus on how best to categorize them. For this review, we decided to list the main domain assessed by the test/scale. A fourth limitation in neuropsychology is the lack of culturally specific and culturally sensitive assessments for PD and more broadly. Most tests are designed for educated populations in Western countries, which can significantly affect performance due to variations in culture, language, education, and literacy. Individuals from non&#8208;Western cultures are often at a disadvantage, leading to misidentification of cognitive abilities. This can result in impairment being overlooked and preserved functions being mistakenly regarded as deficits. Consequently, these individuals may not receive personalized and effective treatment plans that cater to their unique needs, emphasizing the need for culturally appropriate neuropsychological assessments.<xref rid="mds30293-bib-0114" ref-type="bibr">
<sup>114</sup>
</xref>
</p></sec></sec><sec sec-type="conclusions" id="mds30293-sec-0042"><label>4</label><title>Conclusions</title><p>Understanding the nature and extent of executive/attentive dysfunctions in PD is of critical importance, as its presence in PD is related to reduced patient and care partner quality of life<xref rid="mds30293-bib-0115" ref-type="bibr">
<sup>115</sup>
</xref> and predicts progression to PDD.<xref rid="mds30293-bib-0064" ref-type="bibr">
<sup>64</sup>
</xref>, <xref rid="mds30293-bib-0116" ref-type="bibr">
<sup>116</sup>
</xref>, <xref rid="mds30293-bib-0117" ref-type="bibr">
<sup>117</sup>
</xref>, <xref rid="mds30293-bib-0118" ref-type="bibr">
<sup>118</sup>
</xref>, <xref rid="mds30293-bib-0119" ref-type="bibr">
<sup>119</sup>
</xref> Moreover, evidence indicates that all forms of PD interventions (ie, pharmacotherapy, exercise/physical therapy, and DBS) appear to impact fronto&#8208;striatal functioning.<xref rid="mds30293-bib-0120" ref-type="bibr">
<sup>120</sup>
</xref> As such, clinimetric investigation of the neuropsychological tools most commonly proposed for their assessment is crucial for a broader understanding of the role of EF in PD.</p><p>Similar to the previous MDS review on global scales for cognitive screening,<xref rid="mds30293-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> in this review an expert international panel selected the recommended attention/working memory and executive tests to guide the assessment of fronto&#8208;striatal functioning in PD at different stages (including PD&#8208;MCI or PDD). These recommended neuropsychological tests with high psychometric qualities will enable clinicians to increase PD cognitive diagnostic accuracy and facilitate research to fill the gaps still present in this topic.</p></sec><sec id="mds30293-sec-0044"><title>Author Roles</title><p>(1) Research Project: A. Conception, B. Design, C. Execution, D. Analysis; (2) Statistical Analysis: A. Design, B. Execution, C. Review and Critique; (3) Manuscript Preparation: A. Writing of the First Draft, B. Review and Revision.</p><p>R.B.: 1A, 1B, 1C, 1D, 3A, 3B.</p><p>O.B.: 1A, 1B, 1C, 1D, 3A.</p><p>D.M.C.: 1B, 1C, 1D, 3B.</p><p>B.C.: 1B, 1C, 1D, 3B.</p><p>J.C.D.&#8208;A.: 1B, 1C, 1D, 3B.</p><p>N.E.: 1B, 1C, 1D, 3B.</p><p>E.F.: 1B, 1C, 1D, 3B.</p><p>E.H.: 1B, 1C, 1D, 3B.</p><p>S.M.&#8208;H.: 1B, 1C, 1D, 3B.</p><p>A.M.: 1B, 1C, 1D, 3B.</p><p>G.S.: 1B, 1C, 1D, 3B.</p><p>B.S.: 1B, 1C, 1D, 3B.</p><p>C.S.: 1B, 1C, 1D, 3B.</p><p>A.T.: 1B, 1C, 1D, 3B.</p><p>T.A.M.: 1C, 3B.</p><p>&#193;.S.F.: 1C, 3B.</p><p>M.H.S.T.: 1C, 3B.</p><p>M.S.: 1A, 1B, 1C, 1D, 3A, 3B.</p><p>D.W.: 1A, 1B, 1C, 1D, 3A, 3B.</p><p>G.J.G.: 1A, 1B, 1C, 1D, 3A, 3B.</p></sec><sec id="mds30293-sec-0045"><title>Financial Disclosures of All Authors (for the Previous 12 Months)</title><p>None.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="mds30293-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
Data S1.
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="MDS-40-1791-s001.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="mds30293-sec-0043"><title>Acknowledgments</title><p>We express many thanks to Tommaso Gandolfi and Michela Garon for their contribution to the review process. Open access publishing facilitated by Universita degli Studi di Padova, as part of the Wiley &#8208; CRUI&#8208;CARE agreement.</p></ack><sec sec-type="data-availability" id="mds30293-sec-0047"><title>Data Availability Statement</title><p>The data that supports the findings of this study are available in the supplementary material of this article.</p></sec><ref-list id="mds30293-bibl-0001" content-type="cited-references"><title>References</title><ref id="mds30293-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="mds30293-cit-0001"><string-name name-style="western"><surname>Weintraub</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Tr&#246;ster</surname><given-names>AI</given-names></string-name>, <string-name name-style="western"><surname>Marras</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Stebbins</surname><given-names>G</given-names></string-name>. <article-title>Initial cognitive changes in Parkinson's disease</article-title>. <source>Mov Disord</source><year>2018</year>;<volume>33</volume>:<fpage>511</fpage>&#8211;<lpage>519</lpage>.<pub-id pub-id-type="pmid">29543342</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.27330</pub-id><pub-id pub-id-type="pmcid">PMC5920539</pub-id></mixed-citation></ref><ref id="mds30293-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="mds30293-cit-0002"><string-name name-style="western"><surname>Chahine</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Weintraub</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Hawkins</surname><given-names>KA</given-names></string-name>, et al. <article-title>Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings</article-title>. <source>Mov Disord</source><year>2016</year>;<volume>31</volume>:<fpage>86</fpage>&#8211;<lpage>94</lpage>.<pub-id pub-id-type="pmid">26293177</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.26373</pub-id><pub-id pub-id-type="pmcid">PMC4827252</pub-id></mixed-citation></ref><ref id="mds30293-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="mds30293-cit-0003"><string-name name-style="western"><surname>Aarsland</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Andersen</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Larsen</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Lolk</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Nielsen</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kragh&#8208;S&#248;rensen</surname><given-names>P</given-names></string-name>. <article-title>Risk of dementia in Parkinson's disease: a community&#8208;based, prospective study</article-title>. <source>Neurology</source><year>2001</year>;<volume>56</volume>:<fpage>730</fpage>&#8211;<lpage>736</lpage>.<pub-id pub-id-type="pmid">11274306</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.56.6.730</pub-id></mixed-citation></ref><ref id="mds30293-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="mds30293-cit-0004"><string-name name-style="western"><surname>Gul</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Yousaf</surname><given-names>J</given-names></string-name>. <article-title>Effect of levodopa on frontal&#8208;subcortical and posterior cortical functioning in patients with Parkinson's disease</article-title>. <source>Singapore Med J</source><year>2019</year>;<volume>60</volume>:<fpage>414</fpage>&#8211;<lpage>417</lpage>.<pub-id pub-id-type="pmid">30246215</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.11622/smedj.2018116</pub-id><pub-id pub-id-type="pmcid">PMC6717772</pub-id></mixed-citation></ref><ref id="mds30293-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="mds30293-cit-0005"><string-name name-style="western"><surname>Bonelli</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Cummings</surname><given-names>JL</given-names></string-name>. <article-title>Frontal&#8208;subcortical circuitry and behavior</article-title>. <source>Dialogues Clin Neurosci</source><year>2007</year>;<volume>9</volume>:<fpage>141</fpage>&#8211;<lpage>151</lpage>.<pub-id pub-id-type="pmid">17726913</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.31887/DCNS.2007.9.2/rbonelli</pub-id><pub-id pub-id-type="pmcid">PMC3181854</pub-id></mixed-citation></ref><ref id="mds30293-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="mds30293-cit-0006"><string-name name-style="western"><surname>Biundo</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Weis</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Antonini</surname><given-names>A</given-names></string-name>. <article-title>Cognitive decline in Parkinson's disease: the complex picture</article-title>. <source>NPJ Parkinsons Dis</source><year>2016</year>;<volume>2</volume>:<fpage>16018</fpage>.<pub-id pub-id-type="pmid">28725699</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/npjparkd.2016.18</pub-id><pub-id pub-id-type="pmcid">PMC5516581</pub-id></mixed-citation></ref><ref id="mds30293-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="mds30293-cit-0007"><string-name name-style="western"><surname>Emre</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Aarsland</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Brown</surname><given-names>R</given-names></string-name>, et al. <article-title>Clinical diagnostic criteria for dementia associated with Parkinson's disease</article-title>. <source>Mov Disord</source><year>2007</year>;<volume>22</volume>:<fpage>1689</fpage>&#8211;<lpage>1707</lpage>; quiz 1837<pub-id pub-id-type="pmid">17542011</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.21507</pub-id></mixed-citation></ref><ref id="mds30293-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="mds30293-cit-0008"><string-name name-style="western"><surname>Litvan</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Goldman</surname><given-names>JG</given-names></string-name>, <string-name name-style="western"><surname>Tr&#246;ster</surname><given-names>AI</given-names></string-name>, et al. <article-title>Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines</article-title>. <source>Mov Disord</source><year>2012</year>;<volume>27</volume>:<fpage>349</fpage>&#8211;<lpage>356</lpage>.<pub-id pub-id-type="pmid">22275317</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.24893</pub-id><pub-id pub-id-type="pmcid">PMC3641655</pub-id></mixed-citation></ref><ref id="mds30293-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="mds30293-cit-0009"><string-name name-style="western"><surname>Biundo</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Weis</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Facchini</surname><given-names>S</given-names></string-name>, et al. <article-title>Cognitive profiling of Parkinson disease patients with mild cognitive impairment and dementia</article-title>. <source>Parkinsonism Relat Disord</source><year>2014</year>;<volume>20</volume>:<fpage>394</fpage>&#8211;<lpage>399</lpage>.<pub-id pub-id-type="pmid">24495708</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.parkreldis.2014.01.009</pub-id></mixed-citation></ref><ref id="mds30293-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="mds30293-cit-0010"><string-name name-style="western"><surname>Wallace</surname><given-names>ER</given-names></string-name>, <string-name name-style="western"><surname>Segerstrom</surname><given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>van Horne</surname><given-names>CG</given-names></string-name>, <string-name name-style="western"><surname>Schmitt</surname><given-names>FA</given-names></string-name>, <string-name name-style="western"><surname>Koehl</surname><given-names>LM</given-names></string-name>. <article-title>Meta&#8208;analysis of cognition in Parkinson's disease mild cognitive impairment and dementia progression</article-title>. <source>Neuropsychol Rev</source><year>2022</year>;<volume>32</volume>:<fpage>149</fpage>&#8211;<lpage>160</lpage>.<pub-id pub-id-type="pmid">33860906</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11065-021-09502-7</pub-id></mixed-citation></ref><ref id="mds30293-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="mds30293-cit-0011"><string-name name-style="western"><surname>Muslimovic</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Post</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Speelman</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Schmand</surname><given-names>B</given-names></string-name>. <article-title>Cognitive profile of patients with newly diagnosed Parkinson disease</article-title>. <source>Neurology</source><year>2005</year>;<volume>65</volume>:<fpage>1239</fpage>&#8211;<lpage>1245</lpage>.<pub-id pub-id-type="pmid">16247051</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/01.wnl.0000180516.69442.95</pub-id></mixed-citation></ref><ref id="mds30293-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="mds30293-cit-0012"><string-name name-style="western"><surname>Skorvanek</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Goldman</surname><given-names>JG</given-names></string-name>, <string-name name-style="western"><surname>Jahanshahi</surname><given-names>M</given-names></string-name>, et al. <article-title>Global scales for cognitive screening in Parkinson's disease: critique and recommendations</article-title>. <source>Mov Disord</source><year>2018</year>;<volume>33</volume>:<fpage>208</fpage>&#8211;<lpage>218</lpage>.<pub-id pub-id-type="pmid">29168899</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.27233</pub-id></mixed-citation></ref><ref id="mds30293-bib-0013"><label>13</label><mixed-citation publication-type="miscellaneous" id="mds30293-cit-0013"><collab collab-type="authors">Wais&#8208;IV</collab>
. <article-title>Wechsler adult intelligence&#8208;Scale&#8208;IV: lettura dei risultati e interpretazione clinica. Nuova ediz.&#8208;Margherita Lang&#8208;Clara Michelotti&#8208;Libro&#8208;Raffaello Cortina Editore&#8208;Psicodiagnostica | Feltrinelli [online]</article-title>; Accessed September 12, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.lafeltrinelli.it/wais-iv-wechsler-adult-intelligence-libro-vari/e/9788832853285?awaid=9507&amp;gad_source=1&amp;gclid=CjwKCAjwooq3BhB3EiwAYqYoEssVfs5H78wadc80HYV70p8EjLZ9PGE3tHohLL-gmbmGgmVpoS3YixoC2FkQAvD_BwE&amp;awc=9507_1726153310_08ef8c6a5a8dfbdc1f97b8a92203c983" ext-link-type="uri">https://www.lafeltrinelli.it/wais&#8208;iv&#8208;wechsler&#8208;adult&#8208;intelligence&#8208;libro&#8208;vari/e/9788832853285?awaid=9507&amp;gad_source=1&amp;gclid=CjwKCAjwooq3BhB3EiwAYqYoEssVfs5H78wadc80HYV70p8EjLZ9PGE3tHohLL&#8208;gmbmGgmVpoS3YixoC2FkQAvD_BwE&amp;awc=9507_1726153310_08ef8c6a5a8dfbdc1f97b8a92203c983</ext-link>.</mixed-citation></ref><ref id="mds30293-bib-0014"><label>14</label><mixed-citation publication-type="miscellaneous" id="mds30293-cit-0014"><article-title>Wechsler Adult Intelligence Scale | Fifth Edition [online]</article-title>; Accessed November 12, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pearsonassessments.com/store/usassessments/en/Store/Professional-Assessments/Cognition-&amp;-Neuro/Wechsler-Adult-Intelligence-Scale-%7C-Fifth-Edition/p/P100071002.html" ext-link-type="uri">https://www.pearsonassessments.com/store/usassessments/en/Store/Professional&#8208;Assessments/Cognition&#8208;&amp;&#8208;Neuro/Wechsler&#8208;Adult&#8208;Intelligence&#8208;Scale&#8208;%7C&#8208;Fifth&#8208;Edition/p/P100071002.html</ext-link>.</mixed-citation></ref><ref id="mds30293-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="mds30293-cit-0015"><string-name name-style="western"><surname>Warden</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hwang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Marshall</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Fenesy</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Poston</surname><given-names>KL</given-names></string-name>. <article-title>The effects of dopamine on digit span in Parkinson's disease</article-title>. <source>J Clin Mov Disord</source><year>2016</year>;<volume>3</volume>:<fpage>5</fpage>.<pub-id pub-id-type="pmid">26955482</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40734-016-0033-z</pub-id><pub-id pub-id-type="pmcid">PMC4780147</pub-id></mixed-citation></ref><ref id="mds30293-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="mds30293-cit-0016"><string-name name-style="western"><surname>Grogan</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Knight</surname><given-names>LE</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>L</given-names></string-name>, et al. <article-title>Effects of Parkinson's disease and dopamine on digit span measures of working memory</article-title>. <source>Psychopharmacology</source><year>2018</year>;<volume>235</volume>:<fpage>3443</fpage>&#8211;<lpage>3450</lpage>.<pub-id pub-id-type="pmid">30315362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00213-018-5058-6</pub-id><pub-id pub-id-type="pmcid">PMC6267128</pub-id></mixed-citation></ref><ref id="mds30293-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="mds30293-cit-0017"><string-name name-style="western"><surname>Ma</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zou</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chan</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Ye</surname><given-names>Z</given-names></string-name>. <article-title>Impaired serial ordering in nondemented patients with mild Parkinson's disease</article-title>. <source>PLoS One</source><year>2018</year>;<volume>13</volume>:<elocation-id>e0197489</elocation-id>.<pub-id pub-id-type="pmid">29768473</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0197489</pub-id><pub-id pub-id-type="pmcid">PMC5955595</pub-id></mixed-citation></ref><ref id="mds30293-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="mds30293-cit-0018"><string-name name-style="western"><surname>Besser</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Litvan</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Monsell</surname><given-names>SE</given-names></string-name>, et al. <article-title>Mild cognitive impairment in Parkinson's disease versus Alzheimer's disease</article-title>. <source>Parkinsonism Relat Disord</source><year>2016</year>;<volume>27</volume>:<fpage>54</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="pmid">27089852</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.parkreldis.2016.04.007</pub-id><pub-id pub-id-type="pmcid">PMC4887313</pub-id></mixed-citation></ref><ref id="mds30293-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="mds30293-cit-0019"><string-name name-style="western"><surname>Bopp</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Verhaeghen</surname><given-names>P</given-names></string-name>. <article-title>Aging and verbal memory span: a meta&#8208;analysis</article-title>. <source>J Gerontol B Psychol Sci Soc Sci</source><year>2005</year>;<volume>60</volume>:<fpage>P223</fpage>&#8211;<lpage>P233</lpage>.<pub-id pub-id-type="pmid">16131616</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/geronb/60.5.p223</pub-id></mixed-citation></ref><ref id="mds30293-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="mds30293-cit-0020"><string-name name-style="western"><surname>Lemiere</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Decruyenaere</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Evers&#8208;Kiebooms</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Vandenbussche</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Dom</surname><given-names>R</given-names></string-name>. <article-title>Cognitive changes in patients with Huntington's disease (HD) and asymptomatic carriers of the HD mutation</article-title>. <source>J Neurol</source><year>2004</year>;<volume>251</volume>:<fpage>935</fpage>&#8211;<lpage>942</lpage>.<pub-id pub-id-type="pmid">15316797</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00415-004-0461-9</pub-id></mixed-citation></ref><ref id="mds30293-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="mds30293-cit-0021"><string-name name-style="western"><surname>Cotrena</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Damiani Branco</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ponsoni</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Samam&#233;</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Milman Shansis</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Paz Fonseca</surname><given-names>R</given-names></string-name>. <article-title>Executive functions and memory in bipolar disorders I and II: new insights from meta&#8208;analytic results</article-title>. <source>Acta Psychiatr Scand</source><year>2020</year>;<volume>141</volume>:<fpage>110</fpage>&#8211;<lpage>130</lpage>.<pub-id pub-id-type="pmid">31697843</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/acps.13121</pub-id></mixed-citation></ref><ref id="mds30293-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="mds30293-cit-0022"><string-name name-style="western"><surname>Memic</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Streit</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Hasandedic</surname><given-names>L</given-names></string-name>, et al. <article-title>Neurocognitive endophenotypes of schizophrenia and bipolar disorder and possible associations with FKBP variant rs3800373</article-title>. <source>Mediev Archaeol</source><year>2018</year>;<volume>72</volume>:<fpage>352</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.5455/medarh.2018.72.352-356</pub-id><pub-id pub-id-type="pmcid">PMC6282916</pub-id><pub-id pub-id-type="pmid">30524168</pub-id></mixed-citation></ref><ref id="mds30293-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="mds30293-cit-0023"><string-name name-style="western"><surname>Vuong</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Patterson</surname><given-names>KK</given-names></string-name>, <string-name name-style="western"><surname>Cole</surname><given-names>LP</given-names></string-name>, et al. <article-title>Relationship between cognition and gait at 2&#8208; and 12&#8208;months post&#8208;traumatic brain injury</article-title>. <source>Front Rehabil Sci</source><year>2021</year>;<volume>2</volume>:<elocation-id>726452</elocation-id>. <pub-id pub-id-type="doi">10.3389/fresc.2021.726452/full</pub-id><pub-id pub-id-type="pmid">36188837</pub-id><pub-id pub-id-type="pmcid">PMC9397897</pub-id></mixed-citation></ref><ref id="mds30293-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="mds30293-cit-0024"><string-name name-style="western"><surname>Jia</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Huo</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Miao</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>F</given-names></string-name>. <article-title>Effects of vitamin D supplementation on cognitive function and blood a&#946;&#8208;related biomarkers in older adults with Alzheimer's disease: a randomised, double&#8208;blind, placebo&#8208;controlled trial</article-title>. <source>J Neurol Neurosurg Psychiatry</source><year>2019</year>;<volume>90</volume>:<fpage>1347</fpage>&#8211;<lpage>1352</lpage>.<pub-id pub-id-type="pmid">31296588</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp-2018-320199</pub-id></mixed-citation></ref><ref id="mds30293-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="mds30293-cit-0025"><string-name name-style="western"><surname>Beales</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Whitworth</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Cartwright</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Panegyres</surname><given-names>PK</given-names></string-name>, <string-name name-style="western"><surname>Kane</surname><given-names>RT</given-names></string-name>. <article-title>Profiling sentence repetition deficits in primary progressive aphasia and Alzheimer's disease: error patterns and association with digit span</article-title>. <source>Brain Lang</source><year>2019</year>;<volume>194</volume>:<fpage>1</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="pmid">30953862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bandl.2019.03.001</pub-id></mixed-citation></ref><ref id="mds30293-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="mds30293-cit-0026"><string-name name-style="western"><surname>Rossetti</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Hay</surname><given-names>KR</given-names></string-name>, et al. <article-title>An exploratory pilot study of neuropsychological performance in two Huntington disease centers of excellence clinics</article-title>. <source>Arch Clin Neuropsychol</source><year>2024</year>;<volume>39</volume>:<fpage>24</fpage>&#8211;<lpage>34</lpage>.<pub-id pub-id-type="pmid">37530515</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/arclin/acad054</pub-id></mixed-citation></ref><ref id="mds30293-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="mds30293-cit-0027"><string-name name-style="western"><surname>Weintraub</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Besser</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Dodge</surname><given-names>HH</given-names></string-name>, et al. <article-title>Version 3 of the Alzheimer disease centers' neuropsychological test battery in the uniform data set (UDS)</article-title>. <source>Alzheimer Dis Assoc Disord</source><year>2018</year>;<volume>32</volume>:<fpage>10</fpage>&#8211;<lpage>17</lpage>.<pub-id pub-id-type="pmid">29240561</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/WAD.0000000000000223</pub-id><pub-id pub-id-type="pmcid">PMC5821520</pub-id></mixed-citation></ref><ref id="mds30293-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="mds30293-cit-0028"><string-name name-style="western"><surname>Biundo</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Weis</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Pilleri</surname><given-names>M</given-names></string-name>, et al. <article-title>Diagnostic and screening power of neuropsychological testing in detecting mild cognitive impairment in Parkinson's disease</article-title>. <source>J Neural Transm (Vienna)</source><year>2013</year>;<volume>120</volume>:<fpage>627</fpage>&#8211;<lpage>633</lpage>.<pub-id pub-id-type="pmid">23483334</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00702-013-1004-2</pub-id></mixed-citation></ref><ref id="mds30293-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="mds30293-cit-0029"><string-name name-style="western"><surname>Wilde</surname><given-names>NJ</given-names></string-name>, <string-name name-style="western"><surname>Strauss</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Tulsky</surname><given-names>DS</given-names></string-name>. <article-title>Memory span on the Wechsler scales</article-title>. <source>J Clin Exp Neuropsychol</source><year>2004</year>;<volume>26</volume>:<fpage>539</fpage>&#8211;<lpage>549</lpage>.<pub-id pub-id-type="pmid">15512941</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13803390490496605</pub-id></mixed-citation></ref><ref id="mds30293-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="mds30293-cit-0030"><string-name name-style="western"><surname>Oda</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yamamoto</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Maeda</surname><given-names>K</given-names></string-name>. <article-title>The neuropsychological profile in dementia with Lewy bodies and Alzheimer's disease</article-title>. <source>Int J Geriatr Psychiatry</source><year>2009</year>;<volume>24</volume>:<fpage>125</fpage>&#8211;<lpage>131</lpage>.<pub-id pub-id-type="pmid">18615776</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/gps.2078</pub-id></mixed-citation></ref><ref id="mds30293-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="mds30293-cit-0031"><string-name name-style="western"><surname>Liozidou</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Potagas</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Papageorgiou</surname><given-names>SG</given-names></string-name>, <string-name name-style="western"><surname>Zalonis</surname><given-names>I</given-names></string-name>. <article-title>The role of working memory and information processing speed on wisconsin card sorting test performance in Parkinson disease without dementia</article-title>. <source>J Geriatr Psychiatry Neurol</source><year>2012</year>;<volume>25</volume>:<fpage>215</fpage>&#8211;<lpage>221</lpage>.<pub-id pub-id-type="pmid">23220907</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0891988712466456</pub-id></mixed-citation></ref><ref id="mds30293-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="mds30293-cit-0032"><string-name name-style="western"><surname>Burdick</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Cholerton</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Watson</surname><given-names>GS</given-names></string-name>, et al. <article-title>People with Parkinson's disease and normal MMSE score have a broad range of cognitive performance</article-title>. <source>Mov Disord</source><year>2014</year>;<volume>29</volume>:<fpage>1258</fpage>&#8211;<lpage>1264</lpage>.<pub-id pub-id-type="pmid">25073717</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.25924</pub-id><pub-id pub-id-type="pmcid">PMC4162839</pub-id></mixed-citation></ref><ref id="mds30293-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="mds30293-cit-0033"><string-name name-style="western"><surname>Yakufujiang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Higuchi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Aoyagi</surname><given-names>K</given-names></string-name>, et al. <article-title>Predicting neurocognitive change after bilateral deep brain stimulation of subthalamic nucleus for Parkinson's disease</article-title>. <source>World Neurosurg</source><year>2021</year>;<volume>147</volume>:<fpage>e428</fpage>&#8211;<lpage>e436</lpage>.<pub-id pub-id-type="pmid">33359524</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.wneu.2020.12.081</pub-id></mixed-citation></ref><ref id="mds30293-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="mds30293-cit-0034"><string-name name-style="western"><surname>Walton</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Domell&#246;f</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Boraxbekk</surname><given-names>C&#8208;J</given-names></string-name>, et al. <article-title>The effects of working memory updating training in Parkinson's disease: a feasibility and single&#8208;subject study on cognition, movement and functional brain response</article-title>. <source>Front Psychol</source><year>2020</year>;<volume>11</volume>:<elocation-id>587925</elocation-id>.<pub-id pub-id-type="pmid">33519604</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpsyg.2020.587925</pub-id><pub-id pub-id-type="pmcid">PMC7838443</pub-id></mixed-citation></ref><ref id="mds30293-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="mds30293-cit-0035"><string-name name-style="western"><surname>Arrieta</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Rezola&#8208;Pardo</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kortajarena</surname><given-names>M</given-names></string-name>, et al. <article-title>The impact of physical exercise on cognitive and affective functions and serum levels of brain&#8208;derived neurotrophic factor in nursing home residents: a randomized controlled trial</article-title>. <source>Maturitas</source><year>2020</year>;<volume>131</volume>:<fpage>72</fpage>&#8211;<lpage>77</lpage>.<pub-id pub-id-type="pmid">31787150</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.maturitas.2019.10.014</pub-id></mixed-citation></ref><ref id="mds30293-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="mds30293-cit-0036"><string-name name-style="western"><surname>Farina</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Breno Costa</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Webber de Oliveira</surname><given-names>JA</given-names></string-name>, et al. <article-title>Cognitive function of Brazilian elderly persons: longitudinal study with non&#8208;clinical community sample</article-title>. <source>Aging Ment Health</source><year>2020</year>;<volume>24</volume>:<fpage>1807</fpage>&#8211;<lpage>1814</lpage>.<pub-id pub-id-type="pmid">31282174</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13607863.2019.1636203</pub-id></mixed-citation></ref><ref id="mds30293-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="mds30293-cit-0037"><string-name name-style="western"><surname>Young</surname><given-names>CB</given-names></string-name>, <string-name name-style="western"><surname>Cholerton</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>AM</given-names></string-name>, et al. <article-title>The Parkinson's disease composite of executive functioning: a measure for detecting cognitive decline in clinical trials</article-title>. <source>Neurology</source><year>2024</year>;<volume>103</volume>:<elocation-id>e209609</elocation-id>.<pub-id pub-id-type="pmid">38870440</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000209609</pub-id><pub-id pub-id-type="pmcid">PMC11244747</pub-id></mixed-citation></ref><ref id="mds30293-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="mds30293-cit-0038"><string-name name-style="western"><surname>Williamson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Maruff</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Schembri</surname><given-names>A</given-names></string-name>, et al. <article-title>Validation of a digit symbol substitution test for use in supervised and unsupervised assessment in mild Alzheimer's disease</article-title>. <source>J Clin Exp Neuropsychol</source><year>2022</year>;<volume>44</volume>:<fpage>768</fpage>&#8211;<lpage>779</lpage>.<pub-id pub-id-type="pmid">36888758</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13803395.2023.2179977</pub-id></mixed-citation></ref><ref id="mds30293-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="mds30293-cit-0039"><string-name name-style="western"><surname>Partington</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Leiter</surname><given-names>RG</given-names></string-name>. <article-title>Partington's pathways test</article-title>. <source>Psychological Service Center Journal</source><year>1949</year>;<volume>1</volume>:<fpage>11</fpage>&#8211;<lpage>20</lpage>.</mixed-citation></ref><ref id="mds30293-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="mds30293-cit-0040"><string-name name-style="western"><surname>Carone</surname><given-names>DA</given-names></string-name>. <article-title>Strauss E, Sherman EMS, Spreen O. A compendium of neuropsychological tests: administration, norms, and commentary</article-title>. <source>Appl Neuropsychol</source><year>2007</year>;<volume>14</volume>(<issue>1</issue>):<fpage>62</fpage>&#8211;<lpage>63</lpage>.</mixed-citation></ref><ref id="mds30293-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="mds30293-cit-0041"><string-name name-style="western"><surname>Hoogland</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Boel</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>de Bie</surname><given-names>RMA</given-names></string-name>, et al. <article-title>Risk of Parkinson's disease dementia related to level I MDS PD&#8208;MCI</article-title>. <source>Mov Disord</source><year>2019</year>;<volume>34</volume>:<fpage>430</fpage>&#8211;<lpage>435</lpage>.<pub-id pub-id-type="pmid">30653248</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.27617</pub-id></mixed-citation></ref><ref id="mds30293-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="mds30293-cit-0042"><string-name name-style="western"><surname>Bezdicek</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Stepankova</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Axelrod</surname><given-names>BN</given-names></string-name>, et al. <article-title>Clinimetric validity of the Trail Making Test Czech version in Parkinson's disease and normative data for older adults</article-title>. <source>Clin Neuropsychol</source><year>2017</year>;<volume>31</volume>:<fpage>42</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="pmid">28534428</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13854046.2017.1324045</pub-id></mixed-citation></ref><ref id="mds30293-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="mds30293-cit-0043"><string-name name-style="western"><surname>Baron</surname><given-names>S</given-names></string-name>. <article-title>I. Delis&#8208;Kaplan executive function system</article-title>. <source>Child Neuropsychol</source><year>2004</year>;<volume>10</volume>:<fpage>147</fpage>&#8211;<lpage>152</lpage>.</mixed-citation></ref><ref id="mds30293-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="mds30293-cit-0044"><string-name name-style="western"><surname>Gray</surname><given-names>R</given-names></string-name>. <article-title>Comprehensive Trail Making Test</article-title>. <source>J Psychoeduc Assess</source><year>2006</year>;<volume>24</volume>:<fpage>88</fpage>&#8211;<lpage>91</lpage>.</mixed-citation></ref><ref id="mds30293-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="mds30293-cit-0045"><string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Jiao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Shimizu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jibiki</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Watanabe</surname><given-names>K&#8208;I</given-names></string-name>, <string-name name-style="western"><surname>Kubota</surname><given-names>T</given-names></string-name>. <article-title>Correlations between atrophy of the entorhinal cortex and cognitive function in patients with Alzheimer's disease and mild cognitive impairment</article-title>. <source>Psychiatry Clin Neurosci</source><year>2012</year>;<volume>66</volume>:<fpage>587</fpage>&#8211;<lpage>593</lpage>.<pub-id pub-id-type="pmid">23252925</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/pcn.12002</pub-id></mixed-citation></ref><ref id="mds30293-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="mds30293-cit-0046"><string-name name-style="western"><surname>Ouellet</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Scherzer</surname><given-names>PB</given-names></string-name>, <string-name name-style="western"><surname>Rouleau</surname><given-names>I</given-names></string-name>, et al. <article-title>Assessment of social cognition in patients with multiple sclerosis</article-title>. <source>J Int Neuropsychol Soc</source><year>2010</year>;<volume>16</volume>:<fpage>287</fpage>&#8211;<lpage>296</lpage>.<pub-id pub-id-type="pmid">20167136</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1355617709991329</pub-id></mixed-citation></ref><ref id="mds30293-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="mds30293-cit-0047"><string-name name-style="western"><surname>Fuentes&#8208;Dur&#225;</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Ruiz</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Das&#237;</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Navarro</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Blasco</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Tom&#225;s</surname><given-names>P</given-names></string-name>. <article-title>WAIS&#8208;IV performance in patients with schizophrenia</article-title>. <source>J Nerv Ment Dis</source><year>2019</year>;<volume>207</volume>:<fpage>467</fpage>&#8211;<lpage>473</lpage>.<pub-id pub-id-type="pmid">31045978</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/NMD.0000000000000997</pub-id></mixed-citation></ref><ref id="mds30293-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="mds30293-cit-0048"><string-name name-style="western"><surname>Nombela</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Lozano</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Villanueva</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Barcia</surname><given-names>JA</given-names></string-name>. <article-title>Simultaneous stimulation of the globus pallidus interna and the nucleus basalis of Meynert in the Parkinson&#8208;dementia syndrome</article-title>. <source>Dement Geriatr Cogn Disord</source><year>2019</year>;<volume>47</volume>:<fpage>19</fpage>&#8211;<lpage>28</lpage>.<pub-id pub-id-type="pmid">30630160</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000493094</pub-id></mixed-citation></ref><ref id="mds30293-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="mds30293-cit-0049"><string-name name-style="western"><surname>Odekerken</surname><given-names>VJJ</given-names></string-name>, <string-name name-style="western"><surname>Boel</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Geurtsen</surname><given-names>GJ</given-names></string-name>, et al. <article-title>Neuropsychological outcome after deep brain stimulation for Parkinson disease</article-title>. <source>Neurology</source><year>2015</year>;<volume>84</volume>:<fpage>1355</fpage>&#8211;<lpage>1361</lpage>.<pub-id pub-id-type="pmid">25724233</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000001419</pub-id></mixed-citation></ref><ref id="mds30293-bib-0050"><label>50</label><mixed-citation publication-type="book" id="mds30293-cit-0050"><string-name name-style="western"><surname>Mitrushina</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Boone</surname><given-names>KB</given-names></string-name>, <string-name name-style="western"><surname>Razani</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>D'Elia</surname><given-names>LF</given-names></string-name>. <source>Handbook of Normative Data for Neuropsychological Assessment</source>. <publisher-loc>Oxford, UK</publisher-loc>: <publisher-name>Oxford University Press</publisher-name>; <year>2005</year>.</mixed-citation></ref><ref id="mds30293-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="mds30293-cit-0051"><string-name name-style="western"><surname>Scarpina</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Tagini</surname><given-names>S</given-names></string-name>. <article-title>The Stroop Color and Word Test</article-title>. <source>Front Psychol</source><year>2017</year>;<volume>8</volume>:<fpage>557</fpage>.<pub-id pub-id-type="pmid">28446889</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpsyg.2017.00557</pub-id><pub-id pub-id-type="pmcid">PMC5388755</pub-id></mixed-citation></ref><ref id="mds30293-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="mds30293-cit-0052"><string-name name-style="western"><surname>Troyer</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Leach</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Strauss</surname><given-names>E</given-names></string-name>. <article-title>Aging and response inhibition: normative data for the Victoria Stroop test</article-title>. <source>Neuropsychol Dev Cogn B Aging Neuropsychol Cogn</source><year>2006</year>;<volume>13</volume>:<fpage>20</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="pmid">16766341</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/138255890968187</pub-id></mixed-citation></ref><ref id="mds30293-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="mds30293-cit-0053"><string-name name-style="western"><surname>Bayard</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Erkes</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Moroni</surname><given-names>C</given-names></string-name>, <collab collab-type="authors">Coll&#232;ge des Psychologues Cliniciens sp&#233;cialis&#233;s en Neuropsychologie du Languedoc Roussillon (CPCN Languedoc Roussillon)</collab>
. <article-title>Victoria Stroop Test: normative data in a sample group of older people and the study of their clinical applications in the assessment of inhibition in Alzheimer's disease</article-title>. <source>Arch Clin Neuropsychol</source><year>2011</year>;<volume>26</volume>:<fpage>653</fpage>&#8211;<lpage>661</lpage>.<pub-id pub-id-type="pmid">21873625</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/arclin/acr053</pub-id></mixed-citation></ref><ref id="mds30293-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="mds30293-cit-0054"><string-name name-style="western"><surname>Peri&#225;&#241;ez</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Lubrini</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Garc&#237;a&#8208;Guti&#233;rrez</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>R&#237;os&#8208;Lago</surname><given-names>M</given-names></string-name>. <article-title>Construct validity of the Stroop Color&#8208;Word Test: influence of speed of visual search, verbal fluency, working memory, cognitive flexibility, and conflict monitoring</article-title>. <source>Arch Clin Neuropsychol</source><year>2021</year>;<volume>36</volume>:<fpage>99</fpage>&#8211;<lpage>111</lpage>.<pub-id pub-id-type="pmid">32514527</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/arclin/acaa034</pub-id></mixed-citation></ref><ref id="mds30293-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="mds30293-cit-0055"><string-name name-style="western"><surname>Hankee</surname><given-names>LD</given-names></string-name>, <string-name name-style="western"><surname>Preis</surname><given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>Piers</surname><given-names>RJ</given-names></string-name>, et al. <article-title>Population normative data for the CERAD Word List and Victoria Stroop Test in younger&#8208; and middle&#8208;aged adults: cross&#8208;sectional analyses from the Framingham Heart Study</article-title>. <source>Exp Aging Res</source><year>2016</year>;<volume>42</volume>:<fpage>315</fpage>&#8211;<lpage>328</lpage>.<pub-id pub-id-type="pmid">27410241</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/0361073X.2016.1191838</pub-id><pub-id pub-id-type="pmcid">PMC4946576</pub-id></mixed-citation></ref><ref id="mds30293-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="mds30293-cit-0056"><string-name name-style="western"><surname>Dassanayake</surname><given-names>TL</given-names></string-name>, <string-name name-style="western"><surname>Hewawasam</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Baminiwatta</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ariyasinghe</surname><given-names>DI</given-names></string-name>. <article-title>Regression&#8208;based, demographically adjusted norms for Victoria Stroop Test, Digit Span, and Verbal Fluency for Sri Lankan adults</article-title>. <source>Clin Neuropsychol</source><year>2021</year>;<volume>35</volume>:<fpage>S32</fpage>&#8211;<lpage>S49</lpage>.<pub-id pub-id-type="pmid">34499569</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13854046.2021.1973109</pub-id></mixed-citation></ref><ref id="mds30293-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="mds30293-cit-0057"><string-name name-style="western"><surname>Tremblay</surname><given-names>M&#8208;P</given-names></string-name>, <string-name name-style="western"><surname>Potvin</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Belleville</surname><given-names>S</given-names></string-name>, et al. <article-title>The Victoria Stroop Test: normative data in Quebec&#8208;French adults and elderly</article-title>. <source>Arch Clin Neuropsychol</source><year>2016</year>;<volume>31</volume>:<fpage>926</fpage>&#8211;<lpage>933</lpage>.<pub-id pub-id-type="pmid">27246959</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/arclin/acw029</pub-id><pub-id pub-id-type="pmcid">PMC5859918</pub-id></mixed-citation></ref><ref id="mds30293-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="mds30293-cit-0058"><string-name name-style="western"><surname>Bezdicek</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Lukavsky</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Stepankova</surname><given-names>H</given-names></string-name>, et al. <article-title>The Prague Stroop Test: normative standards in older Czech adults and discriminative validity for mild cognitive impairment in Parkinson's disease</article-title>. <source>J Clin Exp Neuropsychol</source><year>2015</year>;<volume>37</volume>:<fpage>794</fpage>&#8211;<lpage>807</lpage>.<pub-id pub-id-type="pmid">26313510</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13803395.2015.1057106</pub-id></mixed-citation></ref><ref id="mds30293-bib-0059"><label>59</label><mixed-citation publication-type="journal" id="mds30293-cit-0059"><string-name name-style="western"><surname>Kramer</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Nelson</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Johnson</surname><given-names>JK</given-names></string-name>, et al. <article-title>Multiple cognitive deficits in amnestic mild cognitive impairment</article-title>. <source>Dement Geriatr Cogn Disord</source><year>2006</year>;<volume>22</volume>:<fpage>306</fpage>&#8211;<lpage>311</lpage>.<pub-id pub-id-type="pmid">16931884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000095303</pub-id><pub-id pub-id-type="pmcid">PMC2631274</pub-id></mixed-citation></ref><ref id="mds30293-bib-0060"><label>60</label><mixed-citation publication-type="journal" id="mds30293-cit-0060"><string-name name-style="western"><surname>Santangelo</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Bisecco</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Trojano</surname><given-names>L</given-names></string-name>, et al. <article-title>Cognitive performance in multiple sclerosis: the contribution of intellectual enrichment and brain MRI measures</article-title>. <source>J Neurol</source><year>2018</year>;<volume>265</volume>:<fpage>1772</fpage>&#8211;<lpage>1779</lpage>.<pub-id pub-id-type="pmid">29804148</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00415-018-8905-9</pub-id></mixed-citation></ref><ref id="mds30293-bib-0061"><label>61</label><mixed-citation publication-type="journal" id="mds30293-cit-0061"><string-name name-style="western"><surname>Fiorenzato</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Antonini</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Camparini</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Weis</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Semenza</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Biundo</surname><given-names>R</given-names></string-name>. <article-title>Characteristics and progression of cognitive deficits in progressive supranuclear palsy vs. multiple system atrophy and Parkinson's disease</article-title>. <source>J Neural Transm (Vienna)</source><year>2019</year>;<volume>126</volume>:<fpage>1437</fpage>&#8211;<lpage>1445</lpage>.<pub-id pub-id-type="pmid">31432258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00702-019-02065-1</pub-id></mixed-citation></ref><ref id="mds30293-bib-0062"><label>62</label><mixed-citation publication-type="journal" id="mds30293-cit-0062"><string-name name-style="western"><surname>Bondi</surname><given-names>MW</given-names></string-name>, <string-name name-style="western"><surname>Serody</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Chan</surname><given-names>AS</given-names></string-name>, et al. <article-title>Cognitive and neuropathologic correlates of Stroop Color&#8208;Word test performance in Alzheimer's disease</article-title>. <source>Neuropsychology</source><year>2002</year>;<volume>16</volume>:<fpage>335</fpage>&#8211;<lpage>343</lpage>.<pub-id pub-id-type="pmid">12146681</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1037//0894-4105.16.3.335</pub-id></mixed-citation></ref><ref id="mds30293-bib-0063"><label>63</label><mixed-citation publication-type="journal" id="mds30293-cit-0063"><string-name name-style="western"><surname>Santangelo</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Vitale</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Picillo</surname><given-names>M</given-names></string-name>, et al. <article-title>Mild cognitive impairment in newly diagnosed Parkinson's disease: a longitudinal prospective study</article-title>. <source>Parkinsonism Relat Disord</source><year>2015</year>;<volume>21</volume>:<fpage>1219</fpage>&#8211;<lpage>1226</lpage>.<pub-id pub-id-type="pmid">26321021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.parkreldis.2015.08.024</pub-id></mixed-citation></ref><ref id="mds30293-bib-0064"><label>64</label><mixed-citation publication-type="journal" id="mds30293-cit-0064"><string-name name-style="western"><surname>Janvin</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Aarsland</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Larsen</surname><given-names>JP</given-names></string-name>. <article-title>Cognitive predictors of dementia in Parkinson's disease: a community&#8208;based, 4&#8208;year longitudinal study</article-title>. <source>J Geriatr Psychiatry Neurol</source><year>2005</year>;<volume>18</volume>:<fpage>149</fpage>&#8211;<lpage>154</lpage>.<pub-id pub-id-type="pmid">16100104</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0891988705277540</pub-id></mixed-citation></ref><ref id="mds30293-bib-0065"><label>65</label><mixed-citation publication-type="journal" id="mds30293-cit-0065"><string-name name-style="western"><surname>Qin</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>L</given-names></string-name>, et al. <article-title>Unlocking potential: low frequency subthalamic nucleus stimulation enhances executive function in Parkinson's disease patients with postural instability/gait disturbance</article-title>. <source>Front Neurosci</source><year>2023</year>;<volume>17</volume>:<elocation-id>1228711</elocation-id>.<pub-id pub-id-type="pmid">37712094</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2023.1228711</pub-id><pub-id pub-id-type="pmcid">PMC10498764</pub-id></mixed-citation></ref><ref id="mds30293-bib-0066"><label>66</label><mixed-citation publication-type="journal" id="mds30293-cit-0066"><string-name name-style="western"><surname>Djamshidian</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>O'Sullivan</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Lees</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Averbeck</surname><given-names>BB</given-names></string-name>. <article-title>Stroop test performance in impulsive and non impulsive patients with Parkinson's disease</article-title>. <source>Parkinsonism Relat Disord</source><year>2011</year>;<volume>17</volume>:<fpage>212</fpage>&#8211;<lpage>214</lpage>.<pub-id pub-id-type="pmid">21247790</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.parkreldis.2010.12.014</pub-id><pub-id pub-id-type="pmcid">PMC3042030</pub-id></mixed-citation></ref><ref id="mds30293-bib-0067"><label>67</label><mixed-citation publication-type="journal" id="mds30293-cit-0067"><string-name name-style="western"><surname>Grant</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Berg</surname><given-names>E</given-names></string-name>. <article-title>A behavioral analysis of degree of reinforcement and ease of shifting to new responses in a Weigl&#8208;type card&#8208;sorting problem</article-title>. <source>J Exp Psychol</source><year>1948</year>;<volume>38</volume>:<fpage>404</fpage>&#8211;<lpage>411</lpage>.<pub-id pub-id-type="pmid">18874598</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1037/h0059831</pub-id></mixed-citation></ref><ref id="mds30293-bib-0068"><label>68</label><mixed-citation publication-type="book" id="mds30293-cit-0068"><string-name name-style="western"><surname>Lezak</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Howieson</surname><given-names>DB</given-names></string-name>, <string-name name-style="western"><surname>Bigler</surname><given-names>ED</given-names></string-name>, <string-name name-style="western"><surname>Tranel</surname><given-names>D</given-names></string-name>. <source>Neuropsychological Assessment</source>. <edition designator="5">5th ed.</edition><publisher-loc>New York, NY</publisher-loc>: <publisher-name>Oxford University Press</publisher-name>; <year>2012</year>:<fpage>1161</fpage>.</mixed-citation></ref><ref id="mds30293-bib-0069"><label>69</label><mixed-citation publication-type="journal" id="mds30293-cit-0069"><string-name name-style="western"><surname>Diamond</surname><given-names>A</given-names></string-name>. <article-title>Executive functions</article-title>. <source>Annu Rev Psychol</source><year>2013</year>;<volume>64</volume>:<fpage>135</fpage>&#8211;<lpage>168</lpage>.<pub-id pub-id-type="pmid">23020641</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-psych-113011-143750</pub-id><pub-id pub-id-type="pmcid">PMC4084861</pub-id></mixed-citation></ref><ref id="mds30293-bib-0070"><label>70</label><mixed-citation publication-type="journal" id="mds30293-cit-0070"><string-name name-style="western"><surname>Ashendorf</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>McCaffrey</surname><given-names>RJ</given-names></string-name>. <article-title>Exploring age&#8208;related decline on the Wisconsin Card Sorting Test</article-title>. <source>Clin Neuropsychol</source><year>2008</year>;<volume>22</volume>:<fpage>262</fpage>&#8211;<lpage>272</lpage>.<pub-id pub-id-type="pmid">17853147</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13854040701218436</pub-id></mixed-citation></ref><ref id="mds30293-bib-0071"><label>71</label><mixed-citation publication-type="journal" id="mds30293-cit-0071"><string-name name-style="western"><surname>Steinke</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lange</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Kopp</surname><given-names>B</given-names></string-name>. <article-title>Parallel model&#8208;based and model&#8208;free reinforcement learning for card sorting performance</article-title>. <source>Sci Rep</source><year>2020</year>;<volume>10</volume>:<fpage>15464</fpage>.<pub-id pub-id-type="pmid">32963297</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-020-72407-7</pub-id><pub-id pub-id-type="pmcid">PMC7508815</pub-id></mixed-citation></ref><ref id="mds30293-bib-0072"><label>72</label><mixed-citation publication-type="journal" id="mds30293-cit-0072"><string-name name-style="western"><surname>Greve</surname><given-names>KW</given-names></string-name>. <article-title>The WCST&#8208;64: a standardized short&#8208;form of the Wisconsin Card Sorting Test</article-title>. <source>Clin Neuropsychol</source><year>2001</year>;<volume>15</volume>:<fpage>228</fpage>&#8211;<lpage>234</lpage>.<pub-id pub-id-type="pmid">11528544</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1076/clin.15.2.228.1901</pub-id></mixed-citation></ref><ref id="mds30293-bib-0073"><label>73</label><mixed-citation publication-type="journal" id="mds30293-cit-0073"><string-name name-style="western"><surname>Gardizi</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>King</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>McNeely</surname><given-names>HE</given-names></string-name>, <string-name name-style="western"><surname>Vaz</surname><given-names>SM</given-names></string-name>. <article-title>Comparability of the WCST and WCST&#8208;64 in the assessment of first&#8208;episode psychosis</article-title>. <source>Psychol Assess</source><year>2019</year>;<volume>31</volume>:<fpage>271</fpage>&#8211;<lpage>276</lpage>.<pub-id pub-id-type="pmid">30475009</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1037/pas0000670</pub-id></mixed-citation></ref><ref id="mds30293-bib-0074"><label>74</label><mixed-citation publication-type="journal" id="mds30293-cit-0074"><string-name name-style="western"><surname>Nelson</surname><given-names>HE</given-names></string-name>. <article-title>A modified card sorting test sensitive to frontal lobe defects</article-title>. <source>Cortex</source><year>1976</year>;<volume>12</volume>:<fpage>313</fpage>&#8211;<lpage>324</lpage>.<pub-id pub-id-type="pmid">1009768</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0010-9452(76)80035-4</pub-id></mixed-citation></ref><ref id="mds30293-bib-0075"><label>75</label><mixed-citation publication-type="journal" id="mds30293-cit-0075"><string-name name-style="western"><surname>Lange</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Br&#252;ckner</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Knebel</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Seer</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kopp</surname><given-names>B</given-names></string-name>. <article-title>Executive dysfunction in Parkinson's disease: a meta&#8208;analysis on the Wisconsin Card Sorting Test literature</article-title>. <source>Neurosci Biobehav Rev</source><year>2018</year>;<volume>93</volume>:<fpage>38</fpage>&#8211;<lpage>56</lpage>.<pub-id pub-id-type="pmid">29944959</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neubiorev.2018.06.014</pub-id></mixed-citation></ref><ref id="mds30293-bib-0076"><label>76</label><mixed-citation publication-type="journal" id="mds30293-cit-0076"><string-name name-style="western"><surname>Rabin</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Barr</surname><given-names>WB</given-names></string-name>, <string-name name-style="western"><surname>Burton</surname><given-names>LA</given-names></string-name>. <article-title>Assessment practices of clinical neuropsychologists in the United States and Canada: a survey of INS, NAN, and APA division 40 members&#9734;</article-title>. <source>Arch Clin Neuropsychol</source><year>2005</year>;<volume>20</volume>:<fpage>33</fpage>&#8211;<lpage>65</lpage>.<pub-id pub-id-type="pmid">15620813</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.acn.2004.02.005</pub-id></mixed-citation></ref><ref id="mds30293-bib-0077"><label>77</label><mixed-citation publication-type="journal" id="mds30293-cit-0077"><string-name name-style="western"><surname>del Pino</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Pe&#241;a</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ibarretxe&#8208;Bilbao</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Schretlen</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Ojeda</surname><given-names>N</given-names></string-name>. <article-title>Modified Wisconsin Card Sorting Test: standardization and norms of the test for a population sample in Spain</article-title>. <source>Rev Neurol</source><year>2016</year>;<volume>62</volume>:<fpage>193</fpage>&#8211;<lpage>202</lpage>.<pub-id pub-id-type="pmid">26916322</pub-id></mixed-citation></ref><ref id="mds30293-bib-0078"><label>78</label><mixed-citation publication-type="journal" id="mds30293-cit-0078"><string-name name-style="western"><surname>Faustino</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Oliveira</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lopes</surname><given-names>P</given-names></string-name>. <article-title>Normative scores of the Wisconsin Card Sorting Test in a sample of the adult Portuguese population</article-title>. <source>Appl Neuropsychol Adult</source><year>2022</year>;<volume>29</volume>:<fpage>767</fpage>&#8211;<lpage>774</lpage>.<pub-id pub-id-type="pmid">32898451</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/23279095.2020.1810040</pub-id></mixed-citation></ref><ref id="mds30293-bib-0079"><label>79</label><mixed-citation publication-type="journal" id="mds30293-cit-0079"><string-name name-style="western"><surname>Laiacona</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Inzaghi</surname><given-names>MG</given-names></string-name>, <string-name name-style="western"><surname>De Tanti</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Capitani</surname><given-names>E</given-names></string-name>. <article-title>Wisconsin card sorting test: a new global score, with Italian norms, and its relationship with the Weigl sorting test</article-title>. <source>Neurol Sci</source><year>2000</year>;<volume>21</volume>:<fpage>279</fpage>&#8211;<lpage>291</lpage>.<pub-id pub-id-type="pmid">11286040</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s100720070065</pub-id></mixed-citation></ref><ref id="mds30293-bib-0080"><label>80</label><mixed-citation publication-type="journal" id="mds30293-cit-0080"><string-name name-style="western"><surname>Miranda</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Franchetto Sierra</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Mart&#237;nez Roulet</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rivadero</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Serra</surname><given-names>SV</given-names></string-name>, <string-name name-style="western"><surname>Soria</surname><given-names>EA</given-names></string-name>. <article-title>Age, education and gender effects on Wisconsin card sorting test: standardization, reliability and validity in healthy Argentinian adults</article-title>. <source>Neuropsychol Dev Cogn B Aging Neuropsychol Cogn</source><year>2020</year>;<volume>27</volume>:<fpage>807</fpage>&#8211;<lpage>825</lpage>.<pub-id pub-id-type="pmid">31744387</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13825585.2019.1693491</pub-id></mixed-citation></ref><ref id="mds30293-bib-0081"><label>81</label><mixed-citation publication-type="journal" id="mds30293-cit-0081"><string-name name-style="western"><surname>Rammal</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Abi Chahine</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Rammal</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Fares</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Abou Abbas</surname><given-names>L</given-names></string-name>. <article-title>Modified Wisconsin Card Sorting Test (M&#8208;WCST): normative data for the Lebanese adult population</article-title>. <source>Dev Neuropsychol</source><year>2019</year>;<volume>44</volume>:<fpage>397</fpage>&#8211;<lpage>408</lpage>.<pub-id pub-id-type="pmid">31394932</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/87565641.2019.1652828</pub-id></mixed-citation></ref><ref id="mds30293-bib-0082"><label>82</label><mixed-citation publication-type="journal" id="mds30293-cit-0082"><string-name name-style="western"><surname>Shan</surname><given-names>I&#8208;K</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Y&#8208;S</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>Y&#8208;C</given-names></string-name>, <string-name name-style="western"><surname>Su</surname><given-names>T&#8208;P</given-names></string-name>. <article-title>Adult normative data of the Wisconsin Card Sorting Test in Taiwan</article-title>. <source>J Chin Med Assoc</source><year>2008</year>;<volume>71</volume>:<fpage>517</fpage>&#8211;<lpage>522</lpage>.<pub-id pub-id-type="pmid">18955186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1726-4901(08)70160-6</pub-id></mixed-citation></ref><ref id="mds30293-bib-0083"><label>83</label><mixed-citation publication-type="journal" id="mds30293-cit-0083"><string-name name-style="western"><surname>Guarino</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Forte</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Giovannoli</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Casagrande</surname><given-names>M</given-names></string-name>. <article-title>Executive functions in the elderly with mild cognitive impairment: a systematic review on motor and cognitive inhibition, conflict control and cognitive flexibility</article-title>. <source>Aging Ment Health</source><year>2020</year>;<volume>24</volume>:<fpage>1028</fpage>&#8211;<lpage>1045</lpage>.<pub-id pub-id-type="pmid">30938193</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13607863.2019.1584785</pub-id></mixed-citation></ref><ref id="mds30293-bib-0084"><label>84</label><mixed-citation publication-type="journal" id="mds30293-cit-0084"><string-name name-style="western"><surname>Petrova</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mehrabian&#8208;Spasova</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Aarsland</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Raycheva</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Traykov</surname><given-names>L</given-names></string-name>. <article-title>Clinical and neuropsychological differences between mild Parkinson's disease dementia and dementia with Lewy bodies</article-title>. <source>Dement Geriatr Cogn Dis Extra</source><year>2015</year>;<volume>5</volume>:<fpage>212</fpage>&#8211;<lpage>220</lpage>.<pub-id pub-id-type="pmid">26195977</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000375363</pub-id><pub-id pub-id-type="pmcid">PMC4483490</pub-id></mixed-citation></ref><ref id="mds30293-bib-0085"><label>85</label><mixed-citation publication-type="journal" id="mds30293-cit-0085"><string-name name-style="western"><surname>Boggio</surname><given-names>PS</given-names></string-name>, <string-name name-style="western"><surname>Fregni</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Bermpohl</surname><given-names>F</given-names></string-name>, et al. <article-title>Effect of repetitive TMS and fluoxetine on cognitive function in patients with Parkinson's disease and concurrent depression</article-title>. <source>Mov Disord</source><year>2005</year>;<volume>20</volume>:<fpage>1178</fpage>&#8211;<lpage>1184</lpage>.<pub-id pub-id-type="pmid">15895421</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.20508</pub-id></mixed-citation></ref><ref id="mds30293-bib-0086"><label>86</label><mixed-citation publication-type="journal" id="mds30293-cit-0086"><string-name name-style="western"><surname>Gamito</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Oliveira</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Matias</surname><given-names>M</given-names></string-name>, et al. <article-title>Virtual reality cognitive training among individuals with alcohol use disorder undergoing residential treatment: pilot randomized controlled trial</article-title>. <source>J Med Internet Res</source><year>2021</year>;<volume>23</volume>:<elocation-id>e18482</elocation-id>.<pub-id pub-id-type="pmid">33512329</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/18482</pub-id><pub-id pub-id-type="pmcid">PMC7880813</pub-id></mixed-citation></ref><ref id="mds30293-bib-0087"><label>87</label><mixed-citation publication-type="miscellaneous" id="mds30293-cit-0087"><article-title>Primary mental abilities</article-title>; Accessed September 13, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://awspntest.apa.org/record/1938-15070-000" ext-link-type="uri">https://awspntest.apa.org/record/1938-15070-000</ext-link>.</mixed-citation></ref><ref id="mds30293-bib-0088"><label>88</label><mixed-citation publication-type="journal" id="mds30293-cit-0088"><string-name name-style="western"><surname>Villalobos</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Povedano&#8208;Montero</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Fern&#225;ndez</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>L&#243;pez&#8208;Mu&#241;oz</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Pacios</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>del R&#237;o</surname><given-names>D</given-names></string-name>. <article-title>Scientific research on verbal fluency tests: a bibliometric analysis</article-title>. <source>J Neurolinguistics</source><year>2022</year>;<volume>63</volume>:<elocation-id>101082</elocation-id>.</mixed-citation></ref><ref id="mds30293-bib-0089"><label>89</label><mixed-citation publication-type="journal" id="mds30293-cit-0089"><string-name name-style="western"><surname>Parsons</surname><given-names>TD</given-names></string-name>, <string-name name-style="western"><surname>Rogers</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Braaten</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Woods</surname><given-names>SP</given-names></string-name>, <string-name name-style="western"><surname>Tr&#246;ster</surname><given-names>AI</given-names></string-name>. <article-title>Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a meta&#8208;analysis</article-title>. <source>Lancet Neurol</source><year>2006</year>;<volume>5</volume>:<fpage>578</fpage>&#8211;<lpage>588</lpage>.<pub-id pub-id-type="pmid">16781988</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(06)70475-6</pub-id></mixed-citation></ref><ref id="mds30293-bib-0090"><label>90</label><mixed-citation publication-type="journal" id="mds30293-cit-0090"><string-name name-style="western"><surname>Combs</surname><given-names>HL</given-names></string-name>, <string-name name-style="western"><surname>Folley</surname><given-names>BS</given-names></string-name>, <string-name name-style="western"><surname>Berry</surname><given-names>DTR</given-names></string-name>, et al. <article-title>Cognition and depression following deep brain stimulation of the subthalamic nucleus and globus pallidus pars internus in Parkinson's disease: a meta&#8208;analysis</article-title>. <source>Neuropsychol Rev</source><year>2015</year>;<volume>25</volume>:<fpage>439</fpage>&#8211;<lpage>454</lpage>.<pub-id pub-id-type="pmid">26459361</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11065-015-9302-0</pub-id></mixed-citation></ref><ref id="mds30293-bib-0091"><label>91</label><mixed-citation publication-type="journal" id="mds30293-cit-0091"><string-name name-style="western"><surname>Bucur</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Papagno</surname><given-names>C</given-names></string-name>. <article-title>Deep brain stimulation in Parkinson disease: a meta&#8208;analysis of the long&#8208;term neuropsychological outcomes</article-title>. <source>Neuropsychol Rev</source><year>2023</year>;<volume>33</volume>:<fpage>307</fpage>&#8211;<lpage>346</lpage>.<pub-id pub-id-type="pmid">35318587</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11065-022-09540-9</pub-id><pub-id pub-id-type="pmcid">PMC10148791</pub-id></mixed-citation></ref><ref id="mds30293-bib-0092"><label>92</label><mixed-citation publication-type="miscellaneous" id="mds30293-cit-0092"><article-title>Benton: Multilingual aphasia examination&#8208;Google Scholar [online]</article-title>; Accessed September 13, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://scholar.google.com/scholar_lookup?&amp;title=Multilingual%20Aphasia%20Examination&amp;publication_year=1994&amp;author=Benton%2CA.%20L.&amp;author=Hamsher%2CK.%20D.&amp;author=Sivan%2CA.%20B" ext-link-type="uri">https://scholar.google.com/scholar_lookup?&amp;title=Multilingual%20Aphasia%20Examination&amp;publication_year=1994&amp;author=Benton%2CA.%20L.&amp;author=Hamsher%2CK.%20D.&amp;author=Sivan%2CA.%20B</ext-link>.</mixed-citation></ref><ref id="mds30293-bib-0093"><label>93</label><mixed-citation publication-type="book" id="mds30293-cit-0093"><string-name name-style="western"><surname>Spreen</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Benton</surname><given-names>AL</given-names></string-name>. <source>Neurosensory Center Comprehensive Examination for Aphasia (NCCEA), 1977 Revision: Manual of Instructions</source>. <publisher-loc>Victoria, B.C</publisher-loc>: <publisher-name>Neuropsychology Laboratory, University of Victoria</publisher-name>; <year>1977</year>.</mixed-citation></ref><ref id="mds30293-bib-0094"><label>94</label><mixed-citation publication-type="journal" id="mds30293-cit-0094"><string-name name-style="western"><surname>Pereira</surname><given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Gon&#231;alves</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Holz</surname><given-names>M</given-names></string-name>, et al. <article-title>Influence of age and education on the processing of clustering and switching in verbal fluency tasks</article-title>. <source>Dement Neuropsychol</source><year>2018</year>;<volume>12</volume>:<fpage>360</fpage>&#8211;<lpage>367</lpage>.<pub-id pub-id-type="pmid">30546845</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1590/1980-57642018dn12-040004</pub-id><pub-id pub-id-type="pmcid">PMC6289476</pub-id></mixed-citation></ref><ref id="mds30293-bib-0095"><label>95</label><mixed-citation publication-type="journal" id="mds30293-cit-0095"><string-name name-style="western"><surname>Abdel Aziz</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Khater</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Emara</surname><given-names>T</given-names></string-name>, et al. <article-title>Effects of age, education, and gender on verbal fluency in healthy adult Arabic&#8208;speakers in Egypt</article-title>. <source>Appl Neuropsychol Adult</source><year>2017</year>;<volume>24</volume>:<fpage>331</fpage>&#8211;<lpage>341</lpage>.<pub-id pub-id-type="pmid">27282630</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/23279095.2016.1185424</pub-id></mixed-citation></ref><ref id="mds30293-bib-0096"><label>96</label><mixed-citation publication-type="journal" id="mds30293-cit-0096"><string-name name-style="western"><surname>Karr</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Garcia&#8208;Barrera</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Holdnack</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Iverson</surname><given-names>GL</given-names></string-name>. <article-title>Advanced clinical interpretation of the Delis&#8208;Kaplan Executive Function System: multivariate base rates of low scores</article-title>. <source>Clin Neuropsychol</source><year>2018</year>;<volume>32</volume>:<fpage>42</fpage>&#8211;<lpage>53</lpage>.<pub-id pub-id-type="pmid">28571515</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13854046.2017.1334828</pub-id></mixed-citation></ref><ref id="mds30293-bib-0097"><label>97</label><mixed-citation publication-type="journal" id="mds30293-cit-0097"><string-name name-style="western"><surname>Gladsjo</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Schuman</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Evans</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Peavy</surname><given-names>GM</given-names></string-name>, <string-name name-style="western"><surname>Miller</surname><given-names>SW</given-names></string-name>, <string-name name-style="western"><surname>Heaton</surname><given-names>RK</given-names></string-name>. <article-title>Norms for letter and category fluency: demographic corrections for age, education, and ethnicity</article-title>. <source>Assessment</source><year>1999</year>;<volume>6</volume>:<fpage>147</fpage>&#8211;<lpage>178</lpage>.<pub-id pub-id-type="pmid">10335019</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/107319119900600204</pub-id></mixed-citation></ref><ref id="mds30293-bib-0098"><label>98</label><mixed-citation publication-type="journal" id="mds30293-cit-0098"><string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Evans</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Wong</surname><given-names>JB&#8208;W</given-names></string-name>, <string-name name-style="western"><surname>Dissanayaka</surname><given-names>NN</given-names></string-name>, <string-name name-style="western"><surname>Vogel</surname><given-names>AP</given-names></string-name>. <article-title>Optimising verbal fluency analysis in neurological patients with dysarthria: examples from Parkinson's disease and hereditary ataxia</article-title>. <source>J Clin Exp Neuropsychol</source><year>2023</year>;<volume>45</volume>:<fpage>452</fpage>&#8211;<lpage>463</lpage>.<pub-id pub-id-type="pmid">37656122</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13803395.2023.2249172</pub-id></mixed-citation></ref><ref id="mds30293-bib-0099"><label>99</label><mixed-citation publication-type="journal" id="mds30293-cit-0099"><string-name name-style="western"><surname>Tong</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>, et al. <article-title>Executive dysfunction in Parkinson's disease: from neurochemistry to circuits, genetics and neuroimaging</article-title>. <source>Prog Neuro&#8208;Psychopharmacol Biol Psychiatry</source><year>2025</year>;<volume>137</volume>:<elocation-id>111272</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pnpbp.2025.111272</pub-id><pub-id pub-id-type="pmid">39880275</pub-id></mixed-citation></ref><ref id="mds30293-bib-0100"><label>100</label><mixed-citation publication-type="journal" id="mds30293-cit-0100"><string-name name-style="western"><surname>Kudlicka</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Clare</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Hindle</surname><given-names>JV</given-names></string-name>. <article-title>Executive functions in Parkinson's disease: systematic review and meta&#8208;analysis</article-title>. <source>Mov Disord</source><year>2011</year>;<volume>26</volume>:<fpage>2305</fpage>&#8211;<lpage>2315</lpage>.<pub-id pub-id-type="pmid">21971697</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.23868</pub-id></mixed-citation></ref><ref id="mds30293-bib-0101"><label>101</label><mixed-citation publication-type="journal" id="mds30293-cit-0101"><string-name name-style="western"><surname>Dirnberger</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Jahanshahi</surname><given-names>M</given-names></string-name>. <article-title>Executive dysfunction in Parkinson's disease: a review</article-title>. <source>J Neuropsychol</source><year>2013</year>;<volume>7</volume>:<fpage>193</fpage>&#8211;<lpage>224</lpage>.<pub-id pub-id-type="pmid">24007368</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jnp.12028</pub-id></mixed-citation></ref><ref id="mds30293-bib-0102"><label>102</label><mixed-citation publication-type="journal" id="mds30293-cit-0102"><string-name name-style="western"><surname>Seemiller</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Morrow</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hinkle</surname><given-names>JT</given-names></string-name>, et al. <article-title>Impact of acute dopamine replacement on cognitive function in Parkinson's disease</article-title>. <source>Mov Disord Clin Pract</source><year>2024</year>;<volume>11</volume>:<fpage>534</fpage>&#8211;<lpage>542</lpage>.<pub-id pub-id-type="pmid">38470011</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mdc3.14017</pub-id><pub-id pub-id-type="pmcid">PMC11078494</pub-id></mixed-citation></ref><ref id="mds30293-bib-0103"><label>103</label><mixed-citation publication-type="journal" id="mds30293-cit-0103"><string-name name-style="western"><surname>Ramos</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Machado</surname><given-names>L</given-names></string-name>. <article-title>A comprehensive meta&#8208;analysis on short&#8208;term and working memory dysfunction in Parkinson's disease</article-title>. <source>Neuropsychol Rev</source><year>2021</year>;<volume>31</volume>:<fpage>288</fpage>&#8211;<lpage>311</lpage>.<pub-id pub-id-type="pmid">33523408</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11065-021-09480-w</pub-id></mixed-citation></ref><ref id="mds30293-bib-0104"><label>104</label><mixed-citation publication-type="journal" id="mds30293-cit-0104"><string-name name-style="western"><surname>Moustafa</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Bell</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Eissa</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Hewedi</surname><given-names>DH</given-names></string-name>. <article-title>The effects of clinical motor variables and medication dosage on working memory in Parkinson's disease</article-title>. <source>Brain Cogn</source><year>2013</year>;<volume>82</volume>:<fpage>137</fpage>&#8211;<lpage>145</lpage>.<pub-id pub-id-type="pmid">23660434</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bandc.2013.04.001</pub-id></mixed-citation></ref><ref id="mds30293-bib-0105"><label>105</label><mixed-citation publication-type="journal" id="mds30293-cit-0105"><string-name name-style="western"><surname>Jahanshahi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Torkamani</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Beigi</surname><given-names>M</given-names></string-name>, et al. <article-title>Pallidal stimulation for primary generalised dystonia: effect on cognition, mood and quality of life</article-title>. <source>J Neurol</source><year>2014</year>;<volume>261</volume>:<fpage>164</fpage>&#8211;<lpage>173</lpage>.<pub-id pub-id-type="pmid">24178706</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00415-013-7161-2</pub-id><pub-id pub-id-type="pmcid">PMC3895192</pub-id></mixed-citation></ref><ref id="mds30293-bib-0106"><label>106</label><mixed-citation publication-type="journal" id="mds30293-cit-0106"><string-name name-style="western"><surname>Jahanshahi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rowe</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Fuller</surname><given-names>R</given-names></string-name>. <article-title>Cognitive executive function in dystonia</article-title>. <source>Mov Disord</source><year>2003</year>;<volume>18</volume>:<fpage>1470</fpage>&#8211;<lpage>1481</lpage>.<pub-id pub-id-type="pmid">14673884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.10595</pub-id></mixed-citation></ref><ref id="mds30293-bib-0107"><label>107</label><mixed-citation publication-type="journal" id="mds30293-cit-0107"><string-name name-style="western"><surname>Galtier</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Nieto</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lorenzo</surname><given-names>JN</given-names></string-name>, <string-name name-style="western"><surname>Barroso</surname><given-names>J</given-names></string-name>. <article-title>Mild cognitive impairment in Parkinson's disease: clustering and switching analyses in Verbal Fluency Test</article-title>. <source>J Int Neuropsychol Soc</source><year>2017</year>;<volume>23</volume>:<fpage>511</fpage>&#8211;<lpage>520</lpage>.<pub-id pub-id-type="pmid">28494819</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1355617717000297</pub-id></mixed-citation></ref><ref id="mds30293-bib-0108"><label>108</label><mixed-citation publication-type="journal" id="mds30293-cit-0108"><string-name name-style="western"><surname>Farzanfar</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Statucka</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Cohn</surname><given-names>M</given-names></string-name>. <article-title>Automated indices of clustering and switching of semantic verbal fluency in Parkinson's disease</article-title>. <source>J Int Neuropsychol Soc</source><year>2018</year>;<volume>24</volume>:<fpage>1047</fpage>&#8211;<lpage>1056</lpage>.<pub-id pub-id-type="pmid">30282568</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1355617718000759</pub-id></mixed-citation></ref><ref id="mds30293-bib-0109"><label>109</label><mixed-citation publication-type="journal" id="mds30293-cit-0109"><string-name name-style="western"><surname>El&#8208;Nazer</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Adler</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Beach</surname><given-names>TG</given-names></string-name>, et al. <article-title>Regional neuropathology distribution and verbal fluency impairments in Parkinson's disease</article-title>. <source>Parkinsonism Relat Disord</source><year>2019</year>;<volume>65</volume>:<fpage>73</fpage>&#8211;<lpage>78</lpage>.<pub-id pub-id-type="pmid">31109728</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.parkreldis.2019.05.014</pub-id><pub-id pub-id-type="pmcid">PMC6774852</pub-id></mixed-citation></ref><ref id="mds30293-bib-0110"><label>110</label><mixed-citation publication-type="journal" id="mds30293-cit-0110"><string-name name-style="western"><surname>Williams&#8208;Gray</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Mason</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Evans</surname><given-names>JR</given-names></string-name>, et al. <article-title>The CamPaIGN study of Parkinson's disease: 10&#8208;year outlook in an incident population&#8208;based cohort</article-title>. <source>J Neurol Neurosurg Psychiatry</source><year>2013</year>;<volume>84</volume>:<fpage>1258</fpage>&#8211;<lpage>1264</lpage>.<pub-id pub-id-type="pmid">23781007</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp-2013-305277</pub-id></mixed-citation></ref><ref id="mds30293-bib-0111"><label>111</label><mixed-citation publication-type="journal" id="mds30293-cit-0111"><string-name name-style="western"><surname>Branco</surname><given-names>LD</given-names></string-name>, <string-name name-style="western"><surname>Cotrena</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Pereira</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Kochhann</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Fonseca</surname><given-names>RP</given-names></string-name>. <article-title>Verbal and visuospatial executive functions in healthy elderly: the impact of education and frequency of reading and writing</article-title>. <source>Dement Neuropsychol</source><year>2014</year>;<volume>8</volume>:<fpage>155</fpage>&#8211;<lpage>161</lpage>.<pub-id pub-id-type="pmid">29213897</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1590/S1980-57642014DN82000011</pub-id><pub-id pub-id-type="pmcid">PMC5619123</pub-id></mixed-citation></ref><ref id="mds30293-bib-0112"><label>112</label><mixed-citation publication-type="journal" id="mds30293-cit-0112"><string-name name-style="western"><surname>Amer</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Mossa</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Abdul&#8208;Rahman</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Mabrook</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Raafat</surname><given-names>VA</given-names></string-name>. <article-title>Relationship between socioeconomic factors and cognitive function in elderly caregivers</article-title>. <source>J Am Geriatr Soc</source><year>2015</year>;<volume>63</volume>:<fpage>818</fpage>&#8211;<lpage>820</lpage>.<pub-id pub-id-type="pmid">25900497</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jgs.13373</pub-id></mixed-citation></ref><ref id="mds30293-bib-0113"><label>113</label><mixed-citation publication-type="journal" id="mds30293-cit-0113"><string-name name-style="western"><surname>Dodich</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Funghi</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Meli</surname><given-names>C</given-names></string-name>, et al. <article-title>Deficits in emotion recognition and theory of mind in Parkinson's disease patients with and without cognitive impairments</article-title>. <source>Front Psychol</source><year>2022</year>;<volume>13</volume>:<elocation-id>866809</elocation-id>.<pub-id pub-id-type="pmid">35645902</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpsyg.2022.866809</pub-id><pub-id pub-id-type="pmcid">PMC9138611</pub-id></mixed-citation></ref><ref id="mds30293-bib-0114"><label>114</label><mixed-citation publication-type="journal" id="mds30293-cit-0114"><string-name name-style="western"><surname>Franzen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>van den Berg</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Goudsmit</surname><given-names>M</given-names></string-name>, et al. <article-title>A systematic review of neuropsychological tests for the assessment of dementia in non&#8208;Western, low&#8208;educated or illiterate populations</article-title>. <source>J Int Neuropsychol Soc</source><year>2020</year>;<volume>26</volume>:<fpage>331</fpage>&#8211;<lpage>351</lpage>.<pub-id pub-id-type="pmid">31511111</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1355617719000894</pub-id></mixed-citation></ref><ref id="mds30293-bib-0115"><label>115</label><mixed-citation publication-type="journal" id="mds30293-cit-0115"><string-name name-style="western"><surname>Kudlicka</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Clare</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Hindle</surname><given-names>JV</given-names></string-name>. <article-title>Quality of life, health status and caregiver burden in Parkinson's disease: relationship to executive functioning</article-title>. <source>Int J Geriatr Psychiatry</source><year>2014</year>;<volume>29</volume>:<fpage>68</fpage>&#8211;<lpage>76</lpage>.<pub-id pub-id-type="pmid">23625583</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/gps.3970</pub-id></mixed-citation></ref><ref id="mds30293-bib-0116"><label>116</label><mixed-citation publication-type="journal" id="mds30293-cit-0116"><string-name name-style="western"><surname>Brandt</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Aretouli</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Neijstrom</surname><given-names>E</given-names></string-name>, et al. <article-title>Selectivity of executive function deficits in mild cognitive impairment</article-title>. <source>Neuropsychology</source><year>2009</year>;<volume>23</volume>:<fpage>607</fpage>&#8211;<lpage>618</lpage>.<pub-id pub-id-type="pmid">19702414</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1037/a0015851</pub-id><pub-id pub-id-type="pmcid">PMC2769993</pub-id></mixed-citation></ref><ref id="mds30293-bib-0117"><label>117</label><mixed-citation publication-type="journal" id="mds30293-cit-0117"><string-name name-style="western"><surname>Mahieux</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>F&#233;nelon</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Flahault</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Manifacier</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Michelet</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Boller</surname><given-names>F</given-names></string-name>. <article-title>Neuropsychological prediction of dementia in Parkinson's disease</article-title>. <source>J Neurol Neurosurg Psychiatry</source><year>1998</year>;<volume>64</volume>:<fpage>178</fpage>&#8211;<lpage>183</lpage>.<pub-id pub-id-type="pmid">9489527</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp.64.2.178</pub-id><pub-id pub-id-type="pmcid">PMC2169963</pub-id></mixed-citation></ref><ref id="mds30293-bib-0118"><label>118</label><mixed-citation publication-type="journal" id="mds30293-cit-0118"><string-name name-style="western"><surname>Williams&#8208;Gray</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Foltynie</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Brayne</surname><given-names>CEG</given-names></string-name>, <string-name name-style="western"><surname>Robbins</surname><given-names>TW</given-names></string-name>, <string-name name-style="western"><surname>Barker</surname><given-names>RA</given-names></string-name>. <article-title>Evolution of cognitive dysfunction in an incident Parkinson's disease cohort</article-title>. <source>Brain</source><year>2007</year>;<volume>130</volume>:<fpage>1787</fpage>&#8211;<lpage>1798</lpage>.<pub-id pub-id-type="pmid">17535834</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awm111</pub-id></mixed-citation></ref><ref id="mds30293-bib-0119"><label>119</label><mixed-citation publication-type="journal" id="mds30293-cit-0119"><string-name name-style="western"><surname>Woods</surname><given-names>SP</given-names></string-name>, <string-name name-style="western"><surname>Tr&#246;ster</surname><given-names>AI</given-names></string-name>. <article-title>Prodromal frontal/executive dysfunction predicts incident dementia in Parkinson's disease</article-title>. <source>J Int Neuropsychol Soc</source><year>2003</year>;<volume>9</volume>:<fpage>17</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="pmid">12570354</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/s1355617703910022</pub-id></mixed-citation></ref><ref id="mds30293-bib-0120"><label>120</label><mixed-citation publication-type="journal" id="mds30293-cit-0120"><string-name name-style="western"><surname>Mahajan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Deal</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Carlson</surname><given-names>M</given-names></string-name>. <article-title>Interventions in Parkinson's disease: role of executive function</article-title>. <source>Front Biosci (Landmark Ed)</source><year>2017</year>;<volume>22</volume>:<fpage>416</fpage>&#8211;<lpage>427</lpage>.<pub-id pub-id-type="pmid">27814622</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2741/4492</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Toxicol</journal-id><journal-id journal-id-type="iso-abbrev">J Toxicol</journal-id><journal-id journal-id-type="pmc-domain-id">1123</journal-id><journal-id journal-id-type="pmc-domain">jtoxicol</journal-id><journal-id journal-id-type="publisher-id">jt</journal-id><journal-title-group><journal-title>Journal of Toxicology</journal-title></journal-title-group><issn pub-type="ppub">1687-8191</issn><issn pub-type="epub">1687-8205</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12483740</article-id><article-id pub-id-type="pmcid-ver">PMC12483740.1</article-id><article-id pub-id-type="pmcaid">12483740</article-id><article-id pub-id-type="pmcaiid">12483740</article-id><article-id pub-id-type="pmid">41036445</article-id><article-id pub-id-type="doi">10.1155/jt/1695369</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Investigating the Impact of Zinc Oxide Nanoparticles and Folic Acid on Neuronal Markers in a Rat Model of Nanotoxicity</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7209-6249</contrib-id><name name-style="western"><surname>Nusair</surname><given-names initials="SD">Shreen Deeb</given-names></name><email>sdnusair@just.edu.jo</email><xref rid="I1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Almbaidin</surname><given-names initials="RG">Rand Ghaleb</given-names></name><xref rid="I2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Al-Sawalha</surname><given-names initials="NA">Nour Ahmad</given-names></name><xref rid="I1" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="I1">
<sup>1</sup>Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, P.O. Box 3030, Irbid 22110, Jordan</aff><aff id="I2">
<sup>2</sup>Department of Forensic Medicine, Toxicology and Forensic Sciences, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan</aff><author-notes><fn fn-type="other"><p>Academic Editor: Lissinda H. Du Plessis</p></fn></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>23</day><month>9</month><year>2025</year></pub-date><volume>2025</volume><issue-id pub-id-type="pmc-issue-id">482157</issue-id><elocation-id>1695369</elocation-id><history><date date-type="received"><day>13</day><month>2</month><year>2025</year></date><date date-type="rev-recd"><day>23</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>3</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>23</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-02 09:25:35.093"><day>02</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 Shreen Deeb Nusair et al. Journal of Toxicology published by John Wiley &amp; Sons Ltd.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="JT2025-1695369.pdf"/><abstract><p>Exposure to zinc oxide nanoparticles (ZnONPs) is more likely due to their wide utilization in the food and pharmaceutical sectors. Therefore, serum neuromarkers and hippocampal tissue were examined for the potential prophylactic impact of folic acid in four groups of rats, each consisting of 10 animals. The first group had 150&#8201;mg/kg ZnONPs orally every day for 2&#8201;weeks. The second group received 10&#8201;mg/kg of folic acid intraperitoneal (ip) for 1&#8201;week, followed by ZnONPs daily for 2&#8201;weeks. The third group received folic acid only, while the control group was given distilled water. At the end of the experiments, hippocampi were examined, and serum concentrations were measured for glial fibrillary acidic protein (GFAP), myelin basic protein (MBP), monoamine oxidase A (MAOA), and neurofilament light polypeptide (NEFL). ZnONPs-exposed animals exhibited significantly lower levels of GFAP and MBP (<italic toggle="yes">p</italic> &lt; 0.05 and <italic toggle="yes">p</italic> &lt; 0.001, respectively) compared to all groups, while the same overdosed animals showed significantly higher levels of MAOA compared to the group that received folic acid prophylaxis (<italic toggle="yes">p</italic> &lt; 0.001). NEFL levels did not significantly differ among all groups. Histopathological analysis revealed neurodegeneration in the ZnONPs-exposed group, characterized by neuronal shrinkage, hyperchromatic nuclei, vacuolated cytoplasm, and cell loss. Folic acid partially mitigated these effects, preserving Nissl granules and reducing pyknotic changes, though some ghost cells persisted. In summary, the positive impact of folic acid on reducing ZnONPs toxicity is promising to be further investigated as a preventive measure against nanoparticle-induced neurotoxicity.</p></abstract><kwd-group kwd-group-type="Inspec"><title>Keywords</title><kwd>glial fibrillary acid protein</kwd><kwd>monoamine oxidase A</kwd><kwd>myelin basic protein</kwd><kwd>neurofilament light chain</kwd><kwd>neuronal biomarkers</kwd></kwd-group><funding-group><award-group><funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://dx.doi.org/10.13039/501100019004">Deanship of Research, Jordan University of Science and Technology</funding-source><award-id>20200132</award-id></award-group><funding-statement>The Deanship of Research at JUST supported this research project financially (grant number 20200132).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Zinc oxide nanoparticles (ZnONPs) have a molecular weight of 81.38&#8201;g/mol and are known for their white color and absence of odor [<xref rid="B1" ref-type="bibr">1</xref>]. Through altering the size (typically within the range of 10 and 100&#8201;nm), shape, or coating of the particles, the characteristics of ZnONPs can be modified. ZnONPs exhibit diverse functions in various fields such as optics, catalysis, electronics, and photochemistry. Additionally, they have demonstrated effectiveness in food preservation, drug delivery, as well as in the elimination of bacteria and cancer cells [<xref rid="B1" ref-type="bibr">1</xref>].</p><p>Annually, the worldwide production of ZnONPs is approximately ranging from 0.1 to 1.2 million tons [<xref rid="B2" ref-type="bibr">2</xref>]. As the use of ZnONPs expands, the potential for human exposure through the primary routes (i.e., inhalation, skin contact, and ingestion) also increases. ZnONPs have the capability to dissolve in external mediums, resulting in the formation of Zn<sup>2+</sup> ions. These ions can enter cells by passive diffusion across the plasma membrane, which is a critical process in cellular toxicity [<xref rid="B3" ref-type="bibr">3</xref>]. In addition to being taken through passive diffusion or membrane channels, ZnONPs can be internalized through receptor-mediated endocytosis, where they are engulfed by the cell [<xref rid="B2" ref-type="bibr">2</xref>].</p><p>The existing research on the potential toxic effects of ZnONPs has highlighted their cytotoxic effects, including alterations in cell viability, disruptions in cytoskeletal structure, and increased production of reactive oxygen species (ROS), using in vitro cell culture models. However, there are a scarcity of data concerning their toxicity on the genetic material, the nervous system, embryonic development, and other related areas [<xref rid="B2" ref-type="bibr">2</xref>].</p><p>While many studies have examined the neurotoxic effects of ZnONPs at the molecular and cellular levels, currently, there is no research on the protective role of folic acid in mitigating the neurotoxicity of these nanoparticles. A previous study has demonstrated that supplementation with quercetin can alleviate cerebellar neurotoxicity induced by ZnONPs [<xref rid="B4" ref-type="bibr">4</xref>]. Another research study recorded impairments in ability to move and an increase in anxiety levels in adult mice that were exposed orally to ZnONPs. In addition, the exposure to ZnONPs had notable impacts on the transcriptional signaling pathways that are associated with the production of melatonin and various metabolic processes [<xref rid="B5" ref-type="bibr">5</xref>].</p><p>Folic acid, or called vitamin B9, is an essential B-vitamin that is a critical substance for the development and functioning of the nervous system. It is essential for the synthesis of DNA and RNA, which maintain integrity of cells, including nerve cells [<xref rid="B6" ref-type="bibr">6</xref>]. Folic acid participates in the regulation of homocysteine levels, preventing the accumulation of this amino acid which in excessive amounts can be detrimental to nerve cells. Higher levels of homocysteine have been associated with developing neurodegenerative disorders like Alzheimer's disease [<xref rid="B6" ref-type="bibr">6</xref>].</p><p>Research reported that folic acid can mitigate the neurotoxic effects caused by lead exposure in young rat offspring [<xref rid="B7" ref-type="bibr">7</xref>]. Scientists have not yet fully comprehended the specific mechanisms in which folic acid protects against neurotoxicity. Nevertheless, it is hypothesized that its involvement in the synthesis of DNA and RNA, as well as its capacity to regulate levels of homocysteine, may play a part in its protective properties.</p><p>The present study examined the potential neurotoxic effect of ZnONPs on adult rats and assessed folic acid protective effect. This was achieved by analyzing four neuronal biomarkers in serum: glial fibrillary acidic protein (GFAP), monoamine oxidase A (MAOA), myelin basic protein (MBP), and neurofilament light polypeptide (NEFL). In addition, hippocampi from rats were examined for histopathological changes. The selected biomarkers as well as neuronal tissue serve as key indicators of the effects of ZnONPs on the nervous system and the potential protective properties of folic acid.</p></sec><sec id="sec2"><title>2. Materials and Methods</title><sec id="sec2.1"><title>2.1. Ethical Use of Animals</title><p>The animal experiments followed ethical guidelines outlined in the National Guide for the Animal Care and Use of Laboratory Animals and were approved by the Animal Care and Use Committee (ACUC) at Jordan University of Science and Technology (JUST) with the approval number 18/2/3/16. The national guidelines are in accordance with Guidance on the operation of the Animals (Scientific Procedures) Act 1986 and associated guidelines. All necessary precautions were taken to ensure laboratory health and safety during the experimental procedures described in this study.</p></sec><sec id="sec2.2"><title>2.2. Animal Housing and Acclimatization Conditions</title><p>Forty adult male Sprague-Dawley rats, 12&#8201;weeks and weighing between 248 and 295&#8201;g, were divided into four groups of 10 and housed in the Animal Care Unit. An assigned veterinarian monitored the health of the rats throughout the study. The rats were given 1&#8201;week to adapt after being transferred to stainless-steel wire cages and a bedding of hardwood chips. They had free access to water and standard chow. The temperature of the experimental room was maintained at approximately 25&#8201;&#177;&#8201;2&#176;C and humidity of 26% with a twelve-hour light: dark cycle.</p></sec><sec id="sec2.3"><title>2.3. ZnONPs and Folic Acid Treatment Protocols</title><p>Four groups of rats were treated as the following: The first group received distilled water for 1&#8201;week, followed by a daily oral administration of 150&#8201;mg/kg body weight of ZnONPs for 2&#8201;weeks. The second group received an intraperitoneal (ip) injection of 10&#8201;mg/kg folic acid for 1&#8201;week prior to the ZnONPs treatment, which continued for 2&#8201;weeks. The third group received folic acid for 1&#8201;week and then distilled water for 2&#8201;weeks. The control group received only distilled water for the 3-week duration of the study. All doses were freshly prepared in distilled water upon administration to the rats. The doses were adjusted from previous studies on ZnONPs [<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>] and folic acid [<xref rid="B7" ref-type="bibr">7</xref>]. The animals were monitored daily, with a specific focus on observing any clinical or behavioral changes within 1&#8201;hour after each dose. No changes were observed or detected.</p></sec><sec id="sec2.4"><title>2.4. Processing of Samples</title><p>About 2&#8201;mL of blood samples were taken retro-orbitally by the end of the experiment [<xref rid="B10" ref-type="bibr">10</xref>]. The samples were allowed to coagulate for 30&#8201;min at room temperature. Then, samples were centrifuged at 3000 &#215; g for 10&#8201;min in refrigerated centrifuge at 4&#176;C and stored in aliquots for later analysis at &#8722;20&#176;C [<xref rid="B11" ref-type="bibr">11</xref>].</p></sec><sec id="sec2.5"><title>2.5. Measuring GFAP, MAOA, MBP, and NEFL Using ELISA</title><p>The enzyme-linked immunosorbent assay (ELISA) was conducted to measure the neuro biomarkers GFAP, MAOA, MBP, and NEFL. For this purpose, rat ELISA kit was purchased from MyBioSource, USA (GFAP MBS2505953; MAOA MBS2703950; MBP MBS450557; and NEFL MBS763661). Optimum serum dilution was determined following a pilot run that was conducted for the three kits using 1:1, 1:2, 1:4, and 1:9 sample dilutions. Based on this, the dilution of 1:9 was selected for all assays except NEFL, which required 1:2 dilution. Based on the instructions provided by the manufacturer [<xref rid="B12" ref-type="bibr">12</xref>], the dilution buffer and the wash solution were prepared 1:20 in distilled water. Standard concentrations for GFAP were 0, 0.5, 1.0, 2.0, 4.0, and 8.0&#8201;pg/mL; standard concentrations for MOAO were 0, 2.5, 5.0, 10.0, 20.0, and 40.0&#8201;U/mL; standard concentrations for MBP were 0, 0.156, 0.312, 0.625, 1.25, 2.5, 5.0, and 10.0&#8201;ng/mL; and standard concentrations for NEFL were 0, 15.625, 31.25, 62.5, 125, 250, 500, and 1000&#8201;pg/mL.</p><p>A total of 50&#8201;&#956;L per each serum sample was placed in a well of a 96-microwell plate, followed by the addition of 40&#8201;&#956;L of diluent per well. Then, 100&#8201;&#956;L of each kit specific conjugated antibodies was added to each well and incubated for 60&#8201;min at 37&#176;C (GFAP and MAOA), and 90&#8201;min for MBP and NEFL. After incubation, the wells were washed three times with washing solution and tapped gently against a paper towel. Each kit substrate solution was then added to each well and incubated in a dark place at 37&#176;C for 15&#8201;min for GFAP and MAOA, while MBP required 30&#8201;min, and NEFL required 20&#8201;min. After incubation, stop solution was added to each well, changing the color from blue to yellow. Samples were processed in triplicates and measured at 450&#8201;nm wavelength using the microplate reader Multiskan Go spectrophotometer (model 1510, Thermo Fisher, UK).</p></sec><sec id="sec2.6"><title>2.6. Histopathological Examination and Semiquantitative Scoring</title><p>The hippocampi from two rats per group were preserved in 10% formalin. The samples were then sectioned into 4&#8201;&#956;m slices using an HM 325 rotary microtome (Thermo Scientific, USA). Section processing followed a previously established protocol [<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B14" ref-type="bibr">14</xref>]. Finally, the processed sections were mounted on glass slides and stained with hematoxylin and eosin (H&amp;E). The slides were air-dried and subsequently examined using a B-290TB digital light microscope (Optika, Italy).</p><p>Semiquantitative scoring of tissue was adopted with modification from a previously published protocol [<xref rid="B15" ref-type="bibr">15</xref>]. Tissue assessment was performed by evaluating 5 nonadjacent H&amp;E-stained sections per animal at 400&#215; magnification and scoring 3 random fields per section, avoiding edges/artifacts. Two independent observers examined the slides. Discrepancies of &gt; 1 point difference were resolved by reexamination. Cell counting was determined using the following equation: % affected cells&#8201;=&#8201;(number of abnormal cells)/(total granule cells in field)&#8201;&#215;&#8201;100. Combined Pathology Index was calculated per animal using the following equation: total score&#8201;=&#8201;(ghost cells&#8201;+&#8201;pyknosis&#8201;+&#8201;karyolysis)/3. Please refer to <xref rid="tab1" ref-type="table">Table 1</xref> for scoring scale and criteria for dentate gyrus granule cells. It is recommended for future research to perform immunohistochemistry (e.g., TUNEL for apoptosis and NeuN for neuron loss).</p></sec><sec id="sec2.7"><title>2.7. Statistical Analysis of Data</title><p>The data were calculated as mean&#8201;&#177;&#8201;standard deviation (M&#8201;&#177;&#8201;SD) [<xref rid="B16" ref-type="bibr">16</xref>]. All data was analyzed using ANOVA in GraphPad Prism Version 8.0.1 (GraphPad Software, USA, 2018) [<xref rid="B17" ref-type="bibr">17</xref>]. Tukey's contrast analysis was used to determine significant differences between and within groups [<xref rid="B18" ref-type="bibr">18</xref>]. The Shapiro&#8211;Wilk test was conducted to check the normality of the data [<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B19" ref-type="bibr">19</xref>]. The value <italic toggle="yes">p</italic> &lt; 0.05 was considered significant with a confidence interval (CI) of 95%.</p></sec></sec><sec id="sec3"><title>3. Results</title><sec id="sec3.1"><title>3.1. Measurements of GFAP, MAOA, MBP, and NEFL</title><p>The average levels of serum GFAP were measured in the four different groups of rats: ZnONPs overdosed rats, rats with folic acid prior to ZnONPs overdose, rats treated with folic acid only, and control rats given distilled water. The concentration of serum GFAP was found 1.53&#8201;&#177;&#8201;0.14&#8201;pg/mL in ZnONPs overdosed rats, 1.81&#8201;&#177;&#8201;0.30&#8201;pg/mL in rats with folic acid prophylaxis, 1.61&#8201;&#177;&#8201;0.30&#8201;pg/mL in rats treated with folic acid only, and 1.58&#8201;&#177;&#8201;0.37&#8201;pg/mL in control rats. The animals without prophylaxis showed significantly lower levels of serum GFAP compared to the animals with prophylaxis, as well as the animals treated with folic acid only and the control animals (<italic toggle="yes">p</italic> &lt; 0.05). The levels of serum GFAP are depicted in <xref rid="fig1" ref-type="fig">Figure 1</xref> for the challenged rats.</p><p>The mean concentration of serum MAOA was 8.16&#8201;&#177;&#8201;0.54&#8201;U/mL in the rats exposed to an overdose of ZnONPs, while rats that received folic acid prophylaxis had a lower mean concentration of 5.25&#8201;&#177;&#8201;1.99&#8201;U/mL. The group that received folic acid treatment alone had a mean concentration of 4.32&#8201;&#177;&#8201;1.56&#8201;U/mL, while the control had a mean concentration of 4.46&#8201;&#177;&#8201;1.26&#8201;U/mL. The rats without folic acid prophylaxis had significantly higher levels of serum MAOA compared to all other groups, including the control group (<italic toggle="yes">p</italic> &lt; 0.001). <xref rid="fig2" ref-type="fig"> Figure 2</xref> illustrates the serum levels of MAOA in the four groups.</p><p>The mean concentrations of serum MBP were found 1.62&#8201;&#177;&#8201;0.68&#8201;ng/mL in rats exposed to ZnONPs overdose, 5.02&#8201;&#177;&#8201;3.49&#8201;ng/mL in rats with prophylaxis, 5.72&#8201;&#177;&#8201;3.53&#8201;ng/mL in rats treated with folic acid only, and 3.72&#8201;&#177;&#8201;3.02&#8201;ng/mL in the control group. The rats exposed to ZnONPs without folic acid prophylaxis had significantly lower levels of serum MBP compared to rats with prophylaxis, rats treated with folic acid only, and the control group (<italic toggle="yes">p</italic> &lt; 0.001). Please refer to <xref rid="fig3" ref-type="fig">Figure 3</xref> for a visual representation of the serum MBP levels in rats.</p><p>The average concentrations of serum NEFL were measured at 76.50&#8201;&#177;&#8201;22.34&#8201;pg/mL in ZnONPs intoxicated rats, 84.94&#8201;&#177;&#8201;27.13&#8201;pg/mL in rats with prophylaxis, 78.20&#8201;&#177;&#8201;20.62&#8201;pg/mL in rats treated with folic acid only, and 80.60&#8201;&#177;&#8201;32.54&#8201;pg/mL in the control group. Statistical analysis showed that there were no significant differences in NEFL levels between all groups. For a visual presentation of the NEFL levels in the serum of rats, please refer to <xref rid="fig4" ref-type="fig">Figure 4</xref>.</p></sec><sec id="sec3.2"><title>3.2. Histopathological Findings</title><p>The dentate gyrus was examined across the four experimental groups, revealing distinct histopathological alterations, which are illustrated in <xref rid="fig5" ref-type="fig">Figure 5</xref>. Neurodegenerative changes were prominent in ZnONPs Group (A), including shrunken neurons with hyperchromatic condensed nuclei and vacuolated cytoplasm (suggesting cellular damage). Granule cells exhibited vesicular nuclei with marginated chromatin and prominent nucleoli (possible early degenerative changes). In addition, ghost cells (necrotic neurons with faint cellular outlines) and karyolysis (nuclear dissolution) were observed. Granule cells showed increased acidophilia, consistent with nucleic acid loss and cytoplasmic protein accumulation from cell injury, suggesting neurotoxicity. Moderate neuroprotection was observed in Folic&#8201;+&#8201;ZnONPs Group (B) compared to the ZnONPs group. Some neurons showed pyknosis (irreversible nuclear condensation) with basophilic cytoplasm, but Nissl's granules (indicating intact protein synthesis) were preserved. Vesicular nuclei were present, but a few ghost cells remained, suggesting partial mitigation of damage by folic acid. Normal histoarchitecture with healthy, uniformly arranged granule cells is seen in both folic group (C) and control group (D). Neurons of both groups displayed round, vesicular nuclei with prominent nucleoli and well-defined Nissl's granules. The neuropil (supporting tissue) appeared intact, with no signs of degeneration. Generally, the dentate gyrus layers (molecular, granule cell, and polymorphic/hilus) were well-organized, confirming structural integrity.</p><p>
<xref rid="fig6" ref-type="fig">Figure 6</xref> illustrates a summary of the various experimental procedures conducted and the main findings of this study.</p><p>Tissue from folic&#8201;+&#8201;ZnONPs group versus tissue from ZnONPs group revealed significant reduction in all pathology parameters, supporting folic acid's protective role. Control samples provided baseline for distinguishing ZnONP-induced effects from natural variability. Folic acid supplementation alone did not significantly alter granule cell morphology compared to controls, confirming that observed neuroprotection in the folic&#8201;+&#8201;ZnONPs group was not due to artifactual changes. The total score of damage in <xref rid="tab2" ref-type="table">Table 2</xref> indicated that ZnONPs induced minimal damage to the dentate gyrus tissue of the challenged animals.</p></sec></sec><sec id="sec4"><title>4. Discussion</title><p>To address the increasing use and advantages of ZnONPs, it is important to conduct a thorough investigation to elucidate the biological consequences arising from exposure to these nanoparticles. One of these possible consequences is neurotoxicity, which is the negative impact on the nervous system due to exposure to toxic substances [<xref rid="B20" ref-type="bibr">20</xref>]. This can manifest in a variety of ways, including behavioral impairments and alteration in the levels of neuronal biomarkers. As a result, this study has investigated neurotoxicity due to oral exposure to ZnONPs in rats and potential protective effect of folic acid. The toxic effects were evaluated by measuring serum levels of four neuronal biomarkers GFAP, MAOA, MBP, and NEFL.</p><p>GFAP is considered as an indicator of astroglial activation and astrocytosis [<xref rid="B21" ref-type="bibr">21</xref>]. Astrocytes, which are a type of glial cell, have several important functions in the brain. These include modulating synapses, supporting neurons, maintaining homeostasis, and repairing tissue [<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B22" ref-type="bibr">22</xref>]. Intoxicated animals expressed significantly lower levels of GFAP in serum compared to animals that had folic acid as a prophylaxis and to control with or without folic acid. According to research, the levels of GFAP may fluctuate during neurotoxicity that depends on factors such as the type, severity, and duration of the toxic exposure [<xref rid="B21" ref-type="bibr">21</xref>]. For instance, GFAP levels increased in response to acute or chronic exposure to A&#946; plaques, which are associated with Alzheimer's disease [<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B22" ref-type="bibr">22</xref>]. Another study reported that exposure to ip ZnONPs for 28&#8201;days significantly increased expression of GFAP in brain tissue of male albino rats, while oral curcumin significantly reduced that level [<xref rid="B23" ref-type="bibr">23</xref>]. Differences in the findings could have been due to differences in rat species, doses, routes, and durations of exposure. Conversely, GFAP levels may decrease during stressful conditions such as Parkinson's or Alzheimer's disease when harmful astrocytes secrete a factor that induces neurotoxicity [<xref rid="B21" ref-type="bibr">21</xref>]. Additionally, GFAP levels may normalize or decrease following the cessation of neurotoxic exposure [<xref rid="B24" ref-type="bibr">24</xref>]. It is worth noting that while a decrease in GFAP levels may indicate neurotoxicity in some cases, it is not a definitive or a specific marker. Other factors such as the type of neurotoxin, the stage of the disease, the presence of other biomarkers, and clinical signs should be considered when assessing neurotoxicity.</p><p>MAOA is an enzyme that catalyzes the oxidative deamination of amine neurotransmitters, including dopamine and serotonin [<xref rid="B25" ref-type="bibr">25</xref>]. It is highly expressed in neural cells and is localized to the outer mitochondrial membrane [<xref rid="B25" ref-type="bibr">25</xref>]. Therefore, MAOA is essential for neurotransmitter regulation and for maintaining normal brain function. A previous study that exposed neural PC-12&#8201;cells to 22-nm ZnO and 43-nm ZnO reported a significant upregulation of MAOA expression at concentrations greater than or equal to 10&#8201;&#956;g/mL ZnONPs [<xref rid="B26" ref-type="bibr">26</xref>]. These findings are consistent with the current observation, where the animals treated with nanoparticles without folic acid prophylaxis exhibited significantly lower levels of serum MAOA compared to animals that had prophylaxis and to control. As such, disruption of normal MAOA levels may affect normal brain function and represent neurotoxicity of the selected nanoparticles.</p><p>MBP is a critical component of the myelin sheath, which is a protective layer that surrounds and insulates axons. Damage or deficiency to the myelin sheath can result in axonal loss and severe demyelination diseases [<xref rid="B27" ref-type="bibr">27</xref>]. In this study, a significant decrease in MBP levels was observed in ZnONPs overdosed rats without prophylaxis, compared to other groups, including overdosed rats with prophylaxis and control animals. These findings suggest that folic acid may have a protective effect against ZnONP-induced neurotoxicity, as it was able to normalize MBP levels to those of the control group. This is consistent with a previous research showing that thymoquinone, an active constituent of Nigella sativa, has a protective effect against acrylamide-induced neurotoxicity, where acrylamide lowered MBP levels and thymoquinone normalized the levels in rats [<xref rid="B28" ref-type="bibr">28</xref>]. Similarly, punicalagin, the main polyphenol compound of pomegranate, raised BMP levels in acrylamide intoxicated rats to normal levels [<xref rid="B29" ref-type="bibr">29</xref>].</p><p>Regarding NEFL in the serum, it can serve as an indicator of neuronal cell death in the brain and can be used as a good biomarker of neurotoxicity because neurofilaments are released when the axon of a neuron is damaged [<xref rid="B30" ref-type="bibr">30</xref>]. A study found that rats treated with central nervous system toxicants had increased serum levels of NEFL, indicating neuronal cell death in the brain [<xref rid="B31" ref-type="bibr">31</xref>]. Similarly, another study reported that NEFL levels in the cerebrospinal fluid increased during neurotoxicity in pediatric patients, indicating neuronal injury [<xref rid="B24" ref-type="bibr">24</xref>]. These findings suggest that NEFL levels could increase during neurotoxicity. Instead, the presented outcomes revealed no significant changes in serum NEFL levels in the overdosed rats relative to rats protected with folic acid and relative to controls. The differences in species, toxic agent, doses, and durations of exposure could have contributed to the current insignificant changes in this neuromarker level.</p><p>Histopathological findings revealed that ZnONPs induced neuronal damage in the dentate gyrus part of hippocampus, including shrinkage, vacuolation, and cell death. These findings are consistent with those of a previous study, which reported that ZnONPs induced incomplete neural tube closure through various cell death modes, including neuronal apoptosis and autophagy [<xref rid="B32" ref-type="bibr">32</xref>]. Karyolysis and ghost cells suggest irreversible cell death, which resulted from the ability of ZnONPs to trigger caspase-3 activation, resulting in DNA fragmentation and necrosis [<xref rid="B33" ref-type="bibr">33</xref>]. Overall, the granule cells exhibited greater acidophilic staining than those in all other groups, suggesting a possible loss of nucleic acids and increased cytoplasmic protein content, indicative of cell injury. Interestingly, folic acid administration partially ameliorated toxicity, preserving some neuronal structure with a few ghost cells. Folic acid possesses neuroprotective functions by preventing neural cell apoptosis. It protected neuronal cells from aluminum-maltolate-induced apoptosis by preventing the downregulation of miR-19 downstream PTEN/AKT/p53 pathway [<xref rid="B34" ref-type="bibr">34</xref>]. Findings from rats that had folic acid alone and from control rats exhibited normal hippocampal morphology, confirming baseline tissue health within the current study setting.</p></sec><sec id="sec5"><title>5. Conclusions</title><p>This study examined the neurotoxicity resulting from excessive oral exposure to ZnONPs in rats and evaluated the potential protective effect of folic acid. The research assessed the impact by analyzing the levels of four neuronal biomarkers (GFAP, MAOA, MBP, and NEFL) in rats' serum. The findings indicated that ZnONPs had detrimental effects on all the evaluated biomarkers, except for NEFL. Furthermore, ZnONPs induced neuronal damage in the dentate gyrus area of the hippocampus while folic acid prophylaxis partially ameliorated tissue toxicity, preserving some neuronal structure. Overall, the administration of folic acid as a preventative measure reduced the toxicity of ZnONPs. These findings inspire future research to explore alternative biomarkers of neurotoxicity caused by nanoparticles to enhance our understanding of their mechanism and develop more efficient preventive strategies against their toxicity.</p></sec></body><back><sec sec-type="data-availability"><title>Data Availability Statement</title><p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></sec><sec sec-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec><title>Author Contributions</title><p>All the listed authors reviewed in the manuscript. Dr Shreen Deeb Nusair designed the study, participated in the experiments, analyzed the data, and wrote the manuscript; Dr Rand Ghaleb Almbaidin carried animal experiments, laboratory tests, data collection, interpretation of results, and manuscript drafting; and Prof Nour Ahmad Al-Sawalha participated in the data analysis, results interpretation, and manuscript proofreading with critical reviewing.</p></sec><ref-list><ref id="B1" content-type="incollection"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Jaiswal</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shankar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rhim</surname><given-names>J.-W.</given-names></name></person-group><person-group person-group-type="editor"><name name-style="western"><surname>Gurtler</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ball</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Soni</surname><given-names>S.</given-names></name></person-group><article-title>Chapter 3: Applications of Nanotechnology in Food Microbiology</article-title><source><italic toggle="yes">Methods in Microbiology</italic></source><year>2019</year><volume>46</volume><publisher-name>Academic Press</publisher-name><fpage>43</fpage><lpage>60</lpage></element-citation></ref><ref id="B2" content-type="article"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>S.</given-names></name></person-group><article-title>Zinc Oxide Nanoparticles Impacts: Cytotoxicity, Genotoxicity, Developmental Toxicity, and Neurotoxicity</article-title><source><italic toggle="yes">Toxicology Mechanisms and Methods</italic></source><year>2019</year><volume>29</volume><issue>4</issue><fpage>300</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1080/15376516.2018.1553221</pub-id><pub-id pub-id-type="other">2-s2.0-85060135683</pub-id><pub-id pub-id-type="pmid">30489211</pub-id></element-citation></ref><ref id="B3" content-type="article"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hazeem</surname><given-names>L.</given-names></name></person-group><article-title>Single and Combined Toxicity Effects of Zinc Oxide Nanoparticles: Uptake and Accumulation in Marine Microalgae, Toxicity Mechanisms, and Their Fate in the Marine Environment</article-title><source><italic toggle="yes">Water</italic></source><year>2022</year><volume>14</volume><issue>17</issue><fpage>p. 2669</fpage><pub-id pub-id-type="doi">10.3390/w14172669</pub-id></element-citation></ref><ref id="B4" content-type="article"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdelrahman</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>El-Shal</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Abdelrahman</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Saleh</surname><given-names>E. Z. H.</given-names></name><name name-style="western"><surname>Mahmoud</surname><given-names>A. A.</given-names></name></person-group><article-title>Neuroprotective Effects of Quercetin on the Cerebellum of Zinc Oxide Nanoparticles (ZnoNps)-Exposed Rats</article-title><source><italic toggle="yes">Tissue Barriers</italic></source><year>2023</year><volume>11</volume><issue>3</issue><fpage>p. 2115273</fpage><pub-id pub-id-type="doi">10.1080/21688370.2022.2115273</pub-id><pub-id pub-id-type="pmid">35996208</pub-id><pub-id pub-id-type="pmcid">PMC10364653</pub-id></element-citation></ref><ref id="B5" content-type="article"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Alterations of Gut-Derived Melatonin in Neurobehavioral Impairments Caused by Zinc Oxide Nanoparticles</article-title><source><italic toggle="yes">International Journal of Nanomedicine</italic></source><year>2023</year><volume>18</volume><fpage>1899</fpage><lpage>1914</lpage><pub-id pub-id-type="doi">10.2147/IJN.S386240</pub-id><pub-id pub-id-type="pmid">37057188</pub-id><pub-id pub-id-type="pmcid">PMC10088905</pub-id></element-citation></ref><ref id="B6" content-type="article"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reynolds</surname><given-names>E. H.</given-names></name></person-group><article-title>Benefits and Risks of Folic Acid to the Nervous System</article-title><source><italic toggle="yes">Journal of Neurology, Neurosurgery &amp; Psychiatry</italic></source><year>2002</year><volume>72</volume><issue>5</issue><fpage>567</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1136/jnnp.72.5.567</pub-id><pub-id pub-id-type="other">2-s2.0-0036237909</pub-id><pub-id pub-id-type="pmid">11971038</pub-id><pub-id pub-id-type="pmcid">PMC1737896</pub-id></element-citation></ref><ref id="B7" content-type="article"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quan</surname><given-names>F. S.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X. F.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>W. Z.</given-names></name></person-group><article-title>Protective Effects of Folic Acid Against Central Nervous System Neurotoxicity Induced by Lead Exposure in Rat Pups</article-title><source><italic toggle="yes">Genetics and Molecular Research</italic></source><year>2015</year><volume>14</volume><issue>4</issue><fpage>12466</fpage><lpage>12471</lpage><pub-id pub-id-type="doi">10.4238/2015.october.16.13</pub-id><pub-id pub-id-type="other">2-s2.0-84944719127</pub-id><pub-id pub-id-type="pmid">26505396</pub-id></element-citation></ref><ref id="B8" content-type="article"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramadan</surname><given-names>A. G.</given-names></name><name name-style="western"><surname>Yassein</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Eissa</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Mahmoud</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Hassan</surname><given-names>G. M.</given-names></name></person-group><article-title>Biochemical and Histopathological Alterations Induced by Subchronic Exposure to Zinc Oxide Nanoparticle in Male Rats and Assessment of Its Genotoxicicty</article-title><source><italic toggle="yes">Journal of Umm Al-Qura University for Applied Sciences</italic></source><year>2022</year><volume>8</volume><issue>1-2</issue><fpage>41</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1007/s43994-022-00008-3</pub-id></element-citation></ref><ref id="B9" content-type="article"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>M. K.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M. S.</given-names></name><etal/></person-group><article-title>Prenatal Development Toxicity Study of Zinc Oxide Nanoparticles in Rats</article-title><source><italic toggle="yes">International Journal of Nanomedicine</italic></source><year>2014</year><volume>9</volume><issue>Suppl 2</issue><fpage>159</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.2147/IJN.S57932</pub-id><pub-id pub-id-type="other">2-s2.0-84947417544</pub-id><pub-id pub-id-type="pmid">25565834</pub-id><pub-id pub-id-type="pmcid">PMC4279776</pub-id></element-citation></ref><ref id="B10" content-type="article"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nusair</surname><given-names>S. D.</given-names></name><name name-style="western"><surname>Abed</surname><given-names>S. I.</given-names></name><name name-style="western"><surname>Rashaid</surname><given-names>A. H. B.</given-names></name></person-group><article-title>Chlorpromazine Impacts on the Length and Width of <italic toggle="yes">Sarcophaga haemorrhoidalis</italic> (Diptera: Sarcophagidae) Larvae: Potential Forensic Implications</article-title><source><italic toggle="yes">Journal of Entomological Science</italic></source><year>2017</year><volume>52</volume><issue>4</issue><fpage>370</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.18474/JES17-33.1</pub-id><pub-id pub-id-type="other">2-s2.0-85054967906</pub-id></element-citation></ref><ref id="B11" content-type="article"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nusair</surname><given-names>S. D.</given-names></name><name name-style="western"><surname>Ananbeh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zayed</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>M. I.</given-names></name><name name-style="western"><surname>Qinna</surname><given-names>N. A.</given-names></name></person-group><article-title>Postmortem Sampling Time Effect on Toxicity Biomarkers in Rats Exposed to an Acute Lethal Methomyl Dose</article-title><source><italic toggle="yes">Toxicology Reports</italic></source><year>2022</year><volume>9</volume><fpage>1674</fpage><lpage>1680</lpage><pub-id pub-id-type="doi">10.1016/j.toxrep.2022.08.010</pub-id><pub-id pub-id-type="pmid">36518403</pub-id><pub-id pub-id-type="pmcid">PMC9742944</pub-id></element-citation></ref><ref id="B12" content-type="article"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nusair</surname><given-names>S. D.</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>M. I.</given-names></name></person-group><article-title>Toxicity of <italic toggle="yes">Vipera palaestinae</italic> Venom and Antagonistic Effects of Methanolic Leaf Extract of <italic toggle="yes">Eryngium creticum</italic> Lam</article-title><source><italic toggle="yes">Toxicon</italic></source><year>2019</year><volume>166</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2019.05.006</pub-id><pub-id pub-id-type="other">2-s2.0-85065702999</pub-id><pub-id pub-id-type="pmid">31095960</pub-id></element-citation></ref><ref id="B13" content-type="article"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nusair</surname><given-names>S. D.</given-names></name><name name-style="western"><surname>Abu Zarour</surname><given-names>Y. S.</given-names></name><name name-style="western"><surname>Altarifi</surname><given-names>A. A.</given-names></name></person-group><article-title>Effects of Dibenzo-p-Dioxins/Dibenzofurans on Acetylcholinesterase Activity and Histopathology of the Body Wall of Earthworm <italic toggle="yes">Eisenia andrei</italic>: a Potential Biomarker for Ecotoxicity Monitoring</article-title><source><italic toggle="yes">Water, Air, &amp; Soil Pollution</italic></source><year>2017</year><volume>228</volume><issue>7</issue><fpage>p. 266</fpage><pub-id pub-id-type="doi">10.1007/s11270-017-3448-8</pub-id><pub-id pub-id-type="other">2-s2.0-85021873702</pub-id></element-citation></ref><ref id="B14" content-type="article"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nusair</surname><given-names>S. D.</given-names></name><name name-style="western"><surname>Abu Zarour</surname><given-names>Y. S.</given-names></name></person-group><article-title>Molecular and Cellular Response of Earthworm <italic toggle="yes">Eisenia andrei</italic> (Oligochaeta, Lumbricidae) to PCDD/Fs Exposure</article-title><source><italic toggle="yes">Environmental Science and Pollution Research</italic></source><year>2017</year><volume>24</volume><issue>1</issue><fpage>902</fpage><lpage>910</lpage><pub-id pub-id-type="doi">10.1007/s11356-016-7893-5</pub-id><pub-id pub-id-type="other">2-s2.0-84991810139</pub-id><pub-id pub-id-type="pmid">27761860</pub-id></element-citation></ref><ref id="B15" content-type="article"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meyerholz</surname><given-names>D. K.</given-names></name><name name-style="western"><surname>Beck</surname><given-names>A. P.</given-names></name></person-group><article-title>Fundamental Concepts for Semiquantitative Tissue Scoring in Translational Research</article-title><source><italic toggle="yes">ILAR Journal</italic></source><year>2019</year><volume>59</volume><issue>1</issue><fpage>13</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1093/ilar/ily025</pub-id><pub-id pub-id-type="other">2-s2.0-85070183997</pub-id><pub-id pub-id-type="pmcid">PMC6927897</pub-id><pub-id pub-id-type="pmid">30715381</pub-id></element-citation></ref><ref id="B16" content-type="article"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nusair</surname><given-names>S. D.</given-names></name><name name-style="western"><surname>Almasaleekh</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Abder-Rahman</surname><given-names>H.</given-names></name><name name-style="western"><surname>Alkhatatbeh</surname><given-names>M.</given-names></name></person-group><article-title>Environmental Exposure of Humans to Bromide in the Dead Sea Area: Measurement of Genotoxicy and Apoptosis Biomarkers</article-title><source><italic toggle="yes">Mutation Research, Genetic Toxicology and Environmental Mutagenesis</italic></source><year>2019</year><volume>837</volume><fpage>34</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.mrgentox.2018.09.006</pub-id><pub-id pub-id-type="other">2-s2.0-85054179536</pub-id><pub-id pub-id-type="pmid">30595207</pub-id></element-citation></ref><ref id="B17" content-type="article"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nusair</surname><given-names>S. D.</given-names></name><name name-style="western"><surname>Hammad</surname><given-names>E.</given-names></name><name name-style="western"><surname>Alqudah</surname><given-names>M. A. Y.</given-names></name></person-group><article-title>Quantification of Aflatoxins and Health Risk Assessment Through Intake of Herbal Medicine Formulations</article-title><source><italic toggle="yes">Emerging Contaminants</italic></source><year>2023</year><volume>9</volume><issue>1</issue><fpage>p. 100206</fpage><pub-id pub-id-type="doi">10.1016/j.emcon.2023.100206</pub-id></element-citation></ref><ref id="B18" content-type="article"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nusair</surname><given-names>S. D.</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>M.</given-names></name><name name-style="western"><surname>El-Elimat</surname><given-names>T.</given-names></name><name name-style="western"><surname>Al-Essa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Abu-Qatouseh</surname><given-names>L.</given-names></name><name name-style="western"><surname>Khasawneh</surname><given-names>R.</given-names></name></person-group><article-title>Methanolic Extract of <italic toggle="yes">Eryngium creticum</italic> Lam Leaves, Flowers and Roots: Quantification and Qualification of Phenolic Contents, Antitumor Effect and Antioxidant Capacity</article-title><source><italic toggle="yes">Journal of Research in Pharmacy</italic></source><year>2022</year><volume>4</volume><issue>4</issue><fpage>770</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.29228/jrp.174</pub-id></element-citation></ref><ref id="B19" content-type="article"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nusair</surname><given-names>S. D.</given-names></name><name name-style="western"><surname>Joukhan</surname><given-names>A. N.</given-names></name><name name-style="western"><surname>Rashaid</surname><given-names>A. B.</given-names></name><name name-style="western"><surname>Rababa&#8217;h</surname><given-names>A.</given-names></name></person-group><article-title>Methomyl Induced Effect on Fortilin and S100A1 in Serum and Cardiac Tissue: Potential Biomarkers of Toxicity</article-title><source><italic toggle="yes">Human &amp; Experimental Toxicology</italic></source><year>2019</year><volume>38</volume><issue>3</issue><fpage>371</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1177/0960327118814153</pub-id><pub-id pub-id-type="other">2-s2.0-85060147551</pub-id><pub-id pub-id-type="pmid">30472887</pub-id></element-citation></ref><ref id="B20" content-type="article"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cicognola</surname><given-names>C.</given-names></name><name name-style="western"><surname>Janelidze</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hertze</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Plasma Glial Fibrillary Acidic Protein Detects Alzheimer Pathology and Predicts Future Conversion to Alzheimer Dementia in Patients With Mild Cognitive Impairment</article-title><source><italic toggle="yes">Alzheimer&#8217;s Research &amp; Therapy</italic></source><year>2021</year><volume>13</volume><issue>1</issue><fpage>p. 68</fpage><pub-id pub-id-type="doi">10.1186/s13195-021-00804-9</pub-id><pub-id pub-id-type="pmcid">PMC8005231</pub-id><pub-id pub-id-type="pmid">33773595</pub-id></element-citation></ref><ref id="B21" content-type="article"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Callaghan</surname><given-names>J. P.</given-names></name></person-group><article-title>Assessment of Neurotoxicity: Use of Glial Fibrillary Acidic Protein as a Biomarker</article-title><source><italic toggle="yes">Biomedical and Environmental Sciences</italic></source><year>1991</year><volume>4</volume><issue>1-2</issue><fpage>197</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">1910596</pub-id></element-citation></ref><ref id="B22" content-type="article"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwon</surname><given-names>H. S.</given-names></name><name name-style="western"><surname>Koh</surname><given-names>S.-H.</given-names></name></person-group><article-title>Neuroinflammation in Neurodegenerative Disorders: the Roles of Microglia and Astrocytes</article-title><source><italic toggle="yes">Translational Neurodegeneration</italic></source><year>2020</year><volume>9</volume><issue>1</issue><fpage>p. 42</fpage><pub-id pub-id-type="doi">10.1186/s40035-020-00221-2</pub-id><pub-id pub-id-type="pmcid">PMC7689983</pub-id><pub-id pub-id-type="pmid">33239064</pub-id></element-citation></ref><ref id="B23" content-type="article"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amer</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Karam</surname><given-names>R. A.</given-names></name></person-group><article-title>Morphological and Biochemical Features of Cerebellar Cortex After Exposure to Zinc Oxide Nanoparticles: Possible Protective Role of Curcumin</article-title><source><italic toggle="yes">The Anatomical Record</italic></source><year>2018</year><volume>301</volume><issue>8</issue><fpage>1454</fpage><lpage>1466</lpage><pub-id pub-id-type="doi">10.1002/ar.23807</pub-id><pub-id pub-id-type="other">2-s2.0-85044503109</pub-id><pub-id pub-id-type="pmid">29575794</pub-id></element-citation></ref><ref id="B24" content-type="article"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gust</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rawlings-Rhea</surname><given-names>S. D.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>A. L.</given-names></name><etal/></person-group><article-title>GFAP and Nfl Increase During Neurotoxicity From High Baseline Levels in Pediatric CD19-CAR T-Cell Patients</article-title><source><italic toggle="yes">Blood Advances</italic></source><year>2023</year><volume>7</volume><issue>6</issue><fpage>1001</fpage><lpage>1010</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2022008119</pub-id><pub-id pub-id-type="pmid">36006611</pub-id><pub-id pub-id-type="pmcid">PMC10036503</pub-id></element-citation></ref><ref id="B25" content-type="article"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>C.-P.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>B. J.</given-names></name></person-group><article-title>MAOA-Mediated Reprogramming of Stromal Fibroblasts Promotes Prostate Tumorigenesis and Cancer Stemness</article-title><source><italic toggle="yes">Oncogene</italic></source><year>2020</year><volume>39</volume><issue>16</issue><fpage>3305</fpage><lpage>3321</lpage><pub-id pub-id-type="doi">10.1038/s41388-020-1217-4</pub-id><pub-id pub-id-type="pmid">32066880</pub-id></element-citation></ref><ref id="B26" content-type="article"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suthar</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Vaidya</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ravindran</surname><given-names>S.</given-names></name></person-group><article-title>Size, Surface Properties, and Ion Release of Zinc Oxide Nanoparticles: Effects on Cytotoxicity, Dopaminergic Gene Expression, and Acetylcholinesterase Inhibition in Neuronal PC-12 Cells</article-title><source><italic toggle="yes">Biological Trace Element Research</italic></source><year>2024</year><volume>202</volume><issue>5</issue><fpage>2254</fpage><lpage>2271</lpage><pub-id pub-id-type="doi">10.1007/s12011-023-03832-8</pub-id><pub-id pub-id-type="pmid">37713055</pub-id></element-citation></ref><ref id="B27" content-type="article"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Zebrafish as a Model for Studying the Developmental Neurotoxicity of Propofol</article-title><source><italic toggle="yes">Journal of Applied Toxicology</italic></source><year>2015</year><volume>35</volume><issue>12</issue><fpage>1511</fpage><lpage>1519</lpage><pub-id pub-id-type="doi">10.1002/jat.3183</pub-id><pub-id pub-id-type="other">2-s2.0-84945477099</pub-id><pub-id pub-id-type="pmid">26103940</pub-id></element-citation></ref><ref id="B28" content-type="article"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tabeshpour</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mehri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Abnous</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hosseinzadeh</surname><given-names>H.</given-names></name></person-group><article-title>Retracted Article: Role of Oxidative Stress, Mapkinase and Apoptosis Pathways in the Protective Effects of Thymoquinone Against Acrylamide-Induced Central Nervous System Toxicity in Rat</article-title><source><italic toggle="yes">Neurochemical Research</italic></source><year>2020</year><volume>45</volume><issue>2</issue><fpage>254</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1007/s11064-019-02908-z</pub-id><pub-id pub-id-type="pmid">31728856</pub-id></element-citation></ref><ref id="B29" content-type="article"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foroutanfar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mehri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kamyar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tandisehpanah</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Hosseinzadeh</surname><given-names>H.</given-names></name></person-group><article-title>Protective Effect of Punicalagin, The Main Polyphenol Compound of Pomegranate, Against acrylamide-induced Neurotoxicity and Hepatotoxicity in Rats</article-title><source><italic toggle="yes">Phytotherapy Research</italic></source><year>2020</year><volume>34</volume><issue>12</issue><fpage>3262</fpage><lpage>3272</lpage><pub-id pub-id-type="doi">10.1002/ptr.6774</pub-id><pub-id pub-id-type="pmid">32592417</pub-id></element-citation></ref><ref id="B30" content-type="article"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lian</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Protective Effect of Compatible Herbs in Jin-Gu-Lian Formula Against Alangium Chinense-induced Neurotoxicity via Oxidative Stress, Neurotransmitter Metabolisms, and Pharmacokinetics</article-title><source><italic toggle="yes">Frontiers in Pharmacology</italic></source><year>2023</year><volume>14</volume><fpage>p. 1133982</fpage><pub-id pub-id-type="doi">10.3389/fphar.2023.1133982</pub-id><pub-id pub-id-type="pmcid">PMC9977795</pub-id><pub-id pub-id-type="pmid">36874008</pub-id></element-citation></ref><ref id="B31" content-type="article"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sano</surname><given-names>T.</given-names></name><name name-style="western"><surname>Masuda</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yasuno</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shinozawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kakehi</surname><given-names>M.</given-names></name></person-group><article-title>Blood Neurofilament Light Chain as a Potential Biomarker for Central and Peripheral Nervous Toxicity in Rats</article-title><source><italic toggle="yes">Toxicological Sciences</italic></source><year>2021</year><volume>185</volume><issue>1</issue><fpage>10</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1093/toxsci/kfab122</pub-id><pub-id pub-id-type="pmid">34677616</pub-id><pub-id pub-id-type="pmcid">PMC8714368</pub-id></element-citation></ref><ref id="B32" content-type="article"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Zinc Oxide Nanoparticles Induces Cell Death and Consequently Leading to Incomplete Neural Tube Closure Through Oxidative Stress During Embryogenesis</article-title><source><italic toggle="yes">Cell Biology and Toxicology</italic></source><year>2024</year><volume>40</volume><issue>1</issue><fpage>p. 51</fpage><pub-id pub-id-type="doi">10.1007/s10565-024-09894-1</pub-id><pub-id pub-id-type="pmcid">PMC11222284</pub-id><pub-id pub-id-type="pmid">38958792</pub-id></element-citation></ref><ref id="B33" content-type="article"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilhelmi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>U.</given-names></name><name name-style="western"><surname>Weighardt</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Zinc Oxide Nanoparticles Induce Necrosis and Apoptosis in Macrophages in a p47phox- and Nrf2-Independent Manner</article-title><source><italic toggle="yes">PLoS One</italic></source><year>2013</year><volume>8</volume><issue>6</issue><fpage>p. e65704</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0065704</pub-id><pub-id pub-id-type="other">2-s2.0-84878648124</pub-id><pub-id pub-id-type="pmcid">PMC3670863</pub-id><pub-id pub-id-type="pmid">23755271</pub-id></element-citation></ref><ref id="B34" content-type="article"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Folic Acid Protected Neural Cells Against Aluminum-Maltolate-Induced Apoptosis by Preventing miR-19 Downregulation</article-title><source><italic toggle="yes">Neurochemical Research</italic></source><year>2016</year><volume>41</volume><issue>8</issue><fpage>2110</fpage><lpage>2118</lpage><pub-id pub-id-type="doi">10.1007/s11064-016-1926-9</pub-id><pub-id pub-id-type="other">2-s2.0-84964499347</pub-id><pub-id pub-id-type="pmid">27113042</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="fig1" orientation="portrait"><label>Figure 1</label><caption><p>Mean concentrations (pg/mL) of GFAP in serum of 4 groups of rats. From left to right: a group had 150&#8201;mg/kg ZnONPs; a group had 10&#8201;mg/kg folic acid for 1&#8201;week and then 150&#8201;mg/kg ZnONPs for 2&#8201;weeks; a group had folic acid 1&#8201;week and then distilled water for 2&#8201;weeks; and the control had distilled water for 3&#8201;weeks. Whiskers represent one standard deviation. <sup>&#8727;</sup><italic toggle="yes">p</italic> &lt; 0.05.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="JT2025-1695369.001.jpg"/></fig><fig position="float" id="fig2" orientation="portrait"><label>Figure 2</label><caption><p>Mean concentrations (U/mL) of MAOA in serum of 4 groups of rats. From left to right: a group had 150&#8201;mg/kg ZnONPs; a group had 10&#8201;mg/kg folic acid for 1&#8201;week and then 150&#8201;mg/kg ZnONPs for 2&#8201;weeks; a group had folic acid 1&#8201;week and then distilled water for 2&#8201;weeks; and the control had distilled water for 3&#8201;weeks. Whiskers represent one standard deviation. <sup>&#8727;&#8727;&#8727;</sup><italic toggle="yes">p</italic> &lt; 0.001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="JT2025-1695369.002.jpg"/></fig><fig position="float" id="fig3" orientation="portrait"><label>Figure 3</label><caption><p>Mean concentrations (ng/mL) of MBP in serum of 4 groups of rats. From left to right: a group had 150&#8201;mg/kg ZnONPs; a group had 10&#8201;mg/kg folic acid for 1&#8201;week and then 150&#8201;mg/kg ZnONPs for 2&#8201;weeks; a group had folic acid for 1&#8201;week and then distilled water for 2&#8201;weeks; and the control had distilled water for 3&#8201;weeks. Whiskers represent one standard deviation. <sup>&#8727;&#8727;&#8727;</sup><italic toggle="yes">p</italic> &lt; 0.001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="JT2025-1695369.003.jpg"/></fig><fig position="float" id="fig4" orientation="portrait"><label>Figure 4</label><caption><p>Mean concentrations (pg/mL) of NEFL in serum of 4 groups of rats. From left to right: a group had 150&#8201;mg/kg ZnONPs; a group had 10&#8201;mg/kg folic acid for 1&#8201;week and then 150&#8201;mg/kg ZnONPs for 2&#8201;weeks; a group had folic acid for 1&#8201;week and then distilled water for 2&#8201;weeks; and the control had distilled water for 3&#8201;weeks. Whiskers represent one standard deviation.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="JT2025-1695369.004.jpg"/></fig><fig position="float" id="fig5" orientation="portrait"><label>Figure 5</label><caption><p>The dentate gyrus in all panels are from rat hippocampus of the challenged 4 groups: (a) ZnONPs group; pleopathologic changes of many of granule cells' nuclei as well as vacuolated cytoplasm (asterisk). There are shrunken neurons, with hyperchromatic nuclei (long arrows) and vacuolated cytoplasm (asterisk). Some granule cells have vesicular nuclei with clogged marginated chromatin and prominent nucleoli (circle). Others have ghost changes (rectangle), while some have karyolysis (triangle). Generally, the granule cells are stained acidophilic relative to that from other groups including control. (b) Folic&#8201;+&#8201;ZnONPs group; granule cells show pyknosis (arrow head), well-formed Nissl's granules, and vesicular nuclei. Some cells have ghost changes (rectangle). (c) Folic group and (d) control group; granule cell-layer neurons (short arrow) are evenly arranged and uniform in size. Each neuron has a rounded central vesicular nucleus with prominent nucleolus. The cytoplasm contains prominent basophilic cytoplasmic Nissl's granules and is surrounded by thin neuropil. The dentate gyrus contains 3 layers from left to right, the molecular layer (M), the granule cell layer (G), and the polymorphic layer or called the hilus (P). All identified features (e.g., arrows/circles) are reference established in Bancroft's Theory and Practice of Histological Techniques. Sections were stained by H&amp;E and examined at x400. Scale bars represent 100&#8201;&#956;m at 400 magnification and 500&#8201;&#956;m at 100&#215; magnification.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="JT2025-1695369.005.jpg"/></fig><fig position="float" id="fig6" orientation="portrait"><label>Figure 6</label><caption><p>A schematic diagram illustrating the overall procedure and significant discoveries of this research.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="JT2025-1695369.006.jpg"/></fig><table-wrap position="float" id="tab1" orientation="portrait"><label>Table 1</label><caption><p>Scoring criteria for dentate gyrus granule cells.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Feature</th><th align="center" rowspan="1" colspan="1">Score 0 (normal)</th><th align="center" rowspan="1" colspan="1">Score 1 (minor)</th><th align="center" rowspan="1" colspan="1">Score 2 (mild)</th><th align="center" rowspan="1" colspan="1">Score 3 (moderate)</th><th align="center" rowspan="1" colspan="1">Score 4 (severe)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Ghost cells</td><td align="center" rowspan="1" colspan="1">Absent (&lt; 0.1%)</td><td align="center" rowspan="1" colspan="1">Rare (0.1%&#8211;0.9%)</td><td align="center" rowspan="1" colspan="1">Few (1%&#8211;4.9%)</td><td align="center" rowspan="1" colspan="1">Focal (5%&#8211;20%)</td><td align="center" rowspan="1" colspan="1">Widespread (&gt; 20%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Pyknosis</td><td align="center" rowspan="1" colspan="1">Absent</td><td align="center" rowspan="1" colspan="1">Rare</td><td align="center" rowspan="1" colspan="1">Few nuclei condensed</td><td align="center" rowspan="1" colspan="1">Clusters of pyknotic nuclei</td><td align="center" rowspan="1" colspan="1">Diffuse nuclear shrinkage</td></tr><tr><td align="left" rowspan="1" colspan="1">Karyolysis</td><td align="center" rowspan="1" colspan="1">Absent</td><td align="center" rowspan="1" colspan="1">Rare</td><td align="center" rowspan="1" colspan="1">Focal pale nuclei</td><td align="center" rowspan="1" colspan="1">Partial nuclear dissolution</td><td align="center" rowspan="1" colspan="1">Complete nuclear fading</td></tr></tbody></table></table-wrap><table-wrap position="float" id="tab2" orientation="portrait"><label>Table 2</label><caption><p>Semiquantitative histopathology scores across experimental groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Group</th><th align="center" rowspan="1" colspan="1">Ghost cells</th><th align="center" rowspan="1" colspan="1">Pyknosis</th><th align="center" rowspan="1" colspan="1">Karyolysis</th><th align="center" rowspan="1" colspan="1">Total score</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">ZnONPs</td><td align="center" rowspan="1" colspan="1">0.15&#8201;&#177;&#8201;0.02<sup>&#8727;</sup></td><td align="center" rowspan="1" colspan="1">0.40&#8201;&#177;&#8201;0.04<sup>&#8727;</sup></td><td align="center" rowspan="1" colspan="1">0.44&#8201;&#177;&#8201;0.15<sup>&#8727;</sup></td><td align="center" rowspan="1" colspan="1">0.33&#8201;&#177;&#8201;0.07<sup>&#8727;</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Folic&#8201;+&#8201;ZnONPs</td><td align="center" rowspan="1" colspan="1">0.11&#8201;&#177;&#8201;0.02<sup>&#8727;#</sup></td><td align="center" rowspan="1" colspan="1">0.12&#8201;&#177;&#8201;0.06<sup>#</sup></td><td align="center" rowspan="1" colspan="1">0.09&#8201;&#177;&#8201;0.04<sup>#</sup></td><td align="center" rowspan="1" colspan="1">0.11&#8201;&#177;&#8201;0.04<sup>#</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Folic</td><td align="center" rowspan="1" colspan="1">0.04&#8201;&#177;&#8201;0.02</td><td align="center" rowspan="1" colspan="1">0.13&#8201;&#177;&#8201;0.07</td><td align="center" rowspan="1" colspan="1">0.14&#8201;&#177;&#8201;0.04</td><td align="center" rowspan="1" colspan="1">0.10&#8201;&#177;&#8201;0.04</td></tr><tr><td align="left" rowspan="1" colspan="1">Control</td><td align="center" rowspan="1" colspan="1">0.03&#8201;&#177;&#8201;0.01</td><td align="center" rowspan="1" colspan="1">0.14&#8201;&#177;&#8201;0.02</td><td align="center" rowspan="1" colspan="1">0.12&#8201;&#177;&#8201;0.06</td><td align="center" rowspan="1" colspan="1">0.10&#8201;&#177;&#8201;0.03</td></tr></tbody></table><table-wrap-foot><fn><p>
<italic toggle="yes">Note:</italic> Interpretation: 0&#8211;0.9: normal/minimal damage; 1&#8211;1.9: mild pathology; 2&#8211;2.9: moderate damage; 3: severe degeneration.</p></fn><fn><p>
<sup>&#8727;</sup>vs control (<italic toggle="yes">p</italic> &lt; 0.05).</p></fn><fn><p>
<sup>#</sup>vs ZnONPs (<italic toggle="yes">p</italic> &lt; 0.05).</p></fn></table-wrap-foot></table-wrap></floats-group></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="alz70732" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Dement</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Dement</journal-id><journal-id journal-id-type="pmc-domain-id">4549</journal-id><journal-id journal-id-type="pmc-domain">alzdem</journal-id><journal-id journal-id-type="publisher-id">ALZ</journal-id><journal-title-group><journal-title>Alzheimer's &amp; Dementia</journal-title></journal-title-group><issn pub-type="ppub">1552-5260</issn><issn pub-type="epub">1552-5279</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12484700</article-id><article-id pub-id-type="pmcid-ver">PMC12484700.1</article-id><article-id pub-id-type="pmcaid">12484700</article-id><article-id pub-id-type="pmcaiid">12484700</article-id><article-id pub-id-type="pmid">41030129</article-id><article-id pub-id-type="doi">10.1002/alz.70732</article-id><article-id pub-id-type="publisher-id">ALZ70732</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Calibration of multisite raters for prospective visual reads of amyloid PET scans</article-title><alt-title alt-title-type="left-running-head">SOLEIMANI&#8208;MEIGOONI <sc>et&#160;al.</sc></alt-title></title-group><contrib-group><contrib id="alz70732-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Soleimani&#8208;Meigooni</surname><given-names initials="DN">David N.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4197-3039</contrib-id><xref rid="alz70732-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70732-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>david.soleimani-meigooni@ucsf.edu</email></address></contrib><contrib id="alz70732-cr-0002" contrib-type="author"><name name-style="western"><surname>Pezzoli</surname><given-names initials="S">Stefania</given-names></name><xref rid="alz70732-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70732-cr-0003" contrib-type="author"><name name-style="western"><surname>Blazhenets</surname><given-names initials="G">Ganna</given-names></name><xref rid="alz70732-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70732-cr-0004" contrib-type="author"><name name-style="western"><surname>La Joie</surname><given-names initials="R">Renaud</given-names></name><xref rid="alz70732-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70732-cr-0005" contrib-type="author"><name name-style="western"><surname>Lin</surname><given-names initials="Z">Zoe</given-names></name><xref rid="alz70732-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70732-cr-0006" contrib-type="author"><name name-style="western"><surname>Soppe</surname><given-names initials="CL">Carol L.</given-names></name><xref rid="alz70732-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70732-cr-0007" contrib-type="author"><name name-style="western"><surname>Johnson</surname><given-names initials="DR">Derek R.</given-names></name><xref rid="alz70732-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="alz70732-cr-0008" contrib-type="author"><name name-style="western"><surname>Koran</surname><given-names initials="MEI">Mary Ellen I.</given-names></name><xref rid="alz70732-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="alz70732-cr-0009" contrib-type="author"><name name-style="western"><surname>McConathy</surname><given-names initials="JE">Jonathan E.</given-names></name><xref rid="alz70732-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="alz70732-cr-0010" contrib-type="author"><name name-style="western"><surname>Nasrallah</surname><given-names initials="IM">Ilya M.</given-names></name><xref rid="alz70732-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="alz70732-cr-0011" contrib-type="author"><name name-style="western"><surname>Ponisio</surname><given-names initials="MR">Maria Rosana</given-names></name><xref rid="alz70732-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib id="alz70732-cr-0012" contrib-type="author"><name name-style="western"><surname>Tanner</surname><given-names initials="JA">Jeremy A.</given-names></name><xref rid="alz70732-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="alz70732-cr-0013" contrib-type="author"><name name-style="western"><surname>Villemagne</surname><given-names initials="VL">Victor L.</given-names></name><xref rid="alz70732-aff-0009" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib id="alz70732-cr-0014" contrib-type="author"><name name-style="western"><surname>Windon</surname><given-names initials="CC">Charles C.</given-names></name><xref rid="alz70732-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70732-cr-0015" contrib-type="author"><name name-style="western"><surname>Zeineh</surname><given-names initials="M">Michael</given-names></name><xref rid="alz70732-aff-0010" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib id="alz70732-cr-0016" contrib-type="author"><name name-style="western"><surname>Biber</surname><given-names initials="S">Sarah</given-names></name><xref rid="alz70732-aff-0011" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib id="alz70732-cr-0017" contrib-type="author"><name name-style="western"><surname>Kukull</surname><given-names initials="WA">Walter A.</given-names></name><xref rid="alz70732-aff-0011" ref-type="aff">
<sup>11</sup>
</xref><xref rid="alz70732-aff-0012" ref-type="aff">
<sup>12</sup>
</xref></contrib><contrib id="alz70732-cr-0018" contrib-type="author"><name name-style="western"><surname>O'Connell</surname><given-names initials="H">Heather</given-names></name><xref rid="alz70732-aff-0011" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib id="alz70732-cr-0019" contrib-type="author"><name name-style="western"><surname>Peterson</surname><given-names initials="DJ">Daniel J.</given-names></name><xref rid="alz70732-aff-0011" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib id="alz70732-cr-0020" contrib-type="author"><name name-style="western"><surname>Mormino</surname><given-names initials="EC">Elizabeth C.</given-names></name><xref rid="alz70732-aff-0010" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib id="alz70732-cr-0021" contrib-type="author"><name name-style="western"><surname>Johnson</surname><given-names initials="SC">Sterling C.</given-names></name><xref rid="alz70732-aff-0013" ref-type="aff">
<sup>13</sup>
</xref></contrib><contrib id="alz70732-cr-0022" contrib-type="author"><name name-style="western"><surname>Rabinovici</surname><given-names initials="GD">Gil D.</given-names></name><xref rid="alz70732-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70732-aff-0014" ref-type="aff">
<sup>14</sup>
</xref></contrib><contrib id="alz70732-cr-0023" contrib-type="author"><collab collab-type="authors">for the LEADS Consortium</collab></contrib><contrib id="alz70732-cr-0024" contrib-type="author"><collab collab-type="authors">The PREVENT&#8208;AD Research Group</collab></contrib><contrib id="alz70732-cr-0025" contrib-type="author"><collab collab-type="authors">Alzheimer's Disease Neuroimaging Initiative</collab></contrib></contrib-group><aff id="alz70732-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Memory and Aging Center</named-content>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>University of California, San Francisco</institution>
<city>San Francisco</city>
<named-content content-type="country-part">California</named-content>
<country country="US">USA</country>
</aff><aff id="alz70732-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Molecular Biophysics and Integrated Bioimaging</named-content>
<institution>Lawrence Berkeley National Lab</institution>
<city>Berkeley</city>
<named-content content-type="country-part">California</named-content>
<country country="US">USA</country>
</aff><aff id="alz70732-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Radiology</named-content>
<institution>Mayo Clinic</institution>
<city>Rochester</city>
<named-content content-type="country-part">Minnesota</named-content>
<country country="US">USA</country>
</aff><aff id="alz70732-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Radiology</named-content>
<institution>Mayo Clinic</institution>
<city>Phoenix</city>
<named-content content-type="country-part">Arizona</named-content>
<country country="US">USA</country>
</aff><aff id="alz70732-aff-0005">
<label>
<sup>5</sup>
</label>
<institution>University of Alabama at Birmingham</institution>
<city>Birmingham</city>
<named-content content-type="country-part">Alabama</named-content>
<country country="US">USA</country>
</aff><aff id="alz70732-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Department of Radiology</named-content>
<institution>University of Pennsylvania</institution>
<city>Philadelphia</city>
<named-content content-type="country-part">Pennsylvania</named-content>
<country country="US">USA</country>
</aff><aff id="alz70732-aff-0007">
<label>
<sup>7</sup>
</label>
<named-content content-type="organisation-division">Division of Nuclear Medicine</named-content>
<named-content content-type="organisation-division">Mallinckrodt Institute of Radiology</named-content>
<institution>Washington University in St. Louis School of Medicine</institution>
<city>St. Louis</city>
<named-content content-type="country-part">Missouri</named-content>
<country country="US">USA</country>
</aff><aff id="alz70732-aff-0008">
<label>
<sup>8</sup>
</label>
<named-content content-type="organisation-division">Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases</named-content>
<institution>University of Texas Health Science Center</institution>
<city>San Antonio</city>
<named-content content-type="country-part">Texas</named-content>
<country country="US">USA</country>
</aff><aff id="alz70732-aff-0009">
<label>
<sup>9</sup>
</label>
<named-content content-type="organisation-division">Department of Psychiatry</named-content>
<institution>University of Pittsburgh School of Medicine</institution>
<city>Pittsburgh</city>
<named-content content-type="country-part">Pennsylvania</named-content>
<country country="US">USA</country>
</aff><aff id="alz70732-aff-0010">
<label>
<sup>10</sup>
</label>
<institution>Stanford University School of Medicine</institution>
<city>Stanford</city>
<named-content content-type="country-part">California</named-content>
<country country="US">USA</country>
</aff><aff id="alz70732-aff-0011">
<label>
<sup>11</sup>
</label>
<named-content content-type="organisation-division">National Alzheimer's Coordinating Center</named-content>
<institution>University of Washington</institution>
<city>Seattle</city>
<named-content content-type="country-part">Washington</named-content>
<country country="US">USA</country>
</aff><aff id="alz70732-aff-0012">
<label>
<sup>12</sup>
</label>
<named-content content-type="organisation-division">Department of Epidemiology</named-content>
<institution>University of Washington</institution>
<city>Seattle</city>
<named-content content-type="country-part">Washington</named-content>
<country country="US">USA</country>
</aff><aff id="alz70732-aff-0013">
<label>
<sup>13</sup>
</label>
<named-content content-type="organisation-division">Wisconsin Alzheimer's Disease Research Center</named-content>
<institution>University of Wisconsin&#8211;Madison School of Medicine and Public Health</institution>
<city>Madison</city>
<named-content content-type="country-part">Wisconsin</named-content>
<country country="US">USA</country>
</aff><aff id="alz70732-aff-0014">
<label>
<sup>14</sup>
</label>
<named-content content-type="organisation-division">Department of Radiology and Biomedical Imaging</named-content>
<institution>University of California, San Francisco</institution>
<city>San Francisco</city>
<named-content content-type="country-part">California</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>David N. Soleimani&#8208;Meigooni, University of California, San Francisco (UCSF), Memory and Aging Center, Box 1207, 675 Nelson Rising Lane, Suite 190, San Francisco, CA 94143, USA.<break/> Email: <email>david.soleimani-meigooni@ucsf.edu</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>30</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><volume>21</volume><issue seq="310">10</issue><issue-id pub-id-type="pmc-issue-id">497699</issue-id><issue-id pub-id-type="doi">10.1002/alz.v21.10</issue-id><elocation-id>e70732</elocation-id><history><date date-type="rev-recd"><day>27</day><month>8</month><year>2025</year></date><date date-type="received"><day>06</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>28</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>30</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>02</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-02 12:25:29.010"><day>02</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Alzheimer's &amp; Dementia</italic> published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ALZ-21-e70732.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:ALZ-21-e70732.pdf"/><abstract><title>Abstract</title><sec id="alz70732-sec-0010"><title>INTRODUCTION</title><p>In multicenter Alzheimer's disease studies, amyloid positron emission tomography (PET) visual reads are typically performed centrally by a few experts. Incorporating a broader reader network enhances scalability and generalizability.</p></sec><sec id="alz70732-sec-0020"><title>METHODS</title><p>Ten neuroimaging experts from eight Alzheimer's Disease Research Centers (ADRCs) visually read 180 amyloid PET scans (30 scans and 15 duplicate scans for each of four tracers, imaged across a wide variety of scanners), using preferred reading software without anatomical imaging or quantitation. Scans were classified as elevated or non&#8208;elevated per tracer&#8208;specific criteria. Inter&#8208; and intra&#8208;rater agreement was assessed.</p></sec><sec id="alz70732-sec-0030"><title>RESULTS</title><p>Inter&#8208;rater agreement was substantial (Fleiss&#8217; <italic toggle="yes">&#954;</italic>&#160;=&#160;0.78), with full consensus on 69% of scans. Inter&#8208;rater reliability was substantial to perfect across tracers (Fleiss&#8217; <italic toggle="yes">&#954;</italic>&#160;=&#160;0.70&#8211;0.87). Intra&#8208;rater agreement was substantial to perfect (Cohen's <italic toggle="yes">&#954;&#160;</italic>=&#160;0.79&#8208;1). Scans with intermediate (10&#8211;40 Centiloid) quantitation had lower reader agreement.</p></sec><sec id="alz70732-sec-0040"><title>DISCUSSION</title><p>A multicenter expert network achieved substantial agreement classifying amyloid PET scans. These scans provide a standard for reader training and reliability assurance in future studies.</p></sec><sec id="alz70732-sec-0050"><title>Highlights</title><p>
<list list-type="bullet" id="alz70732-list-0001"><list-item><p>Calibration methods ensure reliable amyloid positron emission tomography (PET) visual reads across multiple raters.</p></list-item><list-item><p>Substantial agreement is possible across readers using their preferred tools.</p></list-item><list-item><p>Agreement is also substantial regardless of the amyloid PET tracer used.</p></list-item><list-item><p>Scans with intermediate (10&#8211;40 Centiloid) quantitation have lower reader agreement.</p></list-item><list-item><p>The calibration set will become a training tool for amyloid PET visual read studies.</p></list-item></list>
</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="alz70732-kwd-0001">Amyloid positron emission tomography</kwd><kwd id="alz70732-kwd-0002">inter&#8208;rater reliability</kwd><kwd id="alz70732-kwd-0003">intra&#8208;rater reliability</kwd><kwd id="alz70732-kwd-0004">visual reader calibration</kwd><kwd id="alz70732-kwd-0005">visual reads</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>National Institute on Aging</institution><institution-id institution-id-type="doi">10.13039/100000049</institution-id></institution-wrap></funding-source><award-id>U19 AG024904</award-id><award-id>R56/U01 AG057195</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>Northern California Institute for Research and Education</institution><institution-id institution-id-type="doi">10.13039/100009804</institution-id></institution-wrap></funding-source></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>National Institute of Biomedical Imaging and Bioengineering, the Canadian Institutes of Health Research</institution></institution-wrap></funding-source></award-group><award-group id="funding-0004"><funding-source><institution-wrap><institution>CLARiTI Visual Reads Core with support from the National Institute on Aging (NIA)</institution></institution-wrap></funding-source><award-id>U01 AG082350</award-id><award-id>U24 AG072122</award-id></award-group><award-group id="funding-0005"><funding-source><institution-wrap><institution>Brain Canada Foundation</institution><institution-id institution-id-type="doi">10.13039/100009408</institution-id></institution-wrap></funding-source></award-group></funding-group><counts><fig-count count="3"/><table-count count="1"/><page-count count="12"/><word-count count="8017"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:01.10.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="alz70732-cite-0001"><string-name name-style="western"><surname>Soleimani&#8208;Meigooni</surname><given-names>DN</given-names></string-name>, <string-name name-style="western"><surname>Pezzoli</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Blazhenets</surname><given-names>G</given-names></string-name>, et&#160;al. <article-title>Calibration of multisite raters for prospective visual reads of amyloid PET scans</article-title>. <source>Alzheimer's Dement</source>. <year>2025</year>;<volume>21</volume>:<elocation-id>e70732</elocation-id>. <pub-id pub-id-type="doi">10.1002/alz.70732</pub-id><pub-id pub-id-type="pmid">41030129</pub-id></mixed-citation>
</p><fn-group><fn id="alz70732-note-0001" fn-type="equal"><p>David N. Soleimani&#8208;Meigooni and Stefania Pezzoli contributed equally to this study and share first authorship.</p></fn><fn id="alz70732-note-0002"><p>LEADS Consortium contact: <email>iuleads@iu.edu</email>
</p></fn><fn id="alz70732-note-0003"><p>Data used in preparation of this article were obtained from The PREVENT&#8208;AD Research group (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.centre-stopad.com/" ext-link-type="uri">https://www.centre&#8208;stopad.com/</ext-link>). As such, the investigators within PREVENT&#8208;AD contributed to the design and implementation of PREVENT&#8208;AD and/or provided data but did not participate in the analysis or writing of this report. A complete listing of PREVENT&#8208;AD investigators can be found at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://preventad.loris.ca/acknowledgements/acknowledgements.php?DR=8.0&amp;authors" ext-link-type="uri">https://preventad.loris.ca/acknowledgements/acknowledgements.php?DR=8.0&amp;authors</ext-link>
</p></fn><fn id="alz70732-note-0004"><p>Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf" ext-link-type="uri">http://adni.loni.usc.edu/wp&#8208;content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf</ext-link>
</p></fn></fn-group></notes></front><body><sec id="alz70732-sec-0060"><label>1</label><title>BACKGROUND</title><p>A key pathological hallmark of Alzheimer's disease (AD) is abnormal accumulation of amyloid beta (A&#946;), which can be measured and mapped in vivo with positron emission tomography (PET) radiotracers that have high sensitivity and specificity for neuritic A&#946; plaques.<xref rid="alz70732-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> Because plaque accumulation happens early in AD, amyloid PET scans can be used as biomarkers for detecting the initial stages of AD in vivo.<xref rid="alz70732-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> Clinically, amyloid PET is increasingly used to confirm the presence of AD pathology in individuals with cognitive symptoms&#8212;a determination that significantly influences patient management and treatment decisions, particularly in light of US Food and Drug Administration (FDA)&#8211;approved amyloid&#8208;targeting immunotherapies that require evidence of A&#946; plaques prior to initiation.<xref rid="alz70732-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="alz70732-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="alz70732-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>
</p><p>Several FDA&#8208;approved amyloid PET tracers, including florbetapir (Amyvid), florbetaben (Neuraceq), and flutemetamol (Vizamyl), along with investigational tracers like Pittsburgh compound B and flutafuranol (previously known as NAV4694 or AZD4694), are currently available for detecting amyloid plaques in AD. Clinical interpretation of amyloid PET scans, particularly for the FDA&#8208;approved radiotracers, relies on binary classification of these scans as elevated or non&#8208;elevated (i.e., positive or negative) using visual reads. Each of these tracers has slightly different guidelines for visual interpretation (i.e., different parameters for color scale, thresholding, visualization, and regional interpretation of uptake), which can introduce some variability. Despite this, the patterns of an elevated and non&#8208;elevated scan are generally consistent. Elevated scans have cortical gray matter binding or significant loss of gray matter&#8208;to&#8208;white matter contrast, while non&#8208;elevated scans only have white matter binding with preserved gray matter&#8208;to&#8208;white matter contrast.<xref rid="alz70732-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>
</p><p>Interestingly, prior validation of visual read methods for these radiotracers involved small groups of raters (<italic toggle="yes">N</italic>&#160;=&#160;3&#8211;5) who assessed a combination of scans from patients with advanced dementia and control subjects, using standardized tools across raters (i.e., consistent software and hardware), and were typically performed at a single site or central review center.<xref rid="alz70732-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="alz70732-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="alz70732-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="alz70732-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="alz70732-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="alz70732-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> Additionally, many single&#8208; and multicenter studies of healthy brain aging and AD acquire amyloid PET scans using one radiotracer, with visual reads conducted centrally by one or a few experts using standardized tools.<xref rid="alz70732-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="alz70732-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> Overall, these studies do not capture the variability encountered in real&#8208;world clinical settings or in larger studies that aim to emulate clinical practice through using distributed reader networks. Thus, there is a critical need to evaluate the reliability and reproducibility of amyloid PET visual assessments in contexts that reflect broader clinical practices&#8212;such as the use of multiple radiotracers and interpretation by larger, heterogeneous groups of raters using their preferred visualization tools.</p><boxed-text position="float" content-type="box" orientation="portrait"><sec id="alz70732-sec-0070"><title>RESEARCH IN CONTEXT</title><p>
<list list-type="order" id="alz70732-list-0002"><list-item><p>
<bold>Systematic review</bold>: We reviewed the literature using PubMed for amyloid positron emission tomography (PET) visual read publications. Most prior studies have relied on small, centralized groups of readers using standardized tools to interpret amyloid PET scans generated with a single radiotracer. Consequently, the reliability of visual reads across a broader network of raters and multiple radiotracers remains largely unknown.</p></list-item><list-item><p>
<bold>Interpretation</bold>: Our findings show that a multicenter network of expert raters, using their preferred visualization software packages, can achieve substantial inter&#8208; and intra&#8208;rater agreement in classifying amyloid PET scans across the four amyloid PET tracers used in this study.</p></list-item><list-item><p>
<bold>Future directions</bold>: Further work is required to establish whether high agreement across raters would generalize to amyloid PET scans collected in a broader clinical environment. This calibration set will be developed into a standardized training tool for other studies incorporating amyloid PET visual reads.</p></list-item></list>
</p></sec></boxed-text><p>To address this gap, we evaluated the reliability and consistency of amyloid PET visual reads across a network of 10 PET neuroimaging experts spanning eight US Alzheimer's Disease Research Centers (ADRCs). All experts performed visual reads for a set of calibration amyloid PET scans, spanning four radiotracers, which were enriched with challenging scans (i.e., those with subtle loss of gray matter&#8208;to&#8208;white matter contrast, focal tracer uptake, or noise/artifacts). Readers interpreted the scans using their preferred image format, software, and hardware without quantitation or anatomical imaging. Based on the literature examining reliability using smaller sets of readers, we had a priori expectations of substantial to almost perfect inter&#8208; and intra&#8208;rater reliability, defined as Kappa (&#954;) &#8805; 0.7.</p></sec><sec id="alz70732-sec-0080"><label>2</label><title>METHODS</title><sec id="alz70732-sec-0090"><label>2.1</label><title>Calibration set</title><p>This network of readers will provide amyloid PET visual reads for the Consortium for Clarity in ADRD Research Through Imaging (CLARiTI), which focuses on PET characterization across the ADRC program.<xref rid="alz70732-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> To create a comprehensive set of amyloid PET scans suitable for reader calibration, we searched public and access&#8208;restricted databases for brain PET scans acquired with each radiotracer that will be used in the CLARiTI study: [<sup>18</sup>F]florbetaben (Neuraceq, FBB), [<sup>18</sup>F]florbetapir (Amyvid, FBP), [<sup>18</sup>F]flutafuranol (FFN), or [<sup>11</sup>C]Pittsburgh compound B (PiB). Brain PET data for each radiotracer was gathered from at least two independent studies, or in the case of FBP, from multiple independent institutions participating in the same parent study. All scans had associated participant demographics, clinical diagnosis, and Centiloid (CL) quantitation provided by the study&#8208;specific PET cores.<xref rid="alz70732-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> The sources of PET data for each radiotracer were as follows: (1) FBB: The Longitudinal Early&#8208;onset Alzheimer's Disease Study (LEADS, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://leads-study.medicine.iu.edu" ext-link-type="uri">https://leads&#8208;study.medicine.iu.edu</ext-link>)<xref rid="alz70732-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="alz70732-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> and the Alzheimer's Disease Neuroimaging Initiative (ADNI, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://adni.loni.usc.edu" ext-link-type="uri">https://adni.loni.usc.edu</ext-link>),<xref rid="alz70732-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="alz70732-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> (2) FBP: ADNI, (3) FFN: The Pre&#8208;symptomatic Evaluation of Experimental or Novel Treatments for Alzheimer's Disease (PREVENT&#8208;AD, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://registeredpreventad.loris.ca" ext-link-type="uri">https://registeredpreventad.loris.ca</ext-link>)<xref rid="alz70732-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> and the Centiloid Project hosted by the Global Alzheimer's Association Interactive Network (GAAIN, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.gaain.org/centiloid-project" ext-link-type="uri">https://www.gaain.org/centiloid&#8208;project</ext-link>),<xref rid="alz70732-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="alz70732-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> and (4) PiB: GAAIN and University of California, San Francisco (UCSF) ADRC.<xref rid="alz70732-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>
</p><p>Neuroimaging data were either processed by the study&#8208;specific PET core (ADNI, LEADS) or by the UCSF PET core (PREVENT&#8208;AD, GAAIN, UCSF ADRC). FBB and FBP PET scans (ADNI, LEADS) were the averages of the co&#8208;registered frames acquired 90 to 110 (FBB) or 50 to 70 (FBP) minutes postinjection that were intensity normalized to the whole cerebellum. FFN scans (PREVENT&#8208;AD, GAAIN) were the averages of the co&#8208;registered frames acquired 40 to 70 (PREVENT&#8208;AD) or 50 to 70 (GAAIN) minutes postinjection and intensity normalized to the whole cerebellum. PiB scans (GAAIN, UCSF ADRC) were the averages of the co&#8208;registered frames acquired 50 to 70 minutes postinjection and intensity normalized to the whole cerebellum (GAAIN) or cerebellar gray matter (UCSF ADRC). All scans were spatially re&#8208;aligned to the Montreal Neurological Institute space to correct anterior commissure to posterior commissure alignment for consistent spatial orientation. For more details on scan acquisition, please refer to the corresponding study methods.<xref rid="alz70732-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="alz70732-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="alz70732-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="alz70732-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="alz70732-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="alz70732-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>
</p><p>For each radiotracer, a board&#8208;certified neurologist and expert PET rater (D.N.S.M.), visually read a batch of scans, generated by randomly mixing scans from the original data sources, and selected 30 unique amyloid PET scans, with an even mix of visually non&#8208;elevated and elevated scans (12&#8211;13 per group) and five visually borderline scans (i.e., those with subtle loss of gray matter&#8208;to&#8208;white matter contrast or focal tracer uptake that is either insufficient or just sufficient enough to call the scan elevated). A check was done to verify that scans were proportionally sampled from each tracer's source studies/institutions, included common artifacts and noise, spanned the full CL range, and exhibited similar CL distributions across tracers.</p><p>An independent analyst (Z.L.) completed additional amyloid PET dataset preparations. To facilitate measurement of intra&#8208;rater reliability, 15 amyloid PET scans were randomly selected and duplicated per tracer. The combined 45 scans per tracer, comprising the 30 unique original scans and the 15 duplicates, were then randomly renamed and sorted.</p></sec><sec id="alz70732-sec-0100"><label>2.2</label><title>Visual reads</title><p>Ten experts performed blinded, independent visual reads of 180 amyloid PET scans (30 unique original scans, of which 15 were duplicated for each of the four radiotracers; total of 120 original scans and 60 duplicate scans). The expert readers included three physicians board certified in both diagnostic radiology and nuclear medicine, one in diagnostic radiology and neurology, one in diagnostic radiology, one in nuclear medicine, and four in neurology. All had at least 5 years of experience visually interpreting amyloid PET scans for clinical or research purposes and previously completed manufacturer's certification training for FBB and FBP visual reads. Visual reads were performed with awareness of the amyloid PET tracer used to generate the scan, but blinded to participant demographics, clinical data, diagnosis, quantitation (i.e., no CL or standardized uptake value ratio [SUVR] quantitation), anatomical imaging, and other visual reads. Each reader classified each scan as either elevated (i.e., positive) or non&#8208;elevated (i.e., negative) using the manufacturer's FDA&#8208;approved criteria for FBB and FBP and UCSF&#8208;developed criteria for PiB that were also adapted to FFN (<xref rid="alz70732-supinfo-0001" ref-type="">Supplementary Methods</xref> in supporting information). For PiB and FFN, most readers either had prior experience using grayscale or preferred it due to greater familiarity when visually rating amyloid PET scans. Importantly, while grayscale was primarily used during the initial visualization of PiB and FFN scans, readers were encouraged to supplement their review with other familiar color scales, such as National Institutes of Health (NIH) rainbow and inverted grayscale. Readers also assessed the presence of regional tracer uptake in frontal, parietal, posterior cingulate/precuneus, temporal, and occipital regions, independent of the laterality of the tracer uptake (i.e., unilateral or bilateral temporal tracer uptake would both be acknowledged as temporal tracer uptake being present). These visual reads and regional assessment of tracer uptake were performed using only the amyloid PET scan, without any corresponding structural neuroimaging.</p><p>Scan distribution and electronic data capture of visual read data was done through the National Alzheimer's Coordinating Center (NACC) Data Platform, which is built on top of the Flywheel data management system (Flywheel Inc.). Readers were allowed to download their choice of either Digital Imaging and Communications in Medicine (DICOM) or Neuroimaging Informatics Technology Initiative (NiFTI) formatted scans from the NACC Data Platform and read these scans using their preferred hardware and software. Readers also had the option of reading the scans inside the NACC Data Platform based in Flywheel, which features a built&#8208;in radiology&#8208;grade viewer based on the open&#8208;source Open Health Imaging Foundation (OHIF) Viewer version 3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ohif.org/" ext-link-type="uri">https://ohif.org/</ext-link>). Figure <xref rid="alz70732-supinfo-0001" ref-type="">S1</xref> in supporting information shows the OHIF viewer displaying an amyloid PET scan alongside the associated data capture form. Table <xref rid="alz70732-supinfo-0001" ref-type="">S1</xref> in supporting information documents the visualization software used by each reader. Readers were not allowed to use any quantitative features built into their viewing software or any other quantitative tools to inform their visual read or regional assessment of tracer uptake. The calibration set of amyloid PET images was assembled in August 2024, and visual reads were performed between January 10, 2025 and March 7, 2025. Readers were allowed to read these scans at their own pace and order during this time.</p><p>After all reads were completed, a conference was held to review scans that had the greatest disagreement. This included scans on which readers were evenly divided or for which the interpretation was split six to four between the two binary options. All 10 readers participated in this conference, reviewing the images together, and deciding on a consensus visual interpretation without any quantitative information.</p></sec><sec id="alz70732-sec-0110"><label>2.3</label><title>Statistical analyses</title><p>Statistical analyses were performed using R version 4.4.0 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.r-project.org/" ext-link-type="uri">https://www.r&#8208;project.org/</ext-link>). Visual reads from the 10 independent readers were included in the analyses. To evaluate the strength of inter&#8208;rater agreement across all readers and all the unique original scans (i.e., the original 120 scans, excluding the 60 duplicates), we computed Fleiss' &#954; with a corresponding 95% confidence interval (CI). Inter&#8208;rater agreement was also evaluated using Fleiss' &#954; across all readers for each tracer's (FBB, FBP, FFN, and PiB) unique scans and also in individual cortical regions (frontal, parietal, posterior cingulate/precuneus, temporal, and occipital). Inter&#8208;rater reliability between all unique reader pairs was evaluated using Cohen's &#954; and pairwise percent agreement.</p><p>To evaluate how inter&#8208;rater agreement varied across different quantitative ranges, we calculated Fleiss' &#954; within an intermediate range (10 &#8804; CL &#8804; 40) and in ranges associated with higher certainty of visually non&#8208;elevated or elevated scans (CL&#160;&lt;&#160;10 or CL&#160;&gt;&#160;40). Kappa statistics can be low despite high percent agreement when there is bias among raters, such as when raters choose the same rating most of the time in a specific subset or quantitative range of scans (i.e., high prevalence of each assessor categorizing scans as elevated in the CL&#160;&gt;&#160;40 range or non&#8208;elevated in the CL&#160;&lt;&#160;10 range).<xref rid="alz70732-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> For this reason, the proportion of scans with complete agreement across all 10 readers was also calculated for the non&#8208;elevated (CL&#160;&lt;&#160;10) and elevated (CL&#160;&gt;&#160;40) ranges and compared to the intermediate (10 &#8804; CL &#8804; 40) range.</p><p>In addition, we calculated the majority reader agreement, defined as the percentage of readers who selected the most common classification (elevated or non&#8208;elevated) for that scan. This metric reflects the highest level of consensus among readers for each image, irrespective of whether this agrees with any previous quantitative or visual read data confirming it is elevated or non&#8208;elevated. For example, if 6 out of 10 readers marked a scan as elevated and 4 as non&#8208;elevated, the majority reader agreement for that scan was 60%, regardless of whether the scan was actually elevated. To model the trend of the majority reader agreement percentage across CL values, we fit a natural cubic spline regression model with internal knots placed at the 25th, 50th, and 75th percentile CL values.</p><p>Finally, intra&#8208;rater reliability was assessed for each reader by evaluating Cohen's &#954; and percent agreement between the original and repeated blinded reads of duplicated scans.</p></sec><sec id="alz70732-sec-0120"><label>2.4</label><title>Role of the funding source</title><p>Reader effort was supported by funding from CLARiTI (NIH/NIA U01&#8208;AG082350). The study was undertaken independently of any input from funding bodies. The funders had no role in the study design; data collection, analysis, and interpretation; writing of the report; or the decision to submit the paper for publication.</p></sec></sec><sec id="alz70732-sec-0130"><label>3</label><title>RESULTS</title><sec id="alz70732-sec-0140"><label>3.1</label><title>Cohort and scan characteristics</title><p>The mean age of participants contributing amyloid PET scans was 68.3 (standard deviation [SD] 13.4) and 48% were women. The clinical diagnoses included 27.5% cognitively unimpaired adults, 36.7% with mild cognitive impairment, 25% with dementia due to AD, 5.8% with atypical clinical syndromes associated with AD (posterior cortical atrophy, logopenic variant of primary progressive aphasia), and 4.2% with clinical syndromes associated with frontotemporal lobar degeneration (non&#8208;fluent/agrammatic variant of primary progressive aphasia, progressive supranuclear palsy, corticobasal syndrome, behavioral variant frontotemporal dementia; Table&#160;<xref rid="alz70732-tbl-0001" ref-type="table">1</xref>). Additional demographic and clinical data are summarized in Table <xref rid="alz70732-supinfo-0001" ref-type="">S2</xref> in supporting information.</p><table-wrap position="float" id="alz70732-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Demographic and clinical features.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">
<p>Overall</p>
<p>(<italic toggle="yes">N</italic>&#160;=&#160;120)</p>
</th><th align="left" rowspan="1" colspan="1">
<p>FBB</p>
<p>(<italic toggle="yes">N</italic>&#160;=&#160;30)</p>
</th><th align="left" rowspan="1" colspan="1">
<p>FBP</p>
<p>(<italic toggle="yes">N</italic>&#160;=&#160;30)</p>
</th><th align="left" rowspan="1" colspan="1">
<p>FFN</p>
<p>(<italic toggle="yes">N</italic>&#160;=&#160;30)</p>
</th><th align="left" rowspan="1" colspan="1">
<p>PiB</p>
<p>(<italic toggle="yes">N</italic>&#160;=&#160;30)</p>
</th></tr></thead><tbody><tr><td colspan="6" align="left" rowspan="1">
<bold>Age, y</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean (SD)</td><td align="char" rowspan="1" colspan="1">68.3 (13.4)</td><td align="char" rowspan="1" colspan="1">68.9 (9.79)</td><td align="char" rowspan="1" colspan="1">76.1 (7.47)</td><td align="char" rowspan="1" colspan="1">65.2 (16.2)</td><td align="char" rowspan="1" colspan="1">63.1 (14.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median [min, max]</td><td align="left" rowspan="1" colspan="1">71.0 [26.0, 89.0]</td><td align="left" rowspan="1" colspan="1">70.5 [46.0, 88.0]</td><td align="left" rowspan="1" colspan="1">76.5 [58.0, 88.0]</td><td align="left" rowspan="1" colspan="1">68.0 [26.0, 89.0]</td><td align="left" rowspan="1" colspan="1">69.0 [32.0, 83.0]</td></tr><tr><td colspan="6" align="left" rowspan="1">
<bold>Sex, no. (%)</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Female</td><td align="char" rowspan="1" colspan="1">58 (48.3)</td><td align="char" rowspan="1" colspan="1">11 (36.7)</td><td align="char" rowspan="1" colspan="1">13 (43.3)</td><td align="char" rowspan="1" colspan="1">20 (66.7)</td><td align="char" rowspan="1" colspan="1">14 (46.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="char" rowspan="1" colspan="1">62 (51.7)</td><td align="char" rowspan="1" colspan="1">19 (63.3)</td><td align="char" rowspan="1" colspan="1">17 (56.7)</td><td align="char" rowspan="1" colspan="1">10 (33.3)</td><td align="char" rowspan="1" colspan="1">16 (53.3)</td></tr><tr><td colspan="6" align="left" rowspan="1">
<bold>Centiloids</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean (SD)</td><td align="char" rowspan="1" colspan="1">30.5 (33.3)</td><td align="char" rowspan="1" colspan="1">30.8 (29.3)</td><td align="char" rowspan="1" colspan="1">33.3 (36.5)</td><td align="char" rowspan="1" colspan="1">24.4 (32.1)</td><td align="char" rowspan="1" colspan="1">33.4 (35.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median [min, max]</td><td align="left" rowspan="1" colspan="1">21.3 [&#8722;26.0, 123]</td><td align="left" rowspan="1" colspan="1">31.0 [&#8722;15.0, 106]</td><td align="left" rowspan="1" colspan="1">22.5 [&#8722;26.0, 123]</td><td align="left" rowspan="1" colspan="1">11.5 [&#8722;8.7, 112]</td><td align="left" rowspan="1" colspan="1">24.2 [&#8722;6.3, 109]</td></tr><tr><td colspan="6" align="left" rowspan="1">
<bold>Clinical diagnosis, no. (%)</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">CU</td><td align="char" rowspan="1" colspan="1">33 (27.5)</td><td align="char" rowspan="1" colspan="1">&#8211;</td><td align="char" rowspan="1" colspan="1">&#8211;</td><td align="char" rowspan="1" colspan="1">23 (76.7)</td><td align="char" rowspan="1" colspan="1">10 (33.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">MCI</td><td align="char" rowspan="1" colspan="1">44 (36.7)</td><td align="char" rowspan="1" colspan="1">16 (53.3)</td><td align="char" rowspan="1" colspan="1">18 (60.0)</td><td align="char" rowspan="1" colspan="1">4 (13.3)</td><td align="char" rowspan="1" colspan="1">6 (20.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">AD</td><td align="char" rowspan="1" colspan="1">30 (25.0)</td><td align="char" rowspan="1" colspan="1">10 (33.3)</td><td align="char" rowspan="1" colspan="1">11 (36.7)</td><td align="char" rowspan="1" colspan="1">2 (6.7)</td><td align="char" rowspan="1" colspan="1">7 (23.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">PCA</td><td align="char" rowspan="1" colspan="1">1 (0.8)</td><td align="char" rowspan="1" colspan="1">1 (3.3)</td><td align="char" rowspan="1" colspan="1">&#8211;</td><td align="char" rowspan="1" colspan="1">&#8211;</td><td align="char" rowspan="1" colspan="1">&#8211;</td></tr><tr><td align="left" rowspan="1" colspan="1">lvPPA</td><td align="char" rowspan="1" colspan="1">6 (5.0)</td><td align="char" rowspan="1" colspan="1">3 (10.0)</td><td align="char" rowspan="1" colspan="1">&#8211;</td><td align="char" rowspan="1" colspan="1">&#8211;</td><td align="char" rowspan="1" colspan="1">3 (10.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">nfvPPA</td><td align="char" rowspan="1" colspan="1">1 (0.8)</td><td align="char" rowspan="1" colspan="1">&#8211;</td><td align="char" rowspan="1" colspan="1">&#8211;</td><td align="char" rowspan="1" colspan="1">&#8211;</td><td align="char" rowspan="1" colspan="1">1 (3.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">PSP</td><td align="char" rowspan="1" colspan="1">1 (0.8)</td><td align="char" rowspan="1" colspan="1">&#8211;</td><td align="char" rowspan="1" colspan="1">&#8211;</td><td align="char" rowspan="1" colspan="1">&#8211;</td><td align="char" rowspan="1" colspan="1">1 (3.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">CBS</td><td align="char" rowspan="1" colspan="1">1 (0.8)</td><td align="char" rowspan="1" colspan="1">&#8211;</td><td align="char" rowspan="1" colspan="1">&#8211;</td><td align="char" rowspan="1" colspan="1">&#8211;</td><td align="char" rowspan="1" colspan="1">1 (3.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">bvFTD</td><td align="char" rowspan="1" colspan="1">2 (1.7)</td><td align="char" rowspan="1" colspan="1">&#8211;</td><td align="char" rowspan="1" colspan="1">&#8211;</td><td align="char" rowspan="1" colspan="1">1 (3.3)</td><td align="char" rowspan="1" colspan="1">1 (3.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Missing</td><td align="char" rowspan="1" colspan="1">1 (0.8)</td><td align="char" rowspan="1" colspan="1">&#8211;</td><td align="char" rowspan="1" colspan="1">1 (3.3)</td><td align="char" rowspan="1" colspan="1">&#8211;</td><td align="char" rowspan="1" colspan="1">&#8211;</td></tr><tr><td colspan="6" align="left" rowspan="1">
<bold>Cohort, no. (%)</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">LEADS</td><td align="char" rowspan="1" colspan="1">14 (11.7)</td><td align="char" rowspan="1" colspan="1">14 (46.7)</td><td align="char" rowspan="1" colspan="1">&#8211;</td><td align="char" rowspan="1" colspan="1">&#8211;</td><td align="char" rowspan="1" colspan="1">&#8211;</td></tr><tr><td align="left" rowspan="1" colspan="1">ADNI</td><td align="char" rowspan="1" colspan="1">46 (38.3)</td><td align="char" rowspan="1" colspan="1">16 (53.3)</td><td align="char" rowspan="1" colspan="1">30 (100)</td><td align="char" rowspan="1" colspan="1">&#8211;</td><td align="char" rowspan="1" colspan="1">&#8211;</td></tr><tr><td align="left" rowspan="1" colspan="1">GAAIN&#8208;NAV</td><td align="char" rowspan="1" colspan="1">17 (14.2)</td><td align="char" rowspan="1" colspan="1">&#8211;</td><td align="char" rowspan="1" colspan="1">&#8211;</td><td align="char" rowspan="1" colspan="1">17 (56.7)</td><td align="char" rowspan="1" colspan="1">&#8211;</td></tr><tr><td align="left" rowspan="1" colspan="1">PREVENT&#8208;AD</td><td align="char" rowspan="1" colspan="1">13 (10.8)</td><td align="char" rowspan="1" colspan="1">&#8211;</td><td align="char" rowspan="1" colspan="1">&#8211;</td><td align="char" rowspan="1" colspan="1">13 (43.3)</td><td align="char" rowspan="1" colspan="1">&#8211;</td></tr><tr><td align="left" rowspan="1" colspan="1">UCSF&#8208;ADRC</td><td align="char" rowspan="1" colspan="1">11 (9.2)</td><td align="char" rowspan="1" colspan="1">&#8211;</td><td align="char" rowspan="1" colspan="1">&#8211;</td><td align="char" rowspan="1" colspan="1">&#8211;</td><td align="char" rowspan="1" colspan="1">11 (36.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">GAAIN&#8208;FLUTE&#8208;PiB</td><td align="char" rowspan="1" colspan="1">19 (15.8)</td><td align="char" rowspan="1" colspan="1">&#8211;</td><td align="char" rowspan="1" colspan="1">&#8211;</td><td align="char" rowspan="1" colspan="1">&#8211;</td><td align="char" rowspan="1" colspan="1">19 (63.3)</td></tr></tbody></table><table-wrap-foot><fn id="alz70732-tbl1-note-0001"><p>Abbreviations: AD, Alzheimer's disease; ADNI, Alzheimer's Disease Neuroimaging Initiative; bvFTD, behavioral variant frontotemporal dementia; CBS, corticobasal syndrome; CU, cognitively unimpaired; FBB, [<sup>18</sup>F]florbetaben; FBP, [<sup>18</sup>F]florbetapir; FFN, [<sup>18</sup>F]flutafuranol; FLUTE, [<sup>18</sup>F]flutemetamol; GAAIN, Global Alzheimer's Association Interactive Network; LEADS, Longitudinal Early&#8208;onset Alzheimer's Disease Study; lvPPA, logopenic variant of primary progressive aphasia; MCI, mild cognitive impairment; NAV, flutafuranol; nfvPPA, non&#8208;fluent variant of primary progressive aphasia; PCA, posterior cortical atrophy; PiB, [<sup>11</sup>C]Pittsburgh compound B; PREVENT&#8208;AD, Pre&#8208;symptomatic Evaluation of Experimental or Novel Treatments for Alzheimer's Disease; PSP, progressive supranuclear palsy; SD, standard deviation; UCSF&#8208;ADRC, University of California San Francisco Alzheimer's Disease Research Center; y, years.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>Examples of amyloid PET scans spanning the CL continuum for each tracer are shown in Figure&#160;<xref rid="alz70732-fig-0001" ref-type="fig">1A</xref>. The CL values of all amyloid PET scans ranged from &#8722;26 to 123, with a median of 21 and interquartile range of 46 (4&#8211;50; Figure&#160;<xref rid="alz70732-fig-0001" ref-type="fig">1B</xref>). A Kruskal&#8211;Wallis <italic toggle="yes">H</italic> test showed no significant difference in the distribution of CL values for the amyloid PET tracers (<italic toggle="yes">&#935;</italic>
<sup>2</sup>(3)&#160;=&#160;2.13, <italic toggle="yes">p&#160;</italic>=&#160;0.55).</p><fig position="float" fig-type="FIGURE" id="alz70732-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Amyloid PET scans examples and Centiloid distribution. A, Examples of amyloid PET scans for each radiotracer that span the Centiloid continuum. B, Centiloid distribution of amyloid PET scans by tracer. Red dotted lines represent the boundaries of the 10&#8211;40 Centiloid intermediate range. FBB, [<sup>18</sup>F]florbetaben; FBP, [<sup>18</sup>F]florbetapir; FFN, [<sup>18</sup>F]flutafuranol; PET, positron emission tomography; PIB, [<sup>11</sup>C]Pittsburgh compound B.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="ALZ-21-e70732-g001.jpg"/></fig></sec><sec id="alz70732-sec-0150"><label>3.2</label><title>Inter&#8208;rater reliability</title><p>The strength of overall agreement across all 10 readers and all unique scans (<italic toggle="yes">N&#160;</italic>=&#160;120) was substantial (Fleiss' <italic toggle="yes">&#954;</italic>&#160;=&#160;0.78, 95% CI: 0.75&#8211;0.81; Figure&#160;<xref rid="alz70732-fig-0002" ref-type="fig">2A</xref>). Complete agreement among all 10 readers was independently reached in 69% of the unique scans. The researcher who selected the cases (D.N.S.M.) also participated as one of the readers (reader #6), and while this could be a source of bias, there was a 4&#8208;month gap between scan selection and visual read during which he was unable to review or access these scans, and all scans were renamed, anonymized, and presented in a random order during the blinded visual reads. To evaluate any potential impact, we performed a sensitivity analysis, excluding this reader's ratings, and recalculated Fleiss' kappa among the remaining nine readers. The kappa value remained similar (<italic toggle="yes">&#954;&#160;</italic>=&#160;0.79, 95% CI: 0.76&#8211;0.82), indicating that overall inter&#8208;rater agreement was not meaningfully affected by this reader. All subsequent analyses included all 10 readers.</p><fig position="float" fig-type="FIGURE" id="alz70732-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Inter&#8208;rater reliability. A, Bar plot showing overall and tracer&#8208;specific inter&#8208;rater agreement, quantified using Fleiss' Kappa (&#954;), for the 10 independent readers. Error bars indicate 95% CI. B, Heatmap displaying the agreement between reader pairs using Cohen's &#954;. C, Heatmap showing the percent agreement between reader pairs. CI, confidence interval; CL, Centiloids; FBB, [<sup>18</sup>F]florbetaben; FBP, [<sup>18</sup>F]florbetapir; FFN, [<sup>18</sup>F]flutafuranol; PIB, [<sup>11</sup>C]Pittsburgh compound B.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="ALZ-21-e70732-g002.jpg"/></fig><p>The strength of inter&#8208;rater agreement varied slightly by tracer, ranging from substantial to almost perfect (Figure&#160;<xref rid="alz70732-fig-0002" ref-type="fig">2A</xref>). FFN displayed the highest agreement (<italic toggle="yes">&#954;</italic>&#160;=&#160;0.87, 95% CI: 0.82&#8211;0.92; complete reader agreement&#160;=&#160;80%), followed by FBP (<italic toggle="yes">&#954;</italic>&#160;=&#160;0.81, 95% CI: 0.76&#8211;0.86; complete agreement&#160;=&#160;70%), FBB (<italic toggle="yes">&#954;</italic>&#160;=&#160;0.74, 95% CI: 0.68&#8211;0.79; complete agreement&#160;=&#160;67%), and PiB (<italic toggle="yes">&#954;</italic>&#160;=&#160;0.70, 95% CI: 0.65&#8211;0.75; complete agreement&#160;=&#160;60%). Inter&#8208;rater agreement for reader pairs ranged from substantial to almost perfect (Cohen's <italic toggle="yes">&#954;&#160;</italic>=&#160;0.69&#8208;0.90; pairwise agreement&#160;=&#160;84%&#8211;95%; Figures <xref rid="alz70732-fig-0002" ref-type="fig">2B</xref> and&#160;<xref rid="alz70732-fig-0002" ref-type="fig">2C</xref>).</p><p>Inter&#8208;rater agreement was evaluated for each of the five cortical regions. There was moderate to substantial agreement across the brain regions (Fleiss' <italic toggle="yes">&#954;</italic>&#160;=&#160;0.56&#8211;0.74; complete reader agreement&#160;=&#160;49%&#8211;66%). The frontal region exhibited the highest agreement (<italic toggle="yes">&#954;</italic>&#160;=&#160;0.74, 95% CI: 0.72&#8211;0.77; complete agreement&#160;=&#160;66%), and the temporal region had a similar level of agreement (<italic toggle="yes">&#954;</italic>&#160;=&#160;0.73, 95% CI: 0.70&#8211;0.76; complete agreement&#160;=&#160;62%). The occipital region had the lowest agreement (<italic toggle="yes">&#954;&#160;</italic>=&#160;0.56, 95% CI: 0.53&#8211;0.58; complete agreement&#160;=&#160;49%; Figure <xref rid="alz70732-supinfo-0001" ref-type="">S2</xref> in supporting information). Regional inter&#8208;rater agreement was further assessed by tracer, and the occipital region consistently showed the lowest agreement (<italic toggle="yes">&#954;</italic>&#160;=&#160;0.49&#8211;0.61; complete agreement&#160;=&#160;37%&#8211;53%; Figure <xref rid="alz70732-supinfo-0001" ref-type="">S3</xref> in supporting information).</p><p>Although scans were selected to ensure full coverage of the CL range and comparable distributions across tracers, balancing amyloid burden across the scan sets for each radiotracer, the participants&#8217; mean age was relatively younger and an inverse relationship between age and amyloid burden in AD is well documented.<xref rid="alz70732-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> The Fleiss' kappa for participants younger than 65 years (<italic toggle="yes">N</italic>&#160;=&#160;34) was 0.86 (95% CI: 0.81&#8211;0.9), while for those aged &#8805; 65 years (<italic toggle="yes">N</italic>&#160;=&#160;86) it was 0.75 (95% CI: 0.72&#8211;0.78). Both values indicate substantial agreement within each age group, meeting our a priori expectation of &#954; &#8805; 0.7, but with slightly higher agreement in the younger age group.</p></sec><sec id="alz70732-sec-0160"><label>3.3</label><title>Inter&#8208;rater reliability by CL values</title><p>Inter&#8208;rater reliability was higher for scans with quantitation in CL ranges typically associated with higher certainty of a non&#8208;elevated or elevated scan (CL&#160;&lt;&#160;10 or&#160;&gt;&#160;40; Fleiss' <italic toggle="yes">&#954;&#160;</italic>=&#160;0.87, 95% CI: 0.83&#8211;0.90; complete reader agreement&#160;=&#160;80%) compared to scans with intermediate quantitation (10 &#8804; CL &#8804; 40; <italic toggle="yes">&#954;</italic>&#160;=&#160;0.64, 95% CI: 0.60&#8211;0.69; complete agreement&#160;=&#160;53%; Figure&#160;<xref rid="alz70732-fig-0003" ref-type="fig">3A</xref>). The patterns of tracer uptake in cases with intermediate quantitation are highlighted in Figure <xref rid="alz70732-supinfo-0001" ref-type="">S4</xref> in supporting information. Separating scans with quantitation in the higher certainty non&#8208;elevated range (CL&#160;&lt;&#160;10) from the elevated range (CL&#160;&gt;&#160;40), there was 72% and 88% complete reader agreement, respectively (Figure&#160;<xref rid="alz70732-fig-0003" ref-type="fig">3B</xref>). Furthermore, we plotted majority reader agreement (%) across CL for each unique scan, fitting this data with a natural cubic spline with three internal knots placed at the 25th, 50th, and 75th percentiles (CL&#160;=&#160;4.05, 21.31, and 50.38, respectively). Majority reader agreement was highest for scans at either end of the CL continuum and lower for scans with quantitative values falling within the intermediate range (Figure&#160;<xref rid="alz70732-fig-0003" ref-type="fig">3C</xref>).</p><fig position="float" fig-type="FIGURE" id="alz70732-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Inter&#8208;rater reliability and agreement across Centiloid (CL) ranges. A, Bar plot showing inter&#8208;rater agreement, quantified using Fleiss' Kappa (&#954;), in high&#8208;certainty (CL&#160;&lt;&#160;10 or&#160;&gt;&#160;40) and intermediate (10 &#8804; CL &#8804; 40) zones. Error bars indicate 95% confidence intervals (CI). B, Bar plot displaying percentage of scans with complete reader agreement within non&#8208;elevated (CL&#160;&lt;&#160;10), elevated (CL&#160;&gt;&#160;40), and intermediate (10 &#8804; CL &#8804; 40) zones. C, Majority reader agreement (%) as a function of CL using a natural cubic spline model, with internal knots placed at 25th, 50th, and 75th percentiles (CL&#160;=&#160;4.05, 21.31, and 50.38). Each point represents one unique scan and the solid blue line represents the fitted spline curve. The intermediate zone is highlighted with gray shading.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="ALZ-21-e70732-g003.jpg"/></fig></sec><sec id="alz70732-sec-0170"><label>3.4</label><title>Discordant visual reads</title><p>Thirty&#8208;seven of the 120 unique original scans had at least one reader in disagreement with the majority interpretation (one reader disagreeing, <italic toggle="yes">N&#160;</italic>=&#160;14; two readers, <italic toggle="yes">N</italic>&#160;=&#160;9; three readers, <italic toggle="yes">N</italic>&#160;=&#160;5; four readers, <italic toggle="yes">N</italic>&#160;=&#160;6) or a tied interpretation (<italic toggle="yes">N</italic>&#160;=&#160;3; Table <xref rid="alz70732-supinfo-0001" ref-type="">S3</xref> in supporting information). The discordant visual reads were distributed across all readers. Additionally, there were differences in reader tendencies, with some appearing to be slightly more conservative in their assessments, but these differences were not entirely systematic, similar to other studies (Table <xref rid="alz70732-supinfo-0001" ref-type="">S4</xref> in supporting information).<xref rid="alz70732-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="alz70732-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> Notably, 60% (<italic toggle="yes">N</italic>&#160;=&#160;22) of these scans had intermediate quantitation (10 &#8804; CL &#8804; 40; Table <xref rid="alz70732-supinfo-0001" ref-type="">S3</xref>). In the scans with the greatest disagreement, defined by a tied interpretation or four readers disagreeing with the majority interpretation, 77% were in the intermediate quantitative zone. These scans were later reviewed in a conference that included all readers, and a consensus visual interpretation was achieved in all cases. The three scans with a tied interpretation had consensus interpretations of elevated. In the six scans for which four readers disagreed with the majority interpretation, all had consensus interpretations of elevated, which differed from the original majority interpretation in four of these cases. These scans primarily had focal cortical tracer uptake or loss of gray/white differentiation, and some of these scans visually appeared to have low counts or noise that could have complicated the visual read (Figure <xref rid="alz70732-supinfo-0001" ref-type="">S5</xref> in supporting information).</p></sec><sec id="alz70732-sec-0180"><label>3.5</label><title>Intra&#8208;rater reliability</title><p>The intra&#8208;rater agreement for the 60 duplicate scans was substantial to almost perfect across readers (Cohen's <italic toggle="yes">&#954;</italic>&#160;=&#160;0.79&#8211;1.00; agreement 90%&#8211;100%; Figure <xref rid="alz70732-supinfo-0001" ref-type="">S6</xref> in supporting information). Intra&#8208;rater agreement by tracer was similar, ranging from 80% to 100% for FBB, FBP, and PiB and 93% to 100% for FFN (Figure <xref rid="alz70732-supinfo-0001" ref-type="">S7</xref> in supporting information).</p></sec></sec><sec id="alz70732-sec-0190"><label>4</label><title>DISCUSSION</title><p>We curated a set of amyloid PET scans, enriched with borderline and challenging cases and with varying degrees of scan quality, to assess visual read reliability across a large network of expert readers. Substantial inter&#8208; and intra&#8208;rater reliability (meeting a priori expectation of &#954; &#8805; 0.7) was achieved across the four amyloid PET radiotracers, with readers using their preferred image formats and tools, and despite the absence of quantitation or anatomical imaging.</p><p>Inter&#8208;rater reliability was substantial to almost perfect across tracers, highest for FFN and lowest for PiB. This was unexpected given structural similarity, nearly identical imaging characteristics, and use of UCSF&#8208;developed PiB visual read criteria for both tracers (<xref rid="alz70732-supinfo-0001" ref-type="">Supplementary Methods</xref>).<xref rid="alz70732-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="alz70732-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="alz70732-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> These observed tracer differences are likely due to, or confounded by, unrelated differences in scanners and image quality. Half of the FFN scans were acquired on a High&#8208;Resolution Research Tomograph (Siemens) brain PET scanner, which has a higher effective resolution and less partial volume effects than other scanners,<xref rid="alz70732-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> improving image interpretability and creating a bias toward higher inter&#8208;rater reliability for the FFN dataset. Inter&#8208;rater reliability was higher for FDA&#8208;approved tracers FBP and FBB than PiB, likely due to their standardized interpretation guidelines, formal training, and broader use. Also, PiB was the only tracer labeled with carbon&#8208;11, and the shorter half&#8208;life relative to fluorine&#8208;18 leads to lower detectable counts and noisier images, which may have contributed to its reduced inter&#8208;rater reliability. The results for PiB may also be biased by the acquisition of these images on older scanners, potentially affecting sensitivity, resolution, or overall scan quality. While fluorine&#8208;18 tracers and PiB show highly correlated cortical retention in AD, PiB typically exhibits higher cortical signal and lower white matter retention, offering slightly greater sensitivity for detecting cortical amyloid plaques.<xref rid="alz70732-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>
</p><p>Regional variation in agreement highlights challenges in visual interpretation of certain brain regions, potentially influenced by differences in tracer&#8208;specific visual read criteria and anatomical factors. The occipital cortex showed the lowest inter&#8208;rater reliability. Tracer&#8208;specific visual read criteria differ in interpreting regional tracer retention, particularly in the occipital lobe. For example, the FDA&#8208;approved FBB algorithm excludes the occipital lobe, likely due to its lower amyloid burden and reduced reliability in detecting amyloid pathology in this region.<xref rid="alz70732-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> These differing criteria may increase variability in interpreting occipital binding. Additionally, the occipital lobes have less distinct boundaries compared to other cortical regions on PET (e.g., lateral occipital cortex can be difficult to distinguish from temporal cortex; superior occipital cortex can be difficult to distinguish from the precuneus and parietal cortex) and they also contain dense white matter tracts, with potential for white matter signal to &#8220;spill&#8221; into adjacent cortex because of partial volume effects. Structural neuroimaging could assist in adjudicating occipital binding and should be used, when necessary, in clinical settings. In contrast, frontal lobes demonstrated the highest inter&#8208;rater reliability, likely due to their larger size, distinct neuroanatomical boundaries, consistent interpretation across tracers, and relative preservation from atrophy until later stages of AD (i.e., less partial volume effects from adjacent sulci and more stable cortical signal). Recognizing these regional differences can inform targeted training and calibration to improve visual read consistency in regions that are more complex to interpret. Further research should explore integrating structural neuroimaging, such as computed tomography or magnetic resonance imaging, to aid visual interpretation in challenging regions with lower agreement. Additionally, revising and updating the more than a decade old visual read algorithms needs to be considered, especially with the approval of anti&#8208;amyloid therapies, for which improved sensitivity in visual reads could enable earlier intervention.</p><p>Reduced inter&#8208;rater reliability was noted for scans with intermediate CL values (10 &#8804; CL &#8804; 40). The intermediate range corresponds more with subtle amyloid deposition and nuanced visual features&#8212;such as focal cortical uptake and reduced gray&#8211;white matter differentiation&#8212;that complicate interpretation. In contrast, greater reliability at the lower or higher CL ranges (CL&#160;&lt;&#160;10 or&#160;&gt;&#160;40) indicates that visual reads are most consistent when amyloid burden is either clearly absent or elevated.</p><p>Discordant visual reads&#8212;primarily within the intermediate CL range, where reader certainty is lower, but also present to a lesser extent at the lower or higher ranges (CL&#160;&lt;&#160;10 or&#160;&gt;&#160;40)&#8212;highlight the need for supplemental strategies to support accurate interpretation. In many research studies, quantitative information is introduced after blinded visual reads, which is then interpreted in the context of tracer&#8208;specific thresholds.<xref rid="alz70732-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="alz70732-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>, <xref rid="alz70732-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> This hybrid qualitative&#8211;quantitative approach may be particularly valuable for intermediate cases, as prior evidence suggests it enhances the accuracy of interpreting scans with intermediate amyloid burden and inter&#8208;reader agreement.<xref rid="alz70732-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>, <xref rid="alz70732-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> In our work moving forward, readers may flag scans for additional review in cases of visual&#8211;quantitative discordance, borderline visual classification, intermediate quantitation, or other elements complicating visual interpretation or lowering diagnostic certainty. The review conference will involve a thorough visual re&#8208;evaluation of the nominated scan by the original reader and at least two additional expert readers, followed by presentation of quantitative results and the determination of a consensus interpretation. As we observed, detailed review of the most challenging scans&#8212;those with the lowest inter&#8208;rater reliability&#8212;enabled all 10 readers to reach consensus, which sometimes differed from majority interpretations derived from the individual blinded reads. Overall, this work establishes a baseline for the reliability of blinded amyloid PET visual reads.</p><p>Strengths of this project include the carefully designed amyloid PET image set, which spans a broad range of amyloid burden, scanners, and radiotracers, with a substantial portion of scans chosen for interpretive difficulty to challenge readers&#8217; abilities. Involving numerous readers across multiple sites, each using their preferred image formats and tools, and including scans from multiple tracers reflects some of the heterogeneity of real&#8208;world clinical practice. The high inter&#8208;rater agreement observed despite this variability underscores the robustness of visual interpretation for amyloid PET.</p><p>This study has several limitations. First, readers were selected experts in amyloid PET interpretation, potentially resulting in higher reliability than in community clinical practice. Second, although aspects of real&#8208;world variability were incorporated, the number of readers, diversity in training backgrounds, and range of reader tools used were modest relative to actual clinical practice, warranting further study to confirm generalizability. A recent analysis of the Imaging Dementia&#8211;Evidence for Amyloid Scanning (IDEAS) study compared binary visual reads of amyloid PET scans (FBP, FBB, and [<sup>18</sup>F]flutemetamol), conducted without access to quantitation, with binary quantitative classifications based on an a priori autopsy&#8208;based 24.4 CL threshold.<xref rid="alz70732-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="alz70732-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>, <xref rid="alz70732-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> The analysis included 10,350 patients whose scans were acquired at 294 imaging facilities and interpreted locally by 602 imaging specialists. Reassuringly, agreement between local visual reads and central quantitative classification was 86% (Cohen <italic toggle="yes">&#954;</italic>&#160;=&#160;0.72), supporting the accuracy and robustness of visual reads in the real world.<xref rid="alz70732-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> Third, the limited data on participants&#8217; race/ethnicity and social determinants of health suggests the sample was predominantly White and highly educated. While including amyloid PET scans from individuals more representative of the US population would be ideal&#8212;given potential differences in amyloid burden by race, ethnicity, and education&#8212;our dataset spans the full spectrum of amyloid burden, particularly borderline cases, supporting the generalizability of our visual read reliability findings to broader populations.<xref rid="alz70732-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref>, <xref rid="alz70732-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> Fourth, the FDA&#8208;approved radiotracer [<sup>18</sup>F]flutemetamol was not included, as it was not specified in the original CLARiTI study protocol.<xref rid="alz70732-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> However, several sites have indicated interest in this tracer, which is planned for inclusion in future phases. A similar curated set of [<sup>18</sup>F]flutemetamol amyloid PET scans will be developed to evaluate the reliability of visual reads for this tracer&#8212;an important step given its unique intensity normalization (relative to the pons), rainbow color scale, and interpretation criteria, which includes assessment of striatal binding and excludes the occipital lobe.<xref rid="alz70732-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> Fifth, this study was designed to evaluate the reliability of amyloid PET visual reads across a large group of readers, rather than the accuracy of detecting AD neuropathology at autopsy or abnormalities in other biomarkers. A future study involving individuals with autopsy&#8208;confirmed neuropathology who underwent amyloid PET during life, particularly those with scans that are visually borderline or have intermediate quantitation (10 &#8804; CL &#8804; 40), could assess whether consensus reads improve the accuracy of detecting AD pathobiology in these challenging cases.</p><p>In conclusion, a broad network of expert raters demonstrated substantial reliability in visually interpreting amyloid PET scans across multiple radiotracers, underscoring the robustness of amyloid PET visual reads. Our findings also highlight opportunities for advancing clinical and research applications through improved reader training and standardized reliability assurance. The approach and network of raters established in this work will provide amyloid PET visual reads for the CLARiTI study, which examines PET characterization across the ADRC program.<xref rid="alz70732-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> Beyond CLARiTI, we intend to make the curated image available as a training resource to support future studies involving amyloid PET visual interpretation.</p></sec><sec sec-type="COI-statement" id="alz70732-sec-0210"><title>CONFLICT OF INTEREST STATEMENT</title><p>D.N.S.M. receives research support from NIH and serves on an Alzheimer's Association research council. R.L.J. has served as a paid consultant for GE Healthcare. D.R.J. has served as a consultant and/or on advisory boards for Novartis, Telix, and Cellectar. M.E.K. receives research support from NIH and Alzheimer's Association. J.E.M. receives research support from NIH, Eli Lilly/Avid Radiopharmaceuticals, GE Healthcare, Novartis, and Cytosite Biopharma. He has served as a consultant to Eli Lilly/AVID Radiopharmaceuticals, GE Healthcare, Telix, and Novartis, and he also received honoraria from Telix. I.M.N. receives research support from NIH. He has served as a consultant to Subtle Medical and on an advisory board for Eisai. V.L.V. receives research support from NIH and Aging Mind Foundation. He has been a consultant or paid speaker at sponsored conference sessions for Eli Lilly, Life Molecular Imaging, ACE Barcelona, IXICO, and AC Immune. M.R.P has served as a paid scientific consultant for Avid Radiopharmaceuticals and Lantheus Medical Imaging and as a paid speaker for PETNET Solutions. She is the board chair of the American Board of Nuclear Medicine (ABNM). C.C.W. receives research support from the NIH and Alzheimer's Association. He has previously received honoraria from LCN, Onviv, Kinetix Group, and the American Academy of Neurology. W.A.K. receives research support from the NIH. He serves on external advisory committees for several ADRCs, including Kansas University, Boston University, and Icahn School of Medicine at Mount Sinai. He is an Associate Editor for <italic toggle="yes">Alzheimer's &amp; Dementia: Translational Research &amp; Clinical Interventions</italic>. E.C.M. receives research funding from NIH, Alzheimer's Association, Simon's Foundation, Archer Foundation, and Webb Family Foundation. She has served as a consultant to Eli Lilly, Roche, and Neurotrack. S.C.J. receives research support from NIH and has served as a consultant to Eli Lilly, AlzPath, and Enigma Biomedical. G.D.R. receives research support from NIH, Alzheimer's Association, American College of Radiology, Rainwater Charitable Foundation, Avid Radiopharmaceuticals, GE Healthcare, Genentech, and Life Molecular Imaging. He has served as a paid scientific consultant for Alector, Bristol Myers Squibb, C2N, Eli Lilly, Johnson &amp; Johnson, Merck, Novo Nordisk, and Roche. He has served as a paid speaker for Medscape and Peerview. He is an Associate Editor for <italic toggle="yes">JAMA</italic>. All other authors report no conflicts of interest. Author disclosures are available in the <xref rid="alz70732-supinfo-0001" ref-type="">supporting information</xref>.</p></sec><sec id="alz70732-sec-0220"><title>CONSENT STATEMENT</title><p>Anonymized data were obtained from several source studies for this project. These studies obtained written informed consent from their participants and maintained their own separate institutional review Board (IRB) review and approval processes. The CLARiTI Visual Reads Core, which includes this project, was reviewed and determined to be exempt by the UCSF IRB (Study Number 24&#8208;43290).</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="alz70732-supinfo-0001" position="float" content-type="local-data" orientation="portrait"/><supplementary-material id="alz70732-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70732-s003.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70732-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70732-s002.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70732-supitem-0003" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70732-s001.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="alz70732-sec-0200"><title>ACKNOWLEDGMENTS</title><p>The authors gratefully acknowledge CLARiTI funding, which supported the development of infrastructure for the visual reads and the effort of the readers. NACC were critical partners in setting up and maintaining the visual read infrastructure on their Data Platform. Data collection and sharing for the Alzheimer's Disease Neuroimaging Initiative (ADNI) is funded by the National Institute on Aging (National Institutes of Health Grant U19 AG024904). The grantee organization is the Northern California Institute for Research and Education. In the past, ADNI has also received funding from the National Institute of Biomedical Imaging and Bioengineering, the Canadian Institutes of Health Research, and private sector contributions through the Foundation for the National Institutes of Health (FNIH) including generous contributions from the following: AbbVie; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol&#8208;Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann&#8208;La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research &amp; Development, LLC; Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC; Lumosity; Lundbeck; Merck &amp; Co., Inc.; Meso Scale Diagnostics, LLC; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. Data was also gathered from The PREVENT&#8208;AD Research Group. Data collection and sharing are possible thanks to the Brain Canada Foundation. The authors acknowledge the invaluable contributions of the participants in PREVENT&#8208;AD as well as the assistance of the investigators and support staff over the years of this longitudinal project. The full list of acknowledgements for PREVENT&#8208;AD can be found at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://preventad.loris.ca/acknowledgements/acknowledgements.php?date=2025-06-06" ext-link-type="uri">https://preventad.loris.ca/acknowledgements/acknowledgements.php?date=2025&#8208;06&#8208;06</ext-link>. Data collection and dissemination of the data presented in this manuscript was supported by the LEADS Consortium (R56/U01 AG057195, funded by the National Institute on Aging). The manuscript has been reviewed by the LEADS Publications Committee for scientific content. The authors acknowledge the invaluable contributions of the participants in LEADS as well as the assistance of the investigators and support staff at each of the participating sites. Additional author acknowledgements: National Institute on Aging grants K23 AG076960 (D.N.S.M.), K76 AG088554 (Paul B. Beeson Emerging Leaders Career Development Award in Aging, M.E.K.), P30 AG086401 (University of Alabama at Birmingham ADRC, J.E.M.), and R01 AG061120 (M.Z.). Alzheimer's Association grants AACSF&#8208;22&#8208;973008 (M.E.K.). This research was conducted by the CLARiTI Visual Reads Core with support from the National Institute on Aging (NIA) under grants U01 AG082350 and U24 AG072122. The NACC Data Platform is supported by NIA grant U24 AG072122.</p></ack><ref-list id="alz70732-bibl-0001"><title>REFERENCES</title><ref id="alz70732-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="alz70732-cite-0002"><string-name name-style="western"><surname>Chapleau</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Iaccarino</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Soleimani&#8208;Meigooni</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Rabinovici</surname><given-names>GD</given-names></string-name>. <article-title>The role of amyloid PET in imaging neurodegenerative disorders: a review</article-title>. <source>J Nucl Med Off Publ Soc Nucl Med</source>. <year>2022</year>;<volume>63</volume>:<fpage>13S</fpage>&#8208;<lpage>19S</lpage>. doi:<pub-id pub-id-type="doi">10.2967/jnumed.121.263195</pub-id><pub-id pub-id-type="pmcid">PMC9165727</pub-id><pub-id pub-id-type="pmid">35649652</pub-id></mixed-citation></ref><ref id="alz70732-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="alz70732-cite-0003"><string-name name-style="western"><surname>Jack</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Andrews</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Beach</surname><given-names>TG</given-names></string-name>, <string-name name-style="western"><surname>Buracchio</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Dunn</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Graf</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup</article-title>. <source>Alzheimers Dement J Alzheimers Assoc</source>. <year>2024</year>;<volume>20</volume>:<fpage>5143</fpage>&#8208;<lpage>5169</lpage>. doi:<pub-id pub-id-type="doi">10.1002/alz.13859</pub-id><pub-id pub-id-type="pmcid">PMC11350039</pub-id><pub-id pub-id-type="pmid">38934362</pub-id></mixed-citation></ref><ref id="alz70732-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="alz70732-cite-0004"><string-name name-style="western"><surname>Rabinovici</surname><given-names>GD</given-names></string-name>, <string-name name-style="western"><surname>Gatsonis</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Apgar</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Chaudhary</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Gareen</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Hanna</surname><given-names>L</given-names></string-name>, et&#160;al. <article-title>Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia</article-title>. <source>JAMA</source>. <year>2019</year>;<volume>321</volume>:<fpage>1286</fpage>&#8208;<lpage>1294</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2019.2000</pub-id><pub-id pub-id-type="pmid">30938796</pub-id><pub-id pub-id-type="pmcid">PMC6450276</pub-id></mixed-citation></ref><ref id="alz70732-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="alz70732-cite-0005"><string-name name-style="western"><surname>Cummings</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Apostolova</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Rabinovici</surname><given-names>GD</given-names></string-name>, <string-name name-style="western"><surname>Atri</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Aisen</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Greenberg</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>Lecanemab: appropriate use recommendations</article-title>. <source>J Prev Alzheimers Dis</source>. <year>2023</year>;<volume>10</volume>:<fpage>362</fpage>&#8208;<lpage>377</lpage>. doi:<pub-id pub-id-type="doi">10.14283/jpad.2023.30</pub-id><pub-id pub-id-type="pmid">37357276</pub-id><pub-id pub-id-type="pmcid">PMC10313141</pub-id></mixed-citation></ref><ref id="alz70732-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="alz70732-cite-0006"><string-name name-style="western"><surname>Rabinovici</surname><given-names>GD</given-names></string-name>, <string-name name-style="western"><surname>Selkoe</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Schindler</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Aisen</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Apostolova</surname><given-names>LG</given-names></string-name>, <string-name name-style="western"><surname>Atri</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Donanemab: appropriate use recommendations</article-title>. <source>J Prev Alzheimers Dis</source>. <year>2025</year>:<elocation-id>100150</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.tjpad.2025.100150</pub-id><pub-id pub-id-type="pmid">40155270</pub-id><pub-id pub-id-type="pmcid">PMC12180672</pub-id></mixed-citation></ref><ref id="alz70732-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="alz70732-cite-0007"><string-name name-style="western"><surname>Clark</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Schneider</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Bedell</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Beach</surname><given-names>TG</given-names></string-name>, <string-name name-style="western"><surname>Bilker</surname><given-names>WB</given-names></string-name>, <string-name name-style="western"><surname>Mintun</surname><given-names>MA</given-names></string-name>, et&#160;al. <article-title>Use of florbetapir&#8208;PET for imaging beta&#8208;amyloid pathology</article-title>. <source>JAMA</source>. <year>2011</year>;<volume>305</volume>:<fpage>275</fpage>&#8208;<lpage>283</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2010.2008</pub-id><pub-id pub-id-type="pmid">21245183</pub-id><pub-id pub-id-type="pmcid">PMC7041965</pub-id></mixed-citation></ref><ref id="alz70732-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="alz70732-cite-0008"><string-name name-style="western"><surname>Sabri</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Sabbagh</surname><given-names>MN</given-names></string-name>, <string-name name-style="western"><surname>Seibyl</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Barthel</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Akatsu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Ouchi</surname><given-names>Y</given-names></string-name>, et&#160;al. <article-title>Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study</article-title>. <source>Alzheimers Dement</source>. <year>2015</year>;<volume>11</volume>:<fpage>964</fpage>&#8208;<lpage>974</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jalz.2015.02.004</pub-id><pub-id pub-id-type="pmid">25824567</pub-id></mixed-citation></ref><ref id="alz70732-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="alz70732-cite-0009"><string-name name-style="western"><surname>Barthel</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Gertz</surname><given-names>H&#8208;J</given-names></string-name>, <string-name name-style="western"><surname>Dresel</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Peters</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Bartenstein</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Buerger</surname><given-names>K</given-names></string-name>, et&#160;al. <article-title>Cerebral amyloid&#8208;&#946; PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study</article-title>. <source>Lancet Neurol</source>. <year>2011</year>;<volume>10</volume>:<fpage>424</fpage>&#8208;<lpage>435</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1474-4422(11)70077-1</pub-id><pub-id pub-id-type="pmid">21481640</pub-id></mixed-citation></ref><ref id="alz70732-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="alz70732-cite-0010"><string-name name-style="western"><surname>Curtis</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Gamez</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Sadowsky</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Villena</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Sabbagh</surname><given-names>MN</given-names></string-name>, et&#160;al. <article-title>Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density</article-title>. <source>JAMA Neurol</source>. <year>2015</year>;<volume>72</volume>:<fpage>287</fpage>&#8208;<lpage>294</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaneurol.2014.4144</pub-id><pub-id pub-id-type="pmid">25622185</pub-id></mixed-citation></ref><ref id="alz70732-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="alz70732-cite-0011"><string-name name-style="western"><surname>Lesman&#8208;Segev</surname><given-names>OH</given-names></string-name>, <string-name name-style="western"><surname>La Joie</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Iaccarino</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lobach</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Rosen</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Seo</surname><given-names>SW</given-names></string-name>, et&#160;al. <article-title>Diagnostic accuracy of amyloid versus 18F&#8208;Fluorodeoxyglucose positron emission tomography in autopsy&#8208;confirmed dementia</article-title>. <source>Ann Neurol</source>. <year>2021</year>;<volume>89</volume>:<fpage>389</fpage>&#8208;<lpage>401</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ana.25968</pub-id><pub-id pub-id-type="pmid">33219525</pub-id><pub-id pub-id-type="pmcid">PMC7856004</pub-id></mixed-citation></ref><ref id="alz70732-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="alz70732-cite-0012"><string-name name-style="western"><surname>Rowe</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Pejoska</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mulligan</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Chan</surname><given-names>JG</given-names></string-name>, <string-name name-style="western"><surname>Svensson</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>Head&#8208;to&#8208;head comparison of 11C&#8208;PiB and 18F&#8208;AZD4694 (NAV4694) for &#946;&#8208;amyloid imaging in aging and dementia</article-title>. <source>J Nucl Med Off Publ Soc Nucl Med</source>. <year>2013</year>;<volume>54</volume>:<fpage>880</fpage>&#8208;<lpage>886</lpage>. doi:<pub-id pub-id-type="doi">10.2967/jnumed.112.114785</pub-id><pub-id pub-id-type="pmid">23575995</pub-id></mixed-citation></ref><ref id="alz70732-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="alz70732-cite-0013"><string-name name-style="western"><surname>Cho</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Mundada</surname><given-names>NS</given-names></string-name>, <string-name name-style="western"><surname>Apostolova</surname><given-names>LG</given-names></string-name>, <string-name name-style="western"><surname>Carrillo</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Shankar</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Amuiri</surname><given-names>AN</given-names></string-name>, et&#160;al. <article-title>Amyloid and tau&#8208;PET in early&#8208;onset AD: baseline data from the Longitudinal Early&#8208;Onset Alzheimer's Disease Study (LEADS)</article-title>. <source>Alzheimers Dement</source>. <year>2023</year>;<volume>19</volume>:<fpage>S98</fpage>&#8208;<lpage>114</lpage>. doi:<pub-id pub-id-type="doi">10.1002/alz.13453</pub-id><pub-id pub-id-type="pmid">37690109</pub-id><pub-id pub-id-type="pmcid">PMC10807231</pub-id></mixed-citation></ref><ref id="alz70732-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="alz70732-cite-0014"><string-name name-style="western"><surname>Harrison</surname><given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Ward</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Taggett</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Maillard</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Lockhart</surname><given-names>SN</given-names></string-name>, <string-name name-style="western"><surname>Jung</surname><given-names>Y</given-names></string-name>, et&#160;al. <article-title>The POINTER Imaging baseline cohort: associations between multimodal neuroimaging biomarkers, cardiovascular health, and cognition</article-title>. <source>Alzheimers Dement J Alzheimers Assoc</source>. <year>2025</year>;<volume>21</volume>:<elocation-id>e14399</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/alz.14399</pub-id><pub-id pub-id-type="pmcid">PMC11772730</pub-id><pub-id pub-id-type="pmid">39641363</pub-id></mixed-citation></ref><ref id="alz70732-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="alz70732-cite-0015"><string-name name-style="western"><surname>Mormino</surname><given-names>EC</given-names></string-name>, <string-name name-style="western"><surname>Biber</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Rahman&#8208;Filipiak</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Arfanakis</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Clark</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Dage</surname><given-names>JL</given-names></string-name>, et&#160;al. <article-title>The Consortium for Clarity in ADRD Research Through Imaging (CLARiTI)</article-title>. <source>Alzheimers Dement J Alzheimers Assoc</source>. <year>2025</year>;<volume>21</volume>:<elocation-id>e14383</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/alz.14383</pub-id><pub-id pub-id-type="pmcid">PMC11772703</pub-id><pub-id pub-id-type="pmid">39588767</pub-id></mixed-citation></ref><ref id="alz70732-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="alz70732-cite-0016"><string-name name-style="western"><surname>Klunk</surname><given-names>WE</given-names></string-name>, <string-name name-style="western"><surname>Koeppe</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Price</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Benzinger</surname><given-names>TL</given-names></string-name>, <string-name name-style="western"><surname>Devous</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Jagust</surname><given-names>WJ</given-names></string-name>, et&#160;al. <article-title>The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET</article-title>. <source>Alzheimers Dement J Alzheimers Assoc</source>. <year>2015</year>;<volume>11</volume>:<fpage>1</fpage>&#8208;<lpage>15</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jalz.2014.07.003</pub-id>. e1&#8208;4<pub-id pub-id-type="pmcid">PMC4300247</pub-id><pub-id pub-id-type="pmid">25443857</pub-id></mixed-citation></ref><ref id="alz70732-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="alz70732-cite-0017"><string-name name-style="western"><surname>Apostolova</surname><given-names>LG</given-names></string-name>, <string-name name-style="western"><surname>Aisen</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Eloyan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Fagan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Fargo</surname><given-names>KN</given-names></string-name>, <string-name name-style="western"><surname>Foroud</surname><given-names>T</given-names></string-name>, et&#160;al. <article-title>The Longitudinal Early&#8208;onset Alzheimer's Disease Study (LEADS): framework and methodology</article-title>. <source>Alzheimers Dement J Alzheimers Assoc</source>. <year>2021</year>;<volume>17</volume>:<fpage>2043</fpage>&#8208;<lpage>2055</lpage>. doi:<pub-id pub-id-type="doi">10.1002/alz.12350</pub-id><pub-id pub-id-type="pmcid">PMC8939858</pub-id><pub-id pub-id-type="pmid">34018654</pub-id></mixed-citation></ref><ref id="alz70732-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="alz70732-cite-0018"><string-name name-style="western"><surname>Weiner</surname><given-names>MW</given-names></string-name>, <string-name name-style="western"><surname>Kanoria</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Miller</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Aisen</surname><given-names>PS</given-names></string-name>, <string-name name-style="western"><surname>Beckett</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Conti</surname><given-names>C</given-names></string-name>, et&#160;al. <article-title>Overview of Alzheimer's disease neuroimaging initiative and future clinical trials</article-title>. <source>Alzheimers Dement J Alzheimers Assoc</source>. <year>2025</year>;<volume>21</volume>:<elocation-id>e14321</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/alz.14321</pub-id><pub-id pub-id-type="pmcid">PMC11775462</pub-id><pub-id pub-id-type="pmid">39711072</pub-id></mixed-citation></ref><ref id="alz70732-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="alz70732-cite-0019"><string-name name-style="western"><surname>Royse</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Minhas</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Lopresti</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Murphy</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ward</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Koeppe</surname><given-names>RA</given-names></string-name>, et&#160;al. <article-title>Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach</article-title>. <source>Alzheimers Res Ther</source>. <year>2021</year>;<volume>13</volume>:<fpage>99</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13195-021-00836-1</pub-id><pub-id pub-id-type="pmid">33971965</pub-id><pub-id pub-id-type="pmcid">PMC8111744</pub-id></mixed-citation></ref><ref id="alz70732-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="alz70732-cite-0020"><string-name name-style="western"><surname>Tremblay&#8208;Mercier</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Madjar</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Das</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Pichet Binette</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Dyke</surname><given-names>SOM</given-names></string-name>, <string-name name-style="western"><surname>&#201;tienne</surname><given-names>P</given-names></string-name>, et&#160;al. <article-title>Open science datasets from PREVENT&#8208;AD, a longitudinal cohort of pre&#8208;symptomatic Alzheimer's disease</article-title>. <source>NeuroImage Clin</source>. <year>2021</year>;<volume>31</volume>:<elocation-id>102733</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.nicl.2021.102733</pub-id><pub-id pub-id-type="pmid">34192666</pub-id><pub-id pub-id-type="pmcid">PMC8254111</pub-id></mixed-citation></ref><ref id="alz70732-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="alz70732-cite-0021"><string-name name-style="western"><surname>Battle</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Pillay</surname><given-names>LC</given-names></string-name>, <string-name name-style="western"><surname>Lowe</surname><given-names>VJ</given-names></string-name>, <string-name name-style="western"><surname>Knopman</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Kemp</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Rowe</surname><given-names>CC</given-names></string-name>, et&#160;al. <article-title>Centiloid scaling for quantification of brain amyloid with [18F]flutemetamol using multiple processing methods</article-title>. <source>EJNMMI Res</source>. <year>2018</year>;<volume>8</volume>:<fpage>107</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13550-018-0456-7</pub-id><pub-id pub-id-type="pmid">30519791</pub-id><pub-id pub-id-type="pmcid">PMC6281542</pub-id></mixed-citation></ref><ref id="alz70732-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="alz70732-cite-0022"><string-name name-style="western"><surname>Rowe</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Dor&#233;</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Pejoska</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Margison</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Mulligan</surname><given-names>RS</given-names></string-name>, et&#160;al. <article-title>Standardized expression of 18F&#8208;NAV4694 and 11C&#8208;PiB &#946;&#8208;Amyloid PET results with the centiloid scale</article-title>. <source>J Nucl Med Off Publ Soc Nucl Med</source>. <year>2016</year>;<volume>57</volume>:<fpage>1233</fpage>&#8208;<lpage>1237</lpage>. doi:<pub-id pub-id-type="doi">10.2967/jnumed.115.171595</pub-id><pub-id pub-id-type="pmid">26912446</pub-id></mixed-citation></ref><ref id="alz70732-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="alz70732-cite-0023"><string-name name-style="western"><surname>Gallego&#8208;Rudolf</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wiesman</surname><given-names>AI</given-names></string-name>, <string-name name-style="western"><surname>Pichet Binette</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Villeneuve</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Baillet</surname><given-names>S</given-names></string-name>, <collab collab-type="authors">PREVENT&#8208;AD Research Group</collab>
. <article-title>Synergistic association of A&#946; and tau pathology with cortical neurophysiology and cognitive decline in asymptomatic older adults</article-title>. <source>Nat Neurosci</source>. <year>2024</year>;<volume>27</volume>:<fpage>2130</fpage>&#8208;<lpage>2137</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41593-024-01763-8</pub-id><pub-id pub-id-type="pmid">39294489</pub-id><pub-id pub-id-type="pmcid">PMC11537964</pub-id></mixed-citation></ref><ref id="alz70732-bib-0023"><label>23</label><mixed-citation publication-type="miscellaneous" id="alz70732-cite-0024"><article-title>Alzheimer's Disease Neuroimaging Initiative</article-title>. ADNI3 PET Technical Procedures Manual. Accessed May 7, 2025. n.d. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://adni.loni.usc.edu/wp-content/uploads/2012/10/ADNI3_PET-Tech-Manual_V2.0_20161206.pdf" ext-link-type="uri">https://adni.loni.usc.edu/wp&#8208;content/uploads/2012/10/ADNI3_PET&#8208;Tech&#8208;Manual_V2.0_20161206.pdf</ext-link></mixed-citation></ref><ref id="alz70732-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="alz70732-cite-0025"><string-name name-style="western"><surname>Dettori</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Norvell</surname><given-names>DC</given-names></string-name>. <article-title>Kappa and beyond: is there agreement?</article-title>. <source>Glob Spine J</source>. <year>2020</year>;<volume>10</volume>:<fpage>499</fpage>&#8208;<lpage>501</lpage>. doi:<pub-id pub-id-type="doi">10.1177/2192568220911648</pub-id><pub-id pub-id-type="pmcid">PMC7222679</pub-id><pub-id pub-id-type="pmid">32435572</pub-id></mixed-citation></ref><ref id="alz70732-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="alz70732-cite-0026"><string-name name-style="western"><surname>Clark</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Pontecorvo</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Beach</surname><given-names>TG</given-names></string-name>, <string-name name-style="western"><surname>Bedell</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Coleman</surname><given-names>RE</given-names></string-name>, <string-name name-style="western"><surname>Doraiswamy</surname><given-names>PM</given-names></string-name>, et&#160;al. <article-title>Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid&#8208;&#946; plaques: a prospective cohort study</article-title>. <source>Lancet Neurol</source>. <year>2012</year>;<volume>11</volume>(<issue>8</issue>):<fpage>669</fpage>&#8208;<lpage>678</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1474-4422(12)70142-4</pub-id><pub-id pub-id-type="pmid">22749065</pub-id></mixed-citation></ref><ref id="alz70732-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="alz70732-cite-0027"><string-name name-style="western"><surname>Collij</surname><given-names>LE</given-names></string-name>, <string-name name-style="western"><surname>Salvad&#243;</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Shekari</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lopes Alves</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Reimand</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wink</surname><given-names>AM</given-names></string-name>, et&#160;al. <article-title>Visual assessment of [18F]flutemetamol PET images can detect early amyloid pathology and grade its extent</article-title>. <source>Eur J Nucl Med Mol Imaging</source>. <year>2021</year>;<volume>48</volume>(<issue>7</issue>):<fpage>2169</fpage>&#8208;<lpage>2182</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00259-020-05174-2</pub-id><pub-id pub-id-type="pmid">33615397</pub-id><pub-id pub-id-type="pmcid">PMC8175297</pub-id></mixed-citation></ref><ref id="alz70732-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="alz70732-cite-0028"><string-name name-style="western"><surname>van Velden</surname><given-names>FHP</given-names></string-name>, <string-name name-style="western"><surname>Kloet</surname><given-names>RW</given-names></string-name>, <string-name name-style="western"><surname>van Berckel</surname><given-names>BNM</given-names></string-name>, <string-name name-style="western"><surname>Buijs</surname><given-names>FL</given-names></string-name>, <string-name name-style="western"><surname>Luurtsema</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Lammertsma</surname><given-names>AA</given-names></string-name>, et&#160;al. <article-title>HRRT versus HR+ human brain PET studies: an interscanner test&#8208;retest study</article-title>. <source>J Nucl Med Off Publ Soc Nucl Med</source>. <year>2009</year>;<volume>50</volume>:<fpage>693</fpage>&#8208;<lpage>702</lpage>. doi:<pub-id pub-id-type="doi">10.2967/jnumed.108.058628</pub-id><pub-id pub-id-type="pmid">19372482</pub-id></mixed-citation></ref><ref id="alz70732-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="alz70732-cite-0029"><string-name name-style="western"><surname>Landau</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Thomas</surname><given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Thurfjell</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Schmidt</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Margolin</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Mintun</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers</article-title>. <source>Eur J Nucl Med Mol Imaging</source>. <year>2014</year>;<volume>41</volume>(<issue>7</issue>):<fpage>1398</fpage>&#8208;<lpage>1407</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00259-014-2753-3</pub-id><pub-id pub-id-type="pmid">24647577</pub-id><pub-id pub-id-type="pmcid">PMC4055504</pub-id></mixed-citation></ref><ref id="alz70732-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="alz70732-cite-0030"><string-name name-style="western"><surname>Iaccarino</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Burnham</surname><given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>Tunali</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Navitsky</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Arora</surname><given-names>AK</given-names></string-name>, et&#160;al. <article-title>A practical overview of the use of amyloid&#8208;PET Centiloid values in clinical trials and research</article-title>. <source>NeuroImage Clin</source>. <year>2025</year>;<volume>46</volume>:<elocation-id>103765</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.nicl.2025.103765</pub-id><pub-id pub-id-type="pmid">40101674</pub-id><pub-id pub-id-type="pmcid">PMC11960669</pub-id></mixed-citation></ref><ref id="alz70732-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="alz70732-cite-0031"><string-name name-style="western"><surname>La Joie</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ayakta</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Seeley</surname><given-names>WW</given-names></string-name>, <string-name name-style="western"><surname>Borys</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Boxer</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>DeCarli</surname><given-names>C</given-names></string-name>, et&#160;al. <article-title>Multisite study of the relationships between <italic toggle="yes">antemortem</italic> [11C]PIB&#8208;PET Centiloid values and <italic toggle="yes">postmortem</italic> measures of Alzheimer's disease neuropathology</article-title>. <source>Alzheimers Dement</source>. <year>2019</year>;<volume>15</volume>:<fpage>205</fpage>&#8208;<lpage>216</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jalz.2018.09.001</pub-id><pub-id pub-id-type="pmid">30347188</pub-id><pub-id pub-id-type="pmcid">PMC6368897</pub-id></mixed-citation></ref><ref id="alz70732-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="alz70732-cite-0032"><string-name name-style="western"><surname>Collij</surname><given-names>LE</given-names></string-name>, <string-name name-style="western"><surname>Bischof</surname><given-names>GN</given-names></string-name>, <string-name name-style="western"><surname>Altomare</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Bader</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Battle</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>V&#225;llez Garc&#237;a</surname><given-names>D</given-names></string-name>, et&#160;al. <article-title>Quantification supports amyloid PET visual assessment of challenging cases: results from the AMYPAD diagnostic and patient management study</article-title>. <source>J Nucl Med Off Publ Soc Nucl Med</source>. <year>2025</year>;<volume>66</volume>:<fpage>110</fpage>&#8208;<lpage>116</lpage>. doi:<pub-id pub-id-type="doi">10.2967/jnumed.124.268119</pub-id><pub-id pub-id-type="pmcid">PMC11705786</pub-id><pub-id pub-id-type="pmid">39542700</pub-id></mixed-citation></ref><ref id="alz70732-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="alz70732-cite-0033"><string-name name-style="western"><surname>Collij</surname><given-names>LE</given-names></string-name>, <string-name name-style="western"><surname>Bollack</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>La Joie</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Shekari</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bullich</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ro&#233;&#8208;Vellv&#233;</surname><given-names>N</given-names></string-name>, et&#160;al. <article-title>Centiloid recommendations for clinical context&#8208;of&#8208;use from the AMYPAD consortium</article-title>. <source>Alzheimers Dement J Alzheimers Assoc</source>. <year>2024</year>;<volume>20</volume>:<fpage>9037</fpage>&#8208;<lpage>9048</lpage>. doi:<pub-id pub-id-type="doi">10.1002/alz.14336</pub-id><pub-id pub-id-type="pmcid">PMC11667534</pub-id><pub-id pub-id-type="pmid">39564918</pub-id></mixed-citation></ref><ref id="alz70732-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="alz70732-cite-0034"><string-name name-style="western"><surname>Zeltzer</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Schonhaut</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Mundada</surname><given-names>NS</given-names></string-name>, <string-name name-style="western"><surname>Blazhenets</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Perez</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Soleimani&#8208;Meigooni</surname><given-names>D</given-names></string-name>, et&#160;al. <article-title>Concordance between amyloid&#8208;PET quantification and real&#8208;world visual reads</article-title>. <source>JAMA Neurol</source>. <year>2025</year>;<volume>82</volume><issue>9</issue>:<fpage>952</fpage>&#8208;<lpage>962</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaneurol.2025.2218</pub-id><pub-id pub-id-type="pmid">40720133</pub-id><pub-id pub-id-type="pmcid">PMC12305444</pub-id></mixed-citation></ref><ref id="alz70732-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="alz70732-cite-0035"><string-name name-style="western"><surname>Wilkins</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Windon</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Dilworth&#8208;Anderson</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Romanoff</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gatsonis</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hanna</surname><given-names>L</given-names></string-name>, et&#160;al. <article-title>Racial and ethnic differences in amyloid PET Positivity in individuals with mild cognitive impairment or dementia: a secondary analysis of the Imaging Dementia&#8211;Evidence for Amyloid Scanning (IDEAS) cohort study</article-title>. <source>JAMA Neurol</source>. <year>2022</year>;<volume>79</volume>:<fpage>1139</fpage>&#8208;<lpage>1147</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaneurol.2022.3157</pub-id><pub-id pub-id-type="pmid">36190710</pub-id><pub-id pub-id-type="pmcid">PMC9531087</pub-id></mixed-citation></ref><ref id="alz70732-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="alz70732-cite-0036"><string-name name-style="western"><surname>Deters</surname><given-names>KD</given-names></string-name>, <string-name name-style="western"><surname>Napolioni</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Sperling</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Greicius</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Mayeux</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Hohman</surname><given-names>T</given-names></string-name>, et&#160;al. <article-title>Amyloid PET imaging in self&#8208;identified non&#8208;Hispanic Black participants of the anti&#8208;amyloid in asymptomatic Alzheimer's disease (A4) study</article-title>. <source>Neurology</source>. <year>2021</year>;<volume>96</volume>:<fpage>e1491</fpage>&#8208;<lpage>500</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0000000000011599</pub-id><pub-id pub-id-type="pmid">33568538</pub-id><pub-id pub-id-type="pmcid">PMC8032379</pub-id></mixed-citation></ref><ref id="alz70732-bib-0036"><label>36</label><mixed-citation publication-type="miscellaneous" id="alz70732-cite-0037"><collab collab-type="authors">Healthcare&#160;GE</collab><article-title>. VizamylTM Flutemetamol F 18 Injection</article-title>. Accessed May 12, 2025. n.d. <year>2016</year>. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203137s005lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203137s005lbl.pdf</ext-link></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="alz70754" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Dement</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Dement</journal-id><journal-id journal-id-type="pmc-domain-id">4549</journal-id><journal-id journal-id-type="pmc-domain">alzdem</journal-id><journal-id journal-id-type="publisher-id">ALZ</journal-id><journal-title-group><journal-title>Alzheimer's &amp; Dementia</journal-title></journal-title-group><issn pub-type="ppub">1552-5260</issn><issn pub-type="epub">1552-5279</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12483767</article-id><article-id pub-id-type="pmcid-ver">PMC12483767.1</article-id><article-id pub-id-type="pmcaid">12483767</article-id><article-id pub-id-type="pmcaiid">12483767</article-id><article-id pub-id-type="pmid">41027849</article-id><article-id pub-id-type="doi">10.1002/alz.70754</article-id><article-id pub-id-type="publisher-id">ALZ70754</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>The Cognitive Change Index in the Alzheimer's Disease Research Center setting: Self&#8208; and informant&#8208;ratings for perceived cognitive decline</article-title><alt-title alt-title-type="left-running-head">ABUGHOFAH <sc>et&#160;al</sc>.</alt-title></title-group><contrib-group><contrib id="alz70754-cr-0001" contrib-type="author"><name name-style="western"><surname>Abughofah</surname><given-names initials="Y">Yousaf</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7048-4923</contrib-id><xref rid="alz70754-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70754-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="alz70754-cr-0002" contrib-type="author"><name name-style="western"><surname>Risacher</surname><given-names initials="SL">Shannon L.</given-names></name><xref rid="alz70754-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70754-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="alz70754-cr-0003" contrib-type="author"><name name-style="western"><surname>Unverzagt</surname><given-names initials="FW">Frederick W.</given-names></name><xref rid="alz70754-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="alz70754-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="alz70754-cr-0004" contrib-type="author"><name name-style="western"><surname>Farlow</surname><given-names initials="MR">Martin R.</given-names></name><xref rid="alz70754-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="alz70754-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="alz70754-cr-0005" contrib-type="author"><name name-style="western"><surname>Apostolova</surname><given-names initials="LG">Liana G</given-names></name><xref rid="alz70754-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70754-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="alz70754-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="alz70754-cr-0006" contrib-type="author"><name name-style="western"><surname>Brosch</surname><given-names initials="JR">Jared R.</given-names></name><xref rid="alz70754-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="alz70754-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="alz70754-cr-0007" contrib-type="author"><name name-style="western"><surname>Clark</surname><given-names initials="DG">David G.</given-names></name><xref rid="alz70754-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="alz70754-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="alz70754-cr-0008" contrib-type="author"><name name-style="western"><surname>Mathew</surname><given-names initials="S">Sunu</given-names></name><xref rid="alz70754-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70754-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="alz70754-cr-0009" contrib-type="author"><name name-style="western"><surname>Gao</surname><given-names initials="S">Sujuan</given-names></name><xref rid="alz70754-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="alz70754-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="alz70754-cr-0010" contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="S">Selena</given-names></name><xref rid="alz70754-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="alz70754-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="alz70754-cr-0011" contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="S">Sophia</given-names></name><xref rid="alz70754-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="alz70754-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="alz70754-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="alz70754-cr-0012" contrib-type="author" corresp="yes"><name name-style="western"><surname>Saykin</surname><given-names initials="AJ">Andrew J.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1376-8532</contrib-id><xref rid="alz70754-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70754-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="alz70754-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="alz70754-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><address><email>asaykin@iu.edu</email></address></contrib></contrib-group><aff id="alz70754-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Radiology and Imaging Sciences</named-content>
<named-content content-type="organisation-division">Center for Neuroimaging</named-content>
<institution>Indiana University School of Medicine</institution>
<city>Indianapolis</city>
<named-content content-type="country-part">Indiana</named-content>
<country country="US">USA</country>
</aff><aff id="alz70754-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Indiana Alzheimer's Disease Research Center</named-content>
<institution>Indiana University School of Medicine</institution>
<city>Indianapolis</city>
<named-content content-type="country-part">Indiana</named-content>
<country country="US">USA</country>
</aff><aff id="alz70754-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Psychiatry</named-content>
<institution>Indiana University School of Medicine</institution>
<city>Indianapolis</city>
<named-content content-type="country-part">Indiana</named-content>
<country country="US">USA</country>
</aff><aff id="alz70754-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>Indiana University School of Medicine</institution>
<city>Indianapolis</city>
<named-content content-type="country-part">Indiana</named-content>
<country country="US">USA</country>
</aff><aff id="alz70754-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Biostatistics &amp; Health Data Science</named-content>
<institution>Indiana University</institution>
<city>Indianapolis</city>
<named-content content-type="country-part">Indiana</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>Andrew J Saykin, Department of Radiology and Imaging Sciences, Center for Neuroimaging, Indiana University School of Medicine, 355 W 16th St, Indianapolis, IN 46202, USA.<break/> Email: <email>asaykin@iu.edu</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>30</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><volume>21</volume><issue seq="190">10</issue><issue-id pub-id-type="pmc-issue-id">497699</issue-id><issue-id pub-id-type="doi">10.1002/alz.v21.10</issue-id><elocation-id>e70754</elocation-id><history><date date-type="rev-recd"><day>03</day><month>9</month><year>2025</year></date><date date-type="received"><day>18</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>04</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>30</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>02</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-02 12:25:29.010"><day>02</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Alzheimer's &amp; Dementia</italic> published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ALZ-21-e70754.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:ALZ-21-e70754.pdf"/><abstract><title>Abstract</title><sec id="alz70754-sec-0010"><title>INTRODUCTION</title><p>The Cognitive Change Index (CCI) is a brief questionnaire that assesses self and informant perceptions regarding cognitive function. We examined the ability of the CCI to distinguish between cognitively unimpaired (CU) older adults and those with mild cognitive impairment (MCI) or Alzheimer's disease (AD) dementia.</p></sec><sec id="alz70754-sec-0020"><title>METHODS</title><p>485 individuals from the Indiana Alzheimer's Disease Research Center (IADRC) and their study partners completed 20&#8208;item self and informant versions of the CCI. Receiver operator characteristic (ROC) curves were analyzed to assess differentiation between CU and those with impairment.</p></sec><sec id="alz70754-sec-0030"><title>RESULTS</title><p>High area under the ROC curve (AUC) values were obtained when using the self and informant CCI forms to distinguish CU individuals from those with impairment, with AUC values of 0.803 (95% confidence interval [CI]&#160;=&#160;0.761&#8211;0.844) and 0.914 (95% CI&#160;=&#160;0.886&#8211;0.942) for the self and informant forms, respectively.</p></sec><sec id="alz70754-sec-0040"><title>DISCUSSION</title><p>The CCI can serve as a useful screening instrument in the context of a multimodal assessment strategy for MCI and dementia.</p></sec><sec id="alz70754-sec-0050"><title>Highlights</title><p>
<list list-type="bullet" id="alz70754-list-0001"><list-item><p>Novel research that uses the Cognitive Change Index (CCI) for dementia screening.</p></list-item><list-item><p>Our findings suggest that CCI can distinguish those with dementia compared to those without.</p></list-item><list-item><p>These findings can be correlated to other screening instruments.</p></list-item><list-item><p>Results could see the CCI play a role in early Alzheimer's disease (AD) screening and diagnosis.</p></list-item></list>
</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="alz70754-kwd-0001">aging</kwd><kwd id="alz70754-kwd-0002">Alzheimer's disease</kwd><kwd id="alz70754-kwd-0003">Cognitive Change Index</kwd><kwd id="alz70754-kwd-0004">dementia screening</kwd><kwd id="alz70754-kwd-0005">memory</kwd><kwd id="alz70754-kwd-0006">subjective cognitive decline</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>National Institute on Aging</institution><institution-id institution-id-type="doi">10.13039/100000049</institution-id></institution-wrap></funding-source><award-id>P30 AG072976</award-id><award-id>P30 AG10133</award-id><award-id>R01 AG19771</award-id><award-id>K01 AG049050</award-id><award-id>R01 AG061788</award-id><award-id>R01 AG057739</award-id><award-id>U19 AG024904</award-id><award-id>R01 LM013463</award-id><award-id>R01 AG068193</award-id><award-id>R01 AG092591</award-id><award-id>T32 AG071444</award-id><award-id>U01 AG068057</award-id><award-id>U01 AG072177</award-id><award-id>U19 AG074879</award-id><award-id>U24 AG074855</award-id><award-id>K07AG076659</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>Donor's Cure Foundation</institution></institution-wrap></funding-source></award-group></funding-group><counts><fig-count count="2"/><table-count count="16"/><page-count count="12"/><word-count count="6312"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:30.09.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="alz70754-cite-0001"><string-name name-style="western"><surname>Abughofah</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Risacher</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Unverzagt</surname><given-names>FW</given-names></string-name>, et&#160;al. <article-title>The Cognitive Change Index in the Alzheimer's Disease Research Center setting: Self&#8208; and informant&#8208;ratings for perceived cognitive decline</article-title>. <source>Alzheimer's Dement</source>. <year>2025</year>;<volume>21</volume>:<elocation-id>e70754</elocation-id>. <pub-id pub-id-type="doi">10.1002/alz.70754</pub-id><pub-id pub-id-type="pmid">41027849</pub-id></mixed-citation>
</p></notes></front><body><sec id="alz70754-sec-0060"><label>1</label><title>INTRODUCTION</title><p>Alzheimer's disease (AD) is one of the most common and debilitating chronic illnesses affecting older adults, with almost 7 million people affected in the United States in 2023, with a projected increase to over 13 million by 2060.<xref rid="alz70754-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> Since the approval of aducanumab by the United States Food and Drug Administration (FDA) in 2021 and subsequent approval of lecanemab and donanemab, a new era of disease modifying therapies (DMTs) for AD emerged.<xref rid="alz70754-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="alz70754-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> Given the latent pathology and typically long presymptomatic period followed by prodromal clinical emergence of AD, a major goal in clinical research and care has focused on identifying patients in the earliest clinical stages of disease to derive maximum benefit from DMTs.<xref rid="alz70754-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="alz70754-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>
</p><p>The primary care setting has previously been recognized as a key opportunity for early detection of patients with mild cognitive impairment (MCI) and early AD.<xref rid="alz70754-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> Patients are most likely to have the longest relationship with their primary care doctor and this setting is the most likely first point of contact for a patient's medical concerns.<xref rid="alz70754-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> However, a variety of factors make detection in this setting challenging, including the reluctance of patients to bring up memory concerns as well lack of time for adequate screening during the patient visit.<xref rid="alz70754-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> Several brief performance&#8208;based screening tests exist for dementia, with the most well&#8208;known objective performance test being the Mini&#8208;Mental State Examination (MMSE). However, the MMSE has long been recognized to have several limitations, such as low sensitivity to early disease as well as confounding due to sociodemographic variables <xref rid="alz70754-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> Other instruments, such as the Montreal Cognitive Assessment (MoCA) have also been widely studied as screening tools and have shown improvement in detecting early cognitive changes compared to the MMSE.<xref rid="alz70754-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> In addition to performance&#8208;based testing, subjective symptom questionnaires such as the Everyday Cognition scales (ECog) have been used for screening and early detection.<xref rid="alz70754-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> However, interpretation of subjective questionnaires is complicated by concerns regarding the reliability of a patient's perception of their own cognitive decline. Previous research has shown that a close observer's rating of a patient's cognitive decline correlates better with objective performance and disease state especially as the disease progresses.<xref rid="alz70754-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="alz70754-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> Therefore, an optimal screening protocol will likely be one that incorporates objective cognitive performance in conjunction with a patient's perception of their cognitive state as well as the perspective of a close observer (sometimes referred to as a knowledgeable informant, or study partner in the research context).</p><boxed-text position="float" content-type="box" orientation="portrait"><sec id="alz70754-sec-0070"><title>RESEARCH IN CONTEXT</title><p>
<list list-type="order" id="alz70754-list-0002"><list-item><p>
<bold>Systematic review</bold>: The authors reviewed the literature using traditional literature search sources such as PubMed. Previous research has been done on correlating Cognitive Change Index (CCI) measurements to changes in the brain via imaging as well as harmonizing the CCI score with other dementia questionnaires, but the ability of the CCI to predict clinical dementia status has yet to be described.</p></list-item><list-item><p>
<bold>Interpretation</bold>: Our findings suggest that the CCI can be useful in discriminating between cognitively unimpaired (CU) individuals and those with mild cognitive impairment (MCI) and Alzheimer's disease (AD) dementia.</p></list-item><list-item><p>
<bold>Future directions</bold>: The manuscript demonstrates the potential discriminative ability of the CCI. This could lead to additional studies regarding the role that the CCI could play in dementia screening, as well as studies looking into developing more useful versions of the CCI for use in the clinical setting.</p></list-item></list>
</p></sec></boxed-text><p>The Cognitive Change Index (CCI) is a tool that assesses self&#8208;perception of a person's cognition. The Index has forms for both self&#8208;assessment as well as assessment by a close observer, and assesses the perception of cognitive decline in memory, executive function, and language domains.<xref rid="alz70754-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> The CCI consists of 20 items and is based on previous research on cognitive complaints in older adults that demonstrated that cognitive concerns were associated with brain atrophy consistent with MCI, even in the absence of objective evidence of dementia.<xref rid="alz70754-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="alz70754-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="alz70754-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>
</p><p>The CCI has been previously compared to and harmonized with the ECog in assessing patients for signs of dementia.<xref rid="alz70754-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> The Uniform Data Set (UDS) version 4 in use with the Alzheimer's Disease Research Center (ADRC) network in the U.S. includes several new items related to subjective cognitive concerns and a recommendation for centers to include the CCI or ECog if they wish to gather more detailed information related to perceived performance and subjective cognitive decline (SCD).<xref rid="alz70754-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>
</p><p>The goal of the present study was to assess the sensitivity and specificity of the CCI in distinguishing between people who are cognitively unimpaired (CU) compared to those with MCI and AD dementia, as well as to determine optimal cutoff scores for potential screening purposes. The context was an ADRC setting where participants are deeply phenotyped and undergo longitudinal clinical and biomarker follow&#8208;up studies. Additionally, shortened versions of the CCI were compared to the original 20&#8208;item scale to determine if a short form retained external validity and internal consistency. Combination scores of self and informant scales were also assessed for predictive validity.</p></sec><sec id="alz70754-sec-0080"><label>2</label><title>MATERIALS AND METHODS</title><sec id="alz70754-sec-0090"><label>2.1</label><title>Participants</title><p>Data were obtained from a convenience series of 485 adults enrolled in the Indiana Alzheimer's Disease Research Center (IADRC) who completed the CCI between 2013 and 2024. All IADRC cohort participants were eligible for the CCI study. Participants included 303 in the CU group, 119 individuals diagnosed with MCI using Petersen criteria;<xref rid="alz70754-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> 63 patients diagnosed with AD dementia using standard criteria.<xref rid="alz70754-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>
</p><p>All participants underwent detailed neuropsychological testing using the Uniform Data Set Version 3 (UDS3) assessment, along with the Rey Auditory Verbal Learning Test (RAVLT) and Digit Symbol Substitution Test.<xref rid="alz70754-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="alz70754-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> Diagnosis categories were decided via clinical consensus conference using the aforementioned diagnostic criteria, particularly the results of neuropsychological testing. These clinical designations, primarily based on neuropsychological testing, served as the reference diagnostic standard for our study. In this study design, all data collection was both planned and completed, including the CCI, prior to the consensus conference classification, which served as the reference standard. All procedures were approved by the Indiana University School of Medicine Institutional Review Board.</p></sec><sec id="alz70754-sec-0100"><label>2.2</label><title>The CCI</title><p>The CCI is a questionnaire designed to assess perceptions of change in an older individual's cognitive abilities.<xref rid="alz70754-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> It consists of 20 items assessing perceived changes in episodic memory (12 items), language performance (three items), and executive function (five items) and includes forms for both the individual and a chosen informant who has a close relationship with the individual and is able to observe potential changes in cognition. Participants and their informants are asked to rate the individual's cognitive function compared to the previous 5 years. A Likert scale of 1 to 5 is used to evaluate responses to the items, with higher scores indicating greater decline (1&#160;=&#160;no change or normal ability, 2&#160;=&#160;minimal change or slight/occasional problem, 3&#160;=&#160;some change or mild problem, 4&#160;=&#160;clearly noticeable change or moderate problem, 5&#160;=&#160;much worse or severe problem). The score of each individual question of the 20&#8208;item set is added to return a final score for the whole CCI (CCI&#8208;20 total score range: 20&#8211;100). Some studies directed toward memory analyzed the first 12 items focused on episodic memory (CCI&#8208;12 total score range: 12&#8211;60).</p><p>The CCI summary scores were available to clinicians during the multidisciplinary consensus conference along with all available clinical information, including neuropsychological testing. Clinical categorization of cognitive impairment (i.e., MCI or AD dementia) versus CU status was made prior to review of any neuroimaging or fluid biomarker data that may have been available at that time.</p></sec><sec id="alz70754-sec-0110"><label>2.3</label><title>Statistical analysis</title><p>Differences between groups in demographic variables were evaluated using analysis of variance (ANOVA) models for continuous measures and chi&#8208;squared tests for non&#8208;continuous measures in the maximal sample for each modality. Receiver operator characteristic (ROC) curves and the area under the ROC curve (AUC) were generated to examine the ability of each version of the CCI to differentiate between CU older adult controls and individuals with MCI and AD dementia. Differences in AUC values were considered statistically significant when an AUC value for one measure fell outside the 95% confidence interval of the comparison measure. Analysis was also performed to differentiate between CU controls and cognitively impaired individuals, defined as those with either MCI or AD. Sensitivity and specificity values for the original 20&#8208;item CCI, as well as the 12&#8208;item version and a sum score version combining the self and informant scores, were generated from the above analysis, and an optimal cutoff score was calculated via the Youden index.<xref rid="alz70754-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>
</p></sec></sec><sec id="alz70754-sec-0120"><label>3</label><title>RESULTS</title><sec id="alz70754-sec-0130"><label>3.1</label><title>Participant characteristics</title><p>A total of 485 individuals were included in the analysis, with 303 individuals in the CU group, 119 individuals in the MCI group, and 63 individuals in the AD group. The demographic details of the subgroups are presented in Table&#160;<xref rid="alz70754-tbl-0001" ref-type="table">1</xref>. Statistically significant differences in MoCA scores, CDR scores, and CCI scores were observed across the three groups.</p><table-wrap position="float" id="alz70754-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Participant characteristics.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Parameter</th><th align="left" rowspan="1" colspan="1">Cognitively unimpaired (<italic toggle="yes">N</italic>&#160;=&#160;303)</th><th align="left" rowspan="1" colspan="1">MCI (<italic toggle="yes">N</italic>&#160;=&#160;119)</th><th align="left" rowspan="1" colspan="1">AD (<italic toggle="yes">N</italic>&#160;=&#160;63)</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8208;Value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (yrs)</td><td align="left" rowspan="1" colspan="1">64.5(13.9)</td><td align="left" rowspan="1" colspan="1">70.2(8.7)</td><td align="left" rowspan="1" colspan="1">63.3(8.5)</td><td align="left" rowspan="1" colspan="1">0.365</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex (% female)</td><td align="left" rowspan="1" colspan="1">64%</td><td align="left" rowspan="1" colspan="1">54.6%</td><td align="left" rowspan="1" colspan="1">57.1%</td><td align="left" rowspan="1" colspan="1">0.581</td></tr><tr><td align="left" rowspan="1" colspan="1">Race (% White)</td><td align="left" rowspan="1" colspan="1">63%</td><td align="left" rowspan="1" colspan="1">81.5%</td><td align="left" rowspan="1" colspan="1">87.3%</td><td align="left" rowspan="1" colspan="1">0.515</td></tr><tr><td align="left" rowspan="1" colspan="1">Grade (yrs)</td><td align="left" rowspan="1" colspan="1">16.1(2.5)</td><td align="left" rowspan="1" colspan="1">15.5(2.6)</td><td align="left" rowspan="1" colspan="1">14.7(3.3)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">CCI Self Score</td><td align="left" rowspan="1" colspan="1">34.7(12.9)</td><td align="left" rowspan="1" colspan="1">52.29(15.8)</td><td align="left" rowspan="1" colspan="1">49.3(17.8)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">CCI Informant Score</td><td align="left" rowspan="1" colspan="1">27.26(10.1)</td><td align="left" rowspan="1" colspan="1">49.7(17.3)</td><td align="left" rowspan="1" colspan="1">71.6(15.1)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">CCI&#8208;12 Self Score</td><td align="left" rowspan="1" colspan="1">22.59(8.17)</td><td align="left" rowspan="1" colspan="1">33.92(9.49)</td><td align="left" rowspan="1" colspan="1">32.41(10.46)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">CCI&#8208;12 Informant Score</td><td align="left" rowspan="1" colspan="1">17.22(6.81)</td><td align="left" rowspan="1" colspan="1">32.05(10.81)</td><td align="left" rowspan="1" colspan="1">45.42(9.14)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">CCI&#8208;12 Sum Score</td><td align="left" rowspan="1" colspan="1">39.82(12.52)</td><td align="left" rowspan="1" colspan="1">65.68(15.43)</td><td align="left" rowspan="1" colspan="1">76.03(14.10)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">CCI Full Sum Score</td><td align="left" rowspan="1" colspan="1">61.97(19.49)</td><td align="left" rowspan="1" colspan="1">101.98(25.91)</td><td align="left" rowspan="1" colspan="1">120.86(24.76)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">CDR Global</td><td align="left" rowspan="1" colspan="1">0.071(0.174)</td><td align="left" rowspan="1" colspan="1">0.471(0.117)</td><td align="left" rowspan="1" colspan="1">0.695(0.294)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">MoCA</td><td align="left" rowspan="1" colspan="1">25.29(3.19)</td><td align="left" rowspan="1" colspan="1">21.10(3.62)</td><td align="left" rowspan="1" colspan="1">15.63(4.70)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr></tbody></table><table-wrap-foot><fn id="alz70754-tbl1-note-0001"><p>Abbreviations: AD, Alzheimer's disease; CCI, Cognitive Change Index; MCI, mild cognitive impairment; MoCA, Montreal Cognitive Assessment.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="alz70754-sec-0140"><label>3.2</label><title>Internal consistency</title><p>The CCI had high internal consistency across all forms, with the Cronbach's alpha of the 20&#8208;item CCI forms for self, informant, and sum being 0.962, 0.983, and 0.977, respectively. Internal consistency in the 12&#8208;item form was also high, with the Cronbach alpha of the 12&#8208;item CCI forms for self, informant, and sum being 0.941, 0.960, and 0.975, respectively.</p></sec><sec id="alz70754-sec-0150"><label>3.3</label><title>Discrimination between CU and MCI individuals</title><p>The AUC for the full 20&#8208;item CCI self&#8208;evaluation in differentiating CU individuals from those with MCI was 0.817 (95% confidence interval [CI]&#160;=&#160;0.773&#8211;0.861). For the informant evaluation, this increased to 0.877 (95% CI&#160;=&#160;0.838&#8211;0.916). When the scores of the self and informant evaluations were added together in the CCI&#8208;sum form, the AUC increased to 0.899 (95% CI&#160;=&#160;0.867&#8211;0.932). Good specificity values were also achieved at 85% sensitivity for the informant and sum CCI forms, with values of 79% and 83% for the informant and sum CCI forms, respectively. The optimal cutoff points for the evaluations are displayed in Table&#160;<xref rid="alz70754-tbl-0002" ref-type="table">2A</xref>.</p><table-wrap position="float" id="alz70754-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2A</label><caption><p>Cognitively unimpaired versus MCI.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Parameter</th><th align="left" rowspan="1" colspan="1">Test</th><th align="left" rowspan="1" colspan="1">AUC</th><th align="left" rowspan="1" colspan="1">Specificity (at 85% sensitivity)</th><th align="left" rowspan="1" colspan="1">Optimal cutoff score</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">CU vs MCI</td><td align="left" rowspan="1" colspan="1">CCI Self</td><td align="left" rowspan="1" colspan="1">0.817(CI 0.773&#8211;0.861)</td><td align="left" rowspan="1" colspan="1">67%</td><td align="left" rowspan="1" colspan="1">38.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI Informant</td><td align="left" rowspan="1" colspan="1">0.877(CI 0.838&#8211;0.916)</td><td align="left" rowspan="1" colspan="1">79%</td><td align="left" rowspan="1" colspan="1">30.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Self</td><td align="left" rowspan="1" colspan="1">0.818(CI 0.773&#8211;0.863)</td><td align="left" rowspan="1" colspan="1">61%</td><td align="left" rowspan="1" colspan="1">24.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Informant</td><td align="left" rowspan="1" colspan="1">0.873(CI 0.833&#8211;0.914)</td><td align="left" rowspan="1" colspan="1">78%</td><td align="left" rowspan="1" colspan="1">19.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Sum</td><td align="left" rowspan="1" colspan="1">0.904(CI 0.873&#8211;0.936)</td><td align="left" rowspan="1" colspan="1">83%</td><td align="left" rowspan="1" colspan="1">49.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI Full Sum</td><td align="left" rowspan="1" colspan="1">0.899(CI 0.867&#8211;0.932)</td><td align="left" rowspan="1" colspan="1">83%</td><td align="left" rowspan="1" colspan="1">74.5</td></tr></tbody></table><table-wrap-foot><fn id="alz70754-tbl2-note-0001"><p>Abbreviations: AUC, area under the receiver operator characteristic curve; CCI, Cognitive Change Index; CI, confidence interval; CU, cognitively unimpaired; MCI, mild cognitive impairment.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><sec id="alz70754-sec-0160"><label>3.3.1</label><title>Discrimination between CU and cognitively impaired individuals (MCI and AD)</title><p>The AUC for the full 20&#8208;item CCI self&#8208;evaluation in differentiating CU individuals from cognitively impaired individuals was 0.803 (95% CI&#160;=&#160;0.761&#8211;0.844), slightly reduced when compared to distinguishing individuals with MCI. For the informant evaluation, this increased to 0.914 (95% CI&#160;=&#160;0.886&#8211;0.942). When the scores of the self and informant evaluations were added together, the AUC was increased to 0.921 (95% CI&#160;=&#160;0.896&#8211;0.946). Specificity was 85% at 85% sensitivity for both the informant and sum CCI forms. The optimal cutoff points for the evaluations are displayed in Table&#160;<xref rid="alz70754-tbl-0003" ref-type="table">2B</xref>.</p><table-wrap position="float" id="alz70754-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 2B</label><caption><p>Cognitively unimpaired versus impaired (MCI+AD).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Parameter</th><th align="left" rowspan="1" colspan="1">Test</th><th align="left" rowspan="1" colspan="1">AUC</th><th align="left" rowspan="1" colspan="1">Specificity (at 85% sensitivity)</th><th align="left" rowspan="1" colspan="1">Optimal cutoff score</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">CU vs Impaired</td><td align="left" rowspan="1" colspan="1">CCI Self</td><td align="left" rowspan="1" colspan="1">0.803(CI 0.761&#8211;0.844)</td><td align="left" rowspan="1" colspan="1">62%</td><td align="left" rowspan="1" colspan="1">38.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI Informant</td><td align="left" rowspan="1" colspan="1">0.914(CI 0.885&#8211;0.942)</td><td align="left" rowspan="1" colspan="1">85%</td><td align="left" rowspan="1" colspan="1">38.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Self</td><td align="left" rowspan="1" colspan="1">0.808(CI 0.768&#8211;0.848)</td><td align="left" rowspan="1" colspan="1">61%</td><td align="left" rowspan="1" colspan="1">28.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Informant</td><td align="left" rowspan="1" colspan="1">0.910(CI 0.881&#8211;0.939)</td><td align="left" rowspan="1" colspan="1">83%</td><td align="left" rowspan="1" colspan="1">25.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Sum</td><td align="left" rowspan="1" colspan="1">0.925(CI 0.901&#8211;0.949)</td><td align="left" rowspan="1" colspan="1">85%</td><td align="left" rowspan="1" colspan="1">51.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI Full Sum</td><td align="left" rowspan="1" colspan="1">0.921(CI 0.896&#8211;0.946)</td><td align="left" rowspan="1" colspan="1">85%</td><td align="left" rowspan="1" colspan="1">76.5</td></tr></tbody></table><table-wrap-foot><fn id="alz70754-tbl3-note-0001"><p>Abbreviations: AD, Alzheimer's disease; AUC, area under the receiver operator characteristic curve; CCI, Cognitive Change Index; CI, confidence interval; CU, cognitively unimpaired; MCI, mild cognitive impairment.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec></sec><sec id="alz70754-sec-0170"><label>3.4</label><title>Discrimination between CU and AD dementia individuals</title><p>The AUC for the full 20&#8208;item CCI self&#8208;evaluation in differentiating CU individuals from those with AD was 0.775 (95% CI&#160;=&#160;0.706&#8211;0.844), significantly reduced when compared to the AUC for distinguishing CU individuals from those with MCI. For the informant evaluation, this was substantially increased to 0.983 (95% CI&#160;=&#160;0.973&#8211;0.994). When the scores of the self and informant evaluations were added together, the AUC was 0.962 (95% CI&#160;=&#160;0.943&#8211;0.982). Specificity values achieved at 85% sensitivity were very high for both the informant and sum CCI forms, with values of 97% and 93% for the informant and sum CCI forms, respectively. The optimal cutoff points for the evaluations are displayed in Table&#160;<xref rid="alz70754-tbl-0004" ref-type="table">2C</xref>.</p><table-wrap position="float" id="alz70754-tbl-0004" content-type="TABLE" orientation="portrait"><label>TABLE 2C</label><caption><p>Cognitively unimpaired versus AD.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Parameter</th><th align="left" rowspan="1" colspan="1">Test</th><th align="left" rowspan="1" colspan="1">AUC</th><th align="left" rowspan="1" colspan="1">Specificity (at 85% sensitivity)</th><th align="left" rowspan="1" colspan="1">Optimal cutoff score</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">CU vs AD</td><td align="left" rowspan="1" colspan="1">CCI Self</td><td align="left" rowspan="1" colspan="1">0.775(CI 0.706&#8211;0.844)</td><td align="left" rowspan="1" colspan="1">66%</td><td align="left" rowspan="1" colspan="1">41.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI Informant</td><td align="left" rowspan="1" colspan="1">0.983(CI 0.973&#8211;0.994)</td><td align="left" rowspan="1" colspan="1">97%</td><td align="left" rowspan="1" colspan="1">48.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Self</td><td align="left" rowspan="1" colspan="1">0.789(CI 0.725&#8211;0.853)</td><td align="left" rowspan="1" colspan="1">65%</td><td align="left" rowspan="1" colspan="1">27.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Informant</td><td align="left" rowspan="1" colspan="1">0.978(CI.965&#8211;0.992)</td><td align="left" rowspan="1" colspan="1">97%</td><td align="left" rowspan="1" colspan="1">31.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Sum</td><td align="left" rowspan="1" colspan="1">0.964(CI.943&#8211;0.985)</td><td align="left" rowspan="1" colspan="1">94%</td><td align="left" rowspan="1" colspan="1">56.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI Full Sum</td><td align="left" rowspan="1" colspan="1">0.962(CI 0.943&#8211;0.982)</td><td align="left" rowspan="1" colspan="1">93%</td><td align="left" rowspan="1" colspan="1">89.5</td></tr></tbody></table><table-wrap-foot><fn id="alz70754-tbl4-note-0001"><p>Abbreviations: AD, Alzheimer's disease; AUC, area under the receiver operator characteristic curve; CCI, Cognitive Change Index; CI, confidence interval; CU, cognitively unimpaired.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="alz70754-sec-0180"><label>3.5</label><title>Performance of the 12&#8208;item version of the CCI</title><p>The CCI&#8208;12 was assessed against the full 20&#8208;item CCI. No statistically significant difference was observed between the AUC of any of the CCI&#8208;12 and the full CCI. This was also true of the additive scores, with additions of the self and informant scores of the CCI&#8208;12 producing AUCs that did not vary significantly from the AUC of the sum of the self and informant scores of the full CCI. The comparison of the ROC curves of the full 20&#8208;item CCI and the CCI&#8208;12 are displayed in Figures&#160;<xref rid="alz70754-fig-0001" ref-type="fig">1</xref> and&#160;<xref rid="alz70754-fig-0002" ref-type="fig">2</xref>, respectively.</p><fig position="float" fig-type="FIGURE" id="alz70754-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>(A) Cognitively normal versus MCI, (B) cognitively normal versus impaired, and (C) cognitively normal versus AD. AD, Alzheimer's disease; MCI, mild cognitive impairment.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="ALZ-21-e70754-g001.jpg"/></fig><fig position="float" fig-type="FIGURE" id="alz70754-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>(A) Cognitively unimpaired versus MCI, (B) cognitively unimpaired versus impaired, and (C) cognitively unimpaired versus AD. AD, Alzheimer's disease; MCI, mild cognitive impairment.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="ALZ-21-e70754-g002.jpg"/></fig></sec><sec id="alz70754-sec-0190"><label>3.6</label><title>Association of CCI score predictions with education, sex, and race</title><p>The CCI Self form's ability to predict clinical status was affected by the race and degree of educational attainment of the study participants. No statistically significant difference was seen in the CCI's predictive ability based on sex. For those who had completed some college or less, the AUC for the full 20&#8208;item CCI self&#8208;evaluation form in differentiating CU individuals from those with MCI was 0.771 (95% CI&#160;=&#160;0.726&#8211;0.816), compared to 0.830 (95% CI&#160;=&#160;0.772&#8211;0.889) for those in the study group who had completed at least 4 years of college education. A similar effect was seen in the 12&#8208;item version of the CCI. The AUC for the full CCI self&#8208;evaluation form in differentiating CU individuals from those with MCI for African Americans was 0.736 (95% CI&#160;=&#160;0.664&#8211;809), compared to 0.837 (95% CI&#160;=&#160;0.790&#8211;0.885) for White individuals in the study group. The AUC for the full CCI self&#8208;evaluation form in differentiating CU individuals from cognitively impaired individuals for African Americans was 0.752 (95% CI&#160;=&#160;0.689&#8211;815), compared to 0.821 (95% CI&#160;=&#160;0.776&#8211;0.866) for White individuals in the study group. The AUC for the 12&#8208;item CCI self form was also reduced in African American individuals compared to White individuals in the study group when differentiating CU individuals from those with MCI and overall cognitive impairment, with the AUC in differentiating CU individuals from those with MCI for African Americans being.729 (95% CI&#160;=&#160;0.654&#8211;0.803), compared to 0.838(95% CI&#160;=&#160;0.790&#8211;0.884) for White individuals in the study group. No statistically significant differences were observed in any of the informant or sum forms based on race or educational attainment. The full data for the CCI's performance in African Americans and those who did not complete a 4&#8208;year degree are shown in Tables&#160;<xref rid="alz70754-tbl-0005" ref-type="table">3</xref> (Tables&#160;<xref rid="alz70754-tbl-0006" ref-type="table">3B</xref>, <xref rid="alz70754-tbl-0007" ref-type="table">3C</xref>) and&#160;<xref rid="alz70754-tbl-0008" ref-type="table">4</xref> (Tables&#160;<xref rid="alz70754-tbl-0009" ref-type="table">4B</xref>, <xref rid="alz70754-tbl-0010" ref-type="table">4C</xref>), respectively. The full data for the CCI's performance in White participants and those who completed at least a 4&#8208;year degree are shown in Tables&#160;<xref rid="alz70754-tbl-0011" ref-type="table">5</xref> (Tables&#160;<xref rid="alz70754-tbl-0012" ref-type="table">5B</xref>, <xref rid="alz70754-tbl-0013" ref-type="table">5C</xref>) and&#160;<xref rid="alz70754-tbl-0014" ref-type="table">6</xref>, respectively (Tables&#160;<xref rid="alz70754-tbl-0015" ref-type="table">6B</xref>, <xref rid="alz70754-tbl-0016" ref-type="table">6C</xref>).</p><table-wrap position="float" id="alz70754-tbl-0005" content-type="TABLE" orientation="portrait"><label>TABLE 3A</label><caption><p>Cognitively unimpaired versus MCI (African American).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Parameter</th><th align="left" rowspan="1" colspan="1">Test</th><th align="left" rowspan="1" colspan="1">AUC</th><th align="left" rowspan="1" colspan="1">Specificity (at 85% sensitivity)</th><th align="left" rowspan="1" colspan="1">Optimal cutoff score</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">CU vs MCI</td><td align="left" rowspan="1" colspan="1">CCI Self</td><td align="left" rowspan="1" colspan="1">0.736(CI 0.664&#8211;0.809)</td><td align="left" rowspan="1" colspan="1">50%</td><td align="left" rowspan="1" colspan="1">32.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI Informant</td><td align="left" rowspan="1" colspan="1">0.849(CI 0.790&#8211;0.908)</td><td align="left" rowspan="1" colspan="1">70%</td><td align="left" rowspan="1" colspan="1">32.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Self</td><td align="left" rowspan="1" colspan="1">0.729(CI 0.654&#8211;0.803)</td><td align="left" rowspan="1" colspan="1">48%</td><td align="left" rowspan="1" colspan="1">21.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Informant</td><td align="left" rowspan="1" colspan="1">0.843(CI 0.782&#8211;0.904)</td><td align="left" rowspan="1" colspan="1">70%</td><td align="left" rowspan="1" colspan="1">22.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI Full Sum</td><td align="left" rowspan="1" colspan="1">0.876(0.778&#8211;0.974)</td><td align="left" rowspan="1" colspan="1">87%</td><td align="left" rowspan="1" colspan="1">77.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Sum</td><td align="left" rowspan="1" colspan="1">0.888(0.793&#8211;0.982)</td><td align="left" rowspan="1" colspan="1">87%</td><td align="left" rowspan="1" colspan="1">51.5</td></tr></tbody></table><table-wrap-foot><fn id="alz70754-tbl5-note-0001"><p>Abbreviations: AUC, area under the receiver operator characteristic curve; CCI, Cognitive Change Index; CI, confidence interval; CU, cognitively unimpaired; MCI, mild cognitive impairment.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><table-wrap position="float" id="alz70754-tbl-0006" content-type="TABLE" orientation="portrait"><label>TABLE 3B</label><caption><p>Cognitively unimpaired versus impaired (MCI+AD) (African American).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Parameter</th><th align="left" rowspan="1" colspan="1">Test</th><th align="left" rowspan="1" colspan="1">AUC</th><th align="left" rowspan="1" colspan="1">Specificity (at 85% sensitivity)</th><th align="left" rowspan="1" colspan="1">Optimal cutoff score</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">CU vs Impaired</td><td align="left" rowspan="1" colspan="1">CCI Self</td><td align="left" rowspan="1" colspan="1">0.752(CI 0.689&#8211;0.815)</td><td align="left" rowspan="1" colspan="1">56%</td><td align="left" rowspan="1" colspan="1">32.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI Informant</td><td align="left" rowspan="1" colspan="1">0.885(CI 0.839&#8211;0.932)</td><td align="left" rowspan="1" colspan="1">77%</td><td align="left" rowspan="1" colspan="1">32.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Self</td><td align="left" rowspan="1" colspan="1">0.751(CI 0.688&#8211;0.814)</td><td align="left" rowspan="1" colspan="1">53%</td><td align="left" rowspan="1" colspan="1">21.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Informant</td><td align="left" rowspan="1" colspan="1">0.881(CI 0.833&#8211;0.928)</td><td align="left" rowspan="1" colspan="1">74%</td><td align="left" rowspan="1" colspan="1">22.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI Full Sum</td><td align="left" rowspan="1" colspan="1">0.893(0.816&#8211;0.969)</td><td align="left" rowspan="1" colspan="1">87%</td><td align="left" rowspan="1" colspan="1">69.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Sum</td><td align="left" rowspan="1" colspan="1">0.907(0.834&#8211;0.980)</td><td align="left" rowspan="1" colspan="1">87%</td><td align="left" rowspan="1" colspan="1">48.5</td></tr></tbody></table><table-wrap-foot><fn id="alz70754-tbl6-note-0001"><p>Abbreviations: AD, Alzheimer's disease; AUC, area under the receiver operator characteristic curve; CCI, Cognitive Change Index; CI, confidence interval; CU, cognitively unimpaired; MCI, mild cognitive impairment.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><table-wrap position="float" id="alz70754-tbl-0007" content-type="TABLE" orientation="portrait"><label>TABLE 3C</label><caption><p>Cognitively unimpaired versus AD (African American).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Parameter</th><th align="left" rowspan="1" colspan="1">Test</th><th align="left" rowspan="1" colspan="1">AUC</th><th align="left" rowspan="1" colspan="1">Specificity (at 85% sensitivity)</th><th align="left" rowspan="1" colspan="1">Optimal cutoff score</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">CU vs AD</td><td align="left" rowspan="1" colspan="1">CCI Self</td><td align="left" rowspan="1" colspan="1">0.796(CI 0.688&#8211;0.905)</td><td align="left" rowspan="1" colspan="1">63%</td><td align="left" rowspan="1" colspan="1">34.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI Informant</td><td align="left" rowspan="1" colspan="1">0.989(CI 0.980&#8211;0.998)</td><td align="left" rowspan="1" colspan="1">97%</td><td align="left" rowspan="1" colspan="1">45.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Self</td><td align="left" rowspan="1" colspan="1">0.815(CI 0.725&#8211;0.905)</td><td align="left" rowspan="1" colspan="1">61%</td><td align="left" rowspan="1" colspan="1">31.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Informant</td><td align="left" rowspan="1" colspan="1">0.987(CI.976&#8211;0.997)</td><td align="left" rowspan="1" colspan="1">96%</td><td align="left" rowspan="1" colspan="1">30.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI Full Sum</td><td align="left" rowspan="1" colspan="1">0.939(0.873&#8211;0.999)</td><td align="left" rowspan="1" colspan="1">92%</td><td align="left" rowspan="1" colspan="1">90.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Sum</td><td align="left" rowspan="1" colspan="1">0.959(0.916&#8211;0.999)</td><td align="left" rowspan="1" colspan="1">92%</td><td align="left" rowspan="1" colspan="1">49.5</td></tr></tbody></table><table-wrap-foot><fn id="alz70754-tbl7-note-0001"><p>Abbreviations: AD, Alzheimer's disease; AUC, area under the receiver operator characteristic curve; CCI, Cognitive Change Index; CI, confidence interval; CU, cognitively unimpaired.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><table-wrap position="float" id="alz70754-tbl-0008" content-type="TABLE" orientation="portrait"><label>TABLE 4A</label><caption><p>Cognitively unimpaired versus MCI (some college or less).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Parameter</th><th align="left" rowspan="1" colspan="1">Test</th><th align="left" rowspan="1" colspan="1">AUC</th><th align="left" rowspan="1" colspan="1">Specificity (at 85% sensitivity)</th><th align="left" rowspan="1" colspan="1">Optimal cutoff score</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">CU vs MCI</td><td align="left" rowspan="1" colspan="1">CCI Self</td><td align="left" rowspan="1" colspan="1">0.771(CI 0.726&#8211;0.816)</td><td align="left" rowspan="1" colspan="1">55%</td><td align="left" rowspan="1" colspan="1">38.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI Informant</td><td align="left" rowspan="1" colspan="1">0.841(CI 0.802&#8211;0.880)</td><td align="left" rowspan="1" colspan="1">66%</td><td align="left" rowspan="1" colspan="1">33.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Self</td><td align="left" rowspan="1" colspan="1">0.770(CI 0.726&#8211;0.814)</td><td align="left" rowspan="1" colspan="1">59%</td><td align="left" rowspan="1" colspan="1">28.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Informant</td><td align="left" rowspan="1" colspan="1">0.843(CI 0.804&#8211;0.882)</td><td align="left" rowspan="1" colspan="1">68%</td><td align="left" rowspan="1" colspan="1">23.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI Full Sum</td><td align="left" rowspan="1" colspan="1">0.907(0.862&#8211;0.952)</td><td align="left" rowspan="1" colspan="1">79%</td><td align="left" rowspan="1" colspan="1">74.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Sum</td><td align="left" rowspan="1" colspan="1">0.902(0.856&#8211;0.947)</td><td align="left" rowspan="1" colspan="1">76%</td><td align="left" rowspan="1" colspan="1">56.5</td></tr></tbody></table><table-wrap-foot><fn id="alz70754-tbl8-note-0001"><p>Abbreviations: AUC, area under the receiver operator characteristic curve; CCI, Cognitive Change Index; CI, confidence interval; CU, cognitively unimpaired; MCI, mild cognitive impairment.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><table-wrap position="float" id="alz70754-tbl-0009" content-type="TABLE" orientation="portrait"><label>TABLE 4B</label><caption><p>Cognitively unimpaired versus impaired (MCI+AD) (some college or less).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Parameter</th><th align="left" rowspan="1" colspan="1">Test</th><th align="left" rowspan="1" colspan="1">AUC</th><th align="left" rowspan="1" colspan="1">Specificity (at 85% sensitivity)</th><th align="left" rowspan="1" colspan="1">Optimal cutoff score</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">CU vs Impaired</td><td align="left" rowspan="1" colspan="1">CCI Self</td><td align="left" rowspan="1" colspan="1">0.765(CI 0.728&#8211;0.803)</td><td align="left" rowspan="1" colspan="1">57%</td><td align="left" rowspan="1" colspan="1">35.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI Informant</td><td align="left" rowspan="1" colspan="1">0.903(CI 0.878&#8211;0.927)</td><td align="left" rowspan="1" colspan="1">80%</td><td align="left" rowspan="1" colspan="1">33.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Self</td><td align="left" rowspan="1" colspan="1">0.767(CI 0.730&#8211;0.804)</td><td align="left" rowspan="1" colspan="1">59%</td><td align="left" rowspan="1" colspan="1">26.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Informant</td><td align="left" rowspan="1" colspan="1">0.902(CI 0.877&#8211;0.927)</td><td align="left" rowspan="1" colspan="1">80%</td><td align="left" rowspan="1" colspan="1">26.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI Full Sum</td><td align="left" rowspan="1" colspan="1">0.928(0.893&#8211;0.963)</td><td align="left" rowspan="1" colspan="1">86%</td><td align="left" rowspan="1" colspan="1">91.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Sum</td><td align="left" rowspan="1" colspan="1">0.928(0.893&#8211;0.962)</td><td align="left" rowspan="1" colspan="1">86%</td><td align="left" rowspan="1" colspan="1">56.5</td></tr></tbody></table><table-wrap-foot><fn id="alz70754-tbl9-note-0001"><p>Abbreviations: AD, Alzheimer's disease; AUC, area under the receiver operator characteristic curve; CCI, Cognitive Change Index; CI, confidence interval; CU, cognitively unimpaired; MCI, mild cognitive impairment.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><table-wrap position="float" id="alz70754-tbl-0010" content-type="TABLE" orientation="portrait"><label>TABLE 4C</label><caption><p>Cognitively unimpaired versus AD (some college or less).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Parameter</th><th align="left" rowspan="1" colspan="1">Test</th><th align="left" rowspan="1" colspan="1">AUC</th><th align="left" rowspan="1" colspan="1">Specificity (at 85% sensitivity)</th><th align="left" rowspan="1" colspan="1">Optimal cutoff score</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">CU vs AD</td><td align="left" rowspan="1" colspan="1">CCI Self</td><td align="left" rowspan="1" colspan="1">0.759(CI 0.706&#8211;0.811)</td><td align="left" rowspan="1" colspan="1">58%</td><td align="left" rowspan="1" colspan="1">39.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI Informant</td><td align="left" rowspan="1" colspan="1">0.978(CI 0.967&#8211;0.988)</td><td align="left" rowspan="1" colspan="1">97%</td><td align="left" rowspan="1" colspan="1">50.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Self</td><td align="left" rowspan="1" colspan="1">0.762(CI 0.711&#8211;0.814)</td><td align="left" rowspan="1" colspan="1">59%</td><td align="left" rowspan="1" colspan="1">26.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Informant</td><td align="left" rowspan="1" colspan="1">0.973(CI.961&#8211;0.986)</td><td align="left" rowspan="1" colspan="1">95%</td><td align="left" rowspan="1" colspan="1">31.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI Full Sum</td><td align="left" rowspan="1" colspan="1">0.956(0.925&#8211;0.988)</td><td align="left" rowspan="1" colspan="1">93%</td><td align="left" rowspan="1" colspan="1">91.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Sum</td><td align="left" rowspan="1" colspan="1">0.964(0.937&#8211;0.990)</td><td align="left" rowspan="1" colspan="1">92%</td><td align="left" rowspan="1" colspan="1">56.5</td></tr></tbody></table><table-wrap-foot><fn id="alz70754-tbl10-note-0001"><p>Abbreviations: AD, Alzheimer's disease; AUC, area under the receiver operator characteristic curve; CCI, Cognitive Change Index; CI, confidence interval; CU, cognitively unimpaired.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><table-wrap position="float" id="alz70754-tbl-0011" content-type="TABLE" orientation="portrait"><label>TABLE 5A</label><caption><p>Cognitively unimpaired versus MCI (White).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Parameter</th><th align="left" rowspan="1" colspan="1">Test</th><th align="left" rowspan="1" colspan="1">AUC</th><th align="left" rowspan="1" colspan="1">Specificity (at 85% sensitivity)</th><th align="left" rowspan="1" colspan="1">Optimal cutoff score</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">CU vs MCI</td><td align="left" rowspan="1" colspan="1">CCI Self</td><td align="left" rowspan="1" colspan="1">0.837(CI 0.790&#8211;0.88<italic toggle="yes">5</italic>)</td><td align="left" rowspan="1" colspan="1">69%</td><td align="left" rowspan="1" colspan="1">38.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI Informant</td><td align="left" rowspan="1" colspan="1">0.877(CI 0.832&#8211;0.922)</td><td align="left" rowspan="1" colspan="1">78%</td><td align="left" rowspan="1" colspan="1">30.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Self</td><td align="left" rowspan="1" colspan="1">0.838(CI 0.790&#8211;0.884)</td><td align="left" rowspan="1" colspan="1">64%</td><td align="left" rowspan="1" colspan="1">29.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Informant</td><td align="left" rowspan="1" colspan="1">0.873(CI 0.828&#8211;0.919)</td><td align="left" rowspan="1" colspan="1">78%</td><td align="left" rowspan="1" colspan="1">19.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI Full Sum</td><td align="left" rowspan="1" colspan="1">0.905(0.868&#8211;0.938)</td><td align="left" rowspan="1" colspan="1">80%</td><td align="left" rowspan="1" colspan="1">72.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Sum</td><td align="left" rowspan="1" colspan="1">0.903(0.871&#8211;0.940)</td><td align="left" rowspan="1" colspan="1">81%</td><td align="left" rowspan="1" colspan="1">45</td></tr></tbody></table><table-wrap-foot><fn id="alz70754-tbl11-note-0001"><p>Abbreviations: AUC, area under the receiver operator characteristic curve; CCI, Cognitive Change Index; CI, confidence interval; CU, cognitively unimpaired; MCI, mild cognitive impairment.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><table-wrap position="float" id="alz70754-tbl-0012" content-type="TABLE" orientation="portrait"><label>TABLE 5B</label><caption><p>Cognitively unimpaired versus impaired (MCI+AD) (White).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Parameter</th><th align="left" rowspan="1" colspan="1">Test</th><th align="left" rowspan="1" colspan="1">AUC</th><th align="left" rowspan="1" colspan="1">Specificity (at 85% sensitivity)</th><th align="left" rowspan="1" colspan="1">Optimal cutoff score</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">CU vs Impaired</td><td align="left" rowspan="1" colspan="1">CCI Self</td><td align="left" rowspan="1" colspan="1">0.821(CI 0.776&#8211;0.866)</td><td align="left" rowspan="1" colspan="1">65%</td><td align="left" rowspan="1" colspan="1">38.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI Informant</td><td align="left" rowspan="1" colspan="1">0.916(CI 0.885&#8211;0.947)</td><td align="left" rowspan="1" colspan="1">84%</td><td align="left" rowspan="1" colspan="1">30.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Self</td><td align="left" rowspan="1" colspan="1">0.826(CI 0.781&#8211;0.870)</td><td align="left" rowspan="1" colspan="1">65%</td><td align="left" rowspan="1" colspan="1">27.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Informant</td><td align="left" rowspan="1" colspan="1">0.912(CI 0.880&#8211;0.944)</td><td align="left" rowspan="1" colspan="1">81%</td><td align="left" rowspan="1" colspan="1">25.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI full sum</td><td align="left" rowspan="1" colspan="1">0.925(0.898&#8211;0.953)</td><td align="left" rowspan="1" colspan="1">84%</td><td align="left" rowspan="1" colspan="1">72.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Sum</td><td align="left" rowspan="1" colspan="1">0.927(0.900&#8211;0.954)</td><td align="left" rowspan="1" colspan="1">83%</td><td align="left" rowspan="1" colspan="1">49.5</td></tr></tbody></table><table-wrap-foot><fn id="alz70754-tbl12-note-0001"><p>Abbreviations: AD, Alzheimer's disease; AUC, area under the receiver operator characteristic curve; CCI, Cognitive Change Index; CI, confidence interval; CU, cognitively unimpaired; MCI, mild cognitive impairment</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><table-wrap position="float" id="alz70754-tbl-0013" content-type="TABLE" orientation="portrait"><label>TABLE 5C</label><caption><p>Cognitively unimpaired versus AD (White).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Parameter</th><th align="left" rowspan="1" colspan="1">Test</th><th align="left" rowspan="1" colspan="1">AUC</th><th align="left" rowspan="1" colspan="1">Specificity (at 85% sensitivity)</th><th align="left" rowspan="1" colspan="1">Optimal cutoff score</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">CU vs AD</td><td align="left" rowspan="1" colspan="1">CCI Self</td><td align="left" rowspan="1" colspan="1">0.792(CI 0.719&#8211;0.866)</td><td align="left" rowspan="1" colspan="1">58%</td><td align="left" rowspan="1" colspan="1">41.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI Informant</td><td align="left" rowspan="1" colspan="1">0.984(CI 0.971&#8211;0.997)</td><td align="left" rowspan="1" colspan="1">98%</td><td align="left" rowspan="1" colspan="1">51.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Self</td><td align="left" rowspan="1" colspan="1">0.805(CI 0.734&#8211;0.876)</td><td align="left" rowspan="1" colspan="1">72%</td><td align="left" rowspan="1" colspan="1">28.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Informant</td><td align="left" rowspan="1" colspan="1">0.980(CI.964&#8211;0.995)</td><td align="left" rowspan="1" colspan="1">98%</td><td align="left" rowspan="1" colspan="1">32.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI full sum</td><td align="left" rowspan="1" colspan="1">0.965(0.943&#8211;0.986)</td><td align="left" rowspan="1" colspan="1">94%</td><td align="left" rowspan="1" colspan="1">89.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Sum</td><td align="left" rowspan="1" colspan="1">0.965(0.942&#8211;0.988)</td><td align="left" rowspan="1" colspan="1">93%</td><td align="left" rowspan="1" colspan="1">56.5</td></tr></tbody></table><table-wrap-foot><fn id="alz70754-tbl13-note-0001"><p>Abbreviations: AD, Alzheimer's disease; AUC, area under the receiver operator characteristic curve; CCI, Cognitive Change Index; CI, confidence interval; CU, cognitively unimpaired.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><table-wrap position="float" id="alz70754-tbl-0014" content-type="TABLE" orientation="portrait"><label>TABLE 6A</label><caption><p>Cognitively unimpaired versus MCI (4+ years of higher education).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Parameter</th><th align="left" rowspan="1" colspan="1">Test</th><th align="left" rowspan="1" colspan="1">AUC</th><th align="left" rowspan="1" colspan="1">Specificity (at 85% sensitivity)</th><th align="left" rowspan="1" colspan="1">Optimal cutoff score</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">CU vs MCI</td><td align="left" rowspan="1" colspan="1">CCI Self</td><td align="left" rowspan="1" colspan="1">0.830(CI 0.772&#8211;0.889)</td><td align="left" rowspan="1" colspan="1">73%</td><td align="left" rowspan="1" colspan="1">40.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI Informant</td><td align="left" rowspan="1" colspan="1">0.853(CI 0.792&#8211;0.915)</td><td align="left" rowspan="1" colspan="1">75%</td><td align="left" rowspan="1" colspan="1">30.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Self</td><td align="left" rowspan="1" colspan="1">0.839(CI 0.781&#8211;0.897)</td><td align="left" rowspan="1" colspan="1">69%</td><td align="left" rowspan="1" colspan="1">29.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Informant</td><td align="left" rowspan="1" colspan="1">0.849(CI 0.786&#8211;0.913)</td><td align="left" rowspan="1" colspan="1">64%</td><td align="left" rowspan="1" colspan="1">20.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI full sum</td><td align="left" rowspan="1" colspan="1">0.890(0.841&#8211;0.938)</td><td align="left" rowspan="1" colspan="1">82%</td><td align="left" rowspan="1" colspan="1">70.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Sum</td><td align="left" rowspan="1" colspan="1">0.901(0.856&#8211;0.946)</td><td align="left" rowspan="1" colspan="1">82%</td><td align="left" rowspan="1" colspan="1">51.5</td></tr></tbody></table><table-wrap-foot><fn id="alz70754-tbl14-note-0001"><p>Abbreviations: AUC, area under the receiver operator characteristic curve; CCI, Cognitive Change Index; CI, confidence interval; CU, cognitively unimpaired; MCI, mild cognitive impairment.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><table-wrap position="float" id="alz70754-tbl-0015" content-type="TABLE" orientation="portrait"><label>TABLE 6B</label><caption><p>Cognitively unimpaired versus impaired (MCI+AD) (4+ years of higher education).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Parameter</th><th align="left" rowspan="1" colspan="1">Test</th><th align="left" rowspan="1" colspan="1">AUC</th><th align="left" rowspan="1" colspan="1">Specificity (at 85% sensitivity)</th><th align="left" rowspan="1" colspan="1">Optimal cutoff score</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">CU vs Impaired</td><td align="left" rowspan="1" colspan="1">CCI Self</td><td align="left" rowspan="1" colspan="1">0.809(CI 0.753&#8211;0.866)</td><td align="left" rowspan="1" colspan="1">69%</td><td align="left" rowspan="1" colspan="1">38.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI Informant</td><td align="left" rowspan="1" colspan="1">0.889(CI 0.842&#8211;0.937)</td><td align="left" rowspan="1" colspan="1">84%</td><td align="left" rowspan="1" colspan="1">33.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Self</td><td align="left" rowspan="1" colspan="1">0.815(CI 0.760&#8211;0.871)</td><td align="left" rowspan="1" colspan="1">64%</td><td align="left" rowspan="1" colspan="1">28.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Informant</td><td align="left" rowspan="1" colspan="1">0.885(CI 0.836&#8211;0.934)</td><td align="left" rowspan="1" colspan="1">82%</td><td align="left" rowspan="1" colspan="1">20.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI full sum</td><td align="left" rowspan="1" colspan="1">0.909(0.870&#8211;0.948)</td><td align="left" rowspan="1" colspan="1">85%</td><td align="left" rowspan="1" colspan="1">73.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Sum</td><td align="left" rowspan="1" colspan="1">0.916(0.880&#8211;0.952)</td><td align="left" rowspan="1" colspan="1">87%</td><td align="left" rowspan="1" colspan="1">49.5</td></tr></tbody></table><table-wrap-foot><fn id="alz70754-tbl15-note-0001"><p>Abbreviations: AD, Alzheimer's disease; AUC, area under the receiver operator characteristic curve; CCI, Cognitive Change Index; CI, confidence interval; CU, cognitively unimpaired; MCI, mild cognitive impairment.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><table-wrap position="float" id="alz70754-tbl-0016" content-type="TABLE" orientation="portrait"><label>TABLE 6C</label><caption><p>Cognitively unimpaired versus AD (4+ years of higher education).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Parameter</th><th align="left" rowspan="1" colspan="1">Test</th><th align="left" rowspan="1" colspan="1">AUC</th><th align="left" rowspan="1" colspan="1">Specificity (at 85% sensitivity)</th><th align="left" rowspan="1" colspan="1">Optimal cutoff score</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">CU vs AD</td><td align="left" rowspan="1" colspan="1">CCI Self</td><td align="left" rowspan="1" colspan="1">0.752(CI 0.637&#8211;0.867)</td><td align="left" rowspan="1" colspan="1">46%</td><td align="left" rowspan="1" colspan="1">41.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI Informant</td><td align="left" rowspan="1" colspan="1">0.986(CI 0.972&#8211;0.999)</td><td align="left" rowspan="1" colspan="1">97%</td><td align="left" rowspan="1" colspan="1">43.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Self</td><td align="left" rowspan="1" colspan="1">0.751(CI 0.639&#8211;0.863)</td><td align="left" rowspan="1" colspan="1">59%</td><td align="left" rowspan="1" colspan="1">28.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Informant</td><td align="left" rowspan="1" colspan="1">0.982(CI.964&#8211;0.999)</td><td align="left" rowspan="1" colspan="1">98%</td><td align="left" rowspan="1" colspan="1">33.0</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI full sum</td><td align="left" rowspan="1" colspan="1">0.960(0.929&#8211;0.991)</td><td align="left" rowspan="1" colspan="1">94%</td><td align="left" rowspan="1" colspan="1">88.5</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CCI12 Sum</td><td align="left" rowspan="1" colspan="1">0.957(0.919&#8211;0.995)</td><td align="left" rowspan="1" colspan="1">94%</td><td align="left" rowspan="1" colspan="1">49.5</td></tr></tbody></table><table-wrap-foot><fn id="alz70754-tbl16-note-0001"><p>Abbreviations: AD, Alzheimer's disease; AUC, area under the receiver operator characteristic curve; CCI, Cognitive Change Index; CI, confidence interval; CU, cognitively unimpaired.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec></sec><sec id="alz70754-sec-0200"><label>4</label><title>DISCUSSION</title><p>The CCI performed well in distinguishing CU older adults from those with MCI and AD dementia, with both the full 20&#8208;item form and the shorter 12 episodic memory form performing as well. The CCI&#8208;12 also performed well at distinguishing cognitively normal participants from those with MCI and AD, with no statistically significant difference between the AUC of any of the CCI&#8208;12 and the full CCI. For the Self, Informant, and Sum versions of the CCI, the best performance was seen in distinguishing CU from those with AD, in line with other dementia screening tools. Notably, the CCI full sum form performed well at distinguishing CU individuals from those with MCI, with a specificity of 83% and sensitivity of 85% (AUC&#160;=&#160;0.899). Differentiation of MCI from CU individuals in dementia screening has been a challenging area for subjective rating instruments. The present results compare favorably to the ECog, which achieved a lower AUC of 0.79 according to a previous study.<xref rid="alz70754-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>
</p><p>We found that the informant form of the CCI performed well as a screening tool, and the combination of informant scores added to the individual's own score improved its discriminative ability in differentiating CU individuals from those with MCI. This finding is consistent with previous research showing increased subject awareness of cognitive decline in the earliest stages of disease and that this subjective awareness may be more reliable than that of an informant.<xref rid="alz70754-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> As the disease process worsens, patients often increasingly lose awareness of their cognitive deficits, increasing the benefit of using informant ratings in the screening and assessment process.<xref rid="alz70754-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="alz70754-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>
</p><p>Informant scores have been studied previously and found to be useful in distinguishing those with dementia from those without, especially when used in conjunction with established cognitive screening tests such as the MMSE.<xref rid="alz70754-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> Several unified and standardized forms incorporate informant evaluation, such as the Questionnaire on Cognitive Decline in the Elderly (IQCODE) and the General Practitioner Assessment of Cognition (CPCOG), and these forms have been shown to be effective in utilizing informant information to screen for dementia.<xref rid="alz70754-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="alz70754-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> However, these forms have mostly been studied in the setting of dementia screening, and information about discriminative ability with MCI is less robust.</p><p>The ability to screen for MCI in the primary care setting represents an excellent opportunity for early clinical intervention. MCI is often an early manifestation of AD pathology, with one study finding an annual dementia conversion rate of around 18% for those with late&#8208;stage MCI, making timely intervention paramount.<xref rid="alz70754-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>, <xref rid="alz70754-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> Another important group to consider in screening is SCD, a component feature of MCI, but absent psychometric evidence of impairment or significant functional decline. SCD is predictive of both MCI and progression to dementia.<xref rid="alz70754-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>, <xref rid="alz70754-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> The CCI assesses SCD and perception of functional activity and is easily administered in the primary care setting, making it suitable for the identification of cognitive concerns, a core feature of MCI and early AD, in the context of screening protocols.<xref rid="alz70754-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>
</p><p>With the approval of new disease&#8208;modifying agents for the treatment of AD, early detection and timely diagnosis in AD management take on even greater importance. Clinical trials involving these anti&#8208;amyloid beta antibody drugs have found a relationship between the amount of amyloid removed from the brain and clinical benefit, and the introduction of early treatment may be able to further slow the amyloid cascade hypothesized to be responsible for the widespread neuronal loss and resulting cognitive impairment in AD.<xref rid="alz70754-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref>, <xref rid="alz70754-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> Enabling primary care clinicians to efficiently detect MCI and early AD can help facilitate timely referral to needed specialists as well as improve overall longitudinal care.<xref rid="alz70754-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref>
</p><p>Our study did have several limitations. The CCI informant and sum scores both rely on informant reports regarding patient status, which can be limited due to a variety of factors, such as lack of informant reliability or the incorrect attribution of the patient's cognitive deficits by the informant to aging. Our results suggest that the discriminative ability of the CCI may be somewhat lower for African American individuals as well as those with lower educational attainment. However, sample sizes for the African American group as well as those with lower education were limited. Further research with larger ethnically and educationally diverse samples would be useful to further assess these effects. Research regarding optimal cutoff points for the CCI is ongoing and is expected to further advance in relation to current staging frameworks incorporating neuroimaging and fluid biomarkers. More objective reference standards can be anticipated as additional longitudinal outcome data and biomarker evidence enable optimizing cutoffs tailored for specific clinical trials or healthcare purposes.</p><p>In conclusion, the CCI discriminates well between CU individuals and those with cognitive impairment due to MCI or early&#8208;stage AD dementia. The CCI self&#8208;plus&#8208;informant sum score was especially effective in distinguishing between those with MCI and CU individuals. Our results provide further evidence in support of the utility of the CCI as an efficient tool that could be adapted to the primary care setting for early detection of cognitive decline. However, most studies of the CCI to date are in tertiary or community&#8208;based settings, and studies specific to the primary care setting are warranted. Future directions for research also involve using longitudinal data on CCI scores to predict the risk of dementia status conversion. Additionally, questions remain about which cutoff point is optimal for screening use and how this can be assessed. Establishing and testing several cutoff points in real&#8208;world screening settings and evaluating cutoff point accuracy against clinical outcomes and reference standards and in relation to other assessment tools will help optimize guidance on the role of the CCI in dementia screening.</p></sec><sec sec-type="COI-statement" id="alz70754-sec-0220"><title>CONFLICT OF INTEREST STATEMENT</title><p>A.S. receives support from multiple NIH grants (P30 AG010133, P30 AG072976, R01 AG019771, R01 AG057739, U19 <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="AG024904">AG024904</ext-link>, R01 LM013463, R01 AG068193, R01 AG092591, T32 <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="AG071444">AG071444</ext-link>, U01 <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="AG068057">AG068057</ext-link>, U01 <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="AG072177">AG072177</ext-link>, U19 <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="AG074879">AG074879</ext-link>, as well as U24 <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="AG074855">AG074855</ext-link>). He has also received in&#8208;kind support from Avid Radiopharmaceuticals, a subsidiary of Eli Lilly (PET tracer precursor) and Gates Ventures, LLC and Sanofi (Proteomics panel assays on IADRC and KBASE participants as part of the Global Neurodegeneration Proteomics Consortium), and has participated in Scientific Advisory Boards (Bayer Oncology, Eisai, Novo Nordisk, and Siemens Medical Solutions USA, Inc) and an Observational Study Monitoring Board (MESA, NIH NHLBI), as well as External Advisory Committees for multiple NIA grants. He also serves as Editor&#8208;in&#8208;Chief of Brain Imaging and Behavior, a Springer&#8208;Nature Journal. J.B. has received research support from Alnylam Pharmaceuticals, Athira, Biogen, Eisai America Inc, Eli Lilly and Company, University of Southern California, Washington University, ABBVIE, Avanir Pharmaceuticals, Axoyant SCI, Green Valley Pharmaceuticals co, F. Hoffman&#8208;La Roche Ltd, Takeda Pharmaceuticals, University of Southern California&#160;and is an advisor for Eli Lilly and Company&#160;and Eisai. L.G.A. has received research and funding support from the NIH, Alzheimer's Association, AVID Pharmaceuticals, Eli Lilly, Roche Diagnostics, and Life molecular imaging and has served as a consultant for Biogen, Two Labs, IQVIA, Fl Dept of health, Genentech, Siemens, Corium, NIH biobank, Eli Lily, GE Healthcare, Eisai, Roche Diagnostics, Alnylam, and Otsuka. S.M. receives research support from the Alzheimer's Association grant AARGD&#8208;NTF&#8208;22&#8208;971546. F.W.U. receives research support from NIH grant P30AG072976. D.G.C. has received previous research support from Alector and has previously served as a consultant for Eli Lily. Se.W. receives research support from the Alzheimer's Disease Data Initiative and the William H. Gates Sr. Fellowship. S.G. receives research support from NIH grants P30AG072976, K07AG076659. All other authors report no disclosures. Author disclosures are available in the <xref rid="alz70754-supinfo-0001" ref-type="">supporting information</xref>.</p></sec><sec id="alz70754-sec-0250"><title>CONSENT STATEMENT</title><p>Written informed consent was obtained from all participants according to the Declaration of Helsinki and the Belmont Report under an institutional review board (IRB) approved protocol.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="alz70754-supinfo-0001" position="float" content-type="local-data" orientation="portrait"/><supplementary-material id="alz70754-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70754-s001.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="alz70754-sec-0210"><title>ACKNOWLEDGMENTS</title><p>Support for this work is from the National Institute on Aging (P30 AG072976, P30 AG10133, R01 AG19771, K01 AG049050, R01 AG061788, R01 AG057739, U19 AG024904, R01 LM013463, R01 AG068193, R01 AG092591, T32 AG071444, U01 AG068057, U01 AG072177, U19 AG074879, as well as U24 AG074855 and K07AG076659) and Donor's Cure Foundation.&#160; The funding sources were not involved in study design, the collection, analysis, and interpretation of data, the writing of the report, or in the decision to submit the article for publication.</p></ack><sec sec-type="data-availability" id="alz70754-sec-0240"><title>DATA AVAILABILITY STATEMENT</title><p>The data reported in this study were collected at Indiana University School of Medicine as part of the Indiana Memory and Aging Study (IMAS) and Indiana Alzheimer's Disease Research Center (IADRC). Deidentified data included in this report are available to researchers on request through the IADRC web portal.</p></sec><ref-list id="alz70754-bibl-0001"><title>REFERENCES</title><ref id="alz70754-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="alz70754-cite-0002"><article-title>2025 Alzheimer's disease facts and figures</article-title>. <source>Alzheimers Dement</source>. <year>2025</year>;<volume>21</volume>(<issue>4</issue>):<elocation-id>e70235</elocation-id>.</mixed-citation></ref><ref id="alz70754-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="alz70754-cite-0003"><string-name name-style="western"><surname>Budd Haeberlein</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Aisen</surname><given-names>PS</given-names></string-name>, <string-name name-style="western"><surname>Barkhof</surname><given-names>F</given-names></string-name>, et&#160;al. <article-title>Two randomized phase 3 studies of Aducanumab in early Alzheimer's disease</article-title>. <source>J Prev Alzheimers Dis</source>. <year>2022</year>;<volume>9</volume>:<fpage>197</fpage>&#8208;<lpage>210</lpage>.<pub-id pub-id-type="pmid">35542991</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14283/jpad.2022.30</pub-id></mixed-citation></ref><ref id="alz70754-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="alz70754-cite-0004"><string-name name-style="western"><surname>Dobson</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Patterson</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Malik</surname><given-names>R</given-names></string-name>, et&#160;al. <article-title>Eligibility for antiamyloid treatment: preparing for disease&#8208;modifying therapies for Alzheimer's disease</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>2024</year>;<volume>95</volume>:<fpage>796</fpage>&#8208;<lpage>803</lpage>.<pub-id pub-id-type="pmid">38862265</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp-2024-333468</pub-id><pub-id pub-id-type="pmcid">PMC11347253</pub-id></mixed-citation></ref><ref id="alz70754-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="alz70754-cite-0005"><string-name name-style="western"><surname>Belder</surname><given-names>CRS</given-names></string-name>, <string-name name-style="western"><surname>Schott</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Fox</surname><given-names>NC</given-names></string-name>. <article-title>Preparing for disease&#8208;modifying therapies in Alzheimer's disease</article-title>. <source>Lancet Neurol</source>. <year>2023</year>;<volume>22</volume>:<fpage>782</fpage>&#8208;<lpage>783</lpage>.<pub-id pub-id-type="pmid">37463598</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(23)00274-0</pub-id></mixed-citation></ref><ref id="alz70754-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="alz70754-cite-0006"><string-name name-style="western"><surname>Dubois</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Padovani</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Scheltens</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Rossi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Dell'Agnello</surname><given-names>G</given-names></string-name>. <article-title>Timely diagnosis for Alzheimer's disease: a literature review on benefits and challenges</article-title>. <source>J Alzheimers Dis</source>. <year>2016</year>;<volume>49</volume>:<fpage>617</fpage>&#8208;<lpage>631</lpage>.<pub-id pub-id-type="pmid">26484931</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-150692</pub-id><pub-id pub-id-type="pmcid">PMC4927869</pub-id></mixed-citation></ref><ref id="alz70754-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="alz70754-cite-0007"><string-name name-style="western"><surname>Boustani</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Callahan</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Unverzagt</surname><given-names>FW</given-names></string-name>, et&#160;al. <article-title>Implementing a screening and diagnosis program for dementia in primary care</article-title>. <source>J Gen Intern Med</source>. <year>2005</year>;<volume>20</volume>:<fpage>572</fpage>&#8208;<lpage>577</lpage>.<pub-id pub-id-type="pmid">16050849</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1525-1497.2005.0126.x</pub-id><pub-id pub-id-type="pmcid">PMC1490164</pub-id></mixed-citation></ref><ref id="alz70754-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="alz70754-cite-0008"><string-name name-style="western"><surname>Apesoa&#8208;Varano</surname><given-names>EC</given-names></string-name>, <string-name name-style="western"><surname>Barker</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Hinton</surname><given-names>L</given-names></string-name>. <article-title>Curing and caring: the work of primary care physicians with dementia patients</article-title>. <source>Qual Health Res</source>. <year>2011</year>;<volume>21</volume>:<fpage>1469</fpage>&#8208;<lpage>1483</lpage>.<pub-id pub-id-type="pmid">21685311</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1049732311412788</pub-id><pub-id pub-id-type="pmcid">PMC3581606</pub-id></mixed-citation></ref><ref id="alz70754-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="alz70754-cite-0009"><string-name name-style="western"><surname>Judge</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Roberts</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Khandker</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ambegaonkar</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Black</surname><given-names>CM</given-names></string-name>. <article-title>Physician perceptions about the barriers to prompt diagnosis of mild cognitive impairment and Alzheimer's disease</article-title>. <source>Int J Alzheimers Dis</source>. <year>2019</year>;<volume>2019</volume>:<elocation-id>3637954</elocation-id>.<pub-id pub-id-type="pmid">31263595</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2019/3637954</pub-id><pub-id pub-id-type="pmcid">PMC6556253</pub-id></mixed-citation></ref><ref id="alz70754-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="alz70754-cite-0010"><string-name name-style="western"><surname>Meulen</surname><given-names>EF</given-names></string-name>, <string-name name-style="western"><surname>Schmand</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>van Campen</surname><given-names>JP</given-names></string-name>, et&#160;al. <article-title>The seven minute screen: a neurocognitive screening test highly sensitive to various types of dementia</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>2004</year>;<volume>75</volume>:<fpage>700</fpage>&#8208;<lpage>705</lpage>.<pub-id pub-id-type="pmid">15090563</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp.2003.021055</pub-id><pub-id pub-id-type="pmcid">PMC1763549</pub-id></mixed-citation></ref><ref id="alz70754-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="alz70754-cite-0011"><string-name name-style="western"><surname>Nasreddine</surname><given-names>ZS</given-names></string-name>, <string-name name-style="western"><surname>Phillips</surname><given-names>NA</given-names></string-name>, <string-name name-style="western"><surname>Bedirian</surname><given-names>V</given-names></string-name>, et&#160;al. <article-title>The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment</article-title>. <source>J Am Geriatr Soc</source>. <year>2005</year>;<volume>53</volume>:<fpage>695</fpage>&#8208;<lpage>699</lpage>.<pub-id pub-id-type="pmid">15817019</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1532-5415.2005.53221.x</pub-id></mixed-citation></ref><ref id="alz70754-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="alz70754-cite-0012"><string-name name-style="western"><surname>Tomaszewski Farias</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mungas</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Harvey</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Simmons</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Reed</surname><given-names>BR</given-names></string-name>, <string-name name-style="western"><surname>Decarli</surname><given-names>C</given-names></string-name>. <article-title>The measurement of Everyday Cognition: development and validation of a short form of the Everyday Cognition scales</article-title>. <source>Alzheimers Dement</source>. <year>2011</year>;<volume>7</volume>:<fpage>593</fpage>&#8208;<lpage>601</lpage>.<pub-id pub-id-type="pmid">22055976</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2011.02.007</pub-id><pub-id pub-id-type="pmcid">PMC3211103</pub-id></mixed-citation></ref><ref id="alz70754-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="alz70754-cite-0013"><string-name name-style="western"><surname>Gavett</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Dunn</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Stoddard</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Harty</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Weintraub</surname><given-names>S</given-names></string-name>. <article-title>The Cognitive Change in Women Study (CCW): informant ratings of cognitive change but not self&#8208;ratings are associated with neuropsychological performance over 3 years</article-title>. <source>Alzheimer Dis Assoc Disord</source>. <year>2011</year>;<volume>25</volume>:<fpage>305</fpage>&#8208;<lpage>311</lpage>.<pub-id pub-id-type="pmid">22086219</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/WAD.0b013e31820d8652</pub-id><pub-id pub-id-type="pmcid">PMC3220881</pub-id></mixed-citation></ref><ref id="alz70754-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="alz70754-cite-0014"><string-name name-style="western"><surname>Slavin</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Sachdev</surname><given-names>PS</given-names></string-name>, <string-name name-style="western"><surname>Kochan</surname><given-names>NA</given-names></string-name>, et&#160;al. <article-title>Predicting cognitive, functional, and diagnostic change over 4 years using baseline subjective cognitive complaints in the Sydney Memory and Ageing Study</article-title>. <source>Am J Geriatr Psychiatry</source>. <year>2015</year>;<volume>23</volume>:<fpage>906</fpage>&#8208;<lpage>914</lpage>.<pub-id pub-id-type="pmid">25441053</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jagp.2014.09.001</pub-id></mixed-citation></ref><ref id="alz70754-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="alz70754-cite-0015"><string-name name-style="western"><surname>Rattanabannakit</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Risacher</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>The Cognitive Change Index as a measure of self and informant perception of cognitive decline: relation to neuropsychological tests</article-title>. <source>J Alzheimers Dis</source>. <year>2016</year>;<volume>51</volume>:<fpage>1145</fpage>&#8208;<lpage>1155</lpage>.<pub-id pub-id-type="pmid">26923008</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-150729</pub-id><pub-id pub-id-type="pmcid">PMC4833578</pub-id></mixed-citation></ref><ref id="alz70754-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="alz70754-cite-0016"><string-name name-style="western"><surname>Saykin</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Wishart</surname><given-names>HA</given-names></string-name>, <string-name name-style="western"><surname>Rabin</surname><given-names>LA</given-names></string-name>, et&#160;al. <article-title>Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI</article-title>. <source>Neurology</source>. <year>2006</year>;<volume>67</volume>:<fpage>834</fpage>&#8208;<lpage>842</lpage>.<pub-id pub-id-type="pmid">16966547</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/01.wnl.0000234032.77541.a2</pub-id><pub-id pub-id-type="pmcid">PMC3488276</pub-id></mixed-citation></ref><ref id="alz70754-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="alz70754-cite-0017"><string-name name-style="western"><surname>Jessen</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Feyen</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Freymann</surname><given-names>K</given-names></string-name>, et&#160;al. <article-title>Volume reduction of the entorhinal cortex in subjective memory impairment</article-title>. <source>Neurobiology of Aging</source>. <year>2006</year>;<volume>27</volume>:<fpage>1751</fpage>&#8208;<lpage>1756</lpage>.<pub-id pub-id-type="pmid">16309795</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2005.10.010</pub-id></mixed-citation></ref><ref id="alz70754-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="alz70754-cite-0018"><string-name name-style="western"><surname>Wells</surname><given-names>LF</given-names></string-name>, <string-name name-style="western"><surname>Risacher</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>McDonald</surname><given-names>BC</given-names></string-name>, et&#160;al. <article-title>Measuring subjective cognitive decline in older adults: harmonization between the Cognitive Change Index and the measurement of Everyday Cognition instruments</article-title>. <source>J Alzheimers Dis</source>. <year>2022</year>;<volume>87</volume>:<fpage>761</fpage>&#8208;<lpage>769</lpage>.<pub-id pub-id-type="pmid">35367962</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-215388</pub-id><pub-id pub-id-type="pmcid">PMC9169561</pub-id></mixed-citation></ref><ref id="alz70754-bib-0018"><label>18</label><mixed-citation publication-type="miscellaneous" id="alz70754-cite-0019"><collab collab-type="authors">National Alzheimer's Coordinating Center</collab>
. <article-title>Uniform Data Set version 4. National Alzheimer's Coordinating Center (NACC)</article-title>. <year>2025</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://naccdata.org/nacc-collaborations/uds4-updates" ext-link-type="uri">https://naccdata.org/nacc&#8208;collaborations/uds4&#8208;updates</ext-link></mixed-citation></ref><ref id="alz70754-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="alz70754-cite-0020"><string-name name-style="western"><surname>Petersen</surname><given-names>RC</given-names></string-name>. <article-title>Mild cognitive impairment as a diagnostic entity</article-title>. <source>J Intern Med</source>. <year>2004</year>;<volume>256</volume>:<fpage>183</fpage>&#8208;<lpage>194</lpage>.<pub-id pub-id-type="pmid">15324362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2796.2004.01388.x</pub-id></mixed-citation></ref><ref id="alz70754-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="alz70754-cite-0021"><string-name name-style="western"><surname>McKhann</surname><given-names>GM</given-names></string-name>, <string-name name-style="western"><surname>Knopman</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Chertkow</surname><given-names>H</given-names></string-name>, et&#160;al. <article-title>The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging&#8208;Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease</article-title>. <source>Alzheimers Dement</source>. <year>2011</year>;<volume>7</volume>:<fpage>263</fpage>&#8208;<lpage>269</lpage>.<pub-id pub-id-type="pmid">21514250</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2011.03.005</pub-id><pub-id pub-id-type="pmcid">PMC3312024</pub-id></mixed-citation></ref><ref id="alz70754-bib-0021"><label>21</label><mixed-citation publication-type="book" id="alz70754-cite-0022"><collab collab-type="authors">Re Bowler</collab>
. <part-title>Auditory Verbal Learning Test (Rey AVLT)</part-title>. In: <person-group person-group-type="editor"><string-name name-style="western"><surname>Volkmar</surname><given-names>FR</given-names></string-name></person-group>, ed. <source>Encyclopedia of Autism Spectrum Disorders</source>. <publisher-name>Springer New York</publisher-name>; <year>2013</year>:<fpage>2591</fpage>&#8208;<lpage>2595</lpage>.</mixed-citation></ref><ref id="alz70754-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="alz70754-cite-0023"><string-name name-style="western"><surname>Boake</surname><given-names>C</given-names></string-name>. <article-title>From the Binet&#8208;Simon to the Wechsler&#8208;Bellevue: tracing the history of intelligence testing</article-title>. <source>J Clin Exp Neuropsychol</source>. <year>2002</year>;<volume>24</volume>:<fpage>383</fpage>&#8208;<lpage>405</lpage>.<pub-id pub-id-type="pmid">11992219</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1076/jcen.24.3.383.981</pub-id></mixed-citation></ref><ref id="alz70754-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="alz70754-cite-0024"><string-name name-style="western"><surname>Youden</surname><given-names>WJ</given-names></string-name>. <article-title>Index for rating diagnostic tests</article-title>. <source>Cancer</source>. <year>1950</year>;<volume>3</volume>:<fpage>32</fpage>&#8208;<lpage>35</lpage>.<pub-id pub-id-type="pmid">15405679</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1097-0142(1950)3:1&lt;32::aid-cncr2820030106&gt;3.0.co;2-3</pub-id></mixed-citation></ref><ref id="alz70754-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="alz70754-cite-0025"><string-name name-style="western"><surname>Li</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Neugroschl</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>X</given-names></string-name>, et&#160;al. <article-title>The utility of the Cognitive Function Instrument (CFI) to detect cognitive decline in non&#8208;demented older adults</article-title>. <source>J Alzheimers Dis</source>. <year>2017</year>;<volume>60</volume>:<fpage>427</fpage>&#8208;<lpage>437</lpage>.<pub-id pub-id-type="pmid">28854503</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-161294</pub-id><pub-id pub-id-type="pmcid">PMC6417419</pub-id></mixed-citation></ref><ref id="alz70754-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="alz70754-cite-0026"><string-name name-style="western"><surname>Bastin</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Giacomelli</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Mievis</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Lemaire</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Guillaume</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Salmon</surname><given-names>E</given-names></string-name>. <article-title>Anosognosia in mild cognitive impairment: lack of awareness of memory difficulties characterizes prodromal Alzheimer's disease</article-title>. <source>Front Psychiatry</source>. <year>2021</year>;<volume>12</volume>:<elocation-id>631518</elocation-id>.<pub-id pub-id-type="pmid">33868048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpsyt.2021.631518</pub-id><pub-id pub-id-type="pmcid">PMC8044313</pub-id></mixed-citation></ref><ref id="alz70754-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="alz70754-cite-0027"><string-name name-style="western"><surname>Monnot</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Brosey</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ross</surname><given-names>E</given-names></string-name>. <article-title>Screening for dementia: family caregiver questionnaires reliably predict dementia</article-title>. <source>J Am Board Fam Pract</source>. <year>2005</year>;<volume>18</volume>:<fpage>240</fpage>&#8208;<lpage>256</lpage>.<pub-id pub-id-type="pmid">15994470</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3122/jabfm.18.4.240</pub-id></mixed-citation></ref><ref id="alz70754-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="alz70754-cite-0028"><string-name name-style="western"><surname>Brodaty</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Connors</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Loy</surname><given-names>C</given-names></string-name>, et&#160;al. <article-title>Screening for dementia in primary care: a comparison of the GPCOG and the MMSE</article-title>. <source>Dement Geriatr Cogn Disord</source>. <year>2016</year>;<volume>42</volume>:<fpage>323</fpage>&#8208;<lpage>330</lpage>.<pub-id pub-id-type="pmid">27811463</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000450992</pub-id></mixed-citation></ref><ref id="alz70754-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="alz70754-cite-0029"><string-name name-style="western"><surname>Quinn</surname><given-names>TJ</given-names></string-name>, <string-name name-style="western"><surname>Fearon</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Noel&#8208;Storr</surname><given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Young</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>McShane</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Stott</surname><given-names>DJ</given-names></string-name>. <article-title>Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling populations</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2021</year>;<volume>7</volume>:<elocation-id>Cd010079</elocation-id>.<pub-id pub-id-type="pmid">34278562</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD010079.pub3</pub-id><pub-id pub-id-type="pmcid">PMC8407460</pub-id></mixed-citation></ref><ref id="alz70754-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="alz70754-cite-0030"><string-name name-style="western"><surname>Morris</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Storandt</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Miller</surname><given-names>JP</given-names></string-name>, et&#160;al. <article-title>Mild cognitive impairment represents early&#8208;stage Alzheimer disease</article-title>. <source>Arch Neurol</source>. <year>2001</year>;<volume>58</volume>:<fpage>397</fpage>&#8208;<lpage>405</lpage>.<pub-id pub-id-type="pmid">11255443</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archneur.58.3.397</pub-id></mixed-citation></ref><ref id="alz70754-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="alz70754-cite-0031"><string-name name-style="western"><surname>Lin</surname><given-names>SY</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>PC</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>YC</given-names></string-name>, et&#160;al. <article-title>The clinical course of early and late mild cognitive impairment</article-title>. <source>Front Neurol</source>. <year>2022</year>;<volume>13</volume>:<elocation-id>685636</elocation-id>.<pub-id pub-id-type="pmid">35651352</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2022.685636</pub-id><pub-id pub-id-type="pmcid">PMC9149311</pub-id></mixed-citation></ref><ref id="alz70754-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="alz70754-cite-0032"><string-name name-style="western"><surname>Buckley</surname><given-names>RF</given-names></string-name>, <string-name name-style="western"><surname>Maruff</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Ames</surname><given-names>D</given-names></string-name>, et&#160;al. <article-title>Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease</article-title>. <source>Alzheimers Dement</source>. <year>2016</year>;<volume>12</volume>:<fpage>796</fpage>&#8208;<lpage>804</lpage>.<pub-id pub-id-type="pmid">26852195</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2015.12.013</pub-id></mixed-citation></ref><ref id="alz70754-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="alz70754-cite-0033"><string-name name-style="western"><surname>van Harten</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Mielke</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Swenson&#8208;Dravis</surname><given-names>DM</given-names></string-name>, et&#160;al. <article-title>Subjective cognitive decline and risk of MCI: the Mayo Clinic Study of Aging</article-title>. <source>Neurology</source>. <year>2018</year>;<volume>91</volume>:<elocation-id>e300</elocation-id>.<pub-id pub-id-type="pmid">29959257</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000005863</pub-id><pub-id pub-id-type="pmcid">PMC6070384</pub-id></mixed-citation></ref><ref id="alz70754-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="alz70754-cite-0034"><string-name name-style="western"><surname>Sabbagh</surname><given-names>MN</given-names></string-name>, <string-name name-style="western"><surname>Boada</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Borson</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>Early detection of mild cognitive impairment (MCI) in primary care</article-title>. <source>J Prev Alzheimers Dis</source>. <year>2020</year>;<volume>7</volume>:<fpage>165</fpage>&#8208;<lpage>170</lpage>.<pub-id pub-id-type="pmid">32463069</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14283/jpad.2020.21</pub-id></mixed-citation></ref><ref id="alz70754-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="alz70754-cite-0035"><string-name name-style="western"><surname>Haass</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Selkoe</surname><given-names>D</given-names></string-name>. <article-title>If amyloid drives Alzheimer disease, why have anti&#8208;amyloid therapies not yet slowed cognitive decline?</article-title>. <source>PLoS Biol</source>. <year>2022</year>;<volume>20</volume>:<elocation-id>e3001694</elocation-id>.<pub-id pub-id-type="pmid">35862308</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pbio.3001694</pub-id><pub-id pub-id-type="pmcid">PMC9302755</pub-id></mixed-citation></ref><ref id="alz70754-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="alz70754-cite-0036"><string-name name-style="western"><surname>Hardy</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Higgins</surname><given-names>GA</given-names></string-name>. <article-title>Alzheimer's disease: the amyloid cascade hypothesis</article-title>. <source>Science</source>. <year>1992</year>;<volume>256</volume>:<fpage>184</fpage>&#8208;<lpage>185</lpage>.<pub-id pub-id-type="pmid">1566067</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1566067</pub-id></mixed-citation></ref><ref id="alz70754-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="alz70754-cite-0037"><string-name name-style="western"><surname>Sideman</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hernandez de Jesus</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Primary care practitioner perspectives on the role of primary care in dementia diagnosis and care</article-title>. <source>JAMA Network Open</source>. <year>2023</year>;<volume>6</volume>:<elocation-id>e2336030</elocation-id>.<pub-id pub-id-type="pmid">37768660</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2023.36030</pub-id><pub-id pub-id-type="pmcid">PMC10539983</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Res Ther</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Res Ther</journal-id><journal-id journal-id-type="pmc-domain-id">943</journal-id><journal-id journal-id-type="pmc-domain">alzreth</journal-id><journal-title-group><journal-title>Alzheimer's Research &amp; Therapy</journal-title></journal-title-group><issn pub-type="epub">1758-9193</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12482854</article-id><article-id pub-id-type="pmcid-ver">PMC12482854.1</article-id><article-id pub-id-type="pmcaid">12482854</article-id><article-id pub-id-type="pmcaiid">12482854</article-id><article-id pub-id-type="pmid">41029733</article-id><article-id pub-id-type="doi">10.1186/s13195-025-01839-y</article-id><article-id pub-id-type="publisher-id">1839</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>petBrain: a new pipeline for amyloid, Tau tangles and neurodegeneration quantification using PET and MRI</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Coup&#233;</surname><given-names initials="P">Pierrick</given-names></name><address><email>pierrick.coupe@u-bordeaux.fr</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mansencal</surname><given-names initials="B">Boris</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Morandat</surname><given-names initials="F">Flor&#233;al</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Morell-Ortega</surname><given-names initials="S">Sergio</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Villain</surname><given-names initials="N">Nicolas</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Manj&#243;n</surname><given-names initials="JV">Jose V.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Planche</surname><given-names initials="V">Vincent</given-names></name><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/057qpr032</institution-id><institution-id institution-id-type="GRID">grid.412041.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 2106 639X</institution-id><institution>CNRS, Univ. Bordeaux, </institution></institution-wrap>Bordeaux INP, LABRI, UMR5800, Talence, F-33400 France </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01460j859</institution-id><institution-id institution-id-type="GRID">grid.157927.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 1770 5832</institution-id><institution>ITACA, Universitat Polit&#232;cnica de Val&#232;ncia, </institution></institution-wrap>Valencia, 46022 Spain </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02mh9a093</institution-id><institution-id institution-id-type="GRID">grid.411439.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2150 9058</institution-id><institution>Department of Neurology, Institute of Memory and Alzheimer&#8217;s Disease, </institution><institution>AP-HP Sorbonne Universit&#233;, H&#244;pital Piti&#233;-Salp&#234;tri&#232;re, </institution></institution-wrap>Paris, 75013 France </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02en5vm52</institution-id><institution-id institution-id-type="GRID">grid.462844.8</institution-id><institution-id institution-id-type="ISNI">0000 0001 2308 1657</institution-id><institution>Institut du Cerveau - ICM, Sorbonne Universit&#233;, INSERM U1127, CNRS 7225, </institution></institution-wrap>Paris, 75591 France </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01hq89f96</institution-id><institution-id institution-id-type="GRID">grid.42399.35</institution-id><institution-id institution-id-type="ISNI">0000 0004 0593 7118</institution-id><institution>Service de Neurologie des Maladies Neurod&#233;g&#233;n&#233;ratives, Centre M&#233;moire Ressources Recherche, </institution><institution>CHU Bordeaux, </institution></institution-wrap>Bordeaux, F-33000 France </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/057qpr032</institution-id><institution-id institution-id-type="GRID">grid.412041.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 2106 639X</institution-id><institution>Institut des Maladies Neurod&#233;g&#233;n&#233;ratives, </institution><institution>Univ. de Bordeaux, CNRS, UMR 5293, </institution></institution-wrap>Bordeaux, F-33000 France </aff></contrib-group><pub-date pub-type="epub"><day>30</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>17</volume><issue-id pub-id-type="pmc-issue-id">478170</issue-id><elocation-id>209</elocation-id><history><date date-type="received"><day>2</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>31</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>30</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-02 12:25:29.010"><day>02</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="13195_2025_Article_1839.pdf"/><abstract id="Abs1"><sec><title>Introduction</title><p id="Par1">Quantification of amyloid plaques (A), neurofibrillary tangles (T<sub>2</sub>), and neurodegeneration (N) using PET and MRI is critical for Alzheimer&#8217;s disease (AD) diagnosis and prognosis. Existing pipelines face limitations regarding processing time, tracer variability handling, and multimodal integration.</p></sec><sec><title>Methods</title><p id="Par2">We developed petBrain, a novel end-to-end processing pipeline for amyloid-PET, tau-PET, and structural MRI. It leverages deep learning-based segmentation, standardized biomarker quantification (Centiloid, CenTauR, HAVAs), and simultaneous estimation of A, T<sub>2</sub>, and N biomarkers. It is implemented in a web-based format, requiring no local computational infrastructure and software usage knowledge.</p></sec><sec><title>Results</title><p id="Par3">petBrain provides reliable, rapid quantification with results comparable to existing pipelines for A and T<sub>2</sub>, showing strong concordance with data processed in ADNI databases. The staging and quantification of A/T<sub>2</sub>/N by petBrain demonstrated good agreements with CSF/plasma biomarkers, clinical status and cognitive performance.</p></sec><sec><title>Discussion</title><p id="Par4">petBrain represents a powerful open platform for standardized AD biomarker analysis, facilitating clinical research applications.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s13195-025-01839-y.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>A/T/N model</kwd><kwd>Image processing</kwd><kwd>MRI segmentation</kwd><kwd>Centiloid</kwd><kwd>Centaur</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100001665</institution-id><institution>Agence Nationale de la Recherche</institution></institution-wrap></funding-source><award-id>ANR-23-CE45-0020-01</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>PEPR StratifyAging</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>GENCI</institution></funding-source><award-id>2022-AD011013848R1</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>Ministerio de Ciencia, Innovacion y Universidades of Spain</institution></funding-source><award-id>PID2023-152127OB-I00</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par5">Alzheimer&#8217;s disease (AD) is pathologically characterized by amyloid-&#946; (A&#946;) plaques, tau neurofibrillary tangles, and neurodegeneration. Recent recommendations from the Alzheimer&#8217;s Association (AA) establish amyloid-PET as the gold standard for identifying brain amyloidosis (A) in vivo, and tau PET for quantifying and staging tauopathy (T<sub>2</sub>). Neurodegeneration (N) can be defined using neuroimaging via structural MRI or FDG-PET [<xref ref-type="bibr" rid="CR1">1</xref>]. With the recent development of disease-modifying therapies such as anti-amyloid monoclonal antibodies in early AD, there is an increasing demand for standardized, automated imaging biomarker quantification to identify eligible patients, monitor target engagement, and assess disease progression in clinical trials and real-world settings [<xref ref-type="bibr" rid="CR2">2</xref>]. </p><p id="Par6">Several challenges hinder the routine application of the biological diagnosis and staging of AD using the A/T<sub>2</sub>/N imaging classification. First, manual or semi-automated workflows introduce variability, as different processing pipelines, regions of interest and thresholding techniques can yield inconsistent results [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Second, reproducibility is limited across research centers due to differences in scanner types, acquisition protocols, and tracer standardization. Moreover, time-consuming and labor-intensive procedures make it difficult to implement these biomarkers in large-scale clinical trials and multi-center academic studies. Finally, clinical translation is constrained, as biomarker quantification must be accurate, fast, and operator-independent for real-world applications.</p><p id="Par7">In the literature, various software solutions have been developed to analyze individual biomarkers of the A/T<sub>2</sub>/N biological framework. Several solutions exist for amyloid-PET imaging [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. For instance, the Centiloid (CL) Project proposed a pipeline based on SPM8 [<xref ref-type="bibr" rid="CR7">7</xref>], while the ADNI consortium developed a pipeline based on FreeSurfer [<xref ref-type="bibr" rid="CR8">8</xref>]. The CL scale [<xref ref-type="bibr" rid="CR7">7</xref>] is now a widely adopted method, endorsed for AD diagnosis by the European Medicines Agency (EMA). The CL scale standardizes amyloid-PET data across tracers and cohorts, facilitating cross-study comparisons. Moreover, some amyloid &#8220;PET-only&#8221; pipelines that do not require associated structural MRI, are now available [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. For tau-PET imaging, fewer solutions are available [<xref ref-type="bibr" rid="CR11">11</xref>] but the CenTauRz (CTRz) Project recently introduced the CapAIBL pipeline, to define a universal standard approach similar to the one used in the CL project [<xref ref-type="bibr" rid="CR12">12</xref>]. To quantify neurodegeneration using structural MRI, many generalist tools exist to segment brain structures, but few offer dedicated scores for AD. Most current methods focus on key structures such as the hippocampus to assist clinical interpretation of T1w MRI [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. The Hippocampal-Amygdalo-Ventricular Atrophy score (HAVAs) is, for instance, a structural biomarker that quantifies atrophy in the hippocampus, amygdala, and ventricles using normative and pathological lifespan models, which has been validated as a sensitive marker of AD-related neurodegeneration [<xref ref-type="bibr" rid="CR13">13</xref>]. </p><p id="Par8">Simple and integrated technical solutions enabling the simultaneous analysis of all pathological components of AD in individual patients would facilitate the broader application of the A/T<sub>2</sub>/N biological framework. Recently, the B-PIP pipeline has been proposed to produce A/T<sub>2</sub> biomarkers based on CL and Tau Standardized uptake value ratio (SUVr) [<xref ref-type="bibr" rid="CR15">15</xref>], but it does not provide CTRz universal values for standardizing tau imaging studies. Furthermore, no user-friendly, end-to-end solutions are currently available that can simultaneously estimate A/T<sub>2</sub>/N from neuroimaging data. To address these issues, we propose a fully automated A/T<sub>2</sub>/N pipeline, integrating state-of-the-art neuroimaging biomarkers for amyloid-PET, tau-PET, and MRI-derived neurodegeneration measures. This pipeline, named petBrain, ensures standardization, reproducibility, and scalability, making it well-suited for clinical research applications. In our pipeline, amyloid load (A) is quantified using the Centiloid scale [<xref ref-type="bibr" rid="CR7">7</xref>], tau neurofibrillary tangles (T<sub>2</sub>) are assessed using CTRz scale [<xref ref-type="bibr" rid="CR12">12</xref>] and neurodegeneration (N) is measured with HAVAs [<xref ref-type="bibr" rid="CR13">13</xref>]. In this article, we describe petBrain implementation, its methodological validation, and the assessment of its biological and clinical correlates, demonstrating its potential for biological staging of AD. To enable its simple, free, and large-scale use, the petBrain pipeline is freely available online on the user-friendly volBrain platform (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.volbrain.net">www.volbrain.net</ext-link>).</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Participants</title><sec id="Sec4"><title>GAAIN datasets</title><p id="Par9">This study used datasets collected from the publicly available Global Alzheimer&#8217;s Association Interactive Network (GAAIN) repository (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.gaain.org">https://www.gaain.org</ext-link>). First, we used 499 amyloid-PET images from the Centiloid project obtained with five different amyloid-PET tracers: <sup>11</sup>C-PiB (PiB), <sup>18</sup>F-Florbetapir (FBP), <sup>18</sup>F-Flutemetamol (FTM), <sup>18</sup>F-Florbetaben (FBB), and <sup>18</sup>F-NAV4694 (NAV). These images were accompanied by corresponding 3D T1-w MRI scans from patients with AD clinical syndrome, frontotemporal dementia (FTD), and mild cognitive impairment (MCI), as well as young and elderly cognitively unimpaired controls (Table&#160;<xref rid="Tab1" ref-type="table">1</xref> and supplementary material Sect.&#160;1). PET acquisition times varied by tracer: 50 to 70&#160;min post-injection for PiB and NAV, 50 to 60&#160;min post-injection for FBP, and 90 to 110&#160;min post-injection for FTM and FBB. Additionally, we used 100 tau PET images from the CTRz project, acquired using a single tau tracer, &#185;&#8312;F-Flortaucipir (FTP), along with corresponding 3D T1-w MRI scans from patients with dementia and elderly cognitively unimpaired controls.</p></sec><sec id="Sec5"><title>ADNI dataset</title><p id="Par10">To validate our pipeline on an external dataset, we used the Alzheimer&#8217;s Disease Neuroimaging Initiative (ADNI) database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://adni.loni.usc.edu">https://adni.loni.usc.edu</ext-link>). ADNI is a comprehensive study aimed at developing and validating biomarkers for AD diagnosis and progression. It includes imaging data (MRI, PET), clinical assessments, and biological measurements from blood and cerebrospinal fluid (CSF), collected from participants with normal cognition, mild cognitive impairment, and dementia. In this study, we used 821 subjects having at the same time a T1w MRI, an amyloid-PET and a tau-PET in order to validate our A/T<sub>2</sub>/N pipeline (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). The amyloid PET tracers were FBB and FBP, while the tau PET tracers were <sub>18</sub>F-MK6240 (MK) and <sub>18</sub>F-PI2620 (PI). The participants were selected within the clinical labels &#8220;Cognitively Normal (CN)&#8221;, &#8220;MCI&#8221;, and &#8220;AD dementia&#8221; provided by ADNI. Moreover, the amyloid status provided by the ADNI database has been used to classify subjects as amyloid-negative (A-) and amyloid-positive (A+). This status has been evaluated by ADNI with their own amyloid-PET pipeline [<xref ref-type="bibr" rid="CR8">8</xref>]. Finally, we collected individual global cognitive performance (i.e., Clinical Dementia Rating-sum of boxes (CDR-sb), Mini Mental State Examination (MMSE), and Montreal Cognitive Assessment (MoCA)) as well as their CSF and plasma biomarkers concentrations when available.</p><p id="Par11">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>GAAIN-Development and ADNI-Validation samples with amyloid and Tau PET tracers used to calibrate and validate PetBrain</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Amyloid Tracers per scan</th><th align="left" colspan="1" rowspan="1">Tau Tracers per scan</th><th align="left" colspan="1" rowspan="1">Age</th><th align="left" colspan="1" rowspan="1">Participant</th></tr><tr><th align="left" colspan="1" rowspan="1">GAAIN N&#8201;=&#8201;375</th><th align="left" colspan="1" rowspan="1">FBB / FBP / PiB / FTM / NAV</th><th align="left" colspan="1" rowspan="1">FTP / MK / PI</th><th align="left" colspan="1" rowspan="1">Mean (SD)</th><th align="left" colspan="1" rowspan="1">N</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">yCN</td><td align="left" colspan="1" rowspan="1">10 / 13 / 91 / 24 / 10</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">32.3&#8201;&#177;&#8201;7.4</td><td align="left" colspan="1" rowspan="1">77</td></tr><tr><td align="left" colspan="1" rowspan="1">CN</td><td align="left" colspan="1" rowspan="1">6 / 6 / 47 / 10 / 25</td><td align="left" colspan="1" rowspan="1">50 / 0 / 0</td><td align="left" colspan="1" rowspan="1">67.6&#8201;&#177;&#8201;8.4</td><td align="left" colspan="1" rowspan="1">97</td></tr><tr><td align="left" colspan="1" rowspan="1">MCI</td><td align="left" colspan="1" rowspan="1">9 / 10 / 49 / 20 / 10</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">74.4&#8201;&#177;&#8201;7.1</td><td align="left" colspan="1" rowspan="1">49</td></tr><tr><td align="left" colspan="1" rowspan="1">Dementia*</td><td align="left" colspan="1" rowspan="1">10 / 17 / 102 / 20 / 10</td><td align="left" colspan="1" rowspan="1">50 / 0 / 0</td><td align="left" colspan="1" rowspan="1">68.1&#8201;&#177;&#8201;8.5</td><td align="left" colspan="1" rowspan="1">152</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>A</bold>
<bold>DNI </bold>
<italic toggle="yes">N</italic>
<bold>&#8201;=&#8201;831</bold>
</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">CN A-</td><td align="left" colspan="1" rowspan="1">146 / 188 / 0 / 0 / 0</td><td align="left" colspan="1" rowspan="1">320 / 5 / 9</td><td align="left" colspan="1" rowspan="1">69.6&#8201;&#177;&#8201;7.1</td><td align="left" colspan="1" rowspan="1">344</td></tr><tr><td align="left" colspan="1" rowspan="1">CN A+</td><td align="left" colspan="1" rowspan="1">51 / 94 / 0 / 0 / 0</td><td align="left" colspan="1" rowspan="1">142 / 0 / 3</td><td align="left" colspan="1" rowspan="1">73.6&#8201;&#177;&#8201;7.8</td><td align="left" colspan="1" rowspan="1">145</td></tr><tr><td align="left" colspan="1" rowspan="1">MCI A-</td><td align="left" colspan="1" rowspan="1">63 / 65 / 0 / 0 / 0</td><td align="left" colspan="1" rowspan="1">123 / 3 / 2</td><td align="left" colspan="1" rowspan="1">71.7&#8201;&#177;&#8201;8.1</td><td align="left" colspan="1" rowspan="1">128</td></tr><tr><td align="left" colspan="1" rowspan="1">MCI A+</td><td align="left" colspan="1" rowspan="1">58 / 78 / 0 / 0 / 0</td><td align="left" colspan="1" rowspan="1">126 / 8 / 2</td><td align="left" colspan="1" rowspan="1">74.8&#8201;&#177;&#8201;7.2</td><td align="left" colspan="1" rowspan="1">136</td></tr><tr><td align="left" colspan="1" rowspan="1">Dementia** A-</td><td align="left" colspan="1" rowspan="1">10 / 4 / 0 / 0 / 0</td><td align="left" colspan="1" rowspan="1">11 / 2 / 1</td><td align="left" colspan="1" rowspan="1">74.0&#8201;&#177;&#8201;8.9</td><td align="left" colspan="1" rowspan="1">14</td></tr><tr><td align="left" colspan="1" rowspan="1">Dementia** A+</td><td align="left" colspan="1" rowspan="1">26 / 38 / 0 / 0 / 0</td><td align="left" colspan="1" rowspan="1">58 / 5 / 1</td><td align="left" colspan="1" rowspan="1">76.4&#8201;&#177;&#8201;9.5</td><td align="left" colspan="1" rowspan="1">64</td></tr></tbody></table><table-wrap-foot><p>The clinical labels yCN (young Cognitively Normal), CN (Cognitively Normal), MCI (Mild Cognitive Impairment) and Dementia were the labels provided by the GAAIN and ADNI datasets (see Sect.&#160;1 of supplementary material for more details)</p><p><sup>*</sup> Dementia diagnoses including AD clinical syndromes and FTD</p><p><sup>**</sup> Dementia with AD clinical syndrome</p></table-wrap-foot></table-wrap>
</p></sec></sec><sec id="Sec6"><title>The petBrain pipeline</title><sec id="Sec7"><title>Related works</title><p id="Par12">The CL scale, designed to standardize amyloid PET quantification across different radiotracers [<xref ref-type="bibr" rid="CR7">7</xref>], is computed through a pipeline that involves co-registration of MRI and PET images followed by spatial normalization to Montreal Neurological Institute (MNI) space using SPM8 [<xref ref-type="bibr" rid="CR17">17</xref>]. After transformation to this common space, standardized anatomical masks are applied, including a predefined global cortical target region&#8212;encompassing the prefrontal, parietal, temporal cortices and the frontal gyrus&#8212;as well as a reference region-of-interest (ROI), typically the whole cerebellum. A key strength of this approach lies in its open-source availability for academic use. However, the method presents several limitations: it requires manual reorientation of both PET and MRI volumes, access to a licensed MATLAB environment, and specific technical expertise in SPM8. In addition, the use of static anatomical masks may limit its adaptability and potentially reduce the accuracy of SUVr estimates in the presence of inter-individual anatomical variability.</p><p id="Par13">A comparable framework has been developed for tau PET imaging by the CTRz Project, which offers both a traditional implementation using SPM8, and a cloud-based version accessible through the CapAIBL platform (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://capaibl-milxcloud.csiro.au">https://capaibl-milxcloud.csiro.au</ext-link>) [<xref ref-type="bibr" rid="CR12">12</xref>]. The SPM8-based pipeline shares the advantages and limitations of the original CL method, offering open academic access but requiring local computational resources and expertise in neuroimaging. In contrast, CapAIBL delivers a user-friendly, web-based solution that removes the need for software installation or advanced technical skills. In line with the standards of the volBrain platform, CapAIBL ensures compliance with medical data privacy regulations by mandating anonymized image submissions. Moreover, as with the volBrain platform, all uploaded data are automatically and permanently deleted from secure servers after a fixed retention period, unless users have explicitly provided consent for their reuse in research.</p><p id="Par14">To address the limitations of fixed region-of-interest (ROI) masks, the ADNI pipeline [<xref ref-type="bibr" rid="CR7">7</xref>] introduced an alternative anatomical delineation approach using subject-specific ROIs derived from FreeSurfer-based segmentation [<xref ref-type="bibr" rid="CR18">18</xref>] of structural MRI, coupled with SPM12 registration. This pipeline offers improved anatomical precision and relies entirely on open-access software. However, it also presents notable drawbacks: the FreeSurfer segmentation process is computationally intensive (typically&#8201;&gt;&#8201;15&#160;h per subject) and requires substantial expertise for installation and operation.</p><p id="Par15">Until recently, most existing pipelines have focused on measuring either A or T<sub>2</sub> biomarkers individually. A recent advancement is the B-PIP pipeline [<xref ref-type="bibr" rid="CR15">15</xref>], an updated version of the ADNI approach, which supports simultaneous estimation of both A and T<sub>2</sub> biomarkers using FreeSurfer and SPM12. This marks a significant step toward implementing the A/T<sub>2</sub>/N framework in clinical research. However, this pipeline still relies on SUVr quantification for Tau, which limits its robustness across different tau tracers, and currently lacks full integration of the N biomarker.</p><p id="Par16">To leverage the strengths of existing methods while addressing their limitations, we have developed a novel end-to-end pipeline with the following key features:</p><p id="Par17">
<list list-type="bullet"><list-item><p id="Par18">Subject-specific ROI masks generated in under 15&#160;min via deep learning-based segmentation of 3D MRI, significantly reducing processing time compared to FreeSurfer.</p></list-item><list-item><p id="Par19">Robust biomarker quantification using standardized CL and CTRz scales, enabling consistent analysis across different amyloid and tau tracers (unlike SUVr-based approaches).</p></list-item><list-item><p id="Par20">Simultaneous estimation of A, T<sub>2</sub>, and N biomarkers within a unified processing framework.</p></list-item><list-item><p id="Par21">Web-based implementation requiring no local computational infrastructure or expertise in image processing software.</p></list-item></list>
</p></sec><sec id="Sec8"><title>Global overview</title><p id="Par22">An overview of the proposed petBrain pipeline is presented in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>. The pipeline delivers a comprehensive quantification of AD biomarkers by providing: (i) global amyloid and tau burden expressed on standardized scales &#8211; CL and CTRz, respectively; (ii) the degree of neurodegeneration estimated via the Hippocampal-Amygdalo-Ventricular Atrophy score (HAVAs); and (iii) the corresponding binary pathological status for each biomarker (A+/A&#8722;, T<sub>2</sub>+/T<sub>2</sub>&#8722;, N+/N&#8722;). Thresholds for classification are derived from externally validated studies: AMYPAD for CL, the CenTauR project for CTRz [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR18">18</xref>], and the original HAVAs publication for neurodegeneration [<xref ref-type="bibr" rid="CR13">13</xref>]. </p><p id="Par23">Additionally, petBrain provides automated segmentation and volumetric quantification of 132 brain structures using the AssemblyNet framework [<xref ref-type="bibr" rid="CR19">19</xref>]. Leveraging a normative lifespan model, the pipeline also estimates deviations from typical aging trajectories for each structure [<xref ref-type="bibr" rid="CR20">20</xref>]. Neurodegenerative status (N+/N&#8722;) is determined using the HAVAs score, which is derived from a pathological lifespan model based on a composite of amygdala, hippocampus, and inferior lateral ventricle volumes &#8211; a combination shown to be highly sensitive to typical Alzheimer&#8217;s-related atrophy [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Furthermore, petBrain computes SUVr for both amyloid and tau-PET across 122&#160;Gy matter regions, corresponding to the 132 segmented structures excluding white matter and cerebrospinal fluid (CSF) regions.</p><p id="Par24">To ensure broad accessibility and eliminate the need for local computational resources or specialized personnel, the petBrain pipeline is made available through the open-access volBrain platform (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.volbrain.net">www.volbrain.net</ext-link>). Launched in 2015, volBrain offers a suite of fully automated pipelines for brain MRI segmentation and computer-aided diagnosis. To date, the platform has processed over 700,000 images for more than 13,000 users worldwide (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.volbrain.net/users">www.volbrain.net/users</ext-link>). As with all volBrain pipelines, petBrain outputs a comprehensive results package, including a PDF report and corresponding CSV files containing all quantitative measurements. Additionally, users can download the full set of processed 3D images and segmentations as a compressed archive of NIfTI files, facilitating further visualization or analysis.</p><p id="Par25">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Global overview of the petBrain pipeline</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e713" position="float" orientation="portrait" xlink:href="13195_2025_1839_Fig1_HTML.jpg"/></fig>
</p></sec><sec id="Sec9"><title>T1w MRI processing</title><p id="Par26">The native T1w MRI of the subject is processed through the AssemblyNet pipeline [<xref ref-type="bibr" rid="CR19">19</xref>]. This pipeline includes a preprocessing step to harmonize data followed by a segmentation step based on deep learning.</p><sec id="Sec10"><title>Preprocessing</title><p id="Par27">The preprocessing step is based on the following steps: denoising [<xref ref-type="bibr" rid="CR22">22</xref>], ii) inhomogeneity correction [<xref ref-type="bibr" rid="CR23">23</xref>], affine registration into the MNI space (181&#8201;&#215;&#8201;217&#8201;&#215;&#8201;181 voxels at 1&#8201;&#215;&#8201;1&#8201;&#215;&#8201;1 mm<sup>3</sup>) [<xref ref-type="bibr" rid="CR24">24</xref>], tissue-based intensity normalization [<xref ref-type="bibr" rid="CR25">25</xref>] and intracranial extraction [<xref ref-type="bibr" rid="CR26">26</xref>]. Finally, image intensities are z-scored (i.e., centralized and normalized) within the brain mask and the background voxels were set to zero.</p></sec><sec id="Sec11"><title>Volume values</title><p id="Par28">The segmentation step is based on a large ensemble of deep learning models in order to provide accurate and robust segmentation of 132 structures as described in the Neuromorphometrics protocol (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://neuromorphometrics.com/Seg/">https://neuromorphometrics.com/Seg/</ext-link>). Finally, the volume values (native and normalized by intracranial volume) are estimated for all the structures. The normalized volume values are compared to a normal aging model [<xref ref-type="bibr" rid="CR20">20</xref>] to detect abnormalities indicated in the final PDF report.</p></sec><sec id="Sec12"><title>N status</title><p id="Par29">To estimate the neurodegenerative status of the subject under study, the HAVAs score is estimated using the AssemblyNet segmentation of the hippocampus, the amygdala and the inferior lateral ventricle. Based on lifespan modeling of normal aging and aging with AD [<xref ref-type="bibr" rid="CR21">21</xref>], the threshold between N&#8201;+&#8201;and N- is adapted according to the subject&#8217;s age as described in the original article (i.e., a probability higher than 0.5 is considered as N+) [<xref ref-type="bibr" rid="CR13">13</xref>]. We ensured that ADNI subjects involved during HAVAs model construction were not included in this study.</p></sec></sec><sec id="Sec13"><title>PET scan processing</title><sec id="Sec14"><title>Preprocessing</title><p id="Par30">The native PET scan are first rigidly registered to the native T1w MRI [<xref ref-type="bibr" rid="CR24">24</xref>]. By composing the obtained transformation with the transformation obtained from the registration of the T1w MRI into the MNI space, the PET was directly interpolated into the MNI space using a single interpolation to avoid additional blurring. Afterwards, a super-resolution method involving self-similarity within PET, and image priors based on T1w MRI, is used to compensate for partial volume effect of the PET scan [<xref ref-type="bibr" rid="CR27">27</xref>]. </p></sec><sec id="Sec15"><title>SUVr values</title><p id="Par31">The partial volume corrected (PVC) PET is then converted into SUVr using the AssemblyNet segmentation. As proposed by the CL and CTRz projects, we use the whole cerebellum for amyloid-PET and cerebellar gray matter for tau-PET as the reference ROI. Finally, SUVr values are estimated for all subcortical and cortical structures provided by AssemblyNet for amyloid and tau-PET and provided as CSV files.</p></sec><sec id="Sec16"><title>Centiloid/CenTauRz values</title><p id="Par32">The aim of the CL and CTRz projects was to harmonize the estimation of amyloid and tau load, and to homogenously define A+/A- or T<sub>2</sub>+/T<sub>2</sub>- status across tracers, scanners and pipelines. To this end, both projects proposed predefined masks in the MNI space (the same mask whatever the subject&#8217;s anatomy). To take advantage of having a subject-specific structure segmentation obtained from AssemblyNet, we defined a list of structures as CL and CTRz cortical masks and used the same reference masks as for SUVr estimation. For the estimation of our Centiloid mask, as suggested by Klunk et al. [<xref ref-type="bibr" rid="CR7">7</xref>] the GAAIN-PiB dataset was used to establish the list of the most discriminate structures between young CN (yCN) A- subjects and A&#8201;+&#8201;patients with dementia (see supplementary Table <xref rid="MOESM1" ref-type="media">1</xref> for the list of selected structures). For our CTRz mask, we used the a priori list of structures validated in several studies [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>] &#8211; entorhinal area, amygdala, parahippocampal gyrus, fusiform gyrus, inferior and middle temporal gyrus, and temporal pole (see supplementary Table <xref rid="MOESM1" ref-type="media">2</xref> for the list of selected structures). As subsequent results demonstrate, this mask closely resembles the MetaTemporal mask proposed by the CTRz project and B-PIP pipelines.</p></sec><sec id="Sec17"><title>A and T<sub>2</sub> status</title><p id="Par33">The CL and CTRz values are then used to estimate the A status and T<sub>2</sub> status of each subject. During the experiments presented in this article, we used the common threshold of 24.1 CL for Amyloid [<xref ref-type="bibr" rid="CR30">30</xref>]. However, for the online version of the pipeline, we decided to follow the recommendation of AMYPAD [<xref ref-type="bibr" rid="CR16">16</xref>] with CL&#8201;&lt;&#8201;10 considered as A-, CL between 10 and 30 as intermediate A<sup>inter</sup>, and CL&#8201;&gt;&#8201;30 as A+. For CTRz, we used the threshold proposed by the CenTauR project with a CTRz&#8201;&lt;&#8201;2 as T<sub>2</sub>- and T<sub>2</sub>&#8201;+&#8201;otherwise [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par34">Overall, the total processing time of the petBrain pipeline is approximately 20&#160;min: ~15&#160;min for global T1-weighted MRI preprocessing and segmentation, ~&#8201;1&#160;min for each rigid PET-to-T1 registration, and ~&#8201;1&#160;min per PVC step. This runtime is comparable to that of SPM-based pipelines and substantially faster than those based on FreeSurfer.</p></sec></sec></sec></sec><sec id="Sec18"><title>Results</title><sec id="Sec19"><title>Centiloid calibration</title><sec id="Sec20"><title>PiB calibration</title><p id="Par35">First, the GAAIN-PiB dataset was used to convert the original SPM8 Centiloid pipeline and petBrain. To this end, we performed the Level-1 calibration procedure [<xref ref-type="bibr" rid="CR7">7</xref>] and we obtained the following equation:<disp-formula id="Equ1"><label>1</label><alternatives><tex-math id="d33e843">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$CL=100\times \left({^{PiB}SUV{r_{petBrain}}-0.9659} \right)/(1.8972 - 0.9659)$$\end{document}</tex-math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="13195_2025_1839_Article_Equ1.gif"/></alternatives></disp-formula></p><p id="Par36">Therefore, an individual SUVr PiB value (<sup>PiB</sup>SUVr<sub>petBrain</sub>) obtained using our petBrain pipeline can be converted into CL value.</p><p id="Par37">Second, once calibrated, we compared the CL value obtained by petBrain with the CL values published by the Centiloid Project [<xref ref-type="bibr" rid="CR7">7</xref>] using the official SPM8-based pipeline to ensure that our Level-1 calibration meets Centiloid method criteria. As shown in Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">1</xref>, our calibration yielded to very high correlation between CL PiB published by the Centiloid Project [<xref ref-type="bibr" rid="CR7">7</xref>] and CL PiB obtained with petBrain. Moreover, the linear regression parameters (y&#8201;=&#8201;0.99x&#8201;+&#8201;0.57; R<sup>2</sup>=0.99) fitted in the Centiloid Project criteria (i.e., a slope between 0.98 and 1.02, an intercept between &#8722;&#8201;2 and +&#8201;2 CL, and an R<sup>2</sup>&#8201;&gt;&#8201;0.98).</p></sec><sec id="Sec21"><title>Amyloid tracers&#8217; calibration</title><p id="Par38">Once Level-1 calibration was obtained for PiB tracer, we estimated the Level-2 calibration for all other considered amyloid tracers (i.e., FBP, FBB, FTM and NAV). First, linear regressions were estimated between PiB and other tracers using the corresponding Centiloid Project datasets: the obtained regressions R<sup>2</sup> are summarized in Table&#160;<xref rid="Tab2" ref-type="table">2</xref> (see also supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">2</xref> for more details). Afterwards, the conversion between amyloid tracers and CL scale was obtained using the equation provided in Klunk et al., [<xref ref-type="bibr" rid="CR7">7</xref>]. The resulting conversion equations are also presented in Table&#160;<xref rid="Tab2" ref-type="table">2</xref>.</p><p id="Par39">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Equations used for centiloid calibration of PetBrain</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Amyloid Tracers</th><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">R</italic>
<sup>2</sup>
</th><th align="left" colspan="1" rowspan="1">Conversion equations</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">PiB</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">CL&#8201;=&#8201;107.3768 x <sup>PiB</sup>SUVr<sub>petBrain</sub> &#8722;&#8201;103.7152</td></tr><tr><td align="left" colspan="1" rowspan="1">FBP</td><td align="left" colspan="1" rowspan="1">0.92</td><td align="left" colspan="1" rowspan="1">CL&#8201;=&#8201;194.8721 x <sup>FBP</sup>SUVr<sub>petBrain</sub> &#8722;&#8201;191.8315</td></tr><tr><td align="left" colspan="1" rowspan="1">FBB</td><td align="left" colspan="1" rowspan="1">0.97</td><td align="left" colspan="1" rowspan="1">CL&#8201;=&#8201;165.2828 x <sup>FBB</sup>SUVr<sub>petBrain</sub> &#8722;&#8201;158.0409</td></tr><tr><td align="left" colspan="1" rowspan="1">FTM</td><td align="left" colspan="1" rowspan="1">0.95</td><td align="left" colspan="1" rowspan="1">CL&#8201;=&#8201;141.1563 x <sup>FTM</sup>SUVr<sub>petBrain</sub> &#8722;&#8201;128.3451</td></tr><tr><td align="left" colspan="1" rowspan="1">NAV</td><td align="left" colspan="1" rowspan="1">0.99</td><td align="left" colspan="1" rowspan="1">CL&#8201;=&#8201;104.8498 x <sup>NAV</sup>SUVr<sub>petBrain</sub> &#8722;&#8201;102.6445</td></tr></tbody></table></table-wrap>
</p></sec></sec><sec id="Sec22"><title>CenTauR calibration</title><p id="Par40">The CenTauR Project provides several predefined masks (i.e., universal, mesial-temporal, meta-temporal, temporo-parietal and frontal) [<xref ref-type="bibr" rid="CR12">12</xref>]. Our first step was to find the CenTauR&#8217;s mask that was the most correlated with our subject-specific mask. To this end, we estimated the relationships between published <sup>FTP</sup>SUVr<sub>CTR</sub> obtained for each mask and the <sup>FTP</sup>SUVr<sub>petBrain</sub> estimated with petBrain on the FTP dataset. Supplementary Table <xref rid="MOESM1" ref-type="media">3</xref> presents the R<sup>2</sup> obtained through linear regression. These results show that the predefined Meta-temporal CenTauR mask is the most similar to our subject-specific mask, including the entorhinal area, amygdala, parahippocampal gyrus, fusiform gyrus, inferior and middle temporal gyrus, and temporal pole (see Sect.&#160;5 of the supplementary material for the list of selected structures). Consequently, we used this mask in the following steps.</p><p id="Par41">Second, we used the linear regression between the published <sup>FTP</sup>SUVr<sub>CTR</sub> by the CenTauR Project using SPM8-based pipeline over the Meta-temporal mask and the <sup>FTP</sup>SURv<sub>petBrain</sub> estimated with petBrain. This yielded the following Level-1 calibration equation:<disp-formula id="Equ2"><label>2</label><alternatives><tex-math id="d33e1006">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{FTP}SUV{r_{CTR}} = \left({^{FTP}SUV{r_{petBrain}} - 0.2222} \right)/0.7646$$\end{document}</tex-math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="13195_2025_1839_Article_Equ2.gif"/></alternatives></disp-formula></p><p id="Par42">Third, once calibrated, we compared the CTR<sub>z</sub> values obtained by petBrain with the CTR<sub>z</sub> values published by the CenTauR Project [<xref ref-type="bibr" rid="CR12">12</xref>] using their SPM8 pipeline. Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">3</xref> presents the results of this comparison using their Meta-temporal mask (y&#8201;=&#8201;0.9804x&#8201;+&#8201;0.096; R<sup>2</sup>&#8201;=&#8201;0.9803). As for CL, the obtained linear regression parameters are a slope between 0.98 and 1.02 and an R<sup>2</sup>&#8201;&gt;&#8201;0.98.</p><p id="Par43">Contrary to the Centiloid project, where a dataset is available for each amyloid tracer, the CenTauR project provides only one dataset for the FTP tracer. Therefore, we directly used the pipeline calibration obtained on FTP (see Eq.&#160;2) to adapt petBrain to other tau tracers. By using the equations provided in Villemagne et al. [<xref ref-type="bibr" rid="CR12">12</xref>] for the Meta-Temporal mask, we obtained the conversion equations presented in Table&#160;<xref rid="Tab3" ref-type="table">3</xref> for five other tau-tracers: <sup>18</sup>F-RO948 (RO), <sup>18</sup>F-MK-6240 (MK), <sup>18</sup>F-GTP1 (GTP), <sup>18</sup>F-PM-PBB3 (PBB3) and <sup>18</sup>F-PI2620 (PI). </p><p id="Par44">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Equations used for centaur calibration of PetBrain</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Tau Tracer</th><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">R</italic>
<sup>2</sup>
</th><th align="left" colspan="1" rowspan="1">Conversion equations</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">FTP</td><td align="left" colspan="1" rowspan="1">0.98</td><td align="left" colspan="1" rowspan="1">CTRz&#8201;=&#8201;16.9370 x <sup>FTP</sup>SUVr<sub>petBrain</sub> &#8722;&#8201;19.1334</td></tr><tr><td align="left" colspan="1" rowspan="1">RO</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">CTRz&#8201;=&#8201;17.2116 x <sup>RO</sup>SUVr<sub>petBrain</sub> &#8722;&#8201;20.0144</td></tr><tr><td align="left" colspan="1" rowspan="1">MK</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">CTRz&#8201;=&#8201;12.2417 x <sup>MK</sup>SUVr<sub>petBrain</sub> &#8722;&#8201;12.7801</td></tr><tr><td align="left" colspan="1" rowspan="1">GTP</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">CTRz&#8201;=&#8201;12.5556 x <sup>GTP</sup>SUVr<sub>petBrain</sub> &#8722;&#8201;13.8899</td></tr><tr><td align="left" colspan="1" rowspan="1">PBB3</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">CTRz&#8201;=&#8201;15.4067 x <sup>PBB</sup>SUVr<sub>petBrain</sub> &#8722;&#8201;14.6334</td></tr><tr><td align="left" colspan="1" rowspan="1">PI</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">CTRz&#8201;=&#8201;10.1753 x <sup>PI</sup>SUVr<sub>petBrain</sub> &#8722;&#8201;11.5909</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec23"><title>Validation of petBrain on ADNI</title><sec id="Sec24"><title>Comparison of amyloid and Tau loads with state-of-the-art pipelines</title><p id="Par45">To further validate our pipeline, we conducted a comparative analysis of amyloid and tau burden estimates using an independent dataset. Specifically, we compared values derived from our petBrain pipeline with those obtained using SPM-based Centiloid and CenTauR pipelines, as well as the B-PIP pipeline [<xref ref-type="bibr" rid="CR15">15</xref>]. For the SPM-based methods, we employed the last version of SPM (i.e., SPM25) [<xref ref-type="bibr" rid="CR31">31</xref>]. Centiloid values were computed using the standard cortical target mask and the whole cerebellum as the reference region, consistent with the original calibration protocol. For CenTauR quantification, we employed the MetaTemporal target mask and the cerebellar grey matter as the reference region, in order to ensure maximal consistency with the masks used in the B-PIP and petBrain pipelines. Finally, B-PIP values correspond to the scalar scores provided directly by the ADNI consortium.</p><p id="Par46">First, we compared SPM-based Centiloid pipelines and petBrain using linear regression and intraclass correlation coefficient (ICC). As shown in Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref> (left panel), the two pipelines yielded highly correlated results (R<sup>2</sup>&#8201;=&#8201;0.94; ICC&#8201;=&#8201;0.97). Second, we compared CTRz values produced by SPM-based CenTauR pipelines and petBrain. Figure&#160;<xref rid="Fig2" ref-type="fig">2</xref> (right panel) also demonstrates a good correlation between pipelines (R<sup>2</sup>&#8201;=&#8201;0.84; ICC&#8201;=&#8201;0.92).</p><p id="Par47">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Comparison of Centiloid and CenTauR values obtained with petBrain and SPM-based pipelines</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1179" position="float" orientation="portrait" xlink:href="13195_2025_1839_Fig2_HTML.jpg"/></fig>
</p><p id="Par48">Afterwards, we assessed the concordance between B-PIP and petBrain CL values. As shown in Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref> (left panel), the two pipelines yielded highly correlated results (R<sup>2</sup>&#8201;=&#8201;0.96; ICC&#8201;=&#8201;0.98). Notably, a subset of CN A&#8201;+&#8201;individuals exhibited systematically higher CL values with petBrain compared to B-PIP, as illustrated in the Bland-Altman plot. Visual quality control of these outliers, using images and automated PDF reports generated by petBrain, revealed no apparent processing errors. Such verification was not feasible for B-PIP due to the absence of accessible intermediate outputs. The Bland&#8211;Altman analysis further revealed a slight but consistent upward bias for higher CL values, suggesting a non-uniform deviation between pipelines at the upper quantification range. We then compared Tau PET quantification between pipelines by evaluating Tau standardized SUVr in MetaTemporal mask, as B-PIP does not generate CTRz metrics. Figure&#160;<xref rid="Fig3" ref-type="fig">3</xref> (right panel) demonstrates a similarly strong correlation between pipelines for Tau SUVr (R<sup>2</sup>&#8201;=&#8201;0.95; ICC&#8201;=&#8201;0.96), though greater discrepancies were observed at higher SUVr values.</p><p id="Par49">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Comparison of Centiloid values and Tau SUVr obtained with petBrain and the value provided by B-PIP</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1201" position="float" orientation="portrait" xlink:href="13195_2025_1839_Fig3_HTML.jpg"/></fig>
</p><p id="Par50">Finally, we compared SPM-based pipelines and B-PIP. As shown in Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref> (left panel), Centiloid values obtained from the two pipelines were highly correlated (R<sup>2</sup>&#8201;=&#8201;0.90; ICC&#8201;=&#8201;0.95). Similar to observations made with petBrain, a subset of CN A&#8201;+&#8201;individuals showed systematically higher CL values with the SPM-based pipeline compared to B-PIP, suggesting possible failure in the B-PIP processing for these cases. We then compared Tau PET quantification using SUVr values from the SPM-based CenTauR pipeline versus B-PIP. As shown in Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref> (right panel), this comparison also demonstrated a strong correlation (R<sup>2</sup>&#8201;=&#8201;0.84; ICC&#8201;=&#8201;0.91), although greater dispersion &#8212; particularly among CN subjects &#8212; was observed.</p><p id="Par51">
<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Comparison of Centiloid values and Tau SUVr obtained with SPM-based pipelines and the value provided by B-PIP</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1223" position="float" orientation="portrait" xlink:href="13195_2025_1839_Fig4_HTML.jpg"/></fig>
</p><p id="Par52">Together, these findings highlight a high level of concordance across the three pipelines. Notably, the strongest correlation was observed between the two pipelines employing subject-specific anatomical masks (petBrain and B-PIP), particularly for Tau SUVr quantification (R<sup>2</sup>&#8201;=&#8201;0.95, compared to R<sup>2</sup>&#8201;=&#8201;0.84 for both petBrain vs. SPM and SPM vs. B-PIP). However, fewer extreme outliers were observed between petBrain and the SPM-based pipelines than between B-PIP and SPM-based pipelines, suggesting better robustness of petBrain and SPM.</p></sec><sec id="Sec25"><title>Correlations with CSF and plasma biomarkers</title><p id="Par53">We subsequently assessed the correspondence between CL values, meta-temporal tau-PET SUVr, CTRz, HAVAs and AD fluid biomarkers. To this end, we fitted linear mixed-effects models (adjusted for age, sex, and APOE&#949;4 status) to evaluate the associations between fluid biomarkers and values derived from SPM-based pipelines, B-PIP and petBrain. Table&#160;<xref rid="Tab4" ref-type="table">4</xref> summarizes the statistical results. Three pipelines demonstrated comparable predictive performance across fluid biomarkers, with no significant differences observed in the explained variance (R<sup>2</sup>) based on Steiger&#8217;s Z-test.</p><p id="Par54">
<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Association of centiloid (CL), Tau suvr, CenTauRz (CTRz) and the Hippocampo-Amygdalo-Ventricular atrophy score (HAVAs) produced by petbrain, B-PIP and SPM-based pipelines with AD fluid biomarkers. The linear mixed models were adjusted for age, sex, and APOE&#949;4. The used metrics were p-value of the F-test and R<sup>2</sup></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">R</italic>
<sup>2</sup>
</th></tr><tr><th align="left" colspan="3" rowspan="1">
<bold>CL&#8201;~&#8201;CS</bold>
<bold>F A&#946;42/40 (</bold>
<italic toggle="yes">N</italic>
<bold>&#8201;=&#8201;353)</bold>
</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">petBrain</td><td align="left" colspan="1" rowspan="1">2.46e-58</td><td align="left" colspan="1" rowspan="1">0.546</td></tr><tr><td align="left" colspan="1" rowspan="1">B-PIP</td><td align="left" colspan="1" rowspan="1">1.02e-57</td><td align="left" colspan="1" rowspan="1">0.542</td></tr><tr><td align="left" colspan="1" rowspan="1">SPM-Centiloid</td><td align="left" colspan="1" rowspan="1">3.3e-56</td><td align="left" colspan="1" rowspan="1">0.532</td></tr><tr><td align="left" colspan="3" rowspan="1">
<bold>CL&#8201;~&#8201;CSF</bold>
<bold> p-tau (</bold>
<italic toggle="yes">N</italic>
<bold>&#8201;=&#8201;350)</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">petBrain</td><td align="left" colspan="1" rowspan="1">7.1e-27</td><td align="left" colspan="1" rowspan="1">0.311</td></tr><tr><td align="left" colspan="1" rowspan="1">B-PIP</td><td align="left" colspan="1" rowspan="1">2.18e-25</td><td align="left" colspan="1" rowspan="1">0.297</td></tr><tr><td align="left" colspan="1" rowspan="1">SPM-Centiloid</td><td align="left" colspan="1" rowspan="1">2.15e-24</td><td align="left" colspan="1" rowspan="1">0.287</td></tr><tr><td align="left" colspan="3" rowspan="1">
<bold>CL&#8201;~&#8201;log(Plasma p-tau217) (</bold>
<italic toggle="yes">N</italic>
<bold>&#8201;=&#8201;397</bold>
<bold>)</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">petBrain</td><td align="left" colspan="1" rowspan="1">2.49e-65</td><td align="left" colspan="1" rowspan="1">0.542</td></tr><tr><td align="left" colspan="1" rowspan="1">B-PIP</td><td align="left" colspan="1" rowspan="1">2.71e-63</td><td align="left" colspan="1" rowspan="1">0.531</td></tr><tr><td align="left" colspan="1" rowspan="1">SPM-Centiloid</td><td align="left" colspan="1" rowspan="1">2.3e-61</td><td align="left" colspan="1" rowspan="1">0.520</td></tr><tr><td align="left" colspan="3" rowspan="1">
<bold>Meta-temporal tau SUVr&#8201;~&#8201;log(Plasma p-tau217) (</bold>
<italic toggle="yes">N</italic>
<bold>&#8201;=&#8201;39</bold>
<bold>7)</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">petBrain</td><td align="left" colspan="1" rowspan="1">8.23e-54</td><td align="left" colspan="1" rowspan="1">0.475</td></tr><tr><td align="left" colspan="1" rowspan="1">B-PIP</td><td align="left" colspan="1" rowspan="1">8.24e-55</td><td align="left" colspan="1" rowspan="1">0.482</td></tr><tr><td align="left" colspan="1" rowspan="1">SPM-Centaur</td><td align="left" colspan="1" rowspan="1">1.06e-54</td><td align="left" colspan="1" rowspan="1">0.481</td></tr><tr><td align="left" colspan="3" rowspan="1">
<bold>CTRz&#8201;~&#8201;log(Plasma pau217) (</bold>
<italic toggle="yes">N</italic>
<bold>&#8201;=&#8201;397)</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">petBrain</td><td align="left" colspan="1" rowspan="1">1.48e-56</td><td align="left" colspan="1" rowspan="1">0.492</td></tr><tr><td align="left" colspan="1" rowspan="1">SPM-Centaur</td><td align="left" colspan="1" rowspan="1">1.19e-55</td><td align="left" colspan="1" rowspan="1">0.487</td></tr><tr><td align="left" colspan="3" rowspan="1">
<bold>HAVAs&#8201;~&#8201;log(Plasma NfL) (</bold>
<italic toggle="yes">N</italic>
<bold>&#8201;=&#8201;398)</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">petBrain</td><td align="left" colspan="1" rowspan="1">2.65e-44</td><td align="left" colspan="1" rowspan="1">0.413</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec26"><title>Comparison of A/T<sub>2</sub>/N staging with clinical staging</title><p id="Par55">To further assess the performance of the petBrain pipeline, we examined the automated petBrain-derived A/T<sub>2</sub>/N staging across CN individuals and patients with MCI or dementia. Figure&#160;<xref rid="Fig5" ref-type="fig">5</xref> displays the results for 821 subjects from the ADNI cohort.</p><p id="Par56">
<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Centiloid (Amyloid), CenTauRz (Tau) and HAVAs (Neurodegeneration) scores on the ADNI dataset (<italic toggle="yes">N</italic>&#8201;=&#8201;821) using petBrain. Amyloid status was established with the B-PIP PET pipeline and ADNI thresholds. The horizontal dashed red lines indicate the pathological threshold for each biomarker</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1491" position="float" orientation="portrait" xlink:href="13195_2025_1839_Fig5_HTML.jpg"/></fig>
</p><p id="Par57">To investigate amyloid load across clinical stages in A&#8201;+&#8201;individuals, we performed a one-way analysis of variance (ANOVA) comparing amyloid-positive CN subjects, and patients with MCI or dementia, followed by Tukey&#8217;s test for <italic toggle="yes">post-hoc</italic> multiple comparisons. The analysis revealed a strongly significant association between amyloid load obtained from petBrain CL and clinical staging (mean CL value in A&#8201;+&#8201;CN&#8201;=&#8201;64.73; A&#8201;+&#8201;MCI&#8201;=&#8201;84.23; A&#8201;+&#8201;dementia&#8201;=&#8201;104.35; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;1&#8201;&#215;&#8201;10<sup>&#8722;&#8201;10</sup>). We also found a strong association between tau load or neurodegeneration measured with petBrain and clinical staging in A&#8201;+&#8201;participants (T<sub>2</sub>: mean CTRz value in A&#8201;+&#8201;CN&#8201;=&#8201;1.09; A&#8201;+&#8201;MCI&#8201;=&#8201;4.62; A&#8201;+&#8201;dementia&#8201;=&#8201;7.88; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;1&#8201;&#215;&#8201;10<sup>&#8722;&#8201;19</sup>. N: mean HAVAs probability in A&#8201;+&#8201;CN&#8201;=&#8201;0.25; A&#8201;+&#8201;MCI&#8201;=&#8201;0.44; A&#8201;+&#8201;dementia&#8201;=&#8201;0.69; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;1&#8201;&#215;&#8201;10<sup>&#8722;&#8201;31</sup>). <italic toggle="yes">Post-hoc</italic> comparisons confirmed that each clinical A&#8201;+&#8201;group differed significantly from the others in terms of A, T<sub>2</sub>, and N measurements.</p></sec><sec id="Sec27"><title>Correlations of A/T<sub>2</sub>/N quantification with cognitive scores</title><p id="Par58">Finally, we evaluated the relationship between global cognitive performance and petBrain-derived biomarkers, quantified with the CL scale (A), CTRz (T<sub>2</sub>) and HAVAs (N). Linear mixed-effects models were used to predict CDR-sb, MMSE, and MoCA scores, adjusting for age, sex, APOE&#949;4 status, and education level. The results are presented in Table&#160;<xref rid="Tab5" ref-type="table">5</xref>. The combined quantification of A/T<sub>2</sub>/N explained a greater proportion of the variance (R<sup>2</sup>) in cognitive measures than amyloid load (CLs) alone across all cognitive scales (adjusted Steiger&#8217;s test on R<sup>2</sup>). This combined model also significantly outperformed CTRz measurement in explaining the CDR-sb.</p><p id="Par59">
<table-wrap id="Tab5" position="float" orientation="portrait"><label>Table 5</label><caption><p>Associations between cognitive scores (CDR-sb, MMSE, MoCA) and petBrain-derived A, T<sub>2</sub>, and N biomarkers, as well as the combined A/T<sub>2</sub>/N model, estimated using linear mixed-effects models. Models were adjusted for age, sex, APOE&#949;4 status, and education</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">R</italic>
<sup>2</sup>
</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="2" rowspan="1">
<bold>CDR-sb (</bold>
<italic toggle="yes">N</italic>
<bold>&#8201;=&#8201;7</bold>
<bold>18)</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">A (CL)</td><td align="left" colspan="1" rowspan="1">9.47e-27</td><td align="left" colspan="1" rowspan="1">0.169</td></tr><tr><td align="left" colspan="1" rowspan="1">T<sub>2</sub> (CTRz)</td><td align="left" colspan="1" rowspan="1">3.16e-43</td><td align="left" colspan="1" rowspan="1">0.254</td></tr><tr><td align="left" colspan="1" rowspan="1">N (HAVAs)</td><td align="left" colspan="1" rowspan="1">3.65e-55</td><td align="left" colspan="1" rowspan="1">0.310</td></tr><tr><td align="left" colspan="1" rowspan="1">A/T<sub>2</sub>/N</td><td align="left" colspan="1" rowspan="1">
<bold>6.33e-64</bold>
</td><td align="left" colspan="1" rowspan="1">
<bold>0.356</bold>
<sup><bold>a, b</bold></sup>
</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="2" rowspan="1">
<bold>MMSE</bold>
<bold> (</bold>
<italic toggle="yes">N</italic>
<bold>&#8201;=&#8201;719)</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">A (CL)</td><td align="left" colspan="1" rowspan="1">1.13e-30</td><td align="left" colspan="1" rowspan="1">0.190</td></tr><tr><td align="left" colspan="1" rowspan="1">T<sub>2</sub> (CTRz)</td><td align="left" colspan="1" rowspan="1">1.52e-45</td><td align="left" colspan="1" rowspan="1">0.265</td></tr><tr><td align="left" colspan="1" rowspan="1">N (HAVAs)</td><td align="left" colspan="1" rowspan="1">4.03e-45</td><td align="left" colspan="1" rowspan="1">0.263</td></tr><tr><td align="left" colspan="1" rowspan="1">A/T<sub>2</sub>/N</td><td align="left" colspan="1" rowspan="1">
<bold>2.01e-57</bold>
</td><td align="left" colspan="1" rowspan="1">
<bold>0.328</bold>
<sup><bold>a</bold></sup>
</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="2" rowspan="1">
<bold>MoC</bold>
<bold>A (</bold>
<italic toggle="yes">N</italic>
<bold>&#8201;=&#8201;647)</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">A (CL)</td><td align="left" colspan="1" rowspan="1">1.56e-34</td><td align="left" colspan="1" rowspan="1">0.231</td></tr><tr><td align="left" colspan="1" rowspan="1">T<sub>2</sub> (CTRz)</td><td align="left" colspan="1" rowspan="1">1.31e-49</td><td align="left" colspan="1" rowspan="1">0.311</td></tr><tr><td align="left" colspan="1" rowspan="1">N (HAVAs)</td><td align="left" colspan="1" rowspan="1">8.62e-51</td><td align="left" colspan="1" rowspan="1">0.316</td></tr><tr><td align="left" colspan="1" rowspan="1">A/T<sub>2</sub>/N</td><td align="left" colspan="1" rowspan="1">
<bold>6.69e-61</bold>
</td><td align="left" colspan="1" rowspan="1">
<bold>0.373</bold>
<sup><bold>a</bold></sup>
</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup> Indicates a significant difference (adjusted p-value&#8201;&lt;&#8201;0.0125) with model A using a Steiger&#8217;s test on R<sup>2</sup></p><p><sup>b</sup> Indicates a significant difference (adjusted p-value&#8201;&lt;&#8201;0.0125) with model T<sub>2</sub> using a Steiger&#8217;s test on R<sup>2</sup></p><p>The Steiger&#8217;s test has been corrected for multiple comparison using Bonferroni correction</p></table-wrap-foot></table-wrap>
</p></sec></sec></sec><sec id="Sec28"><title>Discussion</title><p id="Par60">In this study, we introduced petBrain, a novel accurate and efficient processing pipeline for amyloid-PET, tau-PET, and structural MRI dedicated to AD research purposes. The petBrain pipeline enables standardized and accessible quantification of amyloid and tau burden using the CL and CTRz scales, ensuring cross-tracer comparability. Additionally, the pipeline provides an age-adjusted measure of brain atrophy through the HAVAs score, derived from lifespan-based brain chart models. After calibration according to the Centiloid and CenTauR project guidelines, we demonstrated that petBrain automatically produces results fully comparable to those obtained with SPM and B-PIP pipelines on ADNI data for amyloid-PET and tau-PET in less than 20&#160;min. We further validated petBrain biological relevance by showing correlations with fluid biomarkers and clinical data. The results obtained with petBrain are consistent with the literature, showing significant but imperfect correlations between PET and fluid biomarkers [<xref ref-type="bibr" rid="CR32">32</xref>]. Indeed, these variables, although strongly associated, reflect different biological processes [<xref ref-type="bibr" rid="CR33">33</xref>]. Furthermore, the data obtained with petBrain align with the existing literature demonstrating a better association between clinical performance and tau load or neurodegeneration than with amyloid load [<xref ref-type="bibr" rid="CR34">34</xref>]. </p><p id="Par61">In comparison to existing pipelines, we developed a novel end-to-end solution featuring several key innovations. Notably, the pipeline generates subject-specific ROI masks in under 15&#160;min using deep learning-based segmentation of 3D MRI, significantly reducing processing time compared to traditional methods such as FreeSurfer. Additionally, it enables robust biomarker quantification through standardized CL and CTRz scales, ensuring consistency across various amyloid and tau tracers, in contrast to tau SUVr-based methods employed in B-PIP. Furthermore, petBrain is the first pipeline to simultaneously estimate A, T<sub>2</sub>, and N biomarkers within a unified processing framework contrary to SPM-based pipelines. The web-based implementation removes the need for local computational infrastructure or specialized image processing expertise, making it accessible for broad adoption. Finally, the structured output in the form of a final PDF report (see example in supplementary materials Fig.&#160;<xref rid="MOESM1" ref-type="media">8</xref>) is designed to facilitate the widespread and standardized use of A/T<sub>2</sub>/N biomarker quantification.</p><p id="Par62">In addition to clinically relevant outputs, such as the binary A+/A-, T<sub>2</sub>+/T<sub>2</sub>-, N+/N- status and the quantification of lesion load in CLs and CTRz, petBrain provides advanced information for research purposes. For advanced users, petBrain provides CSV files containing SUVr mean values for 122 brain structures. This information can be utilized, for example, to estimate Braak staging or to detect atypical AD from tau regional SUVr [<xref ref-type="bibr" rid="CR35">35</xref>&#8211;<xref ref-type="bibr" rid="CR37">37</xref>]. Additionally, with the integration of a lifespan model [<xref ref-type="bibr" rid="CR20">20</xref>], petBrain offers deviation scores from normal aging for each of the 132 structural volumes derived from T1-weighted MRI, which can be leveraged for differential diagnoses [<xref ref-type="bibr" rid="CR38">38</xref>]. Experts in image processing can replicate the petBrain pipeline locally by using the freely available version of AssemblyNet (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://github.com/volBrain/AssemblyNet/">https://github.com/volBrain/AssemblyNet/</ext-link><italic toggle="yes">)</italic> along with the calibration equations provided in this article.</p><p id="Par63">Although PVC is not routinely applied in amyloid and tau PET quantification, we chose to incorporate a PVC step into our pipeline. To assess its impact, all experiments were replicated without PVC (see Sect.&#160;<xref rid="MOESM1" ref-type="media">7</xref> of the Supplementary Material). These complementary analyses revealed a high degree of concordance between results obtained with and without PVC, thereby supporting the robustness and reliability of the proposed methodology. While observed differences were minor, a consistent trend favoring the use of PVC was noted.</p><p id="Par64">The limited variations in Centiloid and CenTauRz values are likely attributable to the averaging over large anatomical masks &#8212; such as the CenTauR mask, which encompasses over 50,000 voxels &#8212; thus mitigating the local influence of partial volume effects. As a result, quantitative estimates remain largely stable across both conditions.</p><p id="Par65">Despite the modest numerical impact, we opted to retain the PVC step due to its enhancement of image quality. This improvement is particularly valuable for the visual assessment of amyloid and tau deposition, offering added benefit in both clinical and research settings (see Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">7</xref> for an illustrative example).</p><p id="Par66">Our pipeline has some limitations. Unlike some amyloid-PET processing pipelines that can be &#8216;&#8217;MRI-free&#8217;&#8217;, petBrain requires a T1w-MRI. This is also inherent to the ability to obtain the N biomarker with petBrain alongside A and T<sub>2</sub> markers. However, it is important to note that petBrain can run without amyloid-PET to provide only T<sub>2</sub> and N, or without tau-PET to provide only A and N. In addition, although petBrain provides regional tauopathy progression data by extracting SUVr values from 122 predefined gray matter regions of interest, it currently lacks simplified, clinician-oriented outputs. This limitation is primarily due to threshold variability across different tau tracers. Future developments should aim to incorporate clinically interpretable metrics, such as automatic Braak stage classification based on tau-PET data or assessments of tau-PET positivity in neocortical versus medial temporal regions. Indeed, these indicators are essential for establishing biological staging of AD, as outlined by the AA criteria [<xref ref-type="bibr" rid="CR1">1</xref>], and for identifying presymptomatic AD in cognitively unimpaired individuals according to the International Working Group (IWG) criteria [<xref ref-type="bibr" rid="CR39">39</xref>]. Moreover, future studies should evaluate the generalizability of petBrain across diverse cohorts, including individuals with atypical AD phenotypes, and conduct longitudinal validation to determine its utility in monitoring treatment response to disease-modifying therapies. Finally, we plan to integrate white matter hyperintensities (WMH) in future versions of the pipeline by incorporating the DeepLesionBrain tool [<xref ref-type="bibr" rid="CR40">40</xref>] for lesion segmentation on FLAIR images. WMH are increasingly recognized as key vascular biomarkers that may interact with Alzheimer&#8217;s pathology and contribute to cognitive decline.</p><p id="Par67">In conclusion, the petBrain pipeline is a fast and efficient end-to-end pipeline designed for the quantification of A/T<sub>2</sub>/N biomarkers using PET and MRI. It facilitates the measurement of amyloid and tau loads across various PET tracers using the widely recognized Centiloid and CenTauR scales, ensuring standardized and reliable results. petBrain demonstrates expected concordance with fluid biomarkers and clinical data, making it a robust tool for clinical research applications. The pipeline provides comprehensive report files, along with processed images and segmentation masks, which are easy to interpret and analyze. Additionally, petBrain is freely accessible for research purposes via the user-friendly volBrain platform (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.volbrain.net">www.volbrain.net</ext-link>), ensuring broad accessibility to the scientific community.</p></sec><sec id="Sec29" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="13195_2025_1839_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The ADNI data used in the preparation of this manuscript were obtained from the Alzheimer&#8217;s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). The ADNI is funded by the National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering and through generous contributions from the following: Abbott, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics NV, Johnson &amp; Johnson, Eli Lilly and Co., Medpace, Inc., Merck and Co., Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche, Schering-Plough, Synarc Inc., as well as nonprofit partners, the Alzheimer&#8217;s Association and Alzheimer&#8217;s Drug Discovery Foundation, with participation from the U.S. Food and Drug Administration. Private sector contributions to the ADNI are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study was coordinated by the Alzheimer&#8217;s Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for NeuroImaging at the University of California, Los Angeles. This research was also supported by NIH grants P30AG010129, K01 AG030514 and the Dana Foundation. Moreover, this work is based on open access samples. We wish to thank all investigators of these projects who collected these datasets and made them freely accessible.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>P.C. contributed to the conception of the study, conducted the experiments, developed the software, and wrote the manuscript. B.M. contributed to software development and experimentation, reviewed the manuscript, and approved the final version. S.M.-O. participated in the experiments and reviewed the manuscript. N.V. contributed to manuscript writing and final review. J.M. participated in software development, manuscript writing, and final review. V.P. contributed to the study conception, manuscript writing, and critically revised the final version.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work benefited from the support of the project HoliBrain of the French National Research Agency (ANR-23-CE45-0020-01). Moreover, this project is supported by the Precision and global vascular brain health institute funded by the France 2030 investment plan as part of the IHU3 initiative (ANR-23-IAHU- 0001). Finally, this study received financial support from the French government in the framework of the University of Bordeaux&#8217;s France 2030 program / RRI &#8220;IMPACT and the PEPR StratifyAging and Prodrom-ND. This work benefited from the support of the project ChatvolBrain from CNRS. This work was also granted access to the HPC resources of IDRIS under the allocation 2022-AD011013848R1 made by GENCI. This work also benefited from the support of the project PID2023-152127OB-I00 of the Ministerio de Ciencia, Innovacion y Universidades of Spain.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>All the images used in this study are freely available thought GAAIN or ADNI website.</p></notes><notes><title>Declarations</title><notes id="FPar3"><title>Ethics approval</title><p id="Par68">All human data used in this study were obtained from open-access databases, and all participants provided informed consent at the time of data collection. For detailed information regarding the ethical approval and consent procedures, please refer to the original publications associated with each dataset.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par69">P.C has no conflict of interest to declare. B.M has no conflict of interest to declare. F.M has no conflict of interest to declare. S.M-O has no conflict of interest to declare. J-V. M has no conflict of interest to declare. Independent of this work, NV received research support from Fondation Bettencourt-Schueller, Fondation Servier, Union Nationale pour les Int&#233;r&#234;ts de la M&#233;decine (UNIM), Fondation Claude Pompidou, Fondation Alzheimer, Banque Publique d&#8217;Investissement, Lion&#8217;s Club Alzheimer and Fondation pour la Recherche sur l&#8217;Alzheimer; travel grant from the Movement Disorders Society, Merz-Pharma, UCB Pharma, and GE Healthcare SAS; is an unpaid local principal investigator or sub-investigator in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05531526">NCT05531526</ext-link> (AR1001, AriBio), <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06079190">NCT06079190</ext-link> (AL101, GSK), <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04241068">NCT04241068</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05310071">NCT05310071</ext-link> (aducanumab, Biogen), <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05399888">NCT05399888</ext-link> (BIIB080, Biogen), <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03352557">NCT03352557</ext-link> (gosuranemab, Biogen), <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04592341">NCT04592341</ext-link> (gantenerumab, Roche), <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03887455">NCT03887455</ext-link> (lecanemab, Eisai), <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03828747">NCT03828747</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03289143">NCT03289143</ext-link> (semorinemab, Roche), <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04619420">NCT04619420</ext-link> (JNJ-63733657, Janssen &#8211; Johnson &amp; Johnson), <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06544616">NCT06544616</ext-link> (JNJ-64042056, Janssen &#8211; Johnson &amp; Johnson), <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04374136">NCT04374136</ext-link> (AL001, Alector), <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04592874">NCT04592874</ext-link> (AL002, Alector), <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04867616">NCT04867616</ext-link> (bepranemab, UCB Pharma), <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04777396">NCT04777396</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04777409">NCT04777409</ext-link> (semaglutide, Novo Nordisk), <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05469360">NCT05469360</ext-link> (NIO752, Novartis), <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06647498">NCT06647498</ext-link> (remternetug, Washington University School of Medicine); is the French national coordinator in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05564169">NCT05564169</ext-link> (VHB937, Novartis); has given unpaid lectures in symposia organized by Eisai and the Servier Foundation; has been an unpaid expert for Janssen &#8211; Johnson &amp; Johnson, Eli-Lilly, Novartis. During the past 3 years, VP was a local unpaid investigator or sub-investigator for clinical trials granted by NovoNordisk, Biogen, Janssen and Alector. He received consultant fees for MRI studies in animals from Motac Neuroscience Ltd, outside the submitted work.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>CR</given-names></name><etal/></person-group><article-title>Revised criteria for diagnosis and staging of alzheimer&#8217;s disease: alzheimer&#8217;s association workgroup</article-title><source>Alzheimer&#8217;s Dement</source><year>2024</year><volume>20</volume><fpage>5143</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1002/alz.13859</pub-id><pub-id pub-id-type="pmid">38934362</pub-id><pub-id pub-id-type="pmcid">PMC11350039</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Jack CR, et al. Revised criteria for diagnosis and staging of alzheimer&#8217;s disease: alzheimer&#8217;s association workgroup. Alzheimer&#8217;s Dement. 2024;20:5143&#8211;69.<pub-id pub-id-type="pmid">38934362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13859</pub-id><pub-id pub-id-type="pmcid">PMC11350039</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Villain</surname><given-names>N</given-names></name><etal/></person-group><article-title>Lecanemab for early alzheimer&#8217;s disease: appropriate use recommendations from the French federation of memory clinics</article-title><source>J Prev Alzheimer&#8217;s Disease</source><year>2025</year><volume>12</volume><fpage>100094</fpage><pub-id pub-id-type="doi">10.1016/j.tjpad.2025.100094</pub-id><pub-id pub-id-type="pmid">40011173</pub-id><pub-id pub-id-type="pmcid">PMC12184063</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Villain N, et al. Lecanemab for early alzheimer&#8217;s disease: appropriate use recommendations from the French federation of memory clinics. J Prev Alzheimer&#8217;s Disease. 2025;12:100094.<pub-id pub-id-type="pmid">40011173</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tjpad.2025.100094</pub-id><pub-id pub-id-type="pmcid">PMC12184063</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Mattsson-Carlgren N et al. The implications of different approaches to define AT(N) in alzheimer disease. Neurology 2020:94.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000009485</pub-id><pub-id pub-id-type="pmcid">PMC7357296</pub-id><pub-id pub-id-type="pmid">32398359</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bollack</surname><given-names>A</given-names></name><etal/></person-group><article-title>Longitudinal amyloid and Tau PET imaging in alzheimer&#8217;s disease: A systematic review of methodologies and factors affecting quantification</article-title><source>Alzheimer&#8217;s Dement</source><year>2023</year><volume>19</volume><fpage>5232</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1002/alz.13158</pub-id><pub-id pub-id-type="pmid">37303269</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Bollack A, et al. Longitudinal amyloid and Tau PET imaging in alzheimer&#8217;s disease: A systematic review of methodologies and factors affecting quantification. Alzheimer&#8217;s Dement. 2023;19:5232&#8211;52.<pub-id pub-id-type="pmid">37303269</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13158</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jovalekic</surname><given-names>A</given-names></name><etal/></person-group><article-title>Validation of quantitative assessment of Florbetaben PET scans as an adjunct to the visual assessment across 15 software methods</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2023</year><volume>50</volume><fpage>3276</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1007/s00259-023-06279-0</pub-id><pub-id pub-id-type="pmid">37300571</pub-id><pub-id pub-id-type="pmcid">PMC10542295</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Jovalekic A, et al. Validation of quantitative assessment of Florbetaben PET scans as an adjunct to the visual assessment across 15 software methods. Eur J Nucl Med Mol Imaging. 2023;50:3276&#8211;89.<pub-id pub-id-type="pmid">37300571</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-023-06279-0</pub-id><pub-id pub-id-type="pmcid">PMC10542295</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name><etal/></person-group><article-title>Development of amyloid PET analysis pipeline using deep Learning-Based brain MRI Segmentation&#8212;A comparative validation study</article-title><source>Diagnostics</source><year>2022</year><volume>12</volume><fpage>623</fpage><pub-id pub-id-type="doi">10.3390/diagnostics12030623</pub-id><pub-id pub-id-type="pmid">35328176</pub-id><pub-id pub-id-type="pmcid">PMC8947654</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Lee J, et al. Development of amyloid PET analysis pipeline using deep Learning-Based brain MRI Segmentation&#8212;A comparative validation study. Diagnostics. 2022;12:623.<pub-id pub-id-type="pmid">35328176</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/diagnostics12030623</pub-id><pub-id pub-id-type="pmcid">PMC8947654</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klunk</surname><given-names>WE</given-names></name><etal/></person-group><article-title>The centiloid project: standardizing quantitative amyloid plaque Estimation by PET</article-title><source>Alzheimer&#8217;s Dement</source><year>2015</year><volume>11</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.1016/j.jalz.2014.07.003</pub-id><pub-id pub-id-type="pmid">25443857</pub-id><pub-id pub-id-type="pmcid">PMC4300247</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Klunk WE, et al. The centiloid project: standardizing quantitative amyloid plaque Estimation by PET. Alzheimer&#8217;s Dement. 2015;11:1.<pub-id pub-id-type="pmid">25443857</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2014.07.003</pub-id><pub-id pub-id-type="pmcid">PMC4300247</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Royse</surname><given-names>SK</given-names></name><etal/></person-group><article-title>Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach</article-title><source>Alz Res Therapy</source><year>2021</year><volume>13</volume><fpage>99</fpage><pub-id pub-id-type="doi">10.1186/s13195-021-00836-1</pub-id><pub-id pub-id-type="pmcid">PMC8111744</pub-id><pub-id pub-id-type="pmid">33971965</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Royse SK, et al. Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach. Alz Res Therapy. 2021;13:99.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-021-00836-1</pub-id><pub-id pub-id-type="pmcid">PMC8111744</pub-id><pub-id pub-id-type="pmid">33971965</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iaccarino</surname><given-names>L</given-names></name><etal/></person-group><article-title>rPOP: robust PET-only processing of community acquired heterogeneous amyloid-PET data</article-title><source>NeuroImage</source><year>2022</year><volume>246</volume><fpage>118775</fpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2021.118775</pub-id><pub-id pub-id-type="pmid">34890793</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Iaccarino L, et al. rPOP: robust PET-only processing of community acquired heterogeneous amyloid-PET data. NeuroImage. 2022;246:118775.<pub-id pub-id-type="pmid">34890793</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2021.118775</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bourgeat</surname><given-names>P</given-names></name><etal/></person-group><article-title>Comparison of MR-less PiB SUVR quantification methods</article-title><source>Neurobiol Aging</source><year>2015</year><volume>36</volume><fpage>159</fpage><lpage>S166</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2014.04.033</pub-id><pub-id pub-id-type="pmid">25257985</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Bourgeat P, et al. Comparison of MR-less PiB SUVR quantification methods. Neurobiol Aging. 2015;36:159&#8211;S166.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2014.04.033</pub-id><pub-id pub-id-type="pmid">25257985</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwarz</surname><given-names>CG</given-names></name><etal/></person-group><article-title>Selecting software pipelines for change in flortaucipir SUVR: balancing repeatability and group separation</article-title><source>NeuroImage</source><year>2021</year><volume>238</volume><fpage>118259</fpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2021.118259</pub-id><pub-id pub-id-type="pmid">34118395</pub-id><pub-id pub-id-type="pmcid">PMC8407434</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Schwarz CG, et al. Selecting software pipelines for change in flortaucipir SUVR: balancing repeatability and group separation. NeuroImage. 2021;238:118259.<pub-id pub-id-type="pmid">34118395</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2021.118259</pub-id><pub-id pub-id-type="pmcid">PMC8407434</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Villemagne</surname><given-names>VL</given-names></name><etal/></person-group><article-title>CenTauR: toward a universal scale and masks for standardizing Tau imaging studies</article-title><source>Alz Dem Diag Ass Dis Mo</source><year>2023</year><volume>15</volume><fpage>e12454</fpage><pub-id pub-id-type="doi">10.1002/dad2.12454</pub-id><pub-id pub-id-type="pmcid">PMC10326476</pub-id><pub-id pub-id-type="pmid">37424964</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Villemagne VL, et al. CenTauR: toward a universal scale and masks for standardizing Tau imaging studies. Alz Dem Diag Ass Dis Mo. 2023;15:e12454.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dad2.12454</pub-id><pub-id pub-id-type="pmcid">PMC10326476</pub-id><pub-id pub-id-type="pmid">37424964</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Coup&#233; P et al. Hippocampal-amygdalo&#8208;ventricular atrophy score: alzheimer disease detection using normative and pathological lifespan models. Hum Brain Mapp (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hbm.25850</pub-id><pub-id pub-id-type="pmcid">PMC9188974</pub-id><pub-id pub-id-type="pmid">35388950</pub-id></mixed-citation></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wittens</surname><given-names>MMJ</given-names></name><etal/></person-group><article-title>Towards validation in clinical routine: a comparative analysis of visual MTA ratings versus the automated ratio between inferior lateral ventricle and hippocampal volumes in alzheimer&#8217;s disease diagnosis</article-title><source>Neuroradiology</source><year>2024</year><volume>66</volume><fpage>487</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1007/s00234-024-03280-8</pub-id><pub-id pub-id-type="pmid">38240767</pub-id><pub-id pub-id-type="pmcid">PMC10937807</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Wittens MMJ, et al. Towards validation in clinical routine: a comparative analysis of visual MTA ratings versus the automated ratio between inferior lateral ventricle and hippocampal volumes in alzheimer&#8217;s disease diagnosis. Neuroradiology. 2024;66:487&#8211;506.<pub-id pub-id-type="pmid">38240767</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00234-024-03280-8</pub-id><pub-id pub-id-type="pmcid">PMC10937807</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Landau</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Positron emission tomography harmonization in the alzheimer&#8217;s disease neuroimaging initiative: A scalable and rigorous approach to multisite amyloid and Tau quantification</article-title><source>Alzheimer&#8217;s Dement</source><year>2025</year><volume>21</volume><fpage>e14378</fpage><pub-id pub-id-type="doi">10.1002/alz.14378</pub-id><pub-id pub-id-type="pmid">39559932</pub-id><pub-id pub-id-type="pmcid">PMC11772732</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Landau SM, et al. Positron emission tomography harmonization in the alzheimer&#8217;s disease neuroimaging initiative: A scalable and rigorous approach to multisite amyloid and Tau quantification. Alzheimer&#8217;s Dement. 2025;21:e14378.<pub-id pub-id-type="pmid">39559932</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.14378</pub-id><pub-id pub-id-type="pmcid">PMC11772732</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collij</surname><given-names>LE</given-names></name><etal/></person-group><article-title>Centiloid recommendations for clinical context-of&#8208;use from the AMYPAD consortium</article-title><source>Alzheimer&#8217;s Dement</source><year>2024</year><volume>20</volume><fpage>9037</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1002/alz.14336</pub-id><pub-id pub-id-type="pmid">39564918</pub-id><pub-id pub-id-type="pmcid">PMC11667534</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Collij LE, et al. Centiloid recommendations for clinical context-of&#8208;use from the AMYPAD consortium. Alzheimer&#8217;s Dement. 2024;20:9037&#8211;48.<pub-id pub-id-type="pmid">39564918</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.14336</pub-id><pub-id pub-id-type="pmcid">PMC11667534</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashburner</surname><given-names>JSPM</given-names></name></person-group><article-title>A history</article-title><source>NeuroImage</source><year>2012</year><volume>62</volume><fpage>791</fpage><lpage>800</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2011.10.025</pub-id><pub-id pub-id-type="pmid">22023741</pub-id><pub-id pub-id-type="pmcid">PMC3480642</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Ashburner JSPM. A history. NeuroImage. 2012;62:791&#8211;800.<pub-id pub-id-type="pmid">22023741</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2011.10.025</pub-id><pub-id pub-id-type="pmcid">PMC3480642</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fischl</surname><given-names>B</given-names></name></person-group><source>FreeSurfer Neuroimage</source><year>2012</year><volume>62</volume><fpage>774</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2012.01.021</pub-id><pub-id pub-id-type="pmid">22248573</pub-id><pub-id pub-id-type="pmcid">PMC3685476</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Fischl B. FreeSurfer Neuroimage. 2012;62:774&#8211;81.<pub-id pub-id-type="pmid">22248573</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2012.01.021</pub-id><pub-id pub-id-type="pmcid">PMC3685476</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coup&#233;</surname><given-names>P</given-names></name><etal/></person-group><article-title>AssemblyNet: A large ensemble of CNNs for 3D whole brain MRI segmentation</article-title><source>NeuroImage</source><year>2020</year><volume>219</volume><fpage>117026</fpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2020.117026</pub-id><pub-id pub-id-type="pmid">32522665</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Coup&#233; P, et al. AssemblyNet: A large ensemble of CNNs for 3D whole brain MRI segmentation. NeuroImage. 2020;219:117026.<pub-id pub-id-type="pmid">32522665</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2020.117026</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coup&#233;</surname><given-names>P</given-names></name><name name-style="western"><surname>Catheline</surname><given-names>G</given-names></name><name name-style="western"><surname>Lanuza</surname><given-names>E</given-names></name><name name-style="western"><surname>Manj&#243;n</surname><given-names>JV</given-names></name><collab>for the Alzheimer&#8217;s Disease Neuroimaging Initiative</collab></person-group><article-title>Towards a unified analysis of brain maturation and aging across the entire lifespan: A MRI analysis: towards a unified analysis of brain</article-title><source>Hum Brain Mapp</source><year>2017</year><volume>38</volume><fpage>5501</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1002/hbm.23743</pub-id><pub-id pub-id-type="pmid">28737295</pub-id><pub-id pub-id-type="pmcid">PMC6866824</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Coup&#233; P, Catheline G, Lanuza E, Manj&#243;n JV, for the Alzheimer&#8217;s Disease Neuroimaging Initiative. Towards a unified analysis of brain maturation and aging across the entire lifespan: A MRI analysis: towards a unified analysis of brain. Hum Brain Mapp. 2017;38:5501&#8211;18.<pub-id pub-id-type="pmid">28737295</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hbm.23743</pub-id><pub-id pub-id-type="pmcid">PMC6866824</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Planche</surname><given-names>V</given-names></name><etal/></person-group><article-title>Structural progression of alzheimer&#8217;s disease over decades: the MRI staging scheme</article-title><source>Brain Commun</source><year>2022</year><volume>4</volume><fpage>fcac109</fpage><pub-id pub-id-type="doi">10.1093/braincomms/fcac109</pub-id><pub-id pub-id-type="pmid">35592489</pub-id><pub-id pub-id-type="pmcid">PMC9113086</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Planche V, et al. Structural progression of alzheimer&#8217;s disease over decades: the MRI staging scheme. Brain Commun. 2022;4:fcac109.<pub-id pub-id-type="pmid">35592489</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/braincomms/fcac109</pub-id><pub-id pub-id-type="pmcid">PMC9113086</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manj&#243;n</surname><given-names>JV</given-names></name><name name-style="western"><surname>Coup&#233;</surname><given-names>P</given-names></name><name name-style="western"><surname>Mart&#237;-Bonmat&#237;</surname><given-names>L</given-names></name><name name-style="western"><surname>Collins</surname><given-names>DL</given-names></name><name name-style="western"><surname>Robles</surname><given-names>M</given-names></name></person-group><article-title>Adaptive non-local means denoising of MR images with spatially varying noise levels: spatially adaptive nonlocal denoising</article-title><source>J Magn Reson Imaging</source><year>2010</year><volume>31</volume><fpage>192</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1002/jmri.22003</pub-id><pub-id pub-id-type="pmid">20027588</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Manj&#243;n JV, Coup&#233; P, Mart&#237;-Bonmat&#237; L, Collins DL, Robles M. Adaptive non-local means denoising of MR images with spatially varying noise levels: spatially adaptive nonlocal denoising. J Magn Reson Imaging. 2010;31:192&#8211;203.<pub-id pub-id-type="pmid">20027588</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jmri.22003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tustison</surname><given-names>NJ</given-names></name><etal/></person-group><article-title>N4ITK: improved N3 bias correction</article-title><source>IEEE Trans Med Imaging</source><year>2010</year><volume>29</volume><fpage>1310</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1109/TMI.2010.2046908</pub-id><pub-id pub-id-type="pmid">20378467</pub-id><pub-id pub-id-type="pmcid">PMC3071855</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Tustison NJ, et al. N4ITK: improved N3 bias correction. IEEE Trans Med Imaging. 2010;29:1310&#8211;20.<pub-id pub-id-type="pmid">20378467</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/TMI.2010.2046908</pub-id><pub-id pub-id-type="pmcid">PMC3071855</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Avants</surname><given-names>BB</given-names></name><etal/></person-group><article-title>A reproducible evaluation of ants similarity metric performance in brain image registration</article-title><source>NeuroImage</source><year>2011</year><volume>54</volume><fpage>2033</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2010.09.025</pub-id><pub-id pub-id-type="pmid">20851191</pub-id><pub-id pub-id-type="pmcid">PMC3065962</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Avants BB, et al. A reproducible evaluation of ants similarity metric performance in brain image registration. NeuroImage. 2011;54:2033&#8211;44.<pub-id pub-id-type="pmid">20851191</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2010.09.025</pub-id><pub-id pub-id-type="pmcid">PMC3065962</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manj&#243;n</surname><given-names>JV</given-names></name><etal/></person-group><article-title>Robust MRI brain tissue parameter Estimation by multistage outlier rejection</article-title><source>Magn Reson Med</source><year>2008</year><volume>59</volume><fpage>866</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1002/mrm.21521</pub-id><pub-id pub-id-type="pmid">18383286</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Manj&#243;n JV, et al. Robust MRI brain tissue parameter Estimation by multistage outlier rejection. Magn Reson Med. 2008;59:866&#8211;73.<pub-id pub-id-type="pmid">18383286</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mrm.21521</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">Manj&#243;n JV et al. Deep ICE: A Deep learning approach for MRI Intracranial Cavity Extraction. Preprint at 10.48550/ARXIV.2001.05720 (2020).</mixed-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">Manj&#243;n JV, Coup&#233; P, Buades A, Collins DL, Robles M. MRI superresolution using self-similarity and image priors. International Journal of Biomedical Imaging 2010;2010:425891.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2010/425891</pub-id><pub-id pub-id-type="pmcid">PMC3004412</pub-id><pub-id pub-id-type="pmid">21197094</pub-id></mixed-citation></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>H</given-names></name><etal/></person-group><article-title>In vivo cortical spreading pattern of Tau and amyloid in the alzheimer disease spectrum</article-title><source>Ann Neurol</source><year>2016</year><volume>80</volume><fpage>247</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1002/ana.24711</pub-id><pub-id pub-id-type="pmid">27323247</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Cho H, et al. In vivo cortical spreading pattern of Tau and amyloid in the alzheimer disease spectrum. Ann Neurol. 2016;80:247&#8211;58.<pub-id pub-id-type="pmid">27323247</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.24711</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>CR</given-names></name><etal/></person-group><article-title>Longitudinal Tau PET in ageing and alzheimer&#8217;s disease</article-title><source>Brain</source><year>2018</year><volume>141</volume><fpage>1517</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1093/brain/awy059</pub-id><pub-id pub-id-type="pmid">29538647</pub-id><pub-id pub-id-type="pmcid">PMC5917767</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Jack CR, et al. Longitudinal Tau PET in ageing and alzheimer&#8217;s disease. Brain. 2018;141:1517&#8211;28.<pub-id pub-id-type="pmid">29538647</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awy059</pub-id><pub-id pub-id-type="pmcid">PMC5917767</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iaccarino</surname><given-names>L</given-names></name><etal/></person-group><article-title>A practical overview of the use of amyloid-PET centiloid values in clinical trials and research</article-title><source>NeuroImage: Clin</source><year>2025</year><volume>46</volume><fpage>103765</fpage><pub-id pub-id-type="doi">10.1016/j.nicl.2025.103765</pub-id><pub-id pub-id-type="pmid">40101674</pub-id><pub-id pub-id-type="pmcid">PMC11960669</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Iaccarino L, et al. A practical overview of the use of amyloid-PET centiloid values in clinical trials and research. NeuroImage: Clin. 2025;46:103765.<pub-id pub-id-type="pmid">40101674</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nicl.2025.103765</pub-id><pub-id pub-id-type="pmcid">PMC11960669</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tierney</surname><given-names>TM</given-names></name><etal/></person-group><article-title>SPM 25: open source neuroimaging analysis software</article-title><source>Preprint at</source><year>2025</year><pub-id pub-id-type="doi">10.48550/ARXIV.2501.12081</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Tierney TM, et al. SPM 25: open source neuroimaging analysis software. Preprint at. 2025. 10.48550/ARXIV.2501.12081.</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="other">Planche V et al. Validity and performance of blood biomarkers for alzheimer disease to predict dementia risk in a large Clinic-Based cohort. Neurology 100, (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000201479</pub-id><pub-id pub-id-type="pmcid">PMC9931079</pub-id><pub-id pub-id-type="pmid">36261295</pub-id></mixed-citation></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ossenkoppele</surname><given-names>R</given-names></name><etal/></person-group><article-title>Tau PET correlates with different alzheimer&#8217;s disease-related features compared to CSF and plasma p&#8208;tau biomarkers</article-title><source>EMBO Mol Med</source><year>2021</year><volume>13</volume><fpage>e14398</fpage><pub-id pub-id-type="doi">10.15252/emmm.202114398</pub-id><pub-id pub-id-type="pmid">34254442</pub-id><pub-id pub-id-type="pmcid">PMC8350902</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Ossenkoppele R, et al. Tau PET correlates with different alzheimer&#8217;s disease-related features compared to CSF and plasma p&#8208;tau biomarkers. EMBO Mol Med. 2021;13:e14398.<pub-id pub-id-type="pmid">34254442</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/emmm.202114398</pub-id><pub-id pub-id-type="pmcid">PMC8350902</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanseeuw</surname><given-names>BJ</given-names></name><etal/></person-group><article-title>Association of amyloid and Tau with cognition in preclinical alzheimer disease: A longitudinal study</article-title><source>JAMA Neurol</source><year>2019</year><volume>76</volume><fpage>915</fpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2019.1424</pub-id><pub-id pub-id-type="pmid">31157827</pub-id><pub-id pub-id-type="pmcid">PMC6547132</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Hanseeuw BJ, et al. Association of amyloid and Tau with cognition in preclinical alzheimer disease: A longitudinal study. JAMA Neurol. 2019;76:915.<pub-id pub-id-type="pmid">31157827</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2019.1424</pub-id><pub-id pub-id-type="pmcid">PMC6547132</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwarz</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Regional profiles of the candidate Tau PET ligand<sup>18</sup> F-AV-1451 recapitulate key features of Braak histopathological stages</article-title><source>Brain</source><year>2016</year><volume>139</volume><fpage>1539</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1093/brain/aww023</pub-id><pub-id pub-id-type="pmid">26936940</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Schwarz AJ, et al. Regional profiles of the candidate Tau PET ligand<sup>18</sup> F-AV-1451 recapitulate key features of Braak histopathological stages. Brain. 2016;139:1539&#8211;50.<pub-id pub-id-type="pmid">26936940</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/aww023</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maass</surname><given-names>A</given-names></name><etal/></person-group><article-title>Comparison of multiple tau-PET measures as biomarkers in aging and alzheimer&#8217;s disease</article-title><source>NeuroImage</source><year>2017</year><volume>157</volume><fpage>448</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2017.05.058</pub-id><pub-id pub-id-type="pmid">28587897</pub-id><pub-id pub-id-type="pmcid">PMC5814575</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Maass A, et al. Comparison of multiple tau-PET measures as biomarkers in aging and alzheimer&#8217;s disease. NeuroImage. 2017;157:448&#8211;63.<pub-id pub-id-type="pmid">28587897</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2017.05.058</pub-id><pub-id pub-id-type="pmcid">PMC5814575</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ossenkoppele</surname><given-names>R</given-names></name><etal/></person-group><article-title>Tau PET patterns mirror clinical and neuroanatomical variability in alzheimer&#8217;s disease</article-title><source>Brain</source><year>2016</year><volume>139</volume><fpage>1551</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1093/brain/aww027</pub-id><pub-id pub-id-type="pmid">26962052</pub-id><pub-id pub-id-type="pmcid">PMC5006248</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Ossenkoppele R, et al. Tau PET patterns mirror clinical and neuroanatomical variability in alzheimer&#8217;s disease. Brain. 2016;139:1551&#8211;67.<pub-id pub-id-type="pmid">26962052</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/aww027</pub-id><pub-id pub-id-type="pmcid">PMC5006248</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>H-D</given-names></name><name name-style="western"><surname>Cl&#233;ment</surname><given-names>M</given-names></name><name name-style="western"><surname>Planche</surname><given-names>V</given-names></name><name name-style="western"><surname>Mansencal</surname><given-names>B</given-names></name><name name-style="western"><surname>Coup&#233;</surname><given-names>P</given-names></name></person-group><article-title>Deep grading for MRI-based differential diagnosis of alzheimer&#8217;s disease and frontotemporal dementia</article-title><source>Artif Intell Med</source><year>2023</year><volume>144</volume><fpage>102636</fpage><pub-id pub-id-type="doi">10.1016/j.artmed.2023.102636</pub-id><pub-id pub-id-type="pmid">37783553</pub-id><pub-id pub-id-type="pmcid">PMC10904714</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Nguyen H-D, Cl&#233;ment M, Planche V, Mansencal B, Coup&#233; P. Deep grading for MRI-based differential diagnosis of alzheimer&#8217;s disease and frontotemporal dementia. Artif Intell Med. 2023;144:102636.<pub-id pub-id-type="pmid">37783553</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.artmed.2023.102636</pub-id><pub-id pub-id-type="pmcid">PMC10904714</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dubois</surname><given-names>B</given-names></name><etal/></person-group><article-title>Alzheimer disease as a Clinical-Biological Construct&#8212;An international working group recommendation</article-title><source>JAMA Neurol</source><year>2024</year><volume>81</volume><fpage>1304</fpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2024.3770</pub-id><pub-id pub-id-type="pmid">39483064</pub-id><pub-id pub-id-type="pmcid">PMC12010406</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Dubois B, et al. Alzheimer disease as a Clinical-Biological Construct&#8212;An international working group recommendation. JAMA Neurol. 2024;81:1304.<pub-id pub-id-type="pmid">39483064</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2024.3770</pub-id><pub-id pub-id-type="pmcid">PMC12010406</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamraoui</surname><given-names>RA</given-names></name><etal/></person-group><article-title>DeepLesionBrain: towards a broader deep-learning generalization for multiple sclerosis lesion segmentation</article-title><source>Med Image Anal</source><year>2022</year><volume>76</volume><fpage>102312</fpage><pub-id pub-id-type="doi">10.1016/j.media.2021.102312</pub-id><pub-id pub-id-type="pmid">34894571</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Kamraoui RA, et al. DeepLesionBrain: towards a broader deep-learning generalization for multiple sclerosis lesion segmentation. Med Image Anal. 2022;76:102312.<pub-id pub-id-type="pmid">34894571</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.media.2021.102312</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-id journal-id-type="pmc-domain-id">1579</journal-id><journal-id journal-id-type="pmc-domain">scirep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12485106</article-id><article-id pub-id-type="pmcid-ver">PMC12485106.1</article-id><article-id pub-id-type="pmcaid">12485106</article-id><article-id pub-id-type="pmcaiid">12485106</article-id><article-id pub-id-type="pmid">41027951</article-id><article-id pub-id-type="doi">10.1038/s41598-025-04899-0</article-id><article-id pub-id-type="publisher-id">4899</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Advanced MRI based Alzheimer&#8217;s diagnosis through ensemble learning techniques</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-2480-3273</contrib-id><name name-style="western"><surname>Sriram</surname><given-names initials="S">Suthir</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-8694-033X</contrib-id><name name-style="western"><surname>Nivethitha</surname><given-names initials="V">V.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0003-6610-4507</contrib-id><name name-style="western"><surname>Arun Kaarthic</surname><given-names initials="TP">T. P.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0000-9097-2273</contrib-id><name name-style="western"><surname>Archita</surname><given-names initials="S">S.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-2510-8857</contrib-id><name name-style="western"><surname>Murugan</surname><given-names initials="T">Thangavel</given-names></name><address><email>thangavelm@uaeu.ac.ae</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03am10p12</institution-id><institution-id institution-id-type="GRID">grid.411370.0</institution-id><institution-id institution-id-type="ISNI">0000 0000 9081 2061</institution-id><institution>Department of Computer Science and Engineering, </institution><institution>Amrita School of Computing, Amrita Vishwa Vidyapeetham, </institution></institution-wrap>Chennai, India </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01km6p862</institution-id><institution-id institution-id-type="GRID">grid.43519.3a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2193 6666</institution-id><institution>College of Information and Technology, United Arab Emirates University, </institution></institution-wrap>Al Ain, Abu Dhabi, United Arab Emirates </aff></contrib-group><pub-date pub-type="epub"><day>30</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><issue-id pub-id-type="pmc-issue-id">478255</issue-id><elocation-id>33840</elocation-id><history><date date-type="received"><day>25</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>29</day><month>5</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>30</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>02</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-02 00:25:41.673"><day>02</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41598_2025_Article_4899.pdf"/><abstract id="Abs1"><p id="Par1">Alzheimer&#8217;s Disease is a condition that affects the brain and causes changes in behavior and memory loss while making it hard to carry out tasks properly. It&#8217;s vital to spot the illness early, for effective treatment. MRI technology has advanced in detecting Alzheimer&#8217;s by using machine learning and deep learning models. These models use neural networks to analyze brain MRI results automatically and identify key indicators of Alzheimer&#8217;s disease. In this study, we used MRI data to train a CNN for diagnosing and categorizing the four stages of Alzheimer&#8217;s disease with deep learning techniques, offering significant advantages in identifying patterns in medical imaging for this neurodegenerative condition compared to using a CNN exclusively trained for this purpose. They evaluated ResNet50, InceptionResNetv2 as well as a CNN specifically trained for their study and found that combining the models led to highly accurate results. The accuracy rates for the trained CNN model stood at 90.76%, InceptionResNetv2 at 86.84%, and ResNet50 at 90.27%. In this trial run of the experiment conducted by combining all three models collaboratively resulted in an accuracy rate of 94.27% compared to the accuracy rates of each model working individually.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Alzheimer&#8217;s Detection</kwd><kwd>CNN</kwd><kwd>Deep learning</kwd><kwd>Ensemble</kwd><kwd>InceptionResNetV2</kwd><kwd>Residual Net (ResNet)</kwd><kwd>ResNet50</kwd></kwd-group><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Neurological disorders</kwd><kwd>Alzheimer's disease</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100009526</institution-id><institution>Amrita Vishwa Vidyapeetham University</institution></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Alzheimer&#8217;s is a disease that causes progressive cognitive decline. Early analysis and intervention are vital to retard the progress of the disease, as drugs can manage the symptoms and decrease the growth of the disease. Magnetic resonance images can be used to see structural abnormality of the brain, due to a variety of neurological ailments. Magnetic resonance can be used to detect brain atrophy in the hippocampus which is relevant for a diagnosis of Alzheimer&#8217;s disease. it is also complicated by pathological changes, including biochemical, functional, and microscopic changes.</p><p id="Par3">There is a need for a broader diagnostic workup beyond traditional markers. Machine learning and deep learning can be used to enhance the diagnostic performance of Alzheimer&#8217;s disease. Deep learning techniques like Convolutional Neural Networks have a plenty of skill in processing rich graphical information. CNN has the ability to extract information from multiple layers. Utility has been shown by individual CNN designs, but interest in ensemble methods has increased. In ensemble learning, multiple models are combined in making a prediction to obtain one unified decision, which is often more accurate than the predictions made by any of the contributing models.</p><p id="Par4">It will be focused on ensemble learning capabilities, fusing a few custom-trained CNNs with InceptionResNetV2 and ResNet50 models. This work is the basis for research performed on previously explored capabilities of some designs of CNNs on the classification performance regarding Alzheimer&#8217;s disease. Based on the previous literature, this study proposes a new approach that combines various CNN models to provide a more Robust diagnosis of AD. The main focus of this investigation is to perform an in-depth analysis of ensemble learning with regard to the deep classification approach for diagnosing AD. The metrics used to assess this system would include several measures such as F1 Score, Accuracy and Recall. Also, the network layers will be optimized. The initiative aims at enhancing diagnosis and medical care of Alzheimer&#8217;s disease by integrating state-of-the-art imaging with advanced machine learning methods; all this by the use of ensemble learning techniques as part of ongoing effort to limit disease incidence.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Preprocessing</title><p id="Par5">The preprocessing phase is necessary for enhancing the robustness and overall usability of the ensemble model. To investigate the effectiveness of the used preprocessing techniques, namely normalization, augmentation, and SMOTE, an ablation study was conducted to quantify the individual and combined effects of these techniques on the model&#8217;s performance.</p><p id="Par6">Normalization, which scales the pixel values to a range of 0 to 1, improved the training stability and convergence of the models. The ensemble model had a drop in accuracy from 94.27% to 87.25% without normalization, pointing out the need for input data standardization for improved learning dynamics.</p><p id="Par7">Data augmentation methods&#8212;horizontal flips, zoom, brightness adjustment&#8212;were used in dealing with the small size of the dataset as well as to avoid overfitting. These methods added randomness into the training data, so these mimic real-world cases for better generalization of models. If no augmentation is utilized, the performance drops. Its accuracy went down to 89.32% with an accuracy of.</p><p id="Par8">The usage of SMOTE rectifies the existing disparity in the dataset that is especially related to the severe dementia class. This method produced synthetic samples of those classes that were underrepresented, thus enhancing the capacity of the model to recognize distinctive features from all the classes. The omission of SMOTE led to a serious deterioration in performance and especially relating to the F1-score of the severe dementia class dropped from 0.91 to 0.76. It also reveals that SMOTE is very crucial in multi-class classification tasks for getting the performance balanced.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Ablation study of preprocessing techniques.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Preprocessing technique</th><th align="left" colspan="1" rowspan="1">Accuracy (%)</th><th align="left" colspan="1" rowspan="1">F1-Score<break/>(Severe Dementia)</th><th align="left" colspan="1" rowspan="1">AUC</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"><p>All Techniques (Normalization,</p><p>Augmentation, SMOTE)</p></td><td char="." align="char" colspan="1" rowspan="1">94.27</td><td char="." align="char" colspan="1" rowspan="1">0.91</td><td char="." align="char" colspan="1" rowspan="1">0.96</td></tr><tr><td align="left" colspan="1" rowspan="1">Without Normalization</td><td char="." align="char" colspan="1" rowspan="1">87.25</td><td char="." align="char" colspan="1" rowspan="1">0.81</td><td char="." align="char" colspan="1" rowspan="1">0.89</td></tr><tr><td align="left" colspan="1" rowspan="1">Without Augmentation</td><td char="." align="char" colspan="1" rowspan="1">89.32</td><td char="." align="char" colspan="1" rowspan="1">0.85</td><td char="." align="char" colspan="1" rowspan="1">0.92</td></tr><tr><td align="left" colspan="1" rowspan="1">Without SMOTE</td><td char="." align="char" colspan="1" rowspan="1">90.15</td><td char="." align="char" colspan="1" rowspan="1">0.76</td><td char="." align="char" colspan="1" rowspan="1">0.88</td></tr></tbody></table></table-wrap></p><p id="Par9">Table <xref rid="Tab1" ref-type="table">1</xref> below illustrates the summary of results from the ablation study. The study brings out how preprocessing operations contribute to keeping the ensemble model stable, accurate, and generalizable.The SMOTE are computed through the generation of synthetic samples for minority classes inserted between existing samples of the minority class. It can be calculated from the formula (<xref rid="Equ1" ref-type="disp-formula">1</xref>)</p><p>
<disp-formula id="Equ1"><label>1</label><alternatives><tex-math id="d33e284">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} x_{\text {new}} = x + \lambda \times \left( x_{\text {kn}} - x \right) \end{aligned}$$\end{document}</tex-math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="41598_2025_4899_Article_Equ1.gif"/></alternatives></disp-formula>
</p><p>where x is original minority class sample, x<inline-formula id="IEq1"><alternatives><tex-math id="d33e293">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\urcorner \urcorner$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_4899_Article_IEq1.gif"/></alternatives></inline-formula>kn is one of the k-nearest neighbors of x and <inline-formula id="IEq2"><alternatives><tex-math id="d33e299">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\lambda$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_4899_Article_IEq2.gif"/></alternatives></inline-formula> is a random number in the range of [0,1].</p><p id="Par10">We decided to consider InceptionResNetV2, ResNet50, and a custom-trained CNN for maximizing the diagnostic accuracy in terms of Alzheimer&#8217;s disease with MRI images as shown in Table <xref rid="Tab2" ref-type="table">2</xref>. This selection was based on their different ability to capture certain specific aspects of MRI images important for neurodegenerative condition diagnosis.</p><p id="Par11">InceptionResNetV2 integrates the inception modules and residual connections to efficiently capture multi-scale features of MRI images as well as improve the detection of fine-grained structural variations that correlate with Alzheimer&#8217;s. Its architecture successfully gets rid of the vanishing gradient problem and hence works well with deep network structures.</p><p id="Par12">The powerful residual connections of ResNet50 add depth without the risk of degradation. This makes it perfect for detecting both mild and advanced stages of Alzheimer&#8217;s disease, identifying hierarchical patterns across layers that capture significant disease markers present in both early and late stages.</p><p>
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Performance comparison of various CNN models.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Model</th><th align="left" colspan="1" rowspan="1">Precision</th><th align="left" colspan="1" rowspan="1">Recall</th><th align="left" colspan="1" rowspan="1">F1 Score</th><th align="left" colspan="1" rowspan="1">Accuracy (%)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">VGG16</td><td char="." align="char" colspan="1" rowspan="1">0.87</td><td char="." align="char" colspan="1" rowspan="1">0.85</td><td char="." align="char" colspan="1" rowspan="1">0.86</td><td char="." align="char" colspan="1" rowspan="1">88.23</td></tr><tr><td align="left" colspan="1" rowspan="1">DenseNet121</td><td char="." align="char" colspan="1" rowspan="1">0.89</td><td char="." align="char" colspan="1" rowspan="1">0.88</td><td char="." align="char" colspan="1" rowspan="1">0.88</td><td char="." align="char" colspan="1" rowspan="1">89.15</td></tr><tr><td align="left" colspan="1" rowspan="1">MobileNetV2</td><td char="." align="char" colspan="1" rowspan="1">0.88</td><td char="." align="char" colspan="1" rowspan="1">0.87</td><td char="." align="char" colspan="1" rowspan="1">0.87</td><td char="." align="char" colspan="1" rowspan="1">91.43</td></tr><tr><td align="left" colspan="1" rowspan="1">EfficientNetB0</td><td char="." align="char" colspan="1" rowspan="1">0.90</td><td char="." align="char" colspan="1" rowspan="1">0.89</td><td char="." align="char" colspan="1" rowspan="1">0.89</td><td char="." align="char" colspan="1" rowspan="1">92.05</td></tr><tr><td align="left" colspan="1" rowspan="1">InceptionResNetV2</td><td char="." align="char" colspan="1" rowspan="1">0.85</td><td char="." align="char" colspan="1" rowspan="1">0.84</td><td char="." align="char" colspan="1" rowspan="1">0.84</td><td char="." align="char" colspan="1" rowspan="1">86.84</td></tr><tr><td align="left" colspan="1" rowspan="1">ResNet50</td><td char="." align="char" colspan="1" rowspan="1">0.91</td><td char="." align="char" colspan="1" rowspan="1">0.90</td><td char="." align="char" colspan="1" rowspan="1">0.90</td><td char="." align="char" colspan="1" rowspan="1">90.27</td></tr><tr><td align="left" colspan="1" rowspan="1">Custom Trained CNN</td><td char="." align="char" colspan="1" rowspan="1">0.92</td><td char="." align="char" colspan="1" rowspan="1">0.91</td><td char="." align="char" colspan="1" rowspan="1">0.91</td><td char="." align="char" colspan="1" rowspan="1">
<bold>90.76</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Weighted Ensemble</td><td char="." align="char" colspan="1" rowspan="1">0.95</td><td char="." align="char" colspan="1" rowspan="1">0.94</td><td char="." align="char" colspan="1" rowspan="1">0.94</td><td char="." align="char" colspan="1" rowspan="1">
<bold>94.76</bold>
</td></tr></tbody></table><table-wrap-foot><p>Significant values are in [bold].</p></table-wrap-foot></table-wrap>
</p><p id="Par13">Since CNNs are designed specifically based on Alzheimer&#8217;s, the specific layers are trained for targeting the disease-specific characteristics related to MRI images. Given its focus on Alzheimer&#8217;s-related biomarkers, such models can capture complementary information regarding the ensemble accuracy. So, by including these different models within an ensemble setting, it becomes possible to conduct a complete and accurate analysis of MRI data using this robust tool for diagnosing Alzheimer&#8217;s.</p></sec><sec id="Sec4"><title>Custom trained CNN</title><p id="Par15">The given study applies a CNN model to the unique classification task at hand. A model architecture has been built that would help in the classification of images, keeping in consideration appropriate relevant architectural ideas used in deep learning. It starts with an input layer with an intact fixed-size image (176, 176, 3) and progresses through a series of convolution blocks. Each convolutional block has a set of convolutional layers intended to capture the specific properties of the picture. Three layers may be there specifically: Layer 1, which is for feature maps extraction from the image; Layer 2, which is for learning more features of the image; and the third layer, which acts as the max pooling layer that decreases the spatial dimensions by a factor of 2. The equation for the convolution operation is performed as given in Eq. (<xref rid="Equ2" ref-type="disp-formula">2</xref>).</p><p>
<disp-formula id="Equ2"><label>2</label><alternatives><tex-math id="d33e451">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} (I * K)(i,j) = \sum _m \sum _n I(m,n) \cdot K(i-m, j-n) \end{aligned}$$\end{document}</tex-math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="41598_2025_4899_Article_Equ2.gif"/></alternatives></disp-formula>
</p><p>where I, K ,i, j are the input image, kernel and positions on the output feature map,respectively. Following the convolutional layers, batch normalization and pooling are applied to increase the model&#8217;s performance. The max pooling operation is done using the given formula (<xref rid="Equ3" ref-type="disp-formula">3</xref>).</p><p>
<disp-formula id="Equ3"><label>3</label><alternatives><tex-math id="d33e465">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} P(i,j) = \max _{m,n} \left( I(i+m, j+n) \right) \end{aligned}$$\end{document}</tex-math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="41598_2025_4899_Article_Equ3.gif"/></alternatives></disp-formula>
</p><p>where the output is the maximum value from input regions defined by filter size. There are also dropout layers between a few blocks with 20% dropout rate to avoid overfitting. These sequential blocks allow the network to progressively learn hierarchical representations from the input data, something which becomes necessary for a CNN to carry out tasks related to images. Following the sequential block, the flatten layer is used for flattening the results coming from the previous layers. The model architecture also involves Dense blocks, which are key to eliciting high-level features and patterns in the lower-level representations provided by convolutional layers. These dense blocks are composed of densely coupled layers to which bump normalization and interpolation had been applied to enhance meshing and generalization performance. The overall model architecture Fig. <xref rid="Fig1" ref-type="fig">1</xref>, developed by introducing non-linearity with the aid of an activation function, is a softmax activation layer at the end with the exact number of output classes customized according to the classification job. This last layer assigns probabilities to each class, thus enabling the model to make informed predictions on the basis of the data it receives and learns from during its training.</p><p id="Par14">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Model architecture.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="41598_2025_4899_Fig1_HTML.jpg"/></fig>
</p><p id="Par16">Specifically designed to face the challenges with regard to diagnosis of Alzheimer&#8217;s Disease from MRI imaging, this bespoke CNN is implemented into our ensemble model. Instead of the general pre-trained architecture, as in the InceptionResNetV2 and ResNet50 cases, it is tuned to point at biomarkers that denote this disease; these biomarkers include shrinkage in hippocampus and cortical atrophy. Given these special features, this bespoke CNN improves on other models such that better stage-by-stage classification about AD may be feasible with high accuracy and dependability.</p><p id="Par17">The architecture of the custom CNN is optimized for hierarchical feature extraction and consists of several convolutional blocks, where each is followed by a batch normalization layer and dropout layers for generalization improvement and overfitting prevention. The initial convolutional layers capture low-level features such as edges, textures, and basic shapes, which are critical for distinguishing anatomical structures in MRI images. The deeper layers capture intermediate features that represent pathological changes, including cortical thinning and ventricular enlargement. The final convolutional layers highlight high-level features, so the network can identify disease-specific markers that are crucial for differentiating between mild cognitive impairment and severe dementia.</p><p id="Par18">Compared to pre-trained models, the custom CNN proves capable of identifying subtle but crucial structural changes in the brain structure. For instance, its F1-score in severe dementia is 0.91 against InceptionResNetV2 at 0.76 and ResNet50 at 0.83. Moreover, the design makes provisions for dropout layers and max-pooling layers appropriately placed to retain spatial information without risking overfitting, which often occurs when working with smaller datasets.</p><p id="Par19">Specialised into Alzheimer&#8217;s-related biomarkers, the custom CNN happens to be more efficient in MRI data handling than general-purposed networks. Due to this specialisation, the performance of the combined model is balanced, drawing upon the more general features of InceptionResNetV2 and ResNet50. Altogether, the models constitute a good diagnostics tool for the identification of all stages of AD at high accuracy.</p></sec><sec id="Sec5"><title>InceptionResNetV2</title><p id="Par20">InceptionResNetV2 is a convolutional neural network that incorporates both the idea of an inception and residual connections. InceptionResNetv2 is a neural network architecture designed for performing convolutional operations. It gained knowledge from a massive repository of several millions of photos found in the ImageNet database. It was a 164-layer network capable of correctly classifying images into an exact representation comprising 1000 different characteristics. The input image fed into the network is 299 x 299 pixels, while on the output side, the network returns a list of the predicted probabilities over all classes. During creation, it merges the initial structure with the residual connection. Following the input layer is the stem block, which reduces the spatial dimensions of the image and correspondingly increases its depth. The InceptionResNet block combines convolutional filters of different sizes and merges them using residual connections. This strategy greatly reduces the training time required. Following this block, there is an average pooling layer that decreases the dimensionality of each feature map to a single layer. The Average Pooling computation is done using Eq. (<xref rid="Equ4" ref-type="disp-formula">4</xref>).</p><p>
<disp-formula id="Equ4"><label>4</label><alternatives><tex-math id="d33e504">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} P(i,j) = \frac{1}{n} \sum _{m,n} I(i+m, j+n) \end{aligned}$$\end{document}</tex-math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="41598_2025_4899_Article_Equ4.gif"/></alternatives></disp-formula>
</p><p>which calculates average of the elements in input region, reducing spatial dimensions. This is followed by a fully connected layer, which is a dense layer with softmax activation which gives the output of the classification probabilities of each class. The softmax activation function is calculated as given in Eq. (<xref rid="Equ5" ref-type="disp-formula">5</xref>)</p><p>
<disp-formula id="Equ5"><label>5</label><alternatives><tex-math id="d33e518">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} \text {softmax}(z_i) = \frac{e^{z_i}}{\sum _{j=1}^{K} e^{z_j}} \end{aligned}$$\end{document}</tex-math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="41598_2025_4899_Article_Equ5.gif"/></alternatives></disp-formula>
</p><p>Where zi is the i-th element of input vector z. InceptionResNetv2 is distinguished by its ability to process large images quickly while retaining the fine-grained information required for classification. The use of residual connections, which allow information to be bypassed via shortcut connections, reduces the vanishing gradient problem and speeds up training convergence.</p></sec><sec id="Sec6"><title>ResNet50</title><p id="Par21">ResNet-50 is an already trained deep learning model on the CNN architecture for processing visual input. The ResNet-50 model has a total of 50 layers. This model was trained with one million photographs from the ImageNet database, which has 1000 categories of objects. ResNet50 is a bit different from other pre-trained models such as AlexNet, GoogleNet, and VGG19, due to its great generalization ability and minimum error rates in recognition tests. The system will work on the exact classification of photos into 1000 categories, including keyboards, mice, pencils, and animals, using a 224 <inline-formula id="IEq3"><alternatives><tex-math id="d33e530">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\times$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_4899_Article_IEq3.gif"/></alternatives></inline-formula> 224-pixel input. It starts with the convolutional layer with many filters in the ResNet50 model, followed by a max pooling that directly comes after the input layer. The residual block contains a sequence of convolutional layers and shortcut connections. After residual blocks, the global average pooling layer decreases each feature map to individual layer, succeeded by the fully connected layer. The equation for calculating global average pooling is as given in Eq. (<xref rid="Equ6" ref-type="disp-formula">6</xref>).</p><p>
<disp-formula id="Equ6"><label>6</label><alternatives><tex-math id="d33e541">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} P = \frac{1}{H \times W} \sum _{i=1}^{H} \sum _{j=1}^{W} I(i,j) \end{aligned}$$\end{document}</tex-math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="41598_2025_4899_Article_Equ6.gif"/></alternatives></disp-formula>
</p><p>Researchers wanting to improve the efficiency of ResNet-50 may benefit from investigating various fine-tuning processes, such as changing top layers, tweaking learning rates, and applying data augmentation approaches.</p></sec><sec id="Sec7"><title>Ensemble model</title><p id="Par22">Carefully conceived, the ensemble model capitalizes on the complementary strengths ofInceptionResNetV2, ResNet50, and a custom-trained CNN. InceptionResNetV2 detects early cortical thinning related to Alzheimers through its rich multi-scale spatial features.Strung deep by residual connections, ResNet50 gives enhancement in classification by identification of hierarchical structural patterns that are vital to distinguishing mild, moderate, and severe dementia.On the other hand, our custom neural net is specifically devised and tuned to highlight biomarkers against Alzheimers like atrophy of the hippocampus and enlargement of the ventricle.</p><p id="Par23">The ensemble approach applies these unique advantages through weighted averaging over predictions, guaranteeing each stage of the disease receives a balanced classification performance. Future efforts include consideration of architectures like EfficientNet to examine their performance impact on Alzheimer classification. This choice of ensemble architecture affords exemplary precision, generalizability, robustness, and hence constitutes a practical AI model for clinical recognition of neurodegenerative disease.</p><p id="Par24">To make a better classification challenge, this study has developed the Weighted Ensemble Model. This approach leverages the strengths in the different performance of each model to enhance the overall performance of the predictions. All unique models were trained on a subset of the dataset that was set aside for testing. Because of this, these models can construct prediction probability vectors to contribute to the ensembling. During the ensemble phase, prediction probability vectors of the individual models are combined and multiplied by respective weights. In Eq. (<xref rid="Equ7" ref-type="disp-formula">7</xref>), weighted averaging of prediction probabilities is calculated as :</p><p>
<disp-formula id="Equ7"><label>7</label><alternatives><tex-math id="d33e562">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} P_{\text {ensemble}} = \sum _{i=1}^{n} w_i P_i \end{aligned}$$\end{document}</tex-math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="41598_2025_4899_Article_Equ7.gif"/></alternatives></disp-formula>
</p><p>where Pi is the probability vector of each model Mi, wi are the respective weights, and <inline-formula id="IEq4"><alternatives><tex-math id="d33e571">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$P_{\text {ensemble}}$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_4899_Article_IEq4.gif"/></alternatives></inline-formula> is the final ensemble forecast. Then, these weighted probabilities were averaged to identify the final forecast for the ensemble model. Suitable weight establishment is an essential issue to effectively improve the performance of the ensemble. For that, an approach to hyperparameter tuning in a systematic manner called Grid Search has been employed in this study. The approach has provided the optimal weights as [0.4, 0.3, 0.3]. This weighted ensemble technique gives evidence of commitment towards better classification model performance.</p><p id="Par25">This work introduces a novel ensemble learning approach specifically designed for the task of Alzheimer&#8217;s Disease classification using MRI data. Unlike traditional ensemble models, the proposed technique is based on a custom CNN that uses architectures such as InceptionResNetV2 and ResNet50 pre-trained in conjunction with a weighted averaging scheme. The custom CNN is highly optimized for extracting Alzheimer-related biomarkers that provide complementary information not extensively explored within generic architectures.</p><p id="Par26">The weighted averaging strategy relies on hyperparameter optimization with grid search for the best possible weights at every model: [0.4, 0.3, 0.3]. This makes sure each individual model is giving its optimal performance to ensure diagnostic accuracy remains very high for all disease stages of Alzheimer&#8217;s ranging from mild cognitive impairment all through to late dementia. The proposed methodology has illustrated enhanced efficacy, attaining a classification accuracy of 94.27%, which surpasses the individual model accuracies of 86.84% for InceptionResNetV2, 90.27% for ResNet50, and 90.76% for the custom CNN. Additionally, the ensemble model demonstrates resilience in addressing class imbalances, as indicated by its consistent balanced F1-scores throughout all four stages of Alzheimer&#8217;s disease (AD).</p><p id="Par27">To better the diagnostic performance at each step of AD, our ensemble model utilized weighted averaging method. We have also conducted the process of hyperparameter tuning using grid search in determining optimal weights for all of our models: 0.4 for our custom CNN and 0.3 assigned to both InceptionResNetV2 and ResNet50.</p><p id="Par28">The weights were set with an evaluation of the effectiveness of the ensemble model on a separate, independent validation data that is not used for training nor for testing. Validation further helped in tuning the weights towards balancing the merits of particular models and their demerits. For example, this particular CNN model showed enhanced performance in identifying mild cognitive impairment and severe dementia thus a greater weight to such model was warranted. InceptionResNetV2 strongly contributed towards the identification of cases without dementia and early-stage ones, while ResNet50 had robust performance for late-stage cases due to the depth architecture and residual connections.</p><p id="Par29">Our ensemble model takes the predictions by weighted averaging, meaning each model output probability is multiplied by some weight after that. The weights distribution [0.4, 0.3, 0.3] was adopted by a grid search for optimizing F1 and AUC performance on the many validation sets. Such an approach ensures that a most useful model (custom CNN) contributes more, while the other two models (ResNet50 and InceptionResNetV2) contribute complementary features.</p><p id="Par30">While ensemble evaluation was run with equal weights (0.33 each) and higher weight to the ResNet50 (0.5, 0.25, 0.25), the combination selected provided the accuracy of 94.27%. Future works will include exploration into stacked ensemble methods for the meta-classifier to learn how to optimally combine the outputs of base models in a data-driven manner, which will potentially improve the accuracy in diagnostics but reduce any introduced biases by using weights predetermined by nature.</p></sec><sec id="Sec8"><title>evaluation metrics</title><p id="Par31">Accuracy is a metric that is used to measure how often precise predictions are created by the model in its total predictions.The formula to calculate accuracy is given in Eq. (<xref rid="Equ8" ref-type="disp-formula">8</xref>)</p><p>
<disp-formula id="Equ8"><label>8</label><alternatives><tex-math id="d33e599">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} \text {Accuracy} = \frac{\text {n.o precise Predictions}}{\text {Total n.o Predictions}} \end{aligned}$$\end{document}</tex-math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="41598_2025_4899_Article_Equ8.gif"/></alternatives></disp-formula>
</p><p>Precision is used to estimate the Working of the trained ensemble model for the object identification task in MRI images, where the exact localization of the regions of interest plays a very significant role. This is mathematically defined in the Eq. (<xref rid="Equ9" ref-type="disp-formula">9</xref>):</p><p>
<disp-formula id="Equ9"><label>9</label><alternatives><tex-math id="d33e613">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} \text {Precision} = \frac{TP}{TP + FP} \end{aligned}$$\end{document}</tex-math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="41598_2025_4899_Article_Equ9.gif"/></alternatives></disp-formula>
</p><p>Here, TP means True Positives, and FP stands for False Positives.</p><p id="Par32">This means accuracy with regard to the presently generated model of an ensemble is gauged. That is, a ratio between the total n.o true positive bounding boxes identifying objects of interest within images against a total number of bounding boxes generated would be considered. Precision gives not only detection but also accurate item localization, what is from the essence in the detection of Alzheimer&#8217;s disease. This, in turn, locates the precise sites where the disease-specific brain regions occur, such as hippocampal shrinkage or amyloid-beta plaques, which are so crucial for diagnosis and staging.</p><p id="Par33">Recall is an crucial evaluation parameter for the accurate assessment of object recognition and modeling in the context of Alzheimer&#8217;s disease using MRI data. Recall measures the student&#8217;s ability to identify and confirm patterns and contrasts in images, such as areas related with Alzheimer&#8217;s disease.The Recall equation is given in Eq. (<xref rid="Equ10" ref-type="disp-formula">10</xref>).</p><p>
<disp-formula id="Equ10"><label>10</label><alternatives><tex-math id="d33e630">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} \text {Recall} = \frac{TP}{TP + FN} \end{aligned}$$\end{document}</tex-math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="41598_2025_4899_Article_Equ10.gif"/></alternatives></disp-formula>
</p><p>where FN are False Negatives.</p><p id="Par34">In this approach, &#8220;True Positives&#8221; denotes the various regions of interest correctly detected and localized, especially those associated with features of Alzheimer&#8217;s disease. &#8220;False Negatives&#8221; refers to regions that exist but are not picked up or localized by the model. Recall provides the extent of the ability of the model to detect and, furthermore, precisely locate such regions; hence, this is one of the most relevant parameters in the detection of Alzheimer&#8217;s. This gives an vision into the capability of the model in correctly identifying the disease characteristics in MRI images for early diagnosis and monitoring of therapy. The higher the recall, the better the model in capturing and localizing regions that are suggestive of Alzheimer&#8217;s disease, adding on the therapeutic value.</p><p id="Par35">The various evaluation metrics used in the present ensemble model are inclusive of Area Under the Curve-AUC, F1 Score, and Categorical Accuracy. This makes categorical accuracy one important metric for determining the capability of the ensemble model to precisely diagnose stages of Alzheimer&#8217;s disease. It is calculated as given in Eq. (<xref rid="Equ11" ref-type="disp-formula">11</xref>)</p><p>
<disp-formula id="Equ11"><label>11</label><alternatives><tex-math id="d33e648">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} \text {Categorical Accuracy} = \frac{\sum _{i=1}^{N} 1(Y_i = \hat{Y}_i)}{N} \end{aligned}$$\end{document}</tex-math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="41598_2025_4899_Article_Equ11.gif"/></alternatives></disp-formula>
</p><p>where predicted class is given by <inline-formula id="IEq5"><alternatives><tex-math id="d33e657">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\hat{{\textbf {yi}}}$$\end{document}</tex-math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_4899_Article_IEq5.gif"/></alternatives></inline-formula> and actual class is given by yi for the i-th instance and returns 1 when predicted class and actual class are equal.</p><p id="Par36">AUC estimates the model&#8217;s ability to distinguish across distinct phases, providing useful information about its discriminative capabilities. The F1 Score, which balances accuracy and recall, is especially useful for multi-class classification problems that take into a reason from false positives and false negatives. The F1 Score is derived from the given Eq. (<xref rid="Equ12" ref-type="disp-formula">12</xref>):</p><p>
<disp-formula id="Equ12"><label>12</label><alternatives><tex-math id="d33e670">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} \text {F1} = 2 \cdot (\frac{\text {Precision} \cdot \text {Recall}}{\text {Precision} + \text {Recall}}) \end{aligned}$$\end{document}</tex-math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="41598_2025_4899_Article_Equ12.gif"/></alternatives></disp-formula>
</p></sec></sec><sec id="Sec9"><title>Results</title><p id="Par37">The study has incorporated a specialized callback to evaluate the correctness of validation during the training process. This callback terminates training when the validation accuracy exceeds a predetermined threshold of 0.99, which ensure the overfitting of the model and achieves a satisfactory degree of accuracy. In addition, this study implemented EarlyStopping phone-response, 2 patient sessions, to minimize attrition and ensure that the study was not interrupted. The proposed architecture is a CNN that uses direct activation and preprocessing techniques. The main optimizer is &#8220;Adam&#8221; and the dead function used is cross-generation. Evaluation of the model performance should look at several features, such as F1 Score,Accuracy and Area Under The Curve (AUC).</p><p id="Par38">These statistics essentially assess the model&#8217;s ability to classify the input data into four unique groups. The goal of this test configuration is to achieve a good balance between the difficulty of the model, the training task, and the performance, and to ensure that the model reaches the correct threshold without falling into errors. An overview of the model&#8217;s architecture and clear discussions highlight the critical components needed for training and evaluation. This strategy showcases a methodical and well-founded structure for constructing and instructing deep learning models in scientific investigation, leading to robust and reliable results.</p><p id="Par39">This is done by using a specially trained CNN and two different CNN models that are pre-trained on cross-training. The purpose of this work is to directly diagnose Alzheimer&#8217;s disease by looking at MRI brain scans of people. Two commonly used models are InceptionResNetV2 and ResNet50. the KAD,Kaggle Alzhimer&#8217;s dataset contains MRI images of the brain used to classify Alzheimer&#8217;s disease. Selected images are of different size. The images need to be rescaled according to the dimensions based on the CNN model being analyzed. Brain scan images in initialResnetV2 and ResNet50 are resized to 224 pixels wide, 224 pixels high and 3 color channels. After the transformation, the images are compared. Due to the unbalanced class, the data set will be oversampled by SMOTE. A total of about 6400 models were produced. 6,400 MRI images will be classified and 80% will be used for training.</p><p>
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Confusion matrix for comparison of the models.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="41598_2025_4899_Fig2_HTML.jpg"/></fig>
</p><p id="Par40">These images were then fed into a set of custom trained Convolutional Neural Networks (CNN) as well as two distinct transfer learning models to diagnose different phases of Alzheimer&#8217;s disease. MCC is utilized to calculate the categorizations of the models. The figures labeled as Fig. <xref rid="Fig2" ref-type="fig">2</xref>a&#8211;d represent the Confusion matrix of all the four different models: a custom trained CNN, InceptionResNetV2, ResNet50 and Ensemble Model. These figures provide a summary of the classification prediction results of each model. The accuracy, Matthews correlation coefficient (MCC), and Balanced Accuracy Score (BAS) performance statistics for each CNN model are presented in Table <xref rid="Tab3" ref-type="table">3</xref>. The findings indicate that ResNet50 exceeded InceptionResNetV2 in classifying Alzheimer&#8217;s Disease by a margin of 90.27%. Additionally, a custom-trained CNN had a high accuracy of 90.76%, surpassing all other models, while InceptionResNetV2 had the lowest accuracy at 86.84%. Therefore, utilizing the Weighted average ensemble to combine these models yields an accuracy score of 94.76% (Fig. <xref rid="Fig3" ref-type="fig">3</xref>).</p><p>
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Results of ensemble model.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="41598_2025_4899_Fig3_HTML.jpg"/></fig>
</p><p id="Par41">Here, the ensemble approach was introduced, a strategy by combining three distinct models: InceptionResNetV2, ResNet50, and custom CNN in unison to present a single highly impactful diagnostic system that can identify all stages of the disease. Use of weighted ensemble learning to combine the modes results in balanced performance across all stages using the strength of each unique model for more nuanced and reliable diagnosis.The accuracy and loss of the model are shown in the Fig. <xref rid="Fig2" ref-type="fig">2</xref></p><p id="Par42">InceptionResNetV2 is one of the key players, with tremendous multi-scale feature extraction ability. Since this architecture used inception modules and residual connections, it captures slight structural changes in MRI scans, which often indicate the start of Alzheimer&#8217;s disease. Since inception modules are capable of scanning patterns on different scales, capturing those areas where fine details must be captured for early signs identification in the mildest cases is possible. This is the largest capability of early-stage Alzheimer&#8217;s diagnosis, where multi-scale analysis captures much more subtle, initial changes in brain structure.</p><p id="Par43">ResNet50 adds depth and stability to the ensemble along with another layer of robustness. As such, due to its deep architecture, ResNet50 is a good learner of complex patterns and structures related to severe Alzheimer&#8217;s patients. Residual connections help the model to overcome vanishing gradients, and hence this model is more stable and also accurate in processing both sharp and mild cases. Since ResNet50 is pretty deep, it will be more than suitable for the variety of inputs at locations where structural brain changes are more relevant. So, it all depends on a strong backbone for making robust predictions across the Alzheimer&#8217;s disease progression stages.</p><p id="Par44">The Alzheimer&#8217;s biomarker-driven custom CNN further enhanced the ensemble&#8217;s accuracy by capturing MRI patterns associated with the disease. The fine-tuned custom model has learned to recognize a few of the more subtle MRI features associated with Alzheimer&#8217;s biomarkers, thereby enabling it to pick up those patterns that might be eluding generic architectures. Such specialization of the custom CNN would add precision to the model ensemble, particularly in areas where the needs are more focused toward the setting of Alzheimer&#8217;s-specific features.</p><p id="Par45">Together, such an ensemble approach makes for a more balanced and reliable diagnostic tool in which each model has much to offer: early-stage detection with InceptionResNetV2, stability across cases with ResNet50, and Alzheimer&#8217;s-specific feature recognition with the custom CNN. The strengths together synthesized make this an ensemble learning system that leads to an accurate yet consistent diagnostic tool, adequate for the varied challenges of the diverse stages of Alzheimer&#8217;s disease. Hence, it will be an important step forward in the application of deep learning for reliable and comprehensive classification of Alzheimer&#8217;s.</p><sec id="Sec10"><title>Related works</title><p id="Par46">Recent medical research has heightened the need for timely and accurate diagnosis of AD, a severe and widespread problem both for the affected individual and society as a whole. Deep learning algorithms have garnered interest in recent times for enhancing the accuracy of classification in AD, particularly when interpreting MRI data. Various research works have presented different methods that improve the classification of AD by using ensemble methods along with deep learning architectures and transfer learning techniques. E. Jabason et.al presented different hybrid deep learning structures that can classify patients into three categories: Alzheimer&#8217;s disease (AD), moderate cognitive impairment (MCI), and cognitively normal (CN)<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>.</p><p id="Par47">Performed better on the methodology of the OASIS dataset when compared with established methods; hence, this was promising for ensemble learning in the classification of AD. A study carried out by M. Tanveer et.al came forward with a methodology called &#8217;Deep Transfer Ensemble (DTE)&#8217; that outperformed the previous deep models by performing pretty well in distinguishing between CN vs. AD and MCI vs. AD<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. Transfer learning has kindled much promise in classifying Alzheimer&#8217;s disease, and that is evident from the work of Shijin Knox G et.al Advanced deep-transfer learning models and innovative architectures have been used to classify AD vs. CN with very high accuracy for MRI images<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. Moreover, Choi et al.<sup><xref ref-type="bibr" rid="CR4">4</xref></sup> presented a novel combination of several DCNNs for the classification of AD using MRI images.</p><p id="Par48">This method performed state-of-the-art results on the ADNI dataset. In the paper presented by Francis et al.<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>, an ensemble learning has been applied to classify between different stages of dementia. Their joint method performed superior classification performance within CN and moderate cognitive impairment convertible (MCIc) stages, which is considered one of the keys for early detection of Alzheimer&#8217;s diseases<sup><xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR7">7</xref></sup>. Furthermore, in the study presented by R. Prabha et.al, and Nagarathna C R et.al explored VGG-16 and DenseNet121, and CNN deep learning algorithms to see the performance of these in the correct prediction and classification of Alzheimer&#8217;s disease into their stages<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR9">9</xref></sup>.</p><p id="Par49">Using the dataset from Kaggle, Zihuan Li et.al identified that a combination of CNN models was more effective compared to single-shot CNN models in correctly distinguishing between different stages of AD<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>. Whereas in another study presented by Sanjeev Kumar et.al also made use of architectures such as InceptionResNetV2 and ResNet50 of CNN to classify MRI images into four severity classes of Alzheimer&#8217;s disease (AD)<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR12">12</xref></sup>. Similarly A. W. Salehi et al., used CNN models for the classification and prediction of Alzheimer&#8217;s disease with very good performance results<sup><xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR14">14</xref></sup>. Altaf et al.<sup><xref ref-type="bibr" rid="CR15">15</xref></sup> developed a multiclassification technique which was based on using anatomic measures of MRI along with demographic data for the diagnosis and classification of AD.</p><p id="Par50">Harsha Nandhini et al.<sup><xref ref-type="bibr" rid="CR16">16</xref></sup> presented a spatiotemporal feature fusion model that achieved higher accuracy in the diagnosis of AD. The proposed model used the spatial, temporal, and deep information obtained from MRI data. Sanjay Kumar et al.<sup><xref ref-type="bibr" rid="CR17">17</xref></sup> conducted a study to assess the influence of epigenetic variables on AD risk across different ethnicities. Their findings presented computational evidence to point out specific implications of each group. Srividhya et al.<sup><xref ref-type="bibr" rid="CR18">18</xref></sup> showed in their research, in how far using structural MRI on the diagnosis of the different stages of AD and monitoring of its progression is important. They used CNN models to come up with a high degree of accuracy.</p><p id="Par51">Javed Mehedi Sharmat et al., presented the AlzheimerNet model for the classification of phases in AD using MRI scans. It proposed a fine-tuning InceptionV3 architecture and was trained with the ADNI dataset, outperforming the five existing CNNs. It also presented early detection and classification of Alzheimer&#8217;s<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. Muhammad et al.<sup><xref ref-type="bibr" rid="CR20">20</xref></sup> proposed the ADD-Net model for early AD detection using MRI scans. The model used was the class imbalance SMOTETOMEK technique and obtained good results with balanced and imbalanced data. Zaabi et al. proposed an AD detection mechanism using deep learning, which was based on the classification of MRI scans into two categories: normal versus AD-affected images using CNN and transfer learning. It involved extracting images with CNN and AlexNet. This achieved better results compared to the pure CNN model<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>.</p><p id="Par52">Amir Ebrahimi et al.<sup><xref ref-type="bibr" rid="CR22">22</xref></sup> also compared 2D and 3D CNNs with RNNs, and used transfer learning from 2D images to 3D CNNs. It was observed that 3D CNNs with transfer learning performed significantly better than other models. Another approach is classification of AD, by Kanghan Oh et al., who proposed volumetric CNN model on MRI data. The approach comprises a convolutional autoencoder for unsupervised learning and transfer learning to classify cognitive impairment into two categories, namely progressive mild and stable mild categories<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. This study also applied a gradient-based visualization to recognize temporal and parietal lobes as regions affecting classification. Ali Nawaz et al. proposed a 2D-CNN model for the diagnosis of AD through MRI data. It converts 3D MRI data into 2D slices. The class imbalance is handled without using any increase in data by the proposed model<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>.</p><p id="Par53">AD is a neurodegenerative disorder, progressive, and irreversible, where cognitive decline, impairment of memory, and loss of mental functions are seen. Millions of people worldwide are affected by it, and it remains the most common cause of dementia, though the causes are not known in totality. Early diagnosis of AD is crucial, because this can help to manage symptoms and delay progression, even though there is no cure<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>. The application of machine learning (ML) and deep learning (DL) technologies has managed to detect AD early in life. Such approaches especially based on structural magnetic resonance imaging (sMRI), allow the identification of some subtle structural alterations in those critical brain regions, as seen in the hippocampus and temporal lobes related to AD<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>.</p><p id="Par54">It is found that modern ML models have demonstrated that use of metadata-including the patient&#8217;s age and gender, education level-contributes to extra information above and beyond solely imaging data for enhancing the precision of diagnosis. As an example, age, gender, disease onset, and progression, etc. help refine model predictions<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. The recent development in ML comprises the designing of an advanced model called Multi-template Meta-information Regularized Network, MMRN, to make use of metadata that allows the incorporation of variability within the brain structure from different demographics and reduces the confounding effect that would arise due to normal aging or due to gender difference<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>.</p><p id="Par55">AD detection also includes robust novel techniques. A widely applied technique for balancing datasets is SMOTE, which aims at oversampling the minority classes in order to enhance model performance on underrepresented groups.<sup><xref ref-type="bibr" rid="CR29">29</xref></sup> Furthermore, deep RVFL networks with ensemble techniques leverage &#8220;privileged information&#8221;&#8212;information available only during training time, such as certain patient conditions&#8212;in order to enhance classification accuracy through both common and unique features in the data<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. Originally developed to create synthetic data, GANs are now being adapted to reconstruct high-quality brain MRI images and retain disease-relevant features<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>. Typically deployed in dual-objective learning setups, these GANs enhance the quality of images and highlight AD-related features, thereby improving the classification of stages of disease such as MCI and predicting conversion from MCI to AD<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>.</p></sec></sec><sec id="Sec11"><title>Dataset</title><p id="Par57">The MRI images in this study were carefully selected from a data set that was fully validated and labeled by experts. There are four unique phenotypes: mild dementia, moderate dementia, no dementia and severe dementia that represent the different stages of Alzheimer&#8217;s disease. Figure <xref rid="Fig4" ref-type="fig">4</xref> shows a set of images of this dataset. The ratio of the given data set is divided into two parts, namely the training set and the test set in the ratio of 80:20 to estimate and verify the accuracy of the model. It is divided in such a way that the models are trained on data animations and a separate data set is kept for evaluation. There are 6400 MRI images in this dataset. In which there are 2240,64,3200,896 in the category of very mild dementia ,moderate dementia,non dementia and mild dementia respectively.</p><p id="Par56">
<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Dataset images.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="41598_2025_4899_Fig4_HTML.jpg"/></fig>
</p><p>
<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Dataset images of OASIS MRI dataset.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO5" position="float" orientation="portrait" xlink:href="41598_2025_4899_Fig5_HTML.jpg"/></fig>
</p><p id="Par58">OASIS MRI dataset, found at OASIS Brains consists of 86,437 images from an MRI divided into four classes with different stages of progression from normal to Alzheimer&#8217;s: Non-Dementia, 67,222 images; Very Mild Dementia, 13,725 images; Mild Dementia, 5,002 images; and Moderate Dementia, 488 images. In this dataset, 69,149 images are assigned to train and 17,288 images to test in the 80:20 ratio. It is a valuable research resource to understand, analyze, and detect early signs of Alzheimer&#8217;s disease, which advances the development of advanced machine learning models for neuroimaging analysis and early diagnosis.The sample images of this dataset are shown in the Fig. <xref rid="Fig5" ref-type="fig">5</xref>.</p><p id="Par59">The dataset utilized in this research, while large, is comparatively small. Future studies will aim for better generalizability through expansion of the dataset by combining publicly available MRI datasets such as ADNI and Kaggle&#8217;s Alzheimer&#8217;s dataset. Furthermore, state-of-the-art data augmentation methods, including the use of Generative Adversarial Networks (GANs), will be explored to generate MRI scans synthetically with disease-specific characteristics retained. To further establish the validity of our model, cross-dataset testing will be conducted by testing the trained model on unseen datasets. Additionally, k-Fold Cross-Validation will be employed to reduce the impact of data skewness. These measures will ensure our model remains effective across diverse populations and imaging conditions. Moreover, the utilization of a larger and more diverse dataset will allow the model to learn more general features associated with Alzheimer&#8217;s disease, thereby enhancing diagnostic accuracy and clinical utility in real-world settings.</p></sec><sec id="Sec12"><title>Discussion</title><p id="Par60">Ablation study has been used to identify the structural components of the model for the model&#8217;s outcome. In the aimo of understanding which part of the prototype architecture shows the best results, Ablation tests have been carried out and four prototypes have been evaluated. The result of the learning are summarized in Table <xref rid="Tab3" ref-type="table">3</xref>.</p><p id="Par61">The custom-trained CNN model demonstrates a consistent performance across all classes, achieving a precision and recall of 0.97 and 0.98 respectively in Non-Dementia class and maintaining a high score in all other classes as well. Its F1 score also indicates a balance between precision and recall which shows an effective classification across all stages of AD.</p><p>
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Ablation study comparing the performance of different models.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Model</th><th align="left" colspan="1" rowspan="1">Precision</th><th align="left" colspan="1" rowspan="1">Recall</th><th align="left" colspan="1" rowspan="1">F1-Score</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"><p>InceptionResNetV2 + Non-</p><p>Demented</p></td><td char="." align="char" colspan="1" rowspan="1">0.9700</td><td char="." align="char" colspan="1" rowspan="1">0.9800</td><td char="." align="char" colspan="1" rowspan="1">0.9800</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>InceptionResNetV2 + Very Mild</p><p>Demented</p></td><td char="." align="char" colspan="1" rowspan="1">1.0000</td><td char="." align="char" colspan="1" rowspan="1">1.0000</td><td char="." align="char" colspan="1" rowspan="1">1.0000</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>InceptionResNetV2 + Mild</p><p>Demented</p></td><td char="." align="char" colspan="1" rowspan="1">0.9200</td><td char="." align="char" colspan="1" rowspan="1">0.9000</td><td char="." align="char" colspan="1" rowspan="1">0.9100</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>InceptionResNetV2 + Moderate</p><p>Demented</p></td><td char="." align="char" colspan="1" rowspan="1">0.9000</td><td char="." align="char" colspan="1" rowspan="1">0.9100</td><td char="." align="char" colspan="1" rowspan="1">0.9000</td></tr><tr><td align="left" colspan="1" rowspan="1">ResNet50 + Non-Demented</td><td char="." align="char" colspan="1" rowspan="1">0.8900</td><td char="." align="char" colspan="1" rowspan="1">0.9500</td><td char="." align="char" colspan="1" rowspan="1">0.9200</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>ResNet50 + Very Mild</p><p>Demented</p></td><td char="." align="char" colspan="1" rowspan="1">1.0000</td><td char="." align="char" colspan="1" rowspan="1">1.0000</td><td char="." align="char" colspan="1" rowspan="1">1.0000</td></tr><tr><td align="left" colspan="1" rowspan="1">ResNet50 + Mild Demented</td><td char="." align="char" colspan="1" rowspan="1">0.8200</td><td char="." align="char" colspan="1" rowspan="1">0.7700</td><td char="." align="char" colspan="1" rowspan="1">0.7900</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>ResNet50 + Moderate</p><p>Demented</p></td><td char="." align="char" colspan="1" rowspan="1">0.7600</td><td char="." align="char" colspan="1" rowspan="1">0.7500</td><td char="." align="char" colspan="1" rowspan="1">0.7600</td></tr><tr><td align="left" colspan="1" rowspan="1">Custom CNN + Non-Demented</td><td char="." align="char" colspan="1" rowspan="1">0.9200</td><td char="." align="char" colspan="1" rowspan="1">0.9600</td><td char="." align="char" colspan="1" rowspan="1">0.9400</td></tr><tr><td align="left" colspan="1" rowspan="1">Custom CNN + Very Mild Demented</td><td char="." align="char" colspan="1" rowspan="1">1.0000</td><td char="." align="char" colspan="1" rowspan="1">1.0000</td><td char="." align="char" colspan="1" rowspan="1">1.0000</td></tr><tr><td align="left" colspan="1" rowspan="1">Custom CNN + Mild Demented</td><td char="." align="char" colspan="1" rowspan="1">0.8600</td><td char="." align="char" colspan="1" rowspan="1">0.8200</td><td char="." align="char" colspan="1" rowspan="1">0.8400</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Custom CNN + Moderate</p><p>Demented</p></td><td char="." align="char" colspan="1" rowspan="1">0.8300</td><td char="." align="char" colspan="1" rowspan="1">0.8300</td><td char="." align="char" colspan="1" rowspan="1">0.8300</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Ensembled Model (Full Model)</p><p>+ Non-Demented</p></td><td char="." align="char" colspan="1" rowspan="1">0.9700</td><td char="." align="char" colspan="1" rowspan="1">0.9900</td><td char="." align="char" colspan="1" rowspan="1">0.9800</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Ensembled Model (Full Model)</p><p>+ Very Mild Demented</p></td><td char="." align="char" colspan="1" rowspan="1">0.9900</td><td char="." align="char" colspan="1" rowspan="1">1.0000</td><td char="." align="char" colspan="1" rowspan="1">0.9900</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Ensembled Model (Full Model)</p><p>+ Mild Demented</p></td><td char="." align="char" colspan="1" rowspan="1">0.9200</td><td char="." align="char" colspan="1" rowspan="1">0.9100</td><td char="." align="char" colspan="1" rowspan="1">0.9100</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Ensembled Model (Full Model)</p><p>+ Moderate Demented</p></td><td char="." align="char" colspan="1" rowspan="1">0.9000</td><td char="." align="char" colspan="1" rowspan="1">0.9100</td><td char="." align="char" colspan="1" rowspan="1">0.9100</td></tr></tbody></table></table-wrap>
</p><p id="Par62">Whereby, the model InceptionResNetV2 attains a slight drop of 0.08 and 0.03 in precision and recall of class Non-Dementia, yet still shows results perfectly for the Very Mild Dementia class. Still, its efficiency drops considerably in the classes of Mild Dementia and Moderate Dementia with scores of 0.79 and 0.76, respectively. From the above observation, it is observed that InceptionResNetV2 is highly correct in identifying minor and non-dementia classes while faltering for more advanced stages.</p><p id="Par63">It can be seen that ResNet50 performs better than InceptionResNetV2 in Non-Dementia and Moderate-Dementia classes with F1-scores of 0.94 and 0.83 respectively. Nevertheless, its performance in the Mild-Dementia class is not as high as custom CNN model suggesting the need for a model that offers a more balanced and superior performance across all classes.</p><p id="Par64">The ensemble model combines the strength of all three architectures and exhibits the highest overall performance across all classes, especially in precision and recall. It achieves near-perfect scores of precision and recall in Non-Dementia and also maintains strong performance in Moderate-Dementia class. The model&#8217;s performance is consistent across all stages of AD as indicated by the steady and balanced F1-scores of the model.</p><p id="Par65">Moreover, observation of the ROC curves and mAP extends further explanation to the performance differences in models. The custom CNN and ensemble models showed more convex ROC curves, which indicate that the true positive rate is higher at a lower false positive rate. The mAPs also emphasize how this model, having high average precision across all classes, underlines its balanced and high-performing nature. The ROC curve for the InceptionResNetV2 is comparably less complex, and the mAP score is low for Mild-Dementia and Moderate-Dementia classes, which displays the limitation of the model. This research focuses on Alzheimer&#8217;s disease, an incurable neurodegenerative condition that significantly impairs cognition and everyday functioning. It examines the possibility of DL, namely CNNs, for AD stage identification using MRI data. Given the lack of a treatment, early detection is critical, emphasizing the need of timely diagnosis and novel deep learning approaches. As feature extractors, we employed both custom-trained CNN and pre-trained networks like InceptionResNetV2 and ResNet50. Our model had high accuracies of 90.76%, 86.84%, and 90.27%, demonstrating the effectiveness of our technique in detecting AD. Further study includes the use of Weighted Average Ensemble, which achieves an accuracy of 94.27%. Furthermore, we verified the model using various datasets and investigated alternative hybrid techniques.</p><p id="Par66">This ensemble approach brings together InceptionResNetV2, ResNet50, and a custom CNN for an improvement in Alzheimer&#8217;s diagnosis from MRI data. Differing models have distinct strengths&#8212;multi-scale details are well captured by InceptionResNetV2, pattern recognition for layered features using ResNet50, while the disease-specific characteristics emerge from the custom CNN. It is a comprehensive approach towards the diagnosis of Alzheimer&#8217;s, and therefore stands out compared to any model presented alone, showing great potential for further enhancement in its early detection and reliable staging. This ensemble model is a leap in the use of deep learning for medical imaging as it combines established architectures with a tailored model for balanced and precise diagnostics. It could be further optimized with various weighting schemes and extensions of the model to take multimodal data, and may make it applicable to the clinical setting.</p><p id="Par67">While ensemble models are known to improve the accuracy of classification, they also present difficulties in their own right, including computational complexity and overfitting due to redundancy between the models. In this work, our methodology addresses these issues by evaluating each individual model within the ensemble with an ablation study. The results demonstrate that the ensemble approach smooths out the weaknesses of individual models, such as InceptionResNetV2&#8217;s failure to correctly classify the more advanced AD cases and ResNet50&#8217;s suboptimal performance in mild dementia. This fine-tuning of the contributions of individual models with weighted averaging is a special feature of our work and, hence, distinguishes our work from the existing ensemble methods.</p><p id="Par68">To contribute to the treatment of this difficult neurodegenerative disease, it is important to expand the scope of the research to improve the performance in real-world circumstances without being constrained by data biases and other causes that may affect the outcome of the prediction.</p><p id="Par69">This research uses a relatively smaller dataset to test its findings. The use of a larger dataset is critical to examine a larger variety in Alzheimer&#8217;s disease. The developments of the study may also differ based on the demographic groups. Future studies should include a larger and more diversified dataset that represents a variety of communities and demographics. This will allow the model to be more resilient and adaptive.</p><p id="Par70">The integration of the multimodal data has large potential. Though the results using MRI data are useful, the combination with other types of data-such as genomes, cerebrospinal fluid biomarkers, and neuropsychological tests-could provide a fuller understanding of Alzheimer&#8217;s disease. Hidden patterns and connections appear in the fusion of multimodal data, which gives a better understanding of the condition of a patient by increasing the accuracy in diagnosis. This might form the basis for future study investigating the benefit of the synergies gained from the combination of diverse data sources in diagnosis and classification of the disease.</p><p id="Par71">The interpretability and explainability of the model are essential for adapting to real-world situations. As we advance in the realm of deep learning for diagnosing Alzheimer&#8217;s disease, it is imperative that our models provide insights into their decision-making processes. The enhancement of transparency and understanding in medical diagnosis is vital in fostering trust between healthcare practitioners and patients. Future research should prioritize the development of models that not only generate accurate results but also offer explanations for their predictions. This will enable the medical community to confidently embrace and utilize new tools.</p><sec id="Sec13"><title>Overfitting and computational complexity</title><p id="Par72">We used dropout layers, mini-batch normalization, and L2 regularization to prevent overfitting and enhance the generalization of their ensemble model. Due to model complexity, further investigations on efficiency, expressed as floating-point operations per second (FLOPs), and inference time have been carried out. Additionally, we applied k-fold cross-validation for a robust assessment of the splits over different datasets. We could state that dropout using a probability of 0. 3 could protect from overfitting by 7% and that the use of batch normalization helped stabilize the training through consistent gradient updates.</p><p id="Par73">Furthermore, we also introduced an early stopping criterion for saving epochs and the amount of time during training. For future work, the development of quantization and pruning approaches will permit practical deployment with lower model complexity while retaining accuracy. This optimization of both model efficiency and generalizability means that we can ensure clinical deployment and high precision of Alzheimer&#8217;s classification for any stages.</p></sec><sec id="Sec14"><title>Explainability techniques</title><p id="Par74">With full transparency, clinical acceptability for AI-based Alzheimer&#8217;s diagnosis has become possible. This is why we chose the Grad-CAM (Gradient-weighted Class Activation Mapping) for model transparency to show how the MRI regions responsible for making a classification decision. The heatmaps produced highlighted certain structural regions related to Alzheimer pathology, especially the hippocampus, ventricles, and cortical regions. By accentuating the specific mechanism of neuron degeneration taken in consideration by every model, clinicians can have an increased degree of confidence in AI-based diagnostics.</p><p id="Par75">SHAP (Shapley additive explanations) provides for each feature how much contribution it had on the classification decision; hence, it clarifies how transparent a model is. It gives explanations for the predictions that AI proposes, thus making it trustworthy to work within clinical settings. As for the authors&#8217; future work, saliency maps and counterfactual explanations are to be used to enable a better understanding of the decision-making process, bridging the gap between AI research and clinical utility.</p></sec></sec><sec id="Sec15"><title>Future works</title><sec id="Sec16"><title>Visualization with CAM</title><p id="Par76">To boost model interpretability, we deployed class activation mapping and grad-CAM for visualising critical MRI sites in Alzheimer&#8217;s classification. Such heat maps highlight vital structures-the hippocampus, temporal lobes, and ventricular regions-that are vastly correlated to Alzheimer&#8217;s progression. The custom CNN self-focuses on localized structural atrophy, while InceptionResNetV2 detects multi-scale spatial changes across regions of differing sizes; ResNet50 captures deep hierarchical patterns, making it efficient for differentiating early vs.</p><p id="Par77">late-stage dementia. Interpretable neural network outputs offer clinicians trust and confidence in what AI systems do in the medical space. Future work will proceed with structural 3D visualization techniques to depict dynamic temporal brain atrophy. These explainability methods create the bridge between black-box AI frameworks and real-world applications in the clinic, judiciously providing for transparent, dependable, and intelligible medical AI solutions.</p></sec><sec id="Sec17"><title>Multimodal data integration</title><p id="Par78">Based on this research work, which focuses on MRI-based classification, additional data sources can enhance diagnostic validity and stability. Other future studies include combining genomic data, cerebrospinal fluid biomarkers, and neuropsychological test scores with MRI scans for a complete approach to the diagnosis of Alzheimer&#8217;s disease. Multi-modality deep learning architectures like fusion models will be considered for the integration of spatial information from MRI scans with biological and clinical parameters.</p><p id="Par79">It will potentially give a window on hitherto unforeseen correlations between structural brain changes and genetic/biochemical markers, thus potentially helping the diagnosis of Alzheimer&#8217;s disease to be performed earlier and with higher accuracy. Besides, it is believed that the application of the transformer-based fusion technique can help in better understanding how the relationships between different data modalities get learned by the model. By providing varied sources of biomedical data, this work will enable computational models to align better with clinical practice in making decisions, thereby establishing AI as a more trustworthy and interpretable tool in assisting Alzheimer&#8217;s disease diagnosis for the healthcare profession.</p></sec><sec id="Sec18"><title>Exploring alternative ensemble strategies</title><p id="Par80">Our weighted ensemble model comes out significantly better than individual CNN; however, alternatives such as boosting, bagging, and stacking would boost up the classification performance considerably. The methods of boosting, such as XGBoost and AdaBoost, iteratively try to improve the weak learners through emphasis on the samples that have been misclassified. The ensembles based on bagging, on the other hand, improve stability by training many models on randomly resampled subsets of data.</p><p id="Par81">In future, we will conduct an experimentation to compare the weighted average to stacking ensembles where meta-learners aggregate predictions from multiple models. Attention-based fusion techniques could also be applied to dynamically assign higher weights to the models through their performance in each of the class categories. Aiming at the optimization of diagnostic accuracy and robustness, one of our objectives is to examine the alternative ensemble strategies so as to boost up the classification accuracy. Future investigations will also include ensemble learning based on the Transformer architectures that can capture spatial-temporal dependencies in MRI scans, increasing its detection efficiency for Alzheimer&#8217;s disease.</p></sec></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgment</title><p>This research work was supported by Amrita Vishwa Vidyapeetham and United Arab Emirates University.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Conceptualisation and supervision, S.S., N.V., T.M.; methodology, data processing, writing, visualisation, A.K.T.P., A.S; funding acquisition, S.S.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This research work was supported by Amrita Vishwa Vidyapeetham and United Arab Emirates University.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets generated and/or analysed during the current study are available in the kaggle repository, Link to the dataset is available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.kaggle.com/datasets/ninadaithal/imagesoasis">https://www.kaggle.com/datasets/ninadaithal/imagesoasis</ext-link></p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par86">All the authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Bagaskara, A. &amp; Suryanegara, M. Evaluation of vgg-16 and vgg-19 deep learning architecture for classifying dementia people. In <italic toggle="yes">2021 4th International Conference of Computer and Informatics Engineering (IC2IE)</italic> 1&#8211;4 (2021). 10.1109/IC2IE53219.2021.9649132.</mixed-citation></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Basher</surname><given-names>A</given-names></name><name name-style="western"><surname>Kim</surname><given-names>BC</given-names></name><name name-style="western"><surname>Lee</surname><given-names>KH</given-names></name><name name-style="western"><surname>Jung</surname><given-names>HY</given-names></name></person-group><article-title>Volumetric feature-based alzheimer&#8217;s disease diagnosis from mri data using a convolutional neural network and a deep neural network</article-title><source>IEEE Access</source><year>2021</year><volume>9</volume><fpage>29870</fpage><lpage>29882</lpage><pub-id pub-id-type="doi">10.1109/ACCESS.2021.3059658</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Basher, A., Kim, B. C., Lee, K. H. &amp; Jung, H. Y. Volumetric feature-based alzheimer&#8217;s disease diagnosis from mri data using a convolutional neural network and a deep neural network. <italic toggle="yes">IEEE Access</italic><bold>9</bold>, 29870&#8211;29882. 10.1109/ACCESS.2021.3059658 (2021).</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pradhan</surname><given-names>A</given-names></name><name name-style="western"><surname>Gige</surname><given-names>J</given-names></name><name name-style="western"><surname>Eliazer</surname><given-names>M</given-names></name></person-group><article-title>Detection of alzheimer&#8217;s disease (ad) in mri images using deep learning</article-title><source>Int. J. Eng. Res. Technol.</source><year>2021</year><volume>10</volume><fpage>56</fpage></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Pradhan, A., Gige, J. &amp; Eliazer, M. Detection of alzheimer&#8217;s disease (ad) in mri images using deep learning. <italic toggle="yes">Int. J. Eng. Res. Technol.</italic><bold>10</bold>, 56 (2021).</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Salehi, A.&#160;W., Baglat, P., Sharma, B.&#160;B., Gupta, G. &amp; Upadhya, A. A cnn model: earlier diagnosis and classification of alzheimer disease using mri. In <italic toggle="yes">2020 International Conference on Smart Electronics and Communication (ICOSEC)</italic> 156&#8211;161 (2020). 10.1109/ICOSEC49089.2020.9215402.</mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">Boyapati, N. et al. Alzheimer&#8217;s disease prediction using convolutional neural network (cnn) with generative adversarial network (gan). In <italic toggle="yes">2023 International Conference on Data Science, Agents &amp; Artificial Intelligence (ICDSAAI)</italic> 1&#8211;6 (2023). 10.1109/ICDSAAI59313.2023.10452539.</mixed-citation></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadhukhan</surname><given-names>D</given-names></name><name name-style="western"><surname>Veluppal</surname><given-names>A</given-names></name><name name-style="western"><surname>Ramaniharan</surname><given-names>AK</given-names></name><name name-style="western"><surname>Swaminathan</surname><given-names>R</given-names></name></person-group><article-title>Lateral ventricle texture analysis in alzheimer brain mr images using kernel density estimation</article-title><source>Biomed. Sci. Instrum.</source><year>2021</year><volume>57</volume><fpage>45</fpage><pub-id pub-id-type="doi">10.34107/YHPN9422.04241</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Sadhukhan, D., Veluppal, A., Ramaniharan, A. K. &amp; Swaminathan, R. Lateral ventricle texture analysis in alzheimer brain mr images using kernel density estimation. <italic toggle="yes">Biomed. Sci. Instrum.</italic><bold>57</bold>, 45 (2021).</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Khagi, B., Lee, C.&#160;G. &amp; Kwon, G.-R. Alzheimer&#8217;s disease classification from brain mri based on transfer learning from cnn. In <italic toggle="yes">2018 11th Biomedical Engineering International Conference (BMEiCON)</italic> 1&#8211;4 (2018). 10.1109/BMEiCON.2018.8609974.</mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">Yadav, B.&#160;K. &amp; Hashmi, M.&#160;F. An attention-based cnn architecture for alzheimer&#8217;s classification and detection. In <italic toggle="yes">2023 IEEE IAS Global Conference on Emerging Technologies (GlobConET)</italic> 1&#8211;5 (2023). 10.1109/GlobConET56651.2023.10150060.</mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Ebrahim, D., Ali-Eldin, A. M.&#160;T., Moustafa, H.&#160;E. &amp; Arafat, H. Alzheimer disease early detection using convolutional neural networks. In <italic toggle="yes">2020 15th International Conference on Computer Engineering and Systems (ICCES)</italic> 1&#8211;6 (2020). 10.1109/ICCES51560.2020.9334594.</mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Shamrat, F. M. et al. Alzheimernet: an effective deep learning based proposition for alzheimer&#8217;s disease stages classification from functional brain changes in magnetic resonance images. <italic toggle="yes">IEEE Access</italic><bold>11</bold>, 16376&#8211;16395. 10.1109/ACCESS.2023.3244952 (2023).</mixed-citation></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>JY</given-names></name><name name-style="western"><surname>Lee</surname><given-names>B</given-names></name></person-group><article-title>Combining of multiple deep networks via ensemble generalization loss, based on mri images, for alzheimer&#8217;s disease classification</article-title><source>IEEE Signal Process. Lett.</source><year>2020</year><volume>27</volume><fpage>206</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1109/LSP.2020.2964161</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Choi, J. Y. &amp; Lee, B. Combining of multiple deep networks via ensemble generalization loss, based on mri images, for alzheimer&#8217;s disease classification. <italic toggle="yes">IEEE Signal Process. Lett.</italic><bold>27</bold>, 206&#8211;210. 10.1109/LSP.2020.2964161 (2020).</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Karthikeyan, A., Jothilakshmi, S. &amp; Suthir, S. Colorectal cancer classification based on deep ensemble model with self-adaptive training model. <italic toggle="yes">Int. J. Biomed. Eng. Technol.</italic> (2021).</mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Karthikeyan, A., Jothilakshmi, S. &amp; Suthir, S. Colorectal cancer detection based on convolutional neural networks (cnn) and ranking algorithm. <italic toggle="yes">TBD</italic> (TBD) (2024).</mixed-citation></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fareed</surname><given-names>MMS</given-names></name><etal/></person-group><article-title>Add-net: an effective deep learning model for early detection of alzheimer disease in mri scans</article-title><source>IEEE Access</source><year>2022</year><volume>10</volume><fpage>96930</fpage><lpage>96951</lpage><pub-id pub-id-type="doi">10.1109/ACCESS.2022.3204395</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Fareed, M. M. S. et al. Add-net: an effective deep learning model for early detection of alzheimer disease in mri scans. <italic toggle="yes">IEEE Access</italic><bold>10</bold>, 96930&#8211;96951. 10.1109/ACCESS.2022.3204395 (2022).</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">Sethi, M., Ahuja, S. &amp; Bawa, P. Classification of alzheimer&#8217;s disease using neuroimaging data by convolution neural network. In <italic toggle="yes">2021 6th International Conference on Signal Processing, Computing and Control (ISPCC)</italic> 402&#8211;406 (2021). 10.1109/ISPCC53510.2021.9609431.</mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">Marusina, M.&#160;Y. &amp; Bukhalov, A.&#160;D. Convolutional neural networks for early prediction of alzheimer&#8217;s diseases. In <italic toggle="yes">2021 International Conference on Quality Management, Transport and Information Security, Information Technologies (IT &amp;QM &amp;IS)</italic> 394&#8211;397 (2021). 10.1109/ITQMIS53292.2021.9642799.</mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Zaabi, M., Smaoui, N., Derbel, H. &amp; Hariri, W. Alzheimer&#8217;s disease detection using convolutional neural networks and transfer learning based methods. In <italic toggle="yes">2020 17th International Multi-Conference on Systems, Signals &amp; Devices (SSD)</italic> 939&#8211;943 (2020). 10.1109/SSD49366.2020.9364155.</mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">Nagarathna, C. R., &amp; Kusuma, M. Comparative study of detection and classification of alzheimer&#8217;s disease using hybrid model and cnn. In <italic toggle="yes">2021 International Conference on Disruptive Technologies for Multi-Disciplinary Research and Applications (CENTCON)</italic> 43&#8211;46 (2021). 10.1109/CENTCON52345.2021.9688082.</mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Prabha, R. et al. Analysis of cognitive emotional and behavioral aspects of alzheimer&#8217;s disease using hybrid cnn model. In <italic toggle="yes">2022 International Conference on Computer, Power and Communications (ICCPC)</italic> 408&#8211;412 (2022). 10.1109/ICCPC55978.2022.10072126.</mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Saju, C. J., &amp; Dhanalakshmi, R. Alzheimer disease diagnosis using convolutional neural network. In <italic toggle="yes">2022 1st International Conference on Computational Science and Technology (ICCST)</italic> 587&#8211;592 (2022). 10.1109/ICCST55948.2022.10040358.</mixed-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Ebrahimi, A. et al. Alzheimer&#8217;s disease detection using multiple convolutional neural networks. In <italic toggle="yes">2022 IEEE International Conference on Distributed Computing and Electrical Circuits and Electronics (ICDCECE)</italic> 1&#8211;7 (2022). 10.1109/ICDCECE53908.2022.9793103.</mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Wang, T. &amp; Cao, L. Deep learning based diagnosis of alzheimer&#8217;s disease using structural magnetic resonance imaging: a survey. In <italic toggle="yes">2021 3rd International Conference on Applied Machine Learning (ICAML)</italic> 408&#8211;412 (2021). 10.1109/ICAML54311.2021.00092.</mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Wu, Y., Yu, X., Liu, X. &amp; Song, Y. Early diagnosis of alzheimer&#8217;s disease based on vgg cascade model. In <italic toggle="yes">2022 16th ICME International Conference on Complex Medical Engineering (CME)</italic> 143&#8211;146 (2022). 10.1109/CME55444.2022.10063263.</mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Li, Z. et al. Ensemble of cnn models for identifying stages of alzheimer&#8217;s disease: an approach using mri scans and smote algorithm. In <italic toggle="yes">2023 3rd International Symposium on Computer Technology and Information Science (ISCTIS)</italic> 496&#8211;500 (2023). 10.1109/ISCTIS58954.2023.10213182.</mixed-citation></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>K</given-names></name><name name-style="western"><surname>Li</surname><given-names>G</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yang</surname><given-names>F</given-names></name></person-group><article-title>Multi-template meta-information regularized network for alzheimer&#8217;s disease diagnosis using structural mri</article-title><source>IEEE Trans. Med. Imaging</source><year>2023</year><volume>43</volume><fpage>1664</fpage><lpage>1676</lpage><pub-id pub-id-type="doi">10.1109/tmi.2023.3344384</pub-id><pub-id pub-id-type="pmid">38109240</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Han, K., Li, G., Fang, Z. &amp; Yang, F. Multi-template meta-information regularized network for alzheimer&#8217;s disease diagnosis using structural mri. <italic toggle="yes">IEEE Trans. Med. Imaging</italic><bold>43</bold>, 1664&#8211;1676. 10.1109/tmi.2023.3344384 (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/TMI.2023.3344384</pub-id><pub-id pub-id-type="pmid">38109240</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Givian</surname><given-names>H</given-names></name><name name-style="western"><surname>Calbimonte</surname><given-names>J</given-names></name></person-group><article-title>A review on machine learning approaches for diagnosis of alzheimer&#8217;s disease and mild cognitive impairment based on brain mri</article-title><source>IEEE Access</source><year>2024</year><volume>12</volume><fpage>109912</fpage><lpage>109929</lpage><pub-id pub-id-type="doi">10.1109/access.2024.3438081</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Givian, H. &amp; Calbimonte, J. A review on machine learning approaches for diagnosis of alzheimer&#8217;s disease and mild cognitive impairment based on brain mri. <italic toggle="yes">IEEE Access</italic><bold>12</bold>, 109912&#8211;109929. 10.1109/access.2024.3438081 (2024).</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anjali</surname><given-names>N</given-names></name><name name-style="western"><surname>Singh</surname><given-names>D</given-names></name><name name-style="western"><surname>Pandey</surname><given-names>OJ</given-names></name><name name-style="western"><surname>Dai</surname><given-names>H</given-names></name></person-group><article-title>Stcnn: Combining smote-tomek with cnn for imbalanced classification of alzheimer&#8217;s disease</article-title><source>IEEE Sens. Lett.</source><year>2024</year><volume>8</volume><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1109/lsens.2024.3357196</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Anjali, N., Singh, D., Pandey, O. J. &amp; Dai, H. Stcnn: Combining smote-tomek with cnn for imbalanced classification of alzheimer&#8217;s disease. <italic toggle="yes">IEEE Sens. Lett.</italic><bold>8</bold>, 1&#8211;4. 10.1109/lsens.2024.3357196 (2024).</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">Razzak, I., Naz, S., Alinejad-Rokny, H., Nguyen, T.&#160;N. &amp; Khalifa, F. A cascaded multi-resolution ensemble deep learning framework for large scale alzheimer&#8217;s disease detection using brain mris. <italic toggle="yes">IEEE/ACM Trans. Comput. Biol. Bioinform.</italic><bold>2022</bold>, 1&#8211;9. 10.1109/tcbb.2022.3219032 (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/TCBB.2022.3219032</pub-id><pub-id pub-id-type="pmid">36322495</pub-id></mixed-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="other">Ganaie, M.&#160;A. &amp; Tanveer, M. Ensemble deep random vector functional link network using privileged information for alzheimer&#8217;s disease diagnosis. <italic toggle="yes">IEEE/ACM Trans. Comput. Biol. Bioinform.</italic><bold>2022</bold>, 1. 10.1109/tcbb.2022.3170351 (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/TCBB.2022.3170351</pub-id><pub-id pub-id-type="pmid">35486562</pub-id></mixed-citation></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name><etal/></person-group><article-title>Adversarial learning for mri reconstruction and classification of cognitively impaired individuals</article-title><source>IEEE Access</source><year>2024</year><volume>12</volume><fpage>83169</fpage><lpage>83182</lpage><pub-id pub-id-type="doi">10.1109/access.2024.3408840</pub-id><pub-id pub-id-type="pmid">39148927</pub-id><pub-id pub-id-type="pmcid">PMC11326336</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Zhou, X. et al. Adversarial learning for mri reconstruction and classification of cognitively impaired individuals. <italic toggle="yes">IEEE Access</italic><bold>12</bold>, 83169&#8211;83182. 10.1109/access.2024.3408840 (2024).<pub-id pub-id-type="pmid">39148927</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/access.2024.3408840</pub-id><pub-id pub-id-type="pmcid">PMC11326336</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">Meghna, M., Athira, B., Saranya, T. &amp; Manakadan, A.&#160;A. in silico single nucleotide polymorphism prediction and design for targeting amyloid precursor protein in alzheimer&#8217;s disease. <italic toggle="yes">Asian J. Chem.</italic><bold>31</bold>, 1959&#8211;1965. 10.14233/ajchem.2019.22020 (2019).</mixed-citation></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Radhagayathri</surname><given-names>KU</given-names></name><etal/></person-group><article-title>Computational modeling and simulation of nanomolecular switch for alzheimer&#8217;s disease (a gene silencing technique)</article-title><source>Int. J. Nanosci.</source><year>2011</year><volume>10</volume><fpage>319</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1142/s0219581x11008010</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Radhagayathri, K. U. et al. Computational modeling and simulation of nanomolecular switch for alzheimer&#8217;s disease (a gene silencing technique). <italic toggle="yes">Int. J. Nanosci.</italic><bold>10</bold>, 319&#8211;322. 10.1142/s0219581x11008010 (2011).</mixed-citation></citation-alternatives></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur J Med Res</journal-id><journal-id journal-id-type="iso-abbrev">Eur J Med Res</journal-id><journal-id journal-id-type="pmc-domain-id">1786</journal-id><journal-id journal-id-type="pmc-domain">eurjmedres</journal-id><journal-title-group><journal-title>European Journal of Medical Research</journal-title></journal-title-group><issn pub-type="ppub">0949-2321</issn><issn pub-type="epub">2047-783X</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12482563</article-id><article-id pub-id-type="pmcid-ver">PMC12482563.1</article-id><article-id pub-id-type="pmcaid">12482563</article-id><article-id pub-id-type="pmcaiid">12482563</article-id><article-id pub-id-type="pmid">41024255</article-id><article-id pub-id-type="doi">10.1186/s40001-025-03204-z</article-id><article-id pub-id-type="publisher-id">3204</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Novel multi-task learning for Alzheimer&#8217;s stage classification using hippocampal MRI segmentation, feature fusion, and nomogram modeling</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Hu</surname><given-names initials="W">Wenqi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Du</surname><given-names initials="Q">Qiaohui</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wei</surname><given-names initials="L">Lisi</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="D">Dawei</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Zhang</surname><given-names initials="G">Guang</given-names></name><address><email>zg_sdfmu2025@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03wnrsb51</institution-id><institution-id institution-id-type="GRID">grid.452422.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 0604 7301</institution-id><institution>Department of Health Management, </institution><institution>The First Affiliated Hospital of Shandong First Medical University &amp; Shandong Provincial Qianfoshan Hospital, </institution></institution-wrap>No.16766, Jingshi Road, Jinan, 250014 China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03wnrsb51</institution-id><institution-id institution-id-type="GRID">grid.452422.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 0604 7301</institution-id><institution>Shandong Engineering Research Center of Health Management, </institution></institution-wrap>No.16766, Jingshi Road, Jinan, 250014 China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05jb9pq57</institution-id><institution-id institution-id-type="GRID">grid.410587.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 6479 2668</institution-id><institution>The First Clinical College, </institution><institution>Shandong First Medical University &amp; Shandong Academy of Medical Sciences, </institution></institution-wrap>No.16766, Jingshi Road, Jinan, 250014 China </aff></contrib-group><pub-date pub-type="epub"><day>29</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>30</volume><issue-id pub-id-type="pmc-issue-id">478380</issue-id><elocation-id>910</elocation-id><history><date date-type="received"><day>25</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>11</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>29</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-01 11:25:52.917"><day>01</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="40001_2025_Article_3204.pdf"/><abstract id="Abs1"><sec><title>Objective</title><p id="Par1">To develop and validate a comprehensive and interpretable framework for multi-class classification of Alzheimer&#8217;s disease (AD) progression stages based on hippocampal MRI, integrating radiomic, deep, and clinical features.</p></sec><sec><title>Materials and methods</title><p id="Par2">This retrospective multi-center study included 2956 patients across four AD stages (Non-Demented, Very Mild Demented, Mild Demented, Moderate Demented). T1-weighted MRI scans were processed through a standardized pipeline involving hippocampal segmentation using four models (U-Net, nnU-Net, Swin-UNet, MedT). Radiomic features (<italic toggle="yes">n</italic>&#8201;=&#8201;215) were extracted using the SERA platform, and deep features (<italic toggle="yes">n</italic>&#8201;=&#8201;256) were learned using an LSTM network with attention applied to hippocampal slices. Fused features were harmonized with ComBat and filtered by ICC (&#8805;&#8201;0.75), followed by LASSO-based feature selection. Classification was performed using five machine learning models, including Logistic Regression (LR), Support Vector Machine (SVM), Random Forest (RF), Multilayer Perceptron (MLP), and eXtreme Gradient Boosting (XGBoost). Model interpretability was addressed using SHAP, and a nomogram and decision curve analysis (DCA) were developed. Additionally, an end-to-end 3D CNN-LSTM model and two transformer-based benchmarks (Vision Transformer, Swin Transformer) were trained for comparative evaluation.</p></sec><sec><title>Results</title><p id="Par3">MedT achieved the best hippocampal segmentation (Dice&#8201;=&#8201;92.03% external). Fused features yielded the highest classification performance with XGBoost (external accuracy&#8201;=&#8201;92.8%, AUC&#8201;=&#8201;94.2%). SHAP identified MMSE, hippocampal volume, and APOE &#949;4 as top contributors. The nomogram accurately predicted early-stage AD with clinical utility confirmed by DCA. The end-to-end model performed acceptably (AUC&#8201;=&#8201;84.0%) but lagged behind the fused pipeline. Statistical tests confirmed significant performance advantages for feature fusion and MedT-based segmentation.</p></sec><sec><title>Conclusions</title><p id="Par4">This study demonstrates that integrating radiomics, deep learning, and clinical data from hippocampal MRI enables accurate and interpretable classification of AD stages. The proposed framework is robust, generalizable, and clinically actionable, representing a scalable solution for AD diagnostics.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Hippocampal radiomics</kwd><kwd>Alzheimer&#8217;s disease classification</kwd><kwd>Deep learning</kwd><kwd>Transformer segmentation</kwd><kwd>Nomogram prediction</kwd></kwd-group><funding-group><award-group><funding-source><institution>Shandong Provincial Natural Science Foundation</institution></funding-source><award-id>ZR2023QG014</award-id><principal-award-recipient><name name-style="western"><surname>Zhang</surname><given-names>Guang</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Alzheimer&#8217;s disease (AD) is a chronic and progressive neurodegenerative disorder that leads to the deterioration of memory, cognitive function, and ultimately the ability to perform everyday tasks (<xref ref-type="bibr" rid="CR1">1</xref>). Clinically, AD progression spans a continuum that includes cognitively normal (CN) individuals, those with mild cognitive impairment (MCI), and patients diagnosed with Alzheimer&#8217;s dementia (<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>). Identifying individuals at each stage of this progression is critical for early intervention, planning of therapeutic strategies, and improving patient outcomes (<xref ref-type="bibr" rid="CR4">4</xref>&#8211;<xref ref-type="bibr" rid="CR6">6</xref>). The hippocampus, a medial temporal lobe structure central to memory consolidation and learning, is among the earliest regions affected in the course of AD. Structural alterations in the hippocampus have thus become a focal point in neuroimaging studies aimed at diagnosing and monitoring disease progression (<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>).</p><p id="Par6">Despite the established clinical relevance of hippocampal atrophy in AD, the precise and automated detection of disease stages remains a complex challenge. Subtle hippocampal changes may be difficult to delineate visually, particularly in preclinical or early symptomatic phases (<xref ref-type="bibr" rid="CR9">9</xref>&#8211;<xref ref-type="bibr" rid="CR11">11</xref>). Manual segmentation of the hippocampus in MRI images is time-consuming and prone to inter-observer variability, prompting the development of automatic segmentation methods (<xref ref-type="bibr" rid="CR12">12</xref>&#8211;<xref ref-type="bibr" rid="CR14">14</xref>). Advances in deep learning have enabled the emergence of automated hippocampal segmentation techniques that offer improved accuracy, reproducibility, and scalability. However, translating these segmentations into meaningful diagnostic information requires further analytical development (<xref ref-type="bibr" rid="CR15">15</xref>&#8211;<xref ref-type="bibr" rid="CR17">17</xref>).</p><p id="Par7">Magnetic resonance imaging (MRI) is a cornerstone of AD diagnostics, offering noninvasive, high-resolution visualization of brain anatomy. Its sensitivity to structural brain changes makes it an ideal modality for detecting early manifestations of AD, especially in the hippocampus (<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>). Radiomics, which involves the extraction of high-dimensional quantitative features from imaging data, has gained traction in recent years for its potential to uncover subtle patterns not apparent to human observers (<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>). In the context of AD, radiomics features derived from hippocampal MRI may reflect microstructural alterations that are indicative of disease progression, enabling improved differentiation between stages (<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>).</p><p id="Par8">Beyond handcrafted features, deep learning models can automatically learn hierarchical feature representations from imaging data (<xref ref-type="bibr" rid="CR24">24</xref>&#8211;<xref ref-type="bibr" rid="CR28">28</xref>). Particularly, networks such as Long Short-Term Memory (LSTM) models augmented with attention mechanisms have shown promise in modeling the sequential and spatial dependencies inherent in neurodegenerative processes (<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>). These deep features can capture abstract imaging patterns linked to cognitive decline and have demonstrated significant potential in classification tasks. Integrating these deep features with radiomics-derived features leverages the complementary strengths of both approaches, offering a more comprehensive representation of disease-related imaging characteristics (<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>).</p><p id="Par9">While enhancing classification performance is crucial, model interpretability remains a central requirement for clinical adoption (<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>). Black-box models limit clinicians&#8217; ability to trust and act on predictions. Methods such as SHAP (SHapley Additive exPlanations) provide transparency by highlighting the contribution of individual features to model decisions (<xref ref-type="bibr" rid="CR35">35</xref>). Furthermore, predictive nomograms derived from model outputs offer a practical tool for individualized risk estimation (<xref ref-type="bibr" rid="CR36">36</xref>&#8211;<xref ref-type="bibr" rid="CR38">38</xref>), translating complex data into clinically interpretable visual aids. Decision curve analysis (DCA) adds another layer of clinical relevance (<xref ref-type="bibr" rid="CR39">39</xref>&#8211;<xref ref-type="bibr" rid="CR41">41</xref>), assessing the net benefit of model-based decisions across a range of thresholds and supporting the integration of AI into decision-making workflows.</p><p id="Par10">A key requirement for clinically robust models is their generalizability across diverse populations and imaging protocols (<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>). Multi-center studies address this by incorporating data from various institutions, thereby enhancing the external validity and reliability of models. Such datasets capture variability in demographics, scanner types, and acquisition settings, ensuring that developed models maintain their accuracy and utility in real-world settings.</p><p id="Par11">In this study, we propose a novel and comprehensive framework for the classification of Alzheimer&#8217;s disease progression stages&#8212;NonDemented, VeryMildDemented, MildDemented, and ModerateDemented&#8212;based on hippocampal MRI. The key contributions of this work are fivefold: (1) the integration of radiomics and deep features extracted from hippocampal regions segmented via advanced auto-segmentation models; (2) the application of an LSTM network with an attention mechanism for extracting temporally aware, salient deep features; (3) the fusion of handcrafted and deep features to enhance discriminative power; (4) the incorporation of model interpretability through SHAP and the construction of a clinically actionable nomogram with DCA; and (5) validation using a multi-center dataset to ensure robustness and generalizability. To the best of our knowledge, this is the first study to implement such a hybrid, interpretable, and clinically focused framework for multi-class AD stage classification based specifically on hippocampal MRI data. Importantly, this study focuses specifically on the early to moderate stages of Alzheimer&#8217;s disease, excluding cases of severe dementia. This reflects a clinically motivated emphasis on detecting AD during the window where diagnosis is most actionable and therapeutic interventions may have the greatest impact.</p></sec><sec id="Sec2"><title>Materials and methods</title><p id="Par12">This study was designed as a retrospective; multi-center investigation aimed at developing and validating a hybrid deep learning framework for classifying AD progression based on hippocampal MRI. Data were sourced from seven clinical centers for training and internal testing, with an additional external dataset used solely for segmentation validation. The study pipeline involved hippocampal segmentation, feature extraction (radiomics and deep features), feature fusion and selection, classification model development, and evaluation of model interpretability and clinical utility. A parallel end-to-end classification pathway was also implemented for comparative analysis.</p><p id="Par13">Figure&#160;<xref rid="Fig1" ref-type="fig">1</xref> illustrates the full architecture of our proposed hybrid framework for classifying AD stages using hippocampal MRI. The pipeline begins with preprocessing and segmentation of the hippocampus using transformer-based and CNN models, followed by extraction of handcrafted radiomic features and deep features via an LSTM-attention network. These features are harmonized and fused, alongside clinical variables, and input into multiple machine learning classifiers. Model performance is interpreted using SHAP, with nomogram construction and decision curve analysis enhancing clinical utility. An end-to-end comparative pipeline is also implemented. The framework is validated through multi-center data and external testing, culminating in a clinically interpretable AD stage classification system.<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>Overview of the hybrid deep learning framework for Alzheimer&#8217;s disease classification based on hippocampal MRI</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="40001_2025_3204_Fig1_HTML.jpg"/></fig></p></sec><sec id="Sec3"><title>Datasets</title><sec id="Sec4"><title>Multi-center dataset description and inclusion and exclusion criteria</title><p id="Par14">A total of 4236 patients were initially screened across seven clinical centers. Inclusion required high-resolution T1-weighted MRI, complete clinical data (including MMSE and CDR), and confirmed diagnostic labels for one of four AD progression stages. The dataset was collected between January 2018 and December 2023 from multiple clinical and research centers located in Jinan, Shandong Province, China. This regional collaboration provided access to a heterogeneous patient population within a consistent healthcare environment, supporting both data quality and variability in clinical presentations. Exclusion criteria included incomplete clinical data (<italic toggle="yes">n</italic>&#8201;=&#8201;411), poor image quality or failed preprocessing (<italic toggle="yes">n</italic>&#8201;=&#8201;313), and segmentation failure (<italic toggle="yes">n</italic>&#8201;=&#8201;284), yielding a final cohort of 2956 patients for model development. The cohort was well-distributed across disease stages: Non-Demented, Very Mild Demented, Mild Demented, and Moderate Demented. An external dataset of 363 subjects from Center 8, with manually annotated hippocampal masks, was used solely for independent validation of segmentation performance.</p><p id="Par15">The seven clinical centers (Centers 1&#8211;7) are geographically distributed across multiple provinces. This diversity ensures heterogeneity in patient demographics and imaging protocols, supporting the robustness and external validity of the classification framework. Center 8 was designated solely for external segmentation validation and did not provide diagnostic stage labels. Only high-resolution T1-weighted MRI scans with corresponding expert-annotated hippocampal masks were available, and thus patients from this center were excluded from classification modeling.</p><p id="Par16">The diagnostic labels for these four progression classes were assigned by experienced neurologists or geriatricians at each center, based on standardized criteria consistent with the National Institute on Aging&#8211;Alzheimer&#8217;s Association (NIA-AA) diagnostic framework and DSM-5 guidelines for neurocognitive disorders (<xref ref-type="bibr" rid="CR44">44</xref>). Classification incorporated Clinical Dementia Rating (CDR) scale scores (e.g., CDR 0&#8201;=&#8201;Non-Demented, CDR 0.5&#8201;=&#8201;Very Mild Demented, CDR 1&#8201;=&#8201;Mild Demented, and CDR 2&#8201;=&#8201;Moderate Demented) (<xref ref-type="bibr" rid="CR45">45</xref>), Mini-Mental State Examination (MMSE) results (<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>), and comprehensive clinical assessments, ensuring consistent and validated staging across centers.</p><p id="Par17">While the term &#8220;Alzheimer&#8217;s disease&#8221; is used throughout this study, it refers to clinical diagnoses made in accordance with NIA-AA and DSM-5 criteria for probable AD. Biomarker confirmation (e.g., amyloid or tau status) was not uniformly available across centers and thus was not a basis for inclusion. As such, our classification framework targets clinically defined stages of cognitive impairment consistent with AD, but not biologically confirmed Alzheimer&#8217;s pathology.</p><p id="Par18">Table <xref rid="Tab1" ref-type="table">1</xref> provides a detailed summary of the distribution of patients across the seven internal clinical centers used for model training and internal validation, as well as the external dataset employed for segmentation evaluation. A total of 2956 patients were included in the internal cohort, stratified into four clinically defined classes: Non-Demented, Very Mild Demented, Mild Demented, and Moderate Demented. This multi-center composition ensures that the model is trained on a representative and heterogeneous population, crucial for achieving robust and clinically applicable performance.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>Distribution of Alzheimer&#8217;s Disease Progression Classes Across Clinical Centers in the Training and External Evaluation Cohorts</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Center</th><th align="left" colspan="1" rowspan="1">Non-Demented (n)</th><th align="left" colspan="1" rowspan="1">Very&#8239;Mild Demented (n)</th><th align="left" colspan="1" rowspan="1">Mild Demented (n)</th><th align="left" colspan="1" rowspan="1">Moderate Demented (n)</th><th align="left" colspan="1" rowspan="1">Total (n)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Center 1</td><td align="left" colspan="1" rowspan="1">210</td><td align="left" colspan="1" rowspan="1">145</td><td align="left" colspan="1" rowspan="1">110</td><td align="left" colspan="1" rowspan="1">70</td><td align="left" colspan="1" rowspan="1">535</td></tr><tr><td align="left" colspan="1" rowspan="1">Center 2</td><td align="left" colspan="1" rowspan="1">195</td><td align="left" colspan="1" rowspan="1">120</td><td align="left" colspan="1" rowspan="1">90</td><td align="left" colspan="1" rowspan="1">55</td><td align="left" colspan="1" rowspan="1">460</td></tr><tr><td align="left" colspan="1" rowspan="1">Center 3</td><td align="left" colspan="1" rowspan="1">180</td><td align="left" colspan="1" rowspan="1">115</td><td align="left" colspan="1" rowspan="1">85</td><td align="left" colspan="1" rowspan="1">50</td><td align="left" colspan="1" rowspan="1">430</td></tr><tr><td align="left" colspan="1" rowspan="1">Center 4</td><td align="left" colspan="1" rowspan="1">170</td><td align="left" colspan="1" rowspan="1">105</td><td align="left" colspan="1" rowspan="1">80</td><td align="left" colspan="1" rowspan="1">45</td><td align="left" colspan="1" rowspan="1">400</td></tr><tr><td align="left" colspan="1" rowspan="1">Center 5</td><td align="left" colspan="1" rowspan="1">160</td><td align="left" colspan="1" rowspan="1">100</td><td align="left" colspan="1" rowspan="1">75</td><td align="left" colspan="1" rowspan="1">40</td><td align="left" colspan="1" rowspan="1">375</td></tr><tr><td align="left" colspan="1" rowspan="1">Center 6</td><td align="left" colspan="1" rowspan="1">125</td><td align="left" colspan="1" rowspan="1">90</td><td align="left" colspan="1" rowspan="1">70</td><td align="left" colspan="1" rowspan="1">35</td><td align="left" colspan="1" rowspan="1">320</td></tr><tr><td align="left" colspan="1" rowspan="1">Center 7</td><td align="left" colspan="1" rowspan="1">160</td><td align="left" colspan="1" rowspan="1">125</td><td align="left" colspan="1" rowspan="1">90</td><td align="left" colspan="1" rowspan="1">61</td><td align="left" colspan="1" rowspan="1">436</td></tr><tr><td align="left" colspan="1" rowspan="1">Total (Internal)</td><td align="left" colspan="1" rowspan="1"><bold>1200</bold></td><td align="left" colspan="1" rowspan="1"><bold>800</bold></td><td align="left" colspan="1" rowspan="1"><bold>600</bold></td><td align="left" colspan="1" rowspan="1"><bold>356</bold></td><td align="left" colspan="1" rowspan="1"><bold>2956</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Center 8 (External)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"><bold>363</bold></td></tr></tbody></table><table-wrap-foot><p>The bold values represent the aggregated totals of data across different centers</p></table-wrap-foot></table-wrap></p><p id="Par19">Table <xref rid="Tab2" ref-type="table">2</xref> summarizes MRI acquisition protocols across centers, which used both 1.5&#160;T and 3.0&#160;T systems from Siemens, GE, and Philips. All centers acquired high-resolution T1-weighted scans with voxel sizes between 0.9 and 1.2&#160;mm, suitable for accurate hippocampal segmentation. Imaging parameters (e.g., matrix size, slice thickness, TR/TE/TI) were largely consistent with standard AD imaging protocols, with minor inter-center variability. This technical diversity enhances the dataset&#8217;s heterogeneity and supports the generalizability of the proposed framework.<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table&#160;2</label><caption><p>Imaging Protocols and MRI Acquisition Parameters Across Clinical Centers</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Center</th><th align="left" colspan="1" rowspan="1">MRI Scanner Model</th><th align="left" colspan="1" rowspan="1">Field Strength (T)</th><th align="left" colspan="1" rowspan="1">Voxel Size (mm<sup>3</sup>)</th><th align="left" colspan="1" rowspan="1">Matrix Size</th><th align="left" colspan="1" rowspan="1">TR (ms)</th><th align="left" colspan="1" rowspan="1">TE (ms)</th><th align="left" colspan="1" rowspan="1">TI (ms)</th><th align="left" colspan="1" rowspan="1">Slice Thickness (mm)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Center 1</td><td align="left" colspan="1" rowspan="1">Siemens Magnetom Trio</td><td char="." align="char" colspan="1" rowspan="1">3.0</td><td align="left" colspan="1" rowspan="1">1.0&#8201;&#215;&#8201;1.0&#8201;&#215;&#8201;1.0</td><td align="left" colspan="1" rowspan="1">256&#8201;&#215;&#8201;256</td><td char="," align="char" colspan="1" rowspan="1">2,300</td><td char="." align="char" colspan="1" rowspan="1">2.98</td><td align="left" colspan="1" rowspan="1">900</td><td char="." align="char" colspan="1" rowspan="1">1.0</td></tr><tr><td align="left" colspan="1" rowspan="1">Center 2</td><td align="left" colspan="1" rowspan="1">GE Discovery MR750</td><td char="." align="char" colspan="1" rowspan="1">3.0</td><td align="left" colspan="1" rowspan="1">1.0&#8201;&#215;&#8201;1.0&#8201;&#215;&#8201;1.2</td><td align="left" colspan="1" rowspan="1">256&#8201;&#215;&#8201;256</td><td char="," align="char" colspan="1" rowspan="1">2,500</td><td char="." align="char" colspan="1" rowspan="1">3.2</td><td align="left" colspan="1" rowspan="1">900</td><td char="." align="char" colspan="1" rowspan="1">1.2</td></tr><tr><td align="left" colspan="1" rowspan="1">Center 3</td><td align="left" colspan="1" rowspan="1">Philips Achieva</td><td char="." align="char" colspan="1" rowspan="1">3.0</td><td align="left" colspan="1" rowspan="1">1.0&#8201;&#215;&#8201;1.0&#8201;&#215;&#8201;1.0</td><td align="left" colspan="1" rowspan="1">240&#8201;&#215;&#8201;240</td><td char="," align="char" colspan="1" rowspan="1">2,200</td><td char="." align="char" colspan="1" rowspan="1">3.5</td><td align="left" colspan="1" rowspan="1">850</td><td char="." align="char" colspan="1" rowspan="1">1.0</td></tr><tr><td align="left" colspan="1" rowspan="1">Center 4</td><td align="left" colspan="1" rowspan="1">Siemens Prisma</td><td char="." align="char" colspan="1" rowspan="1">3.0</td><td align="left" colspan="1" rowspan="1">0.9&#8201;&#215;&#8201;0.9&#8201;&#215;&#8201;0.9</td><td align="left" colspan="1" rowspan="1">256&#8201;&#215;&#8201;256</td><td char="," align="char" colspan="1" rowspan="1">2,300</td><td char="." align="char" colspan="1" rowspan="1">2.9</td><td align="left" colspan="1" rowspan="1">900</td><td char="." align="char" colspan="1" rowspan="1">0.9</td></tr><tr><td align="left" colspan="1" rowspan="1">Center 5</td><td align="left" colspan="1" rowspan="1">GE Signa HDxt</td><td char="." align="char" colspan="1" rowspan="1">1.5</td><td align="left" colspan="1" rowspan="1">1.0&#8201;&#215;&#8201;1.0&#8201;&#215;&#8201;1.2</td><td align="left" colspan="1" rowspan="1">256&#8201;&#215;&#8201;256</td><td char="," align="char" colspan="1" rowspan="1">2,400</td><td char="." align="char" colspan="1" rowspan="1">3.1</td><td align="left" colspan="1" rowspan="1">950</td><td char="." align="char" colspan="1" rowspan="1">1.2</td></tr><tr><td align="left" colspan="1" rowspan="1">Center 6</td><td align="left" colspan="1" rowspan="1">Siemens Avanto</td><td char="." align="char" colspan="1" rowspan="1">1.5</td><td align="left" colspan="1" rowspan="1">1.0&#8201;&#215;&#8201;1.0&#8201;&#215;&#8201;1.0</td><td align="left" colspan="1" rowspan="1">256&#8201;&#215;&#8201;256</td><td char="," align="char" colspan="1" rowspan="1">2,300</td><td char="." align="char" colspan="1" rowspan="1">3.0</td><td align="left" colspan="1" rowspan="1">900</td><td char="." align="char" colspan="1" rowspan="1">1.0</td></tr><tr><td align="left" colspan="1" rowspan="1">Center 7</td><td align="left" colspan="1" rowspan="1">Philips Ingenia</td><td char="." align="char" colspan="1" rowspan="1">3.0</td><td align="left" colspan="1" rowspan="1">1.0&#8201;&#215;&#8201;1.0&#8201;&#215;&#8201;1.0</td><td align="left" colspan="1" rowspan="1">240&#8201;&#215;&#8201;240</td><td char="," align="char" colspan="1" rowspan="1">2,100</td><td char="." align="char" colspan="1" rowspan="1">3.4</td><td align="left" colspan="1" rowspan="1">800</td><td char="." align="char" colspan="1" rowspan="1">1.0</td></tr><tr><td align="left" colspan="1" rowspan="1">Center 8</td><td align="left" colspan="1" rowspan="1">Philips Achieva</td><td char="." align="char" colspan="1" rowspan="1">3.0</td><td align="left" colspan="1" rowspan="1">1.0&#8201;&#215;&#8201;1.0&#8201;&#215;&#8201;1.2</td><td align="left" colspan="1" rowspan="1">256&#8201;&#215;&#8201;256</td><td char="," align="char" colspan="1" rowspan="1">2,100</td><td char="." align="char" colspan="1" rowspan="1">3.4</td><td align="left" colspan="1" rowspan="1">800</td><td char="." align="char" colspan="1" rowspan="1">1.2</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec5"><title>Hippocampal segmentation</title><sec id="Sec6"><title>Preprocessing and normalization</title><p id="Par20">All T1-weighted MRI scans underwent standardized preprocessing to ensure spatial and intensity consistency. Images were reoriented to RAS space and rigidly registered to the MNI152 template using FSL FLIRT (6 DOF, mutual information, trilinear interpolation). Intensity normalization (z-score) was applied within the brain mask. Brain extraction was performed using FSL BET, and all volumes were resampled to 1&#8201;&#215;&#8201;1&#8201;&#215;&#8201;1&#160;mm<sup>3</sup> using third-order spline interpolation. The reference hippocampal masks used for segmentation evaluation in Center 8 were manually annotated by experienced neuroradiologists following standardized anatomical guidelines. All masks were independently reviewed and confirmed by at least two experts to ensure consistency. These annotations served as the ground truth for assessing the accuracy of the automated segmentation models.</p><p id="Par21">All segmentation models were applied to full 3D volumes of the hippocampus. To localize the region of interest, each preprocessed brain scan was automatically cropped to a 3D bounding box, using template-based anatomical priors. This approach preserved anatomical context while reducing input dimensionality. The resulting cropped volumes typically contained&#8201;~&#8201;30 axial slices of 128&#8201;&#215;&#8201;128 pixels per subject, depending on individual brain anatomy and scan orientation. Figure&#160;<xref rid="Fig2" ref-type="fig">2</xref> illustrates an example of hippocampal segmentation and corresponding cropped region for a representative subject.<fig id="Fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>Segmentation performance of five models across training, internal test, and external evaluation datasets using four metrics (% for DSC, IoU; mm for HD and ASSD)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="40001_2025_3204_Fig2_HTML.jpg"/></fig></p><p id="Par22">Although hippocampal involvement is not entirely specific to Alzheimer&#8217;s disease, it remains the most consistently affected structure in typical AD and is a central component of the NIA-AA diagnostic framework for probable AD. Given that our cohort was clinically diagnosed based on probable AD criteria, hippocampal atrophy is expected to be a prominent and reliable imaging feature across stages. Moreover, the hippocampus is among the earliest regions to exhibit structural decline, making it particularly valuable for staging models that target early to moderate cognitive impairment. Thus, its inclusion enhances both the diagnostic sensitivity and clinical relevance of the classification pipeline.</p><p id="Par23">To improve robustness and generalizability, data augmentation was applied during training of all segmentation models. Augmentations included random flipping, affine and elastic transformations, and small rotations (&#177;&#8201;10&#176;), enabling the models to better generalize across anatomical and inter-site variability.</p></sec><sec id="Sec7"><title>Segmentation models: U-Net, nnU-Net, Swin-UNet, and MedT</title><p id="Par24">Four segmentation models were selected based on architectural diversity, interpretability, and demonstrated performance in medical imaging tasks. U-Net, a classical encoder-decoder CNN with skip connections, served as the baseline due to its simplicity and effectiveness in segmenting small structures like the hippocampus (<xref ref-type="bibr" rid="CR48">48</xref>). nnU-Net extends U-Net with automated configuration tailored to dataset properties, offering strong performance without manual tuning&#8212;ideal for heterogeneous multi-center data (<xref ref-type="bibr" rid="CR49">49</xref>).</p><p id="Par25">Swin-UNet integrates Swin Transformer blocks within the U-Net framework, enabling effective modeling of long-range dependencies and spatial hierarchies, especially in 3D neuroimaging contexts (<xref ref-type="bibr" rid="CR50">50</xref>). MedT, a fully transformer-based model, utilizes gated axial and positional self-attention to capture contextual and spatial information without relying on convolution, making it well-suited for complex anatomical delineation (<xref ref-type="bibr" rid="CR51">51</xref>).</p></sec></sec><sec id="Sec8"><title>Feature extraction</title><sec id="Sec9"><title>Radiomics feature extraction from segmented regions</title><p id="Par26">Radiomic features were extracted from bilateral hippocampal ROIs segmented on preprocessed T1-weighted MRI scans. Radiomic features were extracted using the Standardized Environment for Radiomics Analysis (SERA) platform (<xref ref-type="bibr" rid="CR52">52</xref>), which implements a comprehensive set of 487 features in accordance with the Image Biomarker Standardisation Initiative (IBSI) guidelines. 215 handcrafted features were derived from an initial library of 487, including 79 first-order statistics (e.g., mean, variance, skewness, kurtosis, shape) and 136 texture descriptors based on GLCM, GLRLM, and GLSZM matrices. These features quantitatively capture hippocampal intensity distribution, geometric structure, and tissue heterogeneity relevant to Alzheimer&#8217;s disease staging.</p></sec><sec id="Sec10"><title>Deep feature extraction using LSTM with attention mechanism</title><p id="Par27">To model spatial continuity and structural progression within the hippocampus, we implemented a deep feature extraction pipeline combining a CNN encoder with a bidirectional LSTM and attention mechanism. Segmented 3D hippocampal volumes were input as sequential slices, with each slice encoded by a shared CNN to extract spatial features. These features were then processed by a bidirectional LSTM to capture forward and backward dependencies across slices. A self-attention layer assigned dynamic weights to slices, emphasizing diagnostically relevant regions. This pipeline yielded a 256-dimensional deep feature vector per subject, capturing both local texture and global contextual cues. Table <xref rid="Tab3" ref-type="table">3</xref> details the network architecture, including convolutional layers, LSTM configurations, attention computations, and trainable parameters. This 256-D dimensionality reflects the BiLSTM hidden size (128 per direction) and was chosen to balance model capacity and generalization while facilitating stable feature fusion and harmonization with radiomics and clinical variables.<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table&#160;3</label><caption><p>Detailed architecture and parameters of the deep feature extraction network using LSTM with attention mechanism</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Component</th><th align="left" colspan="1" rowspan="1">Layer Details</th><th align="left" colspan="1" rowspan="1">Kernel/Window</th><th align="left" colspan="1" rowspan="1">Stride/Padding</th><th align="left" colspan="1" rowspan="1">Output Shape</th><th align="left" colspan="1" rowspan="1"># Parameters</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Input</td><td align="left" colspan="1" rowspan="1">Cropped hippocampal 3D volume</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8201;~&#8201;30 slices of 128&#8201;&#215;&#8201;128 pixels</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Conv Layer 1</td><td align="left" colspan="1" rowspan="1">Conv2D&#8201;&#8594;&#8201;BatchNorm&#8201;&#8594;&#8201;ReLU</td><td align="left" colspan="1" rowspan="1">3&#8201;&#215;&#8201;3</td><td align="left" colspan="1" rowspan="1">1/1</td><td align="left" colspan="1" rowspan="1">128&#8201;&#215;&#8201;128&#8201;&#215;&#8201;32 (per slice)</td><td align="left" colspan="1" rowspan="1">&#8201;~&#8201;0.9&#160;K</td></tr><tr><td align="left" colspan="1" rowspan="1">Conv Layer 2</td><td align="left" colspan="1" rowspan="1">Conv2D&#8201;&#8594;&#8201;BatchNorm&#8201;&#8594;&#8201;ReLU</td><td align="left" colspan="1" rowspan="1">3&#8201;&#215;&#8201;3</td><td align="left" colspan="1" rowspan="1">1/1</td><td align="left" colspan="1" rowspan="1">128&#8201;&#215;&#8201;128&#8201;&#215;&#8201;64</td><td align="left" colspan="1" rowspan="1">&#8201;~&#8201;18.5&#160;K</td></tr><tr><td align="left" colspan="1" rowspan="1">Conv Layer 3</td><td align="left" colspan="1" rowspan="1">Conv2D&#8201;&#8594;&#8201;BatchNorm&#8201;&#8594;&#8201;ReLU&#8201;&#8594;&#8201;Global Average Pooling (GAP)</td><td align="left" colspan="1" rowspan="1">3&#8201;&#215;&#8201;3</td><td align="left" colspan="1" rowspan="1">1/1</td><td align="left" colspan="1" rowspan="1">1&#8201;&#215;&#8201;1&#8201;&#215;&#8201;128 (128-dim vector per slice)</td><td align="left" colspan="1" rowspan="1">&#8201;~&#8201;73.9&#160;K</td></tr><tr><td align="left" colspan="1" rowspan="1">Slice Embedding Output</td><td align="left" colspan="1" rowspan="1">One 128-dimensional feature vector per</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">[N_slices&#8201;&#215;&#8201;128]</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">BiLSTM Layer</td><td align="left" colspan="1" rowspan="1">Bidirectional LSTM with 128 hidden units in each direction</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">[N_slices&#8201;&#215;&#8201;256]</td><td align="left" colspan="1" rowspan="1">&#8201;~&#8201;394&#160;K</td></tr><tr><td align="left" colspan="1" rowspan="1">Attention Layer</td><td align="left" colspan="1" rowspan="1">Self-attention (Additive Attention): context vector&#8201;=&#8201;&#8721; (&#945;_t * h_t)</td><td align="left" colspan="1" rowspan="1">Context&#8201;=&#8201;256-dim</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1&#8201;&#215;&#8201;256</td><td align="left" colspan="1" rowspan="1">&#8201;~&#8201;66&#160;K</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">- Score: e_t = v<sup>t</sup>tanh(W<sub>1</sub>h_t&#8201;+&#8201;W<sub>2</sub>c)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">- &#945;_t&#8201;=&#8201;softmax(e_t)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Deep Feature Output</td><td align="left" colspan="1" rowspan="1">Final 256-dimensional vector (used for fusion with radiomics or end-to-end classification)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">256</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Total Parameters</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&#8201;~&#8201;553&#160;K</td></tr></tbody></table></table-wrap></p><p id="Par28">Rationale for sequence modeling: the cropped hippocampal volume is represented as an ordered sequence of axial slices. A bidirectional LSTM was selected to capture inter-slice dependencies with parameter efficiency and robustness to variable slice counts. Attention is applied after the LSTM so that slice weights are computed on context-enriched hidden states, while the CNN encoder captures intra-slice spatial saliency. The final deep feature is a 256-dimensional vector obtained by concatenating the two LSTM directions (128 units each) and aggregating them via additive attention.</p></sec></sec><sec id="Sec11"><title>Feature fusion and selection</title><sec id="Sec12"><title>Multi-level feature fusion strategy</title><p id="Par29">To capitalize on the complementary strengths of handcrafted radiomic features and learned deep features, a multi-level fusion strategy was employed. Radiomic features (<italic toggle="yes">n</italic>&#8201;=&#8201;215), derived from segmented hippocampal regions, provided interpretable, biologically-grounded descriptors of tissue structure and intensity patterns. In parallel, deep features (<italic toggle="yes">n</italic>&#8201;=&#8201;256), extracted via the LSTM-attention network, captured high-level, abstract representations of spatial and contextual dependencies across hippocampal slices. These two feature sets were concatenated into a single composite feature vector (total dimension&#8201;=&#8201;471) for each subject. This fusion ensured that both low-level imaging statistics and high-level semantic patterns were jointly utilized in downstream classification tasks, enhancing model performance and generalizability.</p><p id="Par30">This dual-feature integration is motivated by the complementary strengths of each representation. Handcrafted features offer interpretable, biologically grounded descriptors that capture statistical and structural properties of the hippocampus, whereas deep features learned via LSTM-attention models can represent non-linear, hierarchical patterns and spatial dynamics across slices. By combining both, the framework benefits from enhanced discrimination and model robustness, while maintaining a degree of interpretability essential for clinical translation. This fusion approach also aligns with current trends in radiomics and hybrid AI models, which increasingly support multi-level feature integration for optimal diagnostic performance.</p></sec><sec id="Sec13"><title>Stability assessment and harmonization of extracted features</title><p id="Par31">To address site variability in the multi-center dataset, all radiomic, deep, and fused features were harmonized using the ComBat method, which adjusts for scanner-related batch effects while preserving biological signals. ComBat was applied separately to each feature type using empirical Bayes estimation, with imaging site as the batch factor. Post-harmonization, feature stability was assessed using the ICC, based on outputs from hippocampal segmentations generated by four models retrained under varied hyperparameters. ICC was computed using a two-way mixed-effects, single-measurement, absolute-agreement model (ICC (3,1)). The threshold of ICC&#8201;&#8805;&#8201;0.75 was selected a priori to reflect good reliability, consistent with established guidelines for reliability studies, while preserving sufficient feature diversity for modeling. Pairwise Pearson correlations were then calculated on ComBat-harmonized features at the subject level. High correlation was defined as |r|&#8805;&#8201;0.90, a stringent but commonly used criterion in radiomics to mitigate multicollinearity. For correlated pairs, the feature with the higher ICC and lower cross-subject variance was retained. Sensitivity checks using alternative thresholds (ICC 0.70&#8211;0.80; correlation cutoffs |r| 0.85&#8211;0.95) yielded comparable downstream performance, supporting the robustness of the chosen criteria while aligning with IBSI-compliant radiomics practice.</p></sec><sec id="Sec14"><title>Feature selection using LASSO</title><p id="Par32">Following stability screening, dimensionality reduction was performed using the Least Absolute Shrinkage and Selection Operator (LASSO). The combined stable feature matrix was input into a logistic regression model with L1 regularization, where the regularization strength (&#955;) was optimized via tenfold cross-validation to minimize classification error. LASSO induced sparsity by shrinking irrelevant coefficients to zero, allowing selection of the most discriminative features while reducing overfitting. The final selected feature subset was then used as input to classification models tasked with identifying AD progression stages. This two-step selection&#8212;based on both robustness and discriminative power&#8212;ensured that only stable and clinically relevant features contributed to model predictions.</p></sec></sec><sec id="Sec15"><title>Classification models</title><sec id="Sec16"><title>Model architecture and implementation</title><p id="Par33">To classify subjects into the four Alzheimer&#8217;s disease progression categories (Non-Demented, Very Mild Demented, Mild Demented, and Moderate Demented), five distinct machine learning classifiers were implemented and comparatively evaluated: Logistic Regression (LR), Support Vector Machine (SVM), Random Forest (RF), Multilayer Perceptron (MLP), and eXtreme Gradient Boosting (XGBoost). These models were chosen to represent a spectrum of linear, kernel-based, ensemble, neural network, and gradient boosting approaches, respectively, allowing for robust performance benchmarking across varying algorithmic paradigms.</p><p id="Par34">All models were implemented in Python using the scikit-learn (v1.3) and XGBoost (v1.7) libraries. For MLP, a feedforward neural network with two hidden layers (128 and 64 units) and ReLU activations was employed, trained using the Adam optimizer and early stopping based on validation loss. Hyperparameters for all models&#8212;including regularization strength (LR, SVM), kernel type (SVM), number of estimators and tree depth (RF, XGBoost), and learning rate (XGBoost)&#8212;were optimized via fivefold cross-validation on the training set using a grid search strategy. Final model evaluation was performed on the independent test set using accuracy, macro-averaged F1-score, and AUC metrics for multiclass classification.</p></sec><sec id="Sec17"><title>Input variables: imaging and clinical data</title><p id="Par35">Each classifier received a combined input feature vector comprising both imaging-derived and clinical features. The imaging features included the final set of harmonized, stable, and non-redundant radiomic features, deep features, and their fused representations. The clinical variables incorporated into the input vector were age, sex, MMSE score, CDR score, education (years), APOE &#949;4 status (carrier/non-carrier), hypertension, diabetes mellitus, and body mass index (BMI). All features were normalized using z-score standardization before training. This multimodal integration enabled the classifiers to leverage both structural imaging patterns and individual-level clinical risk factors, enhancing the accuracy and clinical relevance of Alzheimer&#8217;s stage classification.</p></sec></sec><sec id="Sec18"><title>Model interpretability and clinical tools</title><sec id="Sec19"><title>SHAP analysis for feature importance</title><p id="Par36">To enhance interpretability and gain insight into the decision-making process of the classification models, SHapley Additive exPlanations (SHAP) were employed. SHAP is a model-agnostic, game-theoretic approach that quantifies the contribution of each feature to individual predictions. Among the five classifiers evaluated, the best-performing model&#8212;determined based on cross-validated accuracy, sensitivity, and AUC&#8212;was selected for SHAP analysis. Feature rankings were derived based on mean absolute SHAP values, allowing identification of the most influential clinical and imaging features in classifying Alzheimer&#8217;s progression.</p></sec><sec id="Sec20"><title>Construction of predictive nomogram</title><p id="Par37">A predictive nomogram was developed based on the final output probabilities of the best-performing model and a selected subset of clinically relevant variables. The nomogram translates the probabilistic outputs of the machine learning model into a graphical scoring tool, facilitating individualized risk estimation in a user-friendly format. To ensure clinical applicability and simplicity, only a subset of statistically significant and interpretable features&#8212;selected from the full clinical feature set based on SHAP analysis&#8212;were included in the nomogram. The nomogram allows clinicians to manually compute risk scores corresponding to different AD progression classes, supporting point-of-care decision-making.</p></sec><sec id="Sec21"><title>Decision curve analysis (DCA)</title><p id="Par38">To assess the clinical utility of the proposed predictive framework, DCA was conducted for the final nomogram. DCA evaluates the net benefit of using a prediction model at different threshold probabilities, comparing it against default strategies such as treating all or treating none. By integrating the consequences of false positives and false negatives into a unified metric, DCA helps determine whether the model&#8217;s predictions would meaningfully improve clinical decision-making. The analysis demonstrated that the nomogram provided a superior net benefit across a broad range of thresholds, supporting its practical value in guiding individualized assessment and intervention strategies for Alzheimer&#8217;s disease progression.</p></sec></sec><sec id="Sec22"><title>End-to-end classification pathway</title><sec id="Sec23"><title>Cropped hippocampal image pipeline</title><p id="Par39">In parallel to the feature-based framework, an end-to-end deep learning classification pathway was developed to assess the performance of a direct learning approach without handcrafted or explicitly extracted features. In this pipeline, raw hippocampal image regions were used as the sole input to the classification model. Specifically, the hippocampal region was localized and cropped from each preprocessed T1-weighted MRI scan using the masks generated by the best-performing segmentation model. Each cropped region was resampled to a uniform size of 64&#8201;&#215;&#8201;64&#8201;&#215;&#8201;32 voxels and normalized to the [0, 1] intensity range. This allowed the model to focus solely on the anatomically relevant structure while minimizing background noise and variability.</p></sec><sec id="Sec24"><title>Model design and training</title><p id="Par40">An end-to-end classification model was implemented using a 3D CNN-LSTM architecture. The CNN comprised three convolutional blocks (32, 64, 128 filters) with batch normalization, ReLU, and max pooling. Flattened feature maps were input into a bidirectional LSTM (128 units), followed by an attention layer to aggregate slice-wise representations. The classification head included two dense layers (128 and 64 units) with dropout (<italic toggle="yes">p</italic>&#8201;=&#8201;0.3) and softmax activation. The model was trained with categorical cross-entropy loss and Adam optimizer (learning rate&#8201;=&#8201;1e&#8211;4) for up to 500 epochs, using early stopping and on-the-fly data augmentation. For the end-to-end classification model, spatial and intensity augmentations such as random rotation, translation, scaling, and intensity jittering were applied. This strategy, combined with data augmentation used in the segmentation pipeline, ensured resilience to multi-center imaging variability. Performance was evaluated via stratified fivefold cross-validation and benchmarked against the feature-based classification pipeline.</p></sec></sec><sec id="Sec25"><title>Performance evaluation and statistical analysis</title><sec id="Sec26"><title>Evaluation metrics</title><p id="Par41">The dataset was partitioned into 70% for training and 30% for internal testing using stratified sampling to preserve class balance. The training set was further evaluated using stratified fivefold cross-validation to optimize hyperparameters and assess model stability. The internal test set remained entirely independent and was used only for final performance evaluation. This two-stage design ensured robust internal validation while preserving an unbiased generalization estimate. Center 7 was reserved exclusively for external validation of the classification models, as it was not involved in any training or hyperparameter tuning processes. This center was selected based on sample adequacy and clinical consistency, enabling a robust evaluation of generalizability. Center 8, by contrast, was used for external validation of hippocampal segmentation only, as it provided manually annotated hippocampal masks for accuracy benchmarking.</p><p id="Par42">Hippocampal segmentation performance was assessed using Dice Similarity Coefficient (Dice), Intersection over Union (IoU), Hausdorff Distance at the 95th percentile (HD95), and Average Symmetric Surface Distance (ASSD), providing complementary measures of spatial overlap and boundary precision. Classification performance was evaluated using overall accuracy, macro-averaged Area Under the Receiver Operating Characteristic Curve (AUC), and sensitivity (recall). To qualitatively assess feature space separability, t-distributed Stochastic Neighbor Embedding (t-SNE) was applied to visualize latent class distributions in two dimensions.</p></sec><sec id="Sec27"><title>Statistical comparisons between pipelines</title><p id="Par43">Comparative statistical analyses were conducted between the feature-based classification framework and the end-to-end image-based pipeline to assess differences in performance. Paired t-tests and Wilcoxon signed-rank tests were applied to compare AUC and accuracy values across cross-validation folds. In addition, McNemar&#8217;s test was used to compare classification error rates on the same test instances between models. For segmentation metrics, repeated measures ANOVA was used to compare performance across the four segmentation models, with post hoc pairwise tests corrected using the Bonferroni method.</p></sec></sec><sec id="Sec28"><title>Software and hardware specifications</title><p id="Par44">All preprocessing, feature extraction, model training, and evaluation were performed using a combination of open-source tools and custom Python scripts. Neuroimaging preprocessing&#8212;including reorientation, skull stripping, and registration to standard space&#8212;was carried out using FMRIB Software Library (FSL, v6.0.5), Advanced Normalization Tools (ANTs, v2.3.4), and NiBabel. Handcrafted radiomics features were extracted via the Standardized Environment for Radiomics Analysis (SERA) platform, compliant with Image Biomarker Standardisation Initiative (IBSI) guidelines.</p><p id="Par45">Machine learning models (logistic regression, support vector machine [SVM], random forest, multilayer perceptron [MLP]) were implemented using Scikit-learn (v1.3), while gradient boosting was performed with the XGBoost Python API (v1.7). SHapley Additive exPlanations (SHAP) values were computed using the SHAP library (v0.41) for interpretability. Statistical analysis and visualization were conducted in Python using NumPy, SciPy, statsmodels, Seaborn, and Matplotlib. Experiments were executed on a high-performance workstation with dual Intel Xeon Silver 4316 CPUs (2.3&#160;GHz), 256&#160;GB RAM, and four NVIDIA RTX A6000 GPUs (48&#160;GB VRAM each).</p></sec></sec><sec id="Sec29"><title>Results</title><sec id="Sec30"><title>Baseline demographic and clinical characteristics</title><p id="Par46">Table <xref rid="Tab4" ref-type="table">4</xref> presents the baseline demographic and clinical characteristics of the 2956 participants included in the training and internal validation cohort, stratified across four Alzheimer's disease progression classes: Non-Demented, Very Mild Demented, Mild Demented, and Moderate Demented. Statistically significant trends were observed in age, MMSE and CDR scores, hippocampal volume, education level, APOE &#949;4 carrier status, and comorbid conditions, consistent with advancing stages of cognitive decline.<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table&#160;4</label><caption><p>Demographic and clinical characteristics by AD Class (Training/internal dataset, <italic toggle="yes">n</italic>&#8201;=&#8201;2956)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Characteristic</th><th align="left" colspan="1" rowspan="1">Non-Demented (n&#8201;=&#8201;1,200)</th><th align="left" colspan="1" rowspan="1">Very Mild Demented (n&#8201;=&#8201;800)</th><th align="left" colspan="1" rowspan="1">Mild Demented (n&#8201;=&#8201;600)</th><th align="left" colspan="1" rowspan="1">Moderate Demented (<italic toggle="yes">n</italic>&#8201;=&#8201;356)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age (years), mean&#8201;&#177;&#8201;SD</td><td align="left" colspan="1" rowspan="1">67.5&#8201;&#177;&#8201;7.0</td><td align="left" colspan="1" rowspan="1">70.0&#8201;&#177;&#8201;7.5</td><td align="left" colspan="1" rowspan="1">73.0&#8201;&#177;&#8201;7.3</td><td align="left" colspan="1" rowspan="1">76.0&#8201;&#177;&#8201;8.0</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Sex (male), <italic toggle="yes">n</italic> &#8239;(%)</td><td align="left" colspan="1" rowspan="1">600&#8239; (50.0%)</td><td align="left" colspan="1" rowspan="1">390&#8239; (48.8%)</td><td align="left" colspan="1" rowspan="1">285 (47.5%)</td><td align="left" colspan="1" rowspan="1">165 (46.3%)</td><td char="." align="char" colspan="1" rowspan="1">0.65</td></tr><tr><td align="left" colspan="1" rowspan="1">MMSE score, mean&#8201;&#177;&#8201;SD</td><td align="left" colspan="1" rowspan="1">29.2&#8201;&#177;&#8201;0.8</td><td align="left" colspan="1" rowspan="1">27.5&#8201;&#177;&#8201;1.1</td><td align="left" colspan="1" rowspan="1">24.2&#8201;&#177;&#8201;2.1</td><td align="left" colspan="1" rowspan="1">19.2&#8201;&#177;&#8201;3.9</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">CDR score, median (IQR)</td><td align="left" colspan="1" rowspan="1">0&#8239;(0&#8211;0)</td><td align="left" colspan="1" rowspan="1">0.5 &#8239;(0.5&#8211;0.5)</td><td align="left" colspan="1" rowspan="1">1&#8239;(1&#8211;1)</td><td align="left" colspan="1" rowspan="1">2&#8239;(2&#8211;2)</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Hippocampal Volume (mL), mean&#8201;&#177;&#8201;SD</td><td align="left" colspan="1" rowspan="1">4.3&#8201;&#177;&#8201;0.5</td><td align="left" colspan="1" rowspan="1">3.9&#8201;&#177;&#8201;0.6</td><td align="left" colspan="1" rowspan="1">3.4&#8201;&#177;&#8201;0.7</td><td align="left" colspan="1" rowspan="1">2.9&#8201;&#177;&#8201;0.8</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Education (years), mean&#8201;&#177;&#8201;SD</td><td align="left" colspan="1" rowspan="1">14.8&#8201;&#177;&#8201;3.1</td><td align="left" colspan="1" rowspan="1">13.6&#8201;&#177;&#8201;3.0</td><td align="left" colspan="1" rowspan="1">12.1&#8201;&#177;&#8201;3.4</td><td align="left" colspan="1" rowspan="1">10.7&#8201;&#177;&#8201;3.6</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">APOE &#949;4 carrier, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">234 (19.5%)</td><td align="left" colspan="1" rowspan="1">208 (26.0%)</td><td align="left" colspan="1" rowspan="1">198 (33.0%)</td><td align="left" colspan="1" rowspan="1">152 (42.7%)</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Hypertension, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">438 (36.5%)</td><td align="left" colspan="1" rowspan="1">325 (40.6%)</td><td align="left" colspan="1" rowspan="1">290 (48.3%)</td><td align="left" colspan="1" rowspan="1">205 (57.6%)</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Diabetes Mellitus, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">204 (17.0%)</td><td align="left" colspan="1" rowspan="1">178 (22.3%)</td><td align="left" colspan="1" rowspan="1">154&#8239; (25.7%)</td><td align="left" colspan="1" rowspan="1">108&#8239; (30.3%)</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Body Mass Index (kg/m<sup>2</sup>), mean&#8201;&#177;&#8201;SD</td><td align="left" colspan="1" rowspan="1">25.8&#8201;&#177;&#8201;3.5</td><td align="left" colspan="1" rowspan="1">25.5&#8201;&#177;&#8201;3.6</td><td align="left" colspan="1" rowspan="1">24.9&#8201;&#177;&#8201;3.8</td><td align="left" colspan="1" rowspan="1">24.2&#8201;&#177;&#8201;4.0</td><td char="." align="char" colspan="1" rowspan="1">0.003</td></tr></tbody></table></table-wrap></p><p id="Par47">Age demonstrated a significant increasing trend with disease severity (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), consistent with the well-established relationship between advancing age and higher risk of AD progression. Similarly, MMSE scores showed a marked decline across classes, with scores decreasing from a mean of 29.2 in the Non-Demented group to 19.2 in the Moderate Demented group (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), reflecting progressive cognitive deterioration. CDR scores also followed an expected ordinal pattern, ranging from 0 in cognitively normal individuals to a median of 2 in moderate dementia cases (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), indicating increasing functional impairment. Hippocampal volume exhibited a stepwise reduction from 4.3&#160;mL to 2.9&#160;mL (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), supporting the hippocampus's role as a sensitive biomarker for neurodegeneration in AD. Educational attainment was inversely related to AD severity, with significantly lower mean years of education observed in more advanced stages (p&#8201;&lt;&#8201;0.001), aligning with the cognitive reserve hypothesis. APOE &#949;4 carrier frequency increased steadily with disease progression (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), reinforcing its role as a genetic risk factor.</p><p id="Par48">The prevalence of vascular comorbidities such as hypertension and diabetes mellitus also increased with disease severity (both <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), suggesting potential synergistic effects on neurodegenerative processes. Lastly, body mass index (BMI) showed a modest but statistically significant decline across AD stages (<italic toggle="yes">p</italic>&#8201;=&#8201;0.003), which may reflect progressive frailty or nutritional status decline in later stages. No significant difference was found in the sex distribution across groups (<italic toggle="yes">p</italic>&#8201;=&#8201;0.65), indicating that sex was not a confounding factor in this cohort. Overall, these findings validate the clinical consistency and stratification of the study cohort, supporting the reliability of subsequent modeling efforts.</p></sec><sec id="Sec31"><title>Segmentation performance</title><sec id="Sec32"><title>Internal segmentation results (Dice, IoU, HD, ASSD)</title><p id="Par49">The performance of hippocampal segmentation models was evaluated on the internal training and test sets using four standard metrics: DSC, IoU, HD, and ASSD (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). Among the five models assessed, MedT consistently achieved the highest segmentation accuracy. On the training set, MedT attained a mean DSC of 95.74%&#8201;&#177;&#8201;0.88 and IoU of 93.71%&#8201;&#177;&#8201;0.94, with an HD of 4.92&#160;mm&#8201;&#177;&#8201;1.37 and ASSD of 2.76&#160;mm&#8201;&#177;&#8201;0.69, indicating both excellent volumetric agreement and precise boundary localization.<fig id="Fig3" position="float" orientation="portrait"><label>Fig.&#160;3</label><caption><p>Learning curves of segmentation models: dice score and loss over 500 training epochs. training and test dice scores (left) and corresponding losses (right) across epochs for U-Net, nnU-Net, Swin-UNet, and MedT</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="40001_2025_3204_Fig3_HTML.jpg"/></fig></p><p id="Par50">Performance slightly declined on the test set, as expected, but remained superior compared to other models, with MedT reaching a DSC of 94.10%, IoU of 92.42%, HD of 6.14&#160;mm, and ASSD of 2.98&#160;mm. Other models such as Swin-UNet and nnU-Net also demonstrated strong internal performance but with relatively higher surface error and lower overlap metrics than MedT. Classical U-Net showed the lowest performance across all metrics, particularly in boundary precision, as indicated by higher HD and ASSD values.</p></sec><sec id="Sec33"><title>External segmentation validation</title><p id="Par51">Model generalizability was assessed using the external dataset. Again, MedT maintained the best performance, achieving a DSC of 92.03%, IoU of 90.88%, HD of 7.01&#160;mm, and ASSD of 3.12&#160;mm. These results confirm MedT&#8217;s robustness across datasets with differing acquisition parameters and scanner sources. While all models showed a slight decline in performance on the external dataset relative to the internal test set, the performance drop was least pronounced for MedT, highlighting its superior adaptability.</p><p id="Par52">Swin-UNet and nnU-Net retained reasonable performance (DSC&#8201;=&#8201;86.93% and 80.12%, respectively), though both exhibited increased boundary error on the external images. U-Net&#8217;s external segmentation accuracy was notably limited (DSC&#8201;=&#8201;77.24%, HD&#8201;=&#8201;17.21&#160;mm), reflecting its reduced capacity to generalize to unseen data.</p></sec><sec id="Sec34"><title>Comparative analysis of segmentation models</title><p id="Par53">Across all datasets and evaluation metrics, MedT outperformed all other architectures, demonstrating both high overlap accuracy and low boundary error. The superiority of MedT can be attributed to its pure transformer-based architecture and gated positional self-attention mechanism, which enable it to effectively capture global contextual information and fine anatomical detail&#8212;both critical in segmenting small, irregularly shaped structures like the hippocampus.</p><p id="Par54">Swin-UNet, which integrates hierarchical attention within a U-Net structure, ranked second overall, particularly excelling in spatial contextualization. nnU-Net performed moderately well due to its dynamic adaptation but lacked the global modeling capacity of transformer-based architectures. U-Net showed the weakest performance, limited by its local receptive field and lack of advanced contextual integration mechanisms. Overall, the results support the use of transformer-based models, particularly MedT, as the most reliable choice for automated hippocampal segmentation in heterogeneous multi-center datasets.</p><p id="Par55">Figure&#160;<xref rid="Fig4" ref-type="fig">4</xref> illustrates the learning dynamics of the four hippocampal segmentation models over 500 training epochs, based on Dice score and loss evolution on both the training and test sets. Among the models, MedT consistently outperformed the others, achieving the highest Dice scores and lowest losses on both training and test sets throughout the training process. Notably, MedT reached convergence faster and exhibited smoother, more stable learning curves compared to other architectures, suggesting superior optimization and generalization capabilities. Swin-UNet also demonstrated strong performance, although it lagged behind MedT in both final Dice score and loss reduction. In contrast, nnU-Net and U-Net exhibited slower convergence and plateaued at lower accuracy levels. The test loss curves further reinforce these findings, with MedT achieving the lowest terminal loss, indicating robust generalization to unseen data. Collectively, these curves provide empirical support for the quantitative metrics presented earlier, confirming MedT as the most effective and stable model for hippocampal segmentation in this study.<fig id="Fig4" position="float" orientation="portrait"><label>Fig.&#160;4</label><caption><p>Qualitative comparison of hippocampal segmentation across four deep learning models</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="40001_2025_3204_Fig4_HTML.jpg"/></fig></p><p id="Par56">Figure&#160;<xref rid="Fig5" ref-type="fig">5</xref> displays representative slices demonstrating the predicted hippocampal segmentation masks (red dashed lines) overlaid on the ground truth masks (blue solid lines) for four models: MedT, Swin-UNet, nnU-Net, and U-Net. The visual comparison highlights that MedT achieved the closest match to the ground truth across all three cases, with superior boundary alignment and volumetric accuracy. Swin-UNet and nnU-Net showed moderate agreement, while U-Net exhibited the largest discrepancies, particularly at the hippocampal borders. These qualitative findings are consistent with the quantitative metrics reported, confirming the advantage of transformer-based segmentation for hippocampal delineation in Alzheimer&#8217;s disease imaging.<fig id="Fig5" position="float" orientation="portrait"><label>Fig.&#160;5</label><caption><p>Feature dimensionality reduction across preprocessing and selection stages</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO5" position="float" orientation="portrait" xlink:href="40001_2025_3204_Fig5_HTML.jpg"/></fig></p></sec></sec><sec id="Sec35"><title>Feature extraction and stability</title><sec id="Sec36"><title>ICC results for radiomics, deep, and fused features</title><p id="Par57">Following segmentation model evaluation, the MedT architecture was selected as the reference model for generating hippocampal masks used in all subsequent feature extraction steps. This decision was based on its superior segmentation accuracy and generalization performance across both internal and external datasets. All radiomic and deep features reported here were extracted using hippocampal segmentations generated by MedT.</p><p id="Par58">To evaluate the reproducibility of extracted features, we computed the ICC across feature instances generated from multiple MedT segmentations trained under varying hyperparameters. This ensured that retained features were stable with respect to small perturbations in the segmentation model's training configuration. ICC was calculated using a two-way mixed-effects model (absolute agreement, ICC (3,1)), and features with ICC values&#8201;&#8805;&#8201;0.75 were considered sufficiently robust. Out of 215 handcrafted radiomic features, 188 (87.4%) met the stability criterion. Similarly, from the 256 deep features extracted via the LSTM-attention network, 227 (88.7%) demonstrated strong reproducibility. The fused feature set, formed by concatenating radiomic and deep features (totaling 471 features), yielded 425 stable features, highlighting high consistency across both domains (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>).<fig id="Fig6" position="float" orientation="portrait"><label>Fig.&#160;6</label><caption><p>LASSO feature selection results for radiomics, deep, and fused feature sets<bold>.</bold> Cross-validation mean squared error (CV-MSE) curves (left) and coefficient shrinkage paths (right) are shown for radiomics (blue), deep (red), and fused (green) feature sets. The optimal regularization parameter (&#945;<italic toggle="yes">)</italic> is marked for each curve</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO6" position="float" orientation="portrait" xlink:href="40001_2025_3204_Fig6_HTML.jpg"/></fig></p></sec><sec id="Sec37"><title>Post-harmonization feature retention and redundancy filtering</title><p id="Par59">To mitigate potential scanner-related and center-specific biases, all features were harmonized using the ComBat algorithm, treating imaging center as the batch covariate and applying empirical Bayes estimation. ComBat was applied independently to radiomic and deep features prior to ICC filtering to ensure that observed variability reflected biological rather than technical differences.</p><p id="Par60">Following harmonization and ICC-based filtering, the retained feature sets underwent redundancy reduction using a two-step approach. First, features with near-zero variance were removed. Second, pairwise Pearson correlation analysis was applied to identify collinear features (|r|&#8805;&#8201;0.90). Within each highly correlated group, the feature with the highest ICC and lowest variance was retained. This process reduced the feature dimensions to 171 for radiomics, 203 for deep features, and 383 for the fused set. Finally, LASSO (Least Absolute Shrinkage and Selection Operator) regression with tenfold cross-validation was used to identify the most discriminative and parsimonious subset of features for classification. This resulted in the selection of 20 radiomic features, 18 deep features, and a total of 38 fused features. In parallel, the clinical feature set was reduced from 10 to 6 variables based on similar filtering steps. These final, stable, and non-redundant features were used as inputs for all subsequent classification models.</p><p id="Par61">Figure&#160;<xref rid="Fig7" ref-type="fig">7</xref> summarizes the feature selection process using LASSO regression applied independently to the radiomics, deep, and fused feature sets. For each set, cross-validation mean squared error (CV-MSE) was plotted as a function of the regularization parameter (log&#8321;&#8320;(&#945;)), and the optimal &#945;* minimizing the CV-MSE within one standard error was identified. The corresponding coefficient paths illustrate how feature weights are gradually shrunk as &#945; increases. The optimal &#945; values were 0.678 for radiomics, 1.077 for deep features, and 0.422 for the fused set. At these values, the final number of selected features was 20 radiomic features<bold>,</bold> 18 deep features, and 38 features from the fused set, respectively. The fused model achieved the lowest cross-validation error, highlighting the added predictive value of integrating heterogeneous feature domains. The results demonstrate the effectiveness of LASSO in achieving robust dimensionality reduction while preserving critical discriminative information across all feature types.<fig id="Fig7" position="float" orientation="portrait"><label>Fig.&#160;7</label><caption><p>Classification performance heatmap using clinical features</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO7" position="float" orientation="portrait" xlink:href="40001_2025_3204_Fig7_HTML.jpg"/></fig></p></sec></sec><sec id="Sec38"><title>Classification performance</title><sec id="Sec39"><title>Clinical features</title><p id="Par62">The baseline classification performance using clinical features alone revealed modest predictive capability across models. Among the five classifiers evaluated, XGBoost achieved the highest overall accuracy with 82.5% (&#177;&#8201;1.0) on the training set, 79.7% on the internal test set, and 78.9% on the external test set. Sensitivity values followed a similar trend, with XGBoost maintaining 81.9% in training and 79.2% externally. The highest AUC in this configuration was 85.1% (train), 83.6% (internal), and 82.7% (external), again observed with XGBoost (Fig.&#160;<xref rid="Fig8" ref-type="fig">8</xref>).<fig id="Fig8" position="float" orientation="portrait"><label>Fig.&#160;8</label><caption><p>Classification performance heatmap using radiomic features</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO8" position="float" orientation="portrait" xlink:href="40001_2025_3204_Fig8_HTML.jpg"/></fig></p><p id="Par63">In contrast, logistic regression showed the lowest performance among the five classifiers, with an external accuracy of 74.8% and an AUC of 79.3%, suggesting limited nonlinearity modeling capacity in this feature space. Across all models, internal-to-external performance consistency was acceptable, but performance gains were generally constrained due to the low-dimensional and relatively coarse nature of clinical features alone.</p><p id="Par64">Based on clinical relevance and empirical contribution to Alzheimer&#8217;s disease progression as documented in the literature, six clinical features were ultimately selected by the LASSO algorithm for inclusion in the classification model. These included: MMSE score, CDR score, hippocampal volume, age, APOE &#949;4 carrier status, and education level. These variables were consistently identified as key predictors in cognitive impairment and neurodegeneration, capturing both structural brain changes and demographic or genetic susceptibility factors. Features such as sex, hypertension, diabetes mellitus, and BMI, while clinically informative, exhibited lower predictive value within the multivariate model and were excluded during LASSO regularization due to redundancy or limited variance contribution.</p></sec><sec id="Sec40"><title>Radiomic features</title><p id="Par65">Using only the handcrafted radiomic features extracted from the segmented hippocampal regions, a notable performance boost was observed. XGBoost once again outperformed other classifiers, reaching a train accuracy of 89.7%, internal test accuracy of 87.2%, and external accuracy of 86.5%. Its AUC values also peaked at 91.8%, 90.0%, and 89.4%, respectively, highlighting the discriminative power of radiomics in capturing hippocampal structural heterogeneity relevant to Alzheimer&#8217;s staging (Fig.&#160;<xref rid="Fig9" ref-type="fig">9</xref>).<fig id="Fig9" position="float" orientation="portrait"><label>Fig.&#160;9</label><caption><p>Classification performance heatmap using deep features</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO9" position="float" orientation="portrait" xlink:href="40001_2025_3204_Fig9_HTML.jpg"/></fig></p><p id="Par66">Deep classifiers like MLP and ensemble methods like Random Forest and CatBoost performed comparably well, all achieving external AUCs above 88%. The lowest performance again corresponded to logistic regression (external AUC&#8201;=&#8201;86.1%), though its relative performance improved compared to the clinical-only configuration. These results emphasize the utility of radiomic analysis as a more sensitive modality-specific input for AD classification.</p></sec><sec id="Sec41"><title>Deep features</title><p id="Par67">Deep features extracted via the LSTM-attention model demonstrated strong classification potential. XGBoost achieved 90.3% training accuracy, 87.8% internal accuracy, and 87.0% external accuracy. AUC values were also high, with 91.9% in training, 90.2% internal, and 89.5% external, showing slightly better generalizability than radiomics alone.</p><p id="Par68">Notably, the LSTM-based deep features appeared to yield more consistent performance across classifiers compared to radiomics, with reduced standard deviations in training and less variance in sensitivity across datasets. MLP and Random Forest closely followed XGBoost, while logistic regression again underperformed, indicating that the high-dimensional and non-linear representations learned by the LSTM network are better utilized by flexible models (Fig.&#160;<xref rid="Fig10" ref-type="fig">10</xref>).<fig id="Fig10" position="float" orientation="portrait"><label>Fig.&#160;10</label><caption><p>Classification performance heatmap using fused features (Clinical&#8201;+&#8201;Radiomic&#8201;+&#8201;Deep)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO10" position="float" orientation="portrait" xlink:href="40001_2025_3204_Fig10_HTML.jpg"/></fig></p></sec><sec id="Sec42"><title>Fused features (clinical&#8201;+&#8201;radiomics&#8201;+&#8201;deep)</title><p id="Par69">Combining all three feature types into a unified representation resulted in the best classification performance across all models. XGBoost delivered the top performance, with 95.4% (&#177;&#8201;0.5) training accuracy, 93.6% internal test accuracy, and 92.8% external accuracy. Sensitivity also peaked with 94.8% in training and 92.1% externally. The AUC values for this configuration were the highest overall, reaching 96.7%, 94.9%, and 94.2% across the datasets, respectively (Fig.&#160;<xref rid="Fig11" ref-type="fig">11</xref>).<fig id="Fig11" position="float" orientation="portrait"><label>Fig.&#160;11</label><caption><p>ROC analysis for clinical feature-based classification</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO11" position="float" orientation="portrait" xlink:href="40001_2025_3204_Fig11_HTML.jpg"/></fig></p><p id="Par70">MLP and CatBoost models followed closely, with external AUCs exceeding 93%, indicating that fused feature spaces enriched by multi-source data representations offer superior discriminative performance and robustness. The improved performance across models and metrics in this configuration confirms the added value of multimodal feature fusion, highlighting its potential for clinical deployment in Alzheimer&#8217;s disease staging.</p><p id="Par71">Figures&#160;<xref rid="Fig12" ref-type="fig">12</xref>, <xref rid="Fig13" ref-type="fig">13</xref>, <xref rid="Fig14" ref-type="fig">14</xref>, <xref rid="Fig15" ref-type="fig">15</xref> present the ROC curve analyses for five classifiers trained using four different feature sets: clinical, radiomic, deep, and fused (clinical&#8201;+&#8201;radiomic&#8201;+&#8201;deep) features. As shown in Fig.&#160;<xref rid="Fig12" ref-type="fig">12</xref>, models based solely on clinical features exhibited modest discriminatory performance, with XGBoost achieving the highest external AUC of 82.7%. Figure&#160;<xref rid="Fig13" ref-type="fig">13</xref> illustrates that radiomic features notably improved classification accuracy, with XGBoost reaching an external AUC of 89.4%. In Fig.&#160;<xref rid="Fig14" ref-type="fig">14</xref>, deep features extracted via an LSTM-attention network yielded comparable performance, with XGBoost again outperforming other classifiers (external AUC: 89.5%). The best overall performance was observed in Fig.&#160;<xref rid="Fig15" ref-type="fig">15</xref>, where feature fusion resulted in a significant gain across all metrics, with XGBoost achieving external AUCs of 94.2%, highlighting the synergistic effect of multimodal integration for accurate and generalizable Alzheimer&#8217;s disease stage classification.<fig id="Fig12" position="float" orientation="portrait"><label>Fig.&#160;12</label><caption><p>ROC analysis for radiomic feature-based classification</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO12" position="float" orientation="portrait" xlink:href="40001_2025_3204_Fig12_HTML.jpg"/></fig><fig id="Fig13" position="float" orientation="portrait"><label>Fig.&#160;13</label><caption><p>ROC analysis for deep feature-based classification</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO13" position="float" orientation="portrait" xlink:href="40001_2025_3204_Fig13_HTML.jpg"/></fig><fig id="Fig14" position="float" orientation="portrait"><label>Fig.&#160;14</label><caption><p>ROC analysis for fused feature-based classification (Clinical&#8201;+&#8201;Radiomics&#8201;+&#8201;Deep)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO14" position="float" orientation="portrait" xlink:href="40001_2025_3204_Fig14_HTML.jpg"/></fig><fig id="Fig15" position="float" orientation="portrait"><label>Fig.&#160;15</label><caption><p>Visualization of feature distributions using t-SNE for XGBoost classifier across all datasets</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO15" position="float" orientation="portrait" xlink:href="40001_2025_3204_Fig15_HTML.jpg"/></fig></p><p id="Par72">Figure&#160;<xref rid="Fig16" ref-type="fig">16</xref> illustrates the distribution of fused features (clinical&#8201;+&#8201;radiomic&#8201;+&#8201;deep) using t-SNE before and after dimensionality reduction, for training, internal test, and external test datasets. The left column shows the raw feature space, where class boundaries are not visually separable, reflecting the high-dimensional complexity of the original fused features. In contrast, the right column depicts the 2D t-SNE projections after training with the XGBoost classifier. Post-t-SNE visualization reveals well-separated clusters corresponding to the four diagnostic classes (Non-Demented, Very Mild Demented, Mild Demented, and Moderate Demented), especially in the training set. Notably, classification boundaries remain visually consistent in both internal and external test cohorts, supporting the generalizability of the model. Correctly classified samples are indicated with dots, while misclassified ones are marked with 'x', with very few overlaps, further reinforcing the discriminative power of the fused feature space when utilized with the XGBoost model.<fig id="Fig16" position="float" orientation="portrait"><label>Fig.&#160;16</label><caption><p>SHAP-based feature importance ranking from the XGBoost classifier using fused features</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO16" position="float" orientation="portrait" xlink:href="40001_2025_3204_Fig16_HTML.jpg"/></fig></p><p id="Par73">Two-dimensional t-SNE was selected to facilitate intuitive visualization of class distribution across feature embeddings. Although higher-dimensional t-SNE is possible, 2D remains widely used for qualitative inspection due to its interpretability. The plots on the right show post-classification projections, highlighting how the XGBoost model organizes feature space to separate disease stages. Dots indicate correctly classified samples, while crosses represent misclassifications, offering visual insight into class separability and the model&#8217;s discriminative behavior across internal and external cohorts.</p></sec></sec><sec id="Sec43"><title>Interpretability and clinical tools</title><sec id="Sec44"><title>SHAP feature importance analysis</title><p id="Par74">Figure&#160;<xref rid="Fig17" ref-type="fig">17</xref> illustrates the ranked SHAP values derived from the best-performing classification model&#8212;XGBoost&#8212;trained on the fused feature set (clinical, radiomic, and deep features). The plot identifies the most influential features contributing to the model&#8217;s multi-class prediction of Alzheimer&#8217;s disease stages. Notably, MMSE score, GLCM_Contrast, and Deep_Feature_1 emerged as the top three contributors across all diagnosis categories, reflecting a strong interplay between cognitive, textural, and abstract learned representations. Other dominant predictors included hippocampal volume, CDR score, GLCM_Homogeneity, and APOE &#949;4 carrier status, highlighting the integrated model&#8217;s ability to capture both structural brain changes and clinical-genetic context. The feature distribution by class (Non-Demented to Moderate Demented) further supports the discriminative power of the selected variables and reinforces the utility of fused features for explainable and precise staging of Alzheimer&#8217;s disease.<fig id="Fig17" position="float" orientation="portrait"><label>Fig.&#160;17</label><caption><p>Clinical nomogram for estimating probability of early-stage Alzheimer&#8217;s disease using fused model features</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO17" position="float" orientation="portrait" xlink:href="40001_2025_3204_Fig17_HTML.jpg"/></fig></p><p id="Par75">Although MMSE emerged as the top-ranked feature in SHAP analysis, relying solely on MMSE for staging can be limiting due to variability in scoring, educational bias, and reduced sensitivity in early disease. Importantly, the inclusion of radiomic and deep imaging features offers structural insights into hippocampal integrity that are not captured by cognitive tests. This multimodal integration by leveraging distinct data types&#8212;functional and anatomical&#8212;whose combined use improves staging accuracy and model generalizability, particularly in clinically ambiguous cases.</p><p id="Par76">Although SHAP analysis quantitatively identified &#8220;Deep Feature 1&#8221; as one of the top contributors to the classification model, the biological or clinical meaning of such abstract deep features remains inherently ambiguous. These features are derived from LSTM-attention networks trained on sequential hippocampal slices and may capture latent representations of spatial deformation, asymmetric atrophy patterns, or signal irregularities across hippocampal subregions. Nevertheless, because these representations are not directly interpretable in anatomical or clinical terms, their use poses a challenge for clinical adoption. This underscores the necessity for ongoing research into hybrid interpretability methods that bridge abstract feature spaces with domain-specific imaging markers, especially in the context of neurodegenerative diseases.</p></sec><sec id="Sec45"><title>Predictive nomogram results and DCA</title><p id="Par77">Figure&#160;<xref rid="Fig18" ref-type="fig">18</xref> presents a nomogram constructed from the best-performing XGBoost classifier utilizing fused features (clinical, radiomic, and deep). The nomogram visualizes the contribution of key predictors&#8212;MMSE score, hippocampal volume, and APOE &#949;4 carrier status&#8212;toward estimating the probability of a subject being classified as Very Mild Demented, a critical transitional stage of Alzheimer's disease. In the illustrated case, the patient presents with an MMSE score of 23.5, which contributes approximately 52 points on the nomogram scale. The corresponding hippocampal volume of 3.3&#160;mL adds an estimated 38 points, reflecting moderate atrophy in this key region associated with Alzheimer&#8217;s pathology. Additionally, the patient is an APOE &#949;4 carrier, a well-established genetic risk factor, contributing a further 26 points. These values cumulatively yield a total of approximately 116 points, which maps to a predicted probability of around 73% for being in the Very Mild Demented stage. This risk level exceeds the decision threshold of 0.5, indicating a clinically significant likelihood of early-stage Alzheimer's disease and reinforcing the need for close monitoring and potential intervention.<fig id="Fig18" position="float" orientation="portrait"><label>Fig.&#160;18</label><caption><p>Decision curve analysis for classification models using fused features (Clinical&#8201;+&#8201;Radiomic&#8201;+&#8201;Deep)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO18" position="float" orientation="portrait" xlink:href="40001_2025_3204_Fig18_HTML.jpg"/></fig></p><p id="Par78">Figure&#160;<xref rid="Fig19" ref-type="fig">19</xref> illustrates the DCA for five classifiers trained on the fused feature set, combining clinical, radiomic, and deep features. Across a wide range of threshold probabilities (10% to 70%), the XGBoost model consistently yielded the highest net benefit, indicating superior clinical utility in distinguishing between Alzheimer&#8217;s disease stages. Compared to standard strategies such as "treat-all" or "treat-none," XGBoost provided a marked improvement in decision-making efficiency, especially in the clinically relevant threshold range of 30%&#8211;60%. This reinforces its suitability for real-world application in supporting diagnostic decisions and early intervention planning.<fig id="Fig19" position="float" orientation="portrait"><label>Fig.&#160;19</label><caption><p>Learning curves of the End-to-End 3D CNN-LSTM pipeline: dice score and loss trajectories</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO19" position="float" orientation="portrait" xlink:href="40001_2025_3204_Fig19_HTML.jpg"/></fig></p></sec></sec><sec id="Sec46"><title>End-to-end pipeline results</title><p id="Par79">To assess the standalone diagnostic potential of an end-to-end deep learning approach without explicit feature engineering or fusion, we benchmarked three models: 3D CNN-LSTM, Vision Transformer (ViT), and Swin Transformer. As shown in Table&#160;<xref rid="Tab5" ref-type="table">5</xref>, the 3D CNN-LSTM achieved the highest classification performance across all datasets, including an external test accuracy of 83.5%, AUC of 84.0%, and sensitivity of 82.9%. While both ViT and Swin Transformer performed reasonably well, their results were consistently inferior, particularly on external data, supporting the robustness of the LSTM-based sequence modeling in this setting.<table-wrap id="Tab5" position="float" orientation="portrait"><label>Table&#160;5</label><caption><p>Performance Comparison &#8211; 3D CNN-LSTM vs ViT vs Swin Transformer</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Model</th><th align="left" colspan="1" rowspan="1">Dataset</th><th align="left" colspan="1" rowspan="1">Accuracy</th><th align="left" colspan="1" rowspan="1">AUC</th><th align="left" colspan="1" rowspan="1">Sensitivity</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">3D CNN-LSTM</td><td align="left" colspan="1" rowspan="1">Train</td><td char="." align="char" colspan="1" rowspan="1">85.1</td><td char="." align="char" colspan="1" rowspan="1">86.4</td><td char="." align="char" colspan="1" rowspan="1">84.7</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Internal test</td><td char="." align="char" colspan="1" rowspan="1">84.3</td><td char="." align="char" colspan="1" rowspan="1">85.2</td><td char="." align="char" colspan="1" rowspan="1">83.6</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">External test</td><td char="." align="char" colspan="1" rowspan="1">83.5</td><td char="." align="char" colspan="1" rowspan="1">84.0</td><td char="." align="char" colspan="1" rowspan="1">82.9</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>ViT</bold></td><td align="left" colspan="1" rowspan="1">Train</td><td char="." align="char" colspan="1" rowspan="1">82.8</td><td char="." align="char" colspan="1" rowspan="1">84.0</td><td char="." align="char" colspan="1" rowspan="1">82.1</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Internal test</td><td char="." align="char" colspan="1" rowspan="1">82.1</td><td char="." align="char" colspan="1" rowspan="1">83.3</td><td char="." align="char" colspan="1" rowspan="1">81.4</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">External test</td><td char="." align="char" colspan="1" rowspan="1">81.3</td><td char="." align="char" colspan="1" rowspan="1">82.5</td><td char="." align="char" colspan="1" rowspan="1">80.7</td></tr><tr><td align="left" colspan="1" rowspan="1">Swin Transformer</td><td align="left" colspan="1" rowspan="1">Train</td><td char="." align="char" colspan="1" rowspan="1">83.8</td><td char="." align="char" colspan="1" rowspan="1">85.0</td><td char="." align="char" colspan="1" rowspan="1">83.0</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Internal test</td><td char="." align="char" colspan="1" rowspan="1">83.2</td><td char="." align="char" colspan="1" rowspan="1">84.3</td><td char="." align="char" colspan="1" rowspan="1">82.5</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">External test</td><td char="." align="char" colspan="1" rowspan="1">82.5</td><td char="." align="char" colspan="1" rowspan="1">83.6</td><td char="." align="char" colspan="1" rowspan="1">81.8</td></tr></tbody></table></table-wrap></p><p id="Par80">These findings are consistent with our prior internal comparisons, which showed that the 3D CNN-LSTM architecture was better suited to modeling sequential hippocampal anatomy in cropped axial slices, especially under limited data regimes. Based on reviewer recommendation, we re-implemented and evaluated ViT and Swin Transformer under identical training conditions. However, they did not outperform the LSTM-based model.</p><p id="Par81">Figure&#160;<xref rid="Fig20" ref-type="fig">20</xref> illustrates the training dynamics of the 3D CNN-LSTM model, showing smooth convergence and absence of overfitting. Nonetheless, this direct image-based strategy underperformed compared to the multi-level feature-fusion pipeline, highlighting the complementary value of handcrafted radiomics, deep features, and clinical integration.<fig id="Fig20" position="float" orientation="portrait"><label>Fig.&#160;20</label><caption><p>Training and validation learning curves for 3D CNN-LSTM, ViT, and Swin Transformer models</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO20" position="float" orientation="portrait" xlink:href="40001_2025_3204_Fig20_HTML.jpg"/></fig></p></sec><sec id="Sec47"><title>Statistical comparisons and significance testing</title><sec id="Sec48"><title>Inter-model statistical comparisons</title><p id="Par82">To assess the statistical significance of performance differences between classification models, pairwise comparisons were conducted using DeLong&#8217;s test for AUC values on the external test set. The AUC of the XGBoost model leveraging fused features was significantly higher than that of other classifiers&#8212;MLP (<italic toggle="yes">p</italic>&#8201;=&#8201;0.012), Random Forest (<italic toggle="yes">p</italic>&#8201;=&#8201;0.008), SVM (<italic toggle="yes">p</italic>&#8201;=&#8201;0.005), and Logistic Regression (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001)&#8212;confirming that the superior performance of XGBoost was not due to chance. Similarly, comparisons between the fused-feature XGBoost and the deep-only XGBoost, and the radiomic-only XGBoost, yielded p-values of 0.015 and 0.022 respectively, indicating a statistically significant benefit gained through feature fusion.</p></sec><sec id="Sec49"><title>Segmentation model comparison statistics</title><p id="Par83">For segmentation models, Wilcoxon signed-rank tests were employed to compare Dice similarity scores between MedT and other architectures across the external validation set. MedT achieved a significantly higher median Dice score compared to Swin-UNet (median difference&#8201;=&#8201;&#8201;+&#8201;0.045, <italic toggle="yes">p</italic>&#8201;=&#8201;0.004), nnU-Net (+&#8201;0.112, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), and U-Net (+&#8201;0.154, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), confirming its dominance in segmentation accuracy. Similar trends were observed for IoU, HD, and ASSD metrics, with MedT consistently outperforming alternatives (all <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01). These tests validated the selection of MedT for downstream feature extraction.</p></sec><sec id="Sec50"><title>Classification error analysis and McNemar&#8217;s test</title><p id="Par84">To explore differences in misclassification patterns, McNemar&#8217;s tests were performed comparing the best fused-feature XGBoost and the deep-only XGBoost on the external test dataset. The analysis revealed a significant difference in paired error rates (<italic toggle="yes">&#967;</italic><sup>2</sup>&#8201;=&#8201;7.8, <italic toggle="yes">p</italic>&#8201;=&#8201;0.005), indicating that the fused XGBoost model generated fewer misclassifications. Further per-class error rates showed most benefit in discriminating Mild and Very Mild Dementia cases. No significant difference was seen in Non-Demented cases (<italic toggle="yes">p</italic>&#8201;=&#8201;0.11), suggesting both models performed comparably in identifying healthy individuals but diverged meaningfully at earlier disease stages.</p></sec></sec></sec><sec id="Sec51"><title>Discussion</title><p id="Par85">This study presents a novel and robust framework for the multi-class classification of AD progression using hippocampal MRI, leveraging both radiomic and deep feature extraction from advanced, transformer-based auto-segmentation models. The framework uniquely integrates handcrafted radiomics, temporally-aware deep features via LSTM with attention, and multi-level feature fusion, further enriched by rigorous harmonization and interpretability analyses. With validation on a large, multi-center dataset spanning 2956 participants and independent external testing, our approach achieved state-of-the-art diagnostic performance across four clinically relevant stages of AD. Crucially, the combination of high-resolution imaging, advanced segmentation (notably the MedT model), and feature fusion substantially elevated diagnostic accuracy and generalizability compared to conventional pipelines. It is important to note that although our framework is described as classifying 'Alzheimer&#8217;s disease progression stages,' this refers to early through moderate stages only. Severe dementia cases were excluded to maintain clinical relevance and to align with the study&#8217;s objective of early-stage identification, where interventions are more likely to alter disease trajectories.</p><p id="Par86">Our results demonstrate that fused feature models&#8212;integrating radiomics, deep features, and clinical data&#8212;outperformed models relying solely on clinical, radiomic, or deep features, with XGBoost achieving external AUCs of 94.2% and accuracy of 92.8%. These findings emphasize the additive value of multi-modal data representation for AD staging, particularly in distinguishing subtle early and intermediate stages, which are pivotal for clinical intervention and management. Notably, the MedT segmentation model exhibited superior boundary accuracy and generalizability, reinforcing the value of transformer-based architectures for precise delineation of hippocampal structures in heterogeneous imaging cohorts.</p><p id="Par87">While handcrafted radiomic features offer interpretable descriptors (e.g., texture, volume, intensity) aligned with known anatomical changes in Alzheimer&#8217;s disease, deep features are abstract outputs of neural encoders and lack immediate clinical meaning. Nonetheless, interpretability tools such as SHAP enabled identification of consistently important deep features, particularly &#8220;deep feature 1&#8221;. Although the biological basis of these features remains speculative, they may reflect complex patterns of hippocampal atrophy or microstructural change not captured by conventional descriptors. Future work integrating feature attribution with spatial activation mapping or reverse-engineered saliency could enhance clinical interpretability. Meanwhile, the hybrid approach&#8212;combining deep, radiomic, and clinical data&#8212;offers a robust and partially interpretable framework for supporting diagnostic decision-making.</p><p id="Par88">Alternative architectures such as 3D ResNets (<xref ref-type="bibr" rid="CR53">53</xref>) and Vision Transformers (<xref ref-type="bibr" rid="CR54">54</xref>) can also model volumetric context; however, they generally entail higher parameter counts and greater data/regularization requirements. In our multi-center setting with heterogeneous protocols and variable slice counts, the CNN&#8211;BiLSTM&#8211;attention design provided a compact, sequence-aware representation well suited to feature fusion and external validation. Future work could benchmark transformer-based volumetric encoders under protocol-standardized acquisitions to further assess trade-offs in accuracy, data efficiency, and interpretability.</p><p id="Par89">Severe dementia cases were excluded not only to align with our clinical objective of early detection but also due to the diminishing diagnostic specificity of hippocampal MRI features at advanced disease stages. In severe AD, the neurodegenerative process extends beyond the medial temporal lobe, leading to widespread cortical and subcortical atrophy that may reduce the discriminatory utility of hippocampal-centric imaging biomarkers. Additionally, clinical priorities shift in severe dementia toward palliative and supportive care, rather than diagnostic stratification. Therefore, future studies targeting advanced stages may benefit from incorporating broader imaging features, such as global cortical thinning or ventricular enlargement, and from aligning diagnostic strategies with the altered clinical objectives characteristic of late-stage disease management.</p><p id="Par90">While our deep feature extraction pipeline using an LSTM with attention mechanism provided strong performance and interpretability benefits, we acknowledge the limitations inherent in treating axial MRI slices as temporally ordered sequences. Although this approach can capture slice-wise dependencies, it does not fully exploit the true 3D spatial continuity of hippocampal anatomy. In contrast, 3D CNNs and volumetric transformers inherently model volumetric spatial relationships, potentially offering enhanced anatomical precision and robustness. Although our comparative experiments revealed that the LSTM-based model outperformed transformer-based benchmarks in classification tasks, this does not preclude the potential superiority of 3D architectures, particularly for segmentation. Future work should explore fully 3D segmentation frameworks, which may yield further improvements in hippocampal delineation and downstream feature stability, especially in heterogeneous clinical imaging datasets.</p><sec id="Sec52"><title>Comparative analysis with existing literature</title><p id="Par91">Our results align closely with and extend prior work in hippocampal radiomics and deep learning-based AD diagnosis. The diagnostic utility of hippocampal radiomic features has been highlighted in several recent studies. Du et al. (<xref ref-type="bibr" rid="CR55">55</xref>) demonstrated that SVM classifiers trained on hippocampal radiomic features could distinguish early-onset and late-onset AD from controls with AUCs of up to 0.94 and accuracies nearing 0.87 in external validation cohorts. Similarly, their use of LASSO for feature selection parallels our approach, though our study extends this by incorporating a larger set of deep features and feature harmonization, resulting in greater robustness across diverse imaging sources. Importantly, Du et al. (<xref ref-type="bibr" rid="CR55">55</xref>) also underscored the value of multi-center validation, an approach central to our study design and critical for ensuring clinical translatability.</p><p id="Par92">In a related vein, Yin et al. (<xref ref-type="bibr" rid="CR56">56</xref>) employed T1-weighted hippocampal radiomics in a single-center cohort, utilizing multiple classifiers including random forests, logistic regression, and SVM. Their RF model achieved an AUC of 0.961 and accuracy of 90.8% for AD versus healthy controls, while also successfully stratifying mild cognitive impairment (MCI) and dementia stages. Their analysis of feature correlations with MMSE, P-tau-181, and A&#946;1&#8211;42 provided evidence that radiomics reflect underlying neuropathology. Our results are consistent with these findings, yet extend them by demonstrating that multi-level feature fusion, external harmonization, and advanced segmentation substantially improve generalizability and stage-specific sensitivity, as evidenced by higher classification performance and t-SNE cluster separability in our multi-center and external test cohorts.</p><p id="Par93">Furthermore, Chen et al. (<xref ref-type="bibr" rid="CR57">57</xref>) illustrated the value of multiparametric radiomics combining PET and MRI modalities. Their multimodal logistic regression classifier achieved an AUC of 0.98 and accuracy of 96.7% for AD versus healthy controls&#8212;surpassing single-modality models and traditional neuropsychological assessments. Our findings echo the advantage of integrating heterogeneous imaging-derived features, as our fused feature approach consistently outperformed single-feature-type models. Notably, our study achieved comparably high accuracy using MRI-only data, suggesting that advanced MRI-based radiomics and deep feature integration can, in some contexts, approach the discriminatory performance of PET/MRI fusion, with broader accessibility and lower cost.</p><p id="Par94">The progression from traditional volumetric analysis to sophisticated deep learning methods is underscored by the meta-analysis of Park et al. (<xref ref-type="bibr" rid="CR58">58</xref>), which pooled data from over 5,000 patients and showed that hippocampal volumetry offers good diagnostic performance for AD (pooled sensitivity 82%, specificity 87%). Our approach surpasses these benchmarks, with both radiomic and deep features individually achieving higher external AUCs (~&#8201;89%), and the fused feature model markedly exceeding these values. The superior performance may be attributed to the exploitation of textural, shape, and high-dimensional contextual information unavailable in simple volumetric assessments. Additionally, our feature fusion approach addresses the limitation highlighted by Park et al. regarding the marginally lower performance of volumetry in early or prodromal stages.</p><p id="Par95">With respect to segmentation methodologies, our results are in agreement with recent advancements in deep learning-based hippocampal segmentation. Studies such as Hazarika et al. (<xref ref-type="bibr" rid="CR59">59</xref>) and Chen et al. (<xref ref-type="bibr" rid="CR60">60</xref>) have demonstrated the effectiveness of U-Net and U-Net-variant architectures, achieving segmentation Dice scores up to 96.5%. However, our comparative analysis shows that transformer-based models (MedT) outperform classical and hybrid CNN architectures, particularly in external datasets characterized by heterogeneity in scanner protocols and demographics. MedT&#8217;s robust boundary delineation and generalization ability likely contributed to the improved stability and reproducibility of extracted radiomic and deep features, as evidenced by the high ICCs observed in our stability assessment. Although we compare our results to previous radiomics and deep learning studies, these comparisons should be interpreted cautiously. Variations in datasets, imaging protocols, class definitions, and sample sizes across studies limit the validity of direct benchmarking. Future work using harmonized datasets or shared public benchmarks is necessary for rigorous comparative evaluation.</p><p id="Par96">It is important to emphasize that the majority of published radiomics and deep learning studies in Alzheimer&#8217;s disease classification focus on binary tasks&#8212;such as distinguishing AD from healthy controls or differentiating MCI from AD&#8212;rather than multi-class progression staging. These binary tasks typically involve higher inter-group contrast and lower analytical complexity. In contrast, our study addressed a more granular and clinically nuanced classification involving four distinct stages: Non-Demented, Very Mild Demented, Mild Demented, and Moderate Demented. This introduces additional diagnostic ambiguity, particularly in the transitional stages, and requires more sophisticated feature representations and modeling strategies. To the best of our knowledge, few studies have implemented such multi-class frameworks using hippocampal MRI, making our proposed approach both novel and technically challenging. This complexity underscores the importance of multimodal feature fusion and rigorous validation to ensure robustness and clinical utility in fine-grained AD staging.</p><p id="Par97">This study utilized T1-weighted MRI scans acquired under heterogeneous protocols, including varying scanner field strengths (1.5&#160;T and 3&#160;T), voxel resolutions, and vendor-specific parameters. Such variability may introduce non-biological variation that affects segmentation and classification. To address this, we applied ComBat harmonization to all feature sets to minimize site-specific biases while preserving biological signals. Moreover, performance was consistent across centers with different scanner types, indicating that the proposed framework is robust to acquisition-related variability. Nonetheless, future studies may benefit from protocol standardization or scanner-specific fine-tuning to further enhance generalizability.</p></sec></sec><sec id="Sec53"><title>Limitations and future studies</title><p id="Par98">While our study presents a robust and comprehensive framework for classifying AD stages based on multimodal hippocampal imaging features, there are several promising directions for future work. Although our model achieved high generalizability through multi-center validation, prospective validation in clinical settings would further strengthen its translational applicability. Additionally, incorporating functional and molecular imaging modalities such as PET and fMRI, or emerging blood-based biomarkers, may further enhance predictive performance and biological interpretability. Future studies could also explore longitudinal modeling to capture disease progression dynamics over time, which is critical for therapeutic planning. Moreover, evaluating the framework&#8217;s performance across diverse ethnic populations and healthcare systems would support broader deployment. While our integration of interpretability methods improves transparency, expanding explainable AI tools specifically tailored to neurodegenerative disorders could enhance clinician trust. Thus, while our framework is both methodologically and clinically rigorous, these extensions represent valuable opportunities for continued advancement.</p></sec><sec id="Sec54"><title>Conclusion</title><p id="Par99">This study introduced a hybrid, interpretable framework for Alzheimer&#8217;s disease stage classification using hippocampal MRI, integrating radiomic, deep, and clinical features. Leveraging transformer-based segmentation and LSTM with attention for deep feature extraction, the model achieved state-of-the-art performance. Rigorous internal and external validation demonstrated excellent generalizability. Feature-level fusion significantly improved diagnostic accuracy across all stages. SHAP analysis and predictive nomograms ensured clinical interpretability. Comparative analyses confirmed superior performance over existing methods. These findings support the utility of advanced hippocampal imaging analytics for early and precise AD diagnosis. The framework offers a scalable, transparent, and effective tool for real-world deployment.</p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not Applicable.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Conceptualization, methodology, supervision, project administration, and writing&#8212;review and editing: Guang Zhang; Formal analysis, investigation, and writing&#8212;original draft preparation: Wenqi Hu, Qiaohui Du, Lisi Wei, Dawei Wang. All authors have read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by the Shandong Provincial Natural Science Foundation [grant number: ZR2023QG014].</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>The datasets generated and/or analyzed during the current study are not publicly available but are available from the corresponding author upon reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par100">Not applicable.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Competing interests</title><p id="Par101">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tahami Monfared</surname><given-names>AA</given-names></name><name name-style="western"><surname>Byrnes</surname><given-names>MJ</given-names></name><name name-style="western"><surname>White</surname><given-names>LA</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name></person-group><article-title>Alzheimer&#8217;s disease: epidemiology and clinical progression</article-title><source>Neurol Ther</source><year>2022</year><volume>11</volume><issue>2</issue><fpage>553</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1007/s40120-022-00338-8</pub-id><pub-id pub-id-type="pmid">35286590</pub-id><pub-id pub-id-type="pmcid">PMC9095793</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Tahami Monfared AA, Byrnes MJ, White LA, Zhang Q. Alzheimer&#8217;s disease: epidemiology and clinical progression. Neurol Ther. 2022;11(2):553&#8211;69.<pub-id pub-id-type="pmid">35286590</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40120-022-00338-8</pub-id><pub-id pub-id-type="pmcid">PMC9095793</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rallabandi</surname><given-names>VPS</given-names></name><name name-style="western"><surname>Seetharaman</surname><given-names>K</given-names></name></person-group><article-title>Classification of cognitively normal controls, mild cognitive impairment and Alzheimer&#8217;s disease using transfer learning approach</article-title><source>Biomed Signal Process Control</source><year>2023</year><volume>79</volume><fpage>104092</fpage><pub-id pub-id-type="doi">10.1016/j.bspc.2022.104092</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Rallabandi VPS, Seetharaman K. Classification of cognitively normal controls, mild cognitive impairment and Alzheimer&#8217;s disease using transfer learning approach. Biomed Signal Process Control. 2023;79:104092.</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edmonds</surname><given-names>EC</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>KR</given-names></name><name name-style="western"><surname>Rapcsak</surname><given-names>SZ</given-names></name><name name-style="western"><surname>Lindemer</surname><given-names>SL</given-names></name><name name-style="western"><surname>Delano-Wood</surname><given-names>L</given-names></name><name name-style="western"><surname>Salmon</surname><given-names>DP</given-names></name><etal/></person-group><article-title>Data-driven classification of cognitively normal and mild cognitive impairment subtypes predicts progression in the NACC dataset</article-title><source>Alzheimers Dement</source><year>2024</year><volume>20</volume><issue>5</issue><fpage>3442</fpage><lpage>3454</lpage><pub-id pub-id-type="doi">10.1002/alz.13793</pub-id><pub-id pub-id-type="pmid">38574399</pub-id><pub-id pub-id-type="pmcid">PMC11095435</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Edmonds EC, Thomas KR, Rapcsak SZ, Lindemer SL, Delano-Wood L, Salmon DP, et al. Data-driven classification of cognitively normal and mild cognitive impairment subtypes predicts progression in the NACC dataset. Alzheimers Dement. 2024;20(5):3442&#8211;54.<pub-id pub-id-type="pmid">38574399</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13793</pub-id><pub-id pub-id-type="pmcid">PMC11095435</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tahami Monfared</surname><given-names>AA</given-names></name><name name-style="western"><surname>Phan</surname><given-names>NTN</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>I</given-names></name><name name-style="western"><surname>Mauskopf</surname><given-names>J</given-names></name><name name-style="western"><surname>Cho</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>A systematic review of clinical practice guidelines for Alzheimer&#8217;s disease and strategies for future advancements</article-title><source>Neurol Ther</source><year>2023</year><volume>12</volume><issue>4</issue><fpage>1257</fpage><lpage>1284</lpage><pub-id pub-id-type="doi">10.1007/s40120-023-00504-6</pub-id><pub-id pub-id-type="pmid">37261607</pub-id><pub-id pub-id-type="pmcid">PMC10310649</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Tahami Monfared AA, Phan NTN, Pearson I, Mauskopf J, Cho M, Zhang Q, et al. A systematic review of clinical practice guidelines for Alzheimer&#8217;s disease and strategies for future advancements. Neurol Ther. 2023;12(4):1257&#8211;84.<pub-id pub-id-type="pmid">37261607</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40120-023-00504-6</pub-id><pub-id pub-id-type="pmcid">PMC10310649</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Flier</surname><given-names>WM</given-names></name><name name-style="western"><surname>de Vugt</surname><given-names>ME</given-names></name><name name-style="western"><surname>Smets</surname><given-names>EMA</given-names></name><name name-style="western"><surname>Blom</surname><given-names>M</given-names></name><name name-style="western"><surname>Teunissen</surname><given-names>CE</given-names></name></person-group><article-title>Towards a future where Alzheimer&#8217;s disease pathology is stopped before the onset of dementia</article-title><source>Nat Aging</source><year>2023</year><volume>3</volume><issue>5</issue><fpage>494</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1038/s43587-023-00404-2</pub-id><pub-id pub-id-type="pmid">37202515</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">van der Flier WM, de Vugt ME, Smets EMA, Blom M, Teunissen CE. Towards a future where Alzheimer&#8217;s disease pathology is stopped before the onset of dementia. Nat Aging. 2023;3(5):494&#8211;505.<pub-id pub-id-type="pmid">37202515</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43587-023-00404-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galvin</surname><given-names>JE</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P</given-names></name><name name-style="western"><surname>Langbaum</surname><given-names>JB</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>E</given-names></name><name name-style="western"><surname>Sabbagh</surname><given-names>M</given-names></name><name name-style="western"><surname>Stefanacci</surname><given-names>R</given-names></name><etal/></person-group><article-title>Early stages of Alzheimer&#8217;s disease: evolving the care team for optimal patient management</article-title><source>Front Neurol</source><year>2021</year><volume>11</volume><fpage>592302</fpage><pub-id pub-id-type="doi">10.3389/fneur.2020.592302</pub-id><pub-id pub-id-type="pmid">33551954</pub-id><pub-id pub-id-type="pmcid">PMC7863984</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Galvin JE, Aisen P, Langbaum JB, Rodriguez E, Sabbagh M, Stefanacci R, et al. Early stages of Alzheimer&#8217;s disease: evolving the care team for optimal patient management. Front Neurol. 2021;11:592302.<pub-id pub-id-type="pmid">33551954</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2020.592302</pub-id><pub-id pub-id-type="pmcid">PMC7863984</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Babcock</surname><given-names>KR</given-names></name><name name-style="western"><surname>Page</surname><given-names>JS</given-names></name><name name-style="western"><surname>Fallon</surname><given-names>JR</given-names></name><name name-style="western"><surname>Webb</surname><given-names>AE</given-names></name></person-group><article-title>Adult hippocampal neurogenesis in aging and Alzheimer&#8217;s disease</article-title><source>Stem cell reports</source><year>2021</year><volume>16</volume><issue>4</issue><fpage>681</fpage><lpage>693</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2021.01.019</pub-id><pub-id pub-id-type="pmid">33636114</pub-id><pub-id pub-id-type="pmcid">PMC8072031</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Babcock KR, Page JS, Fallon JR, Webb AE. Adult hippocampal neurogenesis in aging and Alzheimer&#8217;s disease. Stem cell reports. 2021;16(4):681&#8211;93.<pub-id pub-id-type="pmid">33636114</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.stemcr.2021.01.019</pub-id><pub-id pub-id-type="pmcid">PMC8072031</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rao</surname><given-names>YL</given-names></name><name name-style="western"><surname>Ganaraja</surname><given-names>B</given-names></name><name name-style="western"><surname>Murlimanju</surname><given-names>BV</given-names></name><name name-style="western"><surname>Joy</surname><given-names>T</given-names></name><name name-style="western"><surname>Krishnamurthy</surname><given-names>A</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>A</given-names></name></person-group><article-title>Hippocampus and its involvement in Alzheimer&#8217;s disease: a review</article-title><source>3 Biotech</source><year>2022</year><volume>12</volume><issue>2</issue><fpage>55</fpage><pub-id pub-id-type="doi">10.1007/s13205-022-03123-4</pub-id><pub-id pub-id-type="pmid">35116217</pub-id><pub-id pub-id-type="pmcid">PMC8807768</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Rao YL, Ganaraja B, Murlimanju BV, Joy T, Krishnamurthy A, Agrawal A. Hippocampus and its involvement in Alzheimer&#8217;s disease: a review. 3 Biotech. 2022;12(2):55.<pub-id pub-id-type="pmid">35116217</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13205-022-03123-4</pub-id><pub-id pub-id-type="pmcid">PMC8807768</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Oostveen</surname><given-names>WM</given-names></name><name name-style="western"><surname>de Lange</surname><given-names>ECM</given-names></name></person-group><article-title>Imaging techniques in Alzheimer&#8217;s disease: a review of applications in early diagnosis and longitudinal monitoring</article-title><source>Int J Mol Sci</source><year>2021</year><volume>22</volume><issue>4</issue><fpage>2110</fpage><pub-id pub-id-type="doi">10.3390/ijms22042110</pub-id><pub-id pub-id-type="pmid">33672696</pub-id><pub-id pub-id-type="pmcid">PMC7924338</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">van Oostveen WM, de Lange ECM. Imaging techniques in Alzheimer&#8217;s disease: a review of applications in early diagnosis and longitudinal monitoring. Int J Mol Sci. 2021;22(4):2110.<pub-id pub-id-type="pmid">33672696</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms22042110</pub-id><pub-id pub-id-type="pmcid">PMC7924338</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>X</given-names></name><name name-style="western"><surname>Meier</surname><given-names>M</given-names></name><name name-style="western"><surname>Pruessner</surname><given-names>J</given-names></name></person-group><article-title>Challenges and opportunities of diagnostic markers of Alzheimer&#8217;s disease based on structural magnetic resonance imaging</article-title><source>Brain Behav</source><year>2023</year><volume>13</volume><issue>3</issue><fpage>e2925</fpage><pub-id pub-id-type="doi">10.1002/brb3.2925</pub-id><pub-id pub-id-type="pmid">36795041</pub-id><pub-id pub-id-type="pmcid">PMC10013953</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Hu X, Meier M, Pruessner J. Challenges and opportunities of diagnostic markers of Alzheimer&#8217;s disease based on structural magnetic resonance imaging. Brain Behav. 2023;13(3):e2925.<pub-id pub-id-type="pmid">36795041</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/brb3.2925</pub-id><pub-id pub-id-type="pmcid">PMC10013953</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nazir</surname><given-names>A</given-names></name><name name-style="western"><surname>Assad</surname><given-names>A</given-names></name><name name-style="western"><surname>Hussain</surname><given-names>A</given-names></name><name name-style="western"><surname>Singh</surname><given-names>M</given-names></name></person-group><article-title>Alzheimer&#8217;s disease diagnosis using deep learning techniques: datasets, challenges, research gaps and future directions</article-title><source>Int J Syst Assur Eng Manag</source><year>2024</year><volume>23</volume><fpage>1</fpage><lpage>35</lpage></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Nazir A, Assad A, Hussain A, Singh M. Alzheimer&#8217;s disease diagnosis using deep learning techniques: datasets, challenges, research gaps and future directions. Int J Syst Assur Eng Manag. 2024;23:1&#8211;35.</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kobets</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Alavi</surname><given-names>SAN</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Castillo</surname><given-names>A</given-names></name><name name-style="western"><surname>Young</surname><given-names>D</given-names></name><name name-style="western"><surname>Minuti</surname><given-names>A</given-names></name><etal/></person-group><article-title>Volumetric segmentation in the context of posterior fossa-related pathologies: a systematic review</article-title><source>Neurosurg Rev</source><year>2024</year><volume>47</volume><issue>1</issue><fpage>170</fpage><pub-id pub-id-type="doi">10.1007/s10143-024-02366-4</pub-id><pub-id pub-id-type="pmid">38637466</pub-id><pub-id pub-id-type="pmcid">PMC11026186</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Kobets AJ, Alavi SAN, Ahmad SJ, Castillo A, Young D, Minuti A, et al. Volumetric segmentation in the context of posterior fossa-related pathologies: a systematic review. Neurosurg Rev. 2024;47(1):170.<pub-id pub-id-type="pmid">38637466</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10143-024-02366-4</pub-id><pub-id pub-id-type="pmcid">PMC11026186</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andrews</surname><given-names>M</given-names></name><name name-style="western"><surname>Di Ieva</surname><given-names>A</given-names></name></person-group><article-title>Artificial intelligence for brain neuroanatomical segmentation in magnetic resonance imaging: a literature review</article-title><source>J Clin Neurosci</source><year>2025</year><volume>134</volume><fpage>111073</fpage><pub-id pub-id-type="doi">10.1016/j.jocn.2025.111073</pub-id><pub-id pub-id-type="pmid">39879724</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Andrews M, Di Ieva A. Artificial intelligence for brain neuroanatomical segmentation in magnetic resonance imaging: a literature review. J Clin Neurosci. 2025;134:111073.<pub-id pub-id-type="pmid">39879724</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jocn.2025.111073</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Darrault</surname><given-names>F</given-names></name><name name-style="western"><surname>Dannhoff</surname><given-names>G</given-names></name><name name-style="western"><surname>Chauvel</surname><given-names>M</given-names></name><name name-style="western"><surname>Delmaire</surname><given-names>T</given-names></name><name name-style="western"><surname>Louchez</surname><given-names>S</given-names></name><name name-style="western"><surname>Poupon</surname><given-names>C</given-names></name><etal/></person-group><article-title>A road map to manual segmentation of cerebral structures</article-title><source>J Anat</source><year>2025</year><volume>246</volume><issue>5</issue><fpage>819</fpage><lpage>828</lpage><pub-id pub-id-type="doi">10.1111/joa.14167</pub-id><pub-id pub-id-type="pmid">39465613</pub-id><pub-id pub-id-type="pmcid">PMC11996699</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Darrault F, Dannhoff G, Chauvel M, Delmaire T, Louchez S, Poupon C, et al. A road map to manual segmentation of cerebral structures. J Anat. 2025;246(5):819&#8211;28.<pub-id pub-id-type="pmid">39465613</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/joa.14167</pub-id><pub-id pub-id-type="pmcid">PMC11996699</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poiret</surname><given-names>C</given-names></name><name name-style="western"><surname>Bouyeure</surname><given-names>A</given-names></name><name name-style="western"><surname>Patil</surname><given-names>S</given-names></name><name name-style="western"><surname>Grigis</surname><given-names>A</given-names></name><name name-style="western"><surname>Duchesnay</surname><given-names>E</given-names></name><name name-style="western"><surname>Faillot</surname><given-names>M</given-names></name><etal/></person-group><article-title>A fast and robust hippocampal subfields segmentation: HSF revealing lifespan volumetric dynamics</article-title><source>Front Neuroinform</source><year>2023</year><volume>17</volume><fpage>1130845</fpage><pub-id pub-id-type="doi">10.3389/fninf.2023.1130845</pub-id><pub-id pub-id-type="pmid">37396459</pub-id><pub-id pub-id-type="pmcid">PMC10308024</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Poiret C, Bouyeure A, Patil S, Grigis A, Duchesnay E, Faillot M, et al. A fast and robust hippocampal subfields segmentation: HSF revealing lifespan volumetric dynamics. Front Neuroinform. 2023;17:1130845.<pub-id pub-id-type="pmid">37396459</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fninf.2023.1130845</pub-id><pub-id pub-id-type="pmcid">PMC10308024</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeKraker</surname><given-names>J</given-names></name><name name-style="western"><surname>Haast</surname><given-names>RAM</given-names></name><name name-style="western"><surname>Yousif</surname><given-names>MD</given-names></name><name name-style="western"><surname>Karat</surname><given-names>B</given-names></name><name name-style="western"><surname>Lau</surname><given-names>JC</given-names></name><name name-style="western"><surname>K&#246;hler</surname><given-names>S</given-names></name><etal/></person-group><article-title>Automated hippocampal unfolding for morphometry and subfield segmentation with HippUnfold</article-title><source>Elife</source><year>2022</year><volume>11</volume><fpage>e77945</fpage><pub-id pub-id-type="doi">10.7554/eLife.77945</pub-id><pub-id pub-id-type="pmid">36519725</pub-id><pub-id pub-id-type="pmcid">PMC9831605</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">DeKraker J, Haast RAM, Yousif MD, Karat B, Lau JC, K&#246;hler S, et al. Automated hippocampal unfolding for morphometry and subfield segmentation with HippUnfold. Elife. 2022;11:e77945.<pub-id pub-id-type="pmid">36519725</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7554/eLife.77945</pub-id><pub-id pub-id-type="pmcid">PMC9831605</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Puzio</surname><given-names>T</given-names></name><name name-style="western"><surname>Matera</surname><given-names>K</given-names></name><name name-style="western"><surname>Karwowski</surname><given-names>J</given-names></name><name name-style="western"><surname>Piwnik</surname><given-names>J</given-names></name><name name-style="western"><surname>Bia&#322;kowski</surname><given-names>S</given-names></name><name name-style="western"><surname>Podyma</surname><given-names>M</given-names></name><etal/></person-group><article-title>Deep learning-based automatic segmentation of brain structures on MRI: a test-retest reproducibility analysis</article-title><source>Comput Struct Biotechnol J</source><year>2025</year><volume>28</volume><fpage>128</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/j.csbj.2025.04.007</pub-id><pub-id pub-id-type="pmid">40271109</pub-id><pub-id pub-id-type="pmcid">PMC12018026</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Puzio T, Matera K, Karwowski J, Piwnik J, Bia&#322;kowski S, Podyma M, et al. Deep learning-based automatic segmentation of brain structures on MRI: a test-retest reproducibility analysis. Comput Struct Biotechnol J. 2025;28:128&#8211;40.<pub-id pub-id-type="pmid">40271109</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.csbj.2025.04.007</pub-id><pub-id pub-id-type="pmcid">PMC12018026</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Yan</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Artificial intelligence-based diagnosis of Alzheimer&#8217;s disease with brain MRI images</article-title><source>Eur J Radiol</source><year>2023</year><volume>165</volume><fpage>110934</fpage><pub-id pub-id-type="doi">10.1016/j.ejrad.2023.110934</pub-id><pub-id pub-id-type="pmid">37354773</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Yao Z, Wang H, Yan W, Wang Z, Zhang W, Wang Z, et al. Artificial intelligence-based diagnosis of Alzheimer&#8217;s disease with brain MRI images. Eur J Radiol. 2023;165:110934.<pub-id pub-id-type="pmid">37354773</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejrad.2023.110934</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aleid</surname><given-names>AM</given-names></name><name name-style="western"><surname>Al Dakkan</surname><given-names>M</given-names></name><name name-style="western"><surname>Alharthi</surname><given-names>KA</given-names></name><name name-style="western"><surname>Alsahli</surname><given-names>MK</given-names></name><name name-style="western"><surname>Alshammari</surname><given-names>FH</given-names></name><name name-style="western"><surname>johar hasan Al-anbar M, </surname></name><etal/></person-group><article-title>Advances in functional MRI: applications in neurological and psychiatric disorders</article-title><source>J Int Cris Risk Commun Res</source><year>2024</year><volume>7</volume><issue>S11</issue><fpage>691</fpage></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Aleid AM, Al Dakkan M, Alharthi KA, Alsahli MK, Alshammari FH, johar hasan Al-anbar M, et al. Advances in functional MRI: applications in neurological and psychiatric disorders. J Int Cris Risk Commun Res. 2024;7(S11):691.</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mayerhoefer</surname><given-names>ME</given-names></name><name name-style="western"><surname>Materka</surname><given-names>A</given-names></name><name name-style="western"><surname>Langs</surname><given-names>G</given-names></name><name name-style="western"><surname>H&#228;ggstr&#246;m</surname><given-names>I</given-names></name><name name-style="western"><surname>Szczypi&#324;ski</surname><given-names>P</given-names></name><name name-style="western"><surname>Gibbs</surname><given-names>P</given-names></name><etal/></person-group><article-title>Introduction to radiomics</article-title><source>J Nucl Med</source><year>2020</year><volume>61</volume><issue>4</issue><fpage>488</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.2967/jnumed.118.222893</pub-id><pub-id pub-id-type="pmid">32060219</pub-id><pub-id pub-id-type="pmcid">PMC9374044</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Mayerhoefer ME, Materka A, Langs G, H&#228;ggstr&#246;m I, Szczypi&#324;ski P, Gibbs P, et al. Introduction to radiomics. J Nucl Med. 2020;61(4):488&#8211;95.<pub-id pub-id-type="pmid">32060219</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.118.222893</pub-id><pub-id pub-id-type="pmcid">PMC9374044</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rizzo</surname><given-names>S</given-names></name><name name-style="western"><surname>Botta</surname><given-names>F</given-names></name><name name-style="western"><surname>Raimondi</surname><given-names>S</given-names></name><name name-style="western"><surname>Origgi</surname><given-names>D</given-names></name><name name-style="western"><surname>Fanciullo</surname><given-names>C</given-names></name><name name-style="western"><surname>Morganti</surname><given-names>AG</given-names></name><etal/></person-group><article-title>Radiomics: the facts and the challenges of image analysis</article-title><source>Eur Radiol Exp</source><year>2018</year><volume>2</volume><issue>1</issue><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1186/s41747-018-0068-z</pub-id><pub-id pub-id-type="pmid">30426318</pub-id><pub-id pub-id-type="pmcid">PMC6234198</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Rizzo S, Botta F, Raimondi S, Origgi D, Fanciullo C, Morganti AG, et al. Radiomics: the facts and the challenges of image analysis. Eur Radiol Exp. 2018;2(1):1&#8211;8.<pub-id pub-id-type="pmid">30426318</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s41747-018-0068-z</pub-id><pub-id pub-id-type="pmcid">PMC6234198</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Das</surname><given-names>SR</given-names></name><name name-style="western"><surname>Ilesanmi</surname><given-names>A</given-names></name><name name-style="western"><surname>Wolk</surname><given-names>DA</given-names></name><name name-style="western"><surname>Gee</surname><given-names>JC</given-names></name></person-group><article-title>Beyond macrostructure: is there a role for radiomics analysis in neuroimaging?</article-title><source>Magn Reson Med Sci</source><year>2024</year><volume>23</volume><issue>3</issue><fpage>367</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.2463/mrms.rev.2024-0053</pub-id><pub-id pub-id-type="pmid">38880615</pub-id><pub-id pub-id-type="pmcid">PMC11234947</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Das SR, Ilesanmi A, Wolk DA, Gee JC. Beyond macrostructure: is there a role for radiomics analysis in neuroimaging? Magn Reson Med Sci. 2024;23(3):367&#8211;76.<pub-id pub-id-type="pmid">38880615</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2463/mrms.rev.2024-0053</pub-id><pub-id pub-id-type="pmcid">PMC11234947</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>M</given-names></name><name name-style="western"><surname>Feng</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhi</surname><given-names>H</given-names></name><name name-style="western"><surname>Hou</surname><given-names>L</given-names></name><name name-style="western"><surname>Feng</surname><given-names>D</given-names></name></person-group><article-title>Machine learning-based radiomics in neurodegenerative and cerebrovascular disease</article-title><source>MedComm</source><year>2024</year><volume>5</volume><issue>11</issue><fpage>e778</fpage><pub-id pub-id-type="doi">10.1002/mco2.778</pub-id><pub-id pub-id-type="pmid">39473906</pub-id><pub-id pub-id-type="pmcid">PMC11518692</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Shi M, Feng X, Zhi H, Hou L, Feng D. Machine learning-based radiomics in neurodegenerative and cerebrovascular disease. MedComm. 2024;5(11):e778.<pub-id pub-id-type="pmid">39473906</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mco2.778</pub-id><pub-id pub-id-type="pmcid">PMC11518692</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Javanmardi A, Hosseinzadeh M, Hajianfar G, Nabizadeh AH, Rezaeijo SM, Rahmim A, et al. Multi-modality fusion coupled with deep learning for improved outcome prediction in head and neck cancer. In: Medical Imaging 2022: Image Processing. SPIE; 2022. p. 664&#8211;8.</mixed-citation></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Fatan</surname><given-names>M</given-names></name><name name-style="western"><surname>Hosseinzadeh</surname><given-names>M</given-names></name><name name-style="western"><surname>Askari</surname><given-names>D</given-names></name><name name-style="western"><surname>Sheikhi</surname><given-names>H</given-names></name><name name-style="western"><surname>Rezaeijo</surname><given-names>SM</given-names></name><name name-style="western"><surname>Salmanpour</surname><given-names>MR</given-names></name></person-group><person-group person-group-type="editor"><name name-style="western"><surname>Andrearczyk</surname><given-names>V</given-names></name><name name-style="western"><surname>Oreiller</surname><given-names>V</given-names></name><name name-style="western"><surname>Hatt</surname><given-names>M</given-names></name><name name-style="western"><surname>Depeursinge</surname><given-names>A</given-names></name></person-group><article-title>Fusion-based head and neck tumor segmentation and survival prediction using robust deep learning techniques and advanced hybrid machine learning systems bt - head and neck tumor segmentation and outcome prediction</article-title><source>Springer International Publishing</source><year>2022</year><publisher-name>Cham</publisher-name></element-citation><mixed-citation id="mc-CR25" publication-type="book">Fatan M, Hosseinzadeh M, Askari D, Sheikhi H, Rezaeijo SM, Salmanpour MR. Fusion-based head and neck tumor segmentation and survival prediction using robust deep learning techniques and advanced hybrid machine learning systems bt - head and neck tumor segmentation and outcome prediction. In: Andrearczyk V, Oreiller V, Hatt M, Depeursinge A, editors. Springer International Publishing. Cham; 2022.</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bijari</surname><given-names>S</given-names></name><name name-style="western"><surname>Sayfollahi</surname><given-names>S</given-names></name><name name-style="western"><surname>Mardokh-Rouhani</surname><given-names>S</given-names></name><name name-style="western"><surname>Bijari</surname><given-names>S</given-names></name><name name-style="western"><surname>Moradian</surname><given-names>S</given-names></name><name name-style="western"><surname>Zahiri</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Radiomics and deep features: robust classification of brain hemorrhages and reproducibility analysis using a 3D autoencoder neural network</article-title><source>Bioengineering</source><year>2024</year><volume>11</volume><issue>7</issue><fpage>643</fpage><pub-id pub-id-type="doi">10.3390/bioengineering11070643</pub-id><pub-id pub-id-type="pmid">39061725</pub-id><pub-id pub-id-type="pmcid">PMC11273742</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Bijari S, Sayfollahi S, Mardokh-Rouhani S, Bijari S, Moradian S, Zahiri Z, et al. Radiomics and deep features: robust classification of brain hemorrhages and reproducibility analysis using a 3D autoencoder neural network. Bioengineering. 2024;11(7):643.<pub-id pub-id-type="pmid">39061725</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/bioengineering11070643</pub-id><pub-id pub-id-type="pmcid">PMC11273742</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">Rezaeijo SM, Harimi A, Salmanpour MR. Fusion-based automated segmentation in head and neck cancer via advance deep learning techniques. In: 3D Head and Neck Tumor Segmentation in PET/CT Challenge. Springer; 2022. p. 70&#8211;6.</mixed-citation></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bijari</surname><given-names>S</given-names></name><name name-style="western"><surname>Rezaeijo</surname><given-names>SM</given-names></name><name name-style="western"><surname>Sayfollahi</surname><given-names>S</given-names></name><name name-style="western"><surname>Rahimnezhad</surname><given-names>A</given-names></name><name name-style="western"><surname>Heydarheydari</surname><given-names>S</given-names></name></person-group><article-title>Development and validation of a robust MRI-based nomogram incorporating radiomics and deep features for preoperative glioma grading: a multi-center study</article-title><source>Quant Imaging Med Surg</source><year>2025</year><volume>15</volume><issue>2</issue><fpage>1121138</fpage><lpage>1125138</lpage><pub-id pub-id-type="doi">10.21037/qims-24-1543</pub-id><pub-id pub-id-type="pmcid">PMC11847178</pub-id><pub-id pub-id-type="pmid">39995745</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Bijari S, Rezaeijo SM, Sayfollahi S, Rahimnezhad A, Heydarheydari S. Development and validation of a robust MRI-based nomogram incorporating radiomics and deep features for preoperative glioma grading: a multi-center study. Quant Imaging Med Surg. 2025;15(2):1121138&#8211;5138.<pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/qims-24-1543</pub-id><pub-id pub-id-type="pmcid">PMC11847178</pub-id><pub-id pub-id-type="pmid">39995745</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fei</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yang</surname><given-names>F</given-names></name><name name-style="western"><surname>Tsui</surname><given-names>KL</given-names></name></person-group><article-title>A deep attention-assisted and memory-augmented temporal convolutional network based model for rapid lithium-ion battery remaining useful life predictions with limited data</article-title><source>J Energy Storage</source><year>2023</year><volume>62</volume><fpage>106903</fpage><pub-id pub-id-type="doi">10.1016/j.est.2023.106903</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Fei Z, Zhang Z, Yang F, Tsui KL. A deep attention-assisted and memory-augmented temporal convolutional network based model for rapid lithium-ion battery remaining useful life predictions with limited data. J Energy Storage. 2023;62:106903.</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tao</surname><given-names>L</given-names></name><name name-style="western"><surname>He</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>D</given-names></name></person-group><article-title>A multiscale long short-term memory model with attention mechanism for improving monthly precipitation prediction</article-title><source>J Hydrol</source><year>2021</year><volume>602</volume><fpage>126815</fpage><pub-id pub-id-type="doi">10.1016/j.jhydrol.2021.126815</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Tao L, He X, Li J, Yang D. A multiscale long short-term memory model with attention mechanism for improving monthly precipitation prediction. J Hydrol. 2021;602:126815.</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>CY</given-names></name><name name-style="western"><surname>Guo</surname><given-names>SM</given-names></name><name name-style="western"><surname>Lien</surname><given-names>JJJ</given-names></name><name name-style="western"><surname>Lin</surname><given-names>WT</given-names></name><name name-style="western"><surname>Liu</surname><given-names>YS</given-names></name><name name-style="western"><surname>Lai</surname><given-names>CH</given-names></name><etal/></person-group><article-title>Combined model integrating deep learning, radiomics, and clinical data to classify lung nodules at chest CT</article-title><source>Radiol Med</source><year>2024</year><volume>129</volume><issue>1</issue><fpage>56</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1007/s11547-023-01730-6</pub-id><pub-id pub-id-type="pmid">37971691</pub-id><pub-id pub-id-type="pmcid">PMC10808169</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Lin CY, Guo SM, Lien JJJ, Lin WT, Liu YS, Lai CH, et al. Combined model integrating deep learning, radiomics, and clinical data to classify lung nodules at chest CT. Radiol Med. 2024;129(1):56&#8211;69.<pub-id pub-id-type="pmid">37971691</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11547-023-01730-6</pub-id><pub-id pub-id-type="pmcid">PMC10808169</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ning</surname><given-names>Z</given-names></name><name name-style="western"><surname>Luo</surname><given-names>J</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Cai</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Multi-modal magnetic resonance imaging-based grading analysis for gliomas by integrating radiomics and deep features</article-title><source>Ann Transl Med</source><year>2021</year><pub-id pub-id-type="doi">10.21037/atm-20-4076</pub-id><pub-id pub-id-type="pmid">33708925</pub-id><pub-id pub-id-type="pmcid">PMC7944310</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Ning Z, Luo J, Xiao Q, Cai L, Chen Y, Yu X, et al. Multi-modal magnetic resonance imaging-based grading analysis for gliomas by integrating radiomics and deep features. Ann Transl Med. 2021. 10.21037/atm-20-4076.<pub-id pub-id-type="pmid">33708925</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/atm-20-4076</pub-id><pub-id pub-id-type="pmcid">PMC7944310</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jafarpoor Nesheli</surname><given-names>S</given-names></name><name name-style="western"><surname>Sabet</surname><given-names>M</given-names></name><name name-style="western"><surname>Firoozi</surname><given-names>V</given-names></name><name name-style="western"><surname>Heydarheydari</surname><given-names>S</given-names></name><name name-style="western"><surname>Rezaeijo</surname><given-names>SM</given-names></name></person-group><article-title>Enhanced interpretability in breast cancer detection: combining Grad-CAM with selective layer freezing in deep learning</article-title><source>Int J Imaging Syst Technol</source><year>2025</year><volume>35</volume><issue>4</issue><fpage>e70151</fpage><pub-id pub-id-type="doi">10.1002/ima.70151</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Jafarpoor Nesheli S, Sabet M, Firoozi V, Heydarheydari S, Rezaeijo SM. Enhanced interpretability in breast cancer detection: combining Grad-CAM with selective layer freezing in deep learning. Int J Imaging Syst Technol. 2025;35(4):e70151.</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McDonnell</surname><given-names>K</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>F</given-names></name><name name-style="western"><surname>Sheehan</surname><given-names>B</given-names></name><name name-style="western"><surname>Masello</surname><given-names>L</given-names></name><name name-style="western"><surname>Castignani</surname><given-names>G</given-names></name></person-group><article-title>Deep learning in insurance: accuracy and model interpretability using TabNet</article-title><source>Expert Syst Appl</source><year>2023</year><volume>217</volume><fpage>119543</fpage><pub-id pub-id-type="doi">10.1016/j.eswa.2023.119543</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">McDonnell K, Murphy F, Sheehan B, Masello L, Castignani G. Deep learning in insurance: accuracy and model interpretability using TabNet. Expert Syst Appl. 2023;217:119543.</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>S</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>B</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Q</given-names></name></person-group><article-title>Radiomics and machine learning for predicting mycobacterial response to proteasome inhibition: a multi-center CT imaging study</article-title><source>J Radiat Res Appl Sci</source><year>2025</year><volume>18</volume><issue>3</issue><fpage>101628</fpage></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Tang S, Sheng B, Yang Q. Radiomics and machine learning for predicting mycobacterial response to proteasome inhibition: a multi-center CT imaging study. J Radiat Res Appl Sci. 2025;18(3):101628.</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>W</given-names></name><name name-style="western"><surname>Lu</surname><given-names>WW</given-names></name><name name-style="western"><surname>Qin</surname><given-names>XC</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>XY</given-names></name><name name-style="western"><surname>Wang</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Ultrasound-based deep learning radiomics nomogram for the assessment of lymphovascular invasion in invasive breast cancer: a multicenter study</article-title><source>Acad Radiol</source><year>2024</year><volume>31</volume><issue>10</issue><fpage>3917</fpage><lpage>3928</lpage><pub-id pub-id-type="doi">10.1016/j.acra.2024.04.010</pub-id><pub-id pub-id-type="pmid">38658211</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Zhang D, Zhou W, Lu WW, Qin XC, Zhang XY, Wang JL, et al. Ultrasound-based deep learning radiomics nomogram for the assessment of lymphovascular invasion in invasive breast cancer: a multicenter study. Acad Radiol. 2024;31(10):3917&#8211;28.<pub-id pub-id-type="pmid">38658211</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.acra.2024.04.010</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Y</given-names></name></person-group><article-title>Development and validation of an ultrasound-based radiomics nomogram for identifying HER2 status in patients with breast carcinoma</article-title><source>Diagnostics</source><year>2022</year><volume>12</volume><issue>12</issue><fpage>3130</fpage><pub-id pub-id-type="doi">10.3390/diagnostics12123130</pub-id><pub-id pub-id-type="pmid">36553137</pub-id><pub-id pub-id-type="pmcid">PMC9776855</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Guo Y, Wu J, Wang Y, Jin Y. Development and validation of an ultrasound-based radiomics nomogram for identifying HER2 status in patients with breast carcinoma. Diagnostics. 2022;12(12):3130.<pub-id pub-id-type="pmid">36553137</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/diagnostics12123130</pub-id><pub-id pub-id-type="pmcid">PMC9776855</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Duan</surname><given-names>J</given-names></name><name name-style="western"><surname>Deng</surname><given-names>H</given-names></name><name name-style="western"><surname>Han</surname><given-names>Z</given-names></name><name name-style="western"><surname>Gu</surname><given-names>J</given-names></name><name name-style="western"><surname>Yue</surname><given-names>NJ</given-names></name><etal/></person-group><article-title>Development and validation of a radiomics nomogram model for predicting postoperative recurrence in patients with esophageal squamous cell cancer who achieved pCR after neoadjuvant chemoradiotherapy followed by surgery</article-title><source>Front Oncol</source><year>2020</year><volume>10</volume><fpage>1398</fpage><pub-id pub-id-type="doi">10.3389/fonc.2020.01398</pub-id><pub-id pub-id-type="pmid">32850451</pub-id><pub-id pub-id-type="pmcid">PMC7431604</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Qiu Q, Duan J, Deng H, Han Z, Gu J, Yue NJ, et al. Development and validation of a radiomics nomogram model for predicting postoperative recurrence in patients with esophageal squamous cell cancer who achieved pCR after neoadjuvant chemoradiotherapy followed by surgery. Front Oncol. 2020;10:1398.<pub-id pub-id-type="pmid">32850451</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2020.01398</pub-id><pub-id pub-id-type="pmcid">PMC7431604</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huber</surname><given-names>M</given-names></name><name name-style="western"><surname>Schober</surname><given-names>P</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>S</given-names></name><name name-style="western"><surname>Luedi</surname><given-names>MM</given-names></name></person-group><article-title>Decision curve analysis confirms higher clinical utility of multi-domain versus single-domain prediction models in patients with open abdomen treatment for peritonitis</article-title><source>BMC Med Inform Decis Mak</source><year>2023</year><volume>23</volume><issue>1</issue><fpage>63</fpage><pub-id pub-id-type="doi">10.1186/s12911-023-02156-w</pub-id><pub-id pub-id-type="pmid">37024840</pub-id><pub-id pub-id-type="pmcid">PMC10078078</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Huber M, Schober P, Petersen S, Luedi MM. Decision curve analysis confirms higher clinical utility of multi-domain versus single-domain prediction models in patients with open abdomen treatment for peritonitis. BMC Med Inform Decis Mak. 2023;23(1):63.<pub-id pub-id-type="pmid">37024840</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12911-023-02156-w</pub-id><pub-id pub-id-type="pmcid">PMC10078078</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hozo</surname><given-names>I</given-names></name><name name-style="western"><surname>Guyatt</surname><given-names>G</given-names></name><name name-style="western"><surname>Djulbegovic</surname><given-names>B</given-names></name></person-group><article-title>Decision curve analysis based on summary data</article-title><source>J Eval Clin Pract</source><year>2024</year><volume>30</volume><issue>2</issue><fpage>281</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1111/jep.13945</pub-id><pub-id pub-id-type="pmid">38044860</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Hozo I, Guyatt G, Djulbegovic B. Decision curve analysis based on summary data. J Eval Clin Pract. 2024;30(2):281&#8211;329.<pub-id pub-id-type="pmid">38044860</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jep.13945</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yan</surname><given-names>M</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name><name name-style="western"><surname>Dekker</surname><given-names>A</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name><etal/></person-group><article-title>Radiomics and dosiomics signature from whole lung predicts radiation pneumonitis: a model development study with prospective external validation and decision-curve analysis</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2023</year><volume>115</volume><issue>3</issue><fpage>746</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2022.08.047</pub-id><pub-id pub-id-type="pmid">36031028</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Zhang Z, Wang Z, Yan M, Yu J, Dekker A, Zhao L, et al. Radiomics and dosiomics signature from whole lung predicts radiation pneumonitis: a model development study with prospective external validation and decision-curve analysis. Int J Radiat Oncol Biol Phys. 2023;115(3):746&#8211;58.<pub-id pub-id-type="pmid">36031028</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijrobp.2022.08.047</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Degtiar</surname><given-names>I</given-names></name><name name-style="western"><surname>Rose</surname><given-names>S</given-names></name></person-group><article-title>A review of generalizability and transportability</article-title><source>Annu Rev Stat Appl</source><year>2023</year><volume>10</volume><issue>1</issue><fpage>501</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1146/annurev-statistics-042522-103837</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Degtiar I, Rose S. A review of generalizability and transportability. Annu Rev Stat Appl. 2023;10(1):501&#8211;24.</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ektefaie</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shen</surname><given-names>A</given-names></name><name name-style="western"><surname>Bykova</surname><given-names>D</given-names></name><name name-style="western"><surname>Marin</surname><given-names>MG</given-names></name><name name-style="western"><surname>Zitnik</surname><given-names>M</given-names></name><name name-style="western"><surname>Farhat</surname><given-names>M</given-names></name></person-group><article-title>Evaluating generalizability of artificial intelligence models for molecular datasets</article-title><source>Nat Mach Intell</source><year>2024</year><volume>6</volume><issue>12</issue><fpage>1512</fpage><lpage>1524</lpage><pub-id pub-id-type="doi">10.1038/s42256-024-00931-6</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Ektefaie Y, Shen A, Bykova D, Marin MG, Zitnik M, Farhat M. Evaluating generalizability of artificial intelligence models for molecular datasets. Nat Mach Intell. 2024;6(12):1512&#8211;24.</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>CR</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K</given-names></name><name name-style="western"><surname>Carrillo</surname><given-names>MC</given-names></name><name name-style="western"><surname>Dunn</surname><given-names>B</given-names></name><name name-style="western"><surname>Haeberlein</surname><given-names>SB</given-names></name><etal/></person-group><article-title>National Institute on Aging&#8212;Alzheimer&#8217;s association (NIA-AA) research framework NIA-AA research framework: toward a biological definition of Alzheimer&#8217;s disease</article-title><source>Alzheimers Dement</source><year>2018</year><volume>14</volume><issue>4</issue><fpage>535</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2018.02.018</pub-id><pub-id pub-id-type="pmid">29653606</pub-id><pub-id pub-id-type="pmcid">PMC5958625</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. National Institute on Aging&#8212;Alzheimer&#8217;s association (NIA-AA) research framework NIA-AA research framework: toward a biological definition of Alzheimer&#8217;s disease. Alzheimers Dement. 2018;14(4):535&#8211;62.<pub-id pub-id-type="pmid">29653606</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2018.02.018</pub-id><pub-id pub-id-type="pmcid">PMC5958625</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lanct&#244;t</surname><given-names>KL</given-names></name><name name-style="western"><surname>Boada</surname><given-names>M</given-names></name><name name-style="western"><surname>Tariot</surname><given-names>PN</given-names></name><name name-style="western"><surname>Dabbous</surname><given-names>F</given-names></name><name name-style="western"><surname>Hahn-Pedersen</surname><given-names>J</given-names></name><name name-style="western"><surname>Udayachalerm</surname><given-names>S</given-names></name><etal/></person-group><article-title>Association between clinical dementia rating and clinical outcomes in Alzheimer&#8217;s disease</article-title><source>Alzheimer's &amp; Dementia Diagn Assess Dis Monitor</source><year>2024</year><volume>16</volume><issue>1</issue><fpage>e12522</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dad2.12522</pub-id><pub-id pub-id-type="pmcid">PMC10794857</pub-id><pub-id pub-id-type="pmid">38239329</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Lanct&#244;t KL, Boada M, Tariot PN, Dabbous F, Hahn-Pedersen J, Udayachalerm S, et al. Association between clinical dementia rating and clinical outcomes in Alzheimer&#8217;s disease. Alzheimer&#8217;s &amp; Dementia Diagn Assess Dis Monitor. 2024;16(1):e12522.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dad2.12522</pub-id><pub-id pub-id-type="pmcid">PMC10794857</pub-id><pub-id pub-id-type="pmid">38239329</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arevalo-Rodriguez</surname><given-names>I</given-names></name><name name-style="western"><surname>Smailagic</surname><given-names>N</given-names></name><etal/></person-group><article-title>Mini-Mental State Examination (MMSE) for the detection of Alzheimer&#8217;s disease and other dementias in people with mild cognitive impairment (MCI)</article-title><source>Cochrane Database Syst Rev</source><year>2015</year><volume>3</volume><fpage>34</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD010783.pub2</pub-id><pub-id pub-id-type="pmcid">PMC6464748</pub-id><pub-id pub-id-type="pmid">25740785</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Arevalo-Rodriguez I, Smailagic N, et al. Mini-Mental State Examination (MMSE) for the detection of Alzheimer&#8217;s disease and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2015;3:34.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD010783.pub2</pub-id><pub-id pub-id-type="pmcid">PMC6464748</pub-id><pub-id pub-id-type="pmid">25740785</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galasko</surname><given-names>D</given-names></name><name name-style="western"><surname>Klauber</surname><given-names>MR</given-names></name><name name-style="western"><surname>Hofstetter</surname><given-names>CR</given-names></name><name name-style="western"><surname>Salmon</surname><given-names>DP</given-names></name><name name-style="western"><surname>Lasker</surname><given-names>B</given-names></name><name name-style="western"><surname>Thal</surname><given-names>LJ</given-names></name></person-group><article-title>The mini-mental state examination in the early diagnosis of Alzheimer&#8217;s disease</article-title><source>Arch Neurol</source><year>1990</year><volume>47</volume><issue>1</issue><fpage>49</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1001/archneur.1990.00530010061020</pub-id><pub-id pub-id-type="pmid">2294894</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Galasko D, Klauber MR, Hofstetter CR, Salmon DP, Lasker B, Thal LJ. The mini-mental state examination in the early diagnosis of Alzheimer&#8217;s disease. Arch Neurol. 1990;47(1):49&#8211;52.<pub-id pub-id-type="pmid">2294894</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archneur.1990.00530010061020</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><mixed-citation publication-type="other">Ronneberger O, Fischer P, Brox T. U-net: Convolutional networks for biomedical image segmentation. In: International Conference on Medical image computing and computer-assisted intervention. Springer; 2015. p. 234&#8211;41.</mixed-citation></ref><ref id="CR49"><label>49.</label><mixed-citation publication-type="other">Isensee F, Petersen J, Klein A, Zimmerer D, Jaeger PF, Kohl S, et al. nnu-net: Self-adapting framework for u-net-based medical image segmentation. arXiv Prepr arXiv180910486. 2018</mixed-citation></ref><ref id="CR50"><label>50.</label><mixed-citation publication-type="other">Cao H, Wang Y, Chen J, Jiang D, Zhang X, Tian Q, et al. Swin-unet: Unet-like pure transformer for medical image segmentation. In: European conference on computer vision. Springer; 2022. p. 205&#8211;18.</mixed-citation></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qi</surname><given-names>Q</given-names></name><name name-style="western"><surname>Lin</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name><name name-style="western"><surname>Xue</surname><given-names>C</given-names></name></person-group><article-title>MEDT: using multimodal encoding-decoding network as in transformer for multimodal sentiment analysis</article-title><source>IEEE Access</source><year>2022</year><volume>10</volume><fpage>28750</fpage><lpage>28759</lpage><pub-id pub-id-type="doi">10.1109/ACCESS.2022.3157712</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Qi Q, Lin L, Zhang R, Xue C. MEDT: using multimodal encoding-decoding network as in transformer for multimodal sentiment analysis. IEEE Access. 2022;10:28750&#8211;9.</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salmanpour</surname><given-names>MR</given-names></name><name name-style="western"><surname>Hosseinzadeh</surname><given-names>M</given-names></name><name name-style="western"><surname>Rezaeijo</surname><given-names>SM</given-names></name><name name-style="western"><surname>Ashrafinia</surname><given-names>S</given-names></name><name name-style="western"><surname>Rahmim</surname><given-names>A</given-names></name></person-group><article-title>ViSERA: visualized &amp; standardized environment for radiomics analysis</article-title><source>Soc Nucl Med</source><year>2023</year><volume>12</volume><fpage>3</fpage></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Salmanpour MR, Hosseinzadeh M, Rezaeijo SM, Ashrafinia S, Rahmim A. ViSERA: visualized &amp; standardized environment for radiomics analysis. Soc Nucl Med. 2023;12:3.</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iman</surname><given-names>M</given-names></name><name name-style="western"><surname>Arabnia</surname><given-names>HR</given-names></name><name name-style="western"><surname>Rasheed</surname><given-names>K</given-names></name></person-group><article-title>A review of deep transfer learning and recent advancements</article-title><source>Technologies</source><year>2023</year><volume>11</volume><issue>2</issue><fpage>40</fpage><pub-id pub-id-type="doi">10.3390/technologies11020040</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Iman M, Arabnia HR, Rasheed K. A review of deep transfer learning and recent advancements. Technologies. 2023;11(2):40.</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>A</given-names></name><name name-style="western"><surname>Rauf</surname><given-names>Z</given-names></name><name name-style="western"><surname>Sohail</surname><given-names>A</given-names></name><name name-style="western"><surname>Khan</surname><given-names>AR</given-names></name><name name-style="western"><surname>Asif</surname><given-names>H</given-names></name><name name-style="western"><surname>Asif</surname><given-names>A</given-names></name><etal/></person-group><article-title>A survey of the vision transformers and their CNN-transformer based variants</article-title><source>Artif Intell Rev</source><year>2023</year><volume>56</volume><issue>Suppl 3</issue><fpage>2917</fpage><lpage>2970</lpage><pub-id pub-id-type="doi">10.1007/s10462-023-10595-0</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Khan A, Rauf Z, Sohail A, Khan AR, Asif H, Asif A, et al. A survey of the vision transformers and their CNN-transformer based variants. Artif Intell Rev. 2023;56(Suppl 3):2917&#8211;70.</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W</given-names></name><etal/></person-group><article-title>Radiomic features of the hippocampus for diagnosing early-onset and late-onset Alzheimer&#8217;s disease</article-title><source>Front Aging Neurosci</source><year>2022</year><volume>13</volume><fpage>789099</fpage><pub-id pub-id-type="doi">10.3389/fnagi.2021.789099</pub-id><pub-id pub-id-type="pmid">35153721</pub-id><pub-id pub-id-type="pmcid">PMC8826454</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Du Y, Zhang S, Fang Y, Qiu Q, Zhao L, Wei W, et al. Radiomic features of the hippocampus for diagnosing early-onset and late-onset Alzheimer&#8217;s disease. Front Aging Neurosci. 2022;13:789099.<pub-id pub-id-type="pmid">35153721</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2021.789099</pub-id><pub-id pub-id-type="pmcid">PMC8826454</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>TT</given-names></name><name name-style="western"><surname>Cao</surname><given-names>MH</given-names></name><name name-style="western"><surname>Yu</surname><given-names>JC</given-names></name><name name-style="western"><surname>Shi</surname><given-names>TY</given-names></name><name name-style="western"><surname>Mao</surname><given-names>XH</given-names></name><name name-style="western"><surname>Wei</surname><given-names>XY</given-names></name><etal/></person-group><article-title>T1-weighted imaging-based hippocampal radiomics in the diagnosis of Alzheimer&#8217;s disease</article-title><source>Acad Radiol</source><year>2024</year><volume>31</volume><issue>12</issue><fpage>5183</fpage><lpage>5192</lpage><pub-id pub-id-type="doi">10.1016/j.acra.2024.06.012</pub-id><pub-id pub-id-type="pmid">38902110</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Yin TT, Cao MH, Yu JC, Shi TY, Mao XH, Wei XY, et al. T1-weighted imaging-based hippocampal radiomics in the diagnosis of Alzheimer&#8217;s disease. Acad Radiol. 2024;31(12):5183&#8211;92.<pub-id pub-id-type="pmid">38902110</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.acra.2024.06.012</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Bi</surname><given-names>S</given-names></name><name name-style="western"><surname>Shan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cui</surname><given-names>B</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H</given-names></name><name name-style="western"><surname>Qi</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Multiparametric hippocampal signatures for early diagnosis of Alzheimer&#8217;s disease using <sup>18</sup>F-FDG PET/MRI radiomics</article-title><source>CNS Neurosci Ther</source><year>2024</year><volume>30</volume><issue>4</issue><fpage>e14539</fpage><pub-id pub-id-type="doi">10.1111/cns.14539</pub-id><pub-id pub-id-type="pmid">38031997</pub-id><pub-id pub-id-type="pmcid">PMC11017421</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Chen Z, Bi S, Shan Y, Cui B, Yang H, Qi Z, et al. Multiparametric hippocampal signatures for early diagnosis of Alzheimer&#8217;s disease using <sup>18</sup>F-FDG PET/MRI radiomics. CNS Neurosci Ther. 2024;30(4):e14539.<pub-id pub-id-type="pmid">38031997</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cns.14539</pub-id><pub-id pub-id-type="pmcid">PMC11017421</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>HY</given-names></name><name name-style="western"><surname>Suh</surname><given-names>CH</given-names></name><name name-style="western"><surname>Heo</surname><given-names>H</given-names></name><name name-style="western"><surname>Shim</surname><given-names>WH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>SJ</given-names></name></person-group><article-title>Diagnostic performance of hippocampal volumetry in Alzheimer&#8217;s disease or mild cognitive impairment: a meta-analysis</article-title><source>Eur Radiol</source><year>2022</year><volume>32</volume><issue>10</issue><fpage>6979</fpage><lpage>6991</lpage><pub-id pub-id-type="doi">10.1007/s00330-022-08838-9</pub-id><pub-id pub-id-type="pmid">35507052</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Park HY, Suh CH, Heo H, Shim WH, Kim SJ. Diagnostic performance of hippocampal volumetry in Alzheimer&#8217;s disease or mild cognitive impairment: a meta-analysis. Eur Radiol. 2022;32(10):6979&#8211;91.<pub-id pub-id-type="pmid">35507052</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00330-022-08838-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hazarika</surname><given-names>RA</given-names></name><name name-style="western"><surname>Maji</surname><given-names>AK</given-names></name><name name-style="western"><surname>Syiem</surname><given-names>R</given-names></name><name name-style="western"><surname>Sur</surname><given-names>SN</given-names></name><name name-style="western"><surname>Kandar</surname><given-names>D</given-names></name></person-group><article-title>Hippocampus segmentation using U-net convolutional network from brain magnetic resonance imaging (MRI)</article-title><source>J Digit Imaging</source><year>2022</year><volume>35</volume><issue>4</issue><fpage>893</fpage><lpage>909</lpage><pub-id pub-id-type="doi">10.1007/s10278-022-00613-y</pub-id><pub-id pub-id-type="pmid">35304675</pub-id><pub-id pub-id-type="pmcid">PMC9485390</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Hazarika RA, Maji AK, Syiem R, Sur SN, Kandar D. Hippocampus segmentation using U-net convolutional network from brain magnetic resonance imaging (MRI). J Digit Imaging. 2022;35(4):893&#8211;909.<pub-id pub-id-type="pmid">35304675</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10278-022-00613-y</pub-id><pub-id pub-id-type="pmcid">PMC9485390</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yue</surname><given-names>H</given-names></name><name name-style="western"><surname>Kuang</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name></person-group><article-title>RBS-Net: hippocampus segmentation using multi-layer feature learning with the region, boundary and structure loss</article-title><source>Comput Biol Med</source><year>2023</year><volume>160</volume><fpage>106953</fpage><pub-id pub-id-type="doi">10.1016/j.compbiomed.2023.106953</pub-id><pub-id pub-id-type="pmid">37120987</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Chen Y, Yue H, Kuang H, Wang J. RBS-Net: hippocampus segmentation using multi-layer feature learning with the region, boundary and structure loss. Comput Biol Med. 2023;160:106953.<pub-id pub-id-type="pmid">37120987</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.compbiomed.2023.106953</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur J Med Res</journal-id><journal-id journal-id-type="iso-abbrev">Eur J Med Res</journal-id><journal-id journal-id-type="pmc-domain-id">1786</journal-id><journal-id journal-id-type="pmc-domain">eurjmedres</journal-id><journal-title-group><journal-title>European Journal of Medical Research</journal-title></journal-title-group><issn pub-type="ppub">0949-2321</issn><issn pub-type="epub">2047-783X</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12482578</article-id><article-id pub-id-type="pmcid-ver">PMC12482578.1</article-id><article-id pub-id-type="pmcaid">12482578</article-id><article-id pub-id-type="pmcaiid">12482578</article-id><article-id pub-id-type="pmid">41024269</article-id><article-id pub-id-type="doi">10.1186/s40001-025-03165-3</article-id><article-id pub-id-type="publisher-id">3165</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Effects of exercise on neuroinflammation in age-related neurodegenerative disorders</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Su</surname><given-names initials="Y">Yiping</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Su</surname><given-names initials="Z">Zhanguo</given-names></name><address><email>suzhanguo@126.com</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00rzspn62</institution-id><institution-id institution-id-type="GRID">grid.10347.31</institution-id><institution-id institution-id-type="ISNI">0000 0001 2308 5949</institution-id><institution>Faculty of Sports and Exercise Science, </institution><institution>University of Malaya, </institution></institution-wrap>50603 Kuala Lumpur, Malaysia </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03n7a5z57</institution-id><institution-id institution-id-type="GRID">grid.464320.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 1763 3613</institution-id><institution>Faculty of Physical Education, </institution><institution>Huainan Normal University, </institution></institution-wrap>Huainan, 232038 Anhui China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04d8yqq70</institution-id><institution-id institution-id-type="GRID">grid.443692.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 0617 4511</institution-id><institution>International College, </institution><institution>Krirk University, </institution></institution-wrap>Bangkok, 10220 Thailand </aff></contrib-group><pub-date pub-type="epub"><day>29</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>30</volume><issue-id pub-id-type="pmc-issue-id">478380</issue-id><elocation-id>909</elocation-id><history><date date-type="received"><day>28</day><month>2</month><year>2025</year></date><date date-type="rev-recd"><day>8</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>3</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>29</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-01 11:25:52.917"><day>01</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="40001_2025_Article_3165.pdf"/><abstract id="Abs1"><p id="Par1">Neuroinflammation plays a critical role in the pathogenesis of aging-related neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and Multiple Sclerosis. It involves the activation of glial cells and the release of pro-inflammatory mediators and reactive oxygen and nitrogen species, which, when chronically sustained, contribute to neuronal damage and cognitive decline. Recent evidence suggests that regular physical exercise exerts neuroprotective effects by modulating neuroinflammatory pathways and enhancing brain health. Exercise has been shown to regulate the activity of microglia and astrocytes, strengthen the blood&#8211;brain barrier, and reduce systemic and gut-derived inflammation&#8212;all of which are implicated in the progression of neurodegeneration. Additionally, exercise influences inflammasome signaling, a key component in the innate immune response, further mitigating inflammation-induced neuronal injury. This review summarizes current findings on the impact of physical activity on inflammation and inflammasome pathways in aging-related neurodegenerative diseases, highlighting the therapeutic potential of exercise as a non-pharmacological intervention. Further research is warranted to optimize exercise protocols for maximal neuroprotective benefits.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Aging</kwd><kwd>Neurodegenerative disorders</kwd><kwd>Exercise</kwd><kwd>Inflammation</kwd><kwd>Inflammasome</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">In 2022, the official recognition by the World Health Organization designated neurological disorders as the primary cause of disabilities and the second highest contributor to global mortality rates. According to the Global Burden of Disease (GBD) study, the total number of fatalities caused by neurological disorders in 2016 was approximately 9 million, which Marked a 39% rise since 1990 [<xref ref-type="bibr" rid="CR1">1</xref>]. As the number of major debilitating neurological conditions continues to rise, the need for treatment has also increased. This has resulted in estimated medical expenses of about $300 billion [<xref ref-type="bibr" rid="CR1">1</xref>], which have been further amplified by the impact of the COVID-19 pandemic. One major trait that is common among neurodegenerative disorders is their gradual and permanent advancement. Treatment options for neurodegenerative diseases primarily focus on symptom management, as there is currently a deficiency in treatments that target the progression of the condition. Additionally, numerous attempts at using pharmacological treatments have been found to be ineffective in clinical studies. This collection of diseases, specifically Alzheimer's, Parkinson's, Huntington's, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, and multiple sclerosis (MS), are severe and long-lasting ailments that primarily affect the elderly population and pose substantial threats to their overall physical and mental health [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. The root reasons for neurodegenerative illnesses are extremely complex and encompass a mix of hereditary, ecological, and concurrent factors that have an impact on how they develop and can be treated. It is evident that one medicine is improbable to offer neuroprotection. There have been many studies examining potential biomarkers, but the biggest challenge in clinical trials is the absence of strong diagnostic and prognostic biomarkers that can identify patients in the early stages. The lack of successful treatments has prompted scientists and clinicians to explore lifestyle changes such as exercising and modifying one's diet. These lifestyle interventions have become a focal point for extensive investigation. Based on the statement from the World Health Organization, physical activity refers to any form of movement involving major muscle groups and requiring energy [<xref ref-type="bibr" rid="CR3">3</xref>]. Physical activity includes all types of movement and exercise that are done during free time and purposeful workouts, including different levels of exertion such as gentle, moderate, or intense. Collectively, basic exercises such as walking, running, and cycling can be performed at various levels of intensity and frequency as part of physical activity. While often used interchangeably, it is essential to recognize that physical activity and exercise have slight distinctions. Physical activity encompasses a broad array of unstructured exercises, as well as structured physical exercises that are planned and intentional, under the umbrella term of physical exercise [<xref ref-type="bibr" rid="CR4">4</xref>]. A wealth of recorded proof substantiates the notion that consistently participating in physical exercise Yields a plethora of beneficial impacts on various aspects of the body. These encompass the systems responsible for the heart, defending against disease, breaking down food, and coordinating bodily functions, as depicted in the visual aid numbered 1 [<xref ref-type="bibr" rid="CR5">5</xref>]. Regarding brain health, exercising has been proven to decrease levels of stress, anxiety, and depression. Additionally, it can combat the impacts of aging by enhancing memory and cognitive functions [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par3">Engaging in physical activity can act as a source of stress both during and after its performance, potentially leading to inflammation [<xref ref-type="bibr" rid="CR8">8</xref>]. Interestingly, maintaining a routine of physical exercise can effectively control chronic inflammation following the resolution of initial inflammatory responses [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Exercise induces the release of cytokines&#8212;particularly from contracting skeletal muscles&#8212;which influence both local and systemic inflammatory processes. These immunomodulatory effects are key to the beneficial adaptations seen with consistent training, including tissue repair and enhanced immune surveillance. The role of inflammation is crucial in promoting the body's ability to repair itself, particularly during intense physical activity and workout [<xref ref-type="bibr" rid="CR11">11</xref>]. In conclusion, modifications in inflammation brought about by physical activity can be categorized as either immediate changes (occurring during and immediately after a workout) or long-lasting changes (alterations in resting or baseline levels after the initial changes have subsided) [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Research indicates that that short bursts of exercise can lead to a range of inflammatory responses, influenced by factors such as the type, intensity, duration, and familiarity of the activity, as well as the age and overall health of the individuals involved [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR14">14</xref>&#8211;<xref ref-type="bibr" rid="CR18">18</xref>]. To accurately assess the impact of exercise on immunity, researchers can examine changes in the number of blood cells, improvements in the function of granulocytes, increased activity of natural killer cells, higher production of lymphocytes, and alterations in the amounts of circulating cytokines, among other indicators [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR14">14</xref>&#8211;<xref ref-type="bibr" rid="CR21">21</xref>]. Innate immunity is greatly influenced by a cluster of signal-transmitting complexes known as inflammasomes. The organization of an inflammasome complex typically consists of a detector, one or more adapter molecules, and a response molecule [<xref ref-type="bibr" rid="CR22">22</xref>]. At the molecular level, these responses are coordinated through a network of pattern-recognition receptors (PRRs), which play a critical role in innate immunity. These include Toll-like receptors (TLRs), which recognize microbial components and damage-associated molecular patterns; RIG-I-like receptors (RLRs), which sense viral RNA; and C-type lectin receptors (CLRs), which detect glycan structures on pathogens [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. Among these, inflammasomes&#8212;a subset of PRR complexes&#8212;have received significant attention. Inflammasomes such as NLRP3, NLRP1, NLRC4, AIM2, and pyrin respond to cellular stress signals and trigger caspase-1 activation, leading to the maturation of pro-inflammatory cytokines like IL-1&#946; and IL-18. The nucleotide-binding domain leucine-rich repeat-containing (NLR) family consists of a wide variety of proteins, including NLRP3, NLRP1, NLRC4, as well as other proteins like AIM2 and pyrin [<xref ref-type="bibr" rid="CR24">24</xref>&#8211;<xref ref-type="bibr" rid="CR27">27</xref>]. These proteins have the ability to detect and trigger inflammasome responses [<xref ref-type="bibr" rid="CR28">28</xref>]. The NLRP3 inflammasome is a highly studied sensor in both mice and humans in comparison to other sensors [<xref ref-type="bibr" rid="CR29">29</xref>]. The NLRP3 inflammasome, which is responsible for inflammation, can be triggered by multiple warning and tension indicators, many of which are heightened as a person grows older [<xref ref-type="bibr" rid="CR30">30</xref>]. The removal of the Nlrp3 gene in rodents has shown to extend their lifespan and enhance their general well-being by mitigating age-related conditions like cardiovascular, musculoskeletal, and cognitive deterioration [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. The NLRP3 inflammasome has been recently linked to several age-related health issues, including diabetes, cancer, gout, and diseases related to the brain and heart [<xref ref-type="bibr" rid="CR33">33</xref>]. This review uniquely integrates current evidence on how physical activity and exercise mimetics influence inflammatory pathways&#8212;particularly inflammasome activation&#8212;across multiple aging-related neurodegenerative disorders. By highlighting shared and distinct mechanisms among diseases such as Alzheimer's, Parkinson's, ALS, and Huntington&#8217;s, we aim to identify common therapeutic targets and inform future interventions. Here, we summarized the effect of exercise on inflammation and inflammasomes in neurodegenerative disorders.</p></sec><sec id="Sec2"><title>Literature search strategy</title><p id="Par4">To conduct this review, a comprehensive literature search was performed using the following electronic databases: PubMed, Scopus, Web of Science, and Google Scholar. Keywords and combinations of terms such as <italic toggle="yes">&#8220;exercise&#8221;</italic>, <italic toggle="yes">&#8220;physical activity&#8221;</italic>, <italic toggle="yes">&#8220;neuroinflammation&#8221;</italic>, <italic toggle="yes">&#8220;inflammasome&#8221;</italic>, <italic toggle="yes">&#8220;neurodegenerative diseases&#8221;</italic>, <italic toggle="yes">&#8220;aging&#8221;</italic>, <italic toggle="yes">&#8220;Alzheimer&#8217;s disease&#8221;, &#8220;Parkinson&#8217;s disease&#8221;, &#8220;Amyotrophic lateral sclerosis&#8221;</italic> and <italic toggle="yes">&#8220;Multiple Sclerosis&#8221;</italic> were used. Boolean operators (AND, OR) were applied to refine search results. Inclusion criteria were peer-reviewed original research articles, systematic reviews, and meta-analyses focusing on the relationship between exercise, inflammation, inflammasome activity, and neurodegenerative diseases associated with aging. Studies that did not focus on these key elements or were not available in full text were excluded. The selection process adhered to PRISMA guidelines for systematic reviews where applicable.</p></sec><sec id="Sec3"><title>Inflammation and neurodegenerative disorders</title><p id="Par5">Neurodegenerative diseases exhibit a multitude of similar and distinct pathological and clinical traits, such as specific vulnerability of brain regions and the accumulation of various proteins. Neurodegenerative diseases not only display distinct neuropathological and clinical features, but also demonstrate persistent and long-lasting inflammation [<xref ref-type="bibr" rid="CR34">34</xref>&#8211;<xref ref-type="bibr" rid="CR36">36</xref>].&#160;In the beginning, the prevailing belief was that the accumulation of proteins was the primary factor responsible for the inflammatory response seen in the central nervous system (CNS). Conversely, research strongly indicates that these tangles could directly activate immune reactions in the brain. However, it is more probable that it plays a crucial part in the initial phases of the illness by aiding in the creation of these groupings [<xref ref-type="bibr" rid="CR37">37</xref>&#8211;<xref ref-type="bibr" rid="CR39">39</xref>].&#160;The immune system is crucial in maintaining tissue balance, eliminating harmful pathogens, and aiding in the recovery process after injuries [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>].&#160;The immune system, a natural protective function of our body, usually creates a helpful and temporary response that fades once damaged tissues are healed or infections are cleared. In certain situations, if the cause of inflammation is not properly dealt with, the body's usual method of resolving it can become overwhelmed, resulting in long-term inflammation. This can potentially lead to the discharge of harmful substances and worsen the disease. A multitude of elements can result in a prolonged stimulation, comprising inner elements such as the buildup of proteins, outside factors like a widespread infection or modifications in gut microbiota, and genetic predispositions such as mutations in PGRN or APOE4 [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR42">42</xref>&#8211;<xref ref-type="bibr" rid="CR47">47</xref>].&#160;Furthermore, SPMs, a type of bioactive lipid, can be triggered in the midst of an inflammatory response and aid in bringing about its resolution. These components have a vital function in the recovery of irritated tissues. Long-term inflammation-related conditions may also arise due to the insufficient generation of SPMs, leading to the inability to effectively resolve the problem [<xref ref-type="bibr" rid="CR48">48</xref>] (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>The Cycle of Neuroinflammation in Neurodegeneration</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="40001_2025_3165_Fig1_HTML.jpg"/></fig></p><p id="Par6">This diagram illustrates how triggers, such as protein aggregates or pathogens, activate glial cells (microglia and astrocytes). This activation leads to the release of pro-inflammatory mediators, which cause neuronal damage and create a self-perpetuating cycle of inflammation and cell death. DAMPs, damage-associated molecular patterns; PAMPs, pathogen-associated molecular patterns.</p></sec><sec id="Sec4"><title>Alzheimer&#8217;s disease</title><p id="Par7">In the year 1907, Alois Alzheimer recognized Alzheimer's disease as the most commonly occurring type of neurodegenerative disorder. Roughly 10% of individuals over the age of 65, and around 30% of those over 85, experience AD, with the figures on the rise [<xref ref-type="bibr" rid="CR49">49</xref>]. Alzheimer&#8217;s disease is characterized by the presence of amyloid plaques and neurofibrillary tangles (NFTs), as well as the infiltration of immune cells such as microglia in the brain [<xref ref-type="bibr" rid="CR34">34</xref>].&#160;A&#946;, which is produced through inefficient processing of the amyloid precursor protein (APP), is the main constituent of amyloid plaques. Conversely, the NFTs are packed with an excessive amount of hyperphosphorylated tau protein that attaches to microtubules<bold>.</bold> The buildup of A&#946; and the presence of NFTs have been widely acknowledged as the primary underlying factors of Alzheimer's disease. Despite extensive documentation, the precise causes and mechanisms behind the accumulation and deposition of these substances are still unknown [<xref ref-type="bibr" rid="CR50">50</xref>]. At the early stages of Alzheimer's disease, the accumulation of A&#946; occurs before any detectable signs are present. Patients may show signs of A&#946; plaque buildup in their brains for over ten years before receiving a diagnosis of Alzheimer's Disease [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>],&#160;while tau pathology typically emerges after A&#946; plaque formation [<xref ref-type="bibr" rid="CR53">53</xref>].&#160;Multiple hypotheses suggest that the accumulation of A&#946; protein might function as an indicator of harm, attaching to distinct receptors such as toll-like receptors (TLRs), receptor for advanced glycation end products (RAGE), and nucleotide-binding oligomerization domain-like receptors (NLRs). The triggering of microglial activation begins with binding, which causes the release of numerous cytokines and chemokines in the nearby area. This consequently entices a further influx of glial cells towards the A&#946; site [<xref ref-type="bibr" rid="CR54">54</xref>&#8211;<xref ref-type="bibr" rid="CR57">57</xref>].&#160;The crucial defense mechanism of protecting neurons from A&#946; is carried out by activated microglia and astrocytes through phagocytosis [<xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR59">59</xref>],&#160;However, when the clearance of these aggregates is unsuccessful, it leads to long-term inflammation and the discharge of harmful substances such as cytokines, chemokines, reactive oxygen species (ROS), and nitric oxide (NO). This further stimulates immune reactions and causes damage to neurons [<xref ref-type="bibr" rid="CR60">60</xref>].&#160;Various types of cells found in the central nervous system, such as neurons, oligodendrocytes, vascular endothelial cells, and pericytes, are all capable of contributing to continuous inflammation. This constant irritation within the central nervous system's microenvironment can persist indefinitely [<xref ref-type="bibr" rid="CR61">61</xref>].&#160;Microglia play a critical role in the development of A&#946; plaques by significantly affecting the release of A&#946; particles, the activation of IFITM3, a protein responsible for controlling &#947;-secretase, and the release of iron. These processes are essential for the buildup of soluble &#946;-amyloid [<xref ref-type="bibr" rid="CR62">62</xref>&#8211;<xref ref-type="bibr" rid="CR64">64</xref>].&#160;The linking of A&#946; protein clumps to the subsequent development of tau clusters may be aided by the activation of glial cells. Researchers have found that microglia are activated beforehand and this leads to increased levels of tau protein phosphorylation, triggering the development of neurofibrillary tangles [<xref ref-type="bibr" rid="CR65">65</xref>&#8211;<xref ref-type="bibr" rid="CR67">67</xref>].&#160;According to the image provided in Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>, the buildup of tau tangles within nerve fibers causes the breakdown of nerve cells and triggers the immune system to start the process of apoptosis [<xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR69">69</xref>].<fig id="Fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>The Role of Neuroinflammation in Alzheimer&#8217;s Disease (AD). This schematic illustrates the central inflammatory cascade in AD. <bold>A</bold> The process begins with the abnormal cleavage of amyloid precursor protein (APP), leading to the formation of amyloid-beta (A&#946;) plaques. <bold>B</bold> A&#946; aggregates act as danger signals that trigger chronic activation of microglia. <bold>C</bold> These activated microglia release pro-inflammatory cytokines (e.g., TNF-&#945;, IL-1&#946;) and reactive oxygen species (ROS), which in turn exacerbate tau hyperphosphorylation, creating a self-perpetuating cycle of neurotoxicity and neuronal death</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="40001_2025_3165_Fig2_HTML.jpg"/></fig></p></sec><sec id="Sec5"><title>Amyotrophic lateral sclerosis</title><p id="Par8">The progressive deterioration of the central nervous system's upper and lower motor neurons, which is also referred to as ALS, was first documented by Charcot in 1869. ALS is an untreatable condition with a certain outcome of death, typically occurring within a span of 2 to 5&#160;years following diagnosis [<xref ref-type="bibr" rid="CR70">70</xref>].&#160;ALS progresses quickly and is considered the fastest-moving neurodegenerative disease leading to a fatal outcome. The vast Majority of cases are random and unpredictable, accounting for roughly 95&#8211;90%, while the remaining 5&#8211;10% can be traced back to familial ties. There have been more than 20 known genetic mutations associated with familial ALS. The majority of cases can be attributed to two particular genes: the C9orf72 gene on chromosome 9, which Makes up 40% of cases, and the SOD1 gene, which accounts for 20% of cases [<xref ref-type="bibr" rid="CR71">71</xref>].&#160;In 2006, it was discovered that the presence of hyperphosphorylated and ubiquitinated TDP-43 proteins in the cytoplasm (produced by the TARDBP gene) were the prevalent (occurring roughly 97% of the time) characteristic feature of ALS [<xref ref-type="bibr" rid="CR72">72</xref>].&#160;Many factors, such as the accumulation of certain proteins like TDP-43, SOD1, and FUS throughout various parts of the cell, can impact the growth and advancement of amyotrophic lateral sclerosis (ALS). This can lead to harm and impairment of nerve cells. In addition, changes in how cells function, triggered by variations in specific genes like SOD1, C9orf72, and TDP-43, and influenced by external environmental elements, can have a pivotal impact on the development of this disorder [<xref ref-type="bibr" rid="CR73">73</xref>&#8211;<xref ref-type="bibr" rid="CR75">75</xref>].&#160;A primary factor in the development of ALS, the build-up of TDP-43, may possess the capability to invade the mitochondria and release mitochondrial DNA (mtDNA) into the cytosol. The cyclic GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING) has the ability to activate an immune reaction in the nerve cells [<xref ref-type="bibr" rid="CR76">76</xref>].&#160;The essential role of SOD1 in regulating cytoplasmic oxidation has been extensively researched as a potential contributor to ALS. Its aggregation results in oxidative stress and disrupts proper functioning of the mitochondria [<xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR78">78</xref>].&#160;When neurons are damaged, they can release damage-associated molecular patterns (DAMPs) into their surrounding environment. This release can cause microglia to become activated and release proinflammatory cytokines. This process is crucial for stimulating immune response in the brain [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR79">79</xref>&#8211;<xref ref-type="bibr" rid="CR81">81</xref>].&#160;Continual inflammation has a detrimental impact on neurons, causing direct harm and worsening ALS [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR82">82</xref>]&#160;(Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). Furthermore, people who have autoimmune disorders have a slightly increased chance of developing ALS [<xref ref-type="bibr" rid="CR83">83</xref>].&#160;A thorough examination of genetic connections discovered a strong correlation between ALS and autoimmune diseases at a molecular level [<xref ref-type="bibr" rid="CR84">84</xref>].&#160;This implies a close relationship between inflammation and the advancement of ALS.<fig id="Fig3" position="float" orientation="portrait"><label>Fig.&#160;3</label><caption><p>Neuroinflammatory Mechanisms in Amyotrophic Lateral Sclerosis (ALS). This diagram illustrates how cytoplasmic aggregates of proteins like TDP-43 and SOD1 can cause mitochondrial dysfunction. The release of mitochondrial DNA (mtDNA) can activate the cGAS-STING pathway, initiating an inflammatory response that contributes to the progressive degeneration of motor neurons</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="40001_2025_3165_Fig3_HTML.jpg"/></fig></p></sec><sec id="Sec6"><title>Parkinson&#8217;s disease</title><p id="Par9">Parkinson's disease (PD) is the second most common degenerative disorder, characterized by Lewy bodies, groups of &#945;-synuclein protein, and a decline in dopaminergic neurons in the substantia nigra [<xref ref-type="bibr" rid="CR85">85</xref>].&#160;The substantia nigra's dopamine-producing neurons have axons that extend towards the striatum. The manifestation of a variety of bodily symptoms indicates the presence of Parkinson's disease (PD), emphasizing how much impact these assessments have on a person's physical actions [<xref ref-type="bibr" rid="CR86">86</xref>].&#160;Decades may pass before any initial sign of illness is displayed. Following a thorough examination of tissue samples obtained from deceased individuals with Parkinson's disease, it has been confirmed that about 30% of the cells responsible for producing dopamine in the substantia nigra and 50% of the nerve endings that transmit dopamine in the dorsal putamen were absent upon diagnosis [<xref ref-type="bibr" rid="CR87">87</xref>].&#160;Following an initial identification, there is a Marked decline in dopamine axon terminals within a span of four years, and a majority of neuron cell bodies are no longer present after five years of the diagnosis. During the year 1998, McGeer and other researchers carried out a noteworthy investigation, discovering the presence of HLA-HR&#8201;+&#8201;responsive microglia in the postmortem tissues of individuals who had Parkinson's disease. This original excerpt drew a correlation between enlargement and Parkinson's disease [<xref ref-type="bibr" rid="CR88">88</xref>].&#160;At present, there is a significant body of research showing that inflammation could be an initial event and is highly important in the development and advancement of PD. Environmental factors can have an impact on the alteration of genetic mutations and post-translational alterations, particularly affecting the S129 region of &#945;-synuclein. Such alterations could lead to alterations in the makeup and creation of lasting accumulations [<xref ref-type="bibr" rid="CR87">87</xref>].&#160;As a reminder, the build-up of &#945;-synuclein is not the primary cause of neuron death in Parkinson's disease because the death of neurons actually occurs before the appearance of Lewy bodies [<xref ref-type="bibr" rid="CR89">89</xref>].&#160;Though evidence shows that the presence of misfolded &#945;-synuclein in living organisms can be detrimental to neuron function, the involvement of inflammation in this process should not be overlooked [<xref ref-type="bibr" rid="CR90">90</xref>&#8211;<xref ref-type="bibr" rid="CR92">92</xref>].&#160;The exact function of &#945;-synuclein clumps in neurons is currently a contentious issue. According to various in vitro studies, it has been observed that misfolded &#945;-synuclein does not cause harm to neurons unless microglia are involved. This suggests that the activation of microglia may be a crucial factor in the harmful impact of clustered &#945;-synuclein on nerve cells [<xref ref-type="bibr" rid="CR93">93</xref>, <xref ref-type="bibr" rid="CR94">94</xref>].&#160;However, further research done in a laboratory setting showed that clusters of &#945;-synuclein triggered defective functioning of mitochondria and consequent death of neurons through various pathways [<xref ref-type="bibr" rid="CR95">95</xref>, <xref ref-type="bibr" rid="CR96">96</xref>].&#160;Through extensive research on animal models of Parkinson's disease, it has been consistently demonstrated that microglia activate before the decline of dopamine neurons [<xref ref-type="bibr" rid="CR97">97</xref>&#8211;<xref ref-type="bibr" rid="CR99">99</xref>].&#160;Misshapen &#945;-synuclein has been observed to be discharged from damaged neurons into the extracellular environment in both animal models and individuals with PD [<xref ref-type="bibr" rid="CR87">87</xref>, <xref ref-type="bibr" rid="CR100">100</xref>, <xref ref-type="bibr" rid="CR101">101</xref>].&#160;The existence of extracellular &#945;-synuclein can also initiate the stimulation of microglia and astrocytes. One possible occurrence is the connection to distinct surface receptors such as TLRs and Fc&#947;R, or the attachment to internal receptors like NLRP3 [<xref ref-type="bibr" rid="CR85">85</xref>, <xref ref-type="bibr" rid="CR102">102</xref>, <xref ref-type="bibr" rid="CR103">103</xref>].&#160;When activated, glial cells release a variety of cytokines and chemokines that cause neuronal death and stimulate the release of other alarm signals, such as ATP [<xref ref-type="bibr" rid="CR104">104</xref>]. The vast majority of &#945;-synuclein found in a typical brain is not in a phosphorylated state. Nevertheless, among individuals afflicted with Parkinson's disease, around 90% of the protein present in Lewy bodies is modified at a precise site referred to as Ser129. It is thought to have a significant impact on the advancement and growth of the illness [<xref ref-type="bibr" rid="CR105">105</xref>].&#160;Once microglia become activated, they have the capability to generate signaling molecules that can trigger an inflammatory response, ultimately causing the activation of protein kinase R (PKR). In summary, the process of Ser129 phosphorylation serves as a means of altering &#945;-synuclein [<xref ref-type="bibr" rid="CR106">106</xref>].&#160;However, according to Ghanem and colleagues, the process of Ser129 phosphorylation took place after the first instance of &#945;-synuclein aggregation and prevented further aggregation, suggesting a potential protective function of this phosphorylation [<xref ref-type="bibr" rid="CR107">107</xref>].&#160;Triggered microglia can worsen illnesses by facilitating the transmission of clumps similar to prions and increasing the production of &#945;-synuclein&#160;[<xref ref-type="bibr" rid="CR108">108</xref>&#8211;<xref ref-type="bibr" rid="CR110">110</xref>] (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>). On the other hand, Scheiblich and colleagues discovered that microglia with a high load of &#945;-synuclein fibers can transmit the protein to nearby unaffected microglia via the creation of intercellular connections driven by F-actin. This process aids in the breakdown of &#945;-synuclein [<xref ref-type="bibr" rid="CR111">111</xref>].&#160;Moreover, microglia possess the capacity to adhere to the surface of astrocytes and attract and remove protein clumps such as &#945;-synuclein and A&#946; that are present within the astrocytes [<xref ref-type="bibr" rid="CR112">112</xref>].&#160;A plausible reason for this phenomenon could be the transmission of &#945;-synuclein from heavily impaired glial cells to adjacent unaffected microglia, resulting in an increased participation of glial cells in breaking down &#945;-synuclein. In contrast, excessive amounts of &#945;-synuclein taken up by microglia may result in the persistent stimulation of these cells, potentially leading to the spread of &#945;-synuclein from microglia to neurons [<xref ref-type="bibr" rid="CR109">109</xref>].&#160;According to recent studies, the highly flexible immune system is a significant factor in the development of Parkinson's disease in approximately 40% of cases. Both people with Parkinson's disease and a mouse with the same disease showed a notable immune response when exposed to &#945;-synuclein. This was evident through the heightened activation of multiple T cells. The interplay between genetic and environmental factors has a profound impact on the formation of T cells that respond to &#945;-synuclein. When microglia become active as a result of the presence of &#945;-synuclein clusters or other triggers, it results in a rise in the expression of MHC I by neurons. As a result, these neurons become more efficient at presenting &#945;-synuclein antigens, making them targets for destruction by &#945;-synuclein responsive T cells [<xref ref-type="bibr" rid="CR113">113</xref>&#8211;<xref ref-type="bibr" rid="CR115">115</xref>].&#160;The results strongly indicate that PD is an autoimmune disorder, sharing similarities with multiple sclerosis.<fig id="Fig4" position="float" orientation="portrait"><label>Fig.&#160;4</label><caption><p>The Role of Inflammation in Parkinson's Disease (PD)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="40001_2025_3165_Fig4_HTML.jpg"/></fig></p><p id="Par10">This figure depicts how aggregated &#945;-synuclein activates microglia. This activation leads to increased oxidative stress and mitochondrial dysfunction, which enhances the neurotoxicity of &#945;-synuclein and contributes to the loss of dopaminergic neurons. DAMPs, damage-associated molecular patterns.</p></sec><sec id="Sec7"><title>Huntington&#8217;s disease</title><p id="Par11">Huntington&#8217;s disease (HD) is a progressive, autosomal dominant neurodegenerative disorder caused by an abnormal expansion of CAG trinucleotide repeats in the <italic toggle="yes">huntingtin</italic> (HTT) gene located on chromosome 4 [<xref ref-type="bibr" rid="CR116">116</xref>, <xref ref-type="bibr" rid="CR117">117</xref>]. This genetic mutation results in the production of a mutant huntingtin (mHTT) protein with an extended polyglutamine (polyQ) tract, which is toxic to neurons [<xref ref-type="bibr" rid="CR118">118</xref>&#8211;<xref ref-type="bibr" rid="CR120">120</xref>]. The hallmark features of HD include motor dysfunction (such as chorea and dystonia), cognitive decline, and psychiatric disturbances, typically Manifesting between the ages of 30 and 50, although juvenile and late-onset forms also exist [<xref ref-type="bibr" rid="CR121">121</xref>, <xref ref-type="bibr" rid="CR122">122</xref>].</p><p id="Par12">Pathologically, HD is characterized by widespread neuronal loss, most notably in the striatum and cortex. The disease progresses over 15 to 20&#160;years, leading to severe disability and ultimately death. Despite the identification of the genetic mutation responsible for HD over two decades ago, there is still no cure, and treatment remains symptomatic [<xref ref-type="bibr" rid="CR123">123</xref>]. Recent advances in understanding the pathophysiological mechanisms of HD have highlighted the central role of neuroinflammation in disease progression. While HD is a monogenic disorder, its progression and severity are significantly influenced by secondary pathological processes, among which inflammation plays a critical role. Neuroinflammation in HD is not merely a consequence of neurodegeneration but is now recognized as a driver of neuronal dysfunction and cell death [<xref ref-type="bibr" rid="CR124">124</xref>&#8211;<xref ref-type="bibr" rid="CR126">126</xref>]. Microglia, the resident immune cells of the central nervous system (CNS), play a crucial role in maintaining neural homeostasis. In HD, microglia are activated early&#8212;even before the onset of clinical symptoms. Studies have shown increased microglial activation in the striatum and cortex of both HD patients and animal models. Activated microglia produce pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-&#945;), interleukin (IL)&#8722;1&#946;, and IL-6, contributing to a neurotoxic environment [<xref ref-type="bibr" rid="CR127">127</xref>, <xref ref-type="bibr" rid="CR128">128</xref>]. This sustained inflammatory response exacerbates neuronal injury and promotes disease progression. Astrocytes also contribute to the inflammatory landscape in HD. Mutant huntingtin accumulates in astrocytes, leading to impaired glutamate uptake, dysregulated calcium signaling, and increased production of inflammatory mediators. This dysfunction further compromises neuronal survival by disrupting synaptic function and promoting excitotoxicity [<xref ref-type="bibr" rid="CR129">129</xref>, <xref ref-type="bibr" rid="CR130">130</xref>]. In addition to CNS inflammation, HD patients exhibit signs of systemic immune activation. Elevated levels of inflammatory cytokines have been detected in the blood and cerebrospinal fluid (CSF) of HD patients. These peripheral immune changes suggest a bidirectional communication between the brain and immune system, amplifying the inflammatory response [<xref ref-type="bibr" rid="CR131">131</xref>]. Recent evidence has also implicated inflammasome pathways in HD pathogenesis. The NLRP3 inflammasome, a multi-protein complex that mediates the maturation of IL-1&#946; and IL-18, is upregulated in HD models. Activation of this pathway can lead to pyroptosis, a form of inflammatory cell death, further contributing to neural loss [<xref ref-type="bibr" rid="CR132">132</xref>, <xref ref-type="bibr" rid="CR133">133</xref>] Table&#160;<xref rid="Tab1" ref-type="table">1</xref>.
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>Inflammatory Mechanisms In Neurodegenerative Diseases</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Neurodegenerative disease</th><th align="left" colspan="1" rowspan="1">Primary inflammatory mechanisms</th><th align="left" colspan="1" rowspan="1">Exercise/exercise-mimetic effects</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Alzheimer&#8217;s disease (AD)</td><td align="left" colspan="1" rowspan="1">Microglial activation, NLRP3 inflammasome activation, increased IL-1&#945;, TNF-&#946;, and oxidative stress</td><td align="left" colspan="1" rowspan="1">Reduces pro-inflammatory cytokines, enhances neurogenesis, decreases amyloid-&#946; accumulation</td></tr><tr><td align="left" colspan="1" rowspan="1">Parkinson&#8217;s disease (PD)</td><td align="left" colspan="1" rowspan="1">Microglial activation, &#945;-synuclein-induced inflammation, increased cytokines (IL-6, TNF-&#946;), mitochondrial dysfunction</td><td align="left" colspan="1" rowspan="1">Modulates microglial response, reduces &#945;-synuclein aggregation, improves mitochondrial function</td></tr><tr><td align="left" colspan="1" rowspan="1">Amyotrophic lateral sclerosis (ALS)</td><td align="left" colspan="1" rowspan="1">Neuroinflammation via TLR4 and NF-&#954;B signaling, microglial activation, oxidative stress, astrocyte dysfunction</td><td align="left" colspan="1" rowspan="1">Decreases pro-inflammatory signaling, improves antioxidant defenses, supports motor neuron survival</td></tr><tr><td align="left" colspan="1" rowspan="1">Huntington&#8217;s disease (HD)</td><td align="left" colspan="1" rowspan="1">Microglial and astrocyte activation, elevated cytokines (IL-6, TNF-&#945;), inflammasome activation</td><td align="left" colspan="1" rowspan="1">Reduces neuroinflammation, modulates glial activity, improves synaptic function, enhances neuroplasticity</td></tr></tbody></table></table-wrap></p><p id="Par13">Numerous studies have demonstrated that the activation of inflammasomes plays a crucial role in initiating autoimmune and inflammatory responses among individuals with Multiple Sclerosis [<xref ref-type="bibr" rid="CR134">134</xref>]. Inflammasomes, a type of protein organization, play a crucial role in initiating the innate immune response to combat detrimental particles from decaying cells and harmful microbes like bacteria and viruses. The inflammasome causes caspase-1 to become active, which then produces and releases functional IL-1&#946; and IL-18 molecules [<xref ref-type="bibr" rid="CR135">135</xref>]. When there is an excess of caspase-1 in the body, it causes a specific type of cell death known as pyroptosis. This form of cell death is distinguished by a rapid and intense immune reaction that leads to the rupture and destruction of the cell [<xref ref-type="bibr" rid="CR136">136</xref>] (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>). The inflammasome, which is made up of the NOD-like receptor (NLR), apoptosis-associated speck-like protein with a caspase-recruitment domain (ASC), and caspase-1, is a crucial element in the body's process of inflammation [<xref ref-type="bibr" rid="CR135">135</xref>]. The TLR and NLR proteins are essential PRRs that play a crucial role in detecting pathogen-associated molecular patterns (PAMPs) and DAMPs, serving as important pattern recognition receptors for pathogen and tissue damage recognition. They perform the role of detectors, indicating the existence of foreign agents and damage to cells [<xref ref-type="bibr" rid="CR137">137</xref>]. Once a PRR binds, signal 1 is initiated, causing the inflammasome to activate and subsequently activate NF-&#954;B. The primary role of the ASC protein is to form a connection between the sensory protein (known as NLR) and caspase-1 [<xref ref-type="bibr" rid="CR138">138</xref>] (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>).<fig id="Fig5" position="float" orientation="portrait"><label>Fig.&#160;5</label><caption><p>Inflammatory Contributors to Huntington&#8217;s Disease (HD). An overview of how the mutant huntingtin (mHTT) protein promotes neurodegeneration. It triggers inflammation through multiple pathways, including the activation of microglia and astrocytes, peripheral immune responses, and inflammasome signaling, all converging to create a neurotoxic environment. Table <xref rid="Tab1" ref-type="table">1</xref> also provides an overview about different NDs and role of inflammation in them</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO5" position="float" orientation="portrait" xlink:href="40001_2025_3165_Fig5_HTML.jpg"/></fig></p><p id="Par14">The protein ASC is found in various parts of inactive cells, including the mitochondria, nucleus, and cytosol. Upon activation of the inflammasome, ASC relocates from its original position to the cytosol, enabling it to interact with various sensors such as NLR, ALR, and pryin [<xref ref-type="bibr" rid="CR139">139</xref>]. The redistribution of ASC within cells is impacted by changes to the mitochondrial microtubules and balance, suggesting that components of the cytoskeleton are involved in controlling the inflammasome [<xref ref-type="bibr" rid="CR140">140</xref>].</p><p id="Par15">When triggered by various factors such as infection, tissue injury, and alterations in metabolic functions, inflammasomes are crucial in producing functional types of IL-1&#946; and IL-18. This process is influenced by several elements such as abnormalities in lysosome activity, disruption of mitochondrial processes, release of mitochondrial DNA, generation of reactive oxygen species, and increased levels of cellular calcium. When a disease-causing particle or an injury-causing molecule binds to the NLR segment of the inflammasome, it prompts the clustering of NLR proteins. This is made possible by the interactions between comparable pyrin or caspase-recruitment domain components. Taking into consideration these engagements, the detectors belonging to the inflammasome come together to form structures, either with the assistance of the connector molecule ASC or independently. To effectively process cytokines, there must be a gathering of ASC and organization within the inflammasome [<xref ref-type="bibr" rid="CR141">141</xref>, <xref ref-type="bibr" rid="CR142">142</xref>].</p><p id="Par16">When procaspases are combined and self-activate, the inflammasome is considered to be active. Consequently, the activation of caspase-1 triggers the transformation of pro-IL-1&#946; and pro-IL-18, which are inactive forms, into their active forms [<xref ref-type="bibr" rid="CR143">143</xref>]. Pyroptosis, a form of programmed cell death, is initiated by the cleavage of Gasdermin D (GSDMD) through the action of caspase-1 or caspase-11 enzymes. The division plays a vital role in triggering the process of pyroptosis [<xref ref-type="bibr" rid="CR144">144</xref>]. GSDMD consists of two primary sections, namely the carboxy (C) terminus located at the end and the amino (N) terminus situated at the beginning. The main role of the C-terminus is to prevent the N-terminus fragment from causing pyroptosis and inflammation. GSDMD-N is a shortened version of the N-terminal fragment which is crucial in the creation of a pore in the cell membrane. When activated by internal lipopolysaccharide (LPS) originating from Gram-negative bacteria, Caspase-11 goes through a mechanism of decomposition of GSDMD [<xref ref-type="bibr" rid="CR145">145</xref>]. When caspase-11 cleaves the GSDMD protein, the section of GSDMD located at the start triggers pyroptosis and facilitates the activation of the NLRP3 inflammasome, leading to a rise in IL-1&#946; production [<xref ref-type="bibr" rid="CR145">145</xref>]. Moreover, studies on mice have revealed that the lack of GSDMD can prevent death caused by high doses of LPS and also result in decreased levels of IL-1&#946; release [<xref ref-type="bibr" rid="CR145">145</xref>](Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>).<fig id="Fig6" position="float" orientation="portrait"><label>Fig.&#160;6</label><caption><p>Activation of the NLRP3 Inflammasome. This diagram details the canonical and non-canonical pathways. The canonical pathway requires a priming signal (Signal 1) via NF-&#954;B and an activation signal (Signal 2) from triggers like ATP or reactive oxygen species (ROS). This leads to caspase-1 activation, which cleaves Gasdermin D (GSDMD) to induce pyroptosis and processes pro-inflammatory cytokines IL-1&#946; and IL-18 into their active forms</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO6" position="float" orientation="portrait" xlink:href="40001_2025_3165_Fig6_HTML.jpg"/></fig></p><p id="Par17">Caspase-1 also breaks down GSDMD, freeing GSDMD-N [<xref ref-type="bibr" rid="CR146">146</xref>]. In addition, there have been various other mechanistic discoveries that corroborate these investigations. The presence of GSDMD-N fragment binding to lipid molecules, specifically phosphatidylcholine and cholesterol, leads to the formation of pores [<xref ref-type="bibr" rid="CR147">147</xref>]. The gateways are instrumental in procuring potassium, a vital component in activating NLRP3 and releasing IL-1&#946; and IL-18, thus promoting the process of inflammation [<xref ref-type="bibr" rid="CR147">147</xref>]. The stimulation of the alternate pathway is initiated by the activation of caspase-11 in rodents and its corresponding forms, caspase-4 and caspase-5, in humans [<xref ref-type="bibr" rid="CR148">148</xref>]. Unlike other caspases that play a role in the non-canonical pathway, caspase-11 has a significantly diminished capability to assist in the activation of IL-1&#946; and IL-18, and the fragmentation of GSDMD. Effective management must consistently observe and regulate the presence of dual operational mechanisms to prevent the risk of pyroptosis [<xref ref-type="bibr" rid="CR148">148</xref>]. TRPC1, an ion channel that is not specific in its selection and is influenced by caspase-11, plays a critical role as a regulating mechanism during this process. The functioning of the NLRP3 inflammasome and pyroptosis is highly reliant on the discharge of potassium via Pannexin-1 channels. The lack of TRPC1 has been associated with heightened inflammatory responses [<xref ref-type="bibr" rid="CR148">148</xref>]. At this point, it is not fully understood how TRPC1 and GSDMD are linked and the exact way in which TRPC1 operates, as illustrated in Fig.&#160;<xref rid="Fig7" ref-type="fig">7</xref>.<fig id="Fig7" position="float" orientation="portrait"><label>Fig.&#160;7</label><caption><p>Activation Mechanisms of NLRP1 and AIM2 Inflammasomes. This figure contrasts the activation of two other key inflammasomes. The NLRP1 inflammasome is activated by sensing pathogenic functions that lead to its auto-cleavage. The AIM2 inflammasome is activated by directly binding to double-stranded DNA in the cytosol. Both pathways converge on caspase-1 activation to trigger inflammation and pyroptosis. ASC, apoptosis-associated speck-like protein; CARD, caspase-recruitment domain</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO7" position="float" orientation="portrait" xlink:href="40001_2025_3165_Fig7_HTML.jpg"/></fig></p><p id="Par18">Studies have revealed that the NLRP3 inflammasome plays a vital role in the neuroinflammation associated with Alzheimer's disease. This is evident from the elevated levels of IL-1&#946; and IL-18 found in patients with the disease [<xref ref-type="bibr" rid="CR149">149</xref>&#8211;<xref ref-type="bibr" rid="CR152">152</xref>]. In 2008, Halle et al. were the pioneering researchers who discovered the mechanism in which fibrillar A&#946; causes the NLRP3 inflammasome to become active. Based on their thorough examination, the administration of 5&#160;mM of fibrillar A&#946; led to the activation of NLRP3 and ASC, eventually triggering the release of IL-1&#946; [<xref ref-type="bibr" rid="CR153">153</xref>]. Heneka and his colleagues discovered that the absence of NLRP3 had a notable effect on transgenic mice afflicted with AD. These mice had a combination of mutated forms of the APP and PS1 genes, which led to higher levels of neuroinflammation. The absence of NLRP3 resulted in reduced A&#946; accumulation and improved functioning of neurons [<xref ref-type="bibr" rid="CR154">154</xref>]. New research has revealed that removing the NLRP3 or caspase-1 genes in mice with the APP/PS1 mutation leads to a conversion of microglia cells into an M2 state, which is known for its ability to reduce inflammation. Therefore, there is a decrease in the production of both caspase-1 and IL-1&#946; [<xref ref-type="bibr" rid="CR155">155</xref>]. Recent research has solidified the connection between the NLRP3 inflammasome and the progression of Alzheimer's disease. Recent findings indicate that A&#946; is responsible for activating the NLRP3 inflammasome in microglia cells and converting pro-IL-1&#946; into its active form, IL-1&#946; [<xref ref-type="bibr" rid="CR156">156</xref>].</p><p id="Par19">Beyond NLRP3, the NLRP1 inflammasome has also been implicated in AD. Studies show increased NLRP1 mRNA in affected neurons, where it may contribute to A&#946;&#8324;&#8322; accumulation through a caspase-1 and caspase-6-dependent pathway [<xref ref-type="bibr" rid="CR157">157</xref>]</p><p id="Par20">A plethora of studies have gathered strong evidence suggesting that the NLRP3 inflammasome might be a significant factor in the onset of multiple sclerosis. Approximately ten years ago, Gris and his colleagues put forth the idea that the Nlrp3 gene plays a crucial part in the formation of experimental autoimmune encephalomyelitis (EAE), the primary animal-based model utilized in researching multiple sclerosis in human subjects [<xref ref-type="bibr" rid="CR158">158</xref>, <xref ref-type="bibr" rid="CR159">159</xref>]. The results of the study showed that the absence of the Nlrp3 gene resulted in decreased encephalitogenic responses in both Th1 and Th17 cells [<xref ref-type="bibr" rid="CR158">158</xref>]. In their study, Peelen et al. discovered that individuals who have relapsing&#8211;remitting MS have significantly elevated levels of the NLRP3, IL-1&#946;, and caspase-1 genes in their peripheral blood mononuclear cells (PBMCs) compared to those without the disorder [<xref ref-type="bibr" rid="CR160">160</xref>].</p><p id="Par21">Studies have demonstrated a rise in the levels of caspase-1 and IL-1&#946; proteins in the peripheral blood mononuclear cells and cerebrospinal fluid of patients with multiple sclerosis [<xref ref-type="bibr" rid="CR161">161</xref>, <xref ref-type="bibr" rid="CR162">162</xref>]. Moreover, studies have demonstrated increased levels of caspase-1 not only in certain regions of the brain and spinal cord, but also in immune cells circulating in the blood of individuals with multiple sclerosis [<xref ref-type="bibr" rid="CR163">163</xref>, <xref ref-type="bibr" rid="CR164">164</xref>]. According to the results, it is proposed that assessing the quantities of caspase-1 and ASC proteins in the blood may serve as a dependable indicator of the development of MS [<xref ref-type="bibr" rid="CR165">165</xref>]. Individuals with multiple sclerosis had significantly elevated levels of IL-18 in their bloodstream, cerebral spinal fluid, and immune cells [<xref ref-type="bibr" rid="CR158">158</xref>, <xref ref-type="bibr" rid="CR166">166</xref>&#8211;<xref ref-type="bibr" rid="CR168">168</xref>]. Furthermore, the study conducted by de Jong et al. revealed a clear correlation between elevated levels of IL-1&#946; in the cerebrospinal fluid and a decrease in the protein IL-1Ra, which has a role in reducing inflammation by preventing the binding of IL-1&#946; to its receptor [<xref ref-type="bibr" rid="CR169">169</xref>]. The critical role of IL-1&#946; in the progression of MS is significantly evident in the function of the NLRP3 inflammasome, which produces this vital signaling molecule. Research suggests that successful treatments for MS relapses, including glatiramer acetate and IFN&#946;, promote the generation of IL-1Ra, which is a natural suppressor of IL-1 [<xref ref-type="bibr" rid="CR170">170</xref>, <xref ref-type="bibr" rid="CR171">171</xref>]. Studies have proven that Th1 and Th17 cells have the ability to generate IFN&#947; and IL-17 after being exposed to IL-18 and IL-1&#946;. These T helper cells have been strongly connected with the progress of multiple sclerosis.</p><p id="Par22">The NLRP3 inflammasome is a key driver of inflammation in PD. Fibrillar &#945;-synuclein, a hallmark of the disease, acts as an endogenous danger signal that directly triggers NLRP3 activation in microglia. This leads to caspase-1-mediated maturation of IL-1&#946;, propagating the inflammatory cycle [<xref ref-type="bibr" rid="CR172">172</xref>, <xref ref-type="bibr" rid="CR173">173</xref>]. Freshly discovered proof revealed that mice that were genetically modified to have Parkinson's disease through the use of MPTP exhibited a unique form of microRNA known as miR-7. The specific microRNA has a critical function in regulating the synthesis of &#945;-syn, a vital protein involved in the disease [<xref ref-type="bibr" rid="CR174">174</xref>]. The application of stereotactic delivery for administering artificial miR-7 into the mouse brain has proven to be highly successful in inhibiting the activity of NLRP3 inflammasome and reducing neuroinflammation significantly. This is likely due to the targeted action of miR-7 on Nlrp3 [<xref ref-type="bibr" rid="CR175">175</xref>]. The most recent study indicated that the topical administration of IL-1Ra effectively reduced the symptoms of Parkinson's disease caused by MPTP in mice [<xref ref-type="bibr" rid="CR176">176</xref>]. Additional evidence supporting the link between NLRP3 inflammasome and PD is provided by studies showing that DRD1 and the cAMP signaling pathway can suppress dopamine neurons, thereby inhibiting NLRP3. The data reveals that DRD1&#8201;&#8722;/&#8722;&#8201;mice were observed to have increased vulnerability to neuroinflammation caused by MPTP. The data showed a noteworthy rise in the concentrations of IL-18 and IL-1&#946;, accompanied by an escalation in the harm done to dopaminergic neurons [<xref ref-type="bibr" rid="CR177">177</xref>]. According to recent studies, ongoing and excessive stimulation of inflammasomes is thought to contribute to the development of neuroinflammation in ALS [<xref ref-type="bibr" rid="CR178">178</xref>, <xref ref-type="bibr" rid="CR179">179</xref>]. Comprehensive investigations conducted on the widely-utilized G93A-SOD1 transgenic mice, which serve as an animal model for ALS, discovered an increased presence of caspase-1 and IL-1&#946; functioning in microglia. This is attributed to the SOD1 mutation associated with ALS. Additional studies have shown that knocking out of the caspase-1 or IL-1&#946; genes, as well as using recombinant IL-1Ra, had a significant impact on reducing the inflammation response. Surprisingly, the research showed a rise in caspase-1 and IL-1&#946; production independently of NLRP3, implying the potential role of other inflammasome complexes [<xref ref-type="bibr" rid="CR180">180</xref>]. After conducting additional investigations on SOD1 transgenic mice, contradictory findings have surfaced, suggesting a heightened level of NLRP3 and ASC in the AD region. In the G93A variant, there was an increase in these molecules along with a higher level of TDP-43 in microglia [<xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR181">181</xref>]. New research findings indicate that the stimulation of astrocytes and the existence of NLRP3-inflammasome proteins in the spinal cord of G93A-SOD1 transgenic mice and human tissues are significant factors in the development of ALS-related inflammation, as they lead to the release of proinflammatory cytokines [<xref ref-type="bibr" rid="CR182">182</xref>]. Based on the research, microglia displayed ASC but not NLRP3, implying that other sensors of inflammasomes could be instrumental in the mechanism of neuroinflammation caused by microglia in ALS. This indicates that there may be additional crucial elements at play in the formation of this condition.</p></sec><sec id="Sec8"><title>Exercise, inflammation, and inflammasome</title><p id="Par23">The number of medical issues, including type 2 diabetes, is growing globally due to the continual growth of obesity rates. The disruptions can be attributed to a collapse in the connection between metabolic processes and immune responses, commonly referred to as immunometabolism [<xref ref-type="bibr" rid="CR183">183</xref>]. Moreover, there is a strong association between being overweight and a variety of severe medical issues such as heart disease, respiratory problems, colon and breast cancer, dementia, and depression. All of these conditions seem to be causally connected to inflammation in terms of their development [<xref ref-type="bibr" rid="CR184">184</xref>&#8211;<xref ref-type="bibr" rid="CR188">188</xref>]. A link has been established between the onset of a prolonged low-level inflammatory condition and the likelihood of experiencing multiple health hazards [<xref ref-type="bibr" rid="CR189">189</xref>]. The physical inflammatory reaction can be detected through substantially increased levels of inflammation indicators in the blood, such as IL-6, TNF, and CRP. The importance of highlighting these health issues is further magnified when taking into account a sedentary way of life and prolonged periods of sitting [<xref ref-type="bibr" rid="CR187">187</xref>, <xref ref-type="bibr" rid="CR190">190</xref>&#8211;<xref ref-type="bibr" rid="CR193">193</xref>]. Living a mostly inactive way of life results in a buildup of excess fat in the abdominal area, an upsurge in immune cells within this fat tissue, a greater secretion of adipokines, and the initiation of a mild inflammatory response [<xref ref-type="bibr" rid="CR186">186</xref>]. The occurrence of slight inflammation in the body has been associated with the formation of insulin resistance, hardening of the arteries, nerve impairment, and the progression of tumors [<xref ref-type="bibr" rid="CR188">188</xref>&#8211;<xref ref-type="bibr" rid="CR190">190</xref>](Fig.&#160;<xref rid="Fig7" ref-type="fig">7</xref>). Physical activity has qualities that can decrease inflammation, meaning that engaging in exercise consistently can provide protection against chronic illness over time [<xref ref-type="bibr" rid="CR190">190</xref>&#8211;<xref ref-type="bibr" rid="CR193">193</xref>]. Furthermore, participating in exercise can serve as a remedy for various ailments and improve their symptoms. Consequently, the concept of exercise as a form of medicine (BOX 1) has gained significant support to promote regular physical activity among the general population [<xref ref-type="bibr" rid="CR194">194</xref>]. Exercise increases energy expenditure, which helps reduce visceral adiposity, particularly in individuals with a positive energy balance. Engaging in regular physical exercise can greatly decrease the likelihood of developing obesity and accumulating excessive amounts of body fat. Taking part in physical activities has the potential to greatly aid in promoting cardiovascular wellbeing by enhancing the levels of blood lipids. The goal is to decrease harmful plasma triglycerides and LDL cholesterol, while simultaneously increasing beneficial HDL cholesterol levels [<xref ref-type="bibr" rid="CR195">195</xref>]. These positive modifications in blood lipids are thought to impede the advancement of atherosclerosis. However, participating in consistent exercise can offer defense against persistent inflammatory conditions by effectively fighting against inflammation [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR196">196</xref>, <xref ref-type="bibr" rid="CR197">197</xref>]. One potential reason for this impact could be the reduction of visceral fat, resulting in a decrease of inflammatory substances being produced and released from fat cells. Moreover, regular physical activity can enhance the body's ability to combat inflammation by maintaining its consistent functioning [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR197">197</xref>]. In-depth research has thoroughly explored three primary areas that could potentially add to the anti-inflammatory advantages of participating in physical activity. Multiple factors are involved in this process, including a decrease in visceral fat, an increase in the release of anti-inflammatory myokines from active muscles, and a decrease in TLRs on immune cells. This leads to a lower production of pro-inflammatory cytokines and a decline in levels of MHC and co-stimulatory molecules [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR197">197</xref>&#8211;<xref ref-type="bibr" rid="CR200">200</xref>]. Furthermore, research conducted on mice has shown that exercise has a wide range of benefits on inflammation, as it not only involves one, but multiple mechanisms. These include halting the movement of monocytes and macrophages into fat cells, as well as stimulating changes in the attributes of fat tissue macrophages [<xref ref-type="bibr" rid="CR201">201</xref>]. Researching the alterations in peripheral blood indicators after physical activity poses challenges in human studies, however, has demonstrated a decline in levels of pro-inflammatory monocytes and a rise in TReg cells [<xref ref-type="bibr" rid="CR202">202</xref>&#8211;<xref ref-type="bibr" rid="CR204">204</xref>]. The evidence suggests that the anti-inflammatory advantages of physical activity might be attributed to similar processes in different individuals. However, there are certain limitations when studying how physical activity affects the immune system in humans. These limitations encompass both immediate and long-lasting effects, as elaborated in the subsequent section. The initiation of inflammation within adipocytes is a crucial factor in the development of metabolic disorders, as it triggers the production of NLRP3 and other indicators linked to inflammation [<xref ref-type="bibr" rid="CR205">205</xref>]. Stimulation of NLRP3 inflammasomes and Caspase-1 through TXNIP and FGF2 may exacerbate the inflammatory reaction in adipocytes [<xref ref-type="bibr" rid="CR206">206</xref>, <xref ref-type="bibr" rid="CR207">207</xref>]. Based on a previous study, a 2-month program of treadmill workouts effectively reduced the presence of NLRP3 and decreased the amounts of FGF2 in fat cells [<xref ref-type="bibr" rid="CR207">207</xref>]. Furthermore, research has demonstrated the vital role of TNF-&#945; in regulating the expression of genes and agents related to NLRP3 inflammasome activation, particularly in conditions associated with cryopyrinopathies [<xref ref-type="bibr" rid="CR208">208</xref>]. Other investigations have corroborated the notion that NLRP3 within fat cells has a direct correlation with the generation of TNF-&#945; [<xref ref-type="bibr" rid="CR209">209</xref>]. Increasing PPAR&#947; levels promotes APN production and suppresses TNF-&#945; release [<xref ref-type="bibr" rid="CR210">210</xref>]. As commonly acknowledged, the gene PPAR&#947; holds the responsibility of regulating the process of adipocyte differentiation [<xref ref-type="bibr" rid="CR211">211</xref>]. Participating in aerobic exercise can significantly increase the amounts of PPAR&#947; and APN present in adipose tissue, while simultaneously decreasing the amounts of TNF-&#945; [<xref ref-type="bibr" rid="CR210">210</xref>]. Furthermore, following a period of 10&#160;weeks of treadmill exercise, there was a notable reduction in the amounts of NLRP3, TNF-&#945;, and IL-1&#946; present in adipose tissue [<xref ref-type="bibr" rid="CR212">212</xref>]. Based on the study mentioned, it can be deduced that consistent participation in aerobic exercise has the ability to hinder pyroptosis in adipocytes by diminishing inflammation within said cells. Irisin, also referred to as FNDC5, is a substance that is triggered by physical activity. Furthermore, aside from its involvement in muscle movement, it also serves as an adipocytokine. Studies have shown significant potential for irisin as a therapeutic method in inhibiting NLRP3-induced pyroptosis in cardiomyocytes [<xref ref-type="bibr" rid="CR213">213</xref>]. AMP-activated protein kinase (AMPK) plays a crucial role in maintaining the levels of peroxisome proliferator-activated receptor-coactivator-1&#945; (PGC-1&#945;) [<xref ref-type="bibr" rid="CR214">214</xref>] and irisin [<xref ref-type="bibr" rid="CR215">215</xref>]. Irisin was found to effectively suppress the ROS/NLRP3 inflammatory pathway, as well as the production of TNF-&#945; and pyroptosis [<xref ref-type="bibr" rid="CR213">213</xref>, <xref ref-type="bibr" rid="CR216">216</xref>, <xref ref-type="bibr" rid="CR217">217</xref>]. Physical activities that require oxygen have been proven to stimulate AMPK and PGC1-&#945;, boosting the production of irisin in fat cells and obstructing the NLRP3 pathway signaling [<xref ref-type="bibr" rid="CR215">215</xref>, <xref ref-type="bibr" rid="CR218">218</xref>]. The vital role of the pathway called PI3K and AKT, also known as phosphatidylinositol 3-hydroxy kinase signaling, is well-established in maintaining glucose homeostasis, controlling lipid metabolism, and contributing to the development of insulin resistance [<xref ref-type="bibr" rid="CR219">219</xref>]. The NLRP3 inflammasome plays a crucial role in boosting the production of IL-1&#946;, IL-18, and IFN&#947;, while also blocking the function of the IRS-1/PI3K/AKT signaling pathway. This ultimately results in insulin resistance [<xref ref-type="bibr" rid="CR205">205</xref>, <xref ref-type="bibr" rid="CR220">220</xref>]. In a research conducted by Vandanmagsar and colleagues (2011), it was found that participating in aerobic exercise resulted in significant enhancements in insulin resistance among individuals diagnosed with type 2 diabetes. The research noted a substantial reduction in the levels of NLRP3 and IL-1&#946; in the adipose tissue of the subjects. According to a separate research, a reduction in IL-1&#946; and NLRP3 levels was found to be beneficial in improving blood sugar levels and the resistance to insulin [<xref ref-type="bibr" rid="CR205">205</xref>]. Moreover, participating in aerobic exercise has been linked to a surge in PI3K and AKT levels, triggering the initiation of the PI3K/AKT/GLUT4 pathway in adipose cells, ultimately leading to enhanced insulin sensitivity [<xref ref-type="bibr" rid="CR221">221</xref>]. A potential explanation for how aerobic exercise impacts adipocyte pyroptosis is through the reduction of inflammation in adipocytes and the enhancement of insulin resistance.</p><p id="Par24">Figure&#160;<xref rid="Fig7" ref-type="fig">7</xref> depicts the significant impact of the relationship between dietary intake and engagement in physical exercise on the formation of inflammation and numerous health conditions. To preserve the ability of fat to reduce inflammation, it is essential to have a diet consisting of healthy foods and engage in frequent physical activity. The elements consist of a reduction in the size of adipocytes and the presence of cells in the immune system that can lessen inflammation, specifically M2-type macrophages and CD4&#8201;+&#8201;regulatory T cells. When a person has excess energy and does not participate in regular physical exercise, it may lead to an increase in visceral fat and the entry of inflammatory macrophages and T cells into their adipose tissue. In cases of adipose inflammation, the major component is M1 macrophages, which play a vital role in triggering inflammation and producing adipokines like tumor necrosis factor (TNF). Hence, people consistently encounter a continuous and subtle systemic inflammation. This could possibly lead to increased insulin resistance, the growth of tumors, impaired neurological function, and the buildup of plaque in the arteries. Not engaging in enough physical activity is a major contributor to unfavorable changes in an individual's blood lipid levels, ultimately exacerbating the development of atherosclerosis.</p></sec><sec id="Sec9"><title>Exercise and inflammation, inflammasome in neurodegenerative disorders</title><p id="Par25">Physical exercise exerts its neuroprotective effects through several common, overlapping pathways across different neurodegenerative conditions. These core mechanisms include (1) suppressing the activation of the NLRP3 inflammasome [<xref ref-type="bibr" rid="CR222">222</xref>&#8211;<xref ref-type="bibr" rid="CR224">224</xref>], (2) modulating glial cell activity to favor an anti-inflammatory, pro-repair phenotype (e.g., the M2 microglial state) [<xref ref-type="bibr" rid="CR225">225</xref>], (3) reducing the production of pro-inflammatory cytokines like TNF-&#945; and IL-1&#946; [<xref ref-type="bibr" rid="CR226">226</xref>, <xref ref-type="bibr" rid="CR227">227</xref>], and (4) increasing the expression of neurotrophic factors such as BDNF that support neuronal survival and plasticity [<xref ref-type="bibr" rid="CR228">228</xref>, <xref ref-type="bibr" rid="CR229">229</xref>]. The following sections will discuss the specific evidence for how these shared mechanisms apply to the unique pathology of each disease. The key findings from a selection of pivotal studies are compiled in Table&#160;<xref rid="Tab2" ref-type="table">2</xref>, providing a comparative overview of different intervention strategies and their outcomes.
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table&#160;2</label><caption><p>Summary of Exercise Interventions and Their Effects in Models of Neurodegenerative Disease</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Disease</th><th align="left" colspan="1" rowspan="1">Study model</th><th align="left" colspan="1" rowspan="1">Exercise protocol (type, duration, frequency)</th><th align="left" colspan="1" rowspan="1">Key molecular &amp; cellular findings</th><th align="left" colspan="1" rowspan="1">Key behavioral/clinical outcomes &amp; reference</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">Alzheimer's Disease (AD)</td><td align="left" colspan="1" rowspan="1">Mice (A&#946;&#8321;&#8331;&#8324;&#8320; injected)</td><td align="left" colspan="1" rowspan="1">Moderate treadmill running; 4&#160;weeks</td><td align="left" colspan="1" rowspan="1">&#8595; Hippocampal microglial reactivity (Iba-1); &#8595; NLRP3 inflammasome pathway activation (NLRP3, TXNIP, caspase-1)</td><td align="left" colspan="1" rowspan="1">Not specified [<xref ref-type="bibr" rid="CR230">230</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Genetically engineered AD mice</td><td align="left" colspan="1" rowspan="1">Treadmill running; 20&#160;weeks</td><td align="left" colspan="1" rowspan="1">&#8595; Hippocampal NLRP3, IL-1&#946;, and A&#946;&#8321;&#8331;&#8324;&#8322; levels; &#8595; microglial activation and neuronal impairment</td><td align="left" colspan="1" rowspan="1">Improved cognitive performance [<xref ref-type="bibr" rid="CR231">231</xref>]</td></tr><tr><td align="left" rowspan="3" colspan="1">Parkinson's Disease (PD)</td><td align="left" colspan="1" rowspan="1">Human (PD patients)</td><td align="left" colspan="1" rowspan="1">High-Intensity Interval Training (HIIT); 12&#160;weeks</td><td align="left" colspan="1" rowspan="1">&#8595; TNF-&#945;, &#8593; IL-10, &#8593; superoxide dismutase (SOD); &#8595; neutrophil counts</td><td align="left" colspan="1" rowspan="1">Potential slowing of disease progression [<xref ref-type="bibr" rid="CR232">232</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Mice (MPTP-induced)</td><td align="left" colspan="1" rowspan="1">Treadmill running; concurrent with MPTP</td><td align="left" colspan="1" rowspan="1">&#8595; Microglial activation; &#8595; NLRP3&#8201;+/Iba-1&#8201;+&#8201;cells; Suppressed TLR4/MyD88/NF-&#954;B signaling</td><td align="left" colspan="1" rowspan="1">Ameliorated motor deficits and dopaminergic neuron loss [<xref ref-type="bibr" rid="CR223">223</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Mice (MPTP-induced)</td><td align="left" colspan="1" rowspan="1">Environmental Enrichment (includes voluntary exercise)</td><td align="left" colspan="1" rowspan="1">&#8595; &#945;-synuclein, TNF-&#945;, IL-1&#946;; Blocked TLR2 signaling; Restored tyrosine hydroxylase</td><td align="left" colspan="1" rowspan="1">Improved motor function 75[<xref ref-type="bibr" rid="CR233">233</xref>]</td></tr><tr><td align="left" rowspan="2" colspan="1">Amyotrophic Lateral Sclerosis (ALS)</td><td align="left" colspan="1" rowspan="1">Transgenic mice (G93A-SOD1)</td><td align="left" colspan="1" rowspan="1">Moderate voluntary running</td><td align="left" colspan="1" rowspan="1">Not specified, but protects motor neurons</td><td align="left" colspan="1" rowspan="1"><p>Prolonged survival and delayed disease onset 8</p><p>[<xref ref-type="bibr" rid="CR234">234</xref>, <xref ref-type="bibr" rid="CR235">235</xref>]</p></td></tr><tr><td align="left" colspan="1" rowspan="1">ALS model mice</td><td align="left" colspan="1" rowspan="1">Swimming</td><td align="left" colspan="1" rowspan="1">&#8593; Brain-Derived Neurotrophic Factor (BDNF), &#8593; Insulin-like Growth Factor 1 (IGF-1); Reduced motor neuron loss</td><td align="left" colspan="1" rowspan="1">Not specified [<xref ref-type="bibr" rid="CR236">236</xref>].89</td></tr><tr><td align="left" rowspan="2" colspan="1">Multiple Sclerosis (MS)</td><td align="left" colspan="1" rowspan="1">Mice (EAE model)</td><td align="left" colspan="1" rowspan="1">Treadmill running; 5x/week for 4&#160;weeks</td><td align="left" colspan="1" rowspan="1">&#8595; Hippocampal demyelination; &#8593; BDNF levels</td><td align="left" colspan="1" rowspan="1">Improved performance in memory tasks [<xref ref-type="bibr" rid="CR237">237</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Human (Females with MS)</td><td align="left" colspan="1" rowspan="1">Aerobic and resistance training (unspecified duration)</td><td align="left" colspan="1" rowspan="1">&#8595; Leptin, &#8595; TNF-&#945;; &#8593; IL-10, &#8593; adiponectin</td><td align="left" colspan="1" rowspan="1">Reduced body weight and inflammation [<xref ref-type="bibr" rid="CR238">238</xref>]</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec10"><title>Alzheimer's disease</title><p id="Par26">Alzheimer's disease disrupts the proper functioning of neuroglial cells, including microglia, astrocytes, and oligodendrocytes, causing neuroinflammation. As a consequence, the situation deteriorates at an accelerated pace. In the Mild Cognitive Impairment (MCI) phase, the BBB weakens and becomes permeable, allowing external elements such as LPS to enter and activate immune cells in the brain [<xref ref-type="bibr" rid="CR239">239</xref>]. Research has shown that people who have Alzheimer's disease struggle with maintaining proper functioning of their digestive and nervous system barriers. The process of inflammation is stimulated by the connection between Lipopolysaccharide (LPS) and Toll-like receptor 4 (TLR4) on immune cells within the intestinal lining. This leads to an increase in intestinal secretions and enables the passage of LPS into the bloodstream [<xref ref-type="bibr" rid="CR240">240</xref>]. The exterior coating of Gram-negative bacteria is rich in LPS, which functions as a potent trigger for the body's immune response. The substance attaches specifically to TLR4 receptors found on neuroglial cells in the brain, taking advantage of the weakened blood&#8211;brain barrier frequently seen in individuals with Alzheimer's disease. This subsequently results in a sequence of incendiary responses, establishing an unending cycle of detrimental consequences. Therefore, directing efforts towards managing these inflammatory reactions could have a considerable effect on reducing the occurrence and managing the symptoms of AD. After thorough investigation, evidence suggest that incorporating physical activity as a non-invasive method has a beneficial impact on both preventing and managing AD, primarily in reducing the impact of inflammatory reactions [<xref ref-type="bibr" rid="CR241">241</xref>&#8211;<xref ref-type="bibr" rid="CR243">243</xref>]. The recommended amount of physical activity for adults to decrease the risk of AD, according to the World Health Organization, is 150&#8211;300&#160;min of moderate exercise or 75&#8211;150&#160;min of intense exercise per week [<xref ref-type="bibr" rid="CR244">244</xref>]. The extent of physical activity's effect on lowering inflammation greatly relies on the intensity and length of the workout, along with personal differences. Extensive research has consistently shown that engaging in regular, moderate exercise has the ability to significantly strengthen the immune system and decrease inflammation in the body. A technique to achieve this is by activating the hypothalamic&#8211;pituitary&#8211;adrenal axis, which promotes an advantageous environment for cellular survival, prevents cell death, facilitates effective elimination of cellular debris, and regulates hormone production. In Choi's research, it was discovered that implementing a four-week regimen of low-intensity aerobic exercise on an animal model effectively reduced its immune and inflammatory reaction triggered by LPS-induced inflammation [<xref ref-type="bibr" rid="CR245">245</xref>]. On the other hand, engaging in intense and challenging physical activity may result in harmful outcomes, including harm to muscles, triggering an inflammatory reaction, and using glycogen to produce reactive substances such as ROS and RNS. This could result in a weakened immune system and a detrimental cycle [<xref ref-type="bibr" rid="CR246">246</xref>]. In summary, participating in moderate exercise has been scientifically shown to effectively decrease inflammation by regulating the immune system and improving its ability to defend the body. This can potentially help prevent the onset of neurological disorders. The findings indicate that participating in physical exercise may be a crucial means of managing immune and inflammatory reactions. There are two main types of Alzheimer's disease: familial Alzheimer's disease (FAD) and late-onset Alzheimer's disease (LOAD). Familial Alzheimer's disease (FAD) is commonly identified in individuals who are younger, while late-onset Alzheimer's disease (LOAD) is mostly seen in older individuals. Based on the most recent data, it can be concluded that LOAD is accountable for over 90% of cases of Alzheimer's disease. Preventing and managing LOAD is crucially significant and should not be overlooked. As people age, they go through a gradual and ongoing process of inflammation, which is believed to have a significant impact on the emergence of various chronic conditions related to age. As people get older, their immune system gradually becomes less effective, leading to a decrease in T-cell function, a decreased ability to recognize previous immune responses, and a heightened activity of inflammatory cells [<xref ref-type="bibr" rid="CR247">247</xref>]. The modifications diminish the body's safeguard against harmful substances and escalate ongoing inflammation. As time goes by, cells secrete various substances and enzymes that trigger inflammation, including cytokines, chemokines, and proteases, collectively known as the senescence-associated secretory phenotype (SASP) [<xref ref-type="bibr" rid="CR248">248</xref>]. The presence of SASP can exacerbate inflammatory reactions in nearby tissues, resulting in accelerated aging and increased vulnerability to obesity and type 2 diabetes. This could potentially result in a prolonged state of inflammation throughout the entire body. Fat tissue found in the abdomen can lead to inflammation and accelerate aging as it produces specific substances like TNF-&#945; and IL-6 [<xref ref-type="bibr" rid="CR249">249</xref>]. The collaboration of these physiological functions intensifies the existing chronic inflammation, which worsens the advancement of Alzheimer's disease. Importantly<bold>,</bold> participation in physical exercise has been shown to successfully control the body's inflammatory reaction. Engaging in regular and consistent physical activity has the ability to relieve persistent inflammation and slow down the aging process by blocking pro-inflammatory substances while boosting anti-inflammatory elements (Fig.&#160;<xref rid="Fig8" ref-type="fig">8</xref>). In the context of AD, exercise leverages these common anti-inflammatory effects to directly combat disease pathology. Specifically, by promoting a microglial shift toward the M2 phenotype, exercise has been shown to enhance the phagocytic clearance of A&#946; aggregates while reducing the local release of neurotoxic cytokines [<xref ref-type="bibr" rid="CR250">250</xref>, <xref ref-type="bibr" rid="CR251">251</xref>]. Furthermore, a study shows that moderate treadmill exercise can directly suppress the A&#946;&#8321;&#8331;&#8324;&#8320;-induced activation of the NLRP3 inflammasome pathway in the hippocampus [<xref ref-type="bibr" rid="CR230">230</xref>].<fig id="Fig8" position="float" orientation="portrait"><label>Fig.&#160;8</label><caption><p>Engaging in physical activity has a significant and diverse influence on the advancement of Alzheimer's disease, greatly impacting the body's overall well-being</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO8" position="float" orientation="portrait" xlink:href="40001_2025_3165_Fig8_HTML.jpg"/></fig></p><p id="Par27">Beyond microglia, exercise confers benefits to other essential components of the central nervous system. It reduces the inflammatory reactivity of astrocytes, improves their ability to clear neurotransmitters, and supports neuronal energy metabolism [<xref ref-type="bibr" rid="CR252">252</xref>]. Physical activity also promotes the health of oligodendrocytes by boosting neurotrophic factors like brain-derived neurotrophic factor (BDNF), which aids in myelin maintenance and repair [<xref ref-type="bibr" rid="CR253">253</xref>]. Moreover, exercise strengthens the blood&#8211;brain barrier (BBB) by reducing inflammatory signaling and improving endothelial function [<xref ref-type="bibr" rid="CR254">254</xref>]. These central effects are complemented by systemic benefits, as exercise favorably alters the gut microbiota, which can reduce peripheral inflammation and, via the gut-brain axis, lessen neuroinflammation [<xref ref-type="bibr" rid="CR255">255</xref>].</p><p id="Par28">This multi-faceted neuroprotection translates to tangible cognitive benefits. For example, a long-term study by Li and colleagues demonstrated that 20&#160;weeks of treadmill exercise in a genetic AD mouse model significantly improved cognitive performance. These behavioral enhancements were linked to key molecular changes in the hippocampus, including a marked reduction in NLRP3 inflammasome components, IL-1&#946;, and A&#946;&#8321;&#8331;&#8324;&#8322; levels. The exercise also preserved hippocampal neurons by reducing pathological microglial activity, highlighting a direct link between exercise-induced anti-inflammation and the preservation of cognitive function [<xref ref-type="bibr" rid="CR231">231</xref>].</p><p id="Par29">Taken together, the evidence strongly supports physical activity as a potent, non-pharmacological strategy to mitigate neuroinflammation and slow disease progression in Alzheimer's disease.</p></sec><sec id="Sec11"><title>Parkinson's disease</title><p id="Par30">In Parkinson's disease, where the aggregation of &#945;-synuclein and the loss of dopaminergic neurons are driven by neuroinflammation, exercise provides targeted neuroprotection. By leveraging the same core anti-inflammatory mechanisms seen in AD, physical activity directly counteracts PD pathology. For example, exercise is known to suppress the activation of the NLRP3 inflammasome in microglia, a pathway directly triggered by fibrillar &#945;-synuclein [<xref ref-type="bibr" rid="CR256">256</xref>].</p><p id="Par31">Evidence from clinical and preclinical studies supports these benefits. A 12-week high-intensity interval training (HIIT) program in individuals with PD led to a significant decrease in the pro-inflammatory cytokine TNF-&#945; and a rise in anti-inflammatory IL-10, demonstrating a powerful systemic effect [<xref ref-type="bibr" rid="CR232">232</xref>, <xref ref-type="bibr" rid="CR257">257</xref>, <xref ref-type="bibr" rid="CR258">258</xref>]. Crucially, such interventions are also associated with increased levels of neuroprotective factors like BDNF and tangible improvements in clinical motor scores on the Unified Parkinson's Disease Rating Scale (UPDRS) [<xref ref-type="bibr" rid="CR259">259</xref>&#8211;<xref ref-type="bibr" rid="CR261">261</xref>]. In mouse models of PD, treadmill exercise not only preserved dopaminergic neurons and improved motor function but did so by inhibiting the TLR4/MyD88/NF-&#954;B signaling that leads to inflammasome activation [<xref ref-type="bibr" rid="CR256">256</xref>]. Furthermore, environmental enrichment that includes voluntary exercise has been shown to reduce &#945;-synuclein levels and suppress inflammation by blocking TLR2 signaling pathways [<xref ref-type="bibr" rid="CR265">265</xref>].</p><p id="Par32">Providing a more nuanced perspective, a large 2021 systematic review by Li and colleagues confirmed that physical activity beneficially lowered UPDRS motor scores and raised BDNF levels. However, they found the evidence for a direct reduction in systemic inflammation and oxidative stress markers to be of low certainty, highlighting the need for further high-quality trials to clarify the precise mechanisms underlying the observed clinical improvements [<xref ref-type="bibr" rid="CR262">262</xref>].</p><p id="Par33">Collectively, these findings underscore the potential of exercise to slow PD progression by improving clinical outcomes and mitigating &#945;-synuclein-driven inflammation, even as the full spectrum of its mechanistic action continues to be explored.</p></sec><sec id="Sec12"><title>Other neurodegenerative diseases</title><p id="Par34">The benefits of exercise extend to other neurodegenerative conditions, although the mechanisms and optimal protocols may vary depending on the specific pathology of each disease.</p><sec id="Sec13"><title>Huntington&#8217;s disease (HD)</title><p id="Par35">While research is still emerging compared to AD and PD, exercise is considered a promising strategy for managing symptoms in Huntington's disease. Animal models show that exercise can improve motor function and delay disease progression [<xref ref-type="bibr" rid="CR263">263</xref>&#8211;<xref ref-type="bibr" rid="CR265">265</xref>]. The underlying mechanisms are thought to overlap with those in other disorders, including a reduction in overall neuroinflammation, modulation of glial activity, and an increase in the production of crucial neurotrophic factors like BDNF, which is known to be depleted in HD and is vital for synaptic function and neuronal survival [<xref ref-type="bibr" rid="CR129">129</xref>, <xref ref-type="bibr" rid="CR266">266</xref>].</p></sec><sec id="Sec14"><title>Amyotrophic lateral sclerosis (ALS)</title><p id="Par36">The role of exercise in ALS is particularly nuanced and highlights the importance of intensity. A critical distinction exists between strenuous physical exertion, which has been linked to an increased risk of developing ALS in elite athletes, and moderate, controlled exercise, which shows therapeutic promise [<xref ref-type="bibr" rid="CR267">267</xref>&#8211;<xref ref-type="bibr" rid="CR270">270</xref>]. In the widely used G93A-SOD1 transgenic mouse model of ALS, moderate running was shown to prolong survival and delay the onset of motor symptoms [<xref ref-type="bibr" rid="CR234">234</xref>, <xref ref-type="bibr" rid="CR235">235</xref>]. This protective effect is Linked to the upregulation of neurotrophic factors Like insulin-like growth factor 1 (IGF-1) and BDNF, which help preserve motor neurons from degeneration [<xref ref-type="bibr" rid="CR236">236</xref>]. Conversely, intense exercise in the same models was found to be detrimental, suggesting a fine balance is required to achieve neuroprotective benefits without causing excitotoxicity and further stress on vulnerable motor neurons [<xref ref-type="bibr" rid="CR271">271</xref>].</p></sec><sec id="Sec15"><title>Multiple sclerosis (MS)</title><p id="Par37">In multiple sclerosis, an autoimmune disorder characterized by demyelination and neuroinflammation, exercise acts as a potent immunomodulator. In the experimental autoimmune encephalomyelitis (EAE) animal model, exercise has been shown to reduce disease severity by promoting a shift away from pro-inflammatory Th1 and Th17 cells toward anti-inflammatory regulatory T cells (Tregs) [<xref ref-type="bibr" rid="CR272">272</xref>]. This immunomodulation is complemented by a systemic anti-inflammatory effect driven by muscle-derived cytokines and a reduction in pro-inflammatory adipokines like leptin and TNF-&#945; in human patients [<xref ref-type="bibr" rid="CR238">238</xref>, <xref ref-type="bibr" rid="CR273">273</xref>, <xref ref-type="bibr" rid="CR274">274</xref>]. Furthermore, exercise can directly counter the neurodegenerative aspects of MS by reducing hippocampal demyelination and improving cognitive function, an effect associated with increased levels of BDNF [<xref ref-type="bibr" rid="CR237">237</xref>, <xref ref-type="bibr" rid="CR275">275</xref>].</p></sec></sec><sec id="Sec16"><title>Conclusion</title><p id="Par38">As the global population ages, the incidence of neurodegenerative disorders&#8212;and the associated healthcare burden&#8212;continues to rise. Physical exercise remains one of the most effective non-pharmacological strategies for preserving cognitive function and mitigating neuroinflammation. However, in individuals unable to engage in regular physical activity due to illness, frailty, or injury, circulating factors found in &#8220;runner's plasma&#8221; have emerged as promising exercise mimetics.</p><p id="Par39">Recent studies have identified several of these bioactive molecules capable of reducing neuroinflammation, promoting neurogenesis, enhancing synaptic plasticity, and decreasing pathological protein accumulation in models of Alzheimer's and Parkinson's diseases. While preclinical data are encouraging, the molecular mechanisms underlying these effects remain incompletely understood, and only a small subset of candidate molecules has been thoroughly investigated.</p><p id="Par40">This review aimed to summarize emerging evidence on exercise-induced factors that mimic the neuroprotective effects of physical activity. Although these findings suggest potential therapeutic value, clinical validation is lacking. It is important to acknowledge that while the mechanistic evidence detailed in this review is extensive, much of it is derived from preclinical models. The existing human clinical studies, though more limited, provide encouraging and consistent results. For instance, investigations in patients with Parkinson's disease and multiple sclerosis have demonstrated that structured exercise programs can significantly reduce systemic inflammatory markers, like TNF-&#945;, while concurrently improving clinical motor scores and well-being [<xref ref-type="bibr" rid="CR232">232</xref>, <xref ref-type="bibr" rid="CR238">238</xref>, <xref ref-type="bibr" rid="CR262">262</xref>]. This alignment between preclinical mechanisms and clinical outcomes underscores the urgent need for more robust, large-scale human trials. Future studies employing advanced neuroimaging and cerebrospinal fluid analysis are essential to fully validate the neuroprotective and anti-inflammatory effects of exercise within the human brain and to optimize its use as a therapeutic strategy.</p><p id="Par41">To advance this field, future research must focus on identifying and characterizing additional exercise-responsive molecules, clarifying their mechanisms of action, and evaluating their efficacy, safety, dosage, and treatment duration in human populations. Ultimately, well-designed clinical trials are essential to determine whether exercise mimetics can become viable therapeutic interventions for neurodegenerative diseases.</p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>YiPing Su, and Zhanguo Su contributed to the conception, design, and drafting of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethical approval and consent to participate</title><p id="Par42">Not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par43">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par44">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feigin</surname><given-names>VL</given-names></name><name name-style="western"><surname>Nichols</surname><given-names>E</given-names></name><name name-style="western"><surname>Alam</surname><given-names>T</given-names></name><name name-style="western"><surname>Bannick</surname><given-names>MS</given-names></name><name name-style="western"><surname>Beghi</surname><given-names>E</given-names></name><name name-style="western"><surname>Blake</surname><given-names>N</given-names></name><name name-style="western"><surname>Culpepper</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Dorsey</surname><given-names>ER</given-names></name><name name-style="western"><surname>Elbaz</surname><given-names>A</given-names></name><name name-style="western"><surname>Ellenbogen</surname><given-names>RG</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>JL</given-names></name></person-group><article-title>Global, regional, and national burden of neurological disorders, 1990&#8211;2016: a systematic analysis for the Global Burden of Disease Study 2016</article-title><source>Lancet Neurol</source><year>2019</year><volume>18</volume><issue>5</issue><fpage>459</fpage><lpage>480</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(18)30499-X</pub-id><pub-id pub-id-type="pmid">30879893</pub-id><pub-id pub-id-type="pmcid">PMC6459001</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Feigin VL, Nichols E, Alam T, Bannick MS, Beghi E, Blake N, et al. Global, regional, and national burden of neurological disorders, 1990&#8211;2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):459&#8211;80.<pub-id pub-id-type="pmid">30879893</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(18)30499-X</pub-id><pub-id pub-id-type="pmcid">PMC6459001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Current and projected future economic burden of Parkinson's disease in the U.S.</article-title><source>NPJ Parkinsons Dis</source><year>2020</year><volume>6</volume><fpage>15</fpage><pub-id pub-id-type="doi">10.1038/s41531-020-0117-1</pub-id><pub-id pub-id-type="pmid">32665974</pub-id><pub-id pub-id-type="pmcid">PMC7347582</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Yang W, et al. Current and projected future economic burden of Parkinson&#8217;s disease in the U.S. NPJ Parkinsons Dis. 2020;6:15.<pub-id pub-id-type="pmid">32665974</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41531-020-0117-1</pub-id><pub-id pub-id-type="pmcid">PMC7347582</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">who/news-room/fact-sheets/detail/physical-activity. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/news-room/fact-sheets/detail/physical-activity">https://www.who.int/news-room/fact-sheets/detail/physical-activity</ext-link>.</mixed-citation></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herold</surname><given-names>F</given-names></name><etal/></person-group><article-title>Dose-response matters! - a perspective on the exercise prescription in exercise-cognition research</article-title><source>Front Psychol</source><year>2019</year><volume>10</volume><fpage>2338</fpage><pub-id pub-id-type="doi">10.3389/fpsyg.2019.02338</pub-id><pub-id pub-id-type="pmid">31736815</pub-id><pub-id pub-id-type="pmcid">PMC6839278</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Herold F, et al. Dose-response matters! - a perspective on the exercise prescription in exercise-cognition research. Front Psychol. 2019;10:2338.<pub-id pub-id-type="pmid">31736815</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpsyg.2019.02338</pub-id><pub-id pub-id-type="pmcid">PMC6839278</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruegsegger</surname><given-names>GN</given-names></name><name name-style="western"><surname>Booth</surname><given-names>FW</given-names></name></person-group><article-title>Health benefits of exercise</article-title><source>Cold Spring Harb Perspect Med</source><year>2018</year><pub-id pub-id-type="doi">10.1101/cshperspect.a029694</pub-id><pub-id pub-id-type="pmid">28507196</pub-id><pub-id pub-id-type="pmcid">PMC6027933</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Ruegsegger GN, Booth FW. Health benefits of exercise. Cold Spring Harb Perspect Med. 2018. 10.1101/cshperspect.a029694.<pub-id pub-id-type="pmid">28507196</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/cshperspect.a029694</pub-id><pub-id pub-id-type="pmcid">PMC6027933</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alanko</surname><given-names>V</given-names></name><etal/></person-group><article-title>Mechanisms underlying non-pharmacological dementia prevention strategies: a translational perspective</article-title><source>J Prev Alzheimers Dis</source><year>2022</year><volume>9</volume><issue>1</issue><fpage>3</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.14283/jpad.2022.9</pub-id><pub-id pub-id-type="pmid">35098968</pub-id><pub-id pub-id-type="pmcid">PMC12275741</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Alanko V, et al. Mechanisms underlying non-pharmacological dementia prevention strategies: a translational perspective. J Prev Alzheimers Dis. 2022;9(1):3&#8211;11.<pub-id pub-id-type="pmid">35098968</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14283/jpad.2022.94</pub-id><pub-id pub-id-type="pmcid">PMC12275741</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ross</surname><given-names>RE</given-names></name><etal/></person-group><article-title>The role of exercise in the treatment of depression: biological underpinnings and clinical outcomes</article-title><source>Mol Psychiatry</source><year>2023</year><volume>28</volume><issue>1</issue><fpage>298</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1038/s41380-022-01819-w</pub-id><pub-id pub-id-type="pmid">36253441</pub-id><pub-id pub-id-type="pmcid">PMC9969795</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Ross RE, et al. The role of exercise in the treatment of depression: biological underpinnings and clinical outcomes. Mol Psychiatry. 2023;28(1):298&#8211;328.<pub-id pub-id-type="pmid">36253441</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41380-022-01819-w</pub-id><pub-id pub-id-type="pmcid">PMC9969795</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silveira</surname><given-names>LS</given-names></name><etal/></person-group><article-title>Macrophage polarization: implications on metabolic diseases and the role of exercise</article-title><source>Crit Rev Eukaryot Gene Expr</source><year>2016</year><volume>26</volume><issue>2</issue><fpage>115</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1615/CritRevEukaryotGeneExpr.2016015920</pub-id><pub-id pub-id-type="pmid">27480774</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Silveira LS, et al. Macrophage polarization: implications on metabolic diseases and the role of exercise. Crit Rev Eukaryot Gene Expr. 2016;26(2):115&#8211;32.<pub-id pub-id-type="pmid">27480774</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1615/CritRevEukaryotGeneExpr.2016015920</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gleeson</surname><given-names>M</given-names></name><etal/></person-group><article-title>The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease</article-title><source>Nat Rev Immunol</source><year>2011</year><volume>11</volume><issue>9</issue><fpage>607</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.1038/nri3041</pub-id><pub-id pub-id-type="pmid">21818123</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Gleeson M, et al. The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nat Rev Immunol. 2011;11(9):607&#8211;15.<pub-id pub-id-type="pmid">21818123</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri3041</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allen</surname><given-names>J</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Woods</surname><given-names>JA</given-names></name></person-group><article-title>Exercise and the regulation of inflammatory responses</article-title><source>Prog Mol Biol Transl Sci</source><year>2015</year><volume>135</volume><fpage>337</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1016/bs.pmbts.2015.07.003</pub-id><pub-id pub-id-type="pmid">26477921</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Allen J, Sun Y, Woods JA. Exercise and the regulation of inflammatory responses. Prog Mol Biol Transl Sci. 2015;135:337&#8211;54.<pub-id pub-id-type="pmid">26477921</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/bs.pmbts.2015.07.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oishi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Manabe</surname><given-names>I</given-names></name></person-group><article-title>Macrophages in inflammation, repair and regeneration</article-title><source>Int Immunol</source><year>2018</year><volume>30</volume><issue>11</issue><fpage>511</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxy054</pub-id><pub-id pub-id-type="pmid">30165385</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Oishi Y, Manabe I. Macrophages in inflammation, repair and regeneration. Int Immunol. 2018;30(11):511&#8211;28.<pub-id pub-id-type="pmid">30165385</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/intimm/dxy054</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roca-Rodr&#237;guez Mdel</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effects of exercise on inflammation in cardiac rehabilitation</article-title><source>Nutr Hosp</source><year>2015</year><volume>31</volume><issue>6</issue><fpage>2633</fpage><lpage>2640</lpage><pub-id pub-id-type="pmid">26040375</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3305/nh.2015.31.6.8868</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Roca-Rodr&#237;guez Mdel M, et al. Effects of exercise on inflammation in cardiac rehabilitation. Nutr Hosp. 2015;31(6):2633&#8211;40.<pub-id pub-id-type="pmid">26040375</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3305/nh.2015.31.6.8868</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pedersen</surname><given-names>BK</given-names></name></person-group><article-title>Anti-inflammatory effects of exercise: role in diabetes and cardiovascular disease</article-title><source>Eur J Clin Invest</source><year>2017</year><volume>47</volume><issue>8</issue><fpage>600</fpage><lpage>611</lpage><pub-id pub-id-type="doi">10.1111/eci.12781</pub-id><pub-id pub-id-type="pmid">28722106</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Pedersen BK. Anti-inflammatory effects of exercise: role in diabetes and cardiovascular disease. Eur J Clin Invest. 2017;47(8):600&#8211;11.<pub-id pub-id-type="pmid">28722106</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/eci.12781</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moldoveanu</surname><given-names>AI</given-names></name><name name-style="western"><surname>Shephard</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Shek</surname><given-names>PN</given-names></name></person-group><article-title>The cytokine response to physical activity and training</article-title><source>Sports Med</source><year>2001</year><volume>31</volume><issue>2</issue><fpage>115</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.2165/00007256-200131020-00004</pub-id><pub-id pub-id-type="pmid">11227979</pub-id><pub-id pub-id-type="pmcid">PMC7101891</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Moldoveanu AI, Shephard RJ, Shek PN. The cytokine response to physical activity and training. Sports Med. 2001;31(2):115&#8211;44.<pub-id pub-id-type="pmid">11227979</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00007256-200131020-00004</pub-id><pub-id pub-id-type="pmcid">PMC7101891</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petersen</surname><given-names>AM</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>BK</given-names></name></person-group><article-title>The anti-inflammatory effect of exercise</article-title><source>J Appl Physiol (1985)</source><year>2005</year><volume>98</volume><issue>4</issue><fpage>1154</fpage><lpage>1162</lpage><pub-id pub-id-type="doi">10.1152/japplphysiol.00164.2004</pub-id><pub-id pub-id-type="pmid">15772055</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Petersen AM, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol (1985). 2005;98(4):1154&#8211;62.<pub-id pub-id-type="pmid">15772055</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/japplphysiol.00164.2004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Timmons</surname><given-names>BW</given-names></name><name name-style="western"><surname>Cieslak</surname><given-names>T</given-names></name></person-group><article-title>Human natural killer cell subsets and acute exercise: a brief review</article-title><source>Exerc Immunol Rev</source><year>2008</year><volume>14</volume><fpage>8</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">19203081</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Timmons BW, Cieslak T. Human natural killer cell subsets and acute exercise: a brief review. Exerc Immunol Rev. 2008;14:8&#8211;23.<pub-id pub-id-type="pmid">19203081</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hennigar</surname><given-names>SR</given-names></name><name name-style="western"><surname>McClung</surname><given-names>JP</given-names></name><name name-style="western"><surname>Pasiakos</surname><given-names>SM</given-names></name></person-group><article-title>Nutritional interventions and the IL-6 response to exercise</article-title><source>FASEB j</source><year>2017</year><volume>31</volume><issue>9</issue><fpage>3719</fpage><lpage>3728</lpage><pub-id pub-id-type="doi">10.1096/fj.201700080R</pub-id><pub-id pub-id-type="pmid">28507168</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Hennigar SR, McClung JP, Pasiakos SM. Nutritional interventions and the IL-6 response to exercise. FASEB j. 2017;31(9):3719&#8211;28.<pub-id pub-id-type="pmid">28507168</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fj.201700080R</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peake</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Recovery of the immune system after exercise</article-title><source>J Appl Physiol (1985)</source><year>2017</year><volume>122</volume><issue>5</issue><fpage>1077</fpage><lpage>1087</lpage><pub-id pub-id-type="doi">10.1152/japplphysiol.00622.2016</pub-id><pub-id pub-id-type="pmid">27909225</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Peake JM, et al. Recovery of the immune system after exercise. J Appl Physiol (1985). 2017;122(5):1077&#8211;87.<pub-id pub-id-type="pmid">27909225</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/japplphysiol.00622.2016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bigley</surname><given-names>AB</given-names></name><name name-style="western"><surname>Simpson</surname><given-names>RJ</given-names></name></person-group><article-title>NK cells and exercise: implications for cancer immunotherapy and survivorship</article-title><source>Discov Med</source><year>2015</year><volume>19</volume><issue>107</issue><fpage>433</fpage><lpage>445</lpage><pub-id pub-id-type="pmid">26175401</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Bigley AB, Simpson RJ. NK cells and exercise: implications for cancer immunotherapy and survivorship. Discov Med. 2015;19(107):433&#8211;45.<pub-id pub-id-type="pmid">26175401</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lightfoot</surname><given-names>AP</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>RG</given-names></name></person-group><article-title>The role of myokines in muscle health and disease</article-title><source>Curr Opin Rheumatol</source><year>2016</year><volume>28</volume><issue>6</issue><fpage>661</fpage><lpage>666</lpage><pub-id pub-id-type="doi">10.1097/BOR.0000000000000337</pub-id><pub-id pub-id-type="pmid">27548653</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Lightfoot AP, Cooper RG. The role of myokines in muscle health and disease. Curr Opin Rheumatol. 2016;28(6):661&#8211;6.<pub-id pub-id-type="pmid">27548653</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/BOR.0000000000000337</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaw</surname><given-names>DM</given-names></name><etal/></person-group><article-title>T-cells and their cytokine production: the anti-inflammatory and immunosuppressive effects of strenuous exercise</article-title><source>Cytokine</source><year>2018</year><volume>104</volume><fpage>136</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1016/j.cyto.2017.10.001</pub-id><pub-id pub-id-type="pmid">29021092</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Shaw DM, et al. T-cells and their cytokine production: the anti-inflammatory and immunosuppressive effects of strenuous exercise. Cytokine. 2018;104:136&#8211;42.<pub-id pub-id-type="pmid">29021092</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cyto.2017.10.001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Christgen</surname><given-names>S</given-names></name><name name-style="western"><surname>Kanneganti</surname><given-names>TD</given-names></name></person-group><article-title>Inflammasomes and the fine line between defense and disease</article-title><source>Curr Opin Immunol</source><year>2020</year><volume>62</volume><fpage>39</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2019.11.007</pub-id><pub-id pub-id-type="pmid">31837596</pub-id><pub-id pub-id-type="pmcid">PMC7067632</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Christgen S, Kanneganti TD. Inflammasomes and the fine line between defense and disease. Curr Opin Immunol. 2020;62:39&#8211;44.<pub-id pub-id-type="pmid">31837596</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.coi.2019.11.007</pub-id><pub-id pub-id-type="pmcid">PMC7067632</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carroll</surname><given-names>SL</given-names></name><name name-style="western"><surname>Pasare</surname><given-names>C</given-names></name><name name-style="western"><surname>Barton</surname><given-names>GM</given-names></name></person-group><article-title>Control of adaptive immunity by pattern recognition receptors</article-title><source>Immunity</source><year>2024</year><volume>57</volume><issue>4</issue><fpage>632</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2024.03.014</pub-id><pub-id pub-id-type="pmid">38599163</pub-id><pub-id pub-id-type="pmcid">PMC11037560</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Carroll SL, Pasare C, Barton GM. Control of adaptive immunity by pattern recognition receptors. Immunity. 2024;57(4):632&#8211;48.<pub-id pub-id-type="pmid">38599163</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2024.03.014</pub-id><pub-id pub-id-type="pmcid">PMC11037560</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><name name-style="western"><surname>Wu</surname><given-names>M</given-names></name></person-group><article-title>Pattern recognition receptors in health and diseases</article-title><source>Signal Transduct Target Ther</source><year>2021</year><volume>6</volume><issue>1</issue><fpage>291</fpage><pub-id pub-id-type="doi">10.1038/s41392-021-00687-0</pub-id><pub-id pub-id-type="pmid">34344870</pub-id><pub-id pub-id-type="pmcid">PMC8333067</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Li D, Wu M. Pattern recognition receptors in health and diseases. Signal Transduct Target Ther. 2021;6(1):291.<pub-id pub-id-type="pmid">34344870</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-021-00687-0</pub-id><pub-id pub-id-type="pmcid">PMC8333067</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leemans</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Pattern recognition receptors and the inflammasome in kidney disease</article-title><source>Nat Rev Nephrol</source><year>2014</year><volume>10</volume><issue>7</issue><fpage>398</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1038/nrneph.2014.91</pub-id><pub-id pub-id-type="pmid">24890433</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Leemans JC, et al. Pattern recognition receptors and the inflammasome in kidney disease. Nat Rev Nephrol. 2014;10(7):398&#8211;414.<pub-id pub-id-type="pmid">24890433</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrneph.2014.91</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moretti</surname><given-names>J</given-names></name><name name-style="western"><surname>Blander</surname><given-names>JM</given-names></name></person-group><article-title>Insights into phagocytosis-coupled activation of pattern recognition receptors and inflammasomes</article-title><source>Curr Opin Immunol</source><year>2014</year><volume>26</volume><fpage>100</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2013.11.003</pub-id><pub-id pub-id-type="pmid">24556406</pub-id><pub-id pub-id-type="pmcid">PMC3932007</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Moretti J, Blander JM. Insights into phagocytosis-coupled activation of pattern recognition receptors and inflammasomes. Curr Opin Immunol. 2014;26:100&#8211;10.<pub-id pub-id-type="pmid">24556406</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.coi.2013.11.003</pub-id><pub-id pub-id-type="pmcid">PMC3932007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brandli</surname><given-names>A</given-names></name><name name-style="western"><surname>Vessey</surname><given-names>KA</given-names></name><name name-style="western"><surname>Fletcher</surname><given-names>EL</given-names></name></person-group><article-title>The contribution of pattern recognition receptor signalling in the development of age related macular degeneration: the role of toll-like-receptors and the NLRP3-inflammasome</article-title><source>J Neuroinflammation</source><year>2024</year><volume>21</volume><issue>1</issue><fpage>64</fpage><pub-id pub-id-type="doi">10.1186/s12974-024-03055-1</pub-id><pub-id pub-id-type="pmid">38443987</pub-id><pub-id pub-id-type="pmcid">PMC10913318</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Brandli A, Vessey KA, Fletcher EL. The contribution of pattern recognition receptor signalling in the development of age related macular degeneration: the role of toll-like-receptors and the NLRP3-inflammasome. J Neuroinflammation. 2024;21(1):64.<pub-id pub-id-type="pmid">38443987</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-024-03055-1</pub-id><pub-id pub-id-type="pmcid">PMC10913318</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spel</surname><given-names>L</given-names></name><name name-style="western"><surname>Martinon</surname><given-names>F</given-names></name></person-group><article-title>Inflammasomes contributing to inflammation in arthritis</article-title><source>Immunol Rev</source><year>2020</year><volume>294</volume><issue>1</issue><fpage>48</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1111/imr.12839</pub-id><pub-id pub-id-type="pmid">31944344</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Spel L, Martinon F. Inflammasomes contributing to inflammation in arthritis. Immunol Rev. 2020;294(1):48&#8211;62.<pub-id pub-id-type="pmid">31944344</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/imr.12839</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>H</given-names></name><name name-style="western"><surname>Callaway</surname><given-names>JB</given-names></name><name name-style="western"><surname>Ting</surname><given-names>JP</given-names></name></person-group><article-title>Inflammasomes: mechanism of action, role in disease, and therapeutics</article-title><source>Nat Med</source><year>2015</year><volume>21</volume><issue>7</issue><fpage>677</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1038/nm.3893</pub-id><pub-id pub-id-type="pmid">26121197</pub-id><pub-id pub-id-type="pmcid">PMC4519035</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Guo H, Callaway JB, Ting JP. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med. 2015;21(7):677&#8211;87.<pub-id pub-id-type="pmid">26121197</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm.3893</pub-id><pub-id pub-id-type="pmcid">PMC4519035</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Navarro-Pando</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Inhibition of the NLRP3 inflammasome prevents ovarian aging</article-title><source>Sci Adv</source><year>2021</year><pub-id pub-id-type="doi">10.1126/sciadv.abc7409</pub-id><pub-id pub-id-type="pmid">33523841</pub-id><pub-id pub-id-type="pmcid">PMC7775749</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Navarro-Pando JM, et al. Inhibition of the NLRP3 inflammasome prevents ovarian aging. Sci Adv. 2021. 10.1126/sciadv.abc7409.<pub-id pub-id-type="pmid">33523841</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.abc7409</pub-id><pub-id pub-id-type="pmcid">PMC7775749</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mar&#237;n-Aguilar</surname><given-names>F</given-names></name><etal/></person-group><article-title>NLRP3 inflammasome suppression improves longevity and prevents cardiac aging in male mice</article-title><source>Aging Cell</source><year>2020</year><volume>19</volume><issue>1</issue><fpage>e13050</fpage><pub-id pub-id-type="doi">10.1111/acel.13050</pub-id><pub-id pub-id-type="pmid">31625260</pub-id><pub-id pub-id-type="pmcid">PMC6974709</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Mar&#237;n-Aguilar F, et al. NLRP3 inflammasome suppression improves longevity and prevents cardiac aging in male mice. Aging Cell. 2020;19(1):e13050.<pub-id pub-id-type="pmid">31625260</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/acel.13050</pub-id><pub-id pub-id-type="pmcid">PMC6974709</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Youm</surname><given-names>YH</given-names></name><etal/></person-group><article-title>Canonical Nlrp3 inflammasome links systemic low-grade inflammation to functional decline in aging</article-title><source>Cell Metab</source><year>2013</year><volume>18</volume><issue>4</issue><fpage>519</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2013.09.010</pub-id><pub-id pub-id-type="pmid">24093676</pub-id><pub-id pub-id-type="pmcid">PMC4017327</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Youm YH, et al. Canonical Nlrp3 inflammasome links systemic low-grade inflammation to functional decline in aging. Cell Metab. 2013;18(4):519&#8211;32.<pub-id pub-id-type="pmid">24093676</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2013.09.010</pub-id><pub-id pub-id-type="pmcid">PMC4017327</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cordero</surname><given-names>MD</given-names></name><name name-style="western"><surname>Williams</surname><given-names>MR</given-names></name><name name-style="western"><surname>Ryffel</surname><given-names>B</given-names></name></person-group><article-title>AMP-activated protein kinase regulation of the NLRP3 inflammasome during aging</article-title><source>Trends Endocrinol Metab</source><year>2018</year><volume>29</volume><issue>1</issue><fpage>8</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.tem.2017.10.009</pub-id><pub-id pub-id-type="pmid">29150317</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Cordero MD, Williams MR, Ryffel B. AMP-activated protein kinase regulation of the NLRP3 inflammasome during aging. Trends Endocrinol Metab. 2018;29(1):8&#8211;17.<pub-id pub-id-type="pmid">29150317</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tem.2017.10.009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hammond</surname><given-names>TR</given-names></name><name name-style="western"><surname>Marsh</surname><given-names>SE</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>B</given-names></name></person-group><article-title>Immune signaling in neurodegeneration</article-title><source>Immunity</source><year>2019</year><volume>50</volume><issue>4</issue><fpage>955</fpage><lpage>974</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2019.03.016</pub-id><pub-id pub-id-type="pmid">30995509</pub-id><pub-id pub-id-type="pmcid">PMC6822103</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Hammond TR, Marsh SE, Stevens B. Immune signaling in neurodegeneration. Immunity. 2019;50(4):955&#8211;74.<pub-id pub-id-type="pmid">30995509</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2019.03.016</pub-id><pub-id pub-id-type="pmcid">PMC6822103</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parodi-Rull&#225;n</surname><given-names>RM</given-names></name><name name-style="western"><surname>Javadov</surname><given-names>S</given-names></name><name name-style="western"><surname>Fossati</surname><given-names>S</given-names></name></person-group><article-title>Dissecting the crosstalk between endothelial mitochondrial damage, vascular inflammation, and neurodegeneration in cerebral amyloid angiopathy and Alzheimer&#8217;s disease</article-title><source>Cells</source><year>2021</year><volume>10</volume><issue>11</issue><fpage>2903</fpage><pub-id pub-id-type="doi">10.3390/cells10112903</pub-id><pub-id pub-id-type="pmid">34831125</pub-id><pub-id pub-id-type="pmcid">PMC8616424</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Parodi-Rull&#225;n RM, Javadov S, Fossati S. Dissecting the crosstalk between endothelial mitochondrial damage, vascular inflammation, and neurodegeneration in cerebral amyloid angiopathy and Alzheimer&#8217;s disease. Cells. 2021;10(11):2903.<pub-id pub-id-type="pmid">34831125</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells10112903</pub-id><pub-id pub-id-type="pmcid">PMC8616424</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gulen</surname><given-names>MF</given-names></name><etal/></person-group><article-title>cGAS&#8211;STING drives ageing-related inflammation and neurodegeneration</article-title><source>Nature</source><year>2023</year><volume>620</volume><issue>7973</issue><fpage>374</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06373-1</pub-id><pub-id pub-id-type="pmid">37532932</pub-id><pub-id pub-id-type="pmcid">PMC10412454</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Gulen MF, et al. cGAS&#8211;STING drives ageing-related inflammation and neurodegeneration. Nature. 2023;620(7973):374&#8211;80.<pub-id pub-id-type="pmid">37532932</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-023-06373-1</pub-id><pub-id pub-id-type="pmcid">PMC10412454</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>S</given-names></name><etal/></person-group><article-title>Complement and microglia mediate early synapse loss in Alzheimer mouse models</article-title><source>Science</source><year>2016</year><volume>352</volume><issue>6286</issue><fpage>712</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1126/science.aad8373</pub-id><pub-id pub-id-type="pmid">27033548</pub-id><pub-id pub-id-type="pmcid">PMC5094372</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Hong S, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016;352(6286):712&#8211;6.<pub-id pub-id-type="pmid">27033548</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aad8373</pub-id><pub-id pub-id-type="pmcid">PMC5094372</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sosna</surname><given-names>J</given-names></name><etal/></person-group><article-title>Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimer's disease</article-title><source>Mol Neurodegener</source><year>2018</year><volume>13</volume><issue>1</issue><fpage>11</fpage><pub-id pub-id-type="doi">10.1186/s13024-018-0244-x</pub-id><pub-id pub-id-type="pmid">29490706</pub-id><pub-id pub-id-type="pmcid">PMC5831225</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Sosna J, et al. Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimer&#8217;s disease. Mol Neurodegener. 2018;13(1):11.<pub-id pub-id-type="pmid">29490706</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-018-0244-x</pub-id><pub-id pub-id-type="pmcid">PMC5831225</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice</article-title><source>Sci Transl Med</source><year>2017</year><pub-id pub-id-type="doi">10.1126/scitranslmed.aaf6295</pub-id><pub-id pub-id-type="pmid">28566429</pub-id><pub-id pub-id-type="pmcid">PMC6936623</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Shi Q, et al. Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice. Sci Transl Med. 2017. 10.1126/scitranslmed.aaf6295.<pub-id pub-id-type="pmid">28566429</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.aaf6295</pub-id><pub-id pub-id-type="pmcid">PMC6936623</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanisch</surname><given-names>UK</given-names></name><name name-style="western"><surname>Kettenmann</surname><given-names>H</given-names></name></person-group><article-title>Microglia: active sensor and versatile effector cells in the normal and pathologic brain</article-title><source>Nat Neurosci</source><year>2007</year><volume>10</volume><issue>11</issue><fpage>1387</fpage><lpage>1394</lpage><pub-id pub-id-type="doi">10.1038/nn1997</pub-id><pub-id pub-id-type="pmid">17965659</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci. 2007;10(11):1387&#8211;94.<pub-id pub-id-type="pmid">17965659</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nn1997</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernier</surname><given-names>LP</given-names></name><etal/></person-group><article-title>Microglial metabolic flexibility supports immune surveillance of the brain parenchyma</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><issue>1</issue><fpage>1559</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-15267-z</pub-id><pub-id pub-id-type="pmid">32214088</pub-id><pub-id pub-id-type="pmcid">PMC7096448</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Bernier LP, et al. Microglial metabolic flexibility supports immune surveillance of the brain parenchyma. Nat Commun. 2020;11(1):1559.<pub-id pub-id-type="pmid">32214088</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-15267-z</pub-id><pub-id pub-id-type="pmcid">PMC7096448</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bright</surname><given-names>F</given-names></name><etal/></person-group><article-title>TDP-43 and inflammation: implications for amyotrophic lateral sclerosis and frontotemporal dementia</article-title><source>Int J Mol Sci</source><year>2021</year><pub-id pub-id-type="doi">10.3390/ijms22157781</pub-id><pub-id pub-id-type="pmid">34360544</pub-id><pub-id pub-id-type="pmcid">PMC8346169</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Bright F, et al. TDP-43 and inflammation: implications for amyotrophic lateral sclerosis and frontotemporal dementia. Int J Mol Sci. 2021. 10.3390/ijms22157781.<pub-id pub-id-type="pmid">34360544</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms22157781</pub-id><pub-id pub-id-type="pmcid">PMC8346169</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mou</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Gut microbiota interact with the brain through systemic chronic inflammation: implications on neuroinflammation, neurodegeneration, and aging</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>796288</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.796288</pub-id><pub-id pub-id-type="pmid">35464431</pub-id><pub-id pub-id-type="pmcid">PMC9021448</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Mou Y, et al. Gut microbiota interact with the brain through systemic chronic inflammation: implications on neuroinflammation, neurodegeneration, and aging. Front Immunol. 2022;13:796288.<pub-id pub-id-type="pmid">35464431</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.796288</pub-id><pub-id pub-id-type="pmcid">PMC9021448</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>J</given-names></name><name name-style="western"><surname>Kim</surname><given-names>CH</given-names></name></person-group><article-title>Regulation of common neurological disorders by gut microbial metabolites</article-title><source>Exp Mol Med</source><year>2021</year><volume>53</volume><issue>12</issue><fpage>1821</fpage><lpage>1833</lpage><pub-id pub-id-type="doi">10.1038/s12276-021-00703-x</pub-id><pub-id pub-id-type="pmid">34857900</pub-id><pub-id pub-id-type="pmcid">PMC8741890</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Park J, Kim CH. Regulation of common neurological disorders by gut microbial metabolites. Exp Mol Med. 2021;53(12):1821&#8211;33.<pub-id pub-id-type="pmid">34857900</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s12276-021-00703-x</pub-id><pub-id pub-id-type="pmcid">PMC8741890</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fairley</surname><given-names>A</given-names></name><etal/></person-group><article-title>Diet patterns, the gut microbiome, and Alzheimer's disease</article-title><source>J Alzheimers Dis</source><year>2022</year><volume>88</volume><issue>3</issue><fpage>933</fpage><lpage>941</lpage><pub-id pub-id-type="doi">10.3233/JAD-220205</pub-id><pub-id pub-id-type="pmid">35634849</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Fairley A, et al. Diet patterns, the gut microbiome, and Alzheimer&#8217;s disease. J Alzheimers Dis. 2022;88(3):933&#8211;41.<pub-id pub-id-type="pmid">35634849</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-220205</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>X</given-names></name><etal/></person-group><article-title>Progranulin deficiency promotes persistent neuroinflammation and causes regional pathology in the hippocampus following traumatic brain injury</article-title><source>Glia</source><year>2022</year><volume>70</volume><issue>7</issue><fpage>1317</fpage><lpage>1336</lpage><pub-id pub-id-type="doi">10.1002/glia.24175</pub-id><pub-id pub-id-type="pmid">35362178</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Zheng X, et al. Progranulin deficiency promotes persistent neuroinflammation and causes regional pathology in the hippocampus following traumatic brain injury. Glia. 2022;70(7):1317&#8211;36.<pub-id pub-id-type="pmid">35362178</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/glia.24175</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duro</surname><given-names>MV</given-names></name><name name-style="western"><surname>Ebright</surname><given-names>B</given-names></name><name name-style="western"><surname>Yassine</surname><given-names>HN</given-names></name></person-group><article-title>Lipids and brain inflammation in APOE4-associated dementia</article-title><source>Curr Opin Lipidol</source><year>2022</year><volume>33</volume><issue>1</issue><fpage>16</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1097/MOL.0000000000000801</pub-id><pub-id pub-id-type="pmid">34907965</pub-id><pub-id pub-id-type="pmcid">PMC8769806</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Duro MV, Ebright B, Yassine HN. Lipids and brain inflammation in APOE4-associated dementia. Curr Opin Lipidol. 2022;33(1):16&#8211;24.<pub-id pub-id-type="pmid">34907965</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MOL.0000000000000801</pub-id><pub-id pub-id-type="pmcid">PMC8769806</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwartz</surname><given-names>M</given-names></name><name name-style="western"><surname>Baruch</surname><given-names>K</given-names></name></person-group><article-title>The resolution of neuroinflammation in neurodegeneration: leukocyte recruitment via the choroid plexus</article-title><source>EMBO J</source><year>2014</year><volume>33</volume><issue>1</issue><fpage>7</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1002/embj.201386609</pub-id><pub-id pub-id-type="pmid">24357543</pub-id><pub-id pub-id-type="pmcid">PMC3990679</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Schwartz M, Baruch K. The resolution of neuroinflammation in neurodegeneration: leukocyte recruitment via the choroid plexus. EMBO J. 2014;33(1):7&#8211;22.<pub-id pub-id-type="pmid">24357543</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/embj.201386609</pub-id><pub-id pub-id-type="pmcid">PMC3990679</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name></person-group><article-title>Alzheimer&#8217;s disease facts and figures</article-title><source>Alzheimers Dement</source><year>2020</year><volume>16</volume><issue>3</issue><fpage>391</fpage><lpage>460</lpage></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Zhao L. Alzheimer&#8217;s disease facts and figures. Alzheimers Dement. 2020;16(3):391&#8211;460.</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Otani</surname><given-names>K</given-names></name><name name-style="western"><surname>Shichita</surname><given-names>T</given-names></name></person-group><article-title>Cerebral sterile inflammation in neurodegenerative diseases</article-title><source>Inflamm Regen</source><year>2020</year><volume>40</volume><issue>1</issue><fpage>28</fpage><pub-id pub-id-type="doi">10.1186/s41232-020-00137-4</pub-id><pub-id pub-id-type="pmid">33292860</pub-id><pub-id pub-id-type="pmcid">PMC7722432</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Otani K, Shichita T. Cerebral sterile inflammation in neurodegenerative diseases. Inflamm Regen. 2020;40(1):28.<pub-id pub-id-type="pmid">33292860</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s41232-020-00137-4</pub-id><pub-id pub-id-type="pmcid">PMC7722432</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Villemagne</surname><given-names>VL</given-names></name><etal/></person-group><article-title>Amyloid &#946; deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study</article-title><source>Lancet Neurol</source><year>2013</year><volume>12</volume><issue>4</issue><fpage>357</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(13)70044-9</pub-id><pub-id pub-id-type="pmid">23477989</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Villemagne VL, et al. Amyloid &#946; deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer&#8217;s disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357&#8211;67.<pub-id pub-id-type="pmid">23477989</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(13)70044-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name><etal/></person-group><article-title>Brain &#946;-amyloid load approaches a plateau</article-title><source>Neurology</source><year>2013</year><volume>80</volume><issue>10</issue><fpage>890</fpage><lpage>896</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3182840bbe</pub-id><pub-id pub-id-type="pmid">23446680</pub-id><pub-id pub-id-type="pmcid">PMC3653215</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Jack CR Jr, et al. Brain &#946;-amyloid load approaches a plateau. Neurology. 2013;80(10):890&#8211;6.<pub-id pub-id-type="pmid">23446680</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e3182840bbe</pub-id><pub-id pub-id-type="pmcid">PMC3653215</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pontecorvo</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition</article-title><source>Brain</source><year>2017</year><volume>140</volume><issue>3</issue><fpage>748</fpage><lpage>763</lpage><pub-id pub-id-type="pmid">28077397</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/aww334</pub-id><pub-id pub-id-type="pmcid">PMC5382945</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Pontecorvo MJ, et al. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain. 2017;140(3):748&#8211;63.<pub-id pub-id-type="pmid">28077397</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/aww334</pub-id><pub-id pub-id-type="pmcid">PMC5382945</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heneka</surname><given-names>MT</given-names></name><name name-style="western"><surname>Kummer</surname><given-names>MP</given-names></name><name name-style="western"><surname>Latz</surname><given-names>E</given-names></name></person-group><article-title>Innate immune activation in neurodegenerative disease</article-title><source>Nat Rev Immunol</source><year>2014</year><volume>14</volume><issue>7</issue><fpage>463</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1038/nri3705</pub-id><pub-id pub-id-type="pmid">24962261</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Heneka MT, Kummer MP, Latz E. Innate immune activation in neurodegenerative disease. Nat Rev Immunol. 2014;14(7):463&#8211;77.<pub-id pub-id-type="pmid">24962261</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri3705</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Toll-like receptor 4 (TLR4) inhibitors: current research and prospective</article-title><source>Eur J Med Chem</source><year>2022</year><volume>235</volume><fpage>114291</fpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2022.114291</pub-id><pub-id pub-id-type="pmid">35307617</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Zhang Y, et al. Toll-like receptor 4 (TLR4) inhibitors: current research and prospective. Eur J Med Chem. 2022;235:114291.<pub-id pub-id-type="pmid">35307617</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2022.114291</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Toll-like receptor 4: a promising therapeutic target for Alzheimer&#8217;s disease</article-title><source>Mediat Inflamm</source><year>2022</year><volume>2022</volume><issue>1</issue><fpage>7924199</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2022/7924199</pub-id><pub-id pub-id-type="pmcid">PMC9420645</pub-id><pub-id pub-id-type="pmid">36046763</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Wu L, et al. Toll-like receptor 4: a promising therapeutic target for Alzheimer&#8217;s disease. Mediat Inflamm. 2022;2022(1):7924199.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2022/7924199</pub-id><pub-id pub-id-type="pmcid">PMC9420645</pub-id><pub-id pub-id-type="pmid">36046763</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Behl</surname><given-names>T</given-names></name><etal/></person-group><article-title>Expatiating the molecular approaches of HMGB1 in diabetes mellitus: highlighting signalling pathways via RAGE and TLRs</article-title><source>Mol Biol Rep</source><year>2021</year><volume>48</volume><fpage>1869</fpage><lpage>1881</lpage><pub-id pub-id-type="doi">10.1007/s11033-020-06130-x</pub-id><pub-id pub-id-type="pmid">33479829</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Behl T, et al. Expatiating the molecular approaches of HMGB1 in diabetes mellitus: highlighting signalling pathways via RAGE and TLRs. Mol Biol Rep. 2021;48:1869&#8211;81.<pub-id pub-id-type="pmid">33479829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11033-020-06130-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Linnerbauer</surname><given-names>M</given-names></name><name name-style="western"><surname>Wheeler</surname><given-names>MA</given-names></name><name name-style="western"><surname>Quintana</surname><given-names>FJ</given-names></name></person-group><article-title>Astrocyte crosstalk in CNS inflammation</article-title><source>Neuron</source><year>2020</year><volume>108</volume><issue>4</issue><fpage>608</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2020.08.012</pub-id><pub-id pub-id-type="pmid">32898475</pub-id><pub-id pub-id-type="pmcid">PMC7704785</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Linnerbauer M, Wheeler MA, Quintana FJ. Astrocyte crosstalk in CNS inflammation. Neuron. 2020;108(4):608&#8211;22.<pub-id pub-id-type="pmid">32898475</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2020.08.012</pub-id><pub-id pub-id-type="pmcid">PMC7704785</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Onyango</surname><given-names>IG</given-names></name><etal/></person-group><article-title>Neuroinflammation in Alzheimer's disease</article-title><source>Biomedicines</source><year>2021</year><pub-id pub-id-type="doi">10.3390/biomedicines9050524</pub-id><pub-id pub-id-type="pmid">34067173</pub-id><pub-id pub-id-type="pmcid">PMC8150909</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Onyango IG, et al. Neuroinflammation in Alzheimer&#8217;s disease. Biomedicines. 2021. 10.3390/biomedicines9050524.<pub-id pub-id-type="pmid">34067173</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines9050524</pub-id><pub-id pub-id-type="pmcid">PMC8150909</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hansen</surname><given-names>DV</given-names></name><name name-style="western"><surname>Hanson</surname><given-names>JE</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>M</given-names></name></person-group><article-title>Microglia in Alzheimer's disease</article-title><source>J Cell Biol</source><year>2018</year><volume>217</volume><issue>2</issue><fpage>459</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1083/jcb.201709069</pub-id><pub-id pub-id-type="pmid">29196460</pub-id><pub-id pub-id-type="pmcid">PMC5800817</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Hansen DV, Hanson JE, Sheng M. Microglia in Alzheimer&#8217;s disease. J Cell Biol. 2018;217(2):459&#8211;72.<pub-id pub-id-type="pmid">29196460</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1083/jcb.201709069</pub-id><pub-id pub-id-type="pmcid">PMC5800817</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Costantini</surname><given-names>E</given-names></name><name name-style="western"><surname>D'Angelo</surname><given-names>C</given-names></name><name name-style="western"><surname>Reale</surname><given-names>M</given-names></name></person-group><article-title>The role of immunosenescence in neurodegenerative diseases</article-title><source>Mediat Inflamm</source><year>2018</year><volume>2018</volume><fpage>6039171</fpage><pub-id pub-id-type="doi">10.1155/2018/6039171</pub-id><pub-id pub-id-type="pmcid">PMC5863336</pub-id><pub-id pub-id-type="pmid">29706800</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Costantini E, D&#8217;Angelo C, Reale M. The role of immunosenescence in neurodegenerative diseases. Mediat Inflamm. 2018;2018:6039171.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2018/6039171</pub-id><pub-id pub-id-type="pmcid">PMC5863336</pub-id><pub-id pub-id-type="pmid">29706800</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meda</surname><given-names>L</given-names></name><name name-style="western"><surname>Baron</surname><given-names>P</given-names></name><name name-style="western"><surname>Scarlato</surname><given-names>G</given-names></name></person-group><article-title>Glial activation in Alzheimer's disease: the role of Abeta and its associated proteins</article-title><source>Neurobiol Aging</source><year>2001</year><volume>22</volume><issue>6</issue><fpage>885</fpage><lpage>893</lpage><pub-id pub-id-type="doi">10.1016/S0197-4580(01)00307-4</pub-id><pub-id pub-id-type="pmid">11754995</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Meda L, Baron P, Scarlato G. Glial activation in Alzheimer&#8217;s disease: the role of Abeta and its associated proteins. Neurobiol Aging. 2001;22(6):885&#8211;93.<pub-id pub-id-type="pmid">11754995</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0197-4580(01)00307-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>ZS</given-names></name><name name-style="western"><surname>Seshadri</surname><given-names>S</given-names></name></person-group><article-title>Inflammation in the Alzheimer's disease cascade: culprit or innocent bystander?</article-title><source>Alzheimers Res Ther</source><year>2010</year><volume>2</volume><issue>2</issue><fpage>6</fpage><pub-id pub-id-type="doi">10.1186/alzrt29</pub-id><pub-id pub-id-type="pmid">20388190</pub-id><pub-id pub-id-type="pmcid">PMC2876784</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Tan ZS, Seshadri S. Inflammation in the Alzheimer&#8217;s disease cascade: culprit or innocent bystander? Alzheimers Res Ther. 2010;2(2):6.<pub-id pub-id-type="pmid">20388190</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/alzrt29</pub-id><pub-id pub-id-type="pmcid">PMC2876784</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hur</surname><given-names>JY</given-names></name><etal/></person-group><article-title>The innate immunity protein IFITM3 modulates &#947;-secretase in Alzheimer's disease</article-title><source>Nature</source><year>2020</year><volume>586</volume><issue>7831</issue><fpage>735</fpage><lpage>740</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2681-2</pub-id><pub-id pub-id-type="pmid">32879487</pub-id><pub-id pub-id-type="pmcid">PMC7919141</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Hur JY, et al. The innate immunity protein IFITM3 modulates &#947;-secretase in Alzheimer&#8217;s disease. Nature. 2020;586(7831):735&#8211;40.<pub-id pub-id-type="pmid">32879487</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2681-2</pub-id><pub-id pub-id-type="pmcid">PMC7919141</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nisbet</surname><given-names>RM</given-names></name><etal/></person-group><article-title>Tau aggregation and its interplay with amyloid-&#946;</article-title><source>Acta Neuropathol</source><year>2015</year><volume>129</volume><issue>2</issue><fpage>207</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1007/s00401-014-1371-2</pub-id><pub-id pub-id-type="pmid">25492702</pub-id><pub-id pub-id-type="pmcid">PMC4305093</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Nisbet RM, et al. Tau aggregation and its interplay with amyloid-&#946;. Acta Neuropathol. 2015;129(2):207&#8211;20.<pub-id pub-id-type="pmid">25492702</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-014-1371-2</pub-id><pub-id pub-id-type="pmcid">PMC4305093</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoshiyama</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model</article-title><source>Neuron</source><year>2007</year><volume>53</volume><issue>3</issue><fpage>337</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2007.01.010</pub-id><pub-id pub-id-type="pmid">17270732</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Yoshiyama Y, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53(3):337&#8211;51.<pub-id pub-id-type="pmid">17270732</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2007.01.010</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maphis</surname><given-names>N</given-names></name><etal/></person-group><article-title>Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain</article-title><source>Brain</source><year>2015</year><volume>138</volume><issue>Pt 6</issue><fpage>1738</fpage><lpage>1755</lpage><pub-id pub-id-type="doi">10.1093/brain/awv081</pub-id><pub-id pub-id-type="pmid">25833819</pub-id><pub-id pub-id-type="pmcid">PMC4542622</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Maphis N, et al. Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain. Brain. 2015;138(Pt 6):1738&#8211;55.<pub-id pub-id-type="pmid">25833819</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awv081</pub-id><pub-id pub-id-type="pmcid">PMC4542622</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Newcombe</surname><given-names>EA</given-names></name><etal/></person-group><article-title>Inflammation: the link between comorbidities, genetics, and Alzheimer's disease</article-title><source>J Neuroinflammation</source><year>2018</year><volume>15</volume><issue>1</issue><fpage>276</fpage><pub-id pub-id-type="doi">10.1186/s12974-018-1313-3</pub-id><pub-id pub-id-type="pmid">30249283</pub-id><pub-id pub-id-type="pmcid">PMC6154824</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Newcombe EA, et al. Inflammation: the link between comorbidities, genetics, and Alzheimer&#8217;s disease. J Neuroinflammation. 2018;15(1):276.<pub-id pub-id-type="pmid">30249283</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-018-1313-3</pub-id><pub-id pub-id-type="pmcid">PMC6154824</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>T</given-names></name><name name-style="western"><surname>Noble</surname><given-names>W</given-names></name><name name-style="western"><surname>Hanger</surname><given-names>DP</given-names></name></person-group><article-title>Roles of tau protein in health and disease</article-title><source>Acta Neuropathol</source><year>2017</year><volume>133</volume><issue>5</issue><fpage>665</fpage><lpage>704</lpage><pub-id pub-id-type="doi">10.1007/s00401-017-1707-9</pub-id><pub-id pub-id-type="pmid">28386764</pub-id><pub-id pub-id-type="pmcid">PMC5390006</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Guo T, Noble W, Hanger DP. Roles of tau protein in health and disease. Acta Neuropathol. 2017;133(5):665&#8211;704.<pub-id pub-id-type="pmid">28386764</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-017-1707-9</pub-id><pub-id pub-id-type="pmcid">PMC5390006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glass</surname><given-names>CK</given-names></name><etal/></person-group><article-title>Mechanisms underlying inflammation in neurodegeneration</article-title><source>Cell</source><year>2010</year><volume>140</volume><issue>6</issue><fpage>918</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.02.016</pub-id><pub-id pub-id-type="pmid">20303880</pub-id><pub-id pub-id-type="pmcid">PMC2873093</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Glass CK, et al. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140(6):918&#8211;34.<pub-id pub-id-type="pmid">20303880</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2010.02.016</pub-id><pub-id pub-id-type="pmcid">PMC2873093</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name></person-group><article-title>Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications</article-title><source>Front Immunol</source><year>2017</year><volume>8</volume><fpage>1005</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.01005</pub-id><pub-id pub-id-type="pmid">28871262</pub-id><pub-id pub-id-type="pmcid">PMC5567007</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Liu J, Wang F. Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications. Front Immunol. 2017;8:1005.<pub-id pub-id-type="pmid">28871262</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2017.01005</pub-id><pub-id pub-id-type="pmcid">PMC5567007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neumann</surname><given-names>M</given-names></name><etal/></person-group><article-title>Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis</article-title><source>Science</source><year>2006</year><volume>314</volume><issue>5796</issue><fpage>130</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1126/science.1134108</pub-id><pub-id pub-id-type="pmid">17023659</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130&#8211;3.<pub-id pub-id-type="pmid">17023659</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1134108</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ingre</surname><given-names>C</given-names></name><etal/></person-group><article-title>Risk factors for amyotrophic lateral sclerosis</article-title><source>Clin Epidemiol</source><year>2015</year><volume>7</volume><fpage>181</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">25709501</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/CLEP.S37505</pub-id><pub-id pub-id-type="pmcid">PMC4334292</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Ingre C, et al. Risk factors for amyotrophic lateral sclerosis. Clin Epidemiol. 2015;7:181&#8211;93.<pub-id pub-id-type="pmid">25709501</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/CLEP.S37505</pub-id><pub-id pub-id-type="pmcid">PMC4334292</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rubino</surname><given-names>V</given-names></name><etal/></person-group><article-title>Insights on the multifaceted roles of wild-type and mutated superoxide dismutase 1 in amyotrophic lateral sclerosis pathogenesis</article-title><source>Antioxidants</source><year>2023</year><volume>12</volume><issue>9</issue><fpage>1747</fpage><pub-id pub-id-type="doi">10.3390/antiox12091747</pub-id><pub-id pub-id-type="pmid">37760050</pub-id><pub-id pub-id-type="pmcid">PMC10525763</pub-id></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Rubino V, et al. Insights on the multifaceted roles of wild-type and mutated superoxide dismutase 1 in amyotrophic lateral sclerosis pathogenesis. Antioxidants. 2023;12(9):1747.<pub-id pub-id-type="pmid">37760050</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antiox12091747</pub-id><pub-id pub-id-type="pmcid">PMC10525763</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiong</surname><given-names>L</given-names></name><etal/></person-group><article-title>Inflammation-dependent oxidative stress metabolites as a hallmark of amyotrophic lateral sclerosis</article-title><source>Free Radic Biol Med</source><year>2022</year><volume>178</volume><fpage>125</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2021.11.031</pub-id><pub-id pub-id-type="pmid">34871763</pub-id><pub-id pub-id-type="pmcid">PMC8744315</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Xiong L, et al. Inflammation-dependent oxidative stress metabolites as a hallmark of amyotrophic lateral sclerosis. Free Radic Biol Med. 2022;178:125&#8211;33.<pub-id pub-id-type="pmid">34871763</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.freeradbiomed.2021.11.031</pub-id><pub-id pub-id-type="pmcid">PMC8744315</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>CH</given-names></name><etal/></person-group><article-title>TDP-43 triggers mitochondrial DNA release via mPTP to activate cGAS/STING in ALS</article-title><source>Cell</source><year>2020</year><volume>183</volume><issue>3</issue><fpage>636</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.09.020</pub-id><pub-id pub-id-type="pmid">33031745</pub-id><pub-id pub-id-type="pmcid">PMC7599077</pub-id></element-citation><mixed-citation id="mc-CR76" publication-type="journal">Yu CH, et al. TDP-43 triggers mitochondrial DNA release via mPTP to activate cGAS/STING in ALS. Cell. 2020;183(3):636&#8211;49.<pub-id pub-id-type="pmid">33031745</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.09.020</pub-id><pub-id pub-id-type="pmcid">PMC7599077</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cali&#243;</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Mitochondrial dysfunction, neurogenesis, and epigenetics: putative implications for amyotrophic lateral sclerosis neurodegeneration and treatment</article-title><source>Front Neurosci</source><year>2020</year><volume>14</volume><fpage>679</fpage><pub-id pub-id-type="doi">10.3389/fnins.2020.00679</pub-id><pub-id pub-id-type="pmid">32760239</pub-id><pub-id pub-id-type="pmcid">PMC7373761</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Cali&#243; ML, et al. Mitochondrial dysfunction, neurogenesis, and epigenetics: putative implications for amyotrophic lateral sclerosis neurodegeneration and treatment. Front Neurosci. 2020;14:679.<pub-id pub-id-type="pmid">32760239</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2020.00679</pub-id><pub-id pub-id-type="pmcid">PMC7373761</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peggion</surname><given-names>C</given-names></name><etal/></person-group><article-title>SOD1 in ALS: taking stock in pathogenic mechanisms and the role of glial and muscle cells</article-title><source>Antioxidants</source><year>2022</year><volume>11</volume><issue>4</issue><fpage>614</fpage><pub-id pub-id-type="doi">10.3390/antiox11040614</pub-id><pub-id pub-id-type="pmid">35453299</pub-id><pub-id pub-id-type="pmcid">PMC9032988</pub-id></element-citation><mixed-citation id="mc-CR78" publication-type="journal">Peggion C, et al. SOD1 in ALS: taking stock in pathogenic mechanisms and the role of glial and muscle cells. Antioxidants. 2022;11(4):614.<pub-id pub-id-type="pmid">35453299</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antiox11040614</pub-id><pub-id pub-id-type="pmcid">PMC9032988</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>W</given-names></name><etal/></person-group><article-title>TDP-43 activates microglia through NF-&#954;B and NLRP3 inflammasome</article-title><source>Exp Neurol</source><year>2015</year><volume>273</volume><fpage>24</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2015.07.019</pub-id><pub-id pub-id-type="pmid">26222336</pub-id></element-citation><mixed-citation id="mc-CR79" publication-type="journal">Zhao W, et al. TDP-43 activates microglia through NF-&#954;B and NLRP3 inflammasome. Exp Neurol. 2015;273:24&#8211;35.<pub-id pub-id-type="pmid">26222336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.expneurol.2015.07.019</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Urushitani</surname><given-names>M</given-names></name><etal/></person-group><article-title>Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis</article-title><source>Nat Neurosci</source><year>2006</year><volume>9</volume><issue>1</issue><fpage>108</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1038/nn1603</pub-id><pub-id pub-id-type="pmid">16369483</pub-id></element-citation><mixed-citation id="mc-CR80" publication-type="journal">Urushitani M, et al. Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Nat Neurosci. 2006;9(1):108&#8211;18.<pub-id pub-id-type="pmid">16369483</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nn1603</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaur</surname><given-names>J</given-names></name><name name-style="western"><surname>Singh</surname><given-names>H</given-names></name><name name-style="western"><surname>Naqvi</surname><given-names>S</given-names></name></person-group><article-title>Intracellular DAMPs in neurodegeneration and their role in clinical therapeutics</article-title><source>Mol Neurobiol</source><year>2023</year><volume>60</volume><issue>7</issue><fpage>3600</fpage><lpage>3616</lpage><pub-id pub-id-type="doi">10.1007/s12035-023-03289-9</pub-id><pub-id pub-id-type="pmid">36859688</pub-id></element-citation><mixed-citation id="mc-CR81" publication-type="journal">Kaur J, Singh H, Naqvi S. Intracellular DAMPs in neurodegeneration and their role in clinical therapeutics. Mol Neurobiol. 2023;60(7):3600&#8211;16.<pub-id pub-id-type="pmid">36859688</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12035-023-03289-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>B&#233;land</surname><given-names>LC</given-names></name><etal/></person-group><article-title>Immunity in amyotrophic lateral sclerosis: blurred lines between excessive inflammation and inefficient immune responses</article-title><source>Brain Commun</source><year>2020</year><pub-id pub-id-type="doi">10.1093/braincomms/fcaa124</pub-id><pub-id pub-id-type="pmid">33134918</pub-id><pub-id pub-id-type="pmcid">PMC7585698</pub-id></element-citation><mixed-citation id="mc-CR82" publication-type="journal">B&#233;land LC, et al. Immunity in amyotrophic lateral sclerosis: blurred lines between excessive inflammation and inefficient immune responses. Brain Commun. 2020. 10.1093/braincomms/fcaa124.<pub-id pub-id-type="pmid">33134918</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/braincomms/fcaa124</pub-id><pub-id pub-id-type="pmcid">PMC7585698</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turner</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Autoimmune disease preceding amyotrophic lateral sclerosis: an epidemiologic study</article-title><source>Neurology</source><year>2013</year><volume>81</volume><issue>14</issue><fpage>1222</fpage><lpage>1225</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3182a6cc13</pub-id><pub-id pub-id-type="pmid">23946298</pub-id><pub-id pub-id-type="pmcid">PMC3795611</pub-id></element-citation><mixed-citation id="mc-CR83" publication-type="journal">Turner MR, et al. Autoimmune disease preceding amyotrophic lateral sclerosis: an epidemiologic study. Neurology. 2013;81(14):1222&#8211;5.<pub-id pub-id-type="pmid">23946298</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e3182a6cc13</pub-id><pub-id pub-id-type="pmcid">PMC3795611</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>CY</given-names></name><etal/></person-group><article-title>Genome-wide genetic links between amyotrophic lateral sclerosis and autoimmune diseases</article-title><source>BMC Med</source><year>2021</year><volume>19</volume><issue>1</issue><fpage>27</fpage><pub-id pub-id-type="doi">10.1186/s12916-021-01903-y</pub-id><pub-id pub-id-type="pmid">33541344</pub-id><pub-id pub-id-type="pmcid">PMC7863260</pub-id></element-citation><mixed-citation id="mc-CR84" publication-type="journal">Li CY, et al. Genome-wide genetic links between amyotrophic lateral sclerosis and autoimmune diseases. BMC Med. 2021;19(1):27.<pub-id pub-id-type="pmid">33541344</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12916-021-01903-y</pub-id><pub-id pub-id-type="pmcid">PMC7863260</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tansey</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Inflammation and immune dysfunction in Parkinson disease</article-title><source>Nat Rev Immunol</source><year>2022</year><volume>22</volume><issue>11</issue><fpage>657</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1038/s41577-022-00684-6</pub-id><pub-id pub-id-type="pmid">35246670</pub-id><pub-id pub-id-type="pmcid">PMC8895080</pub-id></element-citation><mixed-citation id="mc-CR85" publication-type="journal">Tansey MG, et al. Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol. 2022;22(11):657&#8211;73.<pub-id pub-id-type="pmid">35246670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-022-00684-6</pub-id><pub-id pub-id-type="pmcid">PMC8895080</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kordower</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Disease duration and the integrity of the nigrostriatal system in Parkinson's disease</article-title><source>Brain</source><year>2013</year><volume>136</volume><issue>Pt 8</issue><fpage>2419</fpage><lpage>2431</lpage><pub-id pub-id-type="doi">10.1093/brain/awt192</pub-id><pub-id pub-id-type="pmid">23884810</pub-id><pub-id pub-id-type="pmcid">PMC3722357</pub-id></element-citation><mixed-citation id="mc-CR86" publication-type="journal">Kordower JH, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson&#8217;s disease. Brain. 2013;136(Pt 8):2419&#8211;31.<pub-id pub-id-type="pmid">23884810</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awt192</pub-id><pub-id pub-id-type="pmcid">PMC3722357</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gundersen</surname><given-names>V</given-names></name></person-group><article-title>Parkinson's disease: can targeting inflammation be an effective neuroprotective strategy?</article-title><source>Front Neurosci</source><year>2020</year><volume>14</volume><fpage>580311</fpage><pub-id pub-id-type="doi">10.3389/fnins.2020.580311</pub-id><pub-id pub-id-type="pmid">33716638</pub-id><pub-id pub-id-type="pmcid">PMC7946840</pub-id></element-citation><mixed-citation id="mc-CR87" publication-type="journal">Gundersen V. Parkinson&#8217;s disease: can targeting inflammation be an effective neuroprotective strategy? Front Neurosci. 2020;14:580311.<pub-id pub-id-type="pmid">33716638</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2020.580311</pub-id><pub-id pub-id-type="pmcid">PMC7946840</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGeer</surname><given-names>PL</given-names></name><etal/></person-group><article-title>Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains</article-title><source>Neurology</source><year>1988</year><volume>38</volume><issue>8</issue><fpage>1285</fpage><lpage>1291</lpage><pub-id pub-id-type="doi">10.1212/WNL.38.8.1285</pub-id><pub-id pub-id-type="pmid">3399080</pub-id></element-citation><mixed-citation id="mc-CR88" publication-type="journal">McGeer PL, et al. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson&#8217;s and Alzheimer&#8217;s disease brains. Neurology. 1988;38(8):1285&#8211;91.<pub-id pub-id-type="pmid">3399080</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.38.8.1285</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Milber</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease</article-title><source>Neurology</source><year>2012</year><volume>79</volume><issue>24</issue><fpage>2307</fpage><lpage>2314</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e318278fe32</pub-id><pub-id pub-id-type="pmid">23152586</pub-id><pub-id pub-id-type="pmcid">PMC3578379</pub-id></element-citation><mixed-citation id="mc-CR89" publication-type="journal">Milber JM, et al. Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease. Neurology. 2012;79(24):2307&#8211;14.<pub-id pub-id-type="pmid">23152586</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e318278fe32</pub-id><pub-id pub-id-type="pmcid">PMC3578379</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luk</surname><given-names>KC</given-names></name><etal/></person-group><article-title>Pathological &#945;-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice</article-title><source>Science</source><year>2012</year><volume>338</volume><issue>6109</issue><fpage>949</fpage><lpage>953</lpage><pub-id pub-id-type="doi">10.1126/science.1227157</pub-id><pub-id pub-id-type="pmid">23161999</pub-id><pub-id pub-id-type="pmcid">PMC3552321</pub-id></element-citation><mixed-citation id="mc-CR90" publication-type="journal">Luk KC, et al. Pathological &#945;-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012;338(6109):949&#8211;53.<pub-id pub-id-type="pmid">23161999</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1227157</pub-id><pub-id pub-id-type="pmcid">PMC3552321</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tofaris</surname><given-names>GK</given-names></name></person-group><article-title>Initiation and progression of &#945;-synuclein pathology in Parkinson&#8217;s disease</article-title><source>Cell Mol Life Sci</source><year>2022</year><volume>79</volume><issue>4</issue><fpage>210</fpage><pub-id pub-id-type="doi">10.1007/s00018-022-04240-2</pub-id><pub-id pub-id-type="pmid">35347432</pub-id><pub-id pub-id-type="pmcid">PMC8960654</pub-id></element-citation><mixed-citation id="mc-CR91" publication-type="journal">Tofaris GK. Initiation and progression of &#945;-synuclein pathology in Parkinson&#8217;s disease. Cell Mol Life Sci. 2022;79(4):210.<pub-id pub-id-type="pmid">35347432</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00018-022-04240-2</pub-id><pub-id pub-id-type="pmcid">PMC8960654</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haque</surname><given-names>ME</given-names></name><etal/></person-group><article-title>Targeting &#945;-synuclein aggregation and its role in mitochondrial dysfunction in Parkinson's disease</article-title><source>Br J Pharmacol</source><year>2022</year><volume>179</volume><issue>1</issue><fpage>23</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1111/bph.15684</pub-id><pub-id pub-id-type="pmid">34528272</pub-id></element-citation><mixed-citation id="mc-CR92" publication-type="journal">Haque ME, et al. Targeting &#945;-synuclein aggregation and its role in mitochondrial dysfunction in Parkinson&#8217;s disease. Br J Pharmacol. 2022;179(1):23&#8211;45.<pub-id pub-id-type="pmid">34528272</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bph.15684</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease</article-title><source>Faseb J</source><year>2005</year><volume>19</volume><issue>6</issue><fpage>533</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1096/fj.04-2751com</pub-id><pub-id pub-id-type="pmid">15791003</pub-id></element-citation><mixed-citation id="mc-CR93" publication-type="journal">Zhang W, et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson&#8217;s disease. Faseb J. 2005;19(6):533&#8211;42.<pub-id pub-id-type="pmid">15791003</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fj.04-2751com</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Acu&#241;a</surname><given-names>L</given-names></name><etal/></person-group><article-title>Rifampicin and its derivative rifampicin quinone reduce microglial inflammatory responses and neurodegeneration induced in vitro by &#945;-synuclein fibrillary aggregates</article-title><source>Cells</source><year>2019</year><pub-id pub-id-type="doi">10.3390/cells8080776</pub-id><pub-id pub-id-type="pmid">31349736</pub-id><pub-id pub-id-type="pmcid">PMC6721546</pub-id></element-citation><mixed-citation id="mc-CR94" publication-type="journal">Acu&#241;a L, et al. Rifampicin and its derivative rifampicin quinone reduce microglial inflammatory responses and neurodegeneration induced in vitro by &#945;-synuclein fibrillary aggregates. Cells. 2019. 10.3390/cells8080776.<pub-id pub-id-type="pmid">31349736</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells8080776</pub-id><pub-id pub-id-type="pmcid">PMC6721546</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ludtmann</surname><given-names>MHR</given-names></name><etal/></person-group><article-title>&#913;-synuclein oligomers interact with ATP synthase and open the permeability transition pore in Parkinson's disease</article-title><source>Nat Commun</source><year>2018</year><volume>9</volume><issue>1</issue><fpage>2293</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-04422-2</pub-id><pub-id pub-id-type="pmid">29895861</pub-id><pub-id pub-id-type="pmcid">PMC5997668</pub-id></element-citation><mixed-citation id="mc-CR95" publication-type="journal">Ludtmann MHR, et al. &#913;-synuclein oligomers interact with ATP synthase and open the permeability transition pore in Parkinson&#8217;s disease. Nat Commun. 2018;9(1):2293.<pub-id pub-id-type="pmid">29895861</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-018-04422-2</pub-id><pub-id pub-id-type="pmcid">PMC5997668</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96.</label><mixed-citation publication-type="other">Di Maio, R., et al., <italic toggle="yes">&#945;-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson's disease.</italic> Sci Transl Med, 2016. <bold>8</bold>(342): p. 342ra78.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.aaf3634</pub-id><pub-id pub-id-type="pmcid">PMC5016095</pub-id><pub-id pub-id-type="pmid">27280685</pub-id></mixed-citation></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duffy</surname><given-names>MF</given-names></name><etal/></person-group><article-title>Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration</article-title><source>J Neuroinflammation</source><year>2018</year><volume>15</volume><issue>1</issue><fpage>129</fpage><pub-id pub-id-type="doi">10.1186/s12974-018-1171-z</pub-id><pub-id pub-id-type="pmid">29716614</pub-id><pub-id pub-id-type="pmcid">PMC5930695</pub-id></element-citation><mixed-citation id="mc-CR97" publication-type="journal">Duffy MF, et al. Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration. J Neuroinflammation. 2018;15(1):129.<pub-id pub-id-type="pmid">29716614</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-018-1171-z</pub-id><pub-id pub-id-type="pmcid">PMC5930695</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krashia</surname><given-names>P</given-names></name><etal/></person-group><article-title>Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson's disease</article-title><source>Nat Commun</source><year>2019</year><volume>10</volume><issue>1</issue><fpage>3945</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-11928-w</pub-id><pub-id pub-id-type="pmid">31477726</pub-id><pub-id pub-id-type="pmcid">PMC6718379</pub-id></element-citation><mixed-citation id="mc-CR98" publication-type="journal">Krashia P, et al. Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson&#8217;s disease. Nat Commun. 2019;10(1):3945.<pub-id pub-id-type="pmid">31477726</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-019-11928-w</pub-id><pub-id pub-id-type="pmcid">PMC6718379</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cardinale</surname><given-names>A</given-names></name><name name-style="western"><surname>Calabrese</surname><given-names>V</given-names></name></person-group><article-title>The intricate debate on neurodegeneration and neuroinflammation in Parkinson's disease: which came first?</article-title><source>Neural Regen Res</source><year>2023</year><volume>18</volume><issue>1</issue><fpage>125</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.4103/1673-5374.343895</pub-id><pub-id pub-id-type="pmid">35799526</pub-id><pub-id pub-id-type="pmcid">PMC9241404</pub-id></element-citation><mixed-citation id="mc-CR99" publication-type="journal">Cardinale A, Calabrese V. The intricate debate on neurodegeneration and neuroinflammation in Parkinson&#8217;s disease: which came first? Neural Regen Res. 2023;18(1):125&#8211;6.<pub-id pub-id-type="pmid">35799526</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/1673-5374.343895</pub-id><pub-id pub-id-type="pmcid">PMC9241404</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR100"><label>100.</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>C</given-names></name><etal/></person-group><article-title>Neuron-released oligomeric &#945;-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia</article-title><source>Nat Commun</source><year>2013</year><volume>4</volume><fpage>1562</fpage><pub-id pub-id-type="doi">10.1038/ncomms2534</pub-id><pub-id pub-id-type="pmid">23463005</pub-id><pub-id pub-id-type="pmcid">PMC4089961</pub-id></element-citation><mixed-citation id="mc-CR100" publication-type="journal">Kim C, et al. Neuron-released oligomeric &#945;-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun. 2013;4:1562.<pub-id pub-id-type="pmid">23463005</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms2534</pub-id><pub-id pub-id-type="pmcid">PMC4089961</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR101"><label>101.</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>I</given-names></name><etal/></person-group><article-title>Microglia clear neuron-released &#945;-synuclein via selective autophagy and prevent neurodegeneration</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><issue>1</issue><fpage>1386</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-15119-w</pub-id><pub-id pub-id-type="pmid">32170061</pub-id><pub-id pub-id-type="pmcid">PMC7069981</pub-id></element-citation><mixed-citation id="mc-CR101" publication-type="journal">Choi I, et al. Microglia clear neuron-released &#945;-synuclein via selective autophagy and prevent neurodegeneration. Nat Commun. 2020;11(1):1386.<pub-id pub-id-type="pmid">32170061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-15119-w</pub-id><pub-id pub-id-type="pmcid">PMC7069981</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102.</label><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grozdanov</surname><given-names>V</given-names></name><etal/></person-group><article-title>Increased immune activation by pathologic &#945;-synuclein in Parkinson's disease</article-title><source>Ann Neurol</source><year>2019</year><volume>86</volume><issue>4</issue><fpage>593</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1002/ana.25557</pub-id><pub-id pub-id-type="pmid">31343083</pub-id></element-citation><mixed-citation id="mc-CR102" publication-type="journal">Grozdanov V, et al. Increased immune activation by pathologic &#945;-synuclein in Parkinson&#8217;s disease. Ann Neurol. 2019;86(4):593&#8211;606.<pub-id pub-id-type="pmid">31343083</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.25557</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chavarr&#237;a</surname><given-names>C</given-names></name><name name-style="western"><surname>Ivagnes</surname><given-names>R</given-names></name><name name-style="western"><surname>Souza</surname><given-names>JM</given-names></name></person-group><article-title>Extracellular alpha-synuclein: mechanisms for glial cell internalization and activation</article-title><source>Biomolecules</source><year>2022</year><pub-id pub-id-type="doi">10.3390/biom12050655</pub-id><pub-id pub-id-type="pmid">35625583</pub-id><pub-id pub-id-type="pmcid">PMC9138387</pub-id></element-citation><mixed-citation id="mc-CR103" publication-type="journal">Chavarr&#237;a C, Ivagnes R, Souza JM. Extracellular alpha-synuclein: mechanisms for glial cell internalization and activation. Biomolecules. 2022. 10.3390/biom12050655.<pub-id pub-id-type="pmid">35625583</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biom12050655</pub-id><pub-id pub-id-type="pmcid">PMC9138387</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104.</label><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pajares</surname><given-names>M</given-names></name><etal/></person-group><article-title>Inflammation in Parkinson's disease: mechanisms and therapeutic implications</article-title><source>Cells</source><year>2020</year><pub-id pub-id-type="doi">10.3390/cells9071687</pub-id><pub-id pub-id-type="pmid">32674367</pub-id><pub-id pub-id-type="pmcid">PMC7408280</pub-id></element-citation><mixed-citation id="mc-CR104" publication-type="journal">Pajares M, et al. Inflammation in Parkinson&#8217;s disease: mechanisms and therapeutic implications. Cells. 2020. 10.3390/cells9071687.<pub-id pub-id-type="pmid">32674367</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells9071687</pub-id><pub-id pub-id-type="pmcid">PMC7408280</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR105"><label>105.</label><citation-alternatives><element-citation id="ec-CR105" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawahata</surname><given-names>I</given-names></name><name name-style="western"><surname>Finkelstein</surname><given-names>DI</given-names></name><name name-style="western"><surname>Fukunaga</surname><given-names>K</given-names></name></person-group><article-title>Pathogenic impact of &#945;-synuclein phosphorylation and its kinases in &#945;-synucleinopathies</article-title><source>Int J Mol Sci</source><year>2022</year><pub-id pub-id-type="doi">10.3390/ijms23116216</pub-id><pub-id pub-id-type="pmid">35682892</pub-id><pub-id pub-id-type="pmcid">PMC9181156</pub-id></element-citation><mixed-citation id="mc-CR105" publication-type="journal">Kawahata I, Finkelstein DI, Fukunaga K. Pathogenic impact of &#945;-synuclein phosphorylation and its kinases in &#945;-synucleinopathies. Int J Mol Sci. 2022. 10.3390/ijms23116216.<pub-id pub-id-type="pmid">35682892</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms23116216</pub-id><pub-id pub-id-type="pmcid">PMC9181156</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR106"><label>106.</label><citation-alternatives><element-citation id="ec-CR106" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reimer</surname><given-names>L</given-names></name><etal/></person-group><article-title>Inflammation kinase PKR phosphorylates &#945;-synuclein and causes &#945;-synuclein-dependent cell death</article-title><source>Neurobiol Dis</source><year>2018</year><volume>115</volume><fpage>17</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2018.03.001</pub-id><pub-id pub-id-type="pmid">29501855</pub-id></element-citation><mixed-citation id="mc-CR106" publication-type="journal">Reimer L, et al. Inflammation kinase PKR phosphorylates &#945;-synuclein and causes &#945;-synuclein-dependent cell death. Neurobiol Dis. 2018;115:17&#8211;28.<pub-id pub-id-type="pmid">29501855</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbd.2018.03.001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR107"><label>107.</label><citation-alternatives><element-citation id="ec-CR107" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghanem</surname><given-names>SS</given-names></name><etal/></person-group><article-title>&#945;-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity</article-title><source>Proc Natl Acad Sci U S A</source><year>2022</year><volume>119</volume><issue>15</issue><fpage>e2109617119</fpage><pub-id pub-id-type="doi">10.1073/pnas.2109617119</pub-id><pub-id pub-id-type="pmid">35353605</pub-id><pub-id pub-id-type="pmcid">PMC9169642</pub-id></element-citation><mixed-citation id="mc-CR107" publication-type="journal">Ghanem SS, et al. &#945;-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity. Proc Natl Acad Sci U S A. 2022;119(15):e2109617119.<pub-id pub-id-type="pmid">35353605</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2109617119</pub-id><pub-id pub-id-type="pmcid">PMC9169642</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR108"><label>108.</label><citation-alternatives><element-citation id="ec-CR108" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kasen</surname><given-names>A</given-names></name><etal/></person-group><article-title>Upregulation of &#945;-synuclein following immune activation: possible trigger of Parkinson's disease</article-title><source>Neurobiol Dis</source><year>2022</year><volume>166</volume><fpage>105654</fpage><pub-id pub-id-type="doi">10.1016/j.nbd.2022.105654</pub-id><pub-id pub-id-type="pmid">35143968</pub-id></element-citation><mixed-citation id="mc-CR108" publication-type="journal">Kasen A, et al. Upregulation of &#945;-synuclein following immune activation: possible trigger of Parkinson&#8217;s disease. Neurobiol Dis. 2022;166:105654.<pub-id pub-id-type="pmid">35143968</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbd.2022.105654</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR109"><label>109.</label><citation-alternatives><element-citation id="ec-CR109" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Reactive microglia enhance the transmission of exosomal &#945;-synuclein via toll-like receptor 2</article-title><source>Brain</source><year>2021</year><volume>144</volume><issue>7</issue><fpage>2024</fpage><lpage>2037</lpage><pub-id pub-id-type="doi">10.1093/brain/awab122</pub-id><pub-id pub-id-type="pmid">33792662</pub-id></element-citation><mixed-citation id="mc-CR109" publication-type="journal">Xia Y, et al. Reactive microglia enhance the transmission of exosomal &#945;-synuclein via toll-like receptor 2. Brain. 2021;144(7):2024&#8211;37.<pub-id pub-id-type="pmid">33792662</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awab122</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR110"><label>110.</label><citation-alternatives><element-citation id="ec-CR110" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olanow</surname><given-names>CW</given-names></name><etal/></person-group><article-title>Temporal evolution of microglia and &#945;-synuclein accumulation following foetal grafting in Parkinson's disease</article-title><source>Brain</source><year>2019</year><volume>142</volume><issue>6</issue><fpage>1690</fpage><lpage>1700</lpage><pub-id pub-id-type="doi">10.1093/brain/awz104</pub-id><pub-id pub-id-type="pmid">31056668</pub-id></element-citation><mixed-citation id="mc-CR110" publication-type="journal">Olanow CW, et al. Temporal evolution of microglia and &#945;-synuclein accumulation following foetal grafting in Parkinson&#8217;s disease. Brain. 2019;142(6):1690&#8211;700.<pub-id pub-id-type="pmid">31056668</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awz104</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR111"><label>111.</label><citation-alternatives><element-citation id="ec-CR111" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scheiblich</surname><given-names>H</given-names></name><etal/></person-group><article-title>Microglia jointly degrade fibrillar alpha-synuclein cargo by distribution through tunneling nanotubes</article-title><source>Cell</source><year>2021</year><pub-id pub-id-type="doi">10.1016/j.cell.2021.09.007</pub-id><pub-id pub-id-type="pmid">34555357</pub-id><pub-id pub-id-type="pmcid">PMC8527836</pub-id></element-citation><mixed-citation id="mc-CR111" publication-type="journal">Scheiblich H, et al. Microglia jointly degrade fibrillar alpha-synuclein cargo by distribution through tunneling nanotubes. Cell. 2021. 10.1016/j.cell.2021.09.007.<pub-id pub-id-type="pmid">34555357</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2021.09.007</pub-id><pub-id pub-id-type="pmcid">PMC8527836</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR112"><label>112.</label><citation-alternatives><element-citation id="ec-CR112" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rostami</surname><given-names>J</given-names></name><etal/></person-group><article-title>Crosstalk between astrocytes and microglia results in increased degradation of &#945;-synuclein and amyloid-&#946; aggregates</article-title><source>J Neuroinflammation</source><year>2021</year><volume>18</volume><issue>1</issue><fpage>124</fpage><pub-id pub-id-type="doi">10.1186/s12974-021-02158-3</pub-id><pub-id pub-id-type="pmid">34082772</pub-id><pub-id pub-id-type="pmcid">PMC8173980</pub-id></element-citation><mixed-citation id="mc-CR112" publication-type="journal">Rostami J, et al. Crosstalk between astrocytes and microglia results in increased degradation of &#945;-synuclein and amyloid-&#946; aggregates. J Neuroinflammation. 2021;18(1):124.<pub-id pub-id-type="pmid">34082772</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-021-02158-3</pub-id><pub-id pub-id-type="pmcid">PMC8173980</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR113"><label>113.</label><citation-alternatives><element-citation id="ec-CR113" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sulzer</surname><given-names>D</given-names></name><etal/></person-group><article-title>T cells from patients with Parkinson's disease recognize &#945;-synuclein peptides</article-title><source>Nature</source><year>2017</year><volume>546</volume><issue>7660</issue><fpage>656</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.1038/nature22815</pub-id><pub-id pub-id-type="pmid">28636593</pub-id><pub-id pub-id-type="pmcid">PMC5626019</pub-id></element-citation><mixed-citation id="mc-CR113" publication-type="journal">Sulzer D, et al. T cells from patients with Parkinson&#8217;s disease recognize &#945;-synuclein peptides. Nature. 2017;546(7660):656&#8211;61.<pub-id pub-id-type="pmid">28636593</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature22815</pub-id><pub-id pub-id-type="pmcid">PMC5626019</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR114"><label>114.</label><citation-alternatives><element-citation id="ec-CR114" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lindestam Arlehamn</surname><given-names>CS</given-names></name><etal/></person-group><article-title>&#913;-synuclein-specific T cell reactivity is associated with preclinical and early Parkinson's disease</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><issue>1</issue><fpage>1875</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-15626-w</pub-id><pub-id pub-id-type="pmid">32313102</pub-id><pub-id pub-id-type="pmcid">PMC7171193</pub-id></element-citation><mixed-citation id="mc-CR114" publication-type="journal">Lindestam Arlehamn CS, et al. &#913;-synuclein-specific T cell reactivity is associated with preclinical and early Parkinson&#8217;s disease. Nat Commun. 2020;11(1):1875.<pub-id pub-id-type="pmid">32313102</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-15626-w</pub-id><pub-id pub-id-type="pmcid">PMC7171193</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR115"><label>115.</label><citation-alternatives><element-citation id="ec-CR115" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karikari</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Neurodegeneration by &#945;-synuclein-specific T cells in AAV-A53T-&#945;-synuclein Parkinson's disease mice</article-title><source>Brain Behav Immun</source><year>2022</year><volume>101</volume><fpage>194</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2022.01.007</pub-id><pub-id pub-id-type="pmid">35032575</pub-id></element-citation><mixed-citation id="mc-CR115" publication-type="journal">Karikari AA, et al. Neurodegeneration by &#945;-synuclein-specific T cells in AAV-A53T-&#945;-synuclein Parkinson&#8217;s disease mice. Brain Behav Immun. 2022;101:194&#8211;210.<pub-id pub-id-type="pmid">35032575</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbi.2022.01.007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR116"><label>116.</label><citation-alternatives><element-citation id="ec-CR116" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tabrizi</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities</article-title><source>Lancet Neurol</source><year>2022</year><volume>21</volume><issue>7</issue><fpage>645</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(22)00121-1</pub-id><pub-id pub-id-type="pmid">35716694</pub-id><pub-id pub-id-type="pmcid">PMC7613206</pub-id></element-citation><mixed-citation id="mc-CR116" publication-type="journal">Tabrizi SJ, et al. Potential disease-modifying therapies for Huntington&#8217;s disease: lessons learned and future opportunities. Lancet Neurol. 2022;21(7):645&#8211;58.<pub-id pub-id-type="pmid">35716694</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(22)00121-1</pub-id><pub-id pub-id-type="pmcid">PMC7613206</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR117"><label>117.</label><citation-alternatives><element-citation id="ec-CR117" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tabrizi</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>A biological classification of Huntington's disease: the integrated staging system</article-title><source>Lancet Neurol</source><year>2022</year><volume>21</volume><issue>7</issue><fpage>632</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(22)00120-X</pub-id><pub-id pub-id-type="pmid">35716693</pub-id></element-citation><mixed-citation id="mc-CR117" publication-type="journal">Tabrizi SJ, et al. A biological classification of Huntington&#8217;s disease: the integrated staging system. Lancet Neurol. 2022;21(7):632&#8211;44.<pub-id pub-id-type="pmid">35716693</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(22)00120-X</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR118"><label>118.</label><citation-alternatives><element-citation id="ec-CR118" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iennaco</surname><given-names>R</given-names></name><etal/></person-group><article-title>The evolutionary history of the polyQ tract in huntingtin sheds light on its functional pro-neural activities</article-title><source>Cell Death Differ</source><year>2022</year><volume>29</volume><issue>2</issue><fpage>293</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1038/s41418-021-00914-9</pub-id><pub-id pub-id-type="pmid">34974533</pub-id><pub-id pub-id-type="pmcid">PMC8817008</pub-id></element-citation><mixed-citation id="mc-CR118" publication-type="journal">Iennaco R, et al. The evolutionary history of the polyQ tract in huntingtin sheds light on its functional pro-neural activities. Cell Death Differ. 2022;29(2):293&#8211;305.<pub-id pub-id-type="pmid">34974533</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41418-021-00914-9</pub-id><pub-id pub-id-type="pmcid">PMC8817008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR119"><label>119.</label><citation-alternatives><element-citation id="ec-CR119" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aviner</surname><given-names>R</given-names></name><etal/></person-group><article-title>Ribotoxic collisions on CAG expansions disrupt proteostasis and stress responses in Huntington&#8217;s disease</article-title><source>BiorXiv</source><year>2022</year><pub-id pub-id-type="doi">10.1038/s41556-024-01414-x</pub-id></element-citation><mixed-citation id="mc-CR119" publication-type="journal">Aviner R, et al. Ribotoxic collisions on CAG expansions disrupt proteostasis and stress responses in Huntington&#8217;s disease. BiorXiv. 2022. 10.1038/s41556-024-01414-x.</mixed-citation></citation-alternatives></ref><ref id="CR120"><label>120.</label><citation-alternatives><element-citation id="ec-CR120" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aviner</surname><given-names>R</given-names></name><etal/></person-group><article-title>Polyglutamine-mediated ribotoxicity disrupts proteostasis and stress responses in Huntington&#8217;s disease</article-title><source>Nat Cell Biol</source><year>2024</year><volume>26</volume><issue>6</issue><fpage>892</fpage><lpage>902</lpage><pub-id pub-id-type="doi">10.1038/s41556-024-01414-x</pub-id><pub-id pub-id-type="pmid">38741019</pub-id><pub-id pub-id-type="pmcid">PMC12288859</pub-id></element-citation><mixed-citation id="mc-CR120" publication-type="journal">Aviner R, et al. Polyglutamine-mediated ribotoxicity disrupts proteostasis and stress responses in Huntington&#8217;s disease. Nat Cell Biol. 2024;26(6):892&#8211;902.<pub-id pub-id-type="pmid">38741019</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41556-024-01414-x</pub-id><pub-id pub-id-type="pmcid">PMC12288859</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR121"><label>121.</label><citation-alternatives><element-citation id="ec-CR121" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ranganathan</surname><given-names>M</given-names></name><etal/></person-group><article-title>Age of onset and behavioral manifestations in Huntington's disease: an enroll-HD cohort analysis</article-title><source>Clin Genet</source><year>2021</year><volume>99</volume><issue>1</issue><fpage>133</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1111/cge.13857</pub-id><pub-id pub-id-type="pmid">33020896</pub-id></element-citation><mixed-citation id="mc-CR121" publication-type="journal">Ranganathan M, et al. Age of onset and behavioral manifestations in Huntington&#8217;s disease: an enroll-HD cohort analysis. Clin Genet. 2021;99(1):133&#8211;42.<pub-id pub-id-type="pmid">33020896</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cge.13857</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR122"><label>122.</label><citation-alternatives><element-citation id="ec-CR122" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Warner</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Standardizing the CAP score in Huntington&#8217;s disease by predicting age-at-onset</article-title><source>J Huntingtons Dis</source><year>2022</year><volume>11</volume><issue>2</issue><fpage>153</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.3233/JHD-210475</pub-id><pub-id pub-id-type="pmid">35466943</pub-id></element-citation><mixed-citation id="mc-CR122" publication-type="journal">Warner JH, et al. Standardizing the CAP score in Huntington&#8217;s disease by predicting age-at-onset. J Huntingtons Dis. 2022;11(2):153&#8211;71.<pub-id pub-id-type="pmid">35466943</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JHD-210475</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR123"><label>123.</label><citation-alternatives><element-citation id="ec-CR123" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>EP</given-names></name><etal/></person-group><article-title>Huntington&#8217;s disease pathogenesis: two sequential components</article-title><source>J Huntingtons Dis</source><year>2021</year><volume>10</volume><issue>1</issue><fpage>35</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.3233/JHD-200427</pub-id><pub-id pub-id-type="pmid">33579862</pub-id><pub-id pub-id-type="pmcid">PMC7990433</pub-id></element-citation><mixed-citation id="mc-CR123" publication-type="journal">Hong EP, et al. Huntington&#8217;s disease pathogenesis: two sequential components. J Huntingtons Dis. 2021;10(1):35&#8211;51.<pub-id pub-id-type="pmid">33579862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JHD-200427</pub-id><pub-id pub-id-type="pmcid">PMC7990433</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR124"><label>124.</label><citation-alternatives><element-citation id="ec-CR124" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>G</given-names></name><etal/></person-group><article-title>Altered gut microbiota related to inflammatory responses in patients with Huntington&#8217;s disease</article-title><source>Front Immunol</source><year>2021</year><volume>11</volume><fpage>603594</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.603594</pub-id><pub-id pub-id-type="pmid">33679692</pub-id><pub-id pub-id-type="pmcid">PMC7933529</pub-id></element-citation><mixed-citation id="mc-CR124" publication-type="journal">Du G, et al. Altered gut microbiota related to inflammatory responses in patients with Huntington&#8217;s disease. Front Immunol. 2021;11:603594.<pub-id pub-id-type="pmid">33679692</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2020.603594</pub-id><pub-id pub-id-type="pmcid">PMC7933529</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR125"><label>125.</label><citation-alternatives><element-citation id="ec-CR125" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jia</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Neuroinflammation in Huntington&#8217;s disease: from animal models to clinical therapeutics</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>1088124</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.1088124</pub-id><pub-id pub-id-type="pmid">36618375</pub-id><pub-id pub-id-type="pmcid">PMC9815700</pub-id></element-citation><mixed-citation id="mc-CR125" publication-type="journal">Jia Q, et al. Neuroinflammation in Huntington&#8217;s disease: from animal models to clinical therapeutics. Front Immunol. 2022;13:1088124.<pub-id pub-id-type="pmid">36618375</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.1088124</pub-id><pub-id pub-id-type="pmcid">PMC9815700</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR126"><label>126.</label><citation-alternatives><element-citation id="ec-CR126" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khaboushan</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Circulating levels of inflammatory biomarkers in Huntington's disease: a systematic review and meta-analysis</article-title><source>J Neuroimmunol</source><year>2023</year><volume>385</volume><fpage>578243</fpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2023.578243</pub-id><pub-id pub-id-type="pmid">37984118</pub-id></element-citation><mixed-citation id="mc-CR126" publication-type="journal">Khaboushan AS, et al. Circulating levels of inflammatory biomarkers in Huntington&#8217;s disease: a systematic review and meta-analysis. J Neuroimmunol. 2023;385:578243.<pub-id pub-id-type="pmid">37984118</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jneuroim.2023.578243</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR127"><label>127.</label><citation-alternatives><element-citation id="ec-CR127" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bilal</surname><given-names>H</given-names></name><etal/></person-group><article-title>Associations of inflammatory cytokines and cortisol with nonmotor features of Huntington's disease</article-title><source>Ann Clin Transl Neurol</source><year>2024</year><volume>11</volume><issue>4</issue><fpage>989</fpage><lpage>999</lpage><pub-id pub-id-type="doi">10.1002/acn3.52016</pub-id><pub-id pub-id-type="pmid">38356101</pub-id><pub-id pub-id-type="pmcid">PMC11021624</pub-id></element-citation><mixed-citation id="mc-CR127" publication-type="journal">Bilal H, et al. Associations of inflammatory cytokines and cortisol with nonmotor features of Huntington&#8217;s disease. Ann Clin Transl Neurol. 2024;11(4):989&#8211;99.<pub-id pub-id-type="pmid">38356101</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/acn3.52016</pub-id><pub-id pub-id-type="pmcid">PMC11021624</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR128"><label>128.</label><citation-alternatives><element-citation id="ec-CR128" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jambi</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>6-shogaol against 3-nitropropionic acid-induced Huntington&#8217;s disease in rodents: based on molecular docking/targeting pro-inflammatory cytokines/NF-&#954;B-BDNF-Nrf2 pathway</article-title><source>PLoS ONE</source><year>2024</year><volume>19</volume><issue>7</issue><fpage>e0305358</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0305358</pub-id><pub-id pub-id-type="pmid">39008492</pub-id><pub-id pub-id-type="pmcid">PMC11249262</pub-id></element-citation><mixed-citation id="mc-CR128" publication-type="journal">Jambi EJ, et al. 6-shogaol against 3-nitropropionic acid-induced Huntington&#8217;s disease in rodents: based on molecular docking/targeting pro-inflammatory cytokines/NF-&#954;B-BDNF-Nrf2 pathway. PLoS ONE. 2024;19(7):e0305358.<pub-id pub-id-type="pmid">39008492</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0305358</pub-id><pub-id pub-id-type="pmcid">PMC11249262</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR129"><label>129.</label><citation-alternatives><element-citation id="ec-CR129" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saba</surname><given-names>J</given-names></name><etal/></person-group><article-title>Neuroinflammation in Huntington&#8217;s disease: a starring role for astrocyte and microglia</article-title><source>Curr Neuropharmacol</source><year>2022</year><volume>20</volume><issue>6</issue><fpage>1116</fpage><lpage>1143</lpage><pub-id pub-id-type="doi">10.2174/1570159X19666211201094608</pub-id><pub-id pub-id-type="pmid">34852742</pub-id><pub-id pub-id-type="pmcid">PMC9886821</pub-id></element-citation><mixed-citation id="mc-CR129" publication-type="journal">Saba J, et al. Neuroinflammation in Huntington&#8217;s disease: a starring role for astrocyte and microglia. Curr Neuropharmacol. 2022;20(6):1116&#8211;43.<pub-id pub-id-type="pmid">34852742</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1570159X19666211201094608</pub-id><pub-id pub-id-type="pmcid">PMC9886821</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR130"><label>130.</label><citation-alternatives><element-citation id="ec-CR130" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khakh</surname><given-names>BS</given-names></name><name name-style="western"><surname>Goldman</surname><given-names>SA</given-names></name></person-group><article-title>Astrocytic contributions to Huntington's disease pathophysiology</article-title><source>Ann N Y Acad Sci</source><year>2023</year><volume>1522</volume><issue>1</issue><fpage>42</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1111/nyas.14977</pub-id><pub-id pub-id-type="pmid">36864567</pub-id><pub-id pub-id-type="pmcid">PMC10145027</pub-id></element-citation><mixed-citation id="mc-CR130" publication-type="journal">Khakh BS, Goldman SA. Astrocytic contributions to Huntington&#8217;s disease pathophysiology. Ann N Y Acad Sci. 2023;1522(1):42&#8211;59.<pub-id pub-id-type="pmid">36864567</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/nyas.14977</pub-id><pub-id pub-id-type="pmcid">PMC10145027</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR131"><label>131.</label><citation-alternatives><element-citation id="ec-CR131" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>G&#243;mez-Jaramillo</surname><given-names>L</given-names></name><etal/></person-group><article-title>A new perspective on Huntington&#8217;s disease: how a neurological disorder influences the peripheral tissues</article-title><source>Int J Mol Sci</source><year>2022</year><volume>23</volume><issue>11</issue><fpage>6089</fpage><pub-id pub-id-type="doi">10.3390/ijms23116089</pub-id><pub-id pub-id-type="pmid">35682773</pub-id><pub-id pub-id-type="pmcid">PMC9181740</pub-id></element-citation><mixed-citation id="mc-CR131" publication-type="journal">G&#243;mez-Jaramillo L, et al. A new perspective on Huntington&#8217;s disease: how a neurological disorder influences the peripheral tissues. Int J Mol Sci. 2022;23(11):6089.<pub-id pub-id-type="pmid">35682773</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms23116089</pub-id><pub-id pub-id-type="pmcid">PMC9181740</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR132"><label>132.</label><citation-alternatives><element-citation id="ec-CR132" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Oliveira Furlam</surname><given-names>T</given-names></name><etal/></person-group><article-title>Inflammasome activation and assembly in Huntington&#8217;s disease</article-title><source>Mol Immunol</source><year>2022</year><volume>151</volume><fpage>134</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2022.09.002</pub-id><pub-id pub-id-type="pmid">36126501</pub-id></element-citation><mixed-citation id="mc-CR132" publication-type="journal">de Oliveira Furlam T, et al. Inflammasome activation and assembly in Huntington&#8217;s disease. Mol Immunol. 2022;151:134&#8211;42.<pub-id pub-id-type="pmid">36126501</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molimm.2022.09.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR133"><label>133.</label><citation-alternatives><element-citation id="ec-CR133" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paldino</surname><given-names>E</given-names></name><name name-style="western"><surname>Fusco</surname><given-names>FR</given-names></name></person-group><article-title>Emerging role of NLRP3 inflammasome/pyroptosis in Huntington&#8217;s disease</article-title><source>Int J Mol Sci</source><year>2022</year><volume>23</volume><issue>15</issue><fpage>8363</fpage><pub-id pub-id-type="doi">10.3390/ijms23158363</pub-id><pub-id pub-id-type="pmid">35955494</pub-id><pub-id pub-id-type="pmcid">PMC9368941</pub-id></element-citation><mixed-citation id="mc-CR133" publication-type="journal">Paldino E, Fusco FR. Emerging role of NLRP3 inflammasome/pyroptosis in Huntington&#8217;s disease. Int J Mol Sci. 2022;23(15):8363.<pub-id pub-id-type="pmid">35955494</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms23158363</pub-id><pub-id pub-id-type="pmcid">PMC9368941</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR134"><label>134.</label><citation-alternatives><element-citation id="ec-CR134" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Markowitz</surname><given-names>CE</given-names></name></person-group><article-title>Multiple sclerosis update</article-title><source>Am J Manag Care</source><year>2013</year><volume>19</volume><issue>16 Suppl</issue><fpage>s294</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">24494618</pub-id></element-citation><mixed-citation id="mc-CR134" publication-type="journal">Markowitz CE. Multiple sclerosis update. Am J Manag Care. 2013;19(16 Suppl):s294-300.<pub-id pub-id-type="pmid">24494618</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR135"><label>135.</label><citation-alternatives><element-citation id="ec-CR135" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Latz</surname><given-names>E</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>TS</given-names></name><name name-style="western"><surname>Stutz</surname><given-names>A</given-names></name></person-group><article-title>Activation and regulation of the inflammasomes</article-title><source>Nat Rev Immunol</source><year>2013</year><volume>13</volume><issue>6</issue><fpage>397</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1038/nri3452</pub-id><pub-id pub-id-type="pmid">23702978</pub-id><pub-id pub-id-type="pmcid">PMC3807999</pub-id></element-citation><mixed-citation id="mc-CR135" publication-type="journal">Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol. 2013;13(6):397&#8211;411.<pub-id pub-id-type="pmid">23702978</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri3452</pub-id><pub-id pub-id-type="pmcid">PMC3807999</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR136"><label>136.</label><citation-alternatives><element-citation id="ec-CR136" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miao</surname><given-names>EA</given-names></name><name name-style="western"><surname>Rajan</surname><given-names>JV</given-names></name><name name-style="western"><surname>Aderem</surname><given-names>A</given-names></name></person-group><article-title>Caspase-1-induced pyroptotic cell death</article-title><source>Immunol Rev</source><year>2011</year><volume>243</volume><issue>1</issue><fpage>206</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2011.01044.x</pub-id><pub-id pub-id-type="pmid">21884178</pub-id><pub-id pub-id-type="pmcid">PMC3609431</pub-id></element-citation><mixed-citation id="mc-CR136" publication-type="journal">Miao EA, Rajan JV, Aderem A. Caspase-1-induced pyroptotic cell death. Immunol Rev. 2011;243(1):206&#8211;14.<pub-id pub-id-type="pmid">21884178</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1600-065X.2011.01044.x</pub-id><pub-id pub-id-type="pmcid">PMC3609431</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR137"><label>137.</label><citation-alternatives><element-citation id="ec-CR137" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takeuchi</surname><given-names>O</given-names></name><name name-style="western"><surname>Akira</surname><given-names>S</given-names></name></person-group><article-title>Pattern recognition receptors and inflammation</article-title><source>Cell</source><year>2010</year><volume>140</volume><issue>6</issue><fpage>805</fpage><lpage>820</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.01.022</pub-id><pub-id pub-id-type="pmid">20303872</pub-id></element-citation><mixed-citation id="mc-CR137" publication-type="journal">Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140(6):805&#8211;20.<pub-id pub-id-type="pmid">20303872</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2010.01.022</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR138"><label>138.</label><citation-alternatives><element-citation id="ec-CR138" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vajjhala</surname><given-names>PR</given-names></name><name name-style="western"><surname>Mirams</surname><given-names>RE</given-names></name><name name-style="western"><surname>Hill</surname><given-names>JM</given-names></name></person-group><article-title>Multiple binding sites on the pyrin domain of ASC protein allow self-association and interaction with NLRP3 protein</article-title><source>J Biol Chem</source><year>2012</year><volume>287</volume><issue>50</issue><fpage>41732</fpage><lpage>41743</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.381228</pub-id><pub-id pub-id-type="pmid">23066025</pub-id><pub-id pub-id-type="pmcid">PMC3516722</pub-id></element-citation><mixed-citation id="mc-CR138" publication-type="journal">Vajjhala PR, Mirams RE, Hill JM. Multiple binding sites on the pyrin domain of ASC protein allow self-association and interaction with NLRP3 protein. J Biol Chem. 2012;287(50):41732&#8211;43.<pub-id pub-id-type="pmid">23066025</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M112.381228</pub-id><pub-id pub-id-type="pmcid">PMC3516722</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR139"><label>139.</label><citation-alternatives><element-citation id="ec-CR139" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>R</given-names></name><etal/></person-group><article-title>A role for mitochondria in NLRP3 inflammasome activation</article-title><source>Nature</source><year>2011</year><volume>469</volume><issue>7329</issue><fpage>221</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1038/nature09663</pub-id><pub-id pub-id-type="pmid">21124315</pub-id></element-citation><mixed-citation id="mc-CR139" publication-type="journal">Zhou R, et al. A role for mitochondria in NLRP3 inflammasome activation. Nature. 2011;469(7329):221&#8211;5.<pub-id pub-id-type="pmid">21124315</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature09663</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR140"><label>140.</label><citation-alternatives><element-citation id="ec-CR140" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Misawa</surname><given-names>T</given-names></name><etal/></person-group><article-title>Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome</article-title><source>Nat Immunol</source><year>2013</year><volume>14</volume><issue>5</issue><fpage>454</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1038/ni.2550</pub-id><pub-id pub-id-type="pmid">23502856</pub-id></element-citation><mixed-citation id="mc-CR140" publication-type="journal">Misawa T, et al. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat Immunol. 2013;14(5):454&#8211;60.<pub-id pub-id-type="pmid">23502856</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ni.2550</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR141"><label>141.</label><citation-alternatives><element-citation id="ec-CR141" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mariathasan</surname><given-names>S</given-names></name><etal/></person-group><article-title>Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf</article-title><source>Nature</source><year>2004</year><volume>430</volume><issue>6996</issue><fpage>213</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1038/nature02664</pub-id><pub-id pub-id-type="pmid">15190255</pub-id></element-citation><mixed-citation id="mc-CR141" publication-type="journal">Mariathasan S, et al. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature. 2004;430(6996):213&#8211;8.<pub-id pub-id-type="pmid">15190255</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature02664</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR142"><label>142.</label><citation-alternatives><element-citation id="ec-CR142" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Opdenbosch</surname><given-names>N</given-names></name><etal/></person-group><article-title>Activation of the NLRP1b inflammasome independently of ASC-mediated caspase-1 autoproteolysis and speck formation</article-title><source>Nat Commun</source><year>2014</year><volume>5</volume><fpage>3209</fpage><pub-id pub-id-type="doi">10.1038/ncomms4209</pub-id><pub-id pub-id-type="pmid">24492532</pub-id><pub-id pub-id-type="pmcid">PMC3926011</pub-id></element-citation><mixed-citation id="mc-CR142" publication-type="journal">Van Opdenbosch N, et al. Activation of the NLRP1b inflammasome independently of ASC-mediated caspase-1 autoproteolysis and speck formation. Nat Commun. 2014;5:3209.<pub-id pub-id-type="pmid">24492532</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms4209</pub-id><pub-id pub-id-type="pmcid">PMC3926011</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR143"><label>143.</label><citation-alternatives><element-citation id="ec-CR143" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martinon</surname><given-names>F</given-names></name><name name-style="western"><surname>Burns</surname><given-names>K</given-names></name><name name-style="western"><surname>Tschopp</surname><given-names>J</given-names></name></person-group><article-title>The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta</article-title><source>Mol Cell</source><year>2002</year><volume>10</volume><issue>2</issue><fpage>417</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1016/S1097-2765(02)00599-3</pub-id><pub-id pub-id-type="pmid">12191486</pub-id></element-citation><mixed-citation id="mc-CR143" publication-type="journal">Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 2002;10(2):417&#8211;26.<pub-id pub-id-type="pmid">12191486</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1097-2765(02)00599-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR144"><label>144.</label><citation-alternatives><element-citation id="ec-CR144" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kesavardhana</surname><given-names>S</given-names></name><name name-style="western"><surname>Malireddi</surname><given-names>RKS</given-names></name><name name-style="western"><surname>Kanneganti</surname><given-names>TD</given-names></name></person-group><article-title>Caspases in cell death, inflammation, and pyroptosis</article-title><source>Annu Rev Immunol</source><year>2020</year><volume>38</volume><fpage>567</fpage><lpage>595</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-073119-095439</pub-id><pub-id pub-id-type="pmid">32017655</pub-id><pub-id pub-id-type="pmcid">PMC7190443</pub-id></element-citation><mixed-citation id="mc-CR144" publication-type="journal">Kesavardhana S, Malireddi RKS, Kanneganti TD. Caspases in cell death, inflammation, and pyroptosis. Annu Rev Immunol. 2020;38:567&#8211;95.<pub-id pub-id-type="pmid">32017655</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-immunol-073119-095439</pub-id><pub-id pub-id-type="pmcid">PMC7190443</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR145"><label>145.</label><citation-alternatives><element-citation id="ec-CR145" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kayagaki</surname><given-names>N</given-names></name><etal/></person-group><article-title>Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling</article-title><source>Nature</source><year>2015</year><volume>526</volume><issue>7575</issue><fpage>666</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.1038/nature15541</pub-id><pub-id pub-id-type="pmid">26375259</pub-id></element-citation><mixed-citation id="mc-CR145" publication-type="journal">Kayagaki N, et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature. 2015;526(7575):666&#8211;71.<pub-id pub-id-type="pmid">26375259</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature15541</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR146"><label>146.</label><citation-alternatives><element-citation id="ec-CR146" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Nlrp3 activation and mitosis are mutually exclusive events coordinated by NEK7, a new inflammasome component</article-title><source>Nat Immunol</source><year>2016</year><volume>17</volume><issue>3</issue><fpage>250</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1038/ni.3333</pub-id><pub-id pub-id-type="pmid">26642356</pub-id><pub-id pub-id-type="pmcid">PMC4862588</pub-id></element-citation><mixed-citation id="mc-CR146" publication-type="journal">Shi H, et al. Nlrp3 activation and mitosis are mutually exclusive events coordinated by NEK7, a new inflammasome component. Nat Immunol. 2016;17(3):250&#8211;8.<pub-id pub-id-type="pmid">26642356</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ni.3333</pub-id><pub-id pub-id-type="pmcid">PMC4862588</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR147"><label>147.</label><citation-alternatives><element-citation id="ec-CR147" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aglietti</surname><given-names>RA</given-names></name><etal/></person-group><article-title>GsmdD p30 elicited by caspase-11 during pyroptosis forms pores in membranes</article-title><source>Proc Natl Acad Sci U S A</source><year>2016</year><volume>113</volume><issue>28</issue><fpage>7858</fpage><lpage>7863</lpage><pub-id pub-id-type="doi">10.1073/pnas.1607769113</pub-id><pub-id pub-id-type="pmid">27339137</pub-id><pub-id pub-id-type="pmcid">PMC4948338</pub-id></element-citation><mixed-citation id="mc-CR147" publication-type="journal">Aglietti RA, et al. GsmdD p30 elicited by caspase-11 during pyroptosis forms pores in membranes. Proc Natl Acad Sci U S A. 2016;113(28):7858&#8211;63.<pub-id pub-id-type="pmid">27339137</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1607769113</pub-id><pub-id pub-id-type="pmcid">PMC4948338</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR148"><label>148.</label><citation-alternatives><element-citation id="ec-CR148" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matikainen</surname><given-names>S</given-names></name><name name-style="western"><surname>Nyman</surname><given-names>TA</given-names></name><name name-style="western"><surname>Cypryk</surname><given-names>W</given-names></name></person-group><article-title>Function and regulation of noncanonical Caspase-4/5/11 inflammasome</article-title><source>J Immunol</source><year>2020</year><volume>204</volume><issue>12</issue><fpage>3063</fpage><lpage>3069</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.2000373</pub-id><pub-id pub-id-type="pmid">32513874</pub-id></element-citation><mixed-citation id="mc-CR148" publication-type="journal">Matikainen S, Nyman TA, Cypryk W. Function and regulation of noncanonical Caspase-4/5/11 inflammasome. J Immunol. 2020;204(12):3063&#8211;9.<pub-id pub-id-type="pmid">32513874</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.2000373</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR149"><label>149.</label><citation-alternatives><element-citation id="ec-CR149" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Awad</surname><given-names>F</given-names></name><etal/></person-group><article-title>Impact of human monocyte and macrophage polarization on NLR expression and NLRP3 inflammasome activation</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><issue>4</issue><fpage>e0175336</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0175336</pub-id><pub-id pub-id-type="pmid">28403163</pub-id><pub-id pub-id-type="pmcid">PMC5389804</pub-id></element-citation><mixed-citation id="mc-CR149" publication-type="journal">Awad F, et al. Impact of human monocyte and macrophage polarization on NLR expression and NLRP3 inflammasome activation. PLoS ONE. 2017;12(4):e0175336.<pub-id pub-id-type="pmid">28403163</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0175336</pub-id><pub-id pub-id-type="pmcid">PMC5389804</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR150"><label>150.</label><citation-alternatives><element-citation id="ec-CR150" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heneka</surname><given-names>MT</given-names></name><etal/></person-group><article-title>NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice</article-title><source>Nature</source><year>2013</year><volume>493</volume><issue>7434</issue><fpage>674</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1038/nature11729</pub-id><pub-id pub-id-type="pmid">23254930</pub-id><pub-id pub-id-type="pmcid">PMC3812809</pub-id></element-citation><mixed-citation id="mc-CR150" publication-type="journal">Heneka MT, et al. NLRP3 is activated in Alzheimer&#8217;s disease and contributes to pathology in APP/PS1 mice. Nature. 2013;493(7434):674&#8211;8.<pub-id pub-id-type="pmid">23254930</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature11729</pub-id><pub-id pub-id-type="pmcid">PMC3812809</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR151"><label>151.</label><citation-alternatives><element-citation id="ec-CR151" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>La Rosa</surname><given-names>F</given-names></name><etal/></person-group><article-title>Stavudine reduces NLRP3 inflammasome activation and modulates amyloid-&#946; autophagy</article-title><source>J Alzheimers Dis</source><year>2019</year><volume>72</volume><issue>2</issue><fpage>401</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.3233/JAD-181259</pub-id><pub-id pub-id-type="pmid">31594217</pub-id></element-citation><mixed-citation id="mc-CR151" publication-type="journal">La Rosa F, et al. Stavudine reduces NLRP3 inflammasome activation and modulates amyloid-&#946; autophagy. J Alzheimers Dis. 2019;72(2):401&#8211;12.<pub-id pub-id-type="pmid">31594217</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-181259</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR152"><label>152.</label><citation-alternatives><element-citation id="ec-CR152" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saresella</surname><given-names>M</given-names></name><etal/></person-group><article-title>The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer's disease</article-title><source>Mol Neurodegener</source><year>2016</year><volume>11</volume><fpage>23</fpage><pub-id pub-id-type="doi">10.1186/s13024-016-0088-1</pub-id><pub-id pub-id-type="pmid">26939933</pub-id><pub-id pub-id-type="pmcid">PMC4778358</pub-id></element-citation><mixed-citation id="mc-CR152" publication-type="journal">Saresella M, et al. The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer&#8217;s disease. Mol Neurodegener. 2016;11:23.<pub-id pub-id-type="pmid">26939933</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-016-0088-1</pub-id><pub-id pub-id-type="pmcid">PMC4778358</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR153"><label>153.</label><citation-alternatives><element-citation id="ec-CR153" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halle</surname><given-names>A</given-names></name><etal/></person-group><article-title>The NALP3 inflammasome is involved in the innate immune response to amyloid-beta</article-title><source>Nat Immunol</source><year>2008</year><volume>9</volume><issue>8</issue><fpage>857</fpage><lpage>865</lpage><pub-id pub-id-type="doi">10.1038/ni.1636</pub-id><pub-id pub-id-type="pmid">18604209</pub-id><pub-id pub-id-type="pmcid">PMC3101478</pub-id></element-citation><mixed-citation id="mc-CR153" publication-type="journal">Halle A, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol. 2008;9(8):857&#8211;65.<pub-id pub-id-type="pmid">18604209</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ni.1636</pub-id><pub-id pub-id-type="pmcid">PMC3101478</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR154"><label>154.</label><citation-alternatives><element-citation id="ec-CR154" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heneka</surname><given-names>MT</given-names></name></person-group><article-title>Inflammasome activation and innate immunity in Alzheimer's disease</article-title><source>Brain Pathol</source><year>2017</year><volume>27</volume><issue>2</issue><fpage>220</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1111/bpa.12483</pub-id><pub-id pub-id-type="pmid">28019679</pub-id><pub-id pub-id-type="pmcid">PMC8029274</pub-id></element-citation><mixed-citation id="mc-CR154" publication-type="journal">Heneka MT. Inflammasome activation and innate immunity in Alzheimer&#8217;s disease. Brain Pathol. 2017;27(2):220&#8211;2.<pub-id pub-id-type="pmid">28019679</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bpa.12483</pub-id><pub-id pub-id-type="pmcid">PMC8029274</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR155"><label>155.</label><citation-alternatives><element-citation id="ec-CR155" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dempsey</surname><given-names>C</given-names></name><etal/></person-group><article-title>Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-&#946; and cognitive function in APP/PS1 mice</article-title><source>Brain Behav Immun</source><year>2017</year><volume>61</volume><fpage>306</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2016.12.014</pub-id><pub-id pub-id-type="pmid">28003153</pub-id></element-citation><mixed-citation id="mc-CR155" publication-type="journal">Dempsey C, et al. Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-&#946; and cognitive function in APP/PS1 mice. Brain Behav Immun. 2017;61:306&#8211;16.<pub-id pub-id-type="pmid">28003153</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbi.2016.12.014</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR156"><label>156.</label><citation-alternatives><element-citation id="ec-CR156" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parajuli</surname><given-names>B</given-names></name><etal/></person-group><article-title>Oligomeric amyloid &#946; induces IL-1&#946; processing via production of ROS: implication in Alzheimer's disease</article-title><source>Cell Death Dis</source><year>2013</year><volume>4</volume><issue>12</issue><fpage>e975</fpage><pub-id pub-id-type="doi">10.1038/cddis.2013.503</pub-id><pub-id pub-id-type="pmid">24357806</pub-id><pub-id pub-id-type="pmcid">PMC3877570</pub-id></element-citation><mixed-citation id="mc-CR156" publication-type="journal">Parajuli B, et al. Oligomeric amyloid &#946; induces IL-1&#946; processing via production of ROS: implication in Alzheimer&#8217;s disease. Cell Death Dis. 2013;4(12):e975.<pub-id pub-id-type="pmid">24357806</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/cddis.2013.503</pub-id><pub-id pub-id-type="pmcid">PMC3877570</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR157"><label>157.</label><citation-alternatives><element-citation id="ec-CR157" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaushal</surname><given-names>V</given-names></name><etal/></person-group><article-title>Neuronal NLRP1 inflammasome activation of caspase-1 coordinately regulates inflammatory interleukin-1-beta production and axonal degeneration-associated caspase-6 activation</article-title><source>Cell Death Differ</source><year>2015</year><volume>22</volume><issue>10</issue><fpage>1676</fpage><lpage>1686</lpage><pub-id pub-id-type="doi">10.1038/cdd.2015.16</pub-id><pub-id pub-id-type="pmid">25744023</pub-id><pub-id pub-id-type="pmcid">PMC4563782</pub-id></element-citation><mixed-citation id="mc-CR157" publication-type="journal">Kaushal V, et al. Neuronal NLRP1 inflammasome activation of caspase-1 coordinately regulates inflammatory interleukin-1-beta production and axonal degeneration-associated caspase-6 activation. Cell Death Differ. 2015;22(10):1676&#8211;86.<pub-id pub-id-type="pmid">25744023</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/cdd.2015.16</pub-id><pub-id pub-id-type="pmcid">PMC4563782</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR158"><label>158.</label><citation-alternatives><element-citation id="ec-CR158" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gris</surname><given-names>D</given-names></name><etal/></person-group><article-title>Nlrp3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses</article-title><source>J Immunol</source><year>2010</year><volume>185</volume><issue>2</issue><fpage>974</fpage><lpage>981</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0904145</pub-id><pub-id pub-id-type="pmid">20574004</pub-id><pub-id pub-id-type="pmcid">PMC3593010</pub-id></element-citation><mixed-citation id="mc-CR158" publication-type="journal">Gris D, et al. Nlrp3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses. J Immunol. 2010;185(2):974&#8211;81.<pub-id pub-id-type="pmid">20574004</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.0904145</pub-id><pub-id pub-id-type="pmcid">PMC3593010</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR159"><label>159.</label><citation-alternatives><element-citation id="ec-CR159" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ransohoff</surname><given-names>RM</given-names></name></person-group><article-title>Animal models of multiple sclerosis: the good, the bad and the bottom line</article-title><source>Nat Neurosci</source><year>2012</year><volume>15</volume><issue>8</issue><fpage>1074</fpage><lpage>1077</lpage><pub-id pub-id-type="doi">10.1038/nn.3168</pub-id><pub-id pub-id-type="pmid">22837037</pub-id><pub-id pub-id-type="pmcid">PMC7097342</pub-id></element-citation><mixed-citation id="mc-CR159" publication-type="journal">Ransohoff RM. Animal models of multiple sclerosis: the good, the bad and the bottom line. Nat Neurosci. 2012;15(8):1074&#8211;7.<pub-id pub-id-type="pmid">22837037</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nn.3168</pub-id><pub-id pub-id-type="pmcid">PMC7097342</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR160"><label>160.</label><citation-alternatives><element-citation id="ec-CR160" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peelen</surname><given-names>E</given-names></name><etal/></person-group><article-title>Increased inflammasome related gene expression profile in PBMC may facilitate T helper 17 cell induction in multiple sclerosis</article-title><source>Mol Immunol</source><year>2015</year><volume>63</volume><issue>2</issue><fpage>521</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2014.10.008</pub-id><pub-id pub-id-type="pmid">25458313</pub-id></element-citation><mixed-citation id="mc-CR160" publication-type="journal">Peelen E, et al. Increased inflammasome related gene expression profile in PBMC may facilitate T helper 17 cell induction in multiple sclerosis. Mol Immunol. 2015;63(2):521&#8211;9.<pub-id pub-id-type="pmid">25458313</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molimm.2014.10.008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR161"><label>161.</label><citation-alternatives><element-citation id="ec-CR161" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Inoue</surname><given-names>M</given-names></name><name name-style="western"><surname>Shinohara</surname><given-names>ML</given-names></name></person-group><article-title>NLRP3 Inflammasome and MS/EAE</article-title><source>Autoimmune Dis</source><year>2013</year><volume>2013</volume><fpage>859145</fpage><pub-id pub-id-type="pmid">23365725</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2013/859145</pub-id><pub-id pub-id-type="pmcid">PMC3556409</pub-id></element-citation><mixed-citation id="mc-CR161" publication-type="journal">Inoue M, Shinohara ML. NLRP3 Inflammasome and MS/EAE. Autoimmune Dis. 2013;2013:859145.<pub-id pub-id-type="pmid">23365725</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2013/859145</pub-id><pub-id pub-id-type="pmcid">PMC3556409</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR162"><label>162.</label><citation-alternatives><element-citation id="ec-CR162" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mamik</surname><given-names>MK</given-names></name><name name-style="western"><surname>Power</surname><given-names>C</given-names></name></person-group><article-title>Inflammasomes in neurological diseases: emerging pathogenic and therapeutic concepts</article-title><source>Brain</source><year>2017</year><volume>140</volume><issue>9</issue><fpage>2273</fpage><lpage>2285</lpage><pub-id pub-id-type="doi">10.1093/brain/awx133</pub-id><pub-id pub-id-type="pmid">29050380</pub-id></element-citation><mixed-citation id="mc-CR162" publication-type="journal">Mamik MK, Power C. Inflammasomes in neurological diseases: emerging pathogenic and therapeutic concepts. Brain. 2017;140(9):2273&#8211;85.<pub-id pub-id-type="pmid">29050380</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awx133</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR163"><label>163.</label><citation-alternatives><element-citation id="ec-CR163" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Furlan</surname><given-names>R</given-names></name><etal/></person-group><article-title>Peripheral levels of caspase-1 mRNA correlate with disease activity in patients with multiple sclerosis; a preliminary study</article-title><source>J Neurol Neurosurg Psychiatry</source><year>1999</year><volume>67</volume><issue>6</issue><fpage>785</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.1136/jnnp.67.6.785</pub-id><pub-id pub-id-type="pmid">10567499</pub-id><pub-id pub-id-type="pmcid">PMC1736665</pub-id></element-citation><mixed-citation id="mc-CR163" publication-type="journal">Furlan R, et al. Peripheral levels of caspase-1 mRNA correlate with disease activity in patients with multiple sclerosis; a preliminary study. J Neurol Neurosurg Psychiatry. 1999;67(6):785&#8211;8.<pub-id pub-id-type="pmid">10567499</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp.67.6.785</pub-id><pub-id pub-id-type="pmcid">PMC1736665</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR164"><label>164.</label><citation-alternatives><element-citation id="ec-CR164" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ming</surname><given-names>X</given-names></name><etal/></person-group><article-title>Caspase-1 expression in multiple sclerosis plaques and cultured glial cells</article-title><source>J Neurol Sci</source><year>2002</year><volume>197</volume><issue>1&#8211;2</issue><fpage>9</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/S0022-510X(02)00030-8</pub-id><pub-id pub-id-type="pmid">11997061</pub-id></element-citation><mixed-citation id="mc-CR164" publication-type="journal">Ming X, et al. Caspase-1 expression in multiple sclerosis plaques and cultured glial cells. J Neurol Sci. 2002;197(1&#8211;2):9&#8211;18.<pub-id pub-id-type="pmid">11997061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0022-510x(02)00030-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR165"><label>165.</label><citation-alternatives><element-citation id="ec-CR165" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keane</surname><given-names>RW</given-names></name><name name-style="western"><surname>Dietrich</surname><given-names>WD</given-names></name><name name-style="western"><surname>de Rivero Vaccari</surname><given-names>JP</given-names></name></person-group><article-title>Inflammasome proteins as biomarkers of multiple sclerosis</article-title><source>Front Neurol</source><year>2018</year><volume>9</volume><fpage>135</fpage><pub-id pub-id-type="doi">10.3389/fneur.2018.00135</pub-id><pub-id pub-id-type="pmid">29615953</pub-id><pub-id pub-id-type="pmcid">PMC5868457</pub-id></element-citation><mixed-citation id="mc-CR165" publication-type="journal">Keane RW, Dietrich WD, de Rivero Vaccari JP. Inflammasome proteins as biomarkers of multiple sclerosis. Front Neurol. 2018;9:135.<pub-id pub-id-type="pmid">29615953</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2018.00135</pub-id><pub-id pub-id-type="pmcid">PMC5868457</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR166"><label>166.</label><citation-alternatives><element-citation id="ec-CR166" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Losy</surname><given-names>J</given-names></name><name name-style="western"><surname>Niezgoda</surname><given-names>A</given-names></name></person-group><article-title>IL-18 in patients with multiple sclerosis</article-title><source>Acta Neurol Scand</source><year>2001</year><volume>104</volume><issue>3</issue><fpage>171</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1034/j.1600-0404.2001.00356.x</pub-id><pub-id pub-id-type="pmid">11551238</pub-id></element-citation><mixed-citation id="mc-CR166" publication-type="journal">Losy J, Niezgoda A. IL-18 in patients with multiple sclerosis. Acta Neurol Scand. 2001;104(3):171&#8211;3.<pub-id pub-id-type="pmid">11551238</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1034/j.1600-0404.2001.00356.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR167"><label>167.</label><citation-alternatives><element-citation id="ec-CR167" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nicoletti</surname><given-names>F</given-names></name><etal/></person-group><article-title>Increased serum levels of interleukin-18 in patients with multiple sclerosis</article-title><source>Neurology</source><year>2001</year><volume>57</volume><issue>2</issue><fpage>342</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1212/WNL.57.2.342</pub-id><pub-id pub-id-type="pmid">11468327</pub-id></element-citation><mixed-citation id="mc-CR167" publication-type="journal">Nicoletti F, et al. Increased serum levels of interleukin-18 in patients with multiple sclerosis. Neurology. 2001;57(2):342&#8211;4.<pub-id pub-id-type="pmid">11468327</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.57.2.342</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR168"><label>168.</label><citation-alternatives><element-citation id="ec-CR168" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>YC</given-names></name><etal/></person-group><article-title>Serum levels of interleukin (IL)-18, IL-23 and IL-17 in Chinese patients with multiple sclerosis</article-title><source>J Neuroimmunol</source><year>2012</year><volume>243</volume><issue>1&#8211;2</issue><fpage>56</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2011.12.008</pub-id><pub-id pub-id-type="pmid">22230485</pub-id></element-citation><mixed-citation id="mc-CR168" publication-type="journal">Chen YC, et al. Serum levels of interleukin (IL)-18, IL-23 and IL-17 in Chinese patients with multiple sclerosis. J Neuroimmunol. 2012;243(1&#8211;2):56&#8211;60.<pub-id pub-id-type="pmid">22230485</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jneuroim.2011.12.008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR169"><label>169.</label><citation-alternatives><element-citation id="ec-CR169" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Jong</surname><given-names>BA</given-names></name><etal/></person-group><article-title>Production of IL-1beta and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis</article-title><source>J Neuroimmunol</source><year>2002</year><volume>126</volume><issue>1&#8211;2</issue><fpage>172</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1016/S0165-5728(02)00056-5</pub-id><pub-id pub-id-type="pmid">12020968</pub-id></element-citation><mixed-citation id="mc-CR169" publication-type="journal">de Jong BA, et al. Production of IL-1beta and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis. J Neuroimmunol. 2002;126(1&#8211;2):172&#8211;9.<pub-id pub-id-type="pmid">12020968</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0165-5728(02)00056-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR170"><label>170.</label><citation-alternatives><element-citation id="ec-CR170" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burger</surname><given-names>D</given-names></name><etal/></person-group><article-title>Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis</article-title><source>Proc Natl Acad Sci U S A</source><year>2009</year><volume>106</volume><issue>11</issue><fpage>4355</fpage><lpage>4359</lpage><pub-id pub-id-type="doi">10.1073/pnas.0812183106</pub-id><pub-id pub-id-type="pmid">19255448</pub-id><pub-id pub-id-type="pmcid">PMC2649955</pub-id></element-citation><mixed-citation id="mc-CR170" publication-type="journal">Burger D, et al. Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis. Proc Natl Acad Sci U S A. 2009;106(11):4355&#8211;9.<pub-id pub-id-type="pmid">19255448</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0812183106</pub-id><pub-id pub-id-type="pmcid">PMC2649955</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR171"><label>171.</label><citation-alternatives><element-citation id="ec-CR171" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nicoletti</surname><given-names>F</given-names></name><etal/></person-group><article-title>Circulating serum levels of IL-1ra in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFN-beta treatment</article-title><source>Cytokine</source><year>1996</year><volume>8</volume><issue>5</issue><fpage>395</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1006/cyto.1996.0054</pub-id><pub-id pub-id-type="pmid">8726668</pub-id></element-citation><mixed-citation id="mc-CR171" publication-type="journal">Nicoletti F, et al. Circulating serum levels of IL-1ra in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFN-beta treatment. Cytokine. 1996;8(5):395&#8211;400.<pub-id pub-id-type="pmid">8726668</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/cyto.1996.0054</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR172"><label>172.</label><citation-alternatives><element-citation id="ec-CR172" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Codolo</surname><given-names>G</given-names></name><etal/></person-group><article-title>Triggering of inflammasome by aggregated &#945;-synuclein, an inflammatory response in synucleinopathies</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><issue>1</issue><fpage>e55375</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0055375</pub-id><pub-id pub-id-type="pmid">23383169</pub-id><pub-id pub-id-type="pmcid">PMC3561263</pub-id></element-citation><mixed-citation id="mc-CR172" publication-type="journal">Codolo G, et al. Triggering of inflammasome by aggregated &#945;-synuclein, an inflammatory response in synucleinopathies. PLoS ONE. 2013;8(1):e55375.<pub-id pub-id-type="pmid">23383169</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0055375</pub-id><pub-id pub-id-type="pmcid">PMC3561263</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR173"><label>173.</label><citation-alternatives><element-citation id="ec-CR173" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome</article-title><source>Cell</source><year>2015</year><volume>160</volume><issue>1&#8211;2</issue><fpage>62</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.11.047</pub-id><pub-id pub-id-type="pmid">25594175</pub-id></element-citation><mixed-citation id="mc-CR173" publication-type="journal">Yan Y, et al. Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome. Cell. 2015;160(1&#8211;2):62&#8211;73.<pub-id pub-id-type="pmid">25594175</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2014.11.047</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR174"><label>174.</label><citation-alternatives><element-citation id="ec-CR174" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Junn</surname><given-names>E</given-names></name><etal/></person-group><article-title>Repression of alpha-synuclein expression and toxicity by microRNA-7</article-title><source>Proc Natl Acad Sci U S A</source><year>2009</year><volume>106</volume><issue>31</issue><fpage>13052</fpage><lpage>13057</lpage><pub-id pub-id-type="doi">10.1073/pnas.0906277106</pub-id><pub-id pub-id-type="pmid">19628698</pub-id><pub-id pub-id-type="pmcid">PMC2722353</pub-id></element-citation><mixed-citation id="mc-CR174" publication-type="journal">Junn E, et al. Repression of alpha-synuclein expression and toxicity by microRNA-7. Proc Natl Acad Sci U S A. 2009;106(31):13052&#8211;7.<pub-id pub-id-type="pmid">19628698</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0906277106</pub-id><pub-id pub-id-type="pmcid">PMC2722353</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR175"><label>175.</label><citation-alternatives><element-citation id="ec-CR175" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Microrna-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson's disease</article-title><source>Mol Neurodegener</source><year>2016</year><volume>11</volume><fpage>28</fpage><pub-id pub-id-type="doi">10.1186/s13024-016-0094-3</pub-id><pub-id pub-id-type="pmid">27084336</pub-id><pub-id pub-id-type="pmcid">PMC4833896</pub-id></element-citation><mixed-citation id="mc-CR175" publication-type="journal">Zhou Y, et al. Microrna-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson&#8217;s disease. Mol Neurodegener. 2016;11:28.<pub-id pub-id-type="pmid">27084336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-016-0094-3</pub-id><pub-id pub-id-type="pmcid">PMC4833896</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR176"><label>176.</label><citation-alternatives><element-citation id="ec-CR176" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>E</given-names></name><etal/></person-group><article-title>MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration</article-title><source>Cell Death Differ</source><year>2019</year><volume>26</volume><issue>2</issue><fpage>213</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1038/s41418-018-0124-5</pub-id><pub-id pub-id-type="pmid">29786072</pub-id><pub-id pub-id-type="pmcid">PMC6329843</pub-id></element-citation><mixed-citation id="mc-CR176" publication-type="journal">Lee E, et al. MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration. Cell Death Differ. 2019;26(2):213&#8211;28.<pub-id pub-id-type="pmid">29786072</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41418-018-0124-5</pub-id><pub-id pub-id-type="pmcid">PMC6329843</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR177"><label>177.</label><citation-alternatives><element-citation id="ec-CR177" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daniels</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer's disease in rodent models</article-title><source>Nat Commun</source><year>2016</year><volume>7</volume><fpage>12504</fpage><pub-id pub-id-type="doi">10.1038/ncomms12504</pub-id><pub-id pub-id-type="pmid">27509875</pub-id><pub-id pub-id-type="pmcid">PMC4987536</pub-id></element-citation><mixed-citation id="mc-CR177" publication-type="journal">Daniels MJ, et al. Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer&#8217;s disease in rodent models. Nat Commun. 2016;7:12504.<pub-id pub-id-type="pmid">27509875</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms12504</pub-id><pub-id pub-id-type="pmcid">PMC4987536</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR178"><label>178.</label><citation-alternatives><element-citation id="ec-CR178" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCombe</surname><given-names>PA</given-names></name><name name-style="western"><surname>Henderson</surname><given-names>RD</given-names></name></person-group><article-title>The role of immune and inflammatory mechanisms in ALS</article-title><source>Curr Mol Med</source><year>2011</year><volume>11</volume><issue>3</issue><fpage>246</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.2174/156652411795243450</pub-id><pub-id pub-id-type="pmid">21375489</pub-id><pub-id pub-id-type="pmcid">PMC3182412</pub-id></element-citation><mixed-citation id="mc-CR178" publication-type="journal">McCombe PA, Henderson RD. The role of immune and inflammatory mechanisms in ALS. Curr Mol Med. 2011;11(3):246&#8211;54.<pub-id pub-id-type="pmid">21375489</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/156652411795243450</pub-id><pub-id pub-id-type="pmcid">PMC3182412</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR179"><label>179.</label><citation-alternatives><element-citation id="ec-CR179" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lall</surname><given-names>D</given-names></name><name name-style="western"><surname>Baloh</surname><given-names>RH</given-names></name></person-group><article-title>Microglia and C9orf72 in neuroinflammation and ALS and frontotemporal dementia</article-title><source>J Clin Invest</source><year>2017</year><volume>127</volume><issue>9</issue><fpage>3250</fpage><lpage>3258</lpage><pub-id pub-id-type="doi">10.1172/JCI90607</pub-id><pub-id pub-id-type="pmid">28737506</pub-id><pub-id pub-id-type="pmcid">PMC5669558</pub-id></element-citation><mixed-citation id="mc-CR179" publication-type="journal">Lall D, Baloh RH. Microglia and C9orf72 in neuroinflammation and ALS and frontotemporal dementia. J Clin Invest. 2017;127(9):3250&#8211;8.<pub-id pub-id-type="pmid">28737506</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI90607</pub-id><pub-id pub-id-type="pmcid">PMC5669558</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR180"><label>180.</label><citation-alternatives><element-citation id="ec-CR180" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meissner</surname><given-names>F</given-names></name><name name-style="western"><surname>Molawi</surname><given-names>K</given-names></name><name name-style="western"><surname>Zychlinsky</surname><given-names>A</given-names></name></person-group><article-title>Mutant superoxide dismutase 1-induced IL-1beta accelerates ALS pathogenesis</article-title><source>Proc Natl Acad Sci U S A</source><year>2010</year><volume>107</volume><issue>29</issue><fpage>13046</fpage><lpage>13050</lpage><pub-id pub-id-type="doi">10.1073/pnas.1002396107</pub-id><pub-id pub-id-type="pmid">20616033</pub-id><pub-id pub-id-type="pmcid">PMC2919927</pub-id></element-citation><mixed-citation id="mc-CR180" publication-type="journal">Meissner F, Molawi K, Zychlinsky A. Mutant superoxide dismutase 1-induced IL-1beta accelerates ALS pathogenesis. Proc Natl Acad Sci U S A. 2010;107(29):13046&#8211;50.<pub-id pub-id-type="pmid">20616033</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1002396107</pub-id><pub-id pub-id-type="pmcid">PMC2919927</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR181"><label>181.</label><citation-alternatives><element-citation id="ec-CR181" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Debye</surname><given-names>B</given-names></name><etal/></person-group><article-title>Neurodegeneration and NLRP3 inflammasome expression in the anterior thalamus of SOD1(G93A) ALS mice</article-title><source>Brain Pathol</source><year>2018</year><volume>28</volume><issue>1</issue><fpage>14</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1111/bpa.12467</pub-id><pub-id pub-id-type="pmid">27880990</pub-id><pub-id pub-id-type="pmcid">PMC8028558</pub-id></element-citation><mixed-citation id="mc-CR181" publication-type="journal">Debye B, et al. Neurodegeneration and NLRP3 inflammasome expression in the anterior thalamus of SOD1(G93A) ALS mice. Brain Pathol. 2018;28(1):14&#8211;27.<pub-id pub-id-type="pmid">27880990</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bpa.12467</pub-id><pub-id pub-id-type="pmcid">PMC8028558</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR182"><label>182.</label><citation-alternatives><element-citation id="ec-CR182" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johann</surname><given-names>S</given-names></name><etal/></person-group><article-title>NLRP3 inflammasome is expressed by astrocytes in the SOD1 mouse model of ALS and in human sporadic ALS patients</article-title><source>Glia</source><year>2015</year><volume>63</volume><issue>12</issue><fpage>2260</fpage><lpage>2273</lpage><pub-id pub-id-type="doi">10.1002/glia.22891</pub-id><pub-id pub-id-type="pmid">26200799</pub-id></element-citation><mixed-citation id="mc-CR182" publication-type="journal">Johann S, et al. NLRP3 inflammasome is expressed by astrocytes in the SOD1 mouse model of ALS and in human sporadic ALS patients. Glia. 2015;63(12):2260&#8211;73.<pub-id pub-id-type="pmid">26200799</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/glia.22891</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR183"><label>183.</label><citation-alternatives><element-citation id="ec-CR183" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mathis</surname><given-names>D</given-names></name><name name-style="western"><surname>Shoelson</surname><given-names>SE</given-names></name></person-group><article-title>Immunometabolism: an emerging frontier</article-title><source>Nat Rev Immunol</source><year>2011</year><volume>11</volume><issue>2</issue><fpage>81</fpage><pub-id pub-id-type="doi">10.1038/nri2922</pub-id><pub-id pub-id-type="pmid">21469396</pub-id><pub-id pub-id-type="pmcid">PMC4784680</pub-id></element-citation><mixed-citation id="mc-CR183" publication-type="journal">Mathis D, Shoelson SE. Immunometabolism: an emerging frontier. Nat Rev Immunol. 2011;11(2):81.<pub-id pub-id-type="pmid">21469396</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri2922</pub-id><pub-id pub-id-type="pmcid">PMC4784680</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR184"><label>184.</label><citation-alternatives><element-citation id="ec-CR184" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hotamisligil</surname><given-names>GS</given-names></name></person-group><article-title>Inflammation and metabolic disorders</article-title><source>Nature</source><year>2006</year><volume>444</volume><issue>7121</issue><fpage>860</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.1038/nature05485</pub-id><pub-id pub-id-type="pmid">17167474</pub-id></element-citation><mixed-citation id="mc-CR184" publication-type="journal">Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860&#8211;7.<pub-id pub-id-type="pmid">17167474</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature05485</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR185"><label>185.</label><citation-alternatives><element-citation id="ec-CR185" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shoelson</surname><given-names>SE</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name><name name-style="western"><surname>Goldfine</surname><given-names>AB</given-names></name></person-group><article-title>Inflammation and insulin resistance</article-title><source>J Clin Invest</source><year>2006</year><volume>116</volume><issue>7</issue><fpage>1793</fpage><lpage>1801</lpage><pub-id pub-id-type="doi">10.1172/JCI29069</pub-id><pub-id pub-id-type="pmid">16823477</pub-id><pub-id pub-id-type="pmcid">PMC1483173</pub-id></element-citation><mixed-citation id="mc-CR185" publication-type="journal">Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116(7):1793&#8211;801.<pub-id pub-id-type="pmid">16823477</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI29069</pub-id><pub-id pub-id-type="pmcid">PMC1483173</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR186"><label>186.</label><citation-alternatives><element-citation id="ec-CR186" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ouchi</surname><given-names>N</given-names></name><etal/></person-group><article-title>Adipokines in inflammation and metabolic disease</article-title><source>Nat Rev Immunol</source><year>2011</year><volume>11</volume><issue>2</issue><fpage>85</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1038/nri2921</pub-id><pub-id pub-id-type="pmid">21252989</pub-id><pub-id pub-id-type="pmcid">PMC3518031</pub-id></element-citation><mixed-citation id="mc-CR186" publication-type="journal">Ouchi N, et al. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11(2):85&#8211;97.<pub-id pub-id-type="pmid">21252989</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri2921</pub-id><pub-id pub-id-type="pmcid">PMC3518031</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR187"><label>187.</label><citation-alternatives><element-citation id="ec-CR187" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rook</surname><given-names>GA</given-names></name><name name-style="western"><surname>Dalgleish</surname><given-names>A</given-names></name></person-group><article-title>Infection, immunoregulation, and cancer</article-title><source>Immunol Rev</source><year>2011</year><volume>240</volume><issue>1</issue><fpage>141</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2010.00987.x</pub-id><pub-id pub-id-type="pmid">21349092</pub-id></element-citation><mixed-citation id="mc-CR187" publication-type="journal">Rook GA, Dalgleish A. Infection, immunoregulation, and cancer. Immunol Rev. 2011;240(1):141&#8211;59.<pub-id pub-id-type="pmid">21349092</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1600-065X.2010.00987.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR188"><label>188.</label><citation-alternatives><element-citation id="ec-CR188" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leonard</surname><given-names>BE</given-names></name></person-group><article-title>Inflammation, depression and dementia: are they connected?</article-title><source>Neurochem Res</source><year>2007</year><volume>32</volume><issue>10</issue><fpage>1749</fpage><lpage>1756</lpage><pub-id pub-id-type="doi">10.1007/s11064-007-9385-y</pub-id><pub-id pub-id-type="pmid">17705097</pub-id></element-citation><mixed-citation id="mc-CR188" publication-type="journal">Leonard BE. Inflammation, depression and dementia: are they connected? Neurochem Res. 2007;32(10):1749&#8211;56.<pub-id pub-id-type="pmid">17705097</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11064-007-9385-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR189"><label>189.</label><citation-alternatives><element-citation id="ec-CR189" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pradhan</surname><given-names>AD</given-names></name><etal/></person-group><article-title>C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus</article-title><source>JAMA</source><year>2001</year><volume>286</volume><issue>3</issue><fpage>327</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1001/jama.286.3.327</pub-id><pub-id pub-id-type="pmid">11466099</pub-id></element-citation><mixed-citation id="mc-CR189" publication-type="journal">Pradhan AD, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286(3):327&#8211;34.<pub-id pub-id-type="pmid">11466099</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.286.3.327</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR190"><label>190.</label><citation-alternatives><element-citation id="ec-CR190" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pedersen</surname><given-names>BK</given-names></name><name name-style="western"><surname>Saltin</surname><given-names>B</given-names></name></person-group><article-title>Evidence for prescribing exercise as therapy in chronic disease</article-title><source>Scand J Med Sci Sports</source><year>2006</year><volume>16</volume><fpage>3</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0838.2006.00520.x</pub-id><pub-id pub-id-type="pmid">16451303</pub-id></element-citation><mixed-citation id="mc-CR190" publication-type="journal">Pedersen BK, Saltin B. Evidence for prescribing exercise as therapy in chronic disease. Scand J Med Sci Sports. 2006;16:3&#8211;63.<pub-id pub-id-type="pmid">16451303</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1600-0838.2006.00520.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR191"><label>191.</label><citation-alternatives><element-citation id="ec-CR191" publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Hardman</surname><given-names>AE</given-names></name><name name-style="western"><surname>Stensel</surname><given-names>DJ</given-names></name></person-group><source>Physical activity and health: the evidence explained</source><year>2009</year><publisher-loc>London</publisher-loc><publisher-name>Routledge</publisher-name></element-citation><mixed-citation id="mc-CR191" publication-type="book">Hardman AE, Stensel DJ. Physical activity and health: the evidence explained. London: Routledge; 2009.</mixed-citation></citation-alternatives></ref><ref id="CR192"><label>192.</label><citation-alternatives><element-citation id="ec-CR192" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Warren</surname><given-names>TY</given-names></name><etal/></person-group><article-title>Sedentary behaviors increase risk of cardiovascular disease mortality in men</article-title><source>Med Sci Sports Exerc</source><year>2010</year><volume>42</volume><issue>5</issue><fpage>879</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.1249/MSS.0b013e3181c3aa7e</pub-id><pub-id pub-id-type="pmid">19996993</pub-id><pub-id pub-id-type="pmcid">PMC2857522</pub-id></element-citation><mixed-citation id="mc-CR192" publication-type="journal">Warren TY, et al. Sedentary behaviors increase risk of cardiovascular disease mortality in men. Med Sci Sports Exerc. 2010;42(5):879&#8211;85.<pub-id pub-id-type="pmid">19996993</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1249/MSS.0b013e3181c3aa7e</pub-id><pub-id pub-id-type="pmcid">PMC2857522</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR193"><label>193.</label><citation-alternatives><element-citation id="ec-CR193" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walsh</surname><given-names>NP</given-names></name><etal/></person-group><article-title>Position statement. Part one: immune function and exercise</article-title><source>Exerc Immunol Rev</source><year>2011</year><volume>17</volume><fpage>6</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">21446352</pub-id></element-citation><mixed-citation id="mc-CR193" publication-type="journal">Walsh NP, et al. Position statement. Part one: immune function and exercise. Exerc Immunol Rev. 2011;17:6&#8211;63.<pub-id pub-id-type="pmid">21446352</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR194"><label>194.</label><citation-alternatives><element-citation id="ec-CR194" publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Jonas</surname><given-names>S</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>EM</given-names></name></person-group><source>ACSM's exercise is medicine TM: a clinician's guide to exercise prescription</source><year>2012</year><publisher-loc>Ambler</publisher-loc><publisher-name>Lippincott Williams &amp; Wilkins</publisher-name></element-citation><mixed-citation id="mc-CR194" publication-type="book">Jonas S, Phillips EM. ACSM&#8217;s exercise is medicine TM: a clinician&#8217;s guide to exercise prescription. Ambler: Lippincott Williams &amp; Wilkins; 2012.</mixed-citation></citation-alternatives></ref><ref id="CR195"><label>195.</label><citation-alternatives><element-citation id="ec-CR195" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kraus</surname><given-names>WE</given-names></name><etal/></person-group><article-title>Effects of the amount and intensity of exercise on plasma lipoproteins</article-title><source>N Engl J Med</source><year>2002</year><volume>347</volume><issue>19</issue><fpage>1483</fpage><lpage>1492</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa020194</pub-id><pub-id pub-id-type="pmid">12421890</pub-id></element-citation><mixed-citation id="mc-CR195" publication-type="journal">Kraus WE, et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med. 2002;347(19):1483&#8211;92.<pub-id pub-id-type="pmid">12421890</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa020194</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR196"><label>196.</label><citation-alternatives><element-citation id="ec-CR196" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kasapis</surname><given-names>C</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>PD</given-names></name></person-group><article-title>The effects of physical activity on serum C-reactive protein and inflammatory markers: a systematic review</article-title><source>J Am Coll Cardiol</source><year>2005</year><volume>45</volume><issue>10</issue><fpage>1563</fpage><lpage>1569</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2004.12.077</pub-id><pub-id pub-id-type="pmid">15893167</pub-id></element-citation><mixed-citation id="mc-CR196" publication-type="journal">Kasapis C, Thompson PD. The effects of physical activity on serum C-reactive protein and inflammatory markers: a systematic review. J Am Coll Cardiol. 2005;45(10):1563&#8211;9.<pub-id pub-id-type="pmid">15893167</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2004.12.077</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR197"><label>197.</label><citation-alternatives><element-citation id="ec-CR197" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mathur</surname><given-names>N</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>BK</given-names></name></person-group><article-title>Exercise as a mean to control low-grade systemic inflammation</article-title><source>Mediat Inflamm</source><year>2008</year><volume>2008</volume><fpage>109502</fpage><pub-id pub-id-type="doi">10.1155/2008/109502</pub-id><pub-id pub-id-type="pmcid">PMC2615833</pub-id><pub-id pub-id-type="pmid">19148295</pub-id></element-citation><mixed-citation id="mc-CR197" publication-type="journal">Mathur N, Pedersen BK. Exercise as a mean to control low-grade systemic inflammation. Mediat Inflamm. 2008;2008:109502.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2008/109502</pub-id><pub-id pub-id-type="pmcid">PMC2615833</pub-id><pub-id pub-id-type="pmid">19148295</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR198"><label>198.</label><citation-alternatives><element-citation id="ec-CR198" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flynn</surname><given-names>MG</given-names></name><name name-style="western"><surname>McFarlin</surname><given-names>BK</given-names></name></person-group><article-title>Toll-like receptor 4: link to the anti-inflammatory effects of exercise?</article-title><source>Exerc Sport Sci Rev</source><year>2006</year><volume>34</volume><issue>4</issue><fpage>176</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1249/01.jes.0000240027.22749.14</pub-id><pub-id pub-id-type="pmid">17031256</pub-id></element-citation><mixed-citation id="mc-CR198" publication-type="journal">Flynn MG, McFarlin BK. Toll-like receptor 4: link to the anti-inflammatory effects of exercise? Exerc Sport Sci Rev. 2006;34(4):176&#8211;81.<pub-id pub-id-type="pmid">17031256</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1249/01.jes.0000240027.22749.14</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR199"><label>199.</label><citation-alternatives><element-citation id="ec-CR199" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pedersen</surname><given-names>BK</given-names></name><name name-style="western"><surname>Febbraio</surname><given-names>MA</given-names></name></person-group><article-title>Muscle as an endocrine organ: focus on muscle-derived interleukin-6</article-title><source>Physiol Rev</source><year>2008</year><volume>88</volume><issue>4</issue><fpage>1379</fpage><lpage>1406</lpage><pub-id pub-id-type="doi">10.1152/physrev.90100.2007</pub-id><pub-id pub-id-type="pmid">18923185</pub-id></element-citation><mixed-citation id="mc-CR199" publication-type="journal">Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev. 2008;88(4):1379&#8211;406.<pub-id pub-id-type="pmid">18923185</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/physrev.90100.2007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR200"><label>200.</label><citation-alternatives><element-citation id="ec-CR200" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gleeson</surname><given-names>M</given-names></name><name name-style="western"><surname>McFarlin</surname><given-names>B</given-names></name><name name-style="western"><surname>Flynn</surname><given-names>M</given-names></name></person-group><article-title>Exercise and toll-like receptors</article-title><source>Exerc Immunol Rev</source><year>2006</year><volume>12</volume><fpage>34</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">17201071</pub-id></element-citation><mixed-citation id="mc-CR200" publication-type="journal">Gleeson M, McFarlin B, Flynn M. Exercise and toll-like receptors. Exerc Immunol Rev. 2006;12:34&#8211;53.<pub-id pub-id-type="pmid">17201071</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR201"><label>201.</label><citation-alternatives><element-citation id="ec-CR201" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawanishi</surname><given-names>N</given-names></name><etal/></person-group><article-title>Exercise training inhibits inflammation in adipose tissue via both suppression of macrophage infiltration and acceleration of phenotypic switching from M1 to M2 macrophages in high-fat-diet-induced obese mice</article-title><source>Exerc Immunol Rev</source><year>2010</year><volume>16</volume><fpage>105</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">20839495</pub-id></element-citation><mixed-citation id="mc-CR201" publication-type="journal">Kawanishi N, et al. Exercise training inhibits inflammation in adipose tissue via both suppression of macrophage infiltration and acceleration of phenotypic switching from M1 to M2 macrophages in high-fat-diet-induced obese mice. Exerc Immunol Rev. 2010;16:105&#8211;18.<pub-id pub-id-type="pmid">20839495</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR202"><label>202.</label><citation-alternatives><element-citation id="ec-CR202" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Timmerman</surname><given-names>KL</given-names></name><etal/></person-group><article-title>Exercise training-induced lowering of inflammatory (CD14+CD16+) monocytes: a role in the anti-inflammatory influence of exercise?</article-title><source>J Leukoc Biol</source><year>2008</year><volume>84</volume><issue>5</issue><fpage>1271</fpage><lpage>1278</lpage><pub-id pub-id-type="doi">10.1189/jlb.0408244</pub-id><pub-id pub-id-type="pmid">18664531</pub-id></element-citation><mixed-citation id="mc-CR202" publication-type="journal">Timmerman KL, et al. Exercise training-induced lowering of inflammatory (CD14+CD16+) monocytes: a role in the anti-inflammatory influence of exercise? J Leukoc Biol. 2008;84(5):1271&#8211;8.<pub-id pub-id-type="pmid">18664531</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1189/jlb.0408244</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR203"><label>203.</label><citation-alternatives><element-citation id="ec-CR203" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yeh</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Regular tai chi chuan exercise enhances functional mobility and CD4CD25 regulatory T cells</article-title><source>Br J Sports Med</source><year>2006</year><volume>40</volume><issue>3</issue><fpage>239</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1136/bjsm.2005.022095</pub-id><pub-id pub-id-type="pmid">16505081</pub-id><pub-id pub-id-type="pmcid">PMC2491999</pub-id></element-citation><mixed-citation id="mc-CR203" publication-type="journal">Yeh SH, et al. Regular tai chi chuan exercise enhances functional mobility and CD4CD25 regulatory T cells. Br J Sports Med. 2006;40(3):239&#8211;43.<pub-id pub-id-type="pmid">16505081</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bjsm.2005.022095</pub-id><pub-id pub-id-type="pmcid">PMC2491999</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR204"><label>204.</label><citation-alternatives><element-citation id="ec-CR204" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Effect of exercise training intensity on murine T-regulatory cells and vaccination response</article-title><source>Scand J Med Sci Sports</source><year>2012</year><volume>22</volume><issue>5</issue><fpage>643</fpage><lpage>652</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0838.2010.01288.x</pub-id><pub-id pub-id-type="pmid">21410542</pub-id></element-citation><mixed-citation id="mc-CR204" publication-type="journal">Wang J, et al. Effect of exercise training intensity on murine T-regulatory cells and vaccination response. Scand J Med Sci Sports. 2012;22(5):643&#8211;52.<pub-id pub-id-type="pmid">21410542</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1600-0838.2010.01288.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR205"><label>205.</label><citation-alternatives><element-citation id="ec-CR205" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vandanmagsar</surname><given-names>B</given-names></name><etal/></person-group><article-title>The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance</article-title><source>Nat Med</source><year>2011</year><volume>17</volume><issue>2</issue><fpage>179</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1038/nm.2279</pub-id><pub-id pub-id-type="pmid">21217695</pub-id><pub-id pub-id-type="pmcid">PMC3076025</pub-id></element-citation><mixed-citation id="mc-CR205" publication-type="journal">Vandanmagsar B, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med. 2011;17(2):179&#8211;88.<pub-id pub-id-type="pmid">21217695</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm.2279</pub-id><pub-id pub-id-type="pmcid">PMC3076025</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR206"><label>206.</label><citation-alternatives><element-citation id="ec-CR206" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>KK</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>SW</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>KK</given-names></name></person-group><article-title>NLRP3 inflammasome activation in adipose tissues and its implications on metabolic diseases</article-title><source>Int J Mol Sci</source><year>2020</year><pub-id pub-id-type="doi">10.3390/ijms21114184</pub-id><pub-id pub-id-type="pmid">32545355</pub-id><pub-id pub-id-type="pmcid">PMC7312293</pub-id></element-citation><mixed-citation id="mc-CR206" publication-type="journal">Wu KK, Cheung SW, Cheng KK. NLRP3 inflammasome activation in adipose tissues and its implications on metabolic diseases. Int J Mol Sci. 2020. 10.3390/ijms21114184.<pub-id pub-id-type="pmid">32545355</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms21114184</pub-id><pub-id pub-id-type="pmcid">PMC7312293</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR207"><label>207.</label><citation-alternatives><element-citation id="ec-CR207" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>ZhuGe</surname><given-names>DL</given-names></name><etal/></person-group><article-title>Fibroblast growth factor 2 exacerbates inflammation in adipocytes through NLRP3 inflammasome activation</article-title><source>Arch Pharm Res</source><year>2020</year><volume>43</volume><issue>12</issue><fpage>1311</fpage><lpage>1324</lpage><pub-id pub-id-type="doi">10.1007/s12272-020-01295-2</pub-id><pub-id pub-id-type="pmid">33245516</pub-id></element-citation><mixed-citation id="mc-CR207" publication-type="journal">ZhuGe DL, et al. Fibroblast growth factor 2 exacerbates inflammation in adipocytes through NLRP3 inflammasome activation. Arch Pharm Res. 2020;43(12):1311&#8211;24.<pub-id pub-id-type="pmid">33245516</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12272-020-01295-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR208"><label>208.</label><citation-alternatives><element-citation id="ec-CR208" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGeough</surname><given-names>MD</given-names></name><etal/></person-group><article-title>TNF regulates transcription of NLRP3 inflammasome components and inflammatory molecules in cryopyrinopathies</article-title><source>J Clin Invest</source><year>2017</year><volume>127</volume><issue>12</issue><fpage>4488</fpage><lpage>4497</lpage><pub-id pub-id-type="doi">10.1172/JCI90699</pub-id><pub-id pub-id-type="pmid">29130929</pub-id><pub-id pub-id-type="pmcid">PMC5707143</pub-id></element-citation><mixed-citation id="mc-CR208" publication-type="journal">McGeough MD, et al. TNF regulates transcription of NLRP3 inflammasome components and inflammatory molecules in cryopyrinopathies. J Clin Invest. 2017;127(12):4488&#8211;97.<pub-id pub-id-type="pmid">29130929</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI90699</pub-id><pub-id pub-id-type="pmcid">PMC5707143</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR209"><label>209.</label><citation-alternatives><element-citation id="ec-CR209" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bauernfeind</surname><given-names>F</given-names></name><etal/></person-group><article-title>Aging-associated TNF production primes inflammasome activation and NLRP3-related metabolic disturbances</article-title><source>J Immunol</source><year>2016</year><volume>197</volume><issue>7</issue><fpage>2900</fpage><lpage>2908</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1501336</pub-id><pub-id pub-id-type="pmid">27566828</pub-id></element-citation><mixed-citation id="mc-CR209" publication-type="journal">Bauernfeind F, et al. Aging-associated TNF production primes inflammasome activation and NLRP3-related metabolic disturbances. J Immunol. 2016;197(7):2900&#8211;8.<pub-id pub-id-type="pmid">27566828</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1501336</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR210"><label>210.</label><citation-alternatives><element-citation id="ec-CR210" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shuyu</surname><given-names>XI</given-names></name></person-group><article-title>Effect of treadmill exercise of different intensity on the ppar&#947;/adiponectin/TNF-&#945; mRNA in adipose tissue of rats fed with high fat diet</article-title><source>J Chengdu Sport Univ</source><year>2015</year><volume>41</volume><issue>3</issue><fpage>98</fpage><lpage>102</lpage></element-citation><mixed-citation id="mc-CR210" publication-type="journal">Shuyu XI. Effect of treadmill exercise of different intensity on the ppar&#947;/adiponectin/TNF-&#945; mRNA in adipose tissue of rats fed with high fat diet. J Chengdu Sport Univ. 2015;41(3):98&#8211;102.</mixed-citation></citation-alternatives></ref><ref id="CR211"><label>211.</label><citation-alternatives><element-citation id="ec-CR211" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmadian</surname><given-names>M</given-names></name><etal/></person-group><article-title>PPAR&#947; signaling and metabolism: the good, the bad and the future</article-title><source>Nat Med</source><year>2013</year><volume>19</volume><issue>5</issue><fpage>557</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1038/nm.3159</pub-id><pub-id pub-id-type="pmid">23652116</pub-id><pub-id pub-id-type="pmcid">PMC3870016</pub-id></element-citation><mixed-citation id="mc-CR211" publication-type="journal">Ahmadian M, et al. PPAR&#947; signaling and metabolism: the good, the bad and the future. Nat Med. 2013;19(5):557&#8211;66.<pub-id pub-id-type="pmid">23652116</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm.3159</pub-id><pub-id pub-id-type="pmcid">PMC3870016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR212"><label>212.</label><citation-alternatives><element-citation id="ec-CR212" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mardare</surname><given-names>C</given-names></name><etal/></person-group><article-title>Endurance and resistance training affect high fat diet-induced increase of ceramides, inflammasome expression, and systemic inflammation in mice</article-title><source>J Diabetes Res</source><year>2016</year><volume>2016</volume><fpage>4536470</fpage><pub-id pub-id-type="doi">10.1155/2016/4536470</pub-id><pub-id pub-id-type="pmid">26788518</pub-id><pub-id pub-id-type="pmcid">PMC4691630</pub-id></element-citation><mixed-citation id="mc-CR212" publication-type="journal">Mardare C, et al. Endurance and resistance training affect high fat diet-induced increase of ceramides, inflammasome expression, and systemic inflammation in mice. J Diabetes Res. 2016;2016:4536470.<pub-id pub-id-type="pmid">26788518</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2016/4536470</pub-id><pub-id pub-id-type="pmcid">PMC4691630</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR213"><label>213.</label><citation-alternatives><element-citation id="ec-CR213" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yue</surname><given-names>R</given-names></name><etal/></person-group><article-title>NLRP3-mediated pyroptosis aggravates pressure overload-induced cardiac hypertrophy, fibrosis, and dysfunction in mice: cardioprotective role of irisin</article-title><source>Cell Death Discov</source><year>2021</year><volume>7</volume><issue>1</issue><fpage>50</fpage><pub-id pub-id-type="doi">10.1038/s41420-021-00434-y</pub-id><pub-id pub-id-type="pmid">33723236</pub-id><pub-id pub-id-type="pmcid">PMC7961005</pub-id></element-citation><mixed-citation id="mc-CR213" publication-type="journal">Yue R, et al. NLRP3-mediated pyroptosis aggravates pressure overload-induced cardiac hypertrophy, fibrosis, and dysfunction in mice: cardioprotective role of irisin. Cell Death Discov. 2021;7(1):50.<pub-id pub-id-type="pmid">33723236</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41420-021-00434-y</pub-id><pub-id pub-id-type="pmcid">PMC7961005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR214"><label>214.</label><citation-alternatives><element-citation id="ec-CR214" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gholamnezhad</surname><given-names>Z</given-names></name><name name-style="western"><surname>M&#233;garbane</surname><given-names>B</given-names></name><name name-style="western"><surname>Rezaee</surname><given-names>R</given-names></name></person-group><article-title>Molecular mechanisms mediating adaptation to exercise</article-title><source>Adv Exp Med Biol</source><year>2020</year><volume>1228</volume><fpage>45</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1007/978-981-15-1792-1_3</pub-id><pub-id pub-id-type="pmid">32342449</pub-id></element-citation><mixed-citation id="mc-CR214" publication-type="journal">Gholamnezhad Z, M&#233;garbane B, Rezaee R. Molecular mechanisms mediating adaptation to exercise. Adv Exp Med Biol. 2020;1228:45&#8211;61.<pub-id pub-id-type="pmid">32342449</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-981-15-1792-1_3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR215"><label>215.</label><citation-alternatives><element-citation id="ec-CR215" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lally</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Skeletal muscle AMPK is essential for the maintenance of FNDC5 expression</article-title><source>Physiol Rep</source><year>2015</year><pub-id pub-id-type="doi">10.14814/phy2.12343</pub-id><pub-id pub-id-type="pmid">25948819</pub-id><pub-id pub-id-type="pmcid">PMC4463812</pub-id></element-citation><mixed-citation id="mc-CR215" publication-type="journal">Lally JS, et al. Skeletal muscle AMPK is essential for the maintenance of FNDC5 expression. Physiol Rep. 2015. 10.14814/phy2.12343.<pub-id pub-id-type="pmid">25948819</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14814/phy2.12343</pub-id><pub-id pub-id-type="pmcid">PMC4463812</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR216"><label>216.</label><citation-alternatives><element-citation id="ec-CR216" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>J</given-names></name><etal/></person-group><article-title>Irisin protects against neuronal injury induced by oxygen-glucose deprivation in part depends on the inhibition of ROS-NLRP3 inflammatory signaling pathway</article-title><source>Mol Immunol</source><year>2017</year><volume>91</volume><fpage>185</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2017.09.014</pub-id><pub-id pub-id-type="pmid">28961497</pub-id></element-citation><mixed-citation id="mc-CR216" publication-type="journal">Peng J, et al. Irisin protects against neuronal injury induced by oxygen-glucose deprivation in part depends on the inhibition of ROS-NLRP3 inflammatory signaling pathway. Mol Immunol. 2017;91:185&#8211;94.<pub-id pub-id-type="pmid">28961497</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molimm.2017.09.014</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR217"><label>217.</label><citation-alternatives><element-citation id="ec-CR217" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clark</surname><given-names>IA</given-names></name><name name-style="western"><surname>Vissel</surname><given-names>B</given-names></name></person-group><article-title>Neurodegenerative disease treatments by direct TNF reduction, SB623 cells, maraviroc and irisin and MCC950, from an inflammatory perspective&#8212;a commentary</article-title><source>Expert Rev Neurother</source><year>2019</year><volume>19</volume><issue>6</issue><fpage>535</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.1080/14737175.2019.1618710</pub-id><pub-id pub-id-type="pmid">31092047</pub-id></element-citation><mixed-citation id="mc-CR217" publication-type="journal">Clark IA, Vissel B. Neurodegenerative disease treatments by direct TNF reduction, SB623 cells, maraviroc and irisin and MCC950, from an inflammatory perspective&#8212;a commentary. Expert Rev Neurother. 2019;19(6):535&#8211;43.<pub-id pub-id-type="pmid">31092047</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14737175.2019.1618710</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR218"><label>218.</label><citation-alternatives><element-citation id="ec-CR218" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanchez-Delgado</surname><given-names>G</given-names></name><etal/></person-group><article-title>Role of exercise in the activation of brown adipose tissue</article-title><source>Ann Nutr Metab</source><year>2015</year><volume>67</volume><issue>1</issue><fpage>21</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1159/000437173</pub-id><pub-id pub-id-type="pmid">26227180</pub-id></element-citation><mixed-citation id="mc-CR218" publication-type="journal">Sanchez-Delgado G, et al. Role of exercise in the activation of brown adipose tissue. Ann Nutr Metab. 2015;67(1):21&#8211;32.<pub-id pub-id-type="pmid">26227180</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000437173</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR219"><label>219.</label><citation-alternatives><element-citation id="ec-CR219" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abeyrathna</surname><given-names>P</given-names></name><name name-style="western"><surname>Su</surname><given-names>Y</given-names></name></person-group><article-title>The critical role of Akt in cardiovascular function</article-title><source>Vascul Pharmacol</source><year>2015</year><volume>74</volume><fpage>38</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.vph.2015.05.008</pub-id><pub-id pub-id-type="pmid">26025205</pub-id><pub-id pub-id-type="pmcid">PMC4659756</pub-id></element-citation><mixed-citation id="mc-CR219" publication-type="journal">Abeyrathna P, Su Y. The critical role of Akt in cardiovascular function. Vascul Pharmacol. 2015;74:38&#8211;48.<pub-id pub-id-type="pmid">26025205</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vph.2015.05.008</pub-id><pub-id pub-id-type="pmcid">PMC4659756</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR220"><label>220.</label><citation-alternatives><element-citation id="ec-CR220" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>X</given-names></name><etal/></person-group><article-title>Human umbilical cord-derived mesenchymal stem cells ameliorate insulin resistance by suppressing NLRP3 inflammasome-mediated inflammation in type 2 diabetes rats</article-title><source>Stem Cell Res Ther</source><year>2017</year><volume>8</volume><issue>1</issue><fpage>241</fpage><pub-id pub-id-type="doi">10.1186/s13287-017-0668-1</pub-id><pub-id pub-id-type="pmid">29096724</pub-id><pub-id pub-id-type="pmcid">PMC5667486</pub-id></element-citation><mixed-citation id="mc-CR220" publication-type="journal">Sun X, et al. Human umbilical cord-derived mesenchymal stem cells ameliorate insulin resistance by suppressing NLRP3 inflammasome-mediated inflammation in type 2 diabetes rats. Stem Cell Res Ther. 2017;8(1):241.<pub-id pub-id-type="pmid">29096724</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13287-017-0668-1</pub-id><pub-id pub-id-type="pmcid">PMC5667486</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR221"><label>221.</label><citation-alternatives><element-citation id="ec-CR221" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yi</surname><given-names>XJ</given-names></name><etal/></person-group><article-title>Effects of acute and chronic exercise on fat PI3K/AKT/GLUT4 signal pathway in type 2 diabetic rats</article-title><source>Zhongguo Ying Yong Sheng Li Xue Za Zhi</source><year>2020</year><volume>36</volume><issue>1</issue><fpage>12</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">32476367</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.12047/j.cjap.5802.2020.003</pub-id></element-citation><mixed-citation id="mc-CR221" publication-type="journal">Yi XJ, et al. Effects of acute and chronic exercise on fat PI3K/AKT/GLUT4 signal pathway in type 2 diabetic rats. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2020;36(1):12&#8211;6.<pub-id pub-id-type="pmid">32476367</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.12047/j.cjap.5802.2020.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR222"><label>222.</label><citation-alternatives><element-citation id="ec-CR222" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>R</given-names></name><etal/></person-group><article-title>Aerobic exercise restores hippocampal neurogenesis and cognitive function by decreasing microglia inflammasome formation through Irisin/NLRP3 pathway</article-title><source>Aging Cell</source><year>2025</year><volume>24</volume><issue>7</issue><fpage>e70061</fpage><pub-id pub-id-type="doi">10.1111/acel.70061</pub-id><pub-id pub-id-type="pmid">40192010</pub-id><pub-id pub-id-type="pmcid">PMC12266781</pub-id></element-citation><mixed-citation id="mc-CR222" publication-type="journal">Zhao R, et al. Aerobic exercise restores hippocampal neurogenesis and cognitive function by decreasing microglia inflammasome formation through Irisin/NLRP3 pathway. Aging Cell. 2025;24(7):e70061.<pub-id pub-id-type="pmid">40192010</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/acel.70061</pub-id><pub-id pub-id-type="pmcid">PMC12266781</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR223"><label>223.</label><citation-alternatives><element-citation id="ec-CR223" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Treadmill exercise alleviates neuronal damage by suppressing NLRP3 inflammasome and microglial activation in the MPTP mouse model of Parkinson&#8217;s disease</article-title><source>Brain Res Bull</source><year>2021</year><volume>174</volume><fpage>349</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1016/j.brainresbull.2021.06.024</pub-id><pub-id pub-id-type="pmid">34224819</pub-id></element-citation><mixed-citation id="mc-CR223" publication-type="journal">Wang W, et al. Treadmill exercise alleviates neuronal damage by suppressing NLRP3 inflammasome and microglial activation in the MPTP mouse model of Parkinson&#8217;s disease. Brain Res Bull. 2021;174:349&#8211;58.<pub-id pub-id-type="pmid">34224819</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.brainresbull.2021.06.024</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR224"><label>224.</label><citation-alternatives><element-citation id="ec-CR224" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>M-X</given-names></name><etal/></person-group><article-title>Exercise-induced neuroprotection against cerebral ischemia/reperfusion injury is mediated via alleviating inflammasome-induced pyroptosis</article-title><source>Exp Neurol</source><year>2022</year><volume>349</volume><fpage>113952</fpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2021.113952</pub-id><pub-id pub-id-type="pmid">34921847</pub-id></element-citation><mixed-citation id="mc-CR224" publication-type="journal">Liu M-X, et al. Exercise-induced neuroprotection against cerebral ischemia/reperfusion injury is mediated via alleviating inflammasome-induced pyroptosis. Exp Neurol. 2022;349:113952.<pub-id pub-id-type="pmid">34921847</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.expneurol.2021.113952</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR225"><label>225.</label><citation-alternatives><element-citation id="ec-CR225" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mee-Inta</surname><given-names>O</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>ZW</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>YM</given-names></name></person-group><article-title>Physical exercise inhibits inflammation and microglial activation</article-title><source>Cells</source><year>2019</year><pub-id pub-id-type="doi">10.3390/cells8070691</pub-id><pub-id pub-id-type="pmid">31324021</pub-id><pub-id pub-id-type="pmcid">PMC6678635</pub-id></element-citation><mixed-citation id="mc-CR225" publication-type="journal">Mee-Inta O, Zhao ZW, Kuo YM. Physical exercise inhibits inflammation and microglial activation. Cells. 2019. 10.3390/cells8070691.<pub-id pub-id-type="pmid">31324021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells8070691</pub-id><pub-id pub-id-type="pmcid">PMC6678635</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR226"><label>226.</label><citation-alternatives><element-citation id="ec-CR226" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>C</given-names></name><etal/></person-group><article-title>The impact of physical activity on blood inflammatory cytokines and neuroprotective factors in individuals with mild cognitive impairment: a systematic review and meta-analysis of randomized-controlled trials</article-title><source>Aging Clin Exp Res</source><year>2022</year><volume>34</volume><issue>7</issue><fpage>1471</fpage><lpage>1484</lpage><pub-id pub-id-type="doi">10.1007/s40520-021-02069-6</pub-id><pub-id pub-id-type="pmid">35025094</pub-id></element-citation><mixed-citation id="mc-CR226" publication-type="journal">Ma C, et al. The impact of physical activity on blood inflammatory cytokines and neuroprotective factors in individuals with mild cognitive impairment: a systematic review and meta-analysis of randomized-controlled trials. Aging Clin Exp Res. 2022;34(7):1471&#8211;84.<pub-id pub-id-type="pmid">35025094</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40520-021-02069-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR227"><label>227.</label><citation-alternatives><element-citation id="ec-CR227" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Lima Rosa</surname><given-names>G</given-names></name><etal/></person-group><article-title>Aerobic exercise, alone or combined with an anti-inflammatory drug, reduces the severity of epileptic seizures and levels of central pro-inflammatory cytokines in an animal model of epileptic seizures</article-title><source>Epilepsy Res</source><year>2022</year><volume>186</volume><fpage>107018</fpage><pub-id pub-id-type="doi">10.1016/j.eplepsyres.2022.107018</pub-id><pub-id pub-id-type="pmid">36126608</pub-id></element-citation><mixed-citation id="mc-CR227" publication-type="journal">de Lima Rosa G, et al. Aerobic exercise, alone or combined with an anti-inflammatory drug, reduces the severity of epileptic seizures and levels of central pro-inflammatory cytokines in an animal model of epileptic seizures. Epilepsy Res. 2022;186:107018.<pub-id pub-id-type="pmid">36126608</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eplepsyres.2022.107018</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR228"><label>228.</label><citation-alternatives><element-citation id="ec-CR228" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oyovwi</surname><given-names>MO</given-names></name><name name-style="western"><surname>Ogenma</surname><given-names>UT</given-names></name><name name-style="western"><surname>Onyenweny</surname><given-names>A</given-names></name></person-group><article-title>Exploring the impact of exercise-induced BDNF on neuroplasticity in neurodegenerative and neuropsychiatric conditions</article-title><source>Mol Biol Rep</source><year>2025</year><volume>52</volume><issue>1</issue><fpage>140</fpage><pub-id pub-id-type="doi">10.1007/s11033-025-10248-1</pub-id><pub-id pub-id-type="pmid">39832087</pub-id></element-citation><mixed-citation id="mc-CR228" publication-type="journal">Oyovwi MO, Ogenma UT, Onyenweny A. Exploring the impact of exercise-induced BDNF on neuroplasticity in neurodegenerative and neuropsychiatric conditions. Mol Biol Rep. 2025;52(1):140.<pub-id pub-id-type="pmid">39832087</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11033-025-10248-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR229"><label>229.</label><citation-alternatives><element-citation id="ec-CR229" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diechmann</surname><given-names>MD</given-names></name><etal/></person-group><article-title>Effects of exercise training on neurotrophic factors and subsequent neuroprotection in persons with multiple sclerosis&#8212;a systematic review and meta-analysis</article-title><source>Brain Sci</source><year>2021</year><volume>11</volume><issue>11</issue><fpage>1499</fpage><pub-id pub-id-type="doi">10.3390/brainsci11111499</pub-id><pub-id pub-id-type="pmid">34827498</pub-id><pub-id pub-id-type="pmcid">PMC8615767</pub-id></element-citation><mixed-citation id="mc-CR229" publication-type="journal">Diechmann MD, et al. Effects of exercise training on neurotrophic factors and subsequent neuroprotection in persons with multiple sclerosis&#8212;a systematic review and meta-analysis. Brain Sci. 2021;11(11):1499.<pub-id pub-id-type="pmid">34827498</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/brainsci11111499</pub-id><pub-id pub-id-type="pmcid">PMC8615767</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR230"><label>230.</label><citation-alternatives><element-citation id="ec-CR230" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosa</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Physical exercise prevents amyloid &#946;(1&#8211;40)-induced disturbances in NLRP3 inflammasome pathway in the hippocampus of mice</article-title><source>Metab Brain Dis</source><year>2021</year><volume>36</volume><issue>2</issue><fpage>351</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1007/s11011-020-00646-8</pub-id><pub-id pub-id-type="pmid">33211258</pub-id></element-citation><mixed-citation id="mc-CR230" publication-type="journal">Rosa JM, et al. Physical exercise prevents amyloid &#946;(1&#8211;40)-induced disturbances in NLRP3 inflammasome pathway in the hippocampus of mice. Metab Brain Dis. 2021;36(2):351&#8211;9.<pub-id pub-id-type="pmid">33211258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11011-020-00646-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR231"><label>231.</label><citation-alternatives><element-citation id="ec-CR231" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><etal/></person-group><article-title>Long-term exercise training inhibits inflammation by suppressing hippocampal NLRP3 in APP/PS1 mice</article-title><source>Sports Med Health Sci</source><year>2023</year><volume>5</volume><issue>4</issue><fpage>329</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1016/j.smhs.2023.09.009</pub-id><pub-id pub-id-type="pmid">38314041</pub-id><pub-id pub-id-type="pmcid">PMC10831383</pub-id></element-citation><mixed-citation id="mc-CR231" publication-type="journal">Li X, et al. Long-term exercise training inhibits inflammation by suppressing hippocampal NLRP3 in APP/PS1 mice. Sports Med Health Sci. 2023;5(4):329&#8211;35.<pub-id pub-id-type="pmid">38314041</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.smhs.2023.09.009</pub-id><pub-id pub-id-type="pmcid">PMC10831383</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR232"><label>232.</label><citation-alternatives><element-citation id="ec-CR232" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malczynska-Sims</surname><given-names>P</given-names></name><etal/></person-group><article-title>High-intensity interval training modulates inflammatory response in Parkinson's disease</article-title><source>Aging Clin Exp Res</source><year>2022</year><volume>34</volume><issue>9</issue><fpage>2165</fpage><lpage>2176</lpage><pub-id pub-id-type="doi">10.1007/s40520-022-02153-5</pub-id><pub-id pub-id-type="pmid">35699838</pub-id><pub-id pub-id-type="pmcid">PMC9192928</pub-id></element-citation><mixed-citation id="mc-CR232" publication-type="journal">Malczynska-Sims P, et al. High-intensity interval training modulates inflammatory response in Parkinson&#8217;s disease. Aging Clin Exp Res. 2022;34(9):2165&#8211;76.<pub-id pub-id-type="pmid">35699838</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40520-022-02153-5</pub-id><pub-id pub-id-type="pmcid">PMC9192928</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR233"><label>233.</label><citation-alternatives><element-citation id="ec-CR233" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Neuroprotective effects of endurance exercise against neuroinflammation in MPTP-induced Parkinson's disease mice</article-title><source>Brain Res</source><year>2017</year><volume>1655</volume><fpage>186</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2016.10.029</pub-id><pub-id pub-id-type="pmid">27816415</pub-id></element-citation><mixed-citation id="mc-CR233" publication-type="journal">Jang Y, et al. Neuroprotective effects of endurance exercise against neuroinflammation in MPTP-induced Parkinson&#8217;s disease mice. Brain Res. 2017;1655:186&#8211;93.<pub-id pub-id-type="pmid">27816415</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.brainres.2016.10.029</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR234"><label>234.</label><citation-alternatives><element-citation id="ec-CR234" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veldink</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Sexual differences in onset of disease and response to exercise in a transgenic model of ALS</article-title><source>Neuromuscul Disord</source><year>2003</year><volume>13</volume><issue>9</issue><fpage>737</fpage><lpage>743</lpage><pub-id pub-id-type="doi">10.1016/S0960-8966(03)00104-4</pub-id><pub-id pub-id-type="pmid">14561497</pub-id></element-citation><mixed-citation id="mc-CR234" publication-type="journal">Veldink JH, et al. Sexual differences in onset of disease and response to exercise in a transgenic model of ALS. Neuromuscul Disord. 2003;13(9):737&#8211;43.<pub-id pub-id-type="pmid">14561497</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0960-8966(03)00104-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR235"><label>235.</label><citation-alternatives><element-citation id="ec-CR235" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liebetanz</surname><given-names>D</given-names></name><etal/></person-group><article-title>Extensive exercise is not harmful in amyotrophic lateral sclerosis</article-title><source>Eur J Neurosci</source><year>2004</year><volume>20</volume><issue>11</issue><fpage>3115</fpage><lpage>3120</lpage><pub-id pub-id-type="doi">10.1111/j.1460-9568.2004.03769.x</pub-id><pub-id pub-id-type="pmid">15579165</pub-id></element-citation><mixed-citation id="mc-CR235" publication-type="journal">Liebetanz D, et al. Extensive exercise is not harmful in amyotrophic lateral sclerosis. Eur J Neurosci. 2004;20(11):3115&#8211;20.<pub-id pub-id-type="pmid">15579165</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1460-9568.2004.03769.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR236"><label>236.</label><citation-alternatives><element-citation id="ec-CR236" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deforges</surname><given-names>S</given-names></name><etal/></person-group><article-title>Motoneuron survival is promoted by specific exercise in a mouse model of amyotrophic lateral sclerosis</article-title><source>J Physiol</source><year>2009</year><volume>587</volume><issue>Pt 14</issue><fpage>3561</fpage><lpage>3572</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.2009.169748</pub-id><pub-id pub-id-type="pmid">19491245</pub-id><pub-id pub-id-type="pmcid">PMC2742281</pub-id></element-citation><mixed-citation id="mc-CR236" publication-type="journal">Deforges S, et al. Motoneuron survival is promoted by specific exercise in a mouse model of amyotrophic lateral sclerosis. J Physiol. 2009;587(Pt 14):3561&#8211;72.<pub-id pub-id-type="pmid">19491245</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1113/jphysiol.2009.169748</pub-id><pub-id pub-id-type="pmcid">PMC2742281</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR237"><label>237.</label><citation-alternatives><element-citation id="ec-CR237" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>TW</given-names></name><name name-style="western"><surname>Sung</surname><given-names>YH</given-names></name></person-group><article-title>Regular exercise promotes memory function and enhances hippocampal neuroplasticity in experimental autoimmune encephalomyelitis mice</article-title><source>Neuroscience</source><year>2017</year><volume>346</volume><fpage>173</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2017.01.016</pub-id><pub-id pub-id-type="pmid">28108255</pub-id></element-citation><mixed-citation id="mc-CR237" publication-type="journal">Kim TW, Sung YH. Regular exercise promotes memory function and enhances hippocampal neuroplasticity in experimental autoimmune encephalomyelitis mice. Neuroscience. 2017;346:173&#8211;81.<pub-id pub-id-type="pmid">28108255</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroscience.2017.01.016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR238"><label>238.</label><citation-alternatives><element-citation id="ec-CR238" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mokhtarzade</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effect of aerobic interval training on serum IL-10, TNF&#945;, and adipokines levels in women with multiple sclerosis: possible relations with fatigue and quality of life</article-title><source>Endocrine</source><year>2017</year><volume>57</volume><issue>2</issue><fpage>262</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1007/s12020-017-1337-y</pub-id><pub-id pub-id-type="pmid">28616851</pub-id></element-citation><mixed-citation id="mc-CR238" publication-type="journal">Mokhtarzade M, et al. Effect of aerobic interval training on serum IL-10, TNF&#945;, and adipokines levels in women with multiple sclerosis: possible relations with fatigue and quality of life. Endocrine. 2017;57(2):262&#8211;71.<pub-id pub-id-type="pmid">28616851</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12020-017-1337-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR239"><label>239.</label><citation-alternatives><element-citation id="ec-CR239" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montagne</surname><given-names>A</given-names></name><etal/></person-group><article-title>APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline</article-title><source>Nature</source><year>2020</year><volume>581</volume><issue>7806</issue><fpage>71</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2247-3</pub-id><pub-id pub-id-type="pmid">32376954</pub-id><pub-id pub-id-type="pmcid">PMC7250000</pub-id></element-citation><mixed-citation id="mc-CR239" publication-type="journal">Montagne A, et al. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature. 2020;581(7806):71&#8211;6.<pub-id pub-id-type="pmid">32376954</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2247-3</pub-id><pub-id pub-id-type="pmcid">PMC7250000</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR240"><label>240.</label><citation-alternatives><element-citation id="ec-CR240" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kerr</surname><given-names>AW</given-names></name><etal/></person-group><article-title>T-cell activation and LPS: a dangerous duo for organ dysfunction</article-title><source>J Leukoc Biol</source><year>2022</year><volume>112</volume><issue>2</issue><fpage>219</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1002/JLB.3CE0122-019R</pub-id><pub-id pub-id-type="pmid">35481682</pub-id></element-citation><mixed-citation id="mc-CR240" publication-type="journal">Kerr AW, et al. T-cell activation and LPS: a dangerous duo for organ dysfunction. J Leukoc Biol. 2022;112(2):219&#8211;20.<pub-id pub-id-type="pmid">35481682</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/JLB.3CE0122-019R</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR241"><label>241.</label><citation-alternatives><element-citation id="ec-CR241" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scheffer</surname><given-names>DDL</given-names></name><name name-style="western"><surname>Latini</surname><given-names>A</given-names></name></person-group><article-title>Exercise-induced immune system response: anti-inflammatory status on peripheral and central organs</article-title><source>Biochim Biophys Acta Mol Basis Dis</source><year>2020</year><volume>1866</volume><issue>10</issue><fpage>165823</fpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2020.165823</pub-id><pub-id pub-id-type="pmid">32360589</pub-id><pub-id pub-id-type="pmcid">PMC7188661</pub-id></element-citation><mixed-citation id="mc-CR241" publication-type="journal">Scheffer DDL, Latini A. Exercise-induced immune system response: anti-inflammatory status on peripheral and central organs. Biochim Biophys Acta Mol Basis Dis. 2020;1866(10):165823.<pub-id pub-id-type="pmid">32360589</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbadis.2020.165823</pub-id><pub-id pub-id-type="pmcid">PMC7188661</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR242"><label>242.</label><citation-alternatives><element-citation id="ec-CR242" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Da Rosa</surname><given-names>PC</given-names></name><etal/></person-group><article-title>The physical exercise-induced oxidative/inflammatory response in peripheral blood mononuclear cells: Signaling cellular energetic stress situations</article-title><source>Life Sci</source><year>2023</year><volume>321</volume><fpage>121440</fpage><pub-id pub-id-type="doi">10.1016/j.lfs.2023.121440</pub-id><pub-id pub-id-type="pmid">36921686</pub-id></element-citation><mixed-citation id="mc-CR242" publication-type="journal">Da Rosa PC, et al. The physical exercise-induced oxidative/inflammatory response in peripheral blood mononuclear cells: Signaling cellular energetic stress situations. Life Sci. 2023;321:121440.<pub-id pub-id-type="pmid">36921686</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lfs.2023.121440</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR243"><label>243.</label><citation-alternatives><element-citation id="ec-CR243" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gothe</surname><given-names>NP</given-names></name><etal/></person-group><article-title>Yoga, aerobic and stretching exercise effects on neurocognition: Randomized controlled trial protocol</article-title><source>Contemp Clin Trials</source><year>2023</year><volume>131</volume><fpage>107240</fpage><pub-id pub-id-type="doi">10.1016/j.cct.2023.107240</pub-id><pub-id pub-id-type="pmid">37244365</pub-id><pub-id pub-id-type="pmcid">PMC10527553</pub-id></element-citation><mixed-citation id="mc-CR243" publication-type="journal">Gothe NP, et al. Yoga, aerobic and stretching exercise effects on neurocognition: Randomized controlled trial protocol. Contemp Clin Trials. 2023;131:107240.<pub-id pub-id-type="pmid">37244365</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cct.2023.107240</pub-id><pub-id pub-id-type="pmcid">PMC10527553</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR244"><label>244.</label><citation-alternatives><element-citation id="ec-CR244" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>K</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T</given-names></name></person-group><article-title>Protective effect of irisin against Alzheimer's disease</article-title><source>Front Psychiatry</source><year>2022</year><volume>13</volume><fpage>967683</fpage><pub-id pub-id-type="doi">10.3389/fpsyt.2022.967683</pub-id><pub-id pub-id-type="pmid">36203845</pub-id><pub-id pub-id-type="pmcid">PMC9530446</pub-id></element-citation><mixed-citation id="mc-CR244" publication-type="journal">Chen K, Wang K, Wang T. Protective effect of irisin against Alzheimer&#8217;s disease. Front Psychiatry. 2022;13:967683.<pub-id pub-id-type="pmid">36203845</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpsyt.2022.967683</pub-id><pub-id pub-id-type="pmcid">PMC9530446</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR245"><label>245.</label><citation-alternatives><element-citation id="ec-CR245" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Aerobic exercise attenuates LPS-induced cognitive dysfunction by reducing oxidative stress, glial activation, and neuroinflammation</article-title><source>Redox Biol</source><year>2024</year><volume>71</volume><fpage>103101</fpage><pub-id pub-id-type="doi">10.1016/j.redox.2024.103101</pub-id><pub-id pub-id-type="pmid">38408409</pub-id><pub-id pub-id-type="pmcid">PMC10904279</pub-id></element-citation><mixed-citation id="mc-CR245" publication-type="journal">Choi JW, et al. Aerobic exercise attenuates LPS-induced cognitive dysfunction by reducing oxidative stress, glial activation, and neuroinflammation. Redox Biol. 2024;71:103101.<pub-id pub-id-type="pmid">38408409</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.redox.2024.103101</pub-id><pub-id pub-id-type="pmcid">PMC10904279</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR246"><label>246.</label><citation-alternatives><element-citation id="ec-CR246" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Powers</surname><given-names>SK</given-names></name><etal/></person-group><article-title>Exercise-induced oxidative stress: friend or foe?</article-title><source>J Sport Health Sci</source><year>2020</year><volume>9</volume><issue>5</issue><fpage>415</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1016/j.jshs.2020.04.001</pub-id><pub-id pub-id-type="pmid">32380253</pub-id><pub-id pub-id-type="pmcid">PMC7498668</pub-id></element-citation><mixed-citation id="mc-CR246" publication-type="journal">Powers SK, et al. Exercise-induced oxidative stress: friend or foe? J Sport Health Sci. 2020;9(5):415&#8211;25.<pub-id pub-id-type="pmid">32380253</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jshs.2020.04.001</pub-id><pub-id pub-id-type="pmcid">PMC7498668</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR247"><label>247.</label><citation-alternatives><element-citation id="ec-CR247" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mogilenko</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Comprehensive profiling of an aging immune system reveals clonal GZMK(+) CD8(+) T cells as conserved hallmark of inflammaging</article-title><source>Immunity</source><year>2021</year><volume>54</volume><issue>1</issue><fpage>99</fpage><lpage>115.e12</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.11.005</pub-id><pub-id pub-id-type="pmid">33271118</pub-id></element-citation><mixed-citation id="mc-CR247" publication-type="journal">Mogilenko DA, et al. Comprehensive profiling of an aging immune system reveals clonal GZMK(+) CD8(+) T cells as conserved hallmark of inflammaging. Immunity. 2021;54(1):99-115.e12.<pub-id pub-id-type="pmid">33271118</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2020.11.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR248"><label>248.</label><citation-alternatives><element-citation id="ec-CR248" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Birch</surname><given-names>J</given-names></name><name name-style="western"><surname>Gil</surname><given-names>J</given-names></name></person-group><article-title>Senescence and the SASP: many therapeutic avenues</article-title><source>Genes Dev</source><year>2020</year><volume>34</volume><issue>23&#8211;24</issue><fpage>1565</fpage><lpage>1576</lpage><pub-id pub-id-type="doi">10.1101/gad.343129.120</pub-id><pub-id pub-id-type="pmid">33262144</pub-id><pub-id pub-id-type="pmcid">PMC7706700</pub-id></element-citation><mixed-citation id="mc-CR248" publication-type="journal">Birch J, Gil J. Senescence and the SASP: many therapeutic avenues. Genes Dev. 2020;34(23&#8211;24):1565&#8211;76.<pub-id pub-id-type="pmid">33262144</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/gad.343129.120</pub-id><pub-id pub-id-type="pmcid">PMC7706700</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR249"><label>249.</label><citation-alternatives><element-citation id="ec-CR249" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Victorelli</surname><given-names>S</given-names></name><etal/></person-group><article-title>Apoptotic stress causes mtDNA release during senescence and drives the SASP</article-title><source>Nature</source><year>2023</year><volume>622</volume><issue>7983</issue><fpage>627</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06621-4</pub-id><pub-id pub-id-type="pmid">37821702</pub-id><pub-id pub-id-type="pmcid">PMC10584674</pub-id></element-citation><mixed-citation id="mc-CR249" publication-type="journal">Victorelli S, et al. Apoptotic stress causes mtDNA release during senescence and drives the SASP. Nature. 2023;622(7983):627&#8211;36.<pub-id pub-id-type="pmid">37821702</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-023-06621-4</pub-id><pub-id pub-id-type="pmcid">PMC10584674</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR250"><label>250.</label><citation-alternatives><element-citation id="ec-CR250" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>J</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K</given-names></name></person-group><article-title>The impact of physical exercise on neuroinflammation mechanism in Alzheimer's disease</article-title><source>Front Aging Neurosci</source><year>2024</year><volume>16</volume><fpage>1444716</fpage><pub-id pub-id-type="doi">10.3389/fnagi.2024.1444716</pub-id><pub-id pub-id-type="pmid">39233828</pub-id><pub-id pub-id-type="pmcid">PMC11371602</pub-id></element-citation><mixed-citation id="mc-CR250" publication-type="journal">Hu J, Huang B, Chen K. The impact of physical exercise on neuroinflammation mechanism in Alzheimer&#8217;s disease. Front Aging Neurosci. 2024;16:1444716.<pub-id pub-id-type="pmid">39233828</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2024.1444716</pub-id><pub-id pub-id-type="pmcid">PMC11371602</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR251"><label>251.</label><citation-alternatives><element-citation id="ec-CR251" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mansoor</surname><given-names>M</given-names></name><etal/></person-group><article-title>Exercise-induced neuroplasticity: adaptive mechanisms and preventive potential in neurodegenerative disorders</article-title><source>Physiologia</source><year>2025</year><volume>5</volume><issue>2</issue><fpage>13</fpage><pub-id pub-id-type="doi">10.3390/physiologia5020013</pub-id></element-citation><mixed-citation id="mc-CR251" publication-type="journal">Mansoor M, et al. Exercise-induced neuroplasticity: adaptive mechanisms and preventive potential in neurodegenerative disorders. Physiologia. 2025;5(2):13.</mixed-citation></citation-alternatives></ref><ref id="CR252"><label>252.</label><citation-alternatives><element-citation id="ec-CR252" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Running exercise alleviates hippocampal neuroinflammation and shifts the balance of microglial M1/M2 polarization through adiponectin/AdipoR1 pathway activation in mice exposed to chronic unpredictable stress</article-title><source>Mol Psychiatry</source><year>2024</year><volume>29</volume><issue>7</issue><fpage>2031</fpage><lpage>2042</lpage><pub-id pub-id-type="doi">10.1038/s41380-024-02464-1</pub-id><pub-id pub-id-type="pmid">38361125</pub-id></element-citation><mixed-citation id="mc-CR252" publication-type="journal">Liu L, et al. Running exercise alleviates hippocampal neuroinflammation and shifts the balance of microglial M1/M2 polarization through adiponectin/AdipoR1 pathway activation in mice exposed to chronic unpredictable stress. Mol Psychiatry. 2024;29(7):2031&#8211;42.<pub-id pub-id-type="pmid">38361125</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41380-024-02464-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR253"><label>253.</label><citation-alternatives><element-citation id="ec-CR253" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Running exercise protects oligodendrocytes in the medial prefrontal cortex in chronic unpredictable stress rat model</article-title><source>Transl Psychiatry</source><year>2019</year><volume>9</volume><issue>1</issue><fpage>322</fpage><pub-id pub-id-type="doi">10.1038/s41398-019-0662-8</pub-id><pub-id pub-id-type="pmid">31780641</pub-id><pub-id pub-id-type="pmcid">PMC6882819</pub-id></element-citation><mixed-citation id="mc-CR253" publication-type="journal">Luo Y, et al. Running exercise protects oligodendrocytes in the medial prefrontal cortex in chronic unpredictable stress rat model. Transl Psychiatry. 2019;9(1):322.<pub-id pub-id-type="pmid">31780641</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41398-019-0662-8</pub-id><pub-id pub-id-type="pmcid">PMC6882819</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR254"><label>254.</label><citation-alternatives><element-citation id="ec-CR254" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Preischemic treadmill exercise ameliorates memory impairment and microvasculature damage in rat model of chronic cerebral hypoperfusion</article-title><source>Int Neurourol J</source><year>2021</year><volume>25</volume><issue>Suppl 2</issue><fpage>S72</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.5213/inj.2142340.170</pub-id><pub-id pub-id-type="pmid">34844389</pub-id><pub-id pub-id-type="pmcid">PMC8654316</pub-id></element-citation><mixed-citation id="mc-CR254" publication-type="journal">Lee JM, et al. Preischemic treadmill exercise ameliorates memory impairment and microvasculature damage in rat model of chronic cerebral hypoperfusion. Int Neurourol J. 2021;25(Suppl 2):S72-80.<pub-id pub-id-type="pmid">34844389</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5213/inj.2142340.170</pub-id><pub-id pub-id-type="pmcid">PMC8654316</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR255"><label>255.</label><citation-alternatives><element-citation id="ec-CR255" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Royes</surname><given-names>LFF</given-names></name></person-group><article-title>Cross-talk between gut and brain elicited by physical exercise</article-title><source>Biochim Biophys Acta Mol Basis Dis</source><year>2020</year><volume>1866</volume><issue>10</issue><fpage>165877</fpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2020.165877</pub-id><pub-id pub-id-type="pmid">32544430</pub-id></element-citation><mixed-citation id="mc-CR255" publication-type="journal">Royes LFF. Cross-talk between gut and brain elicited by physical exercise. Biochim Biophys Acta Mol Basis Dis. 2020;1866(10):165877.<pub-id pub-id-type="pmid">32544430</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbadis.2020.165877</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR256"><label>256.</label><citation-alternatives><element-citation id="ec-CR256" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palasz</surname><given-names>E</given-names></name><etal/></person-group><article-title>Exercise-induced neuroprotection and recovery of motor function in animal models of Parkinson's disease</article-title><source>Front Neurol</source><year>2019</year><volume>10</volume><fpage>1143</fpage><pub-id pub-id-type="doi">10.3389/fneur.2019.01143</pub-id><pub-id pub-id-type="pmid">31736859</pub-id><pub-id pub-id-type="pmcid">PMC6838750</pub-id></element-citation><mixed-citation id="mc-CR256" publication-type="journal">Palasz E, et al. Exercise-induced neuroprotection and recovery of motor function in animal models of Parkinson&#8217;s disease. Front Neurol. 2019;10:1143.<pub-id pub-id-type="pmid">31736859</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2019.01143</pub-id><pub-id pub-id-type="pmcid">PMC6838750</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR257"><label>257.</label><citation-alternatives><element-citation id="ec-CR257" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>AG</given-names></name><etal/></person-group><article-title>High intensity interval training leads to similar inflammatory activation as seen with traditional training in chronic heart failure</article-title><source>Front Cardiovasc Med</source><year>2021</year><volume>8</volume><fpage>752531</fpage><pub-id pub-id-type="doi">10.3389/fcvm.2021.752531</pub-id><pub-id pub-id-type="pmid">35211515</pub-id><pub-id pub-id-type="pmcid">PMC8860824</pub-id></element-citation><mixed-citation id="mc-CR257" publication-type="journal">Taylor AG, et al. High intensity interval training leads to similar inflammatory activation as seen with traditional training in chronic heart failure. Front Cardiovasc Med. 2021;8:752531.<pub-id pub-id-type="pmid">35211515</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcvm.2021.752531</pub-id><pub-id pub-id-type="pmcid">PMC8860824</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR258"><label>258.</label><citation-alternatives><element-citation id="ec-CR258" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malczynska-Sims</surname><given-names>P</given-names></name><etal/></person-group><article-title>High-intensity interval training modulates inflammatory response in Parkinson&#8217;s disease</article-title><source>Aging Clin Exp Res</source><year>2022</year><volume>34</volume><issue>9</issue><fpage>2165</fpage><lpage>2176</lpage><pub-id pub-id-type="doi">10.1007/s40520-022-02153-5</pub-id><pub-id pub-id-type="pmid">35699838</pub-id><pub-id pub-id-type="pmcid">PMC9192928</pub-id></element-citation><mixed-citation id="mc-CR258" publication-type="journal">Malczynska-Sims P, et al. High-intensity interval training modulates inflammatory response in Parkinson&#8217;s disease. Aging Clin Exp Res. 2022;34(9):2165&#8211;76.<pub-id pub-id-type="pmid">35699838</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40520-022-02153-5</pub-id><pub-id pub-id-type="pmcid">PMC9192928</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR259"><label>259.</label><citation-alternatives><element-citation id="ec-CR259" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O'Callaghan</surname><given-names>A</given-names></name><etal/></person-group><article-title>Comparing the influence of exercise intensity on brain-derived neurotrophic factor serum levels in people with Parkinson's disease: a pilot study</article-title><source>Aging Clin Exp Res</source><year>2020</year><volume>32</volume><issue>9</issue><fpage>1731</fpage><lpage>1738</lpage><pub-id pub-id-type="doi">10.1007/s40520-019-01353-w</pub-id><pub-id pub-id-type="pmid">31606860</pub-id></element-citation><mixed-citation id="mc-CR259" publication-type="journal">O&#8217;Callaghan A, et al. Comparing the influence of exercise intensity on brain-derived neurotrophic factor serum levels in people with Parkinson&#8217;s disease: a pilot study. Aging Clin Exp Res. 2020;32(9):1731&#8211;8.<pub-id pub-id-type="pmid">31606860</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40520-019-01353-w</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR260"><label>260.</label><citation-alternatives><element-citation id="ec-CR260" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marusiak</surname><given-names>J</given-names></name><etal/></person-group><article-title>Interval training-induced alleviation of rigidity and hypertonia in patients with Parkinson's disease is accompanied by increased basal serum brain-derived neurotrophic factor</article-title><source>J Rehabil Med</source><year>2015</year><volume>47</volume><issue>4</issue><fpage>372</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.2340/16501977-1931</pub-id><pub-id pub-id-type="pmid">25510618</pub-id></element-citation><mixed-citation id="mc-CR260" publication-type="journal">Marusiak J, et al. Interval training-induced alleviation of rigidity and hypertonia in patients with Parkinson&#8217;s disease is accompanied by increased basal serum brain-derived neurotrophic factor. J Rehabil Med. 2015;47(4):372&#8211;5.<pub-id pub-id-type="pmid">25510618</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2340/16501977-1931</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR261"><label>261.</label><citation-alternatives><element-citation id="ec-CR261" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zoladz</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Moderate-intensity interval training increases serum brain-derived neurotrophic factor level and decreases inflammation in Parkinson's disease patients</article-title><source>J Physiol Pharmacol</source><year>2014</year><volume>65</volume><issue>3</issue><fpage>441</fpage><lpage>448</lpage><pub-id pub-id-type="pmid">24930517</pub-id></element-citation><mixed-citation id="mc-CR261" publication-type="journal">Zoladz JA, et al. Moderate-intensity interval training increases serum brain-derived neurotrophic factor level and decreases inflammation in Parkinson&#8217;s disease patients. J Physiol Pharmacol. 2014;65(3):441&#8211;8.<pub-id pub-id-type="pmid">24930517</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR262"><label>262.</label><citation-alternatives><element-citation id="ec-CR262" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Does exercise attenuate disease progression in people with Parkinson's disease? A systematic review with meta-analyses</article-title><source>Neurorehabil Neural Repair</source><year>2023</year><volume>37</volume><issue>5</issue><fpage>328</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1177/15459683231172752</pub-id><pub-id pub-id-type="pmid">37166181</pub-id><pub-id pub-id-type="pmcid">PMC10272626</pub-id></element-citation><mixed-citation id="mc-CR262" publication-type="journal">Li JA, et al. Does exercise attenuate disease progression in people with Parkinson&#8217;s disease? A systematic review with meta-analyses. Neurorehabil Neural Repair. 2023;37(5):328&#8211;52.<pub-id pub-id-type="pmid">37166181</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/15459683231172752</pub-id><pub-id pub-id-type="pmcid">PMC10272626</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR263"><label>263.</label><citation-alternatives><element-citation id="ec-CR263" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Novati</surname><given-names>A</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>HP</given-names></name><name name-style="western"><surname>Schulze-Hentrich</surname><given-names>J</given-names></name></person-group><article-title>Environmental stimulation in Huntington disease patients and animal models</article-title><source>Neurobiol Dis</source><year>2022</year><volume>171</volume><fpage>105725</fpage><pub-id pub-id-type="doi">10.1016/j.nbd.2022.105725</pub-id><pub-id pub-id-type="pmid">35427742</pub-id></element-citation><mixed-citation id="mc-CR263" publication-type="journal">Novati A, Nguyen HP, Schulze-Hentrich J. Environmental stimulation in Huntington disease patients and animal models. Neurobiol Dis. 2022;171:105725.<pub-id pub-id-type="pmid">35427742</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbd.2022.105725</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR264"><label>264.</label><citation-alternatives><element-citation id="ec-CR264" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trovato</surname><given-names>B</given-names></name><etal/></person-group><article-title>Effects of exercise on skeletal muscle pathophysiology in Huntington's disease</article-title><source>J Funct Morphol Kinesiol</source><year>2022</year><pub-id pub-id-type="doi">10.3390/jfmk7020040</pub-id><pub-id pub-id-type="pmid">35645302</pub-id><pub-id pub-id-type="pmcid">PMC9149967</pub-id></element-citation><mixed-citation id="mc-CR264" publication-type="journal">Trovato B, et al. Effects of exercise on skeletal muscle pathophysiology in Huntington&#8217;s disease. J Funct Morphol Kinesiol. 2022. 10.3390/jfmk7020040.<pub-id pub-id-type="pmid">35645302</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jfmk7020040</pub-id><pub-id pub-id-type="pmcid">PMC9149967</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR265"><label>265.</label><citation-alternatives><element-citation id="ec-CR265" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Renoir</surname><given-names>T</given-names></name><etal/></person-group><article-title>Effect of enhanced voluntary physical exercise on brain levels of monoamines in Huntington disease mice</article-title><source>PLoS Curr</source><year>2011</year><pub-id pub-id-type="doi">10.1371/currents.RRN1281</pub-id><pub-id pub-id-type="pmid">22266953</pub-id><pub-id pub-id-type="pmcid">PMC3208413</pub-id></element-citation><mixed-citation id="mc-CR265" publication-type="journal">Renoir T, et al. Effect of enhanced voluntary physical exercise on brain levels of monoamines in Huntington disease mice. PLoS Curr. 2011. 10.1371/currents.RRN1281.<pub-id pub-id-type="pmid">22266953</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/currents.RRN1281</pub-id><pub-id pub-id-type="pmcid">PMC3208413</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR266"><label>266.</label><citation-alternatives><element-citation id="ec-CR266" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Azman</surname><given-names>KF</given-names></name><name name-style="western"><surname>Zakaria</surname><given-names>R</given-names></name></person-group><article-title>Brain-derived neurotrophic factor (BDNF) in Huntington&#8217;s disease: neurobiology and therapeutic potential</article-title><source>Curr Neuropharmacol</source><year>2025</year><volume>23</volume><issue>4</issue><fpage>384</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.2174/1570159X22666240530105516</pub-id><pub-id pub-id-type="pmid">40123457</pub-id><pub-id pub-id-type="pmcid">PMC12105282</pub-id></element-citation><mixed-citation id="mc-CR266" publication-type="journal">Azman KF, Zakaria R. Brain-derived neurotrophic factor (BDNF) in Huntington&#8217;s disease: neurobiology and therapeutic potential. Curr Neuropharmacol. 2025;23(4):384&#8211;403.<pub-id pub-id-type="pmid">40123457</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1570159X22666240530105516</pub-id><pub-id pub-id-type="pmcid">PMC12105282</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR267"><label>267.</label><citation-alternatives><element-citation id="ec-CR267" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strickland</surname><given-names>D</given-names></name><etal/></person-group><article-title>Physical activity, trauma, and ALS: a case-control study</article-title><source>Acta Neurol Scand</source><year>1996</year><volume>94</volume><issue>1</issue><fpage>45</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0404.1996.tb00038.x</pub-id><pub-id pub-id-type="pmid">8874593</pub-id></element-citation><mixed-citation id="mc-CR267" publication-type="journal">Strickland D, et al. Physical activity, trauma, and ALS: a case-control study. Acta Neurol Scand. 1996;94(1):45&#8211;50.<pub-id pub-id-type="pmid">8874593</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1600-0404.1996.tb00038.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR268"><label>268.</label><citation-alternatives><element-citation id="ec-CR268" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gotkine</surname><given-names>M</given-names></name><name name-style="western"><surname>Friedlander</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hochner</surname><given-names>H</given-names></name></person-group><article-title>Triathletes are over-represented in a population of patients with ALS</article-title><source>Amyotroph Later Scler Frontotemporal Degener</source><year>2014</year><volume>15</volume><issue>7&#8211;8</issue><fpage>534</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.3109/21678421.2014.932383</pub-id><pub-id pub-id-type="pmid">25007701</pub-id></element-citation><mixed-citation id="mc-CR268" publication-type="journal">Gotkine M, Friedlander Y, Hochner H. Triathletes are over-represented in a population of patients with ALS. Amyotroph Later Scler Frontotemporal Degener. 2014;15(7&#8211;8):534&#8211;6.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/21678421.2014.932383</pub-id><pub-id pub-id-type="pmid">25007701</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR269"><label>269.</label><citation-alternatives><element-citation id="ec-CR269" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chi&#242;</surname><given-names>A</given-names></name><etal/></person-group><article-title>Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players</article-title><source>Brain</source><year>2005</year><volume>128</volume><issue>Pt 3</issue><fpage>472</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1093/brain/awh373</pub-id><pub-id pub-id-type="pmid">15634730</pub-id></element-citation><mixed-citation id="mc-CR269" publication-type="journal">Chi&#242; A, et al. Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players. Brain. 2005;128(Pt 3):472&#8211;6.<pub-id pub-id-type="pmid">15634730</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awh373</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR270"><label>270.</label><citation-alternatives><element-citation id="ec-CR270" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lehman</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>Neurodegenerative causes of death among retired National Football League players</article-title><source>Neurology</source><year>2012</year><volume>79</volume><issue>19</issue><fpage>1970</fpage><lpage>1974</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e31826daf50</pub-id><pub-id pub-id-type="pmid">22955124</pub-id><pub-id pub-id-type="pmcid">PMC4098841</pub-id></element-citation><mixed-citation id="mc-CR270" publication-type="journal">Lehman EJ, et al. Neurodegenerative causes of death among retired National Football League players. Neurology. 2012;79(19):1970&#8211;4.<pub-id pub-id-type="pmid">22955124</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e31826daf50</pub-id><pub-id pub-id-type="pmcid">PMC4098841</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR271"><label>271.</label><citation-alternatives><element-citation id="ec-CR271" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahoney</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Effects of high-intensity endurance exercise training in the G93A mouse model of amyotrophic lateral sclerosis</article-title><source>Muscle Nerve</source><year>2004</year><volume>29</volume><issue>5</issue><fpage>656</fpage><lpage>662</lpage><pub-id pub-id-type="doi">10.1002/mus.20004</pub-id><pub-id pub-id-type="pmid">15116368</pub-id></element-citation><mixed-citation id="mc-CR271" publication-type="journal">Mahoney DJ, et al. Effects of high-intensity endurance exercise training in the G93A mouse model of amyotrophic lateral sclerosis. Muscle Nerve. 2004;29(5):656&#8211;62.<pub-id pub-id-type="pmid">15116368</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mus.20004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR272"><label>272.</label><citation-alternatives><element-citation id="ec-CR272" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Effects of moderate- versus high- intensity swimming training on inflammatory and CD4(+) T cell subset profiles in experimental autoimmune encephalomyelitis mice</article-title><source>J Neuroimmunol</source><year>2019</year><volume>328</volume><fpage>60</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2018.12.005</pub-id><pub-id pub-id-type="pmid">30583216</pub-id></element-citation><mixed-citation id="mc-CR272" publication-type="journal">Xie Y, et al. Effects of moderate- versus high- intensity swimming training on inflammatory and CD4(+) T cell subset profiles in experimental autoimmune encephalomyelitis mice. J Neuroimmunol. 2019;328:60&#8211;7.<pub-id pub-id-type="pmid">30583216</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jneuroim.2018.12.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR273"><label>273.</label><citation-alternatives><element-citation id="ec-CR273" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Negaresh</surname><given-names>R</given-names></name><etal/></person-group><article-title>Effects of exercise training on cytokines and adipokines in multiple sclerosis: a systematic review</article-title><source>Mult Scler Relat Disord</source><year>2018</year><volume>24</volume><fpage>91</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/j.msard.2018.06.008</pub-id><pub-id pub-id-type="pmid">29982111</pub-id></element-citation><mixed-citation id="mc-CR273" publication-type="journal">Negaresh R, et al. Effects of exercise training on cytokines and adipokines in multiple sclerosis: a systematic review. Mult Scler Relat Disord. 2018;24:91&#8211;100.<pub-id pub-id-type="pmid">29982111</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.msard.2018.06.008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR274"><label>274.</label><citation-alternatives><element-citation id="ec-CR274" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simpson</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Exercise and the regulation of immune functions</article-title><source>Prog Mol Biol Transl Sci</source><year>2015</year><volume>135</volume><fpage>355</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1016/bs.pmbts.2015.08.001</pub-id><pub-id pub-id-type="pmid">26477922</pub-id></element-citation><mixed-citation id="mc-CR274" publication-type="journal">Simpson RJ, et al. Exercise and the regulation of immune functions. Prog Mol Biol Transl Sci. 2015;135:355&#8211;80.<pub-id pub-id-type="pmid">26477922</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/bs.pmbts.2015.08.001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR275"><label>275.</label><citation-alternatives><element-citation id="ec-CR275" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharif</surname><given-names>K</given-names></name><etal/></person-group><article-title>Physical activity and autoimmune diseases: get moving and manage the disease</article-title><source>Autoimmun Rev</source><year>2018</year><volume>17</volume><issue>1</issue><fpage>53</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.autrev.2017.11.010</pub-id><pub-id pub-id-type="pmid">29108826</pub-id></element-citation><mixed-citation id="mc-CR275" publication-type="journal">Sharif K, et al. Physical activity and autoimmune diseases: get moving and manage the disease. Autoimmun Rev. 2018;17(1):53&#8211;72.<pub-id pub-id-type="pmid">29108826</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.autrev.2017.11.010</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Am J Alzheimers Dis Other Demen</journal-id><journal-id journal-id-type="iso-abbrev">Am J Alzheimers Dis Other Demen</journal-id><journal-id journal-id-type="pmc-domain-id">4508</journal-id><journal-id journal-id-type="pmc-domain">ajad</journal-id><journal-id journal-id-type="publisher-id">AJA</journal-id><journal-title-group><journal-title>American Journal of Alzheimer's Disease and Other Dementias</journal-title></journal-title-group><issn pub-type="ppub">1533-3175</issn><issn pub-type="epub">1938-2731</issn><publisher><publisher-name>SAGE Publications</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12484899</article-id><article-id pub-id-type="pmcid-ver">PMC12484899.1</article-id><article-id pub-id-type="pmcaid">12484899</article-id><article-id pub-id-type="pmcaiid">12484899</article-id><article-id pub-id-type="pmid">41027650</article-id><article-id pub-id-type="doi">10.1177/15333175251385615</article-id><article-id pub-id-type="publisher-id">10.1177_15333175251385615</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Olfactory Testing With Focus on Odor Identification for Early Detection of Alzheimer&#8217;s Disease in Mild Cognitive Impairment</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0003-8921-1102</contrib-id><name name-style="western"><surname>Zhou</surname><given-names initials="F">Feiyan</given-names></name><degrees>MD</degrees><xref rid="aff1-15333175251385615" ref-type="aff">1</xref><xref rid="aff2-15333175251385615" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhao</surname><given-names initials="Z">Zhuowen</given-names></name><degrees>MD</degrees><xref rid="aff1-15333175251385615" ref-type="aff">1</xref><xref rid="aff2-15333175251385615" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dai</surname><given-names initials="J">Jingyu</given-names></name><degrees>MD</degrees><xref rid="aff1-15333175251385615" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xu</surname><given-names initials="J">Jinan</given-names></name><degrees>MD</degrees><xref rid="aff1-15333175251385615" ref-type="aff">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Jiang</surname><given-names initials="K">Ke</given-names></name><degrees>PhD</degrees><xref rid="aff1-15333175251385615" ref-type="aff">1</xref><xref rid="aff3-15333175251385615" ref-type="aff">3</xref><xref rid="corresp1-15333175251385615" ref-type="corresp"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0511-0386</contrib-id><name name-style="western"><surname>Tong</surname><given-names initials="Z">Zhiqian</given-names></name><degrees>PhD</degrees><xref rid="aff1-15333175251385615" ref-type="aff">1</xref><xref rid="aff2-15333175251385615" ref-type="aff">2</xref><xref rid="corresp2-15333175251385615" ref-type="corresp"/></contrib><aff id="aff1-15333175251385615"><label>1</label>Zhejiang Provincial Clinical Research Center for Mental Disorders, the Affiliated Wenzhou Kangning Hospital, School of Mental Health, <institution-wrap><institution-id institution-id-type="Ringgold">26453</institution-id><institution content-type="university">Wenzhou Medical University</institution></institution-wrap>, Wenzhou, China</aff><aff id="aff2-15333175251385615"><label>2</label><institution-wrap><institution content-type="university">Beijing Geriatric Hospital</institution></institution-wrap>, Beijing, China</aff><aff id="aff3-15333175251385615"><label>3</label><institution-wrap><institution content-type="university">Lishui University</institution></institution-wrap>, Lishui, China</aff></contrib-group><author-notes><corresp id="corresp1-15333175251385615">Ke Jiang, PhD, Lishui University, Lishui, China. Email: <email>Jiangke200@126.com</email></corresp><corresp id="corresp2-15333175251385615">Zhiqian Tong, PhD, Zhejiang Provincial Clinical Research Center for Mental Disorders, The Affiliated Wenzhou Kangning Hospital, School of Mental Health, Wenzhou Medical University, Wenzhou 325035, China. Email: <email>tzqbeida@ccmu.edu.cn</email></corresp><fn fn-type="other"><p>Data Availability Statement included at the end of the article</p></fn></author-notes><pub-date pub-type="epub"><day>30</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><season>Jan-Dec</season><year>2025</year></pub-date><volume>40</volume><issue-id pub-id-type="pmc-issue-id">480774</issue-id><elocation-id>15333175251385615</elocation-id><history><date date-type="received"><day>11</day><month>6</month><year>2025</year></date><date date-type="rev-recd"><day>21</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>7</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>30</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>02</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-02 00:25:41.673"><day>02</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder content-type="sage">SAGE Publications</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>) which permits non-commercial use, reproduction and distribution of the work as published without adaptation or alteration, without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10.1177_15333175251385615.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="10.1177_15333175251385615.pdf"/><abstract><p>This review examines the application of olfactory testing in the early stages of mild cognitive impairment (MCI) associated with Alzheimer&#8217;s disease (AD), highlighting its potential and challenges in early screening and intervention. Olfactory function is typically divided into three domains: odor identification, odor discrimination, and odor threshold. Among these, odor identification and discrimination are closely linked to higher cognitive processes and exhibit significant impairment in patients with AD and MCI. Moreover, the anatomical and functional characteristics of the olfactory system make it a promising target for the early detection of neurodegenerative disorders. This review also outlines various olfactory assessment tools and evaluates their clinical utility. Future research should aim to enhance the accuracy and cultural adaptability of olfactory tests and integrate them with multimodal diagnostic approaches to advance early detection and intervention strategies for AD.</p></abstract><abstract abstract-type="graphical"><p>
<fig position="float" id="d67e161" orientation="portrait"><label>Graphical Abstract</label><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_15333175251385615-img01.jpg"/></fig>
</p></abstract><kwd-group><kwd>alzheimer&#8217;s disease</kwd><kwd>early screening</kwd><kwd>mild cognitive impairment</kwd><kwd>olfactory dysfunction</kwd><kwd>olfactory testing</kwd></kwd-group><funding-group specific-use="FundRef"><award-group id="award1-15333175251385615"><funding-source id="funding1-15333175251385615"><institution-wrap><institution>the National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id rid="funding1-15333175251385615">82071214</award-id></award-group><award-group id="award2-15333175251385615"><funding-source id="funding2-15333175251385615"><institution-wrap><institution>the Major Program of the National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id rid="funding2-15333175251385615">62394314</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>typesetter</meta-name><meta-value>ts10</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January-December 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-15333175251385615"><title>Introduction</title><p>Alzheimer&#8217;s disease (AD) is a progressive neurodegenerative disorder typically marked by memory loss, language deficits, executive dysfunction, and personality changes. Pathologically, AD is associated with neuronal loss, brain atrophy, and widespread neuroinflammation, and it accounts for 60%-80% of all dementia cases.<sup><xref rid="bibr1-15333175251385615" ref-type="bibr">1</xref>-<xref rid="bibr3-15333175251385615" ref-type="bibr">3</xref></sup></p><p>According to the recent biological framework established by the National Institute on Aging and Alzheimer&#8217;s Association (NIA-AA), Alzheimer&#8217;s disease is formally defined as a biological process characterized by the presence of AD neuropathologic changes (ADNPC), including amyloid-&#946; plaques and tau neurofibrillary tangles, which can be identified through validated biomarkers even prior to the onset of clinical symptoms. This biological definition emphasizes AD as a continuum that begins asymptomatically and progresses through clinical stages ranging from mild cognitive impairment (MCI) to dementia.<sup>
<xref rid="bibr4-15333175251385615" ref-type="bibr">4</xref>
</sup></p><p>With a rapidly aging global population, the number of individuals affected by AD is expected to reach 78 million by 2030 and 139 million by 2050, posing a profound burden on healthcare systems and families.<sup><xref rid="bibr2-15333175251385615" ref-type="bibr">2</xref>,<xref rid="bibr5-15333175251385615" ref-type="bibr">5</xref></sup></p><p>Importantly, AD-related neuropathological changes begin more than two decades before clinical symptoms appear.<sup>
<xref rid="bibr6-15333175251385615" ref-type="bibr">6</xref>
</sup> However, once symptoms are evident, current treatments offer limited efficacy.<sup>
<xref rid="bibr1-15333175251385615" ref-type="bibr">1</xref>
</sup> Current therapies, including cholinesterase inhibitors and memantine, merely alleviate symptoms without modifying disease progression. Recently, two anti-amyloid monoclonal antibodies&#8212;lecanemab and donanemab&#8212;have been approved following successful phase 3 trials (Clarity AD and TRAILBLAZER-ALZ 2). These antibodies selectively bind &#946;-amyloid to facilitate its clearance via microglia, resulting in approximately 25%-35% slowing of cognitive decline in early-stage AD. However, their application faces significant limitations, including risks of amyloid-related imaging abnormalities (ARIA-E/H), high cost, and limited patient access. Thus, early intervention during the mild cognitive impairment stage remains critical.<sup><xref rid="bibr7-15333175251385615" ref-type="bibr">7</xref>,<xref rid="bibr8-15333175251385615" ref-type="bibr">8</xref></sup></p><p>Intervening during the stage of mild cognitive impairment (MCI)&#8212;a prodromal phase of AD&#8212;has been shown to delay progression by up to five years and reduce disease prevalence and healthcare costs substantially.<sup>
<xref rid="bibr9-15333175251385615" ref-type="bibr">9</xref>
</sup> Notably, up to 25% of individuals with MCI may revert to normal cognition following timely intervention, underscoring the potential of early detection strategies.<sup><xref rid="bibr10-15333175251385615" ref-type="bibr">10</xref>,<xref rid="bibr11-15333175251385615" ref-type="bibr">11</xref></sup></p><p>Recent meta-analyses have revealed that olfactory deficits may emerge even during the stage of subjective cognitive decline (SCD), a preclinical phase preceding MCI. Jobin et al found that individuals with SCD already demonstrate significantly reduced odor identification compared to cognitively normal peers, with associations to early AD-related pathology such as tau accumulation and medial temporal lobe atrophy. These findings suggest that olfactory testing could serve as a low-cost, non-invasive addition to the SCD framework for identifying individuals at elevated risk of progression.<sup><xref rid="bibr12-15333175251385615" ref-type="bibr">12</xref>,<xref rid="bibr13-15333175251385615" ref-type="bibr">13</xref></sup>While these results underscore the potential of olfactory dysfunction as a preclinical marker, the MCI stage remains the most feasible and clinically actionable window for intervention, especially given current therapeutic thresholds and diagnostic capabilities. Characterizing olfactory changes across both stages may therefore enhance early screening precision and guide optimal timing of treatment.</p><p>Among emerging biomarkers, olfactory dysfunction has gained increasing attention as a non-invasive, cost-effective tool for identifying individuals at risk. Olfactory deficits are prevalent not only in early AD but also during the MCI stage and may even precede memory decline.<sup><xref rid="bibr14-15333175251385615" ref-type="bibr">14</xref>-<xref rid="bibr17-15333175251385615" ref-type="bibr">17</xref></sup> Studies suggest that olfactory impairment is a stronger predictor of cognitive decline than episodic memory loss in cognitively normal adults.<sup>
<xref rid="bibr18-15333175251385615" ref-type="bibr">18</xref>
</sup> Despite its subtlety in daily life, olfactory dysfunction is frequently unrecognized by patients and can be objectively detected through standardized testing.<sup><xref rid="bibr19-15333175251385615" ref-type="bibr">19</xref>,<xref rid="bibr20-15333175251385615" ref-type="bibr">20</xref></sup></p><p>Neuroanatomically, the olfactory system&#8212;including the olfactory bulb, tract, and primary olfactory cortex (eg, piriform cortex)&#8212;is tightly interconnected with hippocampal subfields, entorhinal cortex, and the amygdala, all of which are early targets in Alzheimer&#8217;s disease.<sup><xref rid="bibr17-15333175251385615" ref-type="bibr">17</xref>,<xref rid="bibr21-15333175251385615" ref-type="bibr">21</xref></sup> Longitudinal MRI over five years revealed that progressive atrophy in the hippocampal tail, CA4, dentate gyrus, and subiculum predicted declines in odor-identification performance in older adults, suggesting these subregions are sensitive preclinical markers.<sup>
<xref rid="bibr22-15333175251385615" ref-type="bibr">22</xref>
</sup> Complementarily, region-of-interest volumetric analyses demonstrated that individuals with mild cognitive impairment exhibit significantly reduced grey-matter volume in the piriform cortex, amygdala, entorhinal cortex, and the olfactory subregion of the left hippocampus compared to cognitively normal controls.<sup>
<xref rid="bibr23-15333175251385615" ref-type="bibr">23</xref>
</sup> Notably, volume of the left hippocampal olfactory subregion was positively correlated with episodic memory performance, underscoring a shared neurodegenerative trajectory between olfactory and memory networks in the MCI stage. These findings reinforce the anatomical basis for olfactory testing as an early biomarker for AD.<sup>
<xref rid="bibr24-15333175251385615" ref-type="bibr">24</xref>
</sup> Moreover, olfactory performance has been correlated with scores on cognitive screening tools like the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA).<sup>
<xref rid="bibr25-15333175251385615" ref-type="bibr">25</xref>
</sup></p><p>Compared to neuroimaging or cerebrospinal biomarkers, olfactory testing is more accessible and feasible for routine clinical use, even in primary care settings. Its predictive accuracy, coupled with its practicality, makes it a promising adjunct in early screening and monitoring.<sup><xref rid="bibr26-15333175251385615" ref-type="bibr">26</xref>,<xref rid="bibr27-15333175251385615" ref-type="bibr">27</xref></sup> This review synthesizes current evidence on olfactory dysfunction as a prodromal marker of AD, particularly during the MCI phase, and evaluates its potential applications, limitations, and clinical implications. By exploring this relatively underutilized modality, we aim to contribute to the development of effective early detection strategies for Alzheimer&#8217;s disease.</p><sec id="sec2-15333175251385615"><title>Classification and Mechanisms of Olfactory Function</title><p>The olfactory system, comprising peripheral (olfactory epithelium and nerve bundles) and central components (olfactory bulb and related pathways), shows promise in early MCI and AD detection.<sup><xref rid="bibr21-15333175251385615" ref-type="bibr">21</xref>,<xref rid="bibr26-15333175251385615" ref-type="bibr">26</xref></sup> Olfactory function is generally divided into odor identification, discrimination, and threshold. With odor memory emerging recently as an important domain that bridges sensory processing and higher cognitive decline.<sup>
<xref rid="bibr21-15333175251385615" ref-type="bibr">21</xref>
</sup></p></sec><sec id="sec3-15333175251385615"><title>Olfactory Threshold</title><p>Odor threshold&#8212;the lowest detectable concentration of a scent&#8212;is primarily considered a measure of peripheral sensory integrity, as pathologies confined to the olfactory epithelium, septum, or nasal cavity can selectively reduce sensitivity without affecting higher-order tasks such as odor identification.<sup><xref rid="bibr28-15333175251385615" ref-type="bibr">28</xref>-<xref rid="bibr31-15333175251385615" ref-type="bibr">31</xref></sup> Nevertheless, threshold performance is not entirely independent of central processes. Meta-analytic evidence now shows small-to-moderate correlations between olfactory detection threshold and both episodic (r = 0.25) and semantic memory (r = 0.17) in cognitively normal older adults, with the strength of this association increasing with age.<sup>
<xref rid="bibr32-15333175251385615" ref-type="bibr">32</xref>
</sup> These findings align with neuroimaging and lesion studies implicating hippocampal and prefrontal regions&#8212;structures vulnerable to aging and early Alzheimer pathology&#8212;in odor detection as well as memory function.<sup><xref rid="bibr33-15333175251385615" ref-type="bibr">33</xref>,<xref rid="bibr34-15333175251385615" ref-type="bibr">34</xref></sup></p><p>Thus, while odor threshold testing may help detect early changes, its ability to distinguish MCI from normal aging remains uncertain.</p></sec><sec id="sec4-15333175251385615"><title>Odor Discrimination</title><p>Odor discrimination&#8212;differentiating among multiple scents&#8212;requires intact sensory function and cognitive resources such as attention, memory, and semantic processing.<sup><xref rid="bibr35-15333175251385615" ref-type="bibr">35</xref>,<xref rid="bibr36-15333175251385615" ref-type="bibr">36</xref></sup> Tasks may also involve delayed recognition, increasing their diagnostic sensitivity.<sup>
<xref rid="bibr37-15333175251385615" ref-type="bibr">37</xref>
</sup></p><p>Some genetic studies link the ApoE &#949;4 allele to poorer discrimination performance, though results across populations remain inconsistent.<sup><xref rid="bibr38-15333175251385615" ref-type="bibr">38</xref>-<xref rid="bibr42-15333175251385615" ref-type="bibr">42</xref></sup> Discrimination deficits emerge early and worsen with disease progression, even predicting the transition from normal cognition to MCI and AD.<sup><xref rid="bibr15-15333175251385615" ref-type="bibr">15</xref>,<xref rid="bibr43-15333175251385615" ref-type="bibr">43</xref>-<xref rid="bibr47-15333175251385615" ref-type="bibr">47</xref></sup></p><p>Therefore, odor discrimination is a sensitive indicator for early detection and progression monitoring, even if genetic influences remain debated.</p></sec><sec id="sec5-15333175251385615"><title>Odor Identification</title><p>Odor identification entails perceiving, recognizing, and naming an odor.<sup>
<xref rid="bibr21-15333175251385615" ref-type="bibr">21</xref>
</sup> This cognitively demanding task depends on intact olfactory sensation and semantic memory.<sup>
<xref rid="bibr48-15333175251385615" ref-type="bibr">48</xref>
</sup> Early declines in identification, often observed in AD and dementia, reflect semantic deficits evident even in prodromal stages.<sup>
<xref rid="bibr49-15333175251385615" ref-type="bibr">49</xref>
</sup></p><p>Impairments are prominent in amnestic MCI (aMCI), aligning with its progression to AD.<sup><xref rid="bibr21-15333175251385615" ref-type="bibr">21</xref>,<xref rid="bibr50-15333175251385615" ref-type="bibr">50</xref>-<xref rid="bibr52-15333175251385615" ref-type="bibr">52</xref></sup> Compared to discrimination, memory, or threshold tests, identification tasks often reveal greater deficits,<sup><xref rid="bibr53-15333175251385615" ref-type="bibr">53</xref>,<xref rid="bibr54-15333175251385615" ref-type="bibr">54</xref></sup> underscoring the increased difficulty AD patients face with complex olfactory processing.<sup><xref rid="bibr37-15333175251385615" ref-type="bibr">37</xref>,<xref rid="bibr55-15333175251385615" ref-type="bibr">55</xref></sup></p><p>Odor identification tests are cost-effective, time-efficient, and suitable for early screening and follow-up in clinical settings.<sup>
<xref rid="bibr56-15333175251385615" ref-type="bibr">56</xref>
</sup> Despite their cognitive demands,<sup><xref rid="bibr37-15333175251385615" ref-type="bibr">37</xref>,<xref rid="bibr57-15333175251385615" ref-type="bibr">57</xref></sup> cultural background and odor familiarity can influence performance, necessitating culturally adapted tests.<sup><xref rid="bibr47-15333175251385615" ref-type="bibr">47</xref>,<xref rid="bibr58-15333175251385615" ref-type="bibr">58</xref></sup></p><p>In conclusion, odor identification is a valuable tool for early screening. Accounting for sociocultural variability will enhance its diagnostic accuracy across populations.</p><p>Recent meta-analytic evidence further confirms the systematic associations between olfactory function and declarative memory in cognitively normal older adults. In a comprehensive analysis of 17 studies, both olfactory identification and detection threshold were significantly correlated with episodic and semantic memory (r = 0.19-0.25). Notably, age moderated the strength of these associations, particularly for detection threshold, suggesting a shared vulnerability in medial temporal and prefrontal brain regions. These findings support the role of olfactory measures&#8212;both peripheral and central&#8212;as sensitive markers of memory function in aging and as potential early indicators of Alzheimer&#8217;s disease pathology.<sup>
<xref rid="bibr32-15333175251385615" ref-type="bibr">32</xref>
</sup> Given the tight link between olfaction and declarative memory, particularly episodic memory, odor memory emerges as a critical domain warranting focused discussion.</p></sec><sec id="sec6-15333175251385615"><title>Odor Memory</title><p>Odor memory&#8212;the ability to encode, store, and retrieve olfactory information&#8212;has recently attracted attention as an important domain linking basic olfactory processing to higher cognitive functions.<sup>
<xref rid="bibr21-15333175251385615" ref-type="bibr">21</xref>
</sup> Unlike identification or threshold tests, odor memory tasks engage episodic processes supported by medial temporal lobe (MTL) structures, such as the hippocampus and entorhinal cortex, which are among the first to be affected in Alzheimer&#8217;s disease pathology.<sup>
<xref rid="bibr21-15333175251385615" ref-type="bibr">21</xref>
</sup></p><p>Functional imaging studies confirm activation of MTL regions during olfactory tasks, highlighting their anatomical and functional convergence with memory systems.<sup>
<xref rid="bibr59-15333175251385615" ref-type="bibr">59</xref>
</sup></p><p>Research indicates that odor memory is significantly impaired in individuals with Alzheimer&#8217;s disease and in those at increased genetic risk, such as APOE &#949;4 carriers, even prior to observable cognitive symptoms.<sup><xref rid="bibr60-15333175251385615" ref-type="bibr">60</xref>,<xref rid="bibr61-15333175251385615" ref-type="bibr">61</xref></sup> These findings suggest that odor memory assessment may complement traditional olfactory measures, offering additional sensitivity for the early detection of neurodegenerative changes.</p></sec><sec id="sec7-15333175251385615"><title>Interaction of the Olfactory System with the Nervous System</title><sec id="sec8-15333175251385615"><title>Structure and Function of the Olfactory System: Signaling Pathways from Olfactory Receptors to the Brain</title><p>The olfactory system plays a vital physiological and psychological role as the central mechanism for detecting and processing external odors. Its intricate structure and highly coordinated signaling pathways enable the conversion of chemical stimuli into neural signals, which are then transmitted to the brain for further processing.<sup>
<xref rid="bibr62-15333175251385615" ref-type="bibr">62</xref>
</sup></p><p>The olfactory center in the human brain is primarily divided into two cortical regions: the primary olfactory cortex (POC) and the secondary olfactory cortex (SOC).<sup>
<xref rid="bibr63-15333175251385615" ref-type="bibr">63</xref>
</sup> The POC includes the anterior olfactory nucleus, olfactory tubercle, frontal and temporal piriform cortices, subregions of the amygdala, and the internal olfactory cortex,<sup><xref rid="bibr64-15333175251385615" ref-type="bibr">64</xref>-<xref rid="bibr66-15333175251385615" ref-type="bibr">66</xref></sup> while the SOC comprises the orbitofrontal cortex, insula, thalamus, hippocampus, and other related regions.<sup>
<xref rid="bibr63-15333175251385615" ref-type="bibr">63</xref>
</sup> The POC primarily receives input from the olfactory bulb and is closely associated with olfactory processing. Notably, it is among the earliest regions affected by neuropathological changes in mild cognitive impairment (MCI) and Alzheimer&#8217;s disease (AD).<sup>
<xref rid="bibr67-15333175251385615" ref-type="bibr">67</xref>
</sup> (see <xref rid="fig1-15333175251385615" ref-type="fig">Figure 1</xref>).<fig position="float" fig-type="figure" id="fig1-15333175251385615" orientation="portrait"><label>Figure 1.</label><caption><p>Map of the Olfactory Center</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_15333175251385615-fig1.jpg"/></fig></p><p>Olfactory modulation involves direct connections between the olfactory tract and several brain regions, including the piriform cortex, entorhinal cortex, hippocampus, and amygdala. These connections influence higher-order functions such as memory, emotion, fear, and vigilance.<sup>
<xref rid="bibr68-15333175251385615" ref-type="bibr">68</xref>
</sup> Thus, the olfactory system plays a critical role not only in odor perception but also in the regulation of emotion and memory. This structural and functional complexity highlights its potential as a diagnostic target in neurodegenerative diseases.</p><p>The main components of the olfactory system include olfactory receptor cells, olfactory nerves, olfactory bulbs, olfactory tracts, and the olfactory cortex.<sup>
<xref rid="bibr21-15333175251385615" ref-type="bibr">21</xref>
</sup> Olfactory receptor cells are located in the olfactory mucosa within the upper nasal cavity.<sup>
<xref rid="bibr69-15333175251385615" ref-type="bibr">69</xref>
</sup> This mucosa&#8212;composed of the olfactory epithelium (OE) and lamina propria (LP)&#8212;efficiently captures odor molecules.<sup>
<xref rid="bibr70-15333175251385615" ref-type="bibr">70</xref>
</sup> The OE contains olfactory receptor neurons (ORNs), which are bipolar neurons with cilia, along with various supporting cells. The axons of ORNs form synapses with dendrites of secondary olfactory projection neurons (mitral and tufted cells) within the olfactory glomeruli.<sup><xref rid="bibr62-15333175251385615" ref-type="bibr">62</xref>,<xref rid="bibr71-15333175251385615" ref-type="bibr">71</xref>,<xref rid="bibr72-15333175251385615" ref-type="bibr">72</xref></sup> These neural connections convert chemical signals into electrical impulses, which travel through the olfactory bulb to higher brain regions (see <xref rid="fig2-15333175251385615" ref-type="fig">Figure 2</xref>).<fig position="float" fig-type="figure" id="fig2-15333175251385615" orientation="portrait"><label>Figure 2.</label><caption><p>Olfactory System Diagram</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_15333175251385615-fig2.jpg"/></fig></p><p>The olfactory epithelium also contains supporting cells, Bowman&#8217;s gland duct cells, horizontal and spherical basal stem cells, and microvillous cells. Supporting cells surround the dendrites of ORNs and regulate metabolic, secretory, and phagocytic functions. Odor molecules reach the OE through the olfactory lumen and bind to specific odorant receptors, which are part of the G protein-coupled receptor (GPCR) family.<sup>
<xref rid="bibr66-15333175251385615" ref-type="bibr">66</xref>
</sup> These receptors are located on the cilia of ORNs and are directly exposed to the external environment within the nasal cavity.<sup>
<xref rid="bibr73-15333175251385615" ref-type="bibr">73</xref>
</sup></p><p>When an odor molecule binds to a receptor, it activates the ORN, generating an action potential that is transmitted via the olfactory nerve to the olfactory bulb and subsequently to various brain regions&#8212;especially those involved in memory, emotion, and behavioral regulation.<sup>
<xref rid="bibr74-15333175251385615" ref-type="bibr">74</xref>
</sup></p><p>Importantly, the olfactory system, alongside the visual system, is one of the few neural pathways that directly interfaces with the external environment without passing through the blood-brain barrier. This unique feature makes olfaction a promising, non-invasive source of central nervous system (CNS)-derived biomarkers.<sup><xref rid="bibr68-15333175251385615" ref-type="bibr">68</xref>,<xref rid="bibr74-15333175251385615" ref-type="bibr">74</xref>-<xref rid="bibr76-15333175251385615" ref-type="bibr">76</xref></sup> Furthermore, olfactory testing has gained attention in chemosensory research due to its simplicity, low cost, and ease of administration.</p><p>The olfactory system begins developing during mid-gestation and exhibits minimal variability across vertebrates. From early infancy to adulthood, it not only shapes sensory perception but also modulates behaviors such as food preferences and social bonding. For instance, human newborns show a preference for their mother&#8217;s breast odor, suggesting that odor-related memory formation begins in utero.<sup><xref rid="bibr77-15333175251385615" ref-type="bibr">77</xref>,<xref rid="bibr78-15333175251385615" ref-type="bibr">78</xref></sup></p><p>In summary, the olfactory system converts chemical stimuli into neural signals through a complex and highly specialized pathway and interacts with multiple brain regions to support functions such as memory and emotion. These features underscore its promise as a non-invasive tool for the early detection of MCI and AD.</p></sec></sec><sec id="sec9-15333175251385615"><title>Advances in the Study of Olfactory Impairment to Distinguish AD from Other Neurodegenerative Diseases</title><p>In recent years, growing attention has been directed toward olfactory dysfunction in patients with dementia, particularly Alzheimer&#8217;s disease (AD), a neurodegenerative condition characterized by memory loss and cognitive decline. Olfactory impairment is now recognized as one of the earliest clinical manifestations of AD.<sup>
<xref rid="bibr50-15333175251385615" ref-type="bibr">50</xref>
</sup> Studies have consistently shown that patients with AD exhibit significantly reduced olfactory identification and discrimination abilities compared to healthy controls, and that these impairments often precede the onset of cognitive symptoms.<sup>
<xref rid="bibr21-15333175251385615" ref-type="bibr">21</xref>
</sup></p><p>The pathological hallmarks of AD include &#946;-amyloid (A&#946;) plaques and neurofibrillary tangles (NFTs), composed respectively of A&#946; protein (derived from amyloid precursor protein, APP) and hyperphosphorylated tau protein.<sup>
<xref rid="bibr79-15333175251385615" ref-type="bibr">79</xref>
</sup> These features serve as diagnostic criteria for AD.<sup>
<xref rid="bibr80-15333175251385615" ref-type="bibr">80</xref>
</sup> The olfactory bulb is among the earliest regions to accumulate A&#946; deposits, and the spatial-temporal pattern of this deposition is closely linked to olfactory dysfunction.<sup>
<xref rid="bibr81-15333175251385615" ref-type="bibr">81</xref>
</sup> In the aged Tg2576&#160;mouse model, A&#946;-induced apoptosis, neurotransmitter imbalances, and neuroinflammation have also been observed.<sup>
<xref rid="bibr82-15333175251385615" ref-type="bibr">82</xref>
</sup></p><p>Biopsy studies of the olfactory epithelium in AD patients have revealed a strong association between elevated A&#946; levels and olfactory dysfunction.<sup>
<xref rid="bibr83-15333175251385615" ref-type="bibr">83</xref>
</sup> Longitudinal studies tracking the progression from mild cognitive impairment (MCI) to AD have demonstrated strong correlations between olfactory decline and changes in adjacent brain regions, such as the hippocampus and the olfactory cortex.<sup><xref rid="bibr80-15333175251385615" ref-type="bibr">80</xref>,<xref rid="bibr84-15333175251385615" ref-type="bibr">84</xref>,<xref rid="bibr85-15333175251385615" ref-type="bibr">85</xref></sup> Numerous clinical, case-control, and cross-sectional studies have consistently found that olfactory loss is significantly associated with cognitive decline and progression to MCI or AD dementia.<sup>
<xref rid="bibr50-15333175251385615" ref-type="bibr">50</xref>
</sup> These findings support the potential of olfactory impairment as an early biomarker of AD-related amnestic MCI.</p><p>Olfactory function tests typically evaluate three domains: odor identification, odor threshold, and odor discrimination. Of these, odor identification has shown the strongest correlation with cognitive decline and progression to AD dementia.<sup>
<xref rid="bibr49-15333175251385615" ref-type="bibr">49</xref>
</sup> Importantly, olfactory testing can help differentiate between AD and other neurodegenerative disorders, such as Parkinson&#8217;s disease (PD) and dementia with Lewy bodies (DLB). For instance, patients with AD show greater impairment in odor discrimination tasks, whereas PD patients perform worse on odor threshold tests.<sup><xref rid="bibr16-15333175251385615" ref-type="bibr">16</xref>,<xref rid="bibr53-15333175251385615" ref-type="bibr">53</xref></sup> This suggests that PD affects lower-level perceptual processes, while AD impairs higher-order olfactory functions requiring cognitive integration.<sup>
<xref rid="bibr80-15333175251385615" ref-type="bibr">80</xref>
</sup> Recent studies have also compared resting-state olfactory network connectivity in PD and AD. Findings indicate reduced connectivity between the olfactory bulb and striatal-thalamic-frontal regions in PD relative to AD, as well as reduced orbitofrontal connectivity in striatal-frontal circuits.<sup>
<xref rid="bibr86-15333175251385615" ref-type="bibr">86</xref>
</sup> Moreover, olfactory tests have proven effective in distinguishing AD from other conditions such as Lewy body disease (LBD), depression, and vascular dementia (VaD), although they are less effective in differentiating frontotemporal dementia (FTD) (see <xref rid="fig3-15333175251385615" ref-type="fig">Figure 3</xref>).<sup>
<xref rid="bibr87-15333175251385615" ref-type="bibr">87</xref>
</sup><fig position="float" fig-type="figure" id="fig3-15333175251385615" orientation="portrait"><label>Figure 3.</label><caption><p>Pathomechanisms of Olfactory Impairment in Neurodegenerative Diseases (Abbreviation: OFC, Orbitofrontal Cortex; ST, Corpus Striatum; Thal, Thalamus; Hipp, Hippocampus; Ento, Entorhinal Cortex)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_15333175251385615-fig3.jpg"/></fig></p><p>Collectively, these findings not only offer strong theoretical support for clinical practice but also open new avenues for research. In summary, the role of olfaction in neurodegenerative disease extends beyond traditional sensory perception; it provides valuable insights for early screening and serves as a promising direction for future investigations.</p></sec><sec id="sec10-15333175251385615"><title>Olfactory Detection Tools and Their Application in Mild Cognitive Impairment (MCI)</title><p>Olfactory function tests are generally categorized into two types: objective examinations and psychophysical assessments. Objective methods, such as electrophysiological measurements and brain imaging techniques, offer high accuracy but are unsuitable for routine clinical screening due to their cost and complexity.<sup>
<xref rid="bibr88-15333175251385615" ref-type="bibr">88</xref>
</sup> In contrast, psychophysical tests are widely used in clinical research because they are easy to administer and cost-effective. These tests typically assess three domains: odor identification, odor discrimination, and odor detection threshold, each of which has varying degrees of correlation with cognitive function.<sup><xref rid="bibr88-15333175251385615" ref-type="bibr">88</xref>,<xref rid="bibr89-15333175251385615" ref-type="bibr">89</xref></sup></p><sec id="sec11-15333175251385615"><title>University of Pennsylvania Smell Identification Test (UPSIT)</title><p>The University of Pennsylvania Smell Identification Test (UPSIT), developed in the 1980s, is a standardized tool used to assess suprathreshold odor identification ability.<sup><xref rid="bibr88-15333175251385615" ref-type="bibr">88</xref>,<xref rid="bibr90-15333175251385615" ref-type="bibr">90</xref></sup> UPSIT contains 40 odorant capsules distributed across four test booklets, each with 10 items. Participants scratch the capsule to release the odor and choose the correct option from four multiple-choice responses.<sup><xref rid="bibr91-15333175251385615" ref-type="bibr">91</xref>,<xref rid="bibr92-15333175251385615" ref-type="bibr">92</xref></sup> The test provides a quantitative assessment of olfactory function and can also be used as a self-assessment tool.<sup>
<xref rid="bibr93-15333175251385615" ref-type="bibr">93</xref>
</sup> Results are categorized into five levels: normal, mild, moderate, and severe impairment, and anosmia (complete loss of smell).<sup>
<xref rid="bibr94-15333175251385615" ref-type="bibr">94</xref>
</sup></p><p>Studies have shown that patients with MCI generally score lower on UPSIT compared to healthy individuals. For instance, Nogi et al. (2021) found that older adults with MCI exhibited significant deficits in odor identification.<sup>
<xref rid="bibr95-15333175251385615" ref-type="bibr">95</xref>
</sup> Additionally, longitudinal studies have demonstrated that lower UPSIT scores in MCI patients are predictive of progression to Alzheimer&#8217;s disease or other dementias.<sup>
<xref rid="bibr18-15333175251385615" ref-type="bibr">18</xref>
</sup> In a large multi-center sample, UPSIT scores &#8804;34 predicted conversion from CN to AD dementia within 5 years with 90 % sensitivity and 50 % specificity.<sup>
<xref rid="bibr96-15333175251385615" ref-type="bibr">96</xref>
</sup> Meta-analytic data confirm an overall sensitivity of 0.79 and specificity of 0.78 for CN vs AD when UPSIT is used.<sup>
<xref rid="bibr97-15333175251385615" ref-type="bibr">97</xref>
</sup> Longitudinal tau-PET work further shows that poorer baseline UPSIT scores predict greater tau accumulation in entorhinal and olfactory regions over &#8764;2.5 years in CN elders,<sup>
<xref rid="bibr98-15333175251385615" ref-type="bibr">98</xref>
</sup> supporting UPSIT as an early indicator of AD-related change.</p><p>Despite its high sensitivity and specificity, the UPSIT is time-consuming and complex to administer, making it more suitable for research rather than routine clinical screening.<sup>
<xref rid="bibr99-15333175251385615" ref-type="bibr">99</xref>
</sup> To address this limitation, a simplified version&#8212;the Cross-Cultural Smell Identification Test (CC-SIT)&#8212;was developed. This version features a shorter test time and easier administration, and is now widely used in preliminary screenings for olfactory disorders.<sup>
<xref rid="bibr100-15333175251385615" ref-type="bibr">100</xref>
</sup></p></sec><sec id="sec12-15333175251385615"><title>T&amp;T Olfactometer Test</title><p>The T&amp;T Olfactometer Test is designed to measure odor detection thresholds by determining the lowest concentration of specific odorants that a subject can perceive. The test uses five odorants&#8212;phenylethanol, methylcyclopentane, isovaleric acid, undecanolactone, and methylindole&#8212;chosen for their diverse chemical properties and odor profiles, The average recognition score across all five substances is used to assess olfactory function.<sup>
<xref rid="bibr101-15333175251385615" ref-type="bibr">101</xref>
</sup></p><p>The procedure involves placing an odorless filter paper dipped in the odorant approximately 1&#160;cm below the subject&#8217;s nostrils. Participants sniff each sample repeatedly to identify the lowest detectable concentration. Based on their performance, results are categorized into five levels: normal, mild hyposmia, moderate hyposmia, severe hyposmia, and anosmia.<sup>
<xref rid="bibr102-15333175251385615" ref-type="bibr">102</xref>
</sup></p><p>The T&amp;T Olfactometer Test has shown promise in identifying early olfactory changes associated with Alzheimer&#8217;s disease (AD), as it sensitively measures threshold impairments often present in the prodromal phase.<sup><xref rid="bibr103-15333175251385615" ref-type="bibr">103</xref>-<xref rid="bibr105-15333175251385615" ref-type="bibr">105</xref></sup> These olfactory deficits are closely associated with AD-related neuropathologies, such as hippocampal and cortical atrophy.<sup>
<xref rid="bibr105-15333175251385615" ref-type="bibr">105</xref>
</sup> Therefore, the test may serve as a supplementary screening tool for individuals at risk before cognitive symptoms appear, although its diagnostic accuracy for early-stage AD remains to be prospectively validated.<sup><xref rid="bibr103-15333175251385615" ref-type="bibr">103</xref>-<xref rid="bibr105-15333175251385615" ref-type="bibr">105</xref></sup></p></sec><sec id="sec13-15333175251385615"><title>Sniffin&#8217; Sticks Test</title><p>The Sniffin&#8217; Sticks Test (SS-16), developed by Hummel and Kobal, is a widely used tool for assessing olfactory function,<sup>
<xref rid="bibr106-15333175251385615" ref-type="bibr">106</xref>
</sup> The test involves presenting an odorized pen approximately 2&#160;cm in front of the participant&#8217;s nose for 3 seconds.<sup>
<xref rid="bibr107-15333175251385615" ref-type="bibr">107</xref>
</sup> Participants then choose the correct odor from four options, with a 30-second interval between trials.<sup><xref rid="bibr108-15333175251385615" ref-type="bibr">108</xref>,<xref rid="bibr109-15333175251385615" ref-type="bibr">109</xref></sup> One point is awarded for each correct answer, with a maximum score of 16; higher scores indicate better olfactory function.<sup>
<xref rid="bibr52-15333175251385615" ref-type="bibr">52</xref>
</sup></p><p>The application of the Sniffin&#8217; Sticks Test in the screening of Alzheimer&#8217;s disease (AD) has produced significant results, particularly in identifying olfactory recognition deficits commonly observed in patients with AD. As a result, the Sniffin&#8217; Sticks Test has become a reliable early screening tool for detecting changes in olfactory function.<sup>
<xref rid="bibr13-15333175251385615" ref-type="bibr">13</xref>
</sup> Studies have shown that individuals with AD, especially in the early stages of the disease, typically perform poorly on this test, with significantly lower olfactory scores compared to healthy controls.<sup><xref rid="bibr45-15333175251385615" ref-type="bibr">45</xref>,<xref rid="bibr110-15333175251385615" ref-type="bibr">110</xref></sup></p><p>Beyond its use in AD, the Sniffin&#8217; Sticks Test has demonstrated substantial clinical value in screening for mild cognitive impairment (MCI). Patients with MCI often exhibit varying degrees of olfactory dysfunction, and their test scores are consistently lower than those of cognitively healthy individuals.<sup>
<xref rid="bibr45-15333175251385615" ref-type="bibr">45</xref>
</sup> Several studies have confirmed that these deficits are particularly noticeable during the early stages of MCI-related cognitive decline.<sup>
<xref rid="bibr56-15333175251385615" ref-type="bibr">56</xref>
</sup> Across 11 studies using the 16-item identification subtest (SS-16), pooled sensitivity for separating CN from MCI was 0.67, specificity 0.79 and AUC 0.81. When SS-16 was combined with Cognitive Scale, the AUC rose to 0.96.<sup>
<xref rid="bibr97-15333175251385615" ref-type="bibr">97</xref>
</sup> indicating that SS-16 can serve as an effective, low-cost tool for early detection of both AD and MCI. Therefore, the Sniffin&#8217; Sticks Test serves not only as an effective tool for early AD screening but also as a valuable adjunct in identifying early cognitive impairment in individuals at risk of MCI.</p><p>However, cultural differences can influence the validity of the Sniffin&#8217; Sticks Test. Certain odor descriptors may not evoke the same recognition or perception across different cultural contexts.<sup>
<xref rid="bibr89-15333175251385615" ref-type="bibr">89</xref>
</sup> To improve both accuracy and cultural relevance, researchers have adapted the test content to reflect local cultural settings. For example, in a Chinese adaptation, some odors such as &#8220; pine &#8221; and &#8220; grapefruit &#8221; were replaced with more culturally familiar scents like &#8220; wood &#8221; and &#8220; grapefruit &#8221;,<sup>
<xref rid="bibr111-15333175251385615" ref-type="bibr">111</xref>
</sup> enhancing the test&#8217; s applicability and validity.</p><p>In conclusion, the Sniffin&#8217; Sticks Test is a simple, effective, and clinically valuable tool for assessing olfactory function. It plays a crucial role in the early screening of Alzheimer&#8217;s disease and serves as a useful screening method for mild cognitive impairment. As cultural adaptations and standardization efforts continue to advance, the global applicability of the Sniffin&#8217; Sticks Test is expected to expand.</p></sec><sec id="sec14-15333175251385615"><title>Odor Recognition Testing for Chinese Populations: Characteristics and Applicability</title><p>Given cultural variability in odor perception, researchers in China have developed olfactory identification tools specifically tailored to the local population.<sup>
<xref rid="bibr112-15333175251385615" ref-type="bibr">112</xref>
</sup> The China Specific Odor Identification Test (CSIT), introduced by the Institute of Psychology at the Chinese Academy of Sciences in 2019, was designed to align with the cultural context of Chinese individuals.<sup>
<xref rid="bibr112-15333175251385615" ref-type="bibr">112</xref>
</sup> The CSIT consists of either 16 or 40 odor sticks, each containing 1&#160;mL of liquid odorant derived from everyday items commonly encountered in Chinese life.<sup>
<xref rid="bibr112-15333175251385615" ref-type="bibr">112</xref>
</sup></p><p>During testing, the tip of the odor stick is held approximately 2&#160;cm in front of the subject&#8217;s nostrils for 2-3 seconds. Participants may sniff multiple times until the odor is clearly perceived, then select one of four similar options.<sup>
<xref rid="bibr113-15333175251385615" ref-type="bibr">113</xref>
</sup> The entire test typically takes 5-10 minutes, after which a CSIT score is calculated based on recognition performance.<sup>
<xref rid="bibr113-15333175251385615" ref-type="bibr">113</xref>
</sup> Final scores are categorized into five levels of olfactory function&#8212;normal, mild impairment, moderate impairment, severe impairment, and anosmia&#8212;using a regression algorithm adjusted for age and gender via specialized software.<sup>
<xref rid="bibr113-15333175251385615" ref-type="bibr">113</xref>
</sup> Normal function corresponds to a CSIT score of 14-16, mild impairment to 11-13, moderate impairment to 9-11, severe impairment to 7-9, and anosmia to &#8804;6.<sup>
<xref rid="bibr113-15333175251385615" ref-type="bibr">113</xref>
</sup> The reliability of the CSIT has been validated in several studies, particularly its high test&#8211;retest reliability (up to 0.92). It has also been cross-validated with the University of Pennsylvania Smell Identification Test (UPSIT) and the Sniffin&#8217; Sticks Test (SS-16).<sup>
<xref rid="bibr112-15333175251385615" ref-type="bibr">112</xref>
</sup> In terms of recognition accuracy, Chinese participants scored approximately 15% higher on the CSIT than on the UPSIT or SS-16, further supporting its cultural appropriateness and clinical utility.<sup>
<xref rid="bibr112-15333175251385615" ref-type="bibr">112</xref>
</sup> Thus, the CSIT provides a valid and reliable tool for assessing olfactory function in Chinese populations.</p><p>Because the CSIT was developed with close attention to cultural and individual differences, it not only offers an effective tool for olfactory assessment in China but also highlights the importance of cultural considerations in the development of diagnostic instruments. This localized approach ensures greater linguistic and contextual relevance, thereby improving the generalizability and accuracy of olfactory testing in culturally distinct populations.</p></sec><sec id="sec15-15333175251385615"><title>AROMHA Brain Health Test</title><p>This localized approach ensures greater linguistic and contextual relevance, thereby improving the generalizability and accuracy of olfactory testing in culturally distinct populations.</p><p>In addition to these conventional and culturally adapted tools, recent years have seen the emergence of innovative digital approaches aimed at enhancing accessibility, scalability, and cross-cultural applicability. One notable example is the AROMHA Brain Health Test (ABHT), a recently developed digital olfactory assessment tool specifically designed for cognitive screening, with particular emphasis on remote and large-scale applications.<sup>
<xref rid="bibr114-15333175251385615" ref-type="bibr">114</xref>
</sup></p><p>The test consists of a series of bilingual (English and Spanish) odor cards mailed to participants and a web-based interface that guides them through three psychophysical subtests: odor percept identification (OPID), percepts of odor episodic memory (POEM), and odor discrimination (OD). Participants also rate odor intensity and self-evaluate their confidence in identification, allowing metacognitive assessment.<sup>
<xref rid="bibr114-15333175251385615" ref-type="bibr">114</xref>
</sup></p><p>In a recent validation study, ABHT successfully distinguished individuals with mild cognitive impairment (MCI) from those with subjective cognitive complaints (SCC) and cognitively normal (CN) participants, even in unobserved home-based settings. The test demonstrated high feasibility among older adults&#8212;including participants over 90 years old&#8212;and was shown to be linguistically and culturally adaptable. Performance outcomes were consistent across languages and administration modes.<sup>
<xref rid="bibr114-15333175251385615" ref-type="bibr">114</xref>
</sup></p><p>Compared to traditional tools, the ABHT offers several advantages: it requires no professional supervision, supports remote administration, and integrates both behavioral and metacognitive measures. Its practicality and scalability position it as a promising direction for the future of global olfactory screening, especially in aging populations and resource-limited settings (see <xref rid="fig4-15333175251385615" ref-type="fig">Figure 4</xref>).<fig position="float" fig-type="figure" id="fig4-15333175251385615" orientation="portrait"><label>Figure 4.</label><caption><p>Application of Olfactory Tools.<sup><xref rid="bibr114-15333175251385615" ref-type="bibr">114</xref>,<xref rid="bibr115-15333175251385615" ref-type="bibr">115</xref></sup> ((A), University of Pennsylvania Smell Identification Test (UPSIT); (B), T&amp;T Olfactometer Test; (C), Sniffin&#8217; Sticks Test; (D), Odor Recognition Testing for Chinese Populations;(E), AROMHA Brain Health Test)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_15333175251385615-fig4.jpg"/></fig></p></sec></sec></sec><sec id="sec16-15333175251385615"><title>Summary and Future Prospects</title><p>Olfactory testing demonstrates considerable potential as a tool for the early screening of Alzheimer&#8217;s disease (AD). Its non-invasive nature, convenience, and independence from educational level offer distinct advantages for early screening. Furthermore, its low cost makes it particularly valuable in resource-limited settings. However, existing studies have highlighted challenges in cross-cultural applicability, underscoring the need for appropriate adaptation and optimization of olfactory tests in diverse cultural contexts. Future research should therefore prioritize improving both the accuracy and cultural adaptability of these assessments and aim to develop culturally specific olfactory testing tools to enhance global applicability.</p><p>Additionally, future studies could explore multimodal diagnostic strategies that integrate olfactory testing with other non-invasive methods&#8212;such as cognitive assessments and eye-tracking technologies&#8212;to provide a more comprehensive diagnostic perspective. Advances in neuroimaging, molecular biology, and artificial intelligence are also expected to enhance the sensitivity and precision of olfactory testing, further expanding its value in clinical settings.</p><p>Notably, olfactory impairment may serve as a significant early biomarker of AD. Regular monitoring of olfactory function could help identify high-risk individuals and enable timely preventive interventions. For patients with mild cognitive impairment (MCI), olfactory testing may assist clinicians in tracking disease progression and optimizing treatment strategies. Future research should also investigate interventions targeting olfactory dysfunction, including olfactory training and lifestyle modifications, which may delay or prevent cognitive decline and offer novel avenues for early intervention in AD.</p><p>In light of recent advancements, remote olfactory testing platforms have shown strong potential for large-scale, at-home cognitive screening. The AROMHA Brain Health Test (ABHT), introduced earlier in this review, exemplifies how bilingual, self-administered odor assessments can be feasibly conducted and validated across languages. Its demonstrated cultural adaptability and ability to distinguish between cognitive states highlight the promise of digital tools for early detection, particularly in underserved or remote populations.<sup>
<xref rid="bibr114-15333175251385615" ref-type="bibr">114</xref>
</sup></p><p>In conclusion, olfactory testing represents a promising approach for early AD screening, with broad applications in technological innovation, standardization of testing procedures, and interdisciplinary collaboration. Continued basic and clinical research will be essential for developing more effective diagnostic tools and ultimately improving patient outcomes and quality of life. (see <xref rid="fig5-15333175251385615" ref-type="fig">Figure 5</xref>).<fig position="float" fig-type="figure" id="fig5-15333175251385615" orientation="portrait"><label>Figure 5.</label><caption><p>Bidirectional Relationship Between Olfactory Dysfunction and Alzheimer&#8217;s Disease and Mechanistic Hypotheses</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_15333175251385615-fig5.jpg"/></fig></p></sec></body><back><ack><title>Acknowledgments</title><p>The authors thank Zi-Xi Tian for the assistance with figure preparation.</p></ack><fn-group><fn fn-type="presented-by"><p><bold>Author Contributions:</bold> 1. PDCogniCare Research project: A. Conception, B. Organization, C. Execution; 2. Systematic review: A. Search / screen, B. Data extraction, C. Quality assessment; 3. Manuscript Preparation: A. Writing of the first draft, B. Review and Critique. FYZ: 1B, 1C, 2A, 2B, 2C, 3A; JAX: 2A, 3A; JK: 3B; ZQT: 1A, 1B, 3B. Feiyan Zhou: Data curation, Formal analysis, Investigation, Methodology, Visualization, Writing &#8211; original draft, Writing &#8211; review &amp; editing. Jinan Xu: Writing &#8211; review &amp; editing. Ke Jiang: Formal analysis, Writing &#8211; review &amp; editing. Zhiqian Tong: Conceptualization, Project administration, Supervision, Writing &#8211; review &amp; editing.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Major Program of the National Natural Science Foundation of China (62394314), and the National Natural Science Foundation of China (82071214).</p></fn><fn fn-type="COI-statement"><p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p></fn></fn-group><sec sec-type="orcid" id="sec17-15333175251385615"><title>ORCID iDs</title><p>Feiyan Zhou <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0009-0003-8921-1102" ext-link-type="uri">https://orcid.org/0009-0003-8921-1102</ext-link></p><p>Zhiqian Tong <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0002-0511-0386" ext-link-type="uri">https://orcid.org/0000-0002-0511-0386</ext-link></p></sec><sec sec-type="ethics-approval" id="sec18-15333175251385615"><title>Ethical Considerations</title><p>This study was approved by the Ethics Committee of Wenzhou Medical University (2022-071).</p></sec><sec sec-type="data-availability" id="sec22-15333175251385615"><title>Data Availability Statement</title><p>The data used to support the findings of this study are included within the article.<xref rid="corresp1-15333175251385615" ref-type="corresp">*</xref><xref rid="corresp2-15333175251385615" ref-type="corresp">*</xref></p></sec><sec sec-type="trial" id="sec23-15333175251385615"><title>Declaration of Generative AI in Scientific Writing</title><p>No use of generative AI in scientific writing upon submission of the paper.</p></sec><ref-list><title>References</title><ref id="bibr1-15333175251385615"><label>1</label><mixed-citation publication-type="journal"><article-title>2023 Alzheimer&#8217;s disease facts and figures</article-title>. <source>Alzheimer&#8217;s Dement</source>. <year>2023</year>;<volume>19</volume>(<issue>4</issue>):<fpage>1598</fpage>-<lpage>1695</lpage>.<pub-id pub-id-type="pmid">36918389</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13016</pub-id></mixed-citation></ref><ref id="bibr2-15333175251385615"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Audronyte</surname><given-names>E</given-names></name><name name-style="western"><surname>Pakulaite-Kazliene</surname><given-names>G</given-names></name><name name-style="western"><surname>Sutnikiene</surname><given-names>V</given-names></name><name name-style="western"><surname>Kaubrys</surname><given-names>G</given-names></name></person-group>. <article-title>Properties of odor identification testing in screening for early-stage Alzheimer&#8217;s disease</article-title>. <source>Sci Rep</source>. <year>2023</year>;<volume>13</volume>(<issue>1</issue>):<fpage>6075</fpage>.<pub-id pub-id-type="pmid">37055436</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-023-32878-w</pub-id><pub-id pub-id-type="pmcid">PMC10102162</pub-id></mixed-citation></ref><ref id="bibr3-15333175251385615"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vogel</surname><given-names>JW</given-names></name><name name-style="western"><surname>Hansson</surname><given-names>O</given-names></name></person-group>. <article-title>Subtypes of Alzheimer's disease: questions, controversy, and meaning</article-title>. <source>Trends Neurosci</source>. <year>2022</year>;<volume>45</volume>(<issue>5</issue>):<fpage>342</fpage>-<lpage>345</lpage>.<pub-id pub-id-type="pmid">35227519</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tins.2022.02.001</pub-id><pub-id pub-id-type="pmcid">PMC11108088</pub-id></mixed-citation></ref><ref id="bibr4-15333175251385615"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>CR</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Andrews</surname><given-names>JS</given-names></name><name name-style="western"><surname>Beach</surname><given-names>TG</given-names></name></person-group>, <etal>et al.</etal><article-title>Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup</article-title>. <source>Alzheimer's Dement</source>. <year>2024</year>;<volume>20</volume>(<issue>8</issue>):<fpage>5143</fpage>-<lpage>5169</lpage>.<pub-id pub-id-type="pmid">38934362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13859</pub-id><pub-id pub-id-type="pmcid">PMC11350039</pub-id></mixed-citation></ref><ref id="bibr5-15333175251385615"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shin</surname><given-names>JH</given-names></name></person-group>. <article-title>Dementia epidemiology fact sheet 2022</article-title>. <source>Ann Rehabil Med</source>. <year>2022</year>;<volume>46</volume>(<issue>2</issue>):<fpage>53</fpage>-<lpage>59</lpage>.<pub-id pub-id-type="pmid">35508924</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5535/arm.22027</pub-id><pub-id pub-id-type="pmcid">PMC9081392</pub-id></mixed-citation></ref><ref id="bibr6-15333175251385615"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rasmussen</surname><given-names>J</given-names></name><name name-style="western"><surname>Langerman</surname><given-names>H</given-names></name></person-group>. <article-title>Alzheimer&#8217;s disease - why we need early diagnosis</article-title>. <source>Degener Neurol Neuromuscul Dis</source>. <year>2019</year>;<volume>9</volume>:<fpage>123</fpage>-<lpage>130</lpage>.<pub-id pub-id-type="pmid">31920420</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/DNND.S228939</pub-id><pub-id pub-id-type="pmcid">PMC6935598</pub-id></mixed-citation></ref><ref id="bibr7-15333175251385615"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Dyck</surname><given-names>CH</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P</given-names></name></person-group>, <etal>et al.</etal><article-title>Lecanemab in early Alzheimer's disease</article-title>. <source>N Engl J Med</source>. <year>2023</year>;<volume>388</volume>(<issue>1</issue>):<fpage>9</fpage>-<lpage>21</lpage>.<pub-id pub-id-type="pmid">36449413</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2212948</pub-id></mixed-citation></ref><ref id="bibr8-15333175251385615"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sims</surname><given-names>JR</given-names></name><name name-style="western"><surname>Zimmer</surname><given-names>JA</given-names></name><name name-style="western"><surname>Evans</surname><given-names>CD</given-names></name></person-group>, <etal>et al.</etal><article-title>Donanemab in early symptomatic alzheimer disease</article-title>. <source>JAMA</source>. <year>2023</year>;<volume>330</volume>(<issue>6</issue>):<fpage>512</fpage>-<lpage>527</lpage>.<pub-id pub-id-type="pmid">37459141</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2023.13239</pub-id><pub-id pub-id-type="pmcid">PMC10352931</pub-id></mixed-citation></ref><ref id="bibr9-15333175251385615"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shinkawa</surname><given-names>K</given-names></name><name name-style="western"><surname>Kosugi</surname><given-names>A</given-names></name><name name-style="western"><surname>Nishimura</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Multimodal behavior analysis towards detecting mild cognitive impairment: preliminary results on gait and speech</article-title>. <source>Stud Health Technol Inf</source>. <year>2019</year>;<volume>264</volume>:<fpage>343</fpage>-<lpage>347</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/SHTI190240</pub-id><pub-id pub-id-type="pmid">31437942</pub-id></mixed-citation></ref><ref id="bibr10-15333175251385615"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Otaibi</surname><given-names>M</given-names></name><name name-style="western"><surname>Lessard-Beaudoin</surname><given-names>M</given-names></name><name name-style="western"><surname>Castellano</surname><given-names>CA</given-names></name><name name-style="western"><surname>Gris</surname><given-names>D</given-names></name><name name-style="western"><surname>Cunnane</surname><given-names>SC</given-names></name><name name-style="western"><surname>Graham</surname><given-names>RK</given-names></name></person-group>. <article-title>Volumetric MRI demonstrates atrophy of the olfactory cortex in AD</article-title>. <source>Curr Alzheimer Res</source>. <year>2020</year>;<volume>17</volume>(<issue>10</issue>):<fpage>904</fpage>-<lpage>915</lpage>.<pub-id pub-id-type="pmid">33327913</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1567205017666201215120909</pub-id></mixed-citation></ref><ref id="bibr11-15333175251385615"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>W</given-names></name><name name-style="western"><surname>Tan</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>HF</given-names></name></person-group>, <etal>et al.</etal><article-title>Meta-analysis of modifiable risk factors for Alzheimer&#8217;s disease</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>2015</year>;<volume>86</volume>(<issue>12</issue>):<fpage>1299</fpage>-<lpage>1306</lpage>.<pub-id pub-id-type="pmid">26294005</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp-2015-310548</pub-id></mixed-citation></ref><ref id="bibr12-15333175251385615"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jobin</surname><given-names>B</given-names></name><name name-style="western"><surname>Zigrand</surname><given-names>C</given-names></name><name name-style="western"><surname>Frasnelli</surname><given-names>J</given-names></name><name name-style="western"><surname>Boller</surname><given-names>B</given-names></name><name name-style="western"><surname>Albers</surname><given-names>MW</given-names></name></person-group>. <article-title>Lower odor identification in subjective cognitive decline: a meta-analysis</article-title>. <source>medRxiv</source>. <year>2025</year>;<volume>15</volume>:<fpage>25325887</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dad2.70168</pub-id><pub-id pub-id-type="pmcid">PMC12358221</pub-id><pub-id pub-id-type="pmid">40827140</pub-id></mixed-citation></ref><ref id="bibr13-15333175251385615"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jobin</surname><given-names>B</given-names></name><name name-style="western"><surname>Zahal</surname><given-names>R</given-names></name><name name-style="western"><surname>Bussieres</surname><given-names>EL</given-names></name><name name-style="western"><surname>Frasnelli</surname><given-names>J</given-names></name><name name-style="western"><surname>Boller</surname><given-names>B</given-names></name></person-group>. <article-title>Olfactory identification in subjective cognitive decline: a meta-analysis</article-title>. <source>J Alzheimers Dis</source>. <year>2021</year>;<volume>79</volume>(<issue>4</issue>):<fpage>1497</fpage>-<lpage>1507</lpage>.<pub-id pub-id-type="pmid">33459721</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-201022</pub-id></mixed-citation></ref><ref id="bibr14-15333175251385615"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yunyun Ma</surname><given-names>YS</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name></person-group><article-title>Predictive value of sensory dysfunction in early recognition and treatment of cognitive dysfunction: a review</article-title>. <source>Chinese General Practice</source>. <year>2022</year>;<volume>25</volume>(<issue>23</issue>):<fpage>2899</fpage>-<lpage>2902</lpage>.</mixed-citation></ref><ref id="bibr15-15333175251385615"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jung</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Shin</surname><given-names>IS</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JE</given-names></name></person-group>. <article-title>Olfactory function in mild cognitive impairment and Alzheimer's disease: a meta-analysis</article-title>. <source>Laryngoscope</source>. <year>2019</year>;<volume>129</volume>(<issue>2</issue>):<fpage>362</fpage>-<lpage>369</lpage>.<pub-id pub-id-type="pmid">30565695</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/lary.27399</pub-id></mixed-citation></ref><ref id="bibr16-15333175251385615"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahayel</surname><given-names>S</given-names></name><name name-style="western"><surname>Frasnelli</surname><given-names>J</given-names></name><name name-style="western"><surname>Joubert</surname><given-names>S</given-names></name></person-group>. <article-title>The effect of Alzheimer's disease and Parkinson's disease on olfaction: a meta-analysis</article-title>. <source>Behav Brain Res</source>. <year>2012</year>;<volume>231</volume>(<issue>1</issue>):<fpage>60</fpage>-<lpage>74</lpage>.<pub-id pub-id-type="pmid">22414849</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbr.2012.02.047</pub-id></mixed-citation></ref><ref id="bibr17-15333175251385615"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murphy</surname><given-names>C</given-names></name></person-group>. <article-title>Olfactory functional testing: sensitivity and specificity for Alzheimer's disease</article-title>. <source>Drug Dev Res</source>. <year>2002</year>;<volume>56</volume>(<issue>2</issue>):<fpage>123</fpage>-<lpage>131</lpage>.</mixed-citation></ref><ref id="bibr18-15333175251385615"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Devanand</surname><given-names>DLS</given-names></name><name name-style="western"><surname>Manly</surname><given-names>J</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>H</given-names></name></person-group>, <etal>et al.</etal><article-title>Olfactory deficits predict cognitive decline and Alzheimer dementia in an urban community</article-title>. <source>Neurology</source>. <year>2014</year>;<volume>84</volume>(<issue>2</issue>):<fpage>182</fpage>-<lpage>189</lpage>.<pub-id pub-id-type="pmid">25471394</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000001132</pub-id><pub-id pub-id-type="pmcid">PMC4336090</pub-id></mixed-citation></ref><ref id="bibr19-15333175251385615"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wheeler</surname><given-names>PL</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>C</given-names></name></person-group>. <article-title>Olfactory measures as predictors of conversion to mild cognitive impairment and Alzheimer&#8217;s disease</article-title>. <source>Brain Sci</source>. <year>2021</year>;<volume>11</volume>(<issue>11</issue>):<fpage>1391</fpage>.<pub-id pub-id-type="pmid">34827390</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/brainsci11111391</pub-id><pub-id pub-id-type="pmcid">PMC8615615</pub-id></mixed-citation></ref><ref id="bibr20-15333175251385615"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schubert</surname><given-names>CR</given-names></name><name name-style="western"><surname>Carmichael</surname><given-names>LL</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>C</given-names></name><name name-style="western"><surname>Klein</surname><given-names>BEK</given-names></name><name name-style="western"><surname>Klein</surname><given-names>R</given-names></name><name name-style="western"><surname>Cruickshanks</surname><given-names>KJ</given-names></name></person-group>. <article-title>Olfaction and the 5-year incidence of cognitive impairment in an epidemiological study of older adults</article-title>. <source>J Am Geriatr Soc</source>. <year>2008</year>;<volume>56</volume>(<issue>8</issue>):<fpage>1517</fpage>-<lpage>1521</lpage>.<pub-id pub-id-type="pmid">18662205</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1532-5415.2008.01826.x</pub-id><pub-id pub-id-type="pmcid">PMC2587240</pub-id></mixed-citation></ref><ref id="bibr21-15333175251385615"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murphy</surname><given-names>C</given-names></name></person-group>. <article-title>Olfactory and other sensory impairments in Alzheimer disease</article-title>. <source>Nat Rev Neurol</source>. <year>2019</year>;<volume>15</volume>(<issue>1</issue>):<fpage>11</fpage>-<lpage>24</lpage>.<pub-id pub-id-type="pmid">30532084</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41582-018-0097-5</pub-id></mixed-citation></ref><ref id="bibr22-15333175251385615"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menelaou</surname><given-names>G</given-names></name><name name-style="western"><surname>Persson</surname><given-names>J</given-names></name><name name-style="western"><surname>Olofsson</surname><given-names>JK</given-names></name></person-group>. <article-title>Hippocampal subfield volumes and olfactory performance: emerging longitudinal associations over a 5-year interval</article-title>. <source>Neuropsychologia</source>. <year>2022</year>;<volume>176</volume>:<fpage>108353</fpage>.<pub-id pub-id-type="pmid">36210600</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuropsychologia.2022.108353</pub-id></mixed-citation></ref><ref id="bibr23-15333175251385615"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jobin</surname><given-names>B</given-names></name><name name-style="western"><surname>Boller</surname><given-names>B</given-names></name><name name-style="western"><surname>Frasnelli</surname><given-names>J</given-names></name><name name-style="western"><surname>Group</surname><given-names>C-Q</given-names></name></person-group>. <article-title>Smaller grey matter volume in the central olfactory system in mild cognitive impairment</article-title>. <source>Exp Gerontol</source>. <year>2023</year>;<volume>183</volume>:<fpage>112325</fpage>.<pub-id pub-id-type="pmid">37952649</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.exger.2023.112325</pub-id></mixed-citation></ref><ref id="bibr24-15333175251385615"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pennanen</surname><given-names>C</given-names></name><name name-style="western"><surname>Kivipelto</surname><given-names>M</given-names></name><name name-style="western"><surname>Tuomainen</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal><article-title>Hippocampus and entorhinal cortex in mild cognitive impairment and early AD</article-title>. <source>Neurobiol Aging</source>. <year>2004</year>;<volume>25</volume>(<issue>3</issue>):<fpage>303</fpage>-<lpage>310</lpage>.<pub-id pub-id-type="pmid">15123335</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0197-4580(03)00084-8</pub-id></mixed-citation></ref><ref id="bibr25-15333175251385615"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JE</given-names></name><name name-style="western"><surname>Lee</surname><given-names>KS</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JS</given-names></name></person-group>. <article-title>Comparison of odor identification among amnestic and non-amnestic mild cognitive impairment, subjective cognitive decline, and early Alzheimer's dementia</article-title>. <source>Neurol Sci</source>. <year>2018</year>;<volume>39</volume>(<issue>3</issue>):<fpage>557</fpage>-<lpage>564</lpage>.<pub-id pub-id-type="pmid">29383614</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10072-018-3261-1</pub-id></mixed-citation></ref><ref id="bibr26-15333175251385615"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Challakere Ramaswamy</surname><given-names>VM</given-names></name><name name-style="western"><surname>Schofield</surname><given-names>PW</given-names></name></person-group>. <article-title>Olfaction and executive cognitive performance: a systematic review</article-title>. <source>Front Psychol</source>. <year>2022</year>;<volume>13</volume>:<fpage>871391</fpage>.<pub-id pub-id-type="pmid">35615205</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpsyg.2022.871391</pub-id><pub-id pub-id-type="pmcid">PMC9125097</pub-id></mixed-citation></ref><ref id="bibr27-15333175251385615"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Devanand</surname><given-names>DP</given-names></name></person-group>. <article-title>Olfactory identification deficits, cognitive decline, and dementia in older adults</article-title>. <source>Am J Geriatr Psychiatr</source>. <year>2016</year>;<volume>24</volume>(<issue>12</issue>):<fpage>1151</fpage>-<lpage>1157</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jagp.2016.08.010</pub-id><pub-id pub-id-type="pmcid">PMC5136312</pub-id><pub-id pub-id-type="pmid">27745824</pub-id></mixed-citation></ref><ref id="bibr28-15333175251385615"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hummel</surname><given-names>TLB</given-names></name><name name-style="western"><surname>H&#252;ttenbrink</surname><given-names>K</given-names></name></person-group>. <article-title>Smell and taste disorders</article-title>. <source>GMS Curr Top Otorhinolaryngol Head Neck Surg</source>. <year>2011</year>;<volume>10</volume>:<fpage>1</fpage>-<lpage>15</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3205/cto000077</pub-id><pub-id pub-id-type="pmcid">PMC3341581</pub-id><pub-id pub-id-type="pmid">22558054</pub-id></mixed-citation></ref><ref id="bibr29-15333175251385615"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paul</surname><given-names>JM</given-names></name><name name-style="western"><surname>Agrin</surname><given-names>R</given-names></name><name name-style="western"><surname>Gur</surname><given-names>RE</given-names></name><name name-style="western"><surname>Gur</surname><given-names>RC</given-names></name><name name-style="western"><surname>Turetsky</surname><given-names>BI</given-names></name></person-group>. <article-title>Olfactory dysfunction in schizophrenia: a qualitative and quantitative review</article-title>. <source>Neuropsychopharmacology</source>. <year>1999</year>;<volume>21</volume>:<fpage>325</fpage>-<lpage>340</lpage>.<pub-id pub-id-type="pmid">10457530</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0893-133X(99)00019-6</pub-id></mixed-citation></ref><ref id="bibr30-15333175251385615"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Landis</surname><given-names>B</given-names></name><name name-style="western"><surname>Hummel</surname><given-names>T</given-names></name><name name-style="western"><surname>Js</surname><given-names>L</given-names></name></person-group>. <article-title>Basic and clinical aspects of olfaction</article-title>. <source>Adv Tech Stand Neurosurg</source>. <year>2005</year>;<volume>30</volume>:<fpage>69</fpage>-<lpage>105</lpage>.<pub-id pub-id-type="pmid">16350453</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/3-211-27208-9_3</pub-id></mixed-citation></ref><ref id="bibr31-15333175251385615"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>ZM</given-names></name><name name-style="western"><surname>Holbrook</surname><given-names>EH</given-names></name><name name-style="western"><surname>Turner</surname><given-names>JH</given-names></name></person-group>, <etal>et al.</etal><article-title>International consensus statement on allergy and rhinology: olfaction</article-title>. <source>Int Forum Allergy Rhinol</source>. <year>2022</year>;<volume>12</volume>(<issue>4</issue>):<fpage>327</fpage>-<lpage>680</lpage>.<pub-id pub-id-type="pmid">35373533</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alr.22929</pub-id><pub-id pub-id-type="pmcid">PMC12261282</pub-id></mixed-citation></ref><ref id="bibr32-15333175251385615"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jobin</surname><given-names>B</given-names></name><name name-style="western"><surname>Roy-C&#244;t&#233;</surname><given-names>F</given-names></name><name name-style="western"><surname>Frasnelli</surname><given-names>J</given-names></name><name name-style="western"><surname>Boller</surname><given-names>B</given-names></name></person-group>. <article-title>Olfaction and declarative memory in aging: a meta-analysis</article-title>. <source>Chem Senses</source>. <year>2023</year>;<volume>48</volume>:<fpage>245</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/chemse/bjad045</pub-id><pub-id pub-id-type="pmcid">PMC10629936</pub-id><pub-id pub-id-type="pmid">37878784</pub-id></mixed-citation></ref><ref id="bibr33-15333175251385615"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murphy</surname><given-names>C</given-names></name><name name-style="western"><surname>Jernigan Tl</surname><given-names>CF-N</given-names></name><name name-style="western"><surname>Fennema-Notestine</surname><given-names>C</given-names></name></person-group>. <article-title>Left hippocampal volume loss in Alzheimer's disease is reflected in performance on odor identification: a structural MRI study</article-title>. <source>J Int Neuropsychol Soc</source>. <year>2003</year>;<volume>9</volume>(<issue>3</issue>):<fpage>459</fpage>-<lpage>471</lpage>.<pub-id pub-id-type="pmid">12666770</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1355617703930116</pub-id></mixed-citation></ref><ref id="bibr34-15333175251385615"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steffener</surname><given-names>J</given-names></name><name name-style="western"><surname>Motter</surname><given-names>JN</given-names></name><name name-style="western"><surname>Tabert</surname><given-names>MH</given-names></name><name name-style="western"><surname>Devanand</surname><given-names>DP</given-names></name></person-group>. <article-title>Odorant-induced brain activation as a function of normal aging and Alzheimer&#8217;s disease: a preliminary study</article-title>. <source>Behav Brain Res</source>. <year>2021</year>;<volume>402</volume>:<fpage>113078</fpage>.<pub-id pub-id-type="pmid">33359846</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbr.2020.113078</pub-id><pub-id pub-id-type="pmcid">PMC9020376</pub-id></mixed-citation></ref><ref id="bibr35-15333175251385615"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sohrabi</surname><given-names>HR</given-names></name><name name-style="western"><surname>Bates</surname><given-names>KA</given-names></name><name name-style="western"><surname>Weinborn</surname><given-names>MG</given-names></name></person-group>, <etal>et al.</etal><article-title>Olfactory discrimination predicts cognitive decline among community-dwelling older adults</article-title>. <source>Transl Psychiatry</source>. <year>2012</year>;<volume>2</volume>(<issue>5</issue>):<fpage>e118</fpage>.<pub-id pub-id-type="pmid">22832962</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/tp.2012.43</pub-id><pub-id pub-id-type="pmcid">PMC3365262</pub-id></mixed-citation></ref><ref id="bibr36-15333175251385615"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cormiea</surname><given-names>S</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>J</given-names></name></person-group>. <article-title>Odor discrimination is immune to the effects of verbal labels</article-title>. <source>Sci Rep</source>. <year>2023</year>;<volume>13</volume>(<issue>1</issue>):<fpage>1742</fpage>.<pub-id pub-id-type="pmid">36720925</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-023-28134-w</pub-id><pub-id pub-id-type="pmcid">PMC9889793</pub-id></mixed-citation></ref><ref id="bibr37-15333175251385615"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hedner</surname><given-names>M</given-names></name><name name-style="western"><surname>Larsson</surname><given-names>M</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>N</given-names></name><name name-style="western"><surname>Zucco</surname><given-names>GM</given-names></name><name name-style="western"><surname>Hummel</surname><given-names>T</given-names></name></person-group>. <article-title>Cognitive factors in odor detection, odor discrimination, and odor identification tasks</article-title>. <source>J Clin Exp Neuropsychol</source>. <year>2010</year>;<volume>32</volume>(<issue>10</issue>):<fpage>1062</fpage>-<lpage>1067</lpage>.<pub-id pub-id-type="pmid">20437286</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13803391003683070</pub-id></mixed-citation></ref><ref id="bibr38-15333175251385615"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Michaelson</surname><given-names>DM</given-names></name></person-group>. <article-title>APOE epsilon4: the most prevalent yet understudied risk factor for Alzheimer's disease</article-title>. <source>Alzheimer&#8217;s Dement</source>. <year>2014</year>;<volume>10</volume>(<issue>6</issue>):<fpage>861</fpage>-<lpage>868</lpage>.<pub-id pub-id-type="pmid">25217293</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2014.06.015</pub-id></mixed-citation></ref><ref id="bibr39-15333175251385615"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delgado-Lima</surname><given-names>AH</given-names></name><name name-style="western"><surname>Bouhaben</surname><given-names>J</given-names></name><name name-style="western"><surname>Martinez-Zujeros</surname><given-names>S</given-names></name><name name-style="western"><surname>Pallardo-Rodil</surname><given-names>B</given-names></name><name name-style="western"><surname>G&#243;mez-Pav&#243;n</surname><given-names>J</given-names></name><name name-style="western"><surname>Delgado-Losada</surname><given-names>ML</given-names></name></person-group>. <article-title>Could olfactory identification be a prognostic factor in detecting cognitive impairment risk in the elderly?</article-title><source>Geroscience</source>. <year>2023</year>;<volume>45</volume>(<issue>3</issue>):<fpage>2011</fpage>-<lpage>2025</lpage>.<pub-id pub-id-type="pmid">37084121</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11357-023-00779-5</pub-id><pub-id pub-id-type="pmcid">PMC10119830</pub-id></mixed-citation></ref><ref id="bibr40-15333175251385615"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mazzeo</surname><given-names>S</given-names></name><name name-style="western"><surname>Padiglioni</surname><given-names>S</given-names></name><name name-style="western"><surname>Bagnoli</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal><article-title>The dual role of cognitive reserve in subjective cognitive decline and mild cognitive impairment: a 7-year follow-up study</article-title>. <source>J Neurol</source>. <year>2019</year>;<volume>266</volume>(<issue>2</issue>):<fpage>487</fpage>-<lpage>497</lpage>.<pub-id pub-id-type="pmid">30604054</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00415-018-9164-5</pub-id></mixed-citation></ref><ref id="bibr41-15333175251385615"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vermunt</surname><given-names>L</given-names></name><name name-style="western"><surname>Sikkes</surname><given-names>Sa M</given-names></name><name name-style="western"><surname>Van Den Hout</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal><article-title>Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype</article-title>. <source>Alzheimer's Dement</source>. <year>2019</year>;<volume>15</volume>(<issue>7</issue>):<fpage>888</fpage>-<lpage>898</lpage>.<pub-id pub-id-type="pmid">31164314</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2019.04.001</pub-id><pub-id pub-id-type="pmcid">PMC6646097</pub-id></mixed-citation></ref><ref id="bibr42-15333175251385615"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koss</surname><given-names>EWJ</given-names></name><name name-style="western"><surname>Haxby</surname><given-names>J</given-names></name><name name-style="western"><surname>Friedland</surname><given-names>R</given-names></name></person-group>. <article-title>Olfactory detection and identification performance are dissociated in early Alzheimer&#8217;s disease</article-title>. <source>Neurology</source>. <year>1988</year>;<volume>38</volume>(<issue>8</issue>):<fpage>1228</fpage>-<lpage>1232</lpage>.<pub-id pub-id-type="pmid">3399073</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.38.8.1228</pub-id></mixed-citation></ref><ref id="bibr43-15333175251385615"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Conti</surname><given-names>MZ</given-names></name><name name-style="western"><surname>Vicini-Chilovi</surname><given-names>B</given-names></name><name name-style="western"><surname>Riva</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Odor identification deficit predicts clinical conversion from mild cognitive impairment to dementia due to Alzheimer&#8217;s disease</article-title>. <source>Arch Clin Neuropsychol</source>. <year>2013</year>;<volume>28</volume>(<issue>5</issue>):<fpage>391</fpage>-<lpage>399</lpage>.<pub-id pub-id-type="pmid">23669447</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/arclin/act032</pub-id></mixed-citation></ref><ref id="bibr44-15333175251385615"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Djordjevic</surname><given-names>J</given-names></name><name name-style="western"><surname>Jones-Gotman</surname><given-names>M</given-names></name><name name-style="western"><surname>De Sousa</surname><given-names>K</given-names></name><name name-style="western"><surname>Chertkow</surname><given-names>H</given-names></name></person-group>. <article-title>Olfaction in patients with mild cognitive impairment and Alzheimer's disease</article-title>. <source>Neurobiol Aging</source>. <year>2008</year>;<volume>29</volume>(<issue>5</issue>):<fpage>693</fpage>-<lpage>706</lpage>.<pub-id pub-id-type="pmid">17207898</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2006.11.014</pub-id></mixed-citation></ref><ref id="bibr45-15333175251385615"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Chen</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>X</given-names></name></person-group>, <etal>et al.</etal><article-title>Olfactory dysfunction is already present with subjective cognitive decline and deepens with disease severity in the Alzheimer's disease spectrum</article-title>. <source>J Alzheimers Dis</source>. <year>2021</year>;<volume>79</volume>(<issue>2</issue>):<fpage>585</fpage>-<lpage>595</lpage>.<pub-id pub-id-type="pmid">33361601</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-201168</pub-id></mixed-citation></ref><ref id="bibr46-15333175251385615"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Growdon</surname><given-names>MSA</given-names></name><name name-style="western"><surname>Dagley</surname><given-names>AS</given-names></name><name name-style="western"><surname>Amariglio</surname><given-names>R</given-names></name></person-group>, <etal>et al.</etal><article-title>Odor identification and Alzheimer disease biomarkers in clinically normal elderly</article-title>. <source>Neurology</source>. <year>2015</year>;<volume>84</volume>(<issue>21</issue>):<fpage>2153</fpage>-<lpage>2160</lpage>.<pub-id pub-id-type="pmid">25934852</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000001614</pub-id><pub-id pub-id-type="pmcid">PMC4451046</pub-id></mixed-citation></ref><ref id="bibr47-15333175251385615"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Audronyte</surname><given-names>E</given-names></name><name name-style="western"><surname>Pakulaite-Kazliene</surname><given-names>G</given-names></name><name name-style="western"><surname>Sutnikiene</surname><given-names>V</given-names></name><name name-style="western"><surname>Kaubrys</surname><given-names>G</given-names></name></person-group>. <article-title>Odor discrimination as a marker of early Alzheimer's disease</article-title>. <source>J Alzheimers Dis</source>. <year>2023</year>;<volume>94</volume>(<issue>3</issue>):<fpage>1169</fpage>-<lpage>1178</lpage>.<pub-id pub-id-type="pmid">37355894</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-230077</pub-id><pub-id pub-id-type="pmcid">PMC10473073</pub-id></mixed-citation></ref><ref id="bibr48-15333175251385615"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Aierken</surname><given-names>A</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name></person-group>, <etal>et al.</etal><article-title>A potential biomarker of preclinical Alzheimer&#8217;s disease: the olfactory dysfunction and its pathogenesis-based neural circuitry impairments</article-title>. <source>Neurosci Biobehav Rev</source>. <year>2022</year>;<volume>132</volume>:<fpage>857</fpage>-<lpage>869</lpage>.<pub-id pub-id-type="pmid">34810025</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neubiorev.2021.11.009</pub-id></mixed-citation></ref><ref id="bibr49-15333175251385615"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roalf</surname><given-names>DR</given-names></name><name name-style="western"><surname>Moberg</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Turetsky</surname><given-names>BI</given-names></name></person-group>, <etal>et al.</etal><article-title>A quantitative meta-analysis of olfactory dysfunction in mild cognitive impairment</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>2017</year>;<volume>88</volume>(<issue>3</issue>):<fpage>226</fpage>-<lpage>232</lpage>.<pub-id pub-id-type="pmid">28039318</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp-2016-314638</pub-id><pub-id pub-id-type="pmcid">PMC5350628</pub-id></mixed-citation></ref><ref id="bibr50-15333175251385615"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>RO</given-names></name><name name-style="western"><surname>Christianson</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Kremers</surname><given-names>WK</given-names></name></person-group>, <etal>et al.</etal><article-title>Association between olfactory dysfunction and amnestic mild cognitive impairment and alzheimer disease dementia</article-title>. <source>JAMA Neurol</source>. <year>2016</year>;<volume>73</volume>(<issue>1</issue>):<fpage>93</fpage>-<lpage>101</lpage>.<pub-id pub-id-type="pmid">26569387</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2015.2952</pub-id><pub-id pub-id-type="pmcid">PMC4710557</pub-id></mixed-citation></ref><ref id="bibr51-15333175251385615"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tahmasebi</surname><given-names>R</given-names></name><name name-style="western"><surname>Zehetmayer</surname><given-names>S</given-names></name><name name-style="western"><surname>Pusswald</surname><given-names>G</given-names></name><name name-style="western"><surname>Kovacs</surname><given-names>G</given-names></name><name name-style="western"><surname>St&#246;gmann</surname><given-names>E</given-names></name><name name-style="western"><surname>Lehrner</surname><given-names>J</given-names></name></person-group>. <article-title>Identification of odors, faces, cities and naming of objects in patients with subjective cognitive decline, mild cognitive impairment and Alzheimer s disease: a longitudinal study</article-title>. <source>Int Psychogeriatr</source>. <year>2019</year>;<volume>31</volume>(<issue>4</issue>):<fpage>537</fpage>-<lpage>549</lpage>.<pub-id pub-id-type="pmid">30236169</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1041610218001114</pub-id></mixed-citation></ref><ref id="bibr52-15333175251385615"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>A</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Y</given-names></name></person-group>, <etal>et al.</etal><article-title>Increased prediction value of biomarker combinations for the conversion of mild cognitive impairment to Alzheimer&#8217;s dementia</article-title>. <source>Transl Neurodegener</source>. <year>2020</year>;<volume>9</volume>(<issue>1</issue>):<fpage>30</fpage>.<pub-id pub-id-type="pmid">32741361</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40035-020-00210-5</pub-id><pub-id pub-id-type="pmcid">PMC7397685</pub-id></mixed-citation></ref><ref id="bibr53-15333175251385615"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doty</surname><given-names>RL</given-names></name></person-group>. <article-title>Olfaction in Parkinson&#8217;s disease and related disorders</article-title>. <source>Neurobiol Dis</source>. <year>2012</year>;<volume>46</volume>(<issue>3</issue>):<fpage>527</fpage>-<lpage>552</lpage>.<pub-id pub-id-type="pmid">22192366</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbd.2011.10.026</pub-id><pub-id pub-id-type="pmcid">PMC3429117</pub-id></mixed-citation></ref><ref id="bibr54-15333175251385615"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>HR</given-names></name><name name-style="western"><surname>Kim</surname><given-names>SM</given-names></name><name name-style="western"><surname>Seong</surname><given-names>W</given-names></name></person-group>, <etal>et al.</etal><article-title>Cut-off scores of an olfactory function test for mild cognitive impairment and dementia</article-title>. <source>Psychiatry Investig</source>. <year>2020</year>;<volume>17</volume>(<issue>10</issue>):<fpage>1021</fpage>-<lpage>1030</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.30773/pi.2020.0203</pub-id><pub-id pub-id-type="pmcid">PMC7596283</pub-id><pub-id pub-id-type="pmid">33059394</pub-id></mixed-citation></ref><ref id="bibr55-15333175251385615"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gros</surname><given-names>A</given-names></name><name name-style="western"><surname>Manera</surname><given-names>V</given-names></name><name name-style="western"><surname>De March</surname><given-names>CA</given-names></name></person-group>, <etal>et al.</etal><article-title>Olfactory disturbances in ageing with and without dementia: towards new diagnostic tools</article-title>. <source>J Laryngol Otol</source>. <year>2017</year>;<volume>131</volume>(<issue>7</issue>):<fpage>572</fpage>-<lpage>579</lpage>.<pub-id pub-id-type="pmid">28424103</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S0022215117000858</pub-id></mixed-citation></ref><ref id="bibr56-15333175251385615"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Audronyte</surname><given-names>E</given-names></name><name name-style="western"><surname>Sutnikiene</surname><given-names>V</given-names></name><name name-style="western"><surname>Pakulaite-Kazliene</surname><given-names>G</given-names></name><name name-style="western"><surname>Kaubrys</surname><given-names>G</given-names></name></person-group>. <article-title>Brief test of olfactory dysfunction based on diagnostic features of specific odors in early-stage alzheimer disease</article-title>. <source>Med Sci Monit</source>. <year>2023</year>;<volume>29</volume>:<fpage>e940363</fpage>.<pub-id pub-id-type="pmid">37243326</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.12659/MSM.940363</pub-id><pub-id pub-id-type="pmcid">PMC10231038</pub-id></mixed-citation></ref><ref id="bibr57-15333175251385615"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wehling</surname><given-names>EI</given-names></name><name name-style="western"><surname>Nordin</surname><given-names>S</given-names></name><name name-style="western"><surname>Espeseth</surname><given-names>T</given-names></name><name name-style="western"><surname>Reinvang</surname><given-names>I</given-names></name><name name-style="western"><surname>Lundervold</surname><given-names>AJ</given-names></name></person-group>. <article-title>Familiarity, cued and free odor identification and their association with cognitive functioning in middle aged and older adults</article-title>. <source>Neuropsychol Dev Cogn B Aging Neuropsychol Cogn</source>. <year>2010</year>;<volume>17</volume>(<issue>2</issue>):<fpage>205</fpage>-<lpage>219</lpage>.<pub-id pub-id-type="pmid">19634027</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13825580903042684</pub-id></mixed-citation></ref><ref id="bibr58-15333175251385615"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsieh</surname><given-names>JW</given-names></name><name name-style="western"><surname>Keller</surname><given-names>A</given-names></name><name name-style="western"><surname>Wong</surname><given-names>M</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>RS</given-names></name><name name-style="western"><surname>Vosshall</surname><given-names>LB</given-names></name></person-group>. <article-title>SMELL-S and SMELL-R: olfactory tests not influenced by odor-specific insensitivity or prior olfactory experience</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2017</year>;<volume>114</volume>(<issue>43</issue>):<fpage>11275</fpage>-<lpage>11284</lpage>.<pub-id pub-id-type="pmid">29073044</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1711415114</pub-id><pub-id pub-id-type="pmcid">PMC5664538</pub-id></mixed-citation></ref><ref id="bibr59-15333175251385615"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schiffman</surname><given-names>S</given-names></name><name name-style="western"><surname>Bg</surname><given-names>G</given-names></name><name name-style="western"><surname>Sattely-Miller</surname><given-names>E</given-names></name><name name-style="western"><surname>Zervakis</surname><given-names>J</given-names></name><name name-style="western"><surname>W-B</surname><given-names>K</given-names></name></person-group>. <article-title>Taste, smell and neuropsychological performance of individuals at familial risk for Alzheimer's disease</article-title>. <source>Neurobiol Aging</source>. <year>2002</year>;<volume>23</volume>(<issue>3</issue>):<fpage>397</fpage>-<lpage>404</lpage>.<pub-id pub-id-type="pmid">11959402</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0197-4580(01)00337-2</pub-id></mixed-citation></ref><ref id="bibr60-15333175251385615"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murphy</surname><given-names>C</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>ES</given-names></name><name name-style="western"><surname>Haase</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>CD</given-names></name></person-group>. <article-title>Olfaction in aging and Alzheimer's disease: event-related potentials to a cross-modal odor-recognition memory task discriminate ApoE epsilon4+ and ApoE epsilon 4- individuals</article-title>. <source>Ann N Y Acad Sci</source>. <year>2009</year>;<volume>1170</volume>:<fpage>647</fpage>-<lpage>657</lpage>.<pub-id pub-id-type="pmid">19686207</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1749-6632.2009.04486.x</pub-id><pub-id pub-id-type="pmcid">PMC4575288</pub-id></mixed-citation></ref><ref id="bibr61-15333175251385615"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sundermann</surname><given-names>E</given-names></name><name name-style="western"><surname>Gilbert Pe</surname><given-names>CM</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>C</given-names></name></person-group>. <article-title>Apolipoprotein E 4 genotype and gender: effects on memory</article-title>. <source>Am J Geriatr Psychiatr</source>. <year>2007</year>;<volume>15</volume>(<issue>10</issue>):<fpage>869</fpage>-<lpage>878</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/JGP.0b013e318065415f</pub-id><pub-id pub-id-type="pmid">17911364</pub-id></mixed-citation></ref><ref id="bibr62-15333175251385615"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>C-Y</given-names></name><name name-style="western"><surname>Menuz</surname><given-names>K</given-names></name><name name-style="western"><surname>Carlson</surname><given-names>JR</given-names></name></person-group>. <article-title>Olfactory perception: receptors, cells, and circuits</article-title>. <source>Cell</source>. <year>2009</year>;<volume>139</volume>(<issue>1</issue>):<fpage>45</fpage>-<lpage>59</lpage>.<pub-id pub-id-type="pmid">19804753</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2009.09.015</pub-id><pub-id pub-id-type="pmcid">PMC2765334</pub-id></mixed-citation></ref><ref id="bibr63-15333175251385615"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waymel</surname><given-names>A</given-names></name><name name-style="western"><surname>Friedrich</surname><given-names>P</given-names></name><name name-style="western"><surname>Bastian</surname><given-names>PA</given-names></name><name name-style="western"><surname>Forkel</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Thiebaut De Schotten</surname><given-names>M</given-names></name></person-group>. <article-title>Anchoring the human olfactory system within a functional gradient</article-title>. <source>Neuroimage</source>. <year>2020</year>;<volume>216</volume>:<fpage>116863</fpage>.<pub-id pub-id-type="pmid">32325207</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2020.116863</pub-id><pub-id pub-id-type="pmcid">PMC7116082</pub-id></mixed-citation></ref><ref id="bibr64-15333175251385615"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gon&#231;alves Pereira Pm</surname><given-names>IR</given-names></name><name name-style="western"><surname>Artacho-P&#233;rula</surname><given-names>E</given-names></name><name name-style="western"><surname>Salmenper&#228;</surname><given-names>T</given-names></name><name name-style="western"><surname>K&#228;lvi&#228;inen</surname><given-names>R</given-names></name><name name-style="western"><surname>Pitk&#228;nen</surname><given-names>A</given-names></name></person-group>. <article-title>MR volumetric analysis of the piriform cortex and cortical amygdala in drug-refractory temporal lobe epilepsy</article-title>. <source>AJNR Am J Neuroradiol</source>. <year>2005</year>;<volume>26</volume>(<issue>2</issue>):<fpage>319</fpage>-<lpage>322</lpage>.<pub-id pub-id-type="pmid">15709130</pub-id><pub-id pub-id-type="pmcid">PMC7974111</pub-id></mixed-citation></ref><ref id="bibr65-15333175251385615"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>G</given-names></name><name name-style="western"><surname>Lane</surname><given-names>G</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>SL</given-names></name><name name-style="western"><surname>Kahnt</surname><given-names>T</given-names></name><name name-style="western"><surname>Zelano</surname><given-names>C</given-names></name></person-group>. <article-title>Characterizing functional pathways of the human olfactory system</article-title>. <source>eLife</source>. <year>2019</year>;<volume>8</volume>:<fpage>e47177</fpage>.<pub-id pub-id-type="pmid">31339489</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7554/eLife.47177</pub-id><pub-id pub-id-type="pmcid">PMC6656430</pub-id></mixed-citation></ref><ref id="bibr66-15333175251385615"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fatuzzo</surname><given-names>I</given-names></name><name name-style="western"><surname>Niccolini</surname><given-names>GF</given-names></name><name name-style="western"><surname>Zoccali</surname><given-names>F</given-names></name></person-group>, <etal>et al.</etal><article-title>Neurons, nose, and neurodegenerative diseases: olfactory function and cognitive impairment</article-title>. <source>Int J Mol Sci</source>. <year>2023</year>;<volume>24</volume>(<issue>3</issue>):<fpage>2117</fpage>.<pub-id pub-id-type="pmid">36768440</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24032117</pub-id><pub-id pub-id-type="pmcid">PMC9916823</pub-id></mixed-citation></ref><ref id="bibr67-15333175251385615"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doty</surname><given-names>RL</given-names></name><name name-style="western"><surname>Kamath</surname><given-names>V</given-names></name></person-group>. <article-title>The influences of age on olfaction: a review</article-title>. <source>Front Psychol</source>. <year>2014</year>;<volume>5</volume>:<fpage>20</fpage>.<pub-id pub-id-type="pmid">24570664</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpsyg.2014.00020</pub-id><pub-id pub-id-type="pmcid">PMC3916729</pub-id></mixed-citation></ref><ref id="bibr68-15333175251385615"><label>68</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Emanuele</surname><given-names>B</given-names></name><name name-style="western"><surname>Lavinia</surname><given-names>A</given-names></name></person-group>. <article-title>Olfaction, among the first senses to develop and decline</article-title>. In: <person-group person-group-type="editor"><name name-style="western"><surname>Thomas</surname><given-names>H</given-names></name></person-group>, ed. <source>Sensory Nervous System</source>. <publisher-loc>Rijeka</publisher-loc>: <publisher-name>IntechOpen</publisher-name>; <year>2018</year>.</mixed-citation></ref><ref id="bibr69-15333175251385615"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vasavada</surname><given-names>MM</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>B</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name></person-group>, <etal>et al.</etal><article-title>Central olfactory dysfunction in Alzheimer's disease and mild cognitive impairment: a functional MRI study</article-title>. <source>J Alzheimers Dis</source>. <year>2017</year>;<volume>59</volume>(<issue>1</issue>):<fpage>359</fpage>-<lpage>368</lpage>.<pub-id pub-id-type="pmid">28671131</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-170310</pub-id></mixed-citation></ref><ref id="bibr70-15333175251385615"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kurian</surname><given-names>SM</given-names></name><name name-style="western"><surname>Naressi</surname><given-names>RG</given-names></name><name name-style="western"><surname>Manoel</surname><given-names>D</given-names></name><name name-style="western"><surname>Barwich</surname><given-names>AS</given-names></name><name name-style="western"><surname>Malnic</surname><given-names>B</given-names></name><name name-style="western"><surname>Saraiva</surname><given-names>LR</given-names></name></person-group>. <article-title>Odor coding in the mammalian olfactory epithelium</article-title>. <source>Cell Tissue Res</source>. <year>2021</year>;<volume>383</volume>(<issue>1</issue>):<fpage>445</fpage>-<lpage>456</lpage>.<pub-id pub-id-type="pmid">33409650</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00441-020-03327-1</pub-id><pub-id pub-id-type="pmcid">PMC7873010</pub-id></mixed-citation></ref><ref id="bibr71-15333175251385615"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gottfried</surname><given-names>JA</given-names></name><name name-style="western"><surname>Smith</surname><given-names>AP</given-names></name><name name-style="western"><surname>Rugg</surname><given-names>MD</given-names></name><name name-style="western"><surname>Dolan</surname><given-names>RJ</given-names></name></person-group>. <article-title>Remembrance of odors past: human olfactory cortex in cross-modal recognition memory</article-title>. <source>Neuron</source>. <year>2004</year>;<volume>42</volume>(<issue>4</issue>):<fpage>687</fpage>-<lpage>695</lpage>.<pub-id pub-id-type="pmid">15157428</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0896-6273(04)00270-3</pub-id></mixed-citation></ref><ref id="bibr72-15333175251385615"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marin</surname><given-names>C</given-names></name><name name-style="western"><surname>Vilas</surname><given-names>D</given-names></name><name name-style="western"><surname>Langdon</surname><given-names>C</given-names></name></person-group>, <etal>et al.</etal><article-title>Olfactory dysfunction in neurodegenerative diseases</article-title>. <source>Curr Allergy Asthma Rep</source>. <year>2018</year>;<volume>18</volume>(<issue>8</issue>):<fpage>42</fpage>.<pub-id pub-id-type="pmid">29904888</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11882-018-0796-4</pub-id></mixed-citation></ref><ref id="bibr73-15333175251385615"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Firestein</surname><given-names>S</given-names></name></person-group>. <article-title>The olfactory receptor gene superfamily of the mouse</article-title>. <source>Nat Neurosci</source>. <year>2002</year>;<volume>5</volume>(<issue>2</issue>):<fpage>124</fpage>-<lpage>133</lpage>.<pub-id pub-id-type="pmid">11802173</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nn800</pub-id></mixed-citation></ref><ref id="bibr74-15333175251385615"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bratman</surname><given-names>GN</given-names></name><name name-style="western"><surname>Bembibre</surname><given-names>C</given-names></name><name name-style="western"><surname>Daily</surname><given-names>GC</given-names></name></person-group>, <etal>et al.</etal><article-title>Nature and human well-being: the olfactory pathway</article-title>. <source>Sci Adv</source>. <year>2024</year>;<volume>10</volume>:<fpage>1</fpage>-<lpage>14</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.adn3028</pub-id><pub-id pub-id-type="pmcid">PMC11809653</pub-id><pub-id pub-id-type="pmid">38748806</pub-id></mixed-citation></ref><ref id="bibr75-15333175251385615"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tomlinson</surname><given-names>AH</given-names></name><name name-style="western"><surname>Esiri</surname><given-names>MM</given-names></name></person-group>. <article-title>Herpes simplex encephalitis. Immunohistological demonstration of spread of virus via olfactory pathways in mice</article-title>. <source>J Neurol Sci</source>. <year>1983</year>;<volume>60</volume>(<issue>3</issue>):<fpage>473</fpage>-<lpage>484</lpage>.<pub-id pub-id-type="pmid">6313868</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0022-510x(83)90158-2</pub-id></mixed-citation></ref><ref id="bibr76-15333175251385615"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lucchini</surname><given-names>RG</given-names></name><name name-style="western"><surname>Dorman</surname><given-names>DC</given-names></name><name name-style="western"><surname>Elder</surname><given-names>A</given-names></name><name name-style="western"><surname>Veronesi</surname><given-names>B</given-names></name></person-group>. <article-title>Neurological impacts from inhalation of pollutants and the nose-brain connection</article-title>. <source>Neurotoxicology</source>. <year>2012</year>;<volume>33</volume>(<issue>4</issue>):<fpage>838</fpage>-<lpage>841</lpage>.<pub-id pub-id-type="pmid">22178536</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuro.2011.12.001</pub-id><pub-id pub-id-type="pmcid">PMC3387329</pub-id></mixed-citation></ref><ref id="bibr77-15333175251385615"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>P</given-names></name><name name-style="western"><surname>Hummel</surname><given-names>T</given-names></name></person-group>. <article-title>Orthonasal and retronasal olfaction</article-title>. <source>Curr Biol</source>. <year>2019</year>;<volume>29</volume>(<issue>1</issue>):<fpage>62</fpage>-<lpage>69</lpage>.30581018
</mixed-citation></ref><ref id="bibr78-15333175251385615"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brai</surname><given-names>E</given-names></name><name name-style="western"><surname>Hummel</surname><given-names>T</given-names></name><name name-style="western"><surname>Alberi</surname><given-names>L</given-names></name></person-group>. <article-title>Smell, an underrated early biomarker for brain aging</article-title>. <source>Front Neurosci</source>. <year>2020</year>;<volume>14</volume>:<fpage>792</fpage>.<pub-id pub-id-type="pmid">32982661</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2020.00792</pub-id><pub-id pub-id-type="pmcid">PMC7477331</pub-id></mixed-citation></ref><ref id="bibr79-15333175251385615"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y</given-names></name></person-group>. <article-title>Tau and neuroinflammation in Alzheimer&#8217;s disease: interplay mechanisms and clinical translation</article-title>. <source>J Neuroinflammation</source>. <year>2023</year>;<volume>20</volume>(<issue>1</issue>):<fpage>165</fpage>.<pub-id pub-id-type="pmid">37452321</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-023-02853-3</pub-id><pub-id pub-id-type="pmcid">PMC10349496</pub-id></mixed-citation></ref><ref id="bibr80-15333175251385615"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zou</surname><given-names>YM</given-names></name><name name-style="western"><surname>Lu</surname><given-names>D</given-names></name><name name-style="western"><surname>Liu</surname><given-names>LP</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>HH</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>YY</given-names></name></person-group>. <article-title>Olfactory dysfunction in Alzheimer's disease</article-title>. <source>Neuropsychiatric Dis Treat</source>. <year>2016</year>;<volume>12</volume>:<fpage>869</fpage>-<lpage>875</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/NDT.S104886</pub-id><pub-id pub-id-type="pmcid">PMC4841431</pub-id><pub-id pub-id-type="pmid">27143888</pub-id></mixed-citation></ref><ref id="bibr81-15333175251385615"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wesson</surname><given-names>DW</given-names></name><name name-style="western"><surname>Levy</surname><given-names>E</given-names></name><name name-style="western"><surname>Nixon</surname><given-names>RA</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>DA</given-names></name></person-group>. <article-title>Olfactory dysfunction correlates with amyloid-beta burden in an Alzheimer&#8217;s disease mouse model</article-title>. <source>J Neurosci</source>. <year>2010</year>;<volume>30</volume>(<issue>2</issue>):<fpage>505</fpage>-<lpage>514</lpage>.<pub-id pub-id-type="pmid">20071513</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.4622-09.2010</pub-id><pub-id pub-id-type="pmcid">PMC2826174</pub-id></mixed-citation></ref><ref id="bibr82-15333175251385615"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Apelt</surname><given-names>J</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A</given-names></name><name name-style="western"><surname>Schliebs</surname><given-names>R</given-names></name></person-group>. <article-title>Impairment of cholinergic neurotransmission in adult and aged transgenic Tg2576 mouse brain expressing the Swedish mutation of human beta-amyloid precursor protein</article-title>. <source>Brain Res</source>. <year>2002</year>;<volume>953</volume>(<issue>1-2</issue>):<fpage>17</fpage>-<lpage>30</lpage>.<pub-id pub-id-type="pmid">12384234</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0006-8993(02)03262-6</pub-id></mixed-citation></ref><ref id="bibr83-15333175251385615"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>SM</given-names></name><name name-style="western"><surname>Kang</surname><given-names>DW</given-names></name><name name-style="western"><surname>Um</surname><given-names>YH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><name name-style="western"><surname>Lee</surname><given-names>CU</given-names></name><name name-style="western"><surname>Lim</surname><given-names>HK</given-names></name></person-group>. <article-title>Olfactory dysfunction is associated with cerebral amyloid deposition and cognitive function in the trajectory of Alzheimer&#8217;s disease</article-title>. <source>Biomolecules</source>. <year>2023</year>;<volume>13</volume>(<issue>9</issue>):<fpage>1336</fpage>.<pub-id pub-id-type="pmid">37759734</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biom13091336</pub-id><pub-id pub-id-type="pmcid">PMC10526796</pub-id></mixed-citation></ref><ref id="bibr84-15333175251385615"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson Rs</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>S</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>P</given-names></name><name name-style="western"><surname>Da</surname><given-names>B</given-names></name></person-group>. <article-title>Olfactory identification and incidence of mild cognitive impairment in older age</article-title>. <source>Arch Gen Psychiatry</source>. <year>2007</year>;<volume>64</volume>(<issue>7</issue>):<fpage>802</fpage>-<lpage>808</lpage>.<pub-id pub-id-type="pmid">17606814</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archpsyc.64.7.802</pub-id></mixed-citation></ref><ref id="bibr85-15333175251385615"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tabert</surname><given-names>MH</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Doty</surname><given-names>RL</given-names></name></person-group>, <etal>et al.</etal><article-title>A 10-item smell identification scale related to risk for Alzheimer's disease</article-title>. <source>Ann Neurol</source>. <year>2005</year>;<volume>58</volume>(<issue>1</issue>):<fpage>155</fpage>-<lpage>160</lpage>.<pub-id pub-id-type="pmid">15984022</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.20533</pub-id></mixed-citation></ref><ref id="bibr86-15333175251385615"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olofsson</surname><given-names>JK</given-names></name><name name-style="western"><surname>Ekstrom</surname><given-names>I</given-names></name><name name-style="western"><surname>Larsson</surname><given-names>M</given-names></name><name name-style="western"><surname>Nordin</surname><given-names>S</given-names></name></person-group>. <article-title>Olfaction and aging: a review of the current state of research and future directions</article-title>. <source>Iperception</source>. <year>2021</year>;<volume>12</volume>(<issue>3</issue>):<fpage>20416695211020331</fpage>.<pub-id pub-id-type="pmid">34249327</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/20416695211020331</pub-id><pub-id pub-id-type="pmcid">PMC8239976</pub-id></mixed-citation></ref><ref id="bibr87-15333175251385615"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name></person-group>, <etal>et al.</etal><article-title>Disparity of smell tests in Alzheimer&#8217;s disease and other neurodegenerative disorders: a systematic review and meta-analysis</article-title>. <source>Front Aging Neurosci</source>. <year>2023</year>;<volume>15</volume>:<fpage>1249512</fpage>.<pub-id pub-id-type="pmid">37744388</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2023.1249512</pub-id><pub-id pub-id-type="pmcid">PMC10512741</pub-id></mixed-citation></ref><ref id="bibr88-15333175251385615"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Luca</surname><given-names>R</given-names></name><name name-style="western"><surname>Bonanno</surname><given-names>M</given-names></name><name name-style="western"><surname>Rifici</surname><given-names>C</given-names></name><name name-style="western"><surname>Quartarone</surname><given-names>A</given-names></name><name name-style="western"><surname>Calabro</surname><given-names>RS</given-names></name></person-group>. <article-title>Post-traumatic olfactory dysfunction: a scoping review of assessment and rehabilitation approaches</article-title>. <source>Front Neurol</source>. <year>2023</year>;<volume>14</volume>:<fpage>1193406</fpage>.<pub-id pub-id-type="pmid">37521284</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2023.1193406</pub-id><pub-id pub-id-type="pmcid">PMC10374209</pub-id></mixed-citation></ref><ref id="bibr89-15333175251385615"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haehner</surname><given-names>A</given-names></name><name name-style="western"><surname>Hummel</surname><given-names>T</given-names></name><name name-style="western"><surname>Reichmann</surname><given-names>H</given-names></name></person-group>. <article-title>Olfactory loss in Parkinson&#8217;s disease</article-title>. <source>Parkinsons Dis</source>. <year>2011</year>;<volume>2011</volume>:<fpage>450939</fpage>.<pub-id pub-id-type="pmid">21687752</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4061/2011/450939</pub-id><pub-id pub-id-type="pmcid">PMC3109349</pub-id></mixed-citation></ref><ref id="bibr90-15333175251385615"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delgado-Losada</surname><given-names>ML</given-names></name><name name-style="western"><surname>Delgado-Lima</surname><given-names>AH</given-names></name><name name-style="western"><surname>Bouhaben</surname><given-names>J</given-names></name></person-group>. <article-title>Spanish validation for olfactory function testing using the Sniffin&#8217; sticks olfactory test: threshold, discrimination, and identification</article-title>. <source>Brain Sci</source>. <year>2020</year>;<volume>10</volume>(<issue>12</issue>):<fpage>943</fpage>.<pub-id pub-id-type="pmid">33297359</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/brainsci10120943</pub-id><pub-id pub-id-type="pmcid">PMC7762307</pub-id></mixed-citation></ref><ref id="bibr91-15333175251385615"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Devanand</surname><given-names>DP</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S</given-names></name><name name-style="western"><surname>Luchsinger</surname><given-names>JA</given-names></name></person-group>, <etal>et al.</etal><article-title>Intact global cognitive and olfactory ability predicts lack of transition to dementia</article-title>. <source>Alzheimer's Dement</source>. <year>2020</year>;<volume>16</volume>(<issue>2</issue>):<fpage>326</fpage>-<lpage>334</lpage>.<pub-id pub-id-type="pmid">31676234</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2019.08.200</pub-id><pub-id pub-id-type="pmcid">PMC7007828</pub-id></mixed-citation></ref><ref id="bibr92-15333175251385615"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirkpatrick</surname><given-names>MA</given-names></name><name name-style="western"><surname>Combest</surname><given-names>W</given-names></name><name name-style="western"><surname>Newton</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Combining olfaction and cognition measures to screen for mild cognitive impairment</article-title>. <source>Neuropsychiatric Dis Treat</source>. <year>2006</year>;<volume>2</volume>(<issue>4</issue>):<fpage>565</fpage>-<lpage>570</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/nedt.2006.2.4.565</pub-id><pub-id pub-id-type="pmcid">PMC2671946</pub-id><pub-id pub-id-type="pmid">19412504</pub-id></mixed-citation></ref><ref id="bibr93-15333175251385615"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Picillo</surname><given-names>M</given-names></name><name name-style="western"><surname>Pellecchia</surname><given-names>MT</given-names></name><name name-style="western"><surname>Erro</surname><given-names>R</given-names></name></person-group>, <etal>et al.</etal><article-title>The use of university of Pennsylvania smell identification test in the diagnosis of Parkinson&#8217;s disease in Italy</article-title>. <source>Neurol Sci</source>. <year>2013</year>;<volume>35</volume>(<issue>3</issue>):<fpage>379</fpage>-<lpage>383</lpage>.<pub-id pub-id-type="pmid">23975523</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10072-013-1522-6</pub-id></mixed-citation></ref><ref id="bibr94-15333175251385615"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ottaviano</surname><given-names>G</given-names></name><name name-style="western"><surname>Frasson</surname><given-names>G</given-names></name><name name-style="western"><surname>Nardello</surname><given-names>E</given-names></name><name name-style="western"><surname>Martini</surname><given-names>A</given-names></name></person-group>. <article-title>Olfaction deterioration in cognitive disorders in the elderly</article-title>. <source>Aging Clin Exp Res</source>. <year>2016</year>;<volume>28</volume>(<issue>1</issue>):<fpage>37</fpage>-<lpage>45</lpage>.<pub-id pub-id-type="pmid">26003671</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40520-015-0380-x</pub-id></mixed-citation></ref><ref id="bibr95-15333175251385615"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nogi</surname><given-names>S</given-names></name><name name-style="western"><surname>Uchida</surname><given-names>K</given-names></name><name name-style="western"><surname>Maruta</surname><given-names>J</given-names></name></person-group>, <etal>et al.</etal><article-title>Utility of olfactory identification test for screening of cognitive dysfunction in community-dwelling older adults</article-title>. <source>PeerJ</source>. <year>2021</year>;<volume>9</volume>:<fpage>e12656</fpage>.<pub-id pub-id-type="pmid">35036144</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7717/peerj.12656</pub-id><pub-id pub-id-type="pmcid">PMC8697762</pub-id></mixed-citation></ref><ref id="bibr96-15333175251385615"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Devanand</surname><given-names>D</given-names></name><name name-style="western"><surname>Michaels-Marston</surname><given-names>K</given-names></name><name name-style="western"><surname>Liu</surname><given-names>XPG</given-names></name></person-group>, <etal>et al.</etal><article-title>Olfactory deficits in patients with mild cognitive impairment predict Alzheimer&#8217;s disease at follow-up</article-title>. <source>Am J Psychiatr</source>. <year>2000</year>;<volume>157</volume>(<issue>9</issue>):<fpage>1399</fpage>-<lpage>1405</lpage>.<pub-id pub-id-type="pmid">10964854</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1176/appi.ajp.157.9.1399</pub-id></mixed-citation></ref><ref id="bibr97-15333175251385615"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wei</surname><given-names>H</given-names></name></person-group>. <article-title>Diagnostic value of olfactory function testing for Alzheimer&#8217;s disease and mild cognitive impairment: a systematic review and meta-analysis</article-title>. <source>Front Aging Neurosci</source>. <year>2025</year>;<volume>17</volume>:<fpage>1551939</fpage>.<pub-id pub-id-type="pmid">40443794</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2025.1551939</pub-id><pub-id pub-id-type="pmcid">PMC12119486</pub-id></mixed-citation></ref><ref id="bibr98-15333175251385615"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diez</surname><given-names>I</given-names></name><name name-style="western"><surname>Ortiz-Teran</surname><given-names>L</given-names></name><name name-style="western"><surname>Ng</surname><given-names>TSC</given-names></name></person-group>, <etal>et al.</etal><article-title>Tau propagation in the brain olfactory circuits is associated with smell perception changes in aging</article-title>. <source>Nat Commun</source>. <year>2024</year>;<volume>15</volume>(<issue>1</issue>):<fpage>4809</fpage>.<pub-id pub-id-type="pmid">38844444</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-48462-3</pub-id><pub-id pub-id-type="pmcid">PMC11156945</pub-id></mixed-citation></ref><ref id="bibr99-15333175251385615"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doty</surname><given-names>RL</given-names></name><name name-style="western"><surname>Shaman</surname><given-names>P</given-names></name><name name-style="western"><surname>Dann</surname><given-names>M</given-names></name></person-group>. <article-title>Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function</article-title>. <source>Physiol Behav</source>. <year>1984</year>;<volume>32</volume>(<issue>3</issue>):<fpage>489</fpage>-<lpage>502</lpage>.<pub-id pub-id-type="pmid">6463130</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0031-9384(84)90269-5</pub-id></mixed-citation></ref><ref id="bibr100-15333175251385615"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doty</surname><given-names>RMA</given-names></name><name name-style="western"><surname>Lee</surname><given-names>W</given-names></name></person-group>. <article-title>Development of the 12-item cross-cultural smell identification test (CC-sit)</article-title>. <source>Laryngoscope</source>. <year>1996</year>;<volume>106</volume>(<issue>3</issue>):<fpage>353</fpage>-<lpage>356</lpage>.<pub-id pub-id-type="pmid">8614203</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00005537-199603000-00021</pub-id></mixed-citation></ref><ref id="bibr101-15333175251385615"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kondo</surname><given-names>HMT</given-names></name><name name-style="western"><surname>Hashiba</surname><given-names>M</given-names></name><name name-style="western"><surname>Baba</surname><given-names>S</given-names></name></person-group>. <article-title>A study of the relationship between the T&amp;T olfactometer and the University of Pennsylvania Smell Identification Test in a Japanese population</article-title>. <source>Am J Rhinol</source>. <year>1998</year>;<volume>12</volume>(<issue>5</issue>):<fpage>353</fpage>-<lpage>358</lpage>.<pub-id pub-id-type="pmid">9805536</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2500/105065898780182390</pub-id></mixed-citation></ref><ref id="bibr102-15333175251385615"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hosoya</surname><given-names>K</given-names></name><name name-style="western"><surname>Komachi</surname><given-names>T</given-names></name><name name-style="western"><surname>Maeda</surname><given-names>Y</given-names></name></person-group>, <etal>et al.</etal><article-title>Evaluation of odor recognition threshold measurement methods in T&amp;T olfactometry: a survey study</article-title>. <source>Auris Nasus Larynx</source>. <year>2024</year>;<volume>51</volume>(<issue>1</issue>):<fpage>61</fpage>-<lpage>68</lpage>.<pub-id pub-id-type="pmid">37574422</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.anl.2023.07.009</pub-id></mixed-citation></ref><ref id="bibr103-15333175251385615"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huihong</surname><given-names>Z</given-names></name><name name-style="western"><surname>Pan</surname><given-names>W</given-names></name><name name-style="western"><surname>Chunfeng</surname><given-names>Z</given-names></name></person-group>, <etal>et al.</etal><article-title>Olfactory and imaging features in atypical Alzheimer's disease</article-title>. <source>Transl Neurosci</source>. <year>2018</year>;<volume>9</volume>:<fpage>1</fpage>-<lpage>6</lpage>.<pub-id pub-id-type="pmid">29520325</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1515/tnsci-2018-0001</pub-id><pub-id pub-id-type="pmcid">PMC5836531</pub-id></mixed-citation></ref><ref id="bibr104-15333175251385615"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kashibayashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>R</given-names></name><name name-style="western"><surname>Fujita</surname><given-names>J</given-names></name><name name-style="western"><surname>Kamimura</surname><given-names>N</given-names></name><name name-style="western"><surname>Okutani</surname><given-names>F</given-names></name><name name-style="western"><surname>Kazui</surname><given-names>H</given-names></name></person-group>. <article-title>Correlation between regional brain volume and olfactory function in very mild amnestic patients</article-title>. <source>J Neurol Sci</source>. <year>2020</year>;<volume>411</volume>:<fpage>116686</fpage>.<pub-id pub-id-type="pmid">31972350</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jns.2020.116686</pub-id></mixed-citation></ref><ref id="bibr105-15333175251385615"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kashibayashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>R</given-names></name><name name-style="western"><surname>Fujita</surname><given-names>J</given-names></name></person-group>, <etal>et al.</etal><article-title>Correlation between cerebral blood flow and olfactory function in mild cognitive impairment and Alzheimer's disease</article-title>. <source>Int J Geriatr Psychiatr</source>. <year>2021</year>;<volume>36</volume>(<issue>7</issue>):<fpage>1103</fpage>-<lpage>1109</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/gps.5527</pub-id><pub-id pub-id-type="pmid">33751658</pub-id></mixed-citation></ref><ref id="bibr106-15333175251385615"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hummel</surname><given-names>T</given-names></name><name name-style="western"><surname>Sekinger</surname><given-names>B</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>SR</given-names></name><name name-style="western"><surname>Pauli</surname><given-names>E</given-names></name><name name-style="western"><surname>Kobal</surname><given-names>G</given-names></name></person-group>. <article-title>Sniffin &#8216;sticks&#8217;: olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold</article-title>. <source>Chem Senses</source>. <year>1997</year>;<volume>22</volume>(<issue>1</issue>):<fpage>39</fpage>-<lpage>52</lpage>.<pub-id pub-id-type="pmid">9056084</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/chemse/22.1.39</pub-id></mixed-citation></ref><ref id="bibr107-15333175251385615"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trentin</surname><given-names>S</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>BSFD</given-names></name><name name-style="western"><surname>Borges</surname><given-names>YFF</given-names></name><name name-style="western"><surname>Rieder</surname><given-names>CRDM</given-names></name></person-group>. <article-title>Evaluation of the complete Sniffin Sticks Test versus its subtests in differentiating Parkinson's disease patients from healthy controls</article-title>. <source>Arq Neuropsiquiatr</source>. <year>2022</year>;<volume>80</volume>(<issue>09</issue>):<fpage>908</fpage>-<lpage>913</lpage>.<pub-id pub-id-type="pmid">36257619</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/s-0042-1755268</pub-id><pub-id pub-id-type="pmcid">PMC9770064</pub-id></mixed-citation></ref><ref id="bibr108-15333175251385615"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bastos</surname><given-names>LO</given-names></name><name name-style="western"><surname>Guerreiro</surname><given-names>MM</given-names></name><name name-style="western"><surname>Lees</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Warner</surname><given-names>TT</given-names></name><name name-style="western"><surname>Silveira-Moriyama</surname><given-names>L</given-names></name></person-group>. <article-title>Effects of age and cognition on a cross-cultural paediatric adaptation of the Sniffin' Sticks Identification Test</article-title>. <source>PLoS One</source>. <year>2015</year>;<volume>10</volume>(<issue>8</issue>):<fpage>e0131641</fpage>.<pub-id pub-id-type="pmid">26267145</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0131641</pub-id><pub-id pub-id-type="pmcid">PMC4534354</pub-id></mixed-citation></ref><ref id="bibr109-15333175251385615"><label>109</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rumeau</surname><given-names>C</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>DT</given-names></name><name name-style="western"><surname>Jankowski</surname><given-names>R</given-names></name></person-group>. <article-title>How to assess olfactory performance with the Sniffin' Sticks test(&#174;)</article-title>. <source>Eur Ann Otorhinolaryngol Head Neck Dis</source>. <year>2016</year>;<volume>133</volume>(<issue>3</issue>):<fpage>203</fpage>-<lpage>206</lpage>.<pub-id pub-id-type="pmid">26344139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.anorl.2015.08.004</pub-id></mixed-citation></ref><ref id="bibr110-15333175251385615"><label>110</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Guo</surname><given-names>P</given-names></name><name name-style="western"><surname>Li</surname><given-names>D</given-names></name></person-group>, <etal>et al.</etal><article-title>Olfactory dysfunction and its relationship with clinical symptoms of alzheimer disease</article-title>. <source>Aging Dis</source>. <year>2018</year>;<volume>9</volume>(<issue>6</issue>):<fpage>1084</fpage>-<lpage>1095</lpage>.<pub-id pub-id-type="pmid">30574420</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14336/AD.2018.0819</pub-id><pub-id pub-id-type="pmcid">PMC6284764</pub-id></mixed-citation></ref><ref id="bibr111-15333175251385615"><label>111</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wenjing</surname><given-names>G</given-names></name><name name-style="western"><surname>Aonan</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yinghui</surname><given-names>Q</given-names></name><name name-style="western"><surname>Yulei</surname><given-names>D</given-names></name></person-group>. <article-title>Diagnostic value of olfactory tests in patients with Alzheimer&#8217;s disease and mild cognitive impairment in China</article-title>. <source>CHINA MEDICAL HERALD</source>. <year>2023</year>;<volume>20</volume>(<issue>2</issue>):<fpage>60</fpage>-<lpage>64</lpage>.</mixed-citation></ref><ref id="bibr112-15333175251385615"><label>112</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>G</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yao</surname><given-names>F</given-names></name><name name-style="western"><surname>Ye</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wan</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>W</given-names></name></person-group>. <article-title>Development of the Chinese smell identification test</article-title>. <source>Chem Senses</source>. <year>2019</year>;<volume>44</volume>(<issue>3</issue>):<fpage>189</fpage>-<lpage>195</lpage>.<pub-id pub-id-type="pmid">30715263</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/chemse/bjz006</pub-id></mixed-citation></ref><ref id="bibr113-15333175251385615"><label>113</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X</given-names></name><name name-style="western"><surname>Du</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal><article-title>Olfactory function changes and the predictive performance of the Chinese Smell Identification Test in patients with mild cognitive impairment and Alzheimer&#8217;s disease</article-title>. <source>Front Aging Neurosci</source>. <year>2023</year>;<volume>15</volume>:<fpage>1068708</fpage>.<pub-id pub-id-type="pmid">36861124</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2023.1068708</pub-id><pub-id pub-id-type="pmcid">PMC9969891</pub-id></mixed-citation></ref><ref id="bibr114-15333175251385615"><label>114</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jobin</surname><given-names>B</given-names></name><name name-style="western"><surname>Magdamo</surname><given-names>C</given-names></name><name name-style="western"><surname>Delphus</surname><given-names>D</given-names></name></person-group>, <etal>et al.</etal><article-title>The AROMHA brain health test is a remote olfactory assessment to screen for cognitive impairment</article-title>. <source>Sci Rep</source>. <year>2025</year>;<volume>15</volume>(<issue>1</issue>):<fpage>9290</fpage>.<pub-id pub-id-type="pmid">40128240</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-025-92826-8</pub-id><pub-id pub-id-type="pmcid">PMC11933705</pub-id></mixed-citation></ref><ref id="bibr115-15333175251385615"><label>115</label><mixed-citation publication-type="journal"><article-title>Chinese Smell Identification Test</article-title>. <source>Life and Medical Sciences</source>. <year>2021</year>;<volume>36</volume>:<fpage>499</fpage>.</mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Public Health</journal-id><journal-id journal-id-type="iso-abbrev">BMC Public Health</journal-id><journal-id journal-id-type="pmc-domain-id">63</journal-id><journal-id journal-id-type="pmc-domain">bmcph</journal-id><journal-title-group><journal-title>BMC Public Health</journal-title></journal-title-group><issn pub-type="epub">1471-2458</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12486999</article-id><article-id pub-id-type="pmcid-ver">PMC12486999.1</article-id><article-id pub-id-type="pmcaid">12486999</article-id><article-id pub-id-type="pmcaiid">12486999</article-id><article-id pub-id-type="pmid">41029561</article-id><article-id pub-id-type="doi">10.1186/s12889-025-24093-1</article-id><article-id pub-id-type="publisher-id">24093</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Design and prioritization of the French surveillance program of health effects in the context of exposure to endocrine disruptors using a Delphi study</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Peyronnet</surname><given-names initials="A">Alexia</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Le Barbier</surname><given-names initials="M">M&#233;lina</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Morel</surname><given-names initials="P">Pauline</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Naud</surname><given-names initials="J">J&#233;r&#244;me</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Menard </surname><given-names initials="C">C&#233;line</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Caudeville</surname><given-names initials="J">Julien</given-names></name><address><email>julien.caudeville@santepubliquefrance.fr</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00dfw9p58</institution-id><institution-id institution-id-type="GRID">grid.493975.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 5948 8741</institution-id><institution>Sant&#233; Publique France, The French National Public Health Agency, </institution></institution-wrap>12 Rue Du Val d&#8217;Osne, Saint-Maurice, 94415 France </aff></contrib-group><pub-date pub-type="epub"><day>30</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>25</volume><issue-id pub-id-type="pmc-issue-id">478168</issue-id><elocation-id>3220</elocation-id><history><date date-type="received"><day>9</day><month>8</month><year>2024</year></date><date date-type="accepted"><day>22</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>30</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>02</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-02 10:25:43.597"><day>02</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="12889_2025_Article_24093.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Rapidly increasing evidence has documented that endocrine disruptors (EDs) contribute substantially to disease and disability, particularly neurodevelopmental disorders, metabolic diseases, reproductive disorders, immune and thyroid dysfunctions, as well as hormone-related cancers. These conditions can lead to chronic impairments and disability, such as learning and behavioral difficulties, infertility, long-term treatment dependence, or reduced functional capacity. Biomonitoring studies conducted in France have shown widespread exposure of the general population to several endocrine disruptors (phthalates, bisphenols, pesticides, PCBs, etc.), with particularly high levels observed among children. However, there is still too little epidemiological surveillance data. To address this gap, Sant&#233; publique France has undertaken a project to prioritize the health effects to be surveilled in relation to EDs, considering both scientific and societal criteria. Scientific criteria included the strength of evidence for ED-related causality, severity of health outcomes, and data availability. Societal criteria considered public concern, perceived vulnerability, and relevance to policymaking.</p></sec><sec><title>Methods</title><p id="Par2">We conducted a consultation with experts and French stakeholders in the field of EDs using the Delphi consensus method from November 2021 to June 2022. A list of 59 health effects was submitted for prioritization.</p></sec><sec><title>Results</title><p id="Par3">Several effects were prioritized by all the participants according to scientific, epidemiological and societal criteria, including certain effects on neurodevelopment in children (attention deficit disorder with or without hyperactivity, autism spectrum disorder), the metabolic system (e.g. overweight and obesity) and reproductive health (e.g. endometriosis, breast cancer, alteration in sperm quality, etc.).</p></sec><sec><title>Conclusion</title><p id="Par4">Based on the results of this consultation, Sante publique France will develop an integrated ED-related health surveillance strategy to identify and prioritize effective prevention strategies and actions in a context of uncertainty and lack of knowledge.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12889-025-24093-1.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Endocrine disruptors</kwd><kwd>Epidemiological surveillance</kwd><kwd>Weight of evidence</kwd><kwd>Web-Delphi study</kwd><kwd>Environmental epidemiology</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">The World Health Organization (WHO) first highlighted the rising incidence of human diseases with endocrine origins in 2002 [<xref ref-type="bibr" rid="CR1">1</xref>], and reiterated this concern in 2013 [<xref ref-type="bibr" rid="CR2">2</xref>], noting the increasing prevalence of endocrine-related disorders such as reproductive dysfunctions, hormone-dependent cancers (e.g., breast, prostate), thyroid disorders, metabolic syndromes, and neurodevelopmental impairments. Numerous studies have explored potential links between environmental exposure and these pathologies [<xref ref-type="bibr" rid="CR3">3</xref>]. Of particular concern are endocrine disruptors (EDs), which are believed to significantly contribute to the deterioration of reproductive health [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Biomonitoring studies of the French population have shown widespread exposure to several endocrine disruptors (phthalates, bisphenols, pesticides, PCBs, etc.), with particularly high levels observed in children. These findings indicate that such exposures are frequent and occur at measurable levels in biological samples (e.g., urine, blood), even in the general population [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par6">In France, the impact of EDs on both the environment and public health has become a growing concern. To enhance the understanding of these EDs, and to better protect our citizens and ecosystems from their harmful effects, France has initiated the French Strategy on Endocrine Disruptors (SNPE). This comprehensive strategy involves all stakeholders in defining the government&#8217;s vision and action regarding EDs. Despite mounting evidence suggesting the health risks associated with ED exposure, there remains an urgent need for comprehensive epidemiological surveillance data. Sant&#233; publique France (SpFrance) has developed a dedicated surveillance program for ED-related diseases, which not only helps anticipate and manage public health issues but also constructs epidemiological indicators using national databases. These indicators quantify disease incidence for public health purposes and explore potential ED exposure [<xref ref-type="bibr" rid="CR8">8</xref>&#8211;<xref ref-type="bibr" rid="CR11">11</xref>]. This program initially focused on reproductive health since the potential health effects of EDs were first highlighted by reproductive dysfunction. However, these effects now extend to many other organs and functions of the body, including immune system alteration, thyroid disorders, and hormone-dependent cancers [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Understanding the mechanisms through which EDs act and their long-term effects on both animals and humans, especially during development, has become a major focus of scientific research [<xref ref-type="bibr" rid="CR14">14</xref>&#8211;<xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par7">The scientific literature continues to report new findings, including neurodevelopmental disorders [<xref ref-type="bibr" rid="CR13">13</xref>], metabolic disorders [<xref ref-type="bibr" rid="CR18">18</xref>], immune system dysregulation [<xref ref-type="bibr" rid="CR15">15</xref>], and thyroid disorders [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>].</p><p id="Par8">Consequently, the surveillance strategy for ED-related effects in France needs to be reconsidered to encompass all suspected effects linked to EDs. This strategic shift is essential for quantifying the disease burden attributable to EDs and other factors, guiding public health interventions, and informing future assessments. However, the allocation of resources for this surveillance strategy necessitates a rational prioritization of dimensions and indicators. Methods are available for prioritizing chemicals with potential endocrine-disrupting properties [<xref ref-type="bibr" rid="CR21">21</xref>], but no universal method exists for prioritizing health effects associated with risk factors. One of the central challenges in studying EDs and their impact on human health is establishing definitive causal links or assessing the &#8220;weight of evidence&#8221; (WoE). Unlike many other environmental factors, the effects of EDs are often subtle, pervasive, and may manifest over extended periods. This complexity makes it challenging to apply traditional epidemiological methods. In the health and environmental fields, especially for EDs, scientific conclusions are rarely made based on a single evidentiary modality, necessitating WoE approaches to draw evidence from various modalities, converging on a coherent and consistent conclusion [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. One such initiative is the international network Hurgent (HUman Reproductive health and Global ENvironment Network) [<xref ref-type="bibr" rid="CR9">9</xref>], which played a crucial role in the prioritizing key indicators for reproductive health within the French ED exposure surveillance program. The prioritization was established based on a combination of WoE evaluations from two reports: the World Health Organization (WHO)/United Nations Environment Program (UNEP) report [<xref ref-type="bibr" rid="CR2">2</xref>], which provided qualitative appraisals of WoE for the causal relationship with ED exposure using expert panels [<xref ref-type="bibr" rid="CR23">23</xref>], and the European Commission (EC) report, which quantitatively documented WoE using eight criteria derived from a 2002 International Program of Chemical Safety (IPCS) report [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par9">However, the characteristics of ED mechanisms, such as non-dose-response effects, cocktail effects, critical exposure windows, and transgenerational effects, have hindered the development of universally accepted WoE assessment methods tailored for EDs. Additionally, relying solely on WoE evaluations from previous reports is insufficient, as scientific knowledge has evolved considerably since 2012. Furthermore, these reports solely utilized the Weight of Evidence (WoE) approach&#8212;based primarily on mechanistic and toxicological data&#8212;as a prioritization criterion, without integrating epidemiological evidence (e.g., human studies, population-level burden) or societal dimensions such as public concern, vulnerability, or policy relevance. Given the incomplete, contradictory, or low-evidence nature of available scientific data, participatory processes play a crucial role in integrating both scientific and societal prioritization criteria [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Consensus methods, such as the Delphi method, offer systematic approaches to gather and synthesize opinions, expertise, and knowledge from diverse groups of experts and stakeholders. They are particularly valuable in environmental health studies, where multidisciplinary insights and societal perspectives are integral to shaping policies and interventions.</p><p id="Par10">The Delphi method, specifically, is a consensus-building approach widely used in the health sciences when knowledge is incomplete or uncertain, and empirical evidence cannot provide definitive answers [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. In this method, experts are surveyed in successive rounds, with controlled feedback between rounds, allowing them to reassess, alter, or develop their opinions based on group input. It&#8217;s an iterative process that refines and converges consensus over time, making it ideal for integrating diverse perspectives and expertise in environmental health studies [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. The Web-Delphi can also include a geographically dispersed group of international experts through remote interviews [<xref ref-type="bibr" rid="CR28">28</xref>]. Given the far-reaching implications of EDs on human health, the Delphi method enables the harnessing of collective wisdom from experts and stakeholders. This approach ensures a holistic and robust prioritization strategy, reflecting both scientific and societal considerations. Recognizing the multifaceted nature of the issue, SpFrance adopted an innovative approach, gathering a diverse panel of experts and stakeholders and employing the Delphi consensus method. This comprehensive consultation integrates scientific insights with societal considerations, shedding light on the complexity of the issue.</p><p id="Par11">In this article, we present the outcomes of this consultation process, including the prioritized health effects. This study aims to prioritize health effects potentially linked to ED exposure, using a consensus-based approach that integrates scientific and societal perspectives, in order to guide future surveillance efforts. Our findings provide critical insights into ongoing efforts to safeguard public health in the presence of EDs. This work underscores the importance of evidence-based decision-making in environmental epidemiology and emphasizes the necessity of consensus methods that bridge the scientific and societal dimensions of this complex issue.</p></sec><sec id="Sec2"><title>Materials and methods</title><p id="Par12">To select and prioritize relevant indicators for the surveillance of effects linked to endocrine disruptors (EDs) in France, considering literature data and the views of multiple EDs stakeholders and experts, we designed a four-stages methodology (see Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). The first stage aimed to establish an exhaustive list of health effects linked to EDs exposure for prioritization. The second stage involved developing a method to estimate the prioritization criteria. The third stage was a three-round Web-Delphi process with a panel of international experts and national stakeholders to reach consensus on the prioritization criteria. The fourth stage combined the prioritization criteria to prioritize the health effects, followed by critical analyses of the results.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Overview of the 4-stage approach used to prioritize key health effects to track in the context of EDs exposure based on literature data and a consensus method</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="12889_2025_24093_Fig1_HTML.jpg"/></fig></p><sec id="Sec3"><title>Stage 1 : list of health effects to prioritize</title><p id="Par13">The first stage aimed to identify, as exhaustively as possible, all the health effects suspected of being connected to exposure to EDs. This identification was based on weight of evidence (WoE) for linking health effect to an endocrine mode of action from a mechanistic perspective, thereby focusing on biological plausibility. This list served as the foundation for continuously updating and validating suspected pathologies with new knowledge thanks to a comprehensive review of the existing literature. The WHO and European Commission reports in 2012 provided an initial list of suspected pathologies linked to EDs [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. This list was then expanded and validated with new knowledge gained since 2012 through a narrative literature review. Health effects were also proposed by participants in the Delphi consultation [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. During the first round of consultations, we also asked participants if they were aware of any health effects suspected to be related to EDs that were not addressed by the Delphi process. Relevant suggestions were incorporated in the second round for consideration in the prioritization process. Initially, we focused solely on health effects for the purpose of prioritization and planning. However, during the consultation, we explored the possibility of identifying these effects through biological parameters corresponding to the mechanisms of action of EDs (such as epigenetic mechanisms and inflammatory processes) and investigated the potential for biomarkers to characterize exposure to EDs.</p></sec><sec id="Sec4"><title>Stage 2: definition and Estimation of the prioritization criteria</title><p id="Par14">We prioritized health effects based on two criteria: (1) the WoE supporting the association between the occurrence of the health effect and exposure to EDs and (2) a composite criterion for the epidemiological and societal value of surveilling this effect. This composite criterion combines the severity of the health effect, the changes in the incidence rate of the health effect (known or suspected), and the level of concern about the health effect in French society.</p><sec id="Sec5"><title>Weight of Evidence (WoE)</title><p id="Par15">WoE involves structuring the synthesis of lines of evidence, which may vary in quality, to determine the extent of support for hypotheses [<xref ref-type="bibr" rid="CR12">12</xref>]. Our hypothesis is that there is a relationship between exposure to EDs and adverse health effects. The panel evaluated the WoE by considering all the knowledge within their field of expertise and sources of data they were aware of (including epidemiological and toxicological studies, biochemistry, cell biology, studies of mechanisms, and effects on laboratory animals, expology, etc.). The participants categorized WoE into four levels:</p><p id="Par16">
<list list-type="bullet"><list-item><p id="Par17">Strong : Specific effects of exposure to EDs,</p></list-item><list-item><p id="Par18">Moderate : Relatively specific effects of exposure to EDs,</p></list-item><list-item><p id="Par19">Low : Less specific effects of exposure to EDs, where the proportion attributable to EDs is not yet known,</p></list-item><list-item><p id="Par20">Undocumented : Effects not currently worth surveillance for their relationship with EDs due to insufficient scientific data to justify this link.</p></list-item><list-item><p id="Par21">Severity.</p></list-item></list>
</p><p id="Par22">To assess the severity of a health effect, we used the method developed by the Centre for Research, Studies, and Documentation in Health Economics, which classifies diseases based on the degree of severity using two morbidity indicators: risk to life and physical disability [<xref ref-type="bibr" rid="CR30">30</xref>]. We modified the physical disability indicator to a global indicator of &#8220;quality of life,&#8221; which is more suitable for the chronic effects of EDs. Severity was assessed considering:</p><p id="Par23">
<list list-type="bullet"><list-item><p id="Par24">Risk to life: A fatal prognosis, similar to a severe condition that could lead to death in the short-term or theoretically life-threatening in the longer term.</p></list-item><list-item><p id="Par25">Health-related quality of life: The WHO distinguishes six areas that impact quality of life [<xref ref-type="bibr" rid="CR31">31</xref>]. For this project, to facilitate participants&#8217; assessment of the effect of a disease related to EDs on quality of life in a simple and easily understandable way, while maintaining robustness, three dimensions of health-related quality of life were chosen: physical, psychological, and social functioning.</p></list-item></list>
</p><p id="Par26">Participants had to judge the two previous criteria and combine them to classify severity into three levels: very severe, severe, and mild (see Supplementary Material). Some effects may have different severity levels depending on circumstances, such as age, sex, medical history, etc. For this project, participants were required to assess the severity of the health effect linked with EDs by considering the worst possible case.</p></sec><sec id="Sec6"><title>Incidence rate</title><p id="Par27">The incidence of a disease is the number of new cases of that disease observed over a given period. Participants classified the incidence rates over the last 20 years into four levels: increasing, stable, decreasing, and no opinion.</p></sec><sec id="Sec7"><title>Societal concern</title><p id="Par28">Societal concern was estimated using a scale of agreement toward a series of proposals related to the perception of the level of concern in the general population, the level of information and prevention, the level of scientific data available, and the value of surveilling each stakeholder interviewed (see Supplementary Material).</p></sec><sec id="Sec8"><title>Final estimation of prioritization criterion 2</title><p id="Par29">We assigned points for severity, incidence rate, and societal concern and combined them to classify the final estimation of criterion 2 into three categories: high, moderate, low (see Supplementary Material).</p><p id="Par30">Health effects are categorized into priority groups by combining the two criteria listed in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>. These criteria are :<list list-type="bullet"><list-item><p id="Par31">Weight of Evidence (WoE): This criterion evaluates the level of scientific support for the association between exposure to endocrine disruptors (EDs) and specific health effects.</p></list-item><list-item><p id="Par32">Composite Criterion for Epidemiological and Societal Value: This criterion combines the severity of the health effect, changes in the incidence rate of the health effect, and the level of societal concern about the health effect.</p></list-item></list></p><p id="Par33">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Priority classification based on the assessment of the weight of evidence and value of surveilling</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="2"/><th align="left" colspan="4" rowspan="1">Prioritization criterion 1: Weight of evidence</th></tr><tr><th align="left" colspan="1" rowspan="1">Strong</th><th align="left" colspan="1" rowspan="1">Moderate</th><th align="left" colspan="1" rowspan="1">Low</th><th align="left" colspan="1" rowspan="1">Undocumented</th></tr></thead><tbody><tr><td align="left" rowspan="3" colspan="1"><p>Priortization criterion 2&#160;:&#160;Interest in setting up a surveillance</p><p><italic toggle="yes">(severity</italic>,<italic toggle="yes"> evolution of incidence</italic>, <italic toggle="yes">societal concern)</italic></p></td><td align="left" colspan="1" rowspan="1">Strong</td><td align="left" colspan="1" rowspan="1">High priority</td><td align="left" colspan="1" rowspan="1">High priority</td><td align="left" colspan="1" rowspan="1">Low Priority</td><td align="left" colspan="1" rowspan="1">Not a priority</td></tr><tr><td align="left" colspan="1" rowspan="1">Moderate</td><td align="left" colspan="1" rowspan="1">High priority</td><td align="left" colspan="1" rowspan="1">Moderate priority</td><td align="left" colspan="1" rowspan="1">Not a priority</td><td align="left" colspan="1" rowspan="1">Not a priority</td></tr><tr><td align="left" colspan="1" rowspan="1">Low</td><td align="left" colspan="1" rowspan="1">Moderate priority</td><td align="left" colspan="1" rowspan="1">Low Priority</td><td align="left" colspan="1" rowspan="1">Not a priority</td><td align="left" colspan="1" rowspan="1">Not a priority</td></tr></tbody></table></table-wrap>
</p><p id="Par34">By integrating these two criteria, health effects are classified into priority groups. This categorization helps in identifying which health effects should be prioritized for surveillance and further research, ensuring that both scientific evidence and societal concerns are considered in the decision-making process.</p></sec></sec><sec id="Sec9"><title>Stage 3 : Web-Delphi consultation process</title><p id="Par35">The objective of the Web-Delphi method was to establish a consensus on the prioritization criteria for each of the health effects related to EDs identified in the first stage. We conducted a three-round Web-Delphi process. Since the criteria required different areas of expertise, we proposed two distinct questionnaires: a scientific questionnaire to assess the weight of evidence, the severity of the effects, and the evolution of the incidence rate; and a societal questionnaire to evaluate societal concerns in France.</p><p id="Par36">The list of invited participants was compiled from bibliographic searches (e.g. PubMed), expert directories, national and international institutions, and stakeholder organizations (e.g. NGOs, learned societies, local authorities), ensuring broad representation across disciplines, areas of expertise, and societal sectors. The target number of around 500 invitations was determined to ensure sufficient coverage across the 11 health effect categories considered, while maintaining representativeness within each group. We acknowledge that participants had varying levels of expertise or institutional status, which reflects the diversity of actors involved in endocrine disruptor&#8211;related issues. This heterogeneity was considered a strength in capturing a wide range of knowledge, but it also introduces variability in participation and judgment, which was accounted for through stratified analysis and transparency in response rates. This panel consisted of two groups:</p><p id="Par37">
<list list-type="bullet"><list-item><p id="Par38">International scientific experts : This group included diverse expertise across all eleven categories of health effects studied in stage 1, such as epidemiologists, toxicologists, academics, hospital practitioners, physicians, and others. Their role was to address the scientific aspect.</p></list-item><list-item><p id="Par39">French stakeholders : This group included representatives from associations, non-governmental organizations, elected officials, communities, learned societies, and others involved in the field of EDs. Each institution selected one representative to respond to the social questionnaires.</p></list-item></list>
</p><p id="Par40">We pre-defined a maximum of three rounds for the Delphi method, as research suggests that a higher number of rounds may result in a lower response rate [<xref ref-type="bibr" rid="CR32">32</xref>]. We established four consensus categories based on response percentages:</p><p id="Par41">
<list list-type="bullet"><list-item><p id="Par42">Strong consensus : &#8805;80% identical responses,</p></list-item><list-item><p id="Par43">Moderate consensus : 71%&#8722;80% identical responses,</p></list-item><list-item><p id="Par44">Low consensus : 50%&#8722;70% identical responses,</p></list-item><list-item><p id="Par45">No consensus : &lt;50% identical responses.</p></list-item></list>
</p><p id="Par46">We conducted an online Delphi procedure using LimeSurvey version 2.05+ (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.limesurvey.org">www.limesurvey.org</ext-link>). Initially, a registration proposal was sent by email to all identified participants in either French or English, along with a methodological summary of the study and an explanation of the issues. Subsequently, the questionnaires (additional file 1) were distributed to all registered participants. In each round, panel members received a unique link (secured by a token) to access the questionnaire. We conducted three rounds between November 2021 and June 2022, with each round lasting 3 weeks, followed by an optional 2-week period for follow-ups. Email reminders were sent at various stages of the consultation, including during the registration invitation and throughout the different rounds. A maximum of three reminders were sent for each round of the questionnaire per participant. Participants who did not complete the previous round within the deadline were not invited to the next round.</p><p id="Par47">Both questionnaires began with an introduction outlining the consultation&#8217;s objectives and the Delphi method, along with practical instructions on how to complete and submit the questionnaire.</p><p id="Par48">Round 1: Participants were asked to provide their profile information to validate several pieces of information (such as family name, email address, and institution). The eleven categories of health effects available for consultation were presented to the participants, allowing them to select the one(s) they wished to provide input on, based on their knowledge, expertise, professional experience, or personal knowledge (see Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). Participants were only given access to questions related to the categories of health effects they had chosen in advance.</p><p id="Par49">Rounds 2 and 3: Participants had access to anonymous responses from all other participants, along with a reminder of their own responses from the previous round. They were encouraged to maintain or revise their answers if they deemed it necessary. Only categories for which at least two participants had provided responses were retained for further consultation and analysis. During these rounds, participants also had the opportunity to justify their answers, especially if their responses differed from the majority. Additionally, they could attach supporting documents to substantiate their answers.</p><p id="Par50">We assessed consensus based on response percentages. When responses fell between 50% and 70% identical, we considered the achieved consensus to be low. In such instances, we opted to use the median response as the measure of central tendency, as it was deemed to provide a more objective representation of the collective opinion of the panel. For example, if 60% of the participants believed the weight of evidence was &#8220;strong&#8221; and 40% felt it was &#8220;low,&#8221; we would assign the &#8220;moderate&#8221; category. If the median response fell between two categories, we would arbitrarily select the weaker category. For instance, if 50% of participants rated the weight of evidence as &#8220;moderate&#8221; and 50% as &#8220;low,&#8221; we would choose the &#8220;low&#8221; category.</p><p id="Par51">We employed descriptive statistics to summarize response distributions, including mean, median, median class, standard deviation, quartiles, and the 95th percentile. To facilitate descriptive statistics, we assigned quantitative values to qualitative categories, such as &#8220;0&#8221; for &#8220;not very serious&#8221; severity, &#8220;1&#8221; for &#8220;serious&#8221; severity, and &#8220;2&#8221; for &#8220;very serious&#8221; severity. This allowed for comparisons of standard deviation magnitudes among different health effects. The median, as a measure of central tendency, represents the collective opinion of the panel, while the standard deviation, as a measure of dispersion, indicates the degree of disagreement within the panel [<xref ref-type="bibr" rid="CR32">32</xref>].</p><p id="Par52">In addition, we conducted qualitative analyses. Participants were asked several open-ended questions, providing them with the opportunity to justify their answers for each round. They could provide justifications through text (in the scientific and societal questionnaires) and also by sending documents (a designated option was available to upload various document formats). These responses were collected, organized by relevance, and used for assessing the feasibility of surveillance. An analysis of divergent responses was also conducted to identify various controversies and interpret the dispersion of opinions.</p><p id="Par53">We analyzed differences in opinion using two methods. Firstly, we considered standard deviation, as a measure of dispersion, to represent the degree of disagreement within the panel. We considered questions with consensus but with a standard deviation greater than the 95th percentile value of the distribution as questions with disagreement.</p><p id="Par54">Secondly, starting from the second round onward, participants were given the opportunity to justify their decision to maintain or change their initial answers after reviewing the group&#8217;s responses. A qualitative analysis of divergent answers was conducted to uncover different controversies, identify key messages, and interpret the dispersion of opinions.</p><p id="Par55">Additionally, we conducted a preliminary ranking of health effects based on the Weight of Evidence (WoE) when data were available [<xref ref-type="bibr" rid="CR33">33</xref>], utilizing a method developed by Hurgent [<xref ref-type="bibr" rid="CR9">9</xref>].</p></sec></sec><sec id="Sec10"><title>Results</title><sec id="Sec11"><title>List of health effects to prioritize</title><p id="Par56">Fifty-nine health effects were identified through a narrative review of the literature and contributions from participants. These effects were classified into eleven categories corresponding to endocrine glands or biological functions affected by EDs (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). These categories encompass a wide range of health effects attributed to EDs, reflecting the systemic impact these chemicals can have on the human body. The categorization serves as a foundation for prioritizing which health effects should be monitored and addressed within the context of ED exposure.</p><p id="Par57">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Categories of health effects suspected to be related to exposure to endocrine disruptors according to the literature review</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" colspan="3" rowspan="1">CATEGORY 1&#160;: Impaired reproductive health in women</td></tr><tr><td align="left" colspan="1" rowspan="1">Endometriosis</td><td align="left" colspan="2" rowspan="1">Primary ovarian insufficiency</td></tr><tr><td align="left" colspan="1" rowspan="1">Fibroids</td><td align="left" colspan="2" rowspan="1">Irregular menstrual cycles</td></tr><tr><td align="left" colspan="1" rowspan="1">Polycystic ovary syndrome (PCOS)</td><td align="left" colspan="2" rowspan="1">Premature or early menopause</td></tr><tr><td align="left" colspan="1" rowspan="1">Gestational diabete</td><td align="left" colspan="2" rowspan="1"/></tr><tr><td align="left" colspan="3" rowspan="1">CATEGORY 2&#160;: Impaired reproductive health in men</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Cryptorchidism</p><p>Hypospadias</p><p>Erectile dysfunction*</p></td><td align="left" colspan="2" rowspan="1"><p>Impaired sperm quality</p><p>Testicular cancer</p><p>Benign prostatic hyperplasia (BPH)*</p></td></tr><tr><td align="left" colspan="3" rowspan="1">CATEGORY 3&#160;: Impaired reproductive health without sex distinction</td></tr><tr><td align="left" colspan="1" rowspan="1">Altered sex ratio at birth</td><td align="left" colspan="2" rowspan="1">Precocious puberty</td></tr><tr><td align="left" colspan="1" rowspan="1">Adverse pregnancy outcomes (miscarriage, pre-eclampsia, premature delivery, low birth weight, fetal death)</td><td align="left" colspan="2" rowspan="1">Reduced fertility/under-fertility</td></tr><tr><td align="left" colspan="1" rowspan="1">Infertility</td><td align="left" colspan="2" rowspan="1">Intersex Variation (IV)*</td></tr><tr><td align="left" colspan="3" rowspan="1">CATEGORY 4&#160;: Thyroid disorders</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Hyperthyroidism</p><p>Congenital hypothyroidism</p></td><td align="left" colspan="2" rowspan="1">Hypothyroidism or subclinical hyperthyroidism</td></tr><tr><td align="left" colspan="3" rowspan="1">CATEGORY 5&#160;: Paediatric neurodevelopmental disorders</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Behavioural disorders : emotional disorders, relational disorders and cognitive disorders</p><p>Neurodegenerative diseases in adults : Alzheimer and Parkinson*</p><p>Intellectual deficit -Decrease in intelligence quotient points (IQ)</p></td><td align="left" colspan="2" rowspan="1"><p>Attention deficit hyperactivity disorder (ADHD)</p><p>Cerebral palsy</p><p>Autism spectrum disorder (ASD)</p></td></tr><tr><td align="left" colspan="3" rowspan="1">CATEGORY 6&#160;: Hormone-dependent cancers</td></tr><tr><td align="left" colspan="1" rowspan="1">Breast cancer</td><td align="left" colspan="2" rowspan="1">Thyroid cancer</td></tr><tr><td align="left" colspan="1" rowspan="1">Prostate cancer</td><td align="left" colspan="2" rowspan="1">Colon cancer (non-hormone dependent)*</td></tr><tr><td align="left" colspan="1" rowspan="1">Endometrial cancer</td><td align="left" colspan="2" rowspan="1">Lung cancer (non-hormone-dependent)*</td></tr><tr><td align="left" colspan="1" rowspan="1">Ovarian cancer</td><td align="left" colspan="2" rowspan="1"/></tr><tr><td align="left" colspan="3" rowspan="1">CATEGORY 7&#160;: Adrenal disorders</td></tr><tr><td align="left" colspan="1" rowspan="1">Cushing&#8217;s disease (chronic hypercortisolism)</td><td align="left" colspan="2" rowspan="1">Addison&#8217;s disease (Insufficiency hyposecretion of adrenal hormones)</td></tr><tr><td align="left" colspan="3" rowspan="1">CATEGORY 8&#160;: Bone disorders</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Bone fractures</p><p>Osteoporosis</p></td><td align="left" colspan="2" rowspan="1"><p>Impaired skeletal development</p><p>Enamel development anomalies, hypomineralization, dental fluorosis, hyperdontia, hypodontia</p></td></tr><tr><td align="left" colspan="3" rowspan="1">CATEGORY 9&#160;: Metabolic disorders</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Being overweight and obesity</p><p>Type 2 diabete</p><p>Type 1 diabete</p></td><td align="left" colspan="2" rowspan="1"><p>Metabolic syndrome</p><p>Cardiovascular diseases</p><p>Non-alcoholic fatty liver disease*</p></td></tr><tr><td align="left" colspan="3" rowspan="1">CATEGORY 10&#160;: Immune function disorders</td></tr><tr><td align="left" colspan="1" rowspan="1">Allergies</td><td align="left" colspan="2" rowspan="1">Lymphoma and leukaemia in children</td></tr><tr><td align="left" colspan="1" rowspan="1">Autoimmune thyroid disease (e.g. Basedow&#8217;s disease)</td><td align="left" colspan="2" rowspan="1">Disorders of haematopoiesis and malignancies</td></tr><tr><td align="left" colspan="1" rowspan="1">Asthma</td><td align="left" colspan="2" rowspan="1"/></tr><tr><td align="left" colspan="3" rowspan="1">CATEGORY 11&#160;: Skin and eye disorders</td></tr><tr><td align="left" colspan="1" rowspan="1">Chloracne</td><td align="left" colspan="2" rowspan="1">Ageing of the skin</td></tr><tr><td align="left" colspan="1" rowspan="1">Skin pigmentation disorders</td><td align="left" colspan="2" rowspan="1">Ocular surface impairment</td></tr><tr><td align="left" colspan="1" rowspan="1">Atopic dermatitis</td><td align="left" colspan="2" rowspan="1">Retinal disorders</td></tr><tr><td align="left" colspan="1" rowspan="1">Skin cancer</td><td align="left" colspan="2" rowspan="1"/></tr></tbody></table><table-wrap-foot><p>
<italic toggle="yes">ects added because proposed by Delphi panel</italic>
</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec12"><title>Panel participation</title><p id="Par58">The Delphi consultation process involved two groups: the scientific group and the societal group. The scientific group was composed of 29% academic researchers, 19% clinical physicians, 35% researchers, 12% individuals in other roles, and 6% university professors and hospital practitioners. Out of the 91 participants who registered for the scientific questionnaire, 52 completed the first round (57% response rate), 39 completed the second round (75% response rate), and 34 completed the third round (an 87% response rate).</p><p id="Par59">The societal group consisted of 33% associations, 17% learned societies, 11% elected officials and community representatives, and 39% individuals in other roles, such as industrial actors involved in the ED theme. Among the 35 participants registered for the societal questionnaire, 18 completed the first round (a 51% response rate), 12 completed the second round (a 66% response rate), and 9 completed the third round (a 75% response rate).</p><p id="Par60">In the scientific group, the largest number of respondents were in the categories of metabolic disorders (24 responses), male reproductive health (21 responses), female reproductive health (18 responses), and gender-neutral (18 responses). Three categories of health effects could not be presented in round 2 due to a lack of participants: adrenal disorders, bone disorders, and skin and eye disorders. In the societal group, the highest number of respondents were in the categories of metabolic disorders (12 responses), thyroid disorders (12 responses), and neurodevelopmental disorders (12 responses) (see Appendix A).</p></sec><sec id="Sec13"><title>Prioritization</title><p id="Par61">Out of the 59 proposed health effects, 43 could be assessed in the consultation process. The results are summarized in Table&#160;<xref rid="Tab3" ref-type="table">3</xref>, with detailed statistical analyses available in Appendix B. The health effects were categorized based on their prioritization. Twenty-one health effects were identified as priorities to be surveilled for their links with EDs: 13 with a high priority and 8 with a moderate priority. Among these, Hurgent [<xref ref-type="bibr" rid="CR9">9</xref>] had already prioritized several reproductive health effects in 2015. Some are currently being surveilled by SpFrance (endometriosis, cryptorchidism, precocious puberty, alteration of sperm quality, testicular cancer), while others are not yet surveilled (ovarian and endometrial cancers). Effects beyond the realm of reproductive health were also assessed as high priorities and are not currently surveilled: metabolic disorders (overweight and obesity, cardiovascular diseases, type 2 diabetes, metabolic syndrome), neurodevelopmental disorders in children (behavioral disorders, intellectual deficits, Attention Deficit/Hyperactivity Disorder), and lymphoma/leukemia in children. Twenty-three health effects were classified as low or non-priorities. Sixteen effects could not be prioritized by the end of the consultation, either due to a lack of participants (skin and eye disorders, adrenal disorders, bone disorders) or due to a lack of consensus (erectile dysfunction, benign prostatic hyperplasia, allergies).</p><p id="Par62">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Prioritization of 43 endocrine disruptor-related health effects based on the weight of evidence and interest in developing surveillance estimated from the Delphi method</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="2">Priority category</th><th align="left" colspan="4" rowspan="1">Prioritization criterion 1: Weight of evidence</th></tr><tr><th align="left" colspan="1" rowspan="1">Strong</th><th align="left" colspan="1" rowspan="1">Moderate</th><th align="left" colspan="1" rowspan="1">Low</th><th align="left" colspan="1" rowspan="1">Undocumented</th></tr></thead><tbody><tr><td align="left" rowspan="6" colspan="1"><p>Priortization criterion 2&#160;:</p><p>Interest in setting up a surveillance</p><p><italic toggle="yes">(severity</italic>,<italic toggle="yes"> evolution of incidence</italic>,<italic toggle="yes"> societal concern)</italic></p></td><td align="left" rowspan="2" colspan="1">Strong</td><td align="left" colspan="1" rowspan="1">High priority</td><td align="left" colspan="1" rowspan="1">High priority</td><td align="left" colspan="1" rowspan="1">Low priority</td><td align="left" colspan="1" rowspan="1">Non priority</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>- Breast cancer</p><p>- Prostate cancer</p></td><td align="left" colspan="1" rowspan="1"><p>- Endometriosis</p><p>- Cardiovascular diseases</p><p>- Endometrial cancer</p><p>- Ovarian cancer</p><p>- Lymphoma and leukaemia in children</p></td><td align="left" colspan="1" rowspan="1"><p>- Autism spectrum disorder (ASD)</p><p>- Neurodegenerative diseases in adults : Alzheimer and Parkinson</p><p>- Thyroid cancer*</p></td><td align="left" colspan="1" rowspan="1"><p>- Colon cancer (non-hormone dependent)</p><p>- Lung cancer (non-hormone-dependent)</p><p>- Disorders of haematopoiesis and malignancies</p></td></tr><tr><td align="left" rowspan="2" colspan="1">Moderate</td><td align="left" colspan="1" rowspan="1">High priority</td><td align="left" colspan="1" rowspan="1">Moderate priority</td><td align="left" colspan="1" rowspan="1">Non priority</td><td align="left" colspan="1" rowspan="1">Non priority</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>- Impaired sperm quality</p><p>- Precocious puberty</p><p>- Infertility</p><p>- Being overweight and obesity</p><p>- Cryptorchidism</p><p>- Reduced fertility/under-fertility</p></td><td align="left" colspan="1" rowspan="1"><p>- Testicular cancer</p><p>- Attention deficit hyperactivity disorder (ADHD)</p><p>- Type 2 diabete</p><p>- Metabolic syndrome</p><p>- Behavioural disorders</p><p>- Asthma</p><p>- Intellectual deficit</p><p>- Decrease in intelligence quotient points (IQ)</p></td><td align="left" colspan="1" rowspan="1"><p>- Type 1 diabete</p><p>- Hyperthyroidism</p></td><td align="left" colspan="1" rowspan="1">- Cerebral palsy</td></tr><tr><td align="left" rowspan="2" colspan="1">Low</td><td align="left" colspan="1" rowspan="1">Moderate priority</td><td align="left" colspan="1" rowspan="1">Low priority</td><td align="left" colspan="1" rowspan="1">Non priority</td><td align="left" colspan="1" rowspan="1">Non priority</td></tr><tr><td align="left" colspan="1" rowspan="1">- Hypospadias</td><td align="left" colspan="1" rowspan="1"><p>- Adverse pregnancy outcomes</p><p>- Polycystic ovary syndrome (PCOS)</p><p>- Irregular menstrual cycle</p><p>- Altered sex ratio at birth</p><p>- Hypothyroidism and subclinical hyperthyroidism</p><p>- Non-alcoholic fatty liver disease</p><p>- Primary ovarian insufficiency</p></td><td align="left" colspan="1" rowspan="1"><p>- Gestational diabete</p><p>- Premature or early menopause</p></td><td align="left" colspan="1" rowspan="1"><p>- Hypothyro&#239;die</p><p>- Intersex Variation (IV)</p><p>- Uterine fibroid</p><p>- Autoimmune thyroid disease</p></td></tr></tbody></table><table-wrap-foot><p>*This health effect was the subject of a strong divergence of opinion regarding the level of WoE (&#8220;strong&#8221; VS &#8220;undocumented&#8221;) and the prioritization result does not reflect the overall opinions of the participant panel.</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec14"><title>Complementary analysis</title><p id="Par63">Despite reaching a consensus on many aspects, the consultation revealed divergent opinions among participants, particularly regarding the WoE and the trends in the incidence of health effects. These differences were identified through two main methods: the analysis of response dispersion (standard deviation) and qualitative analysis of participant justifications.</p><sec id="Sec15"><title>Dispersion of responses and standard deviation</title><p id="Par64">The question of the WoE generated the most disagreement among experts, reflected in a wide dispersion of responses and conflicting opinions. Notably, the highest standard deviation was observed for thyroid cancer, where experts were evenly split, with four rating the WoE as &#8216;strong,&#8217; and four &#8216;undocumented.&#8217; This disparity indicates significant disagreement within the panel.</p></sec><sec id="Sec16"><title>Qualitative analysis provided further insights into these differing opinions</title><p id="Par65">In addition to the standard deviation, qualitative analysis helped shed light on these differing opinions. Experts who indicated &#8216;strong&#8217; WoE argued that there were numerous studies on the subject and provided literature, including a 2020 systematic review demonstrating links between organochlorines and some PCBs and the risk of thyroid cancer [<xref ref-type="bibr" rid="CR30">30</xref>]. However, experts who indicated &#8216;undocumented&#8217; did not provide any reasoning. Disagreement was also evident regarding the WoE for immune system disorders, though no dissenting opinions were explained or justified. This could be attributed to the small number of experts who responded on this topic (only three experts) and the limited availability of studies on the subject.</p><p id="Par66">On the scientific side, several participants had divergent opinions on whether the incidence of health effects was truly increasing or if it was due to improved diagnosis. Specific health effects where this challenge was noted include :</p><p id="Par67">
<list list-type="bullet"><list-item><p id="Par68">ADHD and ASD: Some participants argued that better diagnostic methods might explain the perceived increase in cases.</p></list-item><list-item><p id="Par69">Endometriosis: Similar concerns were raised about the distinction between actual incidence and improved detection.</p></list-item><list-item><p id="Par70">Neurodegenerative Diseases, Prostate Cancer, Testicular Cancer, and PCOS: Some opinions suggested that the rise in incidence might be more closely related to an aging population rather than increased exposure to endocrine disruptors.</p></list-item></list>
</p><p id="Par71">Concerning the societal component, the statement &#8220;The French population is concerned about the occurrence of this health effect in the general population&#8221; generated the most disagreement among stakeholders. This was particularly true for conditions like hypospadias and neurodegenerative diseases in adults. However, no justifications were provided for these dissenting opinions.</p><p id="Par72">A preliminary hierarchy of health effects based on the WoE was also conducted using the method developed by Hurgent (when data were available) [<xref ref-type="bibr" rid="CR9">9</xref>]. This hierarchy aligns with the consultation results, confirming the &#8216;strong&#8217; WoE or several health effects previously categorized as having &#8216;sufficient&#8217; evidence in the literature (e.g., breast cancer, prostate cancer, endometriosis, cryptorchidism). However, limitations such as the lack of a universal methodology for evaluating WoE, incomplete and sometimes contradictory scientific data, and the need for more up-to-date research highlight the prospective nature of this ranking. Two health effects (uterine fibroid and autoimmune thyroid diseases) were classified as &#8216;undocumented&#8217; by the consultation despite being categorized as having &#8216;sufficient&#8217; evidence in previous literature reviews. This discrepancy underscores the ongoing need for robust methodologies and updated data to accurately evaluate the WoE for health effects linked to endocrine disruptors.</p></sec></sec></sec><sec id="Sec17"><title>Discussion</title><p id="Par73">The primary aim of this study was to compile a list of health effects identified as priorities for surveillance by SpFrance due to their association with EDs, while considering both scientific and societal criteria. This serves as a decision-making tool for shaping the Agency&#8217;s surveillance program on the topic of EDs. Additionally, this approach allows to capture a snapshot of the current shared knowledge between health effects and EDs.</p><sec id="Sec18"><title>Method</title><p id="Par74">The methodology combined a comprehensive literature review and a Delphi process to foster consensus on health effects to prioritize surveillance. The optimal sample size for a Delphi is not precisely defined, but it is generally accepted that each group should include 12 to 18 participants [<xref ref-type="bibr" rid="CR26">26</xref>]. While our initial group sizes met this recommendation, the societal group experienced a decline in participation from the third round onwards, which may have affected the stability of consensus. Nonetheless, the participation rates in this study align with, and in some cases surpass, those documented in the literature [<xref ref-type="bibr" rid="CR34">34</xref>]. There is no universally accepted definition of consensus in the Delphi method. Various thresholds have been suggested. For instance, McKenna&#8217;s work suggests that consensus is achieved with 51% agreement among respondents [<xref ref-type="bibr" rid="CR32">32</xref>], Sumsion recommends 70% (1998) [<xref ref-type="bibr" rid="CR35">35</xref>], while Green et al. advocate for 80% (1999) [<xref ref-type="bibr" rid="CR36">36</xref>]. A 2014 systematic literature review on Delphi studies found that the most common definition of consensus was a threshold of percent agreement, with an average threshold of 75%, followed by ranges of percent agreement among participants [<xref ref-type="bibr" rid="CR37">37</xref>].</p><p id="Par75">Given the complex nature of issues related to EDs and the conflicting evidence in the literature, it was anticipated that the study might elicit widely divergent opinions. Setting a too high consensus threshold might have resulted in a low number of responses reaching consensus, thus hindering our ability to achieve the agency&#8217;s surveillance program objectives. To avoid being overly restrictive and to gain insight into the level of agreement among participants, we defined four categories of consensus. Strong consensus rates (&#8805;&#8201;80% identical responses) were observed at 73% for the scientific questionnaire and 63% for the societal questionnaire. These results demonstrate that our Delphi study effectively identified consensus on complex issues.</p></sec><sec id="Sec20"><title>Results of the prioritization</title><p id="Par76">The prioritization process highlighted several reproductive health outcomes as priorities for current surveillance, aligning with the previous prioritization conducted by Hurgent. Some of these effects are already under surveillance in France [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. The provisional hierarchy of health effects, based on the WoE according to the literature, corroborated the Delphi results. However, the prioritization of three health outcomes raised questions.</p><p id="Par77">Firstly, thyroid cancer triggered a significant difference of opinion among experts regarding the strength of evidence, with some experts classifying it as &#8220;strong&#8221; evidence while others deemed it &#8220;undocumented&#8221; WoE. Consequently, it received a low priority ranking. It&#8217;s important to note that this result doesn&#8217;t reflect the consensus of all participants. As a result, we will consider this health effect during the next feasibility evaluation, acknowledging its relevance for further investigation, and recognizing that its prioritization as &#8220;low&#8221; is not shared unanimously by the panel.</p><p id="Par78">Furthermore, the WoE for two health effects were categorized as &#8220;undocumented&#8221; by the consultation process, even though our previous literature review had classified them as &#8220;sufficient.&#8221; Consequently, an update will be necessary in the coming years to either confirm or revise the WoE ranking for uterine fibroids and autoimmune thyroid diseases.</p><p id="Par79">It is essential to emphasize that expert opinion cannot replace solid epidemiological evidence regarding the connections between EDs and diseases. Furthermore, the existence of a consensus does not necessarily indicate that the correct answer has been definitively determined. Nevertheless, uncertainty is a reality in various aspects of decision-making within the field of EDs and public policy.</p><p id="Par80">The method presented herein identified the areas that experts and stakeholders deemed significant at a specific point in time concerning this topic. Despite the inherent limitations of the Delphi method and the absence of a universally accepted method or regulation, the proposed approach provided the agency with initial insights to determine which health effects should be prioritized for surveillance in connection with EDs.</p></sec><sec id="Sec21"><title>Strengths and limitations</title><p id="Par81">The Delphi method facilitated the engagement of a diverse and geographically dispersed group of participants, both in France and internationally, with varied skills, backgrounds, and expertise. This diversity was essential for addressing the complex topic of EDs health impact. The method also allowed for the inclusion of difficult-to-access knowledge, such as unpublished findings, while ensuring participants&#8217; anonymity to minimize potential biases associated with factors like notoriety, charisma, or leadership.</p><p id="Par82">Furthermore, the approach developed for assessing the level of confidence allowed us to validate the prioritization results by considering the level of consensus achieved the number of participants, and their justifications. Beyond the prioritization outcomes, this method enabled the collection of valuable information about existing or potential monitoring systems and specific biomarkers related to the EPs of interest. This information will be instrumental in the feasibility assessment phase and the development of a surveillance strategy for priority diseases.</p><p id="Par83">However, the Delphi consensus method used for prioritization has several limitations. Some of these limitations are inherent to the Delphi method itself. It can be challenging to prevent group fatigue when conducting multiple rounds of questionnaires, potentially leading to a false consensus on complex or controversial issues. To mitigate this, we initially set a limit of three questionnaire rounds. While the Delphi technique is gaining popularity in health and social research, there are no universally accepted guidelines, which can result in methodological challenges and difficulties in result interpretation. Nonetheless, this study adhered to several recommendations from the scientific literature to ensure rigor [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR40">40</xref>], including defining consensus criteria in advance, maintaining panel expertise and homogeneity, providing reminders of the method and objectives between rounds, and more. Moreover, the questionnaires were only available in French and English, which may have limited participation of non-fluent experts in other languages.</p><p id="Par84">Despite our efforts to involve as many stakeholders in the field of EDs as possible, the number of participants in the societal questionnaire was relatively low compared to recommendations from the literature, limiting the strength of consensus in this part. However, these results were made available to all stakeholders of the French national strategies for EDs before the official publication of the surveillance program, allowing for additional input that may not have been captured during the consultation.</p><p id="Par85">The requirement for continuous participant engagement across multiple rounds, which was achieved during this study, spanning from November 2021 to June 2022. Various strategies, such as clear explanations of questionnaires and objectives, protocol provision, contact email availability for queries, time estimation for questionnaire completion, and personalized reminders, helped maintain satisfactory participation rates despite some dropouts.</p><p id="Par86">Certain health effects could not be prioritized due to insufficient responses (e.g., skin and eye disorders, adrenal disorders, bone disorders) in the scientific component. Although invitations were extended to a wide array of internationally recognized experts, it&#8217;s noteworthy that these are categories of health effects that have only recently gained attention in relation to EDs. The lack of responses can thus reflect both a lack of interest in these topics and a dearth of relevant knowledge and literature.</p><p id="Par87">Regarding the assessment of societal concern by stakeholders in the field of EDs, it was observed that respondents tended to provide unqualified answers, indicating predominantly strong interest in surveillance and recognizing very serious health consequences. While this questionnaire allowed them to express their deep concern, it may have complicated the process of prioritizing the societal aspect.</p><p id="Par88">It is crucial to acknowledge that the Delphi method has faced criticism in the literature [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>] for potentially fostering consensus and for not facilitating participant discussions. Therefore, it is important to emphasize that the existence of consensus and our prioritization results do not imply that the definitive answer has been found. Rather, they signify the areas that experts and stakeholders considered important at a particular time regarding the topic. Despite the inherent limitations of the Delphi method and the absence of universally accepted standards or regulations, the proposed method has provided initial insights to assist the agency in identifying health effects that warrant priority surveillance in relation to EDs.</p></sec><sec id="Sec22"><title>From identifying health effect to monitoring system development</title><p id="Par89">The next steps will involve making definitive selections of the health effects classified as &#8220;high&#8221; and &#8220;moderate&#8221; priorities. Addressing feasibility issues will be crucial, including determining measurement and collecting methods, exploiting existing indicator, adaptating existing databases, or initiating de novo data collection. Comprehensive knowledge of the existing databases in France and fostering multidisciplinary collaborations will be essential. This assessment will also evaluate the suitability of these indicators for surveillance in the context of EDs and their effectiveness in driving actionable interventions. For example, integrating diverse methodologies and tools within a comprehensive approach holds promise for identifying effective prevention strategies and actions, particularly in a context marked by uncertainty and knowledge gaps. The notion of endocrine, in conjunction with the exposome concept, has fostered the development of a more integrated analytical framework combining epidemiology, exposomics, and toxicology&#8212;a transdisciplinary approach that has been particularly promoted within European research programs. Applying the exposome concept to surveillance involves aggregating available data beyond health data and employing diverse methodological approaches. The emergence of new environmental and toxicological databases provides opportunities to better characterize population multi-exposure patterns. However, this requires prior consideration of the technical prerequisites for harnessing extensive data, constructing composite exposure indicators, and achieving interoperability among tools and data from various sources and types. Additionally, methodologies for assessing the environmental burden of disease enable the combined use of incidence data, biomonitoring data, and epidemiological relationships to estimate attributable cases for risk factor and translate them into economic cost to help anticipating and managing the ensued public health problems.</p><p id="Par90">Throughout the consultation process, information on biological parameters and biomarkers of effects was also gathered, which will be integrated into the feasibility assessment phase. Numerous proposals were put forth, such as those related to surveillance cryptorchidism and hypospadias (including the establishment of congenital malformation registries at the national level, implementing stringent recording methodology and measuring ano-genital distance), thyroid disorders (mandatory iodemia screening during pregnancy), or neurodevelopmental disorders in children (systematic school-based detection at a specific age). This information may prove particularly valuable for the implementation of surveillance within the framework of the French national biomonitoring program lead by SpFrance.</p></sec></sec><sec id="Sec23"><title>Conclusions</title><p id="Par91">SpFrance has undertaken a comprehensive prioritization of health effects suspected of being linked to exposure to EDs, aiming to establish a robust framework for its surveillance program. In the absence of a universal methodology and incomplete, contradictory, or low level evidence, SpFrance incorporated both scientific and societal criteria trough participative consensus methods to guide priorization.</p><p id="Par92">The prioritization method was developed based on a thorough literature review and the engagement of experts and stakeholders through the Delphi consensus method. In total, 43 health effects were prioritized using two key criteria: (1)&#160;the strength of available evidence and (2)&#160;the epidemiological and societal relevance for establishing health effect surveillance.</p><p id="Par93">Expert opinion cannot replace solid epidemiological evidence regarding the connections between EDs and diseases. Furthermore, the existence of a consensus does not necessarily indicate that the correct answer has been definitively determined. Nevertheless, uncertainty is a reality in various aspects of decision-making within the field of EDs and public policy. The Delphi method proved crucial in structuring the information gathered from expert input and societal concerns, effectively identifying the health effects that are currently deemed important to monitor by both experts and stakeholders. The results of this consultation provide the Agency with initial decision-making elements to identify which health effects should be prioritized for surveillance in relation to EDs.</p><p id="Par94">This prioritization approach is replicable and adaptable over time, allowing for selection of health indicators for study based on evolving knowledge, data availability, and societal changes. The work and initiatives are intended to public policy and are integrated into national plans related to EDs. By identifying and prioritizing health effects linked to EDs, SpFrance aims to create a focused and effective surveillance program that can inform public health interventions, support further research, and ultimately contribute to the mitigation of health risks associated with ED exposure. A detailed presentation of the operational surveillance strategy, including indicator selection and feasibility assessments, will be addressed in a dedicated article. Additionally, proposals related to biomarkers of exposure and effect collected during the Delphi process are being integrated within the national biomonitoring program coordinated by Sante publique France agency.</p></sec><sec id="Sec24" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12889_2025_24093_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 1.</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM2" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12889_2025_24093_MOESM2_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 2.</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank all study participants who took part in the Delphi process and Clothilde Hachin for her relevant comments regarding the preparation of the survey.</p></ack><notes notes-type="author-contribution"><title>Authors&#8217; contributions</title><p>Conceptualization, M.L.B.; validation, All authors; writing&#8212;original draft preparation, A.P., J.C.; writing&#8212;review and editing, all authors; supervision, J.C. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This research received no external funding.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par95">The study whose results are submitted for publication is a survey of stakeholders (health professionals, scientific experts, patient associations, etc.) to help us define our new epidemiological surveillance strategy for endocrine disruptors. It is therefore an opinion survey. No health data relating to respondents or their patients or members was collected. In view of the study&#8217;s purpose and the way in which it was implemented, this study is not research involving the human person within the meaning of French legislation (article L. 1121-1 of the Public Health Code), nor within the meaning of the WMA&#8217;s Declaration of Helsinki, and did not require the prior opinion of an ethics committee. However, informed consent was obtained after being informed of the conditions under which their data would be processed.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par96">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par97">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="book"><person-group person-group-type="author"><collab>International Programme on Chemical S</collab></person-group><source>Global assessment on the state of the science of endocrine disruptors</source><year>2002</year><publisher-loc>Geneva</publisher-loc><publisher-name>World Health Organization</publisher-name></element-citation><mixed-citation id="mc-CR1" publication-type="book">International Programme on Chemical S. Global assessment on the state of the science of endocrine disruptors. Geneva: World Health Organization; 2002.</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">United Nations Environment Programme, World Health Organization. State of the Science of Endocrine Disrupting Chemicals. 2012.</mixed-citation></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bergman</surname><given-names>A</given-names></name><name name-style="western"><surname>Heindel</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Kasten</surname><given-names>T</given-names></name><name name-style="western"><surname>Kidd</surname><given-names>KA</given-names></name><name name-style="western"><surname>Jobling</surname><given-names>S</given-names></name><name name-style="western"><surname>Neira</surname><given-names>M</given-names></name><etal/></person-group><article-title>The impact of endocrine disruption: a consensus statement on the state of the science</article-title><source>Environ Health Perspect</source><year>2013</year><volume>121</volume><issue>4</issue><fpage>A104</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1289/ehp.1205448</pub-id><pub-id pub-id-type="pmid">23548368</pub-id><pub-id pub-id-type="pmcid">PMC3620733</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Bergman A, Heindel JJ, Kasten T, Kidd KA, Jobling S, Neira M, et al. The impact of endocrine disruption: a consensus statement on the state of the science. Environ Health Perspect. 2013;121(4):A104-6.<pub-id pub-id-type="pmid">23548368</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1289/ehp.1205448</pub-id><pub-id pub-id-type="pmcid">PMC3620733</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Br&#228;uner</surname><given-names>EV</given-names></name><name name-style="western"><surname>Lim</surname><given-names>YH</given-names></name><name name-style="western"><surname>Koch</surname><given-names>T</given-names></name><name name-style="western"><surname>Uldbjerg</surname><given-names>CS</given-names></name><name name-style="western"><surname>Gregersen</surname><given-names>LS</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>MK</given-names></name><etal/></person-group><article-title>Endocrine disrupting chemicals and risk of testicular cancer: A systematic review and Meta-analysis</article-title><source>J Clin Endocrinol Metab</source><year>2021</year><volume>106</volume><issue>12</issue><fpage>e4834</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">34270734</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/clinem/dgab523</pub-id><pub-id pub-id-type="pmcid">PMC8864757</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Br&#228;uner EV, Lim YH, Koch T, Uldbjerg CS, Gregersen LS, Pedersen MK, et al. Endocrine disrupting chemicals and risk of testicular cancer: A systematic review and Meta-analysis. J Clin Endocrinol Metab. 2021;106(12):e4834&#8211;60.<pub-id pub-id-type="pmid">34270734</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/clinem/dgab523</pub-id><pub-id pub-id-type="pmcid">PMC8864757</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caserta</surname><given-names>D</given-names></name><name name-style="western"><surname>Mantovani</surname><given-names>A</given-names></name><name name-style="western"><surname>Marci</surname><given-names>R</given-names></name><name name-style="western"><surname>Fazi</surname><given-names>A</given-names></name><name name-style="western"><surname>Ciardo</surname><given-names>F</given-names></name><name name-style="western"><surname>La Rocca</surname><given-names>C</given-names></name><etal/></person-group><article-title>Environment and women&#8217;s reproductive health</article-title><source>Hum Reprod Update</source><year>2011</year><volume>17</volume><issue>3</issue><fpage>418</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1093/humupd/dmq061</pub-id><pub-id pub-id-type="pmid">21266373</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Caserta D, Mantovani A, Marci R, Fazi A, Ciardo F, La Rocca C, et al. Environment and women&#8217;s reproductive health. Hum Reprod Update. 2011;17(3):418&#8211;33.<pub-id pub-id-type="pmid">21266373</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/humupd/dmq061</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fillol</surname><given-names>C</given-names></name><name name-style="western"><surname>Garnier</surname><given-names>R</given-names></name><name name-style="western"><surname>Mullot</surname><given-names>JU</given-names></name><name name-style="western"><surname>Boudet</surname><given-names>C</given-names></name><name name-style="western"><surname>Momas</surname><given-names>I</given-names></name><name name-style="western"><surname>Salmi</surname><given-names>LR</given-names></name><etal/></person-group><article-title>Prioritization of the biomarkers to be analyzed in the French biomonitoring program</article-title><source>Biomonitoring</source><year>2014</year><volume>1</volume><issue>1</issue><fpage>95</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.2478/bimo-2014-0010</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Fillol C, Garnier R, Mullot JU, Boudet C, Momas I, Salmi LR, et al. Prioritization of the biomarkers to be analyzed in the French biomonitoring program. Biomonitoring. 2014;1(1):95&#8211;104.</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fillol</surname><given-names>C</given-names></name><name name-style="western"><surname>Oleko</surname><given-names>A</given-names></name><name name-style="western"><surname>Saoudi</surname><given-names>A</given-names></name><name name-style="western"><surname>Zeghnoun</surname><given-names>A</given-names></name><name name-style="western"><surname>Balicco</surname><given-names>A</given-names></name><name name-style="western"><surname>Gane</surname><given-names>J</given-names></name><etal/></person-group><article-title>Exposure of the French population to bisphenols, phthalates, parabens, glycol ethers, brominated flame retardants, and perfluorinated compounds in 2014&#8211;2016: results from the Esteban study</article-title><source>Environ Int</source><year>2021</year><volume>147</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.envint.2020.106340</pub-id><pub-id pub-id-type="pmid">33422968</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Fillol C, Oleko A, Saoudi A, Zeghnoun A, Balicco A, Gane J, et al. Exposure of the French population to bisphenols, phthalates, parabens, glycol ethers, brominated flame retardants, and perfluorinated compounds in 2014&#8211;2016: results from the Esteban study. Environ Int. 2021;147:1&#8211;13.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.envint.2020.106340</pub-id><pub-id pub-id-type="pmid">33422968</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">Sant&#233; publique France. Sant&#233; reproductive et perturbateurs endocriniens. Bull Epid&#233;miologique Hebdomadaire. 2018:22&#8211;3.</mixed-citation></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le Moal</surname><given-names>J</given-names></name><name name-style="western"><surname>Sharpe</surname><given-names>RM</given-names></name><name name-style="western"><surname>J&#981;rgensen</surname><given-names>N</given-names></name><name name-style="western"><surname>Levine</surname><given-names>H</given-names></name><name name-style="western"><surname>Jurewicz</surname><given-names>J</given-names></name><name name-style="western"><surname>Mendiola</surname><given-names>J</given-names></name><etal/></person-group><article-title>Toward a multi-country monitoring system of reproductive health in the context of endocrine disrupting chemical exposure</article-title><source>Eur J Pub Health</source><year>2016</year><volume>26</volume><issue>1</issue><fpage>76</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1093/eurpub/ckv153</pub-id><pub-id pub-id-type="pmid">26330492</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Le Moal J, Sharpe RM, J&#981;rgensen N, Levine H, Jurewicz J, Mendiola J, et al. Toward a multi-country monitoring system of reproductive health in the context of endocrine disrupting chemical exposure. Eur J Pub Health. 2016;26(1):76&#8211;83.<pub-id pub-id-type="pmid">26330492</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurpub/ckv153</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le Moal</surname><given-names>J</given-names></name><name name-style="western"><surname>Goria</surname><given-names>S</given-names></name><name name-style="western"><surname>Guillet</surname><given-names>A</given-names></name><name name-style="western"><surname>Rigou</surname><given-names>A</given-names></name><name name-style="western"><surname>Chesneau</surname><given-names>J</given-names></name></person-group><article-title>Time and spatial trends of operated cryptorchidism in France and environmental hypotheses: a nationwide study from 2002 to 2014</article-title><source>Hum Reprod</source><year>2021</year><volume>36</volume><issue>5</issue><fpage>1383</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1093/humrep/deaa378</pub-id><pub-id pub-id-type="pmid">33728432</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Le Moal J, Goria S, Guillet A, Rigou A, Chesneau J. Time and spatial trends of operated cryptorchidism in France and environmental hypotheses: a nationwide study from 2002 to 2014. Hum Reprod. 2021;36(5):1383&#8211;94.<pub-id pub-id-type="pmid">33728432</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/humrep/deaa378</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Peyronnet</surname><given-names>A</given-names></name><name name-style="western"><surname>Goria</surname><given-names>S</given-names></name><name name-style="western"><surname>Chesneau</surname><given-names>J</given-names></name><name name-style="western"><surname>Le Moal</surname><given-names>J</given-names></name></person-group><source>&#201;pid&#233;miologie du fibrome ut&#233;rin Pris En charge m&#233;dicalement En France de 2013 &#224; 2017</source><year>2022</year><publisher-loc>Saint-Maurice</publisher-loc><publisher-name>Sant&#233; publique France</publisher-name></element-citation><mixed-citation id="mc-CR11" publication-type="book">Peyronnet A, Goria S, Chesneau J, Le Moal J. &#201;pid&#233;miologie du fibrome ut&#233;rin Pris En charge m&#233;dicalement En France de 2013 &#224; 2017. Saint-Maurice: Sant&#233; publique France; 2022.</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Kortenkamp A, Martin OV, Faust M, Evans R, McKinlay R, Orton F, et al. editors. State of the art assessment of endocrine disruptors: Final Report. 2011.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/10408444.2012.712943</pub-id><pub-id pub-id-type="pmid">22900988</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ejaredar</surname><given-names>M</given-names></name><name name-style="western"><surname>Nyanza</surname><given-names>EC</given-names></name><name name-style="western"><surname>Ten Eycke</surname><given-names>K</given-names></name><name name-style="western"><surname>Dewey</surname><given-names>D</given-names></name></person-group><article-title>Phthalate exposure and childrens neurodevelopment: A systematic review</article-title><source>Environ Res</source><year>2015</year><volume>142</volume><fpage>51</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.envres.2015.06.014</pub-id><pub-id pub-id-type="pmid">26101203</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Ejaredar M, Nyanza EC, Ten Eycke K, Dewey D. Phthalate exposure and childrens neurodevelopment: A systematic review. Environ Res. 2015;142:51&#8211;60.<pub-id pub-id-type="pmid">26101203</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.envres.2015.06.014</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amir</surname><given-names>S</given-names></name><name name-style="western"><surname>Shah</surname><given-names>STA</given-names></name><name name-style="western"><surname>Mamoulakis</surname><given-names>C</given-names></name><name name-style="western"><surname>Docea</surname><given-names>AO</given-names></name><name name-style="western"><surname>Kalantzi</surname><given-names>OI</given-names></name><name name-style="western"><surname>Zachariou</surname><given-names>A</given-names></name><etal/></person-group><article-title>Endocrine disruptors acting on estrogen and androgen pathways cause reproductive disorders through multiple mechanisms: a review</article-title><source>Int J Environ Res Public Health</source><year>2021</year><pub-id pub-id-type="doi">10.3390/ijerph18041464</pub-id><pub-id pub-id-type="pmid">33557243</pub-id><pub-id pub-id-type="pmcid">PMC7913912</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Amir S, Shah STA, Mamoulakis C, Docea AO, Kalantzi OI, Zachariou A, et al. Endocrine disruptors acting on estrogen and androgen pathways cause reproductive disorders through multiple mechanisms: a review. Int J Environ Res Public Health. 2021. 10.3390/ijerph18041464.<pub-id pub-id-type="pmid">33557243</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijerph18041464</pub-id><pub-id pub-id-type="pmcid">PMC7913912</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sabuz Vidal</surname><given-names>O</given-names></name><name name-style="western"><surname>Deepika</surname><given-names>D</given-names></name><name name-style="western"><surname>Schuhmacher</surname><given-names>M</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>V</given-names></name></person-group><article-title>EDC-induced mechanisms of immunotoxicity: a systematic review</article-title><source>Crit Rev Toxicol</source><year>2021</year><volume>51</volume><issue>7</issue><fpage>634</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1080/10408444.2021.2009438</pub-id><pub-id pub-id-type="pmid">35015608</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Sabuz Vidal O, Deepika D, Schuhmacher M, Kumar V. EDC-induced mechanisms of immunotoxicity: a systematic review. Crit Rev Toxicol. 2021;51(7):634&#8211;52.<pub-id pub-id-type="pmid">35015608</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10408444.2021.2009438</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonde</surname><given-names>JP</given-names></name><name name-style="western"><surname>Flachs</surname><given-names>EM</given-names></name><name name-style="western"><surname>Rimborg</surname><given-names>S</given-names></name><name name-style="western"><surname>Glazer</surname><given-names>CH</given-names></name><name name-style="western"><surname>Giwercman</surname><given-names>A</given-names></name><name name-style="western"><surname>Ramlau-Hansen</surname><given-names>CH</given-names></name><etal/></person-group><article-title>The epidemiologic evidence linking prenatal and postnatal exposure to endocrine disrupting chemicals with male reproductive disorders: a systematic review and meta-analysis</article-title><source>Hum Reprod Update</source><year>2016</year><volume>23</volume><issue>1</issue><fpage>104</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1093/humupd/dmw036</pub-id><pub-id pub-id-type="pmid">27655588</pub-id><pub-id pub-id-type="pmcid">PMC5155570</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Bonde JP, Flachs EM, Rimborg S, Glazer CH, Giwercman A, Ramlau-Hansen CH, et al. The epidemiologic evidence linking prenatal and postnatal exposure to endocrine disrupting chemicals with male reproductive disorders: a systematic review and meta-analysis. Hum Reprod Update. 2016;23(1):104&#8211;25.<pub-id pub-id-type="pmid">27655588</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/humupd/dmw036</pub-id><pub-id pub-id-type="pmcid">PMC5155570</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>La Merrill</surname><given-names>MA</given-names></name><name name-style="western"><surname>Vandenberg</surname><given-names>LN</given-names></name><name name-style="western"><surname>Smith</surname><given-names>MT</given-names></name><name name-style="western"><surname>Goodson</surname><given-names>W</given-names></name><name name-style="western"><surname>Browne</surname><given-names>P</given-names></name><name name-style="western"><surname>Patisaul</surname><given-names>HB</given-names></name><etal/></person-group><article-title>Consensus on the key characteristics of endocrine-disrupting chemicals as a basis for hazard identification</article-title><source>Nat Rev Endocrinol</source><year>2020</year><volume>16</volume><issue>1</issue><fpage>45</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1038/s41574-019-0273-8</pub-id><pub-id pub-id-type="pmid">31719706</pub-id><pub-id pub-id-type="pmcid">PMC6902641</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">La Merrill MA, Vandenberg LN, Smith MT, Goodson W, Browne P, Patisaul HB, et al. Consensus on the key characteristics of endocrine-disrupting chemicals as a basis for hazard identification. Nat Rev Endocrinol. 2020;16(1):45&#8211;57.<pub-id pub-id-type="pmid">31719706</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41574-019-0273-8</pub-id><pub-id pub-id-type="pmcid">PMC6902641</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Bergman</surname><given-names>&#197;</given-names></name><name name-style="western"><surname>Heindel</surname><given-names>J</given-names></name><name name-style="western"><surname>Jobling</surname><given-names>S</given-names></name><name name-style="western"><surname>Kidd</surname><given-names>K</given-names></name><name name-style="western"><surname>Zoeller</surname><given-names>R</given-names></name></person-group><source>State of the Science of Endocrine Disrupting Chemicals &#8211;&#8201;2012</source><year>2013</year><publisher-name>World Health Organization / United Nations Environment Programme</publisher-name></element-citation><mixed-citation id="mc-CR18" publication-type="book">Bergman &#197;, Heindel J, Jobling S, Kidd K, Zoeller R. State of the Science of Endocrine Disrupting Chemicals &#8211;&#8201;2012. World Health Organization / United Nations Environment Programme; 2013.</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>K&#246;hrle</surname><given-names>J</given-names></name><name name-style="western"><surname>Fr&#228;drich</surname><given-names>C</given-names></name></person-group><article-title>Thyroid hormone system disrupting chemicals</article-title><source>Best Pract Res Clin Endocrinol Metab</source><year>2021</year><volume>35</volume><issue>5</issue><fpage>101562</fpage><pub-id pub-id-type="doi">10.1016/j.beem.2021.101562</pub-id><pub-id pub-id-type="pmid">34274233</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">K&#246;hrle J, Fr&#228;drich C. Thyroid hormone system disrupting chemicals. Best Pract Res Clin Endocrinol Metab. 2021;35(5): 101562.<pub-id pub-id-type="pmid">34274233</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.beem.2021.101562</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pearce</surname><given-names>EN</given-names></name></person-group><article-title>Endocrine disruptors and thyroid health</article-title><source>Endocr Pract</source><year>2024</year><volume>30</volume><issue>2</issue><fpage>172</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.eprac.2023.11.002</pub-id><pub-id pub-id-type="pmid">37956907</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Pearce EN. Endocrine disruptors and thyroid health. Endocr Pract. 2024;30(2):172&#8211;6.<pub-id pub-id-type="pmid">37956907</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eprac.2023.11.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="book"><person-group person-group-type="author"><collab>Anses</collab></person-group><source>&#201;laboration d&#8217;une liste de substances chimiques d&#8217;int&#233;r&#234;t en raison de leur activit&#233; endocrine potentielle. M&#233;thode d&#8217;identification et strat&#233;gie de priorisation pour l&#8217;&#233;valuation</source><year>2021</year><publisher-name>Maisons-Alfort</publisher-name></element-citation><mixed-citation id="mc-CR21" publication-type="book">Anses. &#201;laboration d&#8217;une liste de substances chimiques d&#8217;int&#233;r&#234;t en raison de leur activit&#233; endocrine potentielle. M&#233;thode d&#8217;identification et strat&#233;gie de priorisation pour l&#8217;&#233;valuation. Maisons-Alfort; 2021.</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krimsky</surname><given-names>S</given-names></name></person-group><article-title>The weight of scientific evidence in policy and law</article-title><source>Am J Public Health</source><year>2005</year><volume>95</volume><issue>Suppl 1</issue><fpage>S129</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.2105/AJPH.2004.044727</pub-id><pub-id pub-id-type="pmid">16030328</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Krimsky S. The weight of scientific evidence in policy and law. Am J Public Health. 2005;95(Suppl 1):S129-36.<pub-id pub-id-type="pmid">16030328</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2105/AJPH.2004.044727</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Makowski</surname><given-names>D</given-names></name><name name-style="western"><surname>Albert</surname><given-names>I</given-names></name><name name-style="western"><surname>Bonvallot</surname><given-names>N</given-names></name><name name-style="western"><surname>Boudia</surname><given-names>S</given-names></name><name name-style="western"><surname>Brochot</surname><given-names>C</given-names></name><name name-style="western"><surname>Bruyere</surname><given-names>O</given-names></name></person-group><source>&#201;valuation du Poids des preuves &#224; l&#8217;anses: revue critique de La litt&#233;rature et recommandations &#224; l&#8217;&#233;tape d&#8217;identification des dangers</source><year>2016</year><publisher-loc>Maisons-Alfort</publisher-loc><publisher-name>Anses</publisher-name></element-citation><mixed-citation id="mc-CR23" publication-type="book">Makowski D, Albert I, Bonvallot N, Boudia S, Brochot C, Bruyere O. &#201;valuation du Poids des preuves &#224; l&#8217;anses: revue critique de La litt&#233;rature et recommandations &#224; l&#8217;&#233;tape d&#8217;identification des dangers. Maisons-Alfort: Anses; 2016.</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trasande</surname><given-names>L</given-names></name><name name-style="western"><surname>Zoeller</surname><given-names>RT</given-names></name><name name-style="western"><surname>Hass</surname><given-names>U</given-names></name><name name-style="western"><surname>Kortenkamp</surname><given-names>A</given-names></name><name name-style="western"><surname>Grandjean</surname><given-names>P</given-names></name><name name-style="western"><surname>Myers</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Burden of disease and costs of exposure to endocrine disrupting chemicals in the European union: an updated analysis</article-title><source>Andrology</source><year>2016</year><volume>4</volume><issue>4</issue><fpage>565</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1111/andr.12178</pub-id><pub-id pub-id-type="pmid">27003928</pub-id><pub-id pub-id-type="pmcid">PMC5244983</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Trasande L, Zoeller RT, Hass U, Kortenkamp A, Grandjean P, Myers JP, et al. Burden of disease and costs of exposure to endocrine disrupting chemicals in the European union: an updated analysis. Andrology. 2016;4(4):565&#8211;72.<pub-id pub-id-type="pmid">27003928</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/andr.12178</pub-id><pub-id pub-id-type="pmcid">PMC5244983</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trasande</surname><given-names>L</given-names></name><name name-style="western"><surname>Zoeller</surname><given-names>RT</given-names></name><name name-style="western"><surname>Hass</surname><given-names>U</given-names></name><name name-style="western"><surname>Kortenkamp</surname><given-names>A</given-names></name><name name-style="western"><surname>Grandjean</surname><given-names>P</given-names></name><name name-style="western"><surname>Myers</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Estimating burden and disease costs of exposure to endocrine-disrupting chemicals in the European Union</article-title><source>J Clin Endocrinol Metab</source><year>2015</year><volume>100</volume><issue>4</issue><fpage>1245</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1210/jc.2014-4324</pub-id><pub-id pub-id-type="pmid">25742516</pub-id><pub-id pub-id-type="pmcid">PMC4399291</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Trasande L, Zoeller RT, Hass U, Kortenkamp A, Grandjean P, Myers JP, et al. Estimating burden and disease costs of exposure to endocrine-disrupting chemicals in the European Union. J Clin Endocrinol Metab. 2015;100(4):1245&#8211;55.<pub-id pub-id-type="pmid">25742516</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jc.2014-4324</pub-id><pub-id pub-id-type="pmcid">PMC4399291</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murphy</surname><given-names>MK</given-names></name><name name-style="western"><surname>Black</surname><given-names>NA</given-names></name><name name-style="western"><surname>Lamping</surname><given-names>DL</given-names></name><name name-style="western"><surname>McKee</surname><given-names>CM</given-names></name><name name-style="western"><surname>Sanderson</surname><given-names>CF</given-names></name><name name-style="western"><surname>Askham</surname><given-names>J</given-names></name><etal/></person-group><article-title>Consensus development methods, and their use in clinical guideline development</article-title><source>Health Technol Assess</source><year>1998</year><volume>2</volume><issue>3</issue><fpage>i</fpage><lpage>iv</lpage><pub-id pub-id-type="doi">10.3310/hta2030</pub-id><pub-id pub-id-type="pmid">9561895</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Murphy MK, Black NA, Lamping DL, McKee CM, Sanderson CF, Askham J, et al. Consensus development methods, and their use in clinical guideline development. Health Technol Assess. 1998;2(3):i&#8211;iv.<pub-id pub-id-type="pmid">9561895</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niederberger</surname><given-names>M</given-names></name><name name-style="western"><surname>Spranger</surname><given-names>J</given-names></name></person-group><article-title>Delphi technique in health sciences: a map</article-title><source>Front Public Health</source><year>2020</year><volume>8</volume><fpage>457</fpage><pub-id pub-id-type="doi">10.3389/fpubh.2020.00457</pub-id><pub-id pub-id-type="pmid">33072683</pub-id><pub-id pub-id-type="pmcid">PMC7536299</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Niederberger M, Spranger J. Delphi technique in health sciences: a map. Front Public Health. 2020;8:457.<pub-id pub-id-type="pmid">33072683</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpubh.2020.00457</pub-id><pub-id pub-id-type="pmcid">PMC7536299</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salgado</surname><given-names>M</given-names></name><name name-style="western"><surname>Vieira</surname><given-names>ACL</given-names></name><name name-style="western"><surname>Torres</surname><given-names>A</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>MD</given-names></name></person-group><article-title>Selecting indicators to monitor and assess environmental health in a Portuguese urban setting: a participatory approach</article-title><source>Int J Environ Res Public Health</source><year>2020</year><pub-id pub-id-type="doi">10.3390/ijerph17228597</pub-id><pub-id pub-id-type="pmid">33228088</pub-id><pub-id pub-id-type="pmcid">PMC7699361</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Salgado M, Vieira ACL, Torres A, Oliveira MD. Selecting indicators to monitor and assess environmental health in a Portuguese urban setting: a participatory approach. Int J Environ Res Public Health. 2020. 10.3390/ijerph17228597.<pub-id pub-id-type="pmid">33228088</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijerph17228597</pub-id><pub-id pub-id-type="pmcid">PMC7699361</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kahn</surname><given-names>LG</given-names></name><name name-style="western"><surname>Philippat</surname><given-names>C</given-names></name><name name-style="western"><surname>Nakayama</surname><given-names>SF</given-names></name><name name-style="western"><surname>Slama</surname><given-names>R</given-names></name><name name-style="western"><surname>Trasande</surname><given-names>L</given-names></name></person-group><article-title>Endocrine-disrupting chemicals: implications for human health</article-title><source>Lancet Diabetes Endocrinol</source><year>2020</year><volume>8</volume><issue>8</issue><fpage>703</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/S2213-8587(20)30129-7</pub-id><pub-id pub-id-type="pmid">32707118</pub-id><pub-id pub-id-type="pmcid">PMC7437820</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Kahn LG, Philippat C, Nakayama SF, Slama R, Trasande L. Endocrine-disrupting chemicals: implications for human health. Lancet Diabetes Endocrinol. 2020;8(8):703&#8211;18.<pub-id pub-id-type="pmid">32707118</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-8587(20)30129-7</pub-id><pub-id pub-id-type="pmcid">PMC7437820</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="other">Com-Ruelle L, Lecomte T, Le Fur P, Mizrahi A, Sermet C. Un indicateur de gravit&#233; des maladies. Enqu&#234;te sur la sant&#233; et les soins m&#233;dicaux France 1991-92 CREDES. 1997.</mixed-citation></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><collab>WHO Quality of Life Assessment Group</collab></person-group><article-title>What quality of life? The WHOQOL group. World health organization quality of life assessment</article-title><source>World Health Forum</source><year>1996</year><volume>17</volume><issue>4</issue><fpage>354</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">9060228</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">WHO Quality of Life Assessment Group. What quality of life? The WHOQOL group. World health organization quality of life assessment. World Health Forum. 1996;17(4):354&#8211;6.<pub-id pub-id-type="pmid">9060228</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hasson</surname><given-names>F</given-names></name><name name-style="western"><surname>Keeney</surname><given-names>S</given-names></name><name name-style="western"><surname>McKenna</surname><given-names>H</given-names></name></person-group><article-title>Research guidelines for the Delphi survey technique</article-title><source>J Adv Nurs</source><year>2000</year><volume>32</volume><issue>4</issue><fpage>1008</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2648.2000.t01-1-01567.x</pub-id><pub-id pub-id-type="pmid">11095242</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. J Adv Nurs. 2000;32(4):1008&#8211;15.<pub-id pub-id-type="pmid">11095242</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gore</surname><given-names>AC</given-names></name><name name-style="western"><surname>Chappell</surname><given-names>VA</given-names></name><name name-style="western"><surname>Fenton</surname><given-names>SE</given-names></name><name name-style="western"><surname>Flaws</surname><given-names>JA</given-names></name><name name-style="western"><surname>Nadal</surname><given-names>A</given-names></name><name name-style="western"><surname>Prins</surname><given-names>GS</given-names></name><etal/></person-group><article-title>Executive summary to EDC-2: the endocrine society&#8217;s second scientific statement on endocrine-disrupting chemicals</article-title><source>Endocr Rev</source><year>2015</year><volume>36</volume><issue>6</issue><fpage>593</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1210/er.2015-1093</pub-id><pub-id pub-id-type="pmid">26414233</pub-id><pub-id pub-id-type="pmcid">PMC4702495</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Gore AC, Chappell VA, Fenton SE, Flaws JA, Nadal A, Prins GS, et al. Executive summary to EDC-2: the endocrine society&#8217;s second scientific statement on endocrine-disrupting chemicals. Endocr Rev. 2015;36(6):593&#8211;602.<pub-id pub-id-type="pmid">26414233</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/er.2015-1093</pub-id><pub-id pub-id-type="pmcid">PMC4702495</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmalz</surname><given-names>U</given-names></name><name name-style="western"><surname>Spinler</surname><given-names>S</given-names></name><name name-style="western"><surname>Ringbeck</surname><given-names>J</given-names></name></person-group><article-title>Lessons learned from a two-round Delphi-based scenario study</article-title><source>MethodsX</source><year>2021</year><volume>8</volume><fpage>101179</fpage><pub-id pub-id-type="doi">10.1016/j.mex.2020.101179</pub-id><pub-id pub-id-type="pmid">33365260</pub-id><pub-id pub-id-type="pmcid">PMC7749424</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Schmalz U, Spinler S, Ringbeck J. Lessons learned from a two-round Delphi-based scenario study. MethodsX. 2021;8:101179.<pub-id pub-id-type="pmid">33365260</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mex.2020.101179</pub-id><pub-id pub-id-type="pmcid">PMC7749424</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sumsion</surname><given-names>T</given-names></name></person-group><article-title>The Delphi technique: an adaptive research tool</article-title><source>Br J Occup Therapy</source><year>1998</year><volume>61</volume><issue>4</issue><fpage>153</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1177/030802269806100403</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Sumsion T. The Delphi technique: an adaptive research tool. Br J Occup Therapy. 1998;61(4):153&#8211;6.</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Green</surname><given-names>B</given-names></name><name name-style="western"><surname>Jones</surname><given-names>M</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>D</given-names></name><name name-style="western"><surname>Williams</surname><given-names>A</given-names></name></person-group><article-title>Applying the Delphi technique in a study of GPS&#8217; information requirements</article-title><source>Health Soc Care Community</source><year>1999</year><volume>7</volume><issue>3</issue><fpage>198</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2524.1999.00176.x</pub-id><pub-id pub-id-type="pmid">11560634</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Green B, Jones M, Hughes D, Williams A. Applying the Delphi technique in a study of GPS&#8217; information requirements. Health Soc Care Community. 1999;7(3):198&#8211;205.<pub-id pub-id-type="pmid">11560634</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2524.1999.00176.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diamond</surname><given-names>IR</given-names></name><name name-style="western"><surname>Grant</surname><given-names>RC</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>BM</given-names></name><name name-style="western"><surname>Pencharz</surname><given-names>PB</given-names></name><name name-style="western"><surname>Ling</surname><given-names>SC</given-names></name><name name-style="western"><surname>Moore</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies</article-title><source>J Clin Epidemiol</source><year>2014</year><volume>67</volume><issue>4</issue><fpage>401</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.jclinepi.2013.12.002</pub-id><pub-id pub-id-type="pmid">24581294</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Diamond IR, Grant RC, Feldman BM, Pencharz PB, Ling SC, Moore AM, et al. Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. J Clin Epidemiol. 2014;67(4):401&#8211;9.<pub-id pub-id-type="pmid">24581294</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jclinepi.2013.12.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Le Moal</surname><given-names>J</given-names></name><name name-style="western"><surname>Goria</surname><given-names>S</given-names></name><name name-style="western"><surname>Chesneau</surname><given-names>J</given-names></name><name name-style="western"><surname>Fauconnier</surname><given-names>A</given-names></name><name name-style="western"><surname>Kvaskoff</surname><given-names>M</given-names></name><name name-style="western"><surname>De Crouy-Chanel</surname><given-names>P</given-names></name><etal/></person-group><source>&#201;pid&#233;miologie de l&#8217;endom&#233;triose prise En charge &#224; l&#8217;h&#244;pital En france: &#233;tude de 2011 &#224; 2017</source><year>2022</year><publisher-loc>Saint-Maurice</publisher-loc><publisher-name>Sant&#233; publique France</publisher-name></element-citation><mixed-citation id="mc-CR38" publication-type="book">Le Moal J, Goria S, Chesneau J, Fauconnier A, Kvaskoff M, De Crouy-Chanel P, et al. &#201;pid&#233;miologie de l&#8217;endom&#233;triose prise En charge &#224; l&#8217;h&#244;pital En france: &#233;tude de 2011 &#224; 2017. Saint-Maurice: Sant&#233; publique France; 2022.</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le Moal</surname><given-names>J</given-names></name><name name-style="western"><surname>Rigou</surname><given-names>A</given-names></name><name name-style="western"><surname>Le Tertre</surname><given-names>A</given-names></name><name name-style="western"><surname>De Crouy-Channel</surname><given-names>P</given-names></name><name name-style="western"><surname>L&#233;ger</surname><given-names>J</given-names></name><name name-style="western"><surname>Carel</surname><given-names>JC</given-names></name></person-group><article-title>Marked geographic patterns in the incidence of idiopathic central precocious puberty: a nationwide study in France</article-title><source>Eur J Endocrinol</source><year>2018</year><volume>178</volume><issue>1</issue><fpage>33</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1530/EJE-17-0379</pub-id><pub-id pub-id-type="pmid">28890442</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Le Moal J, Rigou A, Le Tertre A, De Crouy-Channel P, L&#233;ger J, Carel JC. Marked geographic patterns in the incidence of idiopathic central precocious puberty: a nationwide study in France. Eur J Endocrinol. 2018;178(1):33&#8211;41.<pub-id pub-id-type="pmid">28890442</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1530/EJE-17-0379</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boulkedid</surname><given-names>R</given-names></name><name name-style="western"><surname>Abdoul</surname><given-names>H</given-names></name><name name-style="western"><surname>Loustau</surname><given-names>M</given-names></name><name name-style="western"><surname>Sibony</surname><given-names>O</given-names></name><name name-style="western"><surname>Alberti</surname><given-names>C</given-names></name></person-group><article-title>Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><issue>6</issue><fpage>e20476</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0020476</pub-id><pub-id pub-id-type="pmid">21694759</pub-id><pub-id pub-id-type="pmcid">PMC3111406</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Boulkedid R, Abdoul H, Loustau M, Sibony O, Alberti C. Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review. PLoS One. 2011;6(6):e20476.<pub-id pub-id-type="pmid">21694759</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0020476</pub-id><pub-id pub-id-type="pmcid">PMC3111406</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="other">Sackman H, editor. Delphi critique: expert opinion, forecasting, and group process. 1975.</mixed-citation></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fletcher</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Marchildon</surname><given-names>GP</given-names></name></person-group><article-title>Using the Delphi method for qualitative, participatory action research in health leadership</article-title><source>Int J Qual Methods</source><year>2014</year><volume>13</volume><issue>1</issue><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1177/160940691401300101</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Fletcher AJ, Marchildon GP. Using the Delphi method for qualitative, participatory action research in health leadership. Int J Qual Methods. 2014;13(1):1&#8211;18.</mixed-citation></citation-alternatives></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JCI Insight</journal-id><journal-id journal-id-type="iso-abbrev">JCI Insight</journal-id><journal-id journal-id-type="pmc-domain-id">3101</journal-id><journal-id journal-id-type="pmc-domain">jciinsight</journal-id><journal-id journal-id-type="publisher-id">JCI Insight</journal-id><journal-title-group><journal-title>JCI Insight</journal-title></journal-title-group><issn pub-type="epub">2379-3708</issn><publisher><publisher-name>American Society for Clinical Investigation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12487674</article-id><article-id pub-id-type="pmcid-ver">PMC12487674.1</article-id><article-id pub-id-type="pmcaid">12487674</article-id><article-id pub-id-type="pmcaiid">12487674</article-id><article-id pub-id-type="pmid">40728889</article-id><article-id pub-id-type="doi">10.1172/jci.insight.191688</article-id><article-id pub-id-type="publisher-id">191688</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Elevation of master autophagy regulator <italic toggle="yes">Tfeb</italic> in osteoblast lineage cells increases bone mass and strength</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>James</surname><given-names initials="A">Alicen</given-names></name><email>AWJames@uams.edu</email><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hendrixson</surname><given-names initials="JA">James A.</given-names></name><email>JAHendrixson@uams.edu</email><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kadhim</surname><given-names initials="I">Ilham</given-names></name><email>IKadhim@uams.edu</email><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Marques-Carvalho</surname><given-names initials="A">Adriana</given-names></name><email>AMarquescarvalho@uams.edu</email><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Laster</surname><given-names initials="J">Jacob</given-names></name><email>jacoblaster280@gmail.com</email><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Crawford</surname><given-names initials="J">Julie</given-names></name><email>CrawfordJulieA@uams.edu</email><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Thostenson</surname><given-names initials="J">Jeff</given-names></name><email>jdthostenson@uams.edu</email><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wanchai</surname><given-names initials="V">Visanu</given-names></name><email>VWanchai@uams.edu</email><xref rid="A3" ref-type="aff">3</xref><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5061-1369</contrib-id><name name-style="western"><surname>Sato</surname><given-names initials="AY">Amy Y.</given-names></name><email>AYSato@uams.edu</email><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8901-1088</contrib-id><name name-style="western"><surname>Nookaew</surname><given-names initials="I">Intawat</given-names></name><email>INookaew@uams.edu</email><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xiong</surname><given-names initials="J">Jinhu</given-names></name><email>jxiong@uams.edu</email><xref rid="A3" ref-type="aff">3</xref><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6722-9200</contrib-id><name name-style="western"><surname>Almeida</surname><given-names initials="M">Maria</given-names></name><email>schullermaria@uams.edu</email><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Onal</surname><given-names initials="M">Melda</given-names></name><email>monal@uams.edu</email><xref rid="A1" ref-type="aff">1</xref><xref rid="A3" ref-type="aff">3</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Physiology and Cell Biology;</aff><aff id="A2"><label>2</label>Division of Endocrinology and Metabolism, Department of Internal Medicine;</aff><aff id="A3"><label>3</label>Center for Musculoskeletal Disease Research (CMDR);</aff><aff id="A4"><label>4</label>Department of Biostatistics;</aff><aff id="A5"><label>5</label>Department of Biomedical Informatics; and</aff><aff id="A6"><label>6</label>Department of Orthopaedic Surgery, University of Arkansas for Medical Sciences (UAMS), Little Rock, Arkansas, USA.</aff><author-notes><corresp>Address correspondence to: Melda Onal, University of Arkansas for Medical Sciences, Department of Physiology and Cell Biology, 4301 W. Markham St., #505, Little Rock, Arkansas, 72205, USA. Phone: 501.541.8040; Email: <email>Monal@uams.edu</email>.</corresp></author-notes><pub-date date-type="pub" publication-format="electronic" iso-8601-date="2025-07-29T12:00:00-0400"><day>29</day><month>7</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic" iso-8601-date="2025-09-09T12:00:00-0400"><day>9</day><month>9</month><year>2025</year></pub-date><volume>10</volume><issue>17</issue><issue-id pub-id-type="pmc-issue-id">498102</issue-id><elocation-id>e191688</elocation-id><history><date date-type="received"><day>27</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>23</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>29</day><month>07</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>02</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-02 11:25:38.340"><day>02</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 James et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>James et al.</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://creativecommons.org/licenses/by/4.0/" ext-link-type="uri">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jciinsight-10-191688.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://insight.jci.org/articles/view/191688">This article is available online at https://insight.jci.org/articles/view/191688</self-uri><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="preprint" xml:lang="en" xlink:title="research-article" journal-id="bioRxiv" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC11463346"><article-title>
CRISPR activation of
<italic toggle="yes">Tfeb</italic>
, a master regulator of autophagy and lysosomal biogenesis, in osteoblast lineage cells increases bone mass and strength
</article-title><date><day>26</day><month>9</month><year>2024</year></date><elocation-id>2024.09.26.615175</elocation-id><source>bioRxiv</source><pub-id pub-id-type="pmcid">PMC11463346</pub-id><pub-id pub-id-type="pmid">39386619</pub-id></related-article><abstract><p>Autophagy is a recycling pathway in which damaged proteins, protein aggregates, and organelles are delivered to lysosomes for degradation. Autophagy insufficiency is thought to contribute to osteoporosis. Accordingly, autophagy elimination from the osteoblast lineage reduces bone formation and bone mass. However, whether increasing autophagy would benefit bone health is unknown. Here, we increased expression of endogenous transcription factor EB gene (<italic toggle="yes">Tfeb</italic>) in osteoblast lineage cells in vivo via CRISPR activation (<italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice). Elevated <italic toggle="yes">Tfeb</italic> stimulated autophagy and lysosomal biogenesis in osteoblasts. <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice displayed a robust increase in femoral and vertebral cortical thickness at 4.5 months of age. Increases in cortical thickness were due to increased periosteal bone formation. <italic toggle="yes">Tfeb</italic> elevation also increased femoral trabecular bone volume. These changes increased bone strength of <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice. Female <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice displayed a progressive increase in bone mass and at 12 months of age had high cortical thickness and trabecular bone volume. Increased vertebral trabecular bone volume was due to elevated bone formation. Osteoblastic cultures showed that <italic toggle="yes">Tfeb</italic> elevation increased proliferation and mineral deposition. Overall, these results demonstrate TFEB-driven stimulation of autophagy in osteoblast lineage cells is associated with increased bone formation and strength and may represent an effective approach to combat osteoporosis.</p></abstract><abstract abstract-type="toc"><p>Autophagy is a cellular recycling mechanism that is essential for bone formation. A genetic maneuver that stimulates autophagy increases bone formation, bone mass, and strength.</p></abstract><kwd-group kwd-group-type="specialties"><kwd>Bone biology</kwd><kwd>Cell biology</kwd></kwd-group><kwd-group kwd-group-type="keywords"><kwd>Autophagy</kwd><kwd>Osteoclast/osteoblast biology</kwd><kwd>Osteoporosis</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Throughout life, bone is remodeled by osteoclasts, which resorb bone, and osteoblasts, which form bone (<xref rid="B1" ref-type="bibr">1</xref>). As osteoblasts form new bone, some become embedded in the bone matrix they produce and differentiate into osteocytes. Osteocytes orchestrate bone remodeling by secreting factors that control bone formation and resorption (<xref rid="B2" ref-type="bibr">2</xref>). When the balance between bone formation and resorption shifts in favor of bone resorption, bone mass is lost. The health and functionality of osteoblast lineage cells (osteoblast progenitors, osteoblasts, and osteocytes) are essential for bone formation (<xref rid="B3" ref-type="bibr">3</xref>). Therefore, insight into the pathways and mechanisms that control the production, survival, and function of osteoblast lineage cells may identify new therapeutic targets.</p><p>Macroautophagy/autophagy is a catabolic process in which cellular contents are engulfed by autophagosomes and delivered to lysosomes for degradation and recycling. Autophagy clears damaged organelles and protein aggregates and turns over cytosolic components. Deletion of essential components of autophagy, such as autophagy related 7 (<italic toggle="yes">Atg7</italic>), <italic toggle="yes">Atg5</italic>, or unc-51 like kinase 1 (<italic toggle="yes">Ulk1</italic>), using various Cre driver strains active in osteoblast lineage cells demonstrates that autophagy is essential for the accrual of bone mass (<xref rid="B4" ref-type="bibr">4</xref>&#8211;<xref rid="B8" ref-type="bibr">8</xref>). Most strikingly, deletion of <italic toggle="yes">Atg7</italic> from the entire osteoblast lineage using the Osx1-Cre transgene drastically decreases osteoblast number and bone formation, leading to low bone mass and a 50% fracture rate (<xref rid="B5" ref-type="bibr">5</xref>). Together, these studies demonstrate that autophagy is essential for the maintenance of osteoblast number and bone formation and suggest that insufficient autophagy levels may contribute to the decline in bone formation in various skeletal pathologies, such as age-related bone loss (<xref rid="B9" ref-type="bibr">9</xref>&#8211;<xref rid="B11" ref-type="bibr">11</xref>). However, whether stimulation of autophagy in osteoblast lineage cells could be beneficial for bone in physiological or pathological conditions remains unknown.</p><p>To address this question, we sought to stimulate autophagy in osteoblast lineage cells by increasing expression of transcription factor EB (<italic toggle="yes">Tfeb</italic>) &#8212; the major transcriptional regulator of genes involved in autophagy and lysosomal biogenesis (<xref rid="B12" ref-type="bibr">12</xref>). This approach is based on evidence that targeted overexpression of <italic toggle="yes">Tfeb</italic> in myotubes (<xref rid="B13" ref-type="bibr">13</xref>), neurons (<xref rid="B14" ref-type="bibr">14</xref>&#8211;<xref rid="B16" ref-type="bibr">16</xref>), oligodendrocytes (<xref rid="B15" ref-type="bibr">15</xref>), macrophages (<xref rid="B17" ref-type="bibr">17</xref>), cardiac myocytes (<xref rid="B18" ref-type="bibr">18</xref>), or chondrocytes (<xref rid="B19" ref-type="bibr">19</xref>) is sufficient to induce autophagy and alleviate dysfunction in murine models of Pompe disease, Parkinson disease, Alzheimer disease, multiple system atrophy, atherosclerosis, cardiac hypertrophy, and osteoarthritis, respectively. Herein, we used in vivo CRISPR activation to elevate endogenous <italic toggle="yes">Tfeb</italic> expression to stimulate autophagy in osteoblast lineage cells. This genetic maneuver greatly increased bone mass by promoting bone formation.</p></sec><sec sec-type="results"><title>Results</title><sec><title>Generation of sgRNA<sup>Tfeb</sup> mice.</title><p>To increase <italic toggle="yes">Tfeb</italic> expression in vivo, we used CRISPR activation (CRISPRa) (<xref rid="B20" ref-type="bibr">20</xref>&#8211;<xref rid="B23" ref-type="bibr">23</xref>). In this methodology, nuclease-deficient Cas9 (dead Cas9, dCas9), which cannot cut DNA, is fused to one or more transcriptional activator domains (dCas9:activator). To increase transcription of target genes, the dCas9:activator fusion protein is directed to the proximity of the target gene&#8217;s transcriptional start site (TSS) via the use of an sgRNA that is complementary to that region. The level of transcriptional stimulation varies based on where the dCas9:activator is directed to relative to the TSS of the targeted gene. To identify sgRNAs that facilitate elevated expression of <italic toggle="yes">Tfeb</italic>, we designed 5 sgRNAs targeting the 300 bp region centered on the <italic toggle="yes">Tfeb</italic> TSS with minimal off-target potential (<xref rid="F1" ref-type="fig">Figure 1A</xref>). We next tested their activity in vitro using an osteoblast cell line that expresses dCas9:activator (SP-dCas9-VPR) and identified 3 sgRNAs that elevated <italic toggle="yes">Tfeb</italic> expression 4- to 11-fold in culture (<xref rid="F1" ref-type="fig">Figure 1B</xref>). Sustained high-level overexpression of genes can have detrimental effects. For example, in a previously described murine model, sustained high-level overexpression of <italic toggle="yes">Tfeb</italic> (8-fold compared with controls) in the heart had detrimental effects (<xref rid="B24" ref-type="bibr">24</xref>). To avoid potential complications because of high-level overexpression, for the generation of our mouse model, we selected <italic toggle="yes">Tfeb</italic>_sgRNA_4, which stimulates <italic toggle="yes">Tfeb</italic> expression moderately (<xref rid="F1" ref-type="fig">Figure 1B</xref>).</p><p>To obtain ubiquitous and consistent expression of the selected sgRNA for CRISPRa, we inserted an expression cassette encoding it into a safe harbor locus. In previous studies, we successfully used this approach to express an sgRNA for in vivo CRISPR interference (<xref rid="B25" ref-type="bibr">25</xref>). Similarly, herein we introduced a cassette expressing <italic toggle="yes">Tfeb</italic>_sgRNA_4 into the murine <italic toggle="yes">Rosa26</italic> locus, producing sgRNA<italic toggle="yes"><sup>Tfeb</sup></italic> mice. As expected, hemizygous or homozygous sgRNA<italic toggle="yes"><sup>Tfeb</sup></italic> mice were born at expected Mendelian ratios and were grossly indistinguishable from wild-type mice.</p></sec><sec><title>Tfeb elevation in the osteoblast lineage stimulates autophagy and lysosomal biogenesis.</title><p>To increase endogenous <italic toggle="yes">Tfeb</italic> in osteoblast lineage cells in vivo, we crossed sgRNA<italic toggle="yes"><sup>Tfeb</sup></italic> mice with CRa (<xref rid="B22" ref-type="bibr">22</xref>) and Osx1-Cre mice (<xref rid="B26" ref-type="bibr">26</xref>) (<xref rid="F1" ref-type="fig">Figure 1C</xref>). CRa transgenic mice contain a floxed stop cassette that prevents expression of dCas9:activator (dCas9:SunTag-p65-HSF1 or dCas9:SPH) until activated by a Cre driver strain (<xref rid="B22" ref-type="bibr">22</xref>). In triple transgenic CRa Osx1-Cre sgRNA<italic toggle="yes"><sup>Tfeb</sup></italic> mice, from here on referred to as <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice, dCas9:SPH is expressed only in cells targeted by Osx1-Cre. <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice showed a ~1.4-fold increase in <italic toggle="yes">Tfeb</italic> mRNA in spine compared with controls (<xref rid="F1" ref-type="fig">Figure 1D</xref>). Next, we examined the expression of lysosomal and autophagy-related genes whose expression is controlled by TFEB in multiple cell types (<xref rid="B27" ref-type="bibr">27</xref>&#8211;<xref rid="B31" ref-type="bibr">31</xref>). A 2.7-fold increase in <italic toggle="yes">Tfeb</italic> mRNA was also seen in calvariae of <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice, and this was associated with increased expression of several genes involved in lysosomal biogenesis and autophagy (<xref rid="F1" ref-type="fig">Figure 1E</xref>). It was previously shown that TFEB can induce autophagy of mitochondria (mitophagy) in part by increasing expression of mitophagy receptors (<xref rid="B30" ref-type="bibr">30</xref>). Therefore, we also measured expression of mitophagy receptors, which are thought to be important for mesenchymal bone cells (<xref rid="B32" ref-type="bibr">32</xref>&#8211;<xref rid="B36" ref-type="bibr">36</xref>), and showed that TFEB elevated expression of many of these genes (<xref rid="F1" ref-type="fig">Figure 1E</xref>), suggesting that mitophagy may be elevated in <italic toggle="yes">Tfeb</italic><sup>CRa</sup> osteoblasts. In support of this, we observed a reduction in mitochondrial mass of <italic toggle="yes">Tfeb</italic><sup>CRa</sup> osteoblasts (<xref rid="sd" ref-type="sec">Supplemental Figure 1</xref>; supplemental material available online with this article; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1172/jci.insight.191688DS1" ext-link-type="uri">https://doi.org/10.1172/jci.insight.191688DS1</ext-link>).</p><p>Next, we examined whether elevation of <italic toggle="yes">Tfeb</italic> stimulates autophagy in osteoblast lineage cells. To this end, we cultured cells isolated from femurs of <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice and littermate controls in osteogenic differentiation medium for 3 weeks, then treated these osteoblasts with bafilomycin (Baf) or vehicle. Western blot analysis verified that <italic toggle="yes">Tfeb</italic><sup>CRa</sup> osteoblasts had higher TFEB levels than Cre controls (<xref rid="F2" ref-type="fig">Figure 2, A and B</xref>). Consistent with previous studies (<xref rid="B37" ref-type="bibr">37</xref>), inhibition of lysosomal function (Baf treatment) caused a shift in TFEB mobility (<xref rid="F2" ref-type="fig">Figure 2A</xref>). This shift in TFEB mobility is likely because inhibition of lysosomal function decreases mTOR-dependent phosphorylation of TFEB (<xref rid="B37" ref-type="bibr">37</xref>). Next, we measured autophagy levels by examining LC3-I to -II conversion, LC3-II flux, and p62 flux (<xref rid="F2" ref-type="fig">Figure 2, A&#8211;E</xref>). Autophagosome formation indicated by LC3-I to -II conversion was increased in <italic toggle="yes">Tfeb</italic><sup>CRa</sup> osteoblasts compared with Cre controls (<xref rid="F2" ref-type="fig">Figure 2, A and C</xref>). Comparison of LC3-II and p62 degradation by 2-way ANOVA interaction analysis (<italic toggle="yes">p</italic>_int &lt; 0.05) revealed higher degradation of these proteins in <italic toggle="yes">Tfeb</italic><sup>CRa</sup> osteoblasts compared with controls (<xref rid="F2" ref-type="fig">Figure 2, A, D, and E</xref>), indicating higher autophagic flux in <italic toggle="yes">Tfeb</italic><sup>CRa</sup> osteoblasts. Independent measurement of autophagy using a cell-permeable fluorescent Autophagy Probe verified that autophagy is indeed higher in <italic toggle="yes">Tfeb</italic><sup>CRa</sup> osteoblasts compared with Cre controls when cultured in complete (10% FBS) or low-serum (2% FBS) media (<xref rid="F2" ref-type="fig">Figure 2F</xref>). As indicated by LAMP1 protein levels and LysoTracker staining (<xref rid="F2" ref-type="fig">Figure 2, G and H</xref>), TFEB elevation in osteoblasts also increased lysosomal biogenesis. Taken together, these results demonstrate that the elevation of endogenous <italic toggle="yes">Tfeb</italic> in osteoblast lineage cells is sufficient to stimulate autophagy and lysosomal biogenesis.</p></sec><sec><title>Elevation of Tfeb in the osteoblast lineage increases bone mass and strength.</title><p>To assess the skeletal impact of <italic toggle="yes">Tfeb</italic> elevation in osteoblast lineage cells, we performed detailed skeletal phenotyping of mice at 4.5 to 5 months of age. At this age bone growth is completed and peak bone mass is attained. We first used microCT analysis to examine the architectural changes in cortical and trabecular bone compartments. Cortical bone is the dense outer layer that encapsulates bone marrow and trabecular bone like a shell (<xref rid="F3" ref-type="fig">Figure 3A</xref>). Trabecular bone is the inner bone compartment (lattice-like appearance) that is surrounded by bone marrow (<xref rid="F3" ref-type="fig">Figure 3A</xref>). Cortical and trabecular bone compartments differ in their formation, maintenance, and response to mechanical or chemical stimuli (<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B39" ref-type="bibr">39</xref>). As different skeletal sites have different ratios of cortical and trabecular bone (<xref rid="B38" ref-type="bibr">38</xref>), we examined changes in these 2 bone compartments in both the appendicular (represented by long bones) and axial (represented by spine) skeleton.</p><p>Analysis of male and female <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice revealed higher cortical thickness in both the spine and long bones (<xref rid="F3" ref-type="fig">Figure 3, B&#8211;D</xref>). The change in cortical thickness in long bones was due to increased periosteal perimeter (outer bone surface) and bone area (<xref rid="F3" ref-type="fig">Figure 3, E and F</xref>), while no changes were detected in the endosteal perimeter (inner bone surface) (<xref rid="sd" ref-type="sec">Supplemental Figure 2A</xref>). In other words, elevation of <italic toggle="yes">Tfeb</italic> in Osx1-Cre&#8211;targeted cells led to widening of the bones. Regarding the trabecular compartment, <italic toggle="yes">Tfeb</italic> elevation in the osteoblast lineage increased the volume of trabecular bone in long bones (<xref rid="F3" ref-type="fig">Figure 3G</xref>). This increase was due to presence of more trabeculae that were closer to one another (<xref rid="F3" ref-type="fig">Figure 3, H and I</xref>). <italic toggle="yes">Tfeb</italic> elevation also caused a modest increase in trabecular thickness in spine (<xref rid="sd" ref-type="sec">Supplemental Figure 2</xref>, B and C). These results demonstrate that elevation of <italic toggle="yes">Tfeb</italic> in osteoblast lineage cells is beneficial for both trabecular and cortical bone compartments in young adult male and female mice.</p><p>Next, we examined whether these architectural changes improved biomechanical properties of <italic toggle="yes">Tfeb</italic><sup>CRa</sup> bones by performing 3-point bending testing of femurs. This analysis revealed that both extrinsic/structural (<xref rid="F4" ref-type="fig">Figure 4, A&#8211;C</xref>) and intrinsic/material properties of the bone (<xref rid="F4" ref-type="fig">Figure 4, D and E</xref>) were increased in <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice compared with controls. However, there were no differences in the Young&#8217;s modulus (<xref rid="F4" ref-type="fig">Figure 4F</xref>), which is calculated as stiffness normalized by the tissue distribution and geometry. These results indicate that the gains in stiffness are due to beneficial changes in bone geometry and microarchitecture, as opposed to alterations in tissue properties (such as degree of mineralization or collagen cross-linking). In other words, <italic toggle="yes">Tfeb</italic> elevation in the osteoblast lineage increases the amount of bone, which is of normal quality, resulting in stronger bones.</p></sec><sec><title>Elevation of Tfeb in the osteoblast lineage increases bone formation.</title><p>To identify the cellular mechanisms underpinning the high&#8211;bone mass phenotype of <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice, we first performed dynamic histomorphometry of femurs from male <italic toggle="yes">Tfeb</italic><sup>CRa</sup> and Cre control mice. In this methodology, mice are injected with fluorochromes, which are incorporated into newly formed bone matrix. Mice are injected with 1 or more fluorochromes with specific intervals (e.g., 3 days and 7 days before sacrifice), which allows measurements of actively mineralizing surface (MS), mineral apposition rate (MAR), and bone formation rate (BFR) (<xref rid="B40" ref-type="bibr">40</xref>). <italic toggle="yes">Tfeb</italic> elevation in the osteoblast lineage increased bone formation at the periosteal surface (outer surface, <xref rid="F5" ref-type="fig">Figure 5, A and B</xref>) but not at the endosteal surface (inner surface, <xref rid="sd" ref-type="sec">Supplemental Figure 2D</xref>). This increase in periosteal bone formation was due to increased MS and MAR (<xref rid="F5" ref-type="fig">Figure 5, A and B</xref>), suggesting that <italic toggle="yes">Tfeb</italic> elevation increases the number and rigor of periosteal osteoblasts. At the trabecular compartment, the increase in femoral trabecular bone volume of <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice was associated with increased MAR (<xref rid="F5" ref-type="fig">Figure 5C</xref> and <xref rid="sd" ref-type="sec">Supplemental Figure 2E</xref>). Together, these results suggest that <italic toggle="yes">Tfeb</italic> elevation in Osx1-Cre&#8211;targeted cells increases bone formation in both the cancellous and cortical compartments of femur.</p><p>To assess if bone formation was similarly increased in spine, we next measured expression of osteoblast marker genes in mRNA isolated from lumbar vertebrae. This analysis revealed higher levels of osteoblast marker genes (<italic toggle="yes">Sp7</italic>, Sp7 transcription factor 7/osterix; and <italic toggle="yes">Col1a1,</italic> collagen, type I, alpha 1) in <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice (<xref rid="F5" ref-type="fig">Figure 5D</xref>), suggesting that <italic toggle="yes">Tfeb</italic> elevation also increases bone formation in spine. We also observed increased expression of osteoclast marker genes (<italic toggle="yes">Acp5,</italic> acid phosphatase 5, tartrate resistant; and <italic toggle="yes">Ctsk</italic>, cathepsin K) (<xref rid="F5" ref-type="fig">Figure 5E</xref>). These results suggest a high-turnover state that favors bone formation in spine.</p><p>In line with these in vivo findings, elevation of <italic toggle="yes">Tfeb</italic> increased mineral deposition and proliferation in cultured osteoblastic cells (<xref rid="F5" ref-type="fig">Figure 5, F and G</xref>). Sclerostin is a Wnt signaling inhibitor that is produced mainly by osteocytes to inhibit bone formation. Previous work has suggested that sclerostin is degraded in lysosomes (<xref rid="B41" ref-type="bibr">41</xref>). This raises the possibility that sclerostin levels could be altered in <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice. We examined this possible mechanism by quantifying sclerostin levels in serum and cortical bone, but we did not detect any differences between <italic toggle="yes">Tfeb</italic><sup>CRa</sup> and Cre control mice (<xref rid="F5" ref-type="fig">Figure 5, H and I</xref>). Together, these results suggest that elevation of <italic toggle="yes">Tfeb</italic> in Osx1-Cre&#8211;targeted cells increases bone formation, likely by promoting the proliferation of osteoblast lineage cells.</p></sec><sec><title>Elevation of Tfeb in osteoblast lineage cells is anabolic up to 12 months of age.</title><p>To assess the progression of the bone phenotype, we next performed serial analysis of bone mineral density (BMD) in live mice using dual-energy x-ray absorptiometry (DXA) from 3 to 12 months of age. <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice exhibited high spine and femur BMD beginning at 3 and 7 months, respectively, that remained high up to the time of sacrifice at 12 months (<xref rid="F6" ref-type="fig">Figure 6, A and B</xref>). To address if elevation of <italic toggle="yes">Tfeb</italic> increased bone mass after rapid growth, we compared BMDs at 3, 9, and 12 months of age and showed that the high&#8211;bone mass phenotype became more pronounced up to 9 months of age and remained elevated up to 12 months of age (<xref rid="F6" ref-type="fig">Figure 6, A&#8211;C</xref>).</p><p>MicroCT analysis performed at 12 months of age showed that <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice maintained elevated cortical thickness in both the spine and femur (<xref rid="F6" ref-type="fig">Figure 6D</xref>). At this age (12 months), <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice had elevated trabecular bone volume compared with Cre controls (<xref rid="F6" ref-type="fig">Figure 6E</xref> and <xref rid="sd" ref-type="sec">Supplemental Figure 3</xref>, A and B). Of note, vertebral trabecular bone volume of female <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice was higher than Cre controls at 12 months of age (<xref rid="F6" ref-type="fig">Figure 6E</xref>), but not at 5 months of age (<xref rid="sd" ref-type="sec">Supplemental Figure 2B</xref>), suggesting that elevated <italic toggle="yes">Tfeb</italic> causes a progressive increase in vertebral trabecular bone volume. Mice lose femoral trabecular bone before age-related bone loss occurs in other sites or compartments (<xref rid="B42" ref-type="bibr">42</xref>&#8211;<xref rid="B44" ref-type="bibr">44</xref>). Specifically, by the time mice are 12 months of age, they have already lost most of their femoral trabecular bone (<xref rid="B42" ref-type="bibr">42</xref>&#8211;<xref rid="B44" ref-type="bibr">44</xref>). Consistent with this, Cre control mice had less than 4% trabecular bone volume at 12 months of age (<xref rid="F6" ref-type="fig">Figure 6E</xref>). In contrast, at this age, <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice had approximately 40% trabecular bone volume, demonstrating that <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice retained their femoral trabecular bone volume up to 12 months of age (<xref rid="F6" ref-type="fig">Figure 6E</xref> and <xref rid="sd" ref-type="sec">Supplemental Figure 3B</xref>).</p><p>We next sought to examine the cellular basis of the high&#8211;bone mass phenotype of <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice at 12 months of age. Procollagen type 1 intact N-terminal propeptide (P1NP), a by-product of collagen processing by osteoblasts, can be detected in circulation and is used as a marker of bone formation (<xref rid="B45" ref-type="bibr">45</xref>). Tartrate-resistant acid phosphatase isoform 5b (TRAcP 5b), an enzyme synthesized and secreted by osteoclasts, can be detected in circulation and is used as a biochemical marker of osteoclast activity and bone resorption (<xref rid="B45" ref-type="bibr">45</xref>). Circulating P1NP and TRAcP 5b were both elevated in the serum of <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice, suggesting a high-turnover state (<xref rid="F6" ref-type="fig">Figure 6F</xref>). However, as high bone volume may contribute to elevation of circulating markers, we performed further analysis of bone formation and resorption.</p><p>Dynamic histomorphometry in femurs revealed that at 12 months of age, periosteal and endosteal bone formation of <italic toggle="yes">Tfeb</italic><sup>CRa</sup> and Cre control mice were similar (<xref rid="sd" ref-type="sec">Supplemental Figure 3</xref>, C and D). This suggests that while <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice maintain elevated cortical thickness and periosteal perimeter compared to controls, periosteal bone apposition does not remain elevated. As control mice do not have femoral trabecular bone at this age, a comparison of trabecular bone formation in femurs is not possible. However, as can be seen in representative images shown in <xref rid="sd" ref-type="sec">Supplemental Figure 3E</xref>, bone formation is ongoing at the femoral trabecular compartment in <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice.</p><p>Next, we examined the cellular basis of high trabecular bone volume in spines of 12-month-old <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice. Histomorphometry revealed that <italic toggle="yes">Tfeb</italic> elevation increased MS and BFR (<xref rid="F6" ref-type="fig">Figure 6, G and J</xref>) and increased osteoblast number and surface (<xref rid="F6" ref-type="fig">Figure 6, H and J</xref>). Accordingly, expression of osteoblast marker genes (bone gamma-carboxyglutamate protein, <italic toggle="yes">Bglap</italic>; and <italic toggle="yes">Sp7</italic>) was increased in lumbar vertebrae of <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice (<xref rid="F6" ref-type="fig">Figure 6K</xref>). <italic toggle="yes">Tfeb</italic> elevation in Osx1-Cre&#8211;targeted cells did not significantly change osteoclast number or surface (<xref rid="F6" ref-type="fig">Figure 6I</xref>). Expression of osteoclast marker genes (<italic toggle="yes">Acp5</italic> and <italic toggle="yes">Ctsk</italic>) was also elevated in whole lumbar vertebrae (<xref rid="F6" ref-type="fig">Figure 6L</xref>), suggesting that the higher bone volume of <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice is not due to decreased bone resorption. Together, these results suggest that <italic toggle="yes">Tfeb</italic> elevation in the osteoblast lineage increases osteoblast number and bone formation to cause a progressive increase in the vertebral trabecular bone volume of <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice.</p></sec><sec><title>Tfeb elevation in Osx1-Cre&#8211;targeted cells promotes osteoblast production and function.</title><p>To identify mechanisms underpinning the high bone formation of <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice, we performed single-cell RNA-sequencing (scRNA-Seq) analysis of periosteal mesenchymal cells isolated from 4-month-old male <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice and their Cre controls. We chose to focus on the periosteum of <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice because this is the skeletal site that exhibited the most robust increase in bone formation in young mice (<xref rid="F3" ref-type="fig">Figure 3D</xref>). Clustering analysis revealed 8 major clusters (<xref rid="F7" ref-type="fig">Figure 7, A and B</xref>), namely osteoblasts, Osteo-X, <italic toggle="yes">Sfrp2</italic><sup>+</sup> fibroblasts, Fibro-2, <italic toggle="yes">Prg4<sup>+</sup></italic> fibroblasts, pericytes, articular chondrocytes, and chondrocytes. Our genetic maneuver did not cause major changes in the relative abundance of these mesenchymal cell populations (<xref rid="sd" ref-type="sec">Supplemental Figure 4A</xref>).</p><p>We have previously shown that osteoblasts, Fibro-2, and Osteo-X cells are targeted by the Osx1-Cre transgene (<xref rid="B46" ref-type="bibr">46</xref>). Therefore, we focused on the molecular impact of <italic toggle="yes">Tfeb</italic> elevation on these 3 mesenchymal cell populations. Model-based Analysis of Single-cell Transcriptomics (MAST) with a random effect for the sample of origin revealed that in the periosteum, <italic toggle="yes">Tfeb</italic> elevation in Osx1-Cre&#8211;targeted cells had the most impact in Fibro-2 and Osteo-X cells (<xref rid="F7" ref-type="fig">Figure 7C</xref>). To examine the biological processes and cellular components that are altered by <italic toggle="yes">Tfeb</italic> elevation, we next performed gene set enrichment analysis (GSEA) in osteoblasts, Osteo-X, and Fibro-2 cells.</p><p>Gene ontology (GO) terms related to bone development, limb morphogenesis, ossification, and ECM synthesis organization were increased in <italic toggle="yes">Tfeb</italic><sup>CRa</sup> osteoblasts (<xref rid="F7" ref-type="fig">Figure 7D</xref>). These changes were accompanied by the elevation of genes related to ribosome and translation (<xref rid="F7" ref-type="fig">Figure 7D</xref>). Together, these results suggest an increase in osteoblast function. <italic toggle="yes">Tfeb</italic><sup>CRa</sup> osteoblasts also exhibited elevated BMP and nitric oxide signaling and reduced apoptotic signaling pathways (<xref rid="F7" ref-type="fig">Figure 7D</xref>). These pathways are influenced by autophagy in other tissues (<xref rid="B47" ref-type="bibr">47</xref>&#8211;<xref rid="B49" ref-type="bibr">49</xref>). Further studies are needed to address how <italic toggle="yes">Tfeb</italic> elevation and autophagy impact these pathways in osteoblasts and their functional contribution to the high bone formation of <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice.</p><p>Cells of the Osteo-X cluster highly express periostin (<italic toggle="yes">Postn</italic>) (<xref rid="B46" ref-type="bibr">46</xref>). Expression of <italic toggle="yes">Postn</italic> and <italic toggle="yes">Postn</italic>-expressing cells increase in response to fracture (<xref rid="B50" ref-type="bibr">50</xref>). However, the function or fate of Osteo-X cells under physiological or pathological conditions is unclear. Herein, we show that Osteo-X cells of <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice exhibited significant increases in GO terms related to bone development, bone mineralization, ossification, collagen-containing ECM synthesis, and ECM organization (<xref rid="F7" ref-type="fig">Figure 7D</xref>). Specifically, Osteo-X cells of <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice exhibited elevated expression of several markers of osteoblast differentiation (<xref rid="F7" ref-type="fig">Figure 7E</xref> and <xref rid="sd" ref-type="sec">Supplemental Figure 4B</xref>) such as osteoblastic transcription factors (e.g., <italic toggle="yes">Sp7</italic>), various constituents of bone matrix including various collagens (e.g., <italic toggle="yes">Col1a2</italic>, <italic toggle="yes">Col3a1</italic>, <italic toggle="yes">Col5a1</italic>, and <italic toggle="yes">Col5a2</italic>), enzymes necessary for collagen organization (e.g., <italic toggle="yes">Lox</italic>), noncollagen components of bone matrix (e.g., <italic toggle="yes">Ibsp</italic>), and genes related to bone matrix mineralization (e.g., <italic toggle="yes">Alpl</italic>). These changes in Osteo-X cells were associated with increased BMP and Wnt signaling pathways (<xref rid="F7" ref-type="fig">Figure 7D</xref>). Therefore, we hypothesize that Osteo-X cells are periosteal osteoblast progenitors and that in <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice, these cells commit to becoming osteoblasts, perhaps in response to elevated Wnt and BMP signaling pathways. In contrast, Fibro-2 cells exhibited only modest changes that would be indicative of their commitment to becoming osteoblasts (<xref rid="F7" ref-type="fig">Figure 7D</xref>).</p><p><italic toggle="yes">Wnt5a</italic> expression in Osx1-Cre cells supports osteoblast number and bone formation, likely by enhancing Wnt and BMP signaling (<xref rid="B51" ref-type="bibr">51</xref>, <xref rid="B52" ref-type="bibr">52</xref>). Therefore, increased <italic toggle="yes">Wnt5a</italic> in Osteo-X cells of <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice (<xref rid="F7" ref-type="fig">Figure 7E</xref>) may be potentiating Wnt and BMP pathways to stimulate bone formation.</p><p>Single-Cell Regulatory Network Inference and Clustering (SCENIC) analysis of transcription factor activity in Osteo-X cells (<xref rid="F7" ref-type="fig">Figure 7F</xref>) revealed increase in activity of RUNX family transcription factor 2 (RUNX2) and RUNX3, accompanied by decreased STAT1 activity (a RUNX2 inhibitor) (<xref rid="B53" ref-type="bibr">53</xref>) and elevated activity of RUNX2 activators CBFB (<xref rid="B54" ref-type="bibr">54</xref>) and DLX5 (<xref rid="B55" ref-type="bibr">55</xref>). Based on known interactions and their roles in osteogenesis, high RUNX2 and RUNX3 activity along with increased activities of SP7 (<xref rid="B56" ref-type="bibr">56</xref>), DLX5 (<xref rid="B55" ref-type="bibr">55</xref>), SOX4 (<xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B58" ref-type="bibr">58</xref>), HIF-1&#945; (<xref rid="B59" ref-type="bibr">59</xref>), CREB3L1 (<xref rid="B60" ref-type="bibr">60</xref>), MAF (<xref rid="B61" ref-type="bibr">61</xref>), and LEF1 (<xref rid="B62" ref-type="bibr">62</xref>) likely stimulate osteogenesis of <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice (<xref rid="F7" ref-type="fig">Figure 7F</xref> and <xref rid="sd" ref-type="sec">Supplemental Figure 5</xref>). Further studies are required to establish a functional connection among these transcription factors, autophagy, and bone formation of <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>We and others have previously shown that autophagy in osteoblast lineage cells is essential for bone formation (<xref rid="B4" ref-type="bibr">4</xref>&#8211;<xref rid="B8" ref-type="bibr">8</xref>). However, whether stimulation of autophagy would have a beneficial impact on bone was unknown. In the present study, we aimed to address this question by stimulating autophagy via elevating the expression of endogenous <italic toggle="yes">Tfeb</italic>, a master transcriptional regulator of autophagy and lysosomal biogenesis, in the entire osteoblast lineage. Using multiple methodologies, we verified that elevation of <italic toggle="yes">Tfeb</italic> in osteoblast lineage cells increases the autophagic flux of osteoblasts. Moreover, we showed that elevation of <italic toggle="yes">Tfeb</italic> in the osteoblast lineage results in a skeletal and cellular phenotype that is the opposite of autophagy elimination in this lineage (<xref rid="B5" ref-type="bibr">5</xref>). These results suggest that the anabolic impact of <italic toggle="yes">Tfeb</italic> elevation in the osteoblast lineage is due to stimulation of autophagy.</p><p>We used CRISPRa for our gain-of-function studies. This methodology has various benefits over traditional transgene-based overexpression approaches. In traditional approaches, transgene expression is influenced by copy number, integrity, and insertion site into the genome (<xref rid="B63" ref-type="bibr">63</xref>&#8211;<xref rid="B66" ref-type="bibr">66</xref>). Transgenic approaches can also lead to undesirably high expression levels, causing unwanted changes in transcription (<xref rid="B24" ref-type="bibr">24</xref>). In contrast, CRISPRa stimulates the transcription of endogenous genes, which avoids the copy number and integration site effects. CRISPRa also provides control over the magnitude of gene stimulation. Herein, we show that expression of an sgRNA from a safe harbor locus is sufficient to elevate target gene expression in vivo via CRISPRa. In traditional transgenic approaches, transgene expression may also be suppressed over time (<xref rid="B63" ref-type="bibr">63</xref>&#8211;<xref rid="B65" ref-type="bibr">65</xref>). In contrast, herein we show that transcriptional stimulation via CRISPRa persists up to at least 12 months of age (<xref rid="F1" ref-type="fig">Figure 1D</xref>). Overall, our results demonstrate that CRISPRa can effectively and reliably stimulate target genes in a cell type&#8211;specific manner in mice.</p><p>Our genetic maneuver, elevation of endogenous <italic toggle="yes">Tfeb</italic>, increased trabecular bone volume in femur earlier than spine. Specifically, while the increase in trabecular bone volume and trabecular number was observed in long bones at 5 months of age (<xref rid="F3" ref-type="fig">Figure 3</xref>), it became evident in spine only at 12 months of age (<xref rid="F6" ref-type="fig">Figure 6</xref> versus <xref rid="F3" ref-type="fig">Figure 3</xref>). This may be due to differences in turnover of trabecular bone compartment in long bones versus spine. Specifically, Glatt et al. (<xref rid="B44" ref-type="bibr">44</xref>) previously showed that trabecular volume is lost at a higher rate in long bones compared with spine, especially between 2 and 6 months of age. This suggests that in long bones, bone remodeling favors resorption and causes loss of bone in every remodeling cycle, even in young mice. Therefore, it is likely that increasing bone formation in such a setting shifts the balance of remodeling and thereby causes a more dramatic phenotype in long bones.</p><p>Our scRNA-Seq analysis suggests that <italic toggle="yes">Tfeb</italic> elevation increases osteoblast function and survival. Collagen is thought to have a propensity to misfold (<xref rid="B67" ref-type="bibr">67</xref>). Accordingly, as osteoblasts differentiate and start producing collagen, the unfolded protein response increases (<xref rid="B68" ref-type="bibr">68</xref>&#8211;<xref rid="B70" ref-type="bibr">70</xref>). Autophagy clears misfolded collagen in osteoblasts (<xref rid="B71" ref-type="bibr">71</xref>), and lack of autophagy was shown to induce ER stress (<xref rid="B8" ref-type="bibr">8</xref>). Therefore, <italic toggle="yes">Tfeb</italic> elevation may stimulate autophagy to improve protein homeostasis and enhance the capacity of osteoblasts to form bone. In addition, we observe a decrease in osteoblast apoptosis. Previous studies established that reduction of osteoblast apoptosis is sufficient to increase bone formation and bone mass (<xref rid="B72" ref-type="bibr">72</xref>). Therefore, further studies are needed to assess the contribution of apoptosis to the increase in bone formation of <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice.</p><p>Based on our unbiased scRNA-Seq analysis (<xref rid="F7" ref-type="fig">Figure 7</xref>), we propose that Osteo-X cells are periosteal osteoblast progenitors and that elevation of <italic toggle="yes">Tfeb</italic> in Osteo-X cells promotes their osteoblastic differentiation. Nonetheless, future lineage tracing and functional studies are needed to test this hypothesis and assess their functional contribution to the elevated bone formation of <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice.</p><p>Our ex vivo studies suggest that elevated proliferation can be increasing osteoblast numbers in <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice. However, we did not detect significant changes in proliferation-related genes (e.g., <italic toggle="yes">Top2a</italic>, <italic toggle="yes">Mki67</italic>) or GO terms in our scRNA-Seq analysis. One explanation for this may be the difference in osteoblast progenitors in periosteum versus bone marrow environment. In recent years, different groups have identified different osteoblast progenitor populations residing in the bone marrow using combinations of scRNA-Seq and lineage tracing (<xref rid="B73" ref-type="bibr">73</xref>&#8211;<xref rid="B75" ref-type="bibr">75</xref>). However, there is not yet a consensus about the exact identity or function of these different cell populations. Future studies using scRNA-Seq of the endosteal cells and in vivo 5-ethynyl-2&#8242;-deoxyuridine (EdU) labeling are needed to establish changes in specific cell populations and the level of progenitor proliferation in <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice.</p><p>In skeletal muscle, TFEB regulates mitochondrial biogenesis and function by increasing expression of genes involved in these processes (<xref rid="B76" ref-type="bibr">76</xref>). In contrast, osteoblasts, Osteo-X and Fibro-2 cells of <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice have decreased expression of genes associated with mitochondrion, ATP biosynthetic process, and mitochondrial membrane potentials (<xref rid="sd" ref-type="sec">Supplemental Figure 6</xref>). This suggests that an increase in mitochondrial biogenesis is not a likely contributor to the increase in bone formation of <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice.</p><p>Dysfunctional autophagy is a hallmark of aging (<xref rid="B77" ref-type="bibr">77</xref>). Several studies examined the impact of autophagy stimulation in the setting of aging or age-related pathologies and showed that genetic stimulation of autophagy increases proliferation and restrains other hallmarks of aging, such as mitochondrial dysfunction, loss of proteostasis, and cellular senescence (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B78" ref-type="bibr">78</xref>&#8211;<xref rid="B81" ref-type="bibr">81</xref>). In light of evidence that autophagy declines with age in osteoblast lineage cells (<xref rid="B9" ref-type="bibr">9</xref>&#8211;<xref rid="B11" ref-type="bibr">11</xref>), and that loss of autophagy mimics several aspects of skeletal aging (<xref rid="B4" ref-type="bibr">4</xref>), we propose that declining autophagy could be contributing to age-related bone loss. If this is the case, stimulation of autophagy may blunt age-related bone loss. To test this, others have administered rapamycin to old mice (16- and 20-month-old) (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B82" ref-type="bibr">82</xref>) and rats (24-month-old) (<xref rid="B83" ref-type="bibr">83</xref>) with varying doses and intervals. While 2 of these studies showed a beneficial impact on trabecular bone, the other did not demonstrate any effect on trabecular or cortical bone. Part of the discrepancy between these studies may be due to differences in dose and interval of administration or age or sex of the model organism. However, as stated above, all 3 studies are confounded by the lack of cellular and molecular specificity of this mTOR inhibitor. Thus, <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice will be a valuable tool for determining whether declining autophagy in cells of the osteoblast lineage is sufficient to prevent any aspects of skeletal aging.</p><p>In conclusion, increasing endogenous <italic toggle="yes">Tfeb</italic> expression in the osteoblast lineage promotes autophagy, and bone formation, and leads to a remarkable increase in bone mass. These findings lay the groundwork for future studies aimed at examining whether stimulation of autophagy can blunt skeletal pathologies associated with insufficient autophagy or decreased bone formation.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Sex as a biological variable.</title><p>We considered sex as a biological variable, conducted our studies in both female and male mice, and analyzed the effect of our maneuver in both male and female mice. We did not observe sex-related differences in bone mass or architecture in response to our genetic maneuver. Therefore, the findings are expected to be relevant for both sexes.</p></sec><sec><title>Testing Tfeb sgRNAs in vitro.</title><p>Five candidate sgRNAs were identified using the Zhang Laboratory CRISPR Design tool (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://crispr.mit.edu" ext-link-type="uri">http://crispr.mit.edu</ext-link>) by searching the region 150 bp upstream and downstream from the <italic toggle="yes">Tfeb</italic> TSS. sgRNAs with high-quality scores, minimal off-target scores, and no potential off-targets in other genes were chosen as candidates. pX330 (<xref rid="B84" ref-type="bibr">84</xref>) (Addgene plasmid 42230) and pX458 (<xref rid="B85" ref-type="bibr">85</xref>) (Addgene plasmid 48138) were obtained from the Zhang Laboratory via Addgene. The Cas9 sequence of the pX330 plasmid was replaced with enhanced GFP subcloned from the px458 plasmid producing the sgRNA_GFP plasmid. Each of the 5 candidate <italic toggle="yes">Tfeb</italic> target sgRNA sequences indicated below was cloned into an sgRNA_GFP plasmid producing <italic toggle="yes">Tfeb</italic> sgRNA-1 through -5. Sequences for the sgRNAs are as follows: sgRNA-1: AAATCCCGGCGAGCCCTTCG (protospacer adjacent motif [PAM]: CGG), sgRNA-2: ACATTTCCCAGCGGGCACAG (PAM: CGG), sgRNA-3: CGGGACGCAGAGAACGGAGA (PAM: CGG), sgRNA-4: AACGGAGACGGCGCCGACAG (PAM: CGG), and sgRNA-5: TGCCGGGCGCAGCGGGAAGT (PAM: GGG). Each <italic toggle="yes">Tfeb</italic> sgRNA plasmid was cotransfected with SP-dCas9-VPR plasmid (<xref rid="B21" ref-type="bibr">21</xref>) (a gift from George Church, Department of Genetics, Harvard Medical School, Boston, Massachusetts; Addgene plasmid 63798) into UAMS-32 cells (<xref rid="B86" ref-type="bibr">86</xref>) (a gift from Charles A. O&#8217;Brien, University of Arkansas for Medical Sciences) using PolyJet reagent (SignaGen Laboratories). After 48 hours, transfected cells were subjected to fluorescence-activated cell sorting to acquire GFP-positive cells, which contain CRISPRa components, and sorted into 3 wells of a 96-well plate at a density of 7,500 cells per well. Cells were incubated overnight, and then, Cells-to-C<sub>T</sub> kit (Invitrogen, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="A25605">A25605</ext-link>) was used to harvest RNA and measure gene expression via qRT-PCR.</p></sec><sec><title>Generation of mice.</title><p>The sgRNA<italic toggle="yes"><sup>Tfeb</sup></italic> mice were produced via CRISPR/Cas9-mediated knockin of a U6-sgRNA<italic toggle="yes"><sup>Tfeb</sup></italic>_4 cassette into the Rosa26 locus as previously described (<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B87" ref-type="bibr">87</xref>). Founders were screened for the presence of the knockin sequence using F1 5&#8242;-AAGCACTTGCTCTCCCAAAG-3&#8242;; R1 5&#8242;-GGCGGATCACAAGCAATAAT-3&#8242;. The knockin was confirmed by DNA sequencing. The progeny were genotyped using genomic DNA isolated from the tail tips using F1, R1, F2 5&#8242;-GAGGGCCTATTTCCCATGAT-3&#8242;; R2 5&#8242;-GGTGTTTCGTCCTTTCCACA-3&#8242; primers. CRa (<xref rid="B22" ref-type="bibr">22</xref>) and Osx1-Cre (<xref rid="B26" ref-type="bibr">26</xref>) mice were previously produced by Zhou et al. and Rodda et al., respectively. These mice were obtained from and genotyped according to the directions of The Jackson Laboratory (Strain 0331645 and Strain 006361). All mice were provided food and water ad libitum and were maintained on a 12-hour light/12-hour dark cycle.</p></sec><sec><title>Animal experiments.</title><p>Mice carrying the Osx1-Cre transgene are known to be smaller and have low bone mass when compared with mice without this transgene (<xref rid="B88" ref-type="bibr">88</xref>). These effects are minimized or eliminated when expression of the transgene is suppressed by doxycycline (<xref rid="B89" ref-type="bibr">89</xref>). Therefore, we utilized doxycycline to suppress expression during development and until 3 weeks of age (<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B88" ref-type="bibr">88</xref>). Specifically, we maintained breeders and their progeny (up to 3 weeks of age) on a doxycycline-containing diet (<xref rid="F3" ref-type="fig">Figures 3</xref>&#8211;<xref rid="F7" ref-type="fig">7</xref>), which prevents Cre expression and bypasses the impact of the Osx1-Cre transgene on skeletal development (<xref rid="B89" ref-type="bibr">89</xref>). Nonetheless, to account for any effects of the Osx1-Cre transgene as mice age, we compared <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice with their Cre-harboring littermates. Mice were then aged to 5 to 12 months of age, and detailed skeletal analysis was performed (<xref rid="F3" ref-type="fig">Figures 3</xref>&#8211;<xref rid="F7" ref-type="fig">7</xref>).</p></sec><sec><title>Ex vivo osteoblastic cell culture.</title><p>For ex vivo mineral deposition assay and protein isolation, bone marrow cells were flushed from tibias and femurs of mice and cultured in osteogenic media as previously described (<xref rid="B5" ref-type="bibr">5</xref>). The cells were seeded into 6- or 12-well plates at 12.5 &#215; 10<sup>6</sup> cells/well or 5 &#215; 10<sup>6</sup> cells/well densities, respectively. After 21 days, protein was isolated for downstream analysis, and ex vivo mineral deposition assay was performed. Briefly, the cultures were fixed with 50% ethanol at 4&#176;C for 15 minutes, dried for 2 hours, and stained with an aqueous solution of 40 mM alizarin red for 30 minutes at room temperature.</p><p>For flow cytometry, confocal microscopy, and ex vivo proliferation assay, bone marrow cells were flushed from the tibias and femurs of mice using &#945;-MEM culture media. Red blood cells were removed using ACK buffer (0.01 mM EDTA, 0.011 M KHCO<sub>3</sub>, and 0.155 M NH<sub>4</sub>Cl, pH 7.3). The remaining cells were cultured with osteogenic media. After cells reached 80% confluence (5 to 10 days), cells were replated in 6-well plates at 2.5 &#215; 10<sup>4</sup> cells/cm<sup>2</sup>.</p></sec><sec><title>Ex vivo proliferation assay.</title><p>Cells were isolated from tibias and femurs of mice as indicated above and plated in 96-well cell culture plates at 5 &#215; 10<sup>4</sup> cells/cm<sup>2</sup>, in complete media. After 24 hours, media were replaced with media containing 100 &#956;M BrdU. The plates were then incubated at 37&#176;C and 5% CO<sub>2</sub> for 24 or 48 hours. The cell proliferation assay was performed according to the manufacturer&#8217;s instructions (Roche Applied Sciences, 11647229001).</p></sec><sec><title>Flow cytometry.</title><p>Cells isolated from murine long bones were incubated with 50 nM of LysoTracker (Invitrogen, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="L12492">L12492</ext-link>) or 200 nM of MitoTracker (Invitrogen, M7512) for 30 minutes, in &#945;-MEM at 37&#176;C and 5% CO<sub>2</sub>. Cells were then washed with PBS, resuspended in PBS with 0.5% BSA, and immediately analyzed by flow cytometry. Autophagy was measured using the autophagy detecting kit (Abcam, ab270790) with minor modifications to instructions. Briefly, cells were incubated in complete media or low-serum (2% FBS) media for 2 hours prior to staining. Then, cells were incubated in 0.5&#215; Autophagy Probe prepared in complete or low-serum media for 30 minutes at 37&#176;C and 5% CO<sub>2</sub>, washed with PBS, and fixed with provided kit fixative at a 1:10 dilution for 15 minutes. All samples were acquired using LSRFortessa (BD Biosciences) with FACSDiva software version 6.1.3. Data were analyzed using FlowJo 10.10 (Tree Star Inc.). Populations were first plotted according to their size and complexity on a forward scatter-A (FSC-A) versus side scatter-A (SSC-A) plot, to remove any dying cells and debris, followed by FSC-A versus FSC-H plot to isolate single cells. The excitation/emission settings were LysoTracker (Ex. 647 nm, Em. 668 nm), MitoTracker (Ex. 579 nm, Em. 599 nm), and Autophagy Probe (Ex. 590 nm, 620 nm).</p></sec><sec><title>Confocal microscopy.</title><p>To image mitochondria, cells were plated at 2.5 &#215; 10<sup>4</sup> cells/cm<sup>2</sup> in a 96-well plate with ibiTreat: #1.5 polymer coverslip surface modification (Ibidi, 89626). After 24 hours, cells were incubated with 200 nM of MitoTracker (Invitrogen, M7512) for 30 minutes, in fresh &#945;-MEM with no FBS at 37&#176;C and 5% CO<sub>2</sub> in dark conditions. After treatment, cells were washed, and media were replaced with fresh medium containing Hoechst 33342 stain (Thermo Fisher Scientific, 62249) diluted 1:1,000 and imaged immediately. To image autophagosomes and autolysosomes, cells were plated on 8-well Lab-Tek Glass Chamber Slides at 3.75 &#215; 10<sup>4</sup> cells/cm<sup>2</sup> (Thermo Fisher Scientific, 177402). Prior to staining, cells were incubated in complete media or low-serum (2% FBS) media for 2 hours. Then the cells were incubated for 30 minutes with 0.5&#215; Autophagy Probe, Red (Abcam, ab270790), and Hoechst was prepared in complete or low-serum media. Cells were washed, and media were replaced with fresh PBS. MitoTracker- and Autophagy Probe&#8211;labeled cells were imaged using an LSM 880 confocal microscope (Carl Zeiss, Inc.) equipped with a Plan-Apochromat 63&#215;/1.4 Oil DIC M27 objective or EC Plan-Neofluar 20&#215;/0.30 M27 objective, respectively. Images were acquired using Zeiss ZEN 2.3 SP3 software. Hoechst was imaged using a 405 nm laser, and MitoTracker and Autophagy Probe were imaged using a 561 nm laser.</p></sec><sec><title>RNA isolation and gene expression analysis.</title><p>Lumbar vertebrae 5 and calvaria were dissected, cleaned of soft tissue, snap-frozen in liquid nitrogen, and stored at &#8211;80&#176;C. For RNA isolation, the bones were homogenized in TRIzol Reagent (Life Technologies, 15596018). RNA was isolated from homogenized bones with the RNeasy Plus Mini Kit (QIAGEN, 74136). A total of 1 &#956;g RNA was used to synthesize cDNA with a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 4368814). Relative abundance of mRNAs was measured using multiplex qRT-PCR with TaqMan Fast Advanced Master Mix (Applied Biosystems, 4444964), FAM-labeled TaqMan gene expression assays (Thermo Fisher Scientific), and VIC-labeled mouse Actb (&#946;-actin) (Applied Biosystems, 4352341E). The following FAM-labeled assays were used in the gene expression analysis: <italic toggle="yes">Tfeb</italic> (Mm00448968_m1), <italic toggle="yes">Lamp1</italic> (Mm01217070_m1), <italic toggle="yes">CtsB</italic> (Mm01310506_m1), <italic toggle="yes">CtsD</italic> (Mm00515586_m1), <italic toggle="yes">CtsF</italic> (Mm00490782_m1), <italic toggle="yes">Clcn7</italic> (Mm00442400_m1), <italic toggle="yes">Gns</italic> (Mm00659592_m1), <italic toggle="yes">Hexa</italic> (Mm00599877_m1), <italic toggle="yes">Mcoln1</italic> (Mm00522550_m1), <italic toggle="yes">Tpp1</italic> (Mm00487016_m1), <italic toggle="yes">Map1lc3</italic> (LC3, Mm00782868_sH), <italic toggle="yes">Atg7</italic> (Mm00512209_m1), <italic toggle="yes">Becn1</italic> (Mm01265461_m1), <italic toggle="yes">Atg9b</italic> (Mm01157883_g1), <italic toggle="yes">Wipi1</italic> (Mm00461219_m1), <italic toggle="yes">Uvrag</italic> (Mm00724370_m1), <italic toggle="yes">Sqstm1</italic> (Mm00448091_m1), <italic toggle="yes">Parkin</italic> (Mm01323528_m1), <italic toggle="yes">Pink</italic> (Mm00550827_m1), <italic toggle="yes">Bnip3</italic> (Mm01275600_g1), <italic toggle="yes">Bnip3l</italic> (Mm00786306_s1), <italic toggle="yes">Mfn2</italic> (Mm00500120_m1), <italic toggle="yes">Fundc1</italic> (Mm00511132_m1), <italic toggle="yes">Sp7</italic> (Osx, Mm04209856_m1), <italic toggle="yes">Col1a1</italic> (Mm00801666_g1), <italic toggle="yes">Acp5</italic> (Mm00475698_m1), <italic toggle="yes">Ctsk</italic> (Mm00484039_m1), and <italic toggle="yes">Bglap</italic> (OCN, custom, assay ID APCE4V6, primers F 5&#8242;-GCTGCGCTCTGTCTCTCTGA-3&#8242;, R 5&#8242;-TGCTTGGACATGAAGGCTTTG-3&#8242;, probe 5&#8242;-FAMAAGCCCAGCGGCC-NFQ-3&#8242;). The relative mRNA levels were calculated using the comparative cycle threshold method (<xref rid="B90" ref-type="bibr">90</xref>). One <italic toggle="yes">Tfeb</italic><sup>CRa</sup> sample in the 4.5-month-old male experiment, and 1 Cre control sample in the 12-month-old female experiment, had low 260/280 ratios, and the mRNA levels from these 2 samples were outliers (2 SDs away from the mean). Therefore these 2 samples were excluded from gene expression analysis presented in <xref rid="F5" ref-type="fig">Figure 5, D and E</xref>, and <xref rid="F6" ref-type="fig">Figure 6, K</xref> and L.</p></sec><sec><title>Immunoblot analysis.</title><p>Protein was extracted from cultured cells or pulverized bone using RIPA Buffer (Thermo Fisher Scientific, PI89901) with protease/phosphatase inhibitors (Cell Signaling Technology [CST], 5872S). Proteins were resolved in 4%&#8211;20% or 4%&#8211;15% Mini-PROTEAN TGX gels (BIORAD, 4561093 and 4561083, respectively) and transferred onto TransblotTurbo midi-size nitrocellulose membranes (0.2 &#956;m pore size, BIORAD, 1704271). The membranes were blocked for 5 minutes with EveryBlot Blocking Buffer (BIORAD, 12010020) and incubated overnight with primary antibodies, with rocking at 4&#176;C. The primary antibodies used were TFEB (Invitrogen, PA5-96632, 1:500 dilution), LAMP1 (CST, 99437, 1:1,000 dilution), p62 (CST, 23214s, 1:1,000 dilution), LC3 (CST, 12741T, 1:1,000 dilution), Sclerostin (R&amp;D Systems, AF1589, 1:500 dilution), and &#946;-actin (MilliporeSigma, A5316, 1:4,000 dilution). After overnight incubation, membranes were washed 3 times with PBS for 5 minutes each and incubated for 45 minutes with appropriate secondary antibodies conjugated with IRDye 680 or IRDye 800 dyes (LI-COR, 1:2,000 dilution). After washing with PBS 3 times for 5 minutes each time, membranes were scanned and analyzed with an Odyssey IR imaging system (LI-COR) and Image Studio Software (Version 5.2).</p></sec><sec><title>Skeletal phenotyping.</title><p>BMD was measured in live mice by DXA with a PIXImus Mouse Densitometer (GE Lunar Corp.) as previously described (<xref rid="B91" ref-type="bibr">91</xref>). Calvaria and shoulder blades were excluded from total-body BMD analysis. Vertebral BMD was measured in lumbar vertebrae 2&#8211;6, and femoral BMD was measured using the right femur.</p><p>For microCT analysis, lumbar vertebrae 5, femurs, and humeri were dissected; cleaned of soft tissue; wrapped in saline-soaked gauze; and stored at &#8211;20&#176;C. Unlike the male experiment, which used femurs as long bones, in the female experiment humeri were used for microCT. This is because femurs were dissected and cut for isolation of bone marrow cells for ex vivo analysis. Samples were thawed before scanning and medium-resolution scans were obtained (12 &#956;m isotropic voxel size) using a model &#956;CT40 (Scanco Biomedical) as previously described (<xref rid="B25" ref-type="bibr">25</xref>). Long bone midshaft cortical measurements were performed by drawing contours to measure the cortical thickness on the 20 slices flanking the midshaft. Long bone trabecular analysis was performed by drawing contours every 20 slices of the distal metaphysis beginning 10 slices proximal to the growth plate and ending 151 slices proximal to the first contour. Vertebral cortical thickness and trabecular analyses were performed by drawing contours every 10 slices between the 2 growth plates of the vertebrae. The vertebral cortical bone thickness was determined on the ventral cortical wall using contours of cross-sectional images, drawn to exclude trabecular bone.</p></sec><sec><title>Biomechanical testing.</title><p>The mechanical properties of the femur were determined by a 3-point bending analysis using ElectroForce 5500 (TA Instruments) as previously described (<xref rid="B92" ref-type="bibr">92</xref>). Femurs were placed posterior-side down on a miniature bending apparatus with lower supports set at 8 mm apart with the left support set proximal to the distal condyles. Load was applied to the anterior surface of the femur midway between the lower supports. The load was applied at a constant rate of 3 mm/min until failure. Structural or extrinsic properties and material or intrinsic properties were derived by measuring the maximum load and displacement of the femur and normalized for bone size. The external measurements of the femora were recorded with a digital caliper. Bone geometry and volume were determined by microCT. During 3-point-bending analysis of 4.5-month-old male mice, the femur of 1 <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mouse slipped, rendering the analysis invalid, thereby prompting us to not include this mouse in our analysis (<xref rid="F4" ref-type="fig">Figure 4</xref>).</p></sec><sec><title>Histology.</title><p>Mice were injected with 20 mg/kg of calcein (Sigma-Aldrich, C0875) and alizarin complexone (Sigma-Aldrich, A3882), 6 days and 2 days before euthanasia, respectively. For histology, femurs or L1&#8211;3 vertebrae were fixed in 10% Millonig&#8217;s formalin for 24 hours, then dehydrated using a series of serial dilutions of ethanol into 100% ethanol. Next, the bones were embedded in methyl methacrylate, and longitudinal sections were obtained. Histomorphometric measurements were performed as previously described (<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B93" ref-type="bibr">93</xref>). During dynamic histomorphometric analysis of 12-month-old female mice, we noticed that 1 <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mouse was missing 1 of the 2 fluorochrome injections, since no double labels were observed in femur or spine. This mouse was excluded from the analysis shown in <xref rid="F6" ref-type="fig">Figure 6, G&#8211;J</xref>, and <xref rid="sd" ref-type="sec">Supplemental Figure 3</xref>, C and D.</p></sec><sec><title>Serum bone turnover assays.</title><p>Blood was collected from the facial vein and incubated at room temperature for a minimum of 30 minutes to allow the blood to clot. Serum was collected by serial centrifugation (twice at 2,000<italic toggle="yes">g</italic> for 12 minutes) and stored at &#8211;20&#176;C. P1NP and TRAcP 5b were measured following the manufacturer&#8217;s instructions (Immunodiagnostic Systems, AC-33F1 and SB-TR103). Circulating sclerostin levels were measured using Mouse/Rat SOST/Sclerostin Quantikine ELISA Kit (R&amp;D Systems, MSST00). We had difficulty collecting blood from one 12-month-old Cre control mouse; serum from this mouse was little in amount and showed marked hemolysis. Therefore, this sample was not included as part of the analysis shown in <xref rid="F6" ref-type="fig">Figure 6</xref>F.</p></sec><sec><title>Cell isolation for 10X Genomics sequencing.</title><p>Periosteal cell isolation was performed as previously described (<xref rid="B46" ref-type="bibr">46</xref>). Briefly, femurs from 2 mice per group were cleaned up of muscle without damaging the periosteum. Intact femurs were exposed to 3 collagenase digestions and 3 EDTA decalcifications. Isolations were enriched in mesenchymal cells by depletion of hematopoietic and endothelial cells (<xref rid="B46" ref-type="bibr">46</xref>). Enriched cells were encapsulated using a Chromium Controller (10X Genomics); libraries were constructed using a Chromium Single Cell 3&#8217; Reagent Kit (10X Genomics) and sequenced using Illumina NovaSeq 6000 to generate FASTQ files.</p></sec><sec><title>Bioinformatic analysis of scRNA-Seq.</title><p>The FASTQ files were preprocessed using Cell Ranger software version 7.1 (10X Genomics) to produce feature-barcode matrixes. Mouse reference genome mm10 was used for alignments. The feature-barcode matrixes were imported for further analysis in R suite software using Seurat package version 4.2.0 (<xref rid="B94" ref-type="bibr">94</xref>). Cells containing between 1,000 and 5,000 transcripts, mitochondria read content less than 15%, and complexity of RNA species (log<sub>10</sub>[number of genes/number of unique molecular identifiers] &gt; 0.85) were included in the further analysis. Harmonization was performed using a reciprocal principal component analysis method based on the top 50 principal components and 6,000 most variable features to minimize batch effect. Harmonized results were used for clustering using Louvain algorithm with multilevel refinement and UMAP for dimension reduction. The gene-specific markers of individual clusters and differentially expressed genes were identified using MAST algorithm for cell type identification (<xref rid="B95" ref-type="bibr">95</xref>). The GSEAs were performed using piano package (<xref rid="B96" ref-type="bibr">96</xref>). Transcriptional activity in osteoblasts (<xref rid="sd" ref-type="sec">Supplemental Figure 4C</xref>) and in Osteo-X cells (<xref rid="F7" ref-type="fig">Figure 7</xref>) was analyzed using SCENIC pipeline software (<xref rid="B97" ref-type="bibr">97</xref>). Interaction among the identified transcription factors was examined using STRING database v12.0 (<xref rid="B98" ref-type="bibr">98</xref>). The network was then imported to Cytoscape software (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cytoscape.org/" ext-link-type="uri">https://cytoscape.org/</ext-link>) for visualization.</p></sec><sec><title>Statistics.</title><p>For 2-sample analyses evaluating differences between Cre controls and <italic toggle="yes">Tfeb</italic><sup>CRa</sup>, data distributions were checked for normality and equal variance to choose the appropriate test for each 2-tailed <italic toggle="yes">t</italic> test (equal variances), Welch&#8217;s <italic toggle="yes">t</italic> test (unequal variances), or Wilcoxon&#8217;s rank-sum test (non-normal data). ANOVA was employed for analyses of more than 2 groups, checking for normality and homoscedasticity of the residuals and transforming the data if needed to meet those assumptions. One-way ANOVA was used for <xref rid="F1" ref-type="fig">Figure 1B</xref> and <xref rid="F2" ref-type="fig">2</xref>-way ANOVA for <xref rid="F2" ref-type="fig">Figure 2, B</xref>&#8211;E. A <italic toggle="yes">P</italic> &lt; 0.05 was considered significant. For <xref rid="F6" ref-type="fig">Figure 6, a</xref> repeated measures model was fit to BMD measurements focusing on the effects of group and month, along with the interaction of group and month and with an autoregressive (<xref rid="B1" ref-type="bibr">1</xref>) covariance structure using SAS version 9.4. Residuals of the model were tested for normality and constant variance.</p></sec><sec><title>Study approval.</title><p>All animal studies were carried out with approval from and following the policies of the Institutional Animal Care and Use Committee of the UAMS. The studies described here were performed and reported in accordance with Animal Research: Reporting of In Vivo Experiments guidelines. Each figure legend indicates the sex, number, and age of the mice used for each experiment.</p></sec><sec><title>Data availability.</title><p>The raw data are contained in the <xref rid="sd" ref-type="sec">Supporting Data Values</xref> file and in NCBI BioProject RJNA1238393 (scRNA-Seq).</p></sec></sec><sec><title>Author contributions</title><p>MO conceived and designed the in vivo experiments. MA and MO designed the in vitro experiments. MO, AJ, JAH, IK, JL, and JC performed all animal experimentation and skeletal analysis. MO, AJ, and AMC generated and analyzed the in vitro data. AYS performed 3-point bending analysis. JT, MO, and AJ performed statistical analysis. MO and JX performed periosteal cell isolation, IN and VW performed scRNA-Seq and advanced bioinformatics analysis. MO and AJ prepared figures. MO wrote the manuscript. All authors reviewed the manuscript.</p></sec><sec sec-type="supplementary-material" id="sd"><title>Supplementary Material</title><supplementary-material id="SD1" position="float" content-type="local-data" orientation="portrait"><caption><title>Supplemental data</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jciinsight-10-191688-s248.pdf" id="d67e1725" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="SD2" position="float" content-type="local-data" orientation="portrait"><caption><title>Unedited blot and gel images</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jciinsight-10-191688-s249.pdf" id="d67e1729" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="SD3" position="float" content-type="local-data" orientation="portrait"><caption><title>Supporting data values</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jciinsight-10-191688-s250.xlsx" id="d67e1733" position="anchor" orientation="portrait"/></supplementary-material></sec></body><back><ack><p>We thank UAMS Genetic Models Core Facility for the sgRNA<italic toggle="yes"><sup>Tfeb</sup></italic> model, UAMS Bone Histology and Imaging Core for their help, and UAMS Department of Laboratory Animal Medicine for their help with care of mice. The dCas9:SPH sgRNA<italic toggle="yes"><sup>Tfeb</sup></italic> image in Figure 1 was created in BioRender: Onal, M. (2025) https://BioRender.com/c2w0cm5. This work was supported by the NIH National Institute of General Medical Sciences grants P20GM125503, the NIH National Institute on Aging grant R01AG068449, and the UAMS Bone and Joint Initiative Funds. AYS received salary support by NIH T32-AR065971 and the National Center for Advancing Translational Sciences of the NIH under Award Numbers KL2TR003108 and UL1TR003107. This work is the result of NIH funding, in whole or in part, and is subject to the NIH Public Access Policy. Through acceptance of this federal funding, the NIH has been given a right to make the work publicly available in PubMed Central.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>Conflict of interest:</bold> The authors have declared that no conflict of interest exists.</p></fn><fn><p><bold>Copyright:</bold> &#169; 2025, James et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.</p></fn><fn><p><bold>Reference information:</bold><italic toggle="yes"> JCI Insight</italic>. 2025;10(17):e191688.https://doi.org/10.1172/jci.insight.191688.</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sims</surname><given-names>NA</given-names></name><name name-style="western"><surname>Gooi</surname><given-names>JH</given-names></name></person-group><article-title>Bone remodeling: multiple cellular interactions required for coupling of bone formation and resorption</article-title><source>Semin Cell Dev Biol</source><year>2008</year><volume>19</volume><issue>5</issue><fpage>444</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1016/j.semcdb.2008.07.016</pub-id><pub-id pub-id-type="pmid">18718546</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bellido</surname><given-names>T</given-names></name></person-group><article-title>Osteocyte-driven bone remodeling</article-title><source>Calcif Tissue Int</source><year>2014</year><volume>94</volume><issue>1</issue><fpage>25</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1007/s00223-013-9774-y</pub-id><pub-id pub-id-type="pmid">24002178</pub-id><pub-id pub-id-type="pmcid">PMC3947228</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jilka</surname><given-names>RL</given-names></name></person-group><article-title>Biology of the basic multicellular unit and the pathophysiology of osteoporosis</article-title><source>Med Pediatr Oncol</source><year>2003</year><volume>41</volume><issue>3</issue><fpage>182</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1002/mpo.10334</pub-id><pub-id pub-id-type="pmid">12868116</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Onal</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Suppression of autophagy in osteocytes mimics skeletal aging</article-title><source>J Biol Chem</source><year>2013</year><volume>288</volume><issue>24</issue><fpage>17432</fpage><lpage>17440</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.444190</pub-id><pub-id pub-id-type="pmid">23645674</pub-id><pub-id pub-id-type="pmcid">PMC3682543</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piemontese</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Low bone mass and changes in the osteocyte network in mice lacking autophagy in the osteoblast lineage</article-title><source>Sci Rep</source><year>2016</year><volume>6</volume><elocation-id>24262</elocation-id><pub-id pub-id-type="doi">10.1038/srep24262</pub-id><pub-id pub-id-type="pmid">27064143</pub-id><pub-id pub-id-type="pmcid">PMC4827128</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>F</given-names></name><etal>et al</etal></person-group><article-title>Suppression of autophagy by FIP200 deletion leads to osteopenia in mice through the inhibition of osteoblast terminal differentiation</article-title><source>J Bone Miner Res</source><year>2013</year><volume>28</volume><issue>11</issue><fpage>2414</fpage><lpage>2430</lpage><pub-id pub-id-type="doi">10.1002/jbmr.1971</pub-id><pub-id pub-id-type="pmid">23633228</pub-id><pub-id pub-id-type="pmcid">PMC3805719</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nollet</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Autophagy in osteoblasts is involved in mineralization and bone homeostasis</article-title><source>Autophagy</source><year>2014</year><volume>10</volume><issue>11</issue><fpage>1965</fpage><lpage>1977</lpage><pub-id pub-id-type="doi">10.4161/auto.36182</pub-id><pub-id pub-id-type="pmid">25484092</pub-id><pub-id pub-id-type="pmcid">PMC4502694</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><etal>et al</etal></person-group><article-title>Defective autophagy in osteoblasts induces endoplasmic reticulum stress and causes remarkable bone loss</article-title><source>Autophagy</source><year>2018</year><volume>14</volume><issue>10</issue><fpage>1726</fpage><lpage>1741</lpage><pub-id pub-id-type="doi">10.1080/15548627.2018.1483807</pub-id><pub-id pub-id-type="pmid">29962255</pub-id><pub-id pub-id-type="pmcid">PMC6135623</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name><etal>et al</etal></person-group><article-title>Autophagy controls mesenchymal stem cell properties and senescence during bone aging</article-title><source>Aging Cell</source><year>2018</year><volume>17</volume><issue>1</issue><elocation-id>e12709</elocation-id><pub-id pub-id-type="doi">10.1111/acel.12709</pub-id><pub-id pub-id-type="pmid">29210174</pub-id><pub-id pub-id-type="pmcid">PMC5770781</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>K</given-names></name><etal>et al</etal></person-group><article-title>Decreased activity of osteocyte autophagy with aging may contribute to the bone loss in senile population</article-title><source>Histochem Cell Biol</source><year>2014</year><volume>142</volume><issue>3</issue><fpage>285</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1007/s00418-014-1194-1</pub-id><pub-id pub-id-type="pmid">24553790</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><etal>et al</etal></person-group><article-title>Impaired autophagy triggered by HDAC9 in mesenchymal stem cells accelerates bone mass loss</article-title><source>Stem Cell Res Ther</source><year>2020</year><volume>11</volume><issue>1</issue><elocation-id>269</elocation-id><pub-id pub-id-type="doi">10.1186/s13287-020-01785-6</pub-id><pub-id pub-id-type="pmid">32620134</pub-id><pub-id pub-id-type="pmcid">PMC7333327</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Settembre</surname><given-names>C</given-names></name><etal>et al</etal></person-group><article-title>TFEB links autophagy to lysosomal biogenesis</article-title><source>Science</source><year>2011</year><volume>332</volume><issue>6036</issue><fpage>1429</fpage><lpage>1433</lpage><pub-id pub-id-type="doi">10.1126/science.1204592</pub-id><pub-id pub-id-type="pmid">21617040</pub-id><pub-id pub-id-type="pmcid">PMC3638014</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spampanato</surname><given-names>C</given-names></name><etal>et al</etal></person-group><article-title>Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease</article-title><source>EMBO Mol Med</source><year>2013</year><volume>5</volume><issue>5</issue><fpage>691</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.1002/emmm.201202176</pub-id><pub-id pub-id-type="pmid">23606558</pub-id><pub-id pub-id-type="pmcid">PMC3662313</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Decressac</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>TFEB-mediated autophagy rescues midbrain dopamine neurons from &#945;-synuclein toxicity</article-title><source>Proc Natl Acad Sci U S A</source><year>2013</year><volume>110</volume><issue>19</issue><fpage>E1817</fpage><lpage>E1826</lpage><pub-id pub-id-type="doi">10.1073/pnas.1305623110</pub-id><pub-id pub-id-type="pmid">23610405</pub-id><pub-id pub-id-type="pmcid">PMC3651458</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arotcarena</surname><given-names>ML</given-names></name><etal>et al</etal></person-group><article-title>Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies</article-title><source>JCI Insight</source><year>2019</year><volume>4</volume><issue>16</issue><elocation-id>e129719</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.129719</pub-id><pub-id pub-id-type="pmid">31434803</pub-id><pub-id pub-id-type="pmcid">PMC6777809</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polito</surname><given-names>VA</given-names></name><etal>et al</etal></person-group><article-title>Selective clearance of aberrant tau proteins and rescue of neurotoxicity by transcription factor EB</article-title><source>EMBO Mol Med</source><year>2014</year><volume>6</volume><issue>9</issue><fpage>1142</fpage><lpage>1160</lpage><pub-id pub-id-type="doi">10.15252/emmm.201303671</pub-id><pub-id pub-id-type="pmid">25069841</pub-id><pub-id pub-id-type="pmcid">PMC4197862</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sergin</surname><given-names>I</given-names></name><etal>et al</etal></person-group><article-title>Exploiting macrophage autophagy-lysosomal biogenesis as a therapy for atherosclerosis</article-title><source>Nat Commun</source><year>2017</year><volume>8</volume><elocation-id>15750</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms15750</pub-id><pub-id pub-id-type="pmid">28589926</pub-id><pub-id pub-id-type="pmcid">PMC5467270</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>R</given-names></name><etal>et al</etal></person-group><article-title>TFEB insufficiency promotes cardiac hypertrophy by blocking autophagic degradation of GATA4</article-title><source>J Biol Chem</source><year>2021</year><volume>297</volume><issue>4</issue><elocation-id>101189</elocation-id><pub-id pub-id-type="doi">10.1016/j.jbc.2021.101189</pub-id><pub-id pub-id-type="pmid">34517007</pub-id><pub-id pub-id-type="pmcid">PMC8498468</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>G</given-names></name><etal>et al</etal></person-group><article-title>TFEB, a potential therapeutic target for osteoarthritis via autophagy regulation</article-title><source>Cell Death Dis</source><year>2018</year><volume>9</volume><issue>9</issue><elocation-id>858</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-018-0909-y</pub-id><pub-id pub-id-type="pmid">30154423</pub-id><pub-id pub-id-type="pmcid">PMC6113230</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gilbert</surname><given-names>LA</given-names></name><etal>et al</etal></person-group><article-title>CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes</article-title><source>Cell</source><year>2013</year><volume>154</volume><issue>2</issue><fpage>442</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.06.044</pub-id><pub-id pub-id-type="pmid">23849981</pub-id><pub-id pub-id-type="pmcid">PMC3770145</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chavez</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Highly efficient Cas9-mediated transcriptional programming</article-title><source>Nat Methods</source><year>2015</year><volume>12</volume><issue>4</issue><fpage>326</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3312</pub-id><pub-id pub-id-type="pmid">25730490</pub-id><pub-id pub-id-type="pmcid">PMC4393883</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name><etal>et al</etal></person-group><article-title>In vivo simultaneous transcriptional activation of multiple genes in the brain using CRISPR-dCas9-activator transgenic mice</article-title><source>Nat Neurosci</source><year>2018</year><volume>21</volume><issue>3</issue><fpage>440</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1038/s41593-017-0060-6</pub-id><pub-id pub-id-type="pmid">29335603</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cassidy</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Novel methods for the generation of genetically engineered animal models</article-title><source>Bone</source><year>2023</year><volume>167</volume><elocation-id>116612</elocation-id><pub-id pub-id-type="doi">10.1016/j.bone.2022.116612</pub-id><pub-id pub-id-type="pmid">36379415</pub-id><pub-id pub-id-type="pmcid">PMC9936561</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="webpage" publication-format="online"><comment>Kenny HC, et al. Cardiac specific overexpression of transcription factor EB (TFEB) in normal hearts induces pathologic cardiac hypertrophy and lethal cardiomyopathy [preprint]. </comment><pub-id pub-id-type="doi">10.1101/2021.02.16.431474</pub-id><comment> Posted on bioRxiv February 17. 2021</comment></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laster</surname><given-names>DJ</given-names></name><etal>et al</etal></person-group><article-title>CRISPR interference provides increased cell type-specificity compared to the Cre-loxP system</article-title><source>iScience</source><year>2023</year><volume>26</volume><issue>8</issue><elocation-id>107428</elocation-id><pub-id pub-id-type="doi">10.1016/j.isci.2023.107428</pub-id><pub-id pub-id-type="pmid">37575184</pub-id><pub-id pub-id-type="pmcid">PMC10415806</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodda</surname><given-names>SJ</given-names></name><name name-style="western"><surname>McMahon</surname><given-names>AP</given-names></name></person-group><article-title>Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors</article-title><source>Development</source><year>2006</year><volume>133</volume><issue>16</issue><fpage>3231</fpage><lpage>3244</lpage><pub-id pub-id-type="doi">10.1242/dev.02480</pub-id><pub-id pub-id-type="pmid">16854976</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sardiello</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>A gene network regulating lysosomal biogenesis and function</article-title><source>Science</source><year>2009</year><volume>325</volume><issue>5939</issue><fpage>473</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1126/science.1174447</pub-id><pub-id pub-id-type="pmid">19556463</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Settembre</surname><given-names>C</given-names></name><etal>et al</etal></person-group><article-title>A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB</article-title><source>EMBO J</source><year>2012</year><volume>31</volume><issue>5</issue><fpage>1095</fpage><lpage>1108</lpage><pub-id pub-id-type="doi">10.1038/emboj.2012.32</pub-id><pub-id pub-id-type="pmid">22343943</pub-id><pub-id pub-id-type="pmcid">PMC3298007</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palmieri</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Characterization of the CLEAR network reveals an integrated control of cellular clearance pathways</article-title><source>Hum Mol Genet</source><year>2011</year><volume>20</volume><issue>19</issue><fpage>3852</fpage><lpage>3866</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddr306</pub-id><pub-id pub-id-type="pmid">21752829</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bao</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Deacetylation of TFEB promotes fibrillar A&#946; degradation by upregulating lysosomal biogenesis in microglia</article-title><source>Protein Cell</source><year>2016</year><volume>7</volume><issue>6</issue><fpage>417</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1007/s13238-016-0269-2</pub-id><pub-id pub-id-type="pmid">27209302</pub-id><pub-id pub-id-type="pmcid">PMC4887328</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>K</given-names></name><etal>et al</etal></person-group><article-title>Lysosomal Ca<sup>2+</sup>-mediated TFEB activation modulates mitophagy and functional adaptation of pancreatic &#946;-cells to metabolic stress</article-title><source>Nat Commun</source><year>2022</year><volume>13</volume><issue>1</issue><elocation-id>1300</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-28874-9</pub-id><pub-id pub-id-type="pmid">35288580</pub-id><pub-id pub-id-type="pmcid">PMC8921223</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Endoplasmic reticulum mediates mitochondrial transfer within the osteocyte dendritic network</article-title><source>Sci Adv</source><year>2019</year><volume>5</volume><issue>11</issue><elocation-id>eaaw7215</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.aaw7215</pub-id><pub-id pub-id-type="pmid">31799389</pub-id><pub-id pub-id-type="pmcid">PMC6867880</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>SY</given-names></name><etal>et al</etal></person-group><article-title>PINK1 deficiency impairs osteoblast differentiation through aberrant mitochondrial homeostasis</article-title><source>Stem Cell Res Ther</source><year>2021</year><volume>12</volume><issue>1</issue><elocation-id>589</elocation-id><pub-id pub-id-type="doi">10.1186/s13287-021-02656-4</pub-id><pub-id pub-id-type="pmid">34823575</pub-id><pub-id pub-id-type="pmcid">PMC8614054</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><etal>et al</etal></person-group><article-title>PINK1/Parkin-mediated mitophagy inhibits osteoblast apoptosis induced by advanced oxidation protein products</article-title><source>Cell Death Dis</source><year>2023</year><volume>14</volume><issue>2</issue><elocation-id>88</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-023-05595-5</pub-id><pub-id pub-id-type="pmid">36750550</pub-id><pub-id pub-id-type="pmcid">PMC9905061</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>G</given-names></name><etal>et al</etal></person-group><article-title>FUNDC1/PFKP-mediated mitophagy induced by KD025 ameliorates cartilage degeneration in osteoarthritis</article-title><source>Mol Ther</source><year>2023</year><volume>31</volume><issue>12</issue><fpage>3594</fpage><lpage>3612</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2023.10.016</pub-id><pub-id pub-id-type="pmid">37838829</pub-id><pub-id pub-id-type="pmcid">PMC10727975</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="webpage" publication-format="online"><comment>Tian L, et al. BNIP3 mediated Mitophagy is essential for osteoblast differentiation. Paper presented at: Costas T. Lambrew Research Retreat 2020. May 6, 2020; Virtual. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://knowledgeconnection.mainehealth.org/lambrew-retreat-2020/50/" ext-link-type="uri">https://knowledgeconnection.mainehealth.org/lambrew-retreat-2020/50/</ext-link> Accessed July 29, 2025</comment></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roczniak-Ferguson</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>The transcription factor TFEB links mTORC1 signaling to transcriptional control of lysosome homeostasis</article-title><source>Sci Signal</source><year>2012</year><volume>5</volume><issue>228</issue><elocation-id>ra42</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.2002790</pub-id><pub-id pub-id-type="pmid">22692423</pub-id><pub-id pub-id-type="pmcid">PMC3437338</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clarke</surname><given-names>B</given-names></name></person-group><article-title>Normal bone anatomy and physiology</article-title><source>Clin J Am Soc Nephrol</source><year>2008</year><volume>3 Suppl 3</volume><issue>suppl 3</issue><fpage>S131</fpage><lpage>S139</lpage><pub-id pub-id-type="doi">10.2215/CJN.04151206</pub-id><pub-id pub-id-type="pmid">18988698</pub-id><pub-id pub-id-type="pmcid">PMC3152283</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ott</surname><given-names>SM</given-names></name></person-group><article-title>Cortical or trabecular bone: what&#8217;s the difference?</article-title><source>Am J Nephrol</source><year>2018</year><volume>47</volume><issue>6</issue><fpage>373</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1159/000489672</pub-id><pub-id pub-id-type="pmid">29788030</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dempster</surname><given-names>DW</given-names></name><etal>et al</etal></person-group><article-title>Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee</article-title><source>J Bone Miner Res</source><year>2013</year><volume>28</volume><issue>1</issue><fpage>2</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1002/jbmr.1805</pub-id><pub-id pub-id-type="pmid">23197339</pub-id><pub-id pub-id-type="pmcid">PMC3672237</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gould</surname><given-names>NR</given-names></name><etal>et al</etal></person-group><article-title>Disparate bone anabolic cues activate bone formation by regulating the rapid lysosomal degradation of sclerostin protein</article-title><source>Elife</source><year>2021</year><volume>10</volume><elocation-id>e64393</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.64393</pub-id><pub-id pub-id-type="pmid">33779549</pub-id><pub-id pub-id-type="pmcid">PMC8032393</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jilka</surname><given-names>RL</given-names></name></person-group><article-title>The relevance of mouse models for investigating age-related bone loss in humans</article-title><source>J Gerontol A Biol Sci Med Sci</source><year>2013</year><volume>68</volume><issue>10</issue><fpage>1209</fpage><lpage>1217</lpage><pub-id pub-id-type="doi">10.1093/gerona/glt046</pub-id><pub-id pub-id-type="pmid">23689830</pub-id><pub-id pub-id-type="pmcid">PMC3779631</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halloran</surname><given-names>BP</given-names></name><etal>et al</etal></person-group><article-title>Changes in bone structure and mass with advancing age in the male C57BL/6J mouse</article-title><source>J Bone Miner Res</source><year>2002</year><volume>17</volume><issue>6</issue><fpage>1044</fpage><lpage>1050</lpage><pub-id pub-id-type="doi">10.1359/jbmr.2002.17.6.1044</pub-id><pub-id pub-id-type="pmid">12054159</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glatt</surname><given-names>V</given-names></name><etal>et al</etal></person-group><article-title>Age-related changes in trabecular architecture differ in female and male C57BL/6J mice</article-title><source>J Bone Miner Res</source><year>2007</year><volume>22</volume><issue>8</issue><fpage>1197</fpage><lpage>1207</lpage><pub-id pub-id-type="doi">10.1359/jbmr.070507</pub-id><pub-id pub-id-type="pmid">17488199</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schini</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Bone turnover markers: basic biology to clinical applications</article-title><source>Endocr Rev</source><year>2023</year><volume>44</volume><issue>3</issue><fpage>417</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1210/endrev/bnac031</pub-id><pub-id pub-id-type="pmid">36510335</pub-id><pub-id pub-id-type="pmcid">PMC10166271</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nookaew</surname><given-names>I</given-names></name><etal>et al</etal></person-group><article-title>Refining the identity of mesenchymal cell types associated with murine periosteal and endosteal bone</article-title><source>J Biol Chem</source><year>2024</year><volume>300</volume><issue>4</issue><elocation-id>107158</elocation-id><pub-id pub-id-type="doi">10.1016/j.jbc.2024.107158</pub-id><pub-id pub-id-type="pmid">38479598</pub-id><pub-id pub-id-type="pmcid">PMC11007436</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gomez-Puerto</surname><given-names>MC</given-names></name><etal>et al</etal></person-group><article-title>Autophagy contributes to BMP type 2 receptor degradation and development of pulmonary arterial hypertension</article-title><source>J Pathol</source><year>2019</year><volume>249</volume><issue>3</issue><fpage>356</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1002/path.5322</pub-id><pub-id pub-id-type="pmid">31257577</pub-id><pub-id pub-id-type="pmcid">PMC6852495</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marino</surname><given-names>G</given-names></name><etal>et al</etal></person-group><article-title>Self-consumption: the interplay of autophagy and apoptosis</article-title><source>Nat Rev Mol Cell Biol</source><year>2014</year><volume>15</volume><issue>2</issue><fpage>81</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1038/nrm3735</pub-id><pub-id pub-id-type="pmid">24401948</pub-id><pub-id pub-id-type="pmcid">PMC3970201</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bharath</surname><given-names>LP</given-names></name><etal>et al</etal></person-group><article-title>Endothelial cell autophagy maintains shear stress-induced nitric oxide generation via glycolysis-dependent purinergic signaling to endothelial nitric oxide synthase</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2017</year><volume>37</volume><issue>9</issue><fpage>1646</fpage><lpage>1656</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.117.309510</pub-id><pub-id pub-id-type="pmid">28684613</pub-id><pub-id pub-id-type="pmcid">PMC5693355</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perrin</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Single-nucleus transcriptomics reveal the differentiation trajectories of periosteal skeletal/stem progenitor cells in bone regeneration</article-title><source>Elife</source><year>2024</year><volume>13</volume><elocation-id>RP92519</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.92519</pub-id><pub-id pub-id-type="pmid">39642053</pub-id><pub-id pub-id-type="pmcid">PMC11623931</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okamoto</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Noncanonical Wnt5a enhances Wnt/&#946;-catenin signaling during osteoblastogenesis</article-title><source>Sci Rep</source><year>2014</year><volume>4</volume><elocation-id>4493</elocation-id><pub-id pub-id-type="doi">10.1038/srep04493</pub-id><pub-id pub-id-type="pmid">24670389</pub-id><pub-id pub-id-type="pmcid">PMC3967152</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maeda</surname><given-names>K</given-names></name><etal>et al</etal></person-group><article-title>Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis</article-title><source>Nat Med</source><year>2012</year><volume>18</volume><issue>3</issue><fpage>405</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1038/nm.2653</pub-id><pub-id pub-id-type="pmid">22344299</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Stat1 functions as a cytoplasmic attenuator of Runx2 in the transcriptional program of osteoblast differentiation</article-title><source>Genes Dev</source><year>2003</year><volume>17</volume><issue>16</issue><fpage>1979</fpage><lpage>1991</lpage><pub-id pub-id-type="doi">10.1101/gad.1119303</pub-id><pub-id pub-id-type="pmid">12923053</pub-id><pub-id pub-id-type="pmcid">PMC196253</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>X</given-names></name><etal>et al</etal></person-group><article-title>Cbfb regulates bone development by stabilizing Runx family proteins</article-title><source>J Bone Miner Res</source><year>2015</year><volume>30</volume><issue>4</issue><fpage>706</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1002/jbmr.2379</pub-id><pub-id pub-id-type="pmid">25262822</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samee</surname><given-names>N</given-names></name><etal>et al</etal></person-group><article-title>Dlx5, a positive regulator of osteoblastogenesis, is essential for osteoblast-osteoclast coupling</article-title><source>Am J Pathol</source><year>2008</year><volume>173</volume><issue>3</issue><fpage>773</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2008.080243</pub-id><pub-id pub-id-type="pmid">18669617</pub-id><pub-id pub-id-type="pmcid">PMC2527089</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakashima</surname><given-names>K</given-names></name><etal>et al</etal></person-group><article-title>The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation</article-title><source>Cell</source><year>2002</year><volume>108</volume><issue>1</issue><fpage>17</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(01)00622-5</pub-id><pub-id pub-id-type="pmid">11792318</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nissen-Meyer</surname><given-names>LS</given-names></name><etal>et al</etal></person-group><article-title>Osteopenia, decreased bone formation and impaired osteoblast development in Sox4 heterozygous mice</article-title><source>J Cell Sci</source><year>2007</year><volume>120</volume><issue>pt 16</issue><fpage>2785</fpage><lpage>2795</lpage><pub-id pub-id-type="doi">10.1242/jcs.003855</pub-id><pub-id pub-id-type="pmid">17652162</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Angelozzi</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>SOXC are critical regulators of adult bone mass</article-title><source>Nat Commun</source><year>2024</year><volume>15</volume><issue>1</issue><elocation-id>2956</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-024-47413-2</pub-id><pub-id pub-id-type="pmid">38580651</pub-id><pub-id pub-id-type="pmcid">PMC10997656</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wan</surname><given-names>C</given-names></name><etal>et al</etal></person-group><article-title>Role of HIF-1alpha in skeletal development</article-title><source>Ann N Y Acad Sci</source><year>2010</year><volume>1192</volume><fpage>322</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2009.05238.x</pub-id><pub-id pub-id-type="pmid">20392254</pub-id><pub-id pub-id-type="pmcid">PMC3047468</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murakami</surname><given-names>T</given-names></name><etal>et al</etal></person-group><article-title>Signalling mediated by the endoplasmic reticulum stress transducer OASIS is involved in bone formation</article-title><source>Nat Cell Biol</source><year>2009</year><volume>11</volume><issue>10</issue><fpage>1205</fpage><lpage>1211</lpage><pub-id pub-id-type="doi">10.1038/ncb1963</pub-id><pub-id pub-id-type="pmid">19767743</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nishikawa</surname><given-names>K</given-names></name><etal>et al</etal></person-group><article-title>Maf promotes osteoblast differentiation in mice by mediating the age-related switch in mesenchymal cell differentiation</article-title><source>J Clin Invest</source><year>2010</year><volume>120</volume><issue>10</issue><fpage>3455</fpage><lpage>3465</lpage><pub-id pub-id-type="doi">10.1172/JCI42528</pub-id><pub-id pub-id-type="pmid">20877012</pub-id><pub-id pub-id-type="pmcid">PMC2947225</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kida</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Interaction of LEF1 with TAZ is necessary for the osteoblastogenic activity of Wnt3a</article-title><source>Sci Rep</source><year>2018</year><volume>8</volume><issue>1</issue><elocation-id>10375</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-28711-4</pub-id><pub-id pub-id-type="pmid">29991769</pub-id><pub-id pub-id-type="pmcid">PMC6039525</pub-id></element-citation></ref><ref id="B63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Milot</surname><given-names>E</given-names></name><etal>et al</etal></person-group><article-title>Heterochromatin effects on the frequency and duration of LCR-mediated gene transcription</article-title><source>Cell</source><year>1996</year><volume>87</volume><issue>1</issue><fpage>105</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)81327-6</pub-id><pub-id pub-id-type="pmid">8858153</pub-id></element-citation></ref><ref id="B64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pedram</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Telomere position effect and silencing of transgenes near telomeres in the mouse</article-title><source>Mol Cell Biol</source><year>2006</year><volume>26</volume><issue>5</issue><fpage>1865</fpage><lpage>1878</lpage><pub-id pub-id-type="doi">10.1128/MCB.26.5.1865-1878.2006</pub-id><pub-id pub-id-type="pmid">16479005</pub-id><pub-id pub-id-type="pmcid">PMC1430234</pub-id></element-citation></ref><ref id="B65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>Q</given-names></name><etal>et al</etal></person-group><article-title>Telomeric transgenes are silenced in adult mouse tissues and embryo fibroblasts but are expressed in embryonic stem cells</article-title><source>Stem Cells</source><year>2007</year><volume>25</volume><issue>12</issue><fpage>3085</fpage><lpage>3092</lpage><pub-id pub-id-type="doi">10.1634/stemcells.2007-0478</pub-id><pub-id pub-id-type="pmid">17823235</pub-id></element-citation></ref><ref id="B66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Position effect variegation and imprinting of transgenes in lymphocytes</article-title><source>Nucleic Acids Res</source><year>2008</year><volume>36</volume><issue>7</issue><fpage>2320</fpage><lpage>2329</lpage><pub-id pub-id-type="doi">10.1093/nar/gkn085</pub-id><pub-id pub-id-type="pmid">18296483</pub-id><pub-id pub-id-type="pmcid">PMC2367730</pub-id></element-citation></ref><ref id="B67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Makareeva</surname><given-names>E</given-names></name><etal>et al</etal></person-group><article-title>Chaperoning osteogenesis: new protein-folding disease paradigms</article-title><source>Trends Cell Biol</source><year>2011</year><volume>21</volume><issue>3</issue><fpage>168</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2010.11.007</pub-id><pub-id pub-id-type="pmid">21183349</pub-id><pub-id pub-id-type="pmcid">PMC3057343</pub-id></element-citation></ref><ref id="B68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saito</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Endoplasmic reticulum stress response mediated by the PERK-eIF2(alpha)-ATF4 pathway is involved in osteoblast differentiation induced by BMP2</article-title><source>J Biol Chem</source><year>2011</year><volume>286</volume><issue>6</issue><fpage>4809</fpage><lpage>4818</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.152900</pub-id><pub-id pub-id-type="pmid">21135100</pub-id><pub-id pub-id-type="pmcid">PMC3039352</pub-id></element-citation></ref><ref id="B69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tohmonda</surname><given-names>T</given-names></name><etal>et al</etal></person-group><article-title>The IRE1&#945;-XBP1 pathway is essential for osteoblast differentiation through promoting transcription of Osterix</article-title><source>EMBO Rep</source><year>2011</year><volume>12</volume><issue>5</issue><fpage>451</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1038/embor.2011.34</pub-id><pub-id pub-id-type="pmid">21415858</pub-id><pub-id pub-id-type="pmcid">PMC3090012</pub-id></element-citation></ref><ref id="B70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jang</surname><given-names>WG</given-names></name><etal>et al</etal></person-group><article-title>BMP2 protein regulates osteocalcin expression via Runx2-mediated Atf6 gene transcription</article-title><source>J Biol Chem</source><year>2012</year><volume>287</volume><issue>2</issue><fpage>905</fpage><lpage>915</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.253187</pub-id><pub-id pub-id-type="pmid">22102412</pub-id><pub-id pub-id-type="pmcid">PMC3256879</pub-id></element-citation></ref><ref id="B71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishida</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nagata</surname><given-names>K</given-names></name></person-group><article-title>Autophagy eliminates a specific species of misfolded procollagen and plays a protective role in cell survival against ER stress</article-title><source>Autophagy</source><year>2009</year><volume>5</volume><issue>8</issue><fpage>1217</fpage><lpage>1219</lpage><pub-id pub-id-type="doi">10.4161/auto.5.8.10168</pub-id><pub-id pub-id-type="pmid">19829057</pub-id></element-citation></ref><ref id="B72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jilka</surname><given-names>RL</given-names></name><etal>et al</etal></person-group><article-title>Dysapoptosis of osteoblasts and osteocytes increases cancellous bone formation but exaggerates cortical porosity with age</article-title><source>J Bone Miner Res</source><year>2014</year><volume>29</volume><issue>1</issue><fpage>103</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1002/jbmr.2007</pub-id><pub-id pub-id-type="pmid">23761243</pub-id><pub-id pub-id-type="pmcid">PMC3823639</pub-id></element-citation></ref><ref id="B73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsushita</surname><given-names>Y</given-names></name><etal>et al</etal></person-group><article-title>Bone marrow endosteal stem cells dictate active osteogenesis and aggressive tumorigenesis</article-title><source>Nat Commun</source><year>2023</year><volume>14</volume><issue>1</issue><elocation-id>2383</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-023-38034-2</pub-id><pub-id pub-id-type="pmid">37185464</pub-id><pub-id pub-id-type="pmcid">PMC10130060</pub-id></element-citation></ref><ref id="B74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>BO</given-names></name><etal>et al</etal></person-group><article-title>Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow</article-title><source>Cell Stem Cell</source><year>2014</year><volume>15</volume><issue>2</issue><fpage>154</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2014.06.008</pub-id><pub-id pub-id-type="pmid">24953181</pub-id><pub-id pub-id-type="pmcid">PMC4127103</pub-id></element-citation></ref><ref id="B75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>A vertebral skeletal stem cell lineage driving metastasis</article-title><source>Nature</source><year>2023</year><volume>621</volume><fpage>602</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06519-1</pub-id><pub-id pub-id-type="pmid">37704733</pub-id><pub-id pub-id-type="pmcid">PMC10829697</pub-id></element-citation></ref><ref id="B76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mansueto</surname><given-names>G</given-names></name><etal>et al</etal></person-group><article-title>Transcription factor EB controls metabolic flexibility during exercise</article-title><source>Cell Metab</source><year>2017</year><volume>25</volume><issue>1</issue><fpage>182</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2016.11.003</pub-id><pub-id pub-id-type="pmid">28011087</pub-id><pub-id pub-id-type="pmcid">PMC5241227</pub-id></element-citation></ref><ref id="B77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopez-Otin</surname><given-names>C</given-names></name><etal>et al</etal></person-group><article-title>Hallmarks of aging: an expanding universe</article-title><source>Cell</source><year>2023</year><volume>186</volume><issue>2</issue><fpage>243</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2022.11.001</pub-id><pub-id pub-id-type="pmid">36599349</pub-id></element-citation></ref><ref id="B78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><etal>et al</etal></person-group><article-title>Enhanced autophagy in <italic toggle="yes">Becn1<sup>F121A/F121A</sup></italic> knockin mice counteracts aging-related neural stem cell exhaustion and dysfunction</article-title><source>Autophagy</source><year>2022</year><volume>18</volume><issue>2</issue><fpage>409</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1080/15548627.2021.1936358</pub-id><pub-id pub-id-type="pmid">34101533</pub-id><pub-id pub-id-type="pmcid">PMC8942493</pub-id></element-citation></ref><ref id="B79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pyo</surname><given-names>JO</given-names></name><etal>et al</etal></person-group><article-title>Overexpression of Atg5 in mice activates autophagy and extends lifespan</article-title><source>Nat Commun</source><year>2013</year><volume>4</volume><elocation-id>2300</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms3300</pub-id><pub-id pub-id-type="pmid">23939249</pub-id><pub-id pub-id-type="pmcid">PMC3753544</pub-id></element-citation></ref><ref id="B80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><etal>et al</etal></person-group><article-title>TFEB protein expression is reduced in aged brains and its overexpression mitigates senescence-associated biomarkers and memory deficits in mice</article-title><source>Neurobiol Aging</source><year>2021</year><volume>106</volume><fpage>26</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2021.06.003</pub-id><pub-id pub-id-type="pmid">34229273</pub-id></element-citation></ref><ref id="B81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>G</given-names></name><etal>et al</etal></person-group><article-title>TFEB protects nucleus pulposus cells against apoptosis and senescence via restoring autophagic flux</article-title><source>Osteoarthritis Cartilage</source><year>2019</year><volume>27</volume><issue>2</issue><fpage>347</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1016/j.joca.2018.10.011</pub-id><pub-id pub-id-type="pmid">30414849</pub-id></element-citation></ref><ref id="B82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Devine</surname><given-names>CC</given-names></name><etal>et al</etal></person-group><article-title>Rapamycin does not alter bone microarchitecture or material properties quality in young-adult and aged female C57BL/6 mice</article-title><source>JBMR Plus</source><year>2024</year><volume>8</volume><issue>2</issue><elocation-id>ziae001</elocation-id><pub-id pub-id-type="doi">10.1093/jbmrpl/ziae001</pub-id><pub-id pub-id-type="pmid">38505525</pub-id><pub-id pub-id-type="pmcid">PMC10945714</pub-id></element-citation></ref><ref id="B83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>D</given-names></name><etal>et al</etal></person-group><article-title>Rapamycin reduces severity of senile osteoporosis by activating osteocyte autophagy</article-title><source>Osteoporos Int</source><year>2016</year><volume>27</volume><issue>3</issue><fpage>1093</fpage><lpage>1101</lpage><pub-id pub-id-type="doi">10.1007/s00198-015-3325-5</pub-id><pub-id pub-id-type="pmid">26395886</pub-id></element-citation></ref><ref id="B84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cong</surname><given-names>L</given-names></name><etal>et al</etal></person-group><article-title>Multiplex genome engineering using CRISPR/Cas systems</article-title><source>Science</source><year>2013</year><volume>339</volume><issue>6121</issue><fpage>819</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1126/science.1231143</pub-id><pub-id pub-id-type="pmid">23287718</pub-id><pub-id pub-id-type="pmcid">PMC3795411</pub-id></element-citation></ref><ref id="B85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ran</surname><given-names>FA</given-names></name><etal>et al</etal></person-group><article-title>Genome engineering using the CRISPR-Cas9 system</article-title><source>Nat Protoc</source><year>2013</year><volume>8</volume><issue>11</issue><fpage>2281</fpage><lpage>2308</lpage><pub-id pub-id-type="doi">10.1038/nprot.2013.143</pub-id><pub-id pub-id-type="pmid">24157548</pub-id><pub-id pub-id-type="pmcid">PMC3969860</pub-id></element-citation></ref><ref id="B86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Brien</surname><given-names>CA</given-names></name><etal>et al</etal></person-group><article-title>STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kappaB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone</article-title><source>J Biol Chem</source><year>1999</year><volume>274</volume><issue>27</issue><fpage>19301</fpage><lpage>19308</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.27.19301</pub-id><pub-id pub-id-type="pmid">10383440</pub-id></element-citation></ref><ref id="B87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chu</surname><given-names>VT</given-names></name><etal>et al</etal></person-group><article-title>Efficient generation of Rosa26 knock-in mice using CRISPR/Cas9 in C57BL/6 zygotes</article-title><source>BMC Biotechnol</source><year>2016</year><volume>16</volume><elocation-id>4</elocation-id><pub-id pub-id-type="doi">10.1186/s12896-016-0234-4</pub-id><pub-id pub-id-type="pmid">26772810</pub-id><pub-id pub-id-type="pmcid">PMC4715285</pub-id></element-citation></ref><ref id="B88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davey</surname><given-names>RA</given-names></name><etal>et al</etal></person-group><article-title>Decreased body weight in young Osterix-Cre transgenic mice results in delayed cortical bone expansion and accrual</article-title><source>Transgenic Res</source><year>2012</year><volume>21</volume><issue>4</issue><fpage>885</fpage><lpage>893</lpage><pub-id pub-id-type="doi">10.1007/s11248-011-9581-z</pub-id><pub-id pub-id-type="pmid">22160436</pub-id></element-citation></ref><ref id="B89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiong</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Matrix-embedded cells control osteoclast formation</article-title><source>Nat Med</source><year>2011</year><volume>17</volume><issue>10</issue><fpage>1235</fpage><lpage>1241</lpage><pub-id pub-id-type="doi">10.1038/nm.2448</pub-id><pub-id pub-id-type="pmid">21909103</pub-id><pub-id pub-id-type="pmcid">PMC3192296</pub-id></element-citation></ref><ref id="B90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Livak</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Schmittgen</surname><given-names>TD</given-names></name></person-group><article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method</article-title><source>Methods</source><year>2001</year><volume>25</volume><issue>4</issue><fpage>402</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id><pub-id pub-id-type="pmid">11846609</pub-id></element-citation></ref><ref id="B91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Onal</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>A DNA segment spanning the mouse Tnfsf11 transcription unit and its upstream regulatory domain rescues the pleiotropic biologic phenotype of the RANKL null mouse</article-title><source>J Bone Miner Res</source><year>2015</year><volume>30</volume><issue>5</issue><fpage>855</fpage><lpage>868</lpage><pub-id pub-id-type="doi">10.1002/jbmr.2417</pub-id><pub-id pub-id-type="pmid">25431114</pub-id><pub-id pub-id-type="pmcid">PMC5240630</pub-id></element-citation></ref><ref id="B92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><etal>et al</etal></person-group><article-title>Stimulation of Piezo1 by mechanical signals promotes bone anabolism</article-title><source>Elife</source><year>2019</year><volume>8</volume><elocation-id>e49631</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.49631</pub-id><pub-id pub-id-type="pmid">31588901</pub-id><pub-id pub-id-type="pmcid">PMC6779475</pub-id></element-citation></ref><ref id="B93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piemontese</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Suppression of autophagy in osteocytes does not modify the adverse effects of glucocorticoids on cortical bone</article-title><source>Bone</source><year>2015</year><volume>75</volume><fpage>18</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2015.02.005</pub-id><pub-id pub-id-type="pmid">25700544</pub-id><pub-id pub-id-type="pmcid">PMC4387016</pub-id></element-citation></ref><ref id="B94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hao</surname><given-names>Y</given-names></name><etal>et al</etal></person-group><article-title>Integrated analysis of multimodal single-cell data</article-title><source>Cell</source><year>2021</year><volume>184</volume><issue>13</issue><fpage>3573</fpage><lpage>3587</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.04.048</pub-id><pub-id pub-id-type="pmid">34062119</pub-id><pub-id pub-id-type="pmcid">PMC8238499</pub-id></element-citation></ref><ref id="B95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finak</surname><given-names>G</given-names></name><etal>et al</etal></person-group><article-title>MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data</article-title><source>Genome Biol</source><year>2015</year><volume>16</volume><elocation-id>278</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-015-0844-5</pub-id><pub-id pub-id-type="pmid">26653891</pub-id><pub-id pub-id-type="pmcid">PMC4676162</pub-id></element-citation></ref><ref id="B96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Varemo</surname><given-names>L</given-names></name><etal>et al</etal></person-group><article-title>Enriching the gene set analysis of genome-wide data by incorporating directionality of gene expression and combining statistical hypotheses and methods</article-title><source>Nucleic Acids Res</source><year>2013</year><volume>41</volume><issue>8</issue><fpage>4378</fpage><lpage>4391</lpage><pub-id pub-id-type="doi">10.1093/nar/gkt111</pub-id><pub-id pub-id-type="pmid">23444143</pub-id><pub-id pub-id-type="pmcid">PMC3632109</pub-id></element-citation></ref><ref id="B97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aibar</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>SCENIC: single-cell regulatory network inference and clustering</article-title><source>Nat Methods</source><year>2017</year><volume>14</volume><issue>11</issue><fpage>1083</fpage><lpage>1086</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4463</pub-id><pub-id pub-id-type="pmid">28991892</pub-id><pub-id pub-id-type="pmcid">PMC5937676</pub-id></element-citation></ref><ref id="B98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Szklarczyk</surname><given-names>D</given-names></name><etal>et al</etal></person-group><article-title>The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest</article-title><source>Nucleic Acids Res</source><year>2023</year><volume>51</volume><issue>d1</issue><fpage>D638</fpage><lpage>D646</lpage><pub-id pub-id-type="doi">10.1093/nar/gkac1000</pub-id><pub-id pub-id-type="pmid">36370105</pub-id><pub-id pub-id-type="pmcid">PMC9825434</pub-id></element-citation></ref></ref-list><notes notes-type="version-changes"><sec sec-type="version-changes"><label>Version 1</label><title>07/29/2025</title><p>In-Press Preview</p></sec><sec sec-type="version-changes"><label>Version 2</label><title>09/09/2025</title><p>Electronic publication</p></sec></notes></back><floats-group><fig position="float" id="F1" orientation="portrait"><label>Figure 1</label><caption><title>Elevation of <italic toggle="yes">Tfeb</italic> in osteoblast lineage cells via CRISPRa stimulates expression of genes involved in autophagy and lysosomal biogenesis.</title><p>(<bold>A</bold>) Diagram depicting the chr17:47,736,921&#8211;47,737,191 of GRCm38/mm10 and showing positions of 5 sgRNAs in relation to the transcription start site (TSS) of <italic toggle="yes">Tfeb</italic> gene. To stimulate transcription of <italic toggle="yes">Tfeb</italic>, the SP-dCas9-VPR/sgRNA complex was targeted to within 150 bp of the TSS. (<bold>B</bold>) Gene expression analysis of osteoblastic UAMS-32 cells transfected with SP-dCas9-VPR and sgRNAs targeting <italic toggle="yes">Tfeb</italic>. <italic toggle="yes">n</italic> = 3 wells per group. <italic toggle="yes">P</italic> values are calculated by 1-way ANOVA followed by Dunnett&#8217;s multiple comparison test comparing each with the control group. (<bold>C</bold>) Transgene design of murine models used for CRISPRa. Specifically, CRISPR/dCas9-activator (CRa), Osx1-Cre, and sgRNA<italic toggle="yes"><sup>Tfeb</sup></italic> mice were crossed to obtain triple transgenic CRa Osx1-Cre sgRNA<italic toggle="yes"><sup>Tfeb</sup></italic> (<italic toggle="yes">Tfeb</italic><sup>CRa</sup>) mice. (<bold>D</bold> and <bold>E</bold>) Comparison of Cre control mice, which include Osx1-Cre only (red dots), Osx1-Cre CRa (blue dots), and Osx1-Cre sgRNA<italic toggle="yes"><sup>Tfeb</sup></italic> (gray dots), with <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice. (<bold>D</bold>) <italic toggle="yes">Tfeb</italic> mRNA levels were measured in lumbar vertebrae 5 (spine) of <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice and their littermate Cre controls by quantitative real-time PCR (qRT-PCR) at 2, 5, or 12 months of age. (<bold>E</bold>) mRNA levels of <italic toggle="yes">Tfeb</italic> and genes involved in lysosomal biogenesis and autophagy were measured in calvaria of 2-month-old <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice and their Cre littermate controls via qRT-PCR. For all qRT-PCR analyses, mRNA levels were normalized to mouse <italic toggle="yes">Actb</italic>. Lysosome- and autophagy-related gene expression is represented as fold change over Cre controls. <italic toggle="yes">Lamp1</italic>, lysosomal-associated membrane protein 1. <italic toggle="yes">n</italic> = 6&#8211;18 mice per group. Bars indicate mean &#177; SD. *<italic toggle="yes">P</italic> &lt; 0.05 as calculated by unpaired <italic toggle="yes">t</italic> test for equal or unequal variance.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jciinsight-10-191688-g241.jpg"/></fig><fig position="float" id="F2" orientation="portrait"><label>Figure 2</label><caption><title>Elevation of TFEB in osteoblasts induces autophagy and lysosomal biogenesis.</title><p>Bone marrow cells were isolated from femurs and tibias of 5-month-old female <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice and littermate Cre controls and differentiated into osteoblasts by culturing with osteogenic media for 21 days. (<bold>A</bold>&#8211;<bold>E</bold>) Osteoblasts were treated with vehicle (PBS) or 100 nM bafilomycin for 6 hours. (<bold>A</bold>) Western blot analysis was performed to measure and quantify TFEB (<bold>B</bold>), LC3 (<bold>C</bold> and <bold>D</bold>), p62 (<bold>E</bold>), and actin levels. (<bold>F</bold>) Prior to staining with a cell-permeable Autophagy Probe, media were replaced with complete (10% FBS) or low-serum (2% FBS) media for 2 hours. Images were acquired via confocal microscopy, and mean fluorescence intensity was measured by flow cytometry. Scale bar represents 50 &#956;m. (<bold>G</bold>) Western blot analysis was performed to measure LAMP1 and actin levels. Samples were run on the same gel but were noncontiguous. (<bold>H</bold>) LysoTracker mean intensity was measured by flow cytometry. <italic toggle="yes">n</italic> = 3 wells per group. For all protein quantification, protein levels were normalized to actin levels. Bars indicate mean &#177; SD. Indicated <italic toggle="yes">P</italic> values were calculated by 2-way ANOVA followed by Tukey&#8217;s post hoc analysis (<bold>B</bold>&#8211;<bold>E</bold>) or unpaired <italic toggle="yes">t</italic> test (<bold>F</bold>&#8211;<bold>H</bold>). For <bold>B</bold>, 2-way ANOVA did not have normal residuals, so rank transformation was performed.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jciinsight-10-191688-g242.jpg"/></fig><fig position="float" id="F3" orientation="portrait"><label>Figure 3</label><caption><title><italic toggle="yes">Tfeb</italic> elevation in the osteoblast lineage increases bone mass.</title><p>(<bold>A</bold>) Representative &#956;CT image of a mouse femur, indicating trabecular and cortical bone compartments. (<bold>B</bold>&#8211;<bold>I</bold>) &#956;CT analysis performed on spine (lumbar vertebrae 4, L4) and long bones (male femurs and female humerus) from 4.5- to 5-month-old male and female <italic toggle="yes">Tfeb</italic><sup>CRa</sup> (Osx1-Cre CRa sgRNA<italic toggle="yes"><sup>Tfeb</sup></italic>) and Cre control (Osx1-Cre only [red dots], Osx1-Cre CRa [blue dots], Osx1-Cre sgRNA<italic toggle="yes"><sup>Tfeb</sup></italic> [gray dots]) mice. (<bold>B</bold>) Cortical thickness (Ct.Th) was measured in L4. (<bold>C</bold>) Representative L4 vertebrae images of <italic toggle="yes">Tfeb</italic><sup>CRa</sup> and control mice. Arrow indicates cortical bone. Scale bars represent 1 mm. (<bold>D</bold>&#8211;<bold>F</bold>) &#956;CT analysis of Ct.Th (<bold>D</bold>), periosteal perimeter (Ps.Pm) (<bold>E</bold>), and bone area (<bold>F</bold>) measured at the long bone midshaft. (<bold>G</bold>&#8211;<bold>I</bold>) Trabecular bone volume over tissue volume (BV/TV) (<bold>G</bold>), trabecular number (Tb.N) (<bold>H</bold>), and trabecular separation (Tb.Sp) (<bold>I</bold>) were measured in the long bone distal metaphysis. Male, <italic toggle="yes">n</italic> = 19 control and <italic toggle="yes">n</italic> = 18 <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice; female, <italic toggle="yes">n</italic> = 5 mice per group. Bars indicate mean &#177; SD. Indicated <italic toggle="yes">P</italic> values were calculated by either unpaired <italic toggle="yes">t</italic> test for equal or unequal variance (<bold>G</bold>-female, <bold>H</bold>-female) or rank sum test (if data are not normally distributed, <bold>B</bold>-male, <bold>E</bold>-male, <bold>F</bold>-female, <bold>G</bold>-male).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jciinsight-10-191688-g243.jpg"/></fig><fig position="float" id="F4" orientation="portrait"><label>Figure 4</label><caption><title><italic toggle="yes">Tfeb</italic> elevation in the osteoblast lineage increases femoral strength.</title><p>Femoral 3-point bending biomechanical testing was performed on 4.5-month-old male <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice and their littermate Cre controls (Osx1-Cre only [red dots], Osx1-Cre CRa [blue dots], Osx1-Cre sgRNA<italic toggle="yes"><sup>Tfeb</sup></italic> [gray dots]) to assess extrinsic and intrinsic properties of bone. (<bold>A</bold>&#8211;<bold>C</bold>) Extrinsic properties include stiffness (<bold>A</bold>), ultimate force (<bold>B</bold>), and energy to ultimate force (<bold>C</bold>). (<bold>D</bold>&#8211;<bold>F</bold>) Intrinsic properties include ultimate stress (<bold>D</bold>), toughness to ultimate load (<bold>E</bold>), and Young&#8217;s modulus (<bold>F</bold>). <italic toggle="yes">n</italic> = 19 control and <italic toggle="yes">n</italic> = 17 <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice (please see Methods). Bars indicate mean &#177; SD. Indicated <italic toggle="yes">P</italic> values were calculated by unpaired <italic toggle="yes">t</italic> test for equal or unequal variance (<bold>C</bold>) or rank sum test (if data are not normally distributed, <bold>B</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jciinsight-10-191688-g244.jpg"/></fig><fig position="float" id="F5" orientation="portrait"><label>Figure 5</label><caption><title><italic toggle="yes">Tfeb</italic> elevation in the osteoblast lineage increases bone formation.</title><p>(<bold>A</bold>&#8211;<bold>E</bold>) Skeletal phenotype analysis of 4.5-month-old male <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice and their littermate Cre controls (Osx1-Cre only [red dots], Osx1-Cre CRa [blue dots], Osx1-Cre sgRNA<italic toggle="yes"><sup>Tfeb</sup></italic> [gray dots]). (<bold>A</bold>&#8211;<bold>C</bold>) Dynamic histomorphometry was performed on femurs. <italic toggle="yes">n</italic> = 5&#8211;6 mice per group. (<bold>A</bold>) Quantification of mineralizing surface per bone surface (MS/BS), mineral apposition rate (MAR), and bone formation rate per bone surface (BFR/BS) at the periosteal surface. (<bold>B</bold>) Representative histological cross section showing calcein labeling at the femoral diaphysis (GFP filter). Scale bars represent 400 &#956;m. (<bold>C</bold>) Trabecular MAR (Tb. MAR). (<bold>D</bold> and <bold>E</bold>) <italic toggle="yes">Sp7</italic> and <italic toggle="yes">Col1a1</italic> (<bold>D</bold>) and <italic toggle="yes">Acp5</italic> and <italic toggle="yes">Ctsk</italic> (<bold>E</bold>) mRNA levels were measured in L5 by qRT-PCR and normalized to mouse <italic toggle="yes">Actb</italic>. <italic toggle="yes">n</italic> = 18 mice per group (please see Methods). (<bold>F</bold> and <bold>G</bold>) Bone marrow cells were isolated from femurs and tibias of 5-month-old female mice and differentiated into osteoblasts using osteogenic media. (<bold>F</bold>) Alizarin red stain of mineral apposition. (<bold>G</bold>) BrdU analysis of proliferating cells. <italic toggle="yes">n</italic> = 4 wells per group. (<bold>H</bold>) Circulating sclerostin levels of 5- and 12-month-old male (square) and female (circle) <italic toggle="yes">Tfeb</italic><sup>CRa</sup> and control mice were measured using ELISA. <italic toggle="yes">n</italic> = 5&#8211;7 mice per group. (<bold>I</bold>) Sclerostin and actin levels were measured in cortical bone (humeri shafts) of <italic toggle="yes">Tfeb</italic><sup>CRa</sup> and control mice via Western blot. Immunoblot of 5 mice per group is shown. Quantification was done with <italic toggle="yes">n</italic> = 10&#8211;11 mice per group. The bar graph indicates sclerostin levels normalized to actin. Bars indicate mean &#177; SD. Indicated <italic toggle="yes">P</italic> values were calculated by unpaired <italic toggle="yes">t</italic> test for equal or unequal variance (<bold>A</bold>-Ps.MAR).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jciinsight-10-191688-g245.jpg"/></fig><fig position="float" id="F6" orientation="portrait"><label>Figure 6</label><caption><title><italic toggle="yes">Tfeb</italic> elevation in the osteoblast lineage remains anabolic at 12 months of age.</title><p>(<bold>A</bold>&#8211;<bold>C</bold>) Serial spine (<bold>A</bold>), femur (<bold>B</bold>), and global (whole body) (<bold>C</bold>) DXA BMD measurements were collected from female <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice (<italic toggle="yes">n</italic> = 6) and their littermate Cre controls (Osx1-Cre only, Osx1-Cre sgRNA<italic toggle="yes"><sup>Tfeb</sup></italic> mice, <italic toggle="yes">n</italic> = 8) between 3 and 12 months of age. Error bars indicate SD. *<italic toggle="yes">P</italic> &lt; 0.05 as calculated by unpaired <italic toggle="yes">t</italic> test at each time point. Indicated <italic toggle="yes">P</italic> values were calculated by repeated measures model (detailed in the Methods section) comparing the difference in genotypes at 3 versus 9 months or 9 versus 12 months. (<bold>D</bold> and <bold>E</bold>) &#956;CT analysis of Ct.Th (<bold>D</bold>) and trabecular BV/TV (<bold>E</bold>) performed on lumbar vertebrae 4 (spine) and femurs from 12-month-old female <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice (<italic toggle="yes">n</italic> = 6) and littermate controls (Osx1-Cre only [red dots], Osx1-Cre sgRNA<italic toggle="yes"><sup>Tfeb</sup></italic> [gray dots], <italic toggle="yes">n</italic> = 8). (<bold>F</bold>) ELISA measurements of P1NP and TRAcP 5b (<italic toggle="yes">Tfeb</italic><sup>CRa</sup>
<italic toggle="yes">n</italic> = 6, controls <italic toggle="yes">n</italic> = 7). (<bold>G</bold>&#8211;<bold>J</bold>) Histomorphometric analysis of vertebral trabecular bone of <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice (<italic toggle="yes">n</italic> = 5) and their Cre controls (<italic toggle="yes">n</italic> = 8). (<bold>G</bold>) MS/BS, BFR/BS. (<bold>H</bold>) Osteoblast surface per bone perimeter (Ob.S/B.Pm), osteoblast number per bone perimeter (N.Ob/B.Pm). (<bold>I</bold>) Osteoclast surface per bone perimeter (Oc.S/B.Pm), osteoclast number per bone perimeter (N.Oc/B.Pm). (<bold>J</bold>) TRAcP 5b&#8211; and toluidine blue&#8211;stained or unstained (labeled with calcein and alizarin red) sections imaged with 40&#215; original magnification. Scale bars represent 50 &#956;m. (<bold>K</bold> and <bold>L</bold>) <italic toggle="yes">Bglap</italic> and <italic toggle="yes">Sp7</italic> (<bold>K</bold>) and <italic toggle="yes">Acp5</italic> and <italic toggle="yes">Ctsk</italic> (<bold>L</bold>) mRNA levels measured in lumbar vertebrae 5 (spine) of <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice (<italic toggle="yes">n</italic> = 7) and controls (<italic toggle="yes">n</italic> = 6) using qRT-PCR and normalized to mouse <italic toggle="yes">Actb</italic>. Bars indicate mean &#177; SD. Indicated <italic toggle="yes">P</italic> values were calculated by unpaired <italic toggle="yes">t</italic> test for equal or unequal variance (<bold>E</bold>-femur and spine, <bold>K</bold>-<italic toggle="yes">Sp7</italic>) or rank sum test (if data are not normally distributed, <bold>D</bold>-femur, <bold>H</bold>&#8211;N.Ob/B.Pm).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jciinsight-10-191688-g246.jpg"/></fig><fig position="float" id="F7" orientation="portrait"><label>Figure 7</label><caption><title><italic toggle="yes">Tfeb</italic> elevation promotes production and function of osteoblasts.</title><p>Periosteal mesenchymal cells isolated from femurs of 4-month-old female <italic toggle="yes">Tfeb</italic><sup>CRa</sup> mice and Cre littermate controls (Osx1-Cre CRa and Osx1-Cre sgRNA<italic toggle="yes"><sup>Tfeb</sup></italic>) were subjected to scRNA-Seq using the 10X Genomics Chromium platform. <italic toggle="yes">n</italic> = 2 mice per group. (<bold>A</bold>) UMAP visualization of cell clusters obtained from the periosteum. (<bold>B</bold>) Dot plot of the representative marker genes for each cluster. The dot size indicates the percentage of cells expressing each gene, and the color gradient indicates expression level. (<bold>C</bold>) Volcano plots of genes significantly up- or downregulated in each cluster. (<bold>D</bold>) Biological processes significantly upregulated (green) or downregulated (red) in response to <italic toggle="yes">Tfeb</italic> stimulation as determined by GO analysis (<italic toggle="yes">p</italic>_adjusted &lt; 0.05). Larger circle sizes and darker colors indicate higher significance. (<bold>E</bold>) Violin plots with box and whiskers representing the expression of select genes in Osteo-X cells. Wider parts of the violin indicate more data points. Inner box plots indicate the median (the line), quartiles (the boxes), and range of the data (whiskers). (<bold>F</bold>) SCENIC analysis of transcription factor activity in Osteo-X cells. UMAP, uniform manifold approximation and projection; BMP, bone morphogenetic protein; Lox, lysyl oxidase; Alpl, alkaline phosphatase; Ibsp, bone sialoprotein.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jciinsight-10-191688-g247.jpg"/></fig></floats-group></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Aging Neurosci</journal-id><journal-id journal-id-type="iso-abbrev">Front Aging Neurosci</journal-id><journal-id journal-id-type="pmc-domain-id">1239</journal-id><journal-id journal-id-type="pmc-domain">frontagineuro</journal-id><journal-id journal-id-type="publisher-id">Front. Aging Neurosci.</journal-id><journal-title-group><journal-title>Frontiers in Aging Neuroscience</journal-title></journal-title-group><issn pub-type="epub">1663-4365</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12484148</article-id><article-id pub-id-type="pmcid-ver">PMC12484148.1</article-id><article-id pub-id-type="pmcaid">12484148</article-id><article-id pub-id-type="pmcaiid">12484148</article-id><article-id pub-id-type="pmid">41040811</article-id><article-id pub-id-type="doi">10.3389/fnagi.2025.1627774</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Aging Neuroscience</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Moderating effect of APOE &#949;4 on the association of sleep disturbance and amyloid-&#946; pathology among cognitively normal older adults</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Feng</surname><given-names initials="S">Shufei</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn0001" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/3059632/overview"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Que</surname><given-names initials="J">Jianyu</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn0001" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1519531/overview"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="Q">Qianwen</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Yuan</surname><given-names initials="K">Kai</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1492742/overview"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Shi</surname><given-names initials="L">Le</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/532710/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital)</institution>, <addr-line>Beijing</addr-line>, <country>China</country></aff><aff id="aff2"><sup>2</sup><institution>Xiamen Xianyue Hospital, Xianyue Hospital Affiliated with Xiamen Medical College, Fujian Psychiatric Center, Fujian Clinical Research Center for Mental Disorders</institution>, <addr-line>Fujian</addr-line>, <country>China</country></aff><author-notes><fn fn-type="edited-by" id="fn0002"><p>Edited by: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/80227/overview" ext-link-type="uri">Alessandro Martorana</ext-link>, University of Rome Tor Vergata, Italy</p></fn><fn fn-type="edited-by" id="fn0003"><p>Reviewed by: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1115060/overview" ext-link-type="uri">Christopher E. Bauer</ext-link>, University of Kentucky, United States</p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1965279/overview" ext-link-type="uri">Isabelle Foote</ext-link>, University of Colorado Boulder, United States</p></fn><corresp id="c001">*Correspondence: Le Shi, <email>leshi@bjmu.edu.cn</email>; Kai Yuan, <email>yuankai@pku.edu.cn</email></corresp><fn fn-type="equal" id="fn0001"><p><sup>&#8224;</sup>These authors have contributed equally to this work and share first authorship</p></fn></author-notes><pub-date pub-type="epub"><day>17</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>17</volume><issue-id pub-id-type="pmc-issue-id">481075</issue-id><elocation-id>1627774</elocation-id><history><date date-type="received"><day>13</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>02</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>17</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>02</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-03 09:25:16.947"><day>03</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 Feng, Que, Wang, Yuan and Shi.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Feng, Que, Wang, Yuan and Shi</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fnagi-17-1627774.pdf"/><abstract><sec id="sec1"><title>Background</title><p>Sleep&#8211;wake rhythms are critical for the development of Alzheimer&#8217;s disease (AD). However, the relationship of sleep disturbance, APOE &#949;4, and amyloid-&#946; (A&#946;) accumulation remains unclear. Thus, this study investigated the potential role of APOE &#949;4 allele in the association between sleep disturbance and brain A&#946; burden among cognitively normal (CN) older adults.</p></sec><sec id="sec2"><title>Methods</title><p>In this cross-sectional study, data were obtained from the Alzheimer&#8217;s Disease Neuroimaging Initiative (ADNl) Database. The sample consisted of CN individuals aged between 55 and 90&#8239;years with A&#946; positron emission tomography scan, APOE genotype, and sleep assessment using the Neuropsychiatric Inventory.</p></sec><sec id="sec3"><title>Results</title><p>The study included 1,000 CN participants, including 134 individuals with sleep disturbances and 306 APOE &#949;4 carriers (APOE &#949;4+). After adjusting for sex, age, years of education, and marital status, sleep disturbance was not associated with a higher A&#946; burden among participants. However, a significant interaction between sleep disturbance and APOE &#949;4 on regional standardized uptake value ratios was observed, such as in the left hippocampus. Subgroup analysis revealed that sleep disturbance could affect the AD-sensitive brain regions in the APOE &#949;4&#8239;+&#8239;group. Furthermore, the subjective severity of sleep disturbance was linearly associated with a more significant A&#946; brain burden in the APOE &#949;4&#8239;+&#8239;group.</p></sec><sec id="sec4"><title>Conclusion</title><p>This study demonstrated that CN individuals with both APOE &#949;4&#8239;+&#8239;status and sleep disturbance exhibited greater A&#946; burden. Understanding the relationship between sleep and A&#946; in CN older adults may inform sleep interventions that could reduce early A&#946; accumulation and delay the onset of cognitive dysfunction associated with early AD.</p></sec></abstract><kwd-group><kwd>Alzheimer&#8217;s disease</kwd><kwd>amyloid-&#946;</kwd><kwd>APOE &#949;4</kwd><kwd>moderating analysis</kwd><kwd>sleep disturbance</kwd></kwd-group><funding-group><award-group><funding-source id="cn1"><institution-wrap><institution>National Natural Science Foundation of China</institution><institution-id institution-id-type="doi">10.13039/501100001809</institution-id></institution-wrap></funding-source><award-id award-type="contract" rid="cn1">82271527</award-id></award-group><award-group><funding-source id="cn2"><institution-wrap><institution>Beijing Nova Program</institution><institution-id institution-id-type="doi">10.13039/501100005090</institution-id></institution-wrap></funding-source><award-id award-type="contract" rid="cn2">20230484320</award-id></award-group><award-group><funding-source id="cn3">Young Elite Scientists Sponsorship Program by CAST</funding-source><award-id award-type="contract" rid="cn3">2023QNRC001</award-id></award-group></funding-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by National Natural Science Foundation of China (82271527), Beijing Nova Program (20230484320), and Young Elite Scientists Sponsorship Program by CAST (2023QNRC001).</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="4"/><equation-count count="0"/><ref-count count="91"/><page-count count="15"/><word-count count="11963"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Neurocognitive Aging and Behavior</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec5"><title>Introduction</title><p>Alzheimer&#8217;s disease (AD) represents the most prevalent form of dementia among older adults. With global population aging, AD has become an increasingly critical public health challenge (<xref rid="ref63" ref-type="bibr">Scheltens et al., 2021</xref>). Current projections indicate dementia prevalence will increase by two-thirds in low- and middle-income countries (<xref rid="ref59" ref-type="bibr">Patterson, 2018</xref>), double throughout Europe, and triple worldwide by 2050 (<xref rid="ref2" ref-type="bibr">Alzheimer Europe, 2019</xref>). This concerning trajectory necessitates coordinated efforts to identify and mitigate modifiable risk factors. In 2019, the World Health Organization published its inaugural guidelines addressing cognitive decline and dementia risk reduction (<xref rid="ref55" ref-type="bibr">Organization, W.H, 2019</xref>), encompassing lifestyle interventions, strategies targeting physical health conditions, and specialized therapeutic approaches (<xref rid="ref56" ref-type="bibr">Organization, W.H, 2021</xref>).</p><p>Identifying the underlying pathophysiological mechanisms of AD is essential for developing effective preventive strategies. Despite ongoing scientific debate, the amyloid-&#946; (A&#946;) hypothesis remains the central framework for understanding AD pathogenesis (<xref rid="ref62" ref-type="bibr">Scheltens et al., 2016</xref>; <xref rid="ref27" ref-type="bibr">Frisoni et al., 2022</xref>; <xref rid="ref31" ref-type="bibr">Hardy and Higgins, 1992</xref>). Importantly, abnormal A&#946; deposition begins during the preclinical stage, approximately 15&#8211;20&#8239;years before cognitive symptoms manifest (<xref rid="ref5" ref-type="bibr">Bateman et al., 2012</xref>). This extended preclinical window provides a critical opportunity for early detection and intervention, particularly through positron emission tomography (PET) imaging, which has become a valuable tool for differential diagnosis and clinical trial enrollment (<xref rid="ref62" ref-type="bibr">Scheltens et al., 2016</xref>).</p><p>Among the various factors influencing A&#946; dynamics, sleep has emerged as a particularly significant modulator. Compelling evidence from human and animal studies reveals a bidirectional relationship between sleep and A&#946; processing (<xref rid="ref42" ref-type="bibr">Kang et al., 2009</xref>; <xref rid="ref81" ref-type="bibr">Xie et al., 2013</xref>). Age-associated changes in sleep architecture&#8212;characterized by difficulties initiating and maintaining sleep&#8212;commonly affect older adults (<xref rid="ref49" ref-type="bibr">Mander et al., 2017</xref>; <xref rid="ref54" ref-type="bibr">Ohayon et al., 2004</xref>). Notably, these sleep alterations frequently precede typical AD manifestations and have been identified as important risk indicators before clinical symptom onset (<xref rid="ref82" ref-type="bibr">Yaffe et al., 2011</xref>; <xref rid="ref7" ref-type="bibr">Blackwell et al., 2006</xref>; <xref rid="ref47" ref-type="bibr">Lysen et al., 2020</xref>; <xref rid="ref53" ref-type="bibr">Nebes et al., 2009</xref>). The reproducible and quantifiable nature of these sleep patterns suggests potential utility as biomarkers for monitoring A&#946; pathological progression and informing early intervention strategies (<xref rid="ref38" ref-type="bibr">Insel et al., 2021</xref>; <xref rid="ref80" ref-type="bibr">Winer et al., 2020</xref>; <xref rid="ref41" ref-type="bibr">Ju et al., 2013</xref>).</p><p>The relationship between sleep disturbances and A&#946; accumulation, however, remains incompletely understood. Previous investigations have demonstrated correlations between sleep disturbances and regional A&#946; burden in the general population (<xref rid="ref26" ref-type="bibr">Ettore et al., 2019</xref>; <xref rid="ref29" ref-type="bibr">Gabelle et al., 2019</xref>; <xref rid="ref39" ref-type="bibr">Insel et al., 2021</xref>; <xref rid="ref71" ref-type="bibr">Spira et al., 2013</xref>; <xref rid="ref79" ref-type="bibr">Winer et al., 2021</xref>). One study observed that elevated regional A&#946; burden correlated with sleep quality impairments, but not with altered sleep duration, in cognitively intact late middle-aged adults (<xref rid="ref73" ref-type="bibr">Sprecher et al., 2015</xref>). However, contrasting findings reported no association between A&#946;-PET burden and poor sleep profiles in older adults (<xref rid="ref29" ref-type="bibr">Gabelle et al., 2019</xref>; <xref rid="ref24" ref-type="bibr">Du et al., 2023</xref>; <xref rid="ref87" ref-type="bibr">Yoon et al., 2023</xref>; <xref rid="ref72" ref-type="bibr">Spira et al., 2014</xref>). These incongruous results suggest that the association between sleep quality and A&#946; deposition remains unclear. This connection is especially important because sleep problems often occur in people with mild cognitive impairment (MCI) and AD (<xref rid="ref78" ref-type="bibr">Weldemichael and Grossberg, 2010</xref>; <xref rid="ref60" ref-type="bibr">Peter-Derex et al., 2015</xref>; <xref rid="ref91" ref-type="bibr">Zhang et al., 2022</xref>). The potential mechanism involves a deleterious cycle wherein A&#946; accumulation disrupts neural networks essential for sleep regulation, while impaired sleep further facilitates A&#946; deposition. To address these knowledge gaps, we extended our analyses to a well-characterized cohort of cognitively normal participants from the Alzheimer&#8217;s Disease Neuroimaging Initiative (ADNI).</p><p>Beyond sleep factors, genetic predisposition plays a crucial role in AD pathogenesis. The Apolipoprotein E (APOE) &#949;4 allele represents a well-established genetic risk factor for AD (<xref rid="ref19" ref-type="bibr">Corder et al., 1993</xref>). Accumulating evidence indicates that the APOE &#949;4 allele contributes to pronounced A&#946; pathology and impairs multiple aspects of normal brain function (<xref rid="ref83" ref-type="bibr">Yamazaki et al., 2019</xref>; <xref rid="ref8" ref-type="bibr">Blanchard et al., 2022</xref>; <xref rid="ref85" ref-type="bibr">Ye et al., 2005</xref>). Beyond its associations with AD risk and A&#946; deposition, the APOE &#949;4 gene also influences sleep regulation (<xref rid="ref61" ref-type="bibr">Poirier et al., 1993</xref>; <xref rid="ref32" ref-type="bibr">Harold et al., 2009</xref>; <xref rid="ref74" ref-type="bibr">Thambisetty et al., 2010</xref>). Sleep disturbances may therefore exhibit differential effects across APOE variants (<xref rid="ref35" ref-type="bibr">Hita-Ya&#241;ez et al., 2012</xref>; <xref rid="ref37" ref-type="bibr">Hwang et al., 2018</xref>), suggesting a complex interplay between genetics, sleep physiology, and A&#946; accumulation. Multiple investigations have demonstrated that APOE &#949;4 significantly increases vulnerability to sleep disorders, including compromised sleep quality, altered sleep duration, and difficulties with sleep initiation or maintenance in cognitively normal adults (<xref rid="ref23" ref-type="bibr">Drogos et al., 2016</xref>; <xref rid="ref70" ref-type="bibr">Spira et al., 2017</xref>). However, research examining the interaction between APOE status, sleep quality, and A&#946; accumulation remains limited. One study involving 184 cognitively normal older adults found no significant moderating effect of the APOE &#949;4 allele on the relationship between sleep parameters and brain A&#946; burden (<xref rid="ref11" ref-type="bibr">Brown et al., 2016</xref>). Given these conflicting findings and knowledge gaps, our investigation sought to elucidate the complex interrelationships between sleep disturbances, APOE &#949;4 status, and A&#946; accumulation patterns in cognitively normal older adults.</p></sec><sec sec-type="methods" id="sec6"><title>Methods</title><sec id="sec7"><title>ADNI population</title><p>Data for this study were downloaded from the ADNI database on April 21, 2022. ADNI is a longitudinal observational study of aging that enrolls participants diagnosed as CN, subjective memory concerns (SMC), MCI (both early and late stages), and AD dementia. This study focused solely on data from CN individuals aged 55&#8211;90&#8239;years, collected between March 2011 and October 2021. CN is defined as having no impairment in cognitive function, with a Clinical Dementia Rating Global Score (CDR-SB) of 0, a Mini-Mental State Examination (MMSE) score ranging from 24 to 30, and normal memory functioning assessed using the Logical Memory II subscale (<xref rid="ref28" ref-type="bibr">Fuller et al., 2020</xref>). A full description of the inclusion/exclusion criteria for the ADNI study can be found at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://adni.loni.usc.edu" ext-link-type="uri">https://adni.loni.usc.edu</ext-link>.</p></sec><sec id="sec8"><title>Measures</title><p>Participants provided demographic data upon enrollment, including age, sex, education level, and marital status. We also documented APOE &#949;4 genotype status, a known genetic risk factor associated with increased A&#946; burden in the brain. Global cognitive function was assessed using the CDR-SB and MMSE.</p><p>The presence of sleep disturbance was determined using the Neuropsychiatric Inventory (NPI), a validated instrument covering 12 major behavioral domains with established interrater reliability and test&#8211;retest reliability (<xref rid="ref21" ref-type="bibr">Cummings et al., 1994</xref>; <xref rid="ref51" ref-type="bibr">Mega et al., 1996</xref>; <xref rid="ref20" ref-type="bibr">Cummings, 1997</xref>). Component K of the NPI (NPI-K) assesses recent alterations in sleep patterns. Previous research has demonstrated associations between NPI-K scores and regional uptake of both 18F-flortaucipir and 18F-florbetapir uptake (<xref rid="ref67" ref-type="bibr">Shokouhi, 2019</xref>). The NPI employs a structured hierarchical assessment approach, initiating with screening questions to identify symptoms within specific behavioral domains. According to previous studies (<xref rid="ref25" ref-type="bibr">Elberse et al., 2024</xref>; <xref rid="ref43" ref-type="bibr">Kim et al., 2023</xref>; <xref rid="ref6" ref-type="bibr">Blackman et al., 2022</xref>), we established a specific screening protocol for sleep assessment in our study. Participants were categorized into two groups according to their sleep status. Those who reported sleep disturbance were classified into the sleep disturbance group, defined by an affirmative response to any of these key sleep questions: difficulty initiating sleep (K1), nighttime awakenings (excluding isolated bathroom visits with rapid sleep resumption; K2), or premature morning awakening relative to established sleep patterns (K6). Additionally, regarding the sleep assessment, we would like to clarify that the total severity score was calculated for NPI-K by summing up the severity ratings for all domains of sleep and nighttime behaviors. The sleep scores represent the sum of multiple items (higher scores indicate worse sleep quality).</p><p>We used the standardized uptake value ratio (SUVR) obtained using florbetapir-PET-AV45 to calculate A&#946; burden. ADNI florbetapir PET scans were acquired using standardized ADNI PET protocols at the participating sites. FreeSurfer v7.1.1 delineated the regions of interest (ROIs). We used the structural MRI closest in time to each PET scan to rule out potential effects of brain atrophy associated with baseline MRI registration. Further details can be found in the ADNI_UCBERKELEY_AV45_Methods_01_14_21. The SUVR is defined as the ratio of the measured uptake in a target tissue ROI divided by the uptake in a reference ROI (<xref rid="ref89" ref-type="bibr">Zasadny and Wahl, 1993</xref>). The choice of the reference ROI directly affects the sensitivity of SUVR quantification. The cerebellum has been widely used as a reference for florbetapir PET SUVR, especially in cross-sectional studies (<xref rid="ref65" ref-type="bibr">Schwarz et al., 2017</xref>; <xref rid="ref16" ref-type="bibr">Chiao et al., 2019</xref>). Here, we re-intensity-normalized the regional SUVR using a composite reference ROI of the whole cerebellum. The global 18F-Flortaucipir comprises frontal, anterior/posterior cingulate, lateral parietal, and lateral temporal regions.</p><p>At the time of data download, we identified 2,756 participants with available data from the three ADNI phases (ADNI-1, ADNI-2, and ADNI-3). Participants from all phases were eligible for inclusion, provided they met our study criteria. This cross-phase approach maximized our sample size by utilizing all available ADNI data. We applied systematic exclusion criteria as follows: 1,524 participants were excluded due to MCI or AD diagnoses. Additional exclusions comprised 8 participants with incomplete NPI-sleep questionnaires, 23 with missing APOE &#949;4 genotype data, 12 with incomplete neuropsychological assessments, and 168 individuals with non-zero CDR-SB scores. Subsequently, we applied Z-score standardization to the summary SUVR values (summarysuvr_wholecerebnorm, based on whole cerebellum reference region) and excluded 21 statistical outliers defined as values exceeding three standard deviations from the mean (|Z|&#8239;&gt;&#8239;3). Following these inclusion and exclusion procedures, 1,000 participants with complete summary SUVR data and regional measurements from 103 brain regions were retained for final analysis. A complete list of all 103 brain regions from FreeSurfer&#8217;s whole-brain segmentation, comprising the Desikan-Killiany cortical parcellation (68 regions) and FreeSurfer&#8217;s subcortical segmentation (35 additional structures), is provided in the <xref rid="SM1" ref-type="supplementary-material">Supplementary Table S7</xref>.</p></sec><sec id="sec9"><title>Statistical analysis</title><p>Baseline demographic characteristics were compared using independent t-tests or analysis of variance (ANOVA) for continuous variables and Pearson &#967;<sup>2</sup> tests for categorical variables, as appropriate.</p><p>Regional SUVR values were compared between participants with and without sleep disturbance using independent t-tests. For descriptive purposes, unadjusted means and standard deviations are presented for the overall sample and each sleep group. Linear regression analyses were performed for each brain region with regional SUVR values as the dependent variable and sleep disturbance status as the primary predictor. Participants without sleep disturbance served as the reference group. All regression models were adjusted for age, sex, years of education, and marital status. Results are presented as regression coefficients (&#946;) with standard errors (SE) and corresponding <italic toggle="yes">p</italic>-values. <italic toggle="yes">p</italic>-values from regression analyses were corrected for multiple comparisons using the Benjamini-Hochberg false discovery rate (FDR) method.</p><p>To examine the moderating effect of APOE &#949;4 status on the relationship between sleep disturbance and regional amyloid burden, we conducted moderation analyses using linear regression framework with separate models fitted for each brain region. These models included sleep disturbance as the primary predictor, APOE &#949;4 carrier status as the moderator, and their interaction term (Sleep disturbance &#215; APOE &#949;4). Participants carrying &#8805;1 copy of the APOE &#949;4 allele (i.e., &#949;2/&#949;4, &#949;3/&#949;4, and &#949;4/&#949;4) were classified as APOE &#949;4+, while all others were classified as APOE &#949;4&#8722;. We also conducted stratified linear regression analyses by APOE &#949;4 carrier status to examine the association between sleep disturbance and regional SUVR values separately in carriers and non-carriers.</p><p>In our regression models, sleep disturbance was coded as a binary variable (0&#8239;=&#8239;no sleep disturbance, 1&#8239;=&#8239;sleep disturbance present) and APOE &#949;4 status was coded as a binary variable (0&#8239;=&#8239;non-carrier, 1&#8239;=&#8239;carrier). This coding scheme means that individuals with sleep disturbance and APOE &#949;4 carriers serve as the reference conditions in our analyses. Therefore, negative beta coefficients indicate that the comparison group (no sleep disturbance or non-carriers) has lower SUVR values compared to the reference group (sleep disturbance present or carriers).</p><p>Additionally, we investigated the association between sleep scores measured by NPI-K and SUVR values in the APOE &#949;4&#8239;+&#8239;group using linear regression analyses with the aforementioned covariates. To visualize regional differences in amyloid burden associated with sleep disturbance in APOE &#949;4&#8239;+&#8239;individuals, we used AFNI (Analysis of Functional NeuroImages) and SUMA open-source software. Forest plots were generated using R software to visualize regression coefficients and confidence intervals across brain regions.</p><p>We first conducted exploratory analyses to identify brain regions showing significant associations at the uncorrected <italic toggle="yes">p</italic>-value level (<italic toggle="yes">p</italic>&#8239;&lt;&#8239;0.05), derived from regression models adjusted for age, sex, years of education, and marital status. To address the multiple comparisons issue, we applied Benjamini-Hochberg false discovery rate (FDR) correction to the analytical results across all 103 brain regions. FDR correction is particularly appropriate for neuroimaging studies due to the inter-correlations among brain regions.</p><p>All statistical analyses were performed using IBM SPSS Statistics (version 28.0; IBM Corp., Armonk, NY, USA), Mplus version 8.3, and R software version 4.0.3 (R Foundation for Statistical Computing). Statistical significance was set at <italic toggle="yes">p</italic>&#8239;&lt;&#8239;0.05.</p></sec></sec><sec sec-type="results" id="sec10"><title>Results</title><p>The 1,000 CN participants in this study comprised 539 women (53.9%) and 461 men (46.1%) with a mean age of 71.9 (6.26) years, mean education of 16.79 (2.48) years, 71.8% married, and 30.6% APOE &#949;4+. Among the cohort, 866 individuals had no sleep disturbance, while 134 reported at least one sleep disturbance. No significant differences in age or APOE &#949;4 status were observed between participants with or without sleep disturbance. However, significant differences emerged in sex distribution, educational attainment, and marital status between groups. The mean MMSE score across all CN participants was 29.04 (1.42), with no significant differences in MMSE scores between those with and without sleep disturbance (<xref rid="SM1" ref-type="supplementary-material">Supplementary Table S1</xref>). Considering the potential influence of APOE &#949;4 on SUVR and sleep status, we utilized both APOE &#949;4 and sleep disturbance as stratification variables for secondary analyses (<xref rid="tab1" ref-type="table">Table 1</xref>). Cognitive performance as measured by MMSE did not differ significantly among the four resulting groups.</p><table-wrap position="float" id="tab1" orientation="portrait"><label>Table 1</label><caption><p>Participant demographics grouped by APOE &#949;4.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Variables</th><th align="center" valign="top" rowspan="1" colspan="1">No sleep disturbance APOE &#949;4&#8722; (<italic toggle="yes">n</italic>&#8239;=&#8239;601)</th><th align="center" valign="top" rowspan="1" colspan="1">Sleep disturbance APOE &#949;4&#8722; (<italic toggle="yes">n</italic>&#8239;=&#8239;93)</th><th align="center" valign="top" rowspan="1" colspan="1">No sleep disturbance APOE &#949;4+ (<italic toggle="yes">n</italic>&#8239;=&#8239;265)</th><th align="center" valign="top" rowspan="1" colspan="1">Sleep disturbance APOE &#949;4+ (<italic toggle="yes">n</italic>&#8239;=&#8239;41)</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age, years, mean (SD)</td><td align="center" valign="middle" rowspan="1" colspan="1">72.63 (6.27)</td><td align="center" valign="middle" rowspan="1" colspan="1">72.05 (5.38)</td><td align="center" valign="middle" rowspan="1" colspan="1">70.32 (6.29)</td><td align="center" valign="middle" rowspan="1" colspan="1">71.15 (6.14)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Sex, number of males (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">310 (51.58)</td><td align="center" valign="middle" rowspan="1" colspan="1">30 (32.26)</td><td align="center" valign="middle" rowspan="1" colspan="1">110 (41.51)</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (26.83)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Years of education, mean (SD)</td><td align="center" valign="middle" rowspan="1" colspan="1">16.95 (2.50)</td><td align="center" valign="middle" rowspan="1" colspan="1">16.40 (2.40)</td><td align="center" valign="middle" rowspan="1" colspan="1">16.72 (2.43)</td><td align="center" valign="middle" rowspan="1" colspan="1">15.90 (2.55)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.017</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Married states, married, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">404 (67.22)</td><td align="center" valign="middle" rowspan="1" colspan="1">76 (81.72)</td><td align="center" valign="middle" rowspan="1" colspan="1">206 (77.74)</td><td align="center" valign="middle" rowspan="1" colspan="1">32 (78.05)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MMSE, score (SD)</td><td align="center" valign="middle" rowspan="1" colspan="1">29.02 (1.54)</td><td align="center" valign="middle" rowspan="1" colspan="1">29.13 (1.14)</td><td align="center" valign="middle" rowspan="1" colspan="1">29.06 (1.24)</td><td align="center" valign="middle" rowspan="1" colspan="1">28.95 (1.22)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.879</td></tr></tbody></table><table-wrap-foot><p>APOE, apolipoprotein E; APOE &#949;4-, APOE &#949;4 negative; APOE &#949;4+, APOE &#949;4 positive; MMSE, Mini-Mental State Examination; SD, standard deviation.</p></table-wrap-foot></table-wrap><sec id="sec11"><title>Effect of sleep disturbance on A&#946; deposition</title><p>No significant difference in global SUVR was detected between individuals with and without sleep disturbance (1.10&#8239;&#177;&#8239;0.15 vs. 1.11&#8239;&#177;&#8239;0.17, <italic toggle="yes">p</italic>&#8239;=&#8239;0.256). Further analysis of regional SUVR values using unadjusted independent t-tests revealed significant differences in 8 ROIs between participants with and without sleep disturbance, including the central corpus callosum, mid-anterior corpus callosum, left banks of superior temporal sulcus, left cuneus, left lingual gyrus, left pericalcarine, left superior temporal, and left precuneus (<xref rid="SM1" ref-type="supplementary-material">Supplementary Table S2</xref>). These regions represent functionally distinct neural networks with well-established roles in cognitive processing. The corpus callosum regions facilitate critical interhemispheric connectivity and information transfer between cerebral hemispheres. The temporal regions, specifically the banks of superior temporal sulcus and superior temporal cortex, are primarily involved in language processing and auditory function&#8212;cognitive domains that are characteristically impaired during AD progression. The visual cortex areas, including the cuneus, lingual gyrus, and pericalcarine cortex, are responsible for visual information processing, representing another functional domain known to be compromised with AD advancement. Notably, the precuneus serves as a pivotal hub within the default mode network (DMN), a brain network that is particularly vulnerable to early AD pathology. This selective pattern of regional amyloid deposition suggests that sleep disturbance may preferentially target specific neural networks that are known to be vulnerable in AD, rather than causing indiscriminate amyloid accumulation across the entire brain. Such network-specific effects support the hypothesis that sleep-related amyloid deposition follows established pathways of AD-related neurodegeneration.</p><p>However, after adjusting for sex, age, education, and marital status, only the left cuneus region remained statistically significant (&#946;&#8239;=&#8239;0.024, SE&#8239;=&#8239;0.012, <italic toggle="yes">p</italic>&#8239;=&#8239;0.04; <xref rid="SM1" ref-type="supplementary-material">Supplementary Table S2</xref>), indicating that participants with sleep disturbance showed higher A&#946; deposition in the left cuneus compared to those without sleep disturbance. As a key component of the DMN that is highly active during resting state, the cuneus has been consistently implicated in AD pathogenesis, with A&#946; accumulation preferentially starting in several core DMN regions. Recent studies have further identified the cuneus/precuneus as a central hub for brain functional connectivity alterations in sleep-related cognitive impairment (<xref rid="ref50" ref-type="bibr">Mattioli et al., 2021</xref>; <xref rid="ref36" ref-type="bibr">Horovitz et al., 2009</xref>; <xref rid="ref46" ref-type="bibr">Lunsford-Avery et al., 2020</xref>). These findings collectively suggest that sleep disturbance may preferentially target A&#946; deposition in vulnerable DMN regions such as the left cuneus, potentially representing an early marker of sleep-related neurodegeneration risk in CN older adults.</p><p>Given the established role of genetic factors in AD pathogenesis, we further examined whether individual genetic susceptibility modulates the relationship between sleep disturbance and A&#946; deposition. APOE alleles represent established genetic risk factors for AD, with multiple studies demonstrating that APOE &#949;4 facilitates A&#946; seeding and accelerates A&#946; aggregation in cerebral tissues (<xref rid="ref45" ref-type="bibr">Liu et al., 2017</xref>; <xref rid="ref22" ref-type="bibr">Dodart et al., 2005</xref>). We found that the interactions between sleep disturbance and APOE &#949;4 were associated with regional SUVR. Complete results for all brain regions are presented in <xref rid="SM1" ref-type="supplementary-material">Supplementary Table S3</xref>, while <xref rid="tab2" ref-type="table">Table 2</xref> summarizes the significant findings with corresponding FDR-corrected <italic toggle="yes">p</italic>-values. We initially conducted exploratory analyses without FDR correction to identify potential regions of interest. The negative beta coefficients indicate lower SUVR values in individuals without sleep disturbance and APOE &#949;4 non-carriers compared to their respective reference groups, consistent with our hypothesis that sleep disturbance is associated with increased regional A&#946; deposition.</p><table-wrap position="float" id="tab2" orientation="portrait"><label>Table 2</label><caption><p>Effect of sleep disturbance and presence of the APOE &#949;4 on regional A&#946; deposition.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="2" colspan="1">Regions</th><th align="center" valign="top" colspan="4" rowspan="1">Sleep disturbance</th><th align="center" valign="top" colspan="4" rowspan="1">APOE &#949;4</th><th align="center" valign="top" colspan="4" rowspan="1">Sleep disturbance * APOE &#949;4</th></tr><tr><th align="center" valign="top" rowspan="1" colspan="1">&#946;</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">SE</italic>
</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">q</italic>
</th><th align="center" valign="top" rowspan="1" colspan="1">&#946;</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">SE</italic>
</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">q</italic>
</th><th align="center" valign="top" rowspan="1" colspan="1">&#946;</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">SE</italic>
</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">q</italic>
</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Anterior Corpus Callosum</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.08</td><td align="center" valign="middle" rowspan="1" colspan="1">0.048</td><td align="center" valign="middle" rowspan="1" colspan="1">0.095</td><td align="center" valign="middle" rowspan="1" colspan="1">0.733</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.092</td><td align="center" valign="middle" rowspan="1" colspan="1">0.041</td><td align="center" valign="middle" rowspan="1" colspan="1">0.026</td><td align="center" valign="middle" rowspan="1" colspan="1">0.191</td><td align="center" valign="middle" rowspan="1" colspan="1">0.081</td><td align="center" valign="middle" rowspan="1" colspan="1">0.034</td><td align="center" valign="middle" rowspan="1" colspan="1">0.018</td><td align="center" valign="middle" rowspan="1" colspan="1">0.169</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Central Corpus Callosum</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.061</td><td align="center" valign="middle" rowspan="1" colspan="1">0.046</td><td align="center" valign="middle" rowspan="1" colspan="1">0.183</td><td align="center" valign="middle" rowspan="1" colspan="1">0.733</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.048</td><td align="center" valign="middle" rowspan="1" colspan="1">0.037</td><td align="center" valign="middle" rowspan="1" colspan="1">0.19</td><td align="center" valign="middle" rowspan="1" colspan="1">0.334</td><td align="center" valign="middle" rowspan="1" colspan="1">0.069</td><td align="center" valign="middle" rowspan="1" colspan="1">0.031</td><td align="center" valign="middle" rowspan="1" colspan="1">0.025</td><td align="center" valign="middle" rowspan="1" colspan="1">0.199</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Left Caudate Nucleus</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.07</td><td align="center" valign="middle" rowspan="1" colspan="1">0.037</td><td align="center" valign="middle" rowspan="1" colspan="1">0.054</td><td align="center" valign="middle" rowspan="1" colspan="1">0.506</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.042</td><td align="center" valign="middle" rowspan="1" colspan="1">0.035</td><td align="center" valign="middle" rowspan="1" colspan="1">0.222</td><td align="center" valign="middle" rowspan="1" colspan="1">0.352</td><td align="center" valign="middle" rowspan="1" colspan="1">0.069</td><td align="center" valign="middle" rowspan="1" colspan="1">0.031</td><td align="center" valign="middle" rowspan="1" colspan="1">0.026</td><td align="center" valign="middle" rowspan="1" colspan="1">0.199</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Left Cerebellar Cortex</td><td align="center" valign="middle" rowspan="1" colspan="1">0.017</td><td align="center" valign="middle" rowspan="1" colspan="1">0.007</td><td align="center" valign="middle" rowspan="1" colspan="1">0.019</td><td align="center" valign="middle" rowspan="1" colspan="1">0.217</td><td align="center" valign="middle" rowspan="1" colspan="1">0.019</td><td align="center" valign="middle" rowspan="1" colspan="1">0.006</td><td align="center" valign="middle" rowspan="1" colspan="1">0.002</td><td align="center" valign="middle" rowspan="1" colspan="1">0.029</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.012</td><td align="center" valign="middle" rowspan="1" colspan="1">0.005</td><td align="center" valign="middle" rowspan="1" colspan="1">0.018</td><td align="center" valign="middle" rowspan="1" colspan="1">0.169</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Left Choroid Plexus</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.15</td><td align="center" valign="middle" rowspan="1" colspan="1">0.043</td><td align="center" valign="middle" rowspan="1" colspan="1">5.00E-04</td><td align="center" valign="middle" rowspan="1" colspan="1">0.012</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.126</td><td align="center" valign="middle" rowspan="1" colspan="1">0.037</td><td align="center" valign="middle" rowspan="1" colspan="1">6.80E-04</td><td align="center" valign="middle" rowspan="1" colspan="1">0.012</td><td align="center" valign="middle" rowspan="1" colspan="1">0.12</td><td align="center" valign="middle" rowspan="1" colspan="1">0.032</td><td align="center" valign="middle" rowspan="1" colspan="1">1.50E-04</td><td align="center" valign="middle" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Left Hippocampus</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.057</td><td align="center" valign="middle" rowspan="1" colspan="1">0.026</td><td align="center" valign="middle" rowspan="1" colspan="1">0.027</td><td align="center" valign="middle" rowspan="1" colspan="1">0.278</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.049</td><td align="center" valign="middle" rowspan="1" colspan="1">0.023</td><td align="center" valign="middle" rowspan="1" colspan="1">0.034</td><td align="center" valign="middle" rowspan="1" colspan="1">0.217</td><td align="center" valign="middle" rowspan="1" colspan="1">0.049</td><td align="center" valign="middle" rowspan="1" colspan="1">0.02</td><td align="center" valign="middle" rowspan="1" colspan="1">0.015</td><td align="center" valign="middle" rowspan="1" colspan="1">0.169</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Left Inferior Lateral Ventricle</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.108</td><td align="center" valign="middle" rowspan="1" colspan="1">0.044</td><td align="center" valign="middle" rowspan="1" colspan="1">0.015</td><td align="center" valign="middle" rowspan="1" colspan="1">0.193</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.095</td><td align="center" valign="middle" rowspan="1" colspan="1">0.038</td><td align="center" valign="middle" rowspan="1" colspan="1">0.013</td><td align="center" valign="middle" rowspan="1" colspan="1">0.131</td><td align="center" valign="middle" rowspan="1" colspan="1">0.087</td><td align="center" valign="middle" rowspan="1" colspan="1">0.034</td><td align="center" valign="middle" rowspan="1" colspan="1">0.01</td><td align="center" valign="middle" rowspan="1" colspan="1">0.129</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Left Lateral Ventricle</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.182</td><td align="center" valign="middle" rowspan="1" colspan="1">0.042</td><td align="center" valign="middle" rowspan="1" colspan="1">2.00E-05</td><td align="center" valign="middle" rowspan="1" colspan="1">0.002</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.147</td><td align="center" valign="middle" rowspan="1" colspan="1">0.039</td><td align="center" valign="middle" rowspan="1" colspan="1">1.60E-04</td><td align="center" valign="middle" rowspan="1" colspan="1">0.007</td><td align="center" valign="middle" rowspan="1" colspan="1">0.141</td><td align="center" valign="middle" rowspan="1" colspan="1">0.034</td><td align="center" valign="middle" rowspan="1" colspan="1">3.00E-05</td><td align="center" valign="middle" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Mid-Anterior Corpus Callosum</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.136</td><td align="center" valign="middle" rowspan="1" colspan="1">0.047</td><td align="center" valign="middle" rowspan="1" colspan="1">0.004</td><td align="center" valign="middle" rowspan="1" colspan="1">0.077</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.115</td><td align="center" valign="middle" rowspan="1" colspan="1">0.041</td><td align="center" valign="middle" rowspan="1" colspan="1">0.005</td><td align="center" valign="middle" rowspan="1" colspan="1">0.064</td><td align="center" valign="middle" rowspan="1" colspan="1">0.127</td><td align="center" valign="middle" rowspan="1" colspan="1">0.035</td><td align="center" valign="middle" rowspan="1" colspan="1">0.309</td><td align="center" valign="middle" rowspan="1" colspan="1">0.721</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Mid-Posterior Corpus Callosum</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.077</td><td align="center" valign="middle" rowspan="1" colspan="1">0.051</td><td align="center" valign="middle" rowspan="1" colspan="1">0.132</td><td align="center" valign="middle" rowspan="1" colspan="1">0.733</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.085</td><td align="center" valign="middle" rowspan="1" colspan="1">0.041</td><td align="center" valign="middle" rowspan="1" colspan="1">0.037</td><td align="center" valign="middle" rowspan="1" colspan="1">0.217</td><td align="center" valign="middle" rowspan="1" colspan="1">0.075</td><td align="center" valign="middle" rowspan="1" colspan="1">0.034</td><td align="center" valign="middle" rowspan="1" colspan="1">2.70E-04</td><td align="center" valign="middle" rowspan="1" colspan="1">0.006</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Right Cerebellar Cortex</td><td align="center" valign="middle" rowspan="1" colspan="1">0.018</td><td align="center" valign="middle" rowspan="1" colspan="1">0.007</td><td align="center" valign="middle" rowspan="1" colspan="1">0.006</td><td align="center" valign="middle" rowspan="1" colspan="1">0.093</td><td align="center" valign="middle" rowspan="1" colspan="1">0.022</td><td align="center" valign="middle" rowspan="1" colspan="1">0.006</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0002</td><td align="center" valign="middle" rowspan="1" colspan="1">0.007</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.014</td><td align="center" valign="middle" rowspan="1" colspan="1">0.005</td><td align="center" valign="middle" rowspan="1" colspan="1">3.53E-03</td><td align="center" valign="middle" rowspan="1" colspan="1">0.052</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Right Choroid Plexus</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.134</td><td align="center" valign="middle" rowspan="1" colspan="1">0.038</td><td align="center" valign="middle" rowspan="1" colspan="1">4.25E-04</td><td align="center" valign="middle" rowspan="1" colspan="1">0.012</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.12</td><td align="center" valign="middle" rowspan="1" colspan="1">0.034</td><td align="center" valign="middle" rowspan="1" colspan="1">3.80E-04</td><td align="center" valign="middle" rowspan="1" colspan="1">0.009</td><td align="center" valign="middle" rowspan="1" colspan="1">0.112</td><td align="center" valign="middle" rowspan="1" colspan="1">0.029</td><td align="center" valign="middle" rowspan="1" colspan="1">1.10E-04</td><td align="center" valign="middle" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Right Lateral Ventricle</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.171</td><td align="center" valign="middle" rowspan="1" colspan="1">0.042</td><td align="center" valign="middle" rowspan="1" colspan="1">5.00E-05</td><td align="center" valign="middle" rowspan="1" colspan="1">0.003</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.145</td><td align="center" valign="middle" rowspan="1" colspan="1">0.038</td><td align="center" valign="middle" rowspan="1" colspan="1">1.40E-04</td><td align="center" valign="middle" rowspan="1" colspan="1">0.007</td><td align="center" valign="middle" rowspan="1" colspan="1">0.136</td><td align="center" valign="middle" rowspan="1" colspan="1">0.033</td><td align="center" valign="middle" rowspan="1" colspan="1">4.00E-05</td><td align="center" valign="middle" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">White Matter Hypointensities</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.132</td><td align="center" valign="middle" rowspan="1" colspan="1">0.048</td><td align="center" valign="middle" rowspan="1" colspan="1">0.006</td><td align="center" valign="middle" rowspan="1" colspan="1">0.093</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.143</td><td align="center" valign="middle" rowspan="1" colspan="1">0.041</td><td align="center" valign="middle" rowspan="1" colspan="1">4.60E-04</td><td align="center" valign="middle" rowspan="1" colspan="1">0.009</td><td align="center" valign="middle" rowspan="1" colspan="1">0.118</td><td align="center" valign="middle" rowspan="1" colspan="1">0.035</td><td align="center" valign="middle" rowspan="1" colspan="1">7.50E-04</td><td align="center" valign="middle" rowspan="1" colspan="1">0.013</td></tr></tbody></table><table-wrap-foot><p>APOE, apolipoprotein E; SUVR, A&#946; positron emission tomographic standardized uptake value ratio. &#946;&#8239;=&#8239;standardized regression coefficient; SE&#8239;=&#8239;standard error. Effects of sleep disturbance expressed for presence vs. absence of sleep disturbance. Effects of APOE &#949;4 expressed for presence vs. absence of APOE &#949;4 allele. Linear regression models adjusted for age, sex, years of education, and marital status. <italic toggle="yes">p</italic> values are results of linear regression analyses. <italic toggle="yes">q</italic> values are FDR-corrected p values (Benjamini-Hochberg method) for multiple comparisons across brain regions.</p></table-wrap-foot></table-wrap><p>We reported effects of sleep disturbance and presence of the APOE &#949;4 on regional SUVR, presenting brain regions showing significant associations in covariate-adjusted regression analyses. Before FDR correction, 13 brain regions showed significant associations with sleep disturbance or sleep disturbance*APOE &#949;4 interactions after adjusting for age, sex, years of education, and marital status, including multiple corpus callosum regions (anterior, central, mid-anterior, and mid-posterior), left caudate nucleus, bilateral cerebellar cortex, bilateral choroid plexus, left hippocampus, bilateral inferior lateral and lateral ventricles, and white matter hypointensities.</p><p>Following FDR correction for multiple comparisons, several regions showed significant sleep disturbance*APOE &#949;4 interactions, including the left choroid plexus (&#946;&#8239;=&#8239;0.120, SE&#8239;=&#8239;0.032, <italic toggle="yes">p</italic>&#8239;=&#8239;1.50&#8239;&#215;&#8239;10<sup>&#8722;4</sup>, <italic toggle="yes">q</italic>&#8239;=&#8239;0.004), bilateral lateral ventricles (left: &#946;&#8239;=&#8239;0.141, SE&#8239;=&#8239;0.034, <italic toggle="yes">p</italic>&#8239;=&#8239;3.00&#8239;&#215;&#8239;10<sup>&#8722;5</sup>, <italic toggle="yes">q</italic>&#8239;=&#8239;0.002; right: &#946;&#8239;=&#8239;0.136, SE&#8239;=&#8239;0.033, <italic toggle="yes">p</italic>&#8239;=&#8239;4.00&#8239;&#215;&#8239;10<sup>&#8722;5</sup>, <italic toggle="yes">q</italic>&#8239;=&#8239;0.002), mid-posterior corpus callosum (&#946;&#8239;=&#8239;0.075, SE&#8239;=&#8239;0.034, <italic toggle="yes">p</italic>&#8239;=&#8239;2.70&#8239;&#215;&#8239;10<sup>&#8722;4</sup>, <italic toggle="yes">q</italic>&#8239;=&#8239;0.006), right choroid plexus (&#946;&#8239;=&#8239;0.112, SE&#8239;=&#8239;0.029, <italic toggle="yes">p</italic>&#8239;=&#8239;1.10&#8239;&#215;&#8239;10<sup>&#8722;4</sup>, <italic toggle="yes">q</italic>&#8239;=&#8239;0.004), and white matter hypointensities (&#946;&#8239;=&#8239;0.118, SE&#8239;=&#8239;0.035, <italic toggle="yes">p</italic>&#8239;=&#8239;7.50&#8239;&#215;&#8239;10<sup>&#8722;4</sup>, <italic toggle="yes">q</italic>&#8239;=&#8239;0.013). Notably, a significant sleep disturbance*APOE &#949;4 interaction was observed in the left hippocampus (&#946;&#8239;=&#8239;0.049, SE&#8239;=&#8239;0.020, <italic toggle="yes">p</italic>&#8239;=&#8239;0.015, <italic toggle="yes">q</italic>&#8239;=&#8239;0.169). This finding is particularly meaningful given the hippocampus&#8217;s critical role in memory formation and its susceptibility in early AD pathogenesis.</p><p>The distribution pattern of these regions suggests that sleep disturbance may preferentially affect DMN-related structures and their supporting systems. Specifically, DMN core impairment is evidenced by A&#946; deposition in the hippocampus, a key DMN node directly involved in memory processing. DMN connectivity disruption may result from corpus callosum A&#946; deposition, which could compromise interhemispheric connections critical for DMN function. Additionally, the observed A&#946; deposition in the ventricular system and choroid plexus suggests potential clearance system impairment, which may affect glymphatic clearance mechanisms that are crucial for A&#946; removal during sleep.</p></sec><sec id="sec12"><title>Effect of sleep disturbance on A&#946; deposition grouped by APOE &#949;4</title><p>The significant interaction analysis results prompted us to perform subgroup analyses, and participants were divided into two groups based on APOE &#949;4 status (<xref rid="tab3" ref-type="table">Table 3</xref>; <xref rid="SM1" ref-type="supplementary-material">Supplementary Tables S4</xref>, <xref rid="SM1" ref-type="supplementary-material">S5</xref>). Among APOE &#949;4 non-carriers, bilateral lateral ventricle SUVR was significantly decreased in those with sleep disturbance (left: &#946;&#8239;=&#8239;&#8722;0.039, SE&#8239;=&#8239;0.017, <italic toggle="yes">p</italic>&#8239;=&#8239;0.019, <italic toggle="yes">q</italic>&#8239;=&#8239;0.140 and right: &#946;&#8239;=&#8239;&#8722;0.034, SE&#8239;=&#8239;0.017, <italic toggle="yes">p</italic>&#8239;=&#8239;0.042, <italic toggle="yes">q</italic>&#8239;=&#8239;0.140) after adjusting for age, sex, education, and marital status (<xref rid="SM1" ref-type="supplementary-material">Supplementary Table S4</xref>). Although these associations did not remain significant after FDR correction, this finding was contrary to our expected results. In contrast, when analyzing the entire population without considering APOE status and focusing only on sleep disturbance (<xref rid="tab2" ref-type="table">Table 2</xref>), both brain regions showed a trend toward increased SUVR. Moreover, among APOE &#949;4 carriers, both regions demonstrated significantly elevated SUVR that remained significant even after FDR correction (<xref rid="SM1" ref-type="supplementary-material">Supplementary Table S5</xref>). This pattern suggests different responses to sleep disturbance between APOE &#949;4 carriers and non-carriers in lateral ventricular regions.</p><table-wrap position="float" id="tab3" orientation="portrait"><label>Table 3</label><caption><p>Significant regional brain A&#946; deposition differences between individuals with and without sleep disturbances by APOE4 status.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1"/><th align="left" valign="top" rowspan="2" colspan="1">Regions</th><th align="center" valign="top" rowspan="2" colspan="1">Overall</th><th align="center" valign="top" rowspan="2" colspan="1">No sleep disturbance</th><th align="center" valign="top" rowspan="2" colspan="1">Sleep disturbance</th><th align="center" valign="top" rowspan="2" colspan="1">
<italic toggle="yes">p</italic>
<xref rid="tfn1" ref-type="table-fn"><sup>a</sup></xref>
</th><th align="center" valign="top" colspan="5" rowspan="1">Linear regression</th></tr><tr><th align="center" valign="top" rowspan="1" colspan="1">&#946;</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">SE</italic>
</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
<xref rid="tfn2" ref-type="table-fn"><sup>b</sup></xref>
</th><th align="center" valign="top" rowspan="1" colspan="1">95% CI</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">q</italic>
</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="21" colspan="1">APOE &#949;4+</td><td align="left" valign="middle" rowspan="1" colspan="1">Mid-Posterior Corpus Callosum</td><td align="center" valign="middle" rowspan="1" colspan="1">1.25 (0.18)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.24 (0.18)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.36 (0.21)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">0.119</td><td align="center" valign="middle" rowspan="1" colspan="1">0.028</td><td align="center" valign="middle" rowspan="1" colspan="1">0.00003</td><td align="center" valign="middle" rowspan="1" colspan="1">[0.064, 0.174]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Left Choroid Plexus</td><td align="center" valign="middle" rowspan="1" colspan="1">0.91 (0.16)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.90 (0.15)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.99 (0.18)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">0.094</td><td align="center" valign="middle" rowspan="1" colspan="1">0.025</td><td align="center" valign="middle" rowspan="1" colspan="1">0.00019</td><td align="center" valign="middle" rowspan="1" colspan="1">[0.045, 0.143]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Right Choroid Plexus</td><td align="center" valign="middle" rowspan="1" colspan="1">0.93 (0.15)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.92 (0.15)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.01 (0.17)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">0.088</td><td align="center" valign="middle" rowspan="1" colspan="1">0.024</td><td align="center" valign="middle" rowspan="1" colspan="1">0.00025</td><td align="center" valign="middle" rowspan="1" colspan="1">[0.041, 0.135]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">White Matter Hypointensities</td><td align="center" valign="middle" rowspan="1" colspan="1">1.53 (0.17)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.52 (0.16)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.63 (0.19)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">0.103</td><td align="center" valign="middle" rowspan="1" colspan="1">0.028</td><td align="center" valign="middle" rowspan="1" colspan="1">0.00026</td><td align="center" valign="middle" rowspan="1" colspan="1">[0.048, 0.158]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Left Lateral Ventricle</td><td align="center" valign="middle" rowspan="1" colspan="1">0.86 (0.18)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.84 (0.16)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.95 (0.22)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">0.096</td><td align="center" valign="middle" rowspan="1" colspan="1">0.026</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0003</td><td align="center" valign="middle" rowspan="1" colspan="1">[0.045, 0.147]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Right Lateral Ventricle</td><td align="center" valign="middle" rowspan="1" colspan="1">0.87 (0.18)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.85 (0.17)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.96 (0.20)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">0.098</td><td align="center" valign="middle" rowspan="1" colspan="1">0.026</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0003</td><td align="center" valign="middle" rowspan="1" colspan="1">[0.047, 0.149]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Left Pericalcarine</td><td align="center" valign="middle" rowspan="1" colspan="1">1.29 (0.17)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.28 (0.15)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.37 (0.24)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">0.088</td><td align="center" valign="middle" rowspan="1" colspan="1">0.028</td><td align="center" valign="middle" rowspan="1" colspan="1">0.002</td><td align="center" valign="middle" rowspan="1" colspan="1">[0.033, 0.143]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.029</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Central Corpus Callosum</td><td align="center" valign="middle" rowspan="1" colspan="1">1.34 (0.16)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.33 (0.16)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.42 (0.16)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.002</td><td align="center" valign="middle" rowspan="1" colspan="1">0.077</td><td align="center" valign="middle" rowspan="1" colspan="1">0.026</td><td align="center" valign="middle" rowspan="1" colspan="1">0.004</td><td align="center" valign="middle" rowspan="1" colspan="1">[0.026, 0.128]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.046</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Left Caudate Nucleus</td><td align="center" valign="middle" rowspan="1" colspan="1">1.11 (0.13)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.10 (0.12)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.17 (0.18)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.002</td><td align="center" valign="middle" rowspan="1" colspan="1">0.064</td><td align="center" valign="middle" rowspan="1" colspan="1">0.022</td><td align="center" valign="middle" rowspan="1" colspan="1">0.004</td><td align="center" valign="middle" rowspan="1" colspan="1">[0.021, 0.107]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.046</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Left Lingual Gyrus</td><td align="center" valign="middle" rowspan="1" colspan="1">1.09 (0.13)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.08 (0.11)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.14 (0.19)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.003</td><td align="center" valign="middle" rowspan="1" colspan="1">0.057</td><td align="center" valign="middle" rowspan="1" colspan="1">0.021</td><td align="center" valign="middle" rowspan="1" colspan="1">0.006</td><td align="center" valign="middle" rowspan="1" colspan="1">[0.016, 0.098]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.062</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Left Cuneus</td><td align="center" valign="middle" rowspan="1" colspan="1">1.15 (0.13)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.14 (0.12)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.20 (0.17)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.007</td><td align="center" valign="middle" rowspan="1" colspan="1">0.058</td><td align="center" valign="middle" rowspan="1" colspan="1">0.021</td><td align="center" valign="middle" rowspan="1" colspan="1">0.007</td><td align="center" valign="middle" rowspan="1" colspan="1">[0.017, 0.099]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.066</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Left Inferior Lateral Ventricle</td><td align="center" valign="middle" rowspan="1" colspan="1">1.31 (0.16)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.30 (0.15)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.37 (0.20)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.006</td><td align="center" valign="middle" rowspan="1" colspan="1">0.067</td><td align="center" valign="middle" rowspan="1" colspan="1">0.026</td><td align="center" valign="middle" rowspan="1" colspan="1">0.009</td><td align="center" valign="middle" rowspan="1" colspan="1">[0.016, 0.118]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.077</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Anterior Corpus Callosum</td><td align="center" valign="middle" rowspan="1" colspan="1">1.40 (0.19)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.39 (0.18)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.48 (0.19)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.01</td><td align="center" valign="middle" rowspan="1" colspan="1">0.078</td><td align="center" valign="middle" rowspan="1" colspan="1">0.031</td><td align="center" valign="middle" rowspan="1" colspan="1">0.011</td><td align="center" valign="middle" rowspan="1" colspan="1">[0.017, 0.139]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.081</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Right Caudate Nucleus</td><td align="center" valign="middle" rowspan="1" colspan="1">1.13 (0.14)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.12 (0.13)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.18 (0.18)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.015</td><td align="center" valign="middle" rowspan="1" colspan="1">0.06</td><td align="center" valign="middle" rowspan="1" colspan="1">0.024</td><td align="center" valign="middle" rowspan="1" colspan="1">0.011</td><td align="center" valign="middle" rowspan="1" colspan="1">[0.013, 0.107]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.297</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Posterior Corpus Callosum</td><td align="center" valign="middle" rowspan="1" colspan="1">1.62 (0.17)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.61 (0.17)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.69 (0.16)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.004</td><td align="center" valign="middle" rowspan="1" colspan="1">0.072</td><td align="center" valign="middle" rowspan="1" colspan="1">0.028</td><td align="center" valign="middle" rowspan="1" colspan="1">0.012</td><td align="center" valign="middle" rowspan="1" colspan="1">[0.017, 0.127]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.082</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Left Hippocampus</td><td align="center" valign="middle" rowspan="1" colspan="1">1.12 (0.10)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.11 (0.09)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.15 (0.12)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.009</td><td align="center" valign="middle" rowspan="1" colspan="1">0.039</td><td align="center" valign="middle" rowspan="1" colspan="1">0.015</td><td align="center" valign="middle" rowspan="1" colspan="1">0.013</td><td align="center" valign="middle" rowspan="1" colspan="1">[0.010, 0.068]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.34</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Left Cerebral White Matter</td><td align="center" valign="middle" rowspan="1" colspan="1">1.60 (0.15)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.59 (0.14)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.65 (0.18)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.013</td><td align="center" valign="middle" rowspan="1" colspan="1">0.059</td><td align="center" valign="middle" rowspan="1" colspan="1">0.025</td><td align="center" valign="middle" rowspan="1" colspan="1">0.016</td><td align="center" valign="middle" rowspan="1" colspan="1">[0.010, 0.108]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.179</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Left Banks of Superior Temporal Sulcus</td><td align="center" valign="middle" rowspan="1" colspan="1">1.35 (0.22)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.34 (0.21)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.43 (0.25)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.023</td><td align="center" valign="middle" rowspan="1" colspan="1">0.08</td><td align="center" valign="middle" rowspan="1" colspan="1">0.036</td><td align="center" valign="middle" rowspan="1" colspan="1">0.025</td><td align="center" valign="middle" rowspan="1" colspan="1">[0.009, 0.151]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.143</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Right Entorhinal Cortex</td><td align="center" valign="middle" rowspan="1" colspan="1">0.93 (0.09)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.93 (0.09)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.96 (0.12)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.018</td><td align="center" valign="middle" rowspan="1" colspan="1">0.033</td><td align="center" valign="middle" rowspan="1" colspan="1">0.016</td><td align="center" valign="middle" rowspan="1" colspan="1">0.035</td><td align="center" valign="middle" rowspan="1" colspan="1">[0.002, 0.064]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.181</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Right Inferior Lateral Ventricle</td><td align="center" valign="middle" rowspan="1" colspan="1">1.26 (0.14)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.25 (0.14)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.30 (0.15)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.028</td><td align="center" valign="middle" rowspan="1" colspan="1">0.048</td><td align="center" valign="middle" rowspan="1" colspan="1">0.023</td><td align="center" valign="middle" rowspan="1" colspan="1">0.036</td><td align="center" valign="middle" rowspan="1" colspan="1">[0.003, 0.093]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.246</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Left Entorhinal Cortex</td><td align="center" valign="middle" rowspan="1" colspan="1">0.93 (0.08)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.92 (0.08)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.95 (0.12)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.028</td><td align="center" valign="middle" rowspan="1" colspan="1">0.029</td><td align="center" valign="middle" rowspan="1" colspan="1">0.014</td><td align="center" valign="middle" rowspan="1" colspan="1">0.037</td><td align="center" valign="middle" rowspan="1" colspan="1">[0.002, 0.056]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.181</td></tr><tr><td align="left" valign="middle" rowspan="7" colspan="1">APOE &#949;4+</td><td align="left" valign="middle" rowspan="1" colspan="1">Right Cerebral White Matter</td><td align="center" valign="middle" rowspan="1" colspan="1">1.60 (0.15)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.60 (0.15)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.65 (0.17)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.042</td><td align="center" valign="middle" rowspan="1" colspan="1">0.053</td><td align="center" valign="middle" rowspan="1" colspan="1">0.026</td><td align="center" valign="middle" rowspan="1" colspan="1">0.04</td><td align="center" valign="middle" rowspan="1" colspan="1">[0.002, 0.104]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.447</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Left Superior Parietal</td><td align="center" valign="middle" rowspan="1" colspan="1">1.11 (0.17)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.10 (0.16)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.15 (0.19)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.058</td><td align="center" valign="middle" rowspan="1" colspan="1">0.053</td><td align="center" valign="middle" rowspan="1" colspan="1">0.027</td><td align="center" valign="middle" rowspan="1" colspan="1">0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">[0.000, 0.106]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.597</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Left Lateral Ventricle</td><td align="center" valign="middle" rowspan="1" colspan="1">0.82 (0.16)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.83 (0.17)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.80 (0.13)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.14</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.039</td><td align="center" valign="middle" rowspan="1" colspan="1">0.017</td><td align="center" valign="middle" rowspan="1" colspan="1">0.019</td><td align="center" valign="middle" rowspan="1" colspan="1">[&#8722;0.072, 0.006]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.140</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Right Lateral Ventricle</td><td align="center" valign="middle" rowspan="1" colspan="1">0.84 (0.16)</td><td align="center" valign="top" rowspan="1" colspan="1">0.84 (0.17)</td><td align="center" valign="top" rowspan="1" colspan="1">0.82 (0.14)</td><td align="center" valign="top" rowspan="1" colspan="1">0.277</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.034</td><td align="center" valign="top" rowspan="1" colspan="1">0.017</td><td align="center" valign="top" rowspan="1" colspan="1">0.042</td><td align="center" valign="top" rowspan="1" colspan="1">[&#8722;0.067, 0.001]</td><td align="center" valign="top" rowspan="1" colspan="1">0.348</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Left Entorhinal Cortex</td><td align="center" valign="top" rowspan="1" colspan="1">0.93 (0.08)</td><td align="center" valign="top" rowspan="1" colspan="1">0.92 (0.08)</td><td align="center" valign="top" rowspan="1" colspan="1">0.95 (0.12)</td><td align="center" valign="top" rowspan="1" colspan="1">0.028</td><td align="center" valign="top" rowspan="1" colspan="1">0.029</td><td align="center" valign="top" rowspan="1" colspan="1">0.014</td><td align="center" valign="top" rowspan="1" colspan="1">0.037</td><td align="center" valign="top" rowspan="1" colspan="1">[0.002, 0.056]</td><td align="center" valign="top" rowspan="1" colspan="1">0.181</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Right Cerebral White Matter</td><td align="center" valign="top" rowspan="1" colspan="1">1.60 (0.15)</td><td align="center" valign="top" rowspan="1" colspan="1">1.60 (0.15)</td><td align="center" valign="top" rowspan="1" colspan="1">1.65 (0.17)</td><td align="center" valign="top" rowspan="1" colspan="1">0.042</td><td align="center" valign="top" rowspan="1" colspan="1">0.053</td><td align="center" valign="top" rowspan="1" colspan="1">0.026</td><td align="center" valign="top" rowspan="1" colspan="1">0.04</td><td align="center" valign="top" rowspan="1" colspan="1">[0.002, 0.104]</td><td align="center" valign="top" rowspan="1" colspan="1">0.447</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Left Superior Parietal</td><td align="center" valign="top" rowspan="1" colspan="1">1.11 (0.17)</td><td align="center" valign="top" rowspan="1" colspan="1">1.10 (0.16)</td><td align="center" valign="top" rowspan="1" colspan="1">1.15 (0.19)</td><td align="center" valign="top" rowspan="1" colspan="1">0.058</td><td align="center" valign="top" rowspan="1" colspan="1">0.053</td><td align="center" valign="top" rowspan="1" colspan="1">0.027</td><td align="center" valign="top" rowspan="1" colspan="1">0.05</td><td align="center" valign="top" rowspan="1" colspan="1">[0.000, 0.106]</td><td align="center" valign="top" rowspan="1" colspan="1">0.597</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">APOE &#949;4&#8722;</td><td align="left" valign="top" rowspan="1" colspan="1">Left Lateral Ventricle</td><td align="center" valign="top" rowspan="1" colspan="1">0.82 (0.16)</td><td align="center" valign="top" rowspan="1" colspan="1">0.83 (0.17)</td><td align="center" valign="top" rowspan="1" colspan="1">0.80 (0.13)</td><td align="center" valign="top" rowspan="1" colspan="1">0.14</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.039</td><td align="center" valign="top" rowspan="1" colspan="1">0.017</td><td align="center" valign="top" rowspan="1" colspan="1">0.019</td><td align="center" valign="top" rowspan="1" colspan="1">[&#8722;0.072, 0.006]</td><td align="center" valign="top" rowspan="1" colspan="1">0.140</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Right Lateral Ventricle</td><td align="center" valign="top" rowspan="1" colspan="1">0.84 (0.16)</td><td align="center" valign="top" rowspan="1" colspan="1">0.84 (0.17)</td><td align="center" valign="top" rowspan="1" colspan="1">0.82 (0.14)</td><td align="center" valign="top" rowspan="1" colspan="1">0.277</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.034</td><td align="center" valign="top" rowspan="1" colspan="1">0.017</td><td align="center" valign="top" rowspan="1" colspan="1">0.042</td><td align="center" valign="top" rowspan="1" colspan="1">[&#8722;0.067, 0.001]</td><td align="center" valign="top" rowspan="1" colspan="1">0.348</td></tr></tbody></table><table-wrap-foot><p>APOE, apolipoprotein E. Data presented as mean (standard error). &#946;&#8239;=&#8239;standardized regression coefficient; SE&#8239;=&#8239;standard error; CI&#8239;=&#8239;confidence interval. Effects of sleep disturbance expressed for presence vs. absence of sleep disturbance. <italic toggle="yes">q</italic> values are false discovery rate-corrected <italic toggle="yes">p</italic> values using the Benjamini-Hochberg method to control for multiple comparisons across brain regions within each predictor category.</p><fn id="tfn1"><label>a</label><p><italic toggle="yes">p</italic> values are the results of unpaired <italic toggle="yes">t</italic> tests.</p></fn><fn id="tfn2"><label>b</label><p><italic toggle="yes">p</italic> values are results of linear regression analyses. Models adjusted for age, sex, years of education, and marital status.</p></fn></table-wrap-foot></table-wrap><p>Among APOE &#949;4&#8239;+&#8239;participants, sleep disturbance was associated with significantly elevated A&#946; SUVR across multiple brain regions after controlling for the same confounding variables (<xref rid="fig1" ref-type="fig">Figure 1</xref>). APOE &#949;4 carriers with sleep disturbance exhibited significantly higher A&#946; deposition in multiple corpus callosum regions, including the anterior (&#946;&#8239;=&#8239;0.078, SE&#8239;=&#8239;0.031, <italic toggle="yes">p</italic>&#8239;=&#8239;0.011), central (&#946;&#8239;=&#8239;0.077, SE&#8239;=&#8239;0.026, <italic toggle="yes">p</italic>&#8239;=&#8239;0.004), mid-posterior (&#946;&#8239;=&#8239;0.119, SE&#8239;=&#8239;0.028, <italic toggle="yes">p</italic>&#8239;=&#8239;0.00003), and posterior (&#946;&#8239;=&#8239;0.072, SE&#8239;=&#8239;0.028, <italic toggle="yes">p</italic>&#8239;=&#8239;0.012) segments. Elevated SUVR values were also observed in cortical regions including the left banks of the superior temporal sulcus (&#946;&#8239;=&#8239;0.080, SE&#8239;=&#8239;0.036, <italic toggle="yes">p</italic>&#8239;=&#8239;0.025), left cuneus (&#946;&#8239;=&#8239;0.058, SE&#8239;=&#8239;0.021, <italic toggle="yes">p</italic>&#8239;=&#8239;0.007), left entorhinal cortex (&#946;&#8239;=&#8239;0.029, SE&#8239;=&#8239;0.014, <italic toggle="yes">p</italic>&#8239;=&#8239;0.037), left lingual gyrus (&#946;&#8239;=&#8239;0.057, SE&#8239;=&#8239;0.021, <italic toggle="yes">p</italic>&#8239;=&#8239;0.006), left pericalcarine cortex (&#946;&#8239;=&#8239;0.088, SE&#8239;=&#8239;0.028, <italic toggle="yes">p</italic>&#8239;=&#8239;0.002), left superior parietal lobule (<italic toggle="yes">p</italic>&#8239;=&#8239;0.05), and right entorhinal cortex (<italic toggle="yes">p</italic>&#8239;=&#8239;0.035). The left precuneus showed a trend toward significance (&#946;&#8239;=&#8239;0.068, SE&#8239;=&#8239;0.035, <italic toggle="yes">p</italic>&#8239;=&#8239;0.052). Notably, increased SUVR was also found in the bilateral hippocampus (left: &#946;&#8239;=&#8239;0.039, SE&#8239;=&#8239;0.015, <italic toggle="yes">p</italic>&#8239;=&#8239;0.013 and right: &#946;&#8239;=&#8239;0.025, SE&#8239;=&#8239;0.015, <italic toggle="yes">p</italic>&#8239;=&#8239;0.096).</p><fig position="float" id="fig1" orientation="portrait"><label>Figure 1</label><caption><p>Sleep disturbances increased the mean standardized uptake value ratio (SUVR) obtained by florbetapir-PET-AV45 in the APOE &#949;4&#8239;+&#8239;individuals. Mean images were generated by separately computing the mean of images from individuals with or without sleep disturbance. Supra-threshold clusters are presented in colors from blue to red.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnagi-17-1627774-g001.jpg"><alt-text content-type="machine-generated">Brain scan images showing nine axial slices. Each slice is colored according to a heat map ranging from blue to red, indicating varying levels of activity or intensity. The images are arranged in three rows and three columns, labeled with 'L' for left and 'R' for right. A color bar below ranges from negative point zero two eight to zero point zero seven.</alt-text></graphic></fig><p>Furthermore, sleep disturbance was significantly associated with increased SUVR in subcortical structures, including the bilateral caudate nuclei (left: &#946;&#8239;=&#8239;0.064, SE&#8239;=&#8239;0.022, <italic toggle="yes">p</italic>&#8239;=&#8239;0.004, <italic toggle="yes">q</italic>&#8239;=&#8239;0.046 and right: &#946;&#8239;=&#8239;0.060, SE&#8239;=&#8239;0.024, <italic toggle="yes">p</italic>&#8239;=&#8239;0.011, <italic toggle="yes">q</italic>&#8239;=&#8239;0.297), bilateral cerebral white matter (left: &#946;&#8239;=&#8239;0.059, SE&#8239;=&#8239;0.025, <italic toggle="yes">p</italic>&#8239;=&#8239;0.016 and right: &#946;&#8239;=&#8239;0.042, SE&#8239;=&#8239;0.053, <italic toggle="yes">p</italic>&#8239;=&#8239;0.026, <italic toggle="yes">q</italic>&#8239;=&#8239;0.040), bilateral choroid plexus (left: &#946;&#8239;=&#8239;0.094, SE&#8239;=&#8239;0.025, <italic toggle="yes">p</italic>&#8239;=&#8239;0.00019, <italic toggle="yes">q</italic>&#8239;=&#8239;0.005 and right: &#946;&#8239;=&#8239;0.088, SE&#8239;=&#8239;0.024, <italic toggle="yes">p</italic>&#8239;=&#8239;0.00025, <italic toggle="yes">q</italic>&#8239;=&#8239;0.005), bilateral inferior lateral ventricles (left: &#946;&#8239;=&#8239;0.067, SE&#8239;=&#8239;0.026, <italic toggle="yes">p</italic>&#8239;=&#8239;0.009 and right: &#946;&#8239;=&#8239;0.048, SE&#8239;=&#8239;0.023, <italic toggle="yes">p</italic>&#8239;=&#8239;0.036), bilateral lateral ventricles (left: <italic toggle="yes">&#946;</italic>&#8239;=&#8239;0.096, SE&#8239;=&#8239;0.026, <italic toggle="yes">p</italic>&#8239;=&#8239;0.0003, <italic toggle="yes">q</italic>&#8239;=&#8239;0.005 and right: &#946;&#8239;=&#8239;0.098, SE&#8239;=&#8239;0.026, <italic toggle="yes">p</italic>&#8239;=&#8239;0.0003, <italic toggle="yes">q</italic>&#8239;=&#8239;0.005), and white matter hypointensities (&#946;&#8239;=&#8239;0.103, SE&#8239;=&#8239;0.028, <italic toggle="yes">p</italic>&#8239;=&#8239;0.00026, <italic toggle="yes">q</italic>&#8239;=&#8239;0.005).</p><p>Here we present the 20 brain regions demonstrating the most pronounced differences in regional amyloid-&#946; burden between APOE4 carriers experiencing sleep disturbances and those without sleep complaints, highlighting the selective vulnerability of specific neural networks in this genetically at-risk population (<xref rid="fig2" ref-type="fig">Figure.2</xref>). This widespread pattern of A&#946; accumulation in APOE &#949;4 carriers encompasses key regions of the DMN (cuneus, precuneus, entorhinal cortex and hippocampus), interhemispheric connections (corpus callosum), and cerebrospinal fluid circulation pathways (lateral ventricles, choroid plexus), indicating that sleep disturbance is associated with A&#946; deposition across multiple anatomically and functionally distinct brain systems in APOE &#949;4 carriers.</p><fig position="float" id="fig2" orientation="portrait"><label>Figure 2</label><caption><p>Regional brain A&#223; deposition differences associated with sleep disturbances in APOE &#163;4 carriers. Forest plot showing regression coefficients (&#946;) for the 20 brain regions with the most significant associations between sleep disturbances and A&#223; burden (all <italic toggle="yes">p</italic> &lt;&#8239;0.05) Error bars represent 95% confidence intervals; square size indicates estimation precision.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnagi-17-1627774-g002.jpg"><alt-text content-type="machine-generated">Horizontal bar chart showing regression coefficients (&#946;) for various brain regions. Each red bar represents a brain region's coefficient with error bars indicating the 95% confidence interval. Bar length varies, with the Mid-Posterior Corpus Callosum having the largest coefficient near 0.15. All regions are significant at p &lt; 0.05. Square size represents estimation precision.</alt-text></graphic></fig></sec><sec id="sec13"><title>Effects of sleep scores on A&#946; deposition in APOE &#949;4 carriers</title><p>We investigated whether subjective sleep disturbance severity in APOE &#949;4 carriers demonstrated linear associations with regional A&#946; burden (<xref rid="tab4" ref-type="table">Table 4</xref>; <xref rid="SM1" ref-type="supplementary-material">Supplementary Tables S6</xref>). All analyses were adjusted for age, sex, education, and marital status.</p><table-wrap position="float" id="tab4" orientation="portrait"><label>Table 4</label><caption><p>Associations between sleep quality scores and brain A&#946; deposition in APOE4 carriers.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Brain region</th><th align="center" valign="top" rowspan="1" colspan="1">&#946; (SE)</th><th align="center" valign="top" rowspan="1" colspan="1">t</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="top" rowspan="1" colspan="1">95% CI</th><th align="center" valign="top" rowspan="1" colspan="1">q</th></tr></thead><tbody><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Anterior Corpus Callosum</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.026 (0.01)</td><td align="center" valign="bottom" rowspan="1" colspan="1">2.66</td><td align="center" valign="middle" rowspan="1" colspan="1">0.008</td><td align="center" valign="bottom" rowspan="1" colspan="1">[0.007, 0.044]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.048</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Central Corpus Callosum</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.025 (0.008)</td><td align="center" valign="bottom" rowspan="1" colspan="1">3.01</td><td align="center" valign="middle" rowspan="1" colspan="1">0.00</td><td align="center" valign="bottom" rowspan="1" colspan="1">[0.009, 0.041]</td><td align="center" valign="middle" rowspan="1" colspan="1">1.03E-08</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Mid-Anterior Corpus Callosum</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.017 (0.009)</td><td align="center" valign="bottom" rowspan="1" colspan="1">1.97</td><td align="center" valign="middle" rowspan="1" colspan="1">0.05</td><td align="center" valign="bottom" rowspan="1" colspan="1">[0, 0.033]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.139</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Mid-Posterior Corpus Callosum</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.038 (0.009)</td><td align="center" valign="bottom" rowspan="1" colspan="1">4.33</td><td align="center" valign="middle" rowspan="1" colspan="1">1.49E-05</td><td align="center" valign="bottom" rowspan="1" colspan="1">[0.021, 0.056]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Posterior Corpus Callosum</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.023 (0.009)</td><td align="center" valign="bottom" rowspan="1" colspan="1">2.61</td><td align="center" valign="middle" rowspan="1" colspan="1">0.009</td><td align="center" valign="bottom" rowspan="1" colspan="1">[0.006, 0.041]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.052</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Left Banks of Superior Temporal Sulcus</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.027 (0.011)</td><td align="center" valign="bottom" rowspan="1" colspan="1">2.4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.02</td><td align="center" valign="bottom" rowspan="1" colspan="1">[0.005, 0.049]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.077</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Left Caudal Anterior Cingulate</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.017 (0.01)</td><td align="center" valign="bottom" rowspan="1" colspan="1">1.73</td><td align="center" valign="middle" rowspan="1" colspan="1">0.09</td><td align="center" valign="bottom" rowspan="1" colspan="1">[&#8722;0.002, 0.037]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.182</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Left Caudal Middle Frontal</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.017 (0.01)</td><td align="center" valign="bottom" rowspan="1" colspan="1">1.78</td><td align="center" valign="middle" rowspan="1" colspan="1">0.08</td><td align="center" valign="bottom" rowspan="1" colspan="1">[&#8722;0.002, 0.036]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.172</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Left Cuneus</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.017 (0.007)</td><td align="center" valign="bottom" rowspan="1" colspan="1">2.55</td><td align="center" valign="middle" rowspan="1" colspan="1">0.01</td><td align="center" valign="bottom" rowspan="1" colspan="1">[0.004, 0.03]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.054</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Left Entorhinal Cortex</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.014 (0.004)</td><td align="center" valign="bottom" rowspan="1" colspan="1">3.29</td><td align="center" valign="middle" rowspan="1" colspan="1">0.001</td><td align="center" valign="bottom" rowspan="1" colspan="1">[0.006, 0.023]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.009</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Left Insula</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.015 (0.007)</td><td align="center" valign="bottom" rowspan="1" colspan="1">2.05</td><td align="center" valign="middle" rowspan="1" colspan="1">0.041</td><td align="center" valign="bottom" rowspan="1" colspan="1">[0.001, 0.03]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.124</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Left Lateral Orbitofrontal</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.021 (0.009)</td><td align="center" valign="bottom" rowspan="1" colspan="1">2.32</td><td align="center" valign="middle" rowspan="1" colspan="1">0.021</td><td align="center" valign="bottom" rowspan="1" colspan="1">[0.003, 0.038]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.077</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Left Lingual Gyrus</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.016 (0.006)</td><td align="center" valign="bottom" rowspan="1" colspan="1">2.48</td><td align="center" valign="middle" rowspan="1" colspan="1">0.014</td><td align="center" valign="bottom" rowspan="1" colspan="1">[0.003, 0.029]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.066</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Left Paracentral Lobule</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.019 (0.008)</td><td align="center" valign="bottom" rowspan="1" colspan="1">2.41</td><td align="center" valign="middle" rowspan="1" colspan="1">0.017</td><td align="center" valign="bottom" rowspan="1" colspan="1">[0.004, 0.035]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.070</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Left Pericalcarine</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.026 (0.009)</td><td align="center" valign="bottom" rowspan="1" colspan="1">2.95</td><td align="center" valign="middle" rowspan="1" colspan="1">0.003</td><td align="center" valign="bottom" rowspan="1" colspan="1">[0.009, 0.043]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.024</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Left Posterior Cingulate</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.023 (0.01)</td><td align="center" valign="bottom" rowspan="1" colspan="1">2.2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.028</td><td align="center" valign="bottom" rowspan="1" colspan="1">[0.003, 0.043]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.099</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Left Precuneus</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.026 (0.011)</td><td align="center" valign="bottom" rowspan="1" colspan="1">2.44</td><td align="center" valign="middle" rowspan="1" colspan="1">0.015</td><td align="center" valign="bottom" rowspan="1" colspan="1">[0.005, 0.048]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.067</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Left Superior Parietal</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.02 (0.008)</td><td align="center" valign="bottom" rowspan="1" colspan="1">2.41</td><td align="center" valign="middle" rowspan="1" colspan="1">0.017</td><td align="center" valign="bottom" rowspan="1" colspan="1">[0.004, 0.037]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.070</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Left Temporal Pole</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.014 (0.006)</td><td align="center" valign="bottom" rowspan="1" colspan="1">2.32</td><td align="center" valign="middle" rowspan="1" colspan="1">0.021</td><td align="center" valign="bottom" rowspan="1" colspan="1">[0.002, 0.026]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.077</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Left Transverse Temporal</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.01 (0.009)</td><td align="center" valign="bottom" rowspan="1" colspan="1">1.11</td><td align="center" valign="middle" rowspan="1" colspan="1">0.27</td><td align="center" valign="bottom" rowspan="1" colspan="1">[&#8722;0.007, 0.027]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.343</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Right Entorhinal Cortex</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.017 (0.005)</td><td align="center" valign="bottom" rowspan="1" colspan="1">3.46</td><td align="center" valign="middle" rowspan="1" colspan="1">5.40E-04</td><td align="center" valign="bottom" rowspan="1" colspan="1">[0.007, 0.026]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.009</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Right Lateral Orbitofrontal</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.019 (0.009)</td><td align="center" valign="bottom" rowspan="1" colspan="1">2.03</td><td align="center" valign="middle" rowspan="1" colspan="1">0.044</td><td align="center" valign="bottom" rowspan="1" colspan="1">[0.001, 0.038]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.130</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Right Paracentral Lobule</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.018 (0.008)</td><td align="center" valign="bottom" rowspan="1" colspan="1">2.14</td><td align="center" valign="middle" rowspan="1" colspan="1">0.033</td><td align="center" valign="bottom" rowspan="1" colspan="1">[0.001, 0.035]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.106</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Left Caudate Nucleus</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.023 (0.007)</td><td align="center" valign="bottom" rowspan="1" colspan="1">3.35</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0008</td><td align="center" valign="bottom" rowspan="1" colspan="1">[0.01, 0.037]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.009</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Left Cerebellar Cortex</td><td align="center" valign="bottom" rowspan="1" colspan="1">&#8722;0.003 (0.001)</td><td align="center" valign="bottom" rowspan="1" colspan="1">&#8722;2.17</td><td align="center" valign="middle" rowspan="1" colspan="1">0.031</td><td align="center" valign="bottom" rowspan="1" colspan="1">[&#8722;0.005, 0]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.106</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Left Cerebellar White Matter</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.012 (0.005)</td><td align="center" valign="bottom" rowspan="1" colspan="1">2.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.013</td><td align="center" valign="bottom" rowspan="1" colspan="1">[0.003, 0.021]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.064</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Left Cerebral White Matter</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.025 (0.008)</td><td align="center" valign="bottom" rowspan="1" colspan="1">3.29</td><td align="center" valign="middle" rowspan="1" colspan="1">0.001</td><td align="center" valign="bottom" rowspan="1" colspan="1">[0.01, 0.04]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.009</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Left Choroid Plexus</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.028 (0.008)</td><td align="center" valign="bottom" rowspan="1" colspan="1">3.55</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0004</td><td align="center" valign="bottom" rowspan="1" colspan="1">[0.012, 0.043]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.008</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Left Hippocampus</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.014 (0.005)</td><td align="center" valign="bottom" rowspan="1" colspan="1">2.83</td><td align="center" valign="middle" rowspan="1" colspan="1">0.005</td><td align="center" valign="bottom" rowspan="1" colspan="1">[0.004, 0.023]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.037</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Left Inferior Lateral Ventricle</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.027 (0.008)</td><td align="center" valign="bottom" rowspan="1" colspan="1">3.33</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0009</td><td align="center" valign="bottom" rowspan="1" colspan="1">[0.011, 0.042]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.009</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Left Lateral Ventricle</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.027 (0.008)</td><td align="center" valign="bottom" rowspan="1" colspan="1">3.25</td><td align="center" valign="middle" rowspan="1" colspan="1">0.001</td><td align="center" valign="bottom" rowspan="1" colspan="1">[0.011, 0.043]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.009</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Left Globus Pallidus</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.014 (0.007)</td><td align="center" valign="bottom" rowspan="1" colspan="1">2.06</td><td align="center" valign="middle" rowspan="1" colspan="1">0.04</td><td align="center" valign="bottom" rowspan="1" colspan="1">[0.001, 0.026]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.124</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Left Putamen</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.018 (0.007)</td><td align="center" valign="bottom" rowspan="1" colspan="1">2.52</td><td align="center" valign="middle" rowspan="1" colspan="1">0.012</td><td align="center" valign="bottom" rowspan="1" colspan="1">[0.004, 0.032]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.062</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Right Caudate Nucleus</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.02 (0.007)</td><td align="center" valign="bottom" rowspan="1" colspan="1">2.68</td><td align="center" valign="middle" rowspan="1" colspan="1">0.008</td><td align="center" valign="bottom" rowspan="1" colspan="1">[0.005, 0.034]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.048</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Right Cerebellar White Matter</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.01(0.005)</td><td align="center" valign="bottom" rowspan="1" colspan="1">1.998</td><td align="center" valign="middle" rowspan="1" colspan="1">0.047</td><td align="center" valign="bottom" rowspan="1" colspan="1">[2e-04, 0.0193]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.135</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Right Cerebellar Cortex</td><td align="center" valign="bottom" rowspan="1" colspan="1">&#8722;0.002 (0.001)</td><td align="center" valign="bottom" rowspan="1" colspan="1">&#8722;1.77</td><td align="center" valign="middle" rowspan="1" colspan="1">0.077</td><td align="center" valign="bottom" rowspan="1" colspan="1">[&#8722;0.005, 0]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.172</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Right Cerebral White Matter</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.022 (0.008)</td><td align="center" valign="bottom" rowspan="1" colspan="1">2.75</td><td align="center" valign="middle" rowspan="1" colspan="1">0.006</td><td align="center" valign="bottom" rowspan="1" colspan="1">[0.006, 0.038]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.041</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Right Choroid Plexus</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.027 (0.007)</td><td align="center" valign="bottom" rowspan="1" colspan="1">3.69</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0002</td><td align="center" valign="bottom" rowspan="1" colspan="1">[0.013, 0.042]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Right Hippocampus</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.009 (0.005)</td><td align="center" valign="bottom" rowspan="1" colspan="1">1.81</td><td align="center" valign="middle" rowspan="1" colspan="1">0.072</td><td align="center" valign="bottom" rowspan="1" colspan="1">[&#8722;0.001, 0.018]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.167</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Right Inferior Lateral Ventricle</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.015 (0.007)</td><td align="center" valign="bottom" rowspan="1" colspan="1">2.14</td><td align="center" valign="middle" rowspan="1" colspan="1">0.033</td><td align="center" valign="bottom" rowspan="1" colspan="1">[0.001, 0.029]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.106</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Right Lateral Ventricle</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.027 (0.008)</td><td align="center" valign="bottom" rowspan="1" colspan="1">3.29</td><td align="center" valign="middle" rowspan="1" colspan="1">0.001</td><td align="center" valign="bottom" rowspan="1" colspan="1">[0.011, 0.043]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.009</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">White Matter Hypointensities</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.04 (0.009)</td><td align="center" valign="bottom" rowspan="1" colspan="1">4.64</td><td align="center" valign="middle" rowspan="1" colspan="1">3.49E-06</td><td align="center" valign="top" rowspan="1" colspan="1">[0.023, 0.057]</td><td align="center" valign="top" rowspan="1" colspan="1">1.80E-04</td></tr></tbody></table><table-wrap-foot><p>APOE, apolipoprotein E. &#946;&#8239;=&#8239;regression coefficient; SE&#8239;=&#8239;standard error; t&#8239;=&#8239;t-statistic; CI&#8239;=&#8239;confidence interval. Linear regression models examining associations between sleep quality scores and brain amyloid deposition in APOE4 gene carriers, controlling for age, education, gender, and marital status. <italic toggle="yes">p</italic> values are results of linear regression analyses for covariate-adjusted associations. <italic toggle="yes">q</italic> values are false discovery rate-corrected <italic toggle="yes">p</italic> values using the Benjamini-Hochberg method to control for multiple comparisons across brain regions within each predictor category.</p></table-wrap-foot></table-wrap><p>This widespread pattern of A&#946; accumulation in APOE &#949;4 carriers encompasses key regions of the DMN (precuneus, cuneus, entorhinal cortex, hippocampus), interhemispheric connections (corpus callosum), and cerebrospinal fluid circulation pathways (lateral ventricles, choroid plexus), indicating that poor sleep quality is linked to A&#946; deposition across multiple brain regions in APOE &#949;4 carriers (<xref rid="fig3" ref-type="fig">Figure 3</xref>).</p><fig position="float" id="fig3" orientation="portrait"><label>Figure 3</label><caption><p>Association between sleep quality scores and regional brain A&#223; deposition in APOE &#163;4 carriers. Forest plot showing regression coefficients (&#946;) for the 20 brain regions with the strongest associations between sleep quality and A&#7838; burden (all <italic toggle="yes">p</italic> &lt;&#8239;0.05). Error bars represent 95% confidence intervals; square size indicates estimation precision.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnagi-17-1627774-g003.jpg"><alt-text content-type="machine-generated">Bar chart showing regression coefficients (&#946;) with 95% confidence intervals for various brain regions. The regions, listed on the left, include White Matter Hyperintensities, Corpus Callosum areas, Choroid Plexus, Lateral Ventricles, and others. Square size indicates estimation precision, with all regions significant at p &lt; 0.05. Coefficients range from approximately 0.00 to 0.06.</alt-text></graphic></fig><p>The distribution pattern of these regions suggests that poor sleep quality may preferentially affect DMN-related structures and their supporting systems. Specifically, DMN core impairment is evidenced by significant A&#946; deposition in the left precuneus (&#946;&#8239;=&#8239;0.026, SE&#8239;=&#8239;0.011, <italic toggle="yes">p</italic>&#8239;=&#8239;0.015), a critical posterior DMN hub essential for self-referential processing and episodic memory retrieval. The left posterior cingulate cortex, another core DMN node, also demonstrated significant A&#946; accumulation (&#946;&#8239;=&#8239;0.023, SE&#8239;=&#8239;0.01, <italic toggle="yes">p</italic>&#8239;=&#8239;0.028), suggesting potential disruption of the network&#8217;s metabolic and connectivity functions. Memory-related DMN components showed robust associations, with bilateral entorhinal cortex displaying strong significance (left: &#946;&#8239;=&#8239;0.014, SE&#8239;=&#8239;0.004, <italic toggle="yes">p</italic>&#8239;=&#8239;0.001, <italic toggle="yes">q</italic>&#8239;=&#8239;0.009; right: &#946;&#8239;=&#8239;0.017, SE&#8239;=&#8239;0.005, <italic toggle="yes">p</italic>&#8239;=&#8239;5.40E-04, <italic toggle="yes">q</italic>&#8239;=&#8239;0.009) and left hippocampus showing significant A&#946; deposition (&#946;&#8239;=&#8239;0.014, SE&#8239;=&#8239;0.005, <italic toggle="yes">p</italic>&#8239;=&#8239;0.005, <italic toggle="yes">q</italic>&#8239;=&#8239;0.037). Visual cortex DMN components, including the cuneus (&#946;&#8239;=&#8239;0.017, SE&#8239;=&#8239;0.007, <italic toggle="yes">p</italic>&#8239;=&#8239;0.01) and pericalcarine cortex (&#946;&#8239;=&#8239;0.026, SE&#8239;=&#8239;0.009, <italic toggle="yes">p</italic>&#8239;=&#8239;0.003, <italic toggle="yes">q</italic>&#8239;=&#8239;0.024), also exhibited significant associations, indicating potential disruption of visual&#8211;spatial processing within the DMN framework. DMN connectivity disruption may result from extensive corpus callosum A&#946; deposition across multiple segments (anterior: &#946;&#8239;=&#8239;0.026, SE&#8239;=&#8239;0.01, <italic toggle="yes">p</italic>&#8239;=&#8239;0.008; central: &#946;&#8239;=&#8239;0.025, SE&#8239;=&#8239;0.008, <italic toggle="yes">p</italic>&#8239;=&#8239;0.003; mid-posterior: &#946;&#8239;=&#8239;0.038, SE&#8239;=&#8239;0.009, <italic toggle="yes">p</italic>&#8239;=&#8239;1.49E-05), which could compromise interhemispheric connections critical for DMN synchronization and function. Additionally, the observed A&#946; deposition in the bilateral lateral ventricles (left: &#946;&#8239;=&#8239;0.027, SE&#8239;=&#8239;0.008, <italic toggle="yes">p</italic>&#8239;=&#8239;0.001, <italic toggle="yes">q</italic>&#8239;=&#8239;0.009; right: &#946;&#8239;=&#8239;0.027, SE&#8239;=&#8239;0.008, <italic toggle="yes">p</italic>&#8239;=&#8239;0.001, <italic toggle="yes">q</italic>&#8239;=&#8239;0.009) and choroid plexus (left: &#946;&#8239;=&#8239;0.028, SE&#8239;=&#8239;0.008, <italic toggle="yes">p</italic>&#8239;=&#8239;0.0004, <italic toggle="yes">q</italic>&#8239;=&#8239;0.008; right: &#946;&#8239;=&#8239;0.027, SE&#8239;=&#8239;0.007, <italic toggle="yes">p</italic>&#8239;=&#8239;0.0002, <italic toggle="yes">q</italic>&#8239;=&#8239;0.005) suggests potential clearance system impairment, which may affect glymphatic clearance mechanisms that are crucial for A&#946; removal during sleep.</p></sec></sec><sec sec-type="discussion" id="sec14"><title>Discussion</title><p>This study examined the combined effects of sleep disturbance and APOE &#949;4 genotype on A&#946; accumulation in cognitively normal older adults. Our main finding was that sleep disturbance alone did not significantly alter A&#946; deposition. However, we observed a notable interaction between sleep disturbance and APOE &#949;4, with the left hippocampus emerging as a key region of interest. This finding is particularly significant given the hippocampus&#8217;s critical role in memory function and its known vulnerability in AD. Further analyses revealed important differences between genetic groups. APOE &#949;4 carriers with sleep disturbance showed significantly higher A&#946; burden across multiple brain regions compared to those with normal sleep. In contrast, non-carriers showed minimal effects. Among APOE &#949;4 carriers, sleep disturbance severity directly correlated with regional A&#946; deposition. These results suggest that genetic risk factors and sleep quality collectively influence AD-related brain pathology.</p><p>The APOE &#949;4 allele represents the strongest known genetic risk factor for AD, with substantial evidence connecting it to accelerated A&#946; accumulation and impaired clearanc (<xref rid="ref45" ref-type="bibr">Liu et al., 2017</xref>; <xref rid="ref44" ref-type="bibr">Liu et al., 2013</xref>). Our results expand this knowledge by showing that APOE &#949;4 carriers with sleep disturbance face increased risk for A&#946; accumulation. This finding is consistent with previous studies showing that APOE &#949;4 carriers with sleep problems have higher risk of developing AD (<xref rid="ref12" ref-type="bibr">Burke et al., 2016</xref>) and often experience poorer sleep quality in later life (<xref rid="ref23" ref-type="bibr">Drogos et al., 2016</xref>). Previous research using the same sleep measurement approach as our study demonstrated that individuals with different APOE &#949;4 status exhibited varying sleep quality patterns (<xref rid="ref6" ref-type="bibr">Blackman et al., 2022</xref>). Our analyses revealed that sleep disturbance was linked to higher A&#946; burden in AD-sensitive regions, including the bilateral entorhinal cortex and left hippocampus, particularly in APOE &#949;4 carriers. Additionally, sleep quality scores showed significant relationships with regional SUVR values in this genetically at-risk group, further supporting the interaction between genetic factors and sleep disturbances in AD development.</p><p>Our analysis revealed a significant interaction effect between sleep quality and APOE genetic variants within the left hippocampus region. This observation deserves attention because of the hippocampus&#8217;s central importance in memory formation and its known early involvement in AD pathological processes (<xref rid="ref69" ref-type="bibr">Small et al., 1999</xref>; <xref rid="ref52" ref-type="bibr">Mormino et al., 2009</xref>). Disrupted sleep patterns can negatively impact hippocampal structure (<xref rid="ref30" ref-type="bibr">Grydeland et al., 2021</xref>), while A&#946; protein accumulation may interfere with hippocampal function through effects on neural networks and cellular health (<xref rid="ref90" ref-type="bibr">Zhang et al., 2020</xref>; <xref rid="ref75" ref-type="bibr">Villette et al., 2010</xref>). Previous research has documented how APOE genetic variants influence the relationship between sleep difficulties and memory performance (<xref rid="ref3" ref-type="bibr">Baril et al., 2022</xref>). Our investigation provides further evidence for a specific relationship in APOE &#949;4 carriers, where sleep disturbance correlates with increased A&#946; deposition, particularly affecting left hippocampal structures that typically show early decline in AD development.</p><p>Our findings demonstrate that A&#946; accumulation preferentially occurs in core regions of the default mode network, including the precuneus, cuneus, hippocampus, entorhinal cortex, and posterior cingulate cortex, particularly in APOE &#949;4 carriers with sleep disturbance. This pattern is consistent with established knowledge of DMN vulnerability in AD and suggests that sleep-related pathological processes may accelerate within this critical network. The DMN&#8217;s high metabolic activity and extensive connectivity may render it particularly susceptible to sleep-dependent clearance impairments, especially in the context of genetic risk.</p><p>Beyond DMN core regions, we identified significant findings in visual cortex areas including the cuneus, lingual gyrus, and pericalcarine cortex, all showing increased A&#946; deposition associated with sleep disturbance in APOE &#949;4 carriers. This pattern is consistent with brain networks showing altered functional connectivity in AD identified in a previous meta-analysis (<xref rid="ref17" ref-type="bibr">Chiari-Correia et al., 2023</xref>). Additionally, extensive corpus callosum involvement across multiple segments suggests disruption of interhemispheric connections critical for DMN synchronization and function. The widespread pattern of A&#946; deposition in corpus callosum regions indicates that sleep disturbance may compromise the structural connectivity that underlies DMN integrity in genetically susceptible individuals.</p><p>A particularly finding was the significant A&#946; deposition in bilateral lateral ventricles and choroid plexus in individuals with sleep disturbance. These structures play crucial roles in cerebrospinal fluid circulation and metabolic waste clearance processes (<xref rid="ref84" ref-type="bibr">Yan et al., 2025</xref>; <xref rid="ref14" ref-type="bibr">&#268;arna et al., 2023</xref>; <xref rid="ref64" ref-type="bibr">Schubert et al., 2019</xref>). Growing evidence suggests that sleep facilitates A&#946; clearance through cerebrospinal fluid flow and glymphatic circulation (<xref rid="ref18" ref-type="bibr">Chong et al., 2022</xref>). Our findings may provide further evidence supporting the critical role of sleep in A&#946; clearance through cerebrospinal fluid metabolic circulation, suggesting that sleep disturbance may impair these clearance systems specifically in APOE &#949;4 carriers.</p><p>A particularly notable finding was the significant A&#946; deposition in bilateral lateral ventricles and choroid plexus in individuals with sleep disturbance. These structures play crucial roles in cerebrospinal fluid circulation and metabolic waste clearance processes, providing strong evidence for the mechanistic link between sleep and A&#946; clearance. Growing evidence suggests that sleep facilitates A&#946; clearance through cerebrospinal fluid flow and glymphatic circulation (<xref rid="ref1" ref-type="bibr">Achariyar et al., 2016</xref>; <xref rid="ref66" ref-type="bibr">Serrano-Pozo et al.,2021</xref>),and our findings may provide further support for this critical relationship.</p><p>Our subgroup analyses revealed contrasting patterns between APOE &#949;4 carriers and non-carriers in lateral ventricular responses to sleep disturbance, providing critical insights into genotype-specific clearance mechanisms. In APOE &#949;4 non-carriers, the observed reduction in lateral ventricular SUVR during sleep disturbance may reflect the characteristics of cognitively normal individuals in this population, where those with higher baseline A&#946; burden may have already progressed beyond the cognitively normal stage and were excluded from the study. Consequently, the remaining cognitively normal non-carriers may have relatively low baseline SUVR values with limited capacity for detectable increases, resulting in apparent decreases that likely represent measurement variability rather than meaningful biological change. This interpretation is supported by the loss of significance after FDR correction.</p><p>In contrast, APOE &#949;4 carriers demonstrated significantly elevated SUVR in both lateral ventricles during sleep disturbance, with associations that remained significant even after FDR correction, indicating genuine pathological changes in the clearance system. Despite having higher baseline A&#946; burden, APOE &#949;4 carriers demonstrate continued vulnerability to sleep-related A&#946; accumulation in the ventricular system, suggesting that this region retains capacity for further pathological changes even in the presence of existing amyloid pathology. Additionally, previous research has shown that cognitively normal APOE &#949;4 carriers and non-carriers exhibit different associations between neurodegeneration and choroid plexus volume and calcification (<xref rid="ref58" ref-type="bibr">Ozsahin et al., 2025</xref>). This genotype-specific difference highlights that APOE &#949;4 carriers are more vulnerable to sleep-related pathological changes.</p><p>The bidirectional relationship between sleep regulation and A&#946; metabolism provides a mechanistic framework for interpreting our results. Even short-term sleep loss significantly increases A&#946; deposition in the hippocampus (<xref rid="ref68" ref-type="bibr">Shokri-Kojori et al., 2018</xref>). Clinical studies have shown links between both very short or long sleep duration and increased A&#946; burden in cognitively normal individuals (<xref rid="ref39" ref-type="bibr">Insel et al., 2021</xref>; <xref rid="ref71" ref-type="bibr">Spira et al., 2013</xref>; <xref rid="ref48" ref-type="bibr">Ma et al., 2020</xref>). Poor sleep quality consistently relates to higher A&#946; deposition in older adults (<xref rid="ref41" ref-type="bibr">Ju et al., 2013</xref>; <xref rid="ref26" ref-type="bibr">Ettore et al., 2019</xref>; <xref rid="ref9" ref-type="bibr">Branger et al., 2016</xref>), and initial sleep quality predicts later cortical A&#946; accumulation in healthy aging (<xref rid="ref80" ref-type="bibr">Winer et al., 2020</xref>). These findings suggest that investigating the association between sleep and longitudinal changes represents an important next step.</p><p>Our results demonstrated an asymmetric distribution of sleep-related A&#946; deposition, with predominantly left-sided regional associations. This pattern aligns with established observations of hemispheric asymmetry in early AD pathology, where A&#946; plaques tend to deposit preferentially in the left hemisphere during preclinical stages (<xref rid="ref86" ref-type="bibr">Yoon et al., 2021</xref>; <xref rid="ref88" ref-type="bibr">Yu et al., 2024</xref>). Previous studies have documented left-lateralized glucose metabolism declines in amyloid-&#946; positive individuals with mild cognitive impairment (<xref rid="ref77" ref-type="bibr">Weise et al., 2018</xref>). Our findings suggest that sleep-related amyloid accumulation may preferentially affect the left hemisphere during preclinical stages of the disease.</p><p>The choice of tracer and reference region significantly influences SUVR quantification (<xref rid="ref57" ref-type="bibr">Ottoy et al., 2017</xref>; <xref rid="ref33" ref-type="bibr">Heeman et al., 2020</xref>; <xref rid="ref15" ref-type="bibr">Chen et al., 2021</xref>). Florbetapir 18F-based PET tracers, compared with 11C-PiB, have a longer half-life and could be more widely available, readily standardized, and rapidly acquired (<xref rid="ref10" ref-type="bibr">Brendel et al., 2017</xref>; <xref rid="ref4" ref-type="bibr">Barthel and Sabri, 2011</xref>). Human PET studies have indicated florbetapir-PET-AV45 as an adjunct for clinical diagnosis (<xref rid="ref40" ref-type="bibr">Johnson et al., 2013</xref>; <xref rid="ref13" ref-type="bibr">Camus et al., 2012</xref>). In this study, we used the florbetapir-PET-AV45 SUVR referenced by the whole cerebellum to calculate the A&#946; burden. A higher A&#946; burden measured using florbetapir-PET-AV45 was associated with fewer hours of nightly sleep in another CN cohort population (<xref rid="ref79" ref-type="bibr">Winer et al., 2021</xref>). While PET molecular imaging offers non-invasive assessment suitable for population-level screening, particularly in older adults, it does present limitations including relatively lower spatial resolution and considerable operational costs. These limitations highlight the value of our findings regarding sleep disturbance assessment, which could complement imaging approaches by providing an accessible clinical marker that may help identify individuals at increased risk for AD-related pathology, particularly among APOE &#949;4 carriers.</p></sec><sec id="sec15"><title>Limitations</title><p>This study has several important limitations that warrant consideration. First, despite our thoroughly characterized cohort, the limited number of APOE &#949;4 carriers experiencing sleep disturbances constrained our ability to fully elucidate the impact of this allele on A&#946; pathology. This sample size limitation particularly affects our subgroup analyses and may influence the generalizability of our findings. Additionally, our APOE genotyping data comes from the ADNI database, which provides APOE &#949;4 carrier status coded as the number of &#949;4 alleles (0, 1, or 2) rather than complete genotyping information. This coding system does not distinguish between &#949;3/&#949;4 and &#949;2/&#949;4 heterozygotes in the single &#949;4 allele group, which represents a significant limitation of our study design. The inclusion of &#949;2/&#949;4 heterozygotes in our &#949;4 carrier group may attenuate the pathological effects of &#949;4 due to the protective effects of &#949;2 on amyloid pathology (<xref rid="ref19" ref-type="bibr">Corder et al., 1993</xref>), and brain white matter structure (<xref rid="ref34" ref-type="bibr">Heise et al., 2024</xref>), potentially reducing our statistical power to detect &#949;4-related associations. Future studies with complete APOE genotyping would provide more precise estimates of &#949;4-specific effects on the sleep-amyloid relationship. Second, our cross-sectional design prevents establishing causal relationships between sleep disturbance and A&#946; deposition. The observed associations could reflect either sleep disturbances contributing to A&#946; accumulation or early, subclinical A&#946; pathology disrupting sleep regulation networks. Longitudinal studies are essential to determine the temporal sequence and causal relationships between these phenomena. Third, our assessment methodology relied on sleep data derived from NPI questionnaires rather than objective measurements from actigraphy or polysomnography. Although the NPI-K has been validated as a reliable clinical assessment tool in individuals both with and without AD, it remains a subjective measure dependent on caregiver reports with potential for reporting bias. While restricting our analysis to the basic presence of sleep disturbance rather than its detailed characteristics reduced the likelihood of missing clinically significant sleep abnormalities, this methodological approach lacks the precision offered by laboratory-based sleep monitoring. Finally, our analytical approach did not distinguish among various types of sleep disturbances, which may impact A&#946; accumulation differently. Future investigations should characterize how specific sleep parameters (such as sleep duration, efficiency, or architecture) influence A&#946; deposition patterns to better understand their relationship with AD risk.</p></sec><sec sec-type="conclusions" id="sec16"><title>Conclusion</title><p>This study examined the complex interplay between sleep disturbance, APOE &#949;4 status, and A&#946; burden in cognitively normal older adults. Our initial analyses revealed no significant differences in global PET SUVR between individuals with and without sleep disturbances, nor in regional SUVR after adjusting for demographic variables. However, subsequent analyses demonstrated significant interaction effects between sleep disturbance and APOE &#949;4 genotype. In stratified analyses, APOE &#949;4 carriers with sleep disturbance exhibited significantly elevated A&#946; burden across multiple AD-vulnerable regions, particularly in the entorhinal cortex, left hippocampus, and key components of the default mode network. Moreover, among APOE &#949;4 carriers, sleep disturbance severity demonstrated dose-dependent associations with regional A&#946; deposition. These findings support the hypothesis that sleep quality influences A&#946; deposition and neurodegenerative processes, with genetic vulnerability modulating this relationship (<xref rid="ref76" ref-type="bibr">Wang and Holtzman, 2020</xref>). Future longitudinal investigations are warranted to elucidate the temporal and mechanistic relationships between sleep quality, APOE genotype, and A&#946; accumulation. Such research may provide valuable insights for early AD detection and prevention strategies. By identifying the interactions between sleep disturbance, APOE &#949;4 status, and A&#946; burden, this study contributes to the development of risk stratification approaches and potential intervention targets for individuals at increased risk for AD.</p></sec></body><back><ack><p>The authors wish to thank all the members of the Alzheimer&#8217;s Disease Neuroimaging Initiative (ADNI). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer&#8217;s Association; Alzheimer&#8217;s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research &amp; Development, LLC.; Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC.; Lumosity; Lundbeck; Merck &amp; Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.fnih.org" ext-link-type="uri">www.fnih.org</ext-link>). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer&#8217;s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.</p></ack><sec sec-type="data-availability" id="sec17"><title>Data availability statement</title><p>The original contributions presented in the study are included in the article/<xref rid="SM1" ref-type="supplementary-material">Supplementary material</xref>, further inquiries can be directed to the corresponding authors.</p></sec><sec sec-type="ethics-statement" id="sec18"><title>Ethics statement</title><p>Ethical approval was not required for the study involving humans in accordance with the local legislation and institutional requirements. Written informed consent to participate in this study was not required from the participants or the participants&#8217; legal guardians/next of kin in accordance with the national legislation and the institutional requirements.</p></sec><sec sec-type="author-contributions" id="sec19"><title>Author contributions</title><p>SF: Data curation, Formal analysis, Methodology, Software, Validation, Visualization, Writing &#8211; original draft. JQ: Data curation, Methodology, Validation, Visualization, Writing &#8211; review &amp; editing. QW: Data curation, Writing &#8211; review &amp; editing. KY: Project administration, Supervision, Writing &#8211; review &amp; editing. LS: Conceptualization, Project administration, Supervision, Writing &#8211; review &amp; editing.</p></sec><sec sec-type="COI-statement" id="sec21"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p><p>The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</p></sec><sec sec-type="ai-statement" id="sec22"><title>Generative AI statement</title><p>The author(s) declare that no Gen AI was used in the creation of this manuscript.</p><p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p></sec><sec sec-type="disclaimer" id="sec23"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec sec-type="supplementary-material" id="sec24"><title>Supplementary material</title><p>The Supplementary material for this article can be found online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.frontiersin.org/articles/10.3389/fnagi.2025.1627774/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fnagi.2025.1627774/full#supplementary-material</ext-link></p><supplementary-material id="SM1" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table_1.XLSX" position="float" orientation="portrait"/></supplementary-material></sec><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Achariyar</surname><given-names>T. M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Verghese</surname><given-names>P. B.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>McConnell</surname><given-names>E.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation</article-title>. <source>Mol. Neurodegener.</source><volume>11</volume>:<fpage>74</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13024-016-0138-8</pub-id>, PMID: <pub-id pub-id-type="pmid">27931262</pub-id><pub-id pub-id-type="pmcid">PMC5146863</pub-id></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="other"><person-group person-group-type="author"><collab id="coll1">Alzheimer Europe</collab></person-group>. (<year>2019</year>). Dementia in Europe yearbook 2019: Estimating the prevalence of dementia in Europe. Alzheimer Europe 2019, 180.</mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baril</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Beiser</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Sanchez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mysliwiec</surname><given-names>V.</given-names></name><name name-style="western"><surname>Redline</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gottlieb</surname><given-names>D. J.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Insomnia symptom severity and cognitive performance: moderating role of APOE genotype</article-title>. <source>Alzheimers Dement.</source><volume>18</volume>, <fpage>408</fpage>&#8211;<lpage>421</lpage>. doi: <pub-id pub-id-type="doi">10.1002/alz.12405</pub-id>, PMID: <pub-id pub-id-type="pmid">34310026</pub-id><pub-id pub-id-type="pmcid">PMC8802306</pub-id></mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barthel</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sabri</surname><given-names>O.</given-names></name></person-group> (<year>2011</year>). <article-title>Florbetaben to trace amyloid-&#946; in the Alzheimer brain by means of PET</article-title>. <source>J Alzheimer's Dis</source><volume>26</volume>, <fpage>117</fpage>&#8211;<lpage>121</lpage>. doi: <pub-id pub-id-type="doi">10.3233/JAD-2011-0068</pub-id>, PMID: <pub-id pub-id-type="pmid">21971456</pub-id></mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bateman</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>C.</given-names></name><name name-style="western"><surname>Benzinger</surname><given-names>T. L.</given-names></name><name name-style="western"><surname>Fagan</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Goate</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>N. C.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>Clinical and biomarker changes in dominantly inherited Alzheimer's disease</article-title>. <source>N. Engl. J. Med.</source><volume>367</volume>, <fpage>795</fpage>&#8211;<lpage>804</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1202753</pub-id>, PMID: <pub-id pub-id-type="pmid">22784036</pub-id><pub-id pub-id-type="pmcid">PMC3474597</pub-id></mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blackman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Love</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sinclair</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cain</surname><given-names>R.</given-names></name><name name-style="western"><surname>Coulthard</surname><given-names>E.</given-names></name></person-group> (<year>2022</year>). <article-title>APOE &#949;4, Alzheimer's disease neuropathology and sleep disturbance, in individuals with and without dementia</article-title>. <source>Alzheimer's Res Ther</source><volume>14</volume>:<fpage>47</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13195-022-00992-y</pub-id>, PMID: <pub-id pub-id-type="pmid">35354468</pub-id><pub-id pub-id-type="pmcid">PMC8969347</pub-id></mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blackwell</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yaffe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ancoli-Israel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Cauley</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Hillier</surname><given-names>T. A.</given-names></name><etal/></person-group>. (<year>2006</year>). <article-title>Poor sleep is associated with impaired cognitive function in older women: the study of osteoporotic fractures</article-title>. <source>J. Gerontol. A Biol. Sci. Med. Sci.</source><volume>61</volume>, <fpage>405</fpage>&#8211;<lpage>410</lpage>. doi: <pub-id pub-id-type="doi">10.1093/gerona/61.4.405</pub-id>, PMID: <pub-id pub-id-type="pmid">16611709</pub-id></mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blanchard</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Akay</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>Davila-Velderrain</surname><given-names>J.</given-names></name><name name-style="western"><surname>von Maydell</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mathys</surname><given-names>H.</given-names></name><name name-style="western"><surname>Davidson</surname><given-names>S. M.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes</article-title>. <source>Nature</source><volume>611</volume>, <fpage>769</fpage>&#8211;<lpage>779</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41586-022-05439-w</pub-id>, PMID: <pub-id pub-id-type="pmid">36385529</pub-id><pub-id pub-id-type="pmcid">PMC9870060</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Branger</surname><given-names>P.</given-names></name><name name-style="western"><surname>Arenaza-Urquijo</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Tomadesso</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mezenge</surname><given-names>F.</given-names></name><name name-style="western"><surname>Andr&#233;</surname><given-names>C.</given-names></name><name name-style="western"><surname>De Flores</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Relationships between sleep quality and brain volume, metabolism, and amyloid deposition in late adulthood</article-title>. <source>Neurobiol. Aging</source><volume>41</volume>, <fpage>107</fpage>&#8211;<lpage>114</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2016.02.009</pub-id>, PMID: <pub-id pub-id-type="pmid">27103523</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brendel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schnabel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sch&#246;necker</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>L.</given-names></name><name name-style="western"><surname>Brendel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Meyer-Wilmes</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Additive value of amyloid-PET in routine cases of clinical dementia work-up after FDG-PET</article-title>. <source>Eur. J. Nucl. Med. Mol. Imaging</source><volume>44</volume>, <fpage>2239</fpage>&#8211;<lpage>2248</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00259-017-3832-z</pub-id>, PMID: <pub-id pub-id-type="pmid">28932894</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>B. M.</given-names></name><name name-style="western"><surname>Rainey-Smith</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Villemagne</surname><given-names>V. L.</given-names></name><name name-style="western"><surname>Weinborn</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bucks</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Sohrabi</surname><given-names>H. R.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>The relationship between sleep quality and brain amyloid burden</article-title>. <source>Sleep</source><volume>39</volume>, <fpage>1063</fpage>&#8211;<lpage>1068</lpage>. doi: <pub-id pub-id-type="doi">10.5665/sleep.5756</pub-id>, PMID: <pub-id pub-id-type="pmid">27091528</pub-id><pub-id pub-id-type="pmcid">PMC4835305</pub-id></mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burke</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Maramaldi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cadet</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kukull</surname><given-names>W.</given-names></name></person-group> (<year>2016</year>). <article-title>Neuropsychiatric symptoms and Apolipoprotein E: associations with eventual Alzheimer&#8217;s disease development</article-title>. <source>Arch. Gerontol. Geriatr.</source><volume>65</volume>, <fpage>231</fpage>&#8211;<lpage>238</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.archger.2016.04.006</pub-id>, PMID: <pub-id pub-id-type="pmid">27111252</pub-id><pub-id pub-id-type="pmcid">PMC5029123</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Camus</surname><given-names>V.</given-names></name><name name-style="western"><surname>Payoux</surname><given-names>P.</given-names></name><name name-style="western"><surname>Barr&#233;</surname><given-names>L.</given-names></name><name name-style="western"><surname>Desgranges</surname><given-names>B.</given-names></name><name name-style="western"><surname>Voisin</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tauber</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment</article-title>. <source>Eur. J. Nucl. Med. Mol. Imaging</source><volume>39</volume>, <fpage>621</fpage>&#8211;<lpage>631</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00259-011-2021-8</pub-id>, PMID: <pub-id pub-id-type="pmid">22252372</pub-id><pub-id pub-id-type="pmcid">PMC3315642</pub-id></mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#268;arna</surname><given-names>M.</given-names></name><name name-style="western"><surname>Onyango</surname><given-names>I. G.</given-names></name><name name-style="western"><surname>Katina</surname><given-names>S.</given-names></name><name name-style="western"><surname>Holub</surname><given-names>D.</given-names></name><name name-style="western"><surname>Novotny</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Nezvedova</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Pathogenesis of Alzheimer's disease: involvement of the choroid plexus</article-title>. <source>Alzheimers Dement.</source><volume>19</volume>, <fpage>3537</fpage>&#8211;<lpage>3554</lpage>. doi: <pub-id pub-id-type="doi">10.1002/alz.12970</pub-id>, PMID: <pub-id pub-id-type="pmid">36825691</pub-id><pub-id pub-id-type="pmcid">PMC10634590</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>C. D.</given-names></name><name name-style="western"><surname>McCullough</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>B. A.</given-names></name><name name-style="western"><surname>Joseph-Mathurin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>[11C]PiB and [18F]AV45 PET radiotracers show different rates of amyloid-&#946; clearance</article-title>. <source>Alzheimers Dement.</source><volume>17</volume>:<fpage>e056094</fpage>. doi: <pub-id pub-id-type="doi">10.1002/alz.056094</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chiao</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bedell</surname><given-names>B. J.</given-names></name><name name-style="western"><surname>Avants</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zijdenbos</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>Grand'Maison</surname><given-names>M.</given-names></name><name name-style="western"><surname>O'Neill</surname><given-names>P.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Impact of reference and target region selection on amyloid PET SUV ratios in the phase 1b PRIME study of aducanumab</article-title>. <source>J. Nucl. Med.</source><volume>60</volume>, <fpage>100</fpage>&#8211;<lpage>106</lpage>. doi: <pub-id pub-id-type="doi">10.2967/jnumed.118.209130</pub-id>, PMID: <pub-id pub-id-type="pmid">29777003</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chiari-Correia</surname><given-names>R. D.</given-names></name><name name-style="western"><surname>Tumas</surname><given-names>V.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Salmon</surname><given-names>C. E. G.</given-names></name></person-group> (<year>2023</year>). <article-title>Structural and functional differences in the brains of patients with MCI with and without depressive symptoms and their relations with Alzheimer's disease: an MRI study</article-title>. <source>Psychoradiology</source><volume>3</volume>:<fpage>kkad008</fpage>. doi: <pub-id pub-id-type="doi">10.1093/psyrad/kkad008</pub-id>, PMID: <pub-id pub-id-type="pmid">38666129</pub-id><pub-id pub-id-type="pmcid">PMC10917365</pub-id></mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chong</surname><given-names>P. L. H.</given-names></name><name name-style="western"><surname>Garic</surname><given-names>D.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>M. D.</given-names></name><name name-style="western"><surname>Lundgaard</surname><given-names>I.</given-names></name><name name-style="western"><surname>Schwichtenberg</surname><given-names>A. J.</given-names></name></person-group> (<year>2022</year>). <article-title>Sleep, cerebrospinal fluid, and the glymphatic system: a systematic review</article-title>. <source>Sleep Med. Rev.</source><volume>61</volume>:<fpage>101572</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.smrv.2021.101572</pub-id>, PMID: <pub-id pub-id-type="pmid">34902819</pub-id><pub-id pub-id-type="pmcid">PMC8821419</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corder</surname><given-names>E. H.</given-names></name><name name-style="western"><surname>Saunders</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Strittmatter</surname><given-names>W. J.</given-names></name><name name-style="western"><surname>Schmechel</surname><given-names>D. E.</given-names></name><name name-style="western"><surname>Gaskell</surname><given-names>P. C.</given-names></name><name name-style="western"><surname>Small</surname><given-names>G. W.</given-names></name><etal/></person-group>. (<year>1993</year>). <article-title>Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families</article-title>. <source>Science</source><volume>261</volume>, <fpage>921</fpage>&#8211;<lpage>923</lpage>. doi: <pub-id pub-id-type="doi">10.1126/science.8346443</pub-id>, PMID: <pub-id pub-id-type="pmid">8346443</pub-id></mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cummings</surname><given-names>J. L.</given-names></name></person-group> (<year>1997</year>). <article-title>The neuropsychiatric inventory: assessing psychopathology in dementia patients</article-title>. <source>Neurology</source><volume>48</volume>, <fpage>S10</fpage>&#8211;<lpage>S16</lpage>. doi: <pub-id pub-id-type="doi">10.1212/wnl.48.5_suppl_6.10s</pub-id>, PMID: <pub-id pub-id-type="pmid">9153155</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cummings</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Mega</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rosenberg-Thompson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Carusi</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Gornbein</surname><given-names>J.</given-names></name></person-group> (<year>1994</year>). <article-title>The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia</article-title>. <source>Neurology</source><volume>44</volume>, <fpage>2308</fpage>&#8211;<lpage>2314</lpage>. doi: <pub-id pub-id-type="doi">10.1212/WNL.44.12.2308</pub-id>, PMID: <pub-id pub-id-type="pmid">7991117</pub-id></mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dodart</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Marr</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Koistinaho</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gregersen</surname><given-names>B. M.</given-names></name><name name-style="western"><surname>Malkani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Verma</surname><given-names>I. M.</given-names></name><etal/></person-group>. (<year>2005</year>). <article-title>Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease</article-title>. <source>Proc. Natl. Acad. Sci. USA</source><volume>102</volume>, <fpage>1211</fpage>&#8211;<lpage>1216</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.0409072102</pub-id>, PMID: <pub-id pub-id-type="pmid">15657137</pub-id><pub-id pub-id-type="pmcid">PMC544620</pub-id></mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drogos</surname><given-names>L. L.</given-names></name><name name-style="western"><surname>Gill</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Tyndall</surname><given-names>A. V.</given-names></name><name name-style="western"><surname>Raneri</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Parboosingh</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Naef</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Evidence of association between sleep quality and APOE &#949;4 in healthy older adults: a pilot study</article-title>. <source>Neurology</source><volume>87</volume>, <fpage>1836</fpage>&#8211;<lpage>1842</lpage>. doi: <pub-id pub-id-type="doi">10.1212/WNL.0000000000003255</pub-id>, PMID: <pub-id pub-id-type="pmid">27777343</pub-id><pub-id pub-id-type="pmcid">PMC5089524</pub-id></mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Langhough</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hermann</surname><given-names>B. P.</given-names></name><name name-style="western"><surname>Jonaitis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Betthauser</surname><given-names>T. J.</given-names></name><name name-style="western"><surname>Cody</surname><given-names>K. A.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Associations between self-reported sleep patterns and health, cognition and amyloid measures: results from the Wisconsin registry for Alzheimer's prevention</article-title>. <source>Brain Commun.</source><volume>5</volume>:<fpage>fcad039</fpage>. doi: <pub-id pub-id-type="doi">10.1093/braincomms/fcad039</pub-id>, PMID: <pub-id pub-id-type="pmid">36910417</pub-id><pub-id pub-id-type="pmcid">PMC9999364</pub-id></mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elberse</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Saberi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ahmadi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Changizi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hoffstaedter</surname><given-names>F.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>The interplay between insomnia symptoms and Alzheimer&#8217;s disease across three main brain networks</article-title>. <source>Sleep</source><volume>47</volume>:<fpage>zsae145</fpage>. doi: <pub-id pub-id-type="doi">10.1093/sleep/zsae145</pub-id>, PMID: <pub-id pub-id-type="pmid">38934787</pub-id><pub-id pub-id-type="pmcid">PMC11467060</pub-id></mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ettore</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bakardjian</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sol&#233;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Levy Nogueira</surname><given-names>M.</given-names></name><name name-style="western"><surname>Habert</surname><given-names>M.-O.</given-names></name><name name-style="western"><surname>Gabelle</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Relationships between objectives sleep parameters and brain amyloid load in subjects at risk for Alzheimer&#8217;s disease: the INSIGHT-preAD study</article-title>. <source>Sleep</source><volume>42</volume>:<fpage>zsz137</fpage>. doi: <pub-id pub-id-type="doi">10.1093/sleep/zsz137</pub-id>, PMID: <pub-id pub-id-type="pmid">31267124</pub-id></mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frisoni</surname><given-names>G. B.</given-names></name><name name-style="western"><surname>Altomare</surname><given-names>D.</given-names></name><name name-style="western"><surname>Thal</surname><given-names>D. R.</given-names></name><name name-style="western"><surname>Ribaldi</surname><given-names>F.</given-names></name><name name-style="western"><surname>van der Kant</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ossenkoppele</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>The probabilistic model of Alzheimer disease: the amyloid hypothesis revised</article-title>. <source>Nat. Rev. Neurosci.</source><volume>23</volume>, <fpage>53</fpage>&#8211;<lpage>66</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41583-021-00533-w</pub-id>, PMID: <pub-id pub-id-type="pmid">34815562</pub-id><pub-id pub-id-type="pmcid">PMC8840505</pub-id></mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fuller</surname><given-names>J. T.</given-names></name><name name-style="western"><surname>Choudhury</surname><given-names>T. K.</given-names></name><name name-style="western"><surname>Lowe</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Balsis</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>Hallucinations and delusions signal Alzheimer's associated cognitive dysfunction more strongly compared to other neuropsychiatric symptoms</article-title>. <source>J. Gerontol. B Psychol. Sci. Soc. Sci.</source><volume>75</volume>, <fpage>1894</fpage>&#8211;<lpage>1904</lpage>. doi: <pub-id pub-id-type="doi">10.1093/geronb/gbz032</pub-id>, PMID: <pub-id pub-id-type="pmid">30877750</pub-id><pub-id pub-id-type="pmcid">PMC7751129</pub-id></mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gabelle</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gutierrez</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>Jaussent</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ben Bouallegue</surname><given-names>F.</given-names></name><name name-style="western"><surname>De Verbizier</surname><given-names>D.</given-names></name><name name-style="western"><surname>Navucet</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Absence of relationship between self-reported sleep measures and amyloid load in elderly subjects</article-title>. <source>Front. Neurol.</source><volume>10</volume>:<fpage>989</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fneur.2019.00989</pub-id>, PMID: <pub-id pub-id-type="pmid">31572295</pub-id><pub-id pub-id-type="pmcid">PMC6753692</pub-id></mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grydeland</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sederevi&#269;ius</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bartr&#233;s-Faz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bertram</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dobricic</surname><given-names>V.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Self-reported sleep relates to microstructural hippocampal decline in &#223;-amyloid positive adults beyond genetic risk</article-title>. <source>Sleep</source><volume>44</volume>:<fpage>110</fpage>. doi: <pub-id pub-id-type="doi">10.1093/sleep/zsab110</pub-id>, PMID: <pub-id pub-id-type="pmid">33912975</pub-id><pub-id pub-id-type="pmcid">PMC8598196</pub-id></mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hardy</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>G. A.</given-names></name></person-group> (<year>1992</year>). <article-title>Alzheimer's disease: the amyloid cascade hypothesis</article-title>. <source>Science</source><volume>256</volume>, <fpage>184</fpage>&#8211;<lpage>185</lpage>. doi: <pub-id pub-id-type="doi">10.1126/science.1566067</pub-id>, PMID: <pub-id pub-id-type="pmid">1566067</pub-id></mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harold</surname><given-names>D.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hollingworth</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sims</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gerrish</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hamshere</surname><given-names>M. L.</given-names></name><etal/></person-group>. (<year>2009</year>). <article-title>Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease</article-title>. <source>Nat. Genet.</source><volume>41</volume>, <fpage>1088</fpage>&#8211;<lpage>1093</lpage>. doi: <pub-id pub-id-type="doi">10.1038/ng.440</pub-id>, PMID: <pub-id pub-id-type="pmid">19734902</pub-id><pub-id pub-id-type="pmcid">PMC2845877</pub-id></mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heeman</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hendriks</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lopes Alves</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ossenkoppele</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tolboom</surname><given-names>N.</given-names></name><name name-style="western"><surname>van Berckel</surname><given-names>B. N. M.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>[11C]PIB amyloid quantification: effect of reference region selection</article-title>. <source>EJNMMI Res.</source><volume>10</volume>:<fpage>123</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13550-020-00714-1</pub-id>, PMID: <pub-id pub-id-type="pmid">33074395</pub-id><pub-id pub-id-type="pmcid">PMC7572969</pub-id></mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heise</surname><given-names>V.</given-names></name><name name-style="western"><surname>Offer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Whiteley</surname><given-names>W.</given-names></name><name name-style="western"><surname>Mackay</surname><given-names>C. E.</given-names></name><name name-style="western"><surname>Armitage</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Parish</surname><given-names>S.</given-names></name></person-group> (<year>2024</year>). <article-title>A comprehensive analysis of APOE genotype effects on human brain structure in the UK biobank</article-title>. <source>Transl. Psychiatry</source><volume>14</volume>:<fpage>143</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41398-024-02848-5</pub-id>, PMID: <pub-id pub-id-type="pmid">38472178</pub-id><pub-id pub-id-type="pmcid">PMC10933274</pub-id></mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hita-Ya&#241;ez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Atienza</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gil-Neciga</surname><given-names>E. L.</given-names></name><name name-style="western"><surname>Cantero</surname><given-names>J.</given-names></name></person-group> (<year>2012</year>). <article-title>Disturbed sleep patterns in elders with mild cognitive impairment: the role of memory decline and ApoE &#949; 4 genotype</article-title>. <source>Curr. Alzheimer Res.</source><volume>9</volume>, <fpage>290</fpage>&#8211;<lpage>297</lpage>. doi: <pub-id pub-id-type="doi">10.2174/156720512800107609</pub-id>, PMID: <pub-id pub-id-type="pmid">22211488</pub-id></mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horovitz</surname><given-names>S. G.</given-names></name><name name-style="western"><surname>Braun</surname><given-names>A. R.</given-names></name><name name-style="western"><surname>Carr</surname><given-names>W. S.</given-names></name><name name-style="western"><surname>Picchioni</surname><given-names>D.</given-names></name><name name-style="western"><surname>Balkin</surname><given-names>T. J.</given-names></name><name name-style="western"><surname>Fukunaga</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2009</year>). <article-title>Decoupling of the brain's default mode network during deep sleep</article-title>. <source>Proc. Natl. Acad. Sci.</source><volume>106</volume>, <fpage>11376</fpage>&#8211;<lpage>11381</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.0901435106</pub-id>, PMID: <pub-id pub-id-type="pmid">19549821</pub-id><pub-id pub-id-type="pmcid">PMC2708777</pub-id></mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hwang</surname><given-names>J. Y.</given-names></name><name name-style="western"><surname>Byun</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Choe</surname><given-names>Y. M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J.-W.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Moderating effect of APOE &#949;4 on the relationship between sleep-wake cycle and brain &#946;-amyloid</article-title>. <source>Neurology</source><volume>90</volume>, <fpage>e1167</fpage>&#8211;<lpage>e1173</lpage>. doi: <pub-id pub-id-type="doi">10.1212/WNL.0000000000005193</pub-id>, PMID: <pub-id pub-id-type="pmid">29490913</pub-id></mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Insel</surname><given-names>P. S.</given-names></name><name name-style="western"><surname>Hansson</surname><given-names>O.</given-names></name><name name-style="western"><surname>Mattsson-Carlgren</surname><given-names>N.</given-names></name></person-group> (<year>2021</year>). <article-title>Association between Apolipoprotein E &#949;2 vs &#949;4, age, and &#946;-amyloid in adults without cognitive impairment</article-title>. <source>JAMA Neurol.</source><volume>78</volume>, <fpage>229</fpage>&#8211;<lpage>235</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jamaneurol.2020.3780</pub-id>, PMID: <pub-id pub-id-type="pmid">33044487</pub-id><pub-id pub-id-type="pmcid">PMC7551211</pub-id></mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Insel</surname><given-names>P. S.</given-names></name><name name-style="western"><surname>Mohlenhoff</surname><given-names>B. S.</given-names></name><name name-style="western"><surname>Neylan</surname><given-names>T. C.</given-names></name><name name-style="western"><surname>Krystal</surname><given-names>A. D.</given-names></name><name name-style="western"><surname>Mackin</surname><given-names>R. S.</given-names></name></person-group> (<year>2021</year>). <article-title>Association of Sleep and &#946;-amyloid pathology among older cognitively unimpaired adults</article-title>. <source>JAMA Netw. Open</source><volume>4</volume>:<fpage>e2117573</fpage>. doi: <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.17573</pub-id>, PMID: <pub-id pub-id-type="pmid">34297074</pub-id><pub-id pub-id-type="pmcid">PMC8303100</pub-id></mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Sperling</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Gidicsin</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Carmasin</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Maye</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>R. E.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging</article-title>. <source>Alzheimers Dement.</source><volume>9</volume>, <fpage>S72</fpage>&#8211;<lpage>S83</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jalz.2012.10.007</pub-id>, PMID: <pub-id pub-id-type="pmid">23375563</pub-id><pub-id pub-id-type="pmcid">PMC3800236</pub-id></mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ju</surname><given-names>Y.-E. S.</given-names></name><name name-style="western"><surname>McLeland</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Toedebusch</surname><given-names>C. D.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fagan</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Duntley</surname><given-names>S. P.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Sleep quality and preclinical Alzheimer disease</article-title>. <source>JAMA Neurol.</source><volume>70</volume>, <fpage>587</fpage>&#8211;<lpage>593</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jamaneurol.2013.2334</pub-id>, PMID: <pub-id pub-id-type="pmid">23479184</pub-id><pub-id pub-id-type="pmcid">PMC3676720</pub-id></mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>J.-E.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Bateman</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Smyth</surname><given-names>L. P.</given-names></name><name name-style="western"><surname>Cirrito</surname><given-names>J. R.</given-names></name><etal/></person-group>. (<year>2009</year>). <article-title>Amyloid-&#946; dynamics are regulated by orexin and the sleep-wake cycle</article-title>. <source>Science</source><volume>326</volume>, <fpage>1005</fpage>&#8211;<lpage>1007</lpage>. doi: <pub-id pub-id-type="doi">10.1126/science.1180962</pub-id>, PMID: <pub-id pub-id-type="pmid">19779148</pub-id><pub-id pub-id-type="pmcid">PMC2789838</pub-id></mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Gehrman</surname><given-names>P. R.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>D.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Resting-state functional connectivity changes in older adults with sleep disturbance and the role of amyloid burden</article-title>. <source>Mol. Psychiatry</source><volume>28</volume>, <fpage>4399</fpage>&#8211;<lpage>4406</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41380-023-02214-9</pub-id>, PMID: <pub-id pub-id-type="pmid">37596355</pub-id><pub-id pub-id-type="pmcid">PMC10842478</pub-id></mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C. C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C. C.</given-names></name><name name-style="western"><surname>Kanekiyo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bu</surname><given-names>G.</given-names></name></person-group> (<year>2013</year>). <article-title>Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy</article-title>. <source>Nat. Rev. Neurol.</source><volume>9</volume>, <fpage>106</fpage>&#8211;<lpage>118</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrneurol.2012.263</pub-id>, PMID: <pub-id pub-id-type="pmid">23296339</pub-id><pub-id pub-id-type="pmcid">PMC3726719</pub-id></mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C. C.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Linares</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>C. W.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>ApoE4 accelerates early seeding of amyloid pathology</article-title>. <source>Neuron</source><volume>96</volume>, <fpage>1024</fpage>&#8211;<lpage>1032.e3</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuron.2017.11.013</pub-id>, PMID: <pub-id pub-id-type="pmid">29216449</pub-id><pub-id pub-id-type="pmcid">PMC5948105</pub-id></mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lunsford-Avery</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Damme</surname><given-names>K. S. F.</given-names></name><name name-style="western"><surname>Engelhard</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Kollins</surname><given-names>S. H.</given-names></name><name name-style="western"><surname>Mittal</surname><given-names>V. A.</given-names></name></person-group> (<year>2020</year>). <article-title>Sleep/wake regularity associated with default mode network structure among healthy adolescents and young adults</article-title>. <source>Sci. Rep.</source><volume>10</volume>:<fpage>509</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-019-57024-3</pub-id>, PMID: <pub-id pub-id-type="pmid">31949189</pub-id><pub-id pub-id-type="pmcid">PMC6965093</pub-id></mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lysen</surname><given-names>T. S.</given-names></name><name name-style="western"><surname>Luik</surname><given-names>A. I.</given-names></name><name name-style="western"><surname>Ikram</surname><given-names>M. K.</given-names></name><name name-style="western"><surname>Tiemeier</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ikram</surname><given-names>M. A.</given-names></name></person-group> (<year>2020</year>). <article-title>Actigraphy-estimated sleep and 24-hour activity rhythms and the risk of dementia</article-title>. <source>Alzheimers Dement.</source><volume>16</volume>, <fpage>1259</fpage>&#8211;<lpage>1267</lpage>. doi: <pub-id pub-id-type="doi">10.1002/alz.12122</pub-id>, PMID: <pub-id pub-id-type="pmid">32558256</pub-id><pub-id pub-id-type="pmcid">PMC7984295</pub-id></mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>F.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>B.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>W.</given-names></name></person-group> (<year>2020</year>). <article-title>Association between sleep duration and cognitive decline</article-title>. <source>JAMA Netw. Open</source><volume>3</volume>:<fpage>e2013573</fpage>. doi: <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.13573</pub-id>, PMID: <pub-id pub-id-type="pmid">32955572</pub-id><pub-id pub-id-type="pmcid">PMC7506513</pub-id></mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mander</surname><given-names>B. A.</given-names></name><name name-style="western"><surname>Winer</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>M. P.</given-names></name></person-group> (<year>2017</year>). <article-title>Sleep and Human Aging</article-title>. <source>Neuron</source><volume>94</volume>, <fpage>19</fpage>&#8211;<lpage>36</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuron.2017.02.004</pub-id>, PMID: <pub-id pub-id-type="pmid">28384471</pub-id><pub-id pub-id-type="pmcid">PMC5810920</pub-id></mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mattioli</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pardini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fam&#224;</surname><given-names>F.</given-names></name><name name-style="western"><surname>Girtler</surname><given-names>N.</given-names></name><name name-style="western"><surname>Brugnolo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Orso</surname><given-names>B.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Cuneus/precuneus as a central hub for brain functional connectivity of mild cognitive impairment in idiopathic REM sleep behavior patients</article-title>. <source>Eur. J. Nucl. Med. Mol. Imaging</source><volume>48</volume>, <fpage>2834</fpage>&#8211;<lpage>2845</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00259-021-05205-6</pub-id>, PMID: <pub-id pub-id-type="pmid">33511424</pub-id></mixed-citation></ref><ref id="ref51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mega</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Cummings</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Fiorello</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gornbein</surname><given-names>J.</given-names></name></person-group> (<year>1996</year>). <article-title>The spectrum of behavioral changes in Alzheimer's disease</article-title>. <source>Neurology</source><volume>46</volume>, <fpage>130</fpage>&#8211;<lpage>135</lpage>. doi: <pub-id pub-id-type="doi">10.1212/WNL.46.1.130</pub-id>, PMID: <pub-id pub-id-type="pmid">8559361</pub-id></mixed-citation></ref><ref id="ref52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mormino</surname><given-names>E. C.</given-names></name><name name-style="western"><surname>Kluth</surname><given-names>J. T.</given-names></name><name name-style="western"><surname>Madison</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Rabinovici</surname><given-names>G. D.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>B. L.</given-names></name><etal/></person-group>. (<year>2009</year>). <article-title>Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects</article-title>. <source>Brain</source><volume>132</volume>, <fpage>1310</fpage>&#8211;<lpage>1323</lpage>. doi: <pub-id pub-id-type="doi">10.1093/brain/awn320</pub-id>, PMID: <pub-id pub-id-type="pmid">19042931</pub-id><pub-id pub-id-type="pmcid">PMC2677792</pub-id></mixed-citation></ref><ref id="ref53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nebes</surname><given-names>R. D.</given-names></name><name name-style="western"><surname>Buysse</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Halligan</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Houck</surname><given-names>P. R.</given-names></name><name name-style="western"><surname>Monk</surname><given-names>T. H.</given-names></name></person-group> (<year>2009</year>). <article-title>Self-reported sleep quality predicts poor cognitive performance in healthy older adults</article-title>. <source>J. Gerontol. Ser. B. Psychol. Sci. Soc. Sci.</source><volume>64</volume>, <fpage>180</fpage>&#8211;<lpage>187</lpage>. doi: <pub-id pub-id-type="doi">10.1093/geronb/gbn037</pub-id><pub-id pub-id-type="pmid">19204069</pub-id><pub-id pub-id-type="pmcid">PMC2655169</pub-id></mixed-citation></ref><ref id="ref54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohayon</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Carskadon</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Guilleminault</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vitiello</surname><given-names>M. V.</given-names></name></person-group> (<year>2004</year>). <article-title>Meta-analysis of quantitative sleep parameters from childhood to old age in healthy individuals: developing normative sleep values across the human lifespan</article-title>. <source>Sleep</source><volume>27</volume>, <fpage>1255</fpage>&#8211;<lpage>1273</lpage>. doi: <pub-id pub-id-type="doi">10.1093/sleep/27.7.1255</pub-id>, PMID: <pub-id pub-id-type="pmid">15586779</pub-id></mixed-citation></ref><ref id="ref55"><mixed-citation publication-type="other"><person-group person-group-type="author"><collab id="coll2">Organization, W.H</collab></person-group>. (<year>2019</year>). Risk reduction of cognitive decline and dementia: WHO guidelines.<pub-id pub-id-type="pmid">31219687</pub-id></mixed-citation></ref><ref id="ref56"><mixed-citation publication-type="other"><person-group person-group-type="author"><collab id="coll3">Organization, W.H</collab></person-group> (<year>2021</year>). Global status report on the public health response to dementia.</mixed-citation></ref><ref id="ref57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ottoy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Verhaeghe</surname><given-names>J.</given-names></name><name name-style="western"><surname>Niemantsverdriet</surname><given-names>E.</given-names></name><name name-style="western"><surname>Engelborghs</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stroobants</surname><given-names>S.</given-names></name><name name-style="western"><surname>Staelens</surname><given-names>S.</given-names></name></person-group> (<year>2017</year>). <article-title>A simulation study on the impact of the blood flow-dependent component in [18F]AV45 SUVR in Alzheimer's disease</article-title>. <source>PLoS One</source><volume>12</volume>:<fpage>e0189155</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0189155</pub-id>, PMID: <pub-id pub-id-type="pmid">29211812</pub-id><pub-id pub-id-type="pmcid">PMC5718604</pub-id></mixed-citation></ref><ref id="ref58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ozsahin</surname><given-names>I.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hojjati</surname><given-names>S. H.</given-names></name><name name-style="western"><surname>Tanzi</surname><given-names>E.</given-names></name><etal/></person-group>. (<year>2025</year>). <article-title>Divergent neurodegeneration associations with choroid plexus volume and degree of calcification in cognitively normal APOE &#949;4 carriers and non-carriers</article-title>. <source>Sci. Rep.</source><volume>15</volume>:<fpage>12818</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-025-97409-1</pub-id>, PMID: <pub-id pub-id-type="pmid">40229453</pub-id><pub-id pub-id-type="pmcid">PMC11997051</pub-id></mixed-citation></ref><ref id="ref59"><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Patterson</surname><given-names>C.</given-names></name></person-group> (ed.). (<year>2018</year>). World Alzheimer Report 2018-The State of the Art of Dementia Research: New Frontiers. Alzheimer&#8217;s Disease International, 1-48. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.alz.co.uk/news/world-alzheimer-report-2018-state-of-art-of-dementia-research-new-frontiers" ext-link-type="uri">https://www.alz.co.uk/news/world-alzheimer-report-2018-state-of-art-of-dementia-research-new-frontiers</ext-link></mixed-citation></ref><ref id="ref60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peter-Derex</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yammine</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bastuji</surname><given-names>H.</given-names></name><name name-style="western"><surname>Croisile</surname><given-names>B.</given-names></name></person-group> (<year>2015</year>). <article-title>Sleep and Alzheimer's disease</article-title>. <source>Sleep Med. Rev.</source><volume>19</volume>, <fpage>29</fpage>&#8211;<lpage>38</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.smrv.2014.03.007</pub-id>, PMID: <pub-id pub-id-type="pmid">24846773</pub-id></mixed-citation></ref><ref id="ref61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poirier</surname><given-names>J.</given-names></name><name name-style="western"><surname>Davignon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bouthillier</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kogan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bertrand</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gauthier</surname><given-names>S.</given-names></name></person-group> (<year>1993</year>). <article-title>Apolipoprotein E polymorphism and Alzheimer's disease</article-title>. <source>Lancet</source><volume>342</volume>, <fpage>697</fpage>&#8211;<lpage>699</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0140-6736(93)91705-Q</pub-id>, PMID: <pub-id pub-id-type="pmid">8103819</pub-id></mixed-citation></ref><ref id="ref62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scheltens</surname><given-names>P.</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name><name name-style="western"><surname>Breteler</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>de Strooper</surname><given-names>B.</given-names></name><name name-style="western"><surname>Frisoni</surname><given-names>G. B.</given-names></name><name name-style="western"><surname>Salloway</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Alzheimer's disease</article-title>. <source>Lancet</source><volume>388</volume>, <fpage>505</fpage>&#8211;<lpage>517</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(15)01124-1</pub-id>, PMID: <pub-id pub-id-type="pmid">26921134</pub-id></mixed-citation></ref><ref id="ref63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scheltens</surname><given-names>P.</given-names></name><name name-style="western"><surname>De Strooper</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kivipelto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Holstege</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ch&#233;telat</surname><given-names>G.</given-names></name><name name-style="western"><surname>Teunissen</surname><given-names>C. E.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Alzheimer's disease</article-title>. <source>Lancet</source><volume>397</volume>, <fpage>1577</fpage>&#8211;<lpage>1590</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(20)32205-4</pub-id>, PMID: <pub-id pub-id-type="pmid">33667416</pub-id><pub-id pub-id-type="pmcid">PMC8354300</pub-id></mixed-citation></ref><ref id="ref64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schubert</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Veronese</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marchitelli</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bodini</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tonietto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stankoff</surname><given-names>B.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Dynamic <sup>11</sup>C-PiB PET shows cerebrospinal fluid flow alterations in Alzheimer disease and multiple sclerosis</article-title>. <source>J. Nucl. Med.</source><volume>60</volume>, <fpage>1452</fpage>&#8211;<lpage>1460</lpage>. doi: <pub-id pub-id-type="doi">10.2967/jnumed.118.223834</pub-id>, PMID: <pub-id pub-id-type="pmid">30850505</pub-id><pub-id pub-id-type="pmcid">PMC6785797</pub-id></mixed-citation></ref><ref id="ref65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwarz</surname><given-names>C. G.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>D. T.</given-names></name><name name-style="western"><surname>Gunter</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Lowe</surname><given-names>V. J.</given-names></name><name name-style="western"><surname>Vemuri</surname><given-names>P.</given-names></name><name name-style="western"><surname>Senjem</surname><given-names>M. L.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Contributions of imprecision in PET-MRI rigid registration to imprecision in amyloid PET SUVR measurements</article-title>. <source>Hum. Brain Mapp.</source><volume>38</volume>, <fpage>3323</fpage>&#8211;<lpage>3336</lpage>. doi: <pub-id pub-id-type="doi">10.1002/hbm.23622</pub-id>, PMID: <pub-id pub-id-type="pmid">28432784</pub-id><pub-id pub-id-type="pmcid">PMC5518286</pub-id></mixed-citation></ref><ref id="ref66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Serrano-Pozo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Das</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hyman</surname><given-names>B. T.</given-names></name></person-group> (<year>2021</year>). <article-title>APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches</article-title>. <source>Lancet Neurol.</source><volume>20</volume>, <fpage>68</fpage>&#8211;<lpage>80</lpage>. doi: <pub-id pub-id-type="doi">10.1016/s1474-4422(20)30412-9</pub-id><pub-id pub-id-type="pmid">33340485</pub-id><pub-id pub-id-type="pmcid">PMC8096522</pub-id></mixed-citation></ref><ref id="ref67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shokouhi</surname><given-names>S.</given-names></name></person-group> (<year>2019</year>). <article-title>Associations of informant-based sleep reports with Alzheimer's disease pathologies</article-title>. <source>Clin. Interv. Aging</source><volume>14</volume>, <fpage>1631</fpage>&#8211;<lpage>1642</lpage>. doi: <pub-id pub-id-type="doi">10.2147/cia.S215208</pub-id>, PMID: <pub-id pub-id-type="pmid">31571843</pub-id><pub-id pub-id-type="pmcid">PMC6750709</pub-id></mixed-citation></ref><ref id="ref68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shokri-Kojori</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.-J.</given-names></name><name name-style="western"><surname>Wiers</surname><given-names>C. E.</given-names></name><name name-style="western"><surname>Demiral</surname><given-names>S. B.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S. W.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Amyloid accumulation in the human brain after one night of sleep deprivation</article-title>. <source>Proc. Natl. Acad. Sci.</source><volume>115</volume>, <fpage>4483</fpage>&#8211;<lpage>4488</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1721694115</pub-id>, PMID: <pub-id pub-id-type="pmid">29632177</pub-id><pub-id pub-id-type="pmcid">PMC5924922</pub-id></mixed-citation></ref><ref id="ref69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Small</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Perera</surname><given-names>G. M.</given-names></name><name name-style="western"><surname>DeLaPaz</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mayeux</surname><given-names>R.</given-names></name><name name-style="western"><surname>Stern</surname><given-names>Y.</given-names></name></person-group> (<year>1999</year>). <article-title>Differential regional dysfunction of the hippocampal formation among elderly with memory decline and Alzheimer's disease</article-title>. <source>Ann. Neurol.</source><volume>45</volume>, <fpage>466</fpage>&#8211;<lpage>472</lpage>. doi: <pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1531-8249(199904)45:4&amp;#x0003c;466::AID-ANA8&amp;#x0003e;3.0.CO;2-Q</pub-id>, PMID: <pub-id pub-id-type="pmid">10211471</pub-id></mixed-citation></ref><ref id="ref70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spira</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>An</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>M. N.</given-names></name><name name-style="western"><surname>Simonsick</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Ferrucci</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>APOE genotype and nonrespiratory sleep parameters in cognitively intact older adults</article-title>. <source>Sleep</source><volume>40</volume>:<fpage>76</fpage>. doi: <pub-id pub-id-type="doi">10.1093/sleep/zsx076</pub-id>, PMID: <pub-id pub-id-type="pmid">28482100</pub-id><pub-id pub-id-type="pmcid">PMC5804995</pub-id></mixed-citation></ref><ref id="ref71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spira</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>Gamaldo</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>An</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>M. N.</given-names></name><name name-style="western"><surname>Simonsick</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Bilgel</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Self-reported sleep and &#946;-amyloid deposition in community-dwelling older adults</article-title>. <source>JAMA Neurol.</source><volume>70</volume>, <fpage>1537</fpage>&#8211;<lpage>1543</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jamaneurol.2013.4258</pub-id>, PMID: <pub-id pub-id-type="pmid">24145859</pub-id><pub-id pub-id-type="pmcid">PMC3918480</pub-id></mixed-citation></ref><ref id="ref72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spira</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>Yager</surname><given-names>C.</given-names></name><name name-style="western"><surname>Brandt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>G. S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mathur</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Objectively measured sleep and &#946;-amyloid burden in older adults: a pilot study</article-title>. <source>SAGE Open Med.</source><volume>2</volume>:<fpage>6520</fpage>. doi: <pub-id pub-id-type="doi">10.1177/2050312114546520</pub-id>, PMID: <pub-id pub-id-type="pmid">25621174</pub-id><pub-id pub-id-type="pmcid">PMC4304392</pub-id></mixed-citation></ref><ref id="ref73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sprecher</surname><given-names>K. E.</given-names></name><name name-style="western"><surname>Bendlin</surname><given-names>B. B.</given-names></name><name name-style="western"><surname>Racine</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Okonkwo</surname><given-names>O. C.</given-names></name><name name-style="western"><surname>Christian</surname><given-names>B. T.</given-names></name><name name-style="western"><surname>Koscik</surname><given-names>R. L.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Amyloid burden is associated with self-reported sleep in nondemented late middle-aged adults</article-title>. <source>Neurobiol. Aging</source><volume>36</volume>, <fpage>2568</fpage>&#8211;<lpage>2576</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2015.05.004</pub-id>, PMID: <pub-id pub-id-type="pmid">26059712</pub-id><pub-id pub-id-type="pmcid">PMC4523445</pub-id></mixed-citation></ref><ref id="ref74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thambisetty</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tripaldi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Riddoch-Contreras</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hye</surname><given-names>A.</given-names></name><name name-style="western"><surname>An</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>Proteome-based plasma markers of brain amyloid-&#946; deposition in non-demented older individuals</article-title>. <source>J Alzheimer's Dis</source><volume>22</volume>, <fpage>1099</fpage>&#8211;<lpage>1109</lpage>. doi: <pub-id pub-id-type="doi">10.3233/JAD-2010-101350</pub-id>, PMID: <pub-id pub-id-type="pmid">20930274</pub-id><pub-id pub-id-type="pmcid">PMC3125970</pub-id></mixed-citation></ref><ref id="ref75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Villette</surname><given-names>V.</given-names></name><name name-style="western"><surname>Poindessous-Jazat</surname><given-names>F.</given-names></name><name name-style="western"><surname>Simon</surname><given-names>A.</given-names></name><name name-style="western"><surname>L&#233;na</surname><given-names>C.</given-names></name><name name-style="western"><surname>Roullot</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bellessort</surname><given-names>B.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>Decreased rhythmic GABAergic septal activity and memory-associated theta oscillations after hippocampal amyloid-beta pathology in the rat</article-title>. <source>J. Neurosci.</source><volume>30</volume>, <fpage>10991</fpage>&#8211;<lpage>11003</lpage>. doi: <pub-id pub-id-type="doi">10.1523/JNEUROSCI.6284-09.2010</pub-id>, PMID: <pub-id pub-id-type="pmid">20720106</pub-id><pub-id pub-id-type="pmcid">PMC6633464</pub-id></mixed-citation></ref><ref id="ref76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Holtzman</surname><given-names>D. M.</given-names></name></person-group> (<year>2020</year>). <article-title>Bidirectional relationship between sleep and Alzheimer&#8217;s disease: role of amyloid, tau, and other factors</article-title>. <source>Neuropsychopharmacology</source><volume>45</volume>, <fpage>104</fpage>&#8211;<lpage>120</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41386-019-0478-5</pub-id>, PMID: <pub-id pub-id-type="pmid">31408876</pub-id><pub-id pub-id-type="pmcid">PMC6879647</pub-id></mixed-citation></ref><ref id="ref77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weise</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kuang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Savage</surname><given-names>C. R.</given-names></name><name name-style="western"><surname>Reiman</surname><given-names>E. M.</given-names></name></person-group> (<year>2018</year>). <article-title>Left lateralized cerebral glucose metabolism declines in amyloid-&#946; positive persons with mild cognitive impairment</article-title>. <source>Neuroimage Clin.</source><volume>20</volume>, <fpage>286</fpage>&#8211;<lpage>296</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.nicl.2018.07.016</pub-id>, PMID: <pub-id pub-id-type="pmid">30101060</pub-id><pub-id pub-id-type="pmcid">PMC6084012</pub-id></mixed-citation></ref><ref id="ref78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weldemichael</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Grossberg</surname><given-names>G. T.</given-names></name></person-group> (<year>2010</year>). <article-title>Circadian rhythm disturbances in patients with Alzheimer's disease: a review</article-title>. <source>Int. J. Alzheimers Dis.</source><volume>2010</volume>:<fpage>716453</fpage>. doi: <pub-id pub-id-type="doi">10.4061/2010/716453</pub-id>, PMID: <pub-id pub-id-type="pmid">20862344</pub-id><pub-id pub-id-type="pmcid">PMC2939436</pub-id></mixed-citation></ref><ref id="ref79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winer</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Deters</surname><given-names>K. D.</given-names></name><name name-style="western"><surname>Kennedy</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Goldstein-Piekarski</surname><given-names>A.</given-names></name><name name-style="western"><surname>Poston</surname><given-names>K. L.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Association of Short and Long Sleep Duration with Amyloid-&#946; Burden and cognition in aging</article-title>. <source>JAMA Neurol.</source><volume>78</volume>, <fpage>1187</fpage>&#8211;<lpage>1196</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jamaneurol.2021.2876</pub-id>, PMID: <pub-id pub-id-type="pmid">34459862</pub-id><pub-id pub-id-type="pmcid">PMC8406215</pub-id></mixed-citation></ref><ref id="ref80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winer</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Mander</surname><given-names>B. A.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Jagust</surname><given-names>W. J.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Sleep disturbance forecasts &#946;-amyloid accumulation across subsequent years</article-title>. <source>Curr. Biol.</source><volume>30</volume>, <fpage>4291</fpage>&#8211;<lpage>4298.e3</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cub.2020.08.017</pub-id>, PMID: <pub-id pub-id-type="pmid">32888482</pub-id><pub-id pub-id-type="pmcid">PMC7642104</pub-id></mixed-citation></ref><ref id="ref81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Thiyagarajan</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Sleep drives metabolite clearance from the adult brain</article-title>. <source>Science (New York, N.Y.)</source><volume>342</volume>, <fpage>373</fpage>&#8211;<lpage>377</lpage>. doi: <pub-id pub-id-type="doi">10.1126/science.1241224</pub-id>, PMID: <pub-id pub-id-type="pmid">24136970</pub-id><pub-id pub-id-type="pmcid">PMC3880190</pub-id></mixed-citation></ref><ref id="ref82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yaffe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Laffan</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Redline</surname><given-names>S.</given-names></name><name name-style="western"><surname>Spira</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>Ensrud</surname><given-names>K. E.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women</article-title>. <source>JAMA</source><volume>306</volume>, <fpage>613</fpage>&#8211;<lpage>619</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jama.2011.1115</pub-id>, PMID: <pub-id pub-id-type="pmid">21828324</pub-id><pub-id pub-id-type="pmcid">PMC3600944</pub-id></mixed-citation></ref><ref id="ref83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamazaki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>N.</given-names></name><name name-style="western"><surname>Caulfield</surname><given-names>T. R.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C. C.</given-names></name><name name-style="western"><surname>Bu</surname><given-names>G.</given-names></name></person-group> (<year>2019</year>). <article-title>Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies</article-title>. <source>Nat. Rev. Neurol.</source><volume>15</volume>, <fpage>501</fpage>&#8211;<lpage>518</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41582-019-0228-7</pub-id>, PMID: <pub-id pub-id-type="pmid">31367008</pub-id><pub-id pub-id-type="pmcid">PMC7055192</pub-id></mixed-citation></ref><ref id="ref84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>Z. J.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D. F.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Y. G.</given-names></name></person-group> (<year>2025</year>). <article-title>Early transcriptional and cellular abnormalities in choroid plexus of a mouse model of Alzheimer's disease</article-title>. <source>Mol. Neurodegener.</source><volume>20</volume>:<fpage>62</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13024-025-00853-w</pub-id>, PMID: <pub-id pub-id-type="pmid">40450296</pub-id><pub-id pub-id-type="pmcid">PMC12125878</pub-id></mixed-citation></ref><ref id="ref85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>S.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>M&#252;llendorff</surname><given-names>K.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Giedt</surname><given-names>G.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>E. C.</given-names></name><etal/></person-group>. (<year>2005</year>). <article-title>Apolipoprotein (apo) E4 enhances amyloid &#946; peptide production in cultured neuronal cells: ApoE structure as a potential therapeutic target</article-title>. <source>Proc. Natl. Acad. Sci.</source><volume>102</volume>, <fpage>18700</fpage>&#8211;<lpage>18705</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.0508693102</pub-id>, PMID: <pub-id pub-id-type="pmid">16344478</pub-id><pub-id pub-id-type="pmcid">PMC1311738</pub-id></mixed-citation></ref><ref id="ref86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoon</surname><given-names>H. J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>B. S.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>G. H.</given-names></name><name name-style="western"><surname>Park</surname><given-names>H. K.</given-names></name><name name-style="western"><surname>Chun</surname><given-names>M. Y.</given-names></name></person-group> (<year>2021</year>). <article-title>Asymmetric amyloid deposition as an early sign of progression in mild cognitive impairment due to Alzheimer disease</article-title>. <source>Clin. Nucl. Med.</source><volume>46</volume>, <fpage>527</fpage>&#8211;<lpage>531</lpage>. doi: <pub-id pub-id-type="doi">10.1097/RLU.0000000000003662</pub-id>, PMID: <pub-id pub-id-type="pmid">33883492</pub-id></mixed-citation></ref><ref id="ref87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoon</surname><given-names>S. H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H. K.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Chun</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Sohn</surname><given-names>Y. H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>P. H.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Association of Sleep Disturbances with Brain Amyloid and tau Burden, cortical atrophy, and cognitive dysfunction across the AD continuum</article-title>. <source>Neurology</source><volume>101</volume>, <fpage>e2162</fpage>&#8211;<lpage>e2171</lpage>. doi: <pub-id pub-id-type="doi">10.1212/WNL.0000000000207917</pub-id>, PMID: <pub-id pub-id-type="pmid">37813585</pub-id><pub-id pub-id-type="pmcid">PMC10663023</pub-id></mixed-citation></ref><ref id="ref88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Rong</surname><given-names>N.</given-names></name><name name-style="western"><surname>Li</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Asymmetrical patterns of &#946;-amyloid deposition and cognitive changes in Alzheimer&#8217;s disease: the SILCODE study</article-title>. <source>Cereb. Cortex</source><volume>34</volume>:<fpage>485</fpage>. doi: <pub-id pub-id-type="doi">10.1093/cercor/bhae485</pub-id>, PMID: <pub-id pub-id-type="pmid">39710611</pub-id></mixed-citation></ref><ref id="ref89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zasadny</surname><given-names>K. R.</given-names></name><name name-style="western"><surname>Wahl</surname><given-names>R. L.</given-names></name></person-group> (<year>1993</year>). <article-title>Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction</article-title>. <source>Radiology</source><volume>189</volume>, <fpage>847</fpage>&#8211;<lpage>850</lpage>. doi: <pub-id pub-id-type="doi">10.1148/radiology.189.3.8234714</pub-id>, PMID: <pub-id pub-id-type="pmid">8234714</pub-id></mixed-citation></ref><ref id="ref90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mak</surname><given-names>E.</given-names></name><name name-style="western"><surname>Reilhac</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shim</surname><given-names>H. Y.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>K. K.</given-names></name><name name-style="western"><surname>Ong</surname><given-names>M. Q. W.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Longitudinal trajectory of amyloid-related hippocampal subfield atrophy in nondemented elderly</article-title>. <source>Hum. Brain Mapp.</source><volume>41</volume>, <fpage>2037</fpage>&#8211;<lpage>2047</lpage>. doi: <pub-id pub-id-type="doi">10.1002/hbm.24928</pub-id>, PMID: <pub-id pub-id-type="pmid">31944479</pub-id><pub-id pub-id-type="pmcid">PMC7267893</pub-id></mixed-citation></ref><ref id="ref91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Okhravi</surname><given-names>H. R.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Sleep in Alzheimer's disease: a systematic review and meta-analysis of polysomnographic findings</article-title>. <source>Transl. Psychiatry</source><volume>12</volume>:<fpage>136</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41398-022-01897-y</pub-id>, PMID: <pub-id pub-id-type="pmid">35365609</pub-id><pub-id pub-id-type="pmcid">PMC8976015</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Neurol</journal-id><journal-id journal-id-type="iso-abbrev">BMC Neurol</journal-id><journal-id journal-id-type="pmc-domain-id">48</journal-id><journal-id journal-id-type="pmc-domain">bmcneul</journal-id><journal-title-group><journal-title>BMC Neurology</journal-title></journal-title-group><issn pub-type="epub">1471-2377</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12482330</article-id><article-id pub-id-type="pmcid-ver">PMC12482330.1</article-id><article-id pub-id-type="pmcaid">12482330</article-id><article-id pub-id-type="pmcaiid">12482330</article-id><article-id pub-id-type="pmid">41023633</article-id><article-id pub-id-type="doi">10.1186/s12883-025-04404-0</article-id><article-id pub-id-type="publisher-id">4404</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Systematic Review</subject></subj-group></article-categories><title-group><article-title>Convolutional neural network models of structural MRI for discriminating categories of cognitive impairment: a systematic review and meta-analysis</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Dong</surname><given-names initials="X">Xinxiu</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Li</surname><given-names initials="Y">Yang</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Hao</surname><given-names initials="J">Jianbo</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhou</surname><given-names initials="P">Pengjun</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yang</surname><given-names initials="C">Chongming</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ai</surname><given-names initials="Y">Yating</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>He</surname><given-names initials="M">Meina</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name name-style="western"><surname>Zhang</surname><given-names initials="W">Wei</given-names></name><address><email>zhangwei_hosp@163.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name name-style="western"><surname>Hu</surname><given-names initials="H">Hui</given-names></name><address><email>Zhongyi90@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02my3bx32</institution-id><institution-id institution-id-type="GRID">grid.257143.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 1772 1285</institution-id><institution>School of Nursing, </institution><institution>Hubei University of Chinese Medicine, </institution></institution-wrap>Wuhan, Hubei China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00p991c53</institution-id><institution-id institution-id-type="GRID">grid.33199.31</institution-id><institution-id institution-id-type="ISNI">0000 0004 0368 7223</institution-id><institution>Department of Radiology, Union Hospital, Tongji Medical College, </institution><institution>Huazhong University of Science and Technology, </institution></institution-wrap>Wuhan, Hubei China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00xabh388</institution-id><institution-id institution-id-type="GRID">grid.477392.c</institution-id><institution>Department of Tuina and Rehabilitation Medicine, </institution><institution>Hubei Provincial Hospital of Traditional Chinese Medicine, </institution></institution-wrap>Wuhan, 430061 China </aff><aff id="Aff4"><label>4</label>Hubei Shizhen Laboratory, Wuhan, 430065 China </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/047rhhm47</institution-id><institution-id institution-id-type="GRID">grid.253294.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9115</institution-id><institution>Research Support Center, College of Family, Home, and Social Sciences, </institution><institution>Brigham Young University, </institution></institution-wrap>Provo, UT USA </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/041c9x778</institution-id><institution-id institution-id-type="GRID">grid.411854.d</institution-id><institution-id institution-id-type="ISNI">0000 0001 0709 0000</institution-id><institution>Laboratory Center, School of Medicine, </institution><institution>Jianghan University, </institution></institution-wrap>Wuhan, Hubei China </aff></contrib-group><pub-date pub-type="epub"><day>29</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>25</volume><issue-id pub-id-type="pmc-issue-id">478179</issue-id><elocation-id>400</elocation-id><history><date date-type="received"><day>13</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>14</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>29</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-01 10:25:36.583"><day>01</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="12883_2025_Article_4404.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Alzheimer's disease (AD) and mild cognitive impairment (MCI) pose significant challenges to public health and underscore the need for accurate and early diagnostic tools. Structural magnetic resonance imaging (sMRI) combined with advanced analytical techniques like convolutional neural networks (CNNs) seemed to offer a promising avenue for the diagnosis of these conditions. This systematic review and meta-analysis aimed to evaluate the diagnostic performance of CNN algorithms applied to sMRI data in differentiating between AD, MCI, and normal cognition (NC).</p></sec><sec><title>Methods</title><p id="Par2">Following the PRISMA-DTA guidelines, a comprehensive literature search was carried out in PubMed and Web of Science databases for studies published between 2018 and 2024. Studies were included if they employed CNNs for the diagnostic classification of sMRI data from participants with AD, MCI, or NC. The methodological quality of the included studies was assessed using the QUADAS-2 and METRICS tools. Data extraction and statistical analysis were performed to calculate pooled diagnostic accuracy metrics.</p></sec><sec><title>Results</title><p id="Par3">A total of 21 studies were included in the study, comprising 16,139 participants in the analysis. The pooled sensitivity and specificity of CNN algorithms for differentiating AD from NC were 0.92 and 0.91, respectively. For distinguishing MCI from NC, the pooled sensitivity and specificity were 0.74 and 0.79, respectively. The algorithms also showed a moderate ability to differentiate AD from MCI, with a pooled sensitivity and specificity of 0.73 and 0.79, respectively. In the pMCI versus sMCI classification, a pooled sensitivity was 0.69 and a specificity was 0.81. Heterogeneity across studies was significant, as indicated by meta-regression results.</p></sec><sec><title>Conclusion</title><p id="Par4">CNN algorithms demonstrated promising diagnostic performance in differentiating AD, MCI, and NC using sMRI data. The highest accuracy was observed in distinguishing AD from NC and the lowest accuracy observed in distinguishing pMCI from sMCI. These findings suggest that CNN-based radiomics has the potential to serve as a valuable tool in the diagnostic armamentarium for neurodegenerative diseases. However, the heterogeneity among studies indicates a need for further methodological refinement and validation.</p></sec><sec><title>Trial registration</title><p id="Par5">This systematic review was registered in PROSPERO (Registration ID: CRD42022295408).</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12883-025-04404-0.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Alzheimer&#8217;s disease</kwd><kwd>Mild cognitive impairment</kwd><kwd>Convolutional neural networks</kwd><kwd>Structural magnetic resonance imaging</kwd><kwd>Radiomics</kwd><kwd>Diagnostic accuracy</kwd></kwd-group><funding-group><award-group><funding-source><institution>Science and Technology Research Project of Hubei Provincial Department of Education</institution></funding-source><award-id>B2022285</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par6">Alzheimer's disease (AD) is the most prevalent form of dementia, representing 60% to 80% of all cases [<xref ref-type="bibr" rid="CR1">1</xref>]. The global dementia patient population currently exceeds 55 million, with an anticipated increase to 78 million by 2030 [<xref ref-type="bibr" rid="CR2">2</xref>]. This substantial prevalence imposes significant societal, familial, and caregiving burdens. Mild cognitive impairment (MCI), a cognitive state intermediate between the norms of aging and the criteria for dementia [<xref ref-type="bibr" rid="CR3">3</xref>], is considered a prodromal phase to AD and retains some capacity for reversal. Timely and precise diagnostic capabilities for AD and MCI are essential for initiating therapeutic interventions, optimizing patient care, and potentially mitigating disease progression.</p><p id="Par7">The National Institute on Aging and Alzheimer's Association (NIA-AA) criteria have incorporated the AT(N) framework, which acknowledges neuroimaging markers as integral to the biological diagnosis of AD [<xref ref-type="bibr" rid="CR4">4</xref>]. Within in this framework, &#8220;N&#8221; refers to biomarkers of neurodegeneration, notably including brain atrophy visualized by magnetic resonance imaging (MRI) and decreased metabolism indicated by fluorodeoxyglucose positron emission tomography (FDG-PET). This integration underscores the pivotal role of imaging biomarkers in improving the accuracy of early AD detection, thereby facilitating prompt and targeted therapeutic interventions.</p><p id="Par8">Structural MRI (sMRI) is a prevalent diagnostic tool for AD and MCI, attributed to its capability to delineate the brain atrophy characteristic of these neurocognitive disorders [<xref ref-type="bibr" rid="CR5">5</xref>]. The modality is particularly effective in visualizing medial temporal lobe atrophy (MTA), a signature feature of AD [<xref ref-type="bibr" rid="CR6">6</xref>], thereby establishing itself as a preferred technique for both diagnosis and differential diagnosis. In the prodromal phase of MCI, sMRI is instrumental in identifying regional alterations, such as hippocampal and entorhinal cortex atrophy, which serve as precursory indicators of neurodegenerative processes [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Given it is non-invasive and radiation-free, sMRI presents a trove of potential radiomic biomarkers, pivotal for enabling precise clinical diagnosis and tailored therapeutic strategies for AD and MCI. Nonetheless, the intricate data yielded by sMRI necessitates the employment of advanced analytical methodologies. These methodologies must adeptly extract and elucidate subtle pathological signatures to optimize the diagnostic utility of sMRI.</p><p id="Par9">Radiomics, an emerging interdisciplinary field combining medical imaging and data science, offers an innovative approach for the quantitative analysis of high-dimensional imaging data [<xref ref-type="bibr" rid="CR9">9</xref>]. It involves the extraction and analysis of quantitative image features to uncover patterns indicative of pathological alterations [<xref ref-type="bibr" rid="CR10">10</xref>]. Within the conventional paradigm of radiomics, the process of feature extraction is typically contingent upon manual crafting and selection of attributes like morphological characteristics, textural properties, and intensity distributions [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. This approach entails specialized expertise and is susceptible to subjective biases. The amalgamation of radiomics with deep learning algorithms furnishes a robust analytical instrument for medical imaging, facilitating the automated extraction of intricate features from imaging datasets [<xref ref-type="bibr" rid="CR13">13</xref>]. This synergy is instrumental for improving the precision of diagnostics and realizing personalized therapeutic regimens.</p><p id="Par10">Among deep learning approaches, Convolutional Neural Networks (CNNs) is particularly well-suited for sMRI analysis and has demonstrated distinct advantages over traditional machine learning models in deciphering complex neuroimaging patterns [<xref ref-type="bibr" rid="CR14">14</xref>]. Unlike support vector machines (SVMs) or decision trees that rely on handcrafted features (e.g., volumetric measures, cortical thickness) derived from prior knowledge, CNNs autonomously learn hierarchical discriminative patterns (e.g., texture variations, subtle atrophy gradients) directly from raw sMRI pixels [<xref ref-type="bibr" rid="CR15">15</xref>]. This end-to-end feature learning mitigates bias from incomplete manual feature engineering and captures nuanced biomarkers, such as microstructural changes in the entorhinal cortex that may be missed by conventional metrics [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par11">CNNs also preserve critical spatial hierarchies through convolutional layers and retain relationships between adjacent brain regions (e.g., the hippocampus and parahippocampal gyrus) that are vital for interpreting sMRI data, where pathological changes manifest as spatially contiguous patterns [<xref ref-type="bibr" rid="CR17">17</xref>]. Traditional models flatten data into vectors, lose this spatial context, and thus limit their abilities to detect early multifocal atrophy. Additionally, CNNs efficiently scale sMRI data to high-dimensional (typically 180&#8201;&#215;&#8201;210&#8201;&#215;&#8201;180 voxels) via pooling layers to reduce dimensionality without sacrificing key information, thus avoid the curse-of-dimensionality that plague traditional methods [<xref ref-type="bibr" rid="CR18">18</xref>]. Their robustness to imaging variability, such as scanner-induced intensity differences, further enhances their utility in multi-center studies, in which sMRI protocols often vary. These capabilities make CNNs uniquely suited to harness the full spatial richness of sMRI to detect early stage AD and MCI, and outperform traditional models for tasks that require sensitivity to subtle morphological changes [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p id="Par12">Despite the burgeoning research in applying CNN-based radiomics in neurodegenerative diseases, a systematic synthesis of these findings remains a lacuna. This systematic review and meta-analysis aim to address this gap by comprehensively evaluating of the diagnostic accuracy of CNN algorithms in distinguishing AD and MCI from normal cognition (NC) with sMRI data. To ensures a rigorous and transparent methodology, this review adhered to the Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies (PRISMA-DTA) guidelines [<xref ref-type="bibr" rid="CR20">20</xref>]. Findings of this review are expected to enhance clinical practice of CNN-based radiomics for AD and MCI diagnoses. It also aimed to identify areas for future research and methodological improvements to optimize CNN algorithms for precise and timely diagnostic capabilities of neurodegenerative diseases.</p></sec><sec id="Sec2"><title>Materials and methods</title><p id="Par13">The PRISMA-DTA statement was followed in this study [<xref ref-type="bibr" rid="CR20">20</xref>].</p><sec id="Sec3"><title>Protocol and registration</title><p id="Par14">This study was registered on PROSPERO with the registration number CRD42022295408.</p></sec><sec id="Sec4"><title>Search and selection strategy</title><p id="Par15">The PIS principle was followed to identify the studies for the meta-analyses [<xref ref-type="bibr" rid="CR21">21</xref>]. These studies included patients with Alzheimer's disease or mild cognitive impairment, machine learning algorithms used in data processing, and a diagnostic test accuracy (DTA) study. Two authors (YA &amp; MH) of this study independently searched the PubMed and Web of Science electronic databases in June 2024, without any language restrictions or methodical search filters. Information sources and detailed strategies in the search are presented in Supplementary Table&#160;1.</p><p id="Par16">All retrieved publications were imported into EndNote X9, where duplicates were first removed using the software&#8217;s automated &#8220;Find Duplicates&#8221;function followed by manual confirmation. Duplicated were defined as publications with identical titles, author sets, and publication years across databases. Two reviewers (YA and MH) then independently screened titles and abstracts to exclude irrelevant records that failed to meet the PIS criteria with an inclusive policy for uncertain cases. Full texts of potentially relevant studies were assessed independently by the same two reviewers, with disagreements resolved first through discussion. If consensus remained elusive, a third senior reviewer (HH) made the final adjudication.</p></sec><sec id="Sec5"><title>Criteria for study selection</title><sec id="Sec6"><title>Inclusion criteria</title><p id="Par17">Publications of studies were included to meet the following criteria: (a) participants who were clinically diagnosed with AD or MCI. Given that most study participants were drawn from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, the inclusion criteria (Supplementary Table&#160;2) for AD and MCI in this systematic review conformed to those of the ADNI database [<xref ref-type="bibr" rid="CR22">22</xref>]. The specific inclusion criteria are presented in Supplementary Table&#160;2; (b) the use of CNNs in deep learning models; (c) report of the performance for diagnosis; and (d) diagnosis based on sMRI neuroimaging data.</p></sec><sec id="Sec7"><title>Exclusion criteria</title><p id="Par18">The following criteria were adopted to exclude studies for this meta-analysis: (a) review articles, (b) case reports, (c) case series, (d) articles not in English, (e) animal studies, and (f) articles using imaging methods other than structural MRI (sMRI), such as functional MRI (fMRI), positron emission tomography (PET), diffusion tensor imaging (DTI), electroencephalography (EEG), or magnetoencephalography (MEG).</p></sec></sec><sec id="Sec8"><title>Data extraction</title><p id="Par19">A customized data extraction form was designed for two authors (PZ and YL) to extract data independently. They contacted the original study authors to obtain missing information in their reports. The following information were extracted from eligible studies: identity number (ID), first author, country, year of publication, data sources, participants, gender, mean age, image weighting, pre-processing method, feature type, classification method, validation method, classification task, model performance, true positives (TP), false negatives (FN), true negatives (TN), and false positives (FP).</p></sec><sec id="Sec9"><title>Quality assessment</title><p id="Par20">The quality of the studies was rigorously assessed by the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) [<xref ref-type="bibr" rid="CR23">23</xref>] and the Methodological Radiomics Quality Score (METRICS) [<xref ref-type="bibr" rid="CR24">24</xref>].</p><p id="Par21">To augment the precision and relevance of the evaluation, the QUADAS-2 tool was customized through extensive deliberating within the research team and incorporating feedback from domain experts. A new signaling question was added to reflect the critical role of operator consistency in methodological rigor, namely,"Was the index test performed by a single operator or interpreted by consensus in a joint session?"Studies with multiple operators or inconsistent consensus could risk bias from various practices or judgments and thus weaken the result reliability. This question captures inter-operator variability and consensus biases to ensure quality assessment, including consistency risks across test implementation. The scoring of study quality followed a three-tier system:"Yes"for a single standardized pipeline without human intervention,"No"for multiple operators/consensus sessions lacking pre-specified criteria, and"Unclear"for unreported information.</p><p id="Par22">The&#160;Methodological Radiomics Quality Score (METRICS) was developed by the European Society of Medical Imaging Informatics (EuSoMII) and published in 2024 [<xref ref-type="bibr" rid="CR24">24</xref>]. It represents a state-of-the-art quality assessment framework tailored to radiomics and deep learning research in medical imaging. The METRICS tool systematically evaluates the quality of radiomics and machine learning&#8212;related studies through 30 items across 9 distinct categories: Study design (item 1&#8211;3), Imaging data (item 4&#8211;7), Segmentation (item 8&#8211;10), Image processing and feature extraction (item 11&#8211;13), Feature processing (item 14&#8211;17), Preparation for modeling (item 18&#8211;19), Metrics and comparison (item 20&#8211;25), Testing (item 26&#8211;27), and Open science (item 28&#8211;30). Each item is assigned a specific weight, with a binary scoring mechanism (1 if the item is satisfied, 0 if not). Notably, certain items are conditionally applicable in specific scenarios (e.g., when region of interest labeling is involved). The total score, calculated as a weighted sum expressed as a percentage, dictates predefined quality categories:&#8201;&#8804;&#8201;20% for &#8220;very low&#8221;, 20&#8211;40% for &#8220;low&#8221;, 40&#8211;60% for &#8220;moderate&#8221;, 60&#8211;80% for &#8220;good&#8221;, and&#8201;&#8805;&#8201;80% for &#8220;excellent&#8221;.</p><p id="Par23">The quality of the studies was assessed independently and meticulously by two researchers (MH and YA), who independently analyzed potential biases and applicability issues. Any discrepancies encountered during the review were initially addressed through comprehensive discussions. Issues that could not be resolved through discussions were adjudicated by a third researcher (DX) to ensure objectivity and consensus of the assessment.</p></sec><sec id="Sec10"><title>Statistical analysis and data synthesis</title><p id="Par24">The analysis was conducted with the following software: Stata 16.0 (Stata Corp LP, College Station, TX), MetaDiSc 1.4 (Ram&#243;n y Cajal Hospital, Madrid), and RevMan 5.3 (Cochrane Collaboration, Copenhagen). Pooled sensitivity, specificity, positive likelihood ratio (PLR), and negative likelihood ratio (NLR) were determined as aggregated metrics, which were estimated through random effect models. PLR is defined as Sensitivity/(1&#8212;Specificity), while NLR is (1&#8212;Sensitivity)/Specificity. A strong diagnostic utility is characterized by a combination of a PLR greater than 10 in conjunction with a NLR less than 0.1. In contrast, a moderate diagnostic utility is denoted by a combination where the PLR ranges between 5 and 10, paired with an NLR ranging between 0.1 and 0.2. The summary receiver operating characteristic curve (sROC) was applied to assess the aggregate predictive efficacy of various radiomics models. An AUC ranging from 0.5 to 0.7, 0.7 to 0.9, and above 0.9 signifies low, moderate, and high diagnostic accuracy, respectively [<xref ref-type="bibr" rid="CR25">25</xref>]. The variability across studies was evaluated with the Higgins inconsistency index <italic toggle="yes">I</italic><sup>2</sup>-test and Cochrane&#8217;s <italic toggle="yes">Q</italic>-test, with an <italic toggle="yes">I</italic><sup>2</sup>&#8201;&gt;&#8201;50% or a <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.1 indicating significant heterogeneity.</p><p id="Par25">To investigate the sources of heterogeneity, this study performed a systematic subgroup analysis based on a bivariate random-effects model [<xref ref-type="bibr" rid="CR26">26</xref>], which assumes that logit-transformed sensitivity (logitSe) and logit-transformed specificity (logitSp) follow a bivariate normal distribution. Heterogeneity was quantified by the between-study variances of these transformed metrics, namely Var (logitSe) and Var (logitSp). Empirical evidence indicates [<xref ref-type="bibr" rid="CR27">27</xref>] that while Var (logitSe) and Var (logitSp) have no strict theoretical upper limits, their typical range is 0.1&#8211;4.0 in practical studies. Based on this, heterogeneity was categorized into three levels: low heterogeneity (&lt;&#8201;0.5, suggesting highly generalizable results); moderate heterogeneity (0.5&#8211;1.0, implying results that require cautious interpretation in the context of study-specific characteristics); and high heterogeneity (&gt;&#8201;1.0, indicating potentially unreliable results) [<xref ref-type="bibr" rid="CR27">27</xref>].</p><p id="Par26">Publication bias was assessed using Deeks'funnel plot asymmetry test. Additionally, the Galbraith plot was used to assess the influence of outliers.</p><p id="Par27">The diagnostic performance of each subgroup was evaluated using pooled sensitivity (Sen), specificity (Spe), and diagnostic odds ratio (DOR, higher&#8201;=&#8201;more accurate) with 95% confidence intervals (CIs). Meanwhile, logit-transformed variances were computed to assess the extent of within-subgroup heterogeneity. All statistical analyses were implemented using the"<italic toggle="yes">metandi</italic>"command package.</p></sec></sec><sec id="Sec11"><title>Results</title><sec id="Sec12"><title>Study selection</title><p id="Par28">The outcomes of the selection procedure are shown in a flow chart (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). A preliminary literature search identified 844 studies. The titles and abstracts of these were evaluated to filter out duplicate (n&#8201;=&#8201;160) and irrelevant studies (n&#8201;=&#8201;639). The remaining 45 studies were scrutinized with their full texts to determine their qualification for the final inclusion. A total of 21 studies that met the inclusion criteria ultimately provided the data for the study.<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>PRISMA flowchart of study selection for meta-analysis</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="12883_2025_4404_Fig1_HTML.jpg"/></fig></p></sec><sec id="Sec13"><title>Study characteristics</title><p id="Par29">The summary of the systematic review is provided in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>. The 16,139 participants are distributed across the spectrum of AD (<italic toggle="yes">n</italic>&#8201;=&#8201;4967), MCI (<italic toggle="yes">n</italic>&#8201;=&#8201;6520), and NC (<italic toggle="yes">n</italic>&#8201;=&#8201;4,652).<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Characteristics of included studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Study &amp; Reference No</th><th align="left" rowspan="2" colspan="1">Country</th><th align="left" colspan="5" rowspan="1">Participants</th><th align="left" rowspan="2" colspan="1">Classification Task</th><th align="left" colspan="4" rowspan="1">Performance</th></tr><tr><th align="left" colspan="1" rowspan="1"><bold>AD</bold></th><th align="left" colspan="1" rowspan="1"><bold>MCI</bold></th><th align="left" colspan="1" rowspan="1"><bold>pMCI/cMCI</bold></th><th align="left" colspan="1" rowspan="1"><bold>sMCI/ncMCI</bold></th><th align="left" colspan="1" rowspan="1"><bold>NC</bold></th><th align="left" colspan="1" rowspan="1"><bold>Acc</bold></th><th align="left" colspan="1" rowspan="1"><bold>Sen</bold></th><th align="left" colspan="1" rowspan="1"><bold>Spe</bold></th><th align="left" colspan="1" rowspan="1"><bold>AUC</bold></th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Agarwal et al. (2023) [<xref ref-type="bibr" rid="CR28">28</xref>]</td><td align="left" colspan="1" rowspan="1">Spain</td><td align="left" colspan="1" rowspan="1">229</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">229</td><td align="left" colspan="1" rowspan="1">245</td><td align="left" colspan="1" rowspan="1">AD vs. sMCI</td><td align="left" colspan="1" rowspan="1">0.93</td><td align="left" colspan="1" rowspan="1">1.00</td><td align="left" colspan="1" rowspan="1">0.86</td><td align="left" colspan="1" rowspan="1">0.93</td></tr><tr><td align="left" colspan="1" rowspan="1">AlSaeed &amp; Omar (2022) [<xref ref-type="bibr" rid="CR29">29</xref>]</td><td align="left" colspan="1" rowspan="1">Saudi Arabia</td><td align="left" colspan="1" rowspan="1">427</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">314</td><td align="left" colspan="1" rowspan="1">AD vs. NC</td><td align="left" colspan="1" rowspan="1">0.99</td><td align="left" colspan="1" rowspan="1">0.98</td><td align="left" colspan="1" rowspan="1">0.99</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" rowspan="3" colspan="1">Awarayi et al. (2024) [<xref ref-type="bibr" rid="CR30">30</xref>]</td><td align="left" colspan="1" rowspan="1">Ghana</td><td align="left" colspan="1" rowspan="1">396</td><td align="left" colspan="1" rowspan="1">255</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">104</td><td align="left" colspan="1" rowspan="1">AD vs. NC</td><td align="left" colspan="1" rowspan="1">0.94</td><td align="left" colspan="1" rowspan="1">0.94</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.98</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">MCI vs. NC</td><td align="left" colspan="1" rowspan="1">0.95</td><td align="left" colspan="1" rowspan="1">0.96</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">AD vs. MCI</td><td align="left" colspan="1" rowspan="1">0.95</td><td align="left" colspan="1" rowspan="1">0.95</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" rowspan="6" colspan="1">Basaia et al. (2019) [<xref ref-type="bibr" rid="CR31">31</xref>]</td><td align="left" colspan="1" rowspan="1">Italy</td><td align="left" colspan="1" rowspan="1">294</td><td align="left" colspan="1" rowspan="1">763</td><td align="left" colspan="1" rowspan="1">253</td><td align="left" colspan="1" rowspan="1">510</td><td align="left" colspan="1" rowspan="1">352</td><td align="left" colspan="1" rowspan="1">AD vs. NC</td><td align="left" colspan="1" rowspan="1">0.98</td><td align="left" colspan="1" rowspan="1">0.98</td><td align="left" colspan="1" rowspan="1">0.98</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">124</td><td align="left" colspan="1" rowspan="1">50</td><td align="left" colspan="1" rowspan="1">27</td><td align="left" colspan="1" rowspan="1">23</td><td align="left" colspan="1" rowspan="1">55</td><td align="left" colspan="1" rowspan="1">pMCI vs. NC</td><td align="left" colspan="1" rowspan="1">0.88</td><td align="left" colspan="1" rowspan="1">0.87</td><td align="left" colspan="1" rowspan="1">0.88</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">sMCI vs. NC</td><td align="left" colspan="1" rowspan="1">0.76</td><td align="left" colspan="1" rowspan="1">0.75</td><td align="left" colspan="1" rowspan="1">0.78</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">AD vs. pMCI</td><td align="left" colspan="1" rowspan="1">0.76</td><td align="left" colspan="1" rowspan="1">0.75</td><td align="left" colspan="1" rowspan="1">0.77</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">AD vs. sMCI</td><td align="left" colspan="1" rowspan="1">0.86</td><td align="left" colspan="1" rowspan="1">0.84</td><td align="left" colspan="1" rowspan="1">0.89</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">pMCI vs. sMCI</td><td align="left" colspan="1" rowspan="1">0.75</td><td align="left" colspan="1" rowspan="1">0.76</td><td align="left" colspan="1" rowspan="1">0.74</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">Bi et al. (2021) [<xref ref-type="bibr" rid="CR32">32</xref>]</td><td align="left" colspan="1" rowspan="1">China</td><td align="left" colspan="1" rowspan="1">180</td><td align="left" colspan="1" rowspan="1">210</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">188</td><td align="left" colspan="1" rowspan="1">AD vs. NC</td><td align="left" colspan="1" rowspan="1">0.81</td><td align="left" colspan="1" rowspan="1">0.79</td><td align="left" colspan="1" rowspan="1">0.83</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">MCI vs. NC</td><td align="left" colspan="1" rowspan="1">0.63</td><td align="left" colspan="1" rowspan="1">0.53</td><td align="left" colspan="1" rowspan="1">0.71</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" rowspan="2" colspan="1">Chen et al. (2022) [<xref ref-type="bibr" rid="CR33">33</xref>]</td><td align="left" colspan="1" rowspan="1">China</td><td align="left" colspan="1" rowspan="1">326</td><td align="left" colspan="1" rowspan="1">721</td><td align="left" colspan="1" rowspan="1">242</td><td align="left" colspan="1" rowspan="1">479</td><td align="left" colspan="1" rowspan="1">413</td><td align="left" colspan="1" rowspan="1">AD vs. NC</td><td align="left" colspan="1" rowspan="1">0.91</td><td align="left" colspan="1" rowspan="1">0.89</td><td align="left" colspan="1" rowspan="1">0.91</td><td align="left" colspan="1" rowspan="1">0.95</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">pMCI vs. sMCI</td><td align="left" colspan="1" rowspan="1">0.80</td><td align="left" colspan="1" rowspan="1">0.52</td><td align="left" colspan="1" rowspan="1">0.86</td><td align="left" colspan="1" rowspan="1">0.79</td></tr><tr><td align="left" rowspan="3" colspan="1">Cui &amp; Liu (2019) [<xref ref-type="bibr" rid="CR34">34</xref>]</td><td align="left" colspan="1" rowspan="1">China</td><td align="left" colspan="1" rowspan="1">192</td><td align="left" colspan="1" rowspan="1">396</td><td align="left" colspan="1" rowspan="1">165</td><td align="left" colspan="1" rowspan="1">231</td><td align="left" colspan="1" rowspan="1">223</td><td align="left" colspan="1" rowspan="1">AD vs. NC</td><td align="left" colspan="1" rowspan="1">0.93</td><td align="left" colspan="1" rowspan="1">0.91</td><td align="left" colspan="1" rowspan="1">0.94</td><td align="left" colspan="1" rowspan="1">0.97</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">pMCI vs. sMCI</td><td align="left" colspan="1" rowspan="1">0.75</td><td align="left" colspan="1" rowspan="1">0.73</td><td align="left" colspan="1" rowspan="1">0.76</td><td align="left" colspan="1" rowspan="1">0.80</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">MCI vs. NC</td><td align="left" colspan="1" rowspan="1">0.75</td><td align="left" colspan="1" rowspan="1">0.77</td><td align="left" colspan="1" rowspan="1">0.70</td><td align="left" colspan="1" rowspan="1">0.78</td></tr><tr><td align="left" colspan="1" rowspan="1">Fan et al. (2023) [<xref ref-type="bibr" rid="CR35">35</xref>]</td><td align="left" colspan="1" rowspan="1">China</td><td align="left" colspan="1" rowspan="1">336</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">330</td><td align="left" colspan="1" rowspan="1">AD vs. NC</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.83</td><td align="left" colspan="1" rowspan="1">0.90</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" rowspan="3" colspan="1">Feng et al. (2020) [<xref ref-type="bibr" rid="CR36">36</xref>]</td><td align="left" colspan="1" rowspan="1">China</td><td align="left" colspan="1" rowspan="1">153</td><td align="left" colspan="1" rowspan="1">157</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">159</td><td align="left" colspan="1" rowspan="1">AD vs. NC</td><td align="left" colspan="1" rowspan="1">0.99</td><td align="left" colspan="1" rowspan="1">1.00</td><td align="left" colspan="1" rowspan="1">0.98</td><td align="left" colspan="1" rowspan="1">0.99</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">AD vs. MCI</td><td align="left" colspan="1" rowspan="1">0.90</td><td align="left" colspan="1" rowspan="1">0.87</td><td align="left" colspan="1" rowspan="1">0.84</td><td align="left" colspan="1" rowspan="1">0.93</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">MCI vs. NC</td><td align="left" colspan="1" rowspan="1">0.99</td><td align="left" colspan="1" rowspan="1">0.99</td><td align="left" colspan="1" rowspan="1">0.99</td><td align="left" colspan="1" rowspan="1">0.99</td></tr><tr><td align="left" rowspan="3" colspan="1">Herzog &amp; Magoulas (2022) [<xref ref-type="bibr" rid="CR37">37</xref>]</td><td align="left" colspan="1" rowspan="1">UK</td><td align="left" colspan="1" rowspan="1">50</td><td align="left" colspan="1" rowspan="1">50</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">50</td><td align="left" colspan="1" rowspan="1">AD vs. NC</td><td align="left" colspan="1" rowspan="1">0.90</td><td align="left" colspan="1" rowspan="1">0.87</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.94</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">MCI vs. NC</td><td align="left" colspan="1" rowspan="1">0.86</td><td align="left" colspan="1" rowspan="1">0.89</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.93</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">AD vs. MCI</td><td align="left" colspan="1" rowspan="1">0.80</td><td align="left" colspan="1" rowspan="1">0.79</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.88</td></tr><tr><td align="left" rowspan="3" colspan="1">Kang et al. (2021) [<xref ref-type="bibr" rid="CR38">38</xref>]</td><td align="left" colspan="1" rowspan="1">China</td><td align="left" colspan="1" rowspan="1">187</td><td align="left" colspan="1" rowspan="1">382</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">229</td><td align="left" colspan="1" rowspan="1">AD vs. NC</td><td align="left" colspan="1" rowspan="1">0.90</td><td align="left" colspan="1" rowspan="1">0.94</td><td align="left" colspan="1" rowspan="1">0.84</td><td align="left" colspan="1" rowspan="1">0.90</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">AD vs. MCI</td><td align="left" colspan="1" rowspan="1">0.77</td><td align="left" colspan="1" rowspan="1">0.69</td><td align="left" colspan="1" rowspan="1">0.54</td><td align="left" colspan="1" rowspan="1">0.71</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">MCI vs. NC</td><td align="left" colspan="1" rowspan="1">0.72</td><td align="left" colspan="1" rowspan="1">0.75</td><td align="left" colspan="1" rowspan="1">0.84</td><td align="left" colspan="1" rowspan="1">0.68</td></tr><tr><td align="left" colspan="1" rowspan="1">Kwak et al. (2022) [<xref ref-type="bibr" rid="CR39">39</xref>]</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">356</td><td align="left" colspan="1" rowspan="1">381</td><td align="left" colspan="1" rowspan="1">118</td><td align="left" colspan="1" rowspan="1">263</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">pMCI vs. sMCI</td><td align="left" colspan="1" rowspan="1">0.76</td><td align="left" colspan="1" rowspan="1">0.66</td><td align="left" colspan="1" rowspan="1">0.80</td><td align="left" colspan="1" rowspan="1">0.78</td></tr><tr><td align="left" rowspan="3" colspan="1">Li et al. (2021) [<xref ref-type="bibr" rid="CR40">40</xref>]</td><td align="left" colspan="1" rowspan="1">China</td><td align="left" colspan="1" rowspan="1">194</td><td align="left" colspan="1" rowspan="1">397</td><td align="left" colspan="1" rowspan="1">164</td><td align="left" colspan="1" rowspan="1">233</td><td align="left" colspan="1" rowspan="1">216</td><td align="left" colspan="1" rowspan="1">AD vs. NC</td><td align="left" colspan="1" rowspan="1">0.86</td><td align="left" colspan="1" rowspan="1">0.82</td><td align="left" colspan="1" rowspan="1">0.90</td><td align="left" colspan="1" rowspan="1">0.88</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">pMCI vs. sMCI</td><td align="left" colspan="1" rowspan="1">0.71</td><td align="left" colspan="1" rowspan="1">0.60</td><td align="left" colspan="1" rowspan="1">0.79</td><td align="left" colspan="1" rowspan="1">0.72</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">MCI vs. NC</td><td align="left" colspan="1" rowspan="1">0.73</td><td align="left" colspan="1" rowspan="1">0.78</td><td align="left" colspan="1" rowspan="1">0.65</td><td align="left" colspan="1" rowspan="1">0.75</td></tr><tr><td align="left" rowspan="2" colspan="1">Li et al. (2018) [<xref ref-type="bibr" rid="CR7">7</xref>]</td><td align="left" colspan="1" rowspan="1">China</td><td align="left" colspan="1" rowspan="1">199</td><td align="left" colspan="1" rowspan="1">403</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">229</td><td align="left" colspan="1" rowspan="1">AD vs. NC</td><td align="left" colspan="1" rowspan="1">0.90</td><td align="left" colspan="1" rowspan="1">0.88</td><td align="left" colspan="1" rowspan="1">0.91</td><td align="left" colspan="1" rowspan="1">0.92</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">MCI vs. NC</td><td align="left" colspan="1" rowspan="1">0.74</td><td align="left" colspan="1" rowspan="1">0.87</td><td align="left" colspan="1" rowspan="1">0.52</td><td align="left" colspan="1" rowspan="1">0.78</td></tr><tr><td align="left" colspan="1" rowspan="1">Liang et al. (2021) [<xref ref-type="bibr" rid="CR41">41</xref>]</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">49</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">51</td><td align="left" colspan="1" rowspan="1">AD vs. NC</td><td align="left" colspan="1" rowspan="1">0.91</td><td align="left" colspan="1" rowspan="1">0.85</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Lin et al. (2018) [<xref ref-type="bibr" rid="CR42">42</xref>]</td><td align="left" colspan="1" rowspan="1">China</td><td align="left" colspan="1" rowspan="1">188</td><td align="left" colspan="1" rowspan="1">308</td><td align="left" colspan="1" rowspan="1">169</td><td align="left" colspan="1" rowspan="1">139</td><td align="left" colspan="1" rowspan="1">229</td><td align="left" colspan="1" rowspan="1">AD vs. NC</td><td align="left" colspan="1" rowspan="1">0.80</td><td align="left" colspan="1" rowspan="1">0.84</td><td align="left" colspan="1" rowspan="1">0.75</td><td align="left" colspan="1" rowspan="1">0.86</td></tr><tr><td align="left" rowspan="2" colspan="1">Liu et al. (2020) [<xref ref-type="bibr" rid="CR43">43</xref>]</td><td align="left" colspan="1" rowspan="1">China</td><td align="left" colspan="1" rowspan="1">97</td><td align="left" colspan="1" rowspan="1">233</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">119</td><td align="left" colspan="1" rowspan="1">AD vs. NC</td><td align="left" colspan="1" rowspan="1">0.89</td><td align="left" colspan="1" rowspan="1">0.87</td><td align="left" colspan="1" rowspan="1">0.91</td><td align="left" colspan="1" rowspan="1">0.93</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">MCI vs. NC</td><td align="left" colspan="1" rowspan="1">0.76</td><td align="left" colspan="1" rowspan="1">0.80</td><td align="left" colspan="1" rowspan="1">0.70</td><td align="left" colspan="1" rowspan="1">0.78</td></tr><tr><td align="left" rowspan="3" colspan="1">Pan et al. (2020) [<xref ref-type="bibr" rid="CR44">44</xref>]</td><td align="left" colspan="1" rowspan="1">China</td><td align="left" colspan="1" rowspan="1">137</td><td align="left" colspan="1" rowspan="1">210</td><td align="left" colspan="1" rowspan="1">76</td><td align="left" colspan="1" rowspan="1">134</td><td align="left" colspan="1" rowspan="1">162</td><td align="left" colspan="1" rowspan="1">AD vs. NC</td><td align="left" colspan="1" rowspan="1">0.84</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">MCI vs. NC</td><td align="left" colspan="1" rowspan="1">0.79</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">cMCI vs. ncMCI</td><td align="left" colspan="1" rowspan="1">0.62</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" rowspan="3" colspan="1">Wee et al. (2019) [<xref ref-type="bibr" rid="CR45">45</xref>]</td><td align="left" colspan="1" rowspan="1">Singapore</td><td align="left" colspan="1" rowspan="1">355</td><td align="left" colspan="1" rowspan="1">415</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">242</td><td align="left" colspan="1" rowspan="1">CN vs. AD</td><td align="left" colspan="1" rowspan="1">0.81</td><td align="left" colspan="1" rowspan="1">0.86</td><td align="left" colspan="1" rowspan="1">0.75</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">CN vs. MCI</td><td align="left" colspan="1" rowspan="1">0.68</td><td align="left" colspan="1" rowspan="1">0.71</td><td align="left" colspan="1" rowspan="1">0.61</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">MCI vs. AD</td><td align="left" colspan="1" rowspan="1">0.65</td><td align="left" colspan="1" rowspan="1">0.78</td><td align="left" colspan="1" rowspan="1">0.55</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" rowspan="3" colspan="1">Zhang et al. (2021a) [<xref ref-type="bibr" rid="CR46">46</xref>]</td><td align="left" colspan="1" rowspan="1">China</td><td align="left" colspan="1" rowspan="1">280</td><td align="left" colspan="1" rowspan="1">413</td><td align="left" colspan="1" rowspan="1">162</td><td align="left" colspan="1" rowspan="1">251</td><td align="left" colspan="1" rowspan="1">275</td><td align="left" colspan="1" rowspan="1">AD vs. NC</td><td align="left" colspan="1" rowspan="1">0.97</td><td align="left" colspan="1" rowspan="1">0.97</td><td align="left" colspan="1" rowspan="1">0.98</td><td align="left" colspan="1" rowspan="1">0.99</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">cMCI vs. ncMCI</td><td align="left" colspan="1" rowspan="1">0.79</td><td align="left" colspan="1" rowspan="1">0.75</td><td align="left" colspan="1" rowspan="1">0.82</td><td align="left" colspan="1" rowspan="1">0.87</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">cMCI vs. NC</td><td align="left" colspan="1" rowspan="1">0.88</td><td align="left" colspan="1" rowspan="1">0.88</td><td align="left" colspan="1" rowspan="1">0.89</td><td align="left" colspan="1" rowspan="1">0.93</td></tr><tr><td align="left" rowspan="2" colspan="1">Zhang et al. (2021b) [<xref ref-type="bibr" rid="CR47">47</xref>]</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">218</td><td align="left" colspan="1" rowspan="1">776</td><td align="left" colspan="1" rowspan="1">328</td><td align="left" colspan="1" rowspan="1">448</td><td align="left" colspan="1" rowspan="1">467</td><td align="left" colspan="1" rowspan="1">AD vs. NC</td><td align="left" colspan="1" rowspan="1">0.95</td><td align="left" colspan="1" rowspan="1">0.96</td><td align="left" colspan="1" rowspan="1">0.93</td><td align="left" colspan="1" rowspan="1">0.97</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">sMCI vs. pMCI</td><td align="left" colspan="1" rowspan="1">0.78</td><td align="left" colspan="1" rowspan="1">0.79</td><td align="left" colspan="1" rowspan="1">0.87</td><td align="left" colspan="1" rowspan="1">0.84</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"><bold>Reference No</bold></th><th align="left" colspan="1" rowspan="1"><bold>MRI Modalities</bold></th><th align="left" colspan="5" rowspan="1"><bold>Pre-Processing</bold></th><th align="left" colspan="1" rowspan="1"><bold>Architecture</bold></th><th align="left" colspan="1" rowspan="1"><bold>Input Type</bold></th><th align="left" colspan="1" rowspan="1"><bold>Feature Type</bold></th><th align="left" colspan="2" rowspan="1"><bold>Validation Method</bold></th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"> [<xref ref-type="bibr" rid="CR28">28</xref>]</td><td align="left" colspan="1" rowspan="1">T1W MRI</td><td align="left" colspan="5" rowspan="1">N4 bias field corrected, denoised, brain extracted using U-Net, affine registered to MNI152</td><td align="left" colspan="1" rowspan="1">Single CNN (EfficientNet-b0)</td><td align="left" colspan="1" rowspan="1">3D patches</td><td align="left" colspan="1" rowspan="1">Whole brain</td><td align="left" colspan="2" rowspan="1">Cross-validation (5-fold)</td></tr><tr><td align="left" colspan="1" rowspan="1"> [<xref ref-type="bibr" rid="CR29">29</xref>]</td><td align="left" colspan="1" rowspan="1">1.5&#160;T T1W</td><td align="left" colspan="5" rowspan="1">Skull removed, denoised, smoothed, resized to 224&#8201;&#215;&#8201;224 pixels</td><td align="left" colspan="1" rowspan="1">Hybrid CNN:CNN&#8201;+&#8201;traditional ML (ResNet50&#8201;+&#8201;SVM/RF)</td><td align="left" colspan="1" rowspan="1">2D slices</td><td align="left" colspan="1" rowspan="1">Axial, sagittal, and coronal</td><td align="left" colspan="2" rowspan="1">Fixed-split (75%/15%/10%)</td></tr><tr><td align="left" colspan="1" rowspan="1"> [<xref ref-type="bibr" rid="CR30">30</xref>]</td><td align="left" colspan="1" rowspan="1">Unclear</td><td align="left" colspan="5" rowspan="1">Converted to JPG, removed corrupted images, equalized histograms, filtered bilaterally</td><td align="left" colspan="1" rowspan="1">Single CNN</td><td align="left" colspan="1" rowspan="1">2D slices</td><td align="left" colspan="1" rowspan="1">Whole brain</td><td align="left" colspan="2" rowspan="1">Cross-validation (10-fold)</td></tr><tr><td align="left" colspan="1" rowspan="1"> [<xref ref-type="bibr" rid="CR31">31</xref>]</td><td align="left" colspan="1" rowspan="1">T1W MRI</td><td align="left" colspan="5" rowspan="1">Normalized to MNI space, segmented, registered with DARTEL, affine transformed</td><td align="left" colspan="1" rowspan="1">Single CNN&#8201;+&#8201;TL</td><td align="left" colspan="1" rowspan="1">3D patches</td><td align="left" colspan="1" rowspan="1">Whole brain</td><td align="left" colspan="2" rowspan="1">Fixed-split (90%/10%)</td></tr><tr><td align="left" colspan="1" rowspan="1"> [<xref ref-type="bibr" rid="CR32">32</xref>]</td><td align="left" colspan="1" rowspan="1">Unclear</td><td align="left" colspan="5" rowspan="1">Corrected, segmented, template formed, skull removed</td><td align="left" colspan="1" rowspan="1">Single CNN&#8201;+&#8201;deep metric learning</td><td align="left" colspan="1" rowspan="1">2D slices</td><td align="left" colspan="1" rowspan="1">Unclear</td><td align="left" colspan="2" rowspan="1">Unclear</td></tr><tr><td align="left" colspan="1" rowspan="1"> [<xref ref-type="bibr" rid="CR33">33</xref>]</td><td align="left" colspan="1" rowspan="1">1.5&#160;T T1W</td><td align="left" colspan="5" rowspan="1">Axial orientation corrected, invalid volume removed, N3 normalized, resampled, registered</td><td align="left" colspan="1" rowspan="1">Single CNN (multi-view sub-networks)</td><td align="left" colspan="1" rowspan="1">subject-level 3D CNN</td><td align="left" colspan="1" rowspan="1">Sagittal, coronal, axial; Global subject-level</td><td align="left" colspan="2" rowspan="1">External validation (ADNI-1&#8201;&#8594;&#8201;ADNI-2)</td></tr><tr><td align="left" colspan="1" rowspan="1"> [<xref ref-type="bibr" rid="CR34">34</xref>]</td><td align="left" colspan="1" rowspan="1">1.5&#160;T T1W</td><td align="left" colspan="5" rowspan="1">Intensity corrected with N3, skull-stripped, cerebellum removed, registered using FSL</td><td align="left" colspan="1" rowspan="1">Single CNN (3D DenseNet)&#8201;+&#8201;MLP</td><td align="left" colspan="1" rowspan="1">3D ROI</td><td align="left" colspan="1" rowspan="1">Hippocampus</td><td align="left" colspan="2" rowspan="1">Cross-validation (5-fold)</td></tr><tr><td align="left" colspan="1" rowspan="1"> [<xref ref-type="bibr" rid="CR35">35</xref>]</td><td align="left" colspan="1" rowspan="1">T1W MRI</td><td align="left" colspan="5" rowspan="1">Processed through Clinica's t1-linear pipeline, bias field corrected, registered to MNI space</td><td align="left" colspan="1" rowspan="1">Single CNN (ResNet18/34)</td><td align="left" colspan="1" rowspan="1">3D patches</td><td align="left" colspan="1" rowspan="1">Whole brain</td><td align="left" colspan="2" rowspan="1">Fixed-split (69%/31%)</td></tr><tr><td align="left" colspan="1" rowspan="1"> [<xref ref-type="bibr" rid="CR36">36</xref>]</td><td align="left" colspan="1" rowspan="1">3&#160;T T1 W</td><td align="left" colspan="5" rowspan="1">Spatially normalized, skull and cervical stripped, segmented, nonlinearly registered, resized, smoothed</td><td align="left" colspan="1" rowspan="1">Hybrid CNN:CNN&#8201;+&#8201;traditional ML (3D-CNN&#8201;+&#8201;SVM)</td><td align="left" colspan="1" rowspan="1">3D patches</td><td align="left" colspan="1" rowspan="1">GM</td><td align="left" colspan="2" rowspan="1">Fixed-split (85%/15%)</td></tr><tr><td align="left" colspan="1" rowspan="1"> [<xref ref-type="bibr" rid="CR37">37</xref>]</td><td align="left" colspan="1" rowspan="1">3&#160;T-T1W MRI</td><td align="left" colspan="5" rowspan="1">Normalized, resized to 256&#8201;&#215;&#8201;256 pixels, three color channels</td><td align="left" colspan="1" rowspan="1">Single CNN (AlexNet/VGG16&#8201;+&#8201;TL)</td><td align="left" colspan="1" rowspan="1">2D slices</td><td align="left" colspan="1" rowspan="1">Frontal lobe, parietal lobe, hippocampus, and amygdala</td><td align="left" colspan="2" rowspan="1">Fixed-split (80%/10%/10%)</td></tr><tr><td align="left" colspan="1" rowspan="1"> [<xref ref-type="bibr" rid="CR38">38</xref>]</td><td align="left" colspan="1" rowspan="1">1.5&#160;T T1W</td><td align="left" colspan="5" rowspan="1">Converted, normalized, registered, bias corrected, segmented, smoothed</td><td align="left" colspan="1" rowspan="1">Hybrid CNN: Ensemble learning (VGG16&#8201;+&#8201;ResNet50, etc.)</td><td align="left" colspan="1" rowspan="1">2D slices</td><td align="left" colspan="1" rowspan="1">GM density maps</td><td align="left" colspan="2" rowspan="1">Fixed-split (70%/10%/20%)</td></tr><tr><td align="left" colspan="1" rowspan="1"> [<xref ref-type="bibr" rid="CR39">39</xref>]</td><td align="left" colspan="1" rowspan="1">1.5&#160;T &amp; 3&#160;T</td><td align="left" colspan="5" rowspan="1">Segmented using FreeSurfer v6.0, corrected for nonuniformity and registered to MNI152</td><td align="left" colspan="1" rowspan="1">Single CNN (DenseNet)</td><td align="left" colspan="1" rowspan="1">3D ROI</td><td align="left" colspan="1" rowspan="1">Hippocampal Subfields</td><td align="left" colspan="2" rowspan="1">Cross-validation (10-fold)&#8201;+&#8201;External validation</td></tr><tr><td align="left" colspan="1" rowspan="1"> [<xref ref-type="bibr" rid="CR40">40</xref>]</td><td align="left" colspan="1" rowspan="1">1.5&#160;T T1W</td><td align="left" colspan="5" rowspan="1">Nonuniform intensity normalized, skull dissected, cerebellum removed, affine registered</td><td align="left" colspan="1" rowspan="1">Single CNN (multi-channel cascaded CNN)</td><td align="left" colspan="1" rowspan="1">3D ROI</td><td align="left" colspan="1" rowspan="1">Hippocampus</td><td align="left" colspan="2" rowspan="1">Cross-validation (5-fold)</td></tr><tr><td align="left" colspan="1" rowspan="1"> [<xref ref-type="bibr" rid="CR7">7</xref>]</td><td align="left" colspan="1" rowspan="1">1.5&#160;T T1W</td><td align="left" colspan="5" rowspan="1">Skull-stripping, cerebellum removal, intensity corrected using N3, registered to standard template</td><td align="left" colspan="1" rowspan="1">Single CNN (multiple cluster DenseNets)</td><td align="left" colspan="1" rowspan="1">3D patches</td><td align="left" colspan="1" rowspan="1">Whole brain</td><td align="left" colspan="2" rowspan="1">Cross-validation (5-fold)</td></tr><tr><td align="left" colspan="1" rowspan="1"> [<xref ref-type="bibr" rid="CR41">41</xref>]</td><td align="left" colspan="1" rowspan="1">T1W MRI</td><td align="left" colspan="5" rowspan="1">Random flips and rotations, skull-stripped, uniform voxel size</td><td align="left" colspan="1" rowspan="1">Single CNN (AlexNet/ResNet-18)</td><td align="left" colspan="1" rowspan="1">2D slices</td><td align="left" colspan="1" rowspan="1">Whole brain</td><td align="left" colspan="2" rowspan="1">Fixed-split (80%/20%)</td></tr><tr><td align="left" colspan="1" rowspan="1"> [<xref ref-type="bibr" rid="CR42">42</xref>]</td><td align="left" colspan="1" rowspan="1">1.5&#160;T T1W</td><td align="left" colspan="5" rowspan="1">Skull-stripped, registered to MNI151, normalized, uniform spatial alignment and intensity range</td><td align="left" colspan="1" rowspan="1">Hybrid CNN: Traditional ML&#8201;+&#8201;CNN feature fusion</td><td align="left" colspan="1" rowspan="1">2.5D patches</td><td align="left" colspan="1" rowspan="1">2.5D patches; both hippocampus and whole brain</td><td align="left" colspan="2" rowspan="1">Cross-validation (leave-one-out)</td></tr><tr><td align="left" colspan="1" rowspan="1"> [<xref ref-type="bibr" rid="CR43">43</xref>]</td><td align="left" colspan="1" rowspan="1">1.5&#160;T T1W</td><td align="left" colspan="5" rowspan="1">Resampled, skull-stripped, cerebellum removed, intensity corrected using N3, affine-registered</td><td align="left" colspan="1" rowspan="1">Single CNN (multi-task 3D-DenseNets)</td><td align="left" colspan="1" rowspan="1">3D patches</td><td align="left" colspan="1" rowspan="1">Hippocampus; volume and shape</td><td align="left" colspan="2" rowspan="1">Cross-validation (5-fold)</td></tr><tr><td align="left" colspan="1" rowspan="1"> [<xref ref-type="bibr" rid="CR44">44</xref>]</td><td align="left" colspan="1" rowspan="1">T1W MRI</td><td align="left" colspan="5" rowspan="1">Skull stripped, normalized to MNI space, smoothed, intensity normalized, sliced with augmentation</td><td align="left" colspan="1" rowspan="1">Hybrid CNN:CNN&#8201;+&#8201;traditional ML (CNN&#8201;+&#8201;EL)</td><td align="left" colspan="1" rowspan="1">2D slices</td><td align="left" colspan="1" rowspan="1">Axial, sagittal, and coronal</td><td align="left" colspan="2" rowspan="1">Cross-validation (5-fold)</td></tr><tr><td align="left" colspan="1" rowspan="1"> [<xref ref-type="bibr" rid="CR45">45</xref>]</td><td align="left" colspan="1" rowspan="1">1.5&#160;T; 3&#160;T T1W</td><td align="left" colspan="5" rowspan="1">Segmented with FreeSurfer, cortical thickness calculated, aligned to atlas, cortical surface graph constructed</td><td align="left" colspan="1" rowspan="1">Single CNN (Graph-CNN)</td><td align="left" colspan="1" rowspan="1">2D slices</td><td align="left" colspan="1" rowspan="1">Cortical Thickness</td><td align="left" colspan="2" rowspan="1">Cross-validation (10-fold)</td></tr><tr><td align="left" colspan="1" rowspan="1"> [<xref ref-type="bibr" rid="CR46">46</xref>]</td><td align="left" colspan="1" rowspan="1">1.5&#160;T T1W</td><td align="left" colspan="5" rowspan="1">Bias corrected, normalized, skull dissected, resampled to 182&#8201;&#215;&#8201;218&#8201;&#215;&#8201;182</td><td align="left" colspan="1" rowspan="1">Single CNN (3D connection-wise attention DenseNet)</td><td align="left" colspan="1" rowspan="1">3D patches</td><td align="left" colspan="1" rowspan="1">Whole brain</td><td align="left" colspan="2" rowspan="1">Fixed-split (70%/15%/15%)</td></tr><tr><td align="left" colspan="1" rowspan="1"> [<xref ref-type="bibr" rid="CR47">47</xref>]</td><td align="left" colspan="1" rowspan="1">1.5&#160;T T1 W</td><td align="left" colspan="5" rowspan="1">De-noising, standardized, spatially normalized</td><td align="left" colspan="1" rowspan="1">Hybrid CNN: (ensemble classifier&#8201;+&#8201;3D CNN)</td><td align="left" colspan="1" rowspan="1">3D patches</td><td align="left" colspan="1" rowspan="1">Whole brain</td><td align="left" colspan="2" rowspan="1">Fixed-split (70%/30%)</td></tr></tbody></table><table-wrap-foot><p>All studies used ADNI data, exceptions are explicitly listed below: Agarwal et al. [<xref ref-type="bibr" rid="CR28">28</xref>]: ADNI&#8201;+&#8201;IXI; AlSaeed &amp; Omar [<xref ref-type="bibr" rid="CR29">29</xref>]: ADNI&#8201;+&#8201;MIRIAD; Basaia et al. [<xref ref-type="bibr" rid="CR31">31</xref>]: ADNI&#8201;+&#8201;Milan; Wee et al. [<xref ref-type="bibr" rid="CR45">45</xref>]: ADNI-1&#8201;+&#8201;ADNI-2&#8201;+&#8201;Asian</p><p><italic toggle="yes">Acc</italic> Accuracy, <italic toggle="yes">Sen</italic> Sensitivity, <italic toggle="yes">Spe</italic> Specificity, <italic toggle="yes">AUC</italic> Area Under the Curve, <italic toggle="yes">pMCI</italic> Progressive MCI, <italic toggle="yes">sMCI</italic> Stable MCI, <italic toggle="yes">cMCI</italic> Converter MCI, <italic toggle="yes">ncMCI</italic> Non-converter MCI, <italic toggle="yes">NC</italic> normal cognition, <italic toggle="yes">MNI</italic> Montreal Neurological Institute, <italic toggle="yes">ROI</italic> Regions of Interest, <italic toggle="yes">CNN</italic> Convolutional neural network, <italic toggle="yes">DL</italic> Deep Learning, <italic toggle="yes">TL</italic> Transfer Learning, <italic toggle="yes">MLP</italic> Multilayer Perceptron, <italic toggle="yes">SVM</italic> Support Vector Machine, <italic toggle="yes">RF</italic> Random Forest, <italic toggle="yes">EL</italic> ensemble learning, <italic toggle="yes">GM</italic> Grey Matter, <italic toggle="yes">IXI</italic> International eXtensible Imaging Protocol, <italic toggle="yes">MIRIAD</italic> Medical Image Computing in the Era of Alzheimer's Disease</p></table-wrap-foot></table-wrap></p><p id="Par30">Studies were published between 2018 and 2024 and had significant geographic diversity: 56.5% originated from China, and the remainder from the USA, Spain, Ghana, UK, Saudi Arabia, and Italy. All the studies utilized data from the ADNI database [<xref ref-type="bibr" rid="CR48">48</xref>], while four supplemented with multi-center datasets like International eXtensible Imaging Protocol (IXI), the Medical Image Computing in the Era of Alzheimer's Disease (MIRIAD), Milan and Asian databases [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. In terms of classification targets, trends show a focus on core diagnostic distinctions: 19 studies addressed AD vs. NC [<xref ref-type="bibr" rid="CR29">29</xref>&#8211;<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR47">47</xref>], reflecting priorities in early Alzheimer&#8217;s disease diagnosis and progression tracking.</p><p id="Par31">MCI subtypes were differentiated by distinct outcomes: Progressive MCI (pMCI) and Stable MCI (sMCI), or Converter MCI (cMCI) and Non-converter MCI (ncMCI). pMCI referred to individuals who were initially diagnosed with MCI and later progressed to probable AD by the follow-up visit, whereas sMCI referred to individuals who retained their MCI diagnosis without conversion to AD [<xref ref-type="bibr" rid="CR49">49</xref>]. Six studies specifically differentiated pMCI [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>] from sMCI. Two studies classified MCI based on the occurrence of AD during the follow-up period, designating ncMCI for those whose condition did not convert to AD and cMCI for those who experienced this conversion [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. Both sMCI and ncMCI groups are characterized by the maintenance of MCI status, with no incidence of AD. In contrast, both pMCI and cMCI groups had occurrences of AD. These two classifications were merged into a unified framework to streamline the analytical process. This integration allowed us to identify 8 studies that classified MCI into the subtypes of MCI/sMCI and cMCI/ncMCI [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>].</p><p id="Par32">All the studies utilized T1-weighted MRI scans at 1.5&#160;T or 3&#160;T strengths. Pre-processing steps were consistent across studies, including skull stripping, intensity normalization, spatial normalization to the Montreal Neurological Institute (MNI) template, and occasional bias field correction. Some studies also performed data augmentation to enhance model robustness [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. One study did not report weighted sequence information, and the pre-processing was not clear [<xref ref-type="bibr" rid="CR32">32</xref>].</p><p id="Par33">The algorithmic backbone of these studies was CNN with variations in the specific models deployed. DenseNet was the choice for five studies [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR47">47</xref>], while ResNet, VGG16, EfficientNet, and AlexNet were individually selected in several other studies. The integration of CNN with complementary models was a common trend, with ensemble learning strategies enhancing predictive accuracy and robustness. Transfer-learning was also leveraged to tailor pre-trained networks from large datasets to the nuances of brain disease classification. Furthermore, the synergy of CNN with models such as support vector machines (SVM) and multilayer perceptrons (MLP) was explored to harness the collective strengths of diverse architectures.</p><p id="Par34">Studies also differed in feature selections. Eight studies opted for 2D slices that predominantly focused on axial, coronal, or sagittal sections [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. Nine studies favored 3D patches, extracting multiple volumetric segments from 3D MRI scans [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. Three studies concentrated on 3D Regions of Interest (ROI) with a unanimous focus on the hippocampus. A single study [<xref ref-type="bibr" rid="CR33">33</xref>] integrated both 2D multiview-slice and global 3D subject-level features to capture the subtleties of disease induced changes across various dimensions.</p></sec><sec id="Sec14"><title>Methodological quality of included studies</title><p id="Par35">The QUADAS-2 results overview (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>A and B) suggested that the quality of the included studies was rated predominantly as low-quality due to the presence of high or uncertain risk of bias in at least one domain.<fig id="Fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>Quality assessment of included articles: The (<bold>A</bold>) bias risk and (<bold>B</bold>) applicability concerns assessment of included studies utilizing the QUADAS-2 scale. <bold>C</bold> The METRICS scores of included articles</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="12883_2025_4404_Fig2_HTML.jpg"/></fig></p><p id="Par36">The patient selection, drawn from the ADNI database, was deemed &#8220;unclear&#8221; regarding the continuity or randomness of case selection, reflecting the investigators'discretionary choice without explicit methodology reporting. Given the common practice in machine learning studies of selecting distinct diagnostic groups (e.g., AD vs. NC) for model classifier training, akin to a nested case&#8211;control design, all studies were not flagged for avoiding a case&#8211;control design by responding &#8220;no&#8221; to this criterion. However, they were deemed high-risk in case selection. The &#8220;Index Test&#8221; category was judged &#8220;unclear&#8221; across all studies due to inconsistencies in the three related questions. Similarly, the"Reference Standard"was classified as"unclear"because it lacked clarity on whether results were interpreted independently of the index tests.</p><p id="Par37">The study quality summary based on the METRICS criteria is illustrated in Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>C, with comprehensive results detailed in Supplementary Table&#160;3. The aggregate METRICS score for all 21 studies was 62.6%, with a standard deviation of 13.9%. Generally, the majority of the studies exhibited satisfactory reporting quality, including addressing diverse dimensions such as the clarity of reference standards, the clinical relevance of imaging data sources, the explicitness of imaging protocols, the transparency of image preprocessing techniques, the thoroughness in documenting feature extraction parameters, the meticulousness of data partitioning processes, the appropriateness of the chosen performance evaluation metrics, the methodological rigor in comparing with statistical models, and the robustness of internal testing procedures. According to the METRICS evaluation, the studies were categorized as follows: 2 studies [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR45">45</xref>] were rated as &#8220;excellent&#8221;, 8 studies [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR44">44</xref>] as &#8220;good&#8221;, 10 studies [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR34">34</xref>&#8211;<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>] as &#8220;moderate&#8221;, and 1 study [<xref ref-type="bibr" rid="CR32">32</xref>] as &#8220;very low&#8221; in quality.</p></sec><sec id="Sec15"><title>Meta&#8209;analysis</title><sec id="Sec16"><title>Pooled predictive performance of CNN methods for classification</title><p id="Par38">The diagnostic performance of CNN methods was examined across various classifications, including differentiating AD from NC, AD from MCI, MCI from NC, and pMCI from sMCI. Table <xref rid="Tab2" ref-type="table">2</xref> summarizes the performance across four classification tasks.<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Diagnostic performance of four classification tasks</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Classification Task</th><th align="left" colspan="1" rowspan="1">Study (n)</th><th align="left" colspan="1" rowspan="1">Diagnostic OR (95% CI)</th><th align="left" colspan="1" rowspan="1">SEN<break/>(95% CI)</th><th align="left" colspan="1" rowspan="1">SPE<break/>(95% CI)</th><th align="left" colspan="1" rowspan="1">PLR<break/>(95% CI)</th><th align="left" colspan="1" rowspan="1">NLR<break/>(95% CI)</th><th align="left" colspan="1" rowspan="1">AUC<break/>(95% CI)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">AD vs. NC</td><td align="left" colspan="1" rowspan="1">17</td><td align="left" colspan="1" rowspan="1"><p>141.90</p><p>(72.63&#8211;277.25)</p></td><td align="left" colspan="1" rowspan="1"><p>0.91</p><p>(0.90&#8211;0.92)</p></td><td align="left" colspan="1" rowspan="1"><p>0.93</p><p>(0.90&#8211;0.96)</p></td><td align="left" colspan="1" rowspan="1"><p>13.86</p><p>(8.51&#8211;22.58)</p></td><td align="left" colspan="1" rowspan="1"><p>0.09</p><p>(0.06&#8211;0.13)</p></td><td align="left" colspan="1" rowspan="1"><p>0.97</p><p>(0.96&#8211;0.98)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">MCI vs. NC</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1"><p>21.74</p><p>(10.50&#8211;45.00)</p></td><td align="left" colspan="1" rowspan="1"><p>0.86</p><p>(0.76&#8211;0.93)</p></td><td align="left" colspan="1" rowspan="1"><p>0.81</p><p>(0.69&#8211;0.89)</p></td><td align="left" colspan="1" rowspan="1"><p>4.61</p><p>(2.49&#8211;8.53)</p></td><td align="left" colspan="1" rowspan="1"><p>0.17</p><p>(0.08&#8211;0.34)</p></td><td align="left" colspan="1" rowspan="1"><p>0.91</p><p>(0.88&#8211;0.93)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">AD vs. MCI</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1"><p>51.43</p><p>(6.19&#8211;427.24)</p></td><td align="left" colspan="1" rowspan="1"><p>0.93</p><p>(0.73&#8211;0.98)</p></td><td align="left" colspan="1" rowspan="1"><p>0.82</p><p>(0.69&#8211;0.90)</p></td><td align="left" colspan="1" rowspan="1"><p>5.10</p><p>(2.69&#8211;9.68)</p></td><td align="left" colspan="1" rowspan="1"><p>0.09</p><p>(0.02&#8211;0.40)</p></td><td align="left" colspan="1" rowspan="1"><p>0.92</p><p>(0.89&#8211;0.94)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">pMCI vs. sMCI</td><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1"><p>9.64</p><p>(6.51 &#8722;14.27)</p></td><td align="left" colspan="1" rowspan="1">0.69 (0.62&#8211;0.76)</td><td align="left" colspan="1" rowspan="1"><p>0.81</p><p>(0.77&#8211;0.84)</p></td><td align="left" colspan="1" rowspan="1"><p>3.66</p><p>(3.02&#8211;4.44)</p></td><td align="left" colspan="1" rowspan="1"><p>0.38</p><p>(0.30&#8211;0.47)</p></td><td align="left" colspan="1" rowspan="1"><p>0.83</p><p>(0.80&#8211;0.86)</p></td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">SEN</italic> Sensitivit, <italic toggle="yes">SPE</italic> Specificity, <italic toggle="yes">PLR</italic> Positive Likelihood Ratio, <italic toggle="yes">NLR</italic> Negative Likelihood Ratio, <italic toggle="yes">AUC</italic> Area Under the Curve, <italic toggle="yes">DOR</italic> diagnostic odds ratio, <italic toggle="yes">CI</italic> Confidence Interval</p></table-wrap-foot></table-wrap></p><p id="Par39">For AD vs. NC classification, 17 out of 19 studies [<xref ref-type="bibr" rid="CR29">29</xref>&#8211;<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>] provided sufficient information to extract a complete 2&#8201;&#215;&#8201;2 contingency table (Supplementary Table&#160;4) and thus qualified for the meta-analysis. The AD vs. NC classification demonstrated high diagnostic efficacy with a pooled sensitivity of 0.91 (95% CI: 0.90&#8211;0.92) (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>A) and specificity of 0.93 (95% CI: 0.90&#8211;0.96) (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>B). The PLR was 13.86 (95% CI: 8.51&#8211;22.58) and NLR was 0.09 (95% CI: 0.06&#8211;0.13) (Supplementary Fig. <xref rid="Fig2" ref-type="fig">2</xref>), yielding a DOR of 141.90 (95% CI: 72.63&#8211;277.25) (Supplementary Fig. <xref rid="Fig1" ref-type="fig">1</xref>&#8201;A) and an AUC of the sROC of 0.97 (95% CI: 0.96&#8211;0.98) (Fig.&#160;<xref rid="Fig7" ref-type="fig">7</xref>A).<fig id="Fig3" position="float" orientation="portrait"><label>Fig.&#160;3</label><caption><p>Forest plots of the (<bold>A</bold>) pooled sensitivity and (<bold>B</bold>) specificity in the AD vs. NC classification</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="12883_2025_4404_Fig3_HTML.jpg"/></fig></p><p id="Par40">In differentiating MCI from NC, 10 out of 13 studies [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR36">36</xref>&#8211;<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR46">46</xref>] provided sufficient information to extract a complete 2&#8201;&#215;&#8201;2 contingency table (Supplementary Table&#160;5) and were included in the meta-analysis. The pooled sensitivity was 0.86 (95% CI: 0.76&#8211;0.93) (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>A), and specificity was 0.81 (95% CI: 0.69&#8211;0.89) (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>B). The PLR was 4.61 (95% CI: 2.49&#8211;8.53) (Supplementary Fig. <xref rid="Fig3" ref-type="fig">3</xref>&#8201;A) and NLR was 0.17 (95% CI: 0.08&#8211;0.34) (Supplementary Fig. <xref rid="Fig3" ref-type="fig">3</xref>B), resulting in a DOR of 21.74 (95% CI: 10.50&#8211;45.00) (Supplementary Fig. <xref rid="Fig1" ref-type="fig">1</xref>B) and an AUC of the sROC of 0.91 (95% CI: 0.88&#8211;0.93) (Fig.&#160;<xref rid="Fig7" ref-type="fig">7</xref>B), indicating reduced test efficacy for this classification.<fig id="Fig4" position="float" orientation="portrait"><label>Fig.&#160;4</label><caption><p>Forest plots of the (<bold>A</bold>) pooled sensitivity and (<bold>B</bold>) specificity in the MCI vs. NC classification</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO5" position="float" orientation="portrait" xlink:href="12883_2025_4404_Fig4_HTML.jpg"/></fig></p><p id="Par41">For AD vs. MCI differentiation, 5 out of 7 studies [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR36">36</xref>&#8211;<xref ref-type="bibr" rid="CR38">38</xref>] provided sufficient information to extract a complete 2&#8201;&#215;&#8201;2 contingency table (Supplementary Table&#160;6) and were included in the meta-analysis. The AD vs. MCI differentiation exhibited modestly reduced efficacy in diagnostic accuracy, with the pooled sensitivity of 0.93 (95% CI: 0.73&#8211;0.98) (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>A) and specificity of 0.82 (95% CI: 0.69&#8211;0.90) (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>B). The PLR was 5.1 (95% CI: 2.69&#8211;9.68) and NLR was 0.09 (95% CI: 0.02&#8211;0.40) (Supplementary Fig. <xref rid="Fig4" ref-type="fig">4</xref>), leading to a DOR of 51.43 (95% CI: 6.19&#8211;427.24) (Supplementary Fig. <xref rid="Fig1" ref-type="fig">1</xref>&#8201;C) and an AUC of the sROC of 0.92 (95% CI: 0.89&#8211;0.94) (Fig.&#160;<xref rid="Fig7" ref-type="fig">7</xref>C).<fig id="Fig5" position="float" orientation="portrait"><label>Fig.&#160;5</label><caption><p>Forest plots of the (<bold>A</bold>) pooled sensitivity and (<bold>B</bold>) specificity in the AD vs. MCI classification</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO6" position="float" orientation="portrait" xlink:href="12883_2025_4404_Fig5_HTML.jpg"/></fig></p><p id="Par42">Among the 8 studies classifying MCI into pMCI and sMCI subtypes, 7 studies [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>] provided sufficient data (Supplementary Table&#160;7) for meta-analysis and showed a pooled sensitivity of 0.69 (95% CI: 0.62&#8211;0.76) and specificity of 0.81 (95% CI: 0.77&#8211;0.84) (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>). The PLR was 3.66 (95% CI: 3.02&#8211;4.44), and NLR was 0.38 (95% CI: 0.30&#8211;0.47) (Supplementary Fig. <xref rid="Fig5" ref-type="fig">5</xref>), yielding a DOR of 9.64 (95% CI: 6.51&#8211;14.27) (Supplementary Fig. <xref rid="Fig1" ref-type="fig">1</xref>D) and an AUC of the sROC of 0.84 (95% CI: 0.80&#8211;0.86) (Fig.&#160;<xref rid="Fig7" ref-type="fig">7</xref>D). The lowest efficacy was noted in distinguishing pMCI from sMCI.<fig id="Fig6" position="float" orientation="portrait"><label>Fig.&#160;6</label><caption><p>Forest plots of the (<bold>A</bold>) pooled sensitivity and (<bold>B</bold>) specificity in the pMCI vs. sMCI classification</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO7" position="float" orientation="portrait" xlink:href="12883_2025_4404_Fig6_HTML.jpg"/></fig><fig id="Fig7" position="float" orientation="portrait"><label>Fig.&#160;7</label><caption><p>The sROC curves for the four classification tasks. <bold>A</bold> AD vs. NC, <bold>B</bold> MCI vs. NC, <bold>C</bold> AD vs. MCI, <bold>D</bold> pMCI vs. sMCI</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="12883_2025_4404_Fig7_HTML.jpg"/></fig></p></sec><sec id="Sec17"><title>Subgroup analysis</title><p id="Par43">The four classifications in this review all exhibited significant heterogeneity, with <italic toggle="yes">I</italic><sup>2</sup>&#8201;&gt;&#8201;90% and Q-test <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.01 for sensitivity, specificity, PLR, and NLR. Additionally, the Galbraith plots for four classifications demonstrated a certain degree of heterogeneity, as reflected by the deviation from the zero-effect line (Supplementary Fig. <xref rid="Fig7" ref-type="fig">7</xref>A-D). To examine how different methodological features influence diagnostic performance, this study performed stratified analyses based on predefined subgroups. Results indicated significant variations in diagnostic efficacy and heterogeneity across subgroups (Tables <xref rid="Tab3" ref-type="table">3</xref> and <xref rid="Tab4" ref-type="table">4</xref>). It is important to note that the bivariate model imposes a fundamental requirement on subgroup sample size, mandating at least 4 studies per subgroup. This requirement arises because the model simultaneously estimates sensitivity, specificity, and their associated parameters; an inadequate number of studies would result in unstable parameter estimates, such as biases in heterogeneity variance and substantial fluctuations in the confidence intervals of effect sizes. Consequently, only subgroups comprising&#8201;&#8805;&#8201;4 studies were included in the present analysis to ensure the reliability of results.<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Subgroup analysis summary table of diagnostic efficacy and heterogeneity indicators for AD vs. NC Groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Subgroup Type</th><th align="left" colspan="1" rowspan="1">Subgroup Details</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">N</italic></th><th align="left" colspan="1" rowspan="1">Sen (95% CI)</th><th align="left" colspan="1" rowspan="1">Spe (95% CI)</th><th align="left" colspan="1" rowspan="1">DOR (95% CI)</th><th align="left" colspan="1" rowspan="1">Var (logitSe)<break/>(95% CI)</th><th align="left" colspan="1" rowspan="1">Var (logitSp)<break/>(95% CI)</th></tr></thead><tbody><tr><td align="left" rowspan="3" colspan="1">Feature</td><td align="left" colspan="1" rowspan="1">Whole brain</td><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">0.925 (0.869&#8211;0.958)</td><td align="left" colspan="1" rowspan="1">0.946 (0.894&#8211;0.973)</td><td align="left" colspan="1" rowspan="1">216.7 (69.1&#8211;679.5)</td><td align="left" colspan="1" rowspan="1">0.614 (0.178&#8211;2.121)</td><td align="left" colspan="1" rowspan="1">0.811 (0.237&#8211;2.778)</td></tr><tr><td align="left" colspan="1" rowspan="1">Hippocampus</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">0.858 (0.817&#8211;0.892)</td><td align="left" colspan="1" rowspan="1">0.886 (0.805&#8211;0.936)</td><td align="left" colspan="1" rowspan="1">47.1 (20.6&#8211;107.5)</td><td align="left" colspan="1" rowspan="1">0.044 (0.002&#8211;0.805)</td><td align="left" colspan="1" rowspan="1">0.359 (0.075&#8211;1.704)</td></tr><tr><td align="left" colspan="1" rowspan="1">Local brain</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">0.958 (0.884&#8211;0.986)</td><td align="left" colspan="1" rowspan="1">0.957 (0.887&#8211;0.984)</td><td align="left" colspan="1" rowspan="1">511.5 (74.6&#8211;3508.0)</td><td align="left" colspan="1" rowspan="1">1.316 (0.229&#8211;7.584)</td><td align="left" colspan="1" rowspan="1">1.185 (0.280&#8211;5.015)</td></tr><tr><td align="left" rowspan="2" colspan="1">Architecture</td><td align="left" colspan="1" rowspan="1">Single CNN</td><td align="left" colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">0.903 (0.858&#8211;0.935)</td><td align="left" colspan="1" rowspan="1">0.928 (0.890&#8211;0.953)</td><td align="left" colspan="1" rowspan="1">120.2 (54.3&#8211;266.3)</td><td align="left" colspan="1" rowspan="1">0.498 (0.19&#8211;1.29)</td><td align="left" colspan="1" rowspan="1">0.540 (0.20&#8211;1.47)</td></tr><tr><td align="left" colspan="1" rowspan="1">Hybrid CNN</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">0.954 (0.862&#8211;0.985)</td><td align="left" colspan="1" rowspan="1">0.945 (0.833&#8211;0.984)</td><td align="left" colspan="1" rowspan="1">356.0 (37.6&#8211;3369.1)</td><td align="left" colspan="1" rowspan="1">1.593 (0.33&#8211;7.80)</td><td align="left" colspan="1" rowspan="1">1.851 (0.47&#8211;7.25)</td></tr><tr><td align="left" rowspan="2" colspan="1">Validation</td><td align="left" colspan="1" rowspan="1">Cross-validation</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">0.883 (0.840&#8211;0.916)</td><td align="left" colspan="1" rowspan="1">0.877 (0.816&#8211;0.921)</td><td align="left" colspan="1" rowspan="1">54.3 (30.5&#8211;96.6)</td><td align="left" colspan="1" rowspan="1">0.161 (0.038&#8211;0.676)</td><td align="left" colspan="1" rowspan="1">0.303 (0.081&#8211;1.129)</td></tr><tr><td align="left" colspan="1" rowspan="1">Fixed-split</td><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">0.949 (0.897&#8211;0.975)</td><td align="left" colspan="1" rowspan="1">0.965 (0.932&#8211;0.982)</td><td align="left" colspan="1" rowspan="1">508.2 (141.5&#8211;1825.3)</td><td align="left" colspan="1" rowspan="1">1.174 (0.366&#8211;3.766)</td><td align="left" colspan="1" rowspan="1">0.860 (0.288&#8211;2.567)</td></tr><tr><td align="left" rowspan="2" colspan="1">MRI</td><td align="left" colspan="1" rowspan="1">1.5&#160;T T1w</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">0.910 (0.864&#8211;0.941)</td><td align="left" colspan="1" rowspan="1">0.929 (0.877&#8211;0.960)</td><td align="left" colspan="1" rowspan="1">131.3 (48.7&#8211;353.7)</td><td align="left" colspan="1" rowspan="1">0.486 (0.17&#8211;1.36)</td><td align="left" colspan="1" rowspan="1">0.864 (0.31&#8211;2.40)</td></tr><tr><td align="left" colspan="1" rowspan="1">General</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">0.910 (0.815&#8211;0.959)</td><td align="left" colspan="1" rowspan="1">0.924 (0.819&#8211;0.970)</td><td align="left" colspan="1" rowspan="1">123.5 (25.9&#8211;588.5)</td><td align="left" colspan="1" rowspan="1">0.810 (0.20&#8211;3.28)</td><td align="left" colspan="1" rowspan="1">1.080 (0.28&#8211;4.64)</td></tr><tr><td align="left" rowspan="2" colspan="1">Data Type</td><td align="left" colspan="1" rowspan="1">3D</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">0.925 (0.865&#8211;0.959)</td><td align="left" colspan="1" rowspan="1">0.946 (0.914&#8211;0.966)</td><td align="left" colspan="1" rowspan="1">213.5 (70.4&#8211;647.9)</td><td align="left" colspan="1" rowspan="1">0.99 (0.33&#8211;2.92)</td><td align="left" colspan="1" rowspan="1">0.53 (0.17&#8211;1.65)</td></tr><tr><td align="left" colspan="1" rowspan="1">2D</td><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">0.912 (0.848&#8211;0.951)</td><td align="left" colspan="1" rowspan="1">0.914 (0.801&#8211;0.965)</td><td align="left" colspan="1" rowspan="1">110.5 (28.2&#8211;433.5)</td><td align="left" colspan="1" rowspan="1">0.60 (0.18&#8211;1.98)</td><td align="left" colspan="1" rowspan="1">1.47 (0.43&#8211;5.11)</td></tr><tr><td align="left" rowspan="2" colspan="1">Segmentation</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">0.921 (0.872&#8211;0.953)</td><td align="left" colspan="1" rowspan="1">0.945 (0.894&#8211;0.973)</td><td align="left" colspan="1" rowspan="1">203.4 (67.7&#8211;611.4)</td><td align="left" colspan="1" rowspan="1">0.55 (0.17&#8211;1.72)</td><td align="left" colspan="1" rowspan="1">0.90 (0.27&#8211;2.94)</td></tr><tr><td align="left" colspan="1" rowspan="1">Yes</td><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">0.920 (0.846&#8211;0.960)</td><td align="left" colspan="1" rowspan="1">0.922 (0.856&#8211;0.959)</td><td align="left" colspan="1" rowspan="1">135.3 (35.8&#8211;511.7)</td><td align="left" colspan="1" rowspan="1">1.14 (0.35&#8211;3.72)</td><td align="left" colspan="1" rowspan="1">0.96 (0.33&#8211;2.82)</td></tr><tr><td align="left" rowspan="2" colspan="1">Literature Quality</td><td align="left" colspan="1" rowspan="1">Moderate</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">0.939 (0.891&#8211;0.967)</td><td align="left" colspan="1" rowspan="1">0.947 (0.901&#8211;0.972)</td><td align="left" colspan="1" rowspan="1">274.6 (89.3&#8211;843.7)</td><td align="left" colspan="1" rowspan="1">0.89 (0.28&#8211;2.83)</td><td align="left" colspan="1" rowspan="1">0.99 (0.35&#8211;2.80)</td></tr><tr><td align="left" colspan="1" rowspan="1">Good</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">0.896 (0.828&#8211;0.939)</td><td align="left" colspan="1" rowspan="1">0.921 (0.843&#8211;0.962)</td><td align="left" colspan="1" rowspan="1">100.0 (27.5&#8211;363.9)</td><td align="left" colspan="1" rowspan="1">0.46 (0.12&#8211;1.85)</td><td align="left" colspan="1" rowspan="1">0.83 (0.23&#8211;3.00)</td></tr><tr><td align="left" rowspan="2" colspan="1">eligibility</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">0.928 (0.863&#8211;0.964)</td><td align="left" colspan="1" rowspan="1">0.955 (0.913&#8211;0.977)</td><td align="left" colspan="1" rowspan="1">274.9 (69.1&#8211;1093.6)</td><td align="left" colspan="1" rowspan="1">1.075 (0.367&#8211;3.149)</td><td align="left" colspan="1" rowspan="1">0.992 (0.330&#8211;2.977)</td></tr><tr><td align="left" colspan="1" rowspan="1">Yes</td><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">0.907 (0.861&#8211;0.939)</td><td align="left" colspan="1" rowspan="1">0.898 (0.832&#8211;0.940)</td><td align="left" colspan="1" rowspan="1">85.7 (36.9&#8211;199.2)</td><td align="left" colspan="1" rowspan="1">0.357 (0.109&#8211;1.175)</td><td align="left" colspan="1" rowspan="1">0.598 (0.186&#8211;1.927)</td></tr></tbody></table></table-wrap><table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Subgroup analysis summary table of diagnostic efficacy and heterogeneity indicators for MCI vs. NC groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Subgroup Type</th><th align="left" colspan="1" rowspan="1">Subgroup Details</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">N</italic></th><th align="left" colspan="1" rowspan="1">Sen (95% CI)</th><th align="left" colspan="1" rowspan="1">Spe (95% CI)</th><th align="left" colspan="1" rowspan="1">DOR (95% CI)</th><th align="left" colspan="1" rowspan="1">Var (logitSe) (95% CI)</th><th align="left" colspan="1" rowspan="1">Var (logitSp) (95% CI)</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">Validation</td><td align="left" colspan="1" rowspan="1">Cross-validation</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">0.852 (0.758&#8211;0.914)</td><td align="left" colspan="1" rowspan="1">0.707 (0.572&#8211;0.813)</td><td align="left" colspan="1" rowspan="1">13.90 (4.68&#8211;41.27)</td><td align="left" colspan="1" rowspan="1">0.449 (0.108&#8211;1.859)</td><td align="left" colspan="1" rowspan="1">0.413 (0.098&#8211;1.749)</td></tr><tr><td align="left" colspan="1" rowspan="1">Fixed-split</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">0.912 (0.738&#8211;0.975)</td><td align="left" colspan="1" rowspan="1">0.917 (0.814&#8211;0.965)</td><td align="left" colspan="1" rowspan="1">114.58 (13.05&#8211;1006.35)</td><td align="left" colspan="1" rowspan="1">1.588 (0.308&#8211;8.187)</td><td align="left" colspan="1" rowspan="1">0.769 (0.133&#8211;4.435)</td></tr><tr><td align="left" rowspan="2" colspan="1">Data Type</td><td align="left" colspan="1" rowspan="1">3D</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">0.876 (0.764&#8211;0.939)</td><td align="left" colspan="1" rowspan="1">0.810 (0.575&#8211;0.931)</td><td align="left" colspan="1" rowspan="1">30.22 (4.71&#8211;193.68)</td><td align="left" colspan="1" rowspan="1">0.874 (0.211&#8211;3.615)</td><td align="left" colspan="1" rowspan="1">1.969 (0.536&#8211;7.234)</td></tr><tr><td align="left" colspan="1" rowspan="1">2D</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">0.827 (0.612&#8211;0.935)</td><td align="left" colspan="1" rowspan="1">0.835 (0.749&#8211;0.895)</td><td align="left" colspan="1" rowspan="1">24.05 (4.96&#8211;116.52)</td><td align="left" colspan="1" rowspan="1">1.195 (0.278&#8211;5.140)</td><td align="left" colspan="1" rowspan="1">0.219 (0.038&#8211;1.262)</td></tr><tr><td align="left" rowspan="2" colspan="1">Eligibility</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">0.855 (0.537&#8211;0.968)</td><td align="left" colspan="1" rowspan="1">0.840 (0.565&#8211;0.955)</td><td align="left" colspan="1" rowspan="1">31.08 (1.63&#8211;593.72)</td><td align="left" colspan="1" rowspan="1">2.618 (0.539&#8211;12.705)</td><td align="left" colspan="1" rowspan="1">1.914 (0.384&#8211;9.545)</td></tr><tr><td align="left" colspan="1" rowspan="1">Yes</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">0.871 (0.796&#8211;0.921)</td><td align="left" colspan="1" rowspan="1">0.794 (0.669&#8211;0.879)</td><td align="left" colspan="1" rowspan="1">25.87 (9.67&#8211;69.17)</td><td align="left" colspan="1" rowspan="1">0.398 (0.109&#8211;1.458)</td><td align="left" colspan="1" rowspan="1">0.585 (0.175&#8211;1.962)</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">SEN</italic> Sensitivit, SPE Specificity, <italic toggle="yes">DOR</italic> diagnostic odds ratio, <italic toggle="yes">Var</italic> (logitSe) variances of logit-transformed sensitivity, <italic toggle="yes">Var</italic> (logitSp) variances of logit-transformed specificity</p></table-wrap-foot></table-wrap></p><p id="Par44"><italic toggle="yes">Eligible subgroups of AD vs. NC</italic> (&#8805;&#8201;4 studies) included those stratified by feature region selection (whole brain, hippocampus, local brain regions), model architecture (single CNN vs. hybrid CNN), validation method (cross-validation vs. fixed-split), MRI sequence (1.5&#160;T T1w vs. general sequences), data dimension (2D vs. 3D), segmentation preprocessing (performed vs. not performed), literature quality (good quality vs. moderate quality), and clarity of eligibility criteria. In the MCI vs. NC group, subgroups meeting the sample size criterion were those categorized by validation method, data dimension, and eligibility criteria. Detailed data from the subgroup analyses are available in Supplementary Tables 4&#8212;Supplementary Tables 7.</p><p id="Par45"><italic toggle="yes">Subgroup analyses of the AD vs. NC</italic> cohort systematically identified key methodological determinants of diagnostic performance in AD, with findings as follows. In terms of feature selection, local brain region features demonstrated significantly superior diagnostic efficacy compared to whole-brain and hippocampal features. The DOR for the local brain region subgroup (511.5, 95% CI: 74.6&#8211;3508.0) was 2.4-fold (95% CI: 1.8&#8211;3.1) higher than that of the whole-brain feature subgroup (216.7, 95% CI: 69.1&#8211;679.5) and 10.8-fold (95% CI: 7.2&#8211;16.1) higher than that of the hippocampal feature subgroup (47.1, 95% CI: 20.6&#8211;107.5), indicating that targeted feature extraction from local brain regions may serve as a pivotal strategy to enhance AD diagnostic performance.</p><p id="Par46"><italic toggle="yes">Model architecture</italic> exerted a significant impact on efficacy. Hybrid CNN models (DOR&#8201;=&#8201;356.0, 95% CI: 37.6&#8211;3369.1) exhibited significantly greater diagnostic efficacy than single CNN architectures (DOR&#8201;=&#8201;120.2, 95% CI: 54.3&#8211;266.3; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001). However, this was accompanied by increased sensitivity heterogeneity in that the variance of logit-transformed sensitivity (Var(logitSe)) for hybrid CNN models (1.593, 95% CI: 0.33&#8211;7.80) was 219% higher than that for single CNN models (0.498, 95% CI: 0.19&#8211;1.29), suggesting that increased model complexity may be associated with reduced inter-study consistency.</p><p id="Par47"><italic toggle="yes">Variations in validation methods</italic> also greatly influenced outcomes. Studies employing fixed-split validation (DOR&#8201;=&#8201;508.2, 95% CI: 141.5&#8211;1825.3) demonstrated a diagnostic efficacy 9.4 times greater than those utilizing cross-validation (DOR&#8201;=&#8201;54.3, 95% CI: 30.5&#8211;96.6). Moreover, the cross-validation subgroup displayed substantially lower sensitivity heterogeneity (Var(logitSe)&#8201;=&#8201;0.16 vs. 1.17), with an 86.3% reduction, indicating that the rigor of validation methods may significantly affect the stability of efficacy estimates and that fixed-split approaches may carry a risk of overestimation.</p><p id="Par48"><italic toggle="yes">Analysis of data characteristics</italic> revealed that the 3D data subgroup outperformed the 2D data subgroup in comprehensive efficacy. The 3D data subgroup exhibited higher sensitivity (0.93, 95% CI: 0.87&#8211;0.96), specificity (0.95, 95% CI: 0.91&#8211;0.97), and DOR (213.5, 95% CI: 70.4&#8211;647.9) than the 2D data subgroup (sensitivity&#8201;=&#8201;0.91, specificity&#8201;=&#8201;0.91, DOR&#8201;=&#8201;110.5). Notably, studies without segmentation preprocessing reported a higher DOR (203.4 vs. 135.3), yet the segmentation subgroup showed a 30% reduction in specificity heterogeneity (Var (logitSp)&#8201;=&#8201;0.96 vs. 0.90), suggesting that segmentation preprocessing may enhance result consistency by mitigating inter-study methodological variability.</p><p id="Par49"><italic toggle="yes">Analyses of study quality</italic> revealed divergent diagnostic performances between subgroups. The relatively good quality subgroup (n&#8201;=&#8201;6) showed a lower DOR of 100.0 (95% CI: 27.5&#8211;363.9), with both sensitivity (0.90, 95% CI: 0.83&#8211;0.94) and specificity (0.92,95% CI: 0.84&#8211;0.96) being lower than those of the moderate quality subgroup (n&#8201;=&#8201;10). In contrast, the moderate quality subgroup exhibited a higher DOR of 274.6 (95% CI: 89.3&#8211;843.7), alongside marginally higher sensitivity (0.94, 95% CI: 0.89&#8211;0.97) and specificity (0.95, 95% CI: 0.90&#8211;0.97) compared to the good quality subgroup. Notably, the good quality subgroup had a 63.6% lower DOR than the moderate subgroup but demonstrated narrower variance in logit sensitivity (0.46 vs. 0.89) and logit specificity (0.83 vs. 0.99), indicating more consistent performance across studies despite the lower overall efficacy.</p><p id="Par50"><italic toggle="yes">Subgroup analysis of MCI vs. NC</italic> showed similar patterns, as presented in Table&#160;<xref rid="Tab4" ref-type="table">4</xref> in detail.</p></sec><sec id="Sec18"><title>Publication bias and clinical interpretation</title><p id="Par51">The Deeks funnel plots (Supplementary Fig.&#160;6A-D) showed no publication bias for the four classifications based on AD vs. NC, AD vs. MCI, MCI vs. NC, and pMCI vs. sMCI with P&#8201;=&#8201;0.77, 0.78, 0.24 and 0.30, respectively (Supplementary Tables 8).</p><p id="Par52">In the construction of a likelihood ratio matrix to assess the diagnostic capabilities of tests across four classification tasks, the AD vs. NC classification task revealed promising results. Specifically, five studies were positioned within the upper left quadrant, signifying high efficacy in both confirming and ruling out AD (Fig.&#160;<xref rid="Fig8" ref-type="fig">8</xref>). An additional six studies were found in the upper right quadrant, implying robust performance in confirming AD, yet potentially lacking in sensitivity for disease exclusion. Conversely, the three remaining classifications exhibited a prevalent shortfall, failing to achieve the desired thresholds for optimal PLR and NLR (Supplementary Fig. <xref rid="Fig8" ref-type="fig">8</xref>A-C).<fig id="Fig8" position="float" orientation="portrait"><label>Fig.&#160;8</label><caption><p>Likelihood ratio matrix illustrating the informative value for the AD vs. NC</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO8" position="float" orientation="portrait" xlink:href="12883_2025_4404_Fig8_HTML.jpg"/></fig></p></sec><sec id="Sec19"><title>Key discriminative brain regions in classification tasks</title><p id="Par53">Among the 21 articles incorporated in this study, only 5 provided detailed information regarding the identified brain regions possessing classification capabilities. The specific details can be found in Table&#160;<xref rid="Tab5" ref-type="table">5</xref>. Three studies have reported the discriminative brain regions in the AD vs. NC classification task. Notably, all these studies have identified and emphasized the discriminative significance of the parahippocampal gyrus. Moreover, both Pan et al. [<xref ref-type="bibr" rid="CR44">44</xref>] and Li et al. [<xref ref-type="bibr" rid="CR50">50</xref>] in their respective studies directed their attention to the amygdala region. On the other hand, Wee et al. [<xref ref-type="bibr" rid="CR45">45</xref>] emphasized cortical regions, including rolandic operculum, precuneus, middle cingulate gyrus, anterior cingulate gyrus, lingual gyrus, etc.<table-wrap id="Tab5" position="float" orientation="portrait"><label>Table 5</label><caption><p>Key discriminative brain regions in AD and MCI classification tasks</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Classification Task</th><th align="left" colspan="1" rowspan="1">Study</th><th align="left" colspan="1" rowspan="1">Brain Regions</th></tr></thead><tbody><tr><td align="left" rowspan="3" colspan="1">AD vs. NC</td><td align="left" colspan="1" rowspan="1">Li et al. (2018) [<xref ref-type="bibr" rid="CR50">50</xref>]</td><td align="left" colspan="1" rowspan="1">Amygdala, Hippocampus, Entorhinal, Thalamus, Temporal, Parahippocampal Gyrus</td></tr><tr><td align="left" colspan="1" rowspan="1">Pan et al. (2020) [<xref ref-type="bibr" rid="CR44">44</xref>]</td><td align="left" colspan="1" rowspan="1">Rostral Hippocampus, Medial Amygdala, Globus Pallidus,Lateral Amygdala, Entorhinal Cortex, Parahippocampal Gyrus</td></tr><tr><td align="left" colspan="1" rowspan="1">Wee et al. (2019) [<xref ref-type="bibr" rid="CR45">45</xref>]</td><td align="left" colspan="1" rowspan="1"><p>Rolandic Operculum, Precuneus, Middle Cingulate Gyrus, Anterior Cingulate Gyrus, Lingual Gyrus, ParaHippocampus,</p><p>Postcentral Gyrus, Superior Temporal Gyrus, Heschl's Gyrus, Paracentral Lobule</p></td></tr><tr><td align="left" rowspan="3" colspan="1">pMCI vs. sMCI</td><td align="left" colspan="1" rowspan="1">Kwak et al. (2022) [<xref ref-type="bibr" rid="CR39">39</xref>]</td><td align="left" colspan="1" rowspan="1">Subiculum, Presubiculum, Cornu Ammonis 1, Molecular Layer</td></tr><tr><td align="left" colspan="1" rowspan="1">Lin et al. (2018) [<xref ref-type="bibr" rid="CR42">42</xref>]</td><td align="left" colspan="1" rowspan="1">Cortical Thickness Average of Left Frontal Pole, Volume of Left Precentral, Volume of Right Post central, Volume of Left Accumbens Area, Cortical Thickness Average of Right Caudal Middle Frontal, Cortical Thickness Average of Right Frontal Pole, Volume of Left Bankssts, Volume of Left Posterior Cingulate, Volume of Left Insula, Cortical Thickness Average of Left Superior Temporal</td></tr><tr><td align="left" colspan="1" rowspan="1">Pan et al. (2020) [<xref ref-type="bibr" rid="CR44">44</xref>]</td><td align="left" colspan="1" rowspan="1">Middle Temporal Gyrus, Superior Temporal Gyrus, Fusiform Gyrus, Inferior Temporal Gyrus, Caudal Hippocampus</td></tr><tr><td align="left" rowspan="2" colspan="1">MCI vs. NC</td><td align="left" colspan="1" rowspan="1">Pan et al. (2020) [<xref ref-type="bibr" rid="CR44">44</xref>]</td><td align="left" colspan="1" rowspan="1">Rostral Hippocampus, Medial Amygdala, Caudal Hippocampus, Lateral Amygdala, Dorsolateral Putamen, Fusiform Gyrus, Globus Pallidus, Entorhinal Cortex, posterior parahippocampal gyrus</td></tr><tr><td align="left" colspan="1" rowspan="1">Wee et al. (2019) [<xref ref-type="bibr" rid="CR45">45</xref>]</td><td align="left" colspan="1" rowspan="1">Heschl's Gyrus, Superior Temporal Gyrus, Middle Temporal Gyrus, Middle Cingulate Gyrus, Olfactory, ParaHippocampus</td></tr></tbody></table></table-wrap></p><p id="Par54">In the pMCI vs. sMCI classification, Pan et al. [<xref ref-type="bibr" rid="CR44">44</xref>] identified temporal lobe regions (middle, superior, Fusiform, and inferior temporal gyri) and caudal hippocampus. Kwak et al. [<xref ref-type="bibr" rid="CR39">39</xref>] focused on key hippocampal subfields (subiculum, presubiculum, cornu ammonis 1, molecular layer). Lin et al. [<xref ref-type="bibr" rid="CR42">42</xref>] reported cortical thickness and volume measures in various brain areas (left frontal pole, precentral, right post central, accumbens area, etc.).&#160;These findings collectively indicate that the discrimination between pMCI and sMCI primarily involves structural changes in the hippocampus (including its subfields) and temporal lobe, with additional contributions from frontal and other cortical regions reflected in thickness and volume metrics.</p><p id="Par55">In the MCI vs. NC classification task, Pan et al. [<xref ref-type="bibr" rid="CR44">44</xref>] identified that the most discriminable brain regions were the rostral hippocampus, medial amygdala, caudal hippocampus, lateral amygdala, dorsolateral putamen, Fusiform gyrus, globus pallidus, entorhinal cortex, and posterior parahippocampal gyrus. Wee et al. [<xref ref-type="bibr" rid="CR45">45</xref>] found that the most discriminating regions for MCI were similar to those for AD, mainly encompassing the bilateral parahippocampus, the middle cingulate gyri, the left middle temporal gyrus, the bilateral superior temporal gyri, the bilateral Heschl's gyri, and the left olfactory region. Thus, the most discriminable brain regions for distinguishing MCI from NC are predominantly concentrated in the hippocampus, parahippocampal gyrus, amygdala, and temporal lobe structures, with involvement of cingulate and olfactory regions, highlighting the overlap of early pathological changes in these regions with those observed in AD.</p></sec></sec></sec><sec id="Sec20"><title>Discussion</title><p id="Par56">The meta-analytic findings of this study provided compelling evidence for utilizing CNN of sMRI data to differentiate AD, MCI, and NC. Specifically, the pooled diagnostic accuracies achieved by CNN models were 0.97 for AD versus NC, 0.91 for MCI versus NC, 0.92 for AD versus MCI, and 0.83 for pMCI versus sMCI. These results not only underscore the robustness of CNNs in automating the identification of neuroanatomical patterns associated with neurodegeneration, but also address a critical limitation in prior research. Unlike earlier studies [<xref ref-type="bibr" rid="CR51">51</xref>&#8211;<xref ref-type="bibr" rid="CR53">53</xref>] that predominantly relied on conventional radiomics approaches or a mix of machine learning algorithms (e.g., SVM, decision trees), this focused analysis on CNNs allowed for a more precise evaluation of their unique capabilities in extracting hierarchical features from sMRI data&#8212;capabilities that are particularly well-suited to capturing the subtle structural changes underlying AD and MCI.&#8203;</p><p id="Par57">A deliberate methodological choice in this study was the exclusive use of sMRI data, a decision rooted in careful consideration of the trade-offs between model robustness and diagnostic scope. Multimodal imaging integration, which combines sMRI with fMRI or PET, has been proposed to enhance diagnostic accuracy by incorporating complementary biological signals. However, such an approach introduces significant challenges, particularly in the context of small sample sizes typical of AD/MCI research [<xref ref-type="bibr" rid="CR54">54</xref>]. The inclusion of multimodal data can triple the dimensionality of input features (e.g., combining sMRI voxels with PET standardized uptake value ratios), thereby amplifying the risk of overfitting&#8212;a concern explicitly highlighted in the METRICS guidelines [<xref ref-type="bibr" rid="CR24">24</xref>], which emphasize rigorous dimensionality reduction in high-parameter models. Furthermore, the heterogeneity of acquisition protocols for modalities like PET (e.g., varying tracers such as (18F) FDG and (18F) florbetapir) across included studies would have invalidated cross-study comparisons, undermining the reliability of pooled results [<xref ref-type="bibr" rid="CR54">54</xref>]. By focusing solely on sMRI, this study mitigates these risks and quantifies the standalone diagnostic value of a modality that is widely accessible in clinical settings, providing a critical baseline for future investigations on the incremental benefits of multimodal integration.</p><p id="Par58">Subgroup analyses further illuminated key factors influencing the performance of CNN models and offered actionable insights for optimizing future neurodegenerative disease detection. Notably, targeted feature extraction from local brain regions&#8212;such as the entorhinal cortex and medial temporal lobe (MTL)&#8212;outperformed both whole-brain and hippocampus-only feature sets [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]. In the AD versus NC classification task, the local brain region subgroup demonstrated a DOR 10.8 times higher than the hippocampal subgroup. This finding aligns with well-established neuropathological evidence [<xref ref-type="bibr" rid="CR6">6</xref>], such as Braak staging [<xref ref-type="bibr" rid="CR57">57</xref>], which highlights the region-specific progression of AD pathology, early involvement of the entorhinal cortex, and subsequent spreading to the hippocampus and other limbic structures. It also underscores the limitations of relying on global or single-region features, which may fail to capture the focal nature of early neurodegenerative changes.&#8203;</p><p id="Par59">Hybrid CNN models that integrate multiple architectural components or feature streams exhibited superior diagnostic efficacy compared to single-architecture models but were associated with greater heterogeneity in sensitivity (219% higher variance in logit sensitivity). This observation points to a"complexity-consistency trade-off": while increased model complexity enhances the capacity to capture diverse neuroanatomical patterns, it also introduces variability stemming from differences in implementation (e.g., feature fusion strategies, training protocols) [<xref ref-type="bibr" rid="CR58">58</xref>]. This finding echoes prior research in medical image analysis, where hybrid models often show promise but require rigorous standardization to ensure reproducibility [<xref ref-type="bibr" rid="CR59">59</xref>].</p><p id="Par60">The superiority of 3D over 2D data in all classification tasks&#8212;consistently yielding higher sensitivity, specificity, and DOR&#8212;can be attributed to the preservation of volumetric and spatial relationships within the brain [<xref ref-type="bibr" rid="CR60">60</xref>]. Unlike 2D slices, which truncate the three-dimensional structure of key regions like the hippocampus, 3D data retains the contextual information necessary to detect subtle morphological changes, such as asymmetric atrophy or microstructural alterations, which are critical for early diagnosis [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR61">61</xref>]. Additionally, while studies that omitted segmentation preprocessing reported marginally higher DORs, those that included segmentation reduced specificity heterogeneity by approximately 30%. This highlights a trade-off between raw performance and result consistency: segmentation minimizes variability introduced by differences in imaging protocols (e.g., scanner resolution, contrast), as noted in prior work on neuroimaging standardization [<xref ref-type="bibr" rid="CR62">62</xref>], making it a valuable step for multi-center studies.</p><p id="Par61">The counterintuitive finding that the relatively high quality subgroup (DOR&#8201;=&#8201;100.0) outperformed the moderate-quality subgroup (DOR&#8201;=&#8201;274.6) in consistency, despite lower raw efficacy, warrants further explanation. This discrepancy likely stems from the stringent criteria defining &#8220;high&#8221; quality&#8212;such as stricter confounding control, rigorous external validation, and transparent reporting [<xref ref-type="bibr" rid="CR24">24</xref>], which mitigate overfitting and inflated estimates. In contrast, the higher DOR of the moderate-quality subgroup may reflect methodological flexibility (e.g., reliance on internal validation alone) and optimistic bias. Supporting this, the high-quality subgroup showed narrower variance in logit sensitivity (0.46 vs. 0.89) and specificity (0.83 vs. 0.99), aligning with evidence that rigorous methods stabilize performance across cohorts [<xref ref-type="bibr" rid="CR63">63</xref>]. The wider DOR confidence interval for the high quality subgroup (27.5&#8211;363.9 vs. 89.3&#8211;843.7 for the moderate) likely reflects its smaller size (n&#8201;=&#8201;6 vs. 10) and inclusion of more heterogeneous populations (e.g., strict NIA-AA criteria), thus reducing selection bias but increasing variability.</p><p id="Par62">Methodological rigor in the included studies was evaluated using two complementary tools: QUADAS-2 and the METRICS quality assessment instrument. QUADAS-2 was selected for its established role as the gold standard in assessing risk of bias in diagnostic accuracy studies, facilitating comparability with prior meta-analyses in the field [<xref ref-type="bibr" rid="CR23">23</xref>]. However, its application revealed critical limitations in the context of deep learning research. Notably, most studies received"unclear"ratings in the patient-selection domain, as QUADAS-2 presupposes predefined, uniform inclusion criteria and prospective consecutive enrollment&#8212;standards that are seldom met in CNN-based studies, which usully rely on retrospective, multi-center datasets (e.g., ADNI, AIBL) with heterogeneous recruitment strategies [<xref ref-type="bibr" rid="CR64">64</xref>]. Additionally, QUADAS-2 lacks guidelines to evaluate machine learning-specific sources of biases, such as data leakage, overfitting, or transparency in model development [<xref ref-type="bibr" rid="CR65">65</xref>].</p><p id="Par63">To address these gaps, this study pioneered the application of the METRICS instrument in the AD and MCI diagnostics. METRICS, which has been tailored to radiomics and machine learning research, provided a more nuanced assessment, assigning a mean quality score of 62.6%&#8201;&#177;&#8201;13.9% to the included studies [<xref ref-type="bibr" rid="CR24">24</xref>]. Key areas for improvement identified by METRICS include stricter adherence to machine learning-specific reporting guidelines, refinement of feature selection processes to exclude non-robust or redundant features, enhanced management of confounding variables, rigorous calibration assessments, and greater emphasis on external validation and open science practices. By combining the broad diagnostic accuracy assessment of QUADAS-2 with the machine learning-specific rigor of METRICS, this review offers a comprehensive evaluation that mitigates the limitations of relying on a single tool.</p><p id="Par64">Heterogeneity across studies was systematically evaluated using Galbraith plots, which indicated a scarcity of extreme outliers and a predominantly symmetrical distribution of effect sizes, suggesting that the observed variability was not driven by anomalous results. Deeks'funnel plots and asymmetry tests further confirmed the absence of significant publication bias, reinforcing the robustness of the meta-analytic conclusions.</p><p id="Par65">Regarding the discriminating brain regions in these classification tasks, those regions demonstrating the most significant discriminatory capacity were primarily located in the temporal lobe (including the temporal and Heschl's gyri), the parahippocampal region, and the cingulate gyri. The outcomes summarized in this review align with the discoveries of previous investigations on AD and MCI patient cohorts, which have recorded substantial atrophy in these brain regions [<xref ref-type="bibr" rid="CR66">66</xref>&#8211;<xref ref-type="bibr" rid="CR73">73</xref>]. The medial temporal lobe (MTL), which is well-recognized for its association with memory deficits [<xref ref-type="bibr" rid="CR74">74</xref>&#8211;<xref ref-type="bibr" rid="CR76">76</xref>], was also subject to impairment as the disease advanced. The atrophy in the parahippocampal region, which has been established as an early biomarker in AD [<xref ref-type="bibr" rid="CR77">77</xref>], substantiates our finding regarding the significant discriminatory capacity of the bilateral parahippocampal gyrus in the context of AD and MCI. Moreover, the measurements of cortical thickness in the superior temporal gyrus and the parahippocampus have been demonstrated to be efficacious in predicting the conversion from MCI to AD [<xref ref-type="bibr" rid="CR73">73</xref>], and this is congruent with the key brain regions identified by Pan in the discrimination between pMCI and sMCI.</p></sec><sec id="Sec21"><title>Limitations and future directions</title><p id="Par66">This study has several limitations that warrant consideration. First, the heterogeneity across included studies, which that stemmed from variations in CNN architectures, preprocessing pipelines, and cohort characteristics, may have influenced pooled results, despite efforts to mitigate this through subgroup analyses and heterogeneity assessments. Second, while justified by concerns about overfitting and protocol variability in multimodal data, the exclusive focus on sMRI limits the incremental value of combining sMRI with other modalities (e.g., PET, fMRI) to enhance diagnostic accuracy. Third, the paucity of reported discriminative brain regions (5/21 studies) hinders validation of the biological plausibility of CNN outputs, highlighting a critical gap in current reporting practices. Fourth, the reliance on retrospective datasets (e.g., ADNI) may introduce selection bias, as these cohorts may not fully represent real-world clinical populations with comorbidities.</p><p id="Par67">Future research may address these limitations through several key directions. First, standardize reporting guidelines for CNN-based neuroimaging studies and mandate details on model architecture, preprocessing steps, discriminative brain regions (using frameworks like NIA-AA), and validation protocols. Second, multimodal integration could be explored in a controlled fashion with autoencoders for dimensionality reduction or attention mechanisms for weighted feature fusion, doing so could harness complementary biological signals while mitigating overfitting risks. Third, prospective studies with diverse, real-world cohorts may be designed to validate the generalizability of CNN models beyond existing datasets. Fourth, Trust in the CNN output can be enhanced by integrating explainability techniques (e.g., Grad-CAM, SHAP) to visualize model attention and linking the output to known neuroanatomical hallmarks of AD and MCI. Fifth, heterogeneity in classification tasks may be reduced by standardizing MCI subtype definitions (e.g., pMCI vs. sMCI) using biological markers (e.g., CSF tau, PET amyloid). Finally, external validation across independent, multi-center cohorts may facilitate the translational potential of CNN-based diagnostics.</p></sec><sec id="Sec22"><title>Conclusion</title><p id="Par68">This systematic review and meta-analysis demonstrates that CNN algorithms applied to sMRI data achieve high diagnostic accuracies in distinguishing between AD, MCI, and NC. CNNs can be utilized in automating the detection of subtle neuroanatomical changes associated with neurodegeneration, with region-specific feature extraction and 3D data as key performance optimizers. The reliability and translational value of these models can be enhanced with methodological standardization, including adherence to reporting guidelines, standardized patient selection criteria, and documentation of discriminative brain regions.</p></sec><sec id="Sec23" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12883_2025_4404_MOESM1_ESM.xlsx" position="float" orientation="portrait"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12883_2025_4404_MOESM2_ESM.xlsx" position="float" orientation="portrait"><caption><p>Supplementary Material 2</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12883_2025_4404_MOESM3_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Material 3</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM4" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12883_2025_4404_MOESM4_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Material 4</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Xinxiu Dong, Yang Li and Jianbo Hao contributed equally to this work and should be considered co-first authors.</p></fn><fn><p>Wei Zhang and Hui Hu contributed equally to this work and should be considered co-corresponding authors.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable for this systematic review and meta-analysis.</p></ack><notes notes-type="author-contribution"><title>Authors&#8217; contributions</title><p>XD: Data curation; Writing &#8211; original draft. YL: Data curation; Writing &#8211; original draft. JH: Data curation; Writing &#8211; original draft. CY: Methodology; Writing &#8211; review &amp; editing. PZ: Literature assessment; Data extraction. MH: Bibliographic retrieval; Quality assessment. YA: Bibliographic retrieval; Quality assessment. WZ: Visualization; Writing &#8211; review &amp; editing. HH: Funding acquisition; Resources; Writing &#8211; review &amp; editing.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This systematic review and meta-analysis were funded by the Science and Technology Research Project of Hubei Provincial Department of Education (No. B2022285).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The original contributions presented in the study are included in the article and Supplementary material, further inquiries can be&#160;directed to the corresponding authors.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par69">Not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par70">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par71">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Alzheimer&#8217;s Association. 2023 Alzheimer&#8217;s disease facts and figures. Alzheimers Dement. 2023;19(4):1598&#8211;695. 10.1002/alz.13016.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13016</pub-id><pub-id pub-id-type="pmid">36918389</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Alzheimer&#8217;s Disease International. World Alzheimer report 2022. 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.alzint.org/resource/world-alzheimer-report-2022/">https://www.alzint.org/resource/world-alzheimer-report-2022/</ext-link>. Accessed 30 Jul 2025.</mixed-citation></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petersen</surname><given-names>RC</given-names></name></person-group><article-title>Mild cognitive impairment</article-title><source>N Engl J Med</source><year>2011</year><volume>364</volume><issue>23</issue><fpage>2227</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1056/NEJMcp0910237</pub-id><pub-id pub-id-type="pmid">21651394</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Petersen RC. Mild cognitive impairment. N Engl J Med. 2011;364(23):2227&#8211;34. 10.1056/NEJMcp0910237.<pub-id pub-id-type="pmid">21651394</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMcp0910237</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>CR</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K</given-names></name><name name-style="western"><surname>Carrillo</surname><given-names>MC</given-names></name><name name-style="western"><surname>Dunn</surname><given-names>B</given-names></name><name name-style="western"><surname>Haeberlein</surname><given-names>SB</given-names></name><etal/></person-group><article-title>NIA-AA research framework: toward a biological definition of Alzheimer&#8217;s disease</article-title><source>Alzheimers Dement</source><year>2018</year><volume>14</volume><issue>4</issue><fpage>535</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2018.02.018</pub-id><pub-id pub-id-type="pmid">29653606</pub-id><pub-id pub-id-type="pmcid">PMC5958625</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer&#8217;s disease. Alzheimers Dement. 2018;14(4):535&#8211;62. 10.1016/j.jalz.2018.02.018.<pub-id pub-id-type="pmid">29653606</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2018.02.018</pub-id><pub-id pub-id-type="pmcid">PMC5958625</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vemuri</surname><given-names>P</given-names></name><name name-style="western"><surname>Jack</surname><given-names>CR</given-names></name></person-group><article-title>Role of structural MRI in Alzheimer&#8217;s disease</article-title><source>Alzheimers Res Ther</source><year>2010</year><volume>2</volume><issue>4</issue><fpage>23</fpage><pub-id pub-id-type="doi">10.1186/alzrt47</pub-id><pub-id pub-id-type="pmid">20807454</pub-id><pub-id pub-id-type="pmcid">PMC2949589</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Vemuri P, Jack CR. Role of structural MRI in Alzheimer&#8217;s disease. Alzheimers Res Ther. 2010;2(4): 23. 10.1186/alzrt47.<pub-id pub-id-type="pmid">20807454</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/alzrt47</pub-id><pub-id pub-id-type="pmcid">PMC2949589</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whitwell</surname><given-names>JL</given-names></name><name name-style="western"><surname>Przybelski</surname><given-names>SA</given-names></name><name name-style="western"><surname>Weigand</surname><given-names>SD</given-names></name><name name-style="western"><surname>Knopman</surname><given-names>DS</given-names></name><name name-style="western"><surname>Boeve</surname><given-names>BF</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>RC</given-names></name><etal/></person-group><article-title>3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer&#8217;s disease</article-title><source>Brain</source><year>2007</year><volume>130</volume><issue>7</issue><fpage>1777</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1093/brain/awm112</pub-id><pub-id pub-id-type="pmid">17533169</pub-id><pub-id pub-id-type="pmcid">PMC2752411</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Whitwell JL, Przybelski SA, Weigand SD, Knopman DS, Boeve BF, Petersen RC, et al. 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer&#8217;s disease. Brain. 2007;130(7):1777&#8211;86. 10.1093/brain/awm112.<pub-id pub-id-type="pmid">17533169</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awm112</pub-id><pub-id pub-id-type="pmcid">PMC2752411</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>K</given-names></name></person-group><article-title>Magnetic resonance imaging measurement of entorhinal cortex in the diagnosis and differential diagnosis of mild cognitive impairment and Alzheimer&#8217;s disease</article-title><source>Brain Sci</source><year>2021</year><volume>11</volume><issue>9</issue><fpage>1129</fpage><pub-id pub-id-type="doi">10.3390/brainsci11091129</pub-id><pub-id pub-id-type="pmid">34573151</pub-id><pub-id pub-id-type="pmcid">PMC8471837</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Li Q, Wang J, Liu J, Wang Y, Li K. Magnetic resonance imaging measurement of entorhinal cortex in the diagnosis and differential diagnosis of mild cognitive impairment and Alzheimer&#8217;s disease. Brain Sci. 2021;11(9): 1129. 10.3390/brainsci11091129.<pub-id pub-id-type="pmid">34573151</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/brainsci11091129</pub-id><pub-id pub-id-type="pmcid">PMC8471837</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>HY</given-names></name><name name-style="western"><surname>Suh</surname><given-names>CH</given-names></name><name name-style="western"><surname>Heo</surname><given-names>H</given-names></name><name name-style="western"><surname>Shim</surname><given-names>WH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>SJ</given-names></name></person-group><article-title>Diagnostic performance of hippocampal volumetry in Alzheimer&#8217;s disease or mild cognitive impairment: a meta-analysis</article-title><source>Eur Radiol</source><year>2022</year><volume>32</volume><issue>10</issue><fpage>6979</fpage><lpage>6991</lpage><pub-id pub-id-type="doi">10.1007/s00330-022-08838-9</pub-id><pub-id pub-id-type="pmid">35507052</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Park HY, Suh CH, Heo H, Shim WH, Kim SJ. Diagnostic performance of hippocampal volumetry in Alzheimer&#8217;s disease or mild cognitive impairment: a meta-analysis. Eur Radiol. 2022;32(10):6979&#8211;91. 10.1007/s00330-022-08838-9.<pub-id pub-id-type="pmid">35507052</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00330-022-08838-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lambin</surname><given-names>P</given-names></name><name name-style="western"><surname>Rios-Velazquez</surname><given-names>E</given-names></name><name name-style="western"><surname>Leijenaar</surname><given-names>R</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>S</given-names></name><name name-style="western"><surname>Van Stiphout</surname><given-names>RGPM</given-names></name><name name-style="western"><surname>Granton</surname><given-names>P</given-names></name><etal/></person-group><article-title>Radiomics: extracting more information from medical images using advanced feature analysis</article-title><source>Eur J Cancer</source><year>2012</year><volume>48</volume><issue>4</issue><fpage>441</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2011.11.036</pub-id><pub-id pub-id-type="pmid">22257792</pub-id><pub-id pub-id-type="pmcid">PMC4533986</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, Van Stiphout RGPM, Granton P, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012;48(4):441&#8211;6. 10.1016/j.ejca.2011.11.036.<pub-id pub-id-type="pmid">22257792</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2011.11.036</pub-id><pub-id pub-id-type="pmcid">PMC4533986</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lambin</surname><given-names>P</given-names></name><name name-style="western"><surname>Leijenaar</surname><given-names>RTH</given-names></name><name name-style="western"><surname>Deist</surname><given-names>TM</given-names></name><name name-style="western"><surname>Peerlings</surname><given-names>J</given-names></name><name name-style="western"><surname>De Jong</surname><given-names>EEC</given-names></name><name name-style="western"><surname>Van Timmeren</surname><given-names>J</given-names></name><etal/></person-group><article-title>Radiomics: the bridge between medical imaging and personalized medicine</article-title><source>Nat Rev Clin Oncol</source><year>2017</year><volume>14</volume><issue>12</issue><fpage>749</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1038/nrclinonc.2017.141</pub-id><pub-id pub-id-type="pmid">28975929</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Lambin P, Leijenaar RTH, Deist TM, Peerlings J, De Jong EEC, Van Timmeren J, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14(12):749&#8211;62. 10.1038/nrclinonc.2017.141.<pub-id pub-id-type="pmid">28975929</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrclinonc.2017.141</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yip</surname><given-names>SSF</given-names></name><name name-style="western"><surname>Aerts</surname><given-names>HJWL</given-names></name></person-group><article-title>Applications and limitations of radiomics</article-title><source>Phys Med Biol</source><year>2016</year><volume>61</volume><issue>13</issue><fpage>R150</fpage><lpage>R166</lpage><pub-id pub-id-type="doi">10.1088/0031-9155/61/13/R150</pub-id><pub-id pub-id-type="pmid">27269645</pub-id><pub-id pub-id-type="pmcid">PMC4927328</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Yip SSF, Aerts HJWL. Applications and limitations of radiomics. Phys Med Biol. 2016;61(13):R150&#8211;66. 10.1088/0031-9155/61/13/R150.<pub-id pub-id-type="pmid">27269645</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1088/0031-9155/61/13/R150</pub-id><pub-id pub-id-type="pmcid">PMC4927328</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Dong</surname><given-names>D</given-names></name><name name-style="western"><surname>Wei</surname><given-names>J</given-names></name><name name-style="western"><surname>Fang</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name><etal/></person-group><article-title>The applications of radiomics in precision diagnosis and treatment of oncology: opportunities and challenges</article-title><source>Theranostics</source><year>2019</year><volume>9</volume><issue>5</issue><fpage>1303</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.7150/thno.30309</pub-id><pub-id pub-id-type="pmid">30867832</pub-id><pub-id pub-id-type="pmcid">PMC6401507</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Liu Z, Wang S, Dong D, Wei J, Fang C, Zhou X, et al. The applications of radiomics in precision diagnosis and treatment of oncology: opportunities and challenges. Theranostics. 2019;9(5):1303&#8211;22. 10.7150/thno.30309.<pub-id pub-id-type="pmid">30867832</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.30309</pub-id><pub-id pub-id-type="pmcid">PMC6401507</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J-G</given-names></name><name name-style="western"><surname>Jun</surname><given-names>S</given-names></name><name name-style="western"><surname>Cho</surname><given-names>Y-W</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H</given-names></name><name name-style="western"><surname>Kim</surname><given-names>GB</given-names></name><name name-style="western"><surname>Seo</surname><given-names>JB</given-names></name><etal/></person-group><article-title>Deep learning in medical imaging: general overview</article-title><source>Korean J Radiol</source><year>2017</year><volume>18</volume><issue>4</issue><fpage>570</fpage><pub-id pub-id-type="doi">10.3348/kjr.2017.18.4.570</pub-id><pub-id pub-id-type="pmid">28670152</pub-id><pub-id pub-id-type="pmcid">PMC5447633</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Lee J-G, Jun S, Cho Y-W, Lee H, Kim GB, Seo JB, et al. Deep learning in medical imaging: general overview. Korean J Radiol. 2017;18(4): 570. 10.3348/kjr.2017.18.4.570.<pub-id pub-id-type="pmid">28670152</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3348/kjr.2017.18.4.570</pub-id><pub-id pub-id-type="pmcid">PMC5447633</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ji</surname><given-names>S</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M</given-names></name><name name-style="western"><surname>Yu</surname><given-names>K</given-names></name></person-group><article-title>3d convolutional neural networks for human action recognition</article-title><source>IEEE Trans Pattern Anal Mach Intell</source><year>2013</year><volume>35</volume><issue>1</issue><fpage>221</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1109/TPAMI.2012.59</pub-id><pub-id pub-id-type="pmid">22392705</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Ji S, Xu W, Yang M, Yu K. 3d convolutional neural networks for human action recognition. IEEE Trans Pattern Anal Mach Intell. 2013;35(1):221&#8211;31. 10.1109/TPAMI.2012.59.<pub-id pub-id-type="pmid">22392705</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/TPAMI.2012.59</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Litjens</surname><given-names>G</given-names></name><name name-style="western"><surname>Kooi</surname><given-names>T</given-names></name><name name-style="western"><surname>Bejnordi</surname><given-names>BE</given-names></name><name name-style="western"><surname>Setio</surname><given-names>AAA</given-names></name><name name-style="western"><surname>Ciompi</surname><given-names>F</given-names></name><name name-style="western"><surname>Ghafoorian</surname><given-names>M</given-names></name><etal/></person-group><article-title>A survey on deep learning in medical image analysis</article-title><source>Med Image Anal</source><year>2017</year><volume>42</volume><fpage>60</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.media.2017.07.005</pub-id><pub-id pub-id-type="pmid">28778026</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Litjens G, Kooi T, Bejnordi BE, Setio AAA, Ciompi F, Ghafoorian M, et al. A survey on deep learning in medical image analysis. Med Image Anal. 2017;42:60&#8211;88. 10.1016/j.media.2017.07.005.<pub-id pub-id-type="pmid">28778026</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.media.2017.07.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anwar</surname><given-names>SM</given-names></name><name name-style="western"><surname>Majid</surname><given-names>M</given-names></name><name name-style="western"><surname>Qayyum</surname><given-names>A</given-names></name><name name-style="western"><surname>Awais</surname><given-names>M</given-names></name><name name-style="western"><surname>Alnowami</surname><given-names>M</given-names></name><name name-style="western"><surname>Khan</surname><given-names>MK</given-names></name></person-group><article-title>Medical image analysis using convolutional neural networks: a review</article-title><source>J Med Syst</source><year>2018</year><volume>42</volume><issue>11</issue><fpage>226</fpage><pub-id pub-id-type="doi">10.1007/s10916-018-1088-1</pub-id><pub-id pub-id-type="pmid">30298337</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Anwar SM, Majid M, Qayyum A, Awais M, Alnowami M, Khan MK. Medical image analysis using convolutional neural networks: a review. J Med Syst. 2018;42(11): 226. 10.1007/s10916-018-1088-1.<pub-id pub-id-type="pmid">30298337</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10916-018-1088-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Chavez</surname><given-names>T</given-names></name><name name-style="western"><surname>Hexemer</surname><given-names>A</given-names></name><name name-style="western"><surname>Zwart</surname><given-names>PH</given-names></name></person-group><article-title>DLSIA: Deep learning for scientific image analysis</article-title><source>J Appl Crystallogr</source><year>2024</year><volume>57</volume><issue>2</issue><fpage>392</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1107/S1600576724001390</pub-id><pub-id pub-id-type="pmid">38596727</pub-id><pub-id pub-id-type="pmcid">PMC11001410</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Roberts EJ, Chavez T, Hexemer A, Zwart PH. DLSIA: Deep learning for scientific image analysis. J Appl Crystallogr. 2024;57(2):392&#8211;402. 10.1107/S1600576724001390.<pub-id pub-id-type="pmid">38596727</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1107/S1600576724001390</pub-id><pub-id pub-id-type="pmcid">PMC11001410</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soffer</surname><given-names>S</given-names></name><name name-style="western"><surname>Ben-Cohen</surname><given-names>A</given-names></name><name name-style="western"><surname>Shimon</surname><given-names>O</given-names></name><name name-style="western"><surname>Amitai</surname><given-names>MM</given-names></name><name name-style="western"><surname>Greenspan</surname><given-names>H</given-names></name><name name-style="western"><surname>Klang</surname><given-names>E</given-names></name></person-group><article-title>Convolutional neural networks for radiologic images: a radiologist&#8217;s guide</article-title><source>Radiology</source><year>2019</year><volume>290</volume><issue>3</issue><fpage>590</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1148/radiol.2018180547</pub-id><pub-id pub-id-type="pmid">30694159</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Soffer S, Ben-Cohen A, Shimon O, Amitai MM, Greenspan H, Klang E. Convolutional neural networks for radiologic images: a radiologist&#8217;s guide. Radiology. 2019;290(3):590&#8211;606. 10.1148/radiol.2018180547.<pub-id pub-id-type="pmid">30694159</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1148/radiol.2018180547</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chuah</surname><given-names>JH</given-names></name><name name-style="western"><surname>Lai</surname><given-names>KW</given-names></name><name name-style="western"><surname>Chow</surname><given-names>C-O</given-names></name><name name-style="western"><surname>Gochoo</surname><given-names>M</given-names></name><name name-style="western"><surname>Dhanalakshmi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Conventional machine learning and deep learning in Alzheimer&#8217;s disease diagnosis using neuroimaging: a review</article-title><source>Front Comput Neurosci</source><year>2023</year><volume>17</volume><fpage>1038636</fpage><pub-id pub-id-type="doi">10.3389/fncom.2023.1038636</pub-id><pub-id pub-id-type="pmid">36814932</pub-id><pub-id pub-id-type="pmcid">PMC9939698</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Zhao Z, Chuah JH, Lai KW, Chow C-O, Gochoo M, Dhanalakshmi S, et al. Conventional machine learning and deep learning in Alzheimer&#8217;s disease diagnosis using neuroimaging: a review. Front Comput Neurosci. 2023;17: 1038636. 10.3389/fncom.2023.1038636.<pub-id pub-id-type="pmid">36814932</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fncom.2023.1038636</pub-id><pub-id pub-id-type="pmcid">PMC9939698</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McInnes</surname><given-names>MDF</given-names></name><name name-style="western"><surname>Moher</surname><given-names>D</given-names></name><name name-style="western"><surname>Thombs</surname><given-names>BD</given-names></name><name name-style="western"><surname>McGrath</surname><given-names>TA</given-names></name><name name-style="western"><surname>Bossuyt</surname><given-names>PM</given-names></name><collab>the PRISMA-DTA Group</collab><etal/></person-group><article-title>Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement</article-title><source>JAMA</source><year>2018</year><volume>319</volume><issue>4</issue><fpage>388</fpage><pub-id pub-id-type="doi">10.1001/jama.2017.19163</pub-id><pub-id pub-id-type="pmid">29362800</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM, the PRISMA-DTA Group, et al. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. JAMA. 2018;319(4):388. 10.1001/jama.2017.19163.<pub-id pub-id-type="pmid">29362800</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2017.19163</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Salameh J-P, Bossuyt PM, McGrath TA, Thombs BD, Hyde CJ, Macaskill P, et al. Preferred reporting items for systematic review and meta-analysis of diagnostic test accuracy studies (PRISMA-DTA): explanation, elaboration, and checklist. BMJ. 2020:m2632. 10.1136/bmj.m2632.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.m2632</pub-id><pub-id pub-id-type="pmid">32816740</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petersen</surname><given-names>RC</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>PS</given-names></name><name name-style="western"><surname>Beckett</surname><given-names>LA</given-names></name><name name-style="western"><surname>Donohue</surname><given-names>MC</given-names></name><name name-style="western"><surname>Gamst</surname><given-names>AC</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Alzheimer&#8217;s disease neuroimaging initiative (ADNI): clinical characterization</article-title><source>Neurology</source><year>2010</year><volume>74</volume><issue>3</issue><fpage>201</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3181cb3e25</pub-id><pub-id pub-id-type="pmid">20042704</pub-id><pub-id pub-id-type="pmcid">PMC2809036</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, et al. Alzheimer&#8217;s disease neuroimaging initiative (ADNI): clinical characterization. Neurology. 2010;74(3):201&#8211;9. 10.1212/WNL.0b013e3181cb3e25.<pub-id pub-id-type="pmid">20042704</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e3181cb3e25</pub-id><pub-id pub-id-type="pmcid">PMC2809036</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whiting</surname><given-names>PF</given-names></name><name name-style="western"><surname>Rutjes</surname><given-names>AWS</given-names></name><name name-style="western"><surname>Westwood</surname><given-names>ME</given-names></name><name name-style="western"><surname>Mallett</surname><given-names>S</given-names></name><name name-style="western"><surname>Deeks</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Reitsma</surname><given-names>JB</given-names></name><etal/></person-group><article-title>QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies</article-title><source>Ann Intern Med</source><year>2011</year><volume>155</volume><issue>8</issue><fpage>529</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-155-8-201110180-00009</pub-id><pub-id pub-id-type="pmid">22007046</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529&#8211;36. 10.7326/0003-4819-155-8-201110180-00009.<pub-id pub-id-type="pmid">22007046</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/0003-4819-155-8-201110180-00009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kocak</surname><given-names>B</given-names></name><name name-style="western"><surname>AkinciD&#8217;Antonoli</surname><given-names>T</given-names></name><name name-style="western"><surname>Mercaldo</surname><given-names>N</given-names></name><name name-style="western"><surname>Alberich-Bayarri</surname><given-names>A</given-names></name><name name-style="western"><surname>Baessler</surname><given-names>B</given-names></name><name name-style="western"><surname>Ambrosini</surname><given-names>I</given-names></name><etal/></person-group><article-title>Methodological radiomics score (METRICS): a quality scoring tool for radiomics research endorsed by EuSoMII</article-title><source>Insights Imaging</source><year>2024</year><volume>15</volume><issue>1</issue><fpage>8</fpage><pub-id pub-id-type="doi">10.1186/s13244-023-01572-w</pub-id><pub-id pub-id-type="pmid">38228979</pub-id><pub-id pub-id-type="pmcid">PMC10792137</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Kocak B, AkinciD&#8217;Antonoli T, Mercaldo N, Alberich-Bayarri A, Baessler B, Ambrosini I, et al. Methodological radiomics score (METRICS): a quality scoring tool for radiomics research endorsed by EuSoMII. Insights Imaging. 2024;15(1): 8. 10.1186/s13244-023-01572-w.<pub-id pub-id-type="pmid">38228979</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13244-023-01572-w</pub-id><pub-id pub-id-type="pmcid">PMC10792137</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moses</surname><given-names>LE</given-names></name><name name-style="western"><surname>Shapiro</surname><given-names>D</given-names></name><name name-style="western"><surname>Littenberg</surname><given-names>B</given-names></name></person-group><article-title>Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations</article-title><source>Stat Med</source><year>1993</year><volume>12</volume><issue>14</issue><fpage>1293</fpage><lpage>1316</lpage><pub-id pub-id-type="doi">10.1002/sim.4780121403</pub-id><pub-id pub-id-type="pmid">8210827</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med. 1993;12(14):1293&#8211;316. 10.1002/sim.4780121403.<pub-id pub-id-type="pmid">8210827</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/sim.4780121403</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reitsma</surname><given-names>JB</given-names></name><name name-style="western"><surname>Glas</surname><given-names>AS</given-names></name><name name-style="western"><surname>Rutjes</surname><given-names>AWS</given-names></name><name name-style="western"><surname>Scholten</surname><given-names>RJPM</given-names></name><name name-style="western"><surname>Bossuyt</surname><given-names>PM</given-names></name><name name-style="western"><surname>Zwinderman</surname><given-names>AH</given-names></name></person-group><article-title>Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews</article-title><source>J Clin Epidemiol</source><year>2005</year><volume>58</volume><issue>10</issue><fpage>982</fpage><lpage>990</lpage><pub-id pub-id-type="doi">10.1016/j.jclinepi.2005.02.022</pub-id><pub-id pub-id-type="pmid">16168343</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Reitsma JB, Glas AS, Rutjes AWS, Scholten RJPM, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol. 2005;58(10):982&#8211;90. 10.1016/j.jclinepi.2005.02.022.<pub-id pub-id-type="pmid">16168343</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jclinepi.2005.02.022</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Higgins</surname><given-names>JPT</given-names></name></person-group><article-title>Measuring inconsistency in meta-analyses</article-title><source>BMJ</source><year>2003</year><volume>327</volume><issue>7414</issue><fpage>557</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1136/bmj.327.7414.557</pub-id><pub-id pub-id-type="pmid">12958120</pub-id><pub-id pub-id-type="pmcid">PMC192859</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Higgins JPT. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557&#8211;60. 10.1136/bmj.327.7414.557.<pub-id pub-id-type="pmid">12958120</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.327.7414.557</pub-id><pub-id pub-id-type="pmcid">PMC192859</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agarwal</surname><given-names>D</given-names></name><name name-style="western"><surname>Berb&#237;s</surname><given-names>M&#193;</given-names></name><name name-style="western"><surname>Luna</surname><given-names>A</given-names></name><name name-style="western"><surname>Lipari</surname><given-names>V</given-names></name><name name-style="western"><surname>Ballester</surname><given-names>JB</given-names></name><name name-style="western"><surname>De La Torre-D&#237;ez</surname><given-names>I</given-names></name></person-group><article-title>Automated medical diagnosis of Alzheimer&#180;s disease using an efficient net convolutional neural network</article-title><source>J Med Syst</source><year>2023</year><volume>47</volume><issue>1</issue><fpage>57</fpage><pub-id pub-id-type="doi">10.1007/s10916-023-01941-4</pub-id><pub-id pub-id-type="pmid">37129723</pub-id><pub-id pub-id-type="pmcid">PMC10154284</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Agarwal D, Berb&#237;s M&#193;, Luna A, Lipari V, Ballester JB, De La Torre-D&#237;ez I. Automated medical diagnosis of Alzheimer&#180;s disease using an efficient net convolutional neural network. J Med Syst. 2023;47(1): 57. 10.1007/s10916-023-01941-4.<pub-id pub-id-type="pmid">37129723</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10916-023-01941-4</pub-id><pub-id pub-id-type="pmcid">PMC10154284</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>AlSaeed</surname><given-names>D</given-names></name><name name-style="western"><surname>Omar</surname><given-names>SF</given-names></name></person-group><article-title>Brain MRI analysis for Alzheimer&#8217;s disease diagnosis using CNN-based feature extraction and machine learning</article-title><source>Sensors</source><year>2022</year><volume>22</volume><issue>8</issue><fpage>2911</fpage><pub-id pub-id-type="doi">10.3390/s22082911</pub-id><pub-id pub-id-type="pmid">35458896</pub-id><pub-id pub-id-type="pmcid">PMC9025443</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">AlSaeed D, Omar SF. Brain MRI analysis for Alzheimer&#8217;s disease diagnosis using CNN-based feature extraction and machine learning. Sensors. 2022;22(8): 2911. 10.3390/s22082911.<pub-id pub-id-type="pmid">35458896</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/s22082911</pub-id><pub-id pub-id-type="pmcid">PMC9025443</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Awarayi</surname><given-names>NS</given-names></name><name name-style="western"><surname>Twum</surname><given-names>F</given-names></name><name name-style="western"><surname>Hayfron-Acquah</surname><given-names>JB</given-names></name><name name-style="western"><surname>Owusu-Agyemang</surname><given-names>K</given-names></name></person-group><article-title>A bilateral filtering-based image enhancement for Alzheimer disease classification using CNN</article-title><source>PLoS One</source><year>2024</year><volume>19</volume><issue>4</issue><fpage>e0302358</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0302358</pub-id><pub-id pub-id-type="pmid">38640105</pub-id><pub-id pub-id-type="pmcid">PMC11029622</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Awarayi NS, Twum F, Hayfron-Acquah JB, Owusu-Agyemang K. A bilateral filtering-based image enhancement for Alzheimer disease classification using CNN. PLoS One. 2024;19(4): e0302358. 10.1371/journal.pone.0302358.<pub-id pub-id-type="pmid">38640105</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0302358</pub-id><pub-id pub-id-type="pmcid">PMC11029622</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Basaia</surname><given-names>S</given-names></name><name name-style="western"><surname>Agosta</surname><given-names>F</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>L</given-names></name><name name-style="western"><surname>Canu</surname><given-names>E</given-names></name><name name-style="western"><surname>Magnani</surname><given-names>G</given-names></name><name name-style="western"><surname>Santangelo</surname><given-names>R</given-names></name><etal/></person-group><article-title>Automated classification of Alzheimer&#8217;s disease and mild cognitive impairment using a single MRI and deep neural networks</article-title><source>NeuroImage: Clinical</source><year>2019</year><volume>21</volume><fpage>101645</fpage><pub-id pub-id-type="doi">10.1016/j.nicl.2018.101645</pub-id><pub-id pub-id-type="pmid">30584016</pub-id><pub-id pub-id-type="pmcid">PMC6413333</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Basaia S, Agosta F, Wagner L, Canu E, Magnani G, Santangelo R, et al. Automated classification of Alzheimer&#8217;s disease and mild cognitive impairment using a single MRI and deep neural networks. NeuroImage: Clinical. 2019;21: 101645. 10.1016/j.nicl.2018.101645.<pub-id pub-id-type="pmid">30584016</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nicl.2018.101645</pub-id><pub-id pub-id-type="pmcid">PMC6413333</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bi</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Shang</surname><given-names>Q</given-names></name></person-group><article-title>Artificial intelligence-based MRI images for brain in prediction of Alzheimer&#8217;s disease</article-title><source>J Healthc Eng</source><year>2021</year><volume>2021</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1155/2021/8198552</pub-id><pub-id pub-id-type="pmcid">PMC8548180</pub-id><pub-id pub-id-type="pmid">34712461</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Bi X, Liu W, Liu H, Shang Q. Artificial intelligence-based MRI images for brain in prediction of Alzheimer&#8217;s disease. J Healthc Eng. 2021;2021:1&#8211;7. 10.1155/2021/8198552.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2021/8198552</pub-id><pub-id pub-id-type="pmcid">PMC8548180</pub-id><pub-id pub-id-type="pmid">34712461</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>F</given-names></name></person-group><article-title>Alzheimer&#8217;s disease diagnosis with brain structural MRI using multiview-slice attention and 3D convolution neural network</article-title><source>Front Aging Neurosci</source><year>2022</year><volume>14</volume><fpage>871706</fpage><pub-id pub-id-type="doi">10.3389/fnagi.2022.871706</pub-id><pub-id pub-id-type="pmid">35557839</pub-id><pub-id pub-id-type="pmcid">PMC9088013</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Chen L, Qiao H, Zhu F. Alzheimer&#8217;s disease diagnosis with brain structural MRI using multiview-slice attention and 3D convolution neural network. Front Aging Neurosci. 2022;14: 871706. 10.3389/fnagi.2022.871706.<pub-id pub-id-type="pmid">35557839</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2022.871706</pub-id><pub-id pub-id-type="pmcid">PMC9088013</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cui</surname><given-names>R</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name></person-group><article-title>Hippocampus analysis by combination of 3D DenseNet and shapes for Alzheimer&#8217;s disease diagnosis</article-title><source>IEEE J Biomed Health Inform</source><year>2019</year><volume>23</volume><issue>5</issue><fpage>2099</fpage><lpage>2107</lpage><pub-id pub-id-type="doi">10.1109/JBHI.2018.2882392</pub-id><pub-id pub-id-type="pmid">30475734</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Cui R, Liu M. Hippocampus analysis by combination of 3D DenseNet and shapes for Alzheimer&#8217;s disease diagnosis. IEEE J Biomed Health Inform. 2019;23(5):2099&#8211;107. 10.1109/JBHI.2018.2882392.<pub-id pub-id-type="pmid">30475734</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/JBHI.2018.2882392</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>C-C</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Peng</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Graph reasoning module for Alzheimer&#8217;s disease diagnosis: a plug-and-play method</article-title><source>IEEE Trans Neural Syst Rehabil Eng</source><year>2023</year><volume>31</volume><fpage>4773</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1109/TNSRE.2023.3337533</pub-id><pub-id pub-id-type="pmid">38015665</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Fan C-C, Yang H, Zhang C, Peng L, Zhou X, Liu S, et al. Graph reasoning module for Alzheimer&#8217;s disease diagnosis: a plug-and-play method. IEEE Trans Neural Syst Rehabil Eng. 2023;31:4773&#8211;80. 10.1109/TNSRE.2023.3337533.<pub-id pub-id-type="pmid">38015665</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/TNSRE.2023.3337533</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>W</given-names></name><name name-style="western"><surname>Halm-Lutterodt</surname><given-names>NV</given-names></name><name name-style="western"><surname>Tang</surname><given-names>H</given-names></name><name name-style="western"><surname>Mecum</surname><given-names>A</given-names></name><name name-style="western"><surname>Mesregah</surname><given-names>MK</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Automated MRI-based deep learning model for detection of Alzheimer&#8217;s disease process</article-title><source>Int J Neural Syst</source><year>2020</year><volume>30</volume><issue>6</issue><fpage>2050032</fpage><pub-id pub-id-type="doi">10.1142/S012906572050032X</pub-id><pub-id pub-id-type="pmid">32498641</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Feng W, Halm-Lutterodt NV, Tang H, Mecum A, Mesregah MK, Ma Y, et al. Automated MRI-based deep learning model for detection of Alzheimer&#8217;s disease process. Int J Neural Syst. 2020;30(6): 2050032. 10.1142/S012906572050032X.<pub-id pub-id-type="pmid">32498641</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1142/S012906572050032X</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herzog</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Magoulas</surname><given-names>GD</given-names></name></person-group><article-title>Convolutional neural networks-based framework for early identification of dementia using MRI of brain asymmetry</article-title><source>Int J Neural Syst</source><year>2022</year><volume>32</volume><issue>12</issue><fpage>2250053</fpage><pub-id pub-id-type="doi">10.1142/S0129065722500538</pub-id><pub-id pub-id-type="pmid">36106446</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Herzog NJ, Magoulas GD. Convolutional neural networks-based framework for early identification of dementia using MRI of brain asymmetry. Int J Neural Syst. 2022;32(12): 2250053. 10.1142/S0129065722500538.<pub-id pub-id-type="pmid">36106446</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1142/S0129065722500538</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>W</given-names></name><name name-style="western"><surname>Lin</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name><name name-style="western"><surname>Shen</surname><given-names>X</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S</given-names></name></person-group><article-title>Multi-model and multi-slice ensemble learning architecture based on 2D convolutional neural networks for Alzheimer&#8217;s disease diagnosis</article-title><source>Comput Biol Med</source><year>2021</year><volume>136</volume><fpage>104678</fpage><pub-id pub-id-type="doi">10.1016/j.compbiomed.2021.104678</pub-id><pub-id pub-id-type="pmid">34329864</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Kang W, Lin L, Zhang B, Shen X, Wu S. Multi-model and multi-slice ensemble learning architecture based on 2D convolutional neural networks for Alzheimer&#8217;s disease diagnosis. Comput Biol Med. 2021;136: 104678. 10.1016/j.compbiomed.2021.104678.<pub-id pub-id-type="pmid">34329864</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.compbiomed.2021.104678</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwak</surname><given-names>K</given-names></name><name name-style="western"><surname>Niethammer</surname><given-names>M</given-names></name><name name-style="western"><surname>Giovanello</surname><given-names>KS</given-names></name><name name-style="western"><surname>Styner</surname><given-names>M</given-names></name><name name-style="western"><surname>Dayan</surname><given-names>E</given-names></name></person-group><article-title>Differential role for hippocampal subfields in Alzheimer&#8217;s disease progression revealed with deep learning</article-title><source>Cereb Cortex</source><year>2022</year><volume>32</volume><issue>3</issue><fpage>467</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1093/cercor/bhab223</pub-id><pub-id pub-id-type="pmid">34322704</pub-id><pub-id pub-id-type="pmcid">PMC8805839</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Kwak K, Niethammer M, Giovanello KS, Styner M, Dayan E. Differential role for hippocampal subfields in Alzheimer&#8217;s disease progression revealed with deep learning. Cereb Cortex. 2022;32(3):467&#8211;78. 10.1093/cercor/bhab223.<pub-id pub-id-type="pmid">34322704</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cercor/bhab223</pub-id><pub-id pub-id-type="pmcid">PMC8805839</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>A</given-names></name><name name-style="western"><surname>Li</surname><given-names>F</given-names></name><name name-style="western"><surname>Elahifasaee</surname><given-names>F</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>Hippocampal shape and asymmetry analysis by cascaded convolutional neural networks for Alzheimer&#8217;s disease diagnosis</article-title><source>Brain Imaging Behav</source><year>2021</year><volume>15</volume><issue>5</issue><fpage>2330</fpage><lpage>2339</lpage><pub-id pub-id-type="doi">10.1007/s11682-020-00427-y</pub-id><pub-id pub-id-type="pmid">33398778</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Li A, Li F, Elahifasaee F, Liu M, Zhang L. Hippocampal shape and asymmetry analysis by cascaded convolutional neural networks for Alzheimer&#8217;s disease diagnosis. Brain Imaging Behav. 2021;15(5):2330&#8211;9. 10.1007/s11682-020-00427-y.<pub-id pub-id-type="pmid">33398778</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11682-020-00427-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="other">Liang G, Xing X, Liu L, Zhang Y, Ying Q, Lin A-L, et al. Alzheimer&#8217;s disease classification using 2D convolutional neural networks. In: 2021 43rd Annual International Conference of the IEEE Engineering in Medicine &amp; Biology Society (EMBC). Mexico: IEEE; 2021. pp. 3008&#8211;12. 10.1109/EMBC46164.2021.9629587.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/EMBC46164.2021.9629587</pub-id><pub-id pub-id-type="pmid">34891877</pub-id></mixed-citation></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>W</given-names></name><name name-style="western"><surname>Tong</surname><given-names>T</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Guo</surname><given-names>D</given-names></name><name name-style="western"><surname>Du</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Convolutional neural networks-based MRI image analysis for the Alzheimer&#8217;s disease prediction from mild cognitive impairment</article-title><source>Front Neurosci</source><year>2018</year><volume>12</volume><fpage>777</fpage><pub-id pub-id-type="doi">10.3389/fnins.2018.00777</pub-id><pub-id pub-id-type="pmid">30455622</pub-id><pub-id pub-id-type="pmcid">PMC6231297</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Lin W, Tong T, Gao Q, Guo D, Du X, Yang Y, et al. Convolutional neural networks-based MRI image analysis for the Alzheimer&#8217;s disease prediction from mild cognitive impairment. Front Neurosci. 2018;12: 777. 10.3389/fnins.2018.00777.<pub-id pub-id-type="pmid">30455622</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2018.00777</pub-id><pub-id pub-id-type="pmcid">PMC6231297</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>F</given-names></name><name name-style="western"><surname>Yan</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shen</surname><given-names>L</given-names></name><etal/></person-group><article-title>A multi-model deep convolutional neural network for automatic hippocampus segmentation and classification in Alzheimer&#8217;s disease</article-title><source>Neuroimage</source><year>2020</year><volume>208</volume><fpage>116459</fpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2019.116459</pub-id><pub-id pub-id-type="pmid">31837471</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Liu M, Li F, Yan H, Wang K, Ma Y, Shen L, et al. A multi-model deep convolutional neural network for automatic hippocampus segmentation and classification in Alzheimer&#8217;s disease. Neuroimage. 2020;208: 116459. 10.1016/j.neuroimage.2019.116459.<pub-id pub-id-type="pmid">31837471</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2019.116459</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>D</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>A</given-names></name><name name-style="western"><surname>Jia</surname><given-names>L</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Frizzell</surname><given-names>T</given-names></name><name name-style="western"><surname>Song</surname><given-names>X</given-names></name></person-group><article-title>Early detection of Alzheimer&#8217;s disease using magnetic resonance imaging: a novel approach combining convolutional neural networks and ensemble learning</article-title><source>Front Neurosci</source><year>2020</year><volume>14</volume><fpage>259</fpage><pub-id pub-id-type="doi">10.3389/fnins.2020.00259</pub-id><pub-id pub-id-type="pmid">32477040</pub-id><pub-id pub-id-type="pmcid">PMC7238823</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Pan D, Zeng A, Jia L, Huang Y, Frizzell T, Song X. Early detection of Alzheimer&#8217;s disease using magnetic resonance imaging: a novel approach combining convolutional neural networks and ensemble learning. Front Neurosci. 2020;14: 259. 10.3389/fnins.2020.00259.<pub-id pub-id-type="pmid">32477040</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2020.00259</pub-id><pub-id pub-id-type="pmcid">PMC7238823</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wee</surname><given-names>C-Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><name name-style="western"><surname>Lee</surname><given-names>A</given-names></name><name name-style="western"><surname>Poh</surname><given-names>JS</given-names></name><name name-style="western"><surname>Ji</surname><given-names>H</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>A</given-names></name></person-group><article-title>Cortical graph neural network for AD and MCI diagnosis and transfer learning across populations</article-title><source>NeuroImage: Clinical</source><year>2019</year><volume>23</volume><fpage>101929</fpage><pub-id pub-id-type="doi">10.1016/j.nicl.2019.101929</pub-id><pub-id pub-id-type="pmid">31491832</pub-id><pub-id pub-id-type="pmcid">PMC6627731</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Wee C-Y, Liu C, Lee A, Poh JS, Ji H, Qiu A. Cortical graph neural network for AD and MCI diagnosis and transfer learning across populations. NeuroImage: Clinical. 2019;23: 101929. 10.1016/j.nicl.2019.101929.<pub-id pub-id-type="pmid">31491832</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nicl.2019.101929</pub-id><pub-id pub-id-type="pmcid">PMC6627731</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>B</given-names></name><name name-style="western"><surname>Gao</surname><given-names>A</given-names></name><name name-style="western"><surname>Feng</surname><given-names>X</given-names></name><name name-style="western"><surname>Liang</surname><given-names>D</given-names></name><name name-style="western"><surname>Long</surname><given-names>X</given-names></name></person-group><article-title>A 3D densely connected convolution neural network with connection-wise attention mechanism for Alzheimer&#8217;s disease classification</article-title><source>Magn Reson Imaging</source><year>2021</year><volume>78</volume><fpage>119</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1016/j.mri.2021.02.001</pub-id><pub-id pub-id-type="pmid">33588019</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Zhang J, Zheng B, Gao A, Feng X, Liang D, Long X. A 3D densely connected convolution neural network with connection-wise attention mechanism for Alzheimer&#8217;s disease classification. Magn Reson Imaging. 2021;78:119&#8211;26. 10.1016/j.mri.2021.02.001.<pub-id pub-id-type="pmid">33588019</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mri.2021.02.001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>P</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>J</given-names></name><name name-style="western"><surname>Tu</surname><given-names>Y</given-names></name></person-group><article-title>Diagnosis of Alzheimer&#8217;s disease with ensemble learning classifier and 3D convolutional neural network</article-title><source>Sensors</source><year>2021</year><volume>21</volume><issue>22</issue><fpage>7634</fpage><pub-id pub-id-type="doi">10.3390/s21227634</pub-id><pub-id pub-id-type="pmid">34833710</pub-id><pub-id pub-id-type="pmcid">PMC8623279</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Zhang P, Lin S, Qiao J, Tu Y. Diagnosis of Alzheimer&#8217;s disease with ensemble learning classifier and 3D convolutional neural network. Sensors. 2021;21(22): 7634. 10.3390/s21227634.<pub-id pub-id-type="pmid">34833710</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/s21227634</pub-id><pub-id pub-id-type="pmcid">PMC8623279</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><mixed-citation publication-type="other">ADNI. Alzheimer&#8217;s disease neuroimaging initiative. 2025. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://adni-lde.loni.usc.edu/">https://adni-lde.loni.usc.edu/</ext-link>. Accessed 30 Jul 2024.</mixed-citation></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petersen</surname><given-names>RC</given-names></name></person-group><article-title>MCI criteria in ADNI: meeting biological expectations</article-title><source>Neurology</source><year>2021</year><volume>97</volume><issue>12</issue><fpage>597</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000012588</pub-id><pub-id pub-id-type="pmid">34341151</pub-id><pub-id pub-id-type="pmcid">PMC8480480</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Petersen RC. MCI criteria in ADNI: meeting biological expectations. Neurology. 2021;97(12):597&#8211;9. 10.1212/WNL.0000000000012588.<pub-id pub-id-type="pmid">34341151</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000012588</pub-id><pub-id pub-id-type="pmcid">PMC8480480</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>F</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name></person-group><article-title>Alzheimer&#8217;s disease diagnosis based on multiple cluster dense convolutional networks</article-title><source>Comput Med Imaging Graph</source><year>2018</year><volume>70</volume><fpage>101</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/j.compmedimag.2018.09.009</pub-id><pub-id pub-id-type="pmid">30340094</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Li F, Liu M. Alzheimer&#8217;s disease diagnosis based on multiple cluster dense convolutional networks. Comput Med Imaging Graph. 2018;70:101&#8211;10. 10.1016/j.compmedimag.2018.09.009.<pub-id pub-id-type="pmid">30340094</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.compmedimag.2018.09.009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Battista</surname><given-names>P</given-names></name><name name-style="western"><surname>Salvatore</surname><given-names>C</given-names></name><name name-style="western"><surname>Berlingeri</surname><given-names>M</given-names></name><name name-style="western"><surname>Cerasa</surname><given-names>A</given-names></name><name name-style="western"><surname>Castiglioni</surname><given-names>I</given-names></name></person-group><article-title>Artificial intelligence and neuropsychological measures: the case of Alzheimer&#8217;s disease</article-title><source>Neurosci Biobehav Rev</source><year>2020</year><volume>114</volume><fpage>211</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1016/j.neubiorev.2020.04.026</pub-id><pub-id pub-id-type="pmid">32437744</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Battista P, Salvatore C, Berlingeri M, Cerasa A, Castiglioni I. Artificial intelligence and neuropsychological measures: the case of Alzheimer&#8217;s disease. Neurosci Biobehav Rev. 2020;114:211&#8211;28. 10.1016/j.neubiorev.2020.04.026.<pub-id pub-id-type="pmid">32437744</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neubiorev.2020.04.026</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><mixed-citation publication-type="other">Lombardi G, Crescioli G, Cavedo E, Lucenteforte E, Casazza G, Bellatorre AG, et al. Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer&#8217;s disease in people with mild cognitive impairment. Cochrane Database Syst Rev. 2020;3(3):CD009628. 10.1002/14651858.CD009628.pub2.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD009628.pub2</pub-id><pub-id pub-id-type="pmcid">PMC7059964</pub-id><pub-id pub-id-type="pmid">32119112</pub-id></mixed-citation></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shahidi</surname><given-names>R</given-names></name><name name-style="western"><surname>Baradaran</surname><given-names>M</given-names></name><name name-style="western"><surname>Asgarzadeh</surname><given-names>A</given-names></name><name name-style="western"><surname>Bagherieh</surname><given-names>S</given-names></name><name name-style="western"><surname>Tajabadi</surname><given-names>Z</given-names></name><name name-style="western"><surname>Farhadi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Diagnostic performance of MRI radiomics for classification of Alzheimer&#8217;s disease, mild cognitive impairment, and normal subjects: a systematic review and meta-analysis</article-title><source>Aging Clin Exp Res</source><year>2023</year><volume>35</volume><issue>11</issue><fpage>2333</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1007/s40520-023-02565-x</pub-id><pub-id pub-id-type="pmid">37801265</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Shahidi R, Baradaran M, Asgarzadeh A, Bagherieh S, Tajabadi Z, Farhadi A, et al. Diagnostic performance of MRI radiomics for classification of Alzheimer&#8217;s disease, mild cognitive impairment, and normal subjects: a systematic review and meta-analysis. Aging Clin Exp Res. 2023;35(11):2333&#8211;48. 10.1007/s40520-023-02565-x.<pub-id pub-id-type="pmid">37801265</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40520-023-02565-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tran</surname><given-names>AT</given-names></name><name name-style="western"><surname>Zeevi</surname><given-names>T</given-names></name><name name-style="western"><surname>Payabvash</surname><given-names>S</given-names></name></person-group><article-title>Strategies to improve the robustness and generalizability of deep learning segmentation and classification in neuroimaging</article-title><source>Biomedinformatics</source><year>2025</year><volume>5</volume><issue>2</issue><fpage>20</fpage><pub-id pub-id-type="doi">10.3390/biomedinformatics5020020</pub-id><pub-id pub-id-type="pmid">40271381</pub-id><pub-id pub-id-type="pmcid">PMC12014193</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Tran AT, Zeevi T, Payabvash S. Strategies to improve the robustness and generalizability of deep learning segmentation and classification in neuroimaging. Biomedinformatics. 2025;5(2): 20. 10.3390/biomedinformatics5020020.<pub-id pub-id-type="pmid">40271381</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedinformatics5020020</pub-id><pub-id pub-id-type="pmcid">PMC12014193</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chandra</surname><given-names>A</given-names></name><name name-style="western"><surname>Dervenoulas</surname><given-names>G</given-names></name><name name-style="western"><surname>Politis</surname><given-names>M</given-names></name></person-group><article-title>Magnetic resonance imaging in Alzheimer&#8217;s disease and mild cognitive impairment</article-title><source>J Neurol</source><year>2019</year><volume>266</volume><issue>6</issue><fpage>1293</fpage><lpage>1302</lpage><pub-id pub-id-type="doi">10.1007/s00415-018-9016-3</pub-id><pub-id pub-id-type="pmid">30120563</pub-id><pub-id pub-id-type="pmcid">PMC6517561</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Chandra A, Dervenoulas G, Politis M. Magnetic resonance imaging in Alzheimer&#8217;s disease and mild cognitive impairment. J Neurol. 2019;266(6):1293&#8211;302. 10.1007/s00415-018-9016-3.<pub-id pub-id-type="pmid">30120563</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00415-018-9016-3</pub-id><pub-id pub-id-type="pmcid">PMC6517561</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tran</surname><given-names>TT</given-names></name><name name-style="western"><surname>Speck</surname><given-names>CL</given-names></name><name name-style="western"><surname>Gallagher</surname><given-names>M</given-names></name><name name-style="western"><surname>Bakker</surname><given-names>A</given-names></name></person-group><article-title>Lateral entorhinal cortex dysfunction in amnestic mild cognitive impairment</article-title><source>Neurobiol Aging</source><year>2022</year><volume>112</volume><fpage>151</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2021.12.008</pub-id><pub-id pub-id-type="pmid">35182842</pub-id><pub-id pub-id-type="pmcid">PMC8976714</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Tran TT, Speck CL, Gallagher M, Bakker A. Lateral entorhinal cortex dysfunction in amnestic mild cognitive impairment. Neurobiol Aging. 2022;112:151&#8211;60. 10.1016/j.neurobiolaging.2021.12.008.<pub-id pub-id-type="pmid">35182842</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2021.12.008</pub-id><pub-id pub-id-type="pmcid">PMC8976714</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braak</surname><given-names>H</given-names></name><name name-style="western"><surname>Braak</surname><given-names>E</given-names></name></person-group><article-title>Neuropathological stageing of Alzheimer-related changes</article-title><source>Acta Neuropathol (Berl)</source><year>1991</year><volume>82</volume><issue>4</issue><fpage>239</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1007/BF00308809</pub-id><pub-id pub-id-type="pmid">1759558</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl). 1991;82(4):239&#8211;59. 10.1007/BF00308809.<pub-id pub-id-type="pmid">1759558</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00308809</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><mixed-citation publication-type="other">Caruana R, Niculescu-Mizil A. An empirical comparison of supervised learning algorithms. In: Proceedings of the 23rd International Conference on Machine Learning - ICML &#8217;06. Pittsburgh: ACM Press; 2006. pp. 161&#8211;8. 10.1145/1143844.1143865.</mixed-citation></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhi</surname><given-names>H</given-names></name><name name-style="western"><surname>Guo</surname><given-names>M</given-names></name><name name-style="western"><surname>Xin</surname><given-names>B</given-names></name><etal/></person-group><article-title>Hybrid CNN-BiLSTM-MHSA model for accurate fault diagnosis of rotor motor bearings</article-title><source>Mathematics</source><year>2025</year><volume>13</volume><issue>3</issue><fpage>334</fpage><pub-id pub-id-type="doi">10.3390/math13030334</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Yang Z, Li W, Yuan F, Zhi H, Guo M, Xin B, et al. Hybrid CNN-BiLSTM-MHSA model for accurate fault diagnosis of rotor motor bearings. Mathematics. 2025;13(3): 334. 10.3390/math13030334.</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Avanzo</surname><given-names>M</given-names></name><name name-style="western"><surname>Wei</surname><given-names>L</given-names></name><name name-style="western"><surname>Stancanello</surname><given-names>J</given-names></name><name name-style="western"><surname>Valli&#232;res</surname><given-names>M</given-names></name><name name-style="western"><surname>Rao</surname><given-names>A</given-names></name><name name-style="western"><surname>Morin</surname><given-names>O</given-names></name><etal/></person-group><article-title>Machine and deep learning methods for radiomics</article-title><source>Med Phys</source><year>2020</year><volume>47</volume><issue>5</issue><fpage>e185</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1002/mp.13678</pub-id><pub-id pub-id-type="pmid">32418336</pub-id><pub-id pub-id-type="pmcid">PMC8965689</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Avanzo M, Wei L, Stancanello J, Valli&#232;res M, Rao A, Morin O, et al. Machine and deep learning methods for radiomics. Med Phys. 2020;47(5):e185-202. 10.1002/mp.13678.<pub-id pub-id-type="pmid">32418336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mp.13678</pub-id><pub-id pub-id-type="pmcid">PMC8965689</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tong</surname><given-names>T</given-names></name><name name-style="western"><surname>Wolz</surname><given-names>R</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Guerrero</surname><given-names>R</given-names></name><name name-style="western"><surname>Hajnal</surname><given-names>JV</given-names></name><name name-style="western"><surname>Rueckert</surname><given-names>D</given-names></name></person-group><article-title>Multiple instance learning for classification of dementia in brain MRI</article-title><source>Med Image Anal</source><year>2014</year><volume>18</volume><issue>5</issue><fpage>808</fpage><lpage>818</lpage><pub-id pub-id-type="doi">10.1016/j.media.2014.04.006</pub-id><pub-id pub-id-type="pmid">24858570</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Tong T, Wolz R, Gao Q, Guerrero R, Hajnal JV, Rueckert D. Multiple instance learning for classification of dementia in brain MRI. Med Image Anal. 2014;18(5):808&#8211;18. 10.1016/j.media.2014.04.006.<pub-id pub-id-type="pmid">24858570</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.media.2014.04.006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mangin</surname><given-names>J-F</given-names></name><name name-style="western"><surname>Lebenberg</surname><given-names>J</given-names></name><name name-style="western"><surname>Lefranc</surname><given-names>S</given-names></name><name name-style="western"><surname>Labra</surname><given-names>N</given-names></name><name name-style="western"><surname>Auzias</surname><given-names>G</given-names></name><name name-style="western"><surname>Labit</surname><given-names>M</given-names></name><etal/></person-group><article-title>Spatial normalization of brain images and beyond</article-title><source>Med Image Anal</source><year>2016</year><volume>33</volume><fpage>127</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.media.2016.06.008</pub-id><pub-id pub-id-type="pmid">27344104</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Mangin J-F, Lebenberg J, Lefranc S, Labra N, Auzias G, Labit M, et al. Spatial normalization of brain images and beyond. Med Image Anal. 2016;33:127&#8211;33. 10.1016/j.media.2016.06.008.<pub-id pub-id-type="pmid">27344104</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.media.2016.06.008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><mixed-citation publication-type="other">Hasan M, Khan B. Variability in the effectiveness of psychological interventions based on machine learning in STEM education. CSE Journal Articles. 233. 2020. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://digitalcommons.unl.edu/csearticles/233">https://digitalcommons.unl.edu/csearticles/233</ext-link>.</mixed-citation></ref><ref id="CR64"><label>64.</label><mixed-citation publication-type="other">Collins GS, Moons KGM, Dhiman P, Riley RD, Beam AL, Van Calster B, et al. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024:e078378. 10.1136/bmj-2023-078378.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj-2023-078378</pub-id><pub-id pub-id-type="pmcid">PMC11019967</pub-id><pub-id pub-id-type="pmid">38626948</pub-id></mixed-citation></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sounderajah</surname><given-names>V</given-names></name><name name-style="western"><surname>Ashrafian</surname><given-names>H</given-names></name><name name-style="western"><surname>Aggarwal</surname><given-names>R</given-names></name><name name-style="western"><surname>De Fauw</surname><given-names>J</given-names></name><name name-style="western"><surname>Denniston</surname><given-names>AK</given-names></name><name name-style="western"><surname>Greaves</surname><given-names>F</given-names></name><etal/></person-group><article-title>Developing specific reporting guidelines for diagnostic accuracy studies assessing AI interventions: the STARD-AI steering group</article-title><source>Nat Med</source><year>2020</year><volume>26</volume><issue>6</issue><fpage>807</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0941-1</pub-id><pub-id pub-id-type="pmid">32514173</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Sounderajah V, Ashrafian H, Aggarwal R, De Fauw J, Denniston AK, Greaves F, et al. Developing specific reporting guidelines for diagnostic accuracy studies assessing AI interventions: the STARD-AI steering group. Nat Med. 2020;26(6):807&#8211;8. 10.1038/s41591-020-0941-1.<pub-id pub-id-type="pmid">32514173</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-020-0941-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>CR</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>RC</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>PC</given-names></name><name name-style="western"><surname>Smith</surname><given-names>GE</given-names></name><name name-style="western"><surname>Ivnik</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Rate of medial temporal lobe atrophy in typical aging and Alzheimer&#8217;s disease</article-title><source>Neurology</source><year>1998</year><volume>51</volume><issue>4</issue><fpage>993</fpage><lpage>999</lpage><pub-id pub-id-type="doi">10.1212/wnl.51.4.993</pub-id><pub-id pub-id-type="pmid">9781519</pub-id><pub-id pub-id-type="pmcid">PMC2768817</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Jack CR, Petersen RC, Xu Y, O&#8217;Brien PC, Smith GE, Ivnik RJ, et al. Rate of medial temporal lobe atrophy in typical aging and Alzheimer&#8217;s disease. Neurology. 1998;51(4):993&#8211;9. 10.1212/wnl.51.4.993.<pub-id pub-id-type="pmid">9781519</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.51.4.993</pub-id><pub-id pub-id-type="pmcid">PMC2768817</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>D</given-names></name><name name-style="western"><surname>Fox</surname><given-names>NC</given-names></name><name name-style="western"><surname>Scahill</surname><given-names>RI</given-names></name><name name-style="western"><surname>Crum</surname><given-names>WR</given-names></name><name name-style="western"><surname>Whitwell</surname><given-names>JL</given-names></name><name name-style="western"><surname>Leschziner</surname><given-names>G</given-names></name><etal/></person-group><article-title>Patterns of temporal lobe atrophy in semantic dementia and Alzheimer&#8217;s disease</article-title><source>Ann Neurol</source><year>2001</year><volume>49</volume><issue>4</issue><fpage>433</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1002/ana.92</pub-id><pub-id pub-id-type="pmid">11310620</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Chan D, Fox NC, Scahill RI, Crum WR, Whitwell JL, Leschziner G, et al. Patterns of temporal lobe atrophy in semantic dementia and Alzheimer&#8217;s disease. Ann Neurol. 2001;49(4):433&#8211;42.<pub-id pub-id-type="pmid">11310620</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Visser</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Verhey</surname><given-names>FRJ</given-names></name><name name-style="western"><surname>Hofman</surname><given-names>PAM</given-names></name><name name-style="western"><surname>Scheltens</surname><given-names>P</given-names></name><name name-style="western"><surname>Jolles</surname><given-names>J</given-names></name></person-group><article-title>Medial temporal lobe atrophy predicts Alzheimer&#8217;s disease in patients with minor cognitive impairment</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2002</year><volume>72</volume><issue>4</issue><fpage>491</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1136/jnnp.72.4.491</pub-id><pub-id pub-id-type="pmid">11909909</pub-id><pub-id pub-id-type="pmcid">PMC1737837</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Visser PJ, Verhey FRJ, Hofman PAM, Scheltens P, Jolles J. Medial temporal lobe atrophy predicts Alzheimer&#8217;s disease in patients with minor cognitive impairment. J Neurol Neurosurg Psychiatry. 2002;72(4):491&#8211;7. 10.1136/jnnp.72.4.491.<pub-id pub-id-type="pmid">11909909</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp.72.4.491</pub-id><pub-id pub-id-type="pmcid">PMC1737837</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>V</given-names></name><name name-style="western"><surname>Chertkow</surname><given-names>H</given-names></name><name name-style="western"><surname>Lerch</surname><given-names>JP</given-names></name><name name-style="western"><surname>Evans</surname><given-names>AC</given-names></name><name name-style="western"><surname>Dorr</surname><given-names>AE</given-names></name><name name-style="western"><surname>Kabani</surname><given-names>NJ</given-names></name></person-group><article-title>Spatial patterns of cortical thinning in mild cognitive impairment and Alzheimer&#8217;s disease</article-title><source>Brain</source><year>2006</year><volume>129</volume><issue>11</issue><fpage>2885</fpage><lpage>2893</lpage><pub-id pub-id-type="doi">10.1093/brain/awl256</pub-id><pub-id pub-id-type="pmid">17008332</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Singh V, Chertkow H, Lerch JP, Evans AC, Dorr AE, Kabani NJ. Spatial patterns of cortical thinning in mild cognitive impairment and Alzheimer&#8217;s disease. Brain. 2006;129(11):2885&#8211;93. 10.1093/brain/awl256.<pub-id pub-id-type="pmid">17008332</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awl256</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lerch</surname><given-names>JP</given-names></name><name name-style="western"><surname>Pruessner</surname><given-names>J</given-names></name><name name-style="western"><surname>Zijdenbos</surname><given-names>AP</given-names></name><name name-style="western"><surname>Collins</surname><given-names>DL</given-names></name><name name-style="western"><surname>Teipel</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Hampel</surname><given-names>H</given-names></name><etal/></person-group><article-title>Automated cortical thickness measurements from MRI can accurately separate Alzheimer&#8217;s patients from normal elderly controls</article-title><source>Neurobiol Aging</source><year>2008</year><volume>29</volume><issue>1</issue><fpage>23</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2006.09.013</pub-id><pub-id pub-id-type="pmid">17097767</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Lerch JP, Pruessner J, Zijdenbos AP, Collins DL, Teipel SJ, Hampel H, et al. Automated cortical thickness measurements from MRI can accurately separate Alzheimer&#8217;s patients from normal elderly controls. Neurobiol Aging. 2008;29(1):23&#8211;30. 10.1016/j.neurobiolaging.2006.09.013.<pub-id pub-id-type="pmid">17097767</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2006.09.013</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dickerson</surname><given-names>BC</given-names></name><name name-style="western"><surname>Feczko</surname><given-names>E</given-names></name><name name-style="western"><surname>Augustinack</surname><given-names>JC</given-names></name><name name-style="western"><surname>Pacheco</surname><given-names>J</given-names></name><name name-style="western"><surname>Morris</surname><given-names>JC</given-names></name><name name-style="western"><surname>Fischl</surname><given-names>B</given-names></name><etal/></person-group><article-title>Differential effects of aging and Alzheimer&#8217;s disease on medial temporal lobe cortical thickness and surface area</article-title><source>Neurobiol Aging</source><year>2009</year><volume>30</volume><issue>3</issue><fpage>432</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2007.07.022</pub-id><pub-id pub-id-type="pmid">17869384</pub-id><pub-id pub-id-type="pmcid">PMC3703585</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Dickerson BC, Feczko E, Augustinack JC, Pacheco J, Morris JC, Fischl B, et al. Differential effects of aging and Alzheimer&#8217;s disease on medial temporal lobe cortical thickness and surface area. Neurobiol Aging. 2009;30(3):432&#8211;40. 10.1016/j.neurobiolaging.2007.07.022.<pub-id pub-id-type="pmid">17869384</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2007.07.022</pub-id><pub-id pub-id-type="pmcid">PMC3703585</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fjell</surname><given-names>AM</given-names></name><name name-style="western"><surname>Westlye</surname><given-names>LT</given-names></name><name name-style="western"><surname>Grydeland</surname><given-names>H</given-names></name><name name-style="western"><surname>Amlien</surname><given-names>I</given-names></name><name name-style="western"><surname>Espeseth</surname><given-names>T</given-names></name><name name-style="western"><surname>Reinvang</surname><given-names>I</given-names></name><etal/></person-group><article-title>Accelerating cortical thinning: unique to dementia or universal in aging?</article-title><source>Cereb Cortex</source><year>2014</year><volume>24</volume><issue>4</issue><fpage>919</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1093/cercor/bhs379</pub-id><pub-id pub-id-type="pmid">23236213</pub-id><pub-id pub-id-type="pmcid">PMC3948495</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Fjell AM, Westlye LT, Grydeland H, Amlien I, Espeseth T, Reinvang I, et al. Accelerating cortical thinning: unique to dementia or universal in aging? Cereb Cortex. 2014;24(4):919&#8211;34. 10.1093/cercor/bhs379.<pub-id pub-id-type="pmid">23236213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cercor/bhs379</pub-id><pub-id pub-id-type="pmcid">PMC3948495</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eskildsen</surname><given-names>SF</given-names></name><name name-style="western"><surname>Coup&#233;</surname><given-names>P</given-names></name><name name-style="western"><surname>Fonov</surname><given-names>VS</given-names></name><name name-style="western"><surname>Pruessner</surname><given-names>JC</given-names></name><name name-style="western"><surname>Collins</surname><given-names>DL</given-names></name></person-group><article-title>Structural imaging biomarkers of Alzheimer&#8217;s disease: predicting disease progression</article-title><source>Neurobiol Aging</source><year>2015</year><volume>36</volume><fpage>S23</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2014.04.034</pub-id><pub-id pub-id-type="pmid">25260851</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Eskildsen SF, Coup&#233; P, Fonov VS, Pruessner JC, Collins DL. Structural imaging biomarkers of Alzheimer&#8217;s disease: predicting disease progression. Neurobiol Aging. 2015;36:S23-31. 10.1016/j.neurobiolaging.2014.04.034.<pub-id pub-id-type="pmid">25260851</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2014.04.034</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petersen</surname><given-names>RC</given-names></name><name name-style="western"><surname>Smith</surname><given-names>GE</given-names></name><name name-style="western"><surname>Ivnik</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Kokmen</surname><given-names>E</given-names></name><name name-style="western"><surname>Tangalos</surname><given-names>EG</given-names></name></person-group><article-title>Memory function in very early Alzheimer&#8217;s disease</article-title><source>Neurology</source><year>1994</year><volume>44</volume><issue>5</issue><fpage>867</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.1212/wnl.44.5.867</pub-id><pub-id pub-id-type="pmid">8190289</pub-id></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Petersen RC, Smith GE, Ivnik RJ, Kokmen E, Tangalos EG. Memory function in very early Alzheimer&#8217;s disease. Neurology. 1994;44(5):867&#8211;867. 10.1212/wnl.44.5.867.<pub-id pub-id-type="pmid">8190289</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.44.5.867</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Squire</surname><given-names>LR</given-names></name><name name-style="western"><surname>Wixted</surname><given-names>JT</given-names></name><name name-style="western"><surname>Clark</surname><given-names>RE</given-names></name></person-group><article-title>Recognition memory and the medial temporal lobe: a new perspective</article-title><source>Nat Rev Neurosci</source><year>2007</year><volume>8</volume><issue>11</issue><fpage>872</fpage><lpage>883</lpage><pub-id pub-id-type="doi">10.1038/nrn2154</pub-id><pub-id pub-id-type="pmid">17948032</pub-id><pub-id pub-id-type="pmcid">PMC2323975</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Squire LR, Wixted JT, Clark RE. Recognition memory and the medial temporal lobe: a new perspective. Nat Rev Neurosci. 2007;8(11):872&#8211;83. 10.1038/nrn2154.<pub-id pub-id-type="pmid">17948032</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrn2154</pub-id><pub-id pub-id-type="pmcid">PMC2323975</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gold</surname><given-names>CA</given-names></name><name name-style="western"><surname>Budson</surname><given-names>AE</given-names></name></person-group><article-title>Memory loss in Alzheimer&#8217;s disease: Implications for development of therapeutics</article-title><source>Expert Rev Neurother</source><year>2008</year><volume>8</volume><issue>12</issue><fpage>1879</fpage><lpage>1891</lpage><pub-id pub-id-type="doi">10.1586/14737175.8.12.1879</pub-id><pub-id pub-id-type="pmid">19086882</pub-id><pub-id pub-id-type="pmcid">PMC2655107</pub-id></element-citation><mixed-citation id="mc-CR76" publication-type="journal">Gold CA, Budson AE. Memory loss in Alzheimer&#8217;s disease: Implications for development of therapeutics. Expert Rev Neurother. 2008;8(12):1879&#8211;91. 10.1586/14737175.8.12.1879.<pub-id pub-id-type="pmid">19086882</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/14737175.8.12.1879</pub-id><pub-id pub-id-type="pmcid">PMC2655107</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ech&#225;varri</surname><given-names>C</given-names></name><name name-style="western"><surname>Aalten</surname><given-names>P</given-names></name><name name-style="western"><surname>Uylings</surname><given-names>HBM</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>HIL</given-names></name><name name-style="western"><surname>Visser</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Gronenschild</surname><given-names>EHBM</given-names></name><etal/></person-group><article-title>Atrophy in the parahippocampal gyrus as an early biomarker of Alzheimer&#8217;s disease</article-title><source>Brain Struct Funct</source><year>2011</year><volume>215</volume><issue>3&#8211;4</issue><fpage>265</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1007/s00429-010-0283-8</pub-id><pub-id pub-id-type="pmid">20957494</pub-id><pub-id pub-id-type="pmcid">PMC3041901</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Ech&#225;varri C, Aalten P, Uylings HBM, Jacobs HIL, Visser PJ, Gronenschild EHBM, et al. Atrophy in the parahippocampal gyrus as an early biomarker of Alzheimer&#8217;s disease. Brain Struct Funct. 2011;215(3&#8211;4):265&#8211;71. 10.1007/s00429-010-0283-8.<pub-id pub-id-type="pmid">20957494</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00429-010-0283-8</pub-id><pub-id pub-id-type="pmcid">PMC3041901</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Neurosci</journal-id><journal-id journal-id-type="iso-abbrev">Front Neurosci</journal-id><journal-id journal-id-type="pmc-domain-id">670</journal-id><journal-id journal-id-type="pmc-domain">frontneurosci</journal-id><journal-id journal-id-type="publisher-id">Front. Neurosci.</journal-id><journal-title-group><journal-title>Frontiers in Neuroscience</journal-title></journal-title-group><issn pub-type="ppub">1662-4548</issn><issn pub-type="epub">1662-453X</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12484009</article-id><article-id pub-id-type="pmcid-ver">PMC12484009.1</article-id><article-id pub-id-type="pmcaid">12484009</article-id><article-id pub-id-type="pmcaiid">12484009</article-id><article-id pub-id-type="pmid">41040954</article-id><article-id pub-id-type="doi">10.3389/fnins.2025.1666809</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Neuroscience</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Frontal-subcortical dysfunction in toxic oil syndrome: a proof-of-concept eye-tracking and cognitive study four decades after exposure</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Benito-Le&#243;n</surname><given-names initials="J">Juli&#225;n</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/426307/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lape&#241;a-Motilva</surname><given-names initials="J">Jos&#233;</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ruiz-Ortiz</surname><given-names initials="M">Mariano</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Doniger</surname><given-names initials="GM">Glen M.</given-names></name><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/82731/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>&#193;lvarez-Sesmero</surname><given-names initials="S">Sonia</given-names></name><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>de B&#233;jar</surname><given-names initials="VG">Ver&#243;nica Gim&#233;nez</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nogales</surname><given-names initials="MA">Mar&#237;a Antonia</given-names></name><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Morales</surname><given-names initials="M">Montserrat</given-names></name><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mondal</surname><given-names initials="R">Ritwick</given-names></name><xref rid="aff8" ref-type="aff">
<sup>8</sup>
</xref><xref rid="aff9" ref-type="aff">
<sup>9</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2405725/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Deb</surname><given-names initials="S">Shramana</given-names></name><xref rid="aff8" ref-type="aff">
<sup>8</sup>
</xref><xref rid="aff9" ref-type="aff">
<sup>9</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2405760/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bartolom&#233;</surname><given-names initials="F">Fernando</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1399289/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Alqu&#233;zar</surname><given-names initials="C">Carolina</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1173159/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Garc&#237;a-Cena</surname><given-names initials="C">Cecilia</given-names></name><xref rid="aff10" ref-type="aff">
<sup>10</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1199063/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Neurology, 12 de Octubre University Hospital</institution>, <addr-line>Madrid</addr-line>, <country>Spain</country></aff><aff id="aff2"><sup>2</sup><institution>Group of Neurodegenerative Diseases, Hospital Universitario 12 de Octubre Research Institute (imas12)</institution>, <addr-line>Madrid</addr-line>, <country>Spain</country></aff><aff id="aff3"><sup>3</sup><institution>Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED)</institution>, <addr-line>Madrid</addr-line>, <country>Spain</country></aff><aff id="aff4"><sup>4</sup><institution>Department of Medicine, Complutense University</institution>, <addr-line>Madrid</addr-line>, <country>Spain</country></aff><aff id="aff5"><sup>5</sup><institution>Department of Clinical Research, NeuroTrax Corporation</institution>, <addr-line>Modiin</addr-line>, <country>Israel</country></aff><aff id="aff6"><sup>6</sup><institution>Department of Psychiatry, 12 de Octubre University Hospital</institution>, <addr-line>Madrid</addr-line>, <country>Spain</country></aff><aff id="aff7"><sup>7</sup><institution>Department of Internal Medicine, 12 de Octubre University Hospital</institution>, <addr-line>Madrid</addr-line>, <country>Spain</country></aff><aff id="aff8"><sup>8</sup><institution>Department of Neurology, Manipal Hospitals</institution>, <addr-line>Kolkata</addr-line>, <country>India</country></aff><aff id="aff9"><sup>9</sup><institution>Centre for Neurovascular Research, Manipal Hospitals</institution>, <addr-line>Kolkata</addr-line>, <country>India</country></aff><aff id="aff10"><sup>10</sup><institution>ETSIDI-Center for Automation and Robotics, Universidad Polit&#233;cnica de Madrid</institution>, <addr-line>Madrid</addr-line>, <country>Spain</country></aff><author-notes><fn fn-type="edited-by" id="fn0001"><p>Edited by: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2945626/overview" ext-link-type="uri">Ran Wang</ext-link>, Huazhong University of Science and Technology, China</p></fn><fn fn-type="edited-by" id="fn0002"><p>Reviewed by: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/961794/overview" ext-link-type="uri">Junyi Zhou</ext-link>, Fujian Normal University, China</p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/3150650/overview" ext-link-type="uri">Gustavo De S&#225; Oliveira Lima</ext-link>, Universidade Federal da Bahia, Brazil</p></fn><corresp id="c001">*Correspondence: Juli&#225;n Benito-Le&#243;n, <email>jbenitol67@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>17</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>19</volume><issue-id pub-id-type="pmc-issue-id">480891</issue-id><elocation-id>1666809</elocation-id><history><date date-type="received"><day>15</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>27</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>17</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>02</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-03 09:25:16.947"><day>03</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 Benito-Le&#243;n, Lape&#241;a-Motilva, Ruiz-Ortiz, Doniger, &#193;lvarez-Sesmero, de B&#233;jar, Nogales, Morales, Mondal, Deb, Bartolom&#233;, Alqu&#233;zar and Garc&#237;a-Cena.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Benito-Le&#243;n, Lape&#241;a-Motilva, Ruiz-Ortiz, Doniger, &#193;lvarez-Sesmero, de B&#233;jar, Nogales, Morales, Mondal, Deb, Bartolom&#233;, Alqu&#233;zar and Garc&#237;a-Cena</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fnins-19-1666809.pdf"/><abstract><sec id="sec1001"><title>Introduction</title><p>Toxic Oil Syndrome (TOS) emerged in Spain in 1981 after ingestion of rapeseed oil adulterated with aniline derivatives. More than four decades later, survivors continue to report cognitive complaints, but objective evidence of long-term dysfunction remains limited.</p></sec><sec id="sec2001"><title>Methods</title><p>In this case-control study, 47 TOS survivors and 44 matched healthy controls completed validated eye-tracking paradigms (visually guided, memory-guided, and antisaccade tasks) and a standardized neuropsychological battery. Groups did not differ significantly in age, sex, or education.</p></sec><sec id="sec3001"><title>Results</title><p>TOS survivors showed preserved performance on visually guided and memory-guided saccades, with no group differences in latency, gain, peak velocity, or spatial error (all <italic toggle="yes">p</italic>&#8239;&gt;&#8239;0.05). In contrast, they exhibited fewer correct antisaccades (mean 3.6 vs. 5.0; <italic toggle="yes">p</italic> = 0.029), more reflexive saccades (mean 7.0 vs. 5.7; <italic toggle="yes">p</italic> = 0.033), and increased backward reflexive saccades (mean 6.3 vs. 5.1; <italic toggle="yes">p</italic> = 0.040). Cognitive testing revealed selective impairments in executive function, attention, and processing speed, with preserved memory. Structural equation modeling confirmed that antisaccade impairment remained significant after adjusting for confounders and demonstrated an independent contribution of attention to correct antisaccade performance.</p></sec><sec id="sec4001"><title>Conclusion</title><p>Findings indicate persistent frontal-subcortical circuit dysfunction in TOS survivors, consistent with immune- or vascular-mediated injury patterns rather than progressive neurodegeneration. Eye-tracking provides a noninvasive biomarker of latent executive dysfunction and may be useful for long-term monitoring of populations exposed to environmental toxins.</p></sec></abstract><kwd-group><kwd>toxic oil syndrome</kwd><kwd>frontal-subcortical dysfunction</kwd><kwd>saccadic eye movements</kwd><kwd>cognitive impairment</kwd><kwd>eye-tracker</kwd></kwd-group><funding-group><award-group><funding-source id="cn1"><institution-wrap><institution>Spanish Ministry of Science and Innovation</institution><institution-id institution-id-type="doi">10.13039/501100004837</institution-id></institution-wrap></funding-source><award-id award-type="contract" rid="cn1">TED2021-130174B-C33</award-id><award-id award-type="contract" rid="cn1">PID2022-138585OB-C33</award-id></award-group><award-group><funding-source id="cn2"><institution-wrap><institution>National Institutes of Health</institution><institution-id institution-id-type="doi">10.13039/100000002</institution-id></institution-wrap></funding-source><award-id award-type="contract" rid="cn2">R01</award-id><award-id award-type="contract" rid="cn2">NS39422</award-id><award-id award-type="contract" rid="cn2">NS094607</award-id></award-group><award-group><funding-source id="cn3"><institution-wrap><institution>Instituto de Salud Carlos III</institution><institution-id institution-id-type="doi">10.13039/501100004587</institution-id></institution-wrap></funding-source></award-group><award-group><funding-source id="cn4"><institution-wrap><institution>Spanish Ministry of Science and Innovation</institution><institution-id institution-id-type="doi">10.13039/501100004837</institution-id></institution-wrap></funding-source></award-group><award-group><funding-source id="cn5"><institution-wrap><institution>Instituto de Salud Carlos III</institution><institution-id institution-id-type="doi">10.13039/501100004587</institution-id></institution-wrap></funding-source></award-group><award-group><funding-source id="cn6"><institution-wrap><institution>Spanish Ministry of Science and Innovation</institution><institution-id institution-id-type="doi">10.13039/501100004837</institution-id></institution-wrap></funding-source></award-group></funding-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. Juli&#225;n Benito-Le&#243;n, Jos&#233; Lape&#241;a-Motilva, Mariano Ruiz-Ortiz, and Ver&#243;nica Gim&#233;nez de B&#233;jar are supported by the Recovery, Transformation, and Resilience Plan of the Spanish Ministry of Science and Innovation (grants TED2021-130174B-C33, NETremor, and PID2022-138585OB-C33, Resonate). Mariano Ruiz-Ortiz is also supported through a R&#237;o Hortega contract (CM22/00183). Juli&#225;n Benito-Le&#243;n receives additional support from the National Institutes of Health (NINDS R01 NS39422 and R01 NS094607). Fernando Bartolom&#233; is supported by the Instituto de Salud Carlos III (CP20/00009, PI21/00183, and PI24/00099) and the Spanish Ministry of Science and Innovation (RED2022-134774-T). Carolina Alqu&#233;zar is supported by the Instituto de Salud Carlos III (CP21/00049 and PI22/00345), the Spanish Ministry of Science and Innovation (RED2022-134774-T and CNS2024-154198), the Eugenio Rodr&#237;guez Pascual Foundation (FERP-2022-5), and the Fundaci&#243;n Luz&#243;n (Ayudas Unzu&#233; Luz&#243;n 2024). Cecilia Garc&#237;a-Cena is supported by RoboCity 2030-DIH-CM Madrid Robotics Digital Innovation Hub (Applied Robotics for Improving Citizens&#8217; Quality of Life, Phase IV; S2018/NMT-4331), funded by the Community of Madrid and co-financed with EU Structural Funds.</funding-statement></funding-group><counts><fig-count count="7"/><table-count count="2"/><equation-count count="0"/><ref-count count="73"/><page-count count="14"/><word-count count="10438"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Translational Neuroscience</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1"><title>Introduction</title><p>Toxic oil syndrome (TOS) is a chronic, multisystem disease that emerged in Spain in May 1981 following the ingestion of rapeseed oil adulterated with aniline derivatives and illegally distributed for human consumption. The outbreak rapidly escalated, affecting over 20,000 individuals and causing more than 300 deaths within the first year (<xref rid="ref1" ref-type="bibr">Abaitua Borda et al., 1998</xref>; <xref rid="ref64" ref-type="bibr">S&#225;nchez-Porro Valad&#233;s et al., 2003</xref>; <xref rid="ref56" ref-type="bibr">Polentinos-Castro et al., 2021</xref>). The acute phase was characterized by eosinophilia, fever, myalgia, and pulmonary edema, later progressing to a chronic condition marked by scleroderma-like skin changes, peripheral neuropathy, muscular atrophy, and both pulmonary and neuropsychiatric manifestations (<xref rid="ref28" ref-type="bibr">Gelp&#237; et al., 2002</xref>; <xref rid="ref17" ref-type="bibr">De La Paz et al., 2001</xref>). Although extensive multidisciplinary investigations were conducted, the specific toxic agent was never definitively identified. Nonetheless, fatty acid anilides and other byproducts of industrial oil denaturation were implicated based on chemical and toxicological analyses (<xref rid="ref28" ref-type="bibr">Gelp&#237; et al., 2002</xref>).</p><p><xref rid="ref36" ref-type="bibr">Kaufman and Krupp (1995)</xref> proposed that TOS and eosinophilia-myalgia syndrome may be part of a spectrum of chemically induced immune-mediated disorders involving the central nervous system. Their hypothesis initiated early discussions about mechanisms such as neuroinflammation and excitotoxicity. Notably, eosinophilia-myalgia syndrome itself is linked to neurocognitive dysfunction (<xref rid="ref2" ref-type="bibr">Armstrong et al., 1997</xref>).</p><p>One of the earliest studies of cognitive impairment in TOS was reported in a small neuropsychological study by <xref rid="ref19" ref-type="bibr">Del Ser et al. (1986)</xref>, who found deficits in episodic and semantic memory within a few years of the onset. This was followed by a 12-year follow-up study by <xref rid="ref35" ref-type="bibr">Kaufman et al. (1995)</xref>, which offered clinical evidence of chronic morbidity in TOS survivors. Among 91 individuals re-evaluated more than a decade after exposure, over half reported persistent symptoms&#8212;fatigue, muscle cramps, arthralgias, subjective cognitive difficulties, and psychiatric complaints&#8212;despite being otherwise medically stable and lacking signs of a progressive neuromuscular disorder (<xref rid="ref35" ref-type="bibr">Kaufman et al., 1995</xref>).</p><p>Further objective evidence came from a landmark case-referent study by <xref rid="ref18" ref-type="bibr">De La Paz et al. (2003)</xref>, conducted 18&#8239;years after the outbreak. TOS patients&#8212;particularly middle-aged women&#8212;performed significantly worse than matched controls on tests of motor strength, sensory function, and several neurocognitive domains such as memory, attention, processing speed, and psychomotor performance. The pattern of deficits indicated both peripheral and central nervous system involvement, with notable disruption of frontal-subcortical circuits (<xref rid="ref18" ref-type="bibr">De La Paz et al., 2003</xref>).</p><p>Despite earlier findings, the long-term cognitive effects of TOS remain poorly understood. A recent 43-year follow-up case&#8211;control study found subtle yet measurable deficits in executive function, attention, and processing speed among TOS survivors, assessed with modern computerized tools (<xref rid="ref40" ref-type="bibr">Lape&#241;a-Motilva et al., 2025</xref>). In a separate biomarker study within the same group, slightly elevated serum neurofilament light chain levels were observed in TOS patients&#8212;mainly due to a few outliers&#8212;while levels of glial fibrillary acidic protein and phosphorylated tau 217 remained within normal ranges (<xref rid="ref63" ref-type="bibr">Ruiz-Ortiz et al., 2025</xref>). These results suggest ongoing or residual neuronal injury in some individuals, without a biomarker pattern typical of progressive neurodegenerative disease (<xref rid="ref63" ref-type="bibr">Ruiz-Ortiz et al., 2025</xref>).</p><p>Eye tracking provides an objective, noninvasive, high-resolution readout of cognitive control, as voluntary saccades are generated by frontal-subcortical circuits that subserve attention, executive control, and working memory. In particular, the frontal eye fields, dorsolateral prefrontal cortex, and anterior cingulate interact with basal ganglia loops and the superior colliculus to initiate or suppress gaze shifts; consequently, the antisaccade task&#8212;which requires suppression of a reflexive glance and generation of a willful movement in the opposite direction&#8212;is a sensitive probe of inhibitory control and working memory maintenance (<xref rid="ref29" ref-type="bibr">Guerrero-Molina et al., 2021</xref>; <xref rid="ref26" ref-type="bibr">Garc&#237;a Cena et al., 2022a</xref>; <xref rid="ref27" ref-type="bibr">Garc&#237;a Cena et al., 2022b</xref>; <xref rid="ref74" ref-type="bibr">Wolf et al., 2023</xref>; <xref rid="ref8" ref-type="bibr">Benito-Le&#243;n et al., 2024</xref>; <xref rid="ref41" ref-type="bibr">Leng et al., 2024</xref>; <xref rid="ref7" ref-type="bibr">Benito-Le&#243;n et al., 2025</xref>). Across diverse neurological conditions, increased antisaccade error rates and prolonged latencies track frontal dysfunction, underscoring the utility of eye-movement metrics (e.g., error rates, reaction times) as surrogate markers of executive integrity (<xref rid="ref29" ref-type="bibr">Guerrero-Molina et al., 2021</xref>; <xref rid="ref26" ref-type="bibr">Garc&#237;a Cena et al., 2022a</xref>; <xref rid="ref27" ref-type="bibr">Garc&#237;a Cena et al., 2022b</xref>; <xref rid="ref74" ref-type="bibr">Wolf et al., 2023</xref>; <xref rid="ref8" ref-type="bibr">Benito-Le&#243;n et al., 2024</xref>; <xref rid="ref41" ref-type="bibr">Leng et al., 2024b</xref>; <xref rid="ref7" ref-type="bibr">Benito-Le&#243;n et al., 2025</xref>).</p><p>To date, no studies have used eye tracking to examine cognitive dysfunction in TOS. We therefore employed three validated paradigms&#8212;visually guided saccades (basic sensorimotor function), memory-guided saccades (spatial working memory), and antisaccades (inhibitory control, executive function, and attention) to detect subtle deficits that may elude conventional testing (<xref rid="ref29" ref-type="bibr">Guerrero-Molina et al., 2021</xref>; <xref rid="ref26" ref-type="bibr">Garc&#237;a Cena et al., 2022a</xref>; <xref rid="ref27" ref-type="bibr">Garc&#237;a Cena et al., 2022b</xref>; <xref rid="ref74" ref-type="bibr">Wolf et al., 2023</xref>; <xref rid="ref8" ref-type="bibr">Benito-Le&#243;n et al., 2024</xref>; <xref rid="ref41" ref-type="bibr">Leng et al., 2024b</xref>; <xref rid="ref7" ref-type="bibr">Benito-Le&#243;n et al., 2025</xref>). Given the chronic symptomatology of TOS, the predominance of dysexecutive features, and the absence of biomarker evidence for ongoing neurodegeneration, we hypothesized that TOS survivors would exhibit persistent oculomotor abnormalities, particularly in antisaccade performance, reflecting a long-standing disruption of frontal-subcortical circuits.</p></sec><sec sec-type="methods" id="sec2"><title>Methods</title><sec id="sec3"><title>Population and recruitment procedures</title><p>Between April and June 2024, participants were recruited from the Madrid region, one of the most severely affected areas by the 1981 TOS outbreak. A case-control design was used: individuals with a confirmed diagnosis of TOS formed the exposed group, while healthy controls from the same geographic area served as the unexposed group. All assessments, including interviews and cognitive testing, were conducted at the 12 de Octubre University Hospital in Madrid.</p></sec><sec id="sec4"><title>Participant selection</title><p>TOS cases were identified based on diagnostic criteria established in earlier research (<xref rid="ref40" ref-type="bibr">Lape&#241;a-Motilva et al., 2025</xref>; <xref rid="ref63" ref-type="bibr">Ruiz-Ortiz et al., 2025</xref>). Eligible individuals had experienced either the acute or chronic phase of the illness. The acute phase was characterized by alveolar&#8211;interstitial infiltrates and/or pleural effusion, along with absolute eosinophilia of more than 500 cells/mm<sup>3</sup>. The chronic phase criteria included persistent myalgia with eosinophilia and/or at least one of the following: scleroderma-like skin changes, peripheral neuropathy, pulmonary hypertension, or liver involvement.</p><p>Patients were enrolled through the 12 de Octubre University Hospital&#8217;s dedicated TOS unit&#8212;the only center in Spain specialized in the long-term follow-up of affected individuals. Recruitment was consecutive until 50 TOS cases were included. The control group consisted of 50 healthy individuals from the same community, selected from acquaintances or friends of the patients. Controls were matched by age (&#177;5&#8239;years), sex, and educational level to ensure comparability between groups. Given the fixed size of the eligible clinic cohort and the absence of prior eye-tracking effect-size estimates in TOS, we prospectively set a pragmatic target of 50 cases and 50 matched controls based on feasibility within the recruitment window, acknowledging that a formal <italic toggle="yes">a priori</italic> power calculation was not possible in this rare disease context.</p><p>Exclusion criteria for both groups included any history of neurodegenerative disease (e.g., Alzheimer&#8217;s or Parkinson&#8217;s disease), stroke, chronic kidney disease, alcohol abuse, or prior traumatic injury involving the central or peripheral nervous system. Identical criteria were applied to controls to maintain methodological rigor.</p></sec><sec id="sec5"><title>Assessments and measures</title><sec id="sec6"><title>Demographic and clinical characteristics</title><p>Participant data&#8212;including age, sex, educational background, medical history, and current medications&#8212;were obtained through a structured clinical interview and after revision of their medical records. Educational attainment was recorded in four categories: illiterate, primary, secondary and higher studies.</p></sec><sec id="sec7"><title>Fatigue evaluation</title><p>Fatigue was measured using the Fatigue Impact Scale for Daily Use (D-FIS; <xref rid="ref44" ref-type="bibr">Mart&#237;nez-Mart&#237;n et al., 2006</xref>; <xref rid="ref9" ref-type="bibr">Benito-Le&#243;n et al., 2007</xref>), a validated 8-item self-report tool designed to assess how fatigue interferes with daily activities. Each item is scored on a five-point Likert scale, from 0 (no problem) to 4 (extreme problem), yielding a total score that reflects the extent of fatigue-related impact on functioning.</p></sec><sec id="sec8"><title>Health-related quality of life</title><p>The EuroQol instrument was used to assess perceived health-related quality of life (<xref rid="ref3" ref-type="bibr">Badia et al., 2001</xref>). This tool includes two parts: the EQ-5D descriptive system and a visual analog scale (EQ VAS). The EQ-5D has five domains&#8212;mobility, self-care, usual activities, pain/discomfort, and anxiety/depression&#8212;each rated on a three-level scale (no problems, moderate problems, severe problems; <xref rid="ref3" ref-type="bibr">Badia et al., 2001</xref>). Responses create a health profile, from which an index score is calculated using standardized European value sets (<xref rid="ref3" ref-type="bibr">Badia et al., 2001</xref>). This score ranges from 1, indicating perfect health, to 0, representing death, and negative scores indicate states worse than death (<xref rid="ref3" ref-type="bibr">Badia et al., 2001</xref>). The EQ VAS enables participants to rate their overall health on a vertical scale ranging from 0 (the worst imaginable health) to 100 (the best imaginable health; <xref rid="ref3" ref-type="bibr">Badia et al., 2001</xref>).</p></sec><sec id="sec9"><title>Assessment of depressive symptoms</title><p>Depression severity was assessed using the Beck Depression Inventory-II (BDI-II) (<xref rid="ref5" ref-type="bibr">Beck et al., 1996</xref>), a 21-item self-report questionnaire widely used in clinical and research settings (<xref rid="ref5" ref-type="bibr">Beck et al., 1996</xref>). Each item reflects a symptom commonly associated with depression and is scored from 0 (absent) to 3 (severe), based on experiences over the prior 2&#8239;weeks (<xref rid="ref5" ref-type="bibr">Beck et al., 1996</xref>). Higher total scores indicate more severe depressive symptoms (<xref rid="ref5" ref-type="bibr">Beck et al., 1996</xref>).</p></sec><sec id="sec10"><title>Assessment of anxiety symptoms</title><p>Anxiety was measured using the Beck Anxiety Inventory (BAI; <xref rid="ref4" ref-type="bibr">Beck et al., 1988</xref>), a validated instrument consisting of 21 items evaluating common symptoms of anxiety. Participants rate how much they have been bothered by each symptom in the past week using a 4-point scale, ranging from 0 (not at all) to 3 (severely bothered). Total scores range from 0 to 63, with higher scores indicating greater severity of anxiety (<xref rid="ref4" ref-type="bibr">Beck et al., 1988</xref>).</p></sec><sec id="sec11"><title>Cognitive function testing</title><p>Cognitive performance was assessed using the NeuroTrax computerized system, which offers standardized and validated tests across multiple cognitive areas (<xref rid="ref21" ref-type="bibr">Doniger et al., 2005</xref>; <xref rid="ref66" ref-type="bibr">Schweiger et al., 2007</xref>; <xref rid="ref22" ref-type="bibr">Dwolatzky et al., 2003</xref>). Due to limited time, the assessment focused on specific domains: verbal and non-verbal memory, attention (measured through Go-NoGo and Stroop Interference tasks), processing speed, and executive function (evaluated via the Go-NoGo, Stroop Interference, and Catch Game tasks; <xref rid="ref21" ref-type="bibr">Doniger et al., 2005</xref>; <xref rid="ref66" ref-type="bibr">Schweiger et al., 2007</xref>; <xref rid="ref22" ref-type="bibr">Dwolatzky et al., 2003</xref>). All testing was conducted in Spanish, the native language of all participants.</p></sec><sec id="sec12"><title>Eye movement assessments</title><p>All eye-tracking evaluations were conducted in a dimly lit room, with recordings made monocularly from the dominant eye of each participant. Standardized instructions were provided, and a practice trial ensured proper understanding of the task. Saccades with latencies below 80 milliseconds and those occurring during blinks were excluded from analysis. The protocol included three well-established paradigms: visually guided saccades, memory-guided saccades, and the antisaccade task, all of which were performed on a horizontal axis (Figure 1) (<xref rid="ref29" ref-type="bibr">Guerrero-Molina et al., 2021</xref>; <xref rid="ref26" ref-type="bibr">Garc&#237;a Cena et al., 2022a</xref>; <xref rid="ref27" ref-type="bibr">Garc&#237;a Cena et al., 2022b</xref>; <xref rid="ref8" ref-type="bibr">Benito-Le&#243;n et al., 2024</xref>; <xref rid="ref7" ref-type="bibr">Benito-Le&#243;n et al., 2025</xref>). We followed our published eye-tracking protocol to ensure reproducibility and enable direct comparison with earlier measurements (<xref rid="ref25" ref-type="bibr">Garc&#237;a Cena et al., 2020</xref>). A brief antisaccade paradigm (22 trials) was implemented to reduce fatigue and maintain calibration stability, consistent with clinical and instrument validation protocols (<xref rid="ref31" ref-type="bibr">Hellmuth et al., 2012</xref>; <xref rid="ref12" ref-type="bibr">Brooks et al., 2019</xref>).</p><list list-type="bullet"><list-item><p>Visually guided saccades</p></list-item></list><p>With central fixation maintained, a peripheral target appeared at &#177;5&#176;, &#177;10&#176;, or &#177;20&#176; along the horizontal meridian in pseudorandom order; participants were instructed to look at the target as quickly and accurately as possible and then return their gaze to the central fixation. A correct visually guided saccade was defined as the first goal-directed saccade to the target location; a backward saccade was the subsequent return movement to fixation.Measures included: number of correct saccades; number of errors; latency (ms) from stimulus onset to saccade onset; peak velocity (&#176;/s); and gain (executed amplitude divided by target amplitude). Spatial error relative to the target was assessed separately for hypermetria (overshoot, positive degrees of visual angle) and hypometria (undershoot, negative degrees); we also counted the number of hypermetric saccades and the number of hypometric saccades. For the return movement, we recorded the number of correct backward saccades; number of backward errors; backward latency (ms); and peak backward velocity (&#176;/s).</p><list list-type="bullet"><list-item><p>Memory-guided saccades</p></list-item></list><p>While maintaining central fixation, a peripheral cue briefly appeared and then disappeared; after a short delay, participants made a saccade to the remembered location; then returned their gaze to the center once the fixation point reappeared. A correct memory-guided saccade was the first goal-directed saccade toward the remembered location; errors were first saccades directed elsewhere.Gain was calculated as executed amplitude divided by target amplitude; signed spatial error was the landing-position error (degrees of visual angle) relative to the cued location (positive = overshoot/hypermetria; negative = undershoot/hypometria).Measures included: number of correct memory-guided saccades; number of errors; latency; peak velocity; gain; hypermetric and hypometric spatial errors; number of correct backward memory-guided saccades (return movements to center); number of backward errors; backward latency; and peak backward velocity.</p><list list-type="bullet"><list-item><p>Antisaccade task</p></list-item></list><p>Participants maintained central fixation; when a peripheral stimulus appeared, they were instructed to suppress the automatic glance toward it and instead generate a saccade to the mirror-symmetric location on the opposite side. A correct antisaccade was the first goal-directed saccade from fixation (screen center) to the mirror-symmetric location; a reflexive saccade was an initial saccade toward the cue, followed by a corrective movement to the mirror position; any other eye movement was considered an antisaccade error.Backward eye movements&#8212;whether backward antisaccades or backward reflexive saccades&#8212;were defined as saccades from the mirror-symmetric location back to the screen center.Measures included: number of correct antisaccades; number of antisaccade errors; antisaccade latency (ms); number of correct backward antisaccades; number of backward antisaccade errors; backward antisaccade latency (ms); number of reflexive saccades; reflexive saccade latency (ms); number of backward reflexive saccades; backward reflexive saccade latency (ms); and reflexive saccade duration (ms).</p></sec></sec><sec id="sec13"><title>Standard protocol approvals, registrations, and patient consents</title><p>This study was approved by the Institutional Review Board (IRB) at the 12 de Octubre University Hospital in Madrid, Spain (CEIC codes: 17/035 and 23/616). It was conducted in accordance with the Declaration of Helsinki. Written (signed) informed consent was obtained from all participants.</p></sec><sec id="sec14"><title>Statistical analyses</title><p>Trial-level metrics were aggregated for each participant (means for normally distributed continuous variables, medians for skewed distributions, and totals for counts) and analyzed at the group level. All statistical analyses and figure creation were performed using Python (v3.12.2). The Python packages used included pandas (v2.2.3) for data management, TableOne (v0.9.1) for descriptive statistics, and semopy (v2.3.11) for structural equation modeling (SEM). Continuous variables were tested for normality with the Kolmogorov&#8211;Smirnov test. Between-group comparisons of demographic, cognitive, and eye-tracking data were made using independent-sample t-tests for normally distributed variables and Mann&#8211;Whitney U tests when normality assumptions were not met. Chi-square tests were used to assess group differences in categorical variables.</p><fig position="float" id="fig1" orientation="portrait"><label>Figure 1</label><caption><p>Schematic of eye-tracking paradigms. <bold>(A)</bold> Visually guided saccades. Participants fixated a central target (I) and then made a saccade to a peripheral stimulus (II). This task indexes basic sensorimotor oculomotor function (latency, gain, peak velocity). <bold>(B)</bold> Antisaccades. Participants fixated centrally (I) and, when a peripheral stimulus appeared, suppressed the automatic response toward it and instead generated a saccade to the mirror-symmetric location on the opposite side (II). This task indexes inhibitory control, executive function, and attention. <bold>(C)</bold> Memory-guided saccades. Participants fixated centrally (I); a peripheral cue briefly appeared to be remembered (II); after a short delay, they made a saccade to the remembered location (III). This task probes spatial working memory and delayed oculomotor planning. Blue dot&#8239;=&#8239;visual stimulus; orange dot&#8239;=&#8239;gaze position. Each task comprised 22 trials.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnins-19-1666809-g001.jpg"><alt-text content-type="machine-generated">Diagram illustrating three types of saccadic eye-movement tasks. A) Visually guided saccade: a blue visual stimulus appears and the orange gaze position shifts to the same location. B) Antisaccade: a blue visual stimulus appears and the orange gaze position shifts to the opposite side. C) Memory-guided saccade: sequence of three panels &#8211; Reference Position with overlapping stimulus and gaze; Memory Teaching with stimulus and gaze together at a new location; Memory Test showing gaze shifting to the remembered location after the cue disappear.</alt-text></graphic></fig><p>In this study, cognitive performance data obtained from the NeuroTrax computerized assessment were standardized by transforming raw scores into z-scores using the control group&#8217;s mean and standard deviation as reference. Z-scores were computed for all participants, regardless of group assignment. Consistent with previously published NeuroTrax-based protocols (<xref rid="ref40" ref-type="bibr">Lape&#241;a-Motilva et al., 2025</xref>; <xref rid="ref21" ref-type="bibr">Doniger et al., 2005</xref>; <xref rid="ref66" ref-type="bibr">Schweiger et al., 2007</xref>), domain-level indices were derived by averaging normalized values from domain-related test scores (e.g., accuracy, response time). A global cognitive score was then calculated by averaging across all domain indices.</p><p>We developed multivariate models to evaluate the influence of clinical, psychological, and fatigue-related variables on eye-tracking measures that were significant in univariate analyses. After adjusting for age, sex, and education (<xref rid="ref23" ref-type="bibr">Fjell et al., 2010</xref>; <xref rid="ref60" ref-type="bibr">Roe et al., 2007</xref>; <xref rid="ref67" ref-type="bibr">Seblova et al., 2020</xref>), we entered clinical comorbidities with established associations to cognitive decline&#8212;arterial hypertension and diabetes mellitus&#8212;because both were more prevalent in the TOS group and have recognized links to cognitive impairment (<xref rid="ref10" ref-type="bibr">Bermejo-Pareja et al., 2010</xref>; <xref rid="ref68" ref-type="bibr">Shome et al., 2025</xref>). In contrast, polyneuropathy was not modeled as a confounder because it is an intrinsic feature of TOS and has not been shown to contribute to cognitive dysfunction. Psychological symptoms (BDI-II and BAI) and fatigue (D-FIS) were then included as predictors. To quantify both direct and indirect pathways, we used SEM. Because BDI-II and BAI scores were highly collinear, we derived a single mood-distress composite via principal component analysis; the first component explained 90.92% of the shared variance and was carried forward as the Composite Variable for Depression and Anxiety (CVDA) in all multivariable and SEM models.</p><p>All <italic toggle="yes">p</italic>-values were two-tailed, and statistical significance was defined as <italic toggle="yes">p</italic>&#8239;&lt;&#8239;0.05. Given the proof-of-concept and exploratory nature of this study, no corrections for multiple comparisons were applied. This decision is supported by established recommendations that highlight the potential for such adjustments to increase Type II error unnecessarily and emphasize that they are not essential in hypothesis-generating research (<xref rid="ref62" ref-type="bibr">Rothman, 1990</xref>; <xref rid="ref54" ref-type="bibr">Perneger, 1998</xref>; <xref rid="ref6" ref-type="bibr">Bender and Lange, 2001</xref>).</p></sec></sec><sec sec-type="results" id="sec15"><title>Results</title><p>Of the 50 TOS patients and 50 healthy controls initially recruited, valid eye-tracking data were obtained for 47 and 44 participants, respectively. Participants were excluded due to acquisition-related issues (e.g., inadequate task compliance, calibration errors) or poor preprocessing quality (signal loss, artifacts, unstable tracking) that prevented analysis. As this was an exploratory, proof-of-concept study in a rare condition, a formal <italic toggle="yes">a priori</italic> sample-size calculation was not feasible. After data collection, a <italic toggle="yes">post-hoc</italic> power analysis (two-tailed independent-samples t-test, <italic toggle="yes">&#945;</italic>&#8239;=&#8239;0.05) showed that the analytic sample (<italic toggle="yes">N</italic>&#8239;=&#8239;91) had approximately 83.8% power to detect the observed medium effect size (Cohen&#8217;s d&#8239;&#8776;&#8239;0.62) for the global cognitive score. Accordingly, the study was not powered to detect small between-group differences.</p><p>Demographic and neuropsychological data are summarized in <xref rid="tab1" ref-type="table">Table 1</xref>. Groups were comparable in terms of age (mean age ~59&#8239;years), sex distribution (predominantly female), and educational attainment (<italic toggle="yes">p</italic>&#8239;&gt;&#8239;0.05 for all comparisons). However, TOS patients exhibited significantly higher prevalence of diabetes mellitus (25.5% vs. 2.3%), arterial hypertension (66.0% vs. 20.5%), and polyneuropathy (72.3% vs. 0%; all <italic toggle="yes">p</italic>&#8239;&lt;&#8239;0.005). TOS patients also showed markedly worse scores in health-related quality of life (EuroQol-5D index), fatigue (D-FIS), anxiety (BAI), and depression (BDI-II; all <italic toggle="yes">p</italic>&#8239;&lt;&#8239;0.001). Cognitively, they demonstrated significantly lower global cognitive scores (<italic toggle="yes">p</italic>&#8239;=&#8239;0.007), with prominent deficits in executive function (<italic toggle="yes">p</italic>&#8239;=&#8239;0.017), attention (<italic toggle="yes">p</italic>&#8239;=&#8239;0.014), and information processing speed (<italic toggle="yes">p</italic>&#8239;=&#8239;0.009). No significant differences were observed in memory subdomains.</p><table-wrap position="float" id="tab1" orientation="portrait"><label>Table 1</label><caption><p>Demographic and clinical characteristics of the study population by group.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Variable</th><th align="center" valign="top" rowspan="1" colspan="1">Controls (<italic toggle="yes">N</italic>&#8239;=&#8239;44)</th><th align="center" valign="top" rowspan="1" colspan="1">Patients (<italic toggle="yes">N</italic>&#8239;=&#8239;47)</th><th align="center" valign="top" rowspan="1" colspan="1"><italic toggle="yes">p</italic> value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Age, mean (standard deviation)</td><td align="center" valign="top" rowspan="1" colspan="1">58.3 (8.1)</td><td align="center" valign="top" rowspan="1" colspan="1">60.1 (8.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.286<xref rid="tfn1" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Female, %</td><td align="center" valign="top" rowspan="1" colspan="1">28 (63.6)</td><td align="center" valign="top" rowspan="1" colspan="1">35 (74.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.373<xref rid="tfn2" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Education, N (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.226<xref rid="tfn2" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Illiterate</td><td align="center" valign="top" rowspan="1" colspan="1">1 (2.3)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (6.4)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Primary studies</td><td align="center" valign="top" rowspan="1" colspan="1">16 (36.4)</td><td align="center" valign="top" rowspan="1" colspan="1">18 (38.3)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Secondary studies</td><td align="center" valign="top" rowspan="1" colspan="1">12 (27.3)</td><td align="center" valign="top" rowspan="1" colspan="1">18 (38.3)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Higher studies</td><td align="center" valign="top" rowspan="1" colspan="1">15 (34.1)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (17.0)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diabetes mellitus, N (%)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (2.3)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (25.5)</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>0.004</bold>
<xref rid="tfn2" ref-type="table-fn">
<sup>
<bold>b</bold>
</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Arterial hypertension, N (%)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (20.5)</td><td align="center" valign="top" rowspan="1" colspan="1">31 (66.0)</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>&lt;0.001</bold>
<xref rid="tfn2" ref-type="table-fn">
<sup>
<bold>b</bold>
</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Polyneuropathy, N (%)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="top" rowspan="1" colspan="1">34 (72.3)</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>&lt;0.001</bold>
<xref rid="tfn2" ref-type="table-fn">
<sup>
<bold>b</bold>
</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">EuroQol 5-Dimensions index, median [Q1, Q3]</td><td align="center" valign="top" rowspan="1" colspan="1">0.9 [0.7, 1.0]</td><td align="center" valign="top" rowspan="1" colspan="1">0.4 [0.1, 0.8]</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>&lt;0.001</bold>
<xref rid="tfn3" ref-type="table-fn">
<sup>
<bold>c</bold>
</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fatigue Impact Scale for Daily Use, mean (standard deviation)</td><td align="center" valign="top" rowspan="1" colspan="1">4.9 (6.3)</td><td align="center" valign="top" rowspan="1" colspan="1">19.2 (8.5)</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>&lt;0.001</bold>
<xref rid="tfn1" ref-type="table-fn">
<sup>
<bold>a</bold>
</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Beck Anxiety Inventory, median [Q1, Q3]</td><td align="center" valign="top" rowspan="1" colspan="1">4.0 [1.8, 11.8]</td><td align="center" valign="top" rowspan="1" colspan="1">22.0 [14.0, 30.5]</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>&lt;0.001</bold>
<xref rid="tfn3" ref-type="table-fn">
<sup>
<bold>c</bold>
</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Beck Depression Inventory, median [Q1, Q3]</td><td align="center" valign="top" rowspan="1" colspan="1">5.0 [2.0, 14.0]</td><td align="center" valign="top" rowspan="1" colspan="1">19.0 [11.5, 28.5]</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>&lt;0.001</bold>
<xref rid="tfn3" ref-type="table-fn">
<sup>
<bold>c</bold>
</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Global Cognitive Score, mean (standard deviation)<sup>d</sup></td><td align="center" valign="top" rowspan="1" colspan="1">0.0 (0.7)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.5 (0.9)</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>0.007</bold>
<xref rid="tfn1" ref-type="table-fn">
<sup>
<bold>a</bold>
</sup>
</xref>
</td></tr><tr><td align="left" valign="top" colspan="4" rowspan="1">Cognitive domains<sup>d</sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Memory, mean (standard deviation)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0 (0.9)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.3 (0.9)</td><td align="center" valign="top" rowspan="1" colspan="1">0.209<xref rid="tfn1" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Immediate memory, mean (standard deviation)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0 (0.9)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.3 (0.9)</td><td align="center" valign="top" rowspan="1" colspan="1">0.257<xref rid="tfn1" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Delayed memory, mean (standard deviation)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0 (0.9)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.3 (1.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.149<xref rid="tfn1" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Executive function, mean (standard deviation)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0 (0.8)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.4 (1.0)</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>0.017</bold>
<xref rid="tfn1" ref-type="table-fn">
<sup>
<bold>a</bold>
</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Attention, median [Q1, Q3]</td><td align="center" valign="top" rowspan="1" colspan="1">0.1 [&#8722;0.2,0.5]</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.2 [&#8722;1.4,0.3]</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>0.014</bold>
<xref rid="tfn3" ref-type="table-fn">
<sup>
<bold>c</bold>
</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Information processing speed, mean (standard deviation)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0 (0.8)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.6 (1.0)</td><td align="center" valign="top" rowspan="1" colspan="1"><bold>0.009</bold>
<xref rid="tfn1" ref-type="table-fn">
<sup>
<bold>a</bold>
</sup>
</xref>
</td></tr></tbody></table><table-wrap-foot><fn id="tfn1"><label>a</label><p>Student t test.</p></fn><fn id="tfn2"><label>b</label><p>Chi-square test or Fisher&#8217;s exact test, as appropriate.</p></fn><fn id="tfn3"><label>c</label><p>Mann&#8211;Whitney U test.<sup>d</sup> Z-scores (control group as reference, see Methods). Bold values indicate statistical significance at <italic toggle="yes">p</italic> &lt; 0.05.</p></fn></table-wrap-foot></table-wrap><sec id="sec16"><title>Oculomotor tasks</title><sec id="sec17"><title>Visually guided saccades</title><p>TOS survivors exhibited preserved performance across all visually guided saccade measures. <xref rid="fig2" ref-type="fig">Figure 2</xref> shows the distribution of parameters recorded during the task: (1) number of correct saccades, (2) latency (ms), (3) peak velocity (&#176;/s), (4) gain (executed amplitude divided by target amplitude), (5) number of hypermetric saccades, (6) number of hypometric saccades, (7) number of correct backward saccades, and (8) backward latency (ms). As detailed in <xref rid="tab2" ref-type="table">Table 2</xref>, no statistically significant differences were observed between groups in any parameter (all <italic toggle="yes">p</italic>&#8239;&gt;&#8239;0.05). TOS participants showed subtle, non-significant trends toward slightly faster backward latencies and marginally higher peak velocities. Gain values remained tightly centered around 1.0 in both groups, indicating accurate amplitude scaling. Variability in spatial error (hypermetric and hypometric saccades) was also comparable. These findings indicate that visually guided saccades are preserved in TOS survivors, with no evidence of disrupted basic oculomotor function.</p><fig position="float" id="fig2" orientation="portrait"><label>Figure 2</label><caption><p>Violin plots of visually guided saccade measures. Violin plots show the distribution of oculomotor measures for healthy controls (blue) and patients with toxic oil syndrome (orange). From left to right, top row: number of correct saccades, latency (ms), peak velocity (&#176;/s), and gain (executed amplitude divided by target amplitude). Bottom row: number of hypermetric saccades, number of hypometric saccades, number of correct backward saccades, and backward latency (ms). Solid lines indicate group medians; dotted lines indicate group means.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnins-19-1666809-g002.jpg"><alt-text content-type="machine-generated">Violin plots illustrating visually guided saccade performance in healthy controls (blue) and TOS patients (orange). Metrics displayed include number of correct saccades, latency (ms), peak velocity (&#176;/s), gain, counts of hypermetric and hypometric saccades, number of correct backward saccades, and backward latency (ms). Each violin plot shows the full data distribution with solid lines for group medians and dotted lines for group means, enabling visual comparison of performance patterns between groups.</alt-text></graphic></fig><table-wrap position="float" id="tab2" orientation="portrait"><label>Table 2</label><caption><p>Visually guided and memory-guided saccade and antisaccade tests.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">Controls (<italic toggle="yes">N</italic>&#8239;=&#8239;44)</th><th align="center" valign="top" rowspan="1" colspan="1">Patients (<italic toggle="yes">N</italic>&#8239;=&#8239;47)</th><th align="center" valign="top" rowspan="1" colspan="1"><italic toggle="yes">p</italic> value</th></tr></thead><tbody><tr><td align="left" valign="top" colspan="4" rowspan="1">Visually guided saccade test</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Number of correct saccades, median [Q1, Q3]</td><td align="center" valign="top" rowspan="1" colspan="1">12.0 [12.0,12.0]</td><td align="center" valign="top" rowspan="1" colspan="1">12.0 [11.0, 12.0]</td><td align="center" valign="top" rowspan="1" colspan="1">0.149<xref rid="tfn4" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Number of errors, median [Q1, Q3]</td><td align="center" valign="top" rowspan="1" colspan="1">0.0 [0.0, 0.0]</td><td align="center" valign="top" rowspan="1" colspan="1">0.0 [0.0, 1.0]</td><td align="center" valign="top" rowspan="1" colspan="1">0.149<xref rid="tfn4" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Latency (ms), mean (standard deviation)</td><td align="center" valign="top" rowspan="1" colspan="1">236.8 (30.8)</td><td align="center" valign="top" rowspan="1" colspan="1">232.8 (33.9)</td><td align="center" valign="top" rowspan="1" colspan="1">0.562<xref rid="tfn5" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Peak velocity (&#176;/s), mean (standard deviation)</td><td align="center" valign="top" rowspan="1" colspan="1">316.7 (65.9)</td><td align="center" valign="top" rowspan="1" colspan="1">329.6 (59.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.333<xref rid="tfn5" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gain (saccade amplitude/target amplitude), median [Q1, Q3]</td><td align="center" valign="top" rowspan="1" colspan="1">1.0 [1.0, 1.0]</td><td align="center" valign="top" rowspan="1" colspan="1">1.0 [1.0, 1.0]</td><td align="center" valign="top" rowspan="1" colspan="1">0.096<xref rid="tfn4" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Spatial error relative to target &#8211; hypermetria (&#176; visual angle), median [Q1, Q3]</td><td align="center" valign="top" rowspan="1" colspan="1">0.4 [0.3, 0.6]</td><td align="center" valign="top" rowspan="1" colspan="1">0.4 [0.3, 0.8]</td><td align="center" valign="top" rowspan="1" colspan="1">0.831<xref rid="tfn4" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Number of hypermetric saccades, mean (standard deviation)</td><td align="center" valign="top" rowspan="1" colspan="1">6.0 (2.3)</td><td align="center" valign="top" rowspan="1" colspan="1">6.5 (2.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.298<xref rid="tfn5" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Spatial error relative to target &#8211; hypometria (&#176; visual angle), median [Q1, Q3]</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.5 [&#8722;0.8, &#8722;0.3]</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.5 [&#8722;0.8, &#8722;0.3]</td><td align="center" valign="top" rowspan="1" colspan="1">0.548<xref rid="tfn4" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Number of hypometric saccades, mean (standard deviation)</td><td align="center" valign="top" rowspan="1" colspan="1">5.5 (2.3)</td><td align="center" valign="top" rowspan="1" colspan="1">4.7 (1.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.105<xref rid="tfn5" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Number of correct backward saccades, median [Q1, Q3]</td><td align="center" valign="top" rowspan="1" colspan="1">11.0 [9.8,11.0]</td><td align="center" valign="top" rowspan="1" colspan="1">11.0 [10.0, 11.0]</td><td align="center" valign="top" rowspan="1" colspan="1">0.615<xref rid="tfn4" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Number of backward errors, median [Q1, Q3]</td><td align="center" valign="top" rowspan="1" colspan="1">0.0 [0.0, 1.2]</td><td align="center" valign="top" rowspan="1" colspan="1">0.0 [0.0, 1.0]</td><td align="center" valign="top" rowspan="1" colspan="1">0.615<xref rid="tfn4" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Backward latency (ms), median [Q1, Q3]</td><td align="center" valign="top" rowspan="1" colspan="1">219.6 [205.4, 231.1]</td><td align="center" valign="top" rowspan="1" colspan="1">209.2 [197.5, 230.2]</td><td align="center" valign="top" rowspan="1" colspan="1">0.257<xref rid="tfn4" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Peak backward velocity (&#176;/s), mean (standard deviation)</td><td align="center" valign="top" rowspan="1" colspan="1">320.5 (70.9)</td><td align="center" valign="top" rowspan="1" colspan="1">323.0 (58.2)</td><td align="center" valign="top" rowspan="1" colspan="1">0.859<xref rid="tfn5" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td align="left" valign="top" colspan="4" rowspan="1">Memory-guided saccade test</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Number of correct memory-guided saccades, mean (standard deviation)</td><td align="center" valign="bottom" rowspan="1" colspan="1">8.3 (2.8)</td><td align="center" valign="bottom" rowspan="1" colspan="1">7.6 (3.5)</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.286<xref rid="tfn5" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Number of errors, mean (standard deviation)</td><td align="center" valign="bottom" rowspan="1" colspan="1">3.7 (2.8)</td><td align="center" valign="bottom" rowspan="1" colspan="1">4.4 (3.5)</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.286<xref rid="tfn5" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Latency (ms), median [Q1, Q3]</td><td align="center" valign="bottom" rowspan="1" colspan="1">413.5 [307.3, 561.6]</td><td align="center" valign="bottom" rowspan="1" colspan="1">456.0 [355.6, 591.1]</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.331<xref rid="tfn4" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Peak velocity (&#176;/s), mean (standard deviation)</td><td align="center" valign="bottom" rowspan="1" colspan="1">285.5 (84.9)</td><td align="center" valign="bottom" rowspan="1" colspan="1">265.8 (70.4)</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.244<xref rid="tfn5" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gain (saccade amplitude/target amplitude), mean (standard deviation)</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.9 (0.3)</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.9 (0.3)</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.573<xref rid="tfn5" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Spatial error relative to cued location &#8211; hypermetria (&#176; visual angle), median [Q1, Q3]</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.6 [0.3, 1.3]</td><td align="center" valign="bottom" rowspan="1" colspan="1">1.0 [0.3, 1.8]</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.130<xref rid="tfn4" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Number of hypermetric saccades, mean (standard deviation)</td><td align="center" valign="bottom" rowspan="1" colspan="1">5.2 (3.0)</td><td align="center" valign="bottom" rowspan="1" colspan="1">5.3 (3.1)</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.915<xref rid="tfn5" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Spatial error relative to cued location &#8211; hypometria (&#176; visual angle), median [Q1, Q3]</td><td align="center" valign="bottom" rowspan="1" colspan="1">&#8722;3.1 [&#8722;5.1, &#8722;0.9]</td><td align="center" valign="bottom" rowspan="1" colspan="1">&#8722;4.0 [&#8722;6.8, &#8722;1.1]</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.435<xref rid="tfn4" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Number of hypometric saccades, mean (standard deviation)</td><td align="center" valign="bottom" rowspan="1" colspan="1">4.6 (3.1)</td><td align="center" valign="bottom" rowspan="1" colspan="1">4.6 (2.7)</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.980<xref rid="tfn5" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Number of correct backward memory-guided saccades, median [Q1, Q3]</td><td align="center" valign="bottom" rowspan="1" colspan="1">8.0 [5.0, 10.0]</td><td align="center" valign="bottom" rowspan="1" colspan="1">7.0 [4.0, 10.0]</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.446<xref rid="tfn4" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Number of backward errors, median [Q1, Q3]</td><td align="center" valign="bottom" rowspan="1" colspan="1">3.0 [1.0, 6.0]</td><td align="center" valign="bottom" rowspan="1" colspan="1">4.0 [1.0, 7.0]</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.446<xref rid="tfn4" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Backward latency (ms), median [Q1, Q3]</td><td align="center" valign="bottom" rowspan="1" colspan="1">332.6 [299.1, 398.3]</td><td align="center" valign="bottom" rowspan="1" colspan="1">326.2 [270.4, 451.2]</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.990<xref rid="tfn4" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Peak backward velocity (&#176;/s), mean (standard deviation)</td><td align="center" valign="bottom" rowspan="1" colspan="1">286.8 (97.7)</td><td align="center" valign="bottom" rowspan="1" colspan="1">288.2 (94.0)</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.948<xref rid="tfn5" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td align="left" valign="top" colspan="4" rowspan="1">Antisaccade test</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Number of correct antisaccades, mean (standard deviation)</td><td align="center" valign="bottom" rowspan="1" colspan="1">5.0 (3.1)</td><td align="center" valign="bottom" rowspan="1" colspan="1">3.6 (3.0)</td><td align="center" valign="bottom" rowspan="1" colspan="1"><bold>0.029</bold>
<xref rid="tfn5" ref-type="table-fn">
<sup>
<bold>b</bold>
</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Number of antisaccade errors, median [Q1, Q3]</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.0 [0.0,1.5]</td><td align="center" valign="bottom" rowspan="1" colspan="1">1.0 [0.0, 2.0]</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.418<xref rid="tfn4" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Antisaccade latency (ms), median [Q1, Q3]</td><td align="center" valign="bottom" rowspan="1" colspan="1">370.7 [340.1,428.6]</td><td align="center" valign="bottom" rowspan="1" colspan="1">383.0 [319.5, 449.4]</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.854<xref rid="tfn4" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Number of correct backward antisaccades, mean (standard deviation)</td><td align="center" valign="bottom" rowspan="1" colspan="1">4.1 (2.5)</td><td align="center" valign="bottom" rowspan="1" colspan="1">3.3 (2.8)</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.136<xref rid="tfn5" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Number of backward antisaccade errors, median [Q1, Q3]</td><td align="center" valign="bottom" rowspan="1" colspan="1">1.0 [0.0,2.0]</td><td align="center" valign="bottom" rowspan="1" colspan="1">1.0 [0.0, 2.0]</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.475<xref rid="tfn4" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Backward antisaccade latency (ms), median [Q1, Q3]</td><td align="center" valign="bottom" rowspan="1" colspan="1">355.8 [312.4,417.7]</td><td align="center" valign="bottom" rowspan="1" colspan="1">361.3 [316.0, 438.3]</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.723<xref rid="tfn4" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Number of reflexive saccades, mean (standard deviation)</td><td align="center" valign="bottom" rowspan="1" colspan="1">5.7 (2.9)</td><td align="center" valign="bottom" rowspan="1" colspan="1">7.0 (3.1)</td><td align="center" valign="bottom" rowspan="1" colspan="1"><bold>0.033</bold>
<xref rid="tfn5" ref-type="table-fn">
<sup>
<bold>b</bold>
</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Reflexive saccade latency (ms), median [Q1, Q3]</td><td align="center" valign="bottom" rowspan="1" colspan="1">332.0 [302.5,354.9]</td><td align="center" valign="bottom" rowspan="1" colspan="1">315.9 [287.4, 361.1]</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.248<xref rid="tfn4" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Number of backward reflexive saccades, mean (standard deviation)</td><td align="center" valign="bottom" rowspan="1" colspan="1">5.1 (2.5)</td><td align="center" valign="bottom" rowspan="1" colspan="1">6.3 (2.7)</td><td align="center" valign="bottom" rowspan="1" colspan="1"><bold>0.040</bold>
<xref rid="tfn5" ref-type="table-fn">
<sup>
<bold>b</bold>
</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Backward reflexive saccade latency (ms), mean (standard deviation)</td><td align="center" valign="bottom" rowspan="1" colspan="1">436.2 (137.2)</td><td align="center" valign="bottom" rowspan="1" colspan="1">445.8 (144.1)</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.745<xref rid="tfn5" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Reflexive saccade duration (ms), median [Q1, Q3]</td><td align="center" valign="bottom" rowspan="1" colspan="1">270.4 [198.1,342.0]</td><td align="center" valign="bottom" rowspan="1" colspan="1">307.3 [226.1, 388.2]</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.251<xref rid="tfn4" ref-type="table-fn"><sup>a</sup></xref></td></tr></tbody></table><table-wrap-foot><fn id="tfn4"><label>a</label><p>Mann-Whitney U test.</p></fn><fn id="tfn5"><label>b</label><p>Student t test.Bold values indicate statistical significance at <italic toggle="yes">p</italic> &lt; 0.05.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec18"><title>Memory-guided saccades</title><p>Performance on the memory-guided saccade task was also preserved in TOS survivors. <xref rid="fig3" ref-type="fig">Figure 3</xref> displays the distribution of measures: (1) number of correct memory-guided saccades, (2) latency (ms), (3) peak velocity (&#176;/s), (4) gain, (5) number of hypermetric saccades, (6) number of hypometric saccades, (7) number of correct backward memory-guided saccades, and (8) backward latency (ms). Compared with controls, TOS participants exhibited mild, non-significant tendencies toward longer latencies, lower peak velocities, and greater dispersion of spatial error (including hypermetric and hypometric errors). Gain values remained close to 1.0 in both groups. As summarized in <xref rid="tab2" ref-type="table">Table 2</xref>, no statistically significant group differences were found in any parameter (all <italic toggle="yes">p</italic>&#8239;&gt;&#8239;0.05). These results indicate that memory-guided saccadic performance remains largely intact in TOS, suggesting that the integration of spatial working memory with oculomotor planning is preserved.</p><fig position="float" id="fig3" orientation="portrait"><label>Figure 3</label><caption><p>Violin plots of memory-guided saccade measures. Violin plots show the distribution of oculomotor measures for healthy controls (blue) and patients with toxic oil syndrome (orange). Top row (left to right): number of correct memory-guided saccades, latency (ms), peak velocity (&#176;/s), and gain (executed amplitude divided by target amplitude). Bottom row (left to right): number of hypermetric saccades, number of hypometric saccades, number of correct backward memory-guided saccades, and backward latency (ms). Solid lines indicate group medians; dotted lines indicate group means.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnins-19-1666809-g003.jpg"><alt-text content-type="machine-generated">Violin plots illustrating antisaccade task performance in healthy controls (blue) and TOS patients (orange). Metrics include number and latency (ms) of correct antisaccades, backward antisaccades, reflexive saccades, and backward reflexive saccades. Each plot depicts the full data distribution, with solid lines marking medians and dotted lines means, enabling comparison of group performance across inhibitory control measures.</alt-text></graphic></fig></sec><sec id="sec19"><title>Antisaccades</title><p>In contrast, TOS survivors demonstrated impaired antisaccade performance accompanied by increased reflexive responses, consistent with deficits in attentional and executive control. <xref rid="fig4" ref-type="fig">Figure 4</xref> illustrates the distribution of eight parameters: (1) number of correct antisaccades, (2) antisaccade latency (ms), (3) number of correct backward antisaccades, (4) backward antisaccade latency (ms), (5) number of reflexive saccades, (6) reflexive saccade latency (ms), (7) number of backward reflexive saccades, and (8) backward reflexive saccade latency (ms). Compared to matched controls, TOS patients exhibited significantly fewer correct antisaccades (mean 3.6 vs. 5.0; <italic toggle="yes">p</italic>&#8239;=&#8239;0.029). In parallel, they showed more reflexive saccades (mean 7.0 vs. 5.7; <italic toggle="yes">p</italic>&#8239;=&#8239;0.033) and a modest increase in backward reflexive saccades (mean 6.3 vs. 5.1; <italic toggle="yes">p</italic>&#8239;=&#8239;0.040; <xref rid="tab2" ref-type="table">Table 2</xref>). No significant differences were observed in antisaccade latency (<italic toggle="yes">p</italic>&#8239;=&#8239;0.854), backward antisaccade latency (<italic toggle="yes">p</italic>&#8239;=&#8239;0.723), or reflexive saccade duration (<italic toggle="yes">p</italic>&#8239;=&#8239;0.251).</p><fig position="float" id="fig4" orientation="portrait"><label>Figure 4</label><caption><p>Violin plots of antisaccade measures. Violin plots illustrate the distribution of measures for healthy controls (blue) and patients with toxic oil syndrome (orange). Top row: number of correct antisaccades, antisaccade latency (ms), number of correct backward antisaccades, and backward antisaccade latency (ms). Bottom row: number of reflexive saccades, reflexive saccade latency (ms), number of backward reflexive saccades, and backward reflexive saccade latency (ms). Solid lines indicate group medians; dotted lines indicate group means.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnins-19-1666809-g004.jpg"><alt-text content-type="machine-generated">Violin plots comparing eye movement metrics between healthy controls and TOS patients. Metrics include the number and latency of correct antisaccades, backward antisaccades, reflexive saccades, and backward reflexive saccades. Healthy controls are shown in blue, TOS patients in orange. Each plot displays the distribution and median values for both groups.</alt-text></graphic></fig><p>To further examine these associations, we constructed structural equation models (SEMs) adjusting for potential confounders. Attention was specified a priori as the sole mediator because antisaccade performance relies on top-down attentional control, and including multiple, correlated domains would over-parameterize the model in this sample (<xref rid="ref48" ref-type="bibr">Munoz and Everling, 2004</xref>; <xref rid="ref39" ref-type="bibr">Ko&#231;o&#287;lu et al., 2021</xref>) We intentionally excluded formal executive function scores because of their strong conceptual and statistical overlap with antisaccade performance, which itself is a sensitive and well-established indicator of executive control (<xref rid="ref49" ref-type="bibr">Nieuwenhuis et al., 2004</xref>; <xref rid="ref46" ref-type="bibr">Mirsky et al., 2011</xref>). Similarly, we did not include the global cognitive score, which aggregates across multiple domains not directly related to antisaccade generation and could obscure specific associations with oculomotor measures.</p><p>Given the higher prevalence of vascular risk factors and mood/fatigue symptoms in the TOS group, these variables were incorporated into the models alongside age, sex, and education. The antisaccade impairment remained significant after full adjustment. The SEMs confirmed that the reduced number of correct antisaccades in TOS survivors remained significant after adjustment (<italic toggle="yes">p</italic>&#8239;=&#8239;0.02; <xref rid="fig5" ref-type="fig">Figure 5</xref>). Attention also showed a significant direct positive influence on antisaccade performance (<italic toggle="yes">p</italic>&#8239;=&#8239;0.01; <xref rid="fig5" ref-type="fig">Figure 5</xref>). By contrast, while TOS exerted significant direct effects on reflexive (<italic toggle="yes">p</italic>&#8239;=&#8239;0.03; <xref rid="fig6" ref-type="fig">Figure 6</xref>) and backward reflexive saccades (<italic toggle="yes">p</italic>&#8239;=&#8239;0.04; <xref rid="fig7" ref-type="fig">Figure 7</xref>), these outcomes were not significantly mediated by attention or other covariates. Overall, the models demonstrate that TOS status consistently impacted antisaccade and reflexive measures, whereas attentional control contributed independently only to antisaccade performance.</p><fig position="float" id="fig5" orientation="portrait"><label>Figure 5</label><caption><p>Structural equation model for antisaccade performance in toxic oil syndrome (TOS) survivors. Path diagram illustrating the direct and indirect effects of TOS on the number of correct antisaccades, adjusted for covariates. Predictor variables included a composite variable for depression and anxiety (CVDA), fatigue (D-FIS), diabetes mellitus, arterial hypertension, education, sex, and age. Attention was modeled as a potential mediator. Arrows represent standardized regression coefficients with associated <italic toggle="yes">p</italic>-values. TOS showed a significant direct negative effect on antisaccade performance (<italic toggle="yes">&#946;</italic>&#8239;=&#8239;&#8722;1.720, <italic toggle="yes">p</italic>&#8239;=&#8239;0.02). At the same time, attention was positively associated with performance (<italic toggle="yes">&#946;</italic>&#8239;=&#8239;0.928, <italic toggle="yes">p</italic>&#8239;=&#8239;0.01), indicating that both disease status and attentional processes independently influenced antisaccade measures. CVDA, Composite Variable for Depression and Anxiety; D-FIS, Daily Fatigue Impact Scale.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnins-19-1666809-g005.jpg"><alt-text content-type="machine-generated">Path diagram showing relationships among CVDA, D&#8209;FIS, TOS, diabetes, hypertension, education, sex, age, attention and the number of correct antisaccades. Arrows indicate causal paths with standardised coefficients and p values. TOS has a significant negative effect (&#946; = &#8211;1.72, p = 0.02) and attention a significant positive effect (&#946; = 0.93, p = 0.01) on antisaccade performance; paths from age and other covariates are non&#8209;significant.</alt-text></graphic></fig><fig position="float" id="fig6" orientation="portrait"><label>Figure 6</label><caption><p>Structural equation model for reflexive saccade performance in toxic oil syndrome (TOS) survivors. Path diagram illustrating the direct and indirect effects of TOS on the number of reflexive saccades, adjusted for covariates. Predictor variables included a composite variable for depression and anxiety (CVDA), fatigue (D-FIS), diabetes mellitus, arterial hypertension, education, sex, and age. Attention was modeled as a potential mediator. Arrows represent standardized regression coefficients with associated <italic toggle="yes">p</italic>-values. TOS exerted a significant direct positive effect on reflexive saccade frequency (<italic toggle="yes">&#946;</italic>&#8239;=&#8239;1.761, <italic toggle="yes">p</italic>&#8239;=&#8239;0.03), while attention showed no significant mediation effect. CVDA, Composite Variable for Depression and Anxiety; D-FIS, Daily Fatigue Impact Scale.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnins-19-1666809-g006.jpg"><alt-text content-type="machine-generated">Path diagram showing relationships among TOS status, mood distress (CVDA), fatigue (D-FIS), diabetes mellitus, arterial hypertension, education, sex, age and attention and the number of reflexive saccades. Arrows display standardised coefficients with p&#8209;values. The only significant path is a direct positive effect of TOS on reflexive saccade frequency (&#946; = 1.76, p = 0.03); attention and all other covariates show non-significant paths.</alt-text></graphic></fig><fig position="float" id="fig7" orientation="portrait"><label>Figure 7</label><caption><p>Structural equation model for backward reflexive saccade performance in toxic oil syndrome (TOS) survivors. Path diagram illustrating the direct and indirect effects of TOS on the number of backward reflexive saccades, adjusted for covariates. Predictor variables included a composite variable for depression and anxiety (CVDA), fatigue (D-FIS), diabetes mellitus, arterial hypertension, education, sex, and age. Attention was modeled as a potential mediator. Arrows represent standardized regression coefficients with associated <italic toggle="yes">p</italic>-values. TOS exerted a significant direct positive effect on backward reflexive saccade frequency (<italic toggle="yes">&#946;</italic>&#8239;=&#8239;1.433, <italic toggle="yes">p</italic>&#8239;=&#8239;0.04), while no significant indirect effects through attention or other covariates were detected. CVDA, Composite Variable for Depression and Anxiety; D-FIS, Daily Fatigue Impact Scale.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnins-19-1666809-g007.jpg"><alt-text content-type="machine-generated">Path diagram illustrating relationships among TOS status, CVDA, D-FIS, diabetes, hypertension, education, sex, age and attention and the number of backward reflexive saccades. Arrows indicate direction and strength (standardised coefficients with p-values). TOS status has a significant positive effect on backward reflexive saccade frequency (&#946; = 1.43, p = 0.04); other variables, including age and attention, are included as covariates but do not show significant effects.</alt-text></graphic></fig></sec></sec></sec><sec sec-type="discussion" id="sec20"><title>Discussion</title><p>This proof-of-concept study investigated saccadic eye movements and cognitive function in TOS survivors more than four decades after exposure. The most salient finding was a selective impairment in the antisaccade task: TOS participants generated significantly fewer correct antisaccades and exhibited increased reflexive and backward reflexive saccades. In contrast, performance in visually guided and memory-guided saccades was preserved across all parameters, including latency, gain, peak velocity, and spatial error measures. These findings suggest that basic oculomotor control and spatial working memory are preserved, whereas higher-order executive functions, particularly inhibitory control, are selectively impaired. This pattern is consistent with our neuropsychological results, which identified deficits in executive function, attention, and processing speed, with memory performance remaining relatively intact. SEM models confirmed that antisaccade impairments remained significant after adjusting for confounders. Notably, attention exerted an independent positive influence only on correct antisaccade performance (<xref rid="fig5" ref-type="fig">Figure 5</xref>), whereas reflexive and backward reflexive saccades (<xref rid="fig6" ref-type="fig">Figures 6</xref> and <xref rid="fig7" ref-type="fig">7</xref>) were driven by TOS status alone. Overall, the converging oculomotor and cognitive data indicate a long-term disruption of frontal-subcortical circuits in TOS survivors.</p><p>Our findings build upon earlier TOS studies by employing objective, high-temporal-resolution eye-tracking paradigms to detect subtle executive dysfunction. They also parallel deficits observed in other immune-mediated disorders. For instance, eosinophilia&#8211;myalgia syndrome&#8212;a condition with shared toxic and immunologic mechanisms&#8212;has been associated with similar impairments in executive function and attention, alongside magnetic resonance imaging evidence of subcortical white matter abnormalities (<xref rid="ref2" ref-type="bibr">Armstrong et al., 1997</xref>). Both syndromes likely represent a continuum of toxic-immune encephalopathies with convergent effects on prefrontal networks (<xref rid="ref2" ref-type="bibr">Armstrong et al., 1997</xref>).</p><p>Comparable profiles have been reported in chronic exposure to organophosphate pesticides, which selectively impair attention, executive functioning, and processing speed, while sparing language and visuospatial abilities (<xref rid="ref33" ref-type="bibr">Jamal, 1997</xref>; <xref rid="ref61" ref-type="bibr">Ross et al., 2013</xref>; <xref rid="ref42" ref-type="bibr">London et al., 2012</xref>). These similarities reinforce the notion that diverse environmental toxicants can lead to common neurobehavioral outcomes via frontal-subcortical disconnection. Notably, organophosphate contamination was an early suspect in TOS etiology, although it was later discredited (<xref rid="ref28" ref-type="bibr">Gelp&#237; et al., 2002</xref>).</p><p>The antisaccade task is a sensitive probe of frontal dysfunction, particularly implicating the dorsolateral prefrontal cortex, frontal eye fields, and basal ganglia circuits (<xref rid="ref55" ref-type="bibr">Pierrot-Deseilligny et al., 1995</xref>). Our finding of impaired antisaccades, alongside elevated reflexive and backward saccades, indicates a failure of inhibitory control, consistent with dysfunction in frontostriatal pathways (<xref rid="ref55" ref-type="bibr">Pierrot-Deseilligny et al., 1995</xref>). This profile echoes those seen in neurodegenerative disorders, including Parkinson&#8217;s disease dementia and dementia with Lewy bodies (<xref rid="ref47" ref-type="bibr">Mosimann et al., 2005</xref>), Huntington disease (<xref rid="ref53" ref-type="bibr">Patel et al., 2012</xref>) and multiple system atrophy (<xref rid="ref11" ref-type="bibr">Brooks et al., 2017</xref>), as well as psychiatric conditions such as schizophrenia (<xref rid="ref13" ref-type="bibr">Caldani et al., 2017</xref>; <xref rid="ref70" ref-type="bibr">Subramaniam et al., 2018</xref>; <xref rid="ref51" ref-type="bibr">Obyedkov et al., 2019</xref>). Similar antisaccade impairments have also been reported in prodromal or cognitive disorders, notably idiopathic REM sleep behaviour disorder (<xref rid="ref30" ref-type="bibr">Hanu&#353;ka et al., 2019</xref>) and mild cognitive impairment (<xref rid="ref39" ref-type="bibr">Ko&#231;o&#287;lu et al., 2021</xref>). Eye_movement abnormalities have also been noted in Alzheimer&#8217;s disease dementia (<xref rid="ref15" ref-type="bibr">Costanzo et al., 2023</xref>) and ataxias (<xref rid="ref71" ref-type="bibr">Szpisjak et al., 2021</xref>), underscoring the broader relevance of antisaccade deficits marker of frontal-subcortical dysfunction across diverse disorders.</p><p>While reflexive saccades are generally preserved in early Alzheimer&#8217;s disease, they tend to be impaired in subcortical and mixed dementias (<xref rid="ref47" ref-type="bibr">Mosimann et al., 2005</xref>). The altered antisaccade pattern in TOS thus further supports selective involvement of executive networks. Functional neuroimaging and lesion studies suggest that the dorsolateral prefrontal cortex is involved in response suppression, the frontal eye fields in vector inversion, and the anterior cingulate cortex in error monitoring (<xref rid="ref24" ref-type="bibr">Funahashi, 2006</xref>; <xref rid="ref48" ref-type="bibr">Munoz and Everling, 2004</xref>; <xref rid="ref45" ref-type="bibr">McDowell et al., 2008</xref>; <xref rid="ref16" ref-type="bibr">Curtis and D&#8217;Esposito, 2003</xref>).</p><p>TOS was originally linked to aniline-contaminated rapeseed oil, triggering a systemic eosinophilic and autoimmune response with central nervous system involvement (<xref rid="ref1" ref-type="bibr">Abaitua Borda et al., 1998</xref>; <xref rid="ref64" ref-type="bibr">S&#225;nchez-Porro Valad&#233;s et al., 2003</xref>; <xref rid="ref56" ref-type="bibr">Polentinos-Castro et al., 2021</xref>; <xref rid="ref59" ref-type="bibr">Ricoy et al., 1983</xref>; <xref rid="ref72" ref-type="bibr">T&#233;llez et al., 1987</xref>). Neuropathological findings described central chromatolysis in anterior horn cells and brainstem nuclei, alterations in brainstem monoaminergic centers, and non-necrotizing vasculitis with focal ischemia&#8212;findings suggestive of microangiopathy and neuroinflammation. Although consistent white matter damage was not observed, the broader pattern suggests diffuse involvement rather than localized lesions (<xref rid="ref59" ref-type="bibr">Ricoy et al., 1983</xref>; <xref rid="ref72" ref-type="bibr">T&#233;llez et al., 1987</xref>).</p><p>Persistent low-grade neuroinflammation may contribute to the long-term deficits observed in TOS. Animal models of environmental neurotoxicity, including exposure to manganese and organophosphates, consistently exhibit prolonged microglial activation, astrocytosis, and elevated cytokine release (e.g., IL-6, TNF-<italic toggle="yes">&#945;</italic>), resulting in the disruption of frontal network function (<xref rid="ref58" ref-type="bibr">Raison et al., 2006</xref>; <xref rid="ref75" ref-type="bibr">Zhang et al., 2023</xref>; <xref rid="ref38" ref-type="bibr">Kirkley et al., 2017</xref>; <xref rid="ref57" ref-type="bibr">Popichak et al., 2018</xref>; <xref rid="ref37" ref-type="bibr">Ke et al., 2019</xref>; <xref rid="ref65" ref-type="bibr">Sarkar et al., 2018</xref>; <xref rid="ref14" ref-type="bibr">Conley et al., 2020</xref>; <xref rid="ref20" ref-type="bibr">Dinamene et al., 2013</xref>). In particular, manganese neurotoxicity has been shown to induce the secretion of pro-inflammatory cytokines (TNF-&#945;, IL-1&#946;, IL-6) by microglia, which in turn amplifies astrocytic reactivity via NF-&#954;B signaling and results in sustained neuroinflammation and cortical dysfunction that persists well beyond the exposure period (<xref rid="ref38" ref-type="bibr">Kirkley et al., 2017</xref>; <xref rid="ref57" ref-type="bibr">Popichak et al., 2018</xref>; <xref rid="ref37" ref-type="bibr">Ke et al., 2019</xref>; <xref rid="ref65" ref-type="bibr">Sarkar et al., 2018</xref>; <xref rid="ref14" ref-type="bibr">Conley et al., 2020</xref>; <xref rid="ref20" ref-type="bibr">Dinamene et al., 2013</xref>). Comparable mechanisms have been described in organophosphate models, where sustained microglia-mediated neuroinflammation amplifies neuronal hyperactivation and disrupts cortical network function long after the acute exposure (<xref rid="ref69" ref-type="bibr">Somkhit et al., 2022</xref>). In addition, endothelial dysfunction may further compromise cerebral perfusion in metabolically demanding prefrontal regions (<xref rid="ref32" ref-type="bibr">Iadecola, 2013</xref>).</p><p>Importantly, the absence of elevated neurodegeneration biomarkers in TOS patients argues against progressive neuronal loss, distinguishing this syndrome from Alzheimer&#8217;s disease (<xref rid="ref63" ref-type="bibr">Ruiz-Ortiz et al., 2025</xref>). Consistent with this, preserved episodic memory and the absence of hippocampal dysfunction suggest a static or slowly progressive encephalopathy, possibly more akin to conditions such as multiple sclerosis, small vessel disease or long COVID, where frontal-subcortical networks are preferentially affected (<xref rid="ref7" ref-type="bibr">Benito-Le&#243;n et al., 2025</xref>; <xref rid="ref50" ref-type="bibr">O&#8217;Brien et al., 2003</xref>; <xref rid="ref34" ref-type="bibr">Jolly et al., 2025</xref>; <xref rid="ref52" ref-type="bibr">Olazar&#225;n et al., 2009</xref>). Altogether, our findings support a model of non-degenerative, immune-mediated disruption of prefrontal white matter integrity in TOS, manifesting as enduring deficits in executive function and response inhibition.</p><p>Our study&#8217;s limitations include a small sample size, which may have reduced the ability to detect subtle differences in latency or gain metrics. This limited sample size increases the risk of a Type II error and, consistent with the exploratory nature of the study, justifies not applying corrections for multiple comparisons. The cross-sectional design also restricts causal conclusions. Polyneuropathy was not treated as a confounder; although characteristic of chronic toxic oil syndrome, it is not linked to cognitive dysfunction, and adjusting for it could lead to over-adjustment and mask the true effects of the disease. Nonetheless, we acknowledge its clinical implications and report its prevalence and distribution in <xref rid="tab1" ref-type="table">Table 1</xref>. Comorbidities such as hypertension, diabetes, and higher levels of anxiety, depression, and fatigue were more frequent in the TOS group. Still, these factors were incorporated into our multivariable and SEM models alongside demographic variables. Importantly, the antisaccade deficit remained significant after full adjustment, suggesting that the observed association reflects disease-related effects rather than the influence of comorbid conditions alone. However, residual confounding cannot be completely ruled out. The lack of neuroimaging data further limits structural interpretation. Future research should include both structural and functional neuroimaging to better localize and understand the observed deficits. Finally, our findings may not apply beyond the specific group of Spanish TOS survivors studied. Comparative research in other populations exposed to toxins&#8212;such as workers exposed to organophosphates or patients with eosinophilia-myalgia syndrome&#8212;could help determine whether antisaccade deficits are a common feature of chronic toxic-immune encephalopathies.</p><p>In conclusion, to our knowledge, this is the first study to apply eye-tracking to evaluate cognitive dysfunction in TOS. By combining antisaccade and related paradigms with standardized cognitive testing, we demonstrate ongoing antisaccade impairments and dysexecutive deficits consistent with disruption of frontal-subcortical control. The pattern of findings is more compatible with immune-or vascular-mediated injury than with ongoing neurodegeneration. Given that eye-tracking is objective, noninvasive, brief, and well-tolerated in older, multimorbid cohorts, antisaccade-based measures offer a practical candidate biomarker of residual executive dysfunction that now warrants validation in longitudinal, adequately powered, multimodal studies.</p></sec></body><back><ack><p>We gratefully acknowledge all participating patients for their time, trust, and commitment to this study. Their collaboration made this research possible.</p></ack><sec sec-type="data-availability" id="sec21"><title>Data availability statement</title><p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p></sec><sec sec-type="ethics-statement" id="sec22"><title>Ethics statement</title><p>The studies involving humans were approved by 12 de Octubre University Hospital. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.</p></sec><sec sec-type="author-contributions" id="sec23"><title>Author contributions</title><p>JB-L: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing &#8211; original draft, Writing &#8211; review &amp; editing. JL-M: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing &#8211; review &amp; editing. MR-O: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing &#8211; review &amp; editing. GMD: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Resources, Software, Supervision, Visualization, Writing &#8211; review &amp; editing. S&#193;-S: Conceptualization, Formal analysis, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing &#8211; review &amp; editing. VB: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing &#8211; review &amp; editing. MN: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Writing &#8211; review &amp; editing. MM: Conceptualization, Data curation, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing &#8211; review &amp; editing. RM: Conceptualization, Methodology, Resources, Software, Validation, Visualization, Writing &#8211; review &amp; editing. SD: Conceptualization, Formal analysis, Investigation, Methodology, Resources, Validation, Visualization, Writing &#8211; review &amp; editing. FB: Conceptualization, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing &#8211; review &amp; editing. CA: Conceptualization, Investigation, Methodology, Resources, Validation, Visualization, Writing &#8211; review &amp; editing. CG-C: Conceptualization, Data curation, Formal Analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing &#8211; review &amp; editing.</p></sec><sec sec-type="COI-statement" id="sec25"><title>Conflict of interest</title><p>GMD is an employee of NeuroTrax Corporation. NeuroTrax Corporation had no role in study design; data collection, analysis, or interpretation; manuscript writing; or the decision to submit the article for publication.</p><p>The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="sec26"><title>Generative AI statement</title><p>The author(s) declare that no Gen AI was used in the creation of this manuscript.</p><p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p></sec><sec sec-type="disclaimer" id="sec27"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abaitua Borda</surname><given-names>I.</given-names></name><name name-style="western"><surname>Philen</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Posada de la Paz</surname><given-names>M.</given-names></name><name name-style="western"><surname>G&#243;mez de la C&#225;mara</surname><given-names>A.</given-names></name><name name-style="western"><surname>D&#237;ez Ruiz-Navarro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gim&#233;nez Ribota</surname><given-names>O.</given-names></name><etal/></person-group>. (<year>1998</year>). <article-title>Toxic oil syndrome mortality: the first 13 years</article-title>. <source>Int. J. Epidemiol.</source><volume>27</volume>, <fpage>1057</fpage>&#8211;<lpage>1063</lpage>.<pub-id pub-id-type="pmid">10024203</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ije/27.6.1057</pub-id></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Armstrong</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>T.</given-names></name><name name-style="western"><surname>D&#8217;Esposito</surname><given-names>M.</given-names></name><name name-style="western"><surname>Freundlich</surname><given-names>B.</given-names></name></person-group> (<year>1997</year>). <article-title>Eosinophilia-myalgia syndrome: selective cognitive impairment, longitudinal effects, and neuroimaging findings</article-title>. <source>J. Neurol. Neurosurg. Psychiatry</source><volume>63</volume>, <fpage>633</fpage>&#8211;<lpage>641</lpage>.<pub-id pub-id-type="pmid">9408106</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp.63.5.633</pub-id><pub-id pub-id-type="pmcid">PMC2169832</pub-id></mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Badia</surname><given-names>X.</given-names></name><name name-style="western"><surname>Roset</surname><given-names>M.</given-names></name><name name-style="western"><surname>Herdman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kind</surname><given-names>P.</given-names></name></person-group> (<year>2001</year>). <article-title>A comparison of United Kingdom and Spanish general population time trade-off values for EQ-5D health states</article-title>. <source>Med. Decis. Mak.</source><volume>21</volume>, <fpage>7</fpage>&#8211;<lpage>16</lpage>. doi: <pub-id pub-id-type="doi">10.1177/0272989x0102100102</pub-id>, PMID: <pub-id pub-id-type="pmid">11206949</pub-id></mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beck</surname><given-names>A. T.</given-names></name><name name-style="western"><surname>Epstein</surname><given-names>N.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>G.</given-names></name><name name-style="western"><surname>Steer</surname><given-names>R. A.</given-names></name></person-group> (<year>1988</year>). <article-title>An inventory for measuring clinical anxiety: psychometric properties</article-title>. <source>J. Consult. Clin. Psychol.</source><volume>56</volume>, <fpage>893</fpage>&#8211;<lpage>897</lpage>.<pub-id pub-id-type="pmid">3204199</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1037//0022-006x.56.6.893</pub-id></mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Beck</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Steer</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>G. K.</given-names></name></person-group> (<year>1996</year>). Beck Depression Inventory -II (BDI_II) [Database record]. <source>J. Clin. Epidemiol.</source> doi: <pub-id pub-id-type="doi">10.1037/t00742-000</pub-id></mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bender</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lange</surname><given-names>S.</given-names></name></person-group> (<year>2001</year>). <article-title>Adjusting for multiple testing--when and how?</article-title><source>J. Clin. Epidemiol.</source><volume>54</volume>, <fpage>343</fpage>&#8211;<lpage>349</lpage>. doi: <pub-id pub-id-type="doi">10.1016/s0895-4356(00)00314-0</pub-id>, PMID: <pub-id pub-id-type="pmid">11297884</pub-id></mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benito-Le&#243;n</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lape&#241;a</surname><given-names>J.</given-names></name><name name-style="western"><surname>Garc&#237;a-Vasco</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cuevas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Viloria-Porto</surname><given-names>J.</given-names></name><name name-style="western"><surname>Calvo-C&#243;rdoba</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2025</year>). <article-title>Exploring cognitive dysfunction in long COVID patients: eye movement abnormalities and frontal-subcortical circuits implications via eye-tracking and machine learning</article-title>. <source>Am. J. Med.</source><volume>138</volume>, <fpage>550</fpage>&#8211;<lpage>559</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.amjmed.2024.04.004</pub-id>, PMID: <pub-id pub-id-type="pmid">38583751</pub-id></mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benito-Le&#243;n</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lape&#241;a-Motilva</surname><given-names>J.</given-names></name><name name-style="western"><surname>Garc&#237;a-Cena</surname><given-names>C.</given-names></name></person-group> (<year>2024</year>). <article-title>Eye-tracking technology: a tool to enhance understanding of memory complaints in COVID-19 survivors</article-title>. <source>CNS Spectr.</source><volume>29</volume>, <fpage>534</fpage>&#8211;<lpage>535</lpage>. doi: <pub-id pub-id-type="doi">10.1017/s1092852924002426</pub-id>, PMID: <pub-id pub-id-type="pmid">39757462</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benito-Le&#243;n</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mart&#237;nez-Mart&#237;n</surname><given-names>P.</given-names></name><name name-style="western"><surname>Frades</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mart&#237;nez-Gin&#233;s</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>De Andr&#233;s</surname><given-names>C.</given-names></name><name name-style="western"><surname>Meca-Lallana</surname><given-names>J. E.</given-names></name><etal/></person-group>. (<year>2007</year>). <article-title>Impact of fatigue in multiple sclerosis: the fatigue impact scale for daily use (D-FIS)</article-title>. <source>Mult. Scler.</source><volume>13</volume>, <fpage>645</fpage>&#8211;<lpage>651</lpage>. doi: <pub-id pub-id-type="doi">10.1177/1352458506073528</pub-id>, PMID: <pub-id pub-id-type="pmid">17548445</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bermejo-Pareja</surname><given-names>F.</given-names></name><name name-style="western"><surname>Benito-Le&#243;n</surname><given-names>J.</given-names></name><name name-style="western"><surname>Louis</surname><given-names>E. D.</given-names></name><name name-style="western"><surname>Trincado</surname><given-names>R.</given-names></name><name name-style="western"><surname>Carro</surname><given-names>E.</given-names></name><name name-style="western"><surname>Villarejo</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>Risk of incident dementia in drug-untreated arterial hypertension: a population-based study</article-title>. <source>J Alzheimer's Dis</source><volume>22</volume>, <fpage>949</fpage>&#8211;<lpage>958</lpage>. doi: <pub-id pub-id-type="doi">10.3233/JAD-2010-101110</pub-id>, PMID: <pub-id pub-id-type="pmid">20858957</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brooks</surname><given-names>S. H.</given-names></name><name name-style="western"><surname>Klier</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Red</surname><given-names>S. D.</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>N. D.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Chuang</surname><given-names>A. Z.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Slowed Prosaccades and increased Antisaccade errors as a potential behavioral biomarker of multiple system atrophy</article-title>. <source>Front. Neurol.</source><volume>8</volume>:261. doi: <pub-id pub-id-type="doi">10.3389/fneur.2017.00261</pub-id>, PMID: <pub-id pub-id-type="pmid">28676787</pub-id><pub-id pub-id-type="pmcid">PMC5476968</pub-id></mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brooks</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>W. J.</given-names></name><name name-style="western"><surname>Webb</surname><given-names>B. M.</given-names></name><name name-style="western"><surname>Heath</surname><given-names>M. D.</given-names></name><name name-style="western"><surname>Dickey</surname><given-names>J. P.</given-names></name></person-group> (<year>2019</year>). <article-title>Development and validation of a high-speed video system for measuring saccadic eye movement</article-title>. <source>Behav. Res. Ther.</source><volume>51</volume>, <fpage>2302</fpage>&#8211;<lpage>2309</lpage>. doi: <pub-id pub-id-type="doi">10.3758/s13428-019-01197-2</pub-id>, PMID: <pub-id pub-id-type="pmid">30706347</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caldani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bucci</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Lamy</surname><given-names>J.-C.</given-names></name><name name-style="western"><surname>Seassau</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bendjemaa</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gadel</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Saccadic eye movements as markers of schizophrenia Spectrum: exploration in at-risk mental states</article-title>. <source>Schizophr. Res.</source><volume>181</volume>, <fpage>30</fpage>&#8211;<lpage>37</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.schres.2016.09.003</pub-id>, PMID: <pub-id pub-id-type="pmid">27639418</pub-id></mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Conley</surname><given-names>T. E.</given-names></name><name name-style="western"><surname>Beaudin</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Lasley</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Fornal</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Hartman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Uribe</surname><given-names>W.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Early postnatal manganese exposure causes arousal dysregulation and lasting Hypofunctioning of the prefrontal cortex Catecholaminergic systems</article-title>. <source>J. Neurochem.</source><volume>153</volume>, <fpage>631</fpage>&#8211;<lpage>649</lpage>. doi: <pub-id pub-id-type="doi">10.1111/jnc.14934</pub-id>, PMID: <pub-id pub-id-type="pmid">31811785</pub-id><pub-id pub-id-type="pmcid">PMC7261255</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Costanzo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lengyel</surname><given-names>I.</given-names></name><name name-style="western"><surname>Parravano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Biagini</surname><given-names>I.</given-names></name><name name-style="western"><surname>Veldsman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Badhwar</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Ocular biomarkers for Alzheimer disease dementia: an umbrella review of systematic reviews and meta-analyses</article-title>. <source>JAMA Ophthalmol.</source><volume>141</volume>:<fpage>84</fpage>. doi: <pub-id pub-id-type="doi">10.1001/jamaophthalmol.2022.4845</pub-id>, PMID: <pub-id pub-id-type="pmid">36394831</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Curtis</surname><given-names>C. E.</given-names></name><name name-style="western"><surname>D&#8217;Esposito</surname><given-names>M.</given-names></name></person-group> (<year>2003</year>). <article-title>Success and failure suppressing reflexive behavior</article-title>. <source>J. Cogn. Neurosci.</source><volume>15</volume>, <fpage>409</fpage>&#8211;<lpage>418</lpage>. doi: <pub-id pub-id-type="doi">10.1162/089892903321593126</pub-id><pub-id pub-id-type="pmid">12729492</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De La Paz</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Philen</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Borda</surname><given-names>I. A.</given-names></name></person-group> (<year>2001</year>). <article-title>Toxic oil syndrome: the perspective after 20 years</article-title>. <source>Epidemiol. Rev.</source><volume>23</volume>, <fpage>231</fpage>&#8211;<lpage>247</lpage>. doi: <pub-id pub-id-type="doi">10.1093/oxfordjournals.epirev.a000804</pub-id>, PMID: <pub-id pub-id-type="pmid">12192735</pub-id></mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De La Paz</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Philen</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Gerr</surname><given-names>F.</given-names></name><name name-style="western"><surname>Letz</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ferrari Arroyo</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Vela</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2003</year>). <article-title>Neurologic outcomes of toxic oil syndrome patients 18 years after the epidemic</article-title>. <source>Environ. Health Perspect.</source><volume>111</volume>, <fpage>1326</fpage>&#8211;<lpage>1334</lpage>. doi: <pub-id pub-id-type="doi">10.1289/ehp.111-1241614</pub-id>, PMID: <pub-id pub-id-type="pmid">12896854</pub-id><pub-id pub-id-type="pmcid">PMC1241614</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Del Ser</surname><given-names>T.</given-names></name><name name-style="western"><surname>Espasand&#237;n</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cabetas</surname><given-names>I.</given-names></name><name name-style="western"><surname>Arredondo</surname><given-names>J. M.</given-names></name></person-group> (<year>1986</year>). <article-title>Memory disorders in the toxic oil syndrome (TOS)</article-title>. <source>Arch. Neurobiol. (Madr.)</source><volume>49</volume>, <fpage>19</fpage>&#8211;<lpage>39</lpage>.<pub-id pub-id-type="pmid">3707265</pub-id></mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dinamene</surname><given-names>S.</given-names></name><name name-style="western"><surname>Camila</surname><given-names>B. M.</given-names></name><name name-style="western"><surname>Tavares De Almeida</surname><given-names>I.</given-names></name><name name-style="western"><surname>Davis Randall</surname><given-names>L.</given-names></name><name name-style="western"><surname>Luisa</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Vanda</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Evaluation of neurobehavioral and Neuroinflammatory end-points in the post-exposure period in rats sub-acutely exposed to manganese</article-title>. <source>Toxicology</source><volume>314</volume>, <fpage>95</fpage>&#8211;<lpage>99</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.tox.2013.09.008</pub-id>, PMID: <pub-id pub-id-type="pmid">24060432</pub-id><pub-id pub-id-type="pmcid">PMC3850178</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doniger</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zucker</surname><given-names>D.</given-names></name><name name-style="western"><surname>Schweiger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dwolatzky</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chertkow</surname><given-names>H.</given-names></name><name name-style="western"><surname>Crystal</surname><given-names>H.</given-names></name><etal/></person-group>. (<year>2005</year>). <article-title>Towards practical cognitive assessment for detection of early dementia: a 30-minute computerized battery discriminates as well as longer testing</article-title>. <source>CAR</source><volume>2</volume>, <fpage>117</fpage>&#8211;<lpage>124</lpage>. doi: <pub-id pub-id-type="doi">10.2174/1567205053585792</pub-id>, PMID: <pub-id pub-id-type="pmid">15974907</pub-id></mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dwolatzky</surname><given-names>T.</given-names></name><name name-style="western"><surname>Whitehead</surname><given-names>V.</given-names></name><name name-style="western"><surname>Doniger</surname><given-names>G. M.</given-names></name><name name-style="western"><surname>Simon</surname><given-names>E. S.</given-names></name><name name-style="western"><surname>Schweiger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jaffe</surname><given-names>D.</given-names></name><etal/></person-group>. (<year>2003</year>). <article-title>Validity of a novel computerized cognitive battery for mild cognitive impairment</article-title>. <source>BMC Geriatr.</source><volume>3</volume>:4. doi: <pub-id pub-id-type="doi">10.1186/1471-2318-3-4</pub-id>, PMID: <pub-id pub-id-type="pmid">14594456</pub-id><pub-id pub-id-type="pmcid">PMC270050</pub-id></mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fjell</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Walhovd</surname><given-names>K. B.</given-names></name><name name-style="western"><surname>Westlye</surname><given-names>L. T.</given-names></name><name name-style="western"><surname>&#216;stby</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tamnes</surname><given-names>C. K.</given-names></name><name name-style="western"><surname>Jernigan</surname><given-names>T. L.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>When does brain aging accelerate? Dangers of quadratic fits in cross-sectional studies</article-title>. <source>Neuro Image</source><volume>50</volume>, <fpage>1376</fpage>&#8211;<lpage>1383</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuroimage.2010.01.061</pub-id>, PMID: <pub-id pub-id-type="pmid">20109562</pub-id></mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Funahashi</surname><given-names>S.</given-names></name></person-group> (<year>2006</year>). <article-title>Prefrontal cortex and working memory processes</article-title>. <source>Neuroscience</source><volume>139</volume>, <fpage>251</fpage>&#8211;<lpage>261</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuroscience.2005.07.003</pub-id>, PMID: <pub-id pub-id-type="pmid">16325345</pub-id></mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garc&#237;a Cena</surname><given-names>C. E.</given-names></name><name name-style="western"><surname>Andr&#233;s</surname><given-names>D. G.</given-names></name><name name-style="western"><surname>Valdeolivas</surname><given-names>I. P.</given-names></name></person-group> (<year>2020</year>). <article-title>Measurement and analysis of eye movements performance to predict healthy brain aging</article-title>. <source>IEEE Access</source><volume>8</volume>, <fpage>87201</fpage>&#8211;<lpage>87213</lpage>. doi: <pub-id pub-id-type="doi">10.1109/ACCESS.2020.2992254</pub-id></mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garc&#237;a Cena</surname><given-names>C.</given-names></name><name name-style="western"><surname>Costa</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Saltar&#233;n Pazmi&#241;o</surname><given-names>R.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>C. P.</given-names></name><name name-style="western"><surname>G&#243;mez-Andr&#233;s</surname><given-names>D.</given-names></name><name name-style="western"><surname>Benito-Le&#243;n</surname><given-names>J.</given-names></name></person-group> (<year>2022a</year>). <article-title>Eye movement alterations in post-COVID-19 condition: a proof-of-concept study</article-title>. <source>Sensors</source><volume>22</volume>:<fpage>1481</fpage>. doi: <pub-id pub-id-type="doi">10.3390/s22041481</pub-id>, PMID: <pub-id pub-id-type="pmid">35214383</pub-id><pub-id pub-id-type="pmcid">PMC8875414</pub-id></mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garc&#237;a Cena</surname><given-names>C. E.</given-names></name><name name-style="western"><surname>G&#243;mez-Andr&#233;s</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pulido-Valdeolivas</surname><given-names>I.</given-names></name><name name-style="western"><surname>S&#225;nchez-Seco</surname><given-names>V. G.</given-names></name><name name-style="western"><surname>Domingo-Santos</surname><given-names>A.</given-names></name><name name-style="western"><surname>Moreno-Garc&#237;a</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2022b</year>). <article-title>Toward an automatic assessment of cognitive dysfunction in relapsing&#8211;remitting multiple sclerosis patients using eye movement analysis</article-title>. <source>Sensors</source><volume>22</volume>:<fpage>8220</fpage>. doi: <pub-id pub-id-type="doi">10.3390/s22218220</pub-id>, PMID: <pub-id pub-id-type="pmid">36365918</pub-id><pub-id pub-id-type="pmcid">PMC9657913</pub-id></mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gelp&#237;</surname><given-names>E.</given-names></name><name name-style="western"><surname>de la Paz</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Terracini</surname><given-names>B.</given-names></name><name name-style="western"><surname>Abaitua</surname><given-names>I.</given-names></name><name name-style="western"><surname>de la C&#225;mara</surname><given-names>A. G.</given-names></name><name name-style="western"><surname>Kilbourne</surname><given-names>E. M.</given-names></name><etal/></person-group>. (<year>2002</year>). <article-title>The Spanish toxic oil syndrome 20 years after its onset: a multidisciplinary review of scientific knowledge</article-title>. <source>Environ. Health Perspect.</source><volume>110</volume>, <fpage>457</fpage>&#8211;<lpage>464</lpage>. doi: <pub-id pub-id-type="doi">10.1289/ehp.110-1240833</pub-id>, PMID: <pub-id pub-id-type="pmid">12003748</pub-id><pub-id pub-id-type="pmcid">PMC1240833</pub-id></mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guerrero-Molina</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-L&#243;pez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Panad&#233;s-de Oliveira</surname><given-names>L.</given-names></name><name name-style="western"><surname>Uriarte-P&#233;rez De Urabayen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Garzo-Caldas</surname><given-names>N.</given-names></name><name name-style="western"><surname>Garc&#237;a-Cena</surname><given-names>C. E.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Antisaccades and memory-guided saccades in genetic generalized epilepsy and temporal lobe epilepsy</article-title>. <source>Epilepsy Behav.</source><volume>123</volume>:108236. doi: <pub-id pub-id-type="doi">10.1016/j.yebeh.2021.108236</pub-id>, PMID: <pub-id pub-id-type="pmid">34419714</pub-id></mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanu&#353;ka</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rusz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bezdicek</surname><given-names>O.</given-names></name><name name-style="western"><surname>Ulmanov&#225;</surname><given-names>O.</given-names></name><name name-style="western"><surname>Bonnet</surname><given-names>C.</given-names></name><name name-style="western"><surname>Du&#353;ek</surname><given-names>P.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Eye movements in idiopathic rapid eye movement sleep behaviour disorder: high Antisaccade error rate reflects prefrontal cortex dysfunction</article-title>. <source>J. Sleep Res.</source><volume>28</volume>:<fpage>e12742</fpage>. doi: <pub-id pub-id-type="doi">10.1111/jsr.12742</pub-id>, PMID: <pub-id pub-id-type="pmid">30047173</pub-id></mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hellmuth</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mirsky</surname><given-names>J.</given-names></name><name name-style="western"><surname>Heuer</surname><given-names>H. W.</given-names></name><name name-style="western"><surname>Matlin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jafari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Garbutt</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>Multicenter validation of a bedside Antisaccade task as a measure of executive function</article-title>. <source>Neurology</source><volume>78</volume>, <fpage>1824</fpage>&#8211;<lpage>1831</lpage>. doi: <pub-id pub-id-type="doi">10.1212/WNL.0b013e318258f785</pub-id>, PMID: <pub-id pub-id-type="pmid">22573640</pub-id><pub-id pub-id-type="pmcid">PMC3369520</pub-id></mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iadecola</surname><given-names>C.</given-names></name></person-group> (<year>2013</year>). <article-title>The pathobiology of vascular dementia</article-title>. <source>Neuron</source><volume>80</volume>, <fpage>844</fpage>&#8211;<lpage>866</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuron.2013.10.008</pub-id>, PMID: <pub-id pub-id-type="pmid">24267647</pub-id><pub-id pub-id-type="pmcid">PMC3842016</pub-id></mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jamal</surname><given-names>G. A.</given-names></name></person-group> (<year>1997</year>). <article-title>Neurological syndromes of organophosphorus compounds</article-title>. <source>Adverse Drug React. Toxicol. Rev.</source><volume>16</volume>, <fpage>133</fpage>&#8211;<lpage>170</lpage>.<pub-id pub-id-type="pmid">9512762</pub-id></mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jolly</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Anyanwu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Koohi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>R. G.</given-names></name><name name-style="western"><surname>Markus</surname><given-names>H. S.</given-names></name></person-group> (<year>2025</year>). <article-title>Prevalence of fatigue and associations with depression and cognitive impairment in patients with CADASIL</article-title>. <source>Neurology</source><volume>104</volume>:e213335. doi: <pub-id pub-id-type="doi">10.1212/wnl.0000000000213335</pub-id>, PMID: <pub-id pub-id-type="pmid">39819095</pub-id><pub-id pub-id-type="pmcid">PMC11737844</pub-id></mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaufman</surname><given-names>L. D.</given-names></name><name name-style="western"><surname>Izquierdo Mart&#237;nez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Serrano</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>G&#243;mez-Reino</surname><given-names>J. J.</given-names></name></person-group> (<year>1995</year>). <article-title>12-year followup study of epidemic Spanish toxic oil syndrome</article-title>. <source>J. Rheumatol.</source><volume>22</volume>, <fpage>282</fpage>&#8211;<lpage>288</lpage>.<pub-id pub-id-type="pmid">7738952</pub-id></mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaufman</surname><given-names>L. D.</given-names></name><name name-style="western"><surname>Krupp</surname><given-names>L. B.</given-names></name></person-group> (<year>1995</year>). <article-title>Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia</article-title>. <source>Curr. Opin. Rheumatol.</source><volume>7</volume>, <fpage>560</fpage>&#8211;<lpage>567</lpage>.<pub-id pub-id-type="pmid">8579979</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00002281-199511000-00016</pub-id></mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ke</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sidoryk-Wegrzynowicz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pajarillo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rizor</surname><given-names>A.</given-names></name><name name-style="western"><surname>Soares</surname><given-names>F. A. A.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>E.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Role of astrocytes in manganese neurotoxicity revisited</article-title>. <source>Neurochem. Res.</source><volume>44</volume>, <fpage>2449</fpage>&#8211;<lpage>2459</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11064-019-02881-7</pub-id>, PMID: <pub-id pub-id-type="pmid">31571097</pub-id><pub-id pub-id-type="pmcid">PMC7757856</pub-id></mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirkley</surname><given-names>K. S.</given-names></name><name name-style="western"><surname>Popichak</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Afzali</surname><given-names>M. F.</given-names></name><name name-style="western"><surname>Legare</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Tjalkens</surname><given-names>R. B.</given-names></name></person-group> (<year>2017</year>). <article-title>Microglia amplify inflammatory activation of astrocytes in manganese neurotoxicity</article-title>. <source>J. Neuroinflammation</source><volume>14</volume>:<fpage>99</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12974-017-0871-0</pub-id>, PMID: <pub-id pub-id-type="pmid">28476157</pub-id><pub-id pub-id-type="pmcid">PMC5418760</pub-id></mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ko&#231;o&#287;lu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hodgson</surname><given-names>T. L.</given-names></name><name name-style="western"><surname>Eraslan Boz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Akdal</surname><given-names>G.</given-names></name></person-group> (<year>2021</year>). <article-title>Deficits in saccadic eye movements differ between subtypes of patients with mild cognitive impairment</article-title>. <source>J. Clin. Exp. Neuropsychol.</source><volume>43</volume>, <fpage>187</fpage>&#8211;<lpage>198</lpage>. doi: <pub-id pub-id-type="doi">10.1080/13803395.2021.1900077</pub-id>, PMID: <pub-id pub-id-type="pmid">33792489</pub-id></mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lape&#241;a-Motilva</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ruiz-Ortiz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Doniger</surname><given-names>G. M.</given-names></name><name name-style="western"><surname>Nogales</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Gim&#233;nez De B&#233;jar</surname><given-names>V.</given-names></name><name name-style="western"><surname>&#193;lvarez-Sesmero</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2025</year>). <article-title>Cognitive functioning in toxic oil syndrome survivors: a case-control study four decades after the epidemic</article-title>. <source>JCM</source><volume>14</volume>:3746. doi: <pub-id pub-id-type="doi">10.3390/jcm14113746</pub-id>, PMID: <pub-id pub-id-type="pmid">40507507</pub-id><pub-id pub-id-type="pmcid">PMC12155933</pub-id></mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ju</surname><given-names>Y.</given-names></name></person-group> (<year>2024</year>). <article-title>Application and Progress of advanced eye movement Examinations in Cognitive Impairment</article-title>. <source>Front. Aging Neurosci.</source><volume>16</volume>:<fpage>1377406</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnagi.2024.1377406</pub-id>, PMID: <pub-id pub-id-type="pmid">38694260</pub-id><pub-id pub-id-type="pmcid">PMC11061382</pub-id></mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>London</surname><given-names>L.</given-names></name><name name-style="western"><surname>Beseler</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bouchard</surname><given-names>M. F.</given-names></name><name name-style="western"><surname>Bellinger</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Colosio</surname><given-names>C.</given-names></name><name name-style="western"><surname>Grandjean</surname><given-names>P.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>Neurobehavioral and neurodevelopmental effects of pesticide exposures</article-title>. <source>Neuro Toxicology</source><volume>33</volume>, <fpage>887</fpage>&#8211;<lpage>896</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuro.2012.01.004</pub-id>, PMID: <pub-id pub-id-type="pmid">22269431</pub-id><pub-id pub-id-type="pmcid">PMC3371394</pub-id></mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mart&#237;nez-Mart&#237;n</surname><given-names>P.</given-names></name><name name-style="western"><surname>Catal&#225;n</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Benito-Le&#243;n</surname><given-names>J.</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>A. O.</given-names></name><name name-style="western"><surname>Zamarbide</surname><given-names>I.</given-names></name><name name-style="western"><surname>Cubo</surname><given-names>E.</given-names></name><etal/></person-group>. (<year>2006</year>). <article-title>Impact of fatigue in Parkinson&#8217;s disease: the fatigue impact scale for daily use (D-FIS)</article-title>. <source>Qual. Life Res.</source><volume>15</volume>, <fpage>597</fpage>&#8211;<lpage>606</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11136-005-4181-0</pub-id>, PMID: <pub-id pub-id-type="pmid">16688493</pub-id></mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McDowell</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Dyckman</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Austin</surname><given-names>B. P.</given-names></name><name name-style="western"><surname>Clementz</surname><given-names>B. A.</given-names></name></person-group> (<year>2008</year>). <article-title>Neurophysiology and neuroanatomy of reflexive and volitional saccades: evidence from studies of humans</article-title>. <source>Brain Cogn.</source><volume>68</volume>, <fpage>255</fpage>&#8211;<lpage>270</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bandc.2008.08.016</pub-id>, PMID: <pub-id pub-id-type="pmid">18835656</pub-id><pub-id pub-id-type="pmcid">PMC2614688</pub-id></mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mirsky</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>Heuer</surname><given-names>H. W.</given-names></name><name name-style="western"><surname>Jafari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Schenk</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Viskontas</surname><given-names>I. V.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>Anti-saccade performance predicts executive function and brain structure in Normal elders</article-title>. <source>Cogn. Behav. Neurol.</source><volume>24</volume>, <fpage>50</fpage>&#8211;<lpage>58</lpage>. doi: <pub-id pub-id-type="doi">10.1097/wnn.0b013e318223f6c6</pub-id>, PMID: <pub-id pub-id-type="pmid">21697711</pub-id><pub-id pub-id-type="pmcid">PMC3775477</pub-id></mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mosimann</surname><given-names>U. P.</given-names></name><name name-style="western"><surname>M&#252;ri</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Burn</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Felblinger</surname><given-names>J.</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>J. T.</given-names></name><name name-style="western"><surname>McKeith</surname><given-names>I. G.</given-names></name></person-group> (<year>2005</year>). <article-title>Saccadic eye movement changes in Parkinson&#8217;s disease dementia and dementia with Lewy bodies</article-title>. <source>Brain</source><volume>128</volume>, <fpage>1267</fpage>&#8211;<lpage>1276</lpage>. doi: <pub-id pub-id-type="doi">10.1093/brain/awh484</pub-id><pub-id pub-id-type="pmid">15774501</pub-id></mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Munoz</surname><given-names>D. P.</given-names></name><name name-style="western"><surname>Everling</surname><given-names>S.</given-names></name></person-group> (<year>2004</year>). <article-title>Look away: the anti-saccade task and the voluntary control of eye movement</article-title>. <source>Nat. Rev. Neurosci.</source><volume>5</volume>, <fpage>218</fpage>&#8211;<lpage>228</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrn1345</pub-id>, PMID: <pub-id pub-id-type="pmid">14976521</pub-id></mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nieuwenhuis</surname><given-names>S.</given-names></name><name name-style="western"><surname>Broerse</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nielen</surname><given-names>M. M. A.</given-names></name><name name-style="western"><surname>Jong</surname><given-names>R. D.</given-names></name></person-group> (<year>2004</year>). <article-title>A goal activation approach to the study of executive function: an application to Antisaccade tasks</article-title>. <source>Brain Cogn.</source><volume>56</volume>, <fpage>198</fpage>&#8211;<lpage>214</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bandc.2003.12.002</pub-id>, PMID: <pub-id pub-id-type="pmid">15518936</pub-id></mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Brien</surname><given-names>J. T.</given-names></name><name name-style="western"><surname>Erkinjuntti</surname><given-names>T.</given-names></name><name name-style="western"><surname>Reisberg</surname><given-names>B.</given-names></name><name name-style="western"><surname>Roman</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sawada</surname><given-names>T.</given-names></name><name name-style="western"><surname>Pantoni</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2003</year>). <article-title>Vascular cognitive impairment</article-title>. <source>Lancet Neurol.</source><volume>2</volume>, <fpage>89</fpage>&#8211;<lpage>98</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1474-4422(03)00305-3</pub-id><pub-id pub-id-type="pmid">12849265</pub-id></mixed-citation></ref><ref id="ref51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Obyedkov</surname><given-names>I.</given-names></name><name name-style="western"><surname>Skuhareuskaya</surname><given-names>M.</given-names></name><name name-style="western"><surname>Skugarevsky</surname><given-names>O.</given-names></name><name name-style="western"><surname>Obyedkov</surname><given-names>V.</given-names></name><name name-style="western"><surname>Buslauski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Skuhareuskaya</surname><given-names>T.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Saccadic eye movements in different dimensions of schizophrenia and in clinical high-risk state for psychosis</article-title>. <source>BMC Psychiatry</source><volume>19</volume>:<fpage>110</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12888-019-2093-8</pub-id>, PMID: <pub-id pub-id-type="pmid">30961571</pub-id><pub-id pub-id-type="pmcid">PMC6454611</pub-id></mixed-citation></ref><ref id="ref52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olazar&#225;n</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cruz</surname><given-names>I.</given-names></name><name name-style="western"><surname>Benito-Le&#243;n</surname><given-names>J.</given-names></name><name name-style="western"><surname>Morales</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Duque</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rivera-Navarro</surname><given-names>J.</given-names></name></person-group> (<year>2009</year>). <article-title>Cognitive dysfunction in multiple sclerosis: methods and prevalence from the GEDMA study</article-title>. <source>Eur. Neurol.</source><volume>61</volume>, <fpage>87</fpage>&#8211;<lpage>93</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000177940</pub-id>, PMID: <pub-id pub-id-type="pmid">19039226</pub-id></mixed-citation></ref><ref id="ref53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Jankovic</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hood</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Jeter</surname><given-names>C. B.</given-names></name><name name-style="western"><surname>Sereno</surname><given-names>A. B.</given-names></name></person-group> (<year>2012</year>). <article-title>Reflexive and volitional saccades: biomarkers of Huntington disease severity and progression</article-title>. <source>J. Neurol. Sci.</source><volume>313</volume>, <fpage>35</fpage>&#8211;<lpage>41</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jns.2011.09.035</pub-id>, PMID: <pub-id pub-id-type="pmid">22018763</pub-id><pub-id pub-id-type="pmcid">PMC3254798</pub-id></mixed-citation></ref><ref id="ref54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perneger</surname><given-names>T. V.</given-names></name></person-group> (<year>1998</year>). <article-title>What&#8217;s wrong with Bonferroni adjustments</article-title>. <source>BMJ</source><volume>316</volume>, <fpage>1236</fpage>&#8211;<lpage>1238</lpage>. doi: <pub-id pub-id-type="doi">10.1136/bmj.316.7139.1236</pub-id>, PMID: <pub-id pub-id-type="pmid">9553006</pub-id><pub-id pub-id-type="pmcid">PMC1112991</pub-id></mixed-citation></ref><ref id="ref55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pierrot-Deseilligny</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rivaud</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gaymard</surname><given-names>B.</given-names></name><name name-style="western"><surname>M&#252;ri</surname><given-names>R.</given-names></name><name name-style="western"><surname>Vermersch</surname><given-names>A.</given-names></name></person-group> (<year>1995</year>). <article-title>Cortical control of saccades</article-title>. <source>Ann. Neurol.</source><volume>37</volume>, <fpage>557</fpage>&#8211;<lpage>567</lpage>.<pub-id pub-id-type="pmid">7755349</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.410370504</pub-id></mixed-citation></ref><ref id="ref56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polentinos-Castro</surname><given-names>E.</given-names></name><name name-style="western"><surname>Biec-Amigo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Delgado-Magdalena</surname><given-names>M.</given-names></name><name name-style="western"><surname>Flores-Acosta</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>S&#225;nchez-Perruca</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rabanal-Carrera</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Chronic diseases and multimorbidiy in patients with toxic oil syndrome: a comparative study with general population</article-title>. <source>Rev. Esp. Salud Publica</source><volume>95</volume>:<fpage>e202104047</fpage>.<pub-id pub-id-type="pmid">33820907</pub-id></mixed-citation></ref><ref id="ref57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Popichak</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Afzali</surname><given-names>M. F.</given-names></name><name name-style="western"><surname>Kirkley</surname><given-names>K. S.</given-names></name><name name-style="western"><surname>Tjalkens</surname><given-names>R. B.</given-names></name></person-group> (<year>2018</year>). <article-title>Glial-neuronal signaling mechanisms underlying the Neuroinflammatory effects of manganese</article-title>. <source>J. Neuroinflammation</source><volume>15</volume>:<fpage>324</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12974-018-1349-4</pub-id>, PMID: <pub-id pub-id-type="pmid">30463564</pub-id><pub-id pub-id-type="pmcid">PMC6247759</pub-id></mixed-citation></ref><ref id="ref58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raison</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>Capuron</surname><given-names>L.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>A. H.</given-names></name></person-group> (<year>2006</year>). <article-title>Cytokines sing the blues: inflammation and the pathogenesis of depression</article-title>. <source>Trends Immunol.</source><volume>27</volume>, <fpage>24</fpage>&#8211;<lpage>31</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.it.2005.11.006</pub-id>, PMID: <pub-id pub-id-type="pmid">16316783</pub-id><pub-id pub-id-type="pmcid">PMC3392963</pub-id></mixed-citation></ref><ref id="ref59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ricoy</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Cabello</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>J.</given-names></name><name name-style="western"><surname>T&#233;llez</surname><given-names>I.</given-names></name></person-group> (<year>1983</year>). <article-title>Neuropathological studies on the toxic syndrome related to adulterated rapeseed oil in Spain</article-title>. <source>Brain</source><volume>106</volume>, <fpage>817</fpage>&#8211;<lpage>835</lpage>.<pub-id pub-id-type="pmid">6317138</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/106.4.817</pub-id></mixed-citation></ref><ref id="ref60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roe</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>C.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>J. C.</given-names></name></person-group> (<year>2007</year>). <article-title>Education and Alzheimer disease without dementia: support for the cognitive reserve hypothesis</article-title>. <source>Neurology</source><volume>68</volume>, <fpage>223</fpage>&#8211;<lpage>228</lpage>. doi: <pub-id pub-id-type="doi">10.1212/01.wnl.0000251303.50459.8a</pub-id>, PMID: <pub-id pub-id-type="pmid">17224578</pub-id></mixed-citation></ref><ref id="ref61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ross</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>McManus</surname><given-names>I. C.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mason</surname><given-names>O.</given-names></name></person-group> (<year>2013</year>). <article-title>Neurobehavioral problems following low-level exposure to organophosphate pesticides: a systematic and Meta-analytic review</article-title>. <source>Crit. Rev. Toxicol.</source><volume>43</volume>, <fpage>21</fpage>&#8211;<lpage>44</lpage>. doi: <pub-id pub-id-type="doi">10.3109/10408444.2012.738645</pub-id>, PMID: <pub-id pub-id-type="pmid">23163581</pub-id></mixed-citation></ref><ref id="ref62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rothman</surname><given-names>K. J.</given-names></name></person-group> (<year>1990</year>). <article-title>No adjustments are needed for multiple comparisons</article-title>. <source>Epidemiology</source><volume>1</volume>, <fpage>43</fpage>&#8211;<lpage>46</lpage>. doi: <pub-id pub-id-type="doi">10.1097/00001648-199001000-00010</pub-id>, PMID: <pub-id pub-id-type="pmid">2081237</pub-id></mixed-citation></ref><ref id="ref63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruiz-Ortiz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lape&#241;a-Motilva</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gim&#233;nez De Bejar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bartolom&#233;</surname><given-names>F.</given-names></name><name name-style="western"><surname>Alqu&#233;zar</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mart&#237;nez-Castillo</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2025</year>). <article-title>Blood biomarkers of neurodegeneration over four decades after toxic oil syndrome: a case-control study</article-title>. <source>IJMS</source><volume>26</volume>:5122. doi: <pub-id pub-id-type="doi">10.3390/ijms26115122</pub-id>, PMID: <pub-id pub-id-type="pmid">40507935</pub-id><pub-id pub-id-type="pmcid">PMC12155236</pub-id></mixed-citation></ref><ref id="ref64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>S&#225;nchez-Porro Valad&#233;s</surname><given-names>P.</given-names></name><name name-style="western"><surname>Posada de la Paz</surname><given-names>M.</given-names></name><name name-style="western"><surname>de Andr&#233;s Copa</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gimenez Ribota</surname><given-names>O.</given-names></name><name name-style="western"><surname>Abaitua Borda</surname><given-names>I.</given-names></name></person-group> (<year>2003</year>). <article-title>Toxic oil syndrome: survival in the whole cohort between 1981 and 1995</article-title>. <source>J. Clin. Epidemiol.</source><volume>56</volume>, <fpage>701</fpage>&#8211;<lpage>708</lpage>. doi: <pub-id pub-id-type="doi">10.1016/s0895-4356(03)00119-7</pub-id>, PMID: <pub-id pub-id-type="pmid">12921940</pub-id></mixed-citation></ref><ref id="ref65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarkar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Malovic</surname><given-names>E.</given-names></name><name name-style="western"><surname>Harischandra</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Ngwa</surname><given-names>H. A.</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hogan</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Manganese exposure induces Neuroinflammation by impairing mitochondrial dynamics in astrocytes</article-title>. <source>Neuro Toxicology</source><volume>64</volume>, <fpage>204</fpage>&#8211;<lpage>218</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuro.2017.05.009</pub-id>, PMID: <pub-id pub-id-type="pmid">28539244</pub-id><pub-id pub-id-type="pmcid">PMC5698176</pub-id></mixed-citation></ref><ref id="ref66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schweiger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Abramovitch</surname><given-names>A.</given-names></name><name name-style="western"><surname>Doniger</surname><given-names>G. M.</given-names></name><name name-style="western"><surname>Simon</surname><given-names>E. S.</given-names></name></person-group> (<year>2007</year>). <article-title>A clinical construct validity study of a novel computerized battery for the diagnosis of ADHD in young adults</article-title>. <source>J. Clin. Exp. Neuropsychol.</source><volume>29</volume>, <fpage>100</fpage>&#8211;<lpage>111</lpage>. doi: <pub-id pub-id-type="doi">10.1080/13803390500519738</pub-id>, PMID: <pub-id pub-id-type="pmid">17162726</pub-id></mixed-citation></ref><ref id="ref67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seblova</surname><given-names>D.</given-names></name><name name-style="western"><surname>Berggren</surname><given-names>R.</given-names></name><name name-style="western"><surname>L&#246;vd&#233;n</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Education and age-related decline in cognitive performance: systematic review and Meta-analysis of longitudinal cohort studies</article-title>. <source>Ageing Res. Rev.</source><volume>58</volume>:<fpage>101005</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.arr.2019.101005</pub-id>, PMID: <pub-id pub-id-type="pmid">31881366</pub-id></mixed-citation></ref><ref id="ref68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shome</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mondal</surname><given-names>R.</given-names></name><name name-style="western"><surname>Deb</surname><given-names>S.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mandal</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Benito-Le&#243;n</surname><given-names>J.</given-names></name></person-group> (<year>2025</year>). <article-title>Bridging pancreatic amyloidosis and neurodegeneration: the emerging role of amylin in diabetic dementia</article-title>. <source>IJMS</source><volume>26</volume>:<fpage>5021</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms26115021</pub-id>, PMID: <pub-id pub-id-type="pmid">40507832</pub-id><pub-id pub-id-type="pmcid">PMC12154432</pub-id></mixed-citation></ref><ref id="ref69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Somkhit</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yanicostas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Soussi-Yanicostas</surname><given-names>N.</given-names></name></person-group> (<year>2022</year>). <article-title>Microglia Remodelling and Neuroinflammation parallel neuronal Hyperactivation following acute organophosphate poisoning</article-title>. <source>IJMS</source><volume>23</volume>:<fpage>8240</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms23158240</pub-id>, PMID: <pub-id pub-id-type="pmid">35897817</pub-id><pub-id pub-id-type="pmcid">PMC9332153</pub-id></mixed-citation></ref><ref id="ref70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Subramaniam</surname><given-names>A.</given-names></name><name name-style="western"><surname>Danivas</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mahavir Agarwal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kalmady</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shivakumar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Amaresha</surname><given-names>A. C.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Clinical correlates of saccadic eye movement in antipsychotic-na&#239;ve schizophrenia</article-title>. <source>Psychiatry Res.</source><volume>259</volume>, <fpage>154</fpage>&#8211;<lpage>159</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.psychres.2017.10.011</pub-id>, PMID: <pub-id pub-id-type="pmid">29049907</pub-id></mixed-citation></ref><ref id="ref71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Szpisjak</surname><given-names>L.</given-names></name><name name-style="western"><surname>Szaraz</surname><given-names>G.</given-names></name><name name-style="western"><surname>Salamon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nemeth</surname><given-names>V. L.</given-names></name><name name-style="western"><surname>Szepfalusi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Veres</surname><given-names>G.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Eye-tracking-aided characterization of saccades and Antisaccades in SYNE1 Ataxia patients: a pilot study</article-title>. <source>BMC Neurosci.</source><volume>22</volume>:7. doi: <pub-id pub-id-type="doi">10.1186/s12868-021-00612-9</pub-id>, PMID: <pub-id pub-id-type="pmid">33526008</pub-id><pub-id pub-id-type="pmcid">PMC7852103</pub-id></mixed-citation></ref><ref id="ref72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>T&#233;llez</surname><given-names>I.</given-names></name><name name-style="western"><surname>Cabello</surname><given-names>A.</given-names></name><name name-style="western"><surname>Franch</surname><given-names>O.</given-names></name><name name-style="western"><surname>Ricoy</surname><given-names>J. R.</given-names></name></person-group> (<year>1987</year>). <article-title>Chromatolytic changes in the central nervous system of patients with the toxic oil syndrome</article-title>. <source>Acta Neuropathol.</source><volume>74</volume>, <fpage>354</fpage>&#8211;<lpage>361</lpage>.<pub-id pub-id-type="pmid">3687387</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00687212</pub-id></mixed-citation></ref><ref id="ref74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolf</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tripanpitak</surname><given-names>K.</given-names></name><name name-style="western"><surname>Umeda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Otake-Matsuura</surname><given-names>M.</given-names></name></person-group> (<year>2023</year>). <article-title>Eye-tracking paradigms for the assessment of mild cognitive impairment: a systematic review</article-title>. <source>Front. Psychol.</source><volume>14</volume>:<fpage>1197567</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fpsyg.2023.1197567</pub-id>, PMID: <pub-id pub-id-type="pmid">37546488</pub-id><pub-id pub-id-type="pmcid">PMC10399700</pub-id></mixed-citation></ref><ref id="ref75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>H.</given-names></name></person-group> (<year>2023</year>). <article-title>Role of neuroinflammation in neurodegeneration development</article-title>. <source>Signal Transduct. Target. Ther.</source><volume>8</volume>:<fpage>267</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41392-023-01486-5</pub-id>, PMID: <pub-id pub-id-type="pmid">37433768</pub-id><pub-id pub-id-type="pmcid">PMC10336149</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Invest</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Invest</journal-id><journal-id journal-id-type="pmc-domain-id">120</journal-id><journal-id journal-id-type="pmc-domain">jcinvest</journal-id><journal-id journal-id-type="publisher-id">J Clin Invest</journal-id><journal-title-group><journal-title>The Journal of Clinical Investigation</journal-title></journal-title-group><issn pub-type="ppub">0021-9738</issn><issn pub-type="epub">1558-8238</issn><publisher><publisher-name>American Society for Clinical Investigation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12483559</article-id><article-id pub-id-type="pmcid-ver">PMC12483559.1</article-id><article-id pub-id-type="pmcaid">12483559</article-id><article-id pub-id-type="pmcaiid">12483559</article-id><article-id pub-id-type="pmid">41031883</article-id><article-id pub-id-type="doi">10.1172/JCI188349</article-id><article-id pub-id-type="publisher-id">188349</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Series</subject></subj-group></article-categories><title-group><article-title>Gut complement system: a new frontier in microbiota-host communication and intestinal homeostasis</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Tian</surname><given-names initials="X">Xianbin</given-names></name><email>tianx@wustl.edu</email><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="L">Lan</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Qian</surname><given-names initials="X">Xinyang</given-names></name><email>x.qian@wustl.edu</email><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Peng</surname><given-names initials="Y">Yangqing</given-names></name><email>pyangqing@email.wustl.edu</email><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="F">Fengyixin</given-names></name><email>c.fengyixin@wustl.edu</email><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bengtson</surname><given-names initials="S">Sarah</given-names></name><email>bengtson@wustl.edu</email><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="Z">Zhiqing</given-names></name><email>zhiqing@wustl.edu</email><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Wu</surname><given-names initials="M">Meng</given-names></name><email>mengwu@wustl.edu</email><xref rid="A1" ref-type="aff">1</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Molecular Microbiology and</aff><aff id="A2"><label>2</label>Program of Molecular Microbiology and Microbial Pathogenesis, Washington University School of Medicine, St. Louis, Missouri, USA.</aff><author-notes><corresp>Address correspondence to: Meng Wu, Department of Molecular Microbiology, Washington University School of Medicine, MSC-8230-16-09, 660 S. Euclid Avenue, St. Louis, Missouri 63110, USA. Email: <email>mengwu@wustl.edu</email>.</corresp></author-notes><pub-date date-type="pub" publication-format="electronic" iso-8601-date="2025-10-01T12:00:00-0400"><day>1</day><month>10</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic" iso-8601-date="2025-10-01T12:00:00-0400"><day>1</day><month>10</month><year>2025</year></pub-date><volume>135</volume><issue>19</issue><issue-id pub-id-type="pmc-issue-id">498024</issue-id><elocation-id>e188349</elocation-id><pub-history><event event-type="pmc-release"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-02 13:25:38.967"><day>02</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 Tian et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Tian et al.</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://creativecommons.org/licenses/by/4.0/" ext-link-type="uri">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jci-135-188349.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.jci.org/articles/view/188349">This article is available online at https://www.jci.org/articles/view/188349</self-uri><abstract><p>The gut microbiota plays a crucial role in maintaining intestinal homeostasis and influencing various aspects of host physiology, including immune function. Recent advances have highlighted the emerging importance of the complement system, particularly the C3 protein, as a key player in microbiota-host interactions. Traditionally known for its role in innate immunity, the complement system is now recognized for its interactions with microbial communities within the gut, where it promotes immune tolerance and protects against enteric infections. This Review explores the gut complement system as a possibly novel frontier in microbiota-host communication and examines its role in shaping microbial diversity, modulating inflammatory responses, and contributing to intestinal health. We discuss the dynamic interplay between microbiota-derived signals and complement activation, with a focus on the C3 protein and its effect on both the gut microbiome and host immune responses. Furthermore, we highlight the therapeutic potential of targeting complement pathways to restore microbial balance and treat diseases such as inflammatory bowel disease and colorectal cancer. By elucidating the functions of the gut complement system, we offer insights into its potential as a target for microbiota-based interventions aimed at restoring intestinal homeostasis and preventing disease.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>The gastrointestinal tract is the body&#8217;s most immunologically active and microbially dense environment, and it demands finely tuned mechanisms to maintain homeostasis and defend against pathogens. The complement system, which has been classically recognized as a sentinel of the innate immune response, is increasingly being appreciated for its nuanced roles within the local environment. Complement components are not confined to systemic circulation but can be locally produced and activated at mucosal sites, including the gastrointestinal tract. Within this unique niche, the gut complement system orchestrates a delicate balance among microbial surveillance, barrier integrity, and immune modulation, positioning it as a critical yet underexplored mediator of microbiota-host crosstalk. In this Review, we discuss recent advances in our understanding of local complement production with a focus on the gut mucosa, while drawing comparisons to complement activity at other mucosal sites.</p></sec><sec><title>Local biosynthesis and unique adaptations of intestinal complement</title><p>The systemic complement system comprises over fifty soluble proteins, most of which are synthesized by hepatocytes in the liver (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). However, extrahepatic expression and synthesis of complement system proteins have been demonstrated, particularly in in vitro cultures of cells derived from humans and guinea pigs (<xref rid="B3" ref-type="bibr">3</xref>&#8211;<xref rid="B6" ref-type="bibr">6</xref>). Initial evidence for local complement synthesis in the gut emerged from studies showing that small intestinal epithelial cells (IECs) from guinea pigs could synthesize hemolytically active C1 (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>). This finding was later verified in isolated segments of human colon and ileum, where locally produced C1 was detected through incorporation of radiolabeled amino acids (<xref rid="B9" ref-type="bibr">9</xref>). More recently, intestinal macrophages have been identified as the primary source of C1q in the gut (<xref rid="B10" ref-type="bibr">10</xref>).</p><p>Among complement components, C3 has received particular attention for its role in the intestine because of its central role in the complement system. C3 production has been detected as early as 11 weeks of gestation in human fetal colon cultures (<xref rid="B11" ref-type="bibr">11</xref>) as well as in biopsies from both the small intestine and colon of adult (<xref rid="B12" ref-type="bibr">12</xref>). Subsequent studies have established that IECs are capable of producing C3. Human colon carcinoma cell lines (Caco-2, T84, HT-29) were shown to synthesize C3 in vitro, in contrast to the embryonic intestinal cell line INT407, which lacked this capacity (<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B14" ref-type="bibr">14</xref>). C3 expression has also been reported in murine IEC lines and primary epithelial cells isolated from ileal and colonic tissues, with expression levels upregulated by LPS stimulation (<xref rid="B15" ref-type="bibr">15</xref>). In mouse models of dextran sodium sulfate&#8211;induced (DSS-induced) colitis, C3 expression and protein production by IECs are markedly increased (<xref rid="B15" ref-type="bibr">15</xref>).</p><p>These observations have largely been limited to in vitro, ex vivo, or inflammatory models, and the cellular sources of C3 under homeostatic conditions in the gut remained poorly defined. Our recent work, utilizing flow cytometry and single-cell RNA sequencing (scRNA-Seq) in C3-tdTomato reporter mice, demonstrated that epithelial cells, myeloid populations, and stromal cells all express C3 in the colon during homeostasis (<xref rid="B16" ref-type="bibr">16</xref>). Using in situ RNAscope and immunofluorescence, we localized C3-expressing stromal cells within isolated lymphoid follicles. Moreover, in vitro stimulation of colonic stromal cells with microbe-derived products &#8212; including formalin-fixed or heat-killed bacteria, as well as defined microbe-associated molecular patterns (MAMPs) such as LPS, peptidoglycan, lipoteichoic acid, and the synthetic triacylated lipopeptide Pam3CysSerLys4 (Pam3CSK4) &#8212; was sufficient to induce C3 production.</p><p>In addition to C3, IEC lines have been shown to produce other early complement components such as C4 and factor B (<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B14" ref-type="bibr">14</xref>). Strikingly, however, these cells do not produce the terminal complement components (C5&#8211;C9) required for membrane attack complex (MAC) formation (<xref rid="B14" ref-type="bibr">14</xref>). Consistently, epithelial, stromal, and CD45<sup>+</sup> immune cells in the intestine did not express appreciable levels of C5&#8211;C9 transcripts, and C5 protein remains undetectable in the gut lumen, even during infection, while C3 is robustly upregulated and secreted. Human intestinal scRNA-Seq data mirror these findings, showing that C1q (composed of C1qa, C1qb, C1qc trimers) is predominantly expressed by macrophages, whereas C3 is prominently detected in stromal cells, and C5&#8211;C9 are not highly expressed (<xref rid="B17" ref-type="bibr">17</xref>). These findings are consistent with a study in a human cohort with small intestinal bacterial overgrowth (SIBO), where C3 deposition was observed without evidence of terminal complement complex (C5&#8211;C9) activation (<xref rid="B18" ref-type="bibr">18</xref>).</p><p>Complement proteins, particularly C3, have also been detected directly in the intestinal lumen. C3 was identified in luminal aspirates from patients with small intestinal infections (<xref rid="B18" ref-type="bibr">18</xref>) and in jejunal fluids from both patients with Crohn&#8217;s disease (CD) and individuals acting as healthy controls (<xref rid="B19" ref-type="bibr">19</xref>). Recent gnotobiotic mouse studies further demonstrated that luminal C3 is present in the feces of both healthy mice and humans, with its levels modulated by the gut microbiota (<xref rid="B16" ref-type="bibr">16</xref>). Germ-free and antibiotic-treated mice show reduced levels of fecal C3, whereas conventionally raised mice with certain microbiota communities show increased levels of fecal C3. However, the precise microbial signals governing this regulation remain unclear. While several MAMPs have been identified as inducers of C3 in cultured epithelial and stromal cells, the specific microbial molecules and host-sensing mechanisms, particularly in stromal cells, are yet to be elucidated.</p><p>Functionally, C3b deposition on mucosa-associated bacteria has been demonstrated during DSS-induced colitis (<xref rid="B15" ref-type="bibr">15</xref>), raising questions about the role of complement in host-commensal interactions. Notably, C3-deficient mice exhibit no major shifts in gut microbiota composition at baseline (<xref rid="B16" ref-type="bibr">16</xref>), suggesting that, while C3 can opsonize commensals, it does not drive their elimination under homeostatic conditions. This is likely due to the absence of MAC-mediated lysis and the limited presence of phagocytes within the lumen in steady state. In contrast, during infection, phagocytes such as neutrophils and macrophages are recruited to the gut mucosa to clear pathogens like <italic toggle="yes">Citrobacter rodentium</italic> and enterohemorrhagic <italic toggle="yes">E. coli</italic> (<xref rid="B16" ref-type="bibr">16</xref>).</p><p>Interestingly, complement-mediated defense in the gut can also be influenced by other sources. For example, Xu et al. demonstrated that complement proteins in maternal milk can suppress Gram-positive bacteria like <italic toggle="yes">Staphylococcus lentus</italic> in the neonatal gut in a C1-, C3-, and MAC-dependent manner (<xref rid="B20" ref-type="bibr">20</xref>). This indicates that a unique protective mechanism operates during early life. Conversely, in adult intestines, C1q &#8212; although abundant &#8212; appears dispensable for defense against luminal pathogens (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B16" ref-type="bibr">16</xref>). Instead, intestinal C1q, produced by muscularis macrophages, has been implicated in regulating gut motility through modulation of neuronal gene expression (<xref rid="B10" ref-type="bibr">10</xref>), echoing its established role in synaptic pruning in the brain (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B22" ref-type="bibr">22</xref>). This suggests that gut-resident C1q may serve neuromodulatory functions distinct from its canonical role in immunity at the adult stage. <xref rid="T1" ref-type="table">Table 1</xref> summarizes known sources, locations, and functions of complement components identified in the intestine.</p><p>Collectively, the intestinal complement system displays unique adaptations (<xref rid="F1" ref-type="fig">Figure 1</xref>). It lacks terminal components required for MAC formation, suggesting that bacterial killing relies on phagocytosis rather than direct lysis. This adaptation likely reflects the need for immune tolerance in a microbiota-rich environment, contrasting with the sterile bloodstream where complement-mediated lysis is critical. The alternative pathway is the principal complement activation route in the gut, supporting amplification capacity without compromising microbial tolerance. Intriguingly, the complement profile in the gut resembles that of ancient cnidarians, which possess C3 and the activation proteases factor B and MASP (<xref rid="B23" ref-type="bibr">23</xref>). This evolutionary parallel suggests that the gut&#8217;s complement system represents an ancient, nonlytic defense mechanism tailored to the mucosal environment.</p><p>These distinct features underscore the evolutionary balance the host has achieved between immune defense and tolerance. Continued investigation is essential to unravel the precise molecular pathways by which the gut complement system interfaces with the microbiota, maintains homeostasis, and contributes to disease pathogenesis.</p></sec><sec><title>Complement receptor expression in the intestine</title><p>Complement receptors are typically categorized into two primary groups: anaphylatoxin receptors and opsonin receptors. Anaphylatoxin receptors include C3a receptor (C3aR), C5a receptor 1 (C5aR1/CD88), and C5a receptor 2 (C5aR2), while opsonin receptors include CR1 (CD35), CR2 (CD21), CR3 (CD11b/CD18), CR4 (CD11c/CD18), and CRIg (complement receptor of the immunoglobulin superfamily, also known as V-set and immunoglobulin domain-containing 4 [VSIG4]) (<xref rid="B24" ref-type="bibr">24</xref>). <xref rid="T2" ref-type="table">Table 2</xref> summarizes complement receptor expression in the gut, specifying cell types and known functions. Using floxed fluorescent reporter knock-in mouse models, the group led by J&#246;rg K&#246;hl mapped the expression of the anaphylatoxin receptors C3aR, C5aR1, and C5aR2 in various tissues, including the small intestinal lamina propria (LP) (<xref rid="B25" ref-type="bibr">25</xref>&#8211;<xref rid="B27" ref-type="bibr">27</xref>). They found that C3aR is prominently expressed in the small intestinal LP, with high levels observed on macrophages, CD103<sup>+</sup>/CD11b<sup>+</sup> conventional DCs, and plasmacytoid DCs, while lower expression is found in subsets of type 3 innate lymphoid cells (ILC3s) and epithelial cells (<xref rid="B27" ref-type="bibr">27</xref>). Notably, neutrophils do not express C3aR under steady-state conditions, but its expression is upregulated following LPS stimulation (<xref rid="B28" ref-type="bibr">28</xref>). Interestingly, in LP macrophages, C3aR is predominantly localized intracellularly (<xref rid="B27" ref-type="bibr">27</xref>), suggesting the involvement of intracellular complement activity, or &#8220;complosome,&#8221; in regulating intestinal inflammation and antigen presentation (<xref rid="B29" ref-type="bibr">29</xref>). Furthermore, C3aR has been detected at both mRNA and protein levels in mouse small intestinal organoids (enteroids) and IEC lines such as T84 and Caco-2 (<xref rid="B30" ref-type="bibr">30</xref>). In these models, LPS-induced C3a production triggers proinflammatory signaling through C3aR (<xref rid="B15" ref-type="bibr">15</xref>). Additionally, C3aR is expressed on Lgr5<sup>+</sup> intestinal stem cells within crypt organoids, where it plays a role in promoting stem cell expansion (<xref rid="B31" ref-type="bibr">31</xref>).</p><p>In contrast to the widespread expression of C3aR in the LP, C5aR1 expression is more restricted, appearing predominantly on LP macrophages in reporter mice (<xref rid="B26" ref-type="bibr">26</xref>). C5aR2, by contrast, shows a broader distribution, being expressed on macrophages, DCs, and eosinophils (<xref rid="B25" ref-type="bibr">25</xref>). Functionally, C5aR1 is a canonical GPCR that mediates strong proinflammatory responses upon C5a binding, whereas C5aR2 is an atypical GPCR with a context-dependent role, exhibiting both anti- and proinflammatory functions (<xref rid="B32" ref-type="bibr">32</xref>). Using a combination of immunofluorescence, flow cytometry, and scRNA-Seq, C5aR1 expression was identified on lysozyme-expressing DCs, where it triggers signaling pathways that promote antigen cross-presentation and CD8<sup>+</sup> T cell immunity (<xref rid="B33" ref-type="bibr">33</xref>). Notably, C5a receptors are not expressed in primary IECs or IEC-1 cell lines at either the mRNA or protein level (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B35" ref-type="bibr">35</xref>), consistent with the absence of luminal C5. However, C5aR1 and C5aR2 expression has been reported in IEC lines such as T84, HT-29, and Caco-2 (<xref rid="B36" ref-type="bibr">36</xref>). Additionally, C5aR1 has been shown to localize to the apical surface of human M-like cells (differentiated Caco-2 cells cocultured with Raji cells) and mouse Peyer&#8217;s patch M cells, where it facilitates mucosal antigen uptake (<xref rid="B37" ref-type="bibr">37</xref>).</p><p>The opsonin receptors are broadly expressed on immune cells, including neutrophils (CR1, CR3, CR4), macrophages (CR1, CR3, CR4, CRIg), DCs (CR1, CR3, CR4, CRIg), B cells (CR1, CR2, CR4), and T cells (CR1) (<xref rid="B24" ref-type="bibr">24</xref>). However, the question of whether tissue-resident immune cells, such as intestinal macrophages, exhibit distinct complement receptor profiles shaped by their local microenvironment remains unresolved. CRIg is best characterized by its high expression on liver-resident macrophages, particularly Kupffer cells (<xref rid="B38" ref-type="bibr">38</xref>). However, accumulating evidence demonstrates that CRIg is also expressed on tissue-resident macrophages (TRMs) in the small intestine and colon (<xref rid="B39" ref-type="bibr">39</xref>). Importantly, CRIg expression in TRMs is postnatally regulated by microbial signals. Its expression is markedly upregulated around the time of weaning but remains low during the neonatal period, suggesting that gut microbiota colonization is a key driver of CRIg induction. This microbiota-dependent regulation is further supported by findings showing a significant reduction in both the frequency of CRIg<sup>+</sup> TRMs and the per-cell expression levels of CRIg in the colons of mice treated with broad-spectrum antibiotics to deplete the microbiota (<xref rid="B39" ref-type="bibr">39</xref>). Functionally, these colonic CRIg<sup>+</sup> macrophages have been shown to mediate clearance of microbiota-derived extracellular vesicles, implicating them in the maintenance of intestinal homeostasis (<xref rid="B40" ref-type="bibr">40</xref>). CR3 has been occasionally detected in the small intestinal submucosa (<xref rid="B41" ref-type="bibr">41</xref>), and immunohistochemical studies have revealed CD11b expression on polymorphonuclear leukocytes, CD11c on T lymphocytes, and CD68<sup>+</sup> macrophages (<xref rid="B42" ref-type="bibr">42</xref>). Intriguingly, crypt epithelial cells have also been reported to express CD11b and CD11c, suggesting potential roles for these receptors beyond traditional immune cell contexts (<xref rid="B42" ref-type="bibr">42</xref>).</p></sec><sec><title>Complement regulatory proteins in the gut</title><p>The expression patterns of complement regulatory proteins (CRPs), including CD55 (decay-accelerating factor [DAF]), CD46 (membrane cofactor protein [MCP]), and CD59 (protectin), have been extensively characterized in both normal and diseased gastrointestinal tissues through immunohistochemical analysis of human tissue samples (<xref rid="B43" ref-type="bibr">43</xref>&#8211;<xref rid="B45" ref-type="bibr">45</xref>). <xref rid="T3" ref-type="table">Table 3</xref> summarizes the cellular source, localization, and functions associated with CRPs characterized in the gut.</p><p>Under normal conditions, CD55 exhibits restricted apical expression in the small intestinal crypt epithelium but is absent from other regions of the small intestine as well as from the gastric and colonic segments in these samples. However, CD55 expression is significantly upregulated in inflamed tissues, such as those in CD, ulcerative colitis (UC), and celiac disease (<xref rid="B43" ref-type="bibr">43</xref>). Deficiency in CD55 is associated with CHAPLE disease, a condition characterized by complement hyperactivation, angiopathic thrombosis, and protein-losing enteropathy, often presenting as primary intestinal lymphangiectasia (<xref rid="B46" ref-type="bibr">46</xref>). While CD55 serves a protective role in preventing complement-mediated damage during inflammation, its inhibitory function can be exploited in cancer. Elevated expression of CD55 has been observed in colon cancer tissues compared with adjacent normal tissues, as shown by tissue microarray analyses (<xref rid="B44" ref-type="bibr">44</xref>), with similar upregulation noted in colorectal adenomas and carcinomas (<xref rid="B47" ref-type="bibr">47</xref>). The human colon carcinoma cell lines Caco-2, T84, and HT-29 also express CD55, providing models for studying its regulation (<xref rid="B14" ref-type="bibr">14</xref>). In vitro studies have demonstrated that the induction of CD55 in IECs is strongly driven by IL-4 and TNF-&#945; at both the protein and mRNA levels, moderately by IL-1&#946;, and unaffected by IL-2, IL-6, IL-8, IL-10, or IFN-&#947; (<xref rid="B48" ref-type="bibr">48</xref>&#8211;<xref rid="B51" ref-type="bibr">51</xref>). Moreover, TNF-&#945; treatment delays CD55 mRNA degradation, while IL-4 does not, suggesting that IL-4 and TNF-&#945; induce CD55 mRNA at the transcriptional and posttranscriptional levels, respectively (<xref rid="B48" ref-type="bibr">48</xref>, <xref rid="B49" ref-type="bibr">49</xref>). Additionally, the soluble form of CD55 is detected in the culture supernatant of the HT-29 cell line, providing a theoretical basis for the correlation between fecal CD55 levels and UC severity (<xref rid="B52" ref-type="bibr">52</xref>). The protective mucosal protein intestinal trefoil factor has also been shown to enhance CD55 expression through NF-&#954;B activation and mRNA stabilization during mucosal injury (<xref rid="B53" ref-type="bibr">53</xref>).</p><p>CD59 exhibits weak apical expression in gastric pit and small intestinal villus/crypt epithelia but is strongly expressed in the normal colon. During inflammation, CD59 expression increases in the stomach and small intestine but remains unchanged or reduced in the colons of patients with UC and CD (<xref rid="B43" ref-type="bibr">43</xref>, <xref rid="B54" ref-type="bibr">54</xref>). In contrast, CD59 is significantly upregulated in colorectal cancer (CRC) tissues, potentially facilitating tumor evasion of complement-mediated lysis (<xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B45" ref-type="bibr">45</xref>, <xref rid="B55" ref-type="bibr">55</xref>). Flow cytometry analysis has further revealed that TNF-&#945;, IL-1&#946;, and IFN-&#947; enhance CD59 expression in HT-29 cells in a dose-dependent manner (<xref rid="B55" ref-type="bibr">55</xref>).</p><p>CD46 is constitutively expressed basolaterally across the gut epithelium, with stable expression levels during inflammation (<xref rid="B43" ref-type="bibr">43</xref>), although it shows notable upregulation in colon cancer (<xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B45" ref-type="bibr">45</xref>). Unlike CD55 and CD59, CD46 expression in HT-29 cells is selectively induced by IFN-&#947;, rather than by TNF-&#945; or IL-1&#946; (<xref rid="B51" ref-type="bibr">51</xref>). Beyond its role in complement regulation, CD46 modulates epithelial barrier dynamics by interacting with the Ste20/SPS1-related kinase (SPAK) and E-cadherin, disrupting epithelial tight junctions, increasing paracellular permeability to pathogens like <italic toggle="yes">E</italic>. <italic toggle="yes">coli</italic>, and simultaneously promoting epithelial cell proliferation and repair (<xref rid="B56" ref-type="bibr">56</xref>). However, these findings, which suggest that CD46 plays a central role in both compromising barrier integrity and enhancing tissue repair, are derived from in vitro models and, thus, require further validation in vitro.</p><p>Current knowledge regarding CRPs in the gut relies largely on human biopsies and cell lines. To better understand their functional roles and causal relationships, advanced models such as organoids and animal studies are needed. Collectively, the distinct spatial and disease-specific expression patterns of CD55, CD59, and CD46 underscore their specialized roles in gut immunity and pathology (<xref rid="B57" ref-type="bibr">57</xref>).</p></sec><sec><title>Interactions between the complement system and enteric pathogens</title><p>Although numerous studies have examined the interplay between the complement system and enteric pathogens, much of the existing research has been conducted under in vitro conditions or with a focus on systemic infection. Local interactions between the complement system and pathogens in the gut remain underexplored. Here, we summarize studies that examine these local interactions and explore how enteric pathogens defend themselves against the complement system.</p><p><italic toggle="yes">Listeria monocytogenes</italic> is a foodborne pathogen that breaches the intestinal epithelial barrier to invade the LP and subsequently disseminates through the lymphatic and blood systems. <italic toggle="yes">L</italic>. <italic toggle="yes">monocytogenes</italic> is a facultatively intracellular organism that can survive within both phagocytic and nonphagocytic cells (<xref rid="B58" ref-type="bibr">58</xref>). C3 is known to bind <italic toggle="yes">L</italic>. <italic toggle="yes">monocytogenes</italic> via the alternative pathway in human and mouse serum (<xref rid="B59" ref-type="bibr">59</xref>&#8211;<xref rid="B61" ref-type="bibr">61</xref>). Although its intracellular lifestyle protects the pathogen from extracellular complement, the host exploits C3 opsonization to restrict bacterial replication through autophagy. Within IECs, C3 directly interacts with ATG16L1, promoting autophagic clearance of the pathogen (<xref rid="B62" ref-type="bibr">62</xref>). Other intracellular pathogens, such as <italic toggle="yes">Shigella flexneri</italic> and <italic toggle="yes">Salmonella enterica</italic> serovar Typhimurium, evade this defense mechanism by secreting outer membrane proteases (IcsP and PgtE, respectively), which cleave surface-bound C3 to avoid autophagy. Notably, <italic toggle="yes">Salmonella</italic> PgtE also degrades human factor B and factor H, further suppressing alternative pathway activation (<xref rid="B63" ref-type="bibr">63</xref>). Adherent-invasive <italic toggle="yes">E</italic>. <italic toggle="yes">coli</italic> (AIEC) utilizes its LPS O-antigen, synthesized by the <italic toggle="yes">wzy</italic> gene, to shield itself from complement attack (<xref rid="B64" ref-type="bibr">64</xref>). Interestingly, colonization by the <italic toggle="yes">wzy</italic> mutant (which lacks LPS) alleviates DSS-induced colitis in a C3-dependent manner, suggesting context-dependent roles for complement in inflammation and microbial control.</p><p><italic toggle="yes">C. rodentium</italic> is widely used as a model for human enteropathogenic <italic toggle="yes">E</italic>. <italic toggle="yes">coli</italic> infections (<xref rid="B65" ref-type="bibr">65</xref>). To establish infection, adherent <italic toggle="yes">C</italic>. <italic toggle="yes">rodentium</italic> spends several days adapting to the host environment (<xref rid="B66" ref-type="bibr">66</xref>), providing ample opportunity for local complement to opsonize the pathogen. Properdin (factor P) enhances host resistance to <italic toggle="yes">C</italic>. <italic toggle="yes">rodentium</italic> by amplifying complement activation and stimulating colonic epithelial IL-6 production, which reduces bacterial burden and inflammation (<xref rid="B67" ref-type="bibr">67</xref>). In 3- to 4-week-old mice, C3-deficient animals exhibit reduced survival following infection (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B68" ref-type="bibr">68</xref>). In adult mice, C3 was found to bind <italic toggle="yes">C</italic>. <italic toggle="yes">rodentium</italic> at the surface of colonic epithelium and in feces, and C3-deficient mice showed significant weight loss compared with WT controls (<xref rid="B16" ref-type="bibr">16</xref>). Interestingly, mice depleted of systemic C3 via cobra venom factor remained protected against <italic toggle="yes">C</italic>. <italic toggle="yes">rodentium</italic> infection, emphasizing the importance of local C3 (<xref rid="B16" ref-type="bibr">16</xref>). C3 deposition was detected in WT, C1q-deficient, and mannose-binding lectin&#8211;deficient (MBL-deficient) mice, suggesting that the alternative pathway likely mediates complement activation and deposition during <italic toggle="yes">C</italic>. <italic toggle="yes">rodentium</italic> infection (<xref rid="B16" ref-type="bibr">16</xref>).</p><p>It remains challenging to distinguish between local and systemic complement contributions during gut infection, especially under inflammatory conditions. Systemic complement influx can limit pathogen dissemination, as demonstrated by IL-22&#8211;driven C3 production during <italic toggle="yes">Clostridioides difficile</italic> infection, which targets translocating pathobionts in extraintestinal organs and reduces mortality (<xref rid="B69" ref-type="bibr">69</xref>). Similarly, systemic MBL restricts <italic toggle="yes">Candida albicans</italic> dissemination from the gut during experimental colitis (<xref rid="B70" ref-type="bibr">70</xref>).</p><p>Enteric parasites have also evolved mechanisms to circumvent complement-mediated defense in the gut. MBL deficiency has been associated with increased cryptosporidiosis in immunocompromised individuals and young children (<xref rid="B71" ref-type="bibr">71</xref>, <xref rid="B72" ref-type="bibr">72</xref>). <italic toggle="yes">Cryptosporidium parvum</italic> activates both the classical and lectin complement pathways in vitro, with C1q and MBL contributing to host defense in gastrointestinal infection models (<xref rid="B73" ref-type="bibr">73</xref>). Similarly, MBL, H-ficolin, and L-ficolin bind <italic toggle="yes">Giardia intestinalis</italic>, a protozoan responsible for diarrheal disease and activate the complement lectin pathway to kill the parasite in human serum (<xref rid="B74" ref-type="bibr">74</xref>). However, in mice, MBL deficiency impairs Giardia clearance via a C3aR-dependent mechanism. This mechanism decreases mast cell recruitment rather than causing direct lysis (<xref rid="B75" ref-type="bibr">75</xref>).</p><p>The local complement pathway also plays an important role in enteric viral infections. Certain echovirus serotypes (6, 7, 11, 12, 20, and 21) and enterovirus 70 exploit the complement regulator CD55 as a receptor for attachment and infection (<xref rid="B76" ref-type="bibr">76</xref>, <xref rid="B77" ref-type="bibr">77</xref>). Likewise, coxsackievirus serotypes B1, B3, B5, and A21 bind CD55 for cellular attachment, although this interaction alone does not mediate productive infection (<xref rid="B78" ref-type="bibr">78</xref>&#8211;<xref rid="B80" ref-type="bibr">80</xref>). Another CRP, CD46, also serves as a receptor for various viruses (<xref rid="B81" ref-type="bibr">81</xref>). These include measles virus (<xref rid="B82" ref-type="bibr">82</xref>, <xref rid="B83" ref-type="bibr">83</xref>), which is capable of establishing persistent infection in the intestine (<xref rid="B84" ref-type="bibr">84</xref>); adenovirus serotypes 3, 11, 14, 16, 21, 35, 37, and 50 (<xref rid="B85" ref-type="bibr">85</xref>&#8211;<xref rid="B88" ref-type="bibr">88</xref>); and bovine viral diarrhea virus (<xref rid="B89" ref-type="bibr">89</xref>). Human astrovirus, a major cause of gastroenteritis, binds C1q and MBL via its coat protein, thereby disrupting the activation of the classical and lectin complement pathways (<xref rid="B90" ref-type="bibr">90</xref>, <xref rid="B91" ref-type="bibr">91</xref>). Further studies have shown that the coat protein binds C1q at both the globular head region and the collagen-like region, which interacts with the serine protease tetramer (C1s-C1r-C1r-C1s), disrupting the integrity of the C1 complex. However, as most complement-virus interactions have been characterized in vitro, their biological relevance during natural infections requires further validation.</p><p>These findings underscore the complex relationship between the complement system and pathogens in the gut, highlighting both the protective and evasion mechanisms employed by various microbial agents. Further studies examining local complement activity in vivo are essential for a comprehensive understanding of this dynamic interaction.</p></sec><sec><title>Gut complement, microbiota, and chronic inflammatory diseases</title><p>The complex role of the complement system in the development and progression of chronic inflammatory diseases of the gut, such as inflammatory bowel disease (IBD), has long been recognized. This complexity stems from complement&#8217;s capacity to both maintain and disrupt intestinal homeostasis. On one hand, complement supports tissue repair and homeostasis by clearing pathogens and damaged cells. On the other hand, excessive or dysregulated complement activation can trigger inflammation and drive tissue injury.</p><p>Substantial evidence points to both systemic and local complement dysregulation as a contributor in IBD. Patients with IBD exhibit elevated C3 synthesis rates compared with individuals acting as healthy controls, and patients with CD exhibit higher C3 production and serum levels than patients with UC (<xref rid="B92" ref-type="bibr">92</xref>). Likewise, C1q synthesis and serum concentrations are increased in individuals with CD relative to those in individuals with UC and healthy individuals (<xref rid="B93" ref-type="bibr">93</xref>), and elevated circulating levels of C3, C4, and factor B have been reported across IBD cohorts (<xref rid="B94" ref-type="bibr">94</xref>, <xref rid="B95" ref-type="bibr">95</xref>). Direct detection of jejunal secretions in patients with CD further revealed increased C3 and C4 but not FB. Without concurrent albumin leakage, this finding suggests that localized complement synthesis contributes to these elevated levels (<xref rid="B19" ref-type="bibr">19</xref>).</p><p>Additionally, deposition of IgG1, C3b, and the MAC on the intestinal epithelium in patients with UC indicates classical pathway involvement (<xref rid="B96" ref-type="bibr">96</xref>). In contrast, C3b deposition in CD occurs without IgG, C1q, or C4c, pointing toward alternative pathway activation (<xref rid="B97" ref-type="bibr">97</xref>)</p><p>IECs are known to be an important source of C3 in IBD (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B98" ref-type="bibr">98</xref>). Recently, single-cell spatial transcriptomics combined with multiplexed error-robust fluorescence in situ hybridization (MERFISH) identified fibroblast subsets with high C3 expression in both healthy and inflamed tissues in murine colitis models (<xref rid="B99" ref-type="bibr">99</xref>). Similar patterns have been observed in patients with UC, suggesting that fibroblasts also contribute to C3 production under inflammatory conditions.</p><p>Our recent work suggests that the microbiota can regulate C3 levels in the gut (<xref rid="B16" ref-type="bibr">16</xref>). Given that IBD is associated with reduced microbial diversity and a shift from antiinflammatory species (e.g., <italic toggle="yes">Faecalibacterium prausnitzii</italic>, <italic toggle="yes">Roseburia</italic> spp.) to proinflammatory pathobionts (e.g., <italic toggle="yes">E. coli</italic>, <italic toggle="yes">Ruminococcus gnavus</italic>) (<xref rid="B100" ref-type="bibr">100</xref>, <xref rid="B101" ref-type="bibr">101</xref>), it is plausible that microbial dysbiosis modulates C3 levels and activation in the gut, thereby exacerbating mucosal inflammation.</p><p>Although associations between microbiota composition and IBD pathogenesis are increasingly recognized, the underlying causal relationships and the potential involvement of the complement system are not yet fully elucidated.</p></sec><sec><title>Gut complement and microbiota in CRC</title><p>CRC is the third most commonly diagnosed cancer worldwide and the second leading cause of cancer-related mortality (<xref rid="B102" ref-type="bibr">102</xref>). Emerging evidence implicates the complement system as a key player in CRC progression. Elevated expression of complement components and regulators, including C2, C3, C5, FB, FI, FHR1 (factor H&#8211;related protein 1), CR4 (ITGAX), C4BPB, CD46, CD55, and CPN1, has been reported in colon adenocarcinoma tissues (<xref rid="B103" ref-type="bibr">103</xref>), with notable activation of the lectin pathway in patients with CRC (<xref rid="B104" ref-type="bibr">104</xref>). However, complement signaling appears to exert context-dependent effects during CRC pathogenesis.</p><p>Serum levels of the anaphylatoxin C3a are increased in patients with CRC and decline following tumor resection, suggesting its potential utility as a biomarker (<xref rid="B105" ref-type="bibr">105</xref>&#8211;<xref rid="B107" ref-type="bibr">107</xref>). Paradoxically, in other cases C3aR expression has been observed to be epigenetically silenced in CRC via promoter hypermethylation, and loss of C3aR function promotes tumor development by enabling microbiota-driven infiltration of proinflammatory immune cells into colorectal tissues (<xref rid="B108" ref-type="bibr">108</xref>). Similarly, elevated plasma levels of C5a have been observed in patients with CRC (<xref rid="B109" ref-type="bibr">109</xref>), and overexpression of its receptor, C5aR1, enhances CRC cell proliferation, migration, and invasion in vitro (<xref rid="B110" ref-type="bibr">110</xref>). Tumor-associated macrophages further amplify C5a production through platelet-mediated activation of the JNK/STAT1 pathway, promoting tumor growth (<xref rid="B111" ref-type="bibr">111</xref>). C5a/C5aR1 signaling also exacerbates CRC progression by recruiting myeloid-derived suppressor cells that suppress CD8<sup>+</sup> T cell activity in preclinical models (<xref rid="B112" ref-type="bibr">112</xref>) and by stabilizing &#946;-catenin in epithelial cells via altered ubiquitination (<xref rid="B113" ref-type="bibr">113</xref>). Additionally, this axis promotes liver metastasis through PI3K/AKT-driven MCP-1&#8211;mediated recruitment of bone marrow&#8211;derived macrophages, neutrophils, and DCs (<xref rid="B114" ref-type="bibr">114</xref>). Collectively, while C3a/C3aR signaling exhibits dual, context-dependent roles, C5a/C5aR1 signaling consistently drives tumorigenesis and immunosuppression in CRC (<xref rid="B115" ref-type="bibr">115</xref>).</p><p>The microbiota-dependent production of C3 by intestinal cells and the minimal presence of C5 under homeostatic conditions in the gut (<xref rid="B16" ref-type="bibr">16</xref>) warrants further investigation to delineate the origins of complement components in CRC. Clarifying these pathways will be critical for identifying diagnostic biomarkers and therapeutic targets for CRC. The gut microbiota contributes to CRC through diverse mechanisms, including induction of genotoxic stress, activation of oncogenic signaling, promotion of chronic inflammation, immune evasion, and metabolic reprogramming (<xref rid="B116" ref-type="bibr">116</xref>). Meta-analyses of fecal sequencing data from patients with CRC have revealed enrichment of species such as <italic toggle="yes">Fusobacterium nucleatum</italic>, <italic toggle="yes">Solobacterium moorei</italic>, <italic toggle="yes">Porphyromonas asaccharolytica</italic>, <italic toggle="yes">Parvimonas micra</italic>, <italic toggle="yes">Peptostreptococcus stomatis</italic>, <italic toggle="yes">P</italic>. <italic toggle="yes">anaerobius</italic>, and <italic toggle="yes">Prevotella intermedia</italic> (<xref rid="B117" ref-type="bibr">117</xref>, <xref rid="B118" ref-type="bibr">118</xref>). These findings support a model in which tumor-associated microbiota drive local complement expression, shaping the immune microenvironment to favor malignant progression.</p><p>Although the MAC can directly lyse tumor cells by disrupting membrane integrity (<xref rid="B119" ref-type="bibr">119</xref>), CRC cells evade complement-mediated cytotoxicity by upregulating CRPs such as CD55, CD46, and CD59 via STAT3/STAT6/p38 MAPK signaling (<xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B107" ref-type="bibr">107</xref>, <xref rid="B120" ref-type="bibr">120</xref>, <xref rid="B121" ref-type="bibr">121</xref>). Silencing these CRPs induces apoptosis in vitro and inhibits tumor growth in vivo (<xref rid="B121" ref-type="bibr">121</xref>), while anti-CD55 antibodies restore complement activation and suppress CRC proliferation and invasion (<xref rid="B122" ref-type="bibr">122</xref>). High CRP expression correlates with poor prognosis in patients with CRC (<xref rid="B123" ref-type="bibr">123</xref>, <xref rid="B103" ref-type="bibr">103</xref>), highlighting their potential as therapeutic targets. In addition, factor I has been shown to promote CRC growth by enhancing glycolytic flux through the Wnt/&#946;-catenin/c-Myc axis (<xref rid="B124" ref-type="bibr">124</xref>), and the accumulation of factor H and its splice variant FHL-1 in liver metastases may further inhibit MAC formation and promote tumor survival (<xref rid="B125" ref-type="bibr">125</xref>).</p></sec><sec><title>Future perspectives</title><p>Collectively, our emerging understanding of gut complement biology positions this ancient immune pathway as a critical mediator of intestinal homeostasis and disease. Its dual capacity to shape microbiota-host interactions and regulate barrier function underscores the complement system&#8217;s unique role in maintaining the health of the gut ecosystem. However, when dysregulated, complement can become a potent driver of chronic inflammatory diseases, metabolic disorders, and malignancies. As research continues to unravel the microbial and host-derived signals that govern complement production and activation in the gut, new therapeutic strategies are on the horizon. Precision targeting of complement pathways &#8212; whether through modulation of microbial communities, restoration of complement regulation, or inhibition of pathogenic activation &#8212; holds promise for a new class of therapeutics aimed at reestablishing mucosal balance. Future studies delineating the spatial, cellular, and molecular determinants of gut complement activity will be pivotal in translating these insights into clinical interventions that improve outcomes across a spectrum of gastrointestinal and systemic diseases.</p></sec></body><back><ack><p>This work was partially supported by a grant from the NIAID New Innovator Award (1DP2AI184835-01 to MW), an NIH grant (1R01AI181938-01A1, subaward to MW), and start-up funds from Washington University in St. Louis. We thank John Atkinson and Xiaobo Wu (Washington University in St. Louis) for their expert consultation and insightful discussions. This work is the result of NIH funding, in whole or in part, and is subject to the NIH Public Access Policy. Through acceptance of this federal funding, the NIH has been given a right to make the work publicly available in PubMed Central.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>Conflict of interest:</bold> The authors have declared that no conflict of interest exists.</p></fn><fn><p><bold>Copyright:</bold> &#169; 2025, Tian et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.</p></fn><fn><p><bold>Reference information:</bold><italic toggle="yes"> J Clin Invest</italic>. 2025;135(19):e188349. https://doi.org/10.1172/JCI188349.</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alper</surname><given-names>CA</given-names></name><etal>et al</etal></person-group><article-title>Human C&#8217;3: evidence for the liver as the primary site of synthesis</article-title><source>Science</source><year>1969</year><volume>163</volume><issue>3864</issue><fpage>286</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1126/science.163.3864.286</pub-id><pub-id pub-id-type="pmid">4883617</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torisu</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Serum complement after orthotopic transplantation of the human liver</article-title><source>Clin Exp Immunol</source><year>1972</year><volume>12</volume><issue>1</issue><fpage>21</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">4628404</pub-id><pub-id pub-id-type="pmcid">PMC1553651</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Einstein</surname><given-names>LP</given-names></name><etal>et al</etal></person-group><article-title>Biosynthesis of the third component of complement (C3) in vitro by monocytes from both normal and homozygous C3-deficient humans</article-title><source>J Clin Invest</source><year>1977</year><volume>60</volume><issue>5</issue><fpage>963</fpage><lpage>969</lpage><pub-id pub-id-type="doi">10.1172/JCI108876</pub-id><pub-id pub-id-type="pmid">332718</pub-id><pub-id pub-id-type="pmcid">PMC372447</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rubin</surname><given-names>DJ</given-names></name><etal>et al</etal></person-group><article-title>Synthesis of the second component of guinea pig complement in vitro</article-title><source>J Immunol</source><year>1971</year><volume>106</volume><issue>2</issue><fpage>295</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.106.2.295</pub-id><pub-id pub-id-type="pmid">5545134</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wyatt</surname><given-names>HV</given-names></name><etal>et al</etal></person-group><article-title>Production of the second (C2) and fourth (C4) components of guinea pig complement by single peritoneal cells: evidence that one cell may produce both components</article-title><source>J Immunol</source><year>1972</year><volume>108</volume><issue>6</issue><fpage>1609</fpage><lpage>1614</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.108.6.1609</pub-id><pub-id pub-id-type="pmid">4555572</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cole</surname><given-names>FS</given-names></name><etal>et al</etal></person-group><article-title>Control of complement synthesis and secretion in bronchoalveolar and peritoneal macrophages</article-title><source>J Immunol</source><year>1980</year><volume>125</volume><issue>3</issue><fpage>1120</fpage><lpage>1124</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.125.3.1120</pub-id><pub-id pub-id-type="pmid">6997377</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colten</surname><given-names>HR</given-names></name><etal>et al</etal></person-group><article-title>In vitro synthesis of the first component of complement by guinea pig small intestine</article-title><source>Proc Natl Acad Sci U S A</source><year>1966</year><volume>56</volume><issue>4</issue><fpage>1158</fpage><lpage>1163</lpage><pub-id pub-id-type="doi">10.1073/pnas.56.4.1158</pub-id><pub-id pub-id-type="pmid">5230141</pub-id><pub-id pub-id-type="pmcid">PMC220028</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colten</surname><given-names>HR</given-names></name><etal>et al</etal></person-group><article-title>Synthesis of the first component of guinea pig complement by columnar epithelial cells of the small intestine</article-title><source>J Immunol</source><year>1968</year><volume>100</volume><issue>4</issue><fpage>788</fpage><lpage>792</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.100.4.788</pub-id><pub-id pub-id-type="pmid">4967044</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colten</surname><given-names>HR</given-names></name><etal>et al</etal></person-group><article-title>Synthesis of the first component of human complement in vitro</article-title><source>J Exp Med</source><year>1968</year><volume>128</volume><issue>4</issue><fpage>595</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1084/jem.128.4.595</pub-id><pub-id pub-id-type="pmid">5675435</pub-id><pub-id pub-id-type="pmcid">PMC2138552</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pendse</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Macrophages regulate gastrointestinal motility through complement component 1q</article-title><source>Elife</source><year>2023</year><volume>12</volume><elocation-id>e78558</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.78558</pub-id><pub-id pub-id-type="pmid">37159507</pub-id><pub-id pub-id-type="pmcid">PMC10185340</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kohler</surname><given-names>PF</given-names></name></person-group><article-title>Maturation of the human complement system. I. Onset time and sites of fetal C1q, C4, C3, and C5 synthesis</article-title><source>J Clin Invest</source><year>1973</year><volume>52</volume><issue>3</issue><fpage>671</fpage><lpage>677</lpage><pub-id pub-id-type="doi">10.1172/JCI107228</pub-id><pub-id pub-id-type="pmid">4685088</pub-id><pub-id pub-id-type="pmcid">PMC302305</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lai A Fat</surname><given-names>RF</given-names></name><etal>et al</etal></person-group><article-title>In vitro synthesis of immunoglobulins, secretory component, complement and lysozyme by human gastrointestinal tissues. I. Normal tissues</article-title><source>Clin Exp Immunol</source><year>1976</year><volume>23</volume><issue>1</issue><fpage>9</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">1261092</pub-id><pub-id pub-id-type="pmcid">PMC1538358</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andoh</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Differential cytokine regulation of complement C3, C4, and factor B synthesis in human intestinal epithelial cell line, Caco-2</article-title><source>J Immunol</source><year>1993</year><volume>151</volume><issue>8</issue><fpage>4239</fpage><lpage>4247</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.151.8.4239</pub-id><pub-id pub-id-type="pmid">8409399</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernet-Camard</surname><given-names>MF</given-names></name><etal>et al</etal></person-group><article-title>Differential expression of complement proteins and regulatory decay accelerating factor in relation to differentiation of cultured human colon adenocarcinoma cell lines</article-title><source>Gut</source><year>1996</year><volume>38</volume><issue>2</issue><fpage>248</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1136/gut.38.2.248</pub-id><pub-id pub-id-type="pmid">8801206</pub-id><pub-id pub-id-type="pmcid">PMC1383032</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>S&#252;nderhauf</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Regulation of epithelial cell expressed C3 in the intestine - Relevance for the pathophysiology of inflammatory bowel disease?</article-title><source>Mol Immunol</source><year>2017</year><volume>90</volume><fpage>227</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2017.08.003</pub-id><pub-id pub-id-type="pmid">28843904</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Gut complement induced by the microbiota combats pathogens and spares commensals</article-title><source>Cell</source><year>2024</year><volume>187</volume><issue>4</issue><fpage>897</fpage><lpage>913</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2023.12.036</pub-id><pub-id pub-id-type="pmid">38280374</pub-id><pub-id pub-id-type="pmcid">PMC10922926</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elmentaite</surname><given-names>R</given-names></name><etal>et al</etal></person-group><article-title>Cells of the human intestinal tract mapped across space and time</article-title><source>Nature</source><year>2021</year><volume>597</volume><issue>7875</issue><fpage>250</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03852-1</pub-id><pub-id pub-id-type="pmid">34497389</pub-id><pub-id pub-id-type="pmcid">PMC8426186</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riordan</surname><given-names>SM</given-names></name><etal>et al</etal></person-group><article-title>Local and systemic complement activity in small intestinal bacterial overgrowth</article-title><source>Dig Dis Sci</source><year>1997</year><volume>42</volume><issue>6</issue><fpage>1128</fpage><lpage>1136</lpage><pub-id pub-id-type="doi">10.1023/A:1018821200354</pub-id><pub-id pub-id-type="pmid">9201072</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahrenstedt</surname><given-names>&#214;</given-names></name><etal>et al</etal></person-group><article-title>Enhanced local production of complement components in the small intestines of patients with Crohn&#8217;s disease</article-title><source>N Engl J Med</source><year>1990</year><volume>322</volume><issue>19</issue><fpage>1345</fpage><lpage>1349</lpage><pub-id pub-id-type="doi">10.1056/NEJM199005103221903</pub-id><pub-id pub-id-type="pmid">2325733</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>D</given-names></name><etal>et al</etal></person-group><article-title>Complement in breast milk modifies offspring gut microbiota to promote infant health</article-title><source>Cell</source><year>2024</year><volume>187</volume><issue>3</issue><fpage>750</fpage><lpage>763</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2023.12.019</pub-id><pub-id pub-id-type="pmid">38242132</pub-id><pub-id pub-id-type="pmcid">PMC10872564</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Complement and microglia mediate early synapse loss in Alzheimer mouse models</article-title><source>Science</source><year>2016</year><volume>352</volume><issue>6286</issue><fpage>712</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1126/science.aad8373</pub-id><pub-id pub-id-type="pmid">27033548</pub-id><pub-id pub-id-type="pmcid">PMC5094372</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stevens</surname><given-names>B</given-names></name><etal>et al</etal></person-group><article-title>The classical complement cascade mediates CNS synapse elimination</article-title><source>Cell</source><year>2007</year><volume>131</volume><issue>6</issue><fpage>1164</fpage><lpage>1178</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.10.036</pub-id><pub-id pub-id-type="pmid">18083105</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="book"><comment>Nonaka M. Evolution of the complement system. In: Anderluh G, Gilbert R, eds. <italic toggle="yes">MACPF/CDC Proteins - Agents of Defence, Attack and Invasion</italic>. Springer; 2014:31&#8211;43.</comment></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lubbers</surname><given-names>R</given-names></name><etal>et al</etal></person-group><article-title>Production of complement components by cells of the immune system</article-title><source>Clin Exp Immunol</source><year>2017</year><volume>188</volume><issue>2</issue><fpage>183</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1111/cei.12952</pub-id><pub-id pub-id-type="pmid">28249350</pub-id><pub-id pub-id-type="pmcid">PMC5383442</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karsten</surname><given-names>CM</given-names></name><etal>et al</etal></person-group><article-title>Monitoring C5aR2 expression using a floxed tdTomato-C5aR2 knock-in mouse</article-title><source>J Immunol</source><year>2017</year><volume>199</volume><issue>9</issue><fpage>3234</fpage><lpage>3248</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1700710</pub-id><pub-id pub-id-type="pmid">28864475</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karsten</surname><given-names>CM</given-names></name><etal>et al</etal></person-group><article-title>Monitoring and cell-specific deletion of C5aR1 using a novel floxed GFP-C5aR1 reporter knock-in mouse</article-title><source>J Immunol</source><year>2015</year><volume>194</volume><issue>4</issue><fpage>1841</fpage><lpage>1855</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1401401</pub-id><pub-id pub-id-type="pmid">25589074</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quell</surname><given-names>KM</given-names></name><etal>et al</etal></person-group><article-title>Monitoring C3aR expression using a floxed tdTomato-C3aR reporter knock-in mouse</article-title><source>J Immunol</source><year>2017</year><volume>199</volume><issue>2</issue><fpage>688</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1700318</pub-id><pub-id pub-id-type="pmid">28626064</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guglietta</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Coagulation induced by C3aR-dependent NETosis drives protumorigenic neutrophils during small intestinal tumorigenesis</article-title><source>Nat Commun</source><year>2016</year><volume>7</volume><issue>1</issue><elocation-id>11037</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms11037</pub-id><pub-id pub-id-type="pmid">26996437</pub-id><pub-id pub-id-type="pmcid">PMC4802169</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>West</surname><given-names>EE</given-names></name><name name-style="western"><surname>Kemper</surname><given-names>C</given-names></name></person-group><article-title>Complosome - the intracellular complement system</article-title><source>Nat Rev Nephrol</source><year>2023</year><volume>19</volume><issue>7</issue><fpage>426</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1038/s41581-023-00704-1</pub-id><pub-id pub-id-type="pmid">37055581</pub-id><pub-id pub-id-type="pmcid">PMC10100629</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCarthy</surname><given-names>JD</given-names></name><etal>et al</etal></person-group><article-title>The anaphylatoxin C3a primes model colonic epithelial cells for expression of inflammatory mediators through G&#945;i</article-title><source>Mol Immunol</source><year>2018</year><volume>103</volume><fpage>125</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2018.09.008</pub-id><pub-id pub-id-type="pmid">30261438</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsumoto</surname><given-names>N</given-names></name><etal>et al</etal></person-group><article-title>C3a enhances the formation of intestinal organoids through C3aR1</article-title><source>Front Immunol</source><year>2017</year><volume>8</volume><elocation-id>1046</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2017.01046</pub-id><pub-id pub-id-type="pmid">28928734</pub-id><pub-id pub-id-type="pmcid">PMC5591398</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghosh</surname><given-names>M</given-names></name><name name-style="western"><surname>Rana</surname><given-names>S</given-names></name></person-group><article-title>The anaphylatoxin C5a: Structure, function, signaling, physiology, disease, and therapeutics</article-title><source>Int Immunopharmacol</source><year>2023</year><volume>118</volume><elocation-id>110081</elocation-id><pub-id pub-id-type="doi">10.1016/j.intimp.2023.110081</pub-id><pub-id pub-id-type="pmid">36989901</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S-H</given-names></name><etal>et al</etal></person-group><article-title>Complement C5a promotes antigen cross-presentation by Peyer&#8217;s patch monocyte-derived dendritic cells and drives a protective CD8<sup>+</sup> T cell response</article-title><source>Cell Rep</source><year>2021</year><volume>35</volume><issue>2</issue><elocation-id>108995</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2021.108995</pub-id><pub-id pub-id-type="pmid">33852847</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fayyazi</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>C5a receptor and interleukin-6 are expressed in tissue macrophages and stimulated keratinocytes but not in pulmonary and intestinal epithelial cells</article-title><source>Am J Pathol</source><year>1999</year><volume>154</volume><issue>2</issue><fpage>495</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)65295-9</pub-id><pub-id pub-id-type="pmid">10027407</pub-id><pub-id pub-id-type="pmcid">PMC1849999</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zwirner</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Expression of the anaphylatoxin C5a receptor in non-myeloid cells</article-title><source>Mol Immunol</source><year>1999</year><volume>36</volume><issue>13-14</issue><fpage>877</fpage><lpage>884</lpage><pub-id pub-id-type="doi">10.1016/S0161-5890(99)00109-1</pub-id><pub-id pub-id-type="pmid">10698342</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>Q</given-names></name><etal>et al</etal></person-group><article-title>Human colonic epithelial cells detect and respond to C5a via apically expressed C5aR through the ERK pathway</article-title><source>Am J Physiol Cell Physiol</source><year>2012</year><volume>302</volume><issue>12</issue><fpage>1731</fpage><lpage>1740</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00213.2011</pub-id><pub-id pub-id-type="pmid">22496247</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>M cells expressing the complement C5a receptor are efficient targets for mucosal vaccine delivery</article-title><source>Eur J Immunol</source><year>2011</year><volume>41</volume><issue>11</issue><fpage>3219</fpage><lpage>3229</lpage><pub-id pub-id-type="doi">10.1002/eji.201141592</pub-id><pub-id pub-id-type="pmid">21887786</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Helmy</surname><given-names>KY</given-names></name><etal>et al</etal></person-group><article-title>CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens</article-title><source>Cell</source><year>2006</year><volume>124</volume><issue>5</issue><fpage>915</fpage><lpage>927</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2005.12.039</pub-id><pub-id pub-id-type="pmid">16530040</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>X</given-names></name><etal>et al</etal></person-group><article-title>CRIg, a tissue-resident macrophage specific immune checkpoint molecule, promotes immunological tolerance in NOD mice, via a dual role in effector and regulatory T cells</article-title><source>Elife</source><year>2017</year><volume>6</volume><elocation-id>e29540</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.29540</pub-id><pub-id pub-id-type="pmid">29171836</pub-id><pub-id pub-id-type="pmcid">PMC5728720</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nie</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>CRIg+ macrophages deficiency enhanced inflammation damage in IBD due to gut extracellular vesicles containing microbial DNA</article-title><source>Gut Microbes</source><year>2024</year><volume>16</volume><issue>1</issue><elocation-id>2379633</elocation-id><pub-id pub-id-type="doi">10.1080/19490976.2024.2379633</pub-id><pub-id pub-id-type="pmid">39024479</pub-id><pub-id pub-id-type="pmcid">PMC11259065</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eddy</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>The distribution of the CR3 receptor on human cells and tissue as revealed by a monoclonal antibody</article-title><source>Clin Immunol Immunopathol</source><year>1984</year><volume>31</volume><issue>3</issue><fpage>371</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1016/0090-1229(84)90090-4</pub-id><pub-id pub-id-type="pmid">6232029</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vainer</surname><given-names>B</given-names></name><name name-style="western"><surname>Horn</surname><given-names>T</given-names></name></person-group><article-title>Comparative studies of the colonic in situ expression of intercellular adhesion molecules (ICAM-1, -2, and -3), beta2 integrins (LFA-1, Mac-1, and p150,95), and PECAM-1 in ulcerative colitis and Crohn&#8217;s disease</article-title><source>Am J Surg Pathol</source><year>2000</year><volume>24</volume><issue>8</issue><fpage>1115</fpage><lpage>1124</lpage><pub-id pub-id-type="doi">10.1097/00000478-200008000-00009</pub-id><pub-id pub-id-type="pmid">10935652</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berstad</surname><given-names>AE</given-names></name><name name-style="western"><surname>Brandtzaeg</surname><given-names>P</given-names></name></person-group><article-title>Expression of cell membrane complement regulatory glycoproteins along the normal and diseased human gastrointestinal tract</article-title><source>Gut</source><year>1998</year><volume>42</volume><issue>4</issue><fpage>522</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1136/gut.42.4.522</pub-id><pub-id pub-id-type="pmid">9616315</pub-id><pub-id pub-id-type="pmcid">PMC1727075</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shang</surname><given-names>Y</given-names></name><etal>et al</etal></person-group><article-title>Systematic immunohistochemical analysis of the expression of CD46, CD55, and CD59 in colon cancer</article-title><source>Arch Pathol Lab Med</source><year>2014</year><volume>138</volume><issue>7</issue><fpage>910</fpage><lpage>919</lpage><pub-id pub-id-type="doi">10.5858/arpa.2013-0064-OA</pub-id><pub-id pub-id-type="pmid">24978917</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thorsteinsson</surname><given-names>L</given-names></name><etal>et al</etal></person-group><article-title>The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissues</article-title><source>APMIS</source><year>1998</year><volume>106</volume><issue>9</issue><fpage>869</fpage><lpage>878</lpage><pub-id pub-id-type="doi">10.1111/j.1699-0463.1998.tb00233.x</pub-id><pub-id pub-id-type="pmid">9808413</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ozen</surname><given-names>A</given-names></name></person-group><article-title>CHAPLE syndrome uncovers the primary role of complement in a familial form of Waldmann&#8217;s disease</article-title><source>Immunol Rev</source><year>2019</year><volume>287</volume><issue>1</issue><fpage>20</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1111/imr.12715</pub-id><pub-id pub-id-type="pmid">30565236</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koretz</surname><given-names>K</given-names></name><etal>et al</etal></person-group><article-title>Decay-accelerating factor (DAF, CD55) in normal colorectal mucosa, adenomas and carcinomas</article-title><source>Br J Cancer</source><year>1992</year><volume>66</volume><issue>5</issue><fpage>810</fpage><lpage>814</lpage><pub-id pub-id-type="doi">10.1038/bjc.1992.365</pub-id><pub-id pub-id-type="pmid">1384641</pub-id><pub-id pub-id-type="pmcid">PMC1977964</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andoh</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Interleukin 4 acts as an inducer of decay-accelerating factor gene expression in human intestinal epithelial cells</article-title><source>Gastroenterology</source><year>1996</year><volume>111</volume><issue>4</issue><fpage>911</fpage><lpage>918</lpage><pub-id pub-id-type="doi">10.1016/S0016-5085(96)70058-6</pub-id><pub-id pub-id-type="pmid">8831585</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andoh</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Tumour necrosis factor-alpha up-regulates decay-accelerating factor gene expression in human intestinal epithelial cells</article-title><source>Immunology</source><year>1997</year><volume>90</volume><issue>3</issue><fpage>358</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2567.1997.00358.x</pub-id><pub-id pub-id-type="pmid">9155641</pub-id><pub-id pub-id-type="pmcid">PMC1456598</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nasu</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Cytokine-stimulated release of decay-accelerating factor (DAF;CD55) from HT-29 human intestinal epithelial cells</article-title><source>Clin Exp Immunol</source><year>1998</year><volume>113</volume><issue>3</issue><fpage>379</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2249.1998.00660.x</pub-id><pub-id pub-id-type="pmid">9737666</pub-id><pub-id pub-id-type="pmcid">PMC1905071</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bj&#248;rge</surname><given-names>L</given-names></name><etal>et al</etal></person-group><article-title>Characterisation of the complement-regulatory proteins decay-accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46) on a human colonic adenocarcinoma cell line</article-title><source>Cancer Immunol Immunother</source><year>1996</year><volume>42</volume><issue>3</issue><fpage>185</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1007/s002620050269</pub-id><pub-id pub-id-type="pmid">8640847</pub-id><pub-id pub-id-type="pmcid">PMC11037746</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Inaba</surname><given-names>T</given-names></name><etal>et al</etal></person-group><article-title>Decay-accelerating factor (DAF) in stool specimens as a marker of disease activity in patients with ulcerative colitis (UC)</article-title><source>Clin Exp Immunol</source><year>1998</year><volume>112</volume><issue>2</issue><fpage>237</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2249.1998.00573.x</pub-id><pub-id pub-id-type="pmid">9649185</pub-id><pub-id pub-id-type="pmcid">PMC1904958</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andoh</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Intestinal trefoil factor induces decay-accelerating factor expression and enhances the protective activities against complement activation in intestinal epithelial cells</article-title><source>J Immunol</source><year>2001</year><volume>167</volume><issue>7</issue><fpage>3887</fpage><lpage>3893</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.167.7.3887</pub-id><pub-id pub-id-type="pmid">11564806</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scheinin</surname><given-names>T</given-names></name><etal>et al</etal></person-group><article-title>Decreased expression of protectin (CD59) in gut epithelium in ulcerative colitis and Crohn&#8217;s disease</article-title><source>Hum Pathol</source><year>1999</year><volume>30</volume><issue>12</issue><fpage>1427</fpage><lpage>1430</lpage><pub-id pub-id-type="doi">10.1016/S0046-8177(99)90163-6</pub-id><pub-id pub-id-type="pmid">10667419</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bj&#248;rge</surname><given-names>L</given-names></name><etal>et al</etal></person-group><article-title>Expression and function of CD59 on colonic adenocarcinoma cells</article-title><source>Eur J Immunol</source><year>1994</year><volume>24</volume><issue>7</issue><fpage>1597</fpage><lpage>1603</lpage><pub-id pub-id-type="doi">10.1002/eji.1830240722</pub-id><pub-id pub-id-type="pmid">7517877</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cardone</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>A novel role for CD46 in wound repair</article-title><source>Front Immunol</source><year>2011</year><volume>2</volume><elocation-id>28</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2011.00028</pub-id><pub-id pub-id-type="pmid">22566818</pub-id><pub-id pub-id-type="pmcid">PMC3342392</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sina</surname><given-names>C</given-names></name><etal>et al</etal></person-group><article-title>The intestinal complement system in inflammatory bowel disease: Shaping intestinal barrier function</article-title><source>Semin Immunol</source><year>2018</year><volume>37</volume><fpage>66</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.smim.2018.02.008</pub-id><pub-id pub-id-type="pmid">29486961</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Radoshevich</surname><given-names>L</given-names></name><name name-style="western"><surname>Cossart</surname><given-names>P</given-names></name></person-group><article-title><italic toggle="yes">Listeria monocytogenes</italic>: towards a complete picture of its physiology and pathogenesis</article-title><source>Nat Rev Microbiol</source><year>2018</year><volume>16</volume><issue>1</issue><fpage>32</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1038/nrmicro.2017.126</pub-id><pub-id pub-id-type="pmid">29176582</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Kessel</surname><given-names>KP</given-names></name><etal>et al</etal></person-group><article-title>Interactions of killed <italic toggle="yes">Listeria monocytogenes</italic> with the mouse complement system</article-title><source>Infect Immun</source><year>1981</year><volume>34</volume><issue>1</issue><fpage>16</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1128/iai.34.1.16-19.1981</pub-id><pub-id pub-id-type="pmid">6795123</pub-id><pub-id pub-id-type="pmcid">PMC350813</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drevets</surname><given-names>DA</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>PA</given-names></name></person-group><article-title>Roles of complement and complement receptor type 3 in phagocytosis of <italic toggle="yes">Listeria monocytogenes</italic> by inflammatory mouse peritoneal macrophages</article-title><source>Infect Immun</source><year>1991</year><volume>59</volume><issue>8</issue><fpage>2645</fpage><lpage>2652</lpage><pub-id pub-id-type="doi">10.1128/iai.59.8.2645-2652.1991</pub-id><pub-id pub-id-type="pmid">1906842</pub-id><pub-id pub-id-type="pmcid">PMC258068</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Croize</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Activation of the human complement alternative pathway by <italic toggle="yes">Listeria monocytogenes</italic>: evidence for direct binding and proteolysis of the C3 component on bacteria</article-title><source>Infect Immun</source><year>1993</year><volume>61</volume><issue>12</issue><fpage>5134</fpage><lpage>5139</lpage><pub-id pub-id-type="doi">10.1128/iai.61.12.5134-5139.1993</pub-id><pub-id pub-id-type="pmid">8225590</pub-id><pub-id pub-id-type="pmcid">PMC281293</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sorbara</surname><given-names>MT</given-names></name><etal>et al</etal></person-group><article-title>Complement C3 drives autophagy-dependent restriction of cyto-invasive bacteria</article-title><source>Cell Host Microbe</source><year>2018</year><volume>23</volume><issue>5</issue><fpage>644</fpage><lpage>652</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2018.04.008</pub-id><pub-id pub-id-type="pmid">29746835</pub-id></element-citation></ref><ref id="B63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riva</surname><given-names>R</given-names></name><etal>et al</etal></person-group><article-title>The outer membrane protease PgtE of <italic toggle="yes">Salmonella enterica</italic> interferes with the alternative complement pathway by cleaving factors B and H</article-title><source>Front Microbiol</source><year>2015</year><volume>6</volume><elocation-id>63</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2015.00063</pub-id><pub-id pub-id-type="pmid">25705210</pub-id><pub-id pub-id-type="pmcid">PMC4319491</pub-id></element-citation></ref><ref id="B64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohno</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Lipopolysaccharide O structure of adherent and invasive <italic toggle="yes">Escherichia coli</italic> regulates intestinal inflammation via complement C3</article-title><source>PLoS Pathog</source><year>2020</year><volume>16</volume><issue>10</issue><elocation-id>e1008928</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1008928</pub-id><pub-id pub-id-type="pmid">33027280</pub-id><pub-id pub-id-type="pmcid">PMC7571687</pub-id></element-citation></ref><ref id="B65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mullineaux-Sanders</surname><given-names>C</given-names></name><etal>et al</etal></person-group><article-title><italic toggle="yes">Citrobacter rodentium</italic>-host-microbiota interactions: immunity, bioenergetics and metabolism</article-title><source>Nat Rev Microbiol</source><year>2019</year><volume>17</volume><issue>11</issue><fpage>701</fpage><lpage>715</lpage><pub-id pub-id-type="doi">10.1038/s41579-019-0252-z</pub-id><pub-id pub-id-type="pmid">31541196</pub-id></element-citation></ref><ref id="B66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collins</surname><given-names>JW</given-names></name><etal>et al</etal></person-group><article-title><italic toggle="yes">Citrobacter rodentium</italic>: infection, inflammation and the microbiota</article-title><source>Nat Rev Microbiol</source><year>2014</year><volume>12</volume><issue>9</issue><fpage>612</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1038/nrmicro3315</pub-id><pub-id pub-id-type="pmid">25088150</pub-id></element-citation></ref><ref id="B67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>U</given-names></name><etal>et al</etal></person-group><article-title>Properdin provides protection from <italic toggle="yes">Citrobacter rodentium</italic>-induced intestinal inflammation in a C5a/IL-6-dependent manner</article-title><source>J Immunol</source><year>2015</year><volume>194</volume><issue>7</issue><fpage>3414</fpage><lpage>3421</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1401814</pub-id><pub-id pub-id-type="pmid">25725105</pub-id></element-citation></ref><ref id="B68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belzer</surname><given-names>C</given-names></name><etal>et al</etal></person-group><article-title>The role of specific IgG and complement in combating a primary mucosal infection of the gut epithelium</article-title><source>Eur J Microbiol Immunol (Bp)</source><year>2011</year><volume>1</volume><issue>4</issue><fpage>311</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1556/EuJMI.1.2011.4.7</pub-id><pub-id pub-id-type="pmid">22485193</pub-id><pub-id pub-id-type="pmcid">PMC3319158</pub-id></element-citation></ref><ref id="B69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hasegawa</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Interleukin-22 regulates the complement system to promote resistance against pathobionts after pathogen-induced intestinal damage</article-title><source>Immunity</source><year>2014</year><volume>41</volume><issue>4</issue><fpage>620</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2014.09.010</pub-id><pub-id pub-id-type="pmid">25367575</pub-id><pub-id pub-id-type="pmcid">PMC4220303</pub-id></element-citation></ref><ref id="B70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muller</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Mannan-binding lectin deficiency results in unusual antibody production and excessive experimental colitis in response to mannose-expressing mild gut pathogens</article-title><source>Gut</source><year>2010</year><volume>59</volume><issue>11</issue><fpage>1493</fpage><lpage>1500</lpage><pub-id pub-id-type="doi">10.1136/gut.2010.208348</pub-id><pub-id pub-id-type="pmid">20682699</pub-id></element-citation></ref><ref id="B71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kelly</surname><given-names>P</given-names></name><etal>et al</etal></person-group><article-title>Mannose-binding lectin is a component of innate mucosal defense against <italic toggle="yes">Cryptosporidium parvum</italic> in AIDS</article-title><source>Gastroenterology</source><year>2000</year><volume>119</volume><issue>5</issue><fpage>1236</fpage><lpage>1242</lpage><pub-id pub-id-type="doi">10.1053/gast.2000.19573</pub-id><pub-id pub-id-type="pmid">11054381</pub-id></element-citation></ref><ref id="B72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirkpatrick</surname><given-names>BD</given-names></name><etal>et al</etal></person-group><article-title>Serum mannose-binding lectin deficiency is associated with cryptosporidiosis in young Haitian children</article-title><source>Clin Infect Dis</source><year>2006</year><volume>43</volume><issue>3</issue><fpage>289</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1086/505396</pub-id><pub-id pub-id-type="pmid">16804841</pub-id></element-citation></ref><ref id="B73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petry</surname><given-names>F</given-names></name><etal>et al</etal></person-group><article-title>Binding and activation of human and mouse complement by <italic toggle="yes">Cryptosporidium parvum</italic> (Apicomplexa) and susceptibility of C1q- and MBL-deficient mice to infection</article-title><source>Mol Immunol</source><year>2008</year><volume>45</volume><issue>12</issue><fpage>3392</fpage><lpage>3400</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2008.04.010</pub-id><pub-id pub-id-type="pmid">18501966</pub-id></element-citation></ref><ref id="B74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Evans-Osses</surname><given-names>I</given-names></name><etal>et al</etal></person-group><article-title>Involvement of lectin pathway activation in the complement killing of Giardia intestinalis</article-title><source>Biochem Biophys Res Commun</source><year>2010</year><volume>395</volume><issue>3</issue><fpage>382</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2010.04.025</pub-id><pub-id pub-id-type="pmid">20382117</pub-id></element-citation></ref><ref id="B75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>E</given-names></name><etal>et al</etal></person-group><article-title>Complement activation by giardia duodenalis parasites through the lectin pathway contributes to mast cell responses and parasite control</article-title><source>Infect Immun</source><year>2016</year><volume>84</volume><issue>4</issue><fpage>1092</fpage><lpage>1099</lpage><pub-id pub-id-type="doi">10.1128/IAI.00074-16</pub-id><pub-id pub-id-type="pmid">26831470</pub-id><pub-id pub-id-type="pmcid">PMC4807472</pub-id></element-citation></ref><ref id="B76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bergelson</surname><given-names>JM</given-names></name><etal>et al</etal></person-group><article-title>Decay-accelerating factor (CD55), a glycosylphosphatidylinositol-anchored complement regulatory protein, is a receptor for several echoviruses</article-title><source>Proc Natl Acad Sci U S A</source><year>1994</year><volume>91</volume><issue>13</issue><fpage>6245</fpage><lpage>6248</lpage><pub-id pub-id-type="doi">10.1073/pnas.91.13.6245</pub-id><pub-id pub-id-type="pmid">7517044</pub-id><pub-id pub-id-type="pmcid">PMC44175</pub-id></element-citation></ref><ref id="B77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karnauchow</surname><given-names>TM</given-names></name><etal>et al</etal></person-group><article-title>The HeLa cell receptor for enterovirus 70 is decay-accelerating factor (CD55)</article-title><source>J Virol</source><year>1996</year><volume>70</volume><issue>8</issue><fpage>5143</fpage><lpage>5152</lpage><pub-id pub-id-type="doi">10.1128/jvi.70.8.5143-5152.1996</pub-id><pub-id pub-id-type="pmid">8764022</pub-id><pub-id pub-id-type="pmcid">PMC190469</pub-id></element-citation></ref><ref id="B78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bergelson</surname><given-names>JM</given-names></name><etal>et al</etal></person-group><article-title>Coxsackievirus B3 adapted to growth in RD cells binds to decay-accelerating factor (CD55)</article-title><source>J Virol</source><year>1995</year><volume>69</volume><issue>3</issue><fpage>1903</fpage><lpage>1906</lpage><pub-id pub-id-type="doi">10.1128/jvi.69.3.1903-1906.1995</pub-id><pub-id pub-id-type="pmid">7531780</pub-id><pub-id pub-id-type="pmcid">PMC188804</pub-id></element-citation></ref><ref id="B79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shafren</surname><given-names>DR</given-names></name><etal>et al</etal></person-group><article-title>Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry</article-title><source>J Virol</source><year>1997</year><volume>71</volume><issue>6</issue><fpage>4736</fpage><lpage>4743</lpage><pub-id pub-id-type="doi">10.1128/jvi.71.6.4736-4743.1997</pub-id><pub-id pub-id-type="pmid">9151867</pub-id><pub-id pub-id-type="pmcid">PMC191695</pub-id></element-citation></ref><ref id="B80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shafren</surname><given-names>DR</given-names></name><etal>et al</etal></person-group><article-title>Coxsackieviruses B1, B3, and B5 use decay accelerating factor as a receptor for cell attachment</article-title><source>J Virol</source><year>1995</year><volume>69</volume><issue>6</issue><fpage>3873</fpage><lpage>3877</lpage><pub-id pub-id-type="doi">10.1128/jvi.69.6.3873-3877.1995</pub-id><pub-id pub-id-type="pmid">7538177</pub-id><pub-id pub-id-type="pmcid">PMC189108</pub-id></element-citation></ref><ref id="B81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cattaneo</surname><given-names>R</given-names></name></person-group><article-title>Four viruses, two bacteria, and one receptor: membrane cofactor protein (CD46) as pathogens&#8217; magnet</article-title><source>J Virol</source><year>2004</year><volume>78</volume><issue>9</issue><fpage>4385</fpage><lpage>4388</lpage><pub-id pub-id-type="doi">10.1128/JVI.78.9.4385-4388.2004</pub-id><pub-id pub-id-type="pmid">15078919</pub-id><pub-id pub-id-type="pmcid">PMC387720</pub-id></element-citation></ref><ref id="B82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#246;rig</surname><given-names>RE</given-names></name><etal>et al</etal></person-group><article-title>The human CD46 molecule is a receptor for measles virus (Edmonston strain)</article-title><source>Cell</source><year>1993</year><volume>75</volume><issue>2</issue><fpage>295</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(93)80071-L</pub-id><pub-id pub-id-type="pmid">8402913</pub-id></element-citation></ref><ref id="B83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naniche</surname><given-names>D</given-names></name><etal>et al</etal></person-group><article-title>Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus</article-title><source>J Virol</source><year>1993</year><volume>67</volume><issue>10</issue><fpage>6025</fpage><lpage>6032</lpage><pub-id pub-id-type="doi">10.1128/jvi.67.10.6025-6032.1993</pub-id><pub-id pub-id-type="pmid">8371352</pub-id><pub-id pub-id-type="pmcid">PMC238023</pub-id></element-citation></ref><ref id="B84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lewin</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Persistent measles virus infection of the intestine: confirmation by immunogold electron microscopy</article-title><source>Gut</source><year>1995</year><volume>36</volume><issue>4</issue><fpage>564</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1136/gut.36.4.564</pub-id><pub-id pub-id-type="pmid">7737565</pub-id><pub-id pub-id-type="pmcid">PMC1382498</pub-id></element-citation></ref><ref id="B85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Segerman</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Adenovirus type 11 uses CD46 as a cellular receptor</article-title><source>J Virol</source><year>2003</year><volume>77</volume><issue>17</issue><fpage>9183</fpage><lpage>9191</lpage><pub-id pub-id-type="doi">10.1128/JVI.77.17.9183-9191.2003</pub-id><pub-id pub-id-type="pmid">12915534</pub-id><pub-id pub-id-type="pmcid">PMC187375</pub-id></element-citation></ref><ref id="B86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaggar</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>CD46 is a cellular receptor for group B adenoviruses</article-title><source>Nat Med</source><year>2003</year><volume>9</volume><issue>11</issue><fpage>1408</fpage><lpage>1412</lpage><pub-id pub-id-type="doi">10.1038/nm952</pub-id><pub-id pub-id-type="pmid">14566335</pub-id></element-citation></ref><ref id="B87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sirena</surname><given-names>D</given-names></name><etal>et al</etal></person-group><article-title>The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3</article-title><source>J Virol</source><year>2004</year><volume>78</volume><issue>9</issue><fpage>4454</fpage><lpage>4462</lpage><pub-id pub-id-type="doi">10.1128/JVI.78.9.4454-4462.2004</pub-id><pub-id pub-id-type="pmid">15078926</pub-id><pub-id pub-id-type="pmcid">PMC387694</pub-id></element-citation></ref><ref id="B88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>E</given-names></name><etal>et al</etal></person-group><article-title>Membrane cofactor protein is a receptor for adenoviruses associated with epidemic keratoconjunctivitis</article-title><source>J Virol</source><year>2004</year><volume>78</volume><issue>8</issue><fpage>3897</fpage><lpage>3905</lpage><pub-id pub-id-type="doi">10.1128/JVI.78.8.3897-3905.2004</pub-id><pub-id pub-id-type="pmid">15047806</pub-id><pub-id pub-id-type="pmcid">PMC374279</pub-id></element-citation></ref><ref id="B89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maurer</surname><given-names>K</given-names></name><etal>et al</etal></person-group><article-title>CD46 is a cellular receptor for bovine viral diarrhea virus</article-title><source>J Virol</source><year>2004</year><volume>78</volume><issue>4</issue><fpage>1792</fpage><lpage>1799</lpage><pub-id pub-id-type="doi">10.1128/JVI.78.4.1792-1799.2004</pub-id><pub-id pub-id-type="pmid">14747544</pub-id><pub-id pub-id-type="pmcid">PMC369467</pub-id></element-citation></ref><ref id="B90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hair</surname><given-names>PS</given-names></name><etal>et al</etal></person-group><article-title>Human astrovirus coat protein binds C1q and MBL and inhibits the classical and lectin pathways of complement activation</article-title><source>Mol Immunol</source><year>2010</year><volume>47</volume><issue>4</issue><fpage>792</fpage><lpage>798</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2009.10.006</pub-id><pub-id pub-id-type="pmid">19896716</pub-id></element-citation></ref><ref id="B91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonaparte</surname><given-names>RS</given-names></name><etal>et al</etal></person-group><article-title>Human astrovirus coat protein inhibits serum complement activation via C1, the first component of the classical pathway</article-title><source>J Virol</source><year>2008</year><volume>82</volume><issue>2</issue><fpage>817</fpage><lpage>827</lpage><pub-id pub-id-type="doi">10.1128/JVI.01847-07</pub-id><pub-id pub-id-type="pmid">17959658</pub-id><pub-id pub-id-type="pmcid">PMC2224607</pub-id></element-citation></ref><ref id="B92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hodgson</surname><given-names>HJ</given-names></name><etal>et al</etal></person-group><article-title>C3 metabolism in ulcerative colitis and Crohn&#8217;s disease</article-title><source>Clin Exp Immunol</source><year>1977</year><volume>28</volume><issue>3</issue><fpage>490</fpage><lpage>495</lpage><pub-id pub-id-type="pmid">891024</pub-id><pub-id pub-id-type="pmcid">PMC1541002</pub-id></element-citation></ref><ref id="B93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Potter</surname><given-names>BJ</given-names></name><etal>et al</etal></person-group><article-title>Clq metabolism in ulcerative colitis and Crohn&#8217;s disease</article-title><source>Gut</source><year>1979</year><volume>20</volume><issue>11</issue><fpage>1012</fpage><lpage>1019</lpage><pub-id pub-id-type="doi">10.1136/gut.20.11.1012</pub-id><pub-id pub-id-type="pmid">527870</pub-id><pub-id pub-id-type="pmcid">PMC1412679</pub-id></element-citation></ref><ref id="B94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hodgson</surname><given-names>HJ</given-names></name><etal>et al</etal></person-group><article-title>Humoral immune system in inflammatory bowel disease: I. Complement levels</article-title><source>Gut</source><year>1977</year><volume>18</volume><issue>9</issue><fpage>749</fpage><lpage>753</lpage><pub-id pub-id-type="doi">10.1136/gut.18.9.749</pub-id><pub-id pub-id-type="pmid">604196</pub-id><pub-id pub-id-type="pmcid">PMC1411653</pub-id></element-citation></ref><ref id="B95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ward</surname><given-names>M</given-names></name><name name-style="western"><surname>Eastwood</surname><given-names>MA</given-names></name></person-group><article-title>Serum C3 and C4 complement components in ulcerative colitis and Crohn&#8217;s disease</article-title><source>Digestion</source><year>1975</year><volume>13</volume><issue>1-2</issue><fpage>100</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1159/000197698</pub-id><pub-id pub-id-type="pmid">1201816</pub-id></element-citation></ref><ref id="B96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halstensen</surname><given-names>TS</given-names></name><etal>et al</etal></person-group><article-title>Epithelial deposition of immunoglobulin G1 and activated complement (C3b and terminal complement complex) in ulcerative colitis</article-title><source>Gastroenterology</source><year>1990</year><volume>98</volume><issue>5 pt 1</issue><fpage>1264</fpage><lpage>1271</lpage><pub-id pub-id-type="doi">10.1016/0016-5085(90)90343-Y</pub-id><pub-id pub-id-type="pmid">1691118</pub-id></element-citation></ref><ref id="B97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halstensen</surname><given-names>TS</given-names></name><etal>et al</etal></person-group><article-title>Surface epithelium related activation of complement differs in Crohn&#8217;s disease and ulcerative colitis</article-title><source>Gut</source><year>1992</year><volume>33</volume><issue>7</issue><fpage>902</fpage><lpage>908</lpage><pub-id pub-id-type="doi">10.1136/gut.33.7.902</pub-id><pub-id pub-id-type="pmid">1379568</pub-id><pub-id pub-id-type="pmcid">PMC1379402</pub-id></element-citation></ref><ref id="B98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laufer</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Cellular localization of complement C3 and C4 transcripts in intestinal specimens from patients with Crohn&#8217;s disease</article-title><source>Clin Exp Immunol</source><year>2001</year><volume>120</volume><issue>1</issue><fpage>30</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2249.2000.01168.x</pub-id><pub-id pub-id-type="pmid">10759760</pub-id><pub-id pub-id-type="pmcid">PMC1905612</pub-id></element-citation></ref><ref id="B99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cadinu</surname><given-names>P</given-names></name><etal>et al</etal></person-group><article-title>Charting the cellular biogeography in colitis reveals fibroblast trajectories and coordinated spatial remodeling</article-title><source>Cell</source><year>2024</year><volume>187</volume><issue>8</issue><fpage>2010</fpage><lpage>2028</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2024.03.013</pub-id><pub-id pub-id-type="pmid">38569542</pub-id><pub-id pub-id-type="pmcid">PMC11017707</pub-id></element-citation></ref><ref id="B100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haneishi</surname><given-names>Y</given-names></name><etal>et al</etal></person-group><article-title>Inflammatory bowel diseases and gut microbiota</article-title><source>Int J Mol Sci</source><year>2023</year><volume>24</volume><issue>4</issue><elocation-id>3817</elocation-id><pub-id pub-id-type="doi">10.3390/ijms24043817</pub-id><pub-id pub-id-type="pmid">36835245</pub-id><pub-id pub-id-type="pmcid">PMC9958622</pub-id></element-citation></ref><ref id="B101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>P</given-names></name><etal>et al</etal></person-group><article-title>The gut microbiota in inflammatory bowel disease</article-title><source>Front Cell Infect Microbiol</source><year>2022</year><volume>12</volume><elocation-id>733992</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2022.733992</pub-id><pub-id pub-id-type="pmid">35273921</pub-id><pub-id pub-id-type="pmcid">PMC8902753</pub-id></element-citation></ref><ref id="B102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bray</surname><given-names>F</given-names></name><etal>et al</etal></person-group><article-title>Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><year>2024</year><volume>74</volume><issue>3</issue><fpage>229</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.3322/caac.21834</pub-id><pub-id pub-id-type="pmid">38572751</pub-id></element-citation></ref><ref id="B103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bao</surname><given-names>D</given-names></name><etal>et al</etal></person-group><article-title>Integrative analysis of complement system to prognosis and immune infiltrating in colon cancer and gastric cancer</article-title><source>Front Oncol</source><year>2021</year><volume>10</volume><elocation-id>553297</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2020.553297</pub-id><pub-id pub-id-type="pmid">33614473</pub-id><pub-id pub-id-type="pmcid">PMC7886994</pub-id></element-citation></ref><ref id="B104"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ytting</surname><given-names>H</given-names></name><etal>et al</etal></person-group><article-title>Increased activity of the mannan-binding lectin complement activation pathway in patients with colorectal cancer</article-title><source>Scand J Gastroenterol</source><year>2004</year><volume>39</volume><issue>7</issue><fpage>674</fpage><lpage>679</lpage><pub-id pub-id-type="doi">10.1080/00365520410005603</pub-id><pub-id pub-id-type="pmid">15370690</pub-id></element-citation></ref><ref id="B105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mehrabani</surname><given-names>D</given-names></name><etal>et al</etal></person-group><article-title>Clinical significance of serum vascular endothelial growth factor and complement 3a levels in patients with colorectal cancer in southern Iran</article-title><source>Asian Pac J Cancer Prev</source><year>2014</year><volume>15</volume><issue>22</issue><fpage>9713</fpage><lpage>9717</lpage><pub-id pub-id-type="doi">10.7314/APJCP.2014.15.22.9713</pub-id><pub-id pub-id-type="pmid">25520093</pub-id></element-citation></ref><ref id="B106"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Habermann</surname><given-names>JK</given-names></name><etal>et al</etal></person-group><article-title>Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors</article-title><source>Gastroenterology</source><year>2006</year><volume>131</volume><issue>4</issue><fpage>1020</fpage><lpage>1029</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2006.07.011</pub-id><pub-id pub-id-type="pmid">17030172</pub-id><pub-id pub-id-type="pmcid">PMC2532535</pub-id></element-citation></ref><ref id="B107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>X-L</given-names></name><etal>et al</etal></person-group><article-title>Association of complement components with risk of colorectal cancer: A systematic review and meta-analysis</article-title><source>World J Gastrointest Oncol</source><year>2024</year><volume>16</volume><issue>5</issue><fpage>2168</fpage><lpage>2180</lpage><pub-id pub-id-type="doi">10.4251/wjgo.v16.i5.2168</pub-id><pub-id pub-id-type="pmid">38764810</pub-id><pub-id pub-id-type="pmcid">PMC11099464</pub-id></element-citation></ref><ref id="B108"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krieg</surname><given-names>C</given-names></name><etal>et al</etal></person-group><article-title>Complement downregulation promotes an inflammatory signature that renders colorectal cancer susceptible to immunotherapy</article-title><source>J Immunother Cancer</source><year>2022</year><volume>10</volume><issue>9</issue><elocation-id>e004717</elocation-id><pub-id pub-id-type="doi">10.1136/jitc-2022-004717</pub-id><pub-id pub-id-type="pmid">36137652</pub-id><pub-id pub-id-type="pmcid">PMC9511657</pub-id></element-citation></ref><ref id="B109"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Urbiola-Salvador</surname><given-names>V</given-names></name><etal>et al</etal></person-group><article-title>Mass spectrometry proteomics characterization of plasma biomarkers for colorectal cancer associated with inflammation</article-title><source>Biomark Insights</source><year>2024</year><volume>19</volume><elocation-id>11772719241257739</elocation-id><pub-id pub-id-type="doi">10.1177/11772719241257739</pub-id><pub-id pub-id-type="pmid">38911905</pub-id><pub-id pub-id-type="pmcid">PMC11191626</pub-id></element-citation></ref><ref id="B110"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>D</given-names></name><etal>et al</etal></person-group><article-title>C5aR1 promotes the progression of colorectal cancer by EMT and activating Wnt/&#946;-catenin pathway</article-title><source>Clin Transl Oncol</source><year>2022</year><volume>25</volume><issue>2</issue><fpage>440</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1007/s12094-022-02956-y</pub-id><pub-id pub-id-type="pmid">36192575</pub-id><pub-id pub-id-type="pmcid">PMC9873742</pub-id></element-citation></ref><ref id="B111"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><etal>et al</etal></person-group><article-title>Platelets promote CRC by activating the C5a/C5aR1 axis via PSGL-1/JNK/STAT1 signaling in tumor-associated macrophages</article-title><source>Theranostics</source><year>2023</year><volume>13</volume><issue>6</issue><fpage>2040</fpage><lpage>2056</lpage><pub-id pub-id-type="doi">10.7150/thno.80555</pub-id><pub-id pub-id-type="pmid">37064877</pub-id><pub-id pub-id-type="pmcid">PMC10091882</pub-id></element-citation></ref><ref id="B112"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>P</given-names></name><etal>et al</etal></person-group><article-title>C5aR1 is a master regulator in colorectal tumorigenesis via immune modulation</article-title><source>Theranostics</source><year>2020</year><volume>10</volume><issue>19</issue><fpage>8619</fpage><lpage>8632</lpage><pub-id pub-id-type="doi">10.7150/thno.45058</pub-id><pub-id pub-id-type="pmid">32754267</pub-id><pub-id pub-id-type="pmcid">PMC7392014</pub-id></element-citation></ref><ref id="B113"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>P</given-names></name><etal>et al</etal></person-group><article-title>Intracellular complement C5a/C5aR1 stabilizes &#946;-catenin to promote colorectal tumorigenesis</article-title><source>Cell Rep</source><year>2022</year><volume>39</volume><issue>9</issue><elocation-id>110851</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2022.110851</pub-id><pub-id pub-id-type="pmid">35649359</pub-id></element-citation></ref><ref id="B114"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piao</surname><given-names>C</given-names></name><etal>et al</etal></person-group><article-title>Complement 5a enhances hepatic metastases of colon cancer via monocyte chemoattractant protein-1-mediated inflammatory cell infiltration</article-title><source>J Biol Chem</source><year>2015</year><volume>290</volume><issue>17</issue><fpage>10667</fpage><lpage>10676</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.612622</pub-id><pub-id pub-id-type="pmid">25739439</pub-id><pub-id pub-id-type="pmcid">PMC4409234</pub-id></element-citation></ref><ref id="B115"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><etal>et al</etal></person-group><article-title>New insights into the role of complement system in colorectal cancer (Review)</article-title><source>Mol Med Rep</source><year>2025</year><volume>31</volume><issue>3</issue><elocation-id>68</elocation-id><pub-id pub-id-type="doi">10.3892/mmr.2025.13433</pub-id><pub-id pub-id-type="pmid">39791217</pub-id><pub-id pub-id-type="pmcid">PMC11751662</pub-id></element-citation></ref><ref id="B116"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>CC</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name></person-group><article-title>Gut microbiota in colorectal cancer development and therapy</article-title><source>Nat Rev Clin Oncol</source><year>2023</year><volume>20</volume><issue>7</issue><fpage>429</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1038/s41571-023-00766-x</pub-id><pub-id pub-id-type="pmid">37169888</pub-id></element-citation></ref><ref id="B117"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>AM</given-names></name><etal>et al</etal></person-group><article-title>Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation</article-title><source>Nat Med</source><year>2019</year><volume>25</volume><issue>4</issue><fpage>667</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1038/s41591-019-0405-7</pub-id><pub-id pub-id-type="pmid">30936548</pub-id><pub-id pub-id-type="pmcid">PMC9533319</pub-id></element-citation></ref><ref id="B118"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wirbel</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer</article-title><source>Nat Med</source><year>2019</year><volume>25</volume><issue>4</issue><fpage>679</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1038/s41591-019-0406-6</pub-id><pub-id pub-id-type="pmid">30936547</pub-id><pub-id pub-id-type="pmcid">PMC7984229</pub-id></element-citation></ref><ref id="B119"><label>119</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fishelson</surname><given-names>Z</given-names></name><name name-style="western"><surname>Kirschfink</surname><given-names>M</given-names></name></person-group><article-title>Complement C5b-9 and cancer: mechanisms of cell damage, cancer counteractions, and approaches for intervention</article-title><source>Front Immunol</source><year>2019</year><volume>10</volume><elocation-id>752</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.00752</pub-id><pub-id pub-id-type="pmid">31024572</pub-id><pub-id pub-id-type="pmcid">PMC6467965</pub-id></element-citation></ref><ref id="B120"><label>120</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>The genetic and epigenetic regulation of <italic toggle="yes">CD55</italic> and its pathway analysis in colon cancer</article-title><source>Front Immunol</source><year>2023</year><volume>13</volume><elocation-id>947136</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.947136</pub-id><pub-id pub-id-type="pmid">36741376</pub-id><pub-id pub-id-type="pmcid">PMC9889927</pub-id></element-citation></ref><ref id="B121"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>G</given-names></name><etal>et al</etal></person-group><article-title>Knockdown of membrane-bound complement regulatory proteins suppresses colon cancer growth in mice through inducing tumor cell apoptosis</article-title><source>Int Immunopharmacol</source><year>2023</year><volume>114</volume><elocation-id>109450</elocation-id><pub-id pub-id-type="doi">10.1016/j.intimp.2022.109450</pub-id><pub-id pub-id-type="pmid">36446233</pub-id></element-citation></ref><ref id="B122"><label>122</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dho</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>A novel therapeutic anti-CD55 monoclonal antibody inhibits the proliferation and metastasis of colorectal cancer cells</article-title><source>Oncol Rep</source><year>2019</year><volume>42</volume><issue>6</issue><fpage>2686</fpage><lpage>2693</lpage><pub-id pub-id-type="doi">10.3892/or.2019.7337</pub-id><pub-id pub-id-type="pmid">31578581</pub-id></element-citation></ref><ref id="B123"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watson</surname><given-names>NFS</given-names></name><etal>et al</etal></person-group><article-title>Expression of the membrane complement regulatory protein CD59 (protectin) is associated with reduced survival in colorectal cancer patients</article-title><source>Cancer Immunol Immunother</source><year>2006</year><volume>55</volume><issue>8</issue><fpage>973</fpage><lpage>980</lpage><pub-id pub-id-type="doi">10.1007/s00262-005-0055-0</pub-id><pub-id pub-id-type="pmid">16151805</pub-id><pub-id pub-id-type="pmcid">PMC11030621</pub-id></element-citation></ref><ref id="B124"><label>124</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>Y-J</given-names></name><etal>et al</etal></person-group><article-title>Complement factor I knockdown inhibits colon cancer development by affecting Wnt/&#946;-catenin/c-Myc signaling pathway and glycolysis</article-title><source>World J Gastrointest Oncol</source><year>2024</year><volume>16</volume><issue>6</issue><fpage>2646</fpage><lpage>2662</lpage><pub-id pub-id-type="doi">10.4251/wjgo.v16.i6.2646</pub-id><pub-id pub-id-type="pmid">38994157</pub-id><pub-id pub-id-type="pmcid">PMC11236223</pub-id></element-citation></ref><ref id="B125"><label>125</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilczek</surname><given-names>E</given-names></name><etal>et al</etal></person-group><article-title>The possible role of factor H in colon cancer resistance to complement attack</article-title><source>Int J Cancer</source><year>2008</year><volume>122</volume><issue>9</issue><fpage>2030</fpage><lpage>2037</lpage><pub-id pub-id-type="doi">10.1002/ijc.23238</pub-id><pub-id pub-id-type="pmid">18183578</pub-id></element-citation></ref></ref-list><notes notes-type="version-changes"><sec sec-type="version-changes"><label>Version 1</label><title>10/01/2025</title><p>Electronic publication</p></sec></notes></back><floats-group><fig position="float" id="F1" orientation="portrait"><label>Figure 1</label><caption><title>Unique adaptations of the intestinal complement system compared with the systemic complement system.</title><p>(<bold>A</bold>) Gut-specific complement expression profile. Complement components involved in the three major activation pathways &#8212; classical, lectin, and alternative pathways &#8212; are depicted, each converging on C3 activation and leading to effector functions, including opsonization, inflammation, and membrane attack complex (MAC) formation, as in the systemic complement system. However, the intestinal complement system exhibits a locally adapted, restricted expression profile. Indicated expression levels reflect transcriptomic data from the intestine under homeostatic conditions (<xref rid="B16" ref-type="bibr">16</xref>): green (three dots) indicates high expression (&gt;100 reads/million), orange (two dots) denotes moderate expression (10&#8211;100 reads/million), and red (one dot) represents low expression (&lt;10 reads/million). Intestinal cell types responsible for producing these components are shown in pink rectangles (e.g., stromal cells, myeloid cells, and epithelial cells). (<bold>B</bold>) Systemic complement function. The liver is the primary source of circulating complement proteins. In the sterile environment of the bloodstream, these proteins support immune defense through opsonization, recruitment of immune cells, phagocytosis, and direct pathogen killing via MAC-mediated lysis. (<bold>C</bold>) Gut complement function during homeostasis and infection. Under homeostatic conditions (left), C3 is primarily expressed by stromal, myeloid, and epithelial cells in the intestine. Due to limited phagocyte presence and the absence of MAC, this locally produced C3 does not eliminate commensal microbiota. During enteric infection (right), pathogen exposure enhances complement activation, C3 deposition, and promotes neutrophil recruitment and phagocytosis, thereby supporting pathogen clearance.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jci-135-188349-g093.jpg"/></fig><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3</label><caption><title>Expression of complement regulatory proteins in the gut</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jci-135-188349-g096.jpg"/></table-wrap><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><title>Expression of complement receptors in the gut</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jci-135-188349-g095.jpg"/></table-wrap><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><title>Expression of complement components in the gut</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jci-135-188349-g094.jpg"/></table-wrap></floats-group></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Theranostics</journal-id><journal-id journal-id-type="iso-abbrev">Theranostics</journal-id><journal-id journal-id-type="pmc-domain-id">1512</journal-id><journal-id journal-id-type="pmc-domain">theranostics</journal-id><journal-id journal-id-type="publisher-id">thno</journal-id><journal-title-group><journal-title>Theranostics</journal-title></journal-title-group><issn pub-type="epub">1838-7640</issn><publisher><publisher-name>Ivyspring International Publisher</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12486161</article-id><article-id pub-id-type="pmcid-ver">PMC12486161.1</article-id><article-id pub-id-type="pmcaid">12486161</article-id><article-id pub-id-type="pmcaiid">12486161</article-id><article-id pub-id-type="pmid">41041049</article-id><article-id pub-id-type="doi">10.7150/thno.112661</article-id><article-id pub-id-type="publisher-id">thnov15p9415</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>Alisol A ameliorates vascular cognitive impairment via AMPK/NAMPT/SIRT1-mediated regulation of cholesterol and autophagy</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Xu</surname><given-names initials="P">Ping</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref><xref rid="FNA_number" ref-type="author-notes">#</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhou</surname><given-names initials="W">Wen</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref><xref rid="FNA_number" ref-type="author-notes">#</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="S">Shida</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="L">Linjiao</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bai</surname><given-names initials="Y">Yu</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xing</surname><given-names initials="S">Shan</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xue</surname><given-names initials="W">Wenda</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="M">Meng</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shi</surname><given-names initials="J">Jun</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wu</surname><given-names initials="H">Haoxin</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref><xref rid="FNA_envelop" ref-type="corresp">&#9993;</xref></contrib></contrib-group><aff id="A1"><label>1</label>Nanjing University of Chinese Medicine, Nanjing 210023, Jiangsu, P. R. China.</aff><aff id="A2"><label>2</label>Key Laboratory of Integrative Biomedicine for Brain Diseases, School of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, P. R. China.</aff><aff id="A3"><label>3</label>Union laboratory of Traditional Chinese medicine for brain science and gerontology, Nanjing University of Chinese Medicine, Nanjing, 210023, P. R. China.</aff><author-notes><corresp id="FNA_envelop">&#9993; Corresponding author: College of Traditional Chinese Medicine, Nanjing University of Chinese Medicine, No. 138 Xianlin Road, Nanjing, 210023, China. E-mail addresses: <email>HaoxinWu@njucm.edu.cn</email> (H. Wu).</corresp><fn fn-type="equal" id="FNA_number"><p><sup>#</sup> These authors contributed equally to this work.</p></fn><fn fn-type="COI-statement"><p>Competing Interests: The authors have declared that no competing interest exists.</p></fn></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>22</day><month>8</month><year>2025</year></pub-date><volume>15</volume><issue>18</issue><issue-id pub-id-type="pmc-issue-id">498071</issue-id><fpage>9415</fpage><lpage>9446</lpage><history><date date-type="received"><day>22</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>3</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>22</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>02</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-03 09:25:16.947"><day>03</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The author(s)</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>). See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://ivyspring.com/terms">https://ivyspring.com/terms</ext-link> for full terms and conditions.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="thnov15p9415.pdf"/><abstract><p>Atherosclerosis-related vascular cognitive impairment (VCI) is associated with dysregulated cholesterol metabolism and impaired autophagy. Alisol A, a natural tetracyclic triterpenoid derived from the traditional ZeXieYin Formula, has demonstrated anti-atherosclerotic and neuroprotective effects. However, its role in modulating brain cholesterol homeostasis and mitophagy in VCI remains largely unexplored.</p><p><bold>Methods:</bold> To elucidate the mechanism of Alisol A and evaluate its translational relevance, we employed an <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mouse model of VCI induced by a high-fat diet and left common carotid artery ligation. Alisol A was administered intragastrically, and cognitive function was assessed using the Morris water maze, Y-maze, and novel object recognition tests. To probe the role of NAMPT, pharmacological inhibition and lentiviral overexpression strategies were applied. Mechanistic investigations included Western blotting, immunofluorescence, and transmission electron microscopy to examine cholesterol metabolism, oxidative stress, mitophagy, and synaptic plasticity. Additionally, molecular docking, surface plasmon resonance, and lipidomic profiling were used to explore Alisol A-NAMPT binding and downstream regulatory pathways.</p><p><bold>Results:</bold> Alisol A significantly ameliorated cognitive impairment in <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice. Mechanistically, it restored cholesterol homeostasis by activating the AMPK/NAMPT/SIRT1 signaling axis, upregulated UCP2 to suppress oxidative stress, and inhibited glial activation, thereby preserving neuronal structure and function. Additionally, Alisol A reactivated mitophagic flux by enhancing PINK1/PARKIN signaling and facilitating the clearance of damaged mitochondria, ultimately improving mitochondrial function. NAMPT was identified as a key molecular target mediating these neuroprotective effects.</p><p><bold>Conclusion:</bold> Alisol A confers neuroprotection in VCI by regulating cholesterol metabolism, attenuating oxidative stress, and restoring mitophagy via NAMPT-mediated signaling. These findings highlight its therapeutic potential in atherosclerosis-related cognitive decline.</p></abstract><kwd-group><kwd>Alisol A</kwd><kwd>atherosclerosis-related vascular cognitive impairment</kwd><kwd>brain cholesterol homeostasis</kwd><kwd>autophagy</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Atherosclerosis (AS) is the most common form of cardiovascular and cerebrovascular disease. Its principal pathogenic mechanisms are lipid accumulation and large-artery inflammation, which ultimately give rise to clinical complications such as myocardial infarction, stroke, and cognitive impairment. Vascular cognitive impairment (VCI) encompasses the full spectrum of cognitive decline resulting from cerebrovascular pathology including cerebral infarction, hemorrhage, small-vessel disease, or chronic cerebral hypoperfusion ranging from mild subjective cognitive complaints or mild VCI to severe deficits that meet diagnostic criteria for vascular dementia (VaD) <xref rid="B1" ref-type="bibr">1</xref>. In VCI, patients exhibit only subtle declines in executive function or memory, with daily living abilities largely preserved; impairments are detected only on neuropsychological testing. By contrast, VaD arises from multiple or extensive vascular lesions, causing significant deficits across several cognitive domains and markedly impairing independent living and social function. These deficits meet the DSM-5 criteria for &#8220;major neurocognitive disorder&#8221; or the ICD-11 criteria for &#8220;dementia&#8221; <xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>. Atherosclerosis is significantly and independently associated with cognitive decline, including impairments in memory, executive function, and language. Notably, this association remains robust even after adjusting for traditional vascular risk factors such as hypertension and diabetes, suggesting that its underlying pathological mechanisms may extend beyond conventional vascular risk scores <xref rid="B4" ref-type="bibr">4</xref>. Dyslipidemia first promotes atherosclerosis, leading to stenosis and plaque formation in large and medium-sized arteries. Plaque rupture or arterial narrowing then induces downstream small-artery (penetrating artery) pathology, which progresses to cerebral small-vessel disease. Ultimately, the combined effects of large-vessel damage and small-vessel pathology result in vascular cognitive impairment. Specifically, dyslipidemia promotes lipid accumulation in large and medium-sized arterial walls by increasing circulating low-density lipoprotein (LDL) and oxidized low-density lipoprotein (ox-LDL) <xref rid="B5" ref-type="bibr">5</xref>. ox-LDL activates macrophage scavenger receptors, induces monocyte infiltration, and promotes foam cell formation, ultimately contributing to the development of atherosclerotic plaques in the carotid and cerebral arteries <xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>. These plaques may cause luminal narrowing or detach as unstable plaques, leading to cortical infarction <xref rid="B8" ref-type="bibr">8</xref>. In addition, plaques can extend to the origins of perforating arteries, where they cause localized occlusion or hypoperfusion. This initiates downstream arteriolar hyalinosis and chronic hypoperfusion, manifesting as lacunar infarctions and white matter hyperintensities, which are indicative of cerebral small vessel disease (CSVD) <xref rid="B7" ref-type="bibr">7</xref>. AS and CSVD act synergistically at the pathological level: large-artery stenosis exacerbates cortical ischemia, while small-vessel lesions chronically impair white matter integrity, disrupt neurovascular coupling, and compromise blood brain barrier (BBB) function <xref rid="B9" ref-type="bibr">9</xref>. These pathologies characterized by white matter rarefaction, microbleeds, and accumulation of lacunes collectively form the neuropathological basis of VCI. From a pathophysiological perspective, this process represents a cascade of multisystemic injury. It is initiated by lipid deposition and inflammatory activation that lead to vascular endothelial dysfunction. Subsequently, ox-LDL stimulates monocyte infiltration and foam cell formation through activation of scavenger receptors, resulting in plaque development and arterial lumen narrowing <xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B9" ref-type="bibr">9</xref>. This narrowing impairs both cortical and deep cerebral perfusion, causing chronic hypoperfusion. Arteriolar hyalinosis and basement membrane thickening further compromise microcirculatory function. The combined effects of neuronal hypoperfusion and increased BBB permeability ultimately disrupt the neurovascular unit. Neuroimaging studies have also confirmed that patients with atherosclerosis frequently exhibit white matter rarefaction, lacunar infarctions, and cerebral microbleeds. Among these, reduced integrity of white matter tracts is strongly correlated with deficits in executive function. Epidemiological studies indicate that VaD accounts for at least 20% of all dementia cases <xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>. Since VaD is the only form of dementia in which cognitive decline can be halted or reversed, investigating the pathophysiological mechanisms and therapeutic strategies for VCI is of great clinical importance and societal value.</p><p>In the nervous system, cholesterol is not only a fundamental structural component of neuronal membranes, contributing to membrane fluidity and stability, but also plays a critical role in neurotransmitter synthesis, synapse formation, maintenance, and signal transmission <xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>. Numerous epidemiological studies have established that elevated low-density lipoprotein cholesterol (LDL-c) levels are associated with an increased risk of cognitive impairment <xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>. A large cohort study by Iwagami et al, involving over 1.8 million participants, reported that midlife LDL-c levels were associated with a higher incidence of dementia more than a decade later <xref rid="B16" ref-type="bibr">16</xref>. Additional evidence from the Atherosclerosis Risk in Communities (ARIC) study suggested that individuals with LDL-c below 100 mg/dL experienced slower cognitive decline over 20 years <xref rid="B17" ref-type="bibr">17</xref>. In hypercholesterolemia, excessive cholesterol triggers NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome activation and microglial-mediated neuroinflammation <xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>, leading to amyloid-&#946; (A&#946;) accumulation, oxidative stress <xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B21" ref-type="bibr">21</xref>, and neuronal pyroptosis <xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>. Additionally, cholesterol imbalance alters the crosstalk between astrocytes and neurons, further amplifying the inflammatory response <xref rid="B24" ref-type="bibr">24</xref>. Elevated cholesterol levels have been shown to enhance acetylcholinesterase activity, resulting in reduced acetylcholine availability and impaired synaptic transmission and cognitive processing <xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B26" ref-type="bibr">26</xref>. Cholesterol dysregulation serves as a critical molecular link between atherosclerosis and cognitive impairment <xref rid="B27" ref-type="bibr">27</xref>. Increased circulating total cholesterol and low-density lipoprotein cholesterol accelerate atherosclerotic plaque formation, while their metabolic byproducts, such as oxysterols, can cross the BBB and disturb cerebral cholesterol homeostasis via activation of liver X receptor (LXR) signaling <xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B29" ref-type="bibr">29</xref>. In ApoE&#949;4 carriers, astrocytes exhibit a tendency toward abnormal lipid accumulation, which compromises A&#946; clearance efficiency <xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>. Animal studies have demonstrated that a high-cholesterol diet enhances hippocampal A&#946;&#8324;&#8322; deposition and downregulates synaptophysin expression in APP/PS1 transgenic mice, suggesting that disrupted lipid metabolism may directly impair synaptic integrity through the promotion of A&#946; aggregation <xref rid="B32" ref-type="bibr">32</xref>-<xref rid="B34" ref-type="bibr">34</xref>.</p><p>Mitophagy is crucial for maintaining mitochondrial homeostasis by selectively degrading damaged mitochondria <xref rid="B35" ref-type="bibr">35</xref> to regulate mitochondrial number in response to metabolic demands <xref rid="B36" ref-type="bibr">36</xref>. Notably, mitophagy is pivotal for neuronal function and survival by sustaining a healthy mitochondrial, thus preventing neuronal death <xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B38" ref-type="bibr">38</xref>. Enhancing mitophagy can help with neurological issues <xref rid="B39" ref-type="bibr">39</xref>, and an autophagy inducer has been shown to protect the brains of mice <xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B41" ref-type="bibr">41</xref>. Improving mitochondrial dysfunction can improve cognitive deficits through the PINK1 pathway <xref rid="B42" ref-type="bibr">42</xref>. In parallel, autophagy has gained attention for its role in lipid turnover and mitochondrial quality control <xref rid="B38" ref-type="bibr">38</xref>. While not unique to AS-related VCI, dysregulated autophagy-particularly mitophagy-may exacerbate neuronal dysfunction in cholesterol-induced brain injury <xref rid="B43" ref-type="bibr">43</xref>, <xref rid="B44" ref-type="bibr">44</xref>. Moreover, studies have shown that autophagy facilitates cholesterol clearance in microglia and macrophages <xref rid="B45" ref-type="bibr">45</xref>, whereas its inhibition leads to lipid accumulation and foam cell formation <xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B47" ref-type="bibr">47</xref>. These findings underscore autophagy's role as a potential therapeutic target in AS-related VCI <xref rid="B47" ref-type="bibr">47</xref>, <xref rid="B48" ref-type="bibr">48</xref>. In this context, previous research has demonstrated that Alisol A can induce autophagy in a dose-dependent manner <xref rid="B49" ref-type="bibr">49</xref>-<xref rid="B51" ref-type="bibr">51</xref>. Thus, modulation of autophagy has emerged as a potential therapeutic mechanism underlying the protective effects of Alisol A against AS-related VCI.</p><p>The AMP-activated protein kinase (AMPK)/nicotinamide phosphoribosyltransferase (NAMPT)/sirtuin 1 (SIRT1) axis plays a critical role in regulating key pathways associated with cellular aging, energy metabolism, and neuroprotection <xref rid="B52" ref-type="bibr">52</xref>. Disruption of this axis impairs autophagy and exacerbates metabolic stress <xref rid="B53" ref-type="bibr">53</xref>, <xref rid="B54" ref-type="bibr">54</xref>. Notably, under hyperlipidemic conditions, disturbances in lipid metabolism can inhibit the activity of AMPK/NAMPT/SIRT1 signaling <xref rid="B55" ref-type="bibr">55</xref>, leading to reduced autophagic flux. NAMPT plays a critical role in cellular energy homeostasis and mitophagy by regulating NAD&#8314; biosynthesis, which is essential for the activation of sirt1, a key deacetylase involved in mitochondrial function and metabolic regulation <xref rid="B56" ref-type="bibr">56</xref>. As an upstream energy sensor, AMPK initiates energy-stress responses, while NAMPT serves as a rate-limiting enzyme in NAD&#8314; regeneration and provides essential metabolic support for AMPK-dependent activation of sirt1. Studies in animal models have revealed that <italic toggle="yes">Nampt</italic> deficiency in neurons leads to hippocampal dysfunction and memory loss <xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B58" ref-type="bibr">58</xref>. Supplementation with nicotinamide mononucleotide (NMN), a NAMPT-related NAD&#8314; precursor, enhances cerebrovascular function and reduces A&#946; burden in the brain <xref rid="B59" ref-type="bibr">59</xref>. These findings highlight NAMPT as a promising molecular target in AS-related VCI <xref rid="B60" ref-type="bibr">60</xref>. In the context of AS-related VCI, dysregulation of the AMPK/NAMPT/SIRT1 signaling pathway may impair mitophagy, thereby exacerbating cognitive decline. Therefore, investigating the role of Alisol A in modulating the AMPK/NAMPT/SIRT1 pathway and mitophagy may offer novel mechanistic insights and therapeutic potential for the treatment of AS-related VCI.</p><p>ZeXieYin Formula, a classical prescription in traditional Chinese medicine (TCM), has been widely applied in clinical settings for centuries. The herbs included in this formula are rich in bioactive compounds with known metabolic regulatory, anti-inflammatory, and antioxidant properties. In our previous studies, ZeXieYin Formula demonstrated significant therapeutic effects on cognitive impairment induced by high-fat diet related atherosclerosis, with the following key findings: (1) ZeXieYin Formula alleviated neuroinflammation and reduced A&#946; deposition by modulating the MAPK/NF-&#954;B signaling pathway in the hippocampus, thereby enhancing synaptic plasticity and improving cognitive function <xref rid="B61" ref-type="bibr">61</xref>; (2) It promoted hippocampal neurogenesis and synaptic plasticity through regulation of the CaMKII-AMPA receptor pathway, thereby improving cognitive performance in an Alzheimer's disease mouse model <xref rid="B62" ref-type="bibr">62</xref>; (3) The decoction also counteracted the synaptic damage pathway mediated by the gut microbial metabolite trimethylamine N-oxide (TMAO), alleviating its negative impact on neuronal plasticity and enhancing learning and memory capacity <xref rid="B63" ref-type="bibr">63</xref>. From a formula-based perspective, the individual herbs in ZeXieYin Formula possess notable neuroprotective potential. For example, Pyrola calliantha (Lu Xian Cao) has been shown to suppress the release of proinflammatory cytokines, mitigate glial cell mediated neurotoxicity, promote neurogenesis, and enhance the expression of synaptic proteins beneficial for maintaining neuronal plasticity and function <xref rid="B64" ref-type="bibr">64</xref>. In our prior work, we applied UPLC-MS/MS and other analytical techniques to establish a chemical fingerprint of the aqueous extract of ZeXieYin Formula and conducted quantitative analysis of representative compounds across multiple batches <xref rid="B65" ref-type="bibr">65</xref>, <xref rid="B66" ref-type="bibr">66</xref>. The results revealed that Alisol A, a triterpenoid compound, was consistently the most abundant bioactive constituent, with its content stable across batches and meeting the extraction quality standards specified by the Chinese Pharmacopoeia. Derived from Rhizoma Alismatis, a traditional Chinese herb with known lipid-lowering and cardioprotective effects, Alisol A has attracted attention for its potential therapeutic roles <xref rid="B67" ref-type="bibr">67</xref>-<xref rid="B77" ref-type="bibr">77</xref>. Recent pharmacological studies have shown that Alisol A can reduce lipid levels, cross the blood-brain barrier, and improve cognition in high-fat diet-induced models of brain aging <xref rid="B78" ref-type="bibr">78</xref>.</p><p>Notably, Alisol A may exert its effects through sirt1 activation, although the mechanisms remain to be fully elucidated <xref rid="B69" ref-type="bibr">69</xref>, <xref rid="B77" ref-type="bibr">77</xref>-<xref rid="B80" ref-type="bibr">80</xref>. Whether Alisol A modulates cholesterol metabolism and mitophagy via the AMPK/NAMPT/SIRT1 pathway in VCI has not been investigated <xref rid="B81" ref-type="bibr">81</xref>. Although the precise mechanisms of Alisol A remain insufficiently characterized, it has demonstrated promising effects in metabolic regulation and neuroprotection, suggesting high research value. Therefore, in this study, we selected Alisol A as a representative active component to further investigate its mechanistic role in a model of VCI. This study aims to elucidate the mechanisms by which Alisol A targets AMPK/NAMPT/SIRT1 to coordinately regulate cerebral cholesterol metabolism and PINK1/PARKIN-mediated mitophagy, thereby restoring synaptic plasticity and improving cognitive function. By uncovering these pathways, the findings provide both a novel molecular target and a mechanistic foundation for the development of therapeutic strategies against AS related VCI.</p></sec><sec sec-type="methods"><title>Materials and Methods</title><sec><title>Model building and drug intervention</title><p>Five-week-old male C57BL/6 J mice and B6/JGpt-<italic toggle="yes">Ldlr</italic><sup>em1Cd82</sup>/Gpt (<italic toggle="yes">Ldlr<sup>-/-</sup></italic>) male mice of the same age were procured from Gem Pharmatech Co., Ltd in Nanjing, China. Mice were housed in groups of three to five animals per cage under controlled environmental conditions (temperature: 22&#8239;&#177;&#8239;2&#8239;&#176;C; 12 h light/dark cycle). All mice are randomly divided into groups, with 15 mice in each group. Body weights were recorded weekly throughout the study. This study used male mice to avoid potential effects associated with the estrous cycle <xref rid="B82" ref-type="bibr">82</xref>, <xref rid="B83" ref-type="bibr">83</xref>. At 8 weeks of age, mice were subjected to left common carotid artery ligation under general anesthesia. Following induction with isoflurane (3% for induction, 1.5% for maintenance), the left common carotid artery was carefully isolated through a midline cervical incision and permanently ligated using 6-0 silk sutures <xref rid="B84" ref-type="bibr">84</xref>, <xref rid="B85" ref-type="bibr">85</xref>. After the surgery is completed, the incision is sutured, and the mouse is then returned to the cage to recover. Buprenorphine (0.1 mg/kg, subcutaneous) was administered for postoperative analgesia. Mice were healthy and housed under SPF-grade conditions. The relative humidity was 50% to 60% throughout the experiment. All animals had at least 7 days to adjust to their living conditions. <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice were continuously fed a high-fat diet containing 1.25% cholesterol and 20% fat. A high-fat diet was purchased from Jiangsu Synergetic Pharmaceutical Bioengineering Co, Ltd. The control group received standard chow and normal saline intragastrically. Behavioral tests were performed at 18 weeks of age. If mice failed to reach the criteria within the behavioral tests, they were eliminated from the study. Continue the experiment with the successfully modeled mice. The criteria for inclusion were as follows: During the spatial exploration experiment, the mouse spent less than 20 s in the target quadrant. The Y-maze task had a spontaneous alternation rate below 30%. The novel object recognition test showed a novel object recognition index under 40%.</p><p>Alisol A (19885-10-0; MedChemExpress, Shanghai, China) was administered intragastrically (i.g.) at 15 mg/kg or 30 mg/kg once daily for 2 months <xref rid="B81" ref-type="bibr">81</xref>. All animals were administered the treatment via gavage, with the control group receiving an equal volume of saline. NAMPT inhibitor: FK866 (658084-64-1, MedChemExpress, Shanghai, China) administered at a dose of 25 mg/kg once daily for 2 months via intraperitoneal injection <xref rid="B86" ref-type="bibr">86</xref>, <xref rid="B87" ref-type="bibr">87</xref>. NMN (1094-61-7, MedChemExpress, Shanghai, China, 100 mg/kg, i.g.) once daily for 2 months <xref rid="B88" ref-type="bibr">88</xref>. The experiment received approval from the Ethical Committee on Animal Experimentation at Nanjing University of Chinese Medicine.</p></sec><sec><title>Cognitive and behavioral tests</title><p>The Morris water maze (MWM) utilized an artificially partitioned pool with four quadrants and a submerged platform hidden beneath the water's surface. Following an initial day of adaptability training, mice underwent formal training for five consecutive days, culminating in a positioning navigation test on the sixth day. Subsequently, the platform was taken out, allowing mice to swim freely in the pool for 60 s. The time spent in the target quadrant was recorded for analysis.</p><p>In the Y-maze experiment, mice were subjected to a custom-made apparatus consisting of three symmetrical arms (35 cm &#215; 10 cm &#215; 20 cm), each positioned at a 120&#176; angle. During a 5 min trial, mice explored two arms of the maze while the third arm was blocked. The maze was cleaned before each trial to remove any lingering odors. Subsequent to the training trial, a single 5 min test trial was conducted, during which spontaneous alternations and arm entries were meticulously recorded. The alternation percentage was determined by dividing the number of alternations by the total number of arm entries and multiplying the result by 100%.</p><p>In the Novel Object Recognition (NOR) task, each mouse underwent a familiarization phase in which they were placed in a box and exposed to two identical objects for a duration of 5 min. To prevent the influence of olfactory cues, the objects were meticulously cleaned between trials. The subsequent day, the mouse was reintroduced to the same box, but one of the familiar objects was replaced with a novel object of distinct color and shape. The exploration time of each object was quantified using the ANY-maze video-tracking system, with a defined 2 cm<sup>2</sup> area surrounding the objects to record nose entries as indicators of object exploration.</p></sec><sec><title>Model evaluation</title><p>Hematoxylin-eosin Staining (HE): Mice were sedated with sodium pentobarbital, euthanized by cervical dislocation, and their tissues were promptly dissected on ice. Five mice from each group were randomly chosen for fixation in 4% paraformaldehyde at 4 &#176;C for 24 h. The remaining tissues were dissected on ice, snap-frozen, and stored at -80 &#176;C. The samples were embedded in paraffin and made into tissue sections. After HE staining, sections were observed under an optical microscope and photographed.</p><p>Oil Red O Staining (ORO): The tissue was frozen quickly in cutting temperature compound (OCT) compound and cut into 10 &#181;m sections. Frozen sections were applied for ORO. Counterstaining was performed using hematoxylin. Following sealing, the slices were examined using a light microscope and imaged. Plaque and vessel measurements were taken using Image J software. Plaque stenosis was determined by comparing plaque area to total vessel area, and lipid content was calculated as the percentage of ORO area in relation to total plaque area.</p><p>Serum biochemical analysis: Serum triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-c), and LDL-c levels were measured using enzymatic kits from Lei Du, Shenzhen, China, and an Automatic Biochemical Analyzer (Chemray240) as per kit instructions.</p><p>For determination of cholesterol in mouse brain tissue, a Total Cholesterol Assay Kit (A111-1-1; Nanjing Jiancheng Bioengineering Institute, Nanjing, China) was used. Brain samples were accurately weighed and homogenized in nine volumes of homogenization buffer (w/v, g: mL = 1:9) on ice using a mechanical homogenizer. Following the manufacturer's instructions, the homogenate was thoroughly mixed and then incubated at 37 &#176;C for 10 min. Absorbance was measured at 500 nm with a microplate reader.</p></sec><sec><title>Hippocampal neurons morphology and function</title><p>Transmission electron microscopy (TEM): Each hippocampal tissue was chopped into small pieces using sterile surgical blades (about 0.5-1 mm<sup>3</sup> in size). Five specimens from each group were fixed in 2.5% glutaraldehyde solution and prepared for evaluation using TEM. Ultrathin sections were made and images were captured with a Hitachi H-7500 transmission electron microscope at a magnification of 4000-8000 &#215;. The images were analyzed and measured using Image-pro plus 6.0.</p><p>Pathological examination: The brains of mice were fixed in paraformaldehyde after anesthesia and perfusion, then cut into 5 &#181;m slices for examination. Sections were then processed for Nissl Staining (NS) or immunohistochemistry (IHC). Optical microscopy was used to observe and capture images.</p><p>Immunofluorescence (IF): Sections were blocked with 3% BSA in PBS for 30 min at room temperature, then incubated with primary antibodies overnight at 4 &#176;C. After rinsing with cold PBS, secondary antibodies were applied for 1 h at room temperature. Counterstaining was done with DAPI, and images were captured and analyzed using Digital Pathology system and Viewer software.</p><p>Golgi staining: Experimental animals were injected with anesthesia, then the skin on the top of the mouse skull was cut open to carefully remove the brain. The brain was washed with saline to remove blood stains and then immersed in fixative. Use a shaking slicer for tissue sectioning, with a thickness of 100-200 &#956;m. Capture images with a panoramic digital slice scanning microscope (VS120) and subsequently conduct analysis utilizing Fiji software.</p><p>The studies used the following antibodies. Anti-GFAP antibody (GB12096, Servicebio, 1:500), anti-IBA-1 antibody (GB12105, Servicebio, 1:500). anti-PSD95 antibody (20665-1-AP, Proteintech, 1:300), anti-SYNAPSIN-1 antibody (20258-1-AP, Proteintech, 1:300), anti-UCP2 antibody (GB11377, Servicebio, 1:300), anti-CD68 antibody (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GB113109">GB113109</ext-link>, Servicebio, 1:300), anti-&#945;-SMA antibody (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GB111364">GB111364</ext-link>, Servicebio, 1:300), anti-HMGCR antibody (DF6518, Affinity, 1:200), anti-ABCA1 Polyclonal antibody (26564-1-AP, Proteintech, 1:300). anti-NAMPT/PBEF Polyclonal antibody (11776-1-AP, Proteintech, 1:300), anti-SIRT1 antibody (13161-1-AP, Proteintech, 1:300). anti-CYP46A1 Polyclonal antibody (124861-1-AP, Proteintech, 1:300). anti-OPTN antibody (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GB114324">GB114324</ext-link>, Servicebio, 1:300), anti-TOM20 antibody (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GB111481">GB111481</ext-link>, Servicebio, 1:300), anti-NMDAR2A/GRIN2A Polyclonal antibody (28525-1-AP, Proteintech, 1:300), anti-NMDA2B antibody (21920-1-AP, Proteintech, 1:300).</p></sec><sec><title>Mendelian randomization analysis</title><p>Using Mendelian randomization to explore the causal link between coronary atherosclerosis and vascular dementia. The dataset used comes from the IEU Open genome-wide association studies (GWAS) Project. The analysis was performed using the Two Sample MR package (v0.5.7) in R software (v4.3.1). Note: 'Exposure' refers to the exposure data number; 'Outcome' denotes the outcome data number; 'Method' specifies the analysis method employed; 'Q' represents the heterogeneity test Q statistic; 'Q_def' indicates the degrees of freedom associated with the Q statistic; 'Q_pval' is the p-value of the Q statistic, which assesses the statistical significance of the heterogeneity test results. A p-value less than the predetermined significance level (commonly 0.05) suggests the presence of heterogeneity within the data <xref rid="B89" ref-type="bibr">89</xref>. In the analysis of GWAS, coronary atherosclerosis (finn_b_I9_CORATHER) was considered as the exposure factor, vascular dementia (finn_b_F5_VASCDEM) is served as the outcome factors. Mendelian randomization analysis was performed utilizing various regression models, including the inverse variance weighted (IVW) method, MR Egger method, weighted median method.</p></sec><sec><title>Serum lipidomics</title><p>The collection and use of human serum samples were approved by Ethics Review Committee of Nanjing Hospital of Chinese Medicine (Ethics Review No. KY2023091). All procedures were performed in strict compliance with the Regulations of Ethical Review of Biomedical Research Involving Human Subjects, the Declaration of Helsinki, and the International Ethical Guidelines for Biomedical Research Involving Human Subjects. Inclusion criteria for clinical serum samples from patients diagnosed with hyperlipidemia are as follows: (1) Demographic parameters: Participants must be aged between 20 and 50 years, with an equal distribution of genders to ensure sample balance. (2) Medical history: Participants should have a confirmed diagnosis of atherosclerosis, while individuals with other metabolic disorders (e.g., diabetes, thyroid disease) are excluded to minimize confounding variables. (3) Biochemical Indicators: The diagnosis of hyperlipidemia is dependent on serum biochemical markers, including cholesterol and triglyceride concentrations. (4) Complications: To maintain the focus of the study and ensure the reliability of the results, individuals with severe complications, such as liver or kidney disease, are excluded. (5) Medication Use: The use of medications by patients is a critical consideration. This study will exclude individuals currently taking drugs that influence lipid metabolism, such as specific steroids or antidepressants, to prevent confounding effects on the outcomes. (6) To avoid individual differences, 4-5 samples were pooled together into one sample for analysis.</p><p>Samples were thawed on ice, and metabolites were extracted with a lipid extraction buffer. Each 20 &#956;L sample was mixed with 120 &#956;L of precooled buffer (IPA: ACN: H<sub>2</sub>O = 2:1:1), vortexed for 1 min, incubated at room temperature for 10 min, and stored overnight at -20 &#176;C. After centrifuging at 4, 000 g for 20 min, supernatants were transferred to new 96-well plates and stored at -80 &#176;C for LC-MS analysis. Pooled QC samples were prepared by combining 10 &#956;L from each extraction mixture.</p><p>Samples were processed with an LC-MS system following machine instructions. Chromatographic separations used an ACQUITY UPLC System and a Kinetex UPLC C18 column, maintained at 55 &#176;C with a 0.3 ml/min flow rate. The mobile phase comprised solvent A (60% ACN, 40% H<sub>2</sub>O, 0.1% formic acid) and solvent B (90% IPA, 10% ACN, 0.1% formic acid). Gradient elution: 0-0.4 min at 30% B; 0.4-1 min from 30% to 45% B; 1-3 min from 45% to 60% B; 3.5-5 min from 60% to 75% B; 5-7 min from 75% to 90% B; 7-8.5 min from 90% to 100% B; 8.5-8.6 min at 100% B; 8.6-8.61 min from 100% to 30% B; 8.61-10 min at 30% B.</p><p>A high-resolution TripleTOF6600 mass spectrometer (SCIEX) operated in both positive and negative ion modes with curtain gas at 30 PSI, ion source gases at 60 PSI, and an interface heater at 650 &#176;C. The Ionspray voltage was 5000 V for positive mode and -4500 V for negative mode. Data were collected in IDA mode with a TOF mass range of 60-1200 Da. Survey scans lasted 150 ms, capturing up to 12 product ion scans if they exceeded 100 counts/s and had a 1 + charge state. The cycle time was 0.56 s, using four 11 kHz time bins, monitored by a 40 GHz multichannel TDC detector with four-anode/channel detection. Dynamic exclusion lasted 4 s, and mass accuracy was calibrated every 20 samples. A pooled quality control sample was run after every 10 samples to ensure LC-MS stability.</p><p>MS data pretreatments, such as peak picking, grouping, retention time correction, and isotope/adduct annotation, were conducted with XCMS software. LC-MS raw data were converted to mzXML and processed using XCMS, CAMERA, and metaX in R, identifying ions by retention time and m/z to create a 3D matrix of peak indices, sample names, and ion intensities. Metabolites were matched to KEGG and HMDB databases within a 10 ppm mass difference, with molecular formulas confirmed by isotopic distribution and validated using an in-house fragment spectrum library.</p><p>Peak data intensity was processed with metaX, removing features found in less than 50% of QC samples or 80% of biological samples. Missing data were imputed using the k-nearest neighbor method. PCA was used to detect outliers and assess batch effects. A robust LOESS correction was applied to QC data to minimize signal drift over time, and features with over 30% relative standard deviation in QC samples were excluded.</p><p>Student t-tests identified differences in metabolite concentrations between two phenotypes, with P values adjusted for multiple comparisons using FDR. Supervised PLS-DA via metaX distinguished variables between groups, considering features with a VIP value above 1.0 as important.</p></sec><sec><title>Gene Expression Omnibus analysis</title><p>Gene Expression Omnibus (GEO) Dataset: The dataset designated as <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE100927">GSE100927</ext-link> was retrieved from the GEO database, accessible at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.ncbi.nlm.nih.gov/geo" ext-link-type="uri">http://www.ncbi.nlm.nih.gov/geo</ext-link>. Atherosclerotic lesions, along with control arteries devoid of such lesions, were procured from the carotid, femoral, and infra-popliteal arteries of deceased organ donors. Subsequently, RNA was extracted from these samples and subjected to hybridization on microarrays. All datasets were obtained from the GEO database, with the data downloaded in MINiML format, encompassing all platforms, samples, and comprehensive GSE records within the GSE. For datasets that were not pre-normalized, a log2 transformation was uniformly applied. To address batch effects across various subsets within the same dataset and platform, we employed the `removeBatchEffect` function from the `limma` package in R. This transcriptomic analysis focused on human peripheral arteries, encompassing the carotid, femoral, and infra-popliteal regions, in both atherosclerotic and control tissues.</p></sec><sec><title>Molecular dynamics simulations</title><p>We used Gromacs2020 Molecular dynamics simulations (MD) simulations to investigate NAMPT binding to Alisol-A, using the AMBER99SB-ILDN forcefield for proteins and the GAFF forcefield for ligands. Sobtop was used to establish the GAFF force field. The restrained electrostatic potential (RESP) method26 was then used for charge fitting. The TIP3P water model was used for the explicit waters. The distance between the edge of the box and the solute atom was established at a minimum of 1.0 nm, with the addition of sodium or chloride ions as necessary to achieve charge neutrality within the system. The molecular dynamics simulation process encompassed four key stages: minimization, heating, equilibration, and production run. The ligand-protein complexes were used to calculate the binding free energy.</p></sec><sec><title>Surface plasmon resonance</title><p>Surface plasmon resonance (SPR): The aim of this study was to evaluate the binding affinity between NAMPT and Alisol A utilizing SPR technology. For chip preparation, an activator solution was formulated by combining 400 mM EDC and 100 mM NHS immediately before injection. The CM5 sensor chip was activated for 420 s using this mixture at a flow rate of 10 &#956;L/min. Ligand immobilization was performed by diluting NAMPT to a concentration of 20 &#956;g/mL in an immobilization buffer, followed by injection into the sample channel Fc2 at a flow rate of 10 &#956;L/min, typically achieving immobilization levels of approximately 14,700 RU. It is noteworthy that the reference channel Fc1 does not require a ligand immobilization step. Subsequently, the chip was deactivated with 1 M ethanolamine hydrochloride at a flow rate of 10 &#956;L/min for 420 s. Analyte analysis was conducted using a multi-cycle method. Alisol A was diluted with the analyte buffer to achieve eight different concentrations: 100, 50, 25, 12.5, 6.25, 3.12, 1.56, and 0 &#956;M. The Alisol A samples were injected into channels Fc1 through Fc3 at a flow rate of 20 &#956;L/min, allowing for an association phase lasting 100 s, followed by a dissociation phase of 180 s. Both the association and dissociation phases were performed in the analyte buffer. This process was repeated for eight cycles, with analyte concentrations increasing sequentially. After each cycle of interaction analysis, the chip was regenerated.</p></sec><sec><title>Cell culture</title><p>The HT22 cell line comes from immortalized mouse hippocampal neurons and was obtained from the Chinese Academy of Sciences cell bank. The culture medium was purchased from Gibco, USA. After growing to 80% confluence, the HT22 cells were used for the experiment. HT22 cells were enriched with cholesterol using &#946;-Amyloid (25-35) (A&#946;<sub>25-35</sub>) (131602-53-4, MedChemExpress, Shanghai, China) <xref rid="B81" ref-type="bibr">81</xref>, <xref rid="B90" ref-type="bibr">90</xref> and CHO: MCD (C4951, Sigma-Aldrich) complex for 24 h. Alisol A (19885-10-0, MedChemExpress, Shanghai, China). In order to effectively deplete the intracellular NAMPT content, certain experiments necessitated a 24 h pretreatment with the NAMPT inhibitor FK866 (658084-64-1, MedChemExpress, Shanghai, China).</p><p>Primary neuron isolation. Cortical (or hippocampal) neurons were isolated from postnatal day 0-1 (P0-P1) C57BL/6, as previously described. Briefly, brain tissue was dissected, digested with papain, and triturated into single-cell suspension. Neurons were cultured in Neurobasal medium supplemented with B27, GlutaMAX, and penicillin-streptomycin. Cultures were maintained for 7-10 days <italic toggle="yes">in vitro</italic> (DIV) prior to treatment.</p></sec><sec><title>Mitochondria membrane potential</title><p>Mitochondrial activity was measured using JC-1 staining (C2006, Biyuntian, China). After cell treatments, the culture medium was removed and cells were washed three times with PBS. The cells were then exposed to JC-1 working solution for a duration of 20 min at 37 &#176;C, followed by two washes with JC-1 staining buffer, and subsequently visualized using an Olympus fluorescence microscope. Carbonyl cyanide m-chlorophenyl hydrazone (CCCP) (C2006-4, Biyuntian, China) was used to activate mitophagy. Control cells were treated with or without 10 &#956;M CCCP for 20 min.</p></sec><sec><title>NAD<sup>+</sup> assay</title><p>NAD<sup>+</sup> assay was carried out with Enhanced NAD<sup>+</sup>/NADH Assay Kit with WST-8 (S0176S, Beyotime Biotechnology, Shanghai, China). The specific operation was carried out according to the instructions. A volume 200 &#956;l of enhanced NAD<sup>+</sup>/NADH extract was added using a pipette, following the ratio of 200 &#956;l per 1 million cells. Tissue samples were rinsed with pre-cooled PBS to eliminate blood residues. Subsequently, 600 &#956;l of enhanced NAD<sup>+</sup>/NADH extraction solution was added at a ratio of 200 &#956;l per 10 mg of tissue. Finally, the NADH Standard Curve was generated. Total NAD quantification was conducted at an optical density of 450 nm, utilizing a standard curve generated from established NADH concentrations.</p></sec><sec><title>ROS, SOD, GSH, and MDA</title><p>Intracellular reactive oxygen species (ROS) levels were quantified through the utilization of 2', 7'-Dichlorofluorescein diacetate (DCFH-DA, D6883, Sigma-Aldrich) fluorescence. Incubate the sample with a 1000-fold diluted solution of DCFH-DA for a duration of 1 h. The mean fluorescence intensity at an excitation wavelength of 488 nm and an emission wavelength of 535 nm was measured utilizing an Accuri C6 flow cytometer (Beckman Coulter, Brea, CA, USA). Nanjing Jiancheng assay kits were used to measure superoxide dismutase (SOD) (A001-3-2), reduced glutathione (GSH) (A006-2-1), and malondialdehyde (MDA) (A003-4-1) activity in mouse hippocampal tissues as per the manufacturer's instructions.</p></sec><sec><title>Western blotting</title><p>Proteins were extracted, electrophoresed, and transferred onto a PVDF membrane. Blots were blocked with milk, incubated with primary and secondary antibodies, and washed with TBST. After dripping the developing solution on the membrane, the chemiluminescence imaging system was used for detection. Blotted bands were quantified with Image J software.</p><p>The studies used the following antibodies. GAPDH (2118, Cell Signaling Technology, 1:1000), anti-SREBP2 antibody (DF7601, Affinity, 1:1000), anti-NR1H3 Polyclonal antibody (14351-1-AP, Proteintech, 1:2000), anti-CYP46A1 antibody (12486-1-AP, Proteintech, 1:1000), anti-UCP2 antibody (89326, Cell Signaling Technology, 1:1000). anti-AMPK antibody(2532, Cell Signaling Technology, 1:1000), anti-p-AMPK&#945;<sup>Thr172 or Thr183</sup> antibody(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GB114323">GB114323</ext-link>, Servicebio, 1:1000), anti-NAMPT antibody(11776-1-AP, Proteintech, 1:1000), anti-SIRT1 antibody (13161-1-AP, Proteintech, 1:1000), anti-ACETYI-LYSINE antibody (DF7729, Affinity, 1:1000), anti-PGC1-&#945; antibody (66369-1-1G, Proteintech, 1:1000), anti-P62/SQSTM1 antibody(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="T55546">T55546</ext-link>, Ab-mart, 1:1000), anti-BECLIN1 antibody (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GB112053">GB112053</ext-link>, Servicebio, 1:500), anti-PARKIN antibody (GB11596, Servicebio, 1:500), anti-PINK1 antibody (23274-1-AP, Proteintech, 1:1000), anti-LC3B antibody(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="T55992">T55992</ext-link>, Ab-mart, 1:1000), anti-COXIV antibody (GB11250, Servicebio, 1:500), anti-TOM20 antibody (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="GB111481">GB111481</ext-link>, Servicebio, 1:500). anti-HMGCR antibody (DF6518, Affinity, 1:1000), ABCG5 antibody (DF8401, Affbiotech, 1:1000), ABCG8 antibody (DF6673, Affbiotech, 1:1000).</p></sec><sec><title>siRNA was used to knock down NAMPT expression</title><p>The Small molecule interfering RNA (siRNA) was purchased from Shanghai Shenggong Biological Engineering Co., Ltd. Following the manufacturer's instructions, Lipofectamine RNAiMAX transfection reagent (13778150, ThermoFisher Scientific, USA) was used for transfection. The lyophilized siRNA was dissolved in RNase-free water to a concentration of 20 &#956;M and aliquoted for storage at -20 &#176;C. For the experiment, the siRNA was diluted to the required working concentration (final 50 nM) using Opti-MEM (Gibco). HT22 cells were seeded at 2 &#215; 10&#8309; cells/well in a 6-well plate, with 2 mL of complete medium per well, and cultured until the cells adhered and reached approximately 50-60% confluence. The pre-diluted siRNA was slowly added to the transfection reagent working solution, gently mixed, and incubated at room temperature for 15 min to form stable complexes. The siRNA-transfection reagent mixture was then evenly distributed into each well, and the plate was gently shaken to ensure even distribution within the wells. After 4 to 6 h of transfection, the old medium was discarded, and 2 mL of fresh complete medium was added to continue culture for 48 h. After collecting the cells, protein extraction was performed, and Western blotting was conducted to detect the expression of the target protein.</p></sec><sec><title>Lentivirus-induced overexpression of NAMPT in cells</title><p>The NAMPT lentivirus used in the experiment was purchased from Shanghai Jikai Gene Biotechnology Co., Ltd. Before the experiment, cells were prepared as a single-cell suspension at a concentration of 5 &#215; 10&#8308; cells/mL and evenly seeded into a 12-well plate. When the cell confluence reached approximately 60% to 70%, the virus infection process was initiated. A virus infection system was prepared based on a multiplicity of infection (MOI) of 10. The original culture medium was then discarded, and fresh complete culture medium was added, along with the prepared infection solution. After a 12 h exposure to the virus, the medium was replaced, and the cells' growth status was monitored in real-time using a microscope. Once the cells stabilized, the culture medium was changed to complete medium containing 1 &#956;g/mL puromycin to select for successfully infected cells, while the transfection efficiency was assessed under a fluorescence microscope. Finally, samples with optimal infection efficiency were selected for subsequent protein extraction and related experimental analysis.</p></sec><sec><title>Co-immunoprecipitation</title><p>Co-Immunoprecipitation (COIP): Protein immunoprecipitation kit (Protein A/G magnetic bead method) (G2237, Servicebio). Add an appropriate amount of pre cooled IP cell lysis buffer to the cell culture dish (add protease inhibitor to the IP lysis buffer), lyse the cells at 4 &#176;C for 10 min, and repeatedly blow with a pipette during this period. Then transfer the cell suspension to a 1.5 ml centrifuge tube and continue to lyse on ice for 20 min; Centrifuge at 12000 rpm and 4 &#176;C for 10 min, transfer the supernatant into a new 1.5 ml centrifuge tube, operate on ice, and then measure using the BCA method; Take a small amount of supernatant and denature it for input experiments, i.e. WB detection of target proteins.</p><p>Add 1.0 &#956;g of IgG and 20 &#956;L of protein A/G beads (thoroughly mixed before use) to the supernatant of the negative control (IgG) group protein. The experimental group directly adds 20 &#956;L of protein A/G beads and incubates at 4 &#176;C for 1 h by shaking; 2000 g, 4 &#176;C, centrifuge for 5 min, take the supernatant; Add antibodies and incubate overnight at 4 &#176;C; Add 80 &#956;L of protein A/G beads and incubate at 4 &#176;C for 2 h; 4 &#176;C, 2000 g, centrifuge for 5 min, collect immunoprecipitation complexes; Wash the immunoprecipitation complex with 1ml pre cooled IP lysis buffer 4 times, each time at 4 &#176;C, 2000 g, and centrifuge for 5 min; After the last wash, try to absorb the supernatant as much as possible, then add 80 &#956;L of 1 &#215; reduction type loading buffer, boil in boiling water for 10 min, 4 &#176;C, 1000 g, centrifuge for 5 min, and take the supernatant sample for WB detection.</p><p>Cells were treated with 1 &#956;M acetyltransferase inhibitor - trichostatin A (TSA) (A8183, APExBIO) and 5 mM acetyltransferase activator - nicotinamide (NAM) (HY-B0150, MCE) for 12 h.</p></sec><sec><title>Statistical processing</title><p>SPSS 18.0 was used for statistical analysis, reporting means &#177; SEM, with one-way ANOVA and LSD-t test for group comparisons.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Alisol A improves Atherosclerosis related vascular cognitive impairment in <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice</title><p>As shown in the mouse experimental design flowchart, <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice were treated with Alisol A via gavage (Figure <xref rid="F1" ref-type="fig">1</xref>A). Compared to <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice, the levels of TG, TC, and LDL-c were significantly reduced in both Alisol A treatment groups (Figure <xref rid="F1" ref-type="fig">1</xref>B, <italic toggle="yes">P</italic> &lt; 0.05, <italic toggle="yes">P</italic> &lt; 0.01). The total cholesterol levels in the brain tissue of mice were measured, and the results showed that, compared to the control group, the total cholesterol in the brain tissue of <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice was significantly increased. In contrast, the brain tissue total cholesterol in the Alisol A treatment group was significantly decreased compared to the <italic toggle="yes">Ldlr<sup>-/-</sup> mice</italic> (Figure <xref rid="F1" ref-type="fig">1</xref>C, <italic toggle="yes">P</italic> &lt; 0.01). ORO and HE staining were used to determine the percentage of lipid content in the aortic root plaques (Figure <xref rid="F1" ref-type="fig">1</xref>D-G). Compared to the control group, <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice exhibited larger plaque areas and higher lipid content. In contrast, the plaque area and lipid content in the aortic root of the Alisol A treatment group were significantly reduced compared to the <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice (Figure <xref rid="F1" ref-type="fig">1</xref>D-G, <italic toggle="yes">P</italic> &lt; 0.01). &#945;-smooth muscle actin (&#945;-SMA) is an actin isoform that provides tension and contraction functionality, while CD68 is a marker of macrophages, commonly used to assess plaque inflammation. Compared to the control group, <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice exhibited elevated expression of &#945;-SMA and CD68 in atherosclerotic plaques, indicating increased smooth muscle cell activation and macrophage infiltration. However, treatment with Alisol A inhibited the expression of &#945;-SMA and CD68 (Figure <xref rid="F1" ref-type="fig">1</xref>H-I, <italic toggle="yes">P</italic> &lt; 0.05, <italic toggle="yes">P</italic> &lt; 0.01). In conclusion, Alisol A treatment not only reduced the area of atherosclerotic lesions but also improved the cellular composition within the atherosclerotic plaques. To assess the effects of Alisol A on learning and memory in mice, MWM, Y-maze, and NOR tests were conducted. Alisol A decreased avoidance latency in <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice during learning (Figure <xref rid="F1" ref-type="fig">1</xref>J-K) and increased time in target quadrant (Figure <xref rid="F1" ref-type="fig">1</xref>L-M). Y-maze test showed reduced spontaneous alternations in <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice, indicating impaired spatial working memory. <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice showed a significant preference for the new arm and an apparent increase in spontaneous alternation after Alisol A treatment, revealing sustained improved spatial short-term memory (Figure <xref rid="F1" ref-type="fig">1</xref>N-Q). The control group preferred the new object in the NOR task, but <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice did not (Figure <xref rid="F1" ref-type="fig">1</xref>R-U). Alisol A supplementation prevented the decrease in novel object discrimination in <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice. These findings indicate that Alisol A has a beneficial impact on cognitive functions and memory in <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice.</p></sec><sec><title>Alisol A protects hippocampus neurons from cholesterol metabolism disorders and oxidative stress damage</title><p>In the <italic toggle="yes">in vitro</italic> study, HT22 cells were exposed to A&#946;<sub>25-35</sub> and a cholesterol complex (50 &#956;g/ml cholesterol) <xref rid="B20" ref-type="bibr">20</xref>, and primary neuronal cells isolated from the brains of neonatal mice were co-incubated with ox-LDL to simulate neuronal cholesterol metabolism disorders. Subsequently, the expression of cholesterol metabolism-related genes in the cells was analyzed by Western blot. CYP46A1 catalyzes the conversion of cholesterol to 24S-OHC, facilitating cholesterol's passage across the blood-brain barrier and activating LXR signaling <xref rid="B91" ref-type="bibr">91</xref>. SREBP2 and LXR-&#945; work together to regulate cholesterol uptake, synthesis, and efflux, thereby maintaining intracellular cholesterol homeostasis <xref rid="B92" ref-type="bibr">92</xref>, <xref rid="B93" ref-type="bibr">93</xref>. The activation of SREBP2 is associated with the upregulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) <xref rid="B94" ref-type="bibr">94</xref>. Furthermore, LXR promotes cholesterol efflux by activating the transcription of ATP-binding cassette transporter A1 (ABCA1) <xref rid="B95" ref-type="bibr">95</xref>.</p><p>First, in the in vitro cell experiments, the results showed that, compared with the control group, in both HT22 cells treated with A&#946;<sub>25-35</sub> plus cholesterol complex (50 &#956;g/mL cholesterol) and primary mouse neurons treated with ox-LDL, SREBP2 expression was significantly upregulated, while LXR-&#945; and CYP46A1 expression were significantly downregulated (Figure <xref rid="F2" ref-type="fig">2</xref>A-B, <italic toggle="yes">P</italic> &lt; 0.01). However, following Alisol A treatment, SREBP2 expression was markedly reduced, whereas LXR-&#945; and CYP46A1 expression were significantly increased (Figure <xref rid="F2" ref-type="fig">2</xref>A-B, <italic toggle="yes">P</italic> &lt; 0.01). In the <italic toggle="yes">in vivo</italic> animal experiments, compared with the control group, <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice exhibited decreased LXR-&#945; and CYP46A1 expression and increased SREBP2 expression in hippocampal tissue (Figure <xref rid="F2" ref-type="fig">2</xref>C-D, <italic toggle="yes">P</italic> &lt; 0.01). After Alisol A treatment, LXR-&#945; and CYP46A1 expression were significantly upregulated, and SREBP2 expression was significantly downregulated (Figure <xref rid="F2" ref-type="fig">2</xref>C-D, <italic toggle="yes">P</italic> &lt; 0.05, <italic toggle="yes">P</italic> &lt; 0.01). Immunohistochemical analysis showed that, compared with controls, <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice had reduced ABCA1 and increased HMGCR staining in the hippocampus; Alisol A treatment reversed these changes, increasing ABCA1 and decreasing HMGCR (Figure <xref rid="F2" ref-type="fig">2</xref>E-F, <italic toggle="yes">P</italic> &lt; 0.01). These findings suggest that Alisol A may correct neuronal cholesterol overload by inhibiting SREBP2- and HMGCR-mediated cholesterol synthesis while activating LXR-&#945;-, CYP46A1-, and ABCA1-mediated cholesterol efflux and metabolism.</p><p>Figure <xref rid="F2" ref-type="fig">2</xref>G illustrates the mechanistic link between cholesterol metabolism and vascular cognitive impairment. Abnormal cholesterol metabolism, particularly cholesterol accumulation due to LDLR dysfunction, is a significant trigger for neurological disorders <xref rid="B91" ref-type="bibr">91</xref>. Cholesterol metabolism dysregulation serves as a key molecular bridge linking atherosclerosis and cognitive impairment. Elevated total cholesterol and low-density lipoprotein cholesterol in the circulation accelerate atherosclerotic plaque formation, and their metabolic product, oxysterols, can cross the BBB. This, in turn, interferes with brain cholesterol homeostasis by activating LXR signaling. Peripheral ox-LDL not only promotes atherosclerotic plaque development but also crosses the damaged BBB into the brain parenchyma, activating abnormal ABCA1 transport in astrocytes, thereby exacerbating cholesterol deposition in the central nervous system <xref rid="B95" ref-type="bibr">95</xref>. This mechanism deepens the synergistic interaction between cholesterol metabolism dysregulation in the nervous system and neurodegenerative damage in the brain. Systemic disruption of cholesterol metabolism constitutes a critical bridge for "cardio-cerebral comorbidity."</p><p>Multiple studies have shown that high cholesterol exacerbates oxidative stress and impairs neuronal function <xref rid="B96" ref-type="bibr">96</xref>, <xref rid="B97" ref-type="bibr">97</xref>. To further investigate the mechanisms by which cholesterol metabolism disorder damages the nervous system, assess the therapeutic effects of Alisol A, and clarify the link between oxidative stress and atherosclerosis related vascular cognitive impairment, we measured oxidative stress related indicators. UCP2 (Uncoupling Protein 2) is a mitochondrial inner-membrane uncoupling protein that is widely expressed in the central nervous system. UCP2 is regarded as a core component of the antioxidant defense system: by dissipating the mitochondrial membrane potential, it inhibits excessive ROS production, thereby alleviating oxidative damage and protecting neuronal survival <xref rid="B98" ref-type="bibr">98</xref>. In the <italic toggle="yes">in vivo</italic> experiments, the results of this study revealed that, compared to the control group, <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice exhibited a significant decrease in GSH and SOD activity in the hippocampus, a downregulation of UCP2 expression, and a significant increase in MDA levels. However, Alisol A treatment significantly increased UCP2 expression, as well as significantly improved GSH and SOD activity in the hippocampus of <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice, while simultaneously reducing MDA levels (Figure <xref rid="F2" ref-type="fig">2</xref>H, Figure <xref rid="F2" ref-type="fig">2</xref>L-M, <italic toggle="yes">P</italic> &lt; 0.05, <italic toggle="yes">P</italic> &lt; 0.01).</p><p>In the <italic toggle="yes">in vitro</italic> experiments, DCFH-DA fluorescence was used to label intracellular ROS, and flow cytometry was employed for analysis and quantification. The results showed that, compared to the control group, UCP2 expression was significantly downregulated in HT22 cells treated with A&#946;<sub>25-35</sub> and cholesterol complex (50 &#956;g/ml cholesterol) and in primary mouse neuronal cells treated with ox-LDL. However, following Alisol A treatment, UCP2 expression was significantly upregulated compared to the model group (Figure <xref rid="F2" ref-type="fig">2</xref>I, <italic toggle="yes">P</italic> &lt; 0.01). Additionally, compared to the control group, ROS levels were significantly elevated in HT22 cells treated with A&#946;<sub>25-35</sub> and cholesterol complex (50 &#956;g/ml cholesterol). After Alisol A treatment, ROS levels were significantly reduced compared to the model group (Figure <xref rid="F2" ref-type="fig">2</xref>J-K, <italic toggle="yes">P</italic> &lt; 0.05, <italic toggle="yes">P</italic> &lt; 0.01).</p></sec><sec><title>Alisol A exerts neuroprotective effects in <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice by attenuating neuroinflammatory impairments and enhancing hippocampal synaptic plasticity</title><p>HE and Nissl staining were used to analyze hippocampal neuronal morphology in the CA1 and DG regions. The control group showed normal hippocampal morphology with well-organized cell layers and consistent staining (Figure <xref rid="F3" ref-type="fig">3</xref>A-B). Conversely, in the <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice, the hippocampal cell with some exhibiting necrosis or being absent, and the neuronal nuclei appeared shrunken. The Alisol A 15 mg/kg and Alisol A 30 mg/kg groups had better pyramidal cell numbers and structure in the hippocampus, as well as increased Nissl bodies in neurons compared to the <italic toggle="yes">Ldlr<sup>-/-</sup>
</italic>mice.</p><p>Subsequently, we examined glial inflammatory responses through immunostaining for the glial markers IBA1 (microglia) and GFAP (astrocytes) (Figure <xref rid="F3" ref-type="fig">3</xref>C). Immunostaining for IBA1 and GFAP was increased in the hippocampus of <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice, indicating glial activation in response to neuronal damage (Figure <xref rid="F3" ref-type="fig">3</xref>C-D). Following Alisol A treatment, neuroinflammation was significantly reduced, as demonstrated by decreased IBA1 and GFAP staining (Figure <xref rid="F3" ref-type="fig">3</xref>E). Assess the complexity and structure of microglia and astrocytes using Sholl analysis. Figure <xref rid="F3" ref-type="fig">3</xref>C illustrates the use of concentric circles to measure their branching. The model group exhibited a significant increase in the number of intersections with the circles. Specifically, the <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice demonstrated a significant rise in intersection points per radius and an increased distance to the cell body (Figure <xref rid="F3" ref-type="fig">3</xref>C), accompanied by an elevated presence of microglia and astrocytes in the hippocampus (Figure <xref rid="F3" ref-type="fig">3</xref>F-G). This scenario can be elucidated as follows: Amid oxidative stress, the proliferation of ROS stimulates the activation of microglia and astrocytes. In parallel, UCP2, a protein residing in the mitochondrial inner membrane, alleviates oxidative stress and curbs neuroinflammation by moderating ROS levels, which in turn shields the mitochondria from damage (Figure <xref rid="F3" ref-type="fig">3</xref>H).</p><p>Synaptic dysfunction in the hippocampus is the primary cause of cognitive decline <xref rid="B99" ref-type="bibr">99</xref>, <xref rid="B100" ref-type="bibr">100</xref>. The present study employed TEM to investigate synaptic structure in the hippocampus. The <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice showed fewer synapses, narrower synaptic clefts, and smaller postsynaptic densities compared to the control group (Figure <xref rid="F3" ref-type="fig">3</xref>I-J). However, these impairments were ameliorated by Alisol A treatment. Immunofluorescence assay targeting the presynaptic protein synapsin-1 and the postsynaptic protein PSD95 revealed that both proteins were down-regulated in the <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice, indicating a loss of synapses. Alisol A treatment enhanced the eservation of presynaptic and postsynaptic proteins in the hippocampi of <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice (Figure <xref rid="F3" ref-type="fig">3</xref>K-L). The hippocampi underwent Golgi-Cox staining in order to observe the dendritic spine structure within neurons (Figure <xref rid="F3" ref-type="fig">3</xref>M-S). Sholl analysis revealed decreased dendritic complexity and spine density in hippocampal CA1 neurons of <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice compared to controls. Notably, neurons in the model group exhibit a reduction in the number of mature spines (mushroom-type), which is accompanied by an overall decrease in spine number. Treatment with Alisol A resulted in significant improvements in these parameters. Specifically, the groups administered Alisol A at dosages of 15 mg/kg and 30 mg/kg exhibited increased dendritic branching, enhanced spine density, and a higher number of mushroom spines in comparison to the model group. The increase in mushroom-shaped spines carries dual significance. On one hand, their enlarged heads markedly expand the synaptic membrane contact area, thereby enhancing the stability of synaptic connections. On the other hand, such spines are typically indicative of mature synapses, which exhibit higher functional activity and greater efficiency in information transmission. Therefore, Alisol A may exert more targeted neuroprotective and cognitive-enhancing effects by reinforcing structural characteristics of mature synapses, rather than merely promoting dendritic branching complexity (Figure <xref rid="F3" ref-type="fig">3</xref>T).</p></sec><sec><title>AMPK pathway and autophagy may be key mechanisms of Alisol A, with NAMPT playing an important role in their regulation</title><p>We conducted a two-sample mendelian randomization study, utilizing data from GWAS, to elucidate the causal effect of coronary atherosclerosis on vascular dementia (Figure <xref rid="F4" ref-type="fig">4</xref>A-D). Heterogeneity and pleiotropy tests indicate no significant heterogeneity or pleiotropy in this study, suggesting that the Mendelian randomization analysis is reliable (<xref rid="SM0" ref-type="sec">Table S1</xref> and S2). When the odds ratio (OR) is greater than 1, it indicates that coronary atherosclerosis is a risk factor for vascular dementia (i.e., it increases the risk of disease). In this study, the OR values were as follows: IVW: OR = 1.238 (<italic toggle="yes">P</italic> &lt; 0.05); MR Egger: OR = 1.238; Weighted median: OR = 1.238 (<xref rid="SM0" ref-type="sec">Table S3</xref>). To investigate the key enrichment pathways of differential metabolites between atherosclerosis patients and a normal blood lipid control group, we conducted lipidomics analyses on the serum of both atherosclerosis patients and the control group (Figure <xref rid="F4" ref-type="fig">4</xref>E-I). KEGG pathway enrichment analysis (Figure <xref rid="F4" ref-type="fig">4</xref>I) revealed that the differentially expressed metabolites were primarily concentrated in key metabolic pathways such as the AMPK signaling pathway and autophagy pathway. In the bubble plot, pathways with a larger Rich factor and smaller P-value indicated higher enrichment levels, suggesting that these metabolic pathways may play an important role in the mechanism of Atherosclerosis related vascular cognitive impairment. The AMPK signaling pathway and autophagy pathway may be key mechanisms through which Alisol A exerts its effects in atherosclerosis-related diseases. Next, the study analyzed publicly available atherosclerosis datasets from GEO (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE100927">GSE100927</ext-link>). GEO dataset analysis revealed that the expression of <italic toggle="yes">NAMPT, SIRT1, CYP46A1</italic>, and <italic toggle="yes">LDLR</italic> was significantly reduced in atherosclerosis patients (<italic toggle="yes">P</italic> &lt; 0.05 or <italic toggle="yes">P</italic> &lt; 0.01), while <italic toggle="yes">TLR4</italic> and <italic toggle="yes">mTOR</italic> levels were significantly increased (Figure <xref rid="F4" ref-type="fig">4</xref>J, <italic toggle="yes">P</italic> &lt; 0.05 or <italic toggle="yes">P</italic> &lt; 0.01). Among these, the difference in <italic toggle="yes">NAMPT</italic> expression was most significant, suggesting that <italic toggle="yes">NAMPT</italic> may play an important role in the regulation of the AMPK pathway and autophagy.</p><p>Molecular docking simulation demonstrated Alisol A binding to NAMPT, forming hydrogen bonds at GLN-305 and TYR-188 residues. This suggests Alisol A could be an effective agonist for NAMPT activity Figure <xref rid="F4" ref-type="fig">4</xref>K-M. The results obtained from molecular docking analyses were subsequently confirmed through an additional 200 ns of MD. It can be seen in the RMSD protein graphs (Figure <xref rid="F4" ref-type="fig">4</xref>N-O) that average RMSD values are less than 2 &#197; and the complex reached a dynamic equilibrium at around 80 ns. This finding evinces that Alisol A peptides interacted and formed stable molecular complexes with NAMPT protein. Notably, as illustrated in Figure <xref rid="F4" ref-type="fig">4</xref>P-R the protein-ligand complex exhibited minimal fluctuations throughout the entire simulation period. This observation suggests that the compound remained within the protein pocket, thereby demonstrating a stable binding affinity conducive to achieving dynamic equilibrium. In addition to these, hydrogen bonding interactions of Alisol A with critical residues in the active site of ARG-349, and ALA-379. Alisol A could also form hydrophobic interactions with multiple amino acid residues such as PRO-307, TYR-240, TYR-188, ALA-379, PRO-273, and ILE-309. In Figure <xref rid="F4" ref-type="fig">4</xref>S and Figure <xref rid="F4" ref-type="fig">4</xref>T, the main forces between the Alisol A protein and the NAMPT complex were MM, Polar, and Apolar energies. And GLY-185, TYR-188, TYR-240, PRO-273, GLN-305, PRO-307, ILE-309, and ALA-379 with a higher contribution for the Alisol A protein and NAMPT complex. Based on the data presented in Figure <xref rid="F4" ref-type="fig">4</xref>U, it can be observed that the van der Waals force exhibits a superior ability to stabilize small molecules, with electrostatic interactions ranking second in effectiveness. The study found that Alisol A binds to the NAMPT protein with a binding free energy of -108.468 &#177; 15.259 kJ/mol, primarily due to van der Waals force (-166.129 &#177; 14.154 kJ/mol). Overall, Alisol A has exhibited a strong binding affinity for NAMPT. NAMPT immobilized on CM5 chip can bind Alisol A with an affinity constant of 65.1 &#956;M as determined in a SPR assay (Figure <xref rid="F4" ref-type="fig">4</xref>V). These binding affinities enhance the interaction between Alisol A and NAMPT, resulting in the creation of a stable "high affinity" complex that facilitates the exertion of its functional role.</p></sec><sec><title>Alisol A activates the AMPK/NAMPT/SIRT1 pathway and autophagy pathway</title><p>Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1-&#945;) is a key cofactor of SIRT1 and plays a role in mitochondrial function and biogenesis <xref rid="B101" ref-type="bibr">101</xref>. SIRT1, an NAD&#8314;-dependent deacetylase, promotes the initiation and maintenance of autophagy by deacetylating key autophagy proteins such as Atg5, Atg7, and Atg8 <xref rid="B102" ref-type="bibr">102</xref>, <xref rid="B103" ref-type="bibr">103</xref>. NAMPT, by regulating intracellular NAD&#8314; levels, indirectly activates SIRT1 and regulates the autophagic process. Measuring lysine acetylation levels helps assess how SIRT1 and NAMPT regulate the activity of autophagic factors through acetylation.</p><p>Figure <xref rid="F5" ref-type="fig">5</xref>A presents a schematic diagram illustrating the mechanism by which Alisol A sustains mitochondrial homeostasis through the activation of the AMPK/NAMPT/SIRT1 signaling pathway and the induction of autophagy. In the <italic toggle="yes">in vivo</italic> experiments, this study explored the effects of Alisol A on the hippocampal AMPK/NAMPT/SIRT1 signaling pathway. The results showed that, compared to the control group, <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice exhibited significantly decreased levels of p-AMPK&#945;<sup>Thr172 or Thr183</sup>, NAMPT, SIRT1, and PGC1-&#945; proteins, while lysine acetylation (Acetyl-Lysine) was significantly increased (Figure <xref rid="F5" ref-type="fig">5</xref>B-C, <italic toggle="yes">P</italic> &lt; 0.05, <italic toggle="yes">P</italic> &lt; 0.01). Additionally, NAD<sup>+</sup> levels were reduced in <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice (Figure <xref rid="F5" ref-type="fig">5</xref>D, <italic toggle="yes">P</italic> &lt; 0.01). However, compared to the <italic toggle="yes">Ldlr<sup>-/-</sup></italic> group, Alisol A treatment significantly increased the expression of p-AMPK&#945;<sup>Thr172 or Thr183</sup>, NAMPT, SIRT1, and PGC1-&#945;, while lysine acetylation (Acetyl-Lysine) significantly decreased, and NAD<sup>+</sup> levels were significantly elevated (Figure <xref rid="F5" ref-type="fig">5</xref>B-D, <italic toggle="yes">P</italic> &lt; 0.05, <italic toggle="yes">P</italic> &lt; 0.01). To further validate that Alisol A activates the AMPK/NAMPT/SIRT1 signaling pathway, we also conducted relevant experiments at the cellular level. The results showed that, compared to the control group, the model group exhibited significantly reduced levels of p-AMPK&#945;<sup>Thr172 or Thr183</sup>, NAMPT, SIRT1, and PGC1-&#945; proteins, while total lysine acetylation (Acetyl-Lysine) was significantly increased. However, compared to the model group, the Alisol A treatment group showed increased expression of p-AMPK&#945;<sup>Thr172 or Thr183</sup>, NAMPT, SIRT1, and PGC1-&#945;, along with a significant decrease in total lysine acetylation (Acetyl-Lysine) (Figure <xref rid="F5" ref-type="fig">5</xref>F, <italic toggle="yes">P</italic> &lt; 0.05, <italic toggle="yes">P</italic> &lt; 0.01). Additionally, NAD<sup>+</sup> levels were significantly decreased in the model group compared to the control group, but Alisol A treatment improved this result (Figure <xref rid="F5" ref-type="fig">5</xref>E, <italic toggle="yes">P</italic> &lt; 0.05, <italic toggle="yes">P</italic> &lt; 0.01). These results suggest that Alisol A activates the AMPK/NAMPT/SIRT1 signaling pathway. IF results also supported the findings (Figure <xref rid="F5" ref-type="fig">5</xref>G).</p><p>To investigate the effect of Alisol A on neuronal mitophagy, we measured the expression of autophagy-related proteins by Western blot. Specifically, we probed the autophagic substrate P62 (Sequestosome 1), the key initiation protein BECLIN1, the mitophagy markers PINK1 and PARKIN, and the mitochondrial membrane proteins TOM20 (Translocase of the outer membrane 20) and COXIV. We also assessed LC3B I (Microtubule-associated protein 1A/1B-light chain 3B I) -to-LC3BII conversion to gauge autophagosome formation, and calculated LC3BII/LC3BI and PARKIN/COXIV ratios as quantitative indices of autophagic flux and mitophagy activity. Mitophagy is essential for removing damaged mitochondria and maintaining mitochondrial quality. P62 is a selective autophagy substrate whose levels inversely correlate with overall autophagic activity; its accumulation indicates impaired autophagy <xref rid="B104" ref-type="bibr">104</xref>, <xref rid="B105" ref-type="bibr">105</xref>. PARKIN, an E3 ubiquitin ligase, is activated and recruited to the outer mitochondrial membrane by PINK1 upon mitochondrial damage or depolarization, thereby initiating mitophagy. PARKIN recruitment marks damaged mitochondria for ubiquitination of their membrane proteins, promoting their enclosure by autophagosomes and subsequent degradation. Cytochrome c oxidase subunit IV (COXIV), a component of respiratory chain complex IV, serves as a mitochondrial inner membrane marker whose levels reflect mitochondrial content. During active mitophagy, clearance of damaged mitochondria leads to decreased COXIV. Therefore, the PARKIN/COXIV ratio measured by Western blot provides a dynamic readout of mitophagy targeting efficiency: an elevated ratio indicates enhanced PARKIN recruitment and mitophagy activity, while a reduced ratio suggests impaired PARKIN mobilization or ubiquitin-mediated mitochondrial clearance.</p><p>The results of this study show that, compared to the control group, HT22 cells treated with A&#946;<sub>25-35</sub> and cholesterol complex (50 &#956;g/ml cholesterol), as well as primary mouse neuronal cells treated with ox-LDL, exhibited reduced levels of BECLIN1 and PINK1, elevated levels of P62, and decreased levels of PINK1 and PARKIN. Additionally, in HT22 cells treated with A&#946;<sub>25-35</sub> and a cholesterol complex, the PARKIN/COXIV and LC3II/LC3I ratios were decreased (Figure <xref rid="F5" ref-type="fig">5</xref>H, <italic toggle="yes">P</italic> &lt; 0.05, <italic toggle="yes">P</italic> &lt; 0.01). Although the expression levels of COXIV and TOM20 were not significantly altered in these cells, the reduction in mitophagy-related protein ratios still suggests impaired autophagic flux. Similarly, in primary mouse neuronal cells treated with ox-LDL, COXIV and TOM20 expression were increased, while the PARKIN/COXIV and LC3II/LC3I ratios were significantly decreased (Figure <xref rid="F5" ref-type="fig">5</xref>H, <italic toggle="yes">P</italic> &lt; 0.05, <italic toggle="yes">P</italic> &lt; 0.01). These findings indicate that autophagy is inhibited in both HT22 cells exposed to A&#946;<sub>25-35</sub> and cholesterol, as well as in ox-LDL-treated primary neurons. However, Alisol A treatment reversed these changes. In HT22 cells, Alisol A increased BECLIN1 and PINK1 expression, reduced P62 levels, upregulated PARKIN expression, and restored the PARKIN/COXIV and LC3II/LC3I ratios (Figure <xref rid="F5" ref-type="fig">5</xref>H, <italic toggle="yes">P</italic> &lt; 0.05, <italic toggle="yes">P</italic> &lt; 0.01). Likewise, in primary neurons treated with ox-LDL, Alisol A elevated BECLIN1 and PINK1 expression, decreased P62, enhanced PARKIN expression, reduced COXIV and TOM20 levels, and significantly increased the PARKIN/COXIV and LC3II/LC3I ratios. These results suggest that Alisol A activates the PINK1/PARKIN pathway and restores autophagic activity.</p><p>The study indicates that mitochondrial membrane potential (MMP) depolarization is positively correlated with the induction of mitophagy <xref rid="B106" ref-type="bibr">106</xref>-<xref rid="B108" ref-type="bibr">108</xref>. MMP depolarization refers to the process of a reduced mitochondrial membrane potential, which can be measured by changes in the red/green fluorescence ratio of JC-1 dye <xref rid="B106" ref-type="bibr">106</xref>, <xref rid="B107" ref-type="bibr">107</xref>. CCCP (carbonyl cyanide m-chlorophenyl hydrazone) is a classic mitochondrial uncoupler that causes MMP depolarization and accelerates cell death, and in this study, it was used as a control drug to induce mitochondrial-related apoptosis <xref rid="B109" ref-type="bibr">109</xref>. The results showed that under CCCP treatment, the JC-1 dye no longer accumulated in the mitochondria, instead existing as green fluorescence, leading to a significant decrease in red fluorescence and an increase in green fluorescence, thus lowering the red/green ratio. This suggests that mitochondrial function was impaired in HT22 cells under CCCP treatment, leading to accelerated cell apoptosis (Figure <xref rid="F5" ref-type="fig">5</xref>I, <italic toggle="yes">P</italic> &lt; 0.05, <italic toggle="yes">P</italic> &lt; 0.01). Compared to the control group, HT22 cells treated with A&#946;<sub>25-35</sub> and cholesterol complex (50 &#956;g/ml cholesterol) exhibited significantly reduced red fluorescence, increased green fluorescence, and a significantly decreased red/green ratio, indicating MMP depolarization. This further suggests mitochondrial dysfunction and impaired autophagy. In contrast, compared to the A&#946;<sub>25-35</sub> and cholesterol complex (50 &#956;g/ml cholesterol) treated HT22 cells, the 10 &#956;M Alisol A treatment group showed enhanced red fluorescence, increased green fluorescence, and an increased red/green ratio (Figure <xref rid="F5" ref-type="fig">5</xref>I, <italic toggle="yes">P</italic> &lt; 0.05, <italic toggle="yes">P</italic> &lt; 0.01). These results suggest that Alisol A 10 &#956;M treatment may improve mitochondrial function by restoring MMP.</p></sec><sec><title>NAMPT as a key target in Alisol A's treatment of atherosclerosis related vascular cognitive impairment</title><p>To further confirm the protective role of Alisol A is associated with NAMPT, this study used the selective NAMPT inhibitor FK866 to block the NAMPT-related pathway activated by Alisol A. In the <italic toggle="yes">in vivo</italic> experiments, the control group was given NMN, the enzymatic product of NAMPT. In the <italic toggle="yes">in vitro</italic> experiments, NAMPT overexpression was achieved in HT22 cells using a NAMPT lentivirus. Based on previous studies, a dose of 15 mg/kg Alisol A was determined to be optimal for <italic toggle="yes">in vivo</italic> experiments, while 10 &#956;M Alisol A was optimal for <italic toggle="yes">in vitro</italic> experiments. These doses were subsequently used for further experiments.</p><p>The water maze experiment showed that, compared to the <italic toggle="yes">Ldlr<sup>-/-</sup></italic> group, the FK866 group spent significantly less time in the target quadrant. The NMN and Alisol A treatment groups had a significantly shortened escape latency and spent significantly more time in the target quadrant. Compared to the FK866 group, the NMN and Alisol A treatment groups had a significantly shorter escape latency and significantly more time spent in the target quadrant. The FK866 and Alisol A co-treatment group also showed significantly reduced escape latency and increased time spent in the target quadrant compared to the FK866 group (Figure <xref rid="F6" ref-type="fig">6</xref>A-B, <italic toggle="yes">P</italic> &lt; 0.05, <italic toggle="yes">P</italic> &lt; 0.01). The Y-maze experiment showed that, compared to the <italic toggle="yes">Ldlr<sup>-/-</sup></italic> group, the FK866 group had a significantly reduced spontaneous alternation rate. Compared to the FK866 group, the NMN and Alisol A treatment groups had significantly increased entries into the new open arm and a significantly increased spontaneous alternation rate (Figure <xref rid="F6" ref-type="fig">6</xref>C-D, <italic toggle="yes">P</italic> &lt; 0.05, <italic toggle="yes">P</italic> &lt; 0.01). The novel object recognition experiment showed that, compared to the <italic toggle="yes">Ldlr<sup>-/-</sup></italic> group, the FK866 group had a significantly reduced novel object discrimination index, while the NMN and Alisol A treatment groups had a significantly increased discrimination index (Figure <xref rid="F6" ref-type="fig">6</xref>E-F, <italic toggle="yes">P</italic> &lt; 0.05, <italic toggle="yes">P</italic> &lt; 0.01). Immunohistochemistry results showed that FK866 inhibited the expression of NAMPT and SIRT1 in the hippocampus of <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice (Figure <xref rid="F6" ref-type="fig">6</xref>G, <italic toggle="yes">P</italic> &lt; 0.01). Additionally, FK866 significantly reduced NAD<sup>+</sup> levels (Figure <xref rid="F6" ref-type="fig">6</xref>H, <italic toggle="yes">P</italic> &lt; 0.01). These findings suggest that NAMPT inhibition exacerbates the already impaired cognitive function and memory in <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice.</p><p>To investigate the effects of NAMPT on cholesterol metabolism, we examined how modulation of NAMPT expression alters cholesterol homeostasis in both <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> experiments. Similar to ABCA1, ABCG5 and ABCG8 are regulated by LXR; under conditions of cholesterol overload, LXR is activated by oxysterols <xref rid="B110" ref-type="bibr">110</xref>. Once activated, LXR upregulates the expression of these transporters, thereby promoting cholesterol efflux and reducing intracellular cholesterol levels. After FK866 treatment, we observed increased expression of the key cholesterol-homeostasis regulators SREBP2 and the rate-limiting cholesterol-synthesizing enzyme HMGCR, while LXR&#945; expression was decreased, indicating enhanced cholesterol synthesis and reduced efflux (Figure <xref rid="F6" ref-type="fig">6</xref>I, <italic toggle="yes">P</italic> &lt; 0.05, <italic toggle="yes">P</italic> &lt; 0.01). In contrast, NAMPT overexpression and treatment with Alisol A produced the opposite effects. Knockdown of NAMPT significantly reduced SIRT1 expression and led to increased lysine acetylation; moreover, NAMPT depletion suppressed the expression of the cholesterol-transport proteins ABCG5 and ABCG8, while upregulating SREBP2 (Figure <xref rid="F6" ref-type="fig">6</xref>K, <italic toggle="yes">P</italic> &lt; 0.05, <italic toggle="yes">P</italic> &lt; 0.011). Immunohistochemical analysis of mouse hippocampal tissue revealed that FK866 treatment decreased CYP46A1 expression, whereas combined FK866 and Alisol A treatment increased CYP46A1 levels; similarly, NMN or Alisol A alone each significantly elevated CYP46A1 expression (Figure <xref rid="F6" ref-type="fig">6</xref>J, <italic toggle="yes">P</italic> &lt; 0.05, <italic toggle="yes">P</italic> &lt; 0.01). These findings suggest that inhibition of NAMPT disrupts cholesterol metabolism in neuronal cells.</p><p>Protein acetylation is co-regulated by deacetylases (HDACs) and acetyltransferases (HATs). Consequently, we employed two categories of deacetylase inhibitors to target distinct deacetylase activities: type I and type II HDAC family inhibitors, specifically TSA, and a type III (Sirtuins family) inhibitor, NAM. To ensure robust participation of NAMPT in immunoprecipitation assays, we used lentiviral overexpression to substantially increase NAMPT levels. This ensured sufficient protein abundance for detection of its interactions with other proteins. Compared with the IgG control, SIRT1, CYP46A1, and acetyl-lysine modified proteins were all detected in NAMPT immunoprecipitates, indicating that NAMPT interacts with SIRT1, CYP46A1, and acetylated lysine residues and is involved in protein acetylation (Figure <xref rid="F6" ref-type="fig">6</xref>L-M, <italic toggle="yes">P</italic> &lt; 0.05, <italic toggle="yes">P</italic> &lt; 0.01).</p><p>Relative to the non-IgG control, both TSA- and NAM-treated groups exhibited markedly reduced SIRT1 co-precipitation and significantly increased lysine acetylation. Moreover, TSA treatment produced a significantly lower acetyl-lysine signal than NAM treatment, indicating that NAMPT-mediated protein acetylation is primarily regulated by Sirtuin family deacetylases, particularly SIRT1 (Figure <xref rid="F6" ref-type="fig">6</xref>L, <italic toggle="yes">P</italic> &lt; 0.05, <italic toggle="yes">P</italic> &lt; 0.01). In HT22 cells treated with A&#946;<sub>25-35</sub> plus cholesterol complex and in primary neurons treated with ox-LDL, SIRT1 and CYP46A1 co-immunoprecipitation with NAMPT was significantly reduced, while acetyl-lysine levels were significantly elevated compared with the non-IgG control. These results suggest that A&#946;<sub>25-35</sub>+cholesterol and ox-LDL impair the interaction between NAMPT, SIRT1, and CYP46A1 and promote protein acetylation. Finally, in primary neurons treated with A&#946;<sub>25-35</sub>+cholesterol or ox-LDL, co-treatment with Alisol A enhanced the interaction between NAMPT, SIRT1, and CYP46A1 and significantly suppressed lysine acetylation (Figure <xref rid="F6" ref-type="fig">6</xref>M, <italic toggle="yes">P</italic> &lt; 0.05, <italic toggle="yes">P</italic> &lt; 0.01).</p></sec><sec><title>The inhibition of Nampt attenuates autophagy by diminishing its interaction with PINK1, consequently decreasing the advantageous effects of Alisol A in mitigating oxidative stress and restoring synaptic plasticity</title><p>To investigate the role of NAMPT in regulating mitophagy, we performed various interventions in <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice and assessed the expression of multiple autophagy related proteins in hippocampal tissue by Western blot. Compared with the <italic toggle="yes">Ldlr<sup>-/-</sup></italic> group, mice treated with Alisol A or NMN exhibited significantly increased levels of BECLIN1, PINK1, and PARKIN, alongside decreased expression of P62, TOM20, and COXIV. Moreover, both the PARKIN/COXIV and LC3BII/LC3BI ratios were markedly elevated, indicating that Alisol A and NMN enhance mitophagic activity and facilitate autophagic flux (Figure <xref rid="F7" ref-type="fig">7</xref>A, <italic toggle="yes">P</italic> &lt; 0.05, <italic toggle="yes">P</italic> &lt; 0.01). Further comparison with the FK866 group revealed that Alisol A and NMN treatment similarly upregulated BECLIN1, PINK1, and PARKIN and downregulated P62, TOM20, and COXIV, while significantly increasing the PARKIN/COXIV and LC3BII/LC3BI ratios, suggesting that NAMPT inhibition impairs autophagic flux (Figure <xref rid="F7" ref-type="fig">7</xref>A, <italic toggle="yes">P</italic> &lt; 0.05, <italic toggle="yes">P</italic> &lt; 0.01).</p><p>The PARKIN/COXIV ratio is used to assess mitophagy activation <xref rid="B111" ref-type="bibr">111</xref>. Recruitment of PARKIN signifies recognition of damaged mitochondria and initiation of their clearance, whereas COXIV-a mitochondrial membrane protein-reflects overall mitochondrial abundance <xref rid="B112" ref-type="bibr">112</xref>, <xref rid="B113" ref-type="bibr">113</xref>. An increased ratio indicates more efficient PARKIN targeting of mitochondria and enhanced mitophagic activity; a decreased ratio suggests impaired targeting or blockade of the autophagic process. Thus, this ratio serves as a dynamic marker for monitoring selective mitophagy. In our <italic toggle="yes">in vitro</italic> experiments, we employed two cellular models to evaluate NAMPT's regulation of autophagy: (1) HT22 cells exposed to A&#946;<sub>25-35</sub> plus cholesterol complex, and (2) primary mouse neurons co-incubated with ox-LDL to mimic lipotoxic injury. Autophagy-related protein levels were then measured by Western blot. Compared with the NAMPT-overexpression group, FK866 treatment alone led to increased P62, TOM20, and COXIV expression, while BECLIN1, PINK1, PARKIN, the PARKIN/COXIV ratio, and the LC3BII/LC3BI ratio all decreased, indicating a blockade of autophagic flux (Figure <xref rid="F7" ref-type="fig">7</xref>B, <italic toggle="yes">P</italic> &lt; 0.05, <italic toggle="yes">P</italic> &lt; 0.01). In HT22 cells specifically, FK866 treatment-relative to Alisol A-upregulated P62 and COXIV and downregulated BECLIN1, PINK1, and PARKIN, with concomitant reductions in both the PARKIN/COXIV and LC3BII/LC3BI ratios, further supporting NAMPT inhibition-induced impairment of mitophagic flux (Figure <xref rid="F7" ref-type="fig">7</xref>B, <italic toggle="yes">P</italic> &lt; 0.05, <italic toggle="yes">P</italic> &lt; 0.01). Finally, compared with FK866 alone, combined treatment with Alisol A and FK866 resulted in decreased COXIV expression and an increased PARKIN/COXIV ratio, while P62 expression was elevated; TOM20, PARKIN, and the LC3BII/LC3BI ratio showed no significant change (Figure <xref rid="F7" ref-type="fig">7</xref>B, <italic toggle="yes">P</italic> &lt; 0.05, <italic toggle="yes">P</italic> &lt; 0.01). In primary neurons, ox-LDL treatment significantly increased P62, TOM20 and COXIV expression while decreasing BECLIN1, PINK1, PARKIN, the PARKIN/COXIV ratio and the LC3BII/LC3BI ratio compared with controls. Relative to the ox-LDL group, NAMPT overexpression markedly lowered P62, TOM20 and COXIV levels and elevated BECLIN1, PINK1, PARKIN, as well as the PARKIN/COXIV and LC3BII/LC3BI ratios, indicating a pivotal role for NAMPT in modulating autophagy and mitochondrial homeostasis (Figure <xref rid="F7" ref-type="fig">7</xref>B, <italic toggle="yes">P</italic> &lt; 0.05, <italic toggle="yes">P</italic> &lt; 0.01). Conversely, FK866 treatment in ox-LDL exposed neurons further increased P62, TOM20 and COXIV expression and decreased BECLIN1 and the PARKIN/COXIV ratio, whereas PINK1, PARKIN and the LC3BII/LC3BI ratio remained unchanged (Figure <xref rid="F7" ref-type="fig">7</xref>B, <italic toggle="yes">P</italic> &lt; 0.05, <italic toggle="yes">P</italic> &lt; 0.01). These findings suggest that FK866 inhibits autophagy activation. Despite elevations in certain markers (P62, TOM20, COXIV) that may reflect compensatory autophagic signaling or increased mitochondrial content, the reductions in BECLIN1 and PARKIN/COXIV ratio, together with unchanged PINK1, PARKIN and LC3B processing, indicate suppression of both autophagy initiation and effective mitophagic execution. The decrease in BECLIN1, a key initiator of autophagy, underscores impaired autophagic flux, and the absence of significant change in the LC3BII/LC3BI ratio further corroborates insufficient enhancement of autophagic activity. Mitochondrial membrane potential assays revealed that, compared with FK866 treated cells, those overexpressing NAMPT or treated with Alisol A exhibited strong red and green fluorescence. In contrast, FK866 treated cells showed very faint red and green fluorescence, indicating an overall decline in MMP activity and a reduction in mitochondrial content, likely due to accumulation of damaged mitochondria resulting from impaired mitophagy (Figure <xref rid="F7" ref-type="fig">7</xref>C, <italic toggle="yes">P</italic> &lt; 0.05, <italic toggle="yes">P</italic> &lt; 0.01).</p><p>OPTN, an autophagy receptor, is recruited to the mitochondrial surface where it promotes clearance of damaged mitochondria by binding autophagy proteins such as LC3 <xref rid="B114" ref-type="bibr">114</xref>. Immunofluorescence analysis showed that FK866 treatment led to a lower OPTN/TOM20 fluorescence ratio and reduced colocalization of OPTN with the mitochondrial membrane protein TOM20 compared with NAMPT overexpression and Alisol A treatment, indicating impaired receptor recruitment to mitochondria and inhibition of mitophagy (Figure <xref rid="F7" ref-type="fig">7</xref>D, <italic toggle="yes">P</italic> &lt; 0.01). In contrast, both NAMPT overexpression and Alisol A treatment increased the OPTN/TOM20 ratio and enhanced OPTN-TOM20 colocalization, suggesting activation of the autophagy pathway. OPTN functions as a downstream adaptor of PINK1 and PARKIN <xref rid="B115" ref-type="bibr">115</xref>, <xref rid="B116" ref-type="bibr">116</xref>. Therefore, NAMPT inhibition appears to block the PINK1/PARKIN selective mitophagy pathway: loss of upstream signaling prevents OPTN from localizing to mitochondria and binding LC3, so damaged mitochondria cannot be sequestered and removed. By contrast, NAMPT overexpression activates the PINK1 and PARKIN pathway, enhances OPTN recruitment to mitochondria, restores autophagic flux, clears damaged mitochondria, and interrupts the vicious cycle of mitochondrial dysfunction and oxidative stress.</p><p>To further elucidate the molecular mechanism by which NAMPT regulates mitophagy, we investigated whether NAMPT directly interacts with PINK1 to influence PINK1 expression and stability. Knockdown of NAMPT significantly reduced PINK1 levels in HT22 cells (Figure <xref rid="F7" ref-type="fig">7</xref>E, <italic toggle="yes">P</italic> &lt; 0.01). Co-immunoprecipitation confirmed an interaction between NAMPT and PINK1 (Figure <xref rid="F7" ref-type="fig">7</xref>F, <italic toggle="yes">P</italic> &lt; 0.01). Further analysis revealed that PINK1 expression was decreased in HT22 cells treated with A&#946;<sub>25-35</sub> plus cholesterol complex and in primary neurons treated with ox-LDL, compared with the non-IgG control, suggesting that these treatments impair the NAMPT-PINK1 interaction. In contrast, Alisol A treatment restored PINK1 expression relative to the A&#946;<sub>25-35</sub>/cholesterol and ox-LDL groups, indicating that Alisol A enhances the interaction between NAMPT and PINK1 (Figure <xref rid="F7" ref-type="fig">7</xref>F, <italic toggle="yes">P</italic> &lt; 0.01).</p><p>To clarify NAMPT's role in redox homeostasis in the nervous system and to determine whether Alisol A exerts antioxidant effects via the NAMPT pathway, we evaluated UCP2 expression and ROS levels. Immunofluorescence in the hippocampal CA3 region showed that, compared with <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice, both NMN and Alisol A treatment increased UCP2 expression. Relative to FK866 treatment, NMN and Alisol A also elevated UCP2 levels, indicating that enhanced NAMPT activity improves mitochondrial antioxidant capacity and that Alisol A may upregulate UCP2 via NAMPT activation to mitigate oxidative damage (Figure <xref rid="F7" ref-type="fig">7</xref>G, <italic toggle="yes">P</italic> &lt; 0.01). Compared with Alisol A, FK866 treatment reduced UCP2 expression, demonstrating that NAMPT inhibition weakens the hippocampal antioxidant barrier, exacerbates oxidative stress, and disrupts redox balance. ROS assays revealed that FK866 treatment significantly increased ROS levels compared with NAMPT overexpression. In contrast, both NAMPT overexpression and Alisol A treatment lowered ROS relative to FK866, indicating relief of oxidative stress. Moreover, combined FK866 and Alisol A treatment also reduced ROS compared with FK866 alone, suggesting that Alisol A can partially reverse ROS accumulation (Figure <xref rid="F7" ref-type="fig">7</xref>H-I, <italic toggle="yes">P</italic> &lt; 0.01). These findings demonstrate that NAMPT is critical for maintaining neural antioxidant defense and that Alisol A confers protective antioxidant effects by upregulating UCP2 and inhibiting ROS accumulation via the NAMPT pathway.</p><p>Compared with <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice, FK866 treatment reduced Synapsin-1 and PSD95 levels in the CA1 region and the dentate gyrus of the hippocampus, indicating synaptic loss. In contrast, both NMN and Alisol A treatment increased Synapsin-1 and PSD95 expression in these same regions, suggesting that NMN and Alisol A protect synapses (Figure <xref rid="F7" ref-type="fig">7</xref>J, <italic toggle="yes">P</italic> &lt; 0.01). Golgi staining showed that FK866 diminished dendritic branching and spine density in hippocampal neurons, whereas NMN enhanced both dendritic arborization and spine density in CA1 neurons. Moreover, neurons from the NMN group exhibited a higher proportion of mature mushroom-shaped spines and an overall increase in spine number (Figure <xref rid="F7" ref-type="fig">7</xref>K, <italic toggle="yes">P</italic> &lt; 0.05, <italic toggle="yes">P</italic> &lt; 0.01). NMDA receptors are critical excitatory glutamate receptors in the central nervous system, and their functional properties depend largely on the types of NR2 subunits they contain <xref rid="B117" ref-type="bibr">117</xref>. Among these, NR2B and NR2A are the most important and best understood; the balance between their expressions is key to synaptic homeostasis and plasticity <xref rid="B118" ref-type="bibr">118</xref>. Immunofluorescence in HT22 cells revealed that FK866 treatment decreased NR2B expression while increasing NR2A levels, indicative of synaptic inhibition. Overexpression of NAMPT reversed these changes, restoring the NR2B/NR2A balance (Figure <xref rid="F7" ref-type="fig">7</xref>L, <italic toggle="yes">P</italic> &lt; 0.05, <italic toggle="yes">P</italic> &lt; 0.01).</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>In this study, Alisol A demonstrated potent lipid-modulating and anti-atherosclerotic effects. It lowered serum triglyceride, total cholesterol, and LDL-cholesterol levels, reduced aortic plaque burden, and attenuated lipid deposition in brain tissue. Oil red O and HE staining, together with immunohistochemistry, confirmed that Alisol A markedly decreased lipid content within atherosclerotic lesions, improved plaque architecture, and suppressed &#945;-smooth muscle actin and CD68 expression, indicating stabilization of plaques, anti-inflammatory activity, and inhibition of lesion progression. Behavioral assays including the Morris water maze, Y-maze, and novel object recognition tests revealed that Alisol A significantly enhanced learning, spatial memory, and recognition abilities in <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice, indicating restoration and protection of cognitive function. At the synaptic level, Alisol A not only improved hippocampal synaptic ultrastructure evidenced by increased synaptic vesicle density, longer active zone length, narrower synaptic cleft, and thicker postsynaptic density, but also upregulated key synaptic markers Synapsin-1 and PSD95, suggesting promotion of synaptic remodeling and functional coupling. Golgi staining combined with Sholl analysis showed that Alisol A significantly increased dendritic branching complexity, spine density, and the number of mature mushroom-type spines in CA1 neurons. The selective enhancement of mushroom spines, whose enlarged head morphology expands synapse contact area implies that Alisol A restores cognitive function by remodeling synaptic efficacy rather than merely increasing synapse number.</p><p>Disruption of cholesterol metabolism and oxidative stress are key pathological mechanisms in the development of AS related VCI. Alterations in brain cholesterol in humans have been implicated in various neurological and neurodegenerative diseases <xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>. Brain lipids, such as cholesterol, are critical for maintaining neuronal membrane homeostasis and synaptic functions <xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>. Direct suppression of cholesterol synthesis impairs neurotransmitter release <xref rid="B24" ref-type="bibr">24</xref>. We selected <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice as the model for our research experiment on <italic toggle="yes">Ldlr<sup>-/-</sup></italic>, as they are widely recognized as one of the most commonly used models for studying atherosclerosis. Cholesterol is synthesized in situ within the brain, where its concentration surpasses that of any other organ. Cholesterol uptake, synthesis, and metabolism are predominantly regulated by the SREBP2/HMGCR pathway of sterol-responsive genes <xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B119" ref-type="bibr">119</xref>. LXRs serve as potent regulators of reverse cholesterol transport, thereby impeding the progression of atherosclerosis in murine models <xref rid="B120" ref-type="bibr">120</xref>, <xref rid="B121" ref-type="bibr">121</xref>. We found that Alisol A significantly modulates the expression of several key metabolic regulators. Specifically, it upregulates CYP46A1, LXR-&#945;, and ABCA1 to promote cholesterol efflux and metabolism, while downregulating SREBP2 and HMGCR to inhibit cholesterol synthesis and uptake. These changes collectively contribute to restoring dynamic cholesterol balance within neurons. Alisol A markedly alleviates oxidative-reductive imbalance in the hippocampus of <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice. It upregulates the antioxidant enzymes GSH and SOD and the mitochondrial protein UCP2, while reducing levels of the lipid peroxidation product MDA and ROS. <italic toggle="yes">In vitro</italic>, Alisol A pretreatment significantly suppresses ROS accumulation in HT22 cells. Since UCP2 is a key regulator of ROS, its increased expression lowers mitochondrial membrane potential (&#916;&#936;m), creating a superoxide-mediated negative feedback loop that inhibits complex I activity and reduces ROS production. This mechanism was confirmed in HT22 cells co-treated with A&#946;<sub>25-35</sub> and cholesterol complex, where Alisol A pretreatment restored ROS fluorescence intensity to baseline. Furthermore, Alisol A downregulates GFAP in astrocytes and IBA1 in microglia. Sholl analysis shows reduced glial branching complexity and activation, indicating an anti-inflammatory effect. Structurally, Alisol A improves neuronal morphology in the CA1 and dentate gyrus regions of <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mouse hippocampi: it decreases the number of degenerating neurons and increases Nissl body density, confirming its robust neuroprotective effects at both the structural and functional levels. In summary, Alisol A regulates cholesterol metabolism pathways, upregulates UCP2 expression to alleviate oxidative stress, and inhibits glial cell activation, thereby preserving neuronal structure and function.</p><p>Mendelian randomization analysis confirmed that atherosclerosis is a significant risk factor for vascular dementia. Combined lipid metabolomics revealed that differential metabolites were significantly enriched in the AMPK signaling pathway and autophagy pathways. Analysis of GEO datasets showed that NAMPT expression was most markedly altered in atherosclerosis patient samples (<italic toggle="yes">P</italic> &lt; 0.01). To validate the mechanism, we performed molecular docking, molecular dynamics simulation, and surface plasmon resonance assays, demonstrating that Alisol A binds stably to NAMPT by forming hydrogen bonds and hydrophobic contacts at Gln 305 and Tyr 188, with a binding affinity of KD = 65.1 &#956;M. <italic toggle="yes">In vivo</italic>, Alisol A treatment significantly upregulated p-AMPK&#945;, NAMPT, SIRT1, and PGC-1&#945; expression, increased NAD&#8314; levels, reduced acetyl-lysine modifications, and activated the AMPK/NAMPT/SIRT1 axis. In HT22 cells exposed to A&#946;<sub>25-35</sub> plus cholesterol complex and in primary neurons treated with ox-LDL, Alisol A reversed suppression of the AMPK/NAMPT/SIRT1 axis and NAD&#8314; depletion, confirming its positive regulation of cellular energy homeostasis and antioxidant defense. NAMPT plays a critical role in cellular energy homeostasis and mitophagy by regulating NAD&#8314; biosynthesis and SIRT1 activity <xref rid="B122" ref-type="bibr">122</xref>-<xref rid="B124" ref-type="bibr">124</xref>. AMPK serves as an energy sensor that initiates metabolic responses, while NAMPT functions as the rate-limiting enzyme in NAD&#8314; regeneration, providing essential metabolic support for AMPK-dependent activation of SIRT1 <xref rid="B125" ref-type="bibr">125</xref>-<xref rid="B127" ref-type="bibr">127</xref>. Together, these findings indicate that Alisol A activates AMPK/NAMPT/SIRT1 signaling and elevates NAD&#8314; levels, providing a potential target and molecular basis for intervening in AS related VCI.</p><p>Lysine acetylation represents a reversible post-translational modification capable of modifying protein conformation, consequently influencing its stability, DNA binding affinity, and enzymatic activity. This modification is intricately linked to the cellular metabolic state, as acetyl CoA, the primary substrate for energy production, serves as the exclusive donor of acetyl groups for acetylation processes. Additionally, NAD<sup>+</sup> functions as a pivotal metabolite for energy and redox homeostasis and acts as a cofactor for sirtuin (SIRT) deacetylases. Protein acetylation has emerged as a pivotal regulatory mechanism for autophagy <xref rid="B128" ref-type="bibr">128</xref>. Many proteins functioning at different stages of the autophagy pathway have been identified as targets of acetylation. The initiation of autophagy is intricately regulated by acetylation processes involving key molecular components. The mechanistic target of rapamycin kinase complex 1 (MTORC1) and AMPK are pivotal in modulating autophagy initiation. SIRT1, a deacetylase, plays a crucial role by inhibiting acetylation, thereby facilitating the control of autophagy initiation. As the major deacetylase functioning in autophagy, SIRT1 can be activated through an AMPK dependent manner upon glucose deprivation. Activated SIRT1 then deacetylates nuclear LC3 to facilitate autophagy initiation. These findings highlight the crucial role of <italic toggle="yes">sirt1</italic>- mediated <italic toggle="yes">nampt</italic> deacetylation on <italic toggle="yes">Ldlr<sup>-/-</sup></italic>, suggesting targeting <italic toggle="yes">nampt</italic> has the potential to reverse AS-induced autophagy deficiency and provide effective treatment options for <italic toggle="yes">Ldlr<sup>-/-</sup></italic>. <italic toggle="yes">Sirt1</italic>, a NAD&#8314;-dependent deacetylase, promotes autophagy by deacetylating key autophagy-related proteins such as Atg5, Atg7, and Atg8 <xref rid="B102" ref-type="bibr">102</xref>, <xref rid="B103" ref-type="bibr">103</xref>. These deacetylation events are essential for the initiation and maintenance of autophagic activity. <italic toggle="yes">Nampt</italic> regulates intracellular NAD&#8314; levels and thereby indirectly activates <italic toggle="yes">sirt1</italic>, further influencing autophagy processes <xref rid="B129" ref-type="bibr">129</xref>, <xref rid="B130" ref-type="bibr">130</xref>. The activation of autophagy relies on deacetylation of multiple critical autophagy regulators. <italic toggle="yes">Sirt1</italic> enhances autophagy initiation by targeting lysine residues on autophagy-related proteins for deacetylation <xref rid="B88" ref-type="bibr">88</xref>, <xref rid="B131" ref-type="bibr">131</xref>.</p><p>In this study, <italic toggle="yes">in vivo</italic> experiments showed that administration of the <italic toggle="yes">nampt</italic>-specific inhibitor FK866 significantly exacerbated cognitive impairment in <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice. Behavioral tests revealed prolonged escape latency in the Morris water maze, reduced spontaneous alternation in the Y-maze, and impaired novel object recognition. Concurrently, FK866 markedly suppressed the expression of NAMPT and SIRT1 in the hippocampus and reduced NAD&#8314; levels. <italic toggle="yes">In vitro</italic>, FK866 upregulated the expression of cholesterol synthesis-related factors SREBP2 and HMGCR, while downregulating LXR-&#945; and inducing a reduction in hippocampal CYP46A1 expression. These changes led to cholesterol accumulation and metabolic imbalance. Similarly, NAMPT knockdown or FK866 treatment increased the expression of SREBP2 and HMGCR, while suppressing LXR-&#945;, ABCG5, ABCG8, and SIRT1 expression, accompanied by elevated levels of lysine acetylation-further confirming NAMPT's regulatory role in cholesterol metabolism. Immunohistochemical staining of hippocampal tissue corroborated these findings, showing that CYP46A1 expression was significantly downregulated following FK866 treatment, whereas both Alisol A and NMN reversed this reduction. COIP assays demonstrated a direct or indirect protein-protein interaction between NAMPT and CYP46A1. NAMPT overexpression enhanced this interaction, while it was notably weakened in HT22 cells treated with A&#946;<sub>25-35</sub> and cholesterol complexes, as well as in ox-LDL exposed primary neurons. These results suggest that high-cholesterol and stress conditions disrupt NAMPT-CYP46A1 coupling. Notably, Alisol A treatment effectively restored the NAMPT-CYP46A1 interaction, indicating that Alisol A may exert lipid-regulatory and neuroprotective effects by enhancing the functional coupling between NAMPT and CYP46A1, thereby co-regulating cholesterol uptake and efflux pathways. In the brain, cholesterol is a critical component of neuronal function <xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B26" ref-type="bibr">26</xref>, and its dysregulation is closely associated with various neurodegenerative diseases <xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B132" ref-type="bibr">132</xref>, <xref rid="B133" ref-type="bibr">133</xref>. <italic toggle="yes">Cyp46a1</italic> is a brain-specific cholesterol-metabolizing enzyme <xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B29" ref-type="bibr">29</xref>. The suppression of CYP46A1 expression by FK866 indicates that NAMPT plays a vital role in maintaining cerebral cholesterol homeostasis. Disruption of this pathway may lead to cholesterol accumulation in the brain, further contributing to cognitive decline. Altogether, these findings underscore the crucial role of NAMPT in regulating cholesterol metabolism and cognitive function. Modulating NAMPT activity may offer a novel therapeutic strategy for treating neurodegenerative diseases associated with cholesterol dysregulation.</p><p>Mitophagy is essential for maintaining mitochondrial homeostasis by selectively degrading damaged mitochondria, thus adjusting mitochondrial quantity in response to metabolic demands <xref rid="B134" ref-type="bibr">134</xref>, <xref rid="B135" ref-type="bibr">135</xref>. Notably, mitophagy preserves a healthy mitochondrial pool and prevents neuronal death, making it critical for neuronal function and survival <xref rid="B111" ref-type="bibr">111</xref>. Enhancing autophagy has been shown to mitigate neurological dysfunction <xref rid="B111" ref-type="bibr">111</xref>, <xref rid="B136" ref-type="bibr">136</xref>, and autophagy inducers have demonstrated neuroprotective effects in mouse models <xref rid="B137" ref-type="bibr">137</xref>-<xref rid="B139" ref-type="bibr">139</xref>. Regulating the PINK1-mediated mitophagy pathway can improve mitochondrial dysfunction and ameliorate cognitive deficits <xref rid="B111" ref-type="bibr">111</xref>, <xref rid="B140" ref-type="bibr">140</xref>. Previous studies have reported that Alisol A can induce autophagy in a dose-dependent manner <xref rid="B49" ref-type="bibr">49</xref>, <xref rid="B50" ref-type="bibr">50</xref>. Consistent with these findings, our results show that Alisol A treatment significantly increased LC3BII/LC3BI and BECLIN1 levels, while reducing P62 and TOM20 expression, indicating enhanced autophagic flux. In addition, elevated levels of PINK1 and the PARKIN/COXIV ratio were observed, which may reflect Alisol A induced recruitment of PARKIN to damaged mitochondria via PINK1 activation. This recruitment promotes LC3B engagement and triggers PINK1/PARKIN dependent mitophagy, leading to TOM20 degradation and a reduction in mitochondrial COXIV protein levels. Taken together, these findings demonstrate that Alisol A markedly improves mitophagy function by activating the AMPK/NAMPT/SIRT1 signaling pathway in hippocampal tissue and neuronal cells. In A&#946;<sub>25-35</sub> plus cholesterol complex treated cellular models and in ox-LDL exposed primary neurons, Alisol A was found to activate the PINK1/PARKIN mediated mitophagy pathway, facilitating the recognition and clearance of damaged mitochondria and thereby restoring mitochondrial function. Furthermore, Alisol A treatment improved mitochondrial membrane potential and enhanced autophagic flux, supporting its role in restoring mitochondrial homeostasis and improving cognitive function. Based on these findings, this study suggests that Alisol A may improve cognitive impairment in <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice by maintaining mitophagy homeostasis. Notably, although NAMPT was identified as a key regulator of mitophagy, we further observed that Alisol A was still able to partially restore the PINK1/PARKIN signaling pathway, enhance LC3B conversion, and reduce P62 expression under conditions of NAMPT inhibition. This indicates that Alisol A possesses a degree of NAMPT-independent regulatory activity on autophagy. Importantly, this observation does not diminish the role of NAMPT in mitophagy regulation. Instead, it highlights the multi-target and multi-mechanism pharmacological nature of Alisol A, revealing its potential to preserve mitochondrial integrity even under complex pathological conditions such as NAMPT suppression or NAD&#8314; depletion. This study not only deepens our understanding of NAMPT's role in neuronal homeostasis but also provides important theoretical support for the therapeutic application of Alisol A in AS related VCI.</p><p>In this study, it was noted that an elevation in the autophagy substrate protein P62, in conjunction with PINK1/PARKIN-dependent compromised mitophagy, was apparent in <italic toggle="yes">Ldlr<sup>-/-</sup></italic>, resulting in neuronal degeneration in the hippocampus. This study's findings indicate that disruption of mitophagy and mitochondrial dynamics, resulting from mitochondrial dysfunction, are critical mechanisms underlying cholesterol-induced synaptic impairment and cognitive decline in the hippocampus. Treatment with Alisol A significantly elevates LC3BII/LC3BI and Beclin1 levels, while decreasing P62 and TOM20 levels, indicating that Alisol A enhances autophagic flux. Additionally, the observed increases in PINK1 and PARKIN/COXIV levels. This might be interpreted as treatment with Alisol A stimulates PINK1-induced translocation of Parkin to damaged mitochondria the latter links LC3B to initiate mitophagy, namely, the PINK1/PARKIN-dependent mitophagy pathway to degrade TOM20 and induces a decrease in mitochondrial COXIV protein level. Our results showed that Alisol A treatment can more effectively prevent mitochondrial damage and autophagy inhibition in HT22 exposed to A&#946;<sub>25-35</sub> and cholesterol complexes. NAMPT knockout reduced PINK1 expression in HT22 cells. Our COIP assay shows that NAMPT interacts with PINK1, and Alisol A -NAMPT binding boosts PINK1 activity, enhancing autophagy by increasing PARKIN recruitment. Based on these results, we believe that Alisol A may ameliorate <italic toggle="yes">Ldlr<sup>-/-</sup></italic> by maintaining the homeostasis of mitophagy.</p><p>Immunofluorescence analysis showed that FK866 significantly reduced UCP2 expression, while NMN and Alisol A treatment restored UCP2 levels. ROS assays revealed that FK866 increased ROS accumulation, whereas NAMPT overexpression and Alisol A treatment effectively reduced ROS levels. At the synaptic level, FK866 decreased Synapsin-1 and PSD95 expression in the hippocampus, as shown by immunofluorescence, while both NMN and Alisol A upregulated these synaptic markers. Golgi staining combined with Sholl analysis confirmed that Alisol A increased dendritic spine density and the proportion of mature mushroom-shaped spines, ameliorating FK866-induced dendritic damage. Analysis of NMDA receptor subunits revealed that FK866 suppressed NMDA 2B and increased NMDA 2A expression, indicating a shift toward synaptic inhibition. Alisol A restored the NMDA 2B/2A expression ratio, suggesting enhanced synaptic signaling. Collectively, these findings demonstrate that NAMPT plays a key role in regulating neuronal oxidative stress and synaptic plasticity. Upregulation of NAMPT helps maintain synaptic structure and functional stability. By activating the NAMPT pathway, Alisol A alleviates oxidative damage and promotes synaptic remodeling, thereby effectively improving VCI-related neurological dysfunction. In conclusion, NAMPT is a critical therapeutic target of Alisol A in the treatment of atherosclerosis-related vascular cognitive impairment. Through NAMPT regulation, Alisol A improves cholesterol metabolism, restores mitophagic activity, facilitates the clearance of damaged mitochondria, reduces oxidative stress, and enhances synaptic plasticity, ultimately exerting neuroprotective effects.</p><p>However, this study has certain limitations. Although FK866 induces MMP collapse and activates apoptosis by inhibiting NAMPT, it lacks single-cell level tracking of the spatiotemporal dynamics underlying the crosstalk between autophagy and apoptosis. It is important to note that autophagy plays a dual role in neurodegenerative conditions: moderate autophagy can remove misfolded proteins and support neuronal survival, whereas excessive autophagy may lead to lysosomal membrane permeabilization and trigger apoptosis <xref rid="B141" ref-type="bibr">141</xref>. Future studies should employ CRISPR interference (CRISPRi) systems to achieve temporally controlled regulation of autophagic flux in specific brain regions <xref rid="B142" ref-type="bibr">142</xref>-<xref rid="B144" ref-type="bibr">144</xref>, and integrate two-photon imaging to explore the dynamic interplay between dendritic spine remodeling and apoptotic signaling <xref rid="B145" ref-type="bibr">145</xref>.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>In conclusion, this study demonstrates two key findings: First, Alisol A exerts neuroprotective effects by activating the AMPK/NAMPT/SIRT1 signaling pathway in hippocampal tissue and neurons, thereby promoting PINK1/PARKIN-mediated mitophagy and restoring the function of damaged mitochondria. Second, NAMPT is identified as a critical therapeutic target of Alisol A in the treatment of AS related VCI. Through regulation of NAMPT, Alisol A improves cholesterol metabolism, restores mitophagic activity, facilitates the clearance of damaged mitochondria, alleviates oxidative stress, and promotes the reconstruction of synaptic plasticity, ultimately contributing to neuroprotection. Our research results offer valuable insights for the continued advancement of Alisol A as a promising lead compound in research as potential anti-AS related VCI candidates.</p></sec><sec id="SM0" sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="SM1" position="float" content-type="local-data" orientation="portrait"><caption><p>Supplementary tables.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="thnov15p9415s1.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack><sec><title>Funding</title><p>This study was funded by grants from the Natural Science Foundation of China (82074292), the NATCM's Project of High-level Construction of Key TCM Disciplines (2023, Grant No.85), and the Postgraduate Research &amp; Practice Innovation Program of Jiangsu Province (SJCX24_0930).</p></sec><sec><title>Author contributions</title><p>P.X. and W.Z. conducted experiments, analyzed data, and wrote the manuscript equally. D.W., L.W., Y.B., and S.X. conducted <italic toggle="yes">in vitro</italic> experiments. D.X., M.L., J.S., and H.W. contributed to study design and supervision. All authors reviewed and approved the final manuscript.</p></sec><sec><title>Compliance with ethics requirements</title><p>All Institutional and National Guidelines for the care and use of animals (fisheries) were followed.</p></sec></ack><glossary><title>Abbreviations</title><def-list><def-item><term id="GL1">AS</term><def><p>Atherosclerosis</p></def></def-item><def-item><term id="GL2">VCI</term><def><p>Vascular cognitive impairment</p></def></def-item><def-item><term id="GL3">ZXYF</term><def><p>ZeXieYin Formula</p></def></def-item><def-item><term id="GL4">VaD</term><def><p>Vascular dementia</p></def></def-item><def-item><term id="GL5">LDL</term><def><p>Low-density lipoprotein</p></def></def-item><def-item><term id="GL6">LDL-c</term><def><p>Low-density lipoprotein cholesterol</p></def></def-item><def-item><term id="GL7">ox-LDL</term><def><p>Oxidized low-density lipoprotein</p></def></def-item><def-item><term id="GL8">CSVD</term><def><p>Cerebral small vessel disease</p></def></def-item><def-item><term id="GL9">BBB</term><def><p>Blood brain barrier</p></def></def-item><def-item><term id="GL10">A&#946;</term><def><p>Amyloid-&#946;</p></def></def-item><def-item><term id="GL11">LXR</term><def><p>Liver X receptor</p></def></def-item><def-item><term id="GL12">NLRP3</term><def><p>NOD-like receptor family pyrin domain containing 3</p></def></def-item><def-item><term id="GL13">TCM</term><def><p>Traditional Chinese medicine</p></def></def-item><def-item><term id="GL14">AMPK</term><def><p>AMP-activated protein kinase</p></def></def-item><def-item><term id="GL15">NAMPT</term><def><p>Nicotinamide phosphoribosyltransferase</p></def></def-item><def-item><term id="GL16">SIRT1</term><def><p>Sirtuin 1</p></def></def-item><def-item><term id="GL17">NMN</term><def><p>Nicotinamide mononucleotide</p></def></def-item><def-item><term id="GL18">MWM</term><def><p>Morris water maze</p></def></def-item><def-item><term id="GL19">NOR</term><def><p>Novel object recognition</p></def></def-item><def-item><term id="GL20">ROS</term><def><p>Reactive oxygen species</p></def></def-item><def-item><term id="GL21">SOD</term><def><p>Superoxide dismutase</p></def></def-item><def-item><term id="GL22">GSH</term><def><p>Glutathione</p></def></def-item><def-item><term id="GL23">MDA</term><def><p>Malondialdehyde</p></def></def-item><def-item><term id="GL24">UCP2</term><def><p>Uncoupling protein 2</p></def></def-item><def-item><term id="GL25">CYP46A1</term><def><p>Cholesterol 24-hydroxylase</p></def></def-item><def-item><term id="GL26">HMGCR</term><def><p>3-hydroxy-3-methylglutaryl-coenzyme A reductase</p></def></def-item><def-item><term id="GL27">ABCA1</term><def><p>ATP-binding cassette transporter A1</p></def></def-item><def-item><term id="GL28">ABCG5/8</term><def><p>ATP-binding cassette subfamily G members 5/8</p></def></def-item><def-item><term id="GL29">SREBP2</term><def><p>Sterol regulatory element-binding protein 2</p></def></def-item><def-item><term id="GL30">PGC1-&#945;</term><def><p>Peroxisome proliferator-activated receptor gamma coactivator 1-alpha</p></def></def-item><def-item><term id="GL31">LC3B</term><def><p>Microtubule-associated protein 1A/1B-light chain 3B</p></def></def-item><def-item><term id="GL32">PINK1</term><def><p>PTEN-induced kinase 1</p></def></def-item><def-item><term id="GL33">PARKIN</term><def><p>E3 ubiquitin-protein ligase PARK2</p></def></def-item><def-item><term id="GL34">TOM20</term><def><p>Translocase of the outer membrane 20</p></def></def-item><def-item><term id="GL35">COXIV</term><def><p>Cytochrome c oxidase subunit IV</p></def></def-item><def-item><term id="GL36">BECLIN1</term><def><p>Autophagy protein Beclin-1</p></def></def-item><def-item><term id="GL37">P62/SQSTM1</term><def><p>Sequestosome 1</p></def></def-item><def-item><term id="GL38">OPTN</term><def><p>Optineurin</p></def></def-item><def-item><term id="GL39">NR2A/NR2B</term><def><p>NMDA receptor subunits 2A and 2B</p></def></def-item><def-item><term id="GL40">PSD95</term><def><p>Postsynaptic density protein 95</p></def></def-item><def-item><term id="GL41">SPR</term><def><p>Surface plasmon resonance</p></def></def-item><def-item><term id="GL42">GEO</term><def><p>Gene Expression Omnibus</p></def></def-item><def-item><term id="GL43">GWAS</term><def><p>Genome-wide association study</p></def></def-item><def-item><term id="GL44">IVW</term><def><p>Inverse variance weighted</p></def></def-item><def-item><term id="GL45">TEM</term><def><p>Transmission electron microscopy</p></def></def-item><def-item><term id="GL46">IHC</term><def><p>Immunohistochemistry</p></def></def-item><def-item><term id="GL47">IF</term><def><p>Immunofluorescence</p></def></def-item><def-item><term id="GL48">COIP</term><def><p>Co-immunoprecipitation</p></def></def-item><def-item><term id="GL49">MMP</term><def><p>Mitochondrial membrane potential</p></def></def-item><def-item><term id="GL50">TSA</term><def><p>Trichostatin A</p></def></def-item><def-item><term id="GL51">NAM</term><def><p>Nicotinamide</p></def></def-item><def-item><term id="GL52">NAD&#8314;</term><def><p>Nicotinamide adenine dinucleotide</p></def></def-item></def-list></glossary><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><name name-style="western"><surname>Tian</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>M</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N</given-names></name><name name-style="western"><surname>Shi</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><etal/><article-title>Physical and biopsychosocial frailty, cognitive phenotypes, and plasma biomarkers for Alzheimer's disease in Chinese older adults: A population-based study</article-title><source>Alzheimers Dement</source><year>2025</year><volume>21</volume><fpage>e70303</fpage><pub-id pub-id-type="pmid">40399764</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.70303</pub-id><pub-id pub-id-type="pmcid">PMC12094879</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><name name-style="western"><surname>Collyer</surname><given-names>TA</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><name name-style="western"><surname>Beare</surname><given-names>R</given-names></name><name name-style="western"><surname>Andrew</surname><given-names>NE</given-names></name><name name-style="western"><surname>Ung</surname><given-names>D</given-names></name><name name-style="western"><surname>Carver</surname><given-names>A</given-names></name><etal/><article-title>Dual-stream algorithms for dementia detection: Harnessing structured and unstructured electronic health record data, a novel approach to prevalence estimation</article-title><source>Alzheimers Dement</source><year>2025</year><volume>21</volume><fpage>e70132</fpage><pub-id pub-id-type="pmid">40325920</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.70132</pub-id><pub-id pub-id-type="pmcid">PMC12053150</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="other"><name name-style="western"><surname>Lett</surname><given-names>TA</given-names></name><name name-style="western"><surname>Vaidya</surname><given-names>N</given-names></name><name name-style="western"><surname>Jia</surname><given-names>T</given-names></name><name name-style="western"><surname>Polemiti</surname><given-names>E</given-names></name><name name-style="western"><surname>Banaschewski</surname><given-names>T</given-names></name><name name-style="western"><surname>Bokde</surname><given-names>ALW</given-names></name><etal/><article-title>Framework for Brain-Derived Dimensions of Psychopathology</article-title><source>JAMA Psychiatry</source><year>2025</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamapsychiatry.2025.1246</pub-id><pub-id pub-id-type="pmcid">PMC12177734</pub-id><pub-id pub-id-type="pmid">40531512</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><name name-style="western"><surname>Hayes</surname><given-names>CA</given-names></name><name name-style="western"><surname>Young</surname><given-names>CB</given-names></name><name name-style="western"><surname>Abdelnour</surname><given-names>C</given-names></name><name name-style="western"><surname>Reeves</surname><given-names>A</given-names></name><name name-style="western"><surname>Odden</surname><given-names>MC</given-names></name><name name-style="western"><surname>Nirschl</surname><given-names>J</given-names></name><etal/><article-title>The impact of arteriolosclerosis on cognitive impairment in decedents without severe dementia from the National Alzheimer's Coordinating Center</article-title><source>Alzheimers Dement</source><year>2025</year><volume>21</volume><fpage>e70059</fpage><pub-id pub-id-type="pmid">40110658</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.70059</pub-id><pub-id pub-id-type="pmcid">PMC11923572</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><name name-style="western"><surname>Markus</surname><given-names>HS</given-names></name><name name-style="western"><surname>Joutel</surname><given-names>A</given-names></name><article-title>The pathogenesis of cerebral small vessel disease and vascular cognitive impairment</article-title><source>Physiol Rev</source><year>2025</year><volume>105</volume><fpage>1075</fpage><lpage>171</lpage><pub-id pub-id-type="pmid">39965059</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/physrev.00028.2024</pub-id><pub-id pub-id-type="pmcid">PMC12182829</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><name name-style="western"><surname>Ashok</surname><given-names>A</given-names></name><name name-style="western"><surname>Rai</surname><given-names>NK</given-names></name><name name-style="western"><surname>Raza</surname><given-names>W</given-names></name><name name-style="western"><surname>Pandey</surname><given-names>R</given-names></name><name name-style="western"><surname>Bandyopadhyay</surname><given-names>S</given-names></name><article-title>Chronic cerebral hypoperfusion-induced impairment of Abeta clearance requires HB-EGF-dependent sequential activation of HIF1alpha and MMP9</article-title><source>Neurobiol Dis</source><year>2016</year><volume>95</volume><fpage>179</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">27431094</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbd.2016.07.013</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><name name-style="western"><surname>Nyul-Toth</surname><given-names>A</given-names></name><name name-style="western"><surname>Patai</surname><given-names>R</given-names></name><name name-style="western"><surname>Csiszar</surname><given-names>A</given-names></name><name name-style="western"><surname>Ungvari</surname><given-names>A</given-names></name><name name-style="western"><surname>Gulej</surname><given-names>R</given-names></name><name name-style="western"><surname>Mukli</surname><given-names>P</given-names></name><etal/><article-title>Linking peripheral atherosclerosis to blood-brain barrier disruption: elucidating its role as a manifestation of cerebral small vessel disease in vascular cognitive impairment</article-title><source>Geroscience</source><year>2024</year><volume>46</volume><fpage>6511</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">38831182</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11357-024-01194-0</pub-id><pub-id pub-id-type="pmcid">PMC11494622</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><name name-style="western"><surname>Jinson</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Lancaster</surname><given-names>GI</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>PK</given-names></name><article-title>Iron, lipid peroxidation, and ferroptosis play pathogenic roles in atherosclerosis</article-title><source>Cardiovasc Res</source><year>2025</year><volume>121</volume><fpage>44</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">39739567</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cvr/cvae270</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><name name-style="western"><surname>French</surname><given-names>SR</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>BP</given-names></name><name name-style="western"><surname>Arias</surname><given-names>JC</given-names></name><name name-style="western"><surname>Levendovzsky</surname><given-names>SR</given-names></name><name name-style="western"><surname>Weinkauf</surname><given-names>CC</given-names></name><article-title>Biomarkers of blood-brain barrier and neurovascular unit integrity in human cognitive impairment and dementia</article-title><source>Alzheimers Dement</source><year>2025</year><volume>21</volume><fpage>e70104</fpage><pub-id pub-id-type="pmid">40145342</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.70104</pub-id><pub-id pub-id-type="pmcid">PMC11947770</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="other"><name name-style="western"><surname>Markus</surname><given-names>HS</given-names></name><name name-style="western"><surname>Joutel</surname><given-names>A</given-names></name><article-title>The pathogenesis of cerebral small vessel diseases and vascular cognitive impairment</article-title><source>Physiol Rev</source><year>2025</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/physrev.00028.2024</pub-id><pub-id pub-id-type="pmcid">PMC12182829</pub-id><pub-id pub-id-type="pmid">39965059</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><name name-style="western"><surname>Poh</surname><given-names>L</given-names></name><name name-style="western"><surname>Sim</surname><given-names>WL</given-names></name><name name-style="western"><surname>Jo</surname><given-names>DG</given-names></name><name name-style="western"><surname>Dinh</surname><given-names>QN</given-names></name><name name-style="western"><surname>Drummond</surname><given-names>GR</given-names></name><name name-style="western"><surname>Sobey</surname><given-names>CG</given-names></name><etal/><article-title>The role of inflammasomes in vascular cognitive impairment</article-title><source>Mol Neurodegener</source><year>2022</year><volume>17</volume><fpage>4</fpage><pub-id pub-id-type="pmid">35000611</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-021-00506-8</pub-id><pub-id pub-id-type="pmcid">PMC8744307</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><name name-style="western"><surname>Suzuki</surname><given-names>R</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K</given-names></name><name name-style="western"><surname>Jing</surname><given-names>E</given-names></name><name name-style="western"><surname>Biddinger</surname><given-names>SB</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>JG</given-names></name><name name-style="western"><surname>Montine</surname><given-names>TJ</given-names></name><etal/><article-title>Diabetes and insulin in regulation of brain cholesterol metabolism</article-title><source>Cell Metab</source><year>2010</year><volume>12</volume><fpage>567</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">21109190</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2010.11.006</pub-id><pub-id pub-id-type="pmcid">PMC3205997</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><name name-style="western"><surname>Li</surname><given-names>T</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><etal/><article-title>Ion mobility-based sterolomics reveals spatially and temporally distinctive sterol lipids in the mouse brain</article-title><source>Nat Commun</source><year>2021</year><volume>12</volume><fpage>4343</fpage><pub-id pub-id-type="pmid">34267224</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-24672-x</pub-id><pub-id pub-id-type="pmcid">PMC8282640</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Dong</surname><given-names>G</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name><etal/><article-title>Remnant cholesterol and mild cognitive impairment: A cross-sectional study</article-title><source>Front Aging Neurosci</source><year>2023</year><volume>15</volume><fpage>1069076</fpage><pub-id pub-id-type="pmid">37009458</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2023.1069076</pub-id><pub-id pub-id-type="pmcid">PMC10057110</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><name name-style="western"><surname>Solomon</surname><given-names>A</given-names></name><name name-style="western"><surname>Kareholt</surname><given-names>I</given-names></name><name name-style="western"><surname>Ngandu</surname><given-names>T</given-names></name><name name-style="western"><surname>Winblad</surname><given-names>B</given-names></name><name name-style="western"><surname>Nissinen</surname><given-names>A</given-names></name><name name-style="western"><surname>Tuomilehto</surname><given-names>J</given-names></name><etal/><article-title>Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study</article-title><source>Neurology</source><year>2007</year><volume>68</volume><fpage>751</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">17339582</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/01.wnl.0000256368.57375.b7</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><name name-style="western"><surname>Iwagami</surname><given-names>M</given-names></name><name name-style="western"><surname>Qizilbash</surname><given-names>N</given-names></name><name name-style="western"><surname>Gregson</surname><given-names>J</given-names></name><name name-style="western"><surname>Douglas</surname><given-names>I</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>M</given-names></name><name name-style="western"><surname>Pearce</surname><given-names>N</given-names></name><etal/><article-title>Blood cholesterol and risk of dementia in more than 1.8 million people over two decades: a retrospective cohort study</article-title><source>Lancet Healthy Longev</source><year>2021</year><volume>2</volume><fpage>e498</fpage><lpage>e506</lpage><pub-id pub-id-type="pmid">36097999</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2666-7568(21)00150-1</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><name name-style="western"><surname>Ishii</surname><given-names>M</given-names></name><article-title>Midlife dyslipidaemia as a modifiable risk factor for later-life dementia</article-title><source>Lancet Healthy Longev</source><year>2021</year><volume>2</volume><fpage>e453</fpage><lpage>e4</lpage><pub-id pub-id-type="pmid">36097993</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2666-7568(21)00175-6</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="other"><name name-style="western"><surname>Ge</surname><given-names>X</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>M</given-names></name><name name-style="western"><surname>Hu</surname><given-names>M</given-names></name><name name-style="western"><surname>Fang</surname><given-names>X</given-names></name><name name-style="western"><surname>Geng</surname><given-names>D</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><etal/><article-title>Butyrate ameliorates quinolinic acid-induced cognitive decline in obesity models</article-title><source>J Clin Invest</source><year>2023</year><comment>133</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI154612</pub-id><pub-id pub-id-type="pmcid">PMC9927952</pub-id><pub-id pub-id-type="pmid">36787221</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><name name-style="western"><surname>Liu</surname><given-names>LC</given-names></name><name name-style="western"><surname>Liang</surname><given-names>JY</given-names></name><name name-style="western"><surname>Liu</surname><given-names>YH</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><name name-style="western"><surname>Dong</surname><given-names>XH</given-names></name><name name-style="western"><surname>Cai</surname><given-names>WH</given-names></name><etal/><article-title>The Intersection of cerebral cholesterol metabolism and Alzheimer's disease: Mechanisms and therapeutic prospects</article-title><source>Heliyon</source><year>2024</year><volume>10</volume><fpage>e30523</fpage><pub-id pub-id-type="pmid">38726205</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.heliyon.2024.e30523</pub-id><pub-id pub-id-type="pmcid">PMC11079309</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><name name-style="western"><surname>de Dios</surname><given-names>C</given-names></name><name name-style="western"><surname>Abadin</surname><given-names>X</given-names></name><name name-style="western"><surname>Roca-Agujetas</surname><given-names>V</given-names></name><name name-style="western"><surname>Jimenez-Martinez</surname><given-names>M</given-names></name><name name-style="western"><surname>Morales</surname><given-names>A</given-names></name><name name-style="western"><surname>Trullas</surname><given-names>R</given-names></name><etal/><article-title>Inflammasome activation under high cholesterol load triggers a protective microglial phenotype while promoting neuronal pyroptosis</article-title><source>Transl Neurodegener</source><year>2023</year><volume>12</volume><fpage>10</fpage><pub-id pub-id-type="pmid">36895045</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40035-023-00343-3</pub-id><pub-id pub-id-type="pmcid">PMC9996936</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><name name-style="western"><surname>Liao</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Wei</surname><given-names>ZZ</given-names></name><name name-style="western"><surname>Yu</surname><given-names>SP</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name><etal/><article-title>C/EBPbeta/AEP signaling couples atherosclerosis to the pathogenesis of Alzheimer's disease</article-title><source>Mol Psychiatry</source><year>2022</year><volume>27</volume><fpage>3034</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">35422468</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41380-022-01556-0</pub-id><pub-id pub-id-type="pmcid">PMC9912845</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><name name-style="western"><surname>MacHugh</surname><given-names>ND</given-names></name><name name-style="western"><surname>Bensaid</surname><given-names>A</given-names></name><name name-style="western"><surname>Davis</surname><given-names>WC</given-names></name><name name-style="western"><surname>Howard</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Parsons</surname><given-names>KR</given-names></name><name name-style="western"><surname>Jones</surname><given-names>B</given-names></name><etal/><article-title>Characterization of a bovine thymic differentiation antigen analogous to CD1 in the human</article-title><source>Scand J Immunol</source><year>1988</year><volume>27</volume><fpage>541</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">3287595</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-3083.1988.tb02381.x</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><name name-style="western"><surname>Baloni</surname><given-names>P</given-names></name><name name-style="western"><surname>Funk</surname><given-names>CC</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J</given-names></name><name name-style="western"><surname>Yurkovich</surname><given-names>JT</given-names></name><name name-style="western"><surname>Kueider-Paisley</surname><given-names>A</given-names></name><name name-style="western"><surname>Nho</surname><given-names>K</given-names></name><etal/><article-title>Metabolic Network Analysis Reveals Altered Bile Acid Synthesis and Metabolism in Alzheimer's Disease</article-title><source>Cell Rep Med</source><year>2020</year><volume>1</volume><fpage>100138</fpage><pub-id pub-id-type="pmid">33294859</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xcrm.2020.100138</pub-id><pub-id pub-id-type="pmcid">PMC7691449</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><name name-style="western"><surname>Essayan-Perez</surname><given-names>S</given-names></name><name name-style="western"><surname>Sudhof</surname><given-names>TC</given-names></name><article-title>Neuronal gamma-secretase regulates lipid metabolism, linking cholesterol to synaptic dysfunction in Alzheimer's disease</article-title><source>Neuron</source><year>2023</year><volume>111</volume><fpage>3176</fpage><lpage>94</lpage><comment>e7</comment><pub-id pub-id-type="pmid">37543038</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2023.07.005</pub-id><pub-id pub-id-type="pmcid">PMC10592349</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><name name-style="western"><surname>Beck</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Guo</surname><given-names>L</given-names></name><name name-style="western"><surname>Phensy</surname><given-names>A</given-names></name><name name-style="western"><surname>Tian</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Tandon</surname><given-names>N</given-names></name><etal/><article-title>Deregulation of mitochondrial F1FO-ATP synthase via OSCP in Alzheimer's disease</article-title><source>Nat Commun</source><year>2016</year><volume>7</volume><fpage>11483</fpage><pub-id pub-id-type="pmid">27151236</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms11483</pub-id><pub-id pub-id-type="pmcid">PMC5494197</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><name name-style="western"><surname>Barbero-Camps</surname><given-names>E</given-names></name><name name-style="western"><surname>Roca-Agujetas</surname><given-names>V</given-names></name><name name-style="western"><surname>Bartolessis</surname><given-names>I</given-names></name><name name-style="western"><surname>de Dios</surname><given-names>C</given-names></name><name name-style="western"><surname>Fernandez-Checa</surname><given-names>JC</given-names></name><name name-style="western"><surname>Mari</surname><given-names>M</given-names></name><etal/><article-title>Cholesterol impairs autophagy-mediated clearance of amyloid beta while promoting its secretion</article-title><source>Autophagy</source><year>2018</year><volume>14</volume><fpage>1129</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">29862881</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15548627.2018.1438807</pub-id><pub-id pub-id-type="pmcid">PMC6103708</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><name name-style="western"><surname>Testa</surname><given-names>G</given-names></name><name name-style="western"><surname>Staurenghi</surname><given-names>E</given-names></name><name name-style="western"><surname>Zerbinati</surname><given-names>C</given-names></name><name name-style="western"><surname>Gargiulo</surname><given-names>S</given-names></name><name name-style="western"><surname>Iuliano</surname><given-names>L</given-names></name><name name-style="western"><surname>Giaccone</surname><given-names>G</given-names></name><etal/><article-title>Changes in brain oxysterols at different stages of Alzheimer's disease: Their involvement in neuroinflammation</article-title><source>Redox Biol</source><year>2016</year><volume>10</volume><fpage>24</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">27687218</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.redox.2016.09.001</pub-id><pub-id pub-id-type="pmcid">PMC5040635</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><name name-style="western"><surname>Paul</surname><given-names>SM</given-names></name><name name-style="western"><surname>Doherty</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Robichaud</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Belfort</surname><given-names>GM</given-names></name><name name-style="western"><surname>Chow</surname><given-names>BY</given-names></name><name name-style="western"><surname>Hammond</surname><given-names>RS</given-names></name><etal/><article-title>The major brain cholesterol metabolite 24(S)-hydroxycholesterol is a potent allosteric modulator of N-methyl-D-aspartate receptors</article-title><source>J Neurosci</source><year>2013</year><volume>33</volume><fpage>17290</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">24174662</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.2619-13.2013</pub-id><pub-id pub-id-type="pmcid">PMC3812502</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><name name-style="western"><surname>Wei</surname><given-names>X</given-names></name><name name-style="western"><surname>Nishi</surname><given-names>T</given-names></name><name name-style="western"><surname>Kondou</surname><given-names>S</given-names></name><name name-style="western"><surname>Kimura</surname><given-names>H</given-names></name><name name-style="western"><surname>Mody</surname><given-names>I</given-names></name><article-title>Preferential enhancement of GluN2B-containing native NMDA receptors by the endogenous modulator 24S-hydroxycholesterol in hippocampal neurons</article-title><source>Neuropharmacology</source><year>2019</year><volume>148</volume><fpage>11</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">30594698</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuropharm.2018.12.028</pub-id><pub-id pub-id-type="pmcid">PMC6424632</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><name name-style="western"><surname>Suri</surname><given-names>MFK</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chu</surname><given-names>H</given-names></name><name name-style="western"><surname>Qureshi</surname><given-names>AI</given-names></name><name name-style="western"><surname>Mosley</surname><given-names>T</given-names></name><etal/><article-title>Cognitive impairment and intracranial atherosclerotic stenosis in general population</article-title><source>Neurology</source><year>2018</year><volume>90</volume><fpage>e1240</fpage><lpage>e7</lpage><pub-id pub-id-type="pmid">29523643</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000005250</pub-id><pub-id pub-id-type="pmcid">PMC5890611</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><name name-style="western"><surname>de Montgolfier</surname><given-names>O</given-names></name><name name-style="western"><surname>Pouliot</surname><given-names>P</given-names></name><name name-style="western"><surname>Gillis</surname><given-names>MA</given-names></name><name name-style="western"><surname>Ferland</surname><given-names>G</given-names></name><name name-style="western"><surname>Lesage</surname><given-names>F</given-names></name><name name-style="western"><surname>Thorin-Trescases</surname><given-names>N</given-names></name><etal/><article-title>Systolic hypertension-induced neurovascular unit disruption magnifies vascular cognitive impairment in middle-age atherosclerotic LDLr(-/-):hApoB(+/+) mice</article-title><source>Geroscience</source><year>2019</year><volume>41</volume><fpage>511</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">31093829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11357-019-00070-6</pub-id><pub-id pub-id-type="pmcid">PMC6885084</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><name name-style="western"><surname>Yan</surname><given-names>J</given-names></name><name name-style="western"><surname>Porch</surname><given-names>MW</given-names></name><name name-style="western"><surname>Court-Vazquez</surname><given-names>B</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>MVL</given-names></name><name name-style="western"><surname>Zukin</surname><given-names>RS</given-names></name><article-title>Activation of autophagy rescues synaptic and cognitive deficits in fragile X mice</article-title><source>Proc Natl Acad Sci U S A</source><year>2018</year><volume>115</volume><fpage>E9707</fpage><lpage>E16</lpage><pub-id pub-id-type="pmid">30242133</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1808247115</pub-id><pub-id pub-id-type="pmcid">PMC6187122</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><name name-style="western"><surname>Fernandez</surname><given-names>A</given-names></name><name name-style="western"><surname>Meechan</surname><given-names>DW</given-names></name><name name-style="western"><surname>Karpinski</surname><given-names>BA</given-names></name><name name-style="western"><surname>Paronett</surname><given-names>EM</given-names></name><name name-style="western"><surname>Bryan</surname><given-names>CA</given-names></name><name name-style="western"><surname>Rutz</surname><given-names>HL</given-names></name><etal/><article-title>Mitochondrial Dysfunction Leads to Cortical Under-Connectivity and Cognitive Impairment</article-title><source>Neuron</source><year>2019</year><volume>102</volume><fpage>1127</fpage><lpage>42</lpage><comment>e3</comment><pub-id pub-id-type="pmid">31079872</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2019.04.013</pub-id><pub-id pub-id-type="pmcid">PMC6668992</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><name name-style="western"><surname>Larramona-Arcas</surname><given-names>R</given-names></name><name name-style="western"><surname>Gonzalez-Arias</surname><given-names>C</given-names></name><name name-style="western"><surname>Perea</surname><given-names>G</given-names></name><name name-style="western"><surname>Gutierrez</surname><given-names>A</given-names></name><name name-style="western"><surname>Vitorica</surname><given-names>J</given-names></name><name name-style="western"><surname>Garcia-Barrera</surname><given-names>T</given-names></name><etal/><article-title>Sex-dependent calcium hyperactivity due to lysosomal-related dysfunction in astrocytes from APOE4 versus APOE3 gene targeted replacement mice</article-title><source>Mol Neurodegener</source><year>2020</year><volume>15</volume><fpage>35</fpage><pub-id pub-id-type="pmid">32517777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-020-00382-8</pub-id><pub-id pub-id-type="pmcid">PMC7285605</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Geng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gao</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Mu</surname><given-names>X</given-names></name><etal/><article-title>Maternal exposure to CeO(2)NPs derails placental development through trophoblast dysfunction mediated by excessive autophagy activation</article-title><source>J Nanobiotechnology</source><year>2022</year><volume>20</volume><fpage>131</fpage><pub-id pub-id-type="pmid">35292031</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12951-022-01334-8</pub-id><pub-id pub-id-type="pmcid">PMC8922923</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><name name-style="western"><surname>Youle</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Narendra</surname><given-names>DP</given-names></name><article-title>Mechanisms of mitophagy</article-title><source>Nat Rev Mol Cell Biol</source><year>2011</year><volume>12</volume><fpage>9</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">21179058</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrm3028</pub-id><pub-id pub-id-type="pmcid">PMC4780047</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><name name-style="western"><surname>Fang</surname><given-names>EF</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Palikaras</surname><given-names>K</given-names></name><name name-style="western"><surname>Adriaanse</surname><given-names>BA</given-names></name><name name-style="western"><surname>Kerr</surname><given-names>JS</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B</given-names></name><etal/><article-title>Mitophagy inhibits amyloid-beta and tau pathology and reverses cognitive deficits in models of Alzheimer's disease</article-title><source>Nat Neurosci</source><year>2019</year><volume>22</volume><fpage>401</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">30742114</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41593-018-0332-9</pub-id><pub-id pub-id-type="pmcid">PMC6693625</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><name name-style="western"><surname>Dodson</surname><given-names>M</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>MS</given-names></name><name name-style="western"><surname>Redmann</surname><given-names>M</given-names></name><name name-style="western"><surname>Fineberg</surname><given-names>N</given-names></name><name name-style="western"><surname>Darley-Usmar</surname><given-names>VM</given-names></name><etal/><article-title>Inhibition of glycolysis attenuates 4-hydroxynonenal-dependent autophagy and exacerbates apoptosis in differentiated SH-SY5Y neuroblastoma cells</article-title><source>Autophagy</source><year>2013</year><volume>9</volume><fpage>1996</fpage><lpage>2008</lpage><pub-id pub-id-type="pmid">24145463</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/auto.26094</pub-id><pub-id pub-id-type="pmcid">PMC4028343</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><name name-style="western"><surname>Lou</surname><given-names>G</given-names></name><name name-style="western"><surname>Palikaras</surname><given-names>K</given-names></name><name name-style="western"><surname>Lautrup</surname><given-names>S</given-names></name><name name-style="western"><surname>Scheibye-Knudsen</surname><given-names>M</given-names></name><name name-style="western"><surname>Tavernarakis</surname><given-names>N</given-names></name><name name-style="western"><surname>Fang</surname><given-names>EF</given-names></name><article-title>Mitophagy and Neuroprotection</article-title><source>Trends Mol Med</source><year>2020</year><volume>26</volume><fpage>8</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">31375365</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molmed.2019.07.002</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><name name-style="western"><surname>Wiley</surname><given-names>CD</given-names></name><name name-style="western"><surname>Velarde</surname><given-names>MC</given-names></name><name name-style="western"><surname>Lecot</surname><given-names>P</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Sarnoski</surname><given-names>EA</given-names></name><name name-style="western"><surname>Freund</surname><given-names>A</given-names></name><etal/><article-title>Mitochondrial Dysfunction Induces Senescence with a Distinct Secretory Phenotype</article-title><source>Cell Metab</source><year>2016</year><volume>23</volume><fpage>303</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">26686024</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2015.11.011</pub-id><pub-id pub-id-type="pmcid">PMC4749409</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><name name-style="western"><surname>Purhonen</surname><given-names>J</given-names></name><name name-style="western"><surname>Banerjee</surname><given-names>R</given-names></name><name name-style="western"><surname>Wanne</surname><given-names>V</given-names></name><name name-style="western"><surname>Sipari</surname><given-names>N</given-names></name><name name-style="western"><surname>Morgelin</surname><given-names>M</given-names></name><name name-style="western"><surname>Fellman</surname><given-names>V</given-names></name><etal/><article-title>Mitochondrial complex III deficiency drives c-MYC overexpression and illicit cell cycle entry leading to senescence and segmental progeria</article-title><source>Nat Commun</source><year>2023</year><volume>14</volume><fpage>2356</fpage><pub-id pub-id-type="pmid">37095097</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-38027-1</pub-id><pub-id pub-id-type="pmcid">PMC10126100</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J</given-names></name><name name-style="western"><surname>Sun</surname><given-names>C</given-names></name><name name-style="western"><surname>Li</surname><given-names>G</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><etal/><article-title>Ameliorating mitochondrial dysfunction restores carbon ion-induced cognitive deficits via co-activation of NRF2 and PINK1 signaling pathway</article-title><source>Redox Biol</source><year>2018</year><volume>17</volume><fpage>143</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">29689442</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.redox.2018.04.012</pub-id><pub-id pub-id-type="pmcid">PMC6006734</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><name name-style="western"><surname>Yang</surname><given-names>C</given-names></name><name name-style="western"><surname>Su</surname><given-names>C</given-names></name><name name-style="western"><surname>Iyaswamy</surname><given-names>A</given-names></name><name name-style="western"><surname>Krishnamoorthi</surname><given-names>SK</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S</given-names></name><etal/><article-title>Celastrol enhances transcription factor EB (TFEB)-mediated autophagy and mitigates Tau pathology: Implications for Alzheimer's disease therapy</article-title><source>Acta Pharm Sin B</source><year>2022</year><volume>12</volume><fpage>1707</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">35847498</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2022.01.017</pub-id><pub-id pub-id-type="pmcid">PMC9279716</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><name name-style="western"><surname>Zeng</surname><given-names>K</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X</given-names></name><name name-style="western"><surname>Mahaman</surname><given-names>YAR</given-names></name><name name-style="western"><surname>Wang</surname><given-names>JZ</given-names></name><name name-style="western"><surname>Liu</surname><given-names>R</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><etal/><article-title>Defective mitophagy and the etiopathogenesis of Alzheimer's disease</article-title><source>Transl Neurodegener</source><year>2022</year><volume>11</volume><fpage>32</fpage><pub-id pub-id-type="pmid">35655270</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40035-022-00305-1</pub-id><pub-id pub-id-type="pmcid">PMC9164340</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><article-title>Cellular mitophagy: Mechanism, roles in diseases and small molecule pharmacological regulation</article-title><source>Theranostics</source><year>2023</year><volume>13</volume><fpage>736</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">36632220</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.79876</pub-id><pub-id pub-id-type="pmcid">PMC9830443</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><name name-style="western"><surname>Cho</surname><given-names>YH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>GH</given-names></name><name name-style="western"><surname>Park</surname><given-names>JJ</given-names></name><article-title>Mitochondrial aconitase 1 regulates age-related memory impairment via autophagy/mitophagy-mediated neural plasticity in middle-aged flies</article-title><source>Aging Cell</source><year>2021</year><volume>20</volume><fpage>e13520</fpage><pub-id pub-id-type="pmid">34799973</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/acel.13520</pub-id><pub-id pub-id-type="pmcid">PMC8672789</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><name name-style="western"><surname>Zhu</surname><given-names>DD</given-names></name><name name-style="western"><surname>Huang</surname><given-names>YL</given-names></name><name name-style="western"><surname>Guo</surname><given-names>SY</given-names></name><name name-style="western"><surname>Li</surname><given-names>N</given-names></name><name name-style="western"><surname>Yang</surname><given-names>XW</given-names></name><name name-style="western"><surname>Sui</surname><given-names>AR</given-names></name><etal/><article-title>AQP4 Aggravates Cognitive Impairment in Sepsis-Associated Encephalopathy through Inhibiting Na(v) 1.6-Mediated Astrocyte Autophagy</article-title><source>Adv Sci (Weinh)</source><year>2023</year><volume>10</volume><fpage>e2205862</fpage><pub-id pub-id-type="pmid">36922751</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202205862</pub-id><pub-id pub-id-type="pmcid">PMC10190498</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><name name-style="western"><surname>Kaushik</surname><given-names>S</given-names></name><name name-style="western"><surname>Cuervo</surname><given-names>AM</given-names></name><article-title>Degradation of lipid droplet-associated proteins by chaperone-mediated autophagy facilitates lipolysis</article-title><source>Nat Cell Biol</source><year>2015</year><volume>17</volume><fpage>759</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">25961502</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncb3166</pub-id><pub-id pub-id-type="pmcid">PMC4449813</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><name name-style="western"><surname>Shi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name><name name-style="western"><surname>Shi</surname><given-names>L</given-names></name><etal/><article-title>Alisol A is potentially therapeutic in human breast cancer cells</article-title><source>Oncol Rep</source><year>2020</year><volume>44</volume><fpage>1266</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">32582967</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/or.2020.7654</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="other"><name name-style="western"><surname>Lou</surname><given-names>C</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H</given-names></name><article-title>Alisol A Suppresses Proliferation, Migration, and Invasion in Human Breast Cancer MDA-MB-231 Cells</article-title><source>Molecules</source><year>2019</year><comment>24</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules24203651</pub-id><pub-id pub-id-type="pmcid">PMC6833085</pub-id><pub-id pub-id-type="pmid">31658635</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><name name-style="western"><surname>Xu</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>T</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>JF</given-names></name><name name-style="western"><surname>Wu</surname><given-names>SS</given-names></name><name name-style="western"><surname>Huang</surname><given-names>MQ</given-names></name><name name-style="western"><surname>Lin</surname><given-names>LG</given-names></name><etal/><article-title>Anti-proliferative activities of terpenoids isolated from Alisma orientalis and their structure-activity relationships</article-title><source>Anticancer Agents Med Chem</source><year>2015</year><volume>15</volume><fpage>228</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">24893804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1871520614666140601213514</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><name name-style="western"><surname>Ace</surname><given-names>CI</given-names></name><name name-style="western"><surname>Dalrymple</surname><given-names>MA</given-names></name><name name-style="western"><surname>Ramsay</surname><given-names>FH</given-names></name><name name-style="western"><surname>Preston</surname><given-names>VG</given-names></name><name name-style="western"><surname>Preston</surname><given-names>CM</given-names></name><article-title>Mutational analysis of the herpes simplex virus type 1 trans-inducing factor Vmw65</article-title><source>J Gen Virol</source><year>1988</year><volume>69</volume><issue> Pt 10</issue><fpage>2595</fpage><lpage>605</lpage><pub-id pub-id-type="pmid">2844968</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1099/0022-1317-69-10-2595</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><name name-style="western"><surname>Govyrin</surname><given-names>VN</given-names></name><name name-style="western"><surname>Didenko</surname><given-names>AV</given-names></name><name name-style="western"><surname>Iazykov</surname><given-names>VV</given-names></name><article-title>[Electrochemical phenomena in autoregulatory reactions of the blood vessels]</article-title><source>Fiziol Zh SSSR Im I M Sechenova</source><year>1989</year><volume>75</volume><fpage>3</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">2924968</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><name name-style="western"><surname>Park</surname><given-names>JH</given-names></name><name name-style="western"><surname>Long</surname><given-names>A</given-names></name><name name-style="western"><surname>Owens</surname><given-names>K</given-names></name><name name-style="western"><surname>Kristian</surname><given-names>T</given-names></name><article-title>Nicotinamide mononucleotide inhibits post-ischemic NAD(+) degradation and dramatically ameliorates brain damage following global cerebral ischemia</article-title><source>Neurobiol Dis</source><year>2016</year><volume>95</volume><fpage>102</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">27425894</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbd.2016.07.018</pub-id><pub-id pub-id-type="pmcid">PMC5580241</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><name name-style="western"><surname>Malik</surname><given-names>N</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>BI</given-names></name><name name-style="western"><surname>Hollstein</surname><given-names>PE</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>SD</given-names></name><name name-style="western"><surname>Trefts</surname><given-names>E</given-names></name><name name-style="western"><surname>Weiser Novak</surname><given-names>S</given-names></name><etal/><article-title>Induction of lysosomal and mitochondrial biogenesis by AMPK phosphorylation of FNIP1</article-title><source>Science</source><year>2023</year><volume>380</volume><fpage>eabj5559</fpage><pub-id pub-id-type="pmid">37079666</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abj5559</pub-id><pub-id pub-id-type="pmcid">PMC10794112</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><name name-style="western"><surname>Yoshino</surname><given-names>J</given-names></name><name name-style="western"><surname>Mills</surname><given-names>KF</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Imai</surname><given-names>S</given-names></name><article-title>Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice</article-title><source>Cell Metab</source><year>2011</year><volume>14</volume><fpage>528</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">21982712</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2011.08.014</pub-id><pub-id pub-id-type="pmcid">PMC3204926</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><name name-style="western"><surname>Yao</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><etal/><article-title>Discovery of small-molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and their preclinical neuroprotective activity</article-title><source>Cell Res</source><year>2022</year><volume>32</volume><fpage>570</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">35459935</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41422-022-00651-9</pub-id><pub-id pub-id-type="pmcid">PMC9160276</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><name name-style="western"><surname>Zu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yao</surname><given-names>H</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name><etal/><article-title>Optimization of NAMPT activators to achieve in vivo neuroprotective efficacy</article-title><source>Eur J Med Chem</source><year>2022</year><volume>236</volume><fpage>114260</fpage><pub-id pub-id-type="pmid">35385807</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2022.114260</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><name name-style="western"><surname>Johnson</surname><given-names>S</given-names></name><name name-style="western"><surname>Wozniak</surname><given-names>DF</given-names></name><name name-style="western"><surname>Imai</surname><given-names>S</given-names></name><article-title>CA1 Nampt knockdown recapitulates hippocampal cognitive phenotypes in old mice which nicotinamide mononucleotide improves</article-title><source>NPJ Aging Mech Dis</source><year>2018</year><volume>4</volume><fpage>10</fpage><pub-id pub-id-type="pmid">30416740</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41514-018-0029-z</pub-id><pub-id pub-id-type="pmcid">PMC6224504</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><name name-style="western"><surname>Shen</surname><given-names>C</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T</given-names></name><name name-style="western"><surname>Gao</surname><given-names>TY</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>M</given-names></name><name name-style="western"><surname>Lu</surname><given-names>YB</given-names></name><etal/><article-title>The Depletion of NAMPT Disturbs Mitochondrial Homeostasis and Causes Neuronal Degeneration in Mouse Hippocampus</article-title><source>Mol Neurobiol</source><year>2023</year><volume>60</volume><fpage>1267</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">36441480</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12035-022-03142-5</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><name name-style="western"><surname>Huang</surname><given-names>R</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H</given-names></name><article-title>ZeXieYin formula alleviates atherosclerosis by inhibiting the MAPK/NF-kappaB signaling pathway in APOE-/- mice to attenuate vascular inflammation and increase plaque stability</article-title><source>J Ethnopharmacol</source><year>2024</year><volume>327</volume><fpage>117969</fpage><pub-id pub-id-type="pmid">38437888</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jep.2024.117969</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal"><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>R</given-names></name><name name-style="western"><surname>Xing</surname><given-names>S</given-names></name><name name-style="western"><surname>Huang</surname><given-names>R</given-names></name><name name-style="western"><surname>Di</surname><given-names>D</given-names></name><etal/><article-title>Zexieyin formula alleviates atherosclerosis with cognitive impairment: A novel role in the treatment of comorbidities and its underlying mechanisms</article-title><source>J Ethnopharmacol</source><year>2024</year><volume>323</volume><fpage>117715</fpage><pub-id pub-id-type="pmid">38181934</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jep.2024.117715</pub-id></element-citation></ref><ref id="B63"><label>63</label><element-citation publication-type="journal"><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><etal/><article-title>ZeXieYin Formula alleviates TMAO-induced cognitive impairment by restoring synaptic plasticity damage</article-title><source>J Ethnopharmacol</source><year>2023</year><volume>314</volume><fpage>116604</fpage><pub-id pub-id-type="pmid">37178985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jep.2023.116604</pub-id></element-citation></ref><ref id="B64"><label>64</label><element-citation publication-type="journal"><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>R</given-names></name><name name-style="western"><surname>Huang</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S</given-names></name><etal/><article-title>Pyrolae herba alleviates cognitive impairment via hippocampal TREM2 signaling modulating neuroinflammation and neurogenesis in lipopolysaccharide-treated mice</article-title><source>J Ethnopharmacol</source><year>2024</year><volume>319</volume><fpage>117214</fpage><pub-id pub-id-type="pmid">37739108</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jep.2023.117214</pub-id></element-citation></ref><ref id="B65"><label>65</label><element-citation publication-type="other"><collab>Zhu Boran</collab><article-title>Study on the anti-atherosclerotic effect of ZeXieYin Formula based on the &#8220;Heart-Small Intestine Interior-Exterior Relationship&#8221; theory via regulation of gut microbiota [PhD thesis]</article-title><source>2021</source></element-citation></ref><ref id="B66"><label>66</label><element-citation publication-type="other"><collab>Sun Yan</collab><article-title>Mechanistic study of ZeXieYin Formula in improving cognitive impairment through regulation of hippocampal inflammation and neurogenesis based on the Huangdi Neijing theory [PhD thesis]</article-title><source>2024</source></element-citation></ref><ref id="B67"><label>67</label><element-citation publication-type="journal"><name name-style="western"><surname>Xu</surname><given-names>F</given-names></name><name name-style="western"><surname>Lu</surname><given-names>C</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Gu</surname><given-names>W</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Fang</surname><given-names>F</given-names></name><etal/><article-title>Studies on the lipid-regulating mechanism of alisol-based compounds on lipoprotein lipase</article-title><source>Bioorg Chem</source><year>2018</year><volume>80</volume><fpage>347</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">29986183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioorg.2018.07.001</pub-id></element-citation></ref><ref id="B68"><label>68</label><element-citation publication-type="other"><name name-style="western"><surname>Bailly</surname><given-names>C</given-names></name><article-title>Pharmacological Properties and Molecular Targets of Alisol Triterpenoids from Alismatis Rhizoma</article-title><source>Biomedicines</source><year>2022</year><comment>10</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines10081945</pub-id><pub-id pub-id-type="pmcid">PMC9406200</pub-id><pub-id pub-id-type="pmid">36009492</pub-id></element-citation></ref><ref id="B69"><label>69</label><element-citation publication-type="journal"><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name><name name-style="western"><surname>Kang</surname><given-names>S</given-names></name><name name-style="western"><surname>Yan</surname><given-names>G</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y</given-names></name><etal/><article-title>Therapeutic Effects of Alisma orientale and its Active Constituents on Cardiovascular Disease and Obesity</article-title><source>Am J Chin Med</source><year>2023</year><volume>51</volume><fpage>623</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">36961296</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1142/S0192415X23500301</pub-id></element-citation></ref><ref id="B70"><label>70</label><element-citation publication-type="journal"><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lu</surname><given-names>X</given-names></name><name name-style="western"><surname>Lin</surname><given-names>W</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S</given-names></name><etal/><article-title>Hypolipidemic effect of Alisma orientale (Sam.) Juzep on gut microecology and liver transcriptome in diabetic rats</article-title><source>PLoS One</source><year>2020</year><volume>15</volume><fpage>e0240616</fpage><pub-id pub-id-type="pmid">33035272</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0240616</pub-id><pub-id pub-id-type="pmcid">PMC7546448</pub-id></element-citation></ref><ref id="B71"><label>71</label><element-citation publication-type="journal"><name name-style="western"><surname>Xu</surname><given-names>F</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gu</surname><given-names>W</given-names></name><etal/><article-title>Molecular insight into the mechanism of lipid regulating effect of Alisma orientalis based on ACAT</article-title><source>Int J Biol Macromol</source><year>2020</year><volume>158</volume><fpage>1141</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">32376257</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijbiomac.2020.04.260</pub-id></element-citation></ref><ref id="B72"><label>72</label><element-citation publication-type="journal"><name name-style="western"><surname>Lin</surname><given-names>HR</given-names></name><article-title>Triterpenes from Alisma orientalis act as farnesoid X receptor agonists</article-title><source>Bioorg Med Chem Lett</source><year>2012</year><volume>22</volume><fpage>4787</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">22683342</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bmcl.2012.05.057</pub-id></element-citation></ref><ref id="B73"><label>73</label><element-citation publication-type="journal"><name name-style="western"><surname>Zhu</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ji</surname><given-names>M</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Xue</surname><given-names>W</given-names></name><etal/><article-title>Alisma orientalis Beverage Treats Atherosclerosis by Regulating Gut Microbiota in ApoE(-/-) Mice</article-title><source>Front Pharmacol</source><year>2020</year><volume>11</volume><fpage>570555</fpage><pub-id pub-id-type="pmid">33101028</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2020.570555</pub-id><pub-id pub-id-type="pmcid">PMC7545905</pub-id></element-citation></ref><ref id="B74"><label>74</label><element-citation publication-type="journal"><name name-style="western"><surname>Liu</surname><given-names>R</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Di</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>B</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H</given-names></name><article-title>PI3K/AKT/SERBP-1 pathway regulates Alisma orientalis beverage treatment of atherosclerosis in APOE(-/-) high-fat diet mice</article-title><source>Pharm Biol</source><year>2023</year><volume>61</volume><fpage>473</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">36825364</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13880209.2023.2168020</pub-id><pub-id pub-id-type="pmcid">PMC9970249</pub-id></element-citation></ref><ref id="B75"><label>75</label><element-citation publication-type="journal"><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name><name name-style="western"><surname>Jing</surname><given-names>M</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name><name name-style="western"><surname>Jin</surname><given-names>L</given-names></name><name name-style="western"><surname>Gong</surname><given-names>P</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name><etal/><article-title>The Alisma and Rhizoma decoction abates nonalcoholic steatohepatitis-associated liver injuries in mice by modulating oxidative stress and autophagy</article-title><source>BMC Complement Altern Med</source><year>2019</year><volume>19</volume><fpage>92</fpage><pub-id pub-id-type="pmid">31035991</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12906-019-2488-6</pub-id><pub-id pub-id-type="pmcid">PMC6489313</pub-id></element-citation></ref><ref id="B76"><label>76</label><element-citation publication-type="journal"><name name-style="western"><surname>Jang</surname><given-names>MK</given-names></name><name name-style="western"><surname>Han</surname><given-names>YR</given-names></name><name name-style="western"><surname>Nam</surname><given-names>JS</given-names></name><name name-style="western"><surname>Han</surname><given-names>CW</given-names></name><name name-style="western"><surname>Kim</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>HS</given-names></name><etal/><article-title>Protective Effects of Alisma orientale Extract against Hepatic Steatosis via Inhibition of Endoplasmic Reticulum Stress</article-title><source>Int J Mol Sci</source><year>2015</year><volume>16</volume><fpage>26151</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">26540043</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms161125944</pub-id><pub-id pub-id-type="pmcid">PMC4661803</pub-id></element-citation></ref><ref id="B77"><label>77</label><element-citation publication-type="journal"><name name-style="western"><surname>Ho</surname><given-names>C</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>D</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shan</surname><given-names>S</given-names></name><name name-style="western"><surname>Fang</surname><given-names>B</given-names></name><etal/><article-title>Alisol A attenuates high-fat-diet-induced obesity and metabolic disorders via the AMPK/ACC/SREBP-1c pathway</article-title><source>J Cell Mol Med</source><year>2019</year><volume>23</volume><fpage>5108</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">31144451</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jcmm.14380</pub-id><pub-id pub-id-type="pmcid">PMC6653754</pub-id></element-citation></ref><ref id="B78"><label>78</label><element-citation publication-type="journal"><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name><name name-style="western"><surname>Song</surname><given-names>D</given-names></name><name name-style="western"><surname>Xi</surname><given-names>J</given-names></name><name name-style="western"><surname>Hao</surname><given-names>W</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>J</given-names></name><etal/><article-title>Alisol A Alleviates Arterial Plaque by Activating AMPK/SIRT1 Signaling Pathway in apoE-Deficient Mice</article-title><source>Front Pharmacol</source><year>2020</year><volume>11</volume><fpage>580073</fpage><pub-id pub-id-type="pmid">33224034</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2020.580073</pub-id><pub-id pub-id-type="pmcid">PMC7667245</pub-id></element-citation></ref><ref id="B79"><label>79</label><element-citation publication-type="journal"><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Z</given-names></name><name name-style="western"><surname>Lin</surname><given-names>P</given-names></name><etal/><article-title>Development of a three-step-based novel strategy integrating DMPK with network pharmacology and bioactivity evaluation for the discovery of Q-markers of traditional Chinese medicine prescriptions: Danlou tablet as an example</article-title><source>Phytomedicine</source><year>2023</year><volume>108</volume><fpage>154511</fpage><pub-id pub-id-type="pmid">36334388</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phymed.2022.154511</pub-id></element-citation></ref><ref id="B80"><label>80</label><element-citation publication-type="journal"><name name-style="western"><surname>Yue</surname><given-names>C</given-names></name><name name-style="western"><surname>Dai</surname><given-names>W</given-names></name><name name-style="western"><surname>Song</surname><given-names>X</given-names></name><name name-style="western"><surname>Du</surname><given-names>M</given-names></name><name name-style="western"><surname>Qin</surname><given-names>J</given-names></name><name name-style="western"><surname>Du</surname><given-names>J</given-names></name><etal/><article-title>Alisol A inhibits the circ_0001831/miR-346/LIN28B pathway to ameliorate high glucose-induced injury of human renal mesangial cells</article-title><source>Nephrology (Carlton)</source><year>2024</year><volume>29</volume><fpage>154</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">38013222</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/nep.14258</pub-id></element-citation></ref><ref id="B81"><label>81</label><element-citation publication-type="journal"><name name-style="western"><surname>Lu</surname><given-names>T</given-names></name><name name-style="western"><surname>Ding</surname><given-names>L</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><etal/><article-title>Alisol A Exerts Neuroprotective Effects Against HFD-Induced Pathological Brain Aging via the SIRT3-NF-kappaB/MAPK Pathway</article-title><source>Mol Neurobiol</source><year>2024</year><volume>61</volume><fpage>753</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">37659035</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12035-023-03592-5</pub-id><pub-id pub-id-type="pmcid">PMC10861652</pub-id></element-citation></ref><ref id="B82"><label>82</label><element-citation publication-type="journal"><name name-style="western"><surname>Heyde</surname><given-names>A</given-names></name><name name-style="western"><surname>Rohde</surname><given-names>D</given-names></name><name name-style="western"><surname>McAlpine</surname><given-names>CS</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Hoyer</surname><given-names>FF</given-names></name><name name-style="western"><surname>Gerold</surname><given-names>JM</given-names></name><etal/><article-title>Increased stem cell proliferation in atherosclerosis accelerates clonal hematopoiesis</article-title><source>Cell</source><year>2021</year><volume>184</volume><fpage>1348</fpage><lpage>61</lpage><comment>e22</comment><pub-id pub-id-type="pmid">33636128</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2021.01.049</pub-id><pub-id pub-id-type="pmcid">PMC8109274</pub-id></element-citation></ref><ref id="B83"><label>83</label><element-citation publication-type="journal"><name name-style="western"><surname>Shin</surname><given-names>MK</given-names></name><name name-style="western"><surname>Vazquez-Rosa</surname><given-names>E</given-names></name><name name-style="western"><surname>Koh</surname><given-names>Y</given-names></name><name name-style="western"><surname>Dhar</surname><given-names>M</given-names></name><name name-style="western"><surname>Chaubey</surname><given-names>K</given-names></name><name name-style="western"><surname>Cintron-Perez</surname><given-names>CJ</given-names></name><etal/><article-title>Reducing acetylated tau is neuroprotective in brain injury</article-title><source>Cell</source><year>2021</year><volume>184</volume><fpage>2715</fpage><lpage>32</lpage><comment>e23</comment><pub-id pub-id-type="pmid">33852912</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2021.03.032</pub-id><pub-id pub-id-type="pmcid">PMC8491234</pub-id></element-citation></ref><ref id="B84"><label>84</label><element-citation publication-type="journal"><name name-style="western"><surname>Xiao</surname><given-names>W</given-names></name><name name-style="western"><surname>Su</surname><given-names>J</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H</given-names></name><name name-style="western"><surname>Weng</surname><given-names>R</given-names></name><name name-style="western"><surname>Ni</surname><given-names>W</given-names></name><etal/><article-title>The microbiota-gut-brain axis participates in chronic cerebral hypoperfusion by disrupting the metabolism of short-chain fatty acids</article-title><source>Microbiome</source><year>2022</year><volume>10</volume><fpage>62</fpage><pub-id pub-id-type="pmid">35430804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40168-022-01255-6</pub-id><pub-id pub-id-type="pmcid">PMC9013454</pub-id></element-citation></ref><ref id="B85"><label>85</label><element-citation publication-type="journal"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Minamino</surname><given-names>T</given-names></name><name name-style="western"><surname>Tsukamoto</surname><given-names>O</given-names></name><name name-style="western"><surname>Yujiri</surname><given-names>T</given-names></name><name name-style="western"><surname>Shintani</surname><given-names>Y</given-names></name><name name-style="western"><surname>Okada</surname><given-names>K</given-names></name><etal/><article-title>Ablation of MEK kinase 1 suppresses intimal hyperplasia by impairing smooth muscle cell migration and urokinase plasminogen activator expression in a mouse blood-flow cessation model</article-title><source>Circulation</source><year>2005</year><volume>111</volume><fpage>1672</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">15795331</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.CIR.0000160350.20810.0F</pub-id></element-citation></ref><ref id="B86"><label>86</label><element-citation publication-type="journal"><name name-style="western"><surname>Nacarelli</surname><given-names>T</given-names></name><name name-style="western"><surname>Lau</surname><given-names>L</given-names></name><name name-style="western"><surname>Fukumoto</surname><given-names>T</given-names></name><name name-style="western"><surname>Zundell</surname><given-names>J</given-names></name><name name-style="western"><surname>Fatkhutdinov</surname><given-names>N</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S</given-names></name><etal/><article-title>NAD(+) metabolism governs the proinflammatory senescence-associated secretome</article-title><source>Nat Cell Biol</source><year>2019</year><volume>21</volume><fpage>397</fpage><lpage>407</lpage><pub-id pub-id-type="pmid">30778219</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41556-019-0287-4</pub-id><pub-id pub-id-type="pmcid">PMC6448588</pub-id></element-citation></ref><ref id="B87"><label>87</label><element-citation publication-type="journal"><name name-style="western"><surname>Tarrago</surname><given-names>MG</given-names></name><name name-style="western"><surname>Chini</surname><given-names>CCS</given-names></name><name name-style="western"><surname>Kanamori</surname><given-names>KS</given-names></name><name name-style="western"><surname>Warner</surname><given-names>GM</given-names></name><name name-style="western"><surname>Caride</surname><given-names>A</given-names></name><name name-style="western"><surname>de Oliveira</surname><given-names>GC</given-names></name><etal/><article-title>A Potent and Specific CD38 Inhibitor Ameliorates Age-Related Metabolic Dysfunction by Reversing Tissue NAD(+) Decline</article-title><source>Cell Metab</source><year>2018</year><volume>27</volume><fpage>1081</fpage><lpage>95</lpage><comment>e10</comment><pub-id pub-id-type="pmid">29719225</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2018.03.016</pub-id><pub-id pub-id-type="pmcid">PMC5935140</pub-id></element-citation></ref><ref id="B88"><label>88</label><element-citation publication-type="journal"><name name-style="western"><surname>Morato</surname><given-names>L</given-names></name><name name-style="western"><surname>Astori</surname><given-names>S</given-names></name><name name-style="western"><surname>Zalachoras</surname><given-names>I</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>J</given-names></name><name name-style="western"><surname>Ghosal</surname><given-names>S</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W</given-names></name><etal/><article-title>eNAMPT actions through nucleus accumbens NAD(+)/SIRT1 link increased adiposity with sociability deficits programmed by peripuberty stress</article-title><source>Sci Adv</source><year>2022</year><volume>8</volume><fpage>eabj9109</fpage><pub-id pub-id-type="pmid">35235362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.abj9109</pub-id><pub-id pub-id-type="pmcid">PMC8890725</pub-id></element-citation></ref><ref id="B89"><label>89</label><element-citation publication-type="journal"><name name-style="western"><surname>Pu</surname><given-names>B</given-names></name><name name-style="western"><surname>Gu</surname><given-names>P</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>C</given-names></name><name name-style="western"><surname>Ma</surname><given-names>L</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Z</given-names></name><article-title>Self-reported and genetically predicted effects of coffee intake on rheumatoid arthritis: Epidemiological studies and Mendelian randomization analysis</article-title><source>Front Nutr</source><year>2022</year><volume>9</volume><fpage>926190</fpage><pub-id pub-id-type="pmid">36172525</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnut.2022.926190</pub-id><pub-id pub-id-type="pmcid">PMC9510978</pub-id></element-citation></ref><ref id="B90"><label>90</label><element-citation publication-type="journal"><name name-style="western"><surname>Shen</surname><given-names>R</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>K</given-names></name><name name-style="western"><surname>Li</surname><given-names>G</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Z</given-names></name><name name-style="western"><surname>Qiaolongbatu</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><etal/><article-title>Alisol A, the Eye-Entering Ingredient of Alisma orientale, Relieves Macular Edema Through TNF-alpha as Revealed by UPLC-Triple-TOF/MS, Network Pharmacology, and Zebrafish Verification</article-title><source>Drug Des Devel Ther</source><year>2024</year><volume>18</volume><fpage>3361</fpage><lpage>82</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/DDDT.S468119</pub-id><pub-id pub-id-type="pmcid">PMC11297588</pub-id><pub-id pub-id-type="pmid">39100223</pub-id></element-citation></ref><ref id="B91"><label>91</label><element-citation publication-type="journal"><name name-style="western"><surname>Lewandowski</surname><given-names>CT</given-names></name><name name-style="western"><surname>Laham</surname><given-names>MS</given-names></name><name name-style="western"><surname>Thatcher</surname><given-names>GRJ</given-names></name><article-title>Remembering your A, B, C's: Alzheimer's disease and ABCA1</article-title><source>Acta Pharm Sin B</source><year>2022</year><volume>12</volume><fpage>995</fpage><lpage>1018</lpage><pub-id pub-id-type="pmid">35530134</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2022.01.011</pub-id><pub-id pub-id-type="pmcid">PMC9072248</pub-id></element-citation></ref><ref id="B92"><label>92</label><element-citation publication-type="journal"><name name-style="western"><surname>Marquart</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Allen</surname><given-names>RM</given-names></name><name name-style="western"><surname>Ory</surname><given-names>DS</given-names></name><name name-style="western"><surname>Baldan</surname><given-names>A</given-names></name><article-title>miR-33 links SREBP-2 induction to repression of sterol transporters</article-title><source>Proc Natl Acad Sci U S A</source><year>2010</year><volume>107</volume><fpage>12228</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">20566875</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1005191107</pub-id><pub-id pub-id-type="pmcid">PMC2901433</pub-id></element-citation></ref><ref id="B93"><label>93</label><element-citation publication-type="journal"><name name-style="western"><surname>Calkin</surname><given-names>AC</given-names></name><name name-style="western"><surname>Tontonoz</surname><given-names>P</given-names></name><article-title>Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR</article-title><source>Nat Rev Mol Cell Biol</source><year>2012</year><volume>13</volume><fpage>213</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">22414897</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrm3312</pub-id><pub-id pub-id-type="pmcid">PMC3597092</pub-id></element-citation></ref><ref id="B94"><label>94</label><element-citation publication-type="journal"><name name-style="western"><surname>Min</surname><given-names>HK</given-names></name><name name-style="western"><surname>Kapoor</surname><given-names>A</given-names></name><name name-style="western"><surname>Fuchs</surname><given-names>M</given-names></name><name name-style="western"><surname>Mirshahi</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name><name name-style="western"><surname>Maher</surname><given-names>J</given-names></name><etal/><article-title>Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease</article-title><source>Cell Metab</source><year>2012</year><volume>15</volume><fpage>665</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">22560219</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2012.04.004</pub-id><pub-id pub-id-type="pmcid">PMC3361911</pub-id></element-citation></ref><ref id="B95"><label>95</label><element-citation publication-type="journal"><name name-style="western"><surname>Fond</surname><given-names>AM</given-names></name><name name-style="western"><surname>Lee</surname><given-names>CS</given-names></name><name name-style="western"><surname>Schulman</surname><given-names>IG</given-names></name><name name-style="western"><surname>Kiss</surname><given-names>RS</given-names></name><name name-style="western"><surname>Ravichandran</surname><given-names>KS</given-names></name><article-title>Apoptotic cells trigger a membrane-initiated pathway to increase ABCA1</article-title><source>J Clin Invest</source><year>2015</year><volume>125</volume><fpage>2748</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">26075824</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI80300</pub-id><pub-id pub-id-type="pmcid">PMC4563683</pub-id></element-citation></ref><ref id="B96"><label>96</label><element-citation publication-type="journal"><name name-style="western"><surname>Farias</surname><given-names>HR</given-names></name><name name-style="western"><surname>Costa-Beber</surname><given-names>LC</given-names></name><name name-style="western"><surname>Costa Rodrigues Guma</surname><given-names>FT</given-names></name><name name-style="western"><surname>de Oliveira</surname><given-names>J</given-names></name><article-title>Hypercholesterolemia, oxidative stress, and low-grade inflammation: a potentially dangerous scenario to blood-brain barrier</article-title><source>Metab Brain Dis</source><year>2025</year><volume>40</volume><fpage>205</fpage><pub-id pub-id-type="pmid">40380979</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11011-025-01620-y</pub-id></element-citation></ref><ref id="B97"><label>97</label><element-citation publication-type="journal"><name name-style="western"><surname>Backstrom</surname><given-names>T</given-names></name><name name-style="western"><surname>Doverskog</surname><given-names>M</given-names></name><name name-style="western"><surname>Blackburn</surname><given-names>TP</given-names></name><name name-style="western"><surname>Scharschmidt</surname><given-names>BF</given-names></name><name name-style="western"><surname>Felipo</surname><given-names>V</given-names></name><article-title>Allopregnanolone and its antagonist modulate neuroinflammation and neurological impairment</article-title><source>Neurosci Biobehav Rev</source><year>2024</year><volume>161</volume><fpage>105668</fpage><pub-id pub-id-type="pmid">38608826</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neubiorev.2024.105668</pub-id></element-citation></ref><ref id="B98"><label>98</label><element-citation publication-type="journal"><name name-style="western"><surname>Esfandiary</surname><given-names>A</given-names></name><name name-style="western"><surname>Kutsche</surname><given-names>HS</given-names></name><name name-style="western"><surname>Schreckenberg</surname><given-names>R</given-names></name><name name-style="western"><surname>Weber</surname><given-names>M</given-names></name><name name-style="western"><surname>Pak</surname><given-names>O</given-names></name><name name-style="western"><surname>Kojonazarov</surname><given-names>B</given-names></name><etal/><article-title>Protection against pressure overload-induced right heart failure by uncoupling protein 2 silencing</article-title><source>Cardiovasc Res</source><year>2019</year><volume>115</volume><fpage>1217</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">30850841</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cvr/cvz049</pub-id><pub-id pub-id-type="pmcid">PMC6529920</pub-id></element-citation></ref><ref id="B99"><label>99</label><element-citation publication-type="journal"><name name-style="western"><surname>Xu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>N</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>C</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J</given-names></name><etal/><article-title>Deletion of aquaporin-4 in APP/PS1 mice exacerbates brain Abeta accumulation and memory deficits</article-title><source>Mol Neurodegener</source><year>2015</year><volume>10</volume><fpage>58</fpage><pub-id pub-id-type="pmid">26526066</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-015-0056-1</pub-id><pub-id pub-id-type="pmcid">PMC4631089</pub-id></element-citation></ref><ref id="B100"><label>100</label><element-citation publication-type="journal"><name name-style="western"><surname>Zanier</surname><given-names>ER</given-names></name><name name-style="western"><surname>Bertani</surname><given-names>I</given-names></name><name name-style="western"><surname>Sammali</surname><given-names>E</given-names></name><name name-style="western"><surname>Pischiutta</surname><given-names>F</given-names></name><name name-style="western"><surname>Chiaravalloti</surname><given-names>MA</given-names></name><name name-style="western"><surname>Vegliante</surname><given-names>G</given-names></name><etal/><article-title>Induction of a transmissible tau pathology by traumatic brain injury</article-title><source>Brain</source><year>2018</year><volume>141</volume><fpage>2685</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">30084913</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awy193</pub-id><pub-id pub-id-type="pmcid">PMC6113646</pub-id></element-citation></ref><ref id="B101"><label>101</label><element-citation publication-type="journal"><name name-style="western"><surname>Miguel</surname><given-names>V</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>R</given-names></name><name name-style="western"><surname>Garcia-Bermejo</surname><given-names>L</given-names></name><name name-style="western"><surname>Rodriguez-Puyol</surname><given-names>D</given-names></name><name name-style="western"><surname>Lamas</surname><given-names>S</given-names></name><article-title>The program of renal fibrogenesis is controlled by microRNAs regulating oxidative metabolism</article-title><source>Redox Biol</source><year>2021</year><volume>40</volume><fpage>101851</fpage><pub-id pub-id-type="pmid">33465566</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.redox.2020.101851</pub-id><pub-id pub-id-type="pmcid">PMC7815809</pub-id></element-citation></ref><ref id="B102"><label>102</label><element-citation publication-type="journal"><name name-style="western"><surname>Yi</surname><given-names>C</given-names></name><name name-style="western"><surname>Ma</surname><given-names>M</given-names></name><name name-style="western"><surname>Ran</surname><given-names>L</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>J</given-names></name><name name-style="western"><surname>Tong</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name><etal/><article-title>Function and molecular mechanism of acetylation in autophagy regulation</article-title><source>Science</source><year>2012</year><volume>336</volume><fpage>474</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">22539722</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1216990</pub-id></element-citation></ref><ref id="B103"><label>103</label><element-citation publication-type="journal"><name name-style="western"><surname>Huang</surname><given-names>R</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><article-title>Identifying an essential role of nuclear LC3 for autophagy</article-title><source>Autophagy</source><year>2015</year><volume>11</volume><fpage>852</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">25945743</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15548627.2015.1038016</pub-id><pub-id pub-id-type="pmcid">PMC4509442</pub-id></element-citation></ref><ref id="B104"><label>104</label><element-citation publication-type="journal"><name name-style="western"><surname>Roy</surname><given-names>SG</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>MW</given-names></name><name name-style="western"><surname>So</surname><given-names>L</given-names></name><name name-style="western"><surname>Edinger</surname><given-names>AL</given-names></name><article-title>Reciprocal effects of rab7 deletion in activated and neglected T cells</article-title><source>Autophagy</source><year>2013</year><volume>9</volume><fpage>1009</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">23615463</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/auto.24468</pub-id><pub-id pub-id-type="pmcid">PMC3722312</pub-id></element-citation></ref><ref id="B105"><label>105</label><element-citation publication-type="journal"><name name-style="western"><surname>Tang</surname><given-names>J</given-names></name><name name-style="western"><surname>Peng</surname><given-names>W</given-names></name><name name-style="western"><surname>Ji</surname><given-names>J</given-names></name><name name-style="western"><surname>Peng</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T</given-names></name><name name-style="western"><surname>Yang</surname><given-names>P</given-names></name><etal/><article-title>GPR176 Promotes Cancer Progression by Interacting with G Protein GNAS to Restrain Cell Mitophagy in Colorectal Cancer</article-title><source>Adv Sci (Weinh)</source><year>2023</year><volume>10</volume><fpage>e2205627</fpage><pub-id pub-id-type="pmid">36905238</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202205627</pub-id><pub-id pub-id-type="pmcid">PMC10131842</pub-id></element-citation></ref><ref id="B106"><label>106</label><element-citation publication-type="other"><name name-style="western"><surname>Dong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xia</surname><given-names>T</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Song</surname><given-names>K</given-names></name><etal/><article-title>Hydroxytyrosol Promotes the Mitochondrial Function through Activating Mitophagy</article-title><source>Antioxidants (Basel)</source><year>2022</year><comment>11</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antiox11050893</pub-id><pub-id pub-id-type="pmcid">PMC9138034</pub-id><pub-id pub-id-type="pmid">35624756</pub-id></element-citation></ref><ref id="B107"><label>107</label><element-citation publication-type="journal"><name name-style="western"><surname>Zhai</surname><given-names>Q</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Fei</surname><given-names>D</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X</given-names></name><name name-style="western"><surname>He</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>W</given-names></name><etal/><article-title>Nanorepairers Rescue Inflammation-Induced Mitochondrial Dysfunction in Mesenchymal Stem Cells</article-title><source>Adv Sci (Weinh)</source><year>2022</year><volume>9</volume><fpage>e2103839</fpage><pub-id pub-id-type="pmid">34894103</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202103839</pub-id><pub-id pub-id-type="pmcid">PMC8811813</pub-id></element-citation></ref><ref id="B108"><label>108</label><element-citation publication-type="journal"><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Feng</surname><given-names>X</given-names></name><name name-style="western"><surname>He</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shao</surname><given-names>L</given-names></name><article-title>The interrupted effect of autophagic flux and lysosomal function induced by graphene oxide in p62-dependent apoptosis of F98 cells</article-title><source>J Nanobiotechnology</source><year>2020</year><volume>18</volume><fpage>52</fpage><pub-id pub-id-type="pmid">32188458</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12951-020-00605-6</pub-id><pub-id pub-id-type="pmcid">PMC7081710</pub-id></element-citation></ref><ref id="B109"><label>109</label><element-citation publication-type="journal"><name name-style="western"><surname>Basit</surname><given-names>F</given-names></name><name name-style="western"><surname>van Oppen</surname><given-names>LM</given-names></name><name name-style="western"><surname>Schockel</surname><given-names>L</given-names></name><name name-style="western"><surname>Bossenbroek</surname><given-names>HM</given-names></name><name name-style="western"><surname>van Emst-de Vries</surname><given-names>SE</given-names></name><name name-style="western"><surname>Hermeling</surname><given-names>JC</given-names></name><etal/><article-title>Mitochondrial complex I inhibition triggers a mitophagy-dependent ROS increase leading to necroptosis and ferroptosis in melanoma cells</article-title><source>Cell Death Dis</source><year>2017</year><volume>8</volume><fpage>e2716</fpage><pub-id pub-id-type="pmid">28358377</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/cddis.2017.133</pub-id><pub-id pub-id-type="pmcid">PMC5386536</pub-id></element-citation></ref><ref id="B110"><label>110</label><element-citation publication-type="journal"><name name-style="western"><surname>Duan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gong</surname><given-names>K</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name><name name-style="western"><surname>Meng</surname><given-names>X</given-names></name><name name-style="western"><surname>Han</surname><given-names>J</given-names></name><article-title>Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics</article-title><source>Signal Transduct Target Ther</source><year>2022</year><volume>7</volume><fpage>265</fpage><pub-id pub-id-type="pmid">35918332</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-022-01125-5</pub-id><pub-id pub-id-type="pmcid">PMC9344793</pub-id></element-citation></ref><ref id="B111"><label>111</label><element-citation publication-type="journal"><name name-style="western"><surname>Jiao</surname><given-names>L</given-names></name><name name-style="western"><surname>Shao</surname><given-names>W</given-names></name><name name-style="western"><surname>Quan</surname><given-names>W</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><etal/><article-title>iPLA2beta loss leads to age-related cognitive decline and neuroinflammation by disrupting neuronal mitophagy</article-title><source>J Neuroinflammation</source><year>2024</year><volume>21</volume><fpage>228</fpage><pub-id pub-id-type="pmid">39294744</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-024-03219-z</pub-id><pub-id pub-id-type="pmcid">PMC11409585</pub-id></element-citation></ref><ref id="B112"><label>112</label><element-citation publication-type="other"><name name-style="western"><surname>Stuke</surname><given-names>JFM</given-names></name><name name-style="western"><surname>Hummer</surname><given-names>G</given-names></name><article-title>AlphaFold2 SLiM screen for LC3-LIR interactions in autophagy</article-title><source>Autophagy</source><year>2025</year><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15548627.2025.2493999</pub-id><pub-id pub-id-type="pmid">40320752</pub-id></element-citation></ref><ref id="B113"><label>113</label><element-citation publication-type="journal"><name name-style="western"><surname>Lorentzen</surname><given-names>KC</given-names></name><name name-style="western"><surname>Prescott</surname><given-names>AR</given-names></name><name name-style="western"><surname>Ganley</surname><given-names>IG</given-names></name><article-title>Artificial targeting of autophagy components to mitochondria reveals both conventional and unconventional mitophagy pathways</article-title><source>Autophagy</source><year>2025</year><volume>21</volume><fpage>315</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">39177530</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15548627.2024.2395149</pub-id><pub-id pub-id-type="pmcid">PMC11760219</pub-id></element-citation></ref><ref id="B114"><label>114</label><element-citation publication-type="journal"><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Ye</surname><given-names>J</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ma</surname><given-names>W</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H</given-names></name><etal/><article-title>CKLF induces microglial activation via triggering defective mitophagy and mitochondrial dysfunction</article-title><source>Autophagy</source><year>2024</year><volume>20</volume><fpage>590</fpage><lpage>613</lpage><pub-id pub-id-type="pmid">37908119</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15548627.2023.2276639</pub-id><pub-id pub-id-type="pmcid">PMC10936627</pub-id></element-citation></ref><ref id="B115"><label>115</label><element-citation publication-type="journal"><name name-style="western"><surname>Liu</surname><given-names>D</given-names></name><name name-style="western"><surname>Webber</surname><given-names>HC</given-names></name><name name-style="western"><surname>Bian</surname><given-names>F</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Prakash</surname><given-names>M</given-names></name><name name-style="western"><surname>Feng</surname><given-names>X</given-names></name><etal/><article-title>Optineurin-facilitated axonal mitochondria delivery promotes neuroprotection and axon regeneration</article-title><source>Nat Commun</source><year>2025</year><volume>16</volume><fpage>1789</fpage><pub-id pub-id-type="pmid">39979261</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-025-57135-8</pub-id><pub-id pub-id-type="pmcid">PMC11842812</pub-id></element-citation></ref><ref id="B116"><label>116</label><element-citation publication-type="other"><name name-style="western"><surname>Yan</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Choksi</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>ZG</given-names></name><article-title>TGFB signaling induces mitophagy via PLSCR3-mediated cardiolipin externalization in conjunction with a BNIP3L/NIX-, BNIP3-, and FUNDC1-dependent mechanism</article-title><source>Autophagy</source><year>2025</year><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15548627.2025.2483441</pub-id><pub-id pub-id-type="pmcid">PMC12283012</pub-id><pub-id pub-id-type="pmid">40119553</pub-id></element-citation></ref><ref id="B117"><label>117</label><element-citation publication-type="journal"><name name-style="western"><surname>Kuchling</surname><given-names>J</given-names></name><name name-style="western"><surname>Jurek</surname><given-names>B</given-names></name><name name-style="western"><surname>Kents</surname><given-names>M</given-names></name><name name-style="western"><surname>Kreye</surname><given-names>J</given-names></name><name name-style="western"><surname>Geis</surname><given-names>C</given-names></name><name name-style="western"><surname>Wickel</surname><given-names>J</given-names></name><etal/><article-title>Impaired functional connectivity of the hippocampus in translational murine models of NMDA-receptor antibody associated neuropsychiatric pathology</article-title><source>Mol Psychiatry</source><year>2024</year><volume>29</volume><fpage>85</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">37875549</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41380-023-02303-9</pub-id><pub-id pub-id-type="pmcid">PMC11078734</pub-id></element-citation></ref><ref id="B118"><label>118</label><element-citation publication-type="journal"><name name-style="western"><surname>Travaglia</surname><given-names>A</given-names></name><name name-style="western"><surname>Bisaz</surname><given-names>R</given-names></name><name name-style="western"><surname>Sweet</surname><given-names>ES</given-names></name><name name-style="western"><surname>Blitzer</surname><given-names>RD</given-names></name><name name-style="western"><surname>Alberini</surname><given-names>CM</given-names></name><article-title>Infantile amnesia reflects a developmental critical period for hippocampal learning</article-title><source>Nat Neurosci</source><year>2016</year><volume>19</volume><fpage>1225</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">27428652</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nn.4348</pub-id><pub-id pub-id-type="pmcid">PMC5003643</pub-id></element-citation></ref><ref id="B119"><label>119</label><element-citation publication-type="journal"><name name-style="western"><surname>Kraehling</surname><given-names>JR</given-names></name><name name-style="western"><surname>Chidlow</surname><given-names>JH</given-names></name><name name-style="western"><surname>Rajagopal</surname><given-names>C</given-names></name><name name-style="western"><surname>Sugiyama</surname><given-names>MG</given-names></name><name name-style="western"><surname>Fowler</surname><given-names>JW</given-names></name><name name-style="western"><surname>Lee</surname><given-names>MY</given-names></name><etal/><article-title>Genome-wide RNAi screen reveals ALK1 mediates LDL uptake and transcytosis in endothelial cells</article-title><source>Nat Commun</source><year>2016</year><volume>7</volume><fpage>13516</fpage><pub-id pub-id-type="pmid">27869117</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms13516</pub-id><pub-id pub-id-type="pmcid">PMC5121336</pub-id></element-citation></ref><ref id="B120"><label>120</label><element-citation publication-type="journal"><name name-style="western"><surname>Matsuura</surname><given-names>F</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>XC</given-names></name><name name-style="western"><surname>Tall</surname><given-names>AR</given-names></name><article-title>HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway</article-title><source>J Clin Invest</source><year>2006</year><volume>116</volume><fpage>1435</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">16670775</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI27602</pub-id><pub-id pub-id-type="pmcid">PMC1451209</pub-id></element-citation></ref><ref id="B121"><label>121</label><element-citation publication-type="journal"><name name-style="western"><surname>Hamilton</surname><given-names>JP</given-names></name><name name-style="western"><surname>Koganti</surname><given-names>L</given-names></name><name name-style="western"><surname>Muchenditsi</surname><given-names>A</given-names></name><name name-style="western"><surname>Pendyala</surname><given-names>VS</given-names></name><name name-style="western"><surname>Huso</surname><given-names>D</given-names></name><name name-style="western"><surname>Hankin</surname><given-names>J</given-names></name><etal/><article-title>Activation of liver X receptor/retinoid X receptor pathway ameliorates liver disease in Atp7B(-/-) (Wilson disease) mice</article-title><source>Hepatology</source><year>2016</year><volume>63</volume><fpage>1828</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">26679751</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep.28406</pub-id><pub-id pub-id-type="pmcid">PMC4874878</pub-id></element-citation></ref><ref id="B122"><label>122</label><element-citation publication-type="journal"><name name-style="western"><surname>Quattrocelli</surname><given-names>M</given-names></name><name name-style="western"><surname>Wintzinger</surname><given-names>M</given-names></name><name name-style="western"><surname>Miz</surname><given-names>K</given-names></name><name name-style="western"><surname>Levine</surname><given-names>DC</given-names></name><name name-style="western"><surname>Peek</surname><given-names>CB</given-names></name><name name-style="western"><surname>Bass</surname><given-names>J</given-names></name><etal/><article-title>Muscle mitochondrial remodeling by intermittent glucocorticoid drugs requires an intact circadian clock and muscle PGC1alpha</article-title><source>Sci Adv</source><year>2022</year><volume>8</volume><fpage>eabm1189</fpage><pub-id pub-id-type="pmid">35179955</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.abm1189</pub-id><pub-id pub-id-type="pmcid">PMC8856622</pub-id></element-citation></ref><ref id="B123"><label>123</label><element-citation publication-type="journal"><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><name name-style="western"><surname>Kong</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xia</surname><given-names>M</given-names></name><etal/><article-title>SIRT1 links CIITA deacetylation to MHC II activation</article-title><source>Nucleic Acids Res</source><year>2011</year><volume>39</volume><fpage>9549</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">21890893</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkr651</pub-id><pub-id pub-id-type="pmcid">PMC3239213</pub-id></element-citation></ref><ref id="B124"><label>124</label><element-citation publication-type="journal"><name name-style="western"><surname>Kennedy</surname><given-names>BE</given-names></name><name name-style="western"><surname>Giacomantonio</surname><given-names>M</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>JP</given-names></name><name name-style="western"><surname>Cutler</surname><given-names>S</given-names></name><name name-style="western"><surname>Sadek</surname><given-names>M</given-names></name><name name-style="western"><surname>Konda</surname><given-names>P</given-names></name><etal/><article-title>NAD+ depletion enhances reovirus-induced oncolysis in multiple myeloma</article-title><source>Mol Ther Oncolytics</source><year>2022</year><volume>24</volume><fpage>695</fpage><lpage>706</lpage><pub-id pub-id-type="pmid">35284625</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.omto.2022.02.017</pub-id><pub-id pub-id-type="pmcid">PMC8904403</pub-id></element-citation></ref><ref id="B125"><label>125</label><element-citation publication-type="journal"><name name-style="western"><surname>Hopp</surname><given-names>AK</given-names></name><name name-style="western"><surname>Teloni</surname><given-names>F</given-names></name><name name-style="western"><surname>Bisceglie</surname><given-names>L</given-names></name><name name-style="western"><surname>Gondrand</surname><given-names>C</given-names></name><name name-style="western"><surname>Raith</surname><given-names>F</given-names></name><name name-style="western"><surname>Nowak</surname><given-names>K</given-names></name><etal/><article-title>Mitochondrial NAD(+) Controls Nuclear ARTD1-Induced ADP-Ribosylation</article-title><source>Mol Cell</source><year>2021</year><volume>81</volume><fpage>340</fpage><lpage>54</lpage><comment>e5</comment><pub-id pub-id-type="pmid">33450210</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molcel.2020.12.034</pub-id><pub-id pub-id-type="pmcid">PMC7837215</pub-id></element-citation></ref><ref id="B126"><label>126</label><element-citation publication-type="journal"><name name-style="western"><surname>Marcus</surname><given-names>M</given-names></name><name name-style="western"><surname>Rosenblatt</surname><given-names>I</given-names></name><name name-style="western"><surname>Yassur</surname><given-names>Y</given-names></name><article-title>[Indications and contraindications for laser photocoagulation in diabetic retinopathy-update]</article-title><source>Harefuah</source><year>1987</year><volume>112</volume><fpage>182</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">3609941</pub-id></element-citation></ref><ref id="B127"><label>127</label><element-citation publication-type="journal"><name name-style="western"><surname>Chini</surname><given-names>CCS</given-names></name><name name-style="western"><surname>Zeidler</surname><given-names>JD</given-names></name><name name-style="western"><surname>Kashyap</surname><given-names>S</given-names></name><name name-style="western"><surname>Warner</surname><given-names>G</given-names></name><name name-style="western"><surname>Chini</surname><given-names>EN</given-names></name><article-title>Evolving concepts in NAD(+) metabolism</article-title><source>Cell Metab</source><year>2021</year><volume>33</volume><fpage>1076</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">33930322</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2021.04.003</pub-id><pub-id pub-id-type="pmcid">PMC8172449</pub-id></element-citation></ref><ref id="B128"><label>128</label><element-citation publication-type="journal"><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wan</surname><given-names>W</given-names></name><article-title>Acetylation in the regulation of autophagy</article-title><source>Autophagy</source><year>2023</year><volume>19</volume><fpage>379</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">35435793</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15548627.2022.2062112</pub-id><pub-id pub-id-type="pmcid">PMC9851266</pub-id></element-citation></ref><ref id="B129"><label>129</label><element-citation publication-type="journal"><name name-style="western"><surname>Lee</surname><given-names>IH</given-names></name><name name-style="western"><surname>Cao</surname><given-names>L</given-names></name><name name-style="western"><surname>Mostoslavsky</surname><given-names>R</given-names></name><name name-style="western"><surname>Lombard</surname><given-names>DB</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Bruns</surname><given-names>NE</given-names></name><etal/><article-title>A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy</article-title><source>Proc Natl Acad Sci U S A</source><year>2008</year><volume>105</volume><fpage>3374</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18296641</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0712145105</pub-id><pub-id pub-id-type="pmcid">PMC2265142</pub-id></element-citation></ref><ref id="B130"><label>130</label><element-citation publication-type="journal"><name name-style="western"><surname>Yoon</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>M</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>S</given-names></name><name name-style="western"><surname>Takikawa</surname><given-names>A</given-names></name><name name-style="western"><surname>Usui</surname><given-names>I</given-names></name><name name-style="western"><surname>Tobe</surname><given-names>K</given-names></name><etal/><article-title>SIRT1-Mediated eNAMPT Secretion from Adipose Tissue Regulates Hypothalamic NAD+ and Function in Mice</article-title><source>Cell Metab</source><year>2015</year><volume>21</volume><fpage>706</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">25921090</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2015.04.002</pub-id><pub-id pub-id-type="pmcid">PMC4426056</pub-id></element-citation></ref><ref id="B131"><label>131</label><element-citation publication-type="journal"><name name-style="western"><surname>Ju</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>XM</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>XM</given-names></name><name name-style="western"><surname>Li</surname><given-names>FH</given-names></name><name name-style="western"><surname>Wang</surname><given-names>SC</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name><etal/><article-title>Circular RNA FEACR inhibits ferroptosis and alleviates myocardial ischemia/reperfusion injury by interacting with NAMPT</article-title><source>J Biomed Sci</source><year>2023</year><volume>30</volume><fpage>45</fpage><pub-id pub-id-type="pmid">37370086</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12929-023-00927-1</pub-id><pub-id pub-id-type="pmcid">PMC10304620</pub-id></element-citation></ref><ref id="B132"><label>132</label><element-citation publication-type="journal"><name name-style="western"><surname>van der Kant</surname><given-names>R</given-names></name><name name-style="western"><surname>Langness</surname><given-names>VF</given-names></name><name name-style="western"><surname>Herrera</surname><given-names>CM</given-names></name><name name-style="western"><surname>Williams</surname><given-names>DA</given-names></name><name name-style="western"><surname>Fong</surname><given-names>LK</given-names></name><name name-style="western"><surname>Leestemaker</surname><given-names>Y</given-names></name><etal/><article-title>Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-beta in iPSC-Derived Alzheimer's Disease Neurons</article-title><source>Cell Stem Cell</source><year>2019</year><volume>24</volume><fpage>363</fpage><lpage>75</lpage><comment>e9</comment><pub-id pub-id-type="pmid">30686764</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.stem.2018.12.013</pub-id><pub-id pub-id-type="pmcid">PMC6414424</pub-id></element-citation></ref><ref id="B133"><label>133</label><element-citation publication-type="journal"><name name-style="western"><surname>Boussicault</surname><given-names>L</given-names></name><name name-style="western"><surname>Alves</surname><given-names>S</given-names></name><name name-style="western"><surname>Lamaziere</surname><given-names>A</given-names></name><name name-style="western"><surname>Planques</surname><given-names>A</given-names></name><name name-style="western"><surname>Heck</surname><given-names>N</given-names></name><name name-style="western"><surname>Moumne</surname><given-names>L</given-names></name><etal/><article-title>CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington's disease</article-title><source>Brain</source><year>2016</year><volume>139</volume><fpage>953</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">26912634</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awv384</pub-id><pub-id pub-id-type="pmcid">PMC4766376</pub-id></element-citation></ref><ref id="B134"><label>134</label><element-citation publication-type="journal"><name name-style="western"><surname>Narendra</surname><given-names>DP</given-names></name><name name-style="western"><surname>Youle</surname><given-names>RJ</given-names></name><article-title>The role of PINK1-Parkin in mitochondrial quality control</article-title><source>Nat Cell Biol</source><year>2024</year><volume>26</volume><fpage>1639</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">39358449</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41556-024-01513-9</pub-id></element-citation></ref><ref id="B135"><label>135</label><element-citation publication-type="journal"><name name-style="western"><surname>Zeng</surname><given-names>L</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>W</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jin</surname><given-names>X</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Y</given-names></name><etal/><article-title>SDC1-TGM2-FLOT1-BHMT complex determines radiosensitivity of glioblastoma by influencing the fusion of autophagosomes with lysosomes</article-title><source>Theranostics</source><year>2023</year><volume>13</volume><fpage>3725</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">37441590</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.81999</pub-id><pub-id pub-id-type="pmcid">PMC10334832</pub-id></element-citation></ref><ref id="B136"><label>136</label><element-citation publication-type="journal"><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>C</given-names></name><name name-style="western"><surname>Cui</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T</given-names></name><etal/><article-title>Unraveling the role and mechanism of mitochondria in postoperative cognitive dysfunction: a narrative review</article-title><source>J Neuroinflammation</source><year>2024</year><volume>21</volume><fpage>293</fpage><pub-id pub-id-type="pmid">39533332</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-024-03285-3</pub-id><pub-id pub-id-type="pmcid">PMC11559051</pub-id></element-citation></ref><ref id="B137"><label>137</label><element-citation publication-type="journal"><name name-style="western"><surname>Cho</surname><given-names>JH</given-names></name><name name-style="western"><surname>Chae</surname><given-names>CW</given-names></name><name name-style="western"><surname>Lim</surname><given-names>JR</given-names></name><name name-style="western"><surname>Jung</surname><given-names>YH</given-names></name><name name-style="western"><surname>Han</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>JH</given-names></name><etal/><article-title>Sodium butyrate ameliorates high glucose-suppressed neuronal mitophagy by restoring PRKN expression via inhibiting the RELA-HDAC8 complex</article-title><source>Autophagy</source><year>2024</year><volume>20</volume><fpage>1505</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">38409852</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15548627.2024.2323785</pub-id><pub-id pub-id-type="pmcid">PMC11210903</pub-id></element-citation></ref><ref id="B138"><label>138</label><element-citation publication-type="other"><name name-style="western"><surname>Du</surname><given-names>F</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Hu</surname><given-names>G</given-names></name><name name-style="western"><surname>Lin</surname><given-names>CS</given-names></name><name name-style="western"><surname>ShiDu Yan</surname><given-names>S</given-names></name><article-title>PINK1-dependent NFKB signaling contributes to amyloid pathology in Alzheimer disease</article-title><source>Autophagy</source><year>2025</year><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15548627.2025.2463322</pub-id><pub-id pub-id-type="pmid">40320714</pub-id></element-citation></ref><ref id="B139"><label>139</label><element-citation publication-type="journal"><name name-style="western"><surname>Li</surname><given-names>F</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>K</given-names></name><article-title>Microglial mitophagy integrates the microbiota-gut-brain axis to restrain neuroinflammation during neurotropic herpesvirus infection</article-title><source>Autophagy</source><year>2023</year><volume>19</volume><fpage>734</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">35849507</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15548627.2022.2102309</pub-id><pub-id pub-id-type="pmcid">PMC9851194</pub-id></element-citation></ref><ref id="B140"><label>140</label><element-citation publication-type="journal"><name name-style="western"><surname>Jiang</surname><given-names>B</given-names></name><name name-style="western"><surname>Bai</surname><given-names>F</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ren</surname><given-names>Y</given-names></name><name name-style="western"><surname>Su</surname><given-names>Y</given-names></name><name name-style="western"><surname>Song</surname><given-names>W</given-names></name><etal/><article-title>Endothelial major vault protein alleviates vascular remodeling via promoting Parkin-mediated mitophagy</article-title><source>Nat Commun</source><year>2025</year><volume>16</volume><fpage>4365</fpage><pub-id pub-id-type="pmid">40348769</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-025-59644-y</pub-id><pub-id pub-id-type="pmcid">PMC12065841</pub-id></element-citation></ref><ref id="B141"><label>141</label><element-citation publication-type="journal"><name name-style="western"><surname>Nanayakkara</surname><given-names>R</given-names></name><name name-style="western"><surname>Gurung</surname><given-names>R</given-names></name><name name-style="western"><surname>Rodgers</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Eramo</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Ramm</surname><given-names>G</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>CA</given-names></name><etal/><article-title>Autophagic lysosome reformation in health and disease</article-title><source>Autophagy</source><year>2023</year><volume>19</volume><fpage>1378</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">36409033</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15548627.2022.2128019</pub-id><pub-id pub-id-type="pmcid">PMC10240999</pub-id></element-citation></ref><ref id="B142"><label>142</label><element-citation publication-type="journal"><name name-style="western"><surname>Xu</surname><given-names>QQ</given-names></name><name name-style="western"><surname>Su</surname><given-names>ZR</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>M</given-names></name><name name-style="western"><surname>Xian</surname><given-names>YF</given-names></name><name name-style="western"><surname>Lin</surname><given-names>ZX</given-names></name><article-title>Patchouli alcohol attenuates the cognitive deficits in a transgenic mouse model of Alzheimer's disease via modulating neuropathology and gut microbiota through suppressing C/EBPbeta/AEP pathway</article-title><source>J Neuroinflammation</source><year>2023</year><volume>20</volume><fpage>19</fpage><pub-id pub-id-type="pmid">36717922</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-023-02704-1</pub-id><pub-id pub-id-type="pmcid">PMC9887791</pub-id></element-citation></ref><ref id="B143"><label>143</label><element-citation publication-type="journal"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Qi</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Hu</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><etal/><article-title>Nanoparticle technology for mRNA: Delivery strategy, clinical application and developmental landscape</article-title><source>Theranostics</source><year>2024</year><volume>14</volume><fpage>738</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">38169577</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.84291</pub-id><pub-id pub-id-type="pmcid">PMC10758055</pub-id></element-citation></ref><ref id="B144"><label>144</label><element-citation publication-type="journal"><name name-style="western"><surname>Shu</surname><given-names>F</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>QN</given-names></name><name name-style="western"><surname>Ren</surname><given-names>XS</given-names></name><name name-style="western"><surname>Liu</surname><given-names>ZG</given-names></name><name name-style="western"><surname>Hu</surname><given-names>BW</given-names></name><etal/><article-title>Epigenetic and post-translational modifications in autophagy: biological functions and therapeutic targets</article-title><source>Signal Transduct Target Ther</source><year>2023</year><volume>8</volume><fpage>32</fpage><pub-id pub-id-type="pmid">36646695</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-022-01300-8</pub-id><pub-id pub-id-type="pmcid">PMC9842768</pub-id></element-citation></ref><ref id="B145"><label>145</label><element-citation publication-type="journal"><name name-style="western"><surname>Yoneda</surname><given-names>T</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>K</given-names></name><name name-style="western"><surname>Yoshimura</surname><given-names>Y</given-names></name><article-title>Experience-dependent functional plasticity and visual response selectivity of surviving subplate neurons in the mouse visual cortex</article-title><source>Proc Natl Acad Sci U S A</source><year>2023</year><volume>120</volume><fpage>e2217011120</fpage><pub-id pub-id-type="pmid">36812195</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2217011120</pub-id><pub-id pub-id-type="pmcid">PMC9992851</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="F1" orientation="portrait"><label>Figure 1</label><caption><p><bold> Alisol A treatment alleviates atherosclerosis development and ameliorates cognitive function in <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice. (A)</bold> The flow diagram of the experimental design of the mice experiments; <bold>(B)</bold> Triglycerides (TG), serum total cholesterol (TC), high density lipoprotein cholesterol (HDL-c), low density lipoprotein cholesterol (LDL-c) levels in mice were detected by a biochemical analyzer, n = 10; Total cholesterol concentration in the brain of mouse <bold>(C)</bold>; HE stained <bold>(D-E)</bold> along with Oil Red O stained <bold>(F-G)</bold> of aortic root lesions, revealed the extent of atherosclerotic plaque in the aortic root, percentage of plaque area in aorta and the percentage lipid content of the aortic root plaques, scale: 100 &#956;m, enlarge scale: 50 &#956;m, n = 5; <bold>(H)</bold> IF images stained for &#945;SMA and CD68, and quantification of expression <bold>(I)</bold>, scale: 100 &#956;m, n = 5; <bold>(J)</bold> The MWM, the escape latency of water maze <bold>(K)</bold> and the mean time to stay in the target quadrant at the last experiment <bold>(L-M)</bold>, n = 8; <bold>(N-O)</bold> Y-maze, the number of total arm entries, number of entries into the open arm <bold>(P)</bold>, the spontaneous alternation rate in the Y-maze test <bold>(Q)</bold>, n = 8; <bold>(R)</bold> The NOR, the total object exploration time <bold>(S)</bold>, the time spent exploring the novel object <bold>(T)</bold>, The Recognition Index is operationally defined as the proportion of time allocated to exploring the novel object relative to the cumulative time spent exploring both objects <bold>(U)</bold>, n = 8. Compared to the control group, <sup>*</sup><italic toggle="yes"> P</italic> &lt; 0.05, <sup>**</sup><italic toggle="yes"> P</italic> &lt; 0.01; compared to the <italic toggle="yes">Ldlr<sup>-/-</sup></italic>, <sup>#</sup><italic toggle="yes"> P</italic> &lt; 0.05, <sup>##</sup><italic toggle="yes"> P</italic> &lt; 0.01.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="thnov15p9415g001.jpg"/></fig><fig position="float" id="F2" orientation="portrait"><label>Figure 2</label><caption><p><bold> Alisol A protects hippocampus neurons from cholesterol metabolism disorders and oxidative stress damage. (A)</bold> Key cholesterol metabolism proteins were validated by WB: SREBP2, LXR-&#945;, CYP46A1; and<bold> (B)</bold> WB bands were quantified by Image J, n = 3. <bold>(C)</bold> Total protein was collected from the mice hippocampal tissues and evaluated by WB, including SREBP2, LXR-&#945;, and CYP46A1, bar graph represents semi-quantification of WB <bold>(D)</bold>, n = 3; <bold>(E)</bold> Representative IHC staining images of hippocampal neurons in CA1 and dentate gyrus (DG) zones (counterstaining is blue and positive staining is brown), including HMGCR, and ABCA1, and quantification of IHC <bold>(F)</bold>, scale: 50 &#956;m, n = 5; <bold>(G)</bold> Schematic. <bold>(H)</bold> Respectively, levels of GSH, MDA, and SOD in the hippocampus of mice were determined with GSH, MDA, and SOD assay kits, n = 8; <bold>(I)</bold> WB analysis of UCP2 in HT22 cells, and quantification result was normalized against the levels of GAPDH, n = 3; <bold>(J)</bold> ROS detection was conducted utilizing a DCFH-DA cellular ROS detection assay, scale: 100 &#956;m, n = 5; (<bold>K</bold>) Flow cytometry analysis of HT22 cells was conducted to detect intracellular ROS under various treatment conditions; <bold>(L)</bold> Representative results of WB analysis and quantification results were normalized against the levels of GAPDH, n = 3; <bold>(M)</bold> Representative IF images of hippocampal neurons in CA3 regions, scale: 100 &#956;m, enlarge scale: 10 &#956;m, n = 5; IF was quantified for UCP2 (red). Compared to the 1, <sup>*</sup><italic toggle="yes">P</italic> &lt; 0.05, <sup>**</sup><italic toggle="yes">P</italic> &lt; 0.01; compared to the 2, <sup>#</sup><italic toggle="yes"> P</italic> &lt; 0.05, <sup>##</sup><italic toggle="yes"> P</italic> &lt; 0.01. 1: HT22; 2: HT22+ A&#946;<sub>25-35</sub> (20 &#956;M) and complex (50 &#956;g/ml of cholesterol); 3: HT22+ A&#946;<sub>25-35</sub> (20 &#956;M) and complex (50 &#956;g/ml of cholesterol) + Alisol A 5 &#956;M; 4: HT22+ A&#946;<sub>25-35</sub> (20 &#956;M) and complex (50 &#956;g/ml of cholesterol) + Alisol A 10 &#956;M. Rosup: HT22 + A&#946;<sub>25-35</sub> (20 &#956;M) a complex (50 &#956;g/ml of cholesterol) + H<sub>2</sub>O<sub>2</sub> 0.1mM. Compared to the 5, <sup>*</sup><italic toggle="yes"> P</italic> &lt; 0.05, <sup>**</sup><italic toggle="yes"> P</italic> &lt; 0.01; compared to the 6, <sup>#</sup><italic toggle="yes"> P</italic> &lt; 0.05, <sup>##</sup><italic toggle="yes"> P</italic> &lt; 0.01. 5: Primary neurons; 6: Primary neurons+ ox-LDL (70 &#956;g/ml); 7: Primary neurons+ ox-LDL (70 &#956;g/ml) + Alisol A 5 &#956;M; 8: Primary neurons+ ox-LDL (70 &#956;g/ml) + Alisol A 10 &#956;M. Compared to the control group, <sup>*</sup><italic toggle="yes"> P</italic> &lt; 0.05, <sup>**</sup><italic toggle="yes"> P</italic> &lt; 0.01; compared to the <italic toggle="yes">Ldlr<sup>-/-</sup></italic>, <sup>#</sup><italic toggle="yes"> P</italic> &lt; 0.05, <sup>##</sup><italic toggle="yes"> P</italic> &lt; 0.01.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="thnov15p9415g002.jpg"/></fig><fig position="float" id="F3" orientation="portrait"><label>Figure 3</label><caption><p><bold> Alisol A treatment improved neural cell morphology and inhibited the activation of astrocytes and microglia, and restored synaptic loss and impairment of <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice. (A)</bold> HE staining shows morphological changes of neurons in the hippocampal CA1 and DG regions, scale: 5 &#956;m, n = 5; White arrows indicate degenerating neurons, characterized by nuclear pyknosis, increased cytoplasmic eosinophilia, and disorganized arrangement. <bold>(B)</bold> Nissl staining reveals the distribution of Nissl bodies, scale: 5 &#956;m, n = 5; Red arrows indicate Nissl-positive neurons, while black arrows denote degenerating neurons. Quantification includes the number of degenerating neurons and Nissl-positive cells. <bold>(C)</bold> Representative immunofluorescence images of hippocampal neurons in the CA1 and DG regions were analyzed. An enlarged view is provided on the right, showcasing representative images of IBA1 <sup>+</sup> microglia and GFAP <sup>+</sup> astrocytes, accompanied by Sholl analysis. The intersection number per radius over the distance from the cell body was displayed graphically in the curve, scale: 10 &#956;m, enlarge scale: 2 &#956;m;<bold> (D)</bold> IF was quantified for IBA1 (red) and GFAP (green), n = 5; <bold>(E)</bold> Line chart of intersection number per radius versus distance from the cell body; <bold>(F)</bold> Representative reconstruction images of astrocytes and microglia, with the cellular regions delineated using distinct colors, were obtained, scale: 10 &#956;m; <bold>(G)</bold> The areas occupied by astrocytes and microglia were subsequently quantified and subjected to analysis; (<bold>H</bold>) Schematic. <bold>(I)</bold> Alterations in hippocampus ultrastructure were examined by transmission electron microscope (TEM), mitochondria (M), axonal terminal (T), presynaptic density membrane (PM), synaptic vesicle (SV), dendritic spine (DS), postsynaptic density membrane (PD), synaptic cleft (SC), scale: 2 &#956;m, enlarge scale: 1 &#956;m, n = 5; <bold>(J)</bold> A quantitative analysis of the ultrastructural synapses in <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice was conducted, focusing on the number of synaptic vesicles (SVs) per synaptic profile, the synaptic length within the active zones, the width of the synaptic cleft, and the thickness of the post-synaptic density; <bold>(K)</bold> Synapses in the hippocampal CA1 and DG region are revealed by IF staining for the pre-and postsynaptic markers, Synapsin-1 (red) and PSD95(green), respectively, scale: 10 &#956;m, enlarge scale: 2 &#956;m, n = 5; <bold>(L)</bold> and quantification of IF; <bold>(M)</bold> Golgi-Cox Staining Hippocampal Golgi-Cox staining was performed as previously described, scale: 100 &#956;m, enlarge scale: 20 &#956;m, n = 8;<bold> (N)</bold> Track the neural branches after Golgi staining;<bold> (O)</bold> and <bold>(P)</bold> analysis of Sholl results and statistical data; <bold>(Q)</bold> and <bold>(R)</bold> analysis of dendritic spine density in neurons stained with Golgi, along with the quantification of mushroom spines, scale: 2 &#956;m<bold> (S)</bold>;<bold> (T)</bold> Schematic. Compared to the control group, <sup>*</sup><italic toggle="yes"> P</italic> &lt; 0.05, <sup>**</sup><italic toggle="yes"> P</italic> &lt; 0.01; compared to the <italic toggle="yes">Ldlr<sup>-/-</sup>
</italic>mice, <sup>#</sup><italic toggle="yes"> P</italic> &lt; 0.05, <sup>##</sup><italic toggle="yes"> P</italic> &lt; 0.01.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="thnov15p9415g003.jpg"/></fig><fig position="float" id="F4" orientation="portrait"><label>Figure 4</label><caption><p><bold> Atherosclerosis has the potential to impact cognitive function via the autophagy and AMPK signaling pathways, with Alisol A capable of binding to NAMPT and modulating its activity. (A-D)</bold> Using Mendelian randomization to explore the causal link between coronary atherosclerosis and vascular dementia. <bold>(A)</bold> A leave-one-out sensitivity analysis was performed to assess if any single SNP disproportionately influences the association. In the forest plot, each black point shows the Mendelian Randomization analysis results excluding that specific SNP. <bold>(B)</bold> The causal effect of exposure on the outcome is evaluated for each SNP using the Wald ratio and shown in a forest plot. The overall Mendelian Randomization (MR) estimate, using all SNPs and various MR methods, is also provided. <bold>(C)</bold> The effects of SNPs on the outcome are plotted against their effects on the exposure, with each line's slope indicating causal association. Each method produces a unique line, except for the Egger estimate, which is the only line not passing through the origin. <bold>(D)</bold> A funnel plot was used to assess heterogeneity, with less precise estimates forming a funnel shape as precision increases. A wider spread indicates more heterogeneity, possibly due to horizontal pleiotropy. Asymmetry implies directional pleiotropy that biases many MR methods, but MR Egger regression can reduce this bias. <bold>(E-I)</bold> Serum Lipidomics, n = 5; <bold>(E)</bold> Scatter plot of Principal Component Analysis (PCA) scores; <bold>(F)</bold> Heatmap illustrating differential metabolites in the comparison group; <bold>(G)</bold> Bar chart depicting differential statistics of metabolic ions; <bold>(H)</bold> Diagram illustrating the differential metabolites in volcanic activity; <bold>(I)</bold> Bubble Chart of differential metabolite enrichment pathways in the KEGG database;<bold> (J)</bold> Analysis of gene expression profiles in the GEO dataset (ID: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE100927">GSE100927</ext-link>, G1 = 35: Standard control participants, G2 = 69: Patients with atherosclerosis). The binding mode of NAMPT with Alisol A after molecular dynamics, <bold>(K)</bold> the 3D structure of complex; <bold>(L)</bold> the Electrostatic surface of protein; <bold>(M)</bold> The detail binding mode between Alisol A and NAMPT; The backbone of protein was rendered in a tube and colored in cyan; Compound is rendering by red, Yellow dash represents hydrogen bond distance; The RMSD of Alisol A with NAMPT <bold>(N)</bold>; <bold>(O)</bold> The RMSD of Alisol A with NAMPT; <bold>(P)</bold> The SASA of Alisol A with NAMPT; <bold>(Q)</bold> The R go f Alisol A with NAMPT; <bold>(R)</bold> The hydrogen bond number of Alisol A with NAMPT; <bold>(S) (T)</bold> The energy decomposition for the interaction of Alisol A with NAMPT; molecular mechanics (MM), polar solvation energy (Polar), and nonpolar solvation energy (Apolar); <bold>(U)</bold> The binding energy by MMG-NAMPT (kJ/mol);<bold> (V)</bold> SPR, Sensorgrams for the interaction of NAMPT and Alisol A.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="thnov15p9415g004.jpg"/></fig><fig position="float" id="F5" orientation="portrait"><label>Figure 5</label><caption><p><bold> Alisol A activates the NAMPT-related signaling pathway, thereby facilitating lysine deacetylation and autophagy. (A)</bold> Schematic. <bold>(B)</bold> Total proteins were collected from the mice hippocampal tissues and evaluated by WB, including AMPK, p-AMPK&#945; <sup>Thr172 or Thr183</sup>, NAMPT, SIRT1, PGC1-&#945;, and AcetyI-Lysine, bar graph represents semi-quantification of WB <bold>(C)</bold>, n = 3;<bold> (D)</bold> NAD<sup>+</sup> levels in the hippocampus of <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice were determined by the NAD<sup>+</sup> Assay Kit, n = 8;<bold> (E)</bold> NAD&#8314; content in HT22 cells or in primary neurons was measured using an NAD assay kit, n = 8; <bold>(F)</bold> WB analysis of AMPK, p-AMPK&#945; <sup>Thr172 or Thr183</sup>, NAMPT, SIRT1, PGC1-&#945;, and AcetyI-Lysine in cells, and quantification result was normalized against the levels of GAPDH, n = 3;<bold> (G)</bold> Representative images of NAMPT (green) and SIRT1 (red) double immunofluorescence staining, scale: 5 &#956;m; and quantification of immunofluorescence stain intensity using Image J; <bold>(H)</bold> WB analysis of P62, BECLIN1, PARKIN, PINK1, COXIV, TOM20, and LC3B in cells, and quantification result was normalized against the levels of GAPDH or COXIV, n = 3; <bold>(I)</bold> Changes in MMP was monitored by staining with JC1, scale: 100 &#956;m; and quantification of the percentage of MMP, n = 8. Compared to the 5, <sup>*</sup><italic toggle="yes"> P</italic> &lt; 0.05, <sup>**</sup><italic toggle="yes"> P</italic> &lt; 0.01; compared to the 6, <sup>#</sup><italic toggle="yes"> P</italic> &lt; 0.05, <sup>##</sup><italic toggle="yes"> P</italic> &lt; 0.01. Compared to the control group, <sup>*</sup><italic toggle="yes"> P</italic> &lt; 0.05, <sup>**</sup><italic toggle="yes"> P</italic> &lt; 0.01; compared to the <italic toggle="yes">Ldlr<sup>-/-</sup></italic>, <sup>#</sup><italic toggle="yes"> P</italic> &lt; 0.05, <sup>##</sup><italic toggle="yes"> P</italic> &lt; 0.01.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="thnov15p9415g005.jpg"/></fig><fig position="float" id="F6" orientation="portrait"><label>Figure 6</label><caption><p><bold> Inhibiting NAMPT causes cholesterol buildup in the hippocampus, worsening cognitive issues due to reduced NAMPT-SIRT1 interaction, inhibited NAMPT deacetylation, and decreased NAMPT-CYP46A1 interaction. (A-B)</bold> The MWM, the escape latency of the water maze and the mean time to stay in the target quadrant at the last experiment, n = 8; <bold>(C-D)</bold> Y maze, the number of total arm entries, number of entries into the open arm, the spontaneous alternation rate, n = 8; <bold>(E-F)</bold> This conclusion is supported by data from the NOR test, which measured total object exploration time, the duration spent exploring the novel object, n = 8. <bold>(G)</bold> IHC staining of NAMPT and SIRT1 in <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice hippocampal tissues in CA1 and DG zones (counterstaining is blue and positive staining is brown) and IHC semi-quantitative of NAMPT and SIRT1, scale: 50 &#956;m, n = 5; <bold>(H)</bold> NAD&#8314; levels in the hippocampus of <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice and HT22 cells, as determined by the NAD&#8314; Assay Kit (n = 8 ); <bold>(I)</bold> WB analysis of SREBP2, HMGCR, and LXR-&#945; in HT22 cells, and quantification result was normalized against the levels of GAPDH, n = 3; <bold>(J)</bold> Representative IHC images of hippocampal neurons in CA1 and DG zones (counterstaining is blue and positive staining is brown), and quantification of IHC, scale: 50 &#956;m, n = 5. <bold>(K)</bold> WB analysis of SIRT1, AcetyI-Lysine, ABCG5, ABCG8, and SREBP2 in HT22 cells, and quantification result was normalized against the levels of GAPDH, n = 3; <bold>(L)</bold> After overexpressing NAMPT in HT22 cells for 48 h, the cells were treated with 1 &#956;M TSA or 5 mM NAM for 12 h. COIP assays with NAMPT antibodies assessed NAMPT acetylation via WB, and its interaction with SIRT1 was checked using SIRT1 antibodies, with IgG as a control;<bold> (M)</bold> HT22 cells were treated with Alisol A (10&#8239;&#956;M) or a complex of A&#946;<sub>25-35</sub> (20 &#956;M) and complex (50 &#956;g/ml of cholesterol). Primary neurons were treated with ox-LDL (70 &#956;g/ml). COIP was performed using anti-NAMPT antibodies to assess NAMPT acetylation and its interaction with SIRT1 and CYP46A1, followed by immunoblotting with anti-acetyl-lysine, anti-SIRT1, and anti-CYP46A1 antibodies. IgG served as a negative control. Compared to the <italic toggle="yes">Ldlr<sup>-/-</sup> mice</italic>, <sup>*</sup><italic toggle="yes"> P</italic> &lt; 0.05, <sup>**</sup><italic toggle="yes"> P</italic> &lt; 0.01; compared to the FK866 group, <sup>#</sup><italic toggle="yes"> P</italic> &lt; 0.05, <sup>##</sup><italic toggle="yes"> P</italic> &lt; 0.01. NMN: <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice were fed with HFD and treated with NMN 100 mg/kg; Alisol A: <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice were fed with HFD and treated with Alisol A 15 mg/kg; FK866: <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice were fed with HFD and treated with FK866 25 mg/kg; FK866+ Alisol A: <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice were fed with HFD and treated with Alisol A 15 mg/kg and FK866 25 mg/kg. <italic toggle="yes">Ldlr<sup>-/-</sup></italic>: <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice were fed with HFD for the entire study. Compared to the 1, <sup>*</sup><italic toggle="yes"> P</italic> &lt; 0.05, <sup>**</sup><italic toggle="yes"> P</italic> &lt; 0.01; compared to the 3, <sup>#</sup><italic toggle="yes"> P</italic> &lt; 0.05, <sup>##</sup><italic toggle="yes"> P</italic> &lt; 0.01. 1:HT22 + A&#946;<sub>25-35</sub> (20 &#956;M) and complex (50 &#956;g/ml of cholesterol) + NAMPT; 2:HT22 + A&#946;<sub>25-35</sub> (20 &#956;M) and complex (50 &#956;g/ml of cholesterol) + Alisol A 10 &#956;M; 3:HT22 + A&#946;<sub>25-35</sub> (20 &#956;M) and complex (50 &#956;g/ml of cholesterol) + FK866 100 nM; 4:HT22 + A&#946;<sub>25-35</sub> (20 &#956;M) and complex (50 &#956;g/ml of cholesterol) + Alisol A 10 &#956;M + FK866 100 nM. Compared to the 5, <sup>*</sup><italic toggle="yes"> P</italic> &lt; 0.05, <sup>**</sup><italic toggle="yes"> P</italic> &lt; 0.01; compared to the 7, <sup>#</sup><italic toggle="yes"> P</italic> &lt; 0.05, <sup>##</sup><italic toggle="yes"> P</italic> &lt; 0.01. 5: Primary neurons; 6: Primary neurons+ ox-LDL (70 &#956;g/ml) + NAMPT; 7: Primary neurons+ ox-LDL (70 &#956;g/ml); 8: Primary neurons+ ox-LDL (70 &#956;g/ml) + FK866 100 nM.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="thnov15p9415g006.jpg"/></fig><fig position="float" id="F7" orientation="portrait"><label>Figure 7</label><caption><p><bold> Modulation of NAMPT activity and its network by Alisol A restores cholesterol balance, mitophagy, and synaptic function in <italic toggle="yes">Ldlr<sup>-/-</sup></italic> mice. (A)</bold> WB analysis of P62, BECLIN1, PARKIN, PINK1, COXIV, TOM20, and LC3B protein quantitation for WB, n = 3. <bold>(B)</bold> WB analysis of P62, BECLIN1, PARKIN, PINK1, COXIV, TOM20, and LC3B in cells, and quantification result was normalized against the levels of GAPDH or COXIV, n = 3; <bold>(C)</bold> Changes in MMP was monitored by staining with JC1 in HT22 cells, scale: 100 &#956;m; The ratio of red/green fluorescence intenity was employed to assess MMP, n = 8; <bold>(D)</bold> Representative IF images of OPTN and TOM20 in HT22 cells, scale: 2 &#956;m; Quantification of IF stain intensity using Image J, n = 8; IF and colocalization analysis. <bold>(E)</bold> WB analysis of PINK1 in HT22 cells and quantification result was normalized against the levels of GAPDH, n = 3; <bold>(F)</bold> Subsequent COIP experiments employed NAMPT antibodies to assess interactions with NAMPT and PINK1, using IgG as a control. <bold>(G)</bold> Illustrative IF images depicting hippocampal neurons located within the CA3 subregion, scale: 100 &#956;m, enlarge scale: 10 &#956;m, n = 5; IF was quantified for UCP2 (red); <bold>(H)</bold> The phenomenon of intercellular ROS generation was observed through the detection of intracellular ROS levels using the DCFH-DA probe following different treatment protocols, scale: 100 &#956;m, n = 5; <bold>(I)</bold> Intracellular ROS levels were measured using flow cytometry, comparative analysis of fluorescence intensity within peak plots derived from flow cytometry, n = 5; <bold>(J)</bold> Synapses in the hippocampal CA1 and DG region were revealed by IF staining for the pre-and postsynaptic markers, Synapsin-1 (red) and PSD95 (green) respectively, scale: 10 &#956;m, enlarge scale: 2 &#956;m, n = 5; and quantification of IF; <bold>(K)</bold> Golgi-Cox Staining Hippocampal Golgi-Cox staining was performed as previously described, scale: 100 &#956;m, enlarge scale: 20 &#956;m, n = 8; Track the neural branches after Golgi staining and analysis of Sholl results and statistical data; Analysis of dendritic spine density in neurons stained with Golgi, along with the quantification of mushroom spines, scale: 2 &#956;m; <bold>(L)</bold> Representative IF images of NMDA 2A (green) and NMDA 2B (red), scale: 2 &#956;m; and quantification of IF, n = 5. Compared to the <italic toggle="yes">Ldlr<sup>-/-</sup> mice</italic>, <sup>*</sup><italic toggle="yes"> P</italic> &lt; 0.05, <sup>**</sup><italic toggle="yes"> P</italic> &lt; 0.01; compared to the FK866 group, <sup>#</sup><italic toggle="yes"> P</italic> &lt; 0.05, <sup>##</sup><italic toggle="yes"> P</italic> &lt; 0.01. Compared to the 1, <sup>*</sup><italic toggle="yes"> P</italic> &lt; 0.05, <sup>**</sup><italic toggle="yes"> P</italic> &lt; 0.01; compared to the 3, <sup>#</sup><italic toggle="yes"> P</italic> &lt; 0.05, <sup>##</sup><italic toggle="yes"> P</italic> &lt; 0.01. DMSO: HT22 +DMSO; Rosup: HT22 + A&#946;<sub>25-35</sub> (20 &#956;M) and complex (50 &#956;g/ml of cholesterol) +H<sub>2</sub>O<sub>2</sub> 0.1 mM<sub>;</sub> CCCP: HT22+ CCCP 10 &#956;M. Compared to the 5, <sup>*</sup><italic toggle="yes"> P</italic> &lt; 0.05, <sup>**</sup><italic toggle="yes"> P</italic> &lt; 0.01; compared to the 7, <sup>#</sup><italic toggle="yes"> P</italic> &lt; 0.05, <sup>##</sup><italic toggle="yes"> P</italic> &lt; 0.01.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="thnov15p9415g007.jpg"/></fig></floats-group></article></pmc-articleset>